{"generated":"2026-08-28T16:42:09Z","content_changed":"2026-08-28T15:15:36Z","count":4443,"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","note":"DOI (kleine letters, zonder https://doi.org/) -> de Nederlandse samenvatting op hartvaat.nl.","doi":{"10.2196/87142":[{"url":"https://hartvaat.nl/2026/08/20/deep-learning-op-mobiele-ecg-voorspelt-atriumfibrilleren-binnen-30-dagen/","title":"Deep learning op mobiele ECG voorspelt atriumfibrilleren binnen 30 dagen","title_en":"Prediction of Atrial Fibrillation Occurrence With Handheld Mobile Electrocardiogram: Deep Learning Model Development Using Real-World Data.","published":"2026-08-28"}],"10.1093/eschf/xvag219":[{"url":"https://hartvaat.nl/2026/08/20/risicofactoren-voor-vroege-tussen-en-late-hartfalenheropnames-na-ontslag/","title":"Risicofactoren voor vroege, tussen- en late hartfalenheropnames na ontslag","title_en":"Timing-Specific Factors Associated With Early, Intermediate, and Late Readmission After Heart Failure Hospitalisation.","published":"2026-08-28"}],"10.1161/jaha.126.049226":[{"url":"https://hartvaat.nl/2026/08/20/long-covid-verhoogt-risico-op-hart-nier-en-longcomplicaties-trinetx-cohort/","title":"Long COVID verhoogt risico op hart-, nier- en longcomplicaties — TriNetX-cohort","title_en":"Cardiovascular, Renal, and Pulmonary Risks of Long COVID: A Retrospective Cohort Study Stratified by Age and Sex.","published":"2026-08-28"}],"10.1007/s11906-026-01379-2":[{"url":"https://hartvaat.nl/2026/08/20/ouderlijke-obesitas-verhoogt-cardiorenale-risico-s-bij-nakomelingen-review/","title":"Ouderlijke obesitas verhoogt cardiorenale risico's bij nakomelingen — review","title_en":"Parental Obesity and Offspring Risk for Cardiorenal Diseases.","published":"2026-08-28"}],"10.2215/cjn.0000001183":[{"url":"https://hartvaat.nl/2026/08/20/aangetaste-tubulaire-secretiecapaciteit-verhoogt-cardiovasculaire-sterfte-hunt-s/","title":"Aangetaste tubulaire secretiecapaciteit verhoogt cardiovasculaire sterfte — HUNT-studie","title_en":"Kidney Tubular Secretion Capacity and Risk of Cardiovascular Mortality in the General Population: The HUNT Study.","published":"2026-08-28"}],"10.1093/eurheartj/ehag099":[{"url":"https://hartvaat.nl/2026/08/28/eerste-esc-richtlijn-hartrevalidatie-multidisciplinair-ook-thuis-en-digitaal-en-/","title":"Eerste ESC-richtlijn hartrevalidatie: multidisciplinair, ook thuis en digitaal, en voor veel meer patiënten dan alleen na een infarct","title_en":"First ESC guideline on cardiac rehabilitation: multidisciplinary, also home-based and digital, and for far more patients than the post-infarction group","published":"2026-08-28"}],"10.1093/eurheartj/ehag101":[{"url":"https://hartvaat.nl/2026/08/28/vijfde-universele-definitie-van-het-myocardinfarct-de-typenummers-verdwijnen-voo/","title":"Vijfde universele definitie van het myocardinfarct: de typenummers verdwijnen, voortaan primair, secundair of procedureel infarct","title_en":"Fifth Universal Definition of Myocardial Infarction: the type numbers go, replaced by primary, secondary and procedure-related infarction","published":"2026-08-28"}],"10.1001/jama.2026.17078":[{"url":"https://hartvaat.nl/2026/08/28/cmr-guide-icd-bij-littekenweefsel-en-lvef-36-tot-50-procent-mist-het-primaire-ei/","title":"CMR GUIDE: ICD bij littekenweefsel en LVEF 36 tot 50 procent mist het primaire eindpunt, maar halveert plotse hartdood en helpt vooral onder de 70","title_en":"CMR GUIDE: an ICD for scar on CMR with LVEF 36 to 50 percent misses its primary endpoint but reduces sudden cardiac death, with benefit confined to patients under 70","published":"2026-08-28"}],"10.1056/nejmoa2607887":[{"url":"https://hartvaat.nl/2026/08/28/poet-ii-responsgestuurde-antibioticaduur-bij-linkszijdige-endocarditis-scheelt-t/","title":"POET-II: responsgestuurde antibioticaduur bij linkszijdige endocarditis scheelt twee weken en is niet-inferieur, maar geeft meer recidieven","title_en":"POET-II: response-tailored antibiotic duration in left-sided endocarditis saves two weeks and is non-inferior, at the cost of more relapses","published":"2026-08-28"}],"10.1093/eurheartj/ehag098":[{"url":"https://hartvaat.nl/2026/08/28/nieuwe-esc-richtlijn-hart-en-nier-2026-egfr-en-albuminurie-bij-elke-hartpatient-/","title":"Nieuwe ESC-richtlijn hart en nier 2026: eGFR en albuminurie bij elke hartpatiënt, SGLT2-remmer ongeacht ejectiefractie, en een Groningse voorzitter","title_en":"New 2026 ESC guideline on cardiovascular disease and chronic kidney disease: eGFR and albuminuria for every cardiac patient, an SGLT2 inhibitor regardless of ejection fraction, and a chair from Groningen","published":"2026-08-28"}],"10.1056/nejmoa2607978":[{"url":"https://hartvaat.nl/2026/08/28/single-af-doac-beschermt-patienten-met-atriumfibrilleren-en-een-risicofactor-zon/","title":"SINGLE-AF: DOAC beschermt patiënten met atriumfibrilleren en één risicofactor, zonder meer ernstige bloedingen","title_en":"SINGLE-AF: a DOAC protects patients with atrial fibrillation and a single stroke risk factor, without excess major bleeding","published":"2026-08-28"}],"10.1056/nejmoa2608510":[{"url":"https://hartvaat.nl/2026/08/28/cardio-ttransform-eplontersen-mist-het-primaire-eindpunt-bij-attr-cardiomyopathi/","title":"CARDIO-TTRansform: eplontersen mist het primaire eindpunt bij ATTR-cardiomyopathie, alleen zonder stabilisator een nominaal signaal","title_en":"CARDIO-TTRansform: eplontersen misses its primary endpoint in ATTR cardiomyopathy, with only a nominal signal in patients not on a stabiliser","published":"2026-08-28"}],"10.1093/eurheartj/ehag100":[{"url":"https://hartvaat.nl/2026/08/28/nieuwe-esc-hartfalenrichtlijn-2026-twee-fenotypes-in-plaats-van-drie-mra-voor-ie/","title":"Nieuwe ESC-hartfalenrichtlijn 2026: twee fenotypes in plaats van drie, MRA voor iedereen, stadia A tot D en semaglutide bij HFpEF met obesitas","title_en":"New 2026 ESC heart failure guideline: two phenotypes instead of three, an MRA for everyone, stages A to D and semaglutide for HFpEF with obesity","published":"2026-08-28"}],"10.1056/nejmoa2603021":[{"url":"https://hartvaat.nl/2026/08/28/acacia-hcm-aficamten-verbetert-symptomen-en-inspanningscapaciteit-bij-niet-obstr/","title":"ACACIA-HCM: aficamten verbetert symptomen en inspanningscapaciteit bij niet-obstructieve HCM, de eerste positieve trial ooit in deze groep","title_en":"ACACIA-HCM: aficamten improves symptoms and exercise capacity in non-obstructive HCM, the first positive trial ever in this population","published":"2026-08-28"}],"10.1016/s0140-6736(26)01206-7":[{"url":"https://hartvaat.nl/2026/08/22/clopidogrel-superieur-aan-aspirine-na-pci-10-jaar-host-exam/","title":"Clopidogrel superieur aan aspirine na PCI — 10-jaar HOST-EXAM","title_en":"Reappraising long-term antiplatelet therapy after percutaneous coronary intervention","published":"2026-08-27"}],"10.4103/npmj.npmj_580_25":[{"url":"https://hartvaat.nl/2026/09/01/verhoogd-10-jaar-ascvd-risico-gekoppeld-aan-linkerventrikelhypertrofie-bij-hyper/","title":"Verhoogd 10-jaar ASCVD-risico gekoppeld aan linkerventrikelhypertrofie bij hypertensiepatiënten","title_en":"Association of 10-year Cardiovascular Risk with Left Ventricular Hypertrophy in a Population of Nigerian Hypertensives.","published":"2026-08-27"}],"10.1212/wnl.0000000000218491":[{"url":"https://hartvaat.nl/2026/09/22/ldl-c-reductie-50-verlaagt-risico-op-secundaire-cardiovasculaire-gebeurtenissen-/","title":"LDL-C-reductie ≥50% verlaagt risico op secundaire cardiovasculaire gebeurtenissen na ischemische stroke","title_en":"Effect of a ≥50% Reduction in Low-Density Lipoprotein Cholesterol From Baseline in Patients With Ischemic Stroke.","published":"2026-08-27"}],"10.1016/j.ijcha.2026.101991":[{"url":"https://hartvaat.nl/2026/10/01/cardiale-amyloidose-komt-bij-9-van-tavi-patienten-voor-ongeacht-stromingspatroon/","title":"Cardiale amyloidose komt bij 9% van TAVI-patiënten voor — ongeacht stromingspatroon","title_en":"Dual pathology in aortic stenosis: Identifying transthyretin amyloidosis likelihood in patients referred for transcatheter aortic valve implantation.","published":"2026-08-27"}],"10.1016/j.metabol.2026.156723":[{"url":"https://hartvaat.nl/2026/10/01/masld-verhoogt-sterfte-en-cv-risico-onafhankelijk-van-lipoproteine-a/","title":"MASLD verhoogt sterfte- en CV-risico, onafhankelijk van lipoproteïne(a)","title_en":"The association of MASLD, lipoprotein(a) and long-term outcomes: Results from the multi-ethnic study of atherosclerosis.","published":"2026-08-27"}],"10.1093/eurheartj/ehag522":[{"url":"https://hartvaat.nl/2026/08/18/finerenone-blijft-effectief-bij-ckm-patienten-met-kankeranamnese-fine-heart/","title":"Finerenone blijft effectief bij CKM-patiënten met kankeranamnese — FINE-HEART","title_en":"Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis.","published":"2026-08-26"}],"10.1093/ehjqcco/qcag129":[{"url":"https://hartvaat.nl/2026/08/18/tafamidis-bij-attr-cardiomyopathie-kosteffectiviteit-onder-de-maat-in-vier-europ/","title":"Tafamidis bij ATTR-cardiomyopathie kosteffectiviteit onder de maat in vier Europese landen","title_en":"Deterministic Economic Modelling Study of Tafamidis in Transthyretin Amyloid Cardiomyopathy Across Four European Healthcare Systems.","published":"2026-08-26"}],"10.1007/s12471-026-02061-7":[{"url":"https://hartvaat.nl/2026/08/18/echocardiografie-overschatte-drukgradienten-na-tav-in-tav-met-ballon-expandable-/","title":"Echocardiografie overschatte drukgradiënten na TAV-in-TAV met ballon-expandable kleppen","title_en":"Invasive and echocardiographic gradients of self- and balloon-expandable valves in failing aortic bioprostheses.","published":"2026-08-26"}],"10.1002/ccd.70808":[{"url":"https://hartvaat.nl/2026/08/18/sheath-to-artery-ratio-voorspelt-access-site-complicaties-bij-femoraal-ingrijpen/","title":"Sheath-to-artery ratio voorspelt access-site complicaties bij femoraal ingrijpen","title_en":"Sheath-to-Artery Diameter Ratio: A Robust Predictor of Early Access-Site Adverse Events in Percutaneous Procedures.","published":"2026-08-26"}],"10.1161/circulationaha.125.074482":[{"url":"https://hartvaat.nl/2026/08/18/semaglutide-verlaagt-hscrp-en-ontstekingsactiviteit-bij-ascvd-patienten-met-over/","title":"Semaglutide verlaagt hsCRP en ontstekingsactiviteit bij ASCVD-patiënten met overgewicht — SELECT","title_en":"Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.","published":"2026-08-26"}],"10.1093/eurjpc/zwag430":[{"url":"https://hartvaat.nl/2026/08/18/glp-1-agonisten-verlagen-cardiovasculaire-risicos-bij-diabetes-en-obesitas-overz/","title":"GLP-1-agonisten verlagen cardiovasculaire risico’s bij diabetes en obesitas — overzicht","title_en":"Glucagon-Like Peptide-1-Based Therapies in Cardiovascular Disease: Evidence, Mechanisms, and Emerging Clinical Applications.","published":"2026-08-25"}],"10.1093/eschf/xvag220":[{"url":"https://hartvaat.nl/2026/08/18/c-mic-apparaat-vermindert-hartfalen-ernst-onafhankelijk-van-gdmt-aanpassingen-c-/","title":"C-MIC-apparaat vermindert hartfalen-ernst onafhankelijk van GDMT-aanpassingen — C-MIC II","title_en":"Differential Rates of Guideline-Directed Medical Therapy Modification in C-MIC and Control Patients: Results from the C-MIC II Trial.","published":"2026-08-25"}],"10.5414/cn111818":[{"url":"https://hartvaat.nl/2026/08/18/fgf23-niveaus-correleren-met-vaatcalcificatie-en-cv-risico-bij-peritonealdialyse/","title":"FGF23-niveaus correleren met vaatcalcificatie en CV-risico bij peritonealdialysepatiënten","title_en":"Clinical association between fibroblast growth factor 23 (FGF23) levels and the severity of vascular calcification and cardiovascular event risk in peritoneal dialysis patients.","published":"2026-08-25"}],"10.5414/cn112100":[{"url":"https://hartvaat.nl/2026/08/18/hif-stabilisatoren-als-orale-alternatief-voor-esas-bij-anemie-bij-chronische-nie/","title":"HIF-stabilisatoren als orale alternatief voor ESAs bij anemie bij chronische nierziekte","title_en":"Beyond erythropoiesis-stimulating agents: The evolving role of hypoxia-inducible factor stabilizers in anemia of chronic kidney disease.","published":"2026-08-25"}],"10.1093/ndt/gfag136":[{"url":"https://hartvaat.nl/2026/08/18/combinatietherapie-bij-t2dm-en-chronische-nierziekte-evidence-naar-praktijk/","title":"Combinatietherapie bij T2DM en chronische nierziekte — evidence naar praktijk","title_en":"Combination Pharmacotherapy in Type 2 Diabetes and Chronic Kidney Disease: Translating Evidence into Clinical Practice.","published":"2026-08-25"}],"10.1016/j.cca.2026.121283":[{"url":"https://hartvaat.nl/2026/08/15/geautomatiseerde-lipidenmonitoring-en-risicoclassificatie-in-de-huisartspraktijk/","title":"Geautomatiseerde lipidenmonitoring en risicoclassificatie in de huisartspraktijk — real-world studie","title_en":"Longitudinal automated lipid target monitoring integrated into a laboratory-based clinical decision support system: a real-world cardiovascular risk management approach.","published":"2026-08-24"}],"10.1007/s12020-026-04751-z":[{"url":"https://hartvaat.nl/2026/08/15/fib-4-en-fni-duiden-op-cardiorenale-en-metabole-belasting-bij-t2dm-en-masld/","title":"FIB-4 en FNI duiden op cardiorenale en metabole belasting bij T2DM en MASLD","title_en":"Association of non-invasive liver-related scores with cardiovascular disease and a four-domain cardiovascular-renal-hepatic-metabolic phenotype in patients with type 2 diabetes mellitus and MASLD.","published":"2026-08-24"}],"10.1007/s10557-026-07934-y":[{"url":"https://hartvaat.nl/2026/08/15/injecteerbare-lipidendalers-bij-gevorderde-chronische-nierziekte-en-dialyse-narr/","title":"Injecteerbare lipidendalers bij gevorderde chronische nierziekte en dialyse — narratieve review","title_en":"Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox.","published":"2026-08-24"}],"10.1007/s12020-026-04757-7":[{"url":"https://hartvaat.nl/2026/08/15/tirzepatide-verlaagt-hypertensierisico-maar-verhoogt-hypotensie-meta-analyse/","title":"Tirzepatide verlaagt hypertensierisico maar verhoogt hypotensie — meta-analyse","title_en":"Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.","published":"2026-08-24"}],"10.1016/j.ekir.2026.106693":[{"url":"https://hartvaat.nl/2026/09/01/pm2-5-blootstelling-versnelt-daling-van-egfr-bij-volwassenen/","title":"PM2.5-blootstelling versnelt daling van eGFR bij volwassenen","title_en":"Long Term Exposure to Ambient Particulate Matter","published":"2026-08-24"}],"10.1055/a-2886-6566":[{"url":"https://hartvaat.nl/2026/09/01/vrouwen-met-perifeer-arterieel-vaatlijden-presenteren-later-met-meer-distale-zie/","title":"Vrouwen met perifeer arterieel vaatlijden presenteren later met meer distale ziekte — overzicht","title_en":"Sex Differences in Peripheral Arterial Disease: Presentation, Treatment, and Outcomes.","published":"2026-08-23"}],"10.1016/j.clinimag.2026.110898":[{"url":"https://hartvaat.nl/2026/10/01/cardiale-ct-als-standaard-in-de-electrophysiologie-planning-en-veiligheid-bij-af/","title":"Cardiale CT als standaard in de electrophysiologie — planning en veiligheid bij AF-ablatie en CIED-behandeling","title_en":"Your map to the heart - Cardiac CT applications in modern electrophysiology.","published":"2026-08-23"}],"10.1016/j.ekir.2026.106703":[{"url":"https://hartvaat.nl/2026/10/01/hepcidine-heeft-beperkte-waarde-voor-het-sturen-van-anemietherapie-bij-ckd/","title":"Hepcidine heeft beperkte waarde voor het sturen van anemietherapie bij CKD","title_en":"Hepcidin and Cardiovascular Events in CKD With and Without Dialysis.","published":"2026-08-23"}],"10.1016/j.jhsg.2026.101102":[{"url":"https://hartvaat.nl/2026/11/01/risicotool-identificeert-attr-cardiomyopathie-bij-patienten-met-carpaaltunnelsyn/","title":"Risicotool identificeert ATTR-cardiomyopathie bij patiënten met carpaaltunnelsyndroom","title_en":"Development of a Three-Source Convergent Risk Assessment Tool for Amyloidosis Screening in Carpal Tunnel Syndrome Patients.","published":"2026-08-23"}],"10.1080/08037051.2026.2717792":[{"url":"https://hartvaat.nl/2026/12/01/kort-slapen-6-uur-verhoogt-kans-op-hypertensie-bij-ouderen-clhls/","title":"Kort slapen (<6 uur) verhoogt kans op hypertensie bij ouderen — CLHLS","title_en":"Association of sleep duration and hypertension in older adults: a cross-sectional study.","published":"2026-08-23"}],"10.1007/s10554-026-03800-y":[{"url":"https://hartvaat.nl/2026/08/14/hogere-hu-drempels-voegen-geen-waarde-toe-aan-ct-calciumscoring-voor-aortaklepst/","title":"Hogere HU-drempels voegen geen waarde toe aan CT-calciumscoring voor aortaklepstenose","title_en":"CT-based multi-threshold calcium scoring for aortic valve assessment: comparable predictive performance across HU thresholds in a pre-TAVI cohort.","published":"2026-08-22"}],"10.1007/s43441-026-01033-8":[{"url":"https://hartvaat.nl/2026/08/14/biotechnologie-en-ai-veranderen-precisielipidenmanagement-van-pcsk9-tot-crispr/","title":"Biotechnologie en AI veranderen precisielipidenmanagement — van PCSK9 tot CRISPR","title_en":"Precision Lipid Management in the Era of Biotechnology and Artificial Intelligence: From Gene Editing to Smart Drug Delivery.","published":"2026-08-22"}],"10.1007/s00223-026-01587-7":[{"url":"https://hartvaat.nl/2026/08/14/dapagliflozin-verlaagt-serum-klotho-bij-dialysepatienten-zonder-effect-op-botbio/","title":"Dapagliflozin verlaagt serum-Klotho bij dialysepatiënten zonder effect op botbiomarkers of fracturen — post-hoc RCT","title_en":"Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis.","published":"2026-08-22"}],"10.1093/joneph/aajag149":[{"url":"https://hartvaat.nl/2026/08/14/kaliumbinders-ondersteunen-raasi-gebruik-bij-ckd-maar-terugkeer-van-hyperkaliemi/","title":"Kaliumbinders ondersteunen RAASi-gebruik bij CKD, maar terugkeer van hyperkaliëmie versnelt nierfunctieverlies","title_en":"Optimizing hyperkalemia management in CKD: real-world nephrologist strategies and impact on patient outcomes.","published":"2026-08-22"}],"10.1093/joneph/aajag150":[{"url":"https://hartvaat.nl/2026/08/14/crp-en-albuminurie-duiden-op-hoog-risico-op-herhalende-hart-en-vaatziekten-bij-c/","title":"CRP en albuminurie duiden op hoog risico op herhalende hart- en vaatziekten bij chronische nierziekte — KNOW-CKD","title_en":"Risk factors for recurrent cardiovascular events in CKD: results from the KNOW-CKD study.","published":"2026-08-22"}],"10.1093/joneph/aajag152":[{"url":"https://hartvaat.nl/2026/08/14/infectie-is-belangrijkste-doodsoorzaak-bij-dialysepatienten-retrospectieve-analy/","title":"Infectie is belangrijkste doodsoorzaak bij dialysepatiënten — retrospectieve analyse","title_en":"Analysis of adjudicated causes of death in a large cohort of Brazilian patients undergoing dialysis.","published":"2026-08-21"}],"10.1007/s10741-026-10664-w":[{"url":"https://hartvaat.nl/2026/08/14/vereenvoudigd-crt-systeem-zonder-atriale-pacing-niet-slechter-dan-conventioneel-/","title":"Vereenvoudigd CRT-systeem zonder atriale pacing niet slechter dan conventioneel — CRT-NEXT","title_en":"Rethinking atrial pacing support in cardiac resynchronization therapy: insights from the CRT-NEXT trial.","published":"2026-08-21"}],"10.1016/j.cpcardiol.2026.103409":[{"url":"https://hartvaat.nl/2026/10/01/sglt2-remmers-geassocieerd-met-lagere-sterfte-bij-attr-cardiomyopathie-meta-anal/","title":"SGLT2-remmers geassocieerd met lagere sterfte bij ATTR-cardiomyopathie — meta-analyse","title_en":"Efficacy and tolerability of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy: A systematic review and stratified meta-analysis.","published":"2026-08-21"}],"10.1016/j.ijcha.2026.101981":[{"url":"https://hartvaat.nl/2026/10/01/voorgebruik-van-opioiden-verhoogt-sterfte-en-ziekenhuisopnames-na-tavi-deens-coh/","title":"Voorgebruik van opioïden verhoogt sterfte en ziekenhuisopnames na TAVI — Deens cohort","title_en":"Associated prognostic impact of opioid use before Transcatheter aortic valve implantation - A Danish nationwide cohort study.","published":"2026-08-21"}],"10.1080/08037051.2026.2715846":[{"url":"https://hartvaat.nl/2026/12/01/verhoogde-bloeddruk-bij-jonge-volwassenen-verdubbelt-sterftekans-nhanes-cohort/","title":"Verhoogde bloeddruk bij jonge volwassenen verdubbelt sterftekans — NHANES-cohort","title_en":"Burden of high blood pressure and associated risk for all-cause and cardiovascular mortality among US young adults.","published":"2026-08-21"}],"10.1007/s44313-026-00161-2":[{"url":"https://hartvaat.nl/2026/08/12/clonale-hematopoiese-voorspelt-nierfunctievermindering-en-sterfte-bij-cytopenie-/","title":"Clonale hematopoïese voorspelt nierfunctievermindering en sterfte bij cytopenie met chronische nierziekte","title_en":"Clonal hematopoietic mutations as a predictor of adverse outcomes in cytopenic patients with chronic kidney disease.","published":"2026-08-20"}],"10.2215/cjn.0000001168":[{"url":"https://hartvaat.nl/2026/08/12/romosozumab-vermindert-wervelfracturen-en-mace-bij-osteoporose-met-chronische-ni/","title":"Romosozumab vermindert wervelfracturen en MACE bij osteoporose met chronische nierziekte — TriNetX-cohort","title_en":"Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD: Target Trial Emulation Study.","published":"2026-08-20"}],"10.1371/journal.pmed.1005120":[{"url":"https://hartvaat.nl/2026/08/12/ivf-gebruik-niet-geassocieerd-met-hart-en-vaatziekten-behalve-herseninfarct/","title":"IVF-gebruik niet geassocieerd met hart- en vaatziekten — behalve herseninfarct","title_en":"Long-term risk of cardiovascular disease after assisted reproductive technology and infertility: A cohort study.","published":"2026-08-20"}],"10.1097/mol.0000000000001052":[{"url":"https://hartvaat.nl/2026/08/13/hdl-eiwitten-bepalen-cvd-en-ontstekingsrisico-onafhankelijk-van-hdl-c/","title":"HDL-eiwitten bepalen CVD- en ontstekingsrisico — onafhankelijk van HDL-C","title_en":"HDL-associated proteins affecting CVD and systemic inflammation.","published":"2026-08-20"}],"10.1111/ahg.70049":[{"url":"https://hartvaat.nl/2026/09/01/metformin-verlaagt-risico-op-buikaorta-aneurysma-mr-en-cohortanalyse/","title":"Metformin verlaagt risico op buikaorta-aneurysma — MR- en cohortanalyse","title_en":"Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets.","published":"2026-08-20"}],"10.1016/j.amjcard.2026.06.030":[{"url":"https://hartvaat.nl/2026/09/01/pre-existent-pfo-of-asd-verhoogt-risico-op-recidief-en-stroke-na-ablatie-bij-atr/","title":"Pre-existent PFO of ASD verhoogt risico op recidief en stroke na ablatie bij atriumfibrilleren","title_en":"Patients With Patent Foramen Ovale or Atrial Septal Defect Have Worse Outcomes After Pulmonary Vein Isolation.","published":"2026-08-19"}],"10.1097/aln.0000000000006139":[{"url":"https://hartvaat.nl/2026/09/01/perioperatieve-opioiden-bij-hartfalen-lokale-cardiale-routes-en-klinische-risico/","title":"Perioperatieve opioiden bij hartfalen: lokale cardiale routes en klinische risico’s","title_en":"Cardiac Opioid System and Its Role in Heart Failure and Ischemia-Reperfusion Injury.","published":"2026-08-19"}],"10.1212/wnl.0000000000218420":[{"url":"https://hartvaat.nl/2026/09/08/gepersonaliseerde-bloeddrukregeling-tijdens-thrombectomie-verbetert-functionele-/","title":"Gepersonaliseerde bloeddrukregeling tijdens thrombectomie verbetert functionele uitkomst niet — DETERMINE","title_en":"Individualized vs Standard Blood Pressure Control During Thrombectomy for Ischemic Stroke: The DETERMINE Randomized Clinical Trial.","published":"2026-08-19"}],"10.1080/07853890.2026.2715272":[{"url":"https://hartvaat.nl/2026/12/01/higs-score-voorspelt-pacemaker-implantatie-en-sterfte-na-tavi/","title":"HIGS-score voorspelt pacemaker-implantatie en sterfte na TAVI","title_en":"Association of the HIGS score with permanent pacemaker implantation and mortality after transcatheter aortic valve implantation.","published":"2026-08-19"}],"10.1080/07853890.2026.2705593":[{"url":"https://hartvaat.nl/2026/12/01/antitrombotica-veilig-bij-incidentele-ongescheurde-intracraniele-aneurysmas-na-i/","title":"Antitrombotica veilig bij incidentele ongescheurde intracraniële aneurysma’s na ischemisch beroerte","title_en":"Impact of antithrombotic therapy on outcomes of incidental unruptured intracranial aneurysms in patients with ischemic stroke.","published":"2026-08-19"}],"10.1007/s11897-026-00774-9":[{"url":"https://hartvaat.nl/2026/08/10/urine-albumine-en-natrium-hebben-prognostische-waarde-bij-hartfalen-experimentel/","title":"Urine-albumine en natrium hebben prognostische waarde bij hartfalen — experimentele biomarkers nog onvoldoende onderbouwd","title_en":"Urinary Biomarkers for the Risk Assessment and Management of Heart Failure: Pearls and Pitfalls.","published":"2026-08-18"}],"10.1007/s11883-026-01444-w":[{"url":"https://hartvaat.nl/2026/08/10/voedingspatronen-en-macronutrientenvervanging-verlagen-triglyceriden-bij-hypertr/","title":"Voedingspatronen en macronutriëntenvervanging verlagen triglyceriden bij hypertriglyceridemie","title_en":"Dietary Interventions for Hypertriglyceridemia.","published":"2026-08-18"}],"10.1016/j.shj.2026.101057":[{"url":"https://hartvaat.nl/2026/09/01/anemie-verergert-mortaliteit-en-hartfalenheropnames-na-tavr-bij-patienten-boven-/","title":"Anemie verergert mortaliteit en hartfalenheropnames na TAVR bij patiënten boven de 80 jaar","title_en":"The Impact of Anemia on Clinical Outcomes of Patients Above 80 Years Old Following Transcatheter Aortic Valve Replacement.","published":"2026-08-18"}],"10.1016/j.jns.2026.126100":[{"url":"https://hartvaat.nl/2026/10/15/posteriorcirculatie-infarcten-na-doorbraakstroke-op-anticoagulantia-duiden-op-sl/","title":"Posteriorcirculatie-infarcten na doorbraakstroke op anticoagulantia duiden op slechtere prognose","title_en":"Posterior versus anterior circulation infarct location and outcomes after breakthrough ischemic stroke in orally anticoagulated patients for atrial fibrillation: An ASPERA-R inverse probability-weighted analysis.","published":"2026-08-18"}],"10.1016/j.jns.2026.126125":[{"url":"https://hartvaat.nl/2026/10/15/vroege-bloeddrukverlaging-bij-acute-ischemische-stroke-verbetert-functioneel-her/","title":"Vroege bloeddrukverlaging bij acute ischemische stroke verbetert functioneel herstel niet — meta-analyse","title_en":"Early antihypertensive therapy in acute ischemic stroke: A Meta-analysis of randomized controlled trials.","published":"2026-08-18"}],"10.1080/0886022x.2026.2711459":[{"url":"https://hartvaat.nl/2026/12/01/ras-remmers-verlagen-risico-op-nieuwe-ckd-bij-diabetes-type-2-met-behoudende-nie/","title":"RAS-remmers verlagen risico op nieuwe CKD bij diabetes type 2 met behoudende nierfunctie","title_en":"Prevention of new-onset chronic kidney disease with renin-angiotensin system blockers in type 2 diabetes with preserved kidney function.","published":"2026-08-17"}],"10.1080/08037051.2026.2692239":[{"url":"https://hartvaat.nl/2026/12/01/positieve-levensorientatie-en-bloeddruk-bij-ouderen-nauwelijks-klinisch-relevant/","title":"Positieve levensoriëntatie en bloeddruk bij ouderen: nauwelijks klinisch relevant verband — TUVA/UTUVA","title_en":"Positive life orientation and blood pressure in older adults: evidence from two Finnish generational cohorts born 20 years apart.","published":"2026-08-17"}],"10.1080/08037051.2026.2702689":[{"url":"https://hartvaat.nl/2026/12/01/lage-richtlijnconformiteit-en-zorgcontinuiteit-bij-hypertensie-in-uruguay/","title":"Lage richtlijnconformiteit en zorgcontinuïteit bij hypertensie in Uruguay","title_en":"Health system competence and care continuity in patients with hypertension: electronic cohort in Uruguay.","published":"2026-08-17"}],"10.1080/07853890.2026.2703887":[{"url":"https://hartvaat.nl/2026/12/01/optimale-cardiometabole-gezondheid-tijdens-zwangerschap-verlaagt-risico-op-compl/","title":"Optimale cardiometabole gezondheid tijdens zwangerschap verlaagt risico op complicaties","title_en":"Gestational cardiovascular health and adverse pregnancy outcomes: a prospective cohort study in China.","published":"2026-08-17"}],"10.1080/10641963.2026.2712543":[{"url":"https://hartvaat.nl/2026/12/31/inter-enkel-bloeddrukverschil-correleert-met-microalbuminurie-bij-hypertensiepat/","title":"Inter-enkel bloeddrukverschil correleert met microalbuminurie bij hypertensiepatiënten","title_en":"Inter-ankle systolic blood pressure difference is associated with microalbuminuria in non-diabetic hypertension patients: A cross-sectional study from two cohorts.","published":"2026-08-17"}],"10.1007/s11886-026-02396-y":[{"url":"https://hartvaat.nl/2026/07/30/vad-implantatie-bij-enkelventrikelhart-overleving-verbetert-maar-complicaties-bl/","title":"VAD-implantatie bij enkelventrikelhart: overleving verbetert maar complicaties blijven frequent","title_en":"Ventricular Assist Device Use in Single Ventricle Heart Disease: Current Outcomes and Considerations.","published":"2026-08-16"}],"10.1007/s11886-026-02392-2":[{"url":"https://hartvaat.nl/2026/07/30/hfpef-bij-vrouwen-vereist-geslachtsspecifieke-diagnostiek-en-behandelstrategieen/","title":"HFpEF bij vrouwen vereist geslachtsspecifieke diagnostiek en behandelstrategieën","title_en":"Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes.","published":"2026-08-16"}],"10.1007/s00394-026-04068-7":[{"url":"https://hartvaat.nl/2026/07/30/visinname-en-visgerelateerde-metabolieten-geassocieerd-met-lagere-triglyceriden-/","title":"Visinname en visgerelateerde metabolieten geassocieerd met lagere triglyceriden en bloeddruk","title_en":"Association between fish-related metabolites and metabolic syndrome risk factors in Japan: INTERLIPID metabolome -wide association study.","published":"2026-08-16"}],"10.1093/eschf/xvag207":[{"url":"https://hartvaat.nl/2026/07/31/uit-het-hospitaal-hartstilstand-komt-12-keer-vaker-voor-bij-niet-ischemische-car/","title":"Uit-het-hospitaal hartstilstand komt 12 keer vaker voor bij niet-ischemische cardiomyopathie — registerstudie","title_en":"Incidence, Analysis and Risk of Out-of-Hospital Cardiac Arrest in Individuals with Non-Ischaemic Dilated Cardiomyopathy.","published":"2026-08-16"}],"10.1093/ndt/gfag023":[{"url":"https://hartvaat.nl/2026/07/31/finerenone-verhoogt-complete-nierremissie-bij-niet-diabetische-iga-nefropatie/","title":"Finerenone verhoogt complete nierremissie bij niet-diabetische IgA-nefropatie","title_en":"Efficacy and safety of finerenone in non-diabetic patients with IgA nephropathy.","published":"2026-08-16"}],"10.1536/ihj.25-558":[{"url":"https://hartvaat.nl/2026/07/31/15-mg-edoxaban-na-pci-bij-atriumfibrilleren-met-hoog-bloedingrisico-geen-superie/","title":"15 mg edoxaban na PCI bij atriumfibrilleren met hoog bloedingrisico — geen superieure uitkomst","title_en":"Efficacy of 15 mg Edoxaban on Long-Term Outcome after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and High Bleeding Risk.","published":"2026-08-15"}],"10.1097/md.0000000000050029":[{"url":"https://hartvaat.nl/2026/07/31/atenolol-vermindert-postoperatief-atriumfibrilleren-na-hartchirurgie/","title":"Atenolol vermindert postoperatief atriumfibrilleren na hartchirurgie","title_en":"A meta-analysis of randomized controlled trials on atenolol's impact on postoperative atrial fibrillation in adults undergoing cardiac surgery.","published":"2026-08-15"}],"10.1016/j.ijcha.2026.101980":[{"url":"https://hartvaat.nl/2026/10/01/sglt2-remmers-bij-zeer-oude-hartfalenpatienten-nierfunctie-en-palliatieve-zorg-b/","title":"SGLT2-remmers bij zeer oude hartfalenpatiënten: nierfunctie en palliatieve zorg bepalen voorschrijfpatroon","title_en":"SGLT2 inhibitor prescription at discharge in very old adults with heart failure irrespective of diabetes status.","published":"2026-08-15"}],"10.1016/j.pharmthera.2026.109089":[{"url":"https://hartvaat.nl/2026/10/01/biomarker-gestuurde-farmacotherapie-biedt-raamwerk-voor-precisiebehandeling-bij-/","title":"Biomarker-gestuurde farmacotherapie biedt raamwerk voor precisiebehandeling bij CKM-syndroom","title_en":"Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring.","published":"2026-08-15"}],"10.1016/j.alcohol.2026.07.003":[{"url":"https://hartvaat.nl/2026/09/01/drinkfrequentie-bepaalt-hdl-c-niveau-meer-dan-hoeveelheid-per-keer-troms-studie/","title":"Drinkfrequentie bepaalt HDL-C-niveau meer dan hoeveelheid per keer — Tromsø-studie","title_en":"The impact of drinking patterns on the relationship between alcohol use and levels of serum high-density lipoprotein cholesterol (HDL-C).","published":"2026-08-15"}],"10.1016/j.diabres.2026.113477":[{"url":"https://hartvaat.nl/2026/07/31/steilere-egfr-daling-voorspelt-nierfalen-en-cardiovasculaire-mortaliteit-narrati/","title":"Steilere eGFR-daling voorspelt nierfalen en cardiovasculaire mortaliteit — narratieve review","title_en":"Estimated glomerular filtration rate slope and clinical outcomes: a narrative review.","published":"2026-08-14"}],"10.1016/j.diabres.2026.113476":[{"url":"https://hartvaat.nl/2026/07/31/verhoogde-serumketonen-verlagen-niercomplicaties-bij-type-2-diabetes-prospectief/","title":"Verhoogde serumketonen verlagen niercomplicaties bij type 2-diabetes — prospectief cohort","title_en":"Serum ketone body levels and risk of incident kidney and cardiovascular events among patients with type 2 diabetes: a prospective cohort study.","published":"2026-08-14"}],"10.5830/cvja-2026-021":[{"url":"https://hartvaat.nl/2026/07/31/hoge-serumbicarbonaat-bij-opname-voorspelt-diuretische-resistentie-bij-acute-har/","title":"Hoge serumbicarbonaat bij opname voorspelt diuretische resistentie bij acute hartfalenexacerbatie","title_en":"Admission serum bicarbonate is associated with early diuretic resistance in acute decompensated heart failure.","published":"2026-08-14"}],"10.1097/md.0000000000050040":[{"url":"https://hartvaat.nl/2026/07/31/ontstekingsrijke-voeding-verhoogt-sterfterisico-bij-ckm-syndroom-nhanes-cohort/","title":"Ontstekingsrijke voeding verhoogt sterfterisico bij CKM-syndroom — NHANES-cohort","title_en":"Associations of dietary inflammatory and antioxidant indices with mortality in adults with cardiovascular-kidney-metabolic syndrome: A mediation analysis.","published":"2026-08-14"}],"10.2196/84506":[{"url":"https://hartvaat.nl/2026/07/31/draagbare-sensoren-voor-comorbiditeit-osa-en-hypertensie-huidige-stand-van-zaken/","title":"Draagbare sensoren voor comorbiditeit OSA en hypertensie: huidige stand van zaken en beperkingen","title_en":"Wearable Devices for Monitoring and Management of Comorbid Obstructive Sleep Apnea and Hypertension: Scoping Review.","published":"2026-08-14"}],"10.7759/cureus.111723":[{"url":"https://hartvaat.nl/2026/06/01/glp-1-agonisten-verlagen-mace-met-14-bij-diabetes-type-2-meta-analyse/","title":"GLP-1-agonisten verlagen MACE met 14% bij diabetes type 2 — meta-analyse","title_en":"Comparative Cardiovascular Outcomes and Safety Profiles of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Trials.","published":"2026-08-13"}],"10.7759/cureus.111728":[{"url":"https://hartvaat.nl/2026/06/01/glp-1-polyagonisten-verbeteren-leverhistologie-en-vetgehalte-bij-masld-mash-meta/","title":"GLP-1-polyagonisten verbeteren leverhistologie en vetgehalte bij MASLD/MASH — meta-analyse","title_en":"Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.","published":"2026-08-13"}],"10.56434/j.arch.esp.urol.20267905.87":[{"url":"https://hartvaat.nl/2026/06/01/cardiovasculair-risico-van-adt-en-arpi-s-bij-prostaatkanker-narrative-review/","title":"Cardiovasculair risico van ADT en ARPI's bij prostaatkanker — narrative review","title_en":"Androgen Deprivation Therapy and Cardiovascular Health: Challenges and Opportunities in Prostate Cancer Care.","published":"2026-08-13"}],"10.1007/s12055-026-02245-1":[{"url":"https://hartvaat.nl/2026/09/01/tavr-met-ballon-expanderbare-klep-heeft-vergelijkbare-overleving-en-minder-compl/","title":"TAVR met ballon-expanderbare klep heeft vergelijkbare overleving en minder complicaties dan chirurgische vervanging bij laag-risico aortastenose","title_en":"Transcatheter versus surgical aortic valve replacement for severe aortic stenosis in low-risk adults: a network meta-analysis.","published":"2026-08-13"}],"10.1007/s12055-026-02240-6":[{"url":"https://hartvaat.nl/2026/09/01/perioperatieve-empagliflozin-verlaagt-trend-postoperatieve-boezemfibrilleren-na-/","title":"Perioperatieve empagliflozin verlaagt trend postoperatieve boezemfibrilleren na klepsurgery — RCT","title_en":"Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart valve surgery: a double-blind, randomized, placebo-controlled trial.","published":"2026-08-13"}],"10.3760/cma.j.cn121430-20260108-00018":[{"url":"https://hartvaat.nl/2026/06/01/vis-score-voorspelt-28-daagse-mortaliteit-bij-atriumfibrilleren-met-hemodynamisc/","title":"VIS-score voorspelt 28-daagse mortaliteit bij atriumfibrilleren met hemodynamische instabiliteit op de IC","title_en":"[Predictive value of the Vasoactive Inotropic Score for 28-day mortality in patients with atrial fibrillation-related hemodynamic deterioration in the intensive care unit].","published":"2026-08-12"}],"10.7759/cureus.111767":[{"url":"https://hartvaat.nl/2026/06/01/oudere-stemi-patienten-hebben-meer-complicaties-en-hogere-sterfte-dan-jongeren-e/","title":"Oudere STEMI-patiënten hebben meer complicaties en hogere sterfte dan jongeren — een prospectieve cohortstudie","title_en":"Comparison of In-Hospital Outcomes of Acute ST Segment Elevation Myocardial Infarction in Young Versus Older Patients.","published":"2026-08-12"}],"10.1093/europace/euag139":[{"url":"https://hartvaat.nl/2026/06/02/smartphone-app-voor-symptoomregistratie-na-ablatie-bij-atriumfibrilleren-isolati/","title":"Smartphone-app voor symptoomregistratie na ablatie bij atriumfibrilleren — ISOLATION","title_en":"Symptom severity assessment in patients with atrial fibrillation after catheter ablation using a smartphone application.","published":"2026-08-12"}],"10.1093/europace/euag152":[{"url":"https://hartvaat.nl/2026/06/02/pulsfield-ablatie-levert-betere-vrijwaring-van-recidief-dan-cryoballoon-bij-paro/","title":"Pulsfield-ablatie levert betere vrijwaring van recidief dan cryoballoon bij paroxysmale AF — SINGLE SHOT CHAMPION","title_en":"Autonomic effects and ablation success after pulsed field and cryoballoon ablation: a SINGLE SHOT CHAMPION substudy.","published":"2026-08-12"}],"10.1093/europace/euag073":[{"url":"https://hartvaat.nl/2026/06/02/vroege-katheterablatie-even-effectief-als-antiaritmica-bij-ischemische-ventricul/","title":"Vroege katheterablatie even effectief als antiaritmica bij ischemische ventriculaire tachycardie — meta-analyse","title_en":"Early catheter ablation vs. antiarrhythmic drugs in treatment-naïve ischaemic ventricular tachyarrhythmias: a meta-analysis of randomized controlled trials.","published":"2026-08-12"}],"10.1093/europace/euag143":[{"url":"https://hartvaat.nl/2026/06/02/catheterablatie-bij-atriumfibrilleren-in-cardiale-amyloidose-levert-42-ritmievri/","title":"Catheterablatie bij atriumfibrilleren in cardiale amyloïdose levert 42% ritmievrije patiënten op — AMYL-AF","title_en":"Catheter ablation of atrial fibrillation in transthyretin and light-chain cardiac amyloidosis: results from the multicentre AMYL-AF study.","published":"2026-08-11"}],"10.1093/europace/euag132":[{"url":"https://hartvaat.nl/2026/06/02/autonoom-remodelling-vormt-onafhankelijk-domein-binnen-atriale-cardiomyopathie/","title":"Autonoom remodelling vormt onafhankelijk domein binnen atriale cardiomyopathie","title_en":"Atrial cardiomyopathy as a multidomain disease: longitudinal evidence for autonomic remodelling.","published":"2026-08-11"}],"10.1093/europace/euag151":[{"url":"https://hartvaat.nl/2026/06/02/doac-gebruik-na-ablatie-voor-atriumfibrilleren-aanhouderij-daalt-na-drie-jaar/","title":"DOAC-gebruik na ablatie voor atriumfibrilleren: aanhouderij daalt na drie jaar","title_en":"Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study.","published":"2026-08-11"}],"10.21542/gcsp.2026.26":[{"url":"https://hartvaat.nl/2026/06/30/catheterablatie-verlaagt-sterfte-en-complicaties-bij-af-in-cardiale-amyloidose-t/","title":"Catheterablatie verlaagt sterfte en complicaties bij AF in cardiale amyloïdose — TriNetX-cohort","title_en":"Catheter ablation versus no ablation for atrial fibrillation in cardiac amyloidosis: a propensity-matched cohort study.","published":"2026-08-11"}],"10.21542/gcsp.2026.25":[{"url":"https://hartvaat.nl/2026/06/30/vutrisiran-remt-ttr-en-vermindert-valrisico-bij-attr-cardiomyopathie-meta-analys/","title":"Vutrisiran remt TTR en vermindert valrisico bij ATTR-cardiomyopathie — meta-analyse","title_en":"Clinical outcomes with vutrisiran in transthyretin amyloidosis: a systematic review and meta-analysis of randomized trials.","published":"2026-08-11"}],"10.1093/fampra/cmag050":[{"url":"https://hartvaat.nl/2026/06/11/longultrasongrafie-onthult-subklinische-longcongestie-bij-stabiele-hfpef-in-de-h/","title":"Longultrasongrafie onthult subklinische longcongestie bij stabiele HFpEF in de huisartspraktijk","title_en":"Pulmonary congestion assessed by lung ultrasound in stable ambulatory patients with heart failure and preserved ejection fraction in primary care.","published":"2026-08-10"}],"10.1093/eschf/xvag145":[{"url":"https://hartvaat.nl/2026/06/13/ml-modellen-voorspellen-sterfte-bij-post-cardiotomisch-shock-op-ecmo-elso-regist/","title":"ML-modellen voorspellen sterfte bij post-cardiotomisch shock op ECMO — ELSO-registry","title_en":"Machine Learning Based Prediction of Hospital Mortality in Post-Cardiotomy Cardiogenic Shock with Mechanical Support.","published":"2026-08-10"}],"10.3791/70890":[{"url":"https://hartvaat.nl/2026/06/16/rivaroxaban-verlaagt-dvt-risico-na-gewrichtsvervanging-maar-verhoogt-bloedingen/","title":"Rivaroxaban verlaagt DVT-risico na gewrichtsvervanging, maar verhoogt bloedingen","title_en":"Multifactorial Risk Assessment and Anticoagulation Strategy Optimization for Deep Vein Thrombosis After Major Joint Surgery: A Retrospective Study.","published":"2026-08-10"}],"10.1093/ndt/gfag135":[{"url":"https://hartvaat.nl/2026/06/19/vrouwen-met-ckd-krijgen-minder-vaak-ras-remmers-en-sglt2-remmers-dan-mannen/","title":"Vrouwen met CKD krijgen minder vaak RAS-remmers en SGLT2-remmers dan mannen","title_en":"Sex disparities in receiving evidence-based medications in patients with CKD.","published":"2026-08-10"}],"10.1093/eschf/xvag172":[{"url":"https://hartvaat.nl/2026/06/22/cardiale-amyloidose-komt-frequent-voor-bij-hfpef-aortastenose-en-lvh-meta-analys/","title":"Cardiale amyloïdose komt frequent voor bij HFpEF, aortastenose en LVH — meta-analyse","title_en":"Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis.","published":"2026-08-10"}],"10.1093/ndt/gfag142":[{"url":"https://hartvaat.nl/2026/06/23/zwangerschapsgeassocieerd-acuut-nierfalen-pathofysiologie-en-verhoogd-langetermi/","title":"Zwangerschapsgeassocieerd acuut nierfalen: pathofysiologie en verhoogd langetermijnrisico op hart- en vaatziekten","title_en":"Pathophysiology of pregnancy-associated acute kidney injury.","published":"2026-08-09"}],"10.3390/jcdd13070291":[{"url":"https://hartvaat.nl/2026/06/23/lifestyle-modificatie-en-metabole-therapieen-bij-cardiometabole-hfpef-overzicht/","title":"Lifestyle-modificatie en metabole therapieën bij cardiometabole HFpEF — overzicht","title_en":"Cardiometabolic Heart Failure with Preserved Ejection Fraction (HFpEF): Epidemiology, Mechanisms, and the Role of Lifestyle Modification.","published":"2026-08-09"}],"10.3390/medicina62071213":[{"url":"https://hartvaat.nl/2026/06/23/rhbnp-therapie-vermindert-congestie-en-dyspnoe-bij-rechterhartfalen-door-longhyp/","title":"rhBNP-therapie vermindert congestie en dyspnoe bij rechterhartfalen door longhypertensie","title_en":"Retrospective Evaluation of Recombinant Human Brain Natriuretic Peptide Therapy for Decompensated Right Heart Failure Across Pulmonary Hypertension Groups.","published":"2026-08-09"}],"10.3390/biom16070927":[{"url":"https://hartvaat.nl/2026/06/23/vldl-en-hdl-tg-verhoogd-bij-overgewicht-bij-kinderen-geavanceerd-lipoproteinepro/","title":"VLDL en HDL-tg verhoogd bij overgewicht bij kinderen — geavanceerd lipoproteïneprofiel toont extra informatie","title_en":"Composition and Characterization of the Different Lipoproteins in Overweight/Obese Children vs. Normal-Weight Children.","published":"2026-08-09"}],"10.1016/j.jacl.2026.06.016":[{"url":"https://hartvaat.nl/2026/06/26/inclisiran-als-monotherapie-verlaagt-ldl-c-met-47-5-in-chinese-volwassenen-victo/","title":"Inclisiran als monotherapie verlaagt LDL-C met 47,5% in Chinese volwassenen — VICTORION-Mono","title_en":"Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial.","published":"2026-08-09"}],"10.3390/nu18132062":[{"url":"https://hartvaat.nl/2026/06/24/meer-kip-dan-rundvlees-of-vis-bij-avondmaaltijd-gekoppeld-aan-grotere-bloeddrukd/","title":"Meer kip dan rundvlees of vis bij avondmaaltijd gekoppeld aan grotere bloeddrukdaling — MED-HDP","title_en":"Observational Assessments of Chicken, Beef, and Seafood Proportions with a Mediterranean-Style Healthy Dietary Pattern and Cardiovascular Risk Factor Changes: Post Hoc Analysis of a Controlled Feeding Trial.","published":"2026-08-08"}],"10.3390/medicina62071224":[{"url":"https://hartvaat.nl/2026/06/24/vexus-scoring-biedt-completer-beeld-van-congestie-bij-hartfalen/","title":"VExUS-scoring biedt completer beeld van congestie bij hartfalen","title_en":"Rethinking Congestion in Heart Failure from Volume Overload to Venous Pressure and Organ Disfunction with VExUS.","published":"2026-08-08"}],"10.3390/medicina62071222":[{"url":"https://hartvaat.nl/2026/06/24/sglt2-remmers-en-bloeddrukdoelen-bij-hypertensief-hfpef-een-overzicht-van-richtl/","title":"SGLT2-remmers en bloeddrukdoelen bij hypertensief HFpEF — een overzicht van richtlijnen en bewijs","title_en":"Hypertensive Heart Failure with Preserved Ejection Fraction: Guidelines vs. Randomized Controlled Trials Evidence Gaps.","published":"2026-08-08"}],"10.3892/mmr.2026.13974":[{"url":"https://hartvaat.nl/2026/10/01/parodontitis-kan-via-systemische-ontsteking-bijdragen-aan-hartfalen-narratieve-r/","title":"Parodontitis kan via systemische ontsteking bijdragen aan hartfalen — narratieve review","title_en":"Association between periodontitis and heart failure: Mechanisms and clinical implications (Review).","published":"2026-08-08"}],"10.1016/j.ijcard.2026.134660":[{"url":"https://hartvaat.nl/2026/10/15/lage-voorspelde-adherentie-verhoogt-stroke-risico-bij-af-patienten-die-starten-m/","title":"Lage voorspelde adherentie verhoogt stroke-risico bij AF-patiënten die starten met orale anticoagulatie","title_en":"Predicted adherence and ischaemic stroke risk in atrial fibrillation patients initiating oral anticoagulation: A cohort study of the medication adherence score.","published":"2026-08-08"}],"10.1016/j.ijcard.2026.134664":[{"url":"https://hartvaat.nl/2026/10/15/ice-gestuurde-laac-toont-lage-stroke-en-bloedingsrisicos-op-lange-termijn/","title":"ICE-gestuurde LAAC toont lage stroke- en bloedingsrisico’s op lange termijn","title_en":"Long-term outcomes of ICE-guided left atrial appendage occlusion from a large single-center experience.","published":"2026-08-07"}],"10.1016/j.ecl.2026.04.007":[{"url":"https://hartvaat.nl/2026/09/01/cardiorenale-bescherming-door-sglt2-remmers-glp-1-agonisten-en-mra-s-bij-type-1-/","title":"Cardiorenale bescherming door SGLT2-remmers, GLP-1-agonisten en MRA's bij type 1-diabetes","title_en":"Emerging Evidence for Cardiorenal Protection with Sodium-Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes.","published":"2026-08-07"}],"10.1016/j.ecl.2026.04.001":[{"url":"https://hartvaat.nl/2026/09/01/naast-insuline-zijn-nieuwe-medicijnen-nodig-om-het-hart-en-vaatrisico-bij-type-1/","title":"Naast insuline zijn nieuwe medicijnen nodig om het hart- en vaatrisico bij type 1-diabetes te verlagen","title_en":"Beyond Insulin: Why Type 1 Diabetes Mellitus Needs More?","published":"2026-08-07"}],"10.1016/j.ecl.2026.04.004":[{"url":"https://hartvaat.nl/2026/09/01/cardiorenale-risicos-bij-type-1-diabetes-een-overzicht-van-de-huidige-stand-van-/","title":"Cardiorenale risico’s bij type 1-diabetes — een overzicht van de huidige stand van zaken","title_en":"Current State of Cardiorenal Disease in People with Type 1 Diabetes.","published":"2026-08-07"}],"10.1016/j.ecl.2026.04.015":[{"url":"https://hartvaat.nl/2026/09/01/sglt2-remmers-glp-1-agonisten-en-finerenone-voor-nierbescherming-bij-type-1-diab/","title":"SGLT2-remmers, GLP-1-agonisten en finerenone voor nierbescherming bij type 1-diabetes","title_en":"Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes.","published":"2026-08-07"}],"10.1093/eschf/xvag185":[{"url":"https://hartvaat.nl/2026/06/26/machine-learning-voorspelt-diureticumrespons-bij-acuut-hartfalen-drc-ahf/","title":"Machine learning voorspelt diureticumrespons bij acuut hartfalen — DRC-AHF","title_en":"A Machine-Learning Model for Accurate Diuresis Prediction in Acute Heart Failure (DRC-AHF).","published":"2026-08-06"}],"10.1093/ndt/gfag150":[{"url":"https://hartvaat.nl/2026/06/26/finerenone-verlaagt-hart-en-vaatrisico-via-vroege-daling-van-uacr-en-systolische/","title":"Finerenone verlaagt hart- en vaatrisico via vroege daling van UACR en systolische bloeddruk — FIDELITY-analyse","title_en":"Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD.","published":"2026-08-06"}],"10.1016/j.pharmr.2026.100150":[{"url":"https://hartvaat.nl/2026/06/26/peptidehormooncombinaties-bieden-superieure-effectiviteit-bij-metabole-multimorb/","title":"Peptidehormooncombinaties bieden superieure effectiviteit bij metabole multimorbiditeit","title_en":"Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases.","published":"2026-08-06"}],"10.3390/pharmacy14040091":[{"url":"https://hartvaat.nl/2026/06/26/sglt2-remmers-kunnen-hyperkaliemie-gerelateerd-stoppen-van-raas-remmers-voorkome/","title":"SGLT2-remmers kunnen hyperkaliëmie-gerelateerd stoppen van RAAS-remmers voorkomen bij MRA-gebruik","title_en":"Sodium-Glucose Co-Transporter 2 Inhibitors and Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors During Mineralocorticoid Receptor Antagonist Therapy: A Real-World Cohort Study.","published":"2026-08-06"}],"10.1016/j.jacl.2026.06.017":[{"url":"https://hartvaat.nl/2026/06/26/correctie-van-ldl-c-voor-lipoproteine-a-verbetert-diagnose-familiaire-hyperchole/","title":"Correctie van LDL-C voor lipoproteïne(a) verbetert diagnose familiaire hypercholesterolemie","title_en":"Improved diagnosis of familial hypercholesterolemia by correcting LDL-C for lipoprotein(a) in a German cohort.","published":"2026-08-06"}],"10.3390/medicina62071246":[{"url":"https://hartvaat.nl/2026/06/27/laag-cachexie-index-voorspelt-overleving-en-heropname-bij-hartfalenpatienten/","title":"Laag cachexie-index voorspelt overleving en heropname bij hartfalenpatiënten","title_en":"The Prognostic Impact of the Cachexia Index in Patients Hospitalized with Heart Failure.","published":"2026-08-05"}],"10.3390/biomedicines14071478":[{"url":"https://hartvaat.nl/2026/06/29/functioneel-nierreservoir-als-aanvulling-op-kdigo-cga-bij-chronische-nierziekte/","title":"Functioneel nierreservoir als aanvulling op KDIGO-CGA bij chronische nierziekte","title_en":"Renal Functional Reserve-Informed Personalized Renoprotection in Chronic Kidney Disease: A Proposed Extension of the KDIGO CGA Framework.","published":"2026-08-05"}],"10.1016/j.lana.2026.101571":[{"url":"https://hartvaat.nl/2026/10/01/dapagliflozin-kosteneffectief-bij-chronisch-hartfalen-economische-evaluatie-in-a/","title":"Dapagliflozin kosteneffectief bij chronisch hartfalen — economische evaluatie in Argentinië","title_en":"Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis.","published":"2026-08-05"}],"10.1016/j.xjse.2026.100123":[{"url":"https://hartvaat.nl/2026/09/01/hogere-ziekenhuisvolumes-verbeteren-efficientie-bij-transcarotide-tavr-maar-mort/","title":"Hogere ziekenhuisvolumes verbeteren efficiëntie bij transcarotide TAVR — maar mortaliteit blijft gelijk","title_en":"Hospital volume and efficiency in transcarotid transcatheter aortic valve replacement: Insights from a national database of 10,000+ cases.","published":"2026-08-05"}],"10.1016/j.ogc.2026.04.003":[{"url":"https://hartvaat.nl/2026/09/01/menopauze-en-cardiovasculaire-veroudering-preventiekansen-in-de-middenleeftijd/","title":"Menopauze en cardiovasculaire veroudering: preventiekansen in de middenleeftijd","title_en":"The Menopausal Transition and Cardiovascular Aging: Implications for Prevention in Midlife.","published":"2026-08-05"}],"10.1093/eschf/xvag178":[{"url":"https://hartvaat.nl/2026/06/27/frailte-versnelt-hartfalenprogressie-en-vermindert-therapietolerantie/","title":"Frailte versnelt hartfalenprogressie en vermindert therapietolerantie","title_en":"Frailty and Heart Failure: An Integrated Review of a Bidirectional Relationship.","published":"2026-08-04"}],"10.3390/life16071075":[{"url":"https://hartvaat.nl/2026/06/27/tavr-bij-patienten-65-jaar-hogere-sterfte-en-heropnames-dan-chirurgie-maar-onvol/","title":"TAVR bij patiënten ≤65 jaar: hogere sterfte en heropnames dan chirurgie, maar onvoldoende bewijs — overzicht","title_en":"Transcatheter Aortic Valve Replacement in Patients Aged 65 Years and Younger: Unresolved Issues and Future Directions.","published":"2026-08-04"}],"10.3390/medicina62071257":[{"url":"https://hartvaat.nl/2026/06/29/familiaire-hypercholesterolemie-en-hypertriglyceridemie-nieuw-diagnostisch-algor/","title":"Familiaire hypercholesterolemie en hypertriglyceridemie: nieuw diagnostisch algoritme combineert genetica, ApoB en Lp(a)","title_en":"From Phenotype to Genotype and Beyond: Insights into Familial Hypercholesterolemia and Familial Hypertriglyceridemia.","published":"2026-08-04"}],"10.3390/pathogens15070697":[{"url":"https://hartvaat.nl/2026/06/30/infectieuze-endocarditis-verschuiving-naar-oudere-patienten-met-comorbiditeiten-/","title":"Infectieuze endocarditis: verschuiving naar oudere patiënten met comorbiditeiten en medische hulpmiddelen","title_en":"Changing Patterns in Infective Endocarditis: A Contemporary Epidemiological Perspective.","published":"2026-08-04"}],"10.1016/j.jhsg.2026.100952":[{"url":"https://hartvaat.nl/2026/05/01/hartfalen-als-belangrijkste-risicofactor-voor-amyloidose-bij-carpaaltunnelsyndro/","title":"Hartfalen als belangrijkste risicofactor voor amyloidose bij carpaaltunnelsyndroom","title_en":"Carpal Tunnel Syndrome and Other Predictors of Amyloidosis.","published":"2026-08-04"}],"10.1016/j.transci.2026.104483":[{"url":"https://hartvaat.nl/2026/08/01/lipoproteine-afseparatie-bij-refractaire-fh-en-lp-a-verschuivende-rol-naar-vaat-/","title":"Lipoproteïne-afseparatie bij refractaire FH en Lp(a) — verschuivende rol naar vaat- en nierziekten","title_en":"Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease.","published":"2026-08-03"}],"10.1007/s11886-026-02384-2":[{"url":"https://hartvaat.nl/2026/06/27/oac-monotherapie-is-superieur-aan-combinatie-met-antiplatelets-bij-stabiele-ccs-/","title":"OAC-monotherapie is superieur aan combinatie met antiplatelets bij stabiele CCS en atriumfibrilleren","title_en":"Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.","published":"2026-08-03"}],"10.3390/s26134103":[{"url":"https://hartvaat.nl/2026/06/28/cryoballoonablatie-resulteert-in-meer-linkeratrium-uitzetting-dan-radiofrequente/","title":"Cryoballoonablatie resulteert in meer linkeratrium-uitzetting dan radiofrequente ablatie na longaderisolatie","title_en":"Left Atrial Structural and Functional Changes After Pulmonary Vein Isolation Using Different Energy Sources.","published":"2026-08-03"}],"10.1093/eurheartj/ehag500":[{"url":"https://hartvaat.nl/2026/06/29/nieuwe-universele-definitie-van-hartfalen-vervangt-vaste-ef-cutoffs-door-verbete/","title":"Nieuwe universele definitie van hartfalen vervangt vaste EF-cutoffs door verbeterde, behouden en verminderde fenotypes","title_en":"AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).","published":"2026-08-03"}],"10.1093/ndt/gfaf252":[{"url":"https://hartvaat.nl/2026/06/30/kfre-aangepast-voor-multimorbiditeit-verbetert-schatting-nierfalenrisico/","title":"KFRE aangepast voor multimorbiditeit verbetert schatting nierfalenrisico","title_en":"The kidney failure risk equation in people with CKD and multimorbidity: the effect of competing mortality risks.","published":"2026-08-03"}],"10.1093/ndt/gfaf265":[{"url":"https://hartvaat.nl/2026/06/30/icodextrin-verlaagt-sterfte-en-mace-bij-dialysepatienten-met-hartfalen/","title":"Icodextrin verlaagt sterfte en MACE bij dialysepatiënten met hartfalen","title_en":"The effect of icodextrin on peritoneal dialysis patients with congestive heart failure: a time-varying exposure design and target trial emulation approach.","published":"2026-08-02"}],"10.1093/ndt/gfag003":[{"url":"https://hartvaat.nl/2026/06/30/combinatietherapie-met-vier-pilaren-verlaagt-nierfalenrisico-bij-ckd/","title":"Combinatietherapie met vier pilaren verlaagt nierfalenrisico bij CKD","title_en":"Trends in nephrology: from \"supportive care\" to CKD combination therapy.","published":"2026-08-02"}],"10.1016/j.atherosclerosis.2026.120823":[{"url":"https://hartvaat.nl/2026/08/01/verhoogde-lp-a-komt-vaker-voor-bij-kinderen-met-familiaire-hypercholesterolemie-/","title":"Verhoogde Lp(a) komt vaker voor bij kinderen met familiaire hypercholesterolemie — systematische review","title_en":"Distribution of Lipoprotein(a) concentrations in children and young people with Familial Hypercholesterolemia (FH) compared to those without FH: A systematic review and narrative synthesis.","published":"2026-08-02"}],"10.1016/j.ijcrp.2026.200681":[{"url":"https://hartvaat.nl/2026/09/01/combinatie-glp-1ra-en-sglt2-remmer-verlaagt-hartritmestoornissen-bij-niet-diabet/","title":"Combinatie GLP-1RA en SGLT2-remmer verlaagt hartritmestoornissen bij niet-diabetische obese patiënten","title_en":"Combination GLP-1 receptor agonist and SGLT2 inhibitor therapy versus GLP-1 receptor agonist monotherapy on arrhythmia outcomes in non-diabetic obese patients: A real-world time-dependent analysis.","published":"2026-08-02"}],"10.1016/j.ekir.2026.106686":[{"url":"https://hartvaat.nl/2026/09/01/hydrocortison-verhoogt-sterfte-en-cardiorenale-uitkomsten-bij-ckd-met-septische-/","title":"Hydrocortison verhoogt sterfte en cardiorenale uitkomsten bij CKD met septische shock","title_en":"Hydrocortisone Use for Septic Shock in Patients With CKD.","published":"2026-08-02"}],"10.69097/43-03-2026-09":[{"url":"https://hartvaat.nl/2026/06/30/sglt2-remmers-breiden-indicatie-uit-naar-niet-diabetische-nier-en-hartfalenziekt/","title":"SGLT2-remmers breiden indicatie uit naar niet-diabetische nier- en hartfalenziekte","title_en":"[Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): A Therapeutic Revolution Beyond Diabetes. New Indications in Non-Diabetic Chronic Kidney Disease and Heart Failure].","published":"2026-08-01"}],"10.1093/sxmrev/qeag046":[{"url":"https://hartvaat.nl/2026/06/30/erectiestoornis-komt-bij-twee-op-drie-hypertensieve-mannen-voor-in-afrika-meta-a/","title":"Erectiestoornis komt bij twee op drie hypertensieve mannen voor in Afrika — meta-analyse","title_en":"Prevalence of erectile dysfunction and its associated factors among hypertensive men in Africa: a systematic review and meta-analysis.","published":"2026-08-01"}],"10.25122/jml-2026-0071":[{"url":"https://hartvaat.nl/2026/05/01/spect-en-cmri-bij-attr-cardiomyopathie-beeldvorming-toont-beperkte-segmentale-na/","title":"SPECT en cMRI bij ATTR-cardiomyopathie: beeldvorming toont beperkte segmentale nauwkeurigheid","title_en":"Segmental and global amyloid burden and myocardial mechanics: a multimodality imaging comparison.","published":"2026-08-01"}],"10.1016/j.rpth.2026.106801":[{"url":"https://hartvaat.nl/2026/05/01/inr-zelftest-verbetert-ttr-en-vermindert-bloedingen-bij-patienten-met-atriumfibr/","title":"INR-zelftest verbetert TTR en vermindert bloedingen bij patiënten met atriumfibrilleren","title_en":"Self-testing and clinical outcomes in Black and White patients on warfarin for atrial fibrillation or venous thromboembolism.","published":"2026-08-01"}],"10.1080/03007995.2026.2692171":[{"url":"https://hartvaat.nl/2026/05/01/cardioselectieve-betablokkers-veilig-en-nuttig-bij-copd-systematische-review/","title":"Cardioselectieve bètablokkers veilig en nuttig bij COPD — systematische review","title_en":"Therapeutic use of cardioselective beta-blockers for patients with chronic obstructive pulmonary disease: a review of current clinical evidence.","published":"2026-08-01"}],"10.1093/eschf/xvag161":[{"url":"https://hartvaat.nl/2026/05/05/grote-variatie-in-diureticabeleid-en-zeldzame-natriummeting-bij-acuut-hartfalen/","title":"Grote variatie in diureticabeleid en zeldzame natriummeting bij acuut hartfalen","title_en":"Reported decision-making regarding diuretic use and urinary sodium monitoring in acute heart failure: a vignette-based survey in three European countries.","published":"2026-07-31"}],"10.1093/eschf/xvag163":[{"url":"https://hartvaat.nl/2026/05/05/perifere-zuurstofextractie-bepaalt-belasting-bij-arrhythmogene-cardiomyopathie-f/","title":"Perifere zuurstofextractie bepaalt belasting bij arrhythmogene cardiomyopathie — fysiologisch pleidooi voor veilige training","title_en":"Oxygen utilization during moderate-intensity resistance and aerobic exercise in arrhythmogenic cardiomyopathy: the central role of the periphery.","published":"2026-07-31"}],"10.1016/j.ccm.2026.04.014":[{"url":"https://hartvaat.nl/2026/09/01/langdurige-lvad-behandeling-klinisch-beheer-en-uitkomsten-in-de-heartmate-3-erat/","title":"Langdurige LVAD-behandeling: klinisch beheer en uitkomsten in de HeartMate 3-eratie","title_en":"Permanent Left Ventricular Assist Devices: Long-Term Management and Outcomes.","published":"2026-07-31"}],"10.1016/j.ccm.2026.04.015":[{"url":"https://hartvaat.nl/2026/09/01/lvad-patienten-op-de-intensive-care-richtlijnen-voor-monitoring-en-acute-zorg/","title":"LVAD-patiënten op de intensive care: richtlijnen voor monitoring en acute zorg","title_en":"The Left Ventricular Assist Device Patient in the Intensive Care Unit: A Clinically Focused Guide for Intensivists.","published":"2026-07-31"}],"10.1016/j.ccm.2026.04.016":[{"url":"https://hartvaat.nl/2026/09/01/lvad-beheer-in-de-icu-praktische-richtlijnen-voor-intensivisten/","title":"LVAD-beheer in de ICU — praktische richtlijnen voor intensivisten","title_en":"Device Management of Patients on Left Ventricular Assist Device Support: A Practical Review for the ICU Clinician.","published":"2026-07-31"}],"10.1093/eschf/xvag162":[{"url":"https://hartvaat.nl/2026/05/05/off-label-dosering-van-sacubitril-valsartan-wijdverspreid-in-de-praktijk/","title":"Off-label dosering van sacubitril-valsartan wijdverspreid in de praktijk","title_en":"Global trend and predictors of non-labelled sacubitril-valsartan dosing: results from IKNOW-HF survey.","published":"2026-07-30"}],"10.1093/eschf/xvag101":[{"url":"https://hartvaat.nl/2026/05/05/apture-shunt-verlaagt-hartfalen-heropnames-bij-patienten-met-hfpef-hfmref-alt-fl/","title":"APTURE-shunt verlaagt hartfalen-heropnames bij patiënten met HFpEF/HFmrEF — ALT-FLOW","title_en":"Predicted versus observed outcomes in the ALT-FLOW early feasibility study.","published":"2026-07-30"}],"10.1093/eschf/xvag160":[{"url":"https://hartvaat.nl/2026/05/05/cmr-parameters-voorspellen-nieuwe-hartklachten-bij-hypertrofische-cardiomyopathi/","title":"CMR-parameters voorspellen nieuwe hartklachten bij hypertrofische cardiomyopathie","title_en":"Cardiac magnetic resonance imaging parameters predict new-onset symptoms of heart failure in hypertrophic cardiomyopathy.","published":"2026-07-30"}],"10.1093/eschf/xvag167":[{"url":"https://hartvaat.nl/2026/05/05/harttransplantatie-bij-hoogste-urgentie-meer-vroege-infecties-en-sterfte-mede-do/","title":"Harttransplantatie bij hoogste urgentie: meer vroege infecties en sterfte, mede door langdurige beademing","title_en":"High-urgency heart transplantation and outcome trade-offs: early post-transplant infection and mortality.","published":"2026-07-30"}],"10.1093/eschf/xvag169":[{"url":"https://hartvaat.nl/2026/05/05/sterftecijfers-in-controle-armen-van-hartfalen-rcts-dalen-niet-ondanks-betere-ac/","title":"Sterftecijfers in controle-armen van hartfalen-RCTs dalen niet ondanks betere achtergrondtherapie","title_en":"Event rates in major Phase 3 heart failure trials over the last 20 years.","published":"2026-07-30"}],"10.1093/eschf/xvag143":[{"url":"https://hartvaat.nl/2026/05/05/vroege-harttoxiciteit-na-doxorubicine-bij-jongvolwassenen-met-sarcoom/","title":"Vroege harttoxiciteit na doxorubicine bij jongvolwassenen met sarcoom","title_en":"Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study.","published":"2026-07-29"}],"10.1093/europace/euag021":[{"url":"https://hartvaat.nl/2026/05/06/transseptale-punctie-bij-linkshartinterventies-nieuwe-esc-consensus-over-technie/","title":"Transseptale punctie bij linkshartinterventies: nieuwe ESC-consensus over techniek, beeldvorming en complicaties","title_en":"Transseptal puncture in cardiovascular interventions: a clinical consensus statement of the European Heart Rhythm Association, the Heart Failure Association, the European Association of Percutaneous Cardiovascular Interventions, the European Association of Cardiovascular Imaging of the ESC, and the Association for European Paediatric and Congenital Cardiology.","published":"2026-07-29"}],"10.1093/europace/euag045":[{"url":"https://hartvaat.nl/2026/05/06/vereenvoudigde-linkervoorhoofdaanhangsel-occlusie-onder-fluoroscopie-met-watchma/","title":"Vereenvoudigde linkervoorhoofdaanhangsel-occlusie onder fluoroscopie met WATCHMAN FLX is veilig en haalbaar","title_en":"Outcomes of simplified left atrial appendage occlusion using the WATCHMAN FLX device: the ROSE-FLX study.","published":"2026-07-29"}],"10.1093/ndt/gfag107":[{"url":"https://hartvaat.nl/2026/05/12/matige-koffiedrinken-waarschijnlijk-veilig-en-mogelijk-gunstig-bij-chronische-ni/","title":"Matige koffiedrinken waarschijnlijk veilig en mogelijk gunstig bij chronische nierziekte","title_en":"Coffee consumption and chronic kidney disease.","published":"2026-07-29"}],"10.1093/ndt/gfag100":[{"url":"https://hartvaat.nl/2026/05/15/verhoogde-albuminurie-drijft-hypercholesterolemie-bij-patienten-met-het-syndroom/","title":"Verhoogde albuminurie drijft hypercholesterolemie bij patiënten met het syndroom van Alport","title_en":"Albuminuria drives hyperlipidemia in patients with Alport syndrome.","published":"2026-07-29"}],"10.3390/medicina62061023":[{"url":"https://hartvaat.nl/2026/05/25/multimodale-beeldvorming-verheldert-atriumfibrilleren-bij-infiltratieve-cardiomy/","title":"Multimodale beeldvorming verheldert atriumfibrilleren bij infiltratieve cardiomyopathieën","title_en":"Atrial Fibrillation in Infiltrative Cardiomyopathies: From Atrial Cardiomyopathy Imaging to Targeted Management-A Narrative Review.","published":"2026-07-28"}],"10.3390/biom16060789":[{"url":"https://hartvaat.nl/2026/05/27/inflammatoire-biomarkers-verbeteren-risicostratificatie-bij-perifeer-arterieel-v/","title":"Inflammatoire biomarkers verbeteren risicostratificatie bij perifeer arterieel vaatlijden","title_en":"Role of Inflammatory Biomarkers in Peripheral Arterial Disease: A Comprehensive Review of Prognostic and Therapeutic Implications.","published":"2026-07-28"}],"10.3390/ph19060833":[{"url":"https://hartvaat.nl/2026/05/27/cardiotoxiciteit-van-her2-remmers-en-multikinaseremmers-mechanismen-en-klinisch-/","title":"Cardiotoxiciteit van HER2-remmers en multikinaseremmers — mechanismen en klinisch beleid","title_en":"Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence.","published":"2026-07-28"}],"10.1093/eschf/xvag152":[{"url":"https://hartvaat.nl/2026/05/28/atriumfibrilleren-en-hartfalen-versterken-elkaar-en-verhogen-sterfte-aanzienlijk/","title":"Atriumfibrilleren en hartfalen versterken elkaar en verhogen sterfte aanzienlijk — UK Biobank","title_en":"Development of Atrial Fibrillation in patients with Heart Failure and vice versa: Incidence, risk factors, and their impact on survival.","published":"2026-07-28"}],"10.1093/ndt/gfaf239":[{"url":"https://hartvaat.nl/2026/05/29/cardiovasculaire-ziekte-blijft-leidend-na-niertransplantatie-overzicht-van-uitda/","title":"Cardiovasculaire ziekte blijft leidend na niertransplantatie — overzicht van uitdagingen en nieuwe therapieën","title_en":"New kidneys, old risks: cardiovascular challenges after transplantation.","published":"2026-07-28"}],"10.1093/ndt/gfaf237":[{"url":"https://hartvaat.nl/2026/05/29/lichaamsrondheidsindex-bri-voorspelt-sterfte-bij-nierpatienten-beter-dan-bmi/","title":"Lichaamsrondheidsindex (BRI) voorspelt sterfte bij nierpatiënten beter dan BMI","title_en":"Body roundness index and mortality risk in patients with chronic kidney disease: moving beyond the obesity paradox.","published":"2026-07-27"}],"10.3390/biom16060807":[{"url":"https://hartvaat.nl/2026/05/29/rna-remmers-verlagen-lp-a-en-triglyceriden-bij-residual-risico-scoping-review/","title":"RNA-remmers verlagen Lp(a) en triglyceriden bij residual risico — scoping review","title_en":"Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives.","published":"2026-07-27"}],"10.1093/eschf/xvag146":[{"url":"https://hartvaat.nl/2026/05/31/hfpef-fenotype-duidt-op-hogere-sterfte-na-tavi-bij-laagstroom-laaggradient-aorta/","title":"HFpEF-fenotype duidt op hogere sterfte na TAVI bij laagstroom, laaggradient aortaklepstenose","title_en":"Phenotyping patients with a low-flow, low-gradient aortic stenosis and a preserved ejection fraction undergoing TAVI.","published":"2026-07-27"}],"10.1016/j.sleep.2026.109093":[{"url":"https://hartvaat.nl/2026/10/01/cpap-therapie-verlaagt-diastolische-bloeddruk-bij-niet-slaapige-osa-systematisch/","title":"CPAP-therapie verlaagt diastolische bloeddruk bij niet-slaapige OSA — systematische review","title_en":"Does treatment of nonsleepy OSA with CPAP therapy change CVD risk? A systematic review.","published":"2026-07-27"}],"10.1016/j.sleep.2026.109109":[{"url":"https://hartvaat.nl/2026/10/01/rusteloze-benen-en-slaapbewegingen-bepalen-lipidenprofiel-bij-slaapapneu/","title":"Rusteloze benen en slaapbewegingen bepalen lipidenprofiel bij slaapapneu","title_en":"Restless legs syndrome determines whether periodic limb movements are associated with altered lipid profiles in sleep-disordered breathing.","published":"2026-07-27"}],"10.1016/j.jhsg.2026.101020":[{"url":"https://hartvaat.nl/2026/09/01/tcl-biopsie-tijdens-carpaaltunneloperatie-heeft-lage-diagnostische-yield-voor-at/","title":"TCL-biopsie tijdens carpaaltunneloperatie heeft lage diagnostische yield voor ATTR-CM","title_en":"Tenosynovial and Transverse Carpal Ligament Biopsy for Early Transthyretin Amyloidosis Cardiomyopathy Detection: A Systematic Review and African American Retrospective Cohort Study","published":"2026-07-26"}],"10.1097/xce.0000000000000360":[{"url":"https://hartvaat.nl/2026/09/01/glp-1-agonisten-verlagen-mace-en-hartfalen-heropnames-bij-diabetes-en-ascvd-meta/","title":"GLP-1-agonisten verlagen MACE en hartfalen-heropnames bij diabetes en ASCVD — meta-analyse","title_en":"","published":"2026-07-26"}],"10.1016/j.ijcrp.2026.200657":[{"url":"https://hartvaat.nl/2026/09/01/verhoogd-lp-a-gekoppeld-aan-ernstiger-coronaire-ziekte-en-pci-uitkomsten-scoping/","title":"Verhoogd Lp(a) gekoppeld aan ernstiger coronaire ziekte en PCI-uitkomsten — scoping review","title_en":"Lipoprotein(a) and premature myocardial infarction: Mechanistic insights and implications for PCI-era residual risk","published":"2026-07-26"}],"10.1016/j.athplu.2026.100574":[{"url":"https://hartvaat.nl/2026/09/01/afstand-tot-ldl-doelwaarde-stuurt-keuze-lipiddalende-therapie/","title":"Afstand tot LDL-doelwaarde stuurt keuze lipiddalende therapie","title_en":"LDL-cholesterol distance to target: A practical tool for guiding lipid-lowering treatment decisions","published":"2026-07-26"}],"10.1016/j.athplu.2026.100570":[{"url":"https://hartvaat.nl/2026/09/01/inflammatie-als-risicofactor-krijgt-onvoldoende-ruimte-in-de-ascvd-en-ckd-prakti/","title":"Inflammatie als risicofactor krijgt onvoldoende ruimte in de ASCVD- en CKD-praktijk — SPARK-CVD","title_en":"Awareness and perceptions of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: The SPARK-CVD China survey","published":"2026-07-26"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26355":[{"url":"https://hartvaat.nl/2026/04/03/hoe-nauwkeurig-is-bloeddrukmeting-bij-opgenomen-patienten-vaak-slordig-blijkt-ui/","title":"Hoe nauwkeurig is bloeddrukmeting bij opgenomen patiënten? Vaak slordig, blijkt uit observatie","title_en":"How Accurate Is Inpatient Blood Pressure Measurement?","published":"2026-07-25"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003749?rss=1":[{"url":"https://hartvaat.nl/2026/04/03/machine-learningmodel-voorspelt-periprocedurele-complicaties-bij-tavi-voor-bicus/","title":"Machine-learningmodel voorspelt periprocedurele complicaties bij TAVI voor bicuspide aortaklepstenose","title_en":"","published":"2026-07-25"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25552":[{"url":"https://hartvaat.nl/2026/04/07/voor-het-voorspellen-van-hypertensie-na-de-zwangerschap-telt-de-obstetrische-voo/","title":"Voor het voorspellen van hypertensie na de zwangerschap telt de obstetrische voorgeschiedenis zwaarder dan biomarkers","title_en":"Obstetric History Versus Biomarkers: Hypertension Risk Up to 15 Years Postpartum","published":"2026-07-25"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004115?rss=1":[{"url":"https://hartvaat.nl/2026/04/03/warrior-trial-intensieve-medicamenteuze-behandeling-verbetert-de-uitkomsten-niet/","title":"WARRIOR-trial: intensieve medicamenteuze behandeling verbetert de uitkomsten niet bij vrouwen met ANOCA/INOCA","title_en":"","published":"2026-07-24"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26414":[{"url":"https://hartvaat.nl/2026/04/07/hoge-bloeddruk-op-de-tienerleeftijd-voorspelt-hart-en-vaatziekten-voor-het-50e-j/","title":"Hoge bloeddruk op de tienerleeftijd voorspelt hart- en vaatziekten vóór het 50e jaar","title_en":"Adolescent Blood Pressure and Cardiovascular Disease Before Age 50 Years","published":"2026-07-24"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25787":[{"url":"https://hartvaat.nl/2026/04/07/bij-2-3-miljoen-amerikaanse-veteranen-was-de-sterfte-het-laagst-bij-een-systolis/","title":"Bij 2,3 miljoen Amerikaanse veteranen was de sterfte het laagst bij een systolische bloeddruk van 130-139 mmHg","title_en":"Blood Pressure Control and Mortality Among US Veterans","published":"2026-07-24"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004039?rss=1":[{"url":"https://hartvaat.nl/2026/04/09/sterftereductie-of-uitstel-van-overlijden-waarom-de-taal-in-cardiovasculaire-tri/","title":"'Sterftereductie' of uitstel van overlijden? Waarom de taal in cardiovasculaire trials ertoe doet","title_en":"","published":"2026-07-24"}],"http://heart.bmj.com/cgi/content/short/112/9/480?rss=1":[{"url":"https://hartvaat.nl/2026/04/10/risicostratificatie-bij-longembolie-hoe-bruikbaar-zijn-de-huidige-instrumenten/","title":"Risicostratificatie bij longembolie: hoe bruikbaar zijn de huidige instrumenten?","title_en":"","published":"2026-07-24"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003856?rss=1":[{"url":"https://hartvaat.nl/2026/04/09/sekseverschillen-in-secundaire-preventie-na-acs-vrouwen-halen-minder-vaak-hun-ld/","title":"Sekseverschillen in secundaire preventie na ACS: vrouwen halen minder vaak hun LDL-doel (TEXTMEDS)","title_en":"","published":"2026-07-23"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26719":[{"url":"https://hartvaat.nl/2026/04/09/aanvullende-ablatie-van-het-aorticorenale-ganglion-versterkt-het-bloeddrukeffect/","title":"Aanvullende ablatie van het aorticorenale ganglion versterkt het bloeddrukeffect van renale denervatie","title_en":"Aorticorenal Ganglion Ablation Enhances Blood Pressure Reduction After Renal Denervation","published":"2026-07-23"}],"http://heart.bmj.com/cgi/content/short/112/9/488?rss=1":[{"url":"https://hartvaat.nl/2026/04/10/zuinig-machine-learningmodel-voorspelt-1-jaarssterfte-en-zinloosheid-na-tavi/","title":"Zuinig machine-learningmodel voorspelt 1-jaarssterfte en zinloosheid na TAVI","title_en":"","published":"2026-07-23"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26407":[{"url":"https://hartvaat.nl/2026/04/09/grootschalige-proteomics-van-bloeddruk-en-hypertensie-wijst-nherf2-aan-als-mogel/","title":"Grootschalige proteomics van bloeddruk en hypertensie wijst NHERF2 aan als mogelijk doelwit","title_en":"Integrative Proteomic Profiling of Blood Pressure and Hypertension","published":"2026-07-23"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004008?rss=1":[{"url":"https://hartvaat.nl/2026/04/15/mitralisklepreparatie-bij-endocarditis-geeft-betere-langetermijnoverleving-dan-k/","title":"Mitralisklepreparatie bij endocarditis geeft betere langetermijnoverleving dan klepvervanging","title_en":"","published":"2026-07-23"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003948?rss=1":[{"url":"https://hartvaat.nl/2026/04/17/direct-naar-ct-coronairangiografie-bij-verdenking-angina-snellere-diagnose-en-mi/","title":"Direct naar CT-coronairangiografie bij verdenking angina: snellere diagnose en minder polibezoeken","title_en":"","published":"2026-07-22"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003782?rss=1":[{"url":"https://hartvaat.nl/2026/04/17/langetermijnuitkomsten-na-de-ross-operatie-een-op-de-vier-krijgt-een-heroperatie/","title":"Langetermijnuitkomsten na de Ross-operatie: één op de vier krijgt een heroperatie","title_en":"","published":"2026-07-22"}],"http://heart.bmj.com/cgi/content/short/112/9/473?rss=1":[{"url":"https://hartvaat.nl/2026/04/10/subklinische-atherosclerose-bij-vrouwen-na-pre-eclampsie-systematische-review-en/","title":"Subklinische atherosclerose bij vrouwen na pre-eclampsie: systematische review en meta-analyse","title_en":"","published":"2026-07-22"}],"http://heart.bmj.com/cgi/content/short/112/9/504?rss=1":[{"url":"https://hartvaat.nl/2026/04/10/proteomics-onthult-vier-subgroepen-van-acuut-hfpef-met-eigen-biologische-routes-/","title":"Proteomics onthult vier subgroepen van acuut HFpEF met eigen biologische routes (PURSUIT-HFpEF)","title_en":"","published":"2026-07-22"}],"http://heart.bmj.com/cgi/content/short/112/9/514?rss=1":[{"url":"https://hartvaat.nl/2026/04/10/tweelingzwangerschap-bij-vrouwen-met-een-hartaandoening-geeft-een-hoog-risico-op/","title":"Tweelingzwangerschap bij vrouwen met een hartaandoening geeft een hoog risico op hartfalen (ROPAC)","title_en":"","published":"2026-07-22"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003513?rss=1":[{"url":"https://hartvaat.nl/2026/04/17/verhoogd-crp-voorspelt-hartfalen-bij-kankeroverlevenden-uk-biobank/","title":"Verhoogd CRP voorspelt hartfalen bij kankeroverlevenden (UK Biobank)","title_en":"","published":"2026-07-21"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004093?rss=1":[{"url":"https://hartvaat.nl/2026/04/17/restrictief-vullingspatroon-voorspelt-heropname-bij-acuut-gedecompenseerd-hfpef-/","title":"Restrictief vullingspatroon voorspelt heropname bij acuut gedecompenseerd HFpEF (KCHF-register)","title_en":"","published":"2026-07-21"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004135?rss=1":[{"url":"https://hartvaat.nl/2026/04/17/niet-invasieve-endotypering-met-stress-mri-verbetert-de-behandeling-van-angina-z/","title":"Niet-invasieve endotypering met stress-MRI verbetert de behandeling van angina zonder vernauwingen (ANOCA)","title_en":"","published":"2026-07-21"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003998?rss=1":[{"url":"https://hartvaat.nl/2026/04/21/delphi-consensus-over-uitgestelde-en-gemiste-diagnose-van-coronairlijden/","title":"Delphi-consensus over 'uitgestelde' en 'gemiste' diagnose van coronairlijden","title_en":"","published":"2026-07-21"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003971?rss=1":[{"url":"https://hartvaat.nl/2026/04/22/een-op-de-tien-volwassenen-met-een-aangeboren-hartafwijking-heeft-een-syndroom-e/","title":"Eén op de tien volwassenen met een aangeboren hartafwijking heeft een syndroom — en dat verhoogt de sterfte","title_en":"","published":"2026-07-21"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003997?rss=1":[{"url":"https://hartvaat.nl/2026/04/21/chirurgie-voor-aortaklependocarditis-blijft-hoogrisico-spoed-en-inotropie-sterks/","title":"Chirurgie voor aortaklependocarditis blijft hoogrisico: spoed en inotropie sterkste voorspellers van sterfte","title_en":"","published":"2026-07-20"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004026?rss=1":[{"url":"https://hartvaat.nl/2026/04/24/sekseverschillen-bij-infectieuze-endocarditis-vrouwen-vaker-conservatief-behande/","title":"Sekseverschillen bij infectieuze endocarditis: vrouwen vaker conservatief behandeld, slechtere overleving","title_en":"","published":"2026-07-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26477":[{"url":"https://hartvaat.nl/2026/04/22/eiwithandtekening-voorspelt-nierschade-bij-hypertensie-uk-biobank-nieuwe-risicos/","title":"Eiwithandtekening voorspelt nierschade bij hypertensie (UK Biobank): nieuwe risicoscore en doelwitten","title_en":"Proteomics Signatures of Chronic Kidney Disease in Hypertension","published":"2026-07-20"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004143?rss=1":[{"url":"https://hartvaat.nl/2026/04/24/relatieve-apicale-sparing-op-strain-echo-voor-cardiale-amyloidose-meta-analyse-v/","title":"Relatieve apicale sparing op strain-echo voor cardiale amyloïdose: meta-analyse van 41 studies","title_en":"","published":"2026-07-20"}],"10.1093/eschf/xvag097":[{"url":"https://hartvaat.nl/2026/04/07/confident-hfpef-machine-learning-voorspelt-sterfte-en-opname-beter-dan-bestaande/","title":"CONFIDENT-HFpEF: machine-learning voorspelt sterfte en opname beter dan bestaande risicoscores","title_en":"CONFIDENT-HFpEF: A Machine Learning-Based Risk Stratification for Mortality and Hospitalization Using Multimodal Real-World Data.","published":"2026-07-20"}],"10.1136/openhrt-2025-003573":[{"url":"https://hartvaat.nl/2026/04/14/sporten-op-je-eigen-bioritme-verlaagt-de-bloeddruk-meer-een-gerandomiseerde-stud/","title":"Sporten op je eigen bioritme verlaagt de bloeddruk meer: een gerandomiseerde studie","title_en":"Chronotype-aligned exercise timing in middle-aged adults at cardiometabolic risk: a randomised controlled trial.","published":"2026-07-19"}],"10.1186/s12933-026-03166-4":[{"url":"https://hartvaat.nl/2026/04/12/lipidenmanagement-bij-type-2-diabetes-richt-je-op-alle-atherogene-lipoproteinen-/","title":"Lipidenmanagement bij type 2-diabetes: richt je op álle atherogene lipoproteïnen (non-HDL-cholesterol)","title_en":"Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.","published":"2026-07-19"}],"10.1093/eschf/xvag105":[{"url":"https://hartvaat.nl/2026/04/09/prefers-stockholm-nieuw-ontstaan-hfpef-heeft-slechtere-langetermijnuitkomsten-da/","title":"PREFERS Stockholm: nieuw ontstaan HFpEF heeft slechtere langetermijnuitkomsten dan HFrEF en HFmrEF","title_en":"Worse Long-Term Outcomes in New-Onset HFpEF vs HFrEF and HFmrEF: Findings from the Stockholm PREFERS Study.","published":"2026-07-19"}],"10.1136/openhrt-2025-003833":[{"url":"https://hartvaat.nl/2026/04/15/opleidingsniveau-verandert-het-effect-van-diabetes-op-de-sterfte-bij-hartfalen-i/","title":"Opleidingsniveau verandert het effect van diabetes op de sterfte bij hartfalen (India)","title_en":"Combined effect of educational attainment and diabetes on 1-year all-cause mortality in heart failure patients: findings from the National Heart Failure Registry, India.","published":"2026-07-19"}],"10.1136/openhrt-2026-004007":[{"url":"https://hartvaat.nl/2026/04/17/atriumfibrilleren-in-catalonie-prevalentie-gestabiliseerd-incidentie-gedaald-2-v/","title":"Atriumfibrilleren in Catalonië: prevalentie gestabiliseerd, incidentie gedaald, 2% van het zorgbudget","title_en":"Epidemiology, economic burden and mortality of atrial fibrillation in a region with very high life expectancy: a contemporary, population-based analysis in Catalonia.","published":"2026-07-19"}],"10.1016/j.jacc.2026.02.5086":[{"url":"https://hartvaat.nl/2026/04/21/jacc-beschouwing-placebo-in-trials-met-incretine-therapie-bij-hartfalen-wetensch/","title":"JACC-beschouwing: placebo in trials met incretine-therapie bij hartfalen — wetenschap versus ethiek","title_en":"Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure.","published":"2026-07-18"}],"10.1016/j.hlc.2025.11.017":[{"url":"https://hartvaat.nl/2026/04/21/lp-a-bepaling-sterk-onderbenut-bij-patienten-met-atherosclerotische-hart-en-vaat/","title":"Lp(a)-bepaling sterk onderbenut bij patiënten met atherosclerotische hart- en vaatziekten (Australië)","title_en":"Prevalence of Lipoprotein(a) Testing in Patients With Atherosclerotic Cardiovascular Disease Within a Large Australian Cardiology Network.","published":"2026-07-18"}],"10.1016/j.ejim.2026.106902":[{"url":"https://hartvaat.nl/2026/04/27/consensus-breid-het-cardio-renaal-metabool-syndroom-uit-met-de-lever-cklms-in-de/","title":"Consensus: breid het cardio-renaal-metabool syndroom uit met de lever (CKLMS) in de eerste lijn","title_en":"Assessment and management of cardiovascular-kidney-liver metabolic-syndrome in the primary care setting: A multidisciplinary consensus statement.","published":"2026-07-18"}],"10.1161/jaha.124.040272":[{"url":"https://hartvaat.nl/2026/04/07/kosteneffectiviteit-van-stapsgewijze-lipidenverlaging-na-coronaire-bypasschirurg/","title":"Kosteneffectiviteit van stapsgewijze lipidenverlaging na coronaire bypasschirurgie","title_en":"Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.","published":"2026-07-18"}],"10.1161/jaha.125.046111":[{"url":"https://hartvaat.nl/2026/04/07/zorgpaden-na-nieuw-vastgesteld-atriumfibrilleren-rol-van-de-elektrofysioloog-en-/","title":"Zorgpaden na nieuw vastgesteld atriumfibrilleren: rol van de elektrofysioloog en uitkomsten","title_en":"Patient Care Pathways and Outcomes Following Newly Diagnosed Atrial Fibrillation.","published":"2026-07-18"}],"10.1161/jaha.125.047064":[{"url":"https://hartvaat.nl/2026/04/07/vrouwen-hebben-slechtere-uitkomsten-na-een-herseninfarct-ondanks-antistolling-bi/","title":"Vrouwen hebben slechtere uitkomsten na een herseninfarct ondanks antistolling bij atriumfibrilleren (ASPERA-R)","title_en":"Sex Differences in Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants for Atrial Fibrillation: An ASPERA-R Inverse Probability Weighted Analysis.","published":"2026-07-17"}],"10.1161/jaha.125.045533":[{"url":"https://hartvaat.nl/2026/04/09/sekseverschillen-in-lipiden-en-lipoproteinen-en-het-cardiovasculaire-risico-uk-b/","title":"Sekseverschillen in lipiden en lipoproteïnen en het cardiovasculaire risico (UK Biobank)","title_en":"Sex Differences in Lipids and Lipoproteins and Their Relationship With Cardiovascular Disease: A Prospective Study of UK Biobank Participants.","published":"2026-07-17"}],"10.1093/eurjpc/zwag221":[{"url":"https://hartvaat.nl/2026/04/16/lp-a-en-hscrp-voorspellen-ascvd-bij-mensen-zonder-klassieke-risicofactoren/","title":"Lp(a) én hsCRP voorspellen ASCVD bij mensen zónder klassieke risicofactoren","title_en":"Lipoprotein(a), High-Sensitivity C-Reactive Protein, and Incident ASCVD Risk in Individuals Without Standard Modifiable Risk Factors.","published":"2026-07-17"}],"10.1161/jaha.125.046180":[{"url":"https://hartvaat.nl/2026/04/16/pandora-register-supra-versus-intra-annulaire-kleppen-bij-tavr-in-tavr/","title":"PANDORA-register: supra- versus intra-annulaire kleppen bij TAVR-in-TAVR","title_en":"Supra-Annular Versus Intra-Annular Devices for Transcatheter Aortic Valve-in-Valve Replacement: The PANDORA International Registry.","published":"2026-07-17"}],"10.1093/eurjpc/zwag226":[{"url":"https://hartvaat.nl/2026/04/17/lagere-kaliuminname-hangt-samen-met-meer-hart-en-vaatziekte-bij-ckd-vooral-bij-v/","title":"Lagere kaliuminname hangt samen met meer hart- en vaatziekte bij CKD — vooral bij vrouwen","title_en":"Sex-Specific Cardiovascular Risk of Lower Potassium Intake in Patients with CKD.","published":"2026-07-17"}],"10.1161/jaha.125.045735":[{"url":"https://hartvaat.nl/2026/04/20/biomarkers-voorspellen-coronairlijden-bij-atriumfibrilleren-regards/","title":"Biomarkers voorspellen coronairlijden bij atriumfibrilleren (REGARDS)","title_en":"Blood Biomarkers and the Risk of Coronary Disease in Atrial Fibrillation.","published":"2026-07-16"}],"10.1093/ejhf/xuag140":[{"url":"https://hartvaat.nl/2026/04/27/nierfunctiestoornis-verergert-pulmonale-vaatziekte-bij-hfpef/","title":"Nierfunctiestoornis verergert pulmonale vaatziekte bij HFpEF","title_en":"Kidney Dysfunction and Pulmonary Vascular Disease in Heart Failure with preserved Ejection Fraction.","published":"2026-07-16"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001422":[{"url":"https://hartvaat.nl/2026/04/02/aha-verklaring-geavanceerde-karakterisering-van-rechterventrikelfalen/","title":"AHA-verklaring: geavanceerde karakterisering van rechterventrikelfalen","title_en":"Advanced Molecular, Metabolic, and Imaging Approaches to Characterizing Right Ventricular Failure: A Scientific Statement From the American Heart Association","published":"2026-07-16"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077579":[{"url":"https://hartvaat.nl/2026/04/07/multi-orgaan-inspanningstekorten-kenmerken-de-aanleg-voor-hfpef/","title":"Multi-orgaan inspanningstekorten kenmerken de aanleg voor HFpEF","title_en":"Multiorgan Physiological Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure With Preserved Ejection Fraction","published":"2026-07-16"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077424":[{"url":"https://hartvaat.nl/2026/04/09/pings-telefonische-verpleegkundig-geleide-bloeddrukcontrole-na-een-beroerte-ghan/","title":"PINGS: telefonische, verpleegkundig geleide bloeddrukcontrole na een beroerte (Ghana)","title_en":"Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana","published":"2026-07-16"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.078843":[{"url":"https://hartvaat.nl/2026/04/17/massieve-linkerventrikelhypertrofie-bij-kinderen-met-hypertrofische-cardiomyopat/","title":"Massieve linkerventrikelhypertrofie bij kinderen met hypertrofische cardiomyopathie (multiregisteranalyse)","title_en":"The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis","published":"2026-07-15"}],"10.1001/jamanetworkopen.2026.6838":[{"url":"https://hartvaat.nl/2026/04/01/prevent-risicoscore-presteert-robuust-in-de-dagelijkse-ehr-praktijk/","title":"PREVENT-risicoscore presteert robuust in de dagelijkse EHR-praktijk","title_en":"Performance of PREVENT Cardiovascular Risk in Electronic Health Record-Based Clinical Practice.","published":"2026-07-15"}],"10.1093/eurheartj/ehag236":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","title":"VISION: postoperatief atriumfibrilleren na hartchirurgie verhoogt sterfte na een jaar","title_en":"New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort.","published":"2026-07-15"}],"10.1093/eurheartj/ehag188":[{"url":"https://hartvaat.nl/2026/04/09/cardiale-screening-van-jonge-sporters-eerste-eapc-aepc-consensus-voor-kinderen/","title":"Cardiale screening van jonge sporters: eerste EAPC/AEPC-consensus voor kinderen","title_en":"Cardiac evaluation of paediatric athletes.","published":"2026-07-15"}],"10.1161/circgen.125.005494":[{"url":"https://hartvaat.nl/2026/04/10/genprobcad-gecombineerde-monogene-en-polygene-risicobepaling-voor-coronairlijden/","title":"GenProbCAD: gecombineerde monogene én polygene risicobepaling voor coronairlijden","title_en":"Development of an Integrated Monogenic and Polygenic Risk Assessment Tool for Coronary Artery Disease and Its Application in a Community-Based Health Care Biobank.","published":"2026-07-15"}],"10.1016/j.jcin.2026.02.024":[{"url":"https://hartvaat.nl/2026/04/13/transkatheter-tricuspidalisreparatie-bij-hoogrisicopatienten-real-world-toets-va/","title":"Transkatheter-tricuspidalisreparatie bij hoogrisicopatiënten: real-world toets van de ESC/EACTS-aanbevelingen","title_en":"Applying the 2025 ESC/EACTS Recommendations for the Treatment of Severe Tricuspid Regurgitation to Real-World Practice.","published":"2026-07-14"}],"10.1093/eurheartj/ehag225":[{"url":"https://hartvaat.nl/2026/04/14/left-bundle-crt-linkerbundeltak-pacing-niet-aantoonbaar-non-inferieur-aan-bivent/","title":"LEFT-BUNDLE-CRT: linkerbundeltak-pacing niet aantoonbaar non-inferieur aan biventriculaire CRT","title_en":"Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial.","published":"2026-07-14"}],"10.1093/eurheartj/ehag291":[{"url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","title":"ULYSSES: echogeleide venapunctie halveert toegangscomplicaties bij AF-ablatie","title_en":"Ultrasound-guided vs conventional venous puncture for atrial fibrillation ablation: the ULYSSES trial.","published":"2026-07-14"}],"10.1093/eurheartj/ehag206":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","title":"CAAN-AF: AV-knoopablatie verbetert CRT-uitkomsten bij permanent atriumfibrilleren niet","title_en":"Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial.","published":"2026-07-14"}],"10.1093/ehjacc/zuag059":[{"url":"https://hartvaat.nl/2026/04/16/winteropname-voor-acuut-hartfalen-gaat-gepaard-met-hogere-sterfte/","title":"Winteropname voor acuut hartfalen gaat gepaard met hogere sterfte","title_en":"Clinical Impact of Seasonal and Environmental Factors in Patients with Acute Heart Failure.","published":"2026-07-14"}],"10.1093/eurheartj/ehag176":[{"url":"https://hartvaat.nl/2026/04/16/pcsk9-remmers-verlagen-events-bij-ascvd-zonder-eerder-infarct-of-beroerte-real-w/","title":"PCSK9-remmers verlagen events bij ASCVD zónder eerder infarct of beroerte (real-world)","title_en":"PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study.","published":"2026-07-13"}],"10.1093/eurheartj/ehag248":[{"url":"https://hartvaat.nl/2026/04/17/schildklierdisfunctie-en-hart-en-vaatziekten-ehj-overzicht/","title":"Schildklierdisfunctie en hart- en vaatziekten (EHJ-overzicht)","title_en":"Thyroid dysfunction and cardiovascular disease.","published":"2026-07-13"}],"10.1016/s0140-6736(26)00367-3":[{"url":"https://hartvaat.nl/2026/04/25/bloeddrukverlaging-beschermt-over-het-hele-spectrum-van-chronische-nierschade-la/","title":"Bloeddrukverlaging beschermt over het hele spectrum van chronische nierschade (Lancet IPD-meta-analyse)","title_en":"Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.","published":"2026-07-13"}],"10.1056/nejmra2411298":[{"url":"https://hartvaat.nl/2026/05/07/cerebrale-amyloidangiopathie-nejm-state-of-the-art-overzicht/","title":"Cerebrale amyloïdangiopathie: NEJM state-of-the-art overzicht","title_en":"Cerebral Amyloid Angiopathy.","published":"2026-07-13"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004051?rss=1":[{"url":"https://hartvaat.nl/2026/04/29/cardiale-revalidatie-verbetering-depressie-hangt-samen-met-betere-loopconditie-p/","title":"Cardiale revalidatie: verbetering depressie hangt samen met betere loopconditie — pleidooi voor geïntegreerde aanpak","title_en":"","published":"2026-07-13"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003954?rss=1":[{"url":"https://hartvaat.nl/2026/04/29/geleidingssysteem-pacing-slaat-rechterventrikel-pacing-bij-av-blok-70-hartfalen-/","title":"Geleidingssysteem-pacing slaat rechterventrikel-pacing bij AV-blok: -70% hartfalen-opnames in RCT-meta-analyse","title_en":"","published":"2026-07-12"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26454":[{"url":"https://hartvaat.nl/2026/04/29/black-women-s-health-study-dagelijks-en-institutioneel-racisme-verhogen-pre-ecla/","title":"Black Women's Health Study: dagelijks en institutioneel racisme verhogen pre-eclampsie-risico met 47-50%","title_en":"Experiences of Racism and Risk of Preeclampsia in the Black Women’s Health Study","published":"2026-07-12"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25633":[{"url":"https://hartvaat.nl/2026/04/29/fibromusculaire-dysplasie-nieuwe-inzichten-voorbij-de-2019-consensus-bredere-cla/","title":"Fibromusculaire dysplasie: nieuwe inzichten voorbij de 2019-consensus — bredere classificatie en biomarkers in zicht","title_en":"Fibromuscular Dysplasia: Emerging Concepts Beyond the International Consensus","published":"2026-07-12"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004063?rss=1":[{"url":"https://hartvaat.nl/2026/04/29/geisoleerde-secundaire-tricuspidalisinsufficientie-na-linkszijdige-klepchirurgie/","title":"Geïsoleerde secundaire tricuspidalisinsufficiëntie na linkszijdige klepchirurgie verhoogt sterfte met 29%","title_en":"","published":"2026-07-12"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26778":[{"url":"https://hartvaat.nl/2026/04/29/centrale-versus-brachiale-ambulante-bloeddruk-brachiaal-volstaat-voor-mortalitei/","title":"Centrale versus brachiale ambulante bloeddruk: brachiaal volstaat voor mortaliteit-stratificatie (n=36.594)","title_en":"Mortality in Relation to Brachial Versus Central Ambulatory Blood Pressure","published":"2026-07-12"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004033?rss=1":[{"url":"https://hartvaat.nl/2026/04/29/erasmus-mc-linkeratrium-strain-voorspelt-aritmieen-na-chirurgische-correctie-van/","title":"Erasmus MC: linkeratrium-strain voorspelt aritmieën na chirurgische correctie van rechtszijdige ACHD","title_en":"","published":"2026-07-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26364":[{"url":"https://hartvaat.nl/2026/04/30/hanzhong-cohort-36-jaar-follow-up-snelle-bloeddrukstijging-in-kindertijd-voorspe/","title":"Hanzhong-cohort (36 jaar follow-up): snelle bloeddrukstijging in kindertijd voorspelt orgaanschade in middelbare leeftijd","title_en":"Blood Pressure Change and Subclinical Target Organ Damage in Mid-Adulthood","published":"2026-07-11"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004072?rss=1":[{"url":"https://hartvaat.nl/2026/04/30/etnische-verschillen-in-sterfte-na-acuut-coronair-syndroom-hogere-mortaliteit-bi/","title":"Etnische verschillen in sterfte na acuut coronair syndroom: hogere mortaliteit bij zwarte STEMI-patiënten","title_en":"","published":"2026-07-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26495":[{"url":"https://hartvaat.nl/2026/04/30/peri-arteriele-zenuwdissectie-tijdens-bijniechirurgie-geeft-renale-denervatie-ef/","title":"Peri-arteriële zenuwdissectie tijdens bijniechirurgie geeft renale-denervatie-effect: betere bloeddrukcontrole en minder medicatie","title_en":"Peri-Arterial Neural Dissection During Adrenal Surgery Provides a Denervation-Like Benefit in Hypertension Control","published":"2026-07-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25982":[{"url":"https://hartvaat.nl/2026/05/01/finse-hypertensie-curve-vlakt-af-vooruitgang-gestopt-zoutinname-30-boven-aanbeve/","title":"Finse hypertensie-curve vlakt af: vooruitgang gestopt, zoutinname 30% boven aanbeveling","title_en":"From Progress to Plateau: 50-Year Trends in Hypertension Prevalence and Salt Intake in the Finnish Population","published":"2026-07-11"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004054?rss=1":[{"url":"https://hartvaat.nl/2026/05/04/angina-toevoegen-aan-de-h2fpef-score-verbetert-hfpef-diagnose-bij-vrouwen-geen-w/","title":"Angina toevoegen aan de H2FPEF-score verbetert HFpEF-diagnose bij vrouwen — geen winst bij mannen","title_en":"","published":"2026-07-10"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004154?rss=1":[{"url":"https://hartvaat.nl/2026/05/04/stami-linkerventrikel-trombus-komt-na-voorwand-stemi-voor-8-bij-takotsubo-nooit-/","title":"STAMI: linkerventrikel-trombus komt na voorwand-STEMI voor (8%), bij Takotsubo nooit — ondanks slechtere LVEF","title_en":"","published":"2026-07-10"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004112?rss=1":[{"url":"https://hartvaat.nl/2026/05/04/noorse-nationale-validatie-myocarditis-na-mrna-covid-vaccinatie-4-5-per-100-000-/","title":"Noorse nationale validatie: myocarditis na mRNA-COVID-vaccinatie 4,5 per 100.000 — meest klinisch mild","title_en":"","published":"2026-07-10"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26295":[{"url":"https://hartvaat.nl/2026/05/06/haiti-cohort-n-2-073-bloeddrukbehandeling-in-extreme-armoede-haalbaar-vier-50-ma/","title":"Haïti-cohort (n=2.073): bloeddrukbehandeling in extreme armoede haalbaar — vier 50-maands BD-trajecten geïdentificeerd","title_en":"Blood Pressure Trajectories Among Adults Living in Extreme Poverty: A Population-Based Cohort in Port-au-Prince, Haiti","published":"2026-07-10"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.079493":[{"url":"https://hartvaat.nl/2026/05/06/dolichoectasie-van-hersenarterien-niet-stenose-drijft-lacunair-cva-en-cerebrale-/","title":"Dolichoectasie van hersenarteriën — niet stenose — drijft lacunair CVA en cerebrale small-vessel-ziekte","title_en":"Implications of Cranial Arterial Stenosis and Dolichoectasia for Cerebral Small-Vessel Disease Etiopathogenesis: Findings From a Prospective Mild Stroke Cohort","published":"2026-07-10"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26988":[{"url":"https://hartvaat.nl/2026/05/06/rasi-verlost-adrenale-veneuze-sampling-van-de-bilaterale-selectiviteit-flessenha/","title":"RASI verlost adrenale veneuze sampling van de bilaterale-selectiviteit-flessenhals bij primair aldosteronisme","title_en":"Subtyping of Primary Aldosteronism in Partial Adrenal Vein Sampling: The Relative Aldosterone Secretion Index","published":"2026-07-09"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.078738":[{"url":"https://hartvaat.nl/2026/05/08/orbita-fire-fysiologische-angina-drempel-ligt-veel-lager-dan-klinische-ffr-grens/","title":"ORBITA-FIRE: fysiologische angina-drempel ligt veel lager dan klinische FFR-grens — pleidooi voor individuele revascularisatie-strategie","title_en":"Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study","published":"2026-07-09"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25339":[{"url":"https://hartvaat.nl/2026/05/08/primaire-aldosteronisme-tijdens-zwangerschap-56-gecompliceerd-36-pre-eclampsie-o/","title":"Primaire aldosteronisme tijdens zwangerschap: 56% gecompliceerd, 36% pre-eclampsie — onmiskenbaar pleidooi voor vroege diagnose","title_en":"Pregnancy-Related Complications in Primary Aldosteronism: A European Survey","published":"2026-07-09"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.080833":[{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamica-bij-hfpef-met-a/","title":"PRAISE-MR: sacubitril/valsartan verbetert inspanningshemodynamica bij HFpEF met atriale functionele mitralis-insufficiëntie","title_en":"Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial","published":"2026-07-09"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26510":[{"url":"https://hartvaat.nl/2026/05/11/wisdom-hmod-nachtelijke-pols-bloeddrukmeting-voorspelt-onafhankelijk-linkerventr/","title":"WISDOM-HMOD: nachtelijke pols-bloeddrukmeting voorspelt onafhankelijk linkerventrikelhypertrofie","title_en":"Wrist-Measured Nighttime Home BP and Left Ventricular Hypertrophy: The WISDOM-HMOD Study","published":"2026-07-09"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26801":[{"url":"https://hartvaat.nl/2026/05/15/crossover-trial-amlodipine-geeft-bij-hfpef-hypertensie-betere-bloeddruk-hogere-v/","title":"Crossover-trial: amlodipine geeft bij HFpEF + hypertensie betere bloeddruk, hogere VO2 én lager NT-proBNP dan metoprolol","title_en":"Calcium Channel Blockade Versus β-Blockade for Hypertension in Heart Failure With Preserved Ejection Fraction: A Randomized Crossover Trial","published":"2026-07-08"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.078320":[{"url":"https://hartvaat.nl/2026/05/18/mint-post-hoc-bloedtransfusie-strategie-bij-infarct-anemie-heeft-geen-sekse-spec/","title":"MINT post-hoc: bloedtransfusie-strategie bij infarct + anemie heeft geen sekse-specifiek effect","title_en":"Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial","published":"2026-07-08"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077980":[{"url":"https://hartvaat.nl/2026/05/18/trajectory-van-eind-expiratoire-co2-bij-ohca-monitor-7-21-minuten-voor-betrouwba/","title":"Trajectory van eind-expiratoire CO2 bij OHCA: monitor 7-21 minuten voor betrouwbare ROSC-voorspelling","title_en":"Resuscitation From Out-of-Hospital Cardiac Arrest When Is EtCO\n                    <sub>2</sub>\n                    Reliably Associated With ROSC?","published":"2026-07-08"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.080616":[{"url":"https://hartvaat.nl/2026/05/19/vesalius-cv-subgroep-prior-pci-zonder-eerder-mi-evolocumab-halveert-hartinfarct-/","title":"VESALIUS-CV subgroep prior PCI zonder eerder MI: evolocumab halveert hartinfarct-risico (n=3.627)","title_en":"Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial","published":"2026-07-08"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.078897":[{"url":"https://hartvaat.nl/2026/05/19/nyc-4h-cohort-sociale-problemen-verviervoudigen-sterfterisico-bij-hiv-patienten-/","title":"NYC 4H-cohort: sociale problemen verviervoudigen sterfterisico bij hiv-patiënten met hartfalen","title_en":"Multidimensional Social Adversity and Mortality in People With HIV Infection and Heart Failure: Insights From NYC Health + Hospitals HIV–Heart Failure Cohort","published":"2026-07-08"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004037?rss=1":[{"url":"https://hartvaat.nl/2026/05/20/cardiale-mri-bij-dystrofinopathie-consensus-voor-dmd-bmd-en-vrouwelijke-draagste/","title":"Cardiale MRI bij dystrofinopathie: consensus voor DMD, BMD en vrouwelijke draagsters","title_en":"","published":"2026-07-07"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26016":[{"url":"https://hartvaat.nl/2026/05/20/ecog-acrin-eaq191-intensieve-bloeddrukcontrole-tijdens-vegfr-tki-therapie-haalba/","title":"ECOG-ACRIN EAQ191: intensieve bloeddrukcontrole tijdens VEGFR-TKI-therapie haalbaar en veilig bij kankerpatiënten","title_en":"Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191","published":"2026-07-07"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004052?rss=1":[{"url":"https://hartvaat.nl/2026/05/20/scapis-cohort-diastolische-dysfunctie-even-vaak-bij-prediabetes-als-diabetes-ple/","title":"SCAPIS-cohort: diastolische dysfunctie even vaak bij prediabetes als diabetes — pleidooi tegen 'diabetische cardiomyopathie'","title_en":"","published":"2026-07-07"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26894":[{"url":"https://hartvaat.nl/2026/05/20/bloeddrukeffecten-van-nitraat-hangen-af-van-de-bron-planten-verlagen-vlees-verho/","title":"Bloeddrukeffecten van nitraat hangen af van de bron: planten verlagen, vlees verhoogt","title_en":"Dietary Intakes of Plant and Animal Nitrate and 5-Year Blood Pressure Changes","published":"2026-07-07"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003583?rss=1":[{"url":"https://hartvaat.nl/2026/05/20/diffuse-myocardfibrose-bij-ernstige-aortastenose-is-ongelijk-verdeeld-vooral-aan/","title":"Diffuse myocardfibrose bij ernstige aortastenose is ongelijk verdeeld — vooral aan de basis van het hart","title_en":"","published":"2026-07-07"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003635?rss=1":[{"url":"https://hartvaat.nl/2026/05/20/hypochloremie-bij-opname-voor-acuut-hartfalen-voorspelt-onafhankelijk-30-daagse-/","title":"Hypochloremie bij opname voor acuut hartfalen voorspelt onafhankelijk 30-daagse sterfte (Vietnamees cohort)","title_en":"","published":"2026-07-06"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004079?rss=1":[{"url":"https://hartvaat.nl/2026/05/20/infectieuze-endocarditis-na-tavi-diabetes-belangrijkste-risicofactor-e-faecalis-/","title":"Infectieuze endocarditis na TAVI: diabetes belangrijkste risicofactor, E. faecalis dominante verwekker, 2× mortaliteit","title_en":"","published":"2026-07-06"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004078?rss=1":[{"url":"https://hartvaat.nl/2026/05/20/klinisch-en-genetisch-risico-op-atriumfibrilleren-versterken-elkaar-additief-13-/","title":"Klinisch en genetisch risico op atriumfibrilleren versterken elkaar additief — 13× risico bij beide hoog","title_en":"","published":"2026-07-06"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25773":[{"url":"https://hartvaat.nl/2026/05/20/aric-over-35-jaar-hogere-bloeddruk-niet-alleen-lage-staande-bd-verklaart-syncope/","title":"ARIC over 35 jaar: hogere bloeddruk — niet alleen lage staande BD — verklaart syncope, vallen én CHD","title_en":"Orthostatic Blood Pressure, Cardiovascular Disease, and Hypotensive Events","published":"2026-07-06"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004185?rss=1":[{"url":"https://hartvaat.nl/2026/05/20/pulmonale-hypertensie-screenen-met-echo-cut-off-trv-2-7-m-s-beter-dan-2-9-onder-/","title":"Pulmonale hypertensie screenen met echo: cut-off TRV 2,7 m/s beter dan 2,9 onder nieuwe PH-definitie","title_en":"","published":"2026-07-06"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003979?rss=1":[{"url":"https://hartvaat.nl/2026/05/20/ct-ffr-voorspelt-mace-4-hoger-bij-waarde-0-80-bijgewerkte-meta-analyse-van-20-06/","title":"CT-FFR voorspelt MACE 4× hoger bij waarde ≤0,80: bijgewerkte meta-analyse van 20.067 patiënten","title_en":"","published":"2026-07-05"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.078250":[{"url":"https://hartvaat.nl/2026/05/21/hoge-jeugdige-conditie-en-af-risico-trade-off-verdwijnt-na-correctie-voor-famili/","title":"Hoge jeugdige conditie en AF-risico: trade-off verdwijnt na correctie voor familiaire factoren (1,1 miljoen Zweden)","title_en":"Adolescent Cardiorespiratory Fitness and the Trade-Off Between Atrial Fibrillation Risk and Cardiovascular Benefits: A Nationwide Sibling-Controlled Cohort Study","published":"2026-07-05"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004046?rss=1":[{"url":"https://hartvaat.nl/2026/05/21/swedeheart-na-een-eerste-hartinfarct-is-fysieke-fitheid-bij-start-cardiale-reval/","title":"SWEDEHEART: na een eerste hartinfarct is fysieke fitheid bij start cardiale revalidatie ver onder de norm","title_en":"","published":"2026-07-05"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003950?rss=1":[{"url":"https://hartvaat.nl/2026/05/21/million-women-study-ernstige-obesitas-verviervoudigt-risico-op-af-en-hartfalen-s/","title":"Million Women Study: ernstige obesitas verviervoudigt risico op AF én hartfalen samen bij vrouwen","title_en":"","published":"2026-07-05"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004011?rss=1":[{"url":"https://hartvaat.nl/2026/05/25/patientspecifieke-3d-hartmodellen-bij-congenitale-hartchirurgie-18-minuten-korte/","title":"Patiëntspecifieke 3D-hartmodellen bij congenitale hartchirurgie: 18 minuten korter opereren en minder complicaties (meta-analyse)","title_en":"","published":"2026-07-05"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004047?rss=1":[{"url":"https://hartvaat.nl/2026/05/25/laparoscopische-pericardio-peritoneale-window-kleine-prospectieve-serie-van-24-p/","title":"Laparoscopische pericardio-peritoneale window: kleine prospectieve serie van 24 patiënten zonder recidief in 12 maanden","title_en":"","published":"2026-07-04"}],"http://heart.bmj.com/cgi/content/short/112/12/658?rss=1":[{"url":"https://hartvaat.nl/2026/05/26/acute-bloeddrukverhoging-tijdens-ziekenhuisopname-hoe-te-handelen-bij-asymptomat/","title":"Acute bloeddrukverhoging tijdens ziekenhuisopname: hoe te handelen bij asymptomatische 'hypertensieve urgentie'?","title_en":"","published":"2026-07-04"}],"http://heart.bmj.com/cgi/content/short/112/12/692?rss=1":[{"url":"https://hartvaat.nl/2026/05/26/12-leads-ecg-onderscheidt-rasopathie-hcm-van-sarcomere-hcm-bij-kinderen-superieu/","title":"12-leads ECG onderscheidt RASopathie-HCM van sarcomere HCM bij kinderen — superieure asdeviatie en rechterventrikel-hypertrofie","title_en":"","published":"2026-07-04"}],"http://heart.bmj.com/cgi/content/short/112/12/684?rss=1":[{"url":"https://hartvaat.nl/2026/05/26/recidief-linkerventrikel-trombus-12-recidief-actieve-eerdere-maligniteit-verzesv/","title":"Recidief linkerventrikel-trombus: 12% recidief — actieve/eerdere maligniteit verzesvoudigt het risico","title_en":"","published":"2026-07-03"}],"http://heart.bmj.com/cgi/content/short/112/12/674?rss=1":[{"url":"https://hartvaat.nl/2026/05/26/routine-huisarts-emd-voorspelt-5-jaars-cardiovasculair-risico-betrouwbaar-austra/","title":"Routine huisarts-EMD voorspelt 5-jaars cardiovasculair risico betrouwbaar — Australische validatie bij 850.000 patiënten","title_en":"","published":"2026-07-03"}],"http://heart.bmj.com/cgi/content/short/112/12/646?rss=1":[{"url":"https://hartvaat.nl/2026/05/26/asymptomatische-matige-ernstige-aortaklepinsufficientie-niet-benigne-meta-analys/","title":"Asymptomatische matige/ernstige aortaklepinsufficiëntie níet benigne — meta-analyse pleit voor vroege interventie","title_en":"","published":"2026-07-03"}],"http://heart.bmj.com/cgi/content/short/112/12/667?rss=1":[{"url":"https://hartvaat.nl/2026/05/26/accurhythm-ai-vermindert-valse-alarmen-bij-ilr-met-62-bespaart-honderden-klinisc/","title":"AccuRhythm AI vermindert valse alarmen bij ILR met 62% — bespaart honderden klinische uren","title_en":"","published":"2026-07-02"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.079484":[{"url":"https://hartvaat.nl/2026/05/26/pfa-sham-pulsed-field-ablatie-verslaat-sham-procedure-overtuigend-bij-atriumfibr/","title":"PFA-SHAM: pulsed field-ablatie verslaat sham-procedure overtuigend bij atriumfibrilleren — placebo-effect uitgesloten","title_en":"","published":"2026-07-02"}],"10.1093/eschf/xvag113":[{"url":"https://hartvaat.nl/2026/04/30/kp-chemo-cumulatieve-incidentie-cancer-therapy-related-cardiac-dysfunction-8-4-h/","title":"KP CHEMO: cumulatieve incidentie cancer-therapy-related cardiac dysfunction 8,4% — hoogste bij HER2-remmers","title_en":"","published":"2026-07-02"}],"10.1016/j.ijcard.2026.134536":[{"url":"https://hartvaat.nl/2026/08/15/3d-ct-fluoroscopie-fusie-maakt-laac-efficienter-minder-contrast-minder-straling-/","title":"3D CT-fluoroscopie-fusie maakt LAAC efficiënter: minder contrast, minder straling, korte procedure","title_en":"","published":"2026-07-01"}],"10.1001/jamanetworkopen.2026.13941":[{"url":"https://hartvaat.nl/2026/05/01/doac-s-cox-2-selectieve-nsaid-s-geven-37-minder-gi-bloedingen-dan-doac-s-niet-se/","title":"DOAC's + COX-2-selectieve NSAID's geven 37% minder GI-bloedingen dan DOAC's + niet-selectieve NSAID's","title_en":"","published":"2026-07-01"}],"10.1093/eschf/xvag126":[{"url":"https://hartvaat.nl/2026/05/04/congestie-bij-chronisch-hartfalen-echografie-vult-klinisch-onderzoek-aan-en-voor/","title":"Congestie bij chronisch hartfalen: echografie vult klinisch onderzoek aan en voorspelt slechte prognose","title_en":"","published":"2026-07-01"}],"10.1093/eschf/xvag125":[{"url":"https://hartvaat.nl/2026/05/04/microbioom-vriendelijk-dieet-di-gm-geassocieerd-met-27-minder-hartfalen-bij-pred/","title":"Microbioom-vriendelijk dieet (DI-GM) geassocieerd met 27% minder hartfalen bij prediabetes (NHANES n=15.219)","title_en":"","published":"2026-06-30"}],"10.1093/eschf/xvag135":[{"url":"https://hartvaat.nl/2026/05/05/apicale-myocardfibrose-bij-lvad-implantatie-voorspelt-cardiale-mortaliteit-singl/","title":"Apicale myocardfibrose bij LVAD-implantatie voorspelt cardiale mortaliteit (single-center, n=47)","title_en":"","published":"2026-06-30"}],"10.1093/eschf/xvag130":[{"url":"https://hartvaat.nl/2026/05/05/cmr-laci-21-identificeert-hoogrisicopatienten-met-hfref-onafhankelijk-van-lvef-e/","title":"CMR-LACI ≥21% identificeert hoogrisicopatiënten met HFrEF — onafhankelijk van LVEF en LGE","title_en":"","published":"2026-06-30"}],"10.1093/eschf/xvag123":[{"url":"https://hartvaat.nl/2026/05/05/uk-biobank-na-ischemisch-cva-of-tia-is-het-risico-op-hartfalen-groter-dan-dat-op/","title":"UK Biobank: na ischemisch CVA of TIA is het risico op hartfalen groter dan dat op hartinfarct","title_en":"","published":"2026-06-29"},{"url":"https://hartvaat.nl/2026/05/13/uk-biobank-na-ischemisch-cva-of-tia-is-het-risico-op-hartfalen-groter-dan-dat-op/","title":"UK Biobank: na ischemisch CVA of TIA is het risico op hartfalen groter dan dat op een infarct","title_en":"","published":"2026-05-15"}],"10.1161/jaha.125.045749":[{"url":"https://hartvaat.nl/2026/05/05/coronaire-embolie-bij-atriumfibrilleren-hoog-rest-trombo-embolisch-risico-ondank/","title":"Coronaire embolie bij atriumfibrilleren: hoog rest-trombo-embolisch risico ondanks antistolling","title_en":"","published":"2026-06-29"}],"10.1093/eschf/xvag104":[{"url":"https://hartvaat.nl/2026/05/05/dapa-hd-eerste-gerandomiseerde-studie-naar-dapagliflozin-bij-hemodialyse-patient/","title":"DAPA-HD: eerste gerandomiseerde studie naar dapagliflozin bij hemodialyse-patiënten — opzet en achtergrond","title_en":"","published":"2026-06-29"}],"10.1093/eschf/xvag083":[{"url":"https://hartvaat.nl/2026/05/05/reduce-mfa-dzhk25-trial-naar-antifibrotische-therapie-tegen-myocardfibrose-na-ta/","title":"Reduce-MFA DZHK25: trial naar antifibrotische therapie tegen myocardfibrose na TAVI — opzet en achtergrond","title_en":"","published":"2026-06-28"}],"10.1093/eschf/xvag128":[{"url":"https://hartvaat.nl/2026/05/05/wereldwijde-hf-registry-28-landen-fev1-is-een-onafhankelijke-prognostische-facto/","title":"Wereldwijde HF-registry (28 landen): FEV1 is een onafhankelijke prognostische factor — pleidooi voor spirometrie","title_en":"","published":"2026-06-28"},{"url":"https://hartvaat.nl/2026/05/13/wereldwijde-hf-registry-fev1-is-een-onafhankelijke-prognostische-factor-pleidooi/","title":"Wereldwijde HF-registry: FEV1 is een onafhankelijke prognostische factor — pleidooi voor routine-spirometrie bij hartfalen","title_en":"","published":"2026-05-15"}],"10.1093/eschf/xvag106":[{"url":"https://hartvaat.nl/2026/05/05/thuis-bio-impedantie-voor-hartfalen-haalbaar-en-acceptabel-klinische-winst-nog-n/","title":"Thuis-bio-impedantie voor hartfalen: haalbaar en acceptabel, klinische winst (nog) niet aangetoond","title_en":"","published":"2026-06-28"}],"10.1093/eschf/xvag103":[{"url":"https://hartvaat.nl/2026/05/05/eurotr-register-co-existente-linkszijdige-kleplek-verhoogt-sterfte-na-transcathe/","title":"EuroTR-register: co-existente linkszijdige kleplek verhoogt sterfte na transcatheter-tricuspidalis-edge-to-edge repair","title_en":"","published":"2026-06-27"}],"10.1161/jaha.125.045994":[{"url":"https://hartvaat.nl/2026/05/05/mavacamten-in-de-praktijk-zwarte-patienten-krijgen-55-minder-vaak-toegang-atrium/","title":"Mavacamten in de praktijk: zwarte patiënten krijgen 55% minder vaak toegang — atriumfibrilleren voorspelt slechtere uitkomst","title_en":"","published":"2026-06-27"}],"10.1093/eschf/xvag124":[{"url":"https://hartvaat.nl/2026/05/05/nederlandse-huisartsenpost-1-op-20-contacten-voor-benauwdheid-betreft-hartfalen-/","title":"Nederlandse huisartsenpost: 1 op 20 contacten voor benauwdheid betreft hartfalen — 6-maands sterfte 32%","title_en":"","published":"2026-06-27"}],"10.1093/eschf/xvag108":[{"url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","title":"EXPANDed: bij 73% verbetert tricuspidalisinsufficiëntie binnen 30 dagen na M-TEER — zonder directe TR-interventie","title_en":"","published":"2026-06-26"}],"10.1093/eschf/xvag117":[{"url":"https://hartvaat.nl/2026/05/05/vericiguat-en-sgc-stimulatoren-bij-hartfalen-werkingsmechanisme-en-plaats-na-vic/","title":"Vericiguat en sGC-stimulatoren bij hartfalen: werkingsmechanisme en plaats na VICTORIA/VICTOR","title_en":"","published":"2026-06-26"}],"10.1093/eschf/xvag132":[{"url":"https://hartvaat.nl/2026/05/08/car-t-therapie-en-cardiovasculaire-uitkomsten-in-duitsland-en-vs-ernstige-events/","title":"CAR-T-therapie en cardiovasculaire uitkomsten in Duitsland en VS: ernstige events zeldzaam acuut, hoger op lange termijn bij pre-existente hartziekte","title_en":"","published":"2026-06-26"}],"10.1093/eschf/xvag133":[{"url":"https://hartvaat.nl/2026/05/09/uf-care-trial-ultrafiltratie-bij-type-2-cardiorenaal-syndroom-geen-significante-/","title":"UF-CARE-trial: ultrafiltratie bij type-2 cardiorenaal syndroom geen significante winst (kleine, onderpowered RCT)","title_en":"","published":"2026-06-25"},{"url":"https://hartvaat.nl/2026/05/09/uf-care-ultrafiltratie-bij-type-2-cardiorenaal-syndroom-mist-primair-eindpunt-in/","title":"UF-CARE: ultrafiltratie bij type-2 cardiorenaal syndroom mist primair eindpunt in kleine Franse RCT","title_en":"","published":"2026-05-11"}],"10.1093/eurheartj/ehag385":[{"url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","title":"DECISION-trial: digoxine staken bij hartfalen leidt tot zevenvoudige stijging in HF-events binnen 6 weken","title_en":"","published":"2026-06-25"},{"url":"https://hartvaat.nl/2026/05/10/decision-onttrekkingssubstudie-stoppen-van-digoxine-na-lange-behandeling-leidt-t/","title":"DECISION-onttrekkingssubstudie: stoppen van digoxine na lange behandeling leidt tot acute verslechtering","title_en":"","published":"2026-05-10"}],"10.1016/j.jcin.2026.02.016":[{"url":"https://hartvaat.nl/2026/05/11/emerge-laa-amulet-occluder-in-12-180-patienten-96-succes-1-jaars-beroerte-1-6-re/","title":"EMERGE LAA: Amulet-occluder in 12.180 patiënten — 96% succes, 1-jaars beroerte 1,6% (real-world register)","title_en":"","published":"2026-06-25"}],"10.5414/cp204964":[{"url":"https://hartvaat.nl/2026/05/11/evolocumab-effectief-en-veilig-bij-ckd-stadium-3-4-56-ldl-zonder-nierfunctiedali/","title":"Evolocumab effectief en veilig bij CKD stadium 3-4: -56% LDL zonder nierfunctiedaling","title_en":"","published":"2026-06-24"}],"10.1093/eschf/xvag134":[{"url":"https://hartvaat.nl/2026/05/11/invasieve-drukvolumelussen-onthullen-mechanisme-van-tricuspidalisinsufficientie-/","title":"Invasieve drukvolumelussen onthullen mechanisme van tricuspidalisinsufficiëntie bij HFrEF: RV-PA-ontkoppeling en sMR","title_en":"","published":"2026-06-24"}],"10.1093/eurheartj/ehag216":[{"url":"https://hartvaat.nl/2026/05/11/volwassenen-met-aangeboren-hartafwijking-hebben-vergelijkbare-overleving-na-hart/","title":"Volwassenen met aangeboren hartafwijking hebben vergelijkbare overleving na hartinfarct als de algemene populatie","title_en":"","published":"2026-06-24"}],"10.1093/ejcts/ezag161":[{"url":"https://hartvaat.nl/2026/05/11/thoracoscopische-af-ablatie-met-bipolaire-clamp-5-jaars-ritmevrijheid-52-met-ant/","title":"Thoracoscopische AF-ablatie met bipolaire clamp: 5-jaars ritmevrijheid 52% met antiaritmica — multicenter register","title_en":"","published":"2026-06-23"}],"10.1093/eurheartj/ehag164":[{"url":"https://hartvaat.nl/2026/05/11/ehj-overzicht-mechanische-complicaties-na-hartinfarct-zeldzaam-1-maar-acuut-leve/","title":"EHJ-overzicht: mechanische complicaties na hartinfarct — zeldzaam (<1%) maar acuut levensbedreigend","title_en":"","published":"2026-06-23"}],"10.1016/j.jacc.2026.02.5124":[{"url":"https://hartvaat.nl/2026/05/12/nhlbi-workshop-bloeddrukmeting-verfijnen-door-de-hele-levensloop-heen-knelpunten/","title":"NHLBI-workshop: bloeddrukmeting verfijnen door de hele levensloop heen — knelpunten en kansen","title_en":"","published":"2026-06-23"}],"10.1093/eschf/xvag137":[{"url":"https://hartvaat.nl/2026/05/13/evoque-transcatheter-tricuspidalisklep-mogelijk-kosteneffectief-bij-ernstige-tr-/","title":"Evoque transcatheter-tricuspidalisklep mogelijk kosteneffectief bij ernstige TR — maar resultaten leunen sterk op extrapolatie","title_en":"","published":"2026-06-22"}],"10.1016/j.echo.2026.05.007":[{"url":"https://hartvaat.nl/2026/05/13/ai-echo-verslaat-ai-ecg-en-klinische-score-voor-diagnose-cardiale-amyloidose-aur/","title":"AI-Echo verslaat AI-ECG en klinische score voor diagnose cardiale amyloïdose (AUROC 0,93)","title_en":"","published":"2026-06-22"}],"10.1093/eurheartj/ehag294":[{"url":"https://hartvaat.nl/2026/05/13/mtmr4-modifier-heeft-tegenovergestelde-invloed-op-aritmierisico-bij-lqt1-en-lqt2/","title":"MTMR4-modifier heeft tegenovergestelde invloed op aritmierisico bij LQT1 en LQT2","title_en":"","published":"2026-06-22"}],"10.1093/eschf/xvag138":[{"url":"https://hartvaat.nl/2026/05/13/verisec-register-vericiguat-halveert-hartfalen-decompensaties-bij-hfref-in-dagel/","title":"VERISEC-register: vericiguat halveert hartfalen-decompensaties bij HFrEF in dagelijkse Spaanse praktijk","title_en":"","published":"2026-06-21"},{"url":"https://hartvaat.nl/2026/05/13/verisec-vericiguat-in-de-praktijk-halveert-hartfalen-decompensaties-bij-hfref-sp/","title":"VERISEC: vericiguat in de praktijk halveert hartfalen-decompensaties bij HFrEF — Spaanse 1-jaars registry van 835 patiënten","title_en":"","published":"2026-05-15"}],"10.1093/eurheartj/ehag292":[{"url":"https://hartvaat.nl/2026/05/13/hypothese-falen-van-het-raas-verklaart-inappropriate-vasodilatatie-bij-cardiogen/","title":"Hypothese: falen van het RAAS verklaart inappropriate vasodilatatie bij cardiogene shock","title_en":"","published":"2026-06-21"}],"10.1007/s00431-026-07057-4":[{"url":"https://hartvaat.nl/2026/05/13/aasi-is-geen-betrouwbare-maat-voor-arteriele-stijfheid-bij-kinderen-met-risico-o/","title":"AASI is geen betrouwbare maat voor arteriële stijfheid bij kinderen met risico op secundaire hypertensie","title_en":"","published":"2026-06-21"}],"10.1093/eurheartj/ehag330":[{"url":"https://hartvaat.nl/2026/05/14/sprint-accord-gepoold-bloeddrukvariabiliteit-is-even-prognostisch-als-gemiddelde/","title":"SPRINT + ACCORD gepoold: bloeddrukvariabiliteit is even prognostisch als gemiddelde bloeddruk — J-vormige curve","title_en":"","published":"2026-06-20"},{"url":"https://hartvaat.nl/2026/05/14/bloeddrukvariabiliteit-sprint-accord-ipd-meta-even-prognostisch-als-gemiddelde-b/","title":"Bloeddrukvariabiliteit (SPRINT + ACCORD IPD-meta): even prognostisch als gemiddelde bloeddruk in hoog-risico patiënten","title_en":"","published":"2026-05-15"}],"10.1186/s12933-026-03209-w":[{"url":"https://hartvaat.nl/2026/05/14/mendeliaanse-randomisatie-hmgcr-remming-verhoogt-diabetesrisico-andere-lipidendo/","title":"Mendeliaanse randomisatie: HMGCR-remming verhoogt diabetesrisico, andere lipidendoelen niet","title_en":"","published":"2026-06-20"}],"10.1136/heartjnl-2025-326404":[{"url":"https://hartvaat.nl/2026/05/14/lipidegerelateerd-cv-risico-voorbij-ldl-focus-verschuift-naar-remnant-cholestero/","title":"Lipidegerelateerd CV-risico voorbij LDL: focus verschuift naar remnant-cholesterol en Lp(a)","title_en":"","published":"2026-06-20"}],"10.1093/eurjpc/zwag207":[{"url":"https://hartvaat.nl/2026/05/15/aspirine-voor-primaire-preventie-bij-verhoogd-lp-a-of-lpa-varianten-levert-geen-/","title":"Aspirine voor primaire preventie bij verhoogd Lp(a) of LPA-varianten levert geen significante winst op","title_en":"","published":"2026-06-19"}],"10.1093/eurheartj/ehag353":[{"url":"https://hartvaat.nl/2026/05/15/eapci-ebc-consensus-intracoronaire-beeldvorming-als-standaard-bij-pci-van-hoofds/","title":"EAPCI/EBC-consensus: intracoronaire beeldvorming als standaard bij PCI van hoofdstam","title_en":"","published":"2026-06-19"}],"10.1161/circulationaha.125.075973":[{"url":"https://hartvaat.nl/2026/05/15/laroprovstat-eerste-orale-pcsk9-remmer-haalt-80-ldl-reductie-in-combinatie-met-r/","title":"Laroprovstat: eerste orale PCSK9-remmer haalt -80% LDL-reductie in combinatie met rosuvastatine (fase 1)","title_en":"","published":"2026-06-19"}],"10.1093/eschf/xvag139":[{"url":"https://hartvaat.nl/2026/05/15/non-invasieve-veneuze-return-cardiac-output-mismatch-onthult-gebufferde-staat-vo/","title":"Non-invasieve veneuze return/cardiac output-mismatch onthult 'gebufferde' staat vóór klinische hartfalen-decompensatie","title_en":"","published":"2026-06-18"}],"10.1016/j.ijcard.2026.134561":[{"url":"https://hartvaat.nl/2026/05/17/langetermijnoverleving-na-icd-implantatie-verschilt-sterk-per-cardiomyopathie-pl/","title":"Langetermijnoverleving na ICD-implantatie verschilt sterk per cardiomyopathie: pleit voor etiologie-gestuurde selectie","title_en":"","published":"2026-06-18"}],"10.1093/ehjqcco/qcag086":[{"url":"https://hartvaat.nl/2026/05/18/naar-precisiecardiologie-na-het-hartinfarct-opkomende-biomarkers-voor-risicostra/","title":"Naar precisiecardiologie na het hartinfarct: opkomende biomarkers voor risicostratificatie","title_en":"","published":"2026-06-18"}],"10.1093/eurheartj/ehag357":[{"url":"https://hartvaat.nl/2026/05/18/global-hicc-register-950-hofh-patienten-uit-45-landen-slechts-4-haalt-ldl-doelen/","title":"Global HICC-register: 950+ HoFH-patiënten uit 45 landen — slechts 4% haalt LDL-doelen, mediane sterfteleeftijd 37 jaar","title_en":"","published":"2026-06-17"}],"10.1016/j.jacasi.2026.03.031":[{"url":"https://hartvaat.nl/2026/05/18/helios-b-post-hoc-vutrisiran-effectief-bij-oost-aziatische-attr-cm-patienten-hr-/","title":"HELIOS-B post-hoc: vutrisiran effectief bij Oost-Aziatische ATTR-CM-patiënten (HR 0,20 voor mortaliteit/CV-events)","title_en":"","published":"2026-06-17"}],"10.1161/jaha.125.047961":[{"url":"https://hartvaat.nl/2026/05/19/finacaf-n-229-565-hartfalen-verhoogt-cva-risico-bij-af-vooral-bij-jongere-patien/","title":"FinACAF (n=229.565): hartfalen verhoogt CVA-risico bij AF vooral bij jongere patiënten","title_en":"","published":"2026-06-17"}],"10.1093/eurheartj/ehag351":[{"url":"https://hartvaat.nl/2026/05/19/clopidogrel-versus-aspirine-bij-chronisch-coronair-syndroom-meta-analyse-toont-w/","title":"Clopidogrel versus aspirine bij chronisch coronair syndroom: meta-analyse toont winst — maar vooral bij Oost-Aziaten","title_en":"","published":"2026-06-16"}],"10.1161/jaha.125.048476":[{"url":"https://hartvaat.nl/2026/05/19/gezond-eetpatroon-verlaagt-cv-risico-bij-kankeroverlevenden-los-van-genetisch-ri/","title":"Gezond eetpatroon verlaagt CV-risico bij kankeroverlevenden — los van genetisch risico (UK Biobank, n=10.414)","title_en":"","published":"2026-06-16"}],"10.1161/jaha.125.042950":[{"url":"https://hartvaat.nl/2026/05/19/eldercare-af-post-hoc-edoxaban-spiegel-en-pt-13s-voorspellen-bloedingsrisico-bij/","title":"ELDERCARE-AF post-hoc: edoxaban-spiegel én PT >13s voorspellen bloedingsrisico bij zeer oude AF-patiënten","title_en":"","published":"2026-06-16"}],"10.1161/jaha.126.049161":[{"url":"https://hartvaat.nl/2026/05/19/sglt2-remmers-bij-oudere-patienten-opgenomen-voor-hfref-24-sterfte-en-16-heropna/","title":"SGLT2-remmers bij oudere patiënten opgenomen voor HFrEF: -24% sterfte en -16% heropname bij start vóór ontslag","title_en":"","published":"2026-06-15"}],"10.1161/jaha.125.046238":[{"url":"https://hartvaat.nl/2026/05/19/sglt2-remmers-head-to-head-empagliflozin-licht-beter-dan-canagliflozin-bij-matig/","title":"SGLT2-remmers head-to-head: empagliflozin licht beter dan canagliflozin bij matig CV-risico (target trial van 137.232 patiënten)","title_en":"","published":"2026-06-15"}],"10.1016/j.ijcard.2026.134560":[{"url":"https://hartvaat.nl/2026/05/19/tirzepatide-bij-hfpef-obesitas-niet-kosteneffectief-en-niet-betaalbaar-tegen-hui/","title":"Tirzepatide bij HFpEF + obesitas: niet kosteneffectief en niet betaalbaar tegen huidige prijs in Duitsland","title_en":"","published":"2026-06-15"}],"10.1161/jaha.125.048272":[{"url":"https://hartvaat.nl/2026/05/19/vertraagde-intracraniele-bloeding-na-trombectomie-geassocieerd-met-slechtere-fun/","title":"Vertraagde intracraniële bloeding na trombectomie geassocieerd met slechtere functionele uitkomst en SBP >150 mmHg","title_en":"","published":"2026-06-14"}],"10.1161/jaha.125.047236":[{"url":"https://hartvaat.nl/2026/05/19/team-gebaseerde-telehealth-bloeddrukbehandeling-acceptabel-en-haalbaar-in-achter/","title":"Team-gebaseerde telehealth-bloeddrukbehandeling acceptabel en haalbaar in achterstandsklinieken — mixed-methods evaluatie","title_en":"","published":"2026-06-14"}],"10.1093/eurheartj/ehag265":[{"url":"https://hartvaat.nl/2026/05/19/ehj-review-dyslipidemie-bij-kankerpatienten-verhoogd-ascvd-risico-beperkte-data-/","title":"EHJ-review: dyslipidemie bij kankerpatiënten — verhoogd ASCVD-risico, beperkte data, behoefte aan kankerspecifieke risicoscores","title_en":"","published":"2026-06-14"}],"10.1161/jaha.125.046659":[{"url":"https://hartvaat.nl/2026/05/19/peulvruchten-in-de-voeding-verlagen-ldl-en-non-hdl-dose-response-meta-analyse-va/","title":"Peulvruchten in de voeding verlagen LDL en non-HDL: dose-response meta-analyse van 38 RCT's","title_en":"","published":"2026-06-13"}],"10.1161/jaha.126.049917":[{"url":"https://hartvaat.nl/2026/05/19/clear-taiwan-bempedoinezuur-verlaagt-ldl-met-19-in-real-world-aziatische-populat/","title":"CLEAR Taiwan: bempedoïnezuur verlaagt LDL met 19% in real-world Aziatische populatie","title_en":"","published":"2026-06-13"}],"10.1093/eurheartj/ehag345":[{"url":"https://hartvaat.nl/2026/05/19/esc-atlas-2025-3-miljoen-cvd-doden-per-jaar-in-europa-middeninkomenlanden-hebben/","title":"ESC Atlas 2025: 3 miljoen CVD-doden per jaar in Europa — middeninkomenlanden hebben dubbele sterfte","title_en":"","published":"2026-06-13"}],"10.1093/eurheartj/ehag328":[{"url":"https://hartvaat.nl/2026/05/19/lipoproteine-aferese-blijft-relevant-in-het-tijdperk-van-pcsk9-remmers-en-sirna/","title":"Lipoproteïne-aferese blijft relevant in het tijdperk van PCSK9-remmers en siRNA","title_en":"","published":"2026-06-12"}],"10.1161/jaha.125.048456":[{"url":"https://hartvaat.nl/2026/05/19/therapietrouw-trajecten-na-ischemisch-cva-vroeg-dubbel-staken-verhoogt-sterfte-e/","title":"Therapietrouw-trajecten na ischemisch CVA: vroeg dubbel staken verhoogt sterfte en recidief met ~50%","title_en":"","published":"2026-06-12"}],"10.1161/jaha.125.043655":[{"url":"https://hartvaat.nl/2026/05/19/victorion-inception-vroege-inclisiran-na-acuut-coronair-syndroom-verviervoudigt-/","title":"VICTORION-INCEPTION: vroege inclisiran na acuut coronair syndroom verviervoudigt het halen van LDL-doel","title_en":"","published":"2026-06-12"}],"10.1161/jaha.125.047852":[{"url":"https://hartvaat.nl/2026/05/19/mobiele-screeningseenheid-in-detroit-70-van-inwoners-in-achtergestelde-wijken-he/","title":"Mobiele screeningseenheid in Detroit: 70% van inwoners in achtergestelde wijken heeft minstens één onbeheerste cardiometabole risicofactor","title_en":"","published":"2026-06-11"}],"10.1161/jaha.125.043789":[{"url":"https://hartvaat.nl/2026/05/19/life-s-essential-8-lichaamsbeweging-is-de-sterkste-schakel-tussen-laag-inkomen-e/","title":"Life's Essential 8: lichaamsbeweging is de sterkste schakel tussen laag inkomen en cardiovasculair risico","title_en":"","published":"2026-06-11"}],"10.1161/jaha.125.044003":[{"url":"https://hartvaat.nl/2026/05/19/beste-bewegingsvorm-voor-bloeddruk-combinatietraining-en-hiit-geven-12-6-mmhg-in/","title":"Beste bewegingsvorm voor bloeddruk: combinatietraining en HIIT geven -12/-6 mmHg in netwerk-meta-analyse","title_en":"","published":"2026-06-11"}],"10.1161/jaha.125.046408":[{"url":"https://hartvaat.nl/2026/05/19/stop-cad-1-op-6-cervicale-arteriedissecties-wordt-aanvankelijk-verkeerd-gediagno/","title":"STOP-CAD: 1 op 6 cervicale arteriedissecties wordt aanvankelijk verkeerd gediagnosticeerd","title_en":"","published":"2026-06-10"}],"10.1161/jaha.125.046625":[{"url":"https://hartvaat.nl/2026/05/19/salamander-register-95-5-technisch-succes-bij-stand-alone-linker-hartoor-occlusi/","title":"SALAMANDER-register: 95,5% technisch succes bij stand-alone linker-hartoor-occlusie in Europese praktijk","title_en":"","published":"2026-06-10"}],"10.1093/eurheartj/ehag308":[{"url":"https://hartvaat.nl/2026/05/20/nutrinet-sante-voedselconserveermiddelen-geassocieerd-met-meer-hypertensie-en-ca/","title":"NutriNet-Santé: voedselconserveermiddelen geassocieerd met meer hypertensie en cardiovasculaire ziekte","title_en":"","published":"2026-06-10"}],"10.1093/eurjpc/zwag279":[{"url":"https://hartvaat.nl/2026/05/21/glp-1-agonisten-kosten-geen-spiermassa-tijdens-intensieve-hartrevalidatie/","title":"GLP-1-agonisten kosten geen spiermassa tijdens intensieve hartrevalidatie","title_en":"","published":"2026-06-09"}],"10.1136/openhrt-2026-004059":[{"url":"https://hartvaat.nl/2026/05/21/1-op-10-patienten-heroptname-binnen-30-dagen-na-tavi-sterfterisico-na-1-jaar-ver/","title":"1 op 10 patiënten heroptname binnen 30 dagen na TAVI — sterfterisico na 1 jaar verdrievoudigd","title_en":"","published":"2026-06-09"}],"10.1136/openhrt-2026-004108":[{"url":"https://hartvaat.nl/2026/05/21/melatonine-en-cardiovasculair-risico-nhanes-nuanceert-recent-hartfalen-signaal-v/","title":"Melatonine en cardiovasculair risico: NHANES nuanceert recent hartfalen-signaal van AHA 2025","title_en":"","published":"2026-06-09"}],"10.1136/openhrt-2025-003858":[{"url":"https://hartvaat.nl/2026/05/21/eplerenon-halveert-recidief-ventriculaire-tachycardie-versus-spironolacton-bij-h/","title":"Eplerenon halveert recidief ventriculaire tachycardie versus spironolacton bij hartfalen","title_en":"","published":"2026-06-08"}],"10.1007/s00380-026-02669-0":[{"url":"https://hartvaat.nl/2026/05/21/bij-coronaire-vasospasmen-zonder-significante-stenose-voorspelt-verhoogd-lp-a-ge/","title":"Bij coronaire vasospasmen zonder significante stenose voorspelt verhoogd Lp(a) geen MACE","title_en":"","published":"2026-06-08"}],"10.1093/eschf/xvag144":[{"url":"https://hartvaat.nl/2026/05/21/find-af-biomarker-stratificeert-prognose-bij-hfref-met-atriale-cardiomyopathie-z/","title":"FIND-AF-biomarker stratificeert prognose bij HFrEF met atriale cardiomyopathie zonder atriumfibrilleren","title_en":"","published":"2026-06-08"}],"10.1093/eurheartj/ehag373":[{"url":"https://hartvaat.nl/2026/05/22/chirurgisch-unroofing-van-myocardiale-brug-verbetert-angina-klachten-langdurig-m/","title":"Chirurgisch unroofing van myocardiale brug verbetert angina-klachten langdurig (mediaan 5 jaar follow-up)","title_en":"","published":"2026-06-07"}],"10.1681/asn.0000001158":[{"url":"https://hartvaat.nl/2026/05/22/autosomaal-dominante-alport-syndroom-meest-voorkomende-monogene-nierziekte-1-van/","title":"Autosomaal dominante Alport-syndroom: meest voorkomende monogene nierziekte (1% van de bevolking)","title_en":"","published":"2026-06-07"}],"10.1093/eurjpc/zwag273":[{"url":"https://hartvaat.nl/2026/05/22/orale-pcsk9-remmers-meta-analyse-bevestigt-krachtige-ldl-daling/","title":"Orale PCSK9-remmers: meta-analyse bevestigt krachtige LDL-daling","title_en":"Efficacy and Safety of Oral PCSK9 Inhibitors: Insights from a Meta-analysis of RCTs.","published":"2026-06-07"}],"10.1093/ejhf/xuag179":[{"url":"https://hartvaat.nl/2026/05/22/epicardiaal-vetweefsel-voorspelt-aritmieen-en-hartfalen-events-bij-genotype-posi/","title":"Epicardiaal vetweefsel voorspelt aritmieën en hartfalen-events bij genotype-positieve HCM","title_en":"","published":"2026-06-06"}],"10.1093/eschf/xvag149":[{"url":"https://hartvaat.nl/2026/05/22/m-teer-werkt-over-het-volledige-lvef-spectrum-vergroot-linkeratrium-volume-voors/","title":"M-TEER werkt over het volledige LVEF-spectrum; vergroot linkeratrium-volume voorspelt slechtere uitkomst","title_en":"","published":"2026-06-06"}],"10.1161/circimaging.125.019408":[{"url":"https://hartvaat.nl/2026/05/22/lge-granulariteit-op-cmr-voorspelt-sterfte-bij-eindstadium-hypertrofische-cardio/","title":"LGE-granulariteit op CMR voorspelt sterfte bij eindstadium hypertrofische cardiomyopathie","title_en":"","published":"2026-06-06"}],"10.1186/s40842-026-00299-z":[{"url":"https://hartvaat.nl/2026/05/22/brede-inzet-van-oraal-semaglutide-in-de-vs-zou-jaarlijks-tot-60-000-cardiovascul/","title":"Brede inzet van oraal semaglutide in de VS zou jaarlijks tot 60.000 cardiovasculaire events kunnen voorkomen","title_en":"","published":"2026-06-05"}],"10.1093/eschf/xvag136":[{"url":"https://hartvaat.nl/2026/05/23/paradise-cohort-hartfalen-en-copd-samen-verhogen-de-langetermijnmortaliteit-met-/","title":"PARADISE-cohort: hartfalen en COPD samen verhogen de langetermijnmortaliteit, met name HF","title_en":"","published":"2026-06-05"}],"10.1093/eurheartj/ehag446":[{"url":"https://hartvaat.nl/2026/05/24/lp-a-japan-verhoogd-lp-a-blijft-risicovol-ondanks-ldl-onder-55-mg-dl/","title":"Lp(a)-JAPAN: verhoogd Lp(a) blijft risicovol ondanks LDL onder 55 mg/dl","title_en":"Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended LDL-C goals.","published":"2026-06-05"}],"10.1016/j.jcin.2026.03.023":[{"url":"https://hartvaat.nl/2026/05/25/rca-en-hoofdstamstenosen-geven-hoogste-kans-op-plotse-hartdood-revascularisatie-/","title":"RCA- en hoofdstamstenosen geven hoogste kans op plotse hartdood — revascularisatie-strategie moduleert risico","title_en":"","published":"2026-06-04"}],"10.1161/jaha.125.048751":[{"url":"https://hartvaat.nl/2026/05/25/1-op-5-oudere-patienten-heeft-hartfalen-opname-binnen-jaar-na-tavr-1-jaarsmortal/","title":"1 op 5 oudere patiënten heeft hartfalen-opname binnen jaar na TAVR — 1-jaarsmortaliteit 44% versus 4%","title_en":"","published":"2026-06-04"}],"10.1186/s12933-026-03215-y":[{"url":"https://hartvaat.nl/2026/05/25/semaglutide-verlaagt-mortaliteit-cv-events-en-nierschade-in-alle-stadia-van-ckm-/","title":"Semaglutide verlaagt mortaliteit, CV-events én nierschade in alle stadia van CKM-syndroom: meta-analyse van 39.204 patiënten","title_en":"","published":"2026-06-04"}],"https://www.leefh.nl/":[{"url":"https://hartvaat.nl/2026/06/04/fh-opsporing-in-nederland-zet-stabiele-lijn-voort-in-2026/","title":"FH-opsporing in Nederland zet stabiele lijn voort in 2026","title_en":"FH cascade screening in the Netherlands holds its steady course in 2026","published":"2026-06-04"}],"10.1093/eurjpc/zwag198":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","title":"EAS FHSC: wereldwijd onderzoek toont grote variatie in genetische FH-diagnostiek — pleidooi voor standaardisatie","title_en":"Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.","published":"2026-06-04"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00123-1/fulltext":[{"url":"https://hartvaat.nl/2026/05/24/eas-consensus-wereldwijde-harmonisatie-van-lipidenklinieken/","title":"EAS-consensus: wereldwijde harmonisatie van lipidenklinieken","title_en":"Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics","published":"2026-06-04"}],"10.1161/jaha.125.046251":[{"url":"https://hartvaat.nl/2026/05/25/explorer-cn-week-78-langetermijneffect-en-veiligheid-van-mavacamten-bij-chinese-/","title":"EXPLORER-CN week 78: langetermijneffect en veiligheid van mavacamten bij Chinese patiënten met obstructieve HCM","title_en":"","published":"2026-06-03"}],"10.1161/circulationaha.126.080999":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","title":"VESALIUS-CV: Lp(a) voorspelt risico, evolocumab werkt ongeacht uitgangswaarde","title_en":"Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.","published":"2026-06-03"}],"10.1093/eurheartj/ehag382":[{"url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","title":"EAS-consensus: familiaire hypercholesterolemie bij kinderen en adolescenten","title_en":"Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.","published":"2026-06-03"}],"10.1093/eurheartj/ehag348":[{"url":"https://hartvaat.nl/2026/05/25/betami-danblock-is-representatief-betablokker-effect-ook-geldig-in-echte-noorse-/","title":"BETAMI-DANBLOCK is representatief: bètablokker-effect ook geldig in echte Noorse infarct-populatie","title_en":"","published":"2026-06-02"}],"10.1093/eurheartj/ehag388":[{"url":"https://hartvaat.nl/2026/05/25/longembolie-epidemiologie-stijgende-last-bij-vergrijzing-preventiestrategieen-bl/","title":"Longembolie-epidemiologie: stijgende last bij vergrijzing — preventiestrategieën blijven achter","title_en":"","published":"2026-06-02"}],"10.1093/eurheartj/ehag399":[{"url":"https://hartvaat.nl/2026/05/25/obicetrapib-verlaagt-naast-ldl-en-apob-ook-lipoproteine-a/","title":"Obicetrapib verlaagt naast LDL en apoB ook lipoproteïne(a)","title_en":"Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.","published":"2026-06-02"}],"10.1136/heartjnl-2025-327389":[{"url":"https://hartvaat.nl/2026/05/25/pah-met-renaal-diabetische-overlap-komt-vaak-voor-en-geeft-tweemaal-zo-hoog-mort/","title":"PAH met renaal-diabetische overlap komt vaak voor en geeft tweemaal zo hoog mortaliteitsrisico","title_en":"","published":"2026-06-01"}],"10.1093/eurheartj/ehag380":[{"url":"https://hartvaat.nl/2026/05/25/koreaanse-studie-van-3-7-miljoen-postmenopauzale-vrouwen-hormonale-levensloop-vo/","title":"Koreaanse studie van 3,7 miljoen postmenopauzale vrouwen: hormonale levensloop voorspelt hartfalen-risico","title_en":"","published":"2026-06-01"}],"10.1186/s12933-026-03219-8":[{"url":"https://hartvaat.nl/2026/05/25/diabetes-en-calcifierende-aortaklepziekte-gedeelde-immunometabole-pathways-en-th/","title":"Diabetes en calcifiërende aortaklepziekte: gedeelde immunometabole pathways en therapeutische kandidaten","title_en":"","published":"2026-06-01"}],"10.1016/j.kint.2026.03.031":[{"url":"https://hartvaat.nl/2026/05/25/kdigo-overzicht-de-nier-centraal-in-het-cardiovasculair-renaal-metabool-ckm-synd/","title":"KDIGO-overzicht: de nier centraal in het cardiovasculair-renaal-metabool (CKM) syndroom","title_en":"","published":"2026-05-31"}],"10.1007/s10741-026-10639-x":[{"url":"https://hartvaat.nl/2026/05/25/het-spectrum-van-congestie-bij-hartfalen-pathofysiologie-en-diagnostische-strate/","title":"Het spectrum van congestie bij hartfalen: pathofysiologie en diagnostische strategieën","title_en":"","published":"2026-05-31"}],"10.1016/j.ijcard.2026.134587":[{"url":"https://hartvaat.nl/2026/05/25/klassieke-lv-gls-overtreft-nieuwe-atriale-cmr-parameters-bij-voorspelling-van-lv/","title":"Klassieke LV-GLS overtreft nieuwe atriale CMR-parameters bij voorspelling van LV-remodelling na voorwand-STEMI","title_en":"","published":"2026-05-31"}],"10.1093/eschf/xvag150":[{"url":"https://hartvaat.nl/2026/05/26/adipokineprofiel-bij-acuut-hartfalen-voorspelt-natriuretische-respons-en-mortali/","title":"Adipokineprofiel bij acuut hartfalen voorspelt natriuretische respons en mortaliteit","title_en":"","published":"2026-05-30"}],"10.1093/eurheartj/ehag394":[{"url":"https://hartvaat.nl/2026/05/26/car-t-therapie-bij-ouderen-5-8-mace-en-sterk-verhoogde-mortaliteit-cardio-oncolo/","title":"CAR-T-therapie bij ouderen: 5,8% MACE en sterk verhoogde mortaliteit — cardio-oncologie attent","title_en":"","published":"2026-05-30"}],"10.1007/s00228-026-04081-z":[{"url":"https://hartvaat.nl/2026/05/26/ongericimab-nieuwe-pcsk9-antistof-verlaagt-ldl-fors-in-meta-analyse/","title":"Ongericimab: nieuwe PCSK9-antistof verlaagt LDL fors in meta-analyse","title_en":"Efficacy and safety of Ongericimab in patients with hypercholesterolemia: a systematic review and meta-analysis.","published":"2026-05-30"}],"10.1093/eurheartj/ehag317":[{"url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","title":"ODYSSEY-OUTCOMES post-hoc: hsCRP en IL-6 zijn complementaire prognostische markers na ACS","title_en":"","published":"2026-05-29"}],"10.1007/s10741-026-10636-0":[{"url":"https://hartvaat.nl/2026/05/26/state-of-the-art-mra-s-bij-hartfalen-en-nierziekte-over-alle-ejectiefracties/","title":"State-of-the-art: MRA's bij hartfalen en nierziekte over alle ejectiefracties","title_en":"","published":"2026-05-29"}],"10.1093/eurheartj/ehag334":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensusverklaring-over-microvasculaire-obstructie-en-no-reflow-na-stemi/","title":"ESC-consensusverklaring over microvasculaire obstructie en no-reflow na STEMI","title_en":"","published":"2026-05-29"}],"10.1093/eurheartj/ehag350":[{"url":"https://hartvaat.nl/2026/05/26/esc-consensus-vrouwenhartcentra-whc-als-nieuw-zorgmodel-in-europa/","title":"ESC-consensus: vrouwenhartcentra (WHC) als nieuw zorgmodel in Europa","title_en":"","published":"2026-05-28"}],"10.1161/circimaging.126.019610":[{"url":"https://hartvaat.nl/2026/05/27/multimodaal-ai-model-verhoogt-accuratesse-van-echo-diagnose-cardiale-amyloidose/","title":"Multimodaal AI-model verhoogt accuratesse van echo-diagnose cardiale amyloïdose","title_en":"","published":"2026-05-28"}],"10.1038/s41366-026-02110-6":[{"url":"https://hartvaat.nl/2026/05/27/sglt2-remmers-verminderen-epicardiaal-vetweefsel-meta-analyse-van-11-studies/","title":"SGLT2-remmers verminderen epicardiaal vetweefsel: meta-analyse van 11 studies","title_en":"","published":"2026-05-28"}],"10.1093/europace/euag080":[{"url":"https://hartvaat.nl/2026/04/12/ehra-statement-pulsed-field-ablatie-als-nieuwe-standaard-voor-ablatie-bij-atrium/","title":"EHRA-statement: pulsed field-ablatie als nieuwe standaard voor ablatie bij atriumfibrilleren","title_en":"Pulsed Field Ablation for the Interventional Treatment of Atrial Fibrillation. A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS) and the Canadian Heart Rhythm Society (CHRS).","published":"2026-05-27"}],"10.1093/eschf/xvag111":[{"url":"https://hartvaat.nl/2026/04/17/glp-1-receptoragonisten-geassocieerd-met-lagere-mortaliteit-bij-hfref/","title":"GLP-1-receptoragonisten geassocieerd met lagere mortaliteit bij HFrEF","title_en":"Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.","published":"2026-05-26"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00098-5/fulltext":[{"url":"https://hartvaat.nl/2026/04/10/vroege-evolocumab-na-hartinfarct-verlaagt-mace-bij-uitgestelde-randstenosen/","title":"Vroege evolocumab na hartinfarct verlaagt MACE bij uitgestelde randstenosen","title_en":"Evolocumab in patients with multivessel coronary disease after acute myocardial infarction: A target trial emulation.","published":"2026-05-25"}],"10.1056/nejmoa2601283":[{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","title":"VERVE-102: eenmalige base-editing schakelt PCSK9 blijvend uit (fase 1)","title_en":"In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia","published":"2026-05-25"}],"10.1093/eschf/xvag120":[{"url":"https://hartvaat.nl/2026/05/05/inotropica-bij-low-output-hartfalen-vergelijkbare-hemodynamische-effecten-in-met/","title":"Inotropica bij low-output hartfalen: vergelijkbare hemodynamische effecten in meta-analyse","title_en":"The Quantitative Haemodynamic Effect of Levosimendan, Dobutamine and Milrinone in Heart Failure Patients: a Meta-Analysis.","published":"2026-05-24"}],"10.1093/europace/euag059":[{"url":"https://hartvaat.nl/2026/04/13/intracardiale-echocardiografie-in-de-elektrofysiologie-gezamenlijk-ehra-eapci-st/","title":"Intracardiale echocardiografie in de elektrofysiologie: gezamenlijk EHRA/EAPCI-statement","title_en":"Intracardiac echocardiography during invasive electrophysiological procedures. A scientific statement of the European Heart Rhythm Association of the ESC, and the European Association of Percutaneous Cardiovascular Interventions of the ESC.","published":"2026-05-23"}],"http://heart.bmj.com/cgi/content/short/112/10/557?rss=1":[{"url":"https://hartvaat.nl/2026/04/24/ita-bypass-veilig-bij-patienten-met-eerdere-mediastinale-bestraling-maryland-coh/","title":"ITA-bypass veilig bij patiënten met eerdere mediastinale bestraling: Maryland-cohort van 29.206","title_en":"Safety of internal thoracic artery use in patients with prior mediastinal radiation undergoing coronary artery bypass grafting: a Maryland statewide propensity-matched analysis","published":"2026-05-22"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26519":[{"url":"https://hartvaat.nl/2026/04/09/thuis-bloeddruk-time-in-target-range-hoger-percentage-in-doel-geassocieerd-met-m/","title":"Thuis-bloeddruk-time-in-target-range: hoger percentage in doel geassocieerd met minder hersenlaesies","title_en":"IoT-Based Home Blood Pressure Time in Target Range and Brain Lesions on MRI","published":"2026-05-22"}],"10.1016/j.pcad.2026.05.005":[{"url":"https://hartvaat.nl/2026/05/22/il-6-sterker-met-hart-en-vaatziekte-geassocieerd-dan-ldl-lp-a-en-crp/","title":"IL-6 sterker met hart- en vaatziekte geassocieerd dan LDL, Lp(a) en CRP","title_en":"Comparative associations of LDL-C, Lp(a), hsCRP, and IL-6 with cardiovascular risk: Insights from the UK Biobank and MESA.","published":"2026-05-22"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00082-1/fulltext":[{"url":"https://hartvaat.nl/2026/04/29/de-secretoire-pcsk-familie-van-moleculaire-schakelaars-tot-doelwit-voor-cardiova/","title":"De secretoire PCSK-familie: van moleculaire schakelaars tot doelwit voor cardiovasculaire therapie","title_en":"The secretory PCSK family in cardiovascular disease and beyond","published":"2026-05-21"}],"10.1161/cir.0000000000001434":[{"url":"https://hartvaat.nl/2026/05/13/aha-scientific-statement-2026-secundaire-preventie-na-coronaire-bypassoperatie-e/","title":"AHA Scientific Statement 2026: secundaire preventie na coronaire bypassoperatie — eerste update sinds 2015","title_en":"","published":"2026-05-15"}],"10.1093/eurheartj/ehag331":[{"url":"https://hartvaat.nl/2026/05/11/ehj-editorial-cleland-wereldwijde-hartfalenprevalentie-overschrijdt-600-miljoen-/","title":"EHJ-editorial Cleland: wereldwijde hartfalenprevalentie overschrijdt 600 miljoen — van gokken naar evidence","title_en":"","published":"2026-05-12"}],"10.1093/eurheartj/ehag384":[{"url":"https://hartvaat.nl/2026/05/11/finearts-hf-subanalyse-virale-luchtweginfecties-triggeren-hartfalen-verslechteri/","title":"FINEARTS-HF subanalyse: virale luchtweginfecties triggeren hartfalen-verslechtering, finerenon-effect blijft behouden","title_en":"","published":"2026-05-12"}],"10.1161/cir.0000000000001428":[{"url":"https://hartvaat.nl/2026/05/12/aha-scientific-statement-evaluatie-en-behandeling-van-het-kind-met-acuut-gedecom/","title":"AHA Scientific Statement: evaluatie en behandeling van het kind met acuut gedecompenseerd hartfalen","title_en":"","published":"2026-05-12"}],"10.1161/circulationaha.126.078843":[{"url":"https://hartvaat.nl/2026/05/12/massieve-lvh-bij-pediatrische-hcm-vroeger-diagnose-vaker-sarcomere-variant-driev/","title":"Massieve LVH bij pediatrische HCM: vroeger diagnose, vaker sarcomere variant, drievoudig verhoogde sterfte","title_en":"","published":"2026-05-12"}],"10.1001/jama.2026.5633":[{"url":"https://hartvaat.nl/2026/05/11/hcmr-nhlbi-multidimensionele-risicovoorspelling-beter-dan-scd-gefocuste-richtlij/","title":"HCMR (NHLBI): multidimensionele risicovoorspelling beter dan SCD-gefocuste richtlijnen bij hypertrofische cardiomyopathie","title_en":"","published":"2026-05-12"}],"10.1161/circulationaha.126.079918":[{"url":"https://hartvaat.nl/2026/05/12/cadence-sotatercept-verlaagt-pulmonale-vaatweerstand-bij-gecombineerde-pre-postc/","title":"CADENCE: sotatercept verlaagt pulmonale vaatweerstand bij gecombineerde pre/postcapillaire PH bij HFpEF","title_en":"","published":"2026-05-12"}],"10.1093/ejhf/xuag160":[{"url":"https://hartvaat.nl/2026/05/10/paradise-gelijktijdig-acuut-hartfalen-plus-luchtweginfectie-verhoogt-sterfte-tij/","title":"PARADISE: gelijktijdig acuut hartfalen plus luchtweginfectie verhoogt sterfte tijdens opname, niet daarna","title_en":"","published":"2026-05-11"}],"10.1093/ejhf/xuag061":[{"url":"https://hartvaat.nl/2026/05/10/hartfalen-en-infarct-verdrievoudigen-het-risico-op-kanker-vooral-hematologisch/","title":"Hartfalen en infarct verdrievoudigen het risico op kanker — vooral hematologisch","title_en":"","published":"2026-05-11"}],"10.1093/ejhf/xuag154":[{"url":"https://hartvaat.nl/2026/05/10/porthos-nt-probnp-afkapwaarden-onbetrouwbaar-bij-obese-patienten-risico-op-gemis/","title":"PORTHOS: NT-proBNP-afkapwaarden onbetrouwbaar bij obese patiënten — risico op gemiste hartfalendiagnose","title_en":"","published":"2026-05-11"}],"10.1093/ejhf/xuag155":[{"url":"https://hartvaat.nl/2026/05/10/poseidon-4-op-10-patienten-met-hartfalen-wereldwijd-heeft-inflammatoir-verhoogd-/","title":"POSEIDON: 4 op 10 patiënten met hartfalen wereldwijd heeft inflammatoir verhoogd hsCRP — basis voor anti-inflammatoire therapie","title_en":"","published":"2026-05-11"}],"https://www.prnewswire.com/news-releases/results-of-the-randomized-controlled-trial-of-at-home-subcutaneous-diuretic-therapy-for-heart-failure-associated-edema-to-be-presented-at-heart-failure-2026-302760746.html":[{"url":"https://hartvaat.nl/2026/05/09/subcut-hf-ii-subcutane-furosemide-thuis-verlaagt-opnameduur-met-5-5-dagen-na-har/","title":"SUBCUT HF II: subcutane furosemide thuis verlaagt opnameduur met 5,5 dagen na hartfalenopname","title_en":"","published":"2026-05-11"}],"http://heart.bmj.com/cgi/content/short/112/10/576?rss=1":[{"url":"https://hartvaat.nl/2026/04/24/astma-geassocieerd-met-verhoogd-risico-op-degeneratieve-hartklepziekte-uk-bioban/","title":"Astma geassocieerd met verhoogd risico op degeneratieve hartklepziekte — UK Biobank","title_en":"","published":"2026-05-11"}],"http://heart.bmj.com/cgi/content/short/112/10/539?rss=1":[{"url":"https://hartvaat.nl/2026/04/24/cardiovasculaire-ziekte-bij-sikkelcelziekte-ondergediagnosticeerde-drijver-van-m/","title":"Cardiovasculaire ziekte bij sikkelcelziekte: ondergediagnosticeerde drijver van mortaliteit","title_en":"","published":"2026-05-11"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001431":[{"url":"https://hartvaat.nl/2026/04/23/aha-statement-kinderen-met-cardiomyopathie-mogen-meer-bewegen/","title":"AHA-statement: kinderen met cardiomyopathie mogen meer bewegen","title_en":"","published":"2026-05-11"}],"10.1093/ejhf/xuag146":[{"url":"https://hartvaat.nl/2026/05/09/telesat-prior-hf-telemonitoring-na-hartfalenopname-verbonden-met-46-lagere-morta/","title":"TELESAT PRIOR-HF: telemonitoring na hartfalenopname verbonden met 46% lagere mortaliteit","title_en":"","published":"2026-05-10"}],"10.1093/ejhf/xuag157":[{"url":"https://hartvaat.nl/2026/05/10/delta-hf-thoracale-duct-lymfedecongestie-via-elym-systeem-haalbaar-bij-acute-har/","title":"DELTA-HF: thoracale-duct lymfedecongestie via eLym-systeem haalbaar bij acute hartfalen","title_en":"","published":"2026-05-10"}],"10.1001/jama.2026.7335":[{"url":"https://hartvaat.nl/2026/05/10/dig-rhd-digoxine-verlaagt-sterfte-en-hartfalen-bij-symptomatische-reumatische-ha/","title":"Dig-RHD: digoxine verlaagt sterfte en hartfalen bij symptomatische reumatische hartziekte","title_en":"","published":"2026-05-10"}],"10.1093/eurheartj/ehag387":[{"url":"https://hartvaat.nl/2026/05/09/meta-analyse-decision-digit-hf-dig-digitalisglycosiden-reduceren-verslechterende/","title":"Meta-analyse DECISION + DIGIT-HF + DIG: digitalisglycosiden reduceren verslechterende hartfalenevents over 9.013 patiënten","title_en":"","published":"2026-05-10"}],"10.1038/s41591-026-04406-6":[{"url":"https://hartvaat.nl/2026/05/10/decision-lage-dosis-digoxine-mist-primair-eindpunt-bij-hf-m-ref-maar-suggereert-/","title":"DECISION: lage-dosis digoxine mist primair eindpunt bij HF(m)rEF, maar suggereert minder verslechterende hartfalenevents","title_en":"","published":"2026-05-10"}],"10.1038/s41591-026-04408-4":[{"url":"https://hartvaat.nl/2026/05/10/hf-revert-antisense-mirna-remmer-cdr132l-mist-primair-eindpunt-na-infarct-met-ve/","title":"HF-REVERT: antisense miRNA-remmer CDR132L mist primair eindpunt na infarct met verminderde EF","title_en":"","published":"2026-05-10"}],"10.1161/circulationaha.126.080833":[{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamiek-bij-hfpef-met-a/","title":"PRAISE-MR: sacubitril-valsartan verbetert inspanningshemodynamiek bij HFpEF met atriale mitralisinsufficiëntie","title_en":"","published":"2026-05-10"}],"10.1136/bmjopen-2025-105379":[{"url":"https://hartvaat.nl/2026/04/24/bij-metabool-syndroom-zonder-diabetes-of-hypertensie-bloeddruk-en-triglyceriden-/","title":"Bij metabool syndroom zonder diabetes of hypertensie: bloeddruk en triglyceriden zijn de sleutel","title_en":"","published":"2026-05-10"}],"http://heart.bmj.com/cgi/content/short/112/10/563?rss=1":[{"url":"https://hartvaat.nl/2026/04/24/grote-ziekenhuisvariatie-in-mcs-gebruik-bij-myocardinfarct-met-cardiogene-shock/","title":"Grote ziekenhuisvariatie in MCS-gebruik bij myocardinfarct met cardiogene shock","title_en":"","published":"2026-05-10"}],"http://heart.bmj.com/cgi/content/short/112/10/530?rss=1":[{"url":"https://hartvaat.nl/2026/04/24/bayesiaanse-netwerkmeta-analyse-vergelijkt-revascularisatie-bij-stabiele-ischemi/","title":"Bayesiaanse netwerkmeta-analyse vergelijkt revascularisatie bij stabiele ischemische hartziekte","title_en":"","published":"2026-05-10"}],"http://heart.bmj.com/cgi/content/short/112/10/549?rss=1":[{"url":"https://hartvaat.nl/2026/04/24/crt-bij-volwassenen-met-systemische-rechterventrikel-gemengde-uitkomsten-in-inte/","title":"CRT bij volwassenen met systemische rechterventrikel: gemengde uitkomsten in internationaal cohort","title_en":"","published":"2026-05-09"}],"10.1093/eurheartj/ehag313":[{"url":"https://hartvaat.nl/2026/04/27/genen-voor-bloeddruk-in-de-kindertijd-voorspellen-cardiometabool-risico-op-later/","title":"Genen voor bloeddruk in de kindertijd voorspellen cardiometabool risico op latere leeftijd","title_en":"","published":"2026-05-09"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.080638":[{"url":"https://hartvaat.nl/2026/04/25/praetorian-dft-defibrillatietest-bij-subcutane-icd-veilig-achterwege-te-laten/","title":"PRAETORIAN-DFT: defibrillatietest bij subcutane ICD veilig achterwege te laten","title_en":"","published":"2026-05-09"}],"10.1136/bmjopen-2025-114031":[{"url":"https://hartvaat.nl/2026/04/24/santorini-uk-ldl-doel-onbereikt-bij-meerderheid-van-hoogrisicopatienten-na-1-jaa/","title":"SANTORINI UK: LDL-doel onbereikt bij meerderheid van hoogrisicopatiënten na 1 jaar","title_en":"","published":"2026-05-08"}],"http://heart.bmj.com/cgi/content/short/112/10/569?rss=1":[{"url":"https://hartvaat.nl/2026/04/24/verminderde-nierfunctie-verhoogt-hartfalenrisico-bij-ouderen-aspree-cohort/","title":"Verminderde nierfunctie verhoogt hartfalenrisico bij ouderen — ASPREE-cohort","title_en":"","published":"2026-05-08"}],"10.1001/jamanetworkopen.2026.9082":[{"url":"https://hartvaat.nl/2026/04/01/noac-s-onder-de-65-jaar-apixaban-heeft-het-gunstigste-baten-risicoprofiel/","title":"NOAC's onder de 65 jaar: apixaban heeft het gunstigste baten-risicoprofiel","title_en":"","published":"2026-05-08"}],"10.1093/ndt/gfag083":[{"url":"https://hartvaat.nl/2026/04/24/nkf-consensus-standaardiseer-urine-afname-om-albuminurie-betrouwbaar-te-meten/","title":"NKF-consensus: standaardiseer urine-afname om albuminurie betrouwbaar te meten","title_en":"","published":"2026-05-07"}],"10.1093/eschf/xvag116":[{"url":"https://hartvaat.nl/2026/05/05/verminderde-rv-vrijewandstrain-voorspelt-mcs-behoefte-bij-cardiogene-shock/","title":"Verminderde RV-vrijewandstrain voorspelt MCS-behoefte bij cardiogene shock","title_en":"","published":"2026-05-07"}],"10.1093/eurheartj/ehag186":[{"url":"https://hartvaat.nl/2026/04/24/gecombineerde-mitraal-en-tricuspidalis-teer-verbetert-overleving-bij-multivalvul/","title":"Gecombineerde mitraal- en tricuspidalis-TEER verbetert overleving bij multivalvulair lijden","title_en":"","published":"2026-05-07"}],"10.1093/europace/euag097":[{"url":"https://hartvaat.nl/2026/05/06/circulerend-mir-10b-5p-voorspelt-af-recidief-na-ablatie/","title":"Circulerend miR-10b-5p voorspelt AF-recidief na ablatie","title_en":"","published":"2026-05-06"}],"10.1016/j.atherosclerosis.2026.120650":[{"url":"https://hartvaat.nl/2026/04/01/risicofactoren-voor-cardiovasculaire-events-bij-heterozygote-familiaire-hypercho/","title":"Risicofactoren voor cardiovasculaire events bij heterozygote familiaire hypercholesterolemie","title_en":"","published":"2026-05-06"}],"10.1093/eurheartj/ehag316":[{"url":"https://hartvaat.nl/2026/04/22/maternale-auto-immuunziekte-verhoogt-cardiovasculair-risico-bij-nakomelingen/","title":"Maternale auto-immuunziekte verhoogt cardiovasculair risico bij nakomelingen","title_en":"","published":"2026-05-06"}],"10.1016/j.atherosclerosis.2026.120668":[{"url":"https://hartvaat.nl/2026/04/19/fh-vrouwen-verliezen-mediaan-2-9-jaar-lipidenverlagende-behandeling-rond-elke-ki/","title":"FH-vrouwen verliezen mediaan 2,9 jaar lipidenverlagende behandeling rond elke kinderwens","title_en":"","published":"2026-05-05"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26227":[{"url":"https://hartvaat.nl/2026/04/22/obesitas-en-primair-aldosteronisme-oorzaak-gevolg-of-beide/","title":"Obesitas en primair aldosteronisme: oorzaak, gevolg of beide?","title_en":"","published":"2026-05-05"}],"10.1093/eurjpc/zwag230":[{"url":"https://hartvaat.nl/2026/04/22/angptl3-remmers-verlagen-breed-lipidenspectrum-vooral-remnant-en-triglyceriden/","title":"ANGPTL3-remmers verlagen breed lipidenspectrum, vooral remnant- en triglyceriden","title_en":"","published":"2026-05-05"}],"10.1093/eurheartj/ehag311":[{"url":"https://hartvaat.nl/2026/04/28/geen-sekseverschillen-in-werkzaamheid-van-hartfalenmedicatie-meta-analyse-van-13/","title":"Geen sekseverschillen in werkzaamheid van hartfalenmedicatie: meta-analyse van 139 RCT's","title_en":"","published":"2026-05-05"}],"10.1016/j.atherosclerosis.2026.120760":[{"url":"https://hartvaat.nl/2026/04/25/preoperatieve-pcsk9-remming-associeert-met-minder-postoperatieve-mace-dan-statin/","title":"Preoperatieve PCSK9-remming associeert met minder postoperatieve MACE dan statines","title_en":"","published":"2026-05-04"}],"10.1093/eschf/xvag119":[{"url":"https://hartvaat.nl/2026/04/27/routinematige-urine-natriummeting-drijft-agressievere-diurese-bij-acuut-hartfale/","title":"Routinematige urine-natriummeting drijft agressievere diurese bij acuut hartfalen","title_en":"","published":"2026-05-04"}],"10.1001/jamanetworkopen.2026.9584":[{"url":"https://hartvaat.nl/2026/04/01/doorgaan-met-dezelfde-doac-na-breakthrough-beroerte-even-goed-als-wisselen/","title":"Doorgaan met dezelfde DOAC na breakthrough-beroerte even goed als wisselen","title_en":"","published":"2026-05-04"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26388":[{"url":"https://hartvaat.nl/2026/04/22/cardiovasculair-polygeen-risico-voorspelt-witte-stof-hyperintensiteiten-in-uk-bi/","title":"Cardiovasculair polygeen risico voorspelt witte-stof-hyperintensiteiten in UK Biobank","title_en":"","published":"2026-05-03"}],"10.1093/europace/euag095":[{"url":"https://hartvaat.nl/2026/05/06/dronedaron-na-af-ablatie-gelijke-werkzaamheid-minder-bijwerkingen-dan-amiodaron/","title":"Dronedaron na AF-ablatie: gelijke werkzaamheid, minder bijwerkingen dan amiodaron","title_en":"","published":"2026-05-03"}],"10.1093/eurheartj/ehag309":[{"url":"https://hartvaat.nl/2026/04/28/viborg-screeningsprogramma-verlaagt-5-jaarssterfte-bij-67-jarigen/","title":"Viborg-screeningsprogramma verlaagt 5-jaarssterfte bij 67-jarigen","title_en":"","published":"2026-05-03"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25807":[{"url":"https://hartvaat.nl/2026/04/27/mexicaanse-hypertensieprevalentie-daalt-over-twee-decennia-behandelingsgaten-bli/","title":"Mexicaanse hypertensieprevalentie daalt over twee decennia, behandelingsgaten blijven","title_en":"","published":"2026-05-02"}],"10.1093/ndt/gfag090":[{"url":"https://hartvaat.nl/2026/04/20/raas-blokkade-in-de-levenscyclus-van-de-nier-actuele-behandelstandaard/","title":"RAAS-blokkade in de levenscyclus van de nier — actuele behandelstandaard","title_en":"","published":"2026-05-02"}],"10.1016/j.jacl.2026.03.019":[{"url":"https://hartvaat.nl/2026/04/01/lp-a-verlaging-vergelijkbaar-tussen-alle-pcsk9-gerichte-middelen/","title":"Lp(a)-verlaging vergelijkbaar tussen alle PCSK9-gerichte middelen","title_en":"","published":"2026-05-02"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.27004":[{"url":"https://hartvaat.nl/2026/04/23/large-language-models-in-de-hypertensiezorg-kansen-en-grenzen/","title":"Large language models in de hypertensiezorg: kansen en grenzen","title_en":"","published":"2026-05-01"}],"10.1093/eschf/xvag115":[{"url":"https://hartvaat.nl/2026/05/05/hfa-consensus-gestructureerde-aanpak-van-recent-ontstane-cardiomyopathie/","title":"HFA-consensus: gestructureerde aanpak van recent ontstane cardiomyopathie","title_en":"","published":"2026-05-01"}],"10.1093/eurheartj/ehag338":[{"url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","title":"STOPSTORM: stereotactische bestraling reduceert refractaire VT met 80%","title_en":"","published":"2026-05-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2849186":[{"url":"https://hartvaat.nl/2026/05/01/jama-cardiology-missie-en-visie/","title":"JAMA Cardiology: missie en visie","title_en":"JAMA Cardiology","published":"2026-05-01"}],"10.1016/j.jacl.2026.03.022":[{"url":"https://hartvaat.nl/2026/04/01/verhoogd-lp-a-hangt-samen-met-mitralisring-calcificatie-maar-niet-met-mitralisin/","title":"Verhoogd Lp(a) hangt samen met mitralisring-calcificatie maar niet met mitralisinsufficiëntie","title_en":"","published":"2026-04-30"}],"10.1093/europace/euag072":[{"url":"https://hartvaat.nl/2026/03/30/leadless-atriaal-pacen-geeft-minder-complicaties-dan-transveneus-1-jaars-medicar/","title":"Leadless atriaal pacen geeft minder complicaties dan transveneus — 1-jaars Medicare-data","title_en":"","published":"2026-04-30"}],"10.1056/nejmoa2515043":[{"url":"https://hartvaat.nl/2026/04/23/triple-pill-verlaagt-risico-op-terugkerende-beroerte-na-hersenbloeding/","title":"Triple-pill verlaagt risico op terugkerende beroerte na hersenbloeding","title_en":"","published":"2026-04-30"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.080072":[{"url":"https://hartvaat.nl/2026/03/30/adapt-cec-adaptief-ai-algoritme-voor-cardiovasculaire-event-adjudicatie-in-klini/","title":"ADAPT-CEC: adaptief AI-algoritme voor cardiovasculaire event-adjudicatie in klinische trials","title_en":"","published":"2026-04-28"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001428":[{"url":"https://hartvaat.nl/2026/04/06/aha-scientific-statement-acute-decompensatie-bij-hartfalen-in-het-kind-integraal/","title":"AHA Scientific Statement: acute decompensatie bij hartfalen in het kind — integraal managementkader","title_en":"","published":"2026-04-28"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(26)00419-8/fulltext":[{"url":"https://hartvaat.nl/2026/03/16/the-lancet-commentaar-vroege-atheroma-preventie-als-kosteneffectieve-route-naar-/","title":"The Lancet-commentaar: vroege atheroma-preventie als kosteneffectieve route naar gezond cardiovasculair ouder worden","title_en":"","published":"2026-04-28"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.078152":[{"url":"https://hartvaat.nl/2026/03/25/fontan-outcomes-network-eerste-bevindingen-uit-noord-amerikaans-register-van-1-1/","title":"Fontan Outcomes Network: eerste bevindingen uit Noord-Amerikaans register van 1.121 Fontan-patiënten","title_en":"","published":"2026-04-27"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.078996":[{"url":"https://hartvaat.nl/2026/03/25/lvad-ondersteuning-activeert-microvasculair-herstel-in-het-falende-hart-mechanis/","title":"LVAD-ondersteuning activeert microvasculair herstel in het falende hart: mechanisme ontrafeld","title_en":"","published":"2026-04-27"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.079781":[{"url":"https://hartvaat.nl/2026/03/28/echofocus-chd-ai-model-detecteert-20-aangeboren-hartafwijkingen-op-standaard-ech/","title":"EchoFocus-CHD: AI-model detecteert 20 aangeboren hartafwijkingen op standaard echocardiografie","title_en":"","published":"2026-04-27"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077833":[{"url":"https://hartvaat.nl/2026/03/31/mr-proadm-voorspelt-mortaliteit-en-hf-events-bij-attr-cardiale-amyloidose/","title":"MR-proADM voorspelt mortaliteit en HF-events bij ATTR cardiale amyloïdose","title_en":"","published":"2026-04-26"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2845161":[{"url":"https://hartvaat.nl/2026/04/01/zwangerschap-als-stresstest-consensus-over-langetermijn-cardiovasculair-risico-b/","title":"Zwangerschap als stresstest: consensus over langetermijn-cardiovasculair risico bij adverse pregnancy outcomes","title_en":"","published":"2026-04-26"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001419":[{"url":"https://hartvaat.nl/2026/03/26/aha-scientific-statement-niet-optimale-omgevingstemperatuur-als-cardiovasculaire/","title":"AHA Scientific Statement: niet-optimale omgevingstemperatuur als cardiovasculaire risicofactor","title_en":"","published":"2026-04-26"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.078763":[{"url":"https://hartvaat.nl/2026/03/18/systematische-review-welke-factoren-voorspellen-langetermijnrisico-op-beroerte-n/","title":"Systematische review: welke factoren voorspellen langetermijnrisico op beroerte na TIA of kleine beroerte?","title_en":"","published":"2026-04-25"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.079859":[{"url":"https://hartvaat.nl/2026/03/30/crt-zonder-atriale-lead-tweeledig-crt-dx-systeem-non-inferieur-aan-klassieke-dri/","title":"CRT zonder atriale lead: tweeledig CRT-DX-systeem non-inferieur aan klassieke drie-leads CRT-D","title_en":"","published":"2026-04-25"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.079918":[{"url":"https://hartvaat.nl/2026/03/29/cadence-sotatercept-verlaagt-pulmonale-vaatweerstand-bij-gecombineerde-pulmonale/","title":"CADENCE: sotatercept verlaagt pulmonale vaatweerstand bij gecombineerde pulmonale hypertensie bij HFpEF","title_en":"","published":"2026-04-25"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077894":[{"url":"https://hartvaat.nl/2026/04/01/aric-ckm-syndroom-stadiering-voorspelt-hartfalen-risico-bij-ouderen-ook-met-subk/","title":"ARIC: CKM-syndroom stadiëring voorspelt hartfalen-risico bij ouderen — ook met subklinisch echoprofiel","title_en":"","published":"2026-04-24"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2845804":[{"url":"https://hartvaat.nl/2026/04/01/conduction-system-pacing-versus-biventriculaire-pacing-twee-trials-vergelijken-b/","title":"Conduction System Pacing versus biventriculaire pacing: twee trials vergelijken beide CRT-strategieën","title_en":"","published":"2026-04-24"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001435":[{"url":"https://hartvaat.nl/2026/03/31/aha-scientific-statement-2026-nieuwe-voedingsleidraad-voor-cardiovasculaire-gezo/","title":"AHA Scientific Statement 2026: nieuwe voedingsleidraad voor cardiovasculaire gezondheid","title_en":"","published":"2026-04-24"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.080234":[{"url":"https://hartvaat.nl/2026/03/28/minoca-oorzaken-bij-vrouwen-en-mannen-in-beeld-gebracht-met-oct-en-cmr/","title":"MINOCA-oorzaken bij vrouwen én mannen in beeld gebracht met OCT en CMR","title_en":"","published":"2026-04-23"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2845590":[{"url":"https://hartvaat.nl/2026/04/01/franse-multicentertrial-lage-dosis-rivaroxaban-verlaagt-linkerventrikeltrombus-n/","title":"Franse multicentertrial: lage dosis rivaroxaban verlaagt linkerventrikeltrombus na anterior STEMI","title_en":"","published":"2026-04-23"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.080012":[{"url":"https://hartvaat.nl/2026/03/30/essence-timi-73b-apoc3-remmer-olezarsen-reduceert-niet-verkalkte-coronairplaque-/","title":"Essence-TIMI 73b: APOC3-remmer olezarsen reduceert niet-verkalkte coronairplaque bij hypertriglyceridemie","title_en":"","published":"2026-04-23"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.079023":[{"url":"https://hartvaat.nl/2026/03/19/memantine-remt-premature-atriumcontracties-in-fase-2-trial-nieuw-aangrijpingspun/","title":"Memantine remt premature atriumcontracties in fase 2-trial — nieuw aangrijpingspunt voor atriale aritmie","title_en":"","published":"2026-04-22"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.126.079839":[{"url":"https://hartvaat.nl/2026/03/30/heparin-stemi-prehospitale-heparine-vergroot-vroege-doorstroming-bij-stemi-zonde/","title":"HEPARIN-STEMI: prehospitale heparine vergroot vroege doorstroming bij STEMI zonder meer bloedingen","title_en":"","published":"2026-04-22"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001423":[{"url":"https://hartvaat.nl/2026/03/13/2026-acc-aha-richtlijn-dyslipidemie-lagere-doelen-meer-rol-voor-non-hdl-lp-a-en-/","title":"2026 ACC/AHA-richtlijn dyslipidemie: lagere doelen, meer rol voor non-HDL, Lp(a) en apoB","title_en":"","published":"2026-04-22"}],"10.1093/eurheartj/ehag189":[{"url":"https://hartvaat.nl/2026/03/25/ehj-review-wearables-in-de-cardiovasculaire-praktijk-hoe-ver-zijn-we/","title":"EHJ-review: wearables in de cardiovasculaire praktijk — hoe ver zijn we?","title_en":"","published":"2026-04-21"}],"10.1093/ndt/gfag070":[{"url":"https://hartvaat.nl/2026/03/23/clorotic-subanalyse-acute-egfr-daling-door-thiaziden-bij-acuut-hf-is-geen-progno/","title":"CLOROTIC-subanalyse: acute eGFR-daling door thiaziden bij acuut HF is geen prognostisch alarm","title_en":"","published":"2026-04-21"}],"10.1093/eurheartj/ehaf1038":[{"url":"https://hartvaat.nl/2026/03/24/myocardiale-brug-praktische-gids-voor-diagnose-en-behandeling-in-het-ccta-tijdpe/","title":"Myocardiale brug: praktische gids voor diagnose en behandeling in het CCTA-tijdperk","title_en":"","published":"2026-04-21"}],"10.1093/eschf/xvag095":[{"url":"https://hartvaat.nl/2026/03/03/tien-jaar-real-world-sacubitril-valsartan-mortaliteitsreductie-bevestigd-maar-sl/","title":"Tien jaar real-world sacubitril/valsartan: mortaliteitsreductie bevestigd, maar slechts 15–25% haalt doeldosis","title_en":"","published":"2026-04-20"}],"10.1016/j.jacadv.2026.102697":[{"url":"https://hartvaat.nl/2026/03/25/mendeliaanse-randomisatie-lp-a-verhoogt-coronarialijden-onafhankelijk-van-ldl-c-/","title":"Mendeliaanse randomisatie: Lp(a) verhoogt coronarialijden onafhankelijk van LDL-C, maar niet het diabetesrisico","title_en":"","published":"2026-04-20"}],"10.1093/europace/euag049":[{"url":"https://hartvaat.nl/2026/03/17/athena-register-pulsed-field-ablatie-voor-atriumfibrilleren-ook-effectief-bij-ha/","title":"ATHENA-register: pulsed field ablatie voor atriumfibrilleren ook effectief bij hartfalen, vooral paroxismaal","title_en":"","published":"2026-04-20"}],"10.1093/eurheartj/ehag214":[{"url":"https://hartvaat.nl/2026/03/28/gestandaardiseerd-stappenplan-voor-tricuspidalisinsufficientie-van-verwijzing-to/","title":"Gestandaardiseerd stappenplan voor tricuspidalisinsufficiëntie: van verwijzing tot expertcentrum","title_en":"","published":"2026-04-19"}],"10.1253/circj.cj-25-1189":[{"url":"https://hartvaat.nl/2026/03/20/hokuriku-plus-genetische-diagnose-bij-familiaire-hypercholesterolemie-verlaagt-m/","title":"Hokuriku-Plus: genetische diagnose bij familiaire hypercholesterolemie verlaagt MACE-risico onafhankelijk van LDL-C","title_en":"","published":"2026-04-19"}],"10.1093/europace/euag046":[{"url":"https://hartvaat.nl/2026/03/30/linear-trial-lattice-tip-katheter-verslaat-standaard-irrigatie-bij-cti-ablatie-v/","title":"LINEAR-trial: lattice-tip-katheter verslaat standaard irrigatie bij CTI-ablatie voor typische atriumflutter","title_en":"","published":"2026-04-19"}],"10.1093/eurheartj/ehag162":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","title":"FINE-HEART: vrouwen met cardiovasculair-renaal-metabool syndroom worden systematisch onderbehandeld","title_en":"","published":"2026-04-18"}],"10.1093/eurheartj/ehag252":[{"url":"https://hartvaat.nl/2026/03/28/lp-a-verhoogt-risico-op-veneuze-trombo-embolie-bij-premenopauzale-vrouwen-en-hor/","title":"Lp(a) verhoogt risico op veneuze trombo-embolie bij premenopauzale vrouwen en hormoon-gebruiksters","title_en":"","published":"2026-04-18"}],"10.1093/eschf/xvag091":[{"url":"https://hartvaat.nl/2026/03/25/meta-analyse-glp-1-agonisten-voorkomen-hartfalen-in-type-2-diabetes-sterkste-eff/","title":"Meta-analyse: GLP-1-agonisten voorkomen hartfalen in type 2 diabetes, sterkste effect met semaglutide","title_en":"","published":"2026-04-18"}],"10.1681/asn.0000001071":[{"url":"https://hartvaat.nl/2026/03/29/confidence-analyse-acute-egfr-daling-bij-empagliflozin-finerenone-is-reversibel-/","title":"CONFIDENCE-analyse: acute eGFR-daling bij empagliflozin + finerenone is reversibel en geen reden om te stoppen","title_en":"","published":"2026-04-17"}],"10.1093/eurheartj/ehag168":[{"url":"https://hartvaat.nl/2026/03/29/uk-biobank-hogere-intensiteit-van-beweging-belangrijker-dan-totale-tijd-voor-car/","title":"UK Biobank: hogere intensiteit van beweging belangrijker dan totale tijd voor cardiovasculair risico","title_en":"","published":"2026-04-17"}],"10.1001/jama.2026.3277":[{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-subgroep-jama-evolocumab-beschermt-ook-diabeten-zonder-vastgestelde-/","title":"VESALIUS-CV-subgroep JAMA: evolocumab beschermt ook diabeten zonder vastgestelde atherosclerose","title_en":"","published":"2026-04-17"}],"10.1093/eurheartj/ehaf1123":[{"url":"https://hartvaat.nl/2026/03/05/nationaal-cardiologisch-netwerk-als-nieuwe-zorgstandaard-in-polen/","title":"Nationaal cardiologisch netwerk als nieuwe zorgstandaard in Polen","title_en":"","published":"2026-04-12"}],"10.5551/jat.66056":[{"url":"https://hartvaat.nl/2026/03/03/prasugrel-vs-clopidogrel-invloed-van-patientkenmerken-op-trombocytenremming-bij-/","title":"Prasugrel vs. clopidogrel: invloed van patiëntkenmerken op trombocytenremming bij acute beroerte","title_en":"","published":"2026-04-12"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00067-5/fulltext":[{"url":"https://hartvaat.nl/2026/03/05/trem-1-remming-vermindert-in-stent-neoatherosclerose-in-diermodel/","title":"TREM-1-remming vermindert in-stent neoatherosclerose in diermodel","title_en":"","published":"2026-04-12"}],"10.1093/eschf/xvag071":[{"url":"https://hartvaat.nl/2026/03/05/nlr-trajecten-versus-absolute-waarden-als-prognostische-marker-bij-acuut-hartfal/","title":"NLR-trajecten versus absolute waarden als prognostische marker bij acuut hartfalen","title_en":"","published":"2026-04-11"}],"10.1093/europace/euag027":[{"url":"https://hartvaat.nl/2026/02/13/leadless-pacemaker-implantatie-ter-hoogte-van-de-bundel-van-bachmann/","title":"Leadless pacemaker-implantatie ter hoogte van de bundel van Bachmann","title_en":"","published":"2026-04-11"}],"10.1093/europace/euag026":[{"url":"https://hartvaat.nl/2026/02/03/ultrakorte-radiofrequentieablatie-voor-vena-cava-superior-isolatie/","title":"Ultrakorte radiofrequentieablatie voor vena cava superior-isolatie","title_en":"","published":"2026-04-11"}],"https://www.kidney-international.org/article/s0085-2538(26)00140-7/fulltext":[{"url":"https://hartvaat.nl/2026/02/27/smoothened-signalering-bevordert-nierfibrose-via-autofagieremming/","title":"Smoothened-signalering bevordert nierfibrose via autofagieremming","title_en":"","published":"2026-04-10"}],"https://www.kidney-international.org/article/s0085-2538(26)00141-9/fulltext":[{"url":"https://hartvaat.nl/2026/02/27/pdgf-b-uit-tubulusepitheel-drijft-nierfibrose-aan/","title":"PDGF-B uit tubulusepitheel drijft nierfibrose aan","title_en":"","published":"2026-04-10"}],"10.1093/eurheartj/ehaf1106":[{"url":"https://hartvaat.nl/2026/03/05/ongelijke-toegang-tot-cardiovasculaire-zorg-in-europa/","title":"Ongelijke toegang tot cardiovasculaire zorg in Europa","title_en":"","published":"2026-04-10"}],"10.1253/circj.cj-25-0590":[{"url":"https://hartvaat.nl/2026/03/04/ivus-segmentatiemethoden-vergeleken-in-de-pacman-ami-trial/","title":"IVUS-segmentatiemethoden vergeleken in de PACMAN-AMI-trial","title_en":"","published":"2026-04-09"}],"10.1093/eurheartj/ehaf1096":[{"url":"https://hartvaat.nl/2026/02/26/cardiologen-onderschatten-omgevingsrisicofactoren/","title":"Cardiologen onderschatten omgevingsrisicofactoren","title_en":"","published":"2026-04-09"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077882":[{"url":"https://hartvaat.nl/2026/03/02/micro-en-nanoplastics-nieuw-perspectief-voor-cardiovasculaire-preventie/","title":"Micro- en nanoplastics: nieuw perspectief voor cardiovasculaire preventie","title_en":"","published":"2026-04-09"}],"https://www.sciencedirect.com/science/article/pii/s0735109725101526?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/kwaliteit-van-hartfalenzorg-bij-aziatische-patienten-in-de-vs/","title":"Kwaliteit van hartfalenzorg bij Aziatische patiënten in de VS","title_en":"","published":"2026-04-08"}],"https://www.sciencedirect.com/science/article/pii/s0735109726003013?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/voedingskwaliteit-en-plantaardige-voeding-centraal-voor-cardiovasculaire-gezondh/","title":"Voedingskwaliteit en plantaardige voeding centraal voor cardiovasculaire gezondheid","title_en":"","published":"2026-04-08"}],"10.5551/jat.rv22048":[{"url":"https://hartvaat.nl/2026/03/03/cardiovasculaire-mortaliteit-bij-chronische-nierziekte-en-dialyse-een-tweestappe/","title":"Cardiovasculaire mortaliteit bij chronische nierziekte en dialyse: een tweestappenmodel","title_en":"","published":"2026-04-08"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00063-8/fulltext":[{"url":"https://hartvaat.nl/2026/03/06/sociaaleconomische-status-en-cardiovasculaire-ziekte-wereldwijde-meta-analyse/","title":"Sociaaleconomische status en cardiovasculaire ziekte: wereldwijde meta-analyse","title_en":"","published":"2026-04-08"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00052-3/fulltext":[{"url":"https://hartvaat.nl/2026/03/03/evolocumab-naast-empagliflozine-verandert-ldl-subdeeltjes-bij-type-2-diabetes/","title":"Evolocumab naast empagliflozine verandert LDL-subdeeltjes bij type 2 diabetes","title_en":"","published":"2026-04-08"}],"10.1093/eschf/xvag069":[{"url":"https://hartvaat.nl/2026/03/05/ai-echocardiografie-door-niet-specialisten-kosteneffectiviteitsanalyse-uit-singa/","title":"AI-echocardiografie door niet-specialisten: kosteneffectiviteitsanalyse uit Singapore","title_en":"","published":"2026-04-08"}],"10.1093/europace/euag037":[{"url":"https://hartvaat.nl/2026/03/03/darmmicrobioom-bevordert-atriumfibrilleren-bij-chronische-nierziekte-via-nlrp3-i/","title":"Darmmicrobioom bevordert atriumfibrilleren bij chronische nierziekte via NLRP3-inflammasoom","title_en":"","published":"2026-04-07"}],"10.1093/eschf/xvag067":[{"url":"https://hartvaat.nl/2026/03/02/stand-van-zaken-palliatieve-zorg-bij-hartfalen/","title":"Stand van zaken: palliatieve zorg bij hartfalen","title_en":"","published":"2026-04-07"}],"10.1111/jch.70221":[{"url":"https://hartvaat.nl/2026/03/01/non-hdl-hdl-ratio-als-voorspeller-van-cardiovasculaire-ziekte-bij-ckm-syndroom/","title":"Non-HDL/HDL-ratio als voorspeller van cardiovasculaire ziekte bij CKM-syndroom","title_en":"","published":"2026-04-07"}],"10.1016/j.ahj.2026.107400":[{"url":"https://hartvaat.nl/2026/02/28/epic-hiv-trial-pcsk9-remming-ter-cardiovasculaire-preventie-bij-hiv-patienten/","title":"EPIC-HIV trial: PCSK9-remming ter cardiovasculaire preventie bij hiv-patiënten","title_en":"","published":"2026-04-06"}],"10.1136/openhrt-2025-003530":[{"url":"https://hartvaat.nl/2026/02/26/ai-clustering-identificeert-functionele-risicofenotypen-bij-hartfalen/","title":"AI-clustering identificeert functionele risicofenotypen bij hartfalen","title_en":"","published":"2026-04-06"}],"10.1093/europace/euag030":[{"url":"https://hartvaat.nl/2026/02/26/fluoroscopieminimalisatie-bij-svt-ablatie-door-vrouwelijke-elektrofysiologen/","title":"Fluoroscopieminimalisatie bij SVT-ablatie door vrouwelijke elektrofysiologen","title_en":"","published":"2026-04-06"}],"10.1093/europace/euag031":[{"url":"https://hartvaat.nl/2026/02/03/klinische-impact-van-veiligheidswaarschuwingen-voor-implanteerbare-pacemakers-en/","title":"Klinische impact van veiligheidswaarschuwingen voor implanteerbare pacemakers en defibrillatoren","title_en":"","published":"2026-04-05"}],"https://www.kidney-international.org/article/s0085-2538(25)00950-0/fulltext":[{"url":"https://hartvaat.nl/2026/03/04/veroudering-immuundysfunctie-en-nierfibrose-kip-of-ei/","title":"Veroudering, immuundysfunctie en nierfibrose: kip of ei?","title_en":"","published":"2026-04-05"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26518":[{"url":"https://hartvaat.nl/2026/03/04/winterhypertensie-koude-als-cardiovasculaire-risicofactor/","title":"Winterhypertensie: koude als cardiovasculaire risicofactor","title_en":"","published":"2026-04-05"}],"https://www.kidney-international.org/article/s0085-2538(26)00145-6/fulltext":[{"url":"https://hartvaat.nl/2026/02/27/gerichte-immunotherapie-bij-nierziekten-b-cel-targeting-en-car-t/","title":"Gerichte immunotherapie bij nierziekten: B-cel-targeting en CAR-T","title_en":"","published":"2026-04-04"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26706":[{"url":"https://hartvaat.nl/2026/02/26/ai-model-voorspelt-nachtelijke-hypertensie-bij-chronische-nierziekte/","title":"AI-model voorspelt nachtelijke hypertensie bij chronische nierziekte","title_en":"","published":"2026-04-04"}],"10.1093/eurheartj/ehag059":[{"url":"https://hartvaat.nl/2026/03/06/editoriaal-langetermijnresultaten-van-aficamten-bij-obstructieve-hcm/","title":"Editoriaal: langetermijnresultaten van aficamten bij obstructieve HCM","title_en":"","published":"2026-04-04"}],"10.1093/eurheartj/ehaf841":[{"url":"https://hartvaat.nl/2026/03/05/microrna-s-in-de-celkern-sturen-hartmetabolisme-bij-hfpef/","title":"MicroRNA's in de celkern sturen hartmetabolisme bij HFpEF","title_en":"","published":"2026-04-03"}],"10.1093/eurheartj/ehag163":[{"url":"https://hartvaat.nl/2026/03/05/coronairverkalkingen-en-myocardiale-flowreserve-na-harttransplantatie/","title":"Coronairverkalkingen en myocardiale flowreserve na harttransplantatie","title_en":"","published":"2026-04-03"}],"10.1093/eurheartj/ehag067":[{"url":"https://hartvaat.nl/2026/03/05/nucleair-ago2-verergert-hfpef-via-myocardiale-ketogenese/","title":"Nucleair AGO2 verergert HFpEF via myocardiale ketogenese","title_en":"","published":"2026-04-03"}],"10.1093/eurheartj/ehag137":[{"url":"https://hartvaat.nl/2026/03/05/cardio-oncologie-een-snel-veranderend-vakgebied/","title":"Cardio-oncologie: een snel veranderend vakgebied","title_en":"","published":"2026-04-02"}],"10.1253/circj.cj-26-0036":[{"url":"https://hartvaat.nl/2026/02/28/onbeantwoorde-vragen-over-lipoproteine-a-en-atherosclerose/","title":"Onbeantwoorde vragen over lipoproteïne(a) en atherosclerose","title_en":"","published":"2026-04-02"}],"10.1161/circresaha.125.327881":[{"url":"https://hartvaat.nl/2026/02/24/adamts-7-vaccin-beschermt-nieren-en-vaten-bij-chronische-nierziekte/","title":"ADAMTS-7-vaccin beschermt nieren en vaten bij chronische nierziekte","title_en":"","published":"2026-04-02"}],"10.1093/eurheartj/ehaf525":[{"url":"https://hartvaat.nl/2026/02/24/parodontale-behandeling-remt-progressie-van-atherosclerose/","title":"Parodontale behandeling remt progressie van atherosclerose","title_en":"","published":"2026-04-01"}],"10.1093/eurheartj/ehag121":[{"url":"https://hartvaat.nl/2026/02/24/kwaliteitscriteria-voor-ai-implementatie-in-de-cardiologie-bijgewerkt/","title":"Kwaliteitscriteria voor AI-implementatie in de cardiologie bijgewerkt","title_en":"","published":"2026-04-01"}],"10.1093/eurheartj/ehag109":[{"url":"https://hartvaat.nl/2026/02/23/ehj-editoriaal-hartfalen-en-cardiomyopathieen/","title":"EHJ-editoriaal: hartfalen en cardiomyopathieën","title_en":"","published":"2026-04-01"}],"10.1016/j.atherosclerosis.2025.120416":[{"url":"https://hartvaat.nl/2026/04/01/kosteneffectiviteit-van-cascadescreening-voor-familiaire-hypercholesterolemie-ti/","title":"Kosteneffectiviteit van cascadescreening voor familiaire hypercholesterolemie (tijdelijk verwijderd)","title_en":"TEMPORARY REMOVAL: Cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolemia with realistic cascade screening acceptance rates and use of novel treatment","published":"2026-04-01"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077172":[{"url":"https://hartvaat.nl/2026/03/02/senescente-p16-cellen-verergeren-hartremodellering-na-ischemie-via-cytotoxische-/","title":"Senescente P16+ cellen verergeren hartremodellering na ischemie via cytotoxische lymfocyten","title_en":"","published":"2026-03-31"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076372":[{"url":"https://hartvaat.nl/2026/03/02/extracellulaire-vesikels-medieren-adipocyt-cardiomyocytcommunicatie-bij-diabetis/","title":"Extracellulaire vesikels mediëren adipocyt-cardiomyocytcommunicatie bij diabetisch ischemisch hartfalen","title_en":"","published":"2026-03-31"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(25)02643-1/fulltext":[{"url":"https://hartvaat.nl/2026/02/28/clopidogrel-versus-aspirine-bij-coronairlijden-kanttekeningen-bij-meta-analyse/","title":"Clopidogrel versus aspirine bij coronairlijden: kanttekeningen bij meta-analyse","title_en":"","published":"2026-03-31"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003750?rss=1":[{"url":"https://hartvaat.nl/2026/03/31/titine-cardiomyopathie-meestal-dcm-of-linksdominante-acm-met-blijvend-ritmestoor/","title":"Titine-cardiomyopathie: meestal DCM of linksdominante ACM, met blijvend ritmestoornisrisico","title_en":"Genotype-phenotype correlations in patients with pathogenic/likely pathogenic titin variants from the Swiss Arrhythmogenic Cardiomyopathy Registry","published":"2026-03-31"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003608?rss=1":[{"url":"https://hartvaat.nl/2026/03/31/gespecialiseerde-hartklepklinieken-leiden-tot-betere-richtlijnconforme-zorg/","title":"Gespecialiseerde hartklepklinieken leiden tot betere richtlijnconforme zorg","title_en":"Specialised heart valve clinics result in greater adherence to guideline-directed care: a comparative study","published":"2026-03-31"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004098?rss=1":[{"url":"https://hartvaat.nl/2026/03/31/volwassenen-met-een-ventrikelseptumdefect-hebben-drie-keer-hogere-sterfte-zweeds/","title":"Volwassenen met een ventrikelseptumdefect hebben drie keer hogere sterfte (Zweeds register)","title_en":"Mortality in patients with ventricular septal defect in Sweden: a national register study","published":"2026-03-31"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003886?rss=1":[{"url":"https://hartvaat.nl/2026/03/31/stemi-uitgestelde-primaire-pci-gaat-gepaard-met-hogere-sterfte-dan-trombolyse-ie/","title":"STEMI: uitgestelde primaire PCI gaat gepaard met hogere sterfte dan trombolyse (Iers register)","title_en":"Outcomes according to timely or delayed primary PCI or fibrinolysis in a national registry of STEMI patients","published":"2026-03-31"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003659?rss=1":[{"url":"https://hartvaat.nl/2026/03/31/tofacitinib-bij-cardiale-sarcoidose-veelbelovend-als-corticosteroidsparende-beha/","title":"Tofacitinib bij cardiale sarcoïdose: veelbelovend als corticosteroïdsparende behandeling","title_en":"Tofacitinib in the treatment of cardiac sarcoidosis: towards steroid-sparing disease management","published":"2026-03-31"}],"10.1093/ndt/gfaf198":[{"url":"https://hartvaat.nl/2026/03/31/era-s-abcde-raamwerk-voor-preventie-van-nierziekten/","title":"ERA's ABCDE-raamwerk voor preventie van nierziekten","title_en":"ERA's ABCDE Framework for Kidney Disease Prevention: Turning the WHO Kidney Health Resolution into action.","published":"2026-03-31"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000732?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/acc-braunwald-lecture-2025-cardiovasculaire-wetenschap-en-maatschappij/","title":"ACC Braunwald Lecture 2025: cardiovasculaire wetenschap en maatschappij","title_en":"","published":"2026-03-30"}],"https://www.sciencedirect.com/science/article/pii/s073510972600207x?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/coronaire-atherosclerose-bij-levertransplantatiepatienten-vergeleken-met-algemen/","title":"Coronaire atherosclerose bij levertransplantatiepatiënten vergeleken met algemene bevolking","title_en":"","published":"2026-03-30"}],"https://www.sciencedirect.com/science/article/pii/s0735109726003293?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/noodprotocollen-voor-plotse-hartstilstand-bij-jonge-sporters-moeten-worden-aange/","title":"Noodprotocollen voor plotse hartstilstand bij jonge sporters moeten worden aangescherpt","title_en":"","published":"2026-03-30"}],"10.1016/j.jacep.2026.03.026":[{"url":"https://hartvaat.nl/2026/03/30/leaf-liraglutide-voor-ablatie-verbetert-af-vrije-overleving/","title":"LEAF: liraglutide vóór ablatie verbetert AF-vrije overleving","title_en":"","published":"2026-03-30"}],"https://www.sciencedirect.com/science/article/pii/s0735109726001488?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/betere-diagnostiek-als-sleutel-tot-vooruitgang-na-acuut-myocardinfarct/","title":"Betere diagnostiek als sleutel tot vooruitgang na acuut myocardinfarct","title_en":"","published":"2026-03-29"}],"https://www.sciencedirect.com/science/article/pii/s0735109726002305?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/luchtvervuiling-en-hypertensierisico-ernst-van-de-ziekte-doet-ertoe/","title":"Luchtvervuiling en hypertensierisico: ernst van de ziekte doet ertoe","title_en":"","published":"2026-03-29"}],"10.1093/europace/euag036":[{"url":"https://hartvaat.nl/2026/03/03/wereldwijde-toename-atriumfibrilleren-treft-steeds-vaker-jongere-volwassenen/","title":"Wereldwijde toename atriumfibrilleren treft steeds vaker jongere volwassenen","title_en":"","published":"2026-03-29"}],"https://www.nejm.org/doi/full/10.1056/nejmoa2517213&rss=currentissue":[{"url":"https://hartvaat.nl/2026/03/28/champion-af-watchman-flx-non-inferieur-aan-noac-s-en-superieur-in-bloedingsreduc/","title":"CHAMPION-AF: WATCHMAN FLX non-inferieur aan NOAC's en superieur in bloedingsreductie bij atriumfibrilleren","title_en":"","published":"2026-03-29"}],"https://www.nejm.org/doi/full/10.1056/nejmoa2516567&rss=currentissue":[{"url":"https://hartvaat.nl/2026/03/28/hi-peitho-katheter-gestuurde-trombolyse-halveert-ernstige-uitkomsten-bij-interme/","title":"HI-PEITHO: katheter-gestuurde trombolyse halveert ernstige uitkomsten bij intermediair-hoog-risico longembolie","title_en":"","published":"2026-03-29"}],"10.1007/s12471-026-02028-8":[{"url":"https://hartvaat.nl/2026/03/02/therapietrouw-aan-lipidenverlagende-medicatie-na-pci-in-nederland/","title":"Therapietrouw aan lipidenverlagende medicatie na PCI in Nederland","title_en":"","published":"2026-03-28"}],"10.1093/europace/euaf303":[{"url":"https://hartvaat.nl/2026/02/03/ryr2-mutaties-als-oorzaak-van-onverklaarde-plotse-hartdood-bij-jongeren/","title":"RYR2-mutaties als oorzaak van onverklaarde plotse hartdood bij jongeren","title_en":"","published":"2026-03-28"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26435":[{"url":"https://hartvaat.nl/2026/03/04/big-data-benadering-voor-aldosteron-renineratio-bij-primair-hyperaldosteronisme/","title":"Big data-benadering voor aldosteron-renineratio bij primair hyperaldosteronisme","title_en":"","published":"2026-03-28"}],"10.1093/eurheartj/ehag145":[{"url":"https://hartvaat.nl/2026/03/28/coronaire-autoregulatie-samenspel-van-epicardiale-en-microvasculaire-weerstand/","title":"Coronaire autoregulatie: samenspel van epicardiale en microvasculaire weerstand","title_en":"","published":"2026-03-28"}],"https://www.jacc.org/doi/10.1016/j.jacc.2026.03.001":[{"url":"https://hartvaat.nl/2026/03/28/kardinal-tonlamarsen-verlaagt-angiotensinogeen-maar-laat-geen-significant-bloedd/","title":"KARDINAL: tonlamarsen verlaagt angiotensinogeen maar laat geen significant bloeddrukeffect zien","title_en":"","published":"2026-03-28"}],"https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.4521":[{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-evolocumab-verlaagt-risico-op-eerste-cardiovasculair-event-met-31-bi/","title":"VESALIUS-CV: evolocumab verlaagt risico op eerste cardiovasculair event met 31% bij patiënten zonder significant atherosclerose","title_en":"","published":"2026-03-28"}],"https://www.nejm.org/doi/full/10.1056/nejmoa2600757":[{"url":"https://hartvaat.nl/2026/03/28/ez-pave-ldl-streefwaarde-55-mg-dl-superieur-aan-70-mg-dl-bij-patienten-met-ather/","title":"Ez-PAVE: LDL-streefwaarde <55 mg/dL superieur aan <70 mg/dL bij patiënten met atherosclerotisch vaatlijden","title_en":"","published":"2026-03-28"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25659":[{"url":"https://hartvaat.nl/2026/03/04/prevalentie-en-behandelpatronen-van-therapieresistente-hypertensie-in-de-vs/","title":"Prevalentie en behandelpatronen van therapieresistente hypertensie in de VS","title_en":"","published":"2026-03-27"}],"https://www.kidney-international.org/article/s0085-2538(26)00012-8/fulltext":[{"url":"https://hartvaat.nl/2026/03/03/kdigo-versnelt-richtlijnontwikkeling-voor-nierziekten/","title":"KDIGO versnelt richtlijnontwikkeling voor nierziekten","title_en":"","published":"2026-03-27"}],"https://www.kidney-international.org/article/s0085-2538(26)00143-2/fulltext":[{"url":"https://hartvaat.nl/2026/02/27/deep-endotypering-onthult-heterogeniteit-van-nierschade-bij-diabetes-type-2/","title":"Deep endotypering onthult heterogeniteit van nierschade bij diabetes type 2","title_en":"","published":"2026-03-27"}],"10.1093/eschf/xvag089":[{"url":"https://hartvaat.nl/2026/03/27/nt-probnp-afkapwaarden-voor-hartfalentrials-optimaliseren-swedehf/","title":"NT-proBNP-afkapwaarden voor hartfalentrials optimaliseren (SwedeHF)","title_en":"Optimizing NT-proBNP Inclusion Cut-offs for Randomized Clinical Trials in Heart Failure: Data from the Swedish Heart Failure Registry","published":"2026-03-27"}],"10.1093/eurheartj/ehag116":[{"url":"https://hartvaat.nl/2026/03/06/metabool-cardiovasculair-risico-nieuwe-mechanismen-en-therapiekansen/","title":"Metabool cardiovasculair risico: nieuwe mechanismen en therapiekansen","title_en":"","published":"2026-03-26"}],"10.1093/eurheartj/ehag095":[{"url":"https://hartvaat.nl/2026/03/06/veroudering-en-myocarddisfunctie-het-hart-jong-houden/","title":"Veroudering en myocarddisfunctie: het hart jong houden","title_en":"","published":"2026-03-26"}],"10.1161/circoutcomes.125.012330":[{"url":"https://hartvaat.nl/2026/03/02/barrieres-bij-implementatie-van-lipidenverlagende-therapie-in-de-praktijk/","title":"Barrières bij implementatie van lipidenverlagende therapie in de praktijk","title_en":"","published":"2026-03-26"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25507":[{"url":"https://hartvaat.nl/2026/03/26/hoge-cardiometabole-last-bij-bilaterale-macronodulaire-bijnierziekte-met-primair/","title":"Hoge cardiometabole last bij bilaterale macronodulaire bijnierziekte met primair aldosteronisme","title_en":"Cardiometabolic Burden in Bilateral Macronodular Adrenal Disease With Primary Aldosteronism","published":"2026-03-26"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26094":[{"url":"https://hartvaat.nl/2026/03/26/kunstmatige-intelligentie-in-de-cardiovasculaire-geneeskunde-focus-op-hypertensi/","title":"Kunstmatige intelligentie in de cardiovasculaire geneeskunde: focus op hypertensie","title_en":"Artificial Intelligence in Cardiovascular Medicine: Focus on Hypertension","published":"2026-03-26"}],"10.1093/eurheartj/ehag144":[{"url":"https://hartvaat.nl/2026/03/26/reverse-cardio-oncologie-obesitas-en-veroudering-als-aanjagers-van-borstkanker/","title":"Reverse cardio-oncologie: obesitas en veroudering als aanjagers van borstkanker","title_en":"","published":"2026-03-26"}],"https://www.sciencedirect.com/science/article/pii/s0735109726055609?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2026/03/26/acc-verklaring-2026-gen-editing-als-therapie-bij-hart-en-vaatziekten/","title":"ACC-verklaring 2026: gen-editing als therapie bij hart- en vaatziekten","title_en":"Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement","published":"2026-03-26"}],"https://www.nejm.org/doi/full/10.1056/nejmoa2513310&rss=currentissue":[{"url":"https://hartvaat.nl/2026/03/18/closure-af-sluiting-van-het-linker-hartoor-niet-non-inferieur-aan-medicamenteuze/","title":"CLOSURE-AF: sluiting van het linker hartoor niet non-inferieur aan medicamenteuze therapie bij atriumfibrilleren","title_en":"","published":"2026-03-26"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.124.071679":[{"url":"https://hartvaat.nl/2026/03/02/diploide-cardiomyocyten-geassocieerd-met-hartregeneratie/","title":"Diploide cardiomyocyten geassocieerd met hartregeneratie","title_en":"","published":"2026-03-25"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.074748":[{"url":"https://hartvaat.nl/2026/03/02/pam-vt-2-littekenverloop-na-vt-ablatie-beoordeeld-met-seriele-cardiale-mri/","title":"PAM-VT 2: littekenverloop na VT-ablatie beoordeeld met seriële cardiale MRI","title_en":"","published":"2026-03-25"}],"https://www.sciencedirect.com/science/article/pii/s0735109725103343?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/aficamten-en-de-toekomst-van-obstructieve-hcm-behandeling/","title":"Aficamten en de toekomst van obstructieve HCM-behandeling","title_en":"","published":"2026-03-25"}],"http://heart.bmj.com/cgi/content/short/112/8/437?rss=1":[{"url":"https://hartvaat.nl/2026/03/25/aortacoarctatie-voorspelt-langetermijnmorbiditeit-na-de-arteriele-switchoperatie/","title":"Aortacoarctatie voorspelt langetermijnmorbiditeit na de arteriële-switchoperatie (EPOCH-ASO)","title_en":"Aortic coarctation and long-term morbidity after arterial switch operation: a multicentre international cohort study","published":"2026-03-25"}],"http://heart.bmj.com/cgi/content/short/112/8/454?rss=1":[{"url":"https://hartvaat.nl/2026/03/25/geleidelijk-afbouwen-van-rilonacept-bij-recidiverende-pericarditis-voorkomt-vake/","title":"Geleidelijk afbouwen van rilonacept bij recidiverende pericarditis voorkomt vaker een recidief dan abrupt stoppen","title_en":"Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis","published":"2026-03-25"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25834":[{"url":"https://hartvaat.nl/2026/03/25/kinderen-van-een-hypertensieve-zwangerschap-hebben-later-vaker-hoge-bloeddruk-en/","title":"Kinderen van een hypertensieve zwangerschap hebben later vaker hoge bloeddruk en hart- en vaatziekten","title_en":"Heritability and Cardiovascular Disease in Adult Offspring of Hypertensive Disorder of Pregnancy: A Systematic Review and Meta-Analysis","published":"2026-03-25"}],"http://heart.bmj.com/cgi/content/short/112/8/422?rss=1":[{"url":"https://hartvaat.nl/2026/03/25/glp-1-agonisten-en-sglt2-remmers-in-de-praktijk-bescherming-van-hart-en-nieren-v/","title":"GLP-1-agonisten en SGLT2-remmers in de praktijk: bescherming van hart en nieren voorbij diabetes","title_en":"Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice","published":"2026-03-25"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26213":[{"url":"https://hartvaat.nl/2026/03/25/sekseverschillen-in-hartremodellering-bij-primair-aldosteronisme-vrouwen-hebben-/","title":"Sekseverschillen in hartremodellering bij primair aldosteronisme: vrouwen hebben een ongunstiger fenotype","title_en":"Sex Differences in Cardiac Remodeling and Dysfunction in Primary Aldosteronism","published":"2026-03-25"}],"http://heart.bmj.com/cgi/content/short/112/8/462?rss=1":[{"url":"https://hartvaat.nl/2026/03/25/vrouwen-krijgen-een-type-a-aortadissectie-bij-een-kleinere-aortadiameter-door-hu/","title":"Vrouwen krijgen een type A-aortadissectie bij een kleinere aortadiameter — door hun kleinere lichaamsbouw","title_en":"Sex differences in ascending aortic diameter at the time of acute type A aortic dissection","published":"2026-03-25"}],"http://heart.bmj.com/cgi/content/short/112/8/446?rss=1":[{"url":"https://hartvaat.nl/2026/03/25/waarom-de-sterfte-na-een-hartinfarct-daalde-15-jaar-nationale-data-uit-engeland-/","title":"Waarom de sterfte na een hartinfarct daalde: 15 jaar nationale data uit Engeland en Wales","title_en":"Drivers of 1-year mortality decline after acute myocardial infarction in England and Wales: a 15-year national cohort study","published":"2026-03-25"}],"http://heart.bmj.com/cgi/content/short/112/8/431?rss=1":[{"url":"https://hartvaat.nl/2026/03/25/vier-klinische-fenotypes-bij-coronairlijden-met-sterk-verschillend-risico-op-nie/","title":"Vier klinische fenotypes bij coronairlijden met sterk verschillend risico op nieuwe events (SWEDEHEART + UCC-SMART)","title_en":"Identifying clinical phenotype clusters in patients with coronary artery disease","published":"2026-03-25"}],"http://heart.bmj.com/cgi/content/short/112/8/413?rss=1":[{"url":"https://hartvaat.nl/2026/03/25/hoe-bouw-je-il-1-remmers-af-bij-recidiverende-pericarditis-strategieen-voor-afbo/","title":"Hoe bouw je IL-1-remmers af bij recidiverende pericarditis? Strategieën voor afbouw en staken","title_en":"Strategies for optimising tapering and withdrawal of interleukin-1 blockers in recurrent pericarditis","published":"2026-03-25"}],"10.1093/eschf/xvag087":[{"url":"https://hartvaat.nl/2026/03/25/inspanningsecho-identificeert-hcm-patienten-die-baat-hebben-bij-mavacamten/","title":"Inspanningsecho identificeert HCM-patiënten die baat hebben bij mavacamten","title_en":"Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors","published":"2026-03-25"}],"10.1093/eschf/xvag050":[{"url":"https://hartvaat.nl/2026/03/25/bmi-en-prognose-bij-acuut-hartfalen-verschillen-per-fenotype-en-geslacht/","title":"BMI en prognose bij acuut hartfalen verschillen per fenotype en geslacht","title_en":"Sex- and Phenotype-Specific Prognostic Implications of Body Mass Index in Acute Heart Failure","published":"2026-03-25"}],"10.1093/eurheartj/ehag173":[{"url":"https://hartvaat.nl/2026/03/25/cardiale-betrokkenheid-bij-parasitaire-infecties/","title":"Cardiale betrokkenheid bij parasitaire infecties","title_en":"","published":"2026-03-25"}],"10.1093/eurheartj/ehaf1121":[{"url":"https://hartvaat.nl/2026/03/25/hart-en-vaatziekten-in-china-epidemiologische-evolutie-19902021/","title":"Hart- en vaatziekten in China: epidemiologische evolutie 1990–2021","title_en":"","published":"2026-03-25"}],"10.1093/eurheartj/ehag219":[{"url":"https://hartvaat.nl/2026/03/25/palliatieve-zorg-in-de-cardiologie-een-state-of-the-art-overzicht/","title":"Palliatieve zorg in de cardiologie: een state-of-the-art overzicht","title_en":"","published":"2026-03-25"}],"https://www.sciencedirect.com/science/article/pii/s0735109725104361?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/medicamenteuze-therapie-bij-niet-obstructieve-hcm-nieuwe-perspectieven/","title":"Medicamenteuze therapie bij niet-obstructieve HCM: nieuwe perspectieven","title_en":"Drug Therapy in Nonobstructive Hypertrophic Cardiomyopathy: Out of the Darkness Into the Light","published":"2026-03-24"}],"https://www.sciencedirect.com/science/article/pii/s0735109726002238?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/troponine-i-t-ratio-bij-myocardschade-nieuwe-inzichten-uit-bekende-biomarkers/","title":"Troponine I/T-ratio bij myocardschade: nieuwe inzichten uit bekende biomarkers","title_en":"High-Sensitivity Troponin I-to-High-Sensitivity Troponin T Ratio in Myocardial Injury: Old Dogs, New Tricks","published":"2026-03-24"}],"https://www.sciencedirect.com/science/article/pii/s0735109726002378?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/innovatie-in-longemboliebehandeling-loopt-de-praktijk-voor-op-het-bewijs/","title":"Innovatie in longemboliebehandeling: loopt de praktijk voor op het bewijs?","title_en":"Innovation and Evidence in Pulmonary Embolism Management: Putting the Cart Before the Horse","published":"2026-03-24"}],"10.1186/s12933-025-03061-4":[{"url":"https://hartvaat.nl/2026/03/24/triglyceride-glucose-index-voorspelt-sterfte-bij-kritiek-zieke-patienten-met-ckm/","title":"Triglyceride-glucose-index voorspelt sterfte bij kritiek zieke patiënten met CKM-syndroom stadium 4","title_en":"Triglyceride-glucose index and mortality in critically ill patients with cardiovascular-kidney-metabolic syndrome stage 4","published":"2026-03-24"}],"10.1093/eurjpc/zwag161":[{"url":"https://hartvaat.nl/2026/03/24/cascadescreening-op-verhoogd-lp-a-via-kinderen-opbrengst-in-de-praktijk-amsterda/","title":"Cascadescreening op verhoogd Lp(a) via kinderen: opbrengst in de praktijk (Amsterdam UMC)","title_en":"Cascade screening for elevated Lp(a) in relatives of children who visited the pediatric lipid clinic: yield of daily clinical practice","published":"2026-03-24"}],"10.1016/j.jacc.2026.02.5067":[{"url":"https://hartvaat.nl/2026/03/16/coronaire-calciumscore-blijft-bruikbaar-bij-verhoogd-lp-a-multicohort-studie-met/","title":"Coronaire calciumscore blijft bruikbaar bij verhoogd Lp(a): multicohort-studie met 11.000 deelnemers","title_en":"Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study","published":"2026-03-24"}],"10.1016/j.jacc.2025.11.016":[{"url":"https://hartvaat.nl/2026/03/13/nieuwe-acc-aha-richtlijn-dyslipidemie-2026-lagere-ldl-streefwaarden-en-lp-a-meti/","title":"Nieuwe ACC/AHA-richtlijn dyslipidemie 2026: lagere LDL-streefwaarden en Lp(a)-meting aanbevolen","title_en":"2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines","published":"2026-03-24"}],"10.1212/wnl.0000000000214701":[{"url":"https://hartvaat.nl/2026/03/24/systemische-inflammatie-en-recidief-na-een-af-gerelateerd-herseninfarct/","title":"Systemische inflammatie en recidief na een AF-gerelateerd herseninfarct","title_en":"Systemic Inflammation and Recurrence After Atrial Fibrillation-Related Stroke: An Individual Participant Data Meta-Analysis.","published":"2026-03-24"}],"https://www.sciencedirect.com/science/article/pii/s0735109726002159?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/vroege-heropnames-na-chirurgische-aortaklepvervanging-beinvloeden-trial-eindpunt/","title":"Vroege heropnames na chirurgische aortaklepvervanging beïnvloeden trial-eindpunten","title_en":"Surgical Aortic Valve Replacement: Early Rehospitalizations and Their Implication for Trial Endpoints","published":"2026-03-23"}],"https://www.sciencedirect.com/science/article/pii/s0735109725103446?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/ai-analyse-van-ecg-als-digitale-biomarker-voor-hartfalen/","title":"AI-analyse van ECG als digitale biomarker voor hartfalen","title_en":"The Emerging Role of ECG-AI as a Digital Risk Biomarker for Incident Heart Failure","published":"2026-03-23"}],"https://www.sciencedirect.com/science/article/pii/s0735109726002093?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/wat-betekent-verbetering-bij-hypertrofische-cardiomyopathie/","title":"Wat betekent 'verbetering' bij hypertrofische cardiomyopathie?","title_en":"What Does Improvement Mean?: Interpreting Progress and Evidence in Hypertrophic Cardiomyopathy","published":"2026-03-23"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003969?rss=1":[{"url":"https://hartvaat.nl/2026/03/23/transapicale-tavi-met-de-j-valve-bij-ernstige-aortaklepinsufficientie-vergelijkb/","title":"Transapicale TAVI met de J-Valve bij ernstige aortaklepinsufficiëntie: vergelijkbaar met chirurgie","title_en":"Comparing TA-TAVR and SAVR in severe aortic regurgitation: outcomes and valve haemodynamics","published":"2026-03-23"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26319":[{"url":"https://hartvaat.nl/2026/03/23/bloeddrukbeloop-vanaf-jongvolwassenheid-voorspelt-leververvetting-op-middelbare-/","title":"Bloeddrukbeloop vanaf jongvolwassenheid voorspelt leververvetting op middelbare leeftijd (CARDIA)","title_en":"Blood Pressure Trajectories in Young Adulthood and Midlife Steatotic Liver Disease","published":"2026-03-23"}],"10.1093/eschf/xvag086":[{"url":"https://hartvaat.nl/2026/03/23/residuele-linker-atriale-v-golf-voorspelt-de-uitkomst-van-mitralisklep-edge-to-e/","title":"Residuele linker-atriale v-golf voorspelt de uitkomst van mitralisklep-edge-to-edge-reparatie","title_en":"Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair","published":"2026-03-23"}],"10.1016/j.jcin.2026.01.281":[{"url":"https://hartvaat.nl/2026/03/23/triplace-register-paravalvulaire-lekkage-na-transkatheter-tricuspidalisklepverva/","title":"TRIPLACE-register: paravalvulaire lekkage na transkatheter-tricuspidalisklepvervanging","title_en":"Incidence, Clinical Implications, and Predictors of Paravalvular Leak Following Transcatheter Tricuspid Valve Replacement: The TRIPLACE Registry","published":"2026-03-23"}],"10.1016/j.jcin.2026.01.285":[{"url":"https://hartvaat.nl/2026/03/23/fate-register-mislukte-transkatheter-tricuspidalisreparatie-t-teer/","title":"FATE-register: mislukte transkatheter-tricuspidalisreparatie (T-TEER)","title_en":"","published":"2026-03-23"}],"10.1001/jamacardio.2026.0006":[{"url":"https://hartvaat.nl/2026/03/04/genetisch-bevestigde-familiaire-hypercholesterolemie-in-de-vs-prevalentie-en-ond/","title":"Genetisch bevestigde familiaire hypercholesterolemie in de VS: prevalentie en onderbehandeling","title_en":"Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.","published":"2026-03-22"}],"10.1093/eschf/xvag068":[{"url":"https://hartvaat.nl/2026/03/03/beeldvorming-bij-atriale-cardiomyopathie-esc-scientific-statement/","title":"Beeldvorming bij atriale cardiomyopathie: ESC scientific statement","title_en":"Role of Imaging Techniques in Monitoring Atrial Cardiomyopathy and Atrial Failure: A Scientific Statement.","published":"2026-03-22"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26084":[{"url":"https://hartvaat.nl/2026/03/04/leeftijd-en-geslacht-beinvloeden-verband-tussen-ambulante-bloeddruk-en-cardiovas/","title":"Leeftijd en geslacht beïnvloeden verband tussen ambulante bloeddruk en cardiovasculaire sterfte","title_en":"Interplay of Age and Sex With Clinic and Ambulatory Blood Pressure and Mortality","published":"2026-03-22"}],"10.1093/eurheartj/ehag103":[{"url":"https://hartvaat.nl/2026/03/06/debat-preventieve-pci-bij-kwetsbare-plaques-als-standaardbehandeling/","title":"Debat: preventieve PCI bij kwetsbare plaques als standaardbehandeling?","title_en":"Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.","published":"2026-03-21"}],"10.1093/eurheartj/ehag104":[{"url":"https://hartvaat.nl/2026/03/06/laminopathieen-natuurlijk-beloop-en-voorspelmodel-voor-hartfalen/","title":"Laminopathieën: natuurlijk beloop en voorspelmodel voor hartfalen","title_en":"Laminopathies: natural history and risk prediction of heart failure.","published":"2026-03-21"}],"10.1093/eurheartj/ehaf1085":[{"url":"https://hartvaat.nl/2026/03/05/aficamten-veilig-en-effectief-bij-langdurige-behandeling-van-obstructieve-hcm/","title":"Aficamten veilig en effectief bij langdurige behandeling van obstructieve HCM","title_en":"Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.","published":"2026-03-21"}],"10.1093/eurheartj/ehaf984":[{"url":"https://hartvaat.nl/2026/03/05/doac-of-vka-bij-kwetsbare-ouderen-met-atriumfibrilleren/","title":"DOAC of VKA bij kwetsbare ouderen met atriumfibrilleren?","title_en":"Direct-acting oral anticoagulant or vitamin K antagonist for the frail elderly patient with atrial fibrillation: does one size fit all?","published":"2026-03-20"}],"10.1093/eurheartj/ehag129":[{"url":"https://hartvaat.nl/2026/03/05/semaglutide-bij-perifeer-arterieel-vaatlijden-en-diabetes-stride-trial/","title":"Semaglutide bij perifeer arterieel vaatlijden en diabetes: STRIDE-trial","title_en":"Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.","published":"2026-03-20"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(26)00253-9/fulltext":[{"url":"https://hartvaat.nl/2026/03/07/aldosteronsynthaseremming-bij-resistente-hypertensie-beloften-en-onzekerheden/","title":"Aldosteronsynthaseremming bij resistente hypertensie: beloften en onzekerheden","title_en":"Aldosterone synthase inhibition in resistant hypertension: promises and unknowns","published":"2026-03-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26126":[{"url":"https://hartvaat.nl/2026/03/20/bloeddrukverlaging-corrigeert-de-gestoorde-maternale-hemodynamiek-bij-pre-eclamp/","title":"Bloeddrukverlaging corrigeert de gestoorde maternale hemodynamiek bij pre-eclampsie niet","title_en":"Effects of Antihypertensive Therapy on Pre- and Postnatal Maternal Hemodynamics","published":"2026-03-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25916":[{"url":"https://hartvaat.nl/2026/03/20/ongunstige-zwangerschapsuitkomsten-en-het-latere-cardiovasculaire-risico-nurses-/","title":"Ongunstige zwangerschapsuitkomsten en het latere cardiovasculaire risico (Nurses' Health Study II)","title_en":"Lifetime Adverse Pregnancy Outcome History and Cardiovascular Risk","published":"2026-03-20"}],"10.1093/eschf/xvag085":[{"url":"https://hartvaat.nl/2026/03/20/evolution-hf-cee-ba-real-world-dapagliflozin-bij-hfref-in-centraal-en-oost-europ/","title":"EVOLUTION-HF CEE-BA: real-world dapagliflozin bij HFrEF in Centraal- en Oost-Europa","title_en":"Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study)","published":"2026-03-20"}],"https://www.nejm.org/doi/full/10.1056/nejme2517834&rss=currentissue":[{"url":"https://hartvaat.nl/2026/03/04/beoordeling-van-niet-culprit-coronairlaesies-bij-stemi/","title":"Beoordeling van niet-culprit coronairlaesies bij STEMI","title_en":"Assessing Nonculprit Coronary-Artery Lesions in STEMI","published":"2026-03-19"}],"https://www.nejm.org/doi/full/10.1056/nejme2600575&rss=currentissue":[{"url":"https://hartvaat.nl/2026/03/04/finerenon-bij-diabetische-nierziekte-en-type-1-diabetes-een-editoriaal/","title":"Finerenon bij diabetische nierziekte en type 1 diabetes: een editoriaal","title_en":"Finerenone for Diabetic Kidney Disease in Type 1 Diabetes — A Fine Answer?","published":"2026-03-19"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076240":[{"url":"https://hartvaat.nl/2026/03/02/aorta-en-iliacale-calcificaties-voorspellen-dissectie-aneurysmaruptuur-en-perife/","title":"Aorta- en iliacale calcificaties voorspellen dissectie, aneurysmaruptuur en perifeer vaatlijden","title_en":"Aortic and Iliac Calcifications as Predictors of Aortic Dissection, Aneurysm Rupture, and Peripheral Vascular Disease: A Prospective Cohort Study from the DANCAVAS Trials","published":"2026-03-19"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26091":[{"url":"https://hartvaat.nl/2026/03/19/angiotensinogeen-als-nieuw-aangrijppunt-bij-hypertensie-opkomst-van-rna-medicijn/","title":"Angiotensinogeen als nieuw aangrijppunt bij hypertensie: opkomst van RNA-medicijnen (zilebesiran, tonlamarsen)","title_en":"Angiotensinogen Reconsidered: Evolving Perspectives in Hypertension Research","published":"2026-03-19"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003898?rss=1":[{"url":"https://hartvaat.nl/2026/03/19/welke-ijzermarker-voorspelt-de-prognose-bij-nieuw-hartfalen-lage-transferrinesat/","title":"Welke ijzermarker voorspelt de prognose bij nieuw hartfalen? Lage transferrinesaturatie wijst op meer events","title_en":"Biomarkers of iron deficiency and prognosis in patients hospitalised with new-onset heart failure and a reduced left ventricular ejection fraction","published":"2026-03-19"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26209":[{"url":"https://hartvaat.nl/2026/03/19/ai-heartage-een-biologische-hartleeftijd-uit-de-polsgolf-voorspelt-hartfalen-en-/","title":"AI-HeartAge: een 'biologische hartleeftijd' uit de polsgolf voorspelt hartfalen en hart- en vaatziekten","title_en":"Development and Validation of the AI-HeartAge Model in Framingham and UK Biobank","published":"2026-03-19"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077983":[{"url":"https://hartvaat.nl/2025/12/25/levensbedreigende-myocardischemie-en-maligne-aritmieen-na-pulsed-field-ablatie-v/","title":"Levensbedreigende myocardischemie en maligne aritmieën na pulsed field ablatie van AF","title_en":"Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias Occurring After Pulsed Field Ablation of Atrial Fibrillation","published":"2026-03-18"}],"https://www.sciencedirect.com/science/article/pii/s0735109725103598?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/maple-hcm-is-aficamten-een-keerpunt-bij-obstructieve-hcm/","title":"MAPLE-HCM: is aficamten een keerpunt bij obstructieve HCM?","title_en":"Aficamten vs Metoprolol: A Turning Point in Obstructive Hypertrophic Cardiomyopathy Care?: The MAPLE-HCM Results","published":"2026-03-18"}],"https://www.sciencedirect.com/science/article/pii/s0735109725103331?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/bisoprolol-versus-verapamil-bij-niet-obstructieve-hcm-gerandomiseerde-crossover-/","title":"Bisoprolol versus verapamil bij niet-obstructieve HCM: gerandomiseerde crossover-trial","title_en":"Beta-Blocker (Bisoprolol) vs Calcium-Channel Blocker (Verapamil) in Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Triple-Crossover Physiologic Trial","published":"2026-03-18"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004019?rss=1":[{"url":"https://hartvaat.nl/2026/03/18/st-elevatie-bij-acute-pericarditis-wijst-op-myocardiale-betrokkenheid/","title":"ST-elevatie bij acute pericarditis wijst op myocardiale betrokkenheid","title_en":"ST-segment elevation in acute pericarditis and myocardial involvement: electrocardiographic and clinical profiling","published":"2026-03-18"}],"https://www.sciencedirect.com/science/article/pii/s073510972600224x?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/coact-trial-langetermijnlessen-over-coronairangiografie-na-reanimatie/","title":"COACT-trial: langetermijnlessen over coronairangiografie na reanimatie","title_en":"Long-Term Lessons From the COACT Trial: Coronary Angiography After Out-of-Hospital Cardiac Arrest Revisited","published":"2026-03-17"}],"https://www.sciencedirect.com/science/article/pii/s073510972510079x?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/ai-voorspelt-hartfalen-op-basis-van-12-afleidingen-ecg-in-grote-cohortanalyse/","title":"AI voorspelt hartfalen op basis van 12-afleidingen-ECG in grote cohortanalyse","title_en":"Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis","published":"2026-03-17"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000707?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/eheart-trial-real-time-hartteam-verbetert-besluitvorming-bij-complexe-coronaire-/","title":"EHEART-trial: real-time hartteam verbetert besluitvorming bij complexe coronaire revascularisatie","title_en":"Real-Time Heart Team for Revascularization in Complex Coronary Artery Disease: The EHEART Randomized Trial","published":"2026-03-17"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26718":[{"url":"https://hartvaat.nl/2026/03/17/veel-vrouwen-met-hypertensie-en-een-doorgemaakte-zwangerschapshypertensie-blijke/","title":"Veel vrouwen met hypertensie en een doorgemaakte zwangerschapshypertensie blijken primair aldosteronisme te hebben","title_en":"Hypertensive Disorders of Pregnancy and Primary Aldosteronism","published":"2026-03-17"}],"10.1093/eschf/xvag082":[{"url":"https://hartvaat.nl/2026/03/17/langetermijneffecten-van-sacubitril-valsartan-bij-hfref-italiaanse-real-world-st/","title":"Langetermijneffecten van sacubitril/valsartan bij HFrEF: Italiaanse real-world studie","title_en":"Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study","published":"2026-03-17"}],"10.1016/j.jacc.2025.10.053":[{"url":"https://hartvaat.nl/2026/03/17/answer-hf-sacubitril-valsartan-versus-enalapril-bij-chagas-hf-primaire-resultate/","title":"ANSWER-HF: sacubitril/valsartan versus enalapril bij Chagas-HF — primaire resultaten","title_en":"Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.","published":"2026-03-17"}],"https://www.sciencedirect.com/science/article/pii/s0735109726056330?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/sotatercept-bij-pah-centrale-hematologische-en-perifere-werkingsmechanismen/","title":"Sotatercept bij PAH: centrale, hematologische en perifere werkingsmechanismen","title_en":"Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit","published":"2026-03-16"}],"https://www.sciencedirect.com/science/article/pii/s0735109726001257?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/strive-trial-neutraal-resultaat-herformuleert-uitdaging-microvasculaire-obstruct/","title":"STRIVE-trial: neutraal resultaat herformuleert uitdaging microvasculaire obstructie","title_en":"The STRIVE Trial: A Neutral Result That Reframes the Challenge of Microvascular Obstruction","published":"2026-03-16"}],"https://www.sciencedirect.com/science/article/pii/s0735109726002330?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/varenicline-vermindert-ventriculaire-ectopie-na-myocardinfarct/","title":"Varenicline vermindert ventriculaire ectopie na myocardinfarct","title_en":"Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study","published":"2026-03-16"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003999?rss=1":[{"url":"https://hartvaat.nl/2026/03/16/eenvoudige-risicofactoren-voorspellen-hart-en-vaatziekten-beter-dan-een-complexe/","title":"Eenvoudige risicofactoren voorspellen hart- en vaatziekten beter dan een complexe comorbiditeitsindex","title_en":"Comorbidity indices in observational studies on cardiovascular risk","published":"2026-03-16"}],"10.1093/eschf/xvag075":[{"url":"https://hartvaat.nl/2026/03/16/natrium-hf-subanalyse-natriuretische-peptiden-lopen-achter-op-de-klinische-ontst/","title":"Natrium-HF-subanalyse: natriuretische peptiden lopen achter op de klinische ontstuwing bij hartfalen","title_en":"Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF Study","published":"2026-03-16"}],"10.1093/eschf/xvag081":[{"url":"https://hartvaat.nl/2026/03/16/vroege-linkerventrikel-reverse-remodellering-na-mitralisklep-edge-to-edge-repara/","title":"Vroege linkerventrikel-reverse-remodellering na mitralisklep-edge-to-edge-reparatie (EXPAND)","title_en":"Left Ventricular Reverse Remodeling after Mitral Transcatheter Edge-to-Edge Repair: Results from the EXPANDed Studies","published":"2026-03-16"}],"10.1093/eschf/xvag076":[{"url":"https://hartvaat.nl/2026/03/16/cdpp3-bij-acuut-hartfalen-geen-prognostische-waarde-strong-hf-en-cortahf/","title":"cDPP3 bij acuut hartfalen: geen prognostische waarde (STRONG-HF en CORTAHF)","title_en":"cDPP3 and Outcomes in Acute Heart Failure: An Analysis of the STRONG-HF and CORTAHF Studies","published":"2026-03-16"}],"10.1038/s44161-026-00794-7":[{"url":"https://hartvaat.nl/2026/03/05/orale-pcsk9-remmer-enlicitide-verlaagt-ldl-cholesterol-in-fase-2-studie/","title":"Orale PCSK9-remmer enlicitide verlaagt LDL-cholesterol in fase 2-studie","title_en":"Oral PCSK9 inhibitor enlicitide lowers LDL cholesterol levels in phase 2 trial.","published":"2026-03-15"}],"https://www.kidney-international.org/article/s0085-2538(25)00884-1/fulltext":[{"url":"https://hartvaat.nl/2026/03/06/kdigo-consensusconferentie-uitdagingen-bij-gecombineerd-hartfalen-en-nierziekte/","title":"KDIGO-consensusconferentie: uitdagingen bij gecombineerd hartfalen en nierziekte","title_en":"Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","published":"2026-03-15"}],"https://www.nejm.org/doi/full/10.1056/nejmc2518964&rss=currentissue":[{"url":"https://hartvaat.nl/2026/03/04/aspirine-na-pci-bij-acuut-coronair-syndroom/","title":"Aspirine na PCI bij acuut coronair syndroom","title_en":"Aspirin after PCI in Acute Coronary Syndromes","published":"2026-03-15"}],"https://www.nejm.org/doi/full/10.1056/nejmclde2505268&rss=currentissue":[{"url":"https://hartvaat.nl/2026/03/04/bloeddrukdoelen-bij-de-behandeling-van-hypertensie/","title":"Bloeddrukdoelen bij de behandeling van hypertensie","title_en":"Blood-Pressure Targets in Hypertension Management","published":"2026-03-14"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(25)02064-1/fulltext":[{"url":"https://hartvaat.nl/2026/02/10/nieuwe-medicamenteuze-therapieen-voor-hypertensie/","title":"Nieuwe medicamenteuze therapieën voor hypertensie","title_en":"New drug therapies for hypertension","published":"2026-03-14"}],"https://www.sciencedirect.com/science/article/pii/s0735109725100685?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/aficamten-bij-obstructieve-hcm-multidomeinanalyse-van-maple-hcm/","title":"Aficamten bij obstructieve HCM: multidomeinanalyse van MAPLE-HCM","title_en":"Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial","published":"2026-03-14"}],"10.1016/s0140-6736(25)02641-8":[{"url":"https://hartvaat.nl/2026/03/14/inte-africa-2-community-based-versus-facilitair-beheer-hiv-dm-htn/","title":"INTE-AFRICA 2: community-based versus facilitair beheer HIV/DM/HTN","title_en":"Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.","published":"2026-03-14"}],"https://www.sciencedirect.com/science/article/pii/s0735109726001361?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/antistolling-alleen-of-met-plaatjesremming-bij-coronairlijden-meta-analyse/","title":"Antistolling alleen of met plaatjesremming bij coronairlijden: meta-analyse","title_en":"Anticoagulation Alone or With Antiaggregation in Patients With Coronary Artery Disease: Meta-Analysis of Randomized Trials","published":"2026-03-13"}],"https://www.sciencedirect.com/science/article/pii/s0735109725100703?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/aficamten-versus-metoprolol-betere-levenskwaliteit-bij-obstructieve-hcm/","title":"Aficamten versus metoprolol: betere levenskwaliteit bij obstructieve HCM","title_en":"Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy","published":"2026-03-13"}],"https://www.sciencedirect.com/science/article/pii/s0735109726001476?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/intravasculaire-beeldvorming-superieur-aan-angiografie-bij-complexe-pci-5-jaarsr/","title":"Intravasculaire beeldvorming superieur aan angiografie bij complexe PCI: 5-jaarsresultaten","title_en":"Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial","published":"2026-03-13"}],"10.1093/eschf/xvag079":[{"url":"https://hartvaat.nl/2026/03/13/tubulaire-nierschade-hangt-samen-met-natriumretentie-en-diureticarespons-bij-acu/","title":"Tubulaire nierschade hangt samen met natriumretentie en diureticarespons bij acuut hartfalen","title_en":"Kidney tubule injury is associated with sodium avidity and diuretic responsiveness in acute heart failure","published":"2026-03-13"}],"10.1056/nejmoa2512854":[{"url":"https://hartvaat.nl/2026/03/05/finerenon-effectief-bij-type-1-diabetes-met-chronische-nierziekte/","title":"Finerenon effectief bij type 1 diabetes met chronische nierziekte","title_en":"Finerenone in Type 1 Diabetes and Chronic Kidney Disease.","published":"2026-03-12"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(25)02166-x/fulltext":[{"url":"https://hartvaat.nl/2026/03/07/lancet-seminar-atriumfibrilleren-in-2026/","title":"Lancet-seminar: atriumfibrilleren in 2026","title_en":"Atrial fibrillation","published":"2026-03-12"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(25)02549-8/fulltext":[{"url":"https://hartvaat.nl/2026/03/07/baxdrostat-verlaagt-bloeddruk-significant-bij-resistente-hypertensie/","title":"Baxdrostat verlaagt bloeddruk significant bij resistente hypertensie","title_en":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","published":"2026-03-12"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003982?rss=1":[{"url":"https://hartvaat.nl/2026/03/12/betere-cardiovasculaire-gezondheid-life-s-simple-7-hangt-samen-met-minder-leverv/","title":"Betere cardiovasculaire gezondheid (Life's Simple 7) hangt samen met minder leververvetting","title_en":"Association of Life's Simple 7 with metabolic-associated steatotic liver disease and non-invasive fibrosis markers","published":"2026-03-12"}],"10.1136/heartjnl-2025-326646":[{"url":"https://hartvaat.nl/2026/03/12/off-label-onderdosering-edoxaban-bij-af-en-systemische-embolieen/","title":"Off-label onderdosering edoxaban bij AF en systemische embolieën","title_en":"Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.","published":"2026-03-12"}],"https://www.sciencedirect.com/science/article/pii/s0735109725077630?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/nieuwe-acc-aha-richtlijn-2025-voor-volwassenen-met-aangeboren-hartafwijkingen/","title":"Nieuwe ACC/AHA-richtlijn 2025 voor volwassenen met aangeboren hartafwijkingen","title_en":"2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines","published":"2026-03-11"}],"10.1097/mol.0000000000001032":[{"url":"https://hartvaat.nl/2026/02/10/lipoproteine-a-bij-familiaire-hypercholesterolemie-een-dubbel-risico/","title":"Lipoproteïne(a) bij familiaire hypercholesterolemie: een dubbel risico","title_en":"Lipoprotein(a) in familial hypercholesterolemia.","published":"2026-03-11"}],"10.1097/mol.0000000000001033":[{"url":"https://hartvaat.nl/2026/02/10/rna-interferentie-bij-lipidestoornissen-de-toekomst-van-cholesterolverlaging/","title":"RNA-interferentie bij lipidestoornissen: de toekomst van cholesterolverlaging?","title_en":"RNA interference for lipid disorders: is this the future?","published":"2026-03-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26238":[{"url":"https://hartvaat.nl/2026/03/11/behandeling-van-primair-aldosteronisme-chirurgie-of-mra-met-zoutbeperking-als-ho/","title":"Behandeling van primair aldosteronisme: chirurgie of MRA, met zoutbeperking als hoeksteen","title_en":"Treatment of Primary Aldosteronism","published":"2026-03-11"}],"10.1097/mol.0000000000001029":[{"url":"https://hartvaat.nl/2026/02/16/polygene-risicoscores-bij-familiaire-hypercholesterolemie-nuttig-of-niet/","title":"Polygene risicoscores bij familiaire hypercholesterolemie: nuttig of niet?","title_en":"Polygenic risk scores in familial hypercholesterolemia. Do they have a role?","published":"2026-03-10"}],"10.1080/17843286.2026.2638804":[{"url":"https://hartvaat.nl/2026/02/28/familiaire-hypercholesterolemie-in-belgie-7-jaar-ervaring/","title":"Familiaire hypercholesterolemie in België: 7 jaar ervaring","title_en":"Clinical characteristics and lipid management of patients with familial hypercholesterolemia: results from a 7 years single-centre experience.","published":"2026-03-10"}],"10.1016/j.amjcard.2026.02.038":[{"url":"https://hartvaat.nl/2026/02/26/lp-a-geassocieerd-met-microvasculaire-disfunctie-bij-niet-obstructief-coronairli/","title":"Lp(a) geassocieerd met microvasculaire disfunctie bij niet-obstructief coronairlijden","title_en":"Association of Coronary Microvascular Dysfunction with Lipoprotein (a) levels in Patients with Non-Obstructive Coronary Artery Disease.","published":"2026-03-10"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003619?rss=1":[{"url":"https://hartvaat.nl/2026/03/10/machine-learning-voorspelt-30-daagse-sterfte-na-een-dotterbehandeling-australisc/","title":"Machine learning voorspelt 30-daagse sterfte na een dotterbehandeling (Australisch register)","title_en":"Risk prediction modelling of 30-day all-cause mortality following percutaneous coronary intervention in an Australian population: leveraging machine learning","published":"2026-03-10"}],"10.1007/s11883-026-01390-7":[{"url":"https://hartvaat.nl/2026/02/26/niet-statine-therapie-welk-middel-voor-welke-patient/","title":"Niet-statine therapie: welk middel voor welke patiënt?","title_en":"Choosing the Right Non-Statin Therapy for the Right Patient - How To Sequence Advanced Lipid-Lowering Therapies.","published":"2026-03-09"}],"10.1253/circj.cj-25-0847":[{"url":"https://hartvaat.nl/2026/02/27/lp-a-en-atherosclerotisch-vaatlijden-een-niet-lineair-verband/","title":"Lp(a) en atherosclerotisch vaatlijden: een niet-lineair verband","title_en":"Linear and Nonlinear Associations Between Lipoprotein(a) and the Risks of Atherosclerotic Cardiovascular Disease.","published":"2026-03-09"}],"10.1093/eschf/xvag065":[{"url":"https://hartvaat.nl/2026/02/27/prognose-takotsubo-syndroom-versus-hartfalen-op-de-lange-termijn/","title":"Prognose takotsubo-syndroom versus hartfalen op de lange termijn","title_en":"Long-term prognosis in Takotsubo Syndrome compared to Heart Failure: Observations from a global federated research network.","published":"2026-03-09"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25991":[{"url":"https://hartvaat.nl/2026/03/09/stress-verhoogt-de-bloeddruk-na-de-bevalling-vooral-bij-vrouwen-die-een-zwangers/","title":"Stress verhoogt de bloeddruk na de bevalling vooral bij vrouwen die een zwangerschapscomplicatie hadden","title_en":"Stress Trajectory and Hypertension 2 to 7 Years After Delivery: A nuMoM2b-HHS Study","published":"2026-03-09"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076036":[{"url":"https://hartvaat.nl/2026/03/09/sarcomere-versus-niet-sarcomere-hypertrofische-cardiomyopathie-een-verschillend-/","title":"Sarcomere versus niet-sarcomere hypertrofische cardiomyopathie: een verschillend ziektebeloop","title_en":"Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy","published":"2026-03-09"}],"10.1093/eurheartj/ehaf690":[{"url":"https://hartvaat.nl/2026/03/09/semaglutide-stimuleert-anti-inflammatoire-stamcelflux-vanuit-beenmerg/","title":"Semaglutide stimuleert anti-inflammatoire stamcelflux vanuit beenmerg","title_en":"Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.","published":"2026-03-09"}],"10.1016/j.vasdi.2026.02.004":[{"url":"https://hartvaat.nl/2026/02/27/obicetrapib-veelbelovende-cetp-remmer-voor-hoogrisicopatienten/","title":"Obicetrapib: veelbelovende CETP-remmer voor hoogrisicopatiënten","title_en":"Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis.","published":"2026-03-08"}],"10.1016/s2213-8587(25)00395-x":[{"url":"https://hartvaat.nl/2026/02/25/glp-1-agonisten-en-gezonde-leefstijl-samen-sterker-tegen-hart-en-vaatziekten/","title":"GLP-1-agonisten én gezonde leefstijl: samen sterker tegen hart- en vaatziekten","title_en":"Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study.","published":"2026-03-08"}],"10.1016/j.jacadv.2026.102621":[{"url":"https://hartvaat.nl/2026/02/27/nieuwe-aldosteronsynthase-remmers-bij-hypertensie-bayesiaanse-meta-analyse/","title":"Nieuwe aldosteronsynthase-remmers bij hypertensie: Bayesiaanse meta-analyse","title_en":"Second-Generation Aldosterone Synthase Inhibitors for Hypertension: A Bayesian Meta-Analysis of Randomized Trials.","published":"2026-03-08"}],"10.1016/j.cardfail.2026.01.020":[{"url":"https://hartvaat.nl/2026/02/27/sglt2-remmers-bij-ernstig-verminderde-nierfunctie-data-uit-credence/","title":"SGLT2-remmers bij ernstig verminderde nierfunctie: data uit CREDENCE","title_en":"SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20ml/min/1.73m","published":"2026-03-07"}],"10.1016/j.amjcard.2026.02.035":[{"url":"https://hartvaat.nl/2026/02/27/finerenon-plus-sglt2-remmer-additief-cardiorenal-voordeel-bij-diabetische-nierzi/","title":"Finerenon plus SGLT2-remmer: additief cardiorenal voordeel bij diabetische nierziekte","title_en":"Additive Cardiorenal Benefits of Finerenone and SGLT2 Inhibitor Combination Therapy in Diabetic CKD: A Propensity-Matched Real-World Study.","published":"2026-03-07"}],"10.1093/eurheartj/ehaf999":[{"url":"https://hartvaat.nl/2026/02/27/van-vitamine-k-antagonist-naar-doac-bij-kwetsbare-ouderen-met-af/","title":"Van vitamine K-antagonist naar DOAC bij kwetsbare ouderen met AF","title_en":"Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.","published":"2026-03-07"}],"10.1016/s0140-6736(25)02549-8":[{"url":"https://hartvaat.nl/2026/03/07/bax24-baxdrostat-en-ambulante-bloeddruk-bij-resistente-hypertensie/","title":"Bax24: baxdrostat en ambulante bloeddruk bij resistente hypertensie","title_en":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.","published":"2026-03-07"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26112":[{"url":"https://hartvaat.nl/2026/02/27/bloeddruk-time-in-target-range-voorspelt-sterfte-bij-hypertensie/","title":"Bloeddruk 'time in target range' voorspelt sterfte bij hypertensie","title_en":"Association Between 24-Hour Systolic Blood Pressure Time in Target Range and Mortality","published":"2026-03-06"}],"10.1093/europace/euag032":[{"url":"https://hartvaat.nl/2026/02/03/lichamelijke-activiteit-en-risico-op-complicaties-bij-atriumfibrilleren/","title":"Lichamelijke activiteit en risico op complicaties bij atriumfibrilleren","title_en":"Physical activity and risk of adverse events in atrial fibrillation: evidence from European and Asian cohorts.","published":"2026-03-06"}],"10.1093/eurheartj/ehag110":[{"url":"https://hartvaat.nl/2026/02/28/hartfalen-bij-ouderen-van-epidemiologie-tot-behandeling/","title":"Hartfalen bij ouderen: van epidemiologie tot behandeling","title_en":"Heart failure in the elderly: epidemiology, mechanisms, and management.","published":"2026-03-06"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25431":[{"url":"https://hartvaat.nl/2026/03/06/kouno-tori-antitrombine-verlengt-de-zwangerschap-niet-bij-vroege-ernstige-pre-ec/","title":"KOUNO-TORI: antitrombine verlengt de zwangerschap niet bij vroege ernstige pre-eclampsie en geeft meer bloedingen","title_en":"Randomized Study of Antithrombin in Early-Onset Preeclampsia: KOUNO-TORI Study","published":"2026-03-06"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003837?rss=1":[{"url":"https://hartvaat.nl/2026/03/06/promise-minimal-risk-score-identificeert-veilig-laagrisicopatienten-met-stabiele/","title":"PROMISE Minimal Risk Score identificeert veilig laagrisicopatiënten met stabiele pijn op de borst","title_en":"Retrospective analysis of the performance of the PROMISE minimal risk tool for patients presenting with recent onset stable chest pain","published":"2026-03-06"}],"http://openheart.bmj.com/cgi/content/short/13/1/e004048?rss=1":[{"url":"https://hartvaat.nl/2026/03/06/cardiale-sarcoidose-een-onderhoudsdosis-corticosteroiden-van-5-10-mg-dag-geeft-d/","title":"Cardiale sarcoïdose: een onderhoudsdosis corticosteroïden van 5-10 mg/dag geeft de beste prognose","title_en":"Prognostic impact of corticosteroid maintenance dose and re-escalation in patients with cardiac sarcoidosis","published":"2026-03-06"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26397":[{"url":"https://hartvaat.nl/2026/03/06/kwetsbaarheid-bepaalt-de-optimale-bloeddrukstreefwaarde-beter-dan-leeftijd-sprin/","title":"Kwetsbaarheid bepaalt de optimale bloeddrukstreefwaarde beter dan leeftijd (SPRINT + ACCORD)","title_en":"Frailty Index Offers Greater Discrimination Than Age for Optimal Blood Pressure Targets: A Pooled Analysis of Two Randomized Trials","published":"2026-03-06"}],"https://www.sciencedirect.com/science/article/pii/s0735109725106281?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/mechanische-trombectomie-bij-longembolie-trends-uit-het-pert-register-2016-2024/","title":"Mechanische trombectomie bij longembolie: trends uit het PERT-register 2016-2024","title_en":"Mechanical Thrombectomy and Catheter-Directed Thrombolysis in Acute Pulmonary Embolism: Trends and Practice Patterns in the PERT Consortium Registry (2016-2024)","published":"2026-03-05"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00058-4/fulltext":[{"url":"https://hartvaat.nl/2026/02/27/albuminurie-geassocieerd-met-verhoogd-risico-op-abdominaal-aorta-aneurysma/","title":"Albuminurie geassocieerd met verhoogd risico op abdominaal aorta-aneurysma","title_en":"Association of albuminuria and changes in albuminuria with the risk of abdominal aortic aneurysm","published":"2026-03-05"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25990":[{"url":"https://hartvaat.nl/2025/12/11/angiotensine-ii-meten-bij-screening-op-primair-hyperaldosteronisme/","title":"Angiotensine II meten bij screening op primair hyperaldosteronisme","title_en":"Time to Measure Angiotensin II When Screening for Primary Aldosteronism in the Evaluation of Secondary Hypertension","published":"2026-03-05"}],"10.1056/nejmoa2512918":[{"url":"https://hartvaat.nl/2026/03/05/directe-versus-uitgestelde-non-culprit-pci-bij-mi-gerandomiseerde-trial/","title":"Directe versus uitgestelde non-culprit PCI bij MI: gerandomiseerde trial","title_en":"Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.","published":"2026-03-05"}],"10.1093/eurheartj/ehaf705":[{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","title":"EMPATHY: hartfalentherapie bij patiënten met gevorderde kanker en palliatieve zorg","title_en":"Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial).","published":"2026-03-05"}],"10.3390/jpm16020097":[{"url":"https://hartvaat.nl/2026/02/06/glp-1-receptoragonisten-en-nieruitkomsten-focus-op-albuminurie/","title":"GLP-1-receptoragonisten en nieruitkomsten: focus op albuminurie","title_en":"Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria.","published":"2026-03-04"}],"10.1093/ndt/gfag020":[{"url":"https://hartvaat.nl/2026/02/17/albuminurie-of-proteinurie-bij-glomerulaire-ziekte-en-ckd-wat-te-gebruiken/","title":"Albuminurie of proteïnurie bij glomerulaire ziekte en CKD: wat te gebruiken?","title_en":"Albuminuria or proteinuria in glomerular disease and CKD - which one to use?","published":"2026-03-04"}],"10.3390/jcm15041676":[{"url":"https://hartvaat.nl/2026/02/23/ijzertekort-bij-chronische-nierziekte-en-hartfalen-expertperspectieven/","title":"IJzertekort bij chronische nierziekte en hartfalen: expertperspectieven","title_en":"Expert Perspectives on Managing Iron Deficiency in People with CKD and/or HF.","published":"2026-03-04"}],"10.1093/europace/euaf322":[{"url":"https://hartvaat.nl/2026/02/03/linkerbundeltakpacing-versus-rechterventrikel-pacing-na-tavi/","title":"Linkerbundeltakpacing versus rechterventrikel pacing na TAVI","title_en":"Left bundle branch area pacing vs. right ventricular pacing in post-transcatheter aortic valve implantation patients: a retrospective propensity-matched analysis.","published":"2026-03-03"}],"10.1093/europace/euag025":[{"url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","title":"VARIPURE-studie: pulsed field ablatie in de dagelijkse AF-praktijk","title_en":"Workflow and sedation choice with the PFA variable-loop circular catheter in real-world AF procedures: insights from the prospective multi-centre VARIPURE clinical study.","published":"2026-03-03"}],"10.1093/europace/euag024":[{"url":"https://hartvaat.nl/2026/02/11/ai-gestuurde-ecg-lokalisatie-verbetert-ablatie-bij-instabiele-ventriculaire-tach/","title":"AI-gestuurde ECG-lokalisatie verbetert ablatie bij instabiele ventriculaire tachycardie","title_en":"Artificial Intelligence ECG Localization Facilitates Focused Activation Mapping and Improves Outcomes in Hemodynamically Unstable Ventricular Tachycardia.","published":"2026-03-03"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003468?rss=1":[{"url":"https://hartvaat.nl/2026/03/03/voorspelmodellen-voor-hartfalen-bij-patienten-met-instabiele-angina-pectoris/","title":"Voorspelmodellen voor hartfalen bij patiënten met instabiele angina pectoris","title_en":"Development and validation of diagnostic and prognostic models for heart failure in unstable angina patients","published":"2026-03-03"}],"10.1093/eschf/xvag102":[{"url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","title":"C-MIC II: hartfunctie, inspanningscapaciteit en kwaliteit van leven zijn verwante maar aparte domeinen","title_en":"Association between functional status and cardiac function in chronic heart failure: insights from the C-MIC II Trial","published":"2026-03-03"}],"10.1093/eschf/xvag052":[{"url":"https://hartvaat.nl/2026/03/03/ai-echotool-voor-hfpef-hoge-specificiteit-lage-sensitiviteit-bij-invasieve-valid/","title":"AI-echotool voor HFpEF: hoge specificiteit, lage sensitiviteit bij invasieve validatie","title_en":"Invasive haemodynamic validation of an artificial intelligence echocardiographic tool for detecting heart failure with preserved ejection fraction","published":"2026-03-03"}],"10.1093/eschf/xvag098":[{"url":"https://hartvaat.nl/2026/03/03/plasma-eiwitprofielen-onthullen-gedeelde-en-fenotype-specifieke-routes-bij-hartf/","title":"Plasma-eiwitprofielen onthullen gedeelde en fenotype-specifieke routes bij hartfalen (UK Biobank)","title_en":"Plasma protein profiles in different heart failure phenotypes","published":"2026-03-03"}],"10.1093/eschf/xvaf035":[{"url":"https://hartvaat.nl/2026/03/03/spierstofwisseling-bij-hfpef-verminderde-oxidatieve-capaciteit-los-van-ijzergebr/","title":"Spierstofwisseling bij HFpEF: verminderde oxidatieve capaciteit los van ijzergebrek (31P-MRS)","title_en":"Quantifying skeletal muscle energy metabolism during exercise in heart failure with preserved ejection fraction using in vivo 31P magnetic resonance spectroscopy","published":"2026-03-03"}],"10.1093/eschf/xvag107":[{"url":"https://hartvaat.nl/2026/03/03/expertopinie-hierarchische-eindpunten-op-basis-van-verslechterend-hartfalen-voor/","title":"Expertopinie: hiërarchische eindpunten op basis van verslechterend hartfalen, voorbij de ziekenhuisopname","title_en":"Worsening heart failure-based hierarchical endpoints beyond HF hospitalization: expert opinion paper","published":"2026-03-03"}],"10.1038/s41591-026-04254-4":[{"url":"https://hartvaat.nl/2026/03/03/yolt-101-base-editing-schakelt-pcsk9-uit-bij-heterozygote-fh-fase-1/","title":"YOLT-101: base-editing schakelt PCSK9 uit bij heterozygote FH (fase 1)","title_en":"In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial.","published":"2026-03-03"}],"10.1093/eschf/xvag010":[{"url":"https://hartvaat.nl/2026/03/03/4-eiwitmodel-voor-cardiogene-shock-prognose-danger-substudie/","title":"4-eiwitmodel voor cardiogene shock prognose: DanGer substudie","title_en":"Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock.","published":"2026-03-03"}],"10.1093/eschf/xvag037":[{"url":"https://hartvaat.nl/2026/02/03/voedingsstatus-voorspelt-ventriculaire-ritmestoornissen-bij-gevorderd-hartfalen/","title":"Voedingsstatus voorspelt ventriculaire ritmestoornissen bij gevorderd hartfalen","title_en":"Controlling Nutritional Status score as a predictor of ventricular arrhythmias in patients with advanced heart failure.","published":"2026-03-02"}],"10.1093/eschf/xvag063":[{"url":"https://hartvaat.nl/2026/02/25/lvad-versus-harttransplantatie-bij-hartfalen-finse-kosten-en-uitkomsten/","title":"LVAD versus harttransplantatie bij hartfalen: Finse kosten en uitkomsten","title_en":"Costs and outcomes in Finnish heart failure patients treated with left ventricular assist device or heart transplant.","published":"2026-03-02"}],"10.1093/eschf/xvag066":[{"url":"https://hartvaat.nl/2026/02/26/cardiogene-shock-bij-myocardinfarct-resultaten-van-het-shock-pol-register/","title":"Cardiogene shock bij myocardinfarct: resultaten van het Shock-POL-register","title_en":"Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.","published":"2026-03-02"}],"https://www.sciencedirect.com/science/article/pii/s0735109725106591?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/de-troponine-i-t-ratio-bij-myocardschade-een-multicohort-synthese/","title":"De troponine I/T-ratio bij myocardschade: een multicohort-synthese","title_en":"The cTnI/cTnT Ratio in Myocardial Injury: A Multicohort and Experimental Synthesis","published":"2026-03-02"}],"https://www.sciencedirect.com/science/article/pii/s0735109725106578?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/ultra-lage-dosis-combinatiepil-als-startbehandeling-voor-hypertensie/","title":"Ultra-lage dosis combinatiepil als startbehandeling voor hypertensie","title_en":"Small But Mighty: Blood Pressure Control Through Ultra-Low-Dose Single-Pill Antihypertensive Medication as Initial Therapy","published":"2026-03-02"}],"10.1093/eurheartj/ehag117":[{"url":"https://hartvaat.nl/2026/02/27/macrofaagbelasting-in-carotisplaque-voorspelt-cardiovasculaire-events-na-endarte/","title":"Macrofaagbelasting in carotisplaque voorspelt cardiovasculaire events na endarterectomie","title_en":"Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy.","published":"2026-03-02"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003754?rss=1":[{"url":"https://hartvaat.nl/2026/03/02/is-depressie-een-onafhankelijke-risicofactor-voor-sterfte-bij-hart-en-vaatziekte/","title":"Is depressie een onafhankelijke risicofactor voor sterfte bij hart- en vaatziekten? Mogelijk niet (NHANES)","title_en":"Depression may not be an independent risk factor for mortality in patients with cardiovascular disease: data from NHANES 2011-2018","published":"2026-03-02"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003894?rss=1":[{"url":"https://hartvaat.nl/2026/03/02/vrouwen-na-coronaire-bypasschirurgie-hoger-ziekenhuisrisico-en-minder-grafts-maa/","title":"Vrouwen na coronaire bypasschirurgie: hoger ziekenhuisrisico en minder grafts, maar vergelijkbare langetermijnoverleving","title_en":"Worse risk profile, number of grafts and hospital death but acceptable late survival in females undergoing coronary surgery: a 20-year propensity matched analysis","published":"2026-03-02"}],"10.1001/jamanetworkopen.2026.3680":[{"url":"https://hartvaat.nl/2026/03/02/staken-van-ras-remmers-na-acute-egfr-daling-hangt-samen-met-meer-nierfalen-en-st/","title":"Staken van RAS-remmers na acute eGFR-daling hangt samen met meer nierfalen en sterfte","title_en":"Discontinuation of RAS Inhibition After an Acute Decline in Estimated Glomerular Filtration Rate","published":"2026-03-02"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26572":[{"url":"https://hartvaat.nl/2026/02/26/intensieve-bloeddrukbehandeling-en-cognitieve-functie-een-gerandomiseerde-klinis/","title":"Intensieve bloeddrukbehandeling en cognitieve functie: een gerandomiseerde klinische trial","title_en":"Intensive BP Control and Cognitive Function: A Randomized Clinical Trial","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000586?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/luchtvervuiling-verhoogt-sterfte-door-hypertensie-case-crossover-studie-bij-2-1-/","title":"Luchtvervuiling verhoogt sterfte door hypertensie: case-crossover studie bij 2,1 miljoen sterfgevallen","title_en":"Short-Term Exposure to Air Pollution Increases Mortality From Hypertension and its Multiorgan Complications: A Case Crossover Study of 2.1 Million Deaths in China","published":"2026-03-01"}],"10.1001/jamacardio.2026.0026":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","title":"APERITIF-trial: laaggedoseerd rivaroxaban voorkomt linkerventrikeltrombose na voorwandinfarct","title_en":"Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial.","published":"2026-03-01"}],"10.1161/hypertensionaha.125.26572":[{"url":"https://hartvaat.nl/2026/04/01/intensieve-bloeddrukcontrole-en-cognitieve-functie-gerandomiseerde-trial/","title":"Intensieve bloeddrukcontrole en cognitieve functie: gerandomiseerde trial","title_en":"Intensive BP Control and Cognitive Function: A Randomized Clinical Trial.","published":"2026-03-01"}],"10.1161/hypertensionaha.125.25810":[{"url":"https://hartvaat.nl/2026/04/01/lage-dosis-tel-aml-chtd-combinatietablet-versus-standaard-tel-fase-iii/","title":"Lage-dosis TEL/AML/CHTD combinatietablet versus standaard TEL: fase III","title_en":"Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.","published":"2026-03-01"}],"10.1161/hypertensionaha.125.26148":[{"url":"https://hartvaat.nl/2026/04/01/mhealth-interventie-verbetert-hypertensiezorg-bij-hoogrisicopatienten/","title":"mHealth-interventie verbetert hypertensiezorg bij hoogrisicopatiënten","title_en":"mHealth Intervention to Improve Hypertension Care in High-Risk Patients.","published":"2026-03-01"}],"10.1001/jamacardio.2025.5418":[{"url":"https://hartvaat.nl/2026/03/01/abelacimab-versus-rivaroxaban-bij-ouderen-met-af-subanalyse/","title":"Abelacimab versus rivaroxaban bij ouderen met AF: subanalyse","title_en":"Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.","published":"2026-03-01"}],"10.1161/hypertensionaha.125.25442":[{"url":"https://hartvaat.nl/2026/03/01/ambulante-arteriele-stijfheidsindex-eindpuntgebaseerde-drempelwaarde/","title":"Ambulante arteriële stijfheidsindex: eindpuntgebaseerde drempelwaarde","title_en":"End Point-Based Threshold for the Ambulatory Arterial Stiffness Index.","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000549?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/2025-richtlijn-voor-aangeboren-hartafwijkingen-bij-volwassenen-vergeleken-met-de/","title":"2025-richtlijn voor aangeboren hartafwijkingen bij volwassenen vergeleken met de 2020-richtlijn kleplijden","title_en":"2025 ACC/AHA/HRS/ISACHD/SCAI Guideline Recommendations for the Treatment of Adult Congenital Heart Disease and Comparison With the 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105858?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/de-2025-richtlijn-voor-aangeboren-hartafwijkingen-bij-volwassenen-vanuit-early-c/","title":"De 2025-richtlijn voor aangeboren hartafwijkingen bij volwassenen vanuit early-career perspectief","title_en":"2025 Adults With Congenital Heart Disease Guideline From the Early-Career Perspective","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725101691?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/richtlijn-volwassenen-met-aangeboren-hartafwijkingen-2025-in-een-oogopslag/","title":"Richtlijn volwassenen met aangeboren hartafwijkingen 2025 in één oogopslag","title_en":"2025 Adults With Congenital Heart Disease Guideline-at-a-Glance","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725104798?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/richtlijn-acute-longembolie-2026-in-een-oogopslag/","title":"Richtlijn acute longembolie 2026 in één oogopslag","title_en":"2026 Acute Pulmonary Embolism Guideline-at-a-Glance","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105950?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/de-2025-richtlijn-voor-volwassenen-met-aangeboren-hartafwijkingen-aanpassen-aan-/","title":"De 2025-richtlijn voor volwassenen met aangeboren hartafwijkingen aanpassen aan lage-inkomenslanden","title_en":"Adapting the 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for Management of Adults With Congenital Heart Disease to Low Resource Settings","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726001312?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/aangeboren-hartafwijkingen-bij-volwassenen-nieuwe-richtlijnen-kennishiaten-en-ka/","title":"Aangeboren hartafwijkingen bij volwassenen: nieuwe richtlijnen, kennishiaten en kansen","title_en":"Adult Congenital Heart Disease: New Guidelines, Remaining Gaps, and Continual Opportunities","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105640?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/atriale-mechanische-contractie-voorspelt-cerebrovasculair-risico-bij-transthyret/","title":"Atriale mechanische contractie voorspelt cerebrovasculair risico bij transthyretine-amyloïdcardiomyopathie en sinusritme","title_en":"Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000689?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/voorbij-de-ventrikels-cardiomyopathiegenen-en-het-risico-op-atriumfibrilleren/","title":"Voorbij de ventrikels: cardiomyopathiegenen en het risico op atriumfibrilleren","title_en":"Beyond the Ventricles: Cardiomyopathy Genes and Atrial Fibrillation Risk","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725103574?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/cardiale-screening-bij-104-369-jongeren-opbrengst-interventies-en-incidentie-van/","title":"Cardiale screening bij 104.369 jongeren: opbrengst, interventies en incidentie van plotse hartdood","title_en":"Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105809?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/cardiale-screening-bij-jongeren-tijd-voor-actie/","title":"Cardiale screening bij jongeren: tijd voor actie?","title_en":"Cardiac Screening in the Young: Time to Sound the Battle CRY?","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725104282?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/cardiomyopathie-genvarianten-en-polygene-risicoscores-bij-atriumfibrilleren-bewi/","title":"Cardiomyopathie-genvarianten en polygene risicoscores bij atriumfibrilleren: bewijs voor een atriaal-eerst fenotype","title_en":"Cardiomyopathy Gene Variants and Polygenic Risk Scores in Atrial Fibrillation: Evidence for an Atrial-First Phenotype","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105883?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/esc-0-1-uur-versus-0-2-of-0-3-uur-hoog-sensitief-troponine-algoritmen-bij-verden/","title":"ESC 0/1-uur versus 0/2- of 0/3-uur hoog-sensitief troponine-algoritmen bij verdenking acuut coronair syndroom","title_en":"Comparison of the European Society of Cardiology 0/1-Hour and High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome 0/2-or-0/3-Hour Algorithms for Rapid Myocardial Infarction Diagnosis: A Prospective Multicenter Study","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s073510972600077x?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/effect-van-baduanjin-op-bloeddruk-bij-hoog-normaal-bloeddruk-gerandomiseerde-tri/","title":"Effect van Baduanjin op bloeddruk bij hoog-normaal bloeddruk: gerandomiseerde trial","title_en":"Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure: A Multicenter, Open-Label, Blinded-Outcome Randomized Controlled Trial","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000793?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/van-overleving-naar-rentmeesterschap-hypergespecialiseerde-cardiovasculaire-zorg/","title":"Van overleving naar rentmeesterschap: hypergespecialiseerde cardiovasculaire zorg op schaal leveren","title_en":"From Survival to Stewardship: Delivering Hyperspecialized Cardiovascular Care at Scale","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105603?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/hartfalenpreventie-bewijsgeneratie-trialontwerp-en-regulatoire-trajecten/","title":"Hartfalenpreventie: bewijsgeneratie, trialontwerp en regulatoire trajecten","title_en":"Heart Failure Prevention: Evidence Generation, Trial Design, and Regulatory Pathways","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s073510972510661x?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/hoge-dosis-griepvaccinatie-bij-atherosclerotisch-vaatlijden-flunity-hd-analyse/","title":"Hoge-dosis griepvaccinatie bij atherosclerotisch vaatlijden: FLUNITY-HD-analyse","title_en":"High-Dose Influenza Vaccination in Atherosclerotic Cardiovascular Disease: A Multinational Pooled Analysis of DANFLU-2 and GALFLU (FLUNITY-HD)","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725102477?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/impact-van-vroege-uitgestelde-of-onderbroken-behandeling-bij-kinderen-met-famili/","title":"Impact van vroege, uitgestelde of onderbroken behandeling bij kinderen met familiaire hypercholesterolemie","title_en":"Impact of Early, Delayed, or Interrupted Treatment in Children With Familial Hypercholesterolemia","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725106608?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/langdurige-blootstelling-aan-bosbranden-pm2-5-en-cardiovasculaire-ziekenhuisopna/","title":"Langdurige blootstelling aan bosbranden-PM2.5 en cardiovasculaire ziekenhuisopnames bij ouderen in de VS","title_en":"Impact of Long-Term Cumulative Exposure to Wildfire Smoke PM<sub>2.5</sub> on Cardiovascular Hospital Admissions Among Older Adults in the United States: A Population-Based Cohort Study","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000574?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/stijging-van-serum-transthyretine-na-tafamidis-voorspelt-betere-overleving-bij-a/","title":"Stijging van serum-transthyretine na tafamidis voorspelt betere overleving bij ATTR-cardiomyopathie","title_en":"Increase in Serum Transthyretin After Tafamidis Is Associated With Improved Survival in Transthyretin Amyloid Cardiomyopathy","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105974?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/langetermijn-cardiovasculaire-en-niet-cardiovasculaire-mortaliteit-na-acuut-coro/","title":"Langetermijn cardiovasculaire en niet-cardiovasculaire mortaliteit na acuut coronair syndroom","title_en":"Long-Term Cardiovascular and Noncardiovascular Mortality After Acute Coronary Syndrome: A Nationwide Competing-Risks Analysis of 1.56 Million Patients","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725101629?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/menopauzale-status-en-docetaxel-geinduceerde-vasculaire-disfunctie-bij-borstkank/","title":"Menopauzale status en docetaxel-geïnduceerde vasculaire disfunctie bij borstkankerpatiënten","title_en":"Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105986?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/mitralisklepherstel-bij-degeneratief-mr-met-matige-tricuspidalisinsufficientie-2/","title":"Mitralisklepherstel bij degeneratief MR met matige tricuspidalisinsufficiëntie: 2-jaarsuitkomsten","title_en":"Mitral Valve Repair for Degenerative MR With Moderate or Less Tricuspid Regurgitation: 2-Year Outcomes From a Multicenter Echocardiographic Core Laboratory–Adjudicated Cohort","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725104750?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/niet-lineair-verband-en-optimale-drempelwaarden-voor-mondiale-pm2-5-blootstellin/","title":"Niet-lineair verband en optimale drempelwaarden voor mondiale PM2.5-blootstelling en cardiovasculaire mortaliteit","title_en":"Nonlinear Association Evidence and Optimal Alert Thresholds for Global Short-Term PM<sub>2.5</sub> Exposure and Cardiovascular Mortality Risk","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725104105?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/fijnstofpieken-en-cardiovasculaire-sterfte-beleidsprioriteiten-voor-luchtkwalite/","title":"Fijnstofpieken en cardiovasculaire sterfte: beleidsprioriteiten voor luchtkwaliteitswaarschuwingen","title_en":"PM<sub>2.5</sub> Spikes and Cardiovascular Mortality: Policy Priorities for Air Quality Alerts","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105639?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/polygeen-risico-gestuurde-detectie-en-behandeling-van-subklinische-coronaire-ath/","title":"Polygeen risico-gestuurde detectie en behandeling van subklinische coronaire atherosclerose (PROACT)","title_en":"Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000525?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/cholesterolmanagement-bij-vrouwen-heroverwogen-van-risicoschatting-naar-levensla/","title":"Cholesterolmanagement bij vrouwen heroverwogen: van risicoschatting naar levenslange gezondheid","title_en":"Rethinking Cholesterol Management in Women: From Short-Term Risk Estimation to Lifecourse Cardiovascular Health","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s073510972600135x?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/risico-op-atherosclerotische-hart-en-vaatziekten-bij-familiaire-restanthyperlipi/","title":"Risico op atherosclerotische hart- en vaatziekten bij familiaire restanthyperlipidemie en FH","title_en":"Risk of Atherosclerotic Cardiovascular Disease in Familial Remnant Hyperlipidemia (Dysbetalipoproteinemia) and Familial Hypercholesterolemia","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000690?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/serum-transthyretine-voor-en-na-tafamidisstart-als-uitkomstvoorspeller-bij-attr-/","title":"Serum-transthyretine vóór en na tafamidisstart als uitkomstvoorspeller bij ATTR-cardiomyopathie","title_en":"Serum Transthyretin Before and After Starting Tafamidis as Outcome Predictors in ATTR Cardiomyopathy","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725098110?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/sekseverschillen-bij-gedilateerde-cardiomyopathie-kennishiaten-en-toekomstige-ri/","title":"Sekseverschillen bij gedilateerde cardiomyopathie: kennishiaten en toekomstige richtingen","title_en":"Sex Differences in Dilated Cardiomyopathy: Evidence Gaps and Future Directions","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000513?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/geslacht-doet-ertoe-cardiovasculaire-opleiding-optimaliseren-voor-vrouwenhartgez/","title":"Geslacht doet ertoe: cardiovasculaire opleiding optimaliseren voor vrouwenhartgezondheid","title_en":"Sex Matters: Optimizing Cardiovascular Education and Training to Improve Women’s (and Men’s) Heart Health","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725105895?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/kortdurende-blootstelling-aan-fijnstof-en-cardiovasculaire-sterfte-mondiale-anal/","title":"Kortdurende blootstelling aan fijnstof en cardiovasculaire sterfte: mondiale analyse voor waarschuwingsdrempels","title_en":"Short-Term PM<sub>2.5</sub> Exposure and Cardiovascular Mortality: A Global Exposure-Response Analysis to Inform Alert Thresholds","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725104920?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/sirolimus-eluerende-bioresorbeerbare-stents-versus-everolimus-eluerende-stents-i/","title":"Sirolimus-eluerende bioresorbeerbare stents versus everolimus-eluerende stents (IRONMAN II)","title_en":"Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II)","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726054239?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/zesjaarsuitkomsten-van-transkatheter-versus-chirurgische-aortaklepvervanging-bij/","title":"Zesjaarsuitkomsten van transkatheter versus chirurgische aortaklepvervanging bij laagrisicopatiënten","title_en":"Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725103392?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/vertrouwen-nodig-om-de-risico-behandelparadox-bij-ckd-te-bestrijden/","title":"Vertrouwen nodig om de risico-behandelparadox bij CKD te bestrijden","title_en":"Some Much-Needed CONFIDENCE to Combat the Risk-Treatment Paradox in Chronic Kidney Disease","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725106566?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/de-toekomst-van-zorg-voor-volwassenen-met-aangeboren-hartafwijkingen-in-de-vs/","title":"De toekomst van zorg voor volwassenen met aangeboren hartafwijkingen in de VS","title_en":"The Future of Adult Congenital Heart Care in the United States: Are We Keeping Up With the Pace of Progress?","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725100715?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/timing-van-cardiovasculaire-en-renale-voordelen-van-finerenon-bij-hartfalen-en-c/","title":"Timing van cardiovasculaire en renale voordelen van finerenon bij hartfalen en CKD met diabetes","title_en":"Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726002925?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/de-cardiovasculaire-professie-in-het-tijdperk-van-ai/","title":"De cardiovasculaire professie in het tijdperk van AI","title_en":"Tip of the Spear: The Cardiovascular Profession in the Age of AI","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725103562?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/vasculaire-disfunctie-in-de-cardio-oncologie-hormoonstatus-chemotherapie-en-risi/","title":"Vasculaire disfunctie in de cardio-oncologie: hormoonstatus, chemotherapie en risico","title_en":"Vascular Dysfunction in Cardio-Oncology: Hormone Status, Chemotherapy, and Risk","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109725106554?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/wat-is-veranderd-sinds-de-eerste-richtlijn-voor-volwassenen-met-aangeboren-harta/","title":"Wat is veranderd sinds de eerste richtlijn voor volwassenen met aangeboren hartafwijkingen?","title_en":"What Has Changed Since the First ACC/AHA Guidelines for the Management of Adult Congenital Heart Disease in 2008?","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726003001?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/wanneer-zorg-autonoom-wordt-ai-en-de-toekomst-van-de-cardiovasculaire-geneeskund/","title":"Wanneer zorg autonoom wordt: AI en de toekomst van de cardiovasculaire geneeskunde","title_en":"When Care Becomes Autonomous: AI and the Future of Cardiovascular Medicine","published":"2026-03-01"}],"https://www.sciencedirect.com/science/article/pii/s0735109726000537?dgcid=rss_sd_all":[{"url":"https://hartvaat.nl/2025/01/01/cardiovasculaire-gezondheid-van-vrouwen-van-inclusie-naar-onderzoeksontwerp/","title":"Cardiovasculaire gezondheid van vrouwen: van inclusie naar onderzoeksontwerp","title_en":"Women’s Cardiovascular Health: From Inclusion to Design","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)00852-x/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/bruine-tumor-van-de-patella-bij-een-langdurig-hemodialysepatient/","title":"Bruine tumor van de patella bij een langdurig hemodialysepatiënt","title_en":"Brown tumor of the patella in a long-term hemodialysis patient","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01021-x/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/causale-claims-vereisen-gedefinieerde-interventies-kanttekening-bij-ckd-mbd-anal/","title":"Causale claims vereisen gedefinieerde interventies: kanttekening bij CKD-MBD-analyse","title_en":"Causal claims require defined interventions: a note on the EQUAL chronic kidney disease–mineral and bone disorder analysis","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01003-8/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/uitdagingen-bij-het-bepalen-van-de-werkelijke-incidentie-van-eindstadium-nierzie/","title":"Uitdagingen bij het bepalen van de werkelijke incidentie van eindstadium nierziekte bij ouderen","title_en":"Challenges in revealing the true incidence of end-stage kidney disease in the elderly population","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)00738-0/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/adpkd-samen-met-primaire-hyperoxalurie-type-3/","title":"ADPKD samen met primaire hyperoxalurie type 3","title_en":"Coexistence of autosomal dominant polycystic kidney disease and primary hyperoxaluria type 3","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)00674-x/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/histoplasma-capsulatum-een-zeldzame-oorzaak-van-interstitiele-nefritis/","title":"Histoplasma capsulatum: een zeldzame oorzaak van interstitiële nefritis","title_en":"Histoplasma capsulatum: a rare cause of interstitial nephritis","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)00991-3/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/tijd-voor-een-vijfde-pijler-bij-lichamelijk-onderzoek-van-kinderen-aan-dialyse/","title":"Tijd voor een vijfde pijler bij lichamelijk onderzoek van kinderen aan dialyse?","title_en":"Is it time to add a fifth pillar to the physical examination in pediatric dialysis?","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01030-0/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/niergezonheid-voor-iedereen-zorg-voor-mensen-bescherming-van-de-planeet/","title":"Niergezonheid voor iedereen: zorg voor mensen, bescherming van de planeet","title_en":"Kidney health for all: caring for people, protecting the planet","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01000-2/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/monoklonaal-versus-monotypisch-bewustwording-van-terminologie-bij-mgrs/","title":"Monoklonaal versus monotypisch: bewustwording van terminologie bij MGRS","title_en":"Monoclonal versus monotypic: promoting awareness of terminology and clinical take-aways","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01002-6/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/optimalisatie-van-caart-voor-wisselende-antilichaamlandschappen/","title":"Optimalisatie van CAART voor wisselende antilichaamlandschappen","title_en":"Optimizing CAART for evolving antibody landscapes","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01040-3/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/pathologische-diagnostiek-met-moleculaire-monitoring-bij-nierxenotransplantatie/","title":"Pathologische diagnostiek met moleculaire monitoring bij nierxenotransplantatie","title_en":"Pathologic diagnosis incorporating molecular monitoring highlights new pathophysiological mechanisms in kidney xenotransplantation","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01029-4/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/rna-methylering-bij-acuut-nierletsel-nieuwe-therapeutische-mogelijkheden/","title":"RNA-methylering bij acuut nierletsel: nieuwe therapeutische mogelijkheden","title_en":"RNA methylation in acute kidney injury: opening up new therapeutic avenues","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)00739-2/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/tsc2-pkd1-contigue-gendeletiesyndroom/","title":"TSC2/PKD1 contigue gendeletiesyndroom","title_en":"TSC2/PKD1 contiguous gene deletion syndrome","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)00742-2/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/slappe-verlamming-en-tetanie-na-chemotherapie-een-diagnostische-uitdaging/","title":"Slappe verlamming en tetanie na chemotherapie: een diagnostische uitdaging","title_en":"The Case | Flaccid paralysis and tetany after chemotherapy: a diagnostic challenge","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)00669-6/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/onverklaarde-transplantaatdisfunctie-bij-een-zeldzame-metabole-stoornis/","title":"Onverklaarde transplantaatdisfunctie bij een zeldzame metabole stoornis","title_en":"The Case | Unexplained post-transplant graft dysfunction in a rare metabolic disorder","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01011-7/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/auteurs-reageren-pravastatine-bij-autosomaal-dominante-polycysteuze-nierziekte/","title":"Auteurs reageren: pravastatine bij autosomaal dominante polycysteuze nierziekte","title_en":"The authors reply","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01041-5/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/in-dit-nummer-xeno-transplantatie-en-moleculaire-respons-bij-orgaantransplantati/","title":"In dit nummer: xeno-transplantatie en moleculaire respons bij orgaantransplantatie","title_en":"in this issue","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01043-9/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/journal-club-ivaleptische-nefropathie-bij-complement-gemedieerde-trombotische-mi/","title":"Journal Club: ivaleptische nefropathie bij complement-gemedieerde trombotische microangiopathie","title_en":"journal club","published":"2026-03-01"}],"10.1080/19382014.2026.2633793":[{"url":"https://hartvaat.nl/2026/12/31/annexine-a1-verergert-activatie-van-eilandjessterrecellen-via-triglyceridenafbra/","title":"Annexine A1 verergert activatie van eilandjessterrecellen via triglyceridenafbraak","title_en":"Annexin A1 exacerbates islet stellate cell activation by regulating triglyceride catabolism via the PPARα/ACOX1/CYP4a pathway.","published":"2026-03-01"}],"10.1080/10641963.2026.2631606":[{"url":"https://hartvaat.nl/2026/12/31/mechanismen-van-hypertensie-tot-hart-en-hersenvaatziekten-een-uitgebreid-overzic/","title":"Mechanismen van hypertensie tot hart- en hersenvaatziekten: een uitgebreid overzicht","title_en":"Mechanisms linking hypertension to cardiovascular and cerebrovascular diseases and their clinical implications: A comprehensive review.","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01005-1/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/bij-niervervanging-bescherm-het-hart/","title":"Bij niervervanging: bescherm het hart","title_en":"When replacing the kidney, protect the heart","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01014-2/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/gepersonaliseerde-gfr-percentielen-een-nieuw-instrument-voor-ckd-detectie/","title":"Gepersonaliseerde GFR-percentielen: een nieuw instrument voor CKD-detectie","title_en":"Percentiles of estimating glomerular filtration rate: a new personalized tool for detection of chronic kidney disease","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01009-9/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/pravastatine-bij-volwassenen-met-adpkd-potentiele-subgroepvoordelen/","title":"Pravastatine bij volwassenen met ADPKD: potentiële subgroepvoordelen","title_en":"Reassessing pravastatin in adult autosomal dominant polycystic kidney disease and potential subgroup benefits","published":"2026-03-01"}],"https://www.kidney-international.org/article/s0085-2538(25)01025-7/fulltext":[{"url":"https://hartvaat.nl/2026/03/01/complementremmers-winnen-terrein-bij-de-behandeling-van-iga-nefropathie/","title":"Complementremmers winnen terrein bij de behandeling van IgA-nefropathie","title_en":"The expanding role of complement inhibitors in the treatment of IgA nephropathy","published":"2026-03-01"}],"10.1080/0886022x.2026.2624299":[{"url":"https://hartvaat.nl/2026/12/01/cardiometabole-index-en-sarcopenie-voorspellen-sterfte-bij-chronische-nierziekte/","title":"Cardiometabole index en sarcopenie voorspellen sterfte bij chronische nierziekte","title_en":"Cardiometabolic index (CMI) and sarcopenia as predictors of all-cause and cardiovascular mortality in chronic kidney disease: a NHANES-based cohort study.","published":"2026-03-01"}],"10.1080/10641963.2026.2635384":[{"url":"https://hartvaat.nl/2026/12/31/tijdgebonden-eten-verlaagt-bloeddruk-bij-kinderen-een-clustergerandomiseerde-tri/","title":"Tijdgebonden eten verlaagt bloeddruk bij kinderen: een clustergerandomiseerde trial","title_en":"Effects of time-restricted eating on blood pressure in children: A cluster randomized controlled trial.","published":"2026-03-01"}],"10.1016/j.ijcrp.2026.200594":[{"url":"https://hartvaat.nl/2026/06/01/hypertensie-wijzigt-de-relatie-tussen-lp-a-en-mortaliteit-bij-acuut-gedecompense/","title":"Hypertensie wijzigt de relatie tussen Lp(a) en mortaliteit bij acuut gedecompenseerd hartfalen","title_en":"Impact of hypertension on associations of all-cause mortality with admission lipoprotein (a) in acute decompensated heart failure.","published":"2026-03-01"}],"10.1016/j.ijcrp.2026.200590":[{"url":"https://hartvaat.nl/2026/06/01/pcsk9-remmers-bij-perifeer-vaatlijden-meta-analyse-toont-vaatfunctie-en-lipidevo/","title":"PCSK9-remmers bij perifeer vaatlijden: meta-analyse toont vaatfunctie- en lipidevoordelen","title_en":"Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis.","published":"2026-03-01"}],"10.1080/07853890.2026.2634484":[{"url":"https://hartvaat.nl/2026/12/01/ezetimibe-als-monotherapie-voor-primaire-preventie-bij-75-plussers/","title":"Ezetimibe als monotherapie voor primaire preventie bij 75-plussers","title_en":"Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events.","published":"2026-03-01"}],"10.1097/ajn.0000000000000261d":[{"url":"https://hartvaat.nl/2026/03/01/lager-ldl-c-verlaagt-risico-op-recidief-cardiovasculaire-events-bij-cva-patiente/","title":"Lager LDL-C verlaagt risico op recidief cardiovasculaire events bij CVA-patiënten","title_en":"Lower LDL-C, lower risk of recurrent cardiovascular events in stroke survivors.","published":"2026-03-01"}],"10.52082/jssm.2026.112":[{"url":"https://hartvaat.nl/2026/03/01/lichaamsbeweging-beinvloedt-de-relatie-tussen-crp-triglyceriden-en-coronaire-ath/","title":"Lichaamsbeweging beïnvloedt de relatie tussen CRP, triglyceriden en coronaire atherosclerose","title_en":"Physical Activity Modifies the Association between C-Reactive Protein - Triglyceride - Glucose Index (CTI) and Dyslipidemia: Evidence from a 10-Year Chinese Cohort.","published":"2026-03-01"}],"10.1111/dom.70603":[{"url":"https://hartvaat.nl/2026/02/27/verhoogd-lp-a-en-diabetes-verergeren-samen-de-prognose-bij-coronairlijden/","title":"Verhoogd Lp(a) en diabetes verergeren samen de prognose bij coronairlijden","title_en":"Association of Elevated Lipoprotein(a) and Diabetes Mellitus With Survival Outcomes in Patients With Coronary Artery Disease: Findings From the CIN-II and RED-CARPET Cohorts.","published":"2026-02-27"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003530?rss=1":[{"url":"https://hartvaat.nl/2026/02/26/ai-clustering-onthult-drie-functionele-risicoprofielen-bij-hartfalen/","title":"AI-clustering onthult drie functionele risicoprofielen bij hartfalen","title_en":"Artificial intelligence-based clustering to identify functional risk phenotypes in heart failure","published":"2026-02-26"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003557?rss=1":[{"url":"https://hartvaat.nl/2026/02/26/cascadescreening-bij-hypertrofische-cardiomyopathie-genotype-positieve-familiele/","title":"Cascadescreening bij hypertrofische cardiomyopathie: genotype-positieve familieleden houden een verhoogd risico","title_en":"Characterising the phenotype and outcomes of cascade-tested relatives of probands with hypertrophic cardiomyopathy","published":"2026-02-26"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003853?rss=1":[{"url":"https://hartvaat.nl/2026/02/26/hiv-infectie-hangt-onafhankelijk-samen-met-meer-en-kwetsbaardere-halsslagaderpla/","title":"Hiv-infectie hangt onafhankelijk samen met meer en kwetsbaardere halsslagaderplaques","title_en":"HIV infection is independently associated with carotid plaque burden and echogenic characteristics","published":"2026-02-26"}],"10.1007/s00467-026-07190-0":[{"url":"https://hartvaat.nl/2026/02/26/niergezondheid-en-bloeddruk-op-schoolleeftijd-na-zeer-vroeggeboorte/","title":"Niergezondheid en bloeddruk op schoolleeftijd na zeer vroeggeboorte","title_en":"Kidney health and blood pressure after very preterm birth: a cohort study at school age.","published":"2026-02-26"}],"10.1093/eurheartj/ehag124":[{"url":"https://hartvaat.nl/2026/02/26/weer-een-stap-vooruit-in-de-verlaging-van-ernstige-hypertriglyceridemie/","title":"Weer een stap vooruit in de verlaging van ernstige hypertriglyceridemie","title_en":"Another brick in the wall of severe hypertriglyceridaemia lowering.","published":"2026-02-26"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003944?rss=1":[{"url":"https://hartvaat.nl/2026/02/25/langetermijnincidentie-van-atriumfibrilleren-en-het-risico-op-beroerte-20-jaar-f/","title":"Langetermijnincidentie van atriumfibrilleren en het risico op beroerte: 20 jaar follow-up (INTERGENE)","title_en":"Long-term incidence of atrial fibrillation and cardiovascular outcomes in men and women with sinus rhythm: a 20-year follow-up of the INTERGENE population-based cohort","published":"2026-02-25"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001406":[{"url":"https://hartvaat.nl/2026/02/25/voorspelling-cardiovasculaire-ziektelast-bij-vrouwen-in-de-vs-tot-2050/","title":"Voorspelling cardiovasculaire ziektelast bij vrouwen in de VS tot 2050","title_en":"Forecasting the Burden of Cardiovascular Disease and Stroke in Women in the United States Through 2050: A Scientific Statement From the American Heart Association","published":"2026-02-25"}],"10.1093/europace/euag029":[{"url":"https://hartvaat.nl/2026/02/25/alcoholgebruik-en-het-ontstaan-van-atriumfibrilleren-dosis-risico-en-dogma-herov/","title":"Alcoholgebruik en het ontstaan van atriumfibrilleren: dosis, risico en dogma heroverwogen","title_en":"Alcohol Consumption and Incident Atrial Fibrillation: Rethinking Dose, Risk, and Dogma.","published":"2026-02-25"}],"10.1093/ndt/gfag040":[{"url":"https://hartvaat.nl/2026/02/25/de-mondiale-ziektelast-van-chronische-nierziekte-elke-20-seconden-een-sterfgeval/","title":"De mondiale ziektelast van chronische nierziekte: elke 20 seconden een sterfgeval","title_en":"The updated global burden of chronic kidney disease: one death every 20 seconds.","published":"2026-02-25"}],"10.1007/s00431-026-06816-7":[{"url":"https://hartvaat.nl/2026/02/25/obesitas-en-hypertensie-bij-kindercardiologiepatienten-voor-en-na-covid-19-lockd/","title":"Obesitas en hypertensie bij kindercardiologiepatiënten voor en na COVID-19-lockdown","title_en":"The prevalence of obesity and hypertension in paediatric cardiology patients before and after COVID-19 lockdown measures.","published":"2026-02-25"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00056-0/fulltext":[{"url":"https://hartvaat.nl/2026/02/25/hemodynamische-en-bloedviscositeitsprofielen-van-culprit-versus-non-culprit-coro/","title":"Hemodynamische en bloedviscositeitsprofielen van culprit- versus non-culprit-coronairvaten","title_en":"Haemodynamic and Blood Viscosity Profiles of Culprit vs. Non-Culprit Coronary Vessels: Insights from NIRS-IVUS and CFD Analysis","published":"2026-02-25"}],"https://www.kidney-international.org/article/s0085-2538(26)00142-0/fulltext":[{"url":"https://hartvaat.nl/2026/02/25/klotho-in-het-distale-nefron-reguleert-calciumreabsorptie-maar-niet-fosfaathomeo/","title":"Klotho in het distale nefron reguleert calciumreabsorptie maar niet fosfaathomeostase","title_en":"Klotho in the kidney distal convolution regulates urinary Klotho excretion and kidney calcium reabsorption, but not phosphate homeostasis.","published":"2026-02-25"}],"10.1017/s1463423626100978":[{"url":"https://hartvaat.nl/2026/02/25/onvervulde-zorgbehoefte-bij-hypertensie-en-diabetes-in-sub-sahara-afrika/","title":"Onvervulde zorgbehoefte bij hypertensie en diabetes in Sub-Sahara Afrika","title_en":"Assessing the burden and inequality in the unmet need for hypertension and type 2 diabetes care using a care cascade framework in Tanzania, Lesotho, and South Africa.","published":"2026-02-25"}],"10.1093/eurheartj/ehaf1074":[{"url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","title":"Uitkomsten van hartfalen naar ejectiefractie: het ESC HF III Register","title_en":"Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.","published":"2026-02-25"}],"10.1161/circresaha.125.327592":[{"url":"https://hartvaat.nl/2026/02/25/foxo1-als-schakel-tussen-hemodynamiek-inflammatie-en-metabolisme-in-atherosclero/","title":"FOXO1 als schakel tussen hemodynamiek, inflammatie en metabolisme in atherosclerose","title_en":"FOXO1 Integrates Endothelial Hemodynamic, Inflammatory, and Metabolic Pathways in Atherosclerosis.","published":"2026-02-25"}],"10.1152/ajpheart.00914.2025":[{"url":"https://hartvaat.nl/2026/02/25/pyelonefritis-verlaagt-serumcholesterol-en-remt-atherosclerose-ondanks-systemisc/","title":"Pyelonefritis verlaagt serumcholesterol en remt atherosclerose ondanks systemische inflammatie","title_en":"Pyelonephritis decreases serum cholesterol and mitigates atherosclerosis severity despite systemic inflammation.","published":"2026-02-25"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00057-2/fulltext":[{"url":"https://hartvaat.nl/2026/02/25/behandeling-van-familiaire-hypercholesterolemie-bij-kinderen-3-jaar-lipigen-regi/","title":"Behandeling van familiaire hypercholesterolemie bij kinderen: 3 jaar LIPIGEN-register","title_en":"Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry","published":"2026-02-25"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003934?rss=1":[{"url":"https://hartvaat.nl/2026/02/24/cardiale-sarcoidose-als-eerste-uiting-van-sarcoidose-verloopt-ernstiger/","title":"Cardiale sarcoïdose als eerste uiting van sarcoïdose verloopt ernstiger","title_en":"Diagnostic delay and phenotypic differences in cardiac sarcoidosis: a descriptive study of diagnostic and follow-up clinical data","published":"2026-02-24"}],"10.1161/circulationaha.125.075275":[{"url":"https://hartvaat.nl/2026/02/24/systemische-embolieen-bij-af-ipd-mega-meta-analyse-van-71-683-patienten/","title":"Systemische embolieën bij AF: IPD mega-meta-analyse van 71.683 patiënten","title_en":"Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.","published":"2026-02-24"}],"10.1093/eurheartj/ehaf1042":[{"url":"https://hartvaat.nl/2026/02/24/van-biobank-naar-voorspelling-polygenetische-risicoscores-voor-perifeer-vaatlijd/","title":"Van biobank naar voorspelling: polygenetische risicoscores voor perifeer vaatlijden","title_en":"From biobank to prediction: polygenic risk scores for peripheral artery disease.","published":"2026-02-24"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.24937":[{"url":"https://hartvaat.nl/2026/02/24/perinatale-hiv-blootstelling-en-hiv-ernst-geassocieerd-met-bloeddruk-bij-jongere/","title":"Perinatale HIV-blootstelling en HIV-ernst geassocieerd met bloeddruk bij jongeren","title_en":"Association of Perinatal HIV Exposure and HIV Disease Severity With BP in Youth","published":"2026-02-24"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00054-7/fulltext":[{"url":"https://hartvaat.nl/2026/02/24/invloed-van-coronaire-ziekte-patronen-op-klinische-uitkomsten-pullback-pressure-/","title":"Invloed van coronaire ziekte patronen op klinische uitkomsten: pullback pressure gradient meta-analyse","title_en":"Impact of Coronary Artery Disease Patterns Assessed with Pullback Pressure Gradient on Clinical Outcomes: Meta-analysis","published":"2026-02-24"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001405":[{"url":"https://hartvaat.nl/2026/02/24/ondervoeding-en-cachexie-bij-opgenomen-patienten-met-acute-cardiale-aandoeningen/","title":"Ondervoeding en cachexie bij opgenomen patiënten met acute cardiale aandoeningen","title_en":"Malnutrition and Cachexia in Inpatients With Acute Cardiac Conditions: A Scientific Statement From the American Heart Association","published":"2026-02-24"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26543":[{"url":"https://hartvaat.nl/2026/02/24/uitkomstgericht-cardiovasculair-risicoframework-nodig-na-dwarslaesie/","title":"Uitkomstgericht cardiovasculair risicoframework nodig na dwarslaesie","title_en":"Outcome-Based Cardiovascular Risk Framework is Required After Spinal Cord Injury","published":"2026-02-24"}],"https://www.kidney-international.org/article/s0085-2538(26)00134-1/fulltext":[{"url":"https://hartvaat.nl/2026/02/24/polygene-risicoscores-en-hla-klasse-ii-als-biomarkers-voor-corticosteroidrespons/","title":"Polygene risicoscores en HLA klasse II als biomarkers voor corticosteroïdrespons bij nefrotisch syndroom","title_en":"Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome","published":"2026-02-24"}],"10.1182/bloodadvances.2025017653":[{"url":"https://hartvaat.nl/2026/02/24/s100a8-a9-versnelt-cox-1-herstel-in-bloedplaatjes-en-beperkt-aspirinerespons/","title":"S100A8/A9 versnelt COX-1-herstel in bloedplaatjes en beperkt aspirinerespons","title_en":"Circulating S100A8/A9 drives faster platelet COX-1 recovery via MRP4, impairing the duration of aspirin response.","published":"2026-02-24"}],"10.1080/00325481.2026.2634426":[{"url":"https://hartvaat.nl/2026/02/24/cystatine-c-bij-chronische-nierziekte-betere-diagnostiek-en-patientuitkomsten/","title":"Cystatine C bij chronische nierziekte: betere diagnostiek en patiëntuitkomsten","title_en":"Cystatin C in chronic kidney disease: enhancing diagnostic accuracy and patient outcomes.","published":"2026-02-24"}],"10.1093/ndt/gfag034":[{"url":"https://hartvaat.nl/2026/02/24/effecten-van-micro-en-nanoplastics-op-de-nieren/","title":"Effecten van micro- en nanoplastics op de nieren","title_en":"Effects of Microplastics and Nanoplastics on the Kidneys.","published":"2026-02-24"}],"10.1073/pnas.2531159123":[{"url":"https://hartvaat.nl/2026/02/24/mfsd2a-is-essentieel-voor-de-epidermale-homeostase/","title":"Mfsd2a is essentieel voor de epidermale homeostase","title_en":"Mfsd2a is important for maintaining epidermal homeostasis.","published":"2026-02-24"}],"10.1136/bcr-2025-265520":[{"url":"https://hartvaat.nl/2026/02/24/aortacoarctatie-met-zeldzame-congenitale-afwijkingen-casuistiek/","title":"Aortacoarctatie met zeldzame congenitale afwijkingen: casuïstiek","title_en":"Rebuttal: aortic coarctation and concomitant anomalies - left circumflex fistula, persistent left SVC and ventricular diverticulum.","published":"2026-02-24"}],"10.5414/cn111953":[{"url":"https://hartvaat.nl/2026/02/24/systemische-effecten-van-metabole-acidose/","title":"Systemische effecten van metabole acidose","title_en":"Systemic effects of metabolic acidosis.","published":"2026-02-24"}],"https://pubmed.ncbi.nlm.nih.gov/41718673/":[{"url":"https://hartvaat.nl/2026/02/24/de-overgang-naar-de-menopauze-tien-klinische-vragen-beantwoord/","title":"De overgang naar de menopauze: tien klinische vragen beantwoord","title_en":"[Menopausal transition].","published":"2026-02-24"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.075157":[{"url":"https://hartvaat.nl/2026/02/24/glp-1-agonisten-versus-dpp-4-remmers-en-sglt2-remmers-bij-hartfalenrisico/","title":"GLP-1-agonisten versus DPP-4-remmers en SGLT2-remmers bij hartfalenrisico","title_en":"Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation","published":"2026-02-24"}],"10.1136/bcr-2025-267313":[{"url":"https://hartvaat.nl/2026/02/24/af-geinduceerde-ernstige-lv-disfunctie-na-mitralisklepprocedure-bij-adolescent/","title":"AF-geïnduceerde ernstige LV-disfunctie na mitralisklepprocedure bij adolescent","title_en":"Atrial fibrillation-induced severe left ventricular dysfunction postmitral valve replacement in an adolescent with rheumatic mitral regurgitation.","published":"2026-02-24"}],"10.1007/s00415-026-13692-6":[{"url":"https://hartvaat.nl/2026/02/24/uitgebreid-cta-bereik-detecteert-vroegtijdig-thrombus-in-het-linker-atrium-bij-a/","title":"Uitgebreid CTA-bereik detecteert vroegtijdig thrombus in het linker atrium bij acute CVA","title_en":"Extended CTA scan range for early detection of left atrial and left atrial appendage thrombus and other filling defects in acute ischemic stroke.","published":"2026-02-24"}],"10.1093/eschf/xvag058":[{"url":"https://hartvaat.nl/2026/02/24/colchicine-bij-chronische-inflammatoire-cardiomyopathie-de-cmp-mythic-trial/","title":"Colchicine bij chronische inflammatoire cardiomyopathie: de CMP-MYTHiC-trial","title_en":"Colchicine in patients with chronic inflammatory cardiomyopathy: Rationale and design of the CMP-MYTHiC.","published":"2026-02-24"}],"10.1002/14651858.cd007131.pub5":[{"url":"https://hartvaat.nl/2026/02/24/cochrane-review-interventies-om-deelname-aan-hartrevalidatie-te-bevorderen/","title":"Cochrane-review: interventies om deelname aan hartrevalidatie te bevorderen","title_en":"Interventions to promote patient utilisation of cardiac rehabilitation.","published":"2026-02-24"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26601":[{"url":"https://hartvaat.nl/2026/02/24/renale-denervatie-verbetert-leververvetting-bij-hypertensieve-patienten-met-meta/","title":"Renale denervatie verbetert leververvetting bij hypertensieve patiënten met metabool syndroom","title_en":"Renal Denervation Improves Hepatic Steatosis in Hypertensive Patients With Metabolic Syndrome","published":"2026-02-24"}],"10.1111/imj.70334":[{"url":"https://hartvaat.nl/2026/02/24/multidisciplinaire-cardiometabole-kliniek-ldl-c-verlaging-in-de-dagelijkse-prakt/","title":"Multidisciplinaire cardiometabole kliniek: LDL-C-verlaging in de dagelijkse praktijk","title_en":"Early outcomes from a new multidisciplinary cardiometabolic clinic: real-world experience in lowering low-density lipoprotein cholesterol.","published":"2026-02-24"}],"10.1016/j.jcmg.2025.12.013":[{"url":"https://hartvaat.nl/2026/02/24/yellow-iii-intracoronaire-beeldvorming-en-genexpressie-na-maximale-lipideverlagi/","title":"YELLOW-III: intracoronaire beeldvorming en genexpressie na maximale lipideverlaging met evolocumab","title_en":"Intracoronary Imaging and Transcriptomic Characteristics Before and After Maximum Lipid-Lowering Therapy: YELLOW-III Study of Evolocumab and Maximum Statin Therapy in Chronic Coronary Disease.","published":"2026-02-24"}],"10.1093/eurjpc/zwag126":[{"url":"https://hartvaat.nl/2026/02/24/lp-a-spiegels-bij-kinderen-met-hypercholesterolemie-impact-op-ldl-c-interpretati/","title":"Lp(a)-spiegels bij kinderen met hypercholesterolemie: impact op LDL-C-interpretatie","title_en":"Lipoprotein(a) levels in children with hypercholesterolemia.","published":"2026-02-24"}],"10.1093/eurjpc/zwag089":[{"url":"https://hartvaat.nl/2026/02/24/lipide-aferese-verlaagt-lp-a-met-60-75-systematische-review-en-meta-analyse/","title":"Lipide-aferese verlaagt Lp(a) met 60-75%: systematische review en meta-analyse","title_en":"The impact of lipid apheresis on changes of lipoprotein(a): a systematic review and meta-analysis.","published":"2026-02-24"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003910?rss=1":[{"url":"https://hartvaat.nl/2026/02/23/invasieve-coronaire-functietest-bij-anoca-verandert-de-behandeling-bij-driekwart/","title":"Invasieve coronaire functietest bij ANOCA verandert de behandeling bij driekwart van de patiënten","title_en":"Impact of invasive coronary function testing on management of ANOCA patients and secondary care resource utilisation: a multicentre retrospective study in the UK","published":"2026-02-23"}],"10.1093/eurheartj/ehaf745":[{"url":"https://hartvaat.nl/2026/02/23/aspirinestop-bij-lvad-met-vka-veiligheidsanalyse/","title":"Aspirinestop bij LVAD met VKA: veiligheidsanalyse","title_en":"Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.","published":"2026-02-23"}],"10.1136/heartjnl-2025-326218":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-mi-voordeel-risico-analyse/","title":"Colchicine en spironolacton bij acuut MI: voordeel-risico analyse","title_en":"Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial.","published":"2026-02-23"}],"10.1093/eurheartj/ehag028":[{"url":"https://hartvaat.nl/2026/02/23/het-jaar-in-de-cardiovasculaire-geneeskunde-2025-top-10-publicaties-ischemische-/","title":"Het jaar in de cardiovasculaire geneeskunde 2025: top 10 publicaties ischemische hartziekten","title_en":"The year in cardiovascular medicine 2025: the top 10 papers in ischaemic heart disease.","published":"2026-02-23"}],"10.1093/eurheartj/ehaf1055":[{"url":"https://hartvaat.nl/2026/02/23/immunoadsorptie-bij-gedilateerde-cardiomyopathie-de-iaso-dcm-trial/","title":"Immunoadsorptie bij gedilateerde cardiomyopathie: de IASO-DCM-trial","title_en":"Immunoadsorption in dilated cardiomyopathy: the IASO-DCM trial.","published":"2026-02-23"}],"http://heart.bmj.com/cgi/content/short/112/6/295?rss=1":[{"url":"https://hartvaat.nl/2026/02/23/ai-adoptie-in-de-cardiologie-regulering-op-een-mondiaal-kruispunt/","title":"AI-adoptie in de cardiologie: regulering op een mondiaal kruispunt","title_en":"AI adoption in cardiology: regulation at a global crossroad","published":"2026-02-23"}],"http://heart.bmj.com/cgi/content/short/112/6/350?rss=1":[{"url":"https://hartvaat.nl/2026/02/23/cysteuze-massa-bij-een-jonge-vrouw-met-atriumseptumdefect/","title":"Cysteuze massa bij een jonge vrouw met atriumseptumdefect","title_en":"Abnormal echocardiographic finding: what is the cystic mass in a young woman with secundum atrial septal defect","published":"2026-02-23"}],"http://heart.bmj.com/cgi/content/short/112/6/333?rss=1":[{"url":"https://hartvaat.nl/2026/02/23/objectief-gemeten-lichaamsbeweging-en-levenskwaliteit-bij-hypertrofische-cardiom/","title":"Objectief gemeten lichaamsbeweging en levenskwaliteit bij hypertrofische cardiomyopathie","title_en":"Accelerometry-defined physical activity and quality of life in hypertrophic cardiomyopathy","published":"2026-02-23"}],"http://heart.bmj.com/cgi/content/short/112/6/341?rss=1":[{"url":"https://hartvaat.nl/2026/02/23/biologische-versus-mechanische-prothesen-bij-aortaklepvervanging-op-middelbare-l/","title":"Biologische versus mechanische prothesen bij aortaklepvervanging op middelbare leeftijd","title_en":"Comparative evaluation of biological and mechanical prostheses for aortic valve replacement in a middle-aged population: a population-based cohort study","published":"2026-02-23"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001418":[{"url":"https://hartvaat.nl/2026/02/23/correctie-ai-evaluatie-en-monitoring-in-de-gezondheidszorg-aha/","title":"Correctie: AI-evaluatie en monitoring in de gezondheidszorg (AHA)","title_en":"Correction to: Pragmatic Approaches to the Evaluation and Monitoring of Artificial Intelligence in Health Care: A Science Advisory From the American Heart Association","published":"2026-02-23"}],"http://heart.bmj.com/cgi/content/short/112/6/307?rss=1":[{"url":"https://hartvaat.nl/2026/02/23/elektrocardiografische-beeldvorming-technische-ontwikkelingen-en-toekomst/","title":"Elektrocardiografische beeldvorming: technische ontwikkelingen en toekomst","title_en":"Electrocardiographic imaging: technical developments and future applications for non-invasive electroanatomical study of the human heart","published":"2026-02-23"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.075723":[{"url":"https://hartvaat.nl/2026/02/23/brief-over-intensieve-lichaamsbeweging-en-coronaire-uitkomsten-huang-fogacci/","title":"Brief over intensieve lichaamsbeweging en coronaire uitkomsten (Huang & Fogacci)","title_en":"Letter by Huang and Fogacci Regarding Article, “High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study”","published":"2026-02-23"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.075503":[{"url":"https://hartvaat.nl/2026/02/23/brief-over-intensieve-lichaamsbeweging-en-coronaire-uitkomsten-xie-et-al/","title":"Brief over intensieve lichaamsbeweging en coronaire uitkomsten (Xie et al.)","title_en":"Letter by Xie et al Regarding Article, “High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study”","published":"2026-02-23"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077402":[{"url":"https://hartvaat.nl/2026/02/23/reactie-op-brief-over-intensieve-lichaamsbeweging-en-coronaire-uitkomsten/","title":"Reactie op brief over intensieve lichaamsbeweging en coronaire uitkomsten","title_en":"Response by Berry et al to Letter Regarding Article, “High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study”","published":"2026-02-23"}],"10.1093/ndt/gfag036":[{"url":"https://hartvaat.nl/2026/02/23/semaglutide-vermindert-infectierisico-bij-diabetes-en-chronische-nierziekte/","title":"Semaglutide vermindert infectierisico bij diabetes en chronische nierziekte","title_en":"Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.","published":"2026-02-23"}],"10.1186/s12933-026-03098-z":[{"url":"https://hartvaat.nl/2026/02/23/van-internationale-richtlijnen-naar-nationale-implementatie-bij-cardio-renaal-me/","title":"Van internationale richtlijnen naar nationale implementatie bij cardio-renaal-metabole ziekten","title_en":"From global guidelines for cardio-kidney-metabolic diseases management to national implementation: perspectives from the guideline workshop taskforce.","published":"2026-02-23"}],"10.2196/78859":[{"url":"https://hartvaat.nl/2026/02/23/telehealth-verbetert-zelfzorg-bij-kwetsbare-hartfalenpatienten/","title":"Telehealth verbetert zelfzorg bij kwetsbare hartfalenpatiënten","title_en":"How and Why Telehealth Interventions Improve Self-Care Among Vulnerable Groups of Patients With Heart Failure: Scoping Review and Rapid Realist Synthesis.","published":"2026-02-23"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076235":[{"url":"https://hartvaat.nl/2026/02/23/polygene-en-monogene-bijdragen-aan-tachycardie-geassocieerde-cardiomyopathie/","title":"Polygene en monogene bijdragen aan tachycardie-geassocieerde cardiomyopathie","title_en":"Polygenic and Monogenic Contributions to Tachycardia-Associated Cardiomyopathy","published":"2026-02-23"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.078151":[{"url":"https://hartvaat.nl/2026/02/23/remming-van-vetzuuroxidatie-bij-hartfalen-met-behouden-ejectiefractie/","title":"Remming van vetzuuroxidatie bij hartfalen met behouden ejectiefractie","title_en":"Inhibiting Fatty Acid Oxidation With a Mitotrope in Heart Failure With Preserved Ejection Fraction","published":"2026-02-23"}],"http://heart.bmj.com/cgi/content/short/112/6/326?rss=1":[{"url":"https://hartvaat.nl/2026/02/23/colchicine-en-spironolacton-bij-acuut-myocardinfarct-winratio-analyse-uit-de-cle/","title":"Colchicine en spironolacton bij acuut myocardinfarct: winratio-analyse uit de CLEAR-trial","title_en":"Benefit-risk of colchicine and spironolactone in acute myocardial infarction: a prespecified generalised pairwise comparisons analysis of the CLEAR trial","published":"2026-02-23"}],"http://heart.bmj.com/cgi/content/short/112/6/318?rss=1":[{"url":"https://hartvaat.nl/2026/02/23/luchtvervuiling-en-multimorbiditeit-verhogen-het-risico-op-atriumfibrilleren/","title":"Luchtvervuiling en multimorbiditeit verhogen het risico op atriumfibrilleren","title_en":"Impact of air pollution and multimorbidity on the risk of incident atrial fibrillation","published":"2026-02-23"}],"http://heart.bmj.com/cgi/content/short/112/6/300?rss=1":[{"url":"https://hartvaat.nl/2026/02/23/regulering-van-ai-in-de-cardiologie-door-de-fda-een-scoping-review/","title":"Regulering van AI in de cardiologie door de FDA: een scoping review","title_en":"Is the FDA regulation of cardiology AI devices supporting cardiovascular innovation: a scoping review","published":"2026-02-23"}],"10.1161/circheartfailure.125.013747":[{"url":"https://hartvaat.nl/2026/02/23/nierbescherming-na-harttransplantatie-risicoreductie-en-therapeutische-mogelijkh/","title":"Nierbescherming na harttransplantatie: risicoreductie en therapeutische mogelijkheden","title_en":"Mitigating Risk of Kidney Dysfunction After Heart Transplantation and Therapeutic Approaches.","published":"2026-02-23"}],"10.1093/eschf/xvag064":[{"url":"https://hartvaat.nl/2026/02/23/diabetes-verhoogt-het-risico-op-hartfalen-bij-myocarditis/","title":"Diabetes verhoogt het risico op hartfalen bij myocarditis","title_en":"Diabetes Increases the Risk of Heart Failure in Myocarditis: A Propensity-Matched Nationwide Database Analysis.","published":"2026-02-23"}],"10.1093/eschf/xvag062":[{"url":"https://hartvaat.nl/2026/02/23/verhoogd-activine-a-bij-peripartum-cardiomyopathie-en-tijdens-lv-herstel/","title":"Verhoogd Activine-A bij peripartum cardiomyopathie en tijdens LV-herstel","title_en":"Elevated Activin-A serum levels in patients with acute peripartum cardiomyopathy and during left ventricular recovery.","published":"2026-02-23"}],"10.1093/eschf/xvag061":[{"url":"https://hartvaat.nl/2026/02/23/pathfinder-trial-betere-naleving-van-hartfalenrichtlijnen-in-de-huisartsenprakti/","title":"PATHFINDER-trial: betere naleving van hartfalenrichtlijnen in de huisartsenpraktijk","title_en":"Primary care Adherence To Heart failure guidelines in post-Discharge, Evaluation & Routine management (PATHFINDER): a randomised controlled trial.","published":"2026-02-23"}],"10.2196/83022":[{"url":"https://hartvaat.nl/2026/02/23/hartfalen-app-verbetert-ziektekennis-bij-patienten-een-gerandomiseerde-pilotstud/","title":"Hartfalen-app verbetert ziektekennis bij patiënten: een gerandomiseerde pilotstudie","title_en":"Impact of the Cardio-Meds Mobile App on Heart Failure Knowledge and Medication Adherence: Pilot Randomized Controlled Trial.","published":"2026-02-23"}],"10.1136/bmjopen-2025-111865":[{"url":"https://hartvaat.nl/2026/02/23/arni-verbetert-kwaliteit-van-leven-en-vermindert-ziekenhuisopnames-bij-hartfalen/","title":"ARNI verbetert kwaliteit van leven en vermindert ziekenhuisopnames bij hartfalen","title_en":"Association between angiotensin receptor-neprilysin inhibitor use and clinical outcomes in patients with heart failure: a 1-year prospective cohort study from Jordan.","published":"2026-02-23"}],"10.3346/jkms.2026.41.e94":[{"url":"https://hartvaat.nl/2026/02/23/lichamelijke-activiteit-op-het-werk-en-bloeddruk-sekseverschillen-en-de-rol-van-/","title":"Lichamelijke activiteit op het werk en bloeddruk: sekseverschillen en de rol van vrije tijd","title_en":"Occupational Physical Activity and Blood Pressure: The Role of Leisure Time Physical Activity and Sex Differences.","published":"2026-02-23"}],"10.1016/j.jlr.2026.101008":[{"url":"https://hartvaat.nl/2026/02/23/analytische-validatie-van-een-directe-lp-a-cholesterolbepaling/","title":"Analytische validatie van een directe Lp(a)-cholesterolbepaling","title_en":"Analytical Validation of Direct Lipoprotein(a)-Cholesterol Assay.","published":"2026-02-23"}],"10.1093/ehjci/jeag051":[{"url":"https://hartvaat.nl/2026/02/23/lp-a-en-ai-ccta-onthullen-onzichtbaar-restrisico-voorbij-de-calciumscore/","title":"Lp(a) en AI-CCTA onthullen 'onzichtbaar' restrisico voorbij de calciumscore","title_en":"Beyond CACS: Can Lp(a) and AI-CCTA Unmask \"Invisible\" Residual Cardiovascular Risk?","published":"2026-02-23"}],"10.1016/j.mvr.2026.104925":[{"url":"https://hartvaat.nl/2026/02/23/pcsk9-remmers-bij-cardiaal-syndroom-x-nieuw-perspectief-op-microvasculaire-angin/","title":"PCSK9-remmers bij cardiaal syndroom X: nieuw perspectief op microvasculaire angina","title_en":"The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.","published":"2026-02-23"}],"10.1136/bmjopen-2025-105830":[{"url":"https://hartvaat.nl/2026/02/22/bloeddrukcontrole-bij-hypertensie-in-gezondheidscentra-in-shenzhen/","title":"Bloeddrukcontrole bij hypertensie in gezondheidscentra in Shenzhen","title_en":"Blood pressure control rates among hypertensive patients managed in community health centres in Shenzhen, China: a megacity population-based observational study.","published":"2026-02-22"}],"10.1136/bmjopen-2025-111579":[{"url":"https://hartvaat.nl/2026/02/22/liposomaal-bupivacaine-peng-blok-tegen-diepveneuze-trombose-bij-heupfracturen/","title":"Liposomaal bupivacaïne PENG-blok tegen diepveneuze trombose bij heupfracturen","title_en":"Effect of preoperative liposomal bupivacaine single-injection pericapsular nerve group (PENG) block on lower extremity deep vein thrombosis in elderly patients with hip fractures: a randomised controlled, double-blind, prospective clinical study protocol.","published":"2026-02-22"}],"10.1503/cmaj.250591":[{"url":"https://hartvaat.nl/2026/02/22/kosteneffectiviteit-van-sglt2-remmers-en-glp-1-agonisten-bij-hoog-cardiovasculai/","title":"Kosteneffectiviteit van SGLT2-remmers en GLP-1-agonisten bij hoog cardiovasculair risico in Canada","title_en":"Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada.","published":"2026-02-22"}],"10.64898/2026.02.20.26346738":[{"url":"https://hartvaat.nl/2026/02/22/genetische-voorspelling-van-lp-a-spiegels-in-diverse-populaties/","title":"Genetische voorspelling van Lp(a)-spiegels in diverse populaties","title_en":"Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations.","published":"2026-02-22"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(26)00315-6/fulltext":[{"url":"https://hartvaat.nl/2026/02/21/erratum-sapien-3-versus-myval-bij-tavi-compare-tavi-1/","title":"Erratum: SAPIEN 3 versus Myval bij TAVI (COMPARE-TAVI 1)","title_en":"Department of Error","published":"2026-02-21"}],"10.1186/s12913-026-14175-0":[{"url":"https://hartvaat.nl/2026/02/21/barrieres-en-facilitatoren-voor-mhealth-programma-diabetes-en-hypertensie-in-gha/","title":"Barrières en facilitatoren voor mHealth-programma diabetes en hypertensie in Ghana","title_en":"Barriers and Facilitators to the implementation and scale-up of a mHealth integrated care program for diabetes and hypertension in Ghana: a qualitative study of the Akoma Pa program.","published":"2026-02-21"}],"10.1093/eurheartj/ehaf1127":[{"url":"https://hartvaat.nl/2026/02/21/driedimensionale-echocardiografie-bij-kleplijden-klinische-implicaties/","title":"Driedimensionale echocardiografie bij kleplijden: klinische implicaties","title_en":"Three-dimensional echocardiography for valvular heart disease: clinical implications.","published":"2026-02-21"}],"10.1093/eurheartj/ehag018":[{"url":"https://hartvaat.nl/2026/02/21/aspirine-lipoproteine-a-en-aortaklepstenose-de-mesa-studie/","title":"Aspirine, lipoproteïne(a) en aortaklepstenose: de MESA-studie","title_en":"Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis.","published":"2026-02-21"}],"10.1093/eurheartj/ehag073":[{"url":"https://hartvaat.nl/2026/02/21/pelacarsen-vermindert-de-behoefte-aan-lipoproteine-a-aferese-lp-a-frontiers-aphe/","title":"Pelacarsen vermindert de behoefte aan lipoproteïne(a)-aferese: Lp(a)FRONTIERS APHERESIS","title_en":"Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.","published":"2026-02-21"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003914?rss=1":[{"url":"https://hartvaat.nl/2026/02/20/kosteneffectiviteit-van-mavacamten-bij-obstructieve-hcm-gezondheidswinst-maar-ee/","title":"Kosteneffectiviteit van mavacamten bij obstructieve HCM: gezondheidswinst, maar een hoge prijs","title_en":"Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system","published":"2026-02-20"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003568?rss=1":[{"url":"https://hartvaat.nl/2026/02/20/virtuele-afdeling-met-thuismonitoring-is-veilig-voor-patienten-die-wachten-op-sp/","title":"Virtuele afdeling met thuismonitoring is veilig voor patiënten die wachten op spoed-bypasschirurgie","title_en":"Feasibility, safety and outcomes of a virtual ward with remote monitoring for patients awaiting urgent coronary artery bypass graft surgery","published":"2026-02-20"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003827?rss=1":[{"url":"https://hartvaat.nl/2026/02/20/geintegreerd-machine-learningmodel-voorspelt-cardiovasculair-risico-beter-dan-de/","title":"Geïntegreerd machine-learningmodel voorspelt cardiovasculair risico beter dan de Framingham-score (UK Biobank)","title_en":"Enhanced cardiovascular disease risk prediction using integrated machine learning models: a study from the UK Biobank cohort","published":"2026-02-20"}],"https://www.kidney-international.org/article/s0085-2538(26)00129-8/fulltext":[{"url":"https://hartvaat.nl/2026/02/20/darmmicrobiota-en-geschatte-glomerulaire-filtratiesnelheid-in-twee-zweedse-cohor/","title":"Darmmicrobiota en geschatte glomerulaire filtratiesnelheid in twee Zweedse cohorten","title_en":"Association between the gut microbiota and estimated glomerular filtration rate in two Swedish population-based cohorts","published":"2026-02-20"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076423":[{"url":"https://hartvaat.nl/2026/02/20/hev-gericht-antilichaam-medicijnconjugaat-bevordert-langdurige-acceptatie-van-ha/","title":"HEV-gericht antilichaam-medicijnconjugaat bevordert langdurige acceptatie van harttransplantaat","title_en":"HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance","published":"2026-02-20"}],"https://www.kidney-international.org/article/s0085-2538(26)00135-3/fulltext":[{"url":"https://hartvaat.nl/2026/02/20/in-memoriam-claudio-ponticelli-1936-2026/","title":"In memoriam: Claudio Ponticelli (1936-2026)","title_en":"Memories of Claudio Ponticelli","published":"2026-02-20"}],"https://www.kidney-international.org/article/s0085-2538(26)00132-8/fulltext":[{"url":"https://hartvaat.nl/2026/02/20/milt-norepinefrine-2-adrenerge-as-verergert-sepsis-geassocieerd-acuut-nierletsel/","title":"Milt-norepinefrine-β2-adrenerge as verergert sepsis-geassocieerd acuut nierletsel","title_en":"The splenic norepinephrine–β2-adrenergic receptor axis aggravates sepsis-associated acute kidney injury via neutrophil-mediated immunosuppression","published":"2026-02-20"}],"10.1097/md.0000000000047736":[{"url":"https://hartvaat.nl/2026/02/20/longdan-xiegan-formule-als-aanvullende-therapie-bij-hypertensie-systematische-re/","title":"Longdan Xiegan-formule als aanvullende therapie bij hypertensie: systematische review","title_en":"Longdan Xiegan formula as adjuvant therapy for hypertension: A systematic review and meta-analysis.","published":"2026-02-20"}],"10.3760/cma.j.cn121094-20241029-00494":[{"url":"https://hartvaat.nl/2026/02/20/rol-van-appelzuurenzym-1-bij-ferroptose-en-zenuwschade-bij-hypertensieve-muizen-/","title":"Rol van appelzuurenzym-1 bij ferroptose en zenuwschade bij hypertensieve muizen na loodblootstelling","title_en":"[The role of malic enzyme 1 regulating ferroptosis on nerve impairment of hypertensive mice following lead exposure].","published":"2026-02-20"}],"10.1097/md.0000000000047589":[{"url":"https://hartvaat.nl/2026/02/20/intensief-bewegen-verlaagt-het-risico-op-veneuze-trombo-embolie-mendeliaanse-ran/","title":"Intensief bewegen verlaagt het risico op veneuze trombo-embolie: Mendeliaanse randomisatie","title_en":"The impact of different intensities of physical activity on the risk of venous thromboembolism: A Mendelian randomization study.","published":"2026-02-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26014":[{"url":"https://hartvaat.nl/2026/02/20/hartslagvariabiliteit-modereert-het-verband-tussen-angst-en-sympathische-zenuwac/","title":"Hartslagvariabiliteit modereert het verband tussen angst en sympathische zenuwactiviteit","title_en":"Heart Rate Variability Moderates the Association Between Trait Anxiety and Sympathetic Nerve Activity in Humans","published":"2026-02-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25810":[{"url":"https://hartvaat.nl/2026/02/20/lage-dosis-drievoudige-combinatiepil-versus-standaard-telmisartan-bij-hypertensi/","title":"Lage dosis drievoudige combinatiepil versus standaard telmisartan bij hypertensie","title_en":"Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT","published":"2026-02-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26321":[{"url":"https://hartvaat.nl/2026/02/20/proteomische-risicoscore-voorspelt-het-ontstaan-van-hypertensie/","title":"Proteomische risicoscore voorspelt het ontstaan van hypertensie","title_en":"Proteomic Risk Score for Prediction of Incident Hypertension","published":"2026-02-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26148":[{"url":"https://hartvaat.nl/2026/02/20/mhealth-interventie-verbetert-hypertensiezorg-bij-hoogrisicopatienten/","title":"mHealth-interventie verbetert hypertensiezorg bij hoogrisicopatiënten","title_en":"mHealth Intervention to Improve Hypertension Care in High-Risk Patients","published":"2026-02-20"}],"10.1097/md.0000000000047799":[{"url":"https://hartvaat.nl/2026/02/20/risicofactoren-voor-pulmonale-hypertensie-bij-linkszijdig-hartlijden/","title":"Risicofactoren voor pulmonale hypertensie bij linkszijdig hartlijden","title_en":"The risk factors associated with pulmonary hypertension in patients with left heart diseases.","published":"2026-02-20"}],"10.1097/md.0000000000047704":[{"url":"https://hartvaat.nl/2026/02/20/hypertensie-bij-45-plussers-in-china-prevalentie-bewustzijn-en-behandeling/","title":"Hypertensie bij 45-plussers in China: prevalentie, bewustzijn en behandeling","title_en":"Prevalence and management of hypertension among adults aged 45 and older in mainland China: Insights from the 2020 CHARLS survey.","published":"2026-02-20"}],"10.64898/2026.02.18.26346592":[{"url":"https://hartvaat.nl/2026/02/20/biomarkers-voor-atherosclerotische-events-bij-reumatoide-artritis-lp-a-als-voors/","title":"Biomarkers voor atherosclerotische events bij reumatoïde artritis: Lp(a) als voorspeller","title_en":"Biomarkers for Atherosclerotic Cardiovascular Events in Rheumatoid Arthritis: Towards Validation of a Biomarker-Enhanced Risk Model.","published":"2026-02-20"}],"10.3390/jcdd13020100":[{"url":"https://hartvaat.nl/2026/02/20/secundaire-preventie-na-myocardinfarct-in-saudi-arabie-het-4s-register/","title":"Secundaire preventie na myocardinfarct in Saudi-Arabië: het 4S-register","title_en":"Saudi Secondary Prevention Survey Study in Patients with Prior Acute Myocardial Infarction (4S Registry): Study Design and Pilot Phase Results.","published":"2026-02-20"}],"10.1056/nejmoa2509766":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","title":"PARTNER 3: TAVR versus chirurgie bij laagrisico — zevenjaarsresultaten NEJM","title_en":"Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.","published":"2026-02-19"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001415":[{"url":"https://hartvaat.nl/2026/02/19/2026-aha-acc-richtlijn-voor-evaluatie-en-behandeling-van-acute-longembolie/","title":"2026 AHA/ACC-richtlijn voor evaluatie en behandeling van acute longembolie","title_en":"2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines","published":"2026-02-19"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00049-3/fulltext":[{"url":"https://hartvaat.nl/2026/02/19/kanker-en-coronaire-atherosclerotische-plaquebelasting-inzichten-uit-de-bravado-/","title":"Kanker en coronaire atherosclerotische plaquebelasting: inzichten uit de BRAVADO-studie","title_en":"Association of Cancer on Coronary Atherosclerotic Burden and Plaque Rupture: Insights from the BRAVADO Study","published":"2026-02-19"}],"https://www.kidney-international.org/article/s0085-2538(26)00133-x/fulltext":[{"url":"https://hartvaat.nl/2026/02/19/mettl3-interventie-onderdrukt-pathogene-th17-differentiatie-en-herstelt-nierscha/","title":"METTL3-interventie onderdrukt pathogene Th17-differentiatie en herstelt nierschade bij lupusnefritis","title_en":"METTL3-targeted intervention on nuclear factors RORA/RORγt suppressing pathogenic T helper 17 cell differentiation and restores kidney damage in lupus nephritis.","published":"2026-02-19"}],"10.1093/eurheartj/ehag093":[{"url":"https://hartvaat.nl/2026/02/19/geleidingsstoornissen-na-transkatheter-aortaklepimplantatie/","title":"Geleidingsstoornissen na transkatheter aortaklepimplantatie","title_en":"Conduction disturbances after transcatheter aortic valve implantation.","published":"2026-02-19"}],"10.1093/ndt/gfag037":[{"url":"https://hartvaat.nl/2026/02/19/creatinine-cystatine-c-of-beide-voor-gfr-schatting-bij-niertransplantatiepatient/","title":"Creatinine, cystatine C of beide voor GFR-schatting bij niertransplantatiepatiënten?","title_en":"Creatinine, cystatin C or both to estimate glomerular filtration rate in kidney transplant recipients?","published":"2026-02-19"}],"10.1093/eurheartj/ehag088":[{"url":"https://hartvaat.nl/2026/02/19/delirium-in-de-cardiovasculaire-geneeskunde/","title":"Delirium in de cardiovasculaire geneeskunde","title_en":"Delirium in cardiovascular medicine.","published":"2026-02-19"}],"10.1093/eurheartj/ehaf1037":[{"url":"https://hartvaat.nl/2026/02/19/competenties-na-certificering-en-cardiovasculaire-zorgverlening/","title":"Competenties na certificering en cardiovasculaire zorgverlening","title_en":"Post-certification competencies and cardiovascular care delivery.","published":"2026-02-19"}],"10.1056/nejmcp2415601":[{"url":"https://hartvaat.nl/2026/02/19/secundaire-preventie-na-ischemisch-cva-overzicht-uit-het-nejm/","title":"Secundaire preventie na ischemisch CVA: overzicht uit het NEJM","title_en":"Secondary Prevention after Ischemic Stroke.","published":"2026-02-19"}],"10.1093/europace/euag028":[{"url":"https://hartvaat.nl/2026/02/19/cardiovasculair-renaal-metabool-samenspel-bij-patienten-met-atriumfibrilleren/","title":"Cardiovasculair-renaal-metabool samenspel bij patiënten met atriumfibrilleren","title_en":"Cardiovascular-Kidney-Metabolic Interplay in Patients with Atrial Fibrillation Receiving Direct Oral Anticoagulants.","published":"2026-02-19"}],"10.1111/dom.70590":[{"url":"https://hartvaat.nl/2026/02/19/evolocumab-en-doorgankelijkheid-van-veneuze-bypasses-na-cabg-newton-cabg-cardiol/","title":"Evolocumab en doorgankelijkheid van veneuze bypasses na CABG: NEWTON-CABG CardioLink-5","title_en":"Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON-CABG CardioLink-5 trial.","published":"2026-02-19"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00051-1/fulltext":[{"url":"https://hartvaat.nl/2026/02/19/enkelvoudige-onverzadigde-vetzuren-in-vetweefsel-en-het-risico-op-perifeer-vaatl/","title":"Enkelvoudige onverzadigde vetzuren in vetweefsel en het risico op perifeer vaatlijden","title_en":"Monounsaturated Fatty Acids in Adipose Tissue and the Risk of Peripheral Artery Disease: A Danish Case-Cohort study","published":"2026-02-19"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26262":[{"url":"https://hartvaat.nl/2026/02/18/angiotensine-1-7-activeert-pomc-neuronen-in-de-nucleus-arcuatus/","title":"Angiotensine-(1-7) activeert POMC-neuronen in de nucleus arcuatus","title_en":"Angiotensin-(1–7) Activates Proopiomelanocortin Neurons in the Arcuate Nucleus","published":"2026-02-18"}],"https://www.nejm.org/doi/full/10.1056/nejmc2518019&rss=currentissue":[{"url":"https://hartvaat.nl/2026/02/18/betablokkers-na-een-myocardinfarct/","title":"Bètablokkers na een myocardinfarct","title_en":"Beta-Blockers after Myocardial Infarction","published":"2026-02-18"}],"https://www.kidney-international.org/article/s0085-2538(26)00131-6/fulltext":[{"url":"https://hartvaat.nl/2026/02/18/verstoring-van-de-cystine-1-myristoyl-elektrostatische-schakelaar-veroorzaakt-po/","title":"Verstoring van de cystine-1 myristoyl-elektrostatische schakelaar veroorzaakt polycysteuze nierziekte","title_en":"Disruption of the human cystin-1 myristoyl-electrostatic switch causes polycystic kidney disease that phenocopies autosomal recessive polycystic kidney disease","published":"2026-02-18"}],"https://www.nejm.org/doi/full/10.1056/nejme2600177&rss=currentissue":[{"url":"https://hartvaat.nl/2026/02/18/gentherapie-voor-nefropathische-cystinose/","title":"Gentherapie voor nefropathische cystinose","title_en":"Gene Therapy for Nephropathic Cystinosis","published":"2026-02-18"}],"https://www.kidney-international.org/article/s0085-2538(26)00079-7/fulltext":[{"url":"https://hartvaat.nl/2026/02/18/groene-dialyse-duurzame-zorg-groei-en-innovatie-kdigo-conferentie/","title":"Groene dialyse: duurzame zorg, groei en innovatie (KDIGO-conferentie)","title_en":"Green Dialysis: Environmentally Sustainable Care, Growth, and Innovation: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","published":"2026-02-18"}],"https://www.nejm.org/doi/full/10.1056/nejmc2518967&rss=currentissue":[{"url":"https://hartvaat.nl/2026/02/18/osilodrostat-bij-bilaterale-bijnieroverproductie-van-cortisol-bij-primair-aldost/","title":"Osilodrostat bij bilaterale bijnieroverproductie van cortisol bij primair aldosteronisme","title_en":"More on Osilodrostat for Bilateral Adrenal Hypercortisolism in Primary Aldosteronism","published":"2026-02-18"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26461":[{"url":"https://hartvaat.nl/2026/02/18/nox4-gemedieerde-metabole-herprogrammering-bij-zoutgevoelige-hypertensie/","title":"Nox4-gemedieerde metabole herprogrammering bij zoutgevoelige hypertensie","title_en":"Renox Reloaded: How Metabolic Reprogramming by the NADPH Oxidase Nox4 Promotes Salt-Sensitive Hypertension","published":"2026-02-18"}],"https://www.ahajournals.org/doi/abs/10.1161/hyp.0000000000000261":[{"url":"https://hartvaat.nl/2026/02/18/retractie-abstract-over-ruimtelijk-temporele-dynamiek-van-diabetesprevalentie/","title":"Retractie: abstract over ruimtelijk-temporele dynamiek van diabetesprevalentie","title_en":"Retraction of: Abstract FR512: Spatio-Temporal Dynamics of Diabetes Prevalence: Structural and Environmental Drivers of Chronic Disease Burdens","published":"2026-02-18"}],"https://www.kidney-international.org/article/s0085-2538(26)00130-4/fulltext":[{"url":"https://hartvaat.nl/2026/02/18/telomeerherstel-via-gentherapie-bij-cardiorenaal-syndroom-type-4/","title":"Telomeerherstel via gentherapie bij cardiorenaal syndroom type 4","title_en":"Telomere recapping via gene therapy as a beneficial strategy for cardio-renal syndrome type 4","published":"2026-02-18"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26196":[{"url":"https://hartvaat.nl/2026/02/18/trends-in-het-gebruik-van-zoutvervangingsmiddelen-in-de-vs-2003-2020/","title":"Trends in het gebruik van zoutvervangingsmiddelen in de VS (2003-2020)","title_en":"Trends in Salt Substitute Use Among Adults in the United States from 2003 to 2020","published":"2026-02-18"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26081":[{"url":"https://hartvaat.nl/2026/02/18/ongecontroleerde-hypertensie-bij-jongvolwassenen-in-de-verenigde-staten/","title":"Ongecontroleerde hypertensie bij jongvolwassenen in de Verenigde Staten","title_en":"Uncontrolled Hypertension in Young Adults: A Real-World Analysis of 89,130 Adults in the United States","published":"2026-02-18"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00037-7/fulltext":[{"url":"https://hartvaat.nl/2026/02/18/gezondheidsgeletterdheid-en-kwaliteit-van-leven-na-een-acuut-coronair-syndroom/","title":"Gezondheidsgeletterdheid en kwaliteit van leven na een acuut coronair syndroom","title_en":"Health Literacy and Quality of Life after Acute Coronary Syndrome: The Mediating Role of Self-Care in Palestine","published":"2026-02-18"}],"10.1016/j.jacc.2025.09.019":[{"url":"https://hartvaat.nl/2026/02/17/danger-shock-sekseverschillen-in-impella-gebruik-bij-cardiogene-shock/","title":"DanGer Shock: sekseverschillen in Impella-gebruik bij cardiogene shock","title_en":"Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.","published":"2026-02-17"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25378":[{"url":"https://hartvaat.nl/2026/02/17/lactylering-van-bcat2-k377-draagt-bij-aan-ernstige-pre-eclampsie/","title":"Lactylering van BCAT2-K377 draagt bij aan ernstige pre-eclampsie","title_en":"Lactylation of BCAT2-K377 Contributes to the Progression of Severe Preeclampsia","published":"2026-02-17"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25658":[{"url":"https://hartvaat.nl/2026/02/17/ngal-veroorzaakt-cardiale-remodeling-bij-ratten-met-chronische-nierziekte/","title":"NGAL veroorzaakt cardiale remodeling bij ratten met chronische nierziekte","title_en":"Neutrophil Gelatinase–Associated Lipocalin Drives Cardiac Remodeling in Rats With Chronic Kidney Disease","published":"2026-02-17"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003882?rss=1":[{"url":"https://hartvaat.nl/2026/02/16/smart2-risicomodel-onderschat-het-recidiefrisico-bij-kwetsbare-groepen-leids-haa/","title":"SMART2-risicomodel onderschat het recidiefrisico bij kwetsbare groepen (Leids-Haagse validatie)","title_en":"External validation of the SMART2 model for recurrent cardiovascular risk: performance in socioeconomic, ethnic and psychiatric subgroups","published":"2026-02-16"}],"https://www.kidney-international.org/article/s0085-2538(26)00091-8/fulltext":[{"url":"https://hartvaat.nl/2026/02/16/landelijk-aki-alarmsysteem-effecten-op-zorg-en-patientuitkomsten/","title":"Landelijk AKI-alarmsysteem: effecten op zorg en patiëntuitkomsten","title_en":"A population-based, regression discontinuity analysis examined the effects of nationwide alerting for acute kidney injury on health care and patient outcomes","published":"2026-02-16"}],"https://www.kidney-international.org/article/s0085-2538(26)00090-6/fulltext":[{"url":"https://hartvaat.nl/2026/02/16/fibrilline-1-is-een-nieuw-ligand-van-de-egf-receptor-dat-mesangiumcellen-activee/","title":"Fibrilline-1 is een nieuw ligand van de EGF-receptor dat mesangiumcellen activeert","title_en":"Fibrillin-1 is a novel ligand of the epidermal growth factor receptor promoting mesangial cell activation and glomerulosclerosis","published":"2026-02-16"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.074493":[{"url":"https://hartvaat.nl/2026/02/16/nieuwe-plasma-eiwitbiomarkers-en-risico-op-veneuze-trombo-embolie/","title":"Nieuwe plasma-eiwitbiomarkers en risico op veneuze trombo-embolie","title_en":"Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism","published":"2026-02-16"}],"10.4244/eij-d-25-00598":[{"url":"https://hartvaat.nl/2026/02/16/aanvullende-farmacologische-strategieen-voor-restrisicoreductie-na-revascularisa/","title":"Aanvullende farmacologische strategieën voor restrisicoreductie na revascularisatie","title_en":"Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation.","published":"2026-02-16"}],"10.1007/s10072-025-08789-1":[{"url":"https://hartvaat.nl/2026/02/16/vroege-versus-late-antistolling-na-ischemisch-cva-met-atriumfibrilleren-meta-ana/","title":"Vroege versus late antistolling na ischemisch CVA met atriumfibrilleren: meta-analyse","title_en":"Early versus late anticoagulation treatment after acute ischemic stroke with atrial fibrillation: a meta-analysis of randomized controlled trials.","published":"2026-02-16"}],"10.1136/bmjopen-2025-103632":[{"url":"https://hartvaat.nl/2026/02/16/sluiting-van-het-linker-hartoor-versus-doac-s-na-longembolie/","title":"Sluiting van het linker hartoor versus DOAC's na longembolie","title_en":"Left atrial appendage closure versus direct oral anticoagulants after pulmonary vein isolation for atrial fibrillation: protocol for a multicentre, prospective, randomised, non-inferiority trial (PROMOTE study).","published":"2026-02-16"}],"10.1136/openhrt-2025-003536":[{"url":"https://hartvaat.nl/2026/02/16/trends-in-gebruik-van-directe-orale-anticoagulantia-een-case-controlstudie/","title":"Trends in gebruik van directe orale anticoagulantia: een case-controlstudie","title_en":"Overview of direct oral anticoagulation trends in the Bronx: case control study of patient and systemic factors in medication non-adherence.","published":"2026-02-16"}],"10.1016/j.redox.2026.104088":[{"url":"https://hartvaat.nl/2026/02/16/apolipoproteine-c3-verergert-vaatverkalking-via-ferroptose-bij-chronisch-nierfal/","title":"Apolipoproteïne C3 verergert vaatverkalking via ferroptose bij chronisch nierfalen","title_en":"Apolipoprotein C3 exacerbates vascular calcification by promoting ferroptosis via the TLR2/AMPK pathway in vascular smooth muscle cells.","published":"2026-02-16"}],"10.26442/00403660.2026.01.203470":[{"url":"https://hartvaat.nl/2026/02/15/hormonale-menopauzetherapie-bij-cardiovasculaire-en-metabole-ziekten-russische-d/","title":"Hormonale menopauzetherapie bij cardiovasculaire en metabole ziekten: Russische Delphi-consensus","title_en":"[Menopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists].","published":"2026-02-15"}],"10.26442/00403660.2026.01.203520":[{"url":"https://hartvaat.nl/2026/02/15/risicofactoren-voor-een-slechte-jaarprognose-na-acute-decompensatie-van-hartfale/","title":"Risicofactoren voor een slechte jaarprognose na acute decompensatie van hartfalen","title_en":"[Risk factors for poor annual prognosis in patients after acute decompensation of heart failure].","published":"2026-02-15"}],"10.26442/00403660.2026.01.203492":[{"url":"https://hartvaat.nl/2026/02/15/kenmerken-en-vijfjaarsuitkomsten-bij-patienten-met-cll-en-atriumfibrilleren/","title":"Kenmerken en vijfjaarsuitkomsten bij patiënten met CLL en atriumfibrilleren","title_en":"[Characteristics and 5-year outcomes in patients with chronic lymphocytic leukemia receiving ibrutinib (a real-world study)].","published":"2026-02-15"}],"10.1016/s0140-6736(25)01578-8":[{"url":"https://hartvaat.nl/2026/02/14/bijwerkingen-toegeschreven-aan-statines-in-bijsluiters-meta-analyse-van-rct-s/","title":"Bijwerkingen toegeschreven aan statines in bijsluiters: meta-analyse van RCT's","title_en":"Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.","published":"2026-02-14"}],"10.1016/s0140-6736(25)02156-7":[{"url":"https://hartvaat.nl/2026/02/14/tricorder-ai-stethoscoop-voor-triple-cv-ziektedetectie/","title":"TRICORDER: AI-stethoscoop voor triple CV-ziektedetectie","title_en":"Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial.","published":"2026-02-14"}],"10.26442/00403660.2025.12.203499":[{"url":"https://hartvaat.nl/2026/02/14/snelheid-van-lipidedoelbereik-en-langetermijnuitkomsten-na-acuut-coronair-syndro/","title":"Snelheid van lipidedoelbereik en langetermijnuitkomsten na acuut coronair syndroom","title_en":"[Time to achieve target lipid metabolism parameters and its impact on long-term outcomes after acute coronary syndrome in conditions of multicomponent lipid-lowering therapy].","published":"2026-02-14"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26187":[{"url":"https://hartvaat.nl/2026/02/13/aldosteron-en-de-mineralocorticoidreceptor-bij-atriumfibrilleren/","title":"Aldosteron en de mineralocorticoïdreceptor bij atriumfibrilleren","title_en":"Aldosterone and the Mineralocorticoid Receptor in Atrial Fibrillation","published":"2026-02-13"}],"https://www.kidney-international.org/article/s0085-2538(26)00092-x/fulltext":[{"url":"https://hartvaat.nl/2026/02/13/bcma-gerichte-t-cel-engagertherapie-bij-refractaire-hla-sensitisatie/","title":"BCMA-gerichte T-cel-engagertherapie bij refractaire HLA-sensitisatie","title_en":"B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization","published":"2026-02-13"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077606":[{"url":"https://hartvaat.nl/2026/02/13/verhoogde-wiggendruk-bij-groep-1-pulmonale-hypertensie/","title":"Verhoogde wiggendruk bij groep 1 pulmonale hypertensie","title_en":"Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension","published":"2026-02-13"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.126.26229":[{"url":"https://hartvaat.nl/2026/02/13/nieuwe-medicamenteuze-therapieen-bij-primair-aldosteronisme/","title":"Nieuwe medicamenteuze therapieën bij primair aldosteronisme","title_en":"Emerging Medical Therapies for Primary Aldosteronism","published":"2026-02-13"}],"https://www.kidney-international.org/article/s0085-2538(26)00089-x/fulltext":[{"url":"https://hartvaat.nl/2026/02/13/endotheliale-prolylhydroxylase-3-vermindert-maladaptieve-inflammatie-bij-nierher/","title":"Endotheliale prolylhydroxylase 3 vermindert maladaptieve inflammatie bij nierherstel na ischemie","title_en":"Endothelial prolyl hydroxylase 3 mitigates maladaptive inflammation to promote post-ischemic kidney repair","published":"2026-02-13"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00046-8/fulltext":[{"url":"https://hartvaat.nl/2026/02/13/genetisch-bepaalde-afkomst-en-morfologische-en-moleculaire-kenmerken-van-carotis/","title":"Genetisch bepaalde afkomst en morfologische en moleculaire kenmerken van carotisplaques","title_en":"Genetically determined ancestry associates with morphological and molecular carotid plaque features","published":"2026-02-13"}],"https://www.kidney-international.org/article/s0085-2538(26)00081-5/fulltext":[{"url":"https://hartvaat.nl/2026/02/13/nierbeschermende-medicatie-tijdens-borstvoeding/","title":"Nierbeschermende medicatie tijdens borstvoeding","title_en":"Use of kidney-preserving medications in breastfeeding","published":"2026-02-13"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076426":[{"url":"https://hartvaat.nl/2026/02/13/ccr8-expressie-op-regulatoire-t-cellen-beschermt-tegen-myocardinfarctschade/","title":"CCR8-expressie op regulatoire T-cellen beschermt tegen myocardinfarctschade","title_en":"CCR8 Expression on Regulatory T Cells Reveals Trajectories of Tissue Adaptation and Protects Against Myocardial Infarction–Induced Tissue Damage","published":"2026-02-13"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25816":[{"url":"https://hartvaat.nl/2026/02/13/mydgf-beschermt-de-endotheelfunctie-bij-hypertensie/","title":"MYDGF beschermt de endotheelfunctie bij hypertensie","title_en":"MYDGF Governs Endothelial Homeostasis in Hypertension","published":"2026-02-13"}],"10.3390/jcm15041461":[{"url":"https://hartvaat.nl/2026/02/13/verdeling-van-lp-a-spiegels-en-klinische-associaties-in-een-libanese-populatie/","title":"Verdeling van Lp(a)-spiegels en klinische associaties in een Libanese populatie","title_en":"Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational Study.","published":"2026-02-13"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003919?rss=1":[{"url":"https://hartvaat.nl/2026/02/12/ct-coronairangiografie-bij-nstemi-uitstekende-diagnostische-nauwkeurigheid-maar-/","title":"CT-coronairangiografie bij NSTEMI: uitstekende diagnostische nauwkeurigheid, maar nog geen duidelijke winst in uitkomsten","title_en":"CT coronary angiography guided treatment versus routine invasive coronary angiography in patients with non-ST elevation myocardial infarction: a systematic review and meta-analysis","published":"2026-02-12"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003623?rss=1":[{"url":"https://hartvaat.nl/2026/02/12/stress-perfusie-mri-bepaalt-het-risico-na-een-niet-conclusieve-inspanningstest-b/","title":"Stress-perfusie-MRI bepaalt het risico na een niet-conclusieve inspanningstest bij verdenking coronairlijden","title_en":"Prognostic utility of stress perfusion cardiac magnetic resonance in patients with known or suspected coronary artery disease and inconclusive exercise stress testing","published":"2026-02-12"}],"10.1056/nejmoa2512091":[{"url":"https://hartvaat.nl/2026/02/12/af-therapie-bij-patienten-met-drug-eluting-stents/","title":"AF-therapie bij patiënten met drug-eluting stents","title_en":"Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.","published":"2026-02-12"}],"10.1136/heartjnl-2025-325670":[{"url":"https://hartvaat.nl/2026/02/12/gdmt-na-functioneel-complete-revascularisatie-prognostische-impact/","title":"GDMT na functioneel complete revascularisatie: prognostische impact","title_en":"Prognostic impact of guideline-directed medical therapy after functionally complete revascularisation in patients with obstructive coronary artery diseases.","published":"2026-02-12"}],"https://www.kidney-international.org/article/s0085-2538(25)01013-0/fulltext":[{"url":"https://hartvaat.nl/2026/02/12/multi-lijns-assemblage-brengt-ruimtelijke-orde-in-menselijke-nierorganoiden/","title":"Multi-lijns assemblage brengt ruimtelijke orde in menselijke nierorganoïden","title_en":"Multilineage assembly brings spatial order to human kidney organoids","published":"2026-02-12"}],"https://www.kidney-international.org/article/s0085-2538(26)00074-8/fulltext":[{"url":"https://hartvaat.nl/2026/02/12/niet-langer-vergeten-lymfevaten-in-het-afstotende-transplantaat/","title":"Niet langer vergeten: lymfevaten in het afstotende transplantaat","title_en":"Neglected no longer: lymphatic vessels in the rejecting allograft","published":"2026-02-12"}],"https://www.kidney-international.org/article/s0085-2538(26)00072-4/fulltext":[{"url":"https://hartvaat.nl/2026/02/12/fenotype-eerst-een-datagestuurde-benadering-van-genetische-penetrantie/","title":"Fenotype eerst: een datagestuurde benadering van genetische penetrantie","title_en":"Phenotype first: a data-driven approach to genetic penetrance","published":"2026-02-12"}],"10.1093/immhor/vlag005":[{"url":"https://hartvaat.nl/2026/02/12/aanhoudende-monocytactivatie-door-geoxideerd-ldl-en-vrij-cholesterol/","title":"Aanhoudende monocytactivatie door geoxideerd LDL en vrij cholesterol","title_en":"Sustained monocyte activation by persistent challenges with either oxLDL or free cholesterol and underlying mechanisms.","published":"2026-02-12"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077764":[{"url":"https://hartvaat.nl/2026/02/12/bcr-abl-tyrosinekinaseremmers-en-het-risico-op-pulmonale-arteriele-hypertensie/","title":"BCR-ABL-tyrosinekinaseremmers en het risico op pulmonale arteriële hypertensie","title_en":"Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design","published":"2026-02-12"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.075327":[{"url":"https://hartvaat.nl/2026/02/12/obesitas-en-de-ernst-ervan-voorspellen-negen-cardiovasculaire-aandoeningen/","title":"Obesitas en de ernst ervan voorspellen negen cardiovasculaire aandoeningen","title_en":"Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration","published":"2026-02-12"}],"10.1093/eurheartj/ehaf746":[{"url":"https://hartvaat.nl/2026/02/11/ffr-geleide-nierslagaderstenting-bij-atherosclerotische-renovasculaire-hypertens/","title":"FFR-geleide nierslagaderstenting bij atherosclerotische renovasculaire hypertensie","title_en":"Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.","published":"2026-02-11"}],"10.1093/eurheartj/ehaf680":[{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","title":"ANDAMAN: aspirinedosering na ACS met verdenking aspirineresistentie","title_en":"Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial.","published":"2026-02-11"}],"10.1093/eurheartj/ehaf673":[{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","title":"REBOOT: bètablokkers na MI — sekseverschillen","title_en":"Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.","published":"2026-02-11"}],"10.1093/eurheartj/ehaf689":[{"url":"https://hartvaat.nl/2026/02/11/gepersonaliseerde-leefstijlinterventie-verbetert-af-ablatie-uitkomsten/","title":"Gepersonaliseerde leefstijlinterventie verbetert AF-ablatie-uitkomsten","title_en":"Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial.","published":"2026-02-11"}],"10.1093/eurheartj/ehaf655":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","title":"VICTOR: vericiguat en mortaliteit bij HFrEF — definitieve analyse","title_en":"Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.","published":"2026-02-11"}],"https://www.kidney-international.org/article/s0085-2538(26)00087-6/fulltext":[{"url":"https://hartvaat.nl/2026/02/11/drosophila-model-voor-de-ziekte-van-dent-type-1-onthult-pathogeen-mechanisme/","title":"Drosophila-model voor de ziekte van Dent type 1 onthult pathogeen mechanisme","title_en":"A Drosophila model for Dent’s disease type 1 revealed impaired endoplasmic reticulum export of Cubilin as pathogenic mechanism","published":"2026-02-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25872":[{"url":"https://hartvaat.nl/2026/02/11/bloeddruk-voor-zwangerschap-en-ivf-uitkomsten/","title":"Bloeddruk vóór zwangerschap en IVF-uitkomsten","title_en":"Association Between Prepregnancy Blood Pressure and Reproductive Outcomes of In Vitro Fertilization","published":"2026-02-11"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001401":[{"url":"https://hartvaat.nl/2026/02/11/criteria-voor-beoordeling-van-nieuwe-cardiovasculaire-risicomodellen-aha/","title":"Criteria voor beoordeling van nieuwe cardiovasculaire risicomodellen (AHA)","title_en":"Criteria to Assess the Predictive and Clinical Utility of Novel Models, Biomarkers, and Tools for Risk of Cardiovascular Disease: A Scientific Statement From the American Heart Association","published":"2026-02-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25388":[{"url":"https://hartvaat.nl/2026/02/11/dna-methyleringsmarkers-voor-zwangerschapshypertensie-via-machine-learning/","title":"DNA-methyleringsmarkers voor zwangerschapshypertensie via machine learning","title_en":"DNA Methylation Markers for Pregnancy Hypertension via Machine Learning Methods","published":"2026-02-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26377":[{"url":"https://hartvaat.nl/2026/02/11/factoren-bij-discordante-bloeddrukmeting-bij-zeer-oude-volwassenen-aric-studie/","title":"Factoren bij discordante bloeddrukmeting bij zeer oude volwassenen (ARIC-studie)","title_en":"Factors Associated With Discordant Blood Pressure Measures among Very Old Adults: Results From the Atherosclerosis Risk in Communities (ARIC) Study","published":"2026-02-11"}],"https://www.kidney-international.org/article/s0085-2538(26)00070-0/fulltext":[{"url":"https://hartvaat.nl/2026/02/11/hybride-car-s-macrofaagsignalering-herbedraden-voor-gerichte-niertherapie/","title":"Hybride CAR's: macrofaagsignalering herbedraden voor gerichte niertherapie","title_en":"Hybrid CARs: rewiring macrophage signaling for targeted therapy in acute and chronic kidney inflammation","published":"2026-02-11"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076101":[{"url":"https://hartvaat.nl/2026/02/11/macrofaag-prmt9-verbetert-uitkomsten-na-acuut-myocardinfarct-via-stat1-degradati/","title":"Macrofaag-PRMT9 verbetert uitkomsten na acuut myocardinfarct via STAT1-degradatie","title_en":"Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1","published":"2026-02-11"}],"https://www.kidney-international.org/article/s0085-2538(26)00071-2/fulltext":[{"url":"https://hartvaat.nl/2026/02/11/proteogenomische-ontleding-van-nierziekte-en-cardiovasculair-renaal-metabool-syn/","title":"Proteogenomische ontleding van nierziekte en cardiovasculair-renaal-metabool syndroom","title_en":"Proteogenomic dissection of kidney disease and cardiovascular-kidney-metabolic syndrome","published":"2026-02-11"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003920?rss=1":[{"url":"https://hartvaat.nl/2026/02/10/welke-hartfalenpatienten-ontwikkelen-ernstige-mitralisinsufficientie-voorspellen/","title":"Welke hartfalenpatiënten ontwikkelen ernstige mitralisinsufficiëntie? Voorspellende factoren","title_en":"Factors associated with the development of severe mitral regurgitation in patients with heart failure","published":"2026-02-10"}],"10.1161/circulationaha.125.076421":[{"url":"https://hartvaat.nl/2026/02/10/stressor-geassocieerd-af-incidentie-risicofactoren-en-uitkomsten/","title":"Stressor-geassocieerd AF: incidentie, risicofactoren en uitkomsten","title_en":"Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.","published":"2026-02-10"}],"10.1016/j.jacc.2025.09.004":[{"url":"https://hartvaat.nl/2026/02/10/2025-acc-attr-cm-evaluatie-en-management-beknopte-klinische-richtlijn/","title":"2025 ACC: ATTR-CM evaluatie en management — beknopte klinische richtlijn","title_en":"Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.","published":"2026-02-10"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26401":[{"url":"https://hartvaat.nl/2026/02/10/resistente-hypertensie-is-geen-essentiele-hypertensie-het-is-vooral-aldosteronis/","title":"Resistente hypertensie is geen essentiële hypertensie — het is vooral aldosteronisme","title_en":"Resistant Hypertension Is Not Essential: It Is Primarily Aldosteronism","published":"2026-02-10"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001404":[{"url":"https://hartvaat.nl/2026/02/10/klonale-hematopoese-en-cardiovasculaire-implicaties-aha-statement/","title":"Klonale hematopoëse en cardiovasculaire implicaties (AHA-statement)","title_en":"Clonal Hematopoiesis and Its Cardiovascular Implications: A Scientific Statement From the American Heart Association","published":"2026-02-10"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.075875":[{"url":"https://hartvaat.nl/2026/02/10/spontaan-myocardinfarct-na-linkerhoofdstamrevascularisatie-de-excel-trial/","title":"Spontaan myocardinfarct na linkerhoofdstamrevascularisatie: de EXCEL-trial","title_en":"Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial","published":"2026-02-10"}],"10.1093/ndt/gfag028":[{"url":"https://hartvaat.nl/2026/02/10/risico-op-nier-en-urotheelkanker-bij-sglt2-remmers-versus-glp-1-receptoragoniste/","title":"Risico op nier- en urotheelkanker bij SGLT2-remmers versus GLP-1-receptoragonisten","title_en":"Renal and urothelial cancer risks with SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes: a target trial emulation.","published":"2026-02-10"}],"10.1093/eurheartj/ehaf884":[{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","title":"OCCUPI: OCT-geleide stentoptimalisatie bij complexe coronairlaesies","title_en":"Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial.","published":"2026-02-09"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001391":[{"url":"https://hartvaat.nl/2026/02/09/coronaire-atherosclerose-bij-kankerpatienten-en-overlevenden-aha-statement/","title":"Coronaire atherosclerose bij kankerpatiënten en -overlevenden (AHA-statement)","title_en":"Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association","published":"2026-02-09"}],"https://www.kidney-international.org/article/s0085-2538(26)00077-3/fulltext":[{"url":"https://hartvaat.nl/2026/02/09/podocyt-endotheline-1-en-endotheelcel-eta-receptoren-essentieel-bij-fsgs/","title":"Podocyt-endotheline-1 en endotheelcel-ETA-receptoren essentieel bij FSGS","title_en":"Podocyte-derived endothelin-1 and endothelial cell endothelin A receptors are essential for glomerular injury in mouse models of focal segmental glomerulosclerosis","published":"2026-02-09"}],"10.1093/ndt/gfag022":[{"url":"https://hartvaat.nl/2026/02/09/communicatie-tussen-nier-en-hart-via-extracellulaire-vesikels/","title":"Communicatie tussen nier en hart via extracellulaire vesikels","title_en":"Kidney-Heart Crosstalk: The Extracellular Vesicles Connection.","published":"2026-02-09"}],"10.3390/cells15040315":[{"url":"https://hartvaat.nl/2026/02/07/lipoproteine-a-en-cardiovasculaire-ziekte-van-genetische-risicofactor-naar-thera/","title":"Lipoproteïne(a) en cardiovasculaire ziekte: van genetische risicofactor naar therapeutisch doelwit","title_en":"Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target.","published":"2026-02-07"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003937?rss=1":[{"url":"https://hartvaat.nl/2026/02/06/jonge-patienten-met-een-hartinfarct-meer-leefstijl-en-psychosociale-risicofactor/","title":"Jonge patiënten met een hartinfarct: meer leefstijl- en psychosociale risicofactoren","title_en":"Risk factors, clinical profile, angiographic characteristics and reperfusion therapy in young patients (<=45 years) with acute ST-elevation myocardial infarction compared to older patients: a tertiary centre in South India","published":"2026-02-06"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003193?rss=1":[{"url":"https://hartvaat.nl/2026/02/06/nierfunctiebeloop-bij-nieuw-ontstaan-hfref-voorspelt-de-uitkomst/","title":"Nierfunctiebeloop bij nieuw ontstaan HFrEF voorspelt de uitkomst","title_en":"Renal function trajectories in 'de novo' heart failure with reduced ejection fraction: impact on outcomes","published":"2026-02-06"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077356":[{"url":"https://hartvaat.nl/2026/02/06/apolipoproteine-d-een-nieuw-ligand-voor-cd36-is-essentieel-voor-de-bloed-hersenb/","title":"Apolipoproteïne D, een nieuw ligand voor CD36, is essentieel voor de bloed-hersenbarrière","title_en":"Apolipoprotein D, a Novel Ligand for CD36, Is Essential for Blood–Brain Barrier Integrity","published":"2026-02-06"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26228":[{"url":"https://hartvaat.nl/2026/02/06/verbreding-van-screening-op-primair-aldosteronisme-consensus-tussen-richtlijnen/","title":"Verbreding van screening op primair aldosteronisme: consensus tussen richtlijnen","title_en":"Broadening Primary Aldosteronism Screening: Alignment Across Contemporary Guidelines","published":"2026-02-06"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.074752":[{"url":"https://hartvaat.nl/2026/02/06/genoom-en-transcriptoomanalyses-identificeren-kandidaatgenen-bij-bicuspide-aorta/","title":"Genoom- en transcriptoomanalyses identificeren kandidaatgenen bij bicuspide aortaklep","title_en":"Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve","published":"2026-02-06"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.124.072850":[{"url":"https://hartvaat.nl/2026/02/06/insulineresistentie-compromitteert-pentosefosfaatroute-en-lvad-gemedieerd-herste/","title":"Insulineresistentie compromitteert pentosefosfaatroute en LVAD-gemedieerd herstel bij obese hartfalenpatiënten","title_en":"Insulin Resistance Compromises the Pentose Phosphate Pathway and Impairs Left Ventricular Assist Device–Mediated Myocardial Recovery in Obese Patients with Heart Failure","published":"2026-02-06"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.074797":[{"url":"https://hartvaat.nl/2026/02/06/natuurlijk-beloop-van-histologisch-bewezen-acute-eosinofiele-myocarditis/","title":"Natuurlijk beloop van histologisch bewezen acute eosinofiele myocarditis","title_en":"Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis","published":"2026-02-06"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26144":[{"url":"https://hartvaat.nl/2026/02/06/sirt1-ncor2-corepressor-moduleert-trofoblast-macrofaaginteracties-bij-pre-eclamp/","title":"SIRT1-NCOR2-corepressor moduleert trofoblast-macrofaaginteracties bij pre-eclampsie","title_en":"SIRT1-NCOR2 Corepressor Modulates Trophoblast-Macrophage Interactions in Preeclampsia","published":"2026-02-06"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.074791":[{"url":"https://hartvaat.nl/2026/02/06/trpm7-deficientie-beschermt-tegen-myocardiale-ischemie-reperfusieschade/","title":"TRPM7-deficiëntie beschermt tegen myocardiale ischemie-reperfusieschade","title_en":"TRPM7 Deficiency Protects Against Myocardial Ischemia-Reperfusion Injury by Regulating Intracellular Zn2+ Homeostasis","published":"2026-02-06"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.074318":[{"url":"https://hartvaat.nl/2026/02/06/aldh2-rs671-variant-versterkt-plaatjesactivatie-en-arteriele-trombose/","title":"ALDH2 rs671-variant versterkt plaatjesactivatie en arteriële trombose","title_en":"The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis","published":"2026-02-06"}],"10.3791/69496":[{"url":"https://hartvaat.nl/2026/02/06/onvoldoende-eiwit-en-energie-inname-bij-subklinische-congestie-bij-hartfalen/","title":"Onvoldoende eiwit- en energie-inname bij subklinische congestie bij hartfalen","title_en":"Use of a Structured Interview to Assess the Association of Inadequate Energy and Protein Intake with Subclinical Congestion in Heart Failure Patients.","published":"2026-02-06"}],"10.1016/j.jacl.2026.02.003":[{"url":"https://hartvaat.nl/2026/02/06/voorbij-lipidenverlaging-pcsk9-remming-vermindert-ook-inflammatie-en-verbetert-h/","title":"Voorbij lipidenverlaging: PCSK9-remming vermindert ook inflammatie en verbetert HDL-functie","title_en":"Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function.","published":"2026-02-06"}],"10.1056/nejmra2405153":[{"url":"https://hartvaat.nl/2026/02/05/de-erfelijke-basis-van-coronairlijden-nejm-overzicht/","title":"De erfelijke basis van coronairlijden (NEJM-overzicht)","title_en":"The Inherited Basis of Coronary Artery Disease","published":"2026-02-05"}],"10.1056/nejmoa2511002":[{"url":"https://hartvaat.nl/2026/02/05/orale-pcsk9-remmer-enlicitide-verlaagt-ldl-met-57-placebogecontroleerde-trial/","title":"Orale PCSK9-remmer enlicitide verlaagt LDL met 57% (placebogecontroleerde trial)","title_en":"A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide","published":"2026-02-05"}],"https://www.kidney-international.org/article/s0085-2538(26)00067-0/fulltext":[{"url":"https://hartvaat.nl/2026/02/05/angiopoetine-2-remming-en-tie2-reactivatie-bij-chronische-nierziekte/","title":"Angiopoëtine-2-remming en TIE2-reactivatie bij chronische nierziekte","title_en":"Angiopoietin-2 inhibition and TIE2 reactivation in chronic kidney disease: the next step forward","published":"2026-02-05"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25518":[{"url":"https://hartvaat.nl/2026/02/05/postprandiale-hypotensie-en-valrisico-bij-oudere-hypertensieve-patienten-ambrosi/","title":"Postprandiale hypotensie en valrisico bij oudere hypertensieve patiënten (AMBROSIA)","title_en":"Association Between Postprandial Hypotension Determined by Ambulatory Blood Pressure Monitoring and Falls Among Older Adults With Hypertension Who Are Taking Antihypertensive Medication: Results From the AMBROSIA Study","published":"2026-02-05"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25854":[{"url":"https://hartvaat.nl/2026/02/05/concordante-en-discordante-transcriptomische-kenmerken-van-tweelingplacenta-s-bi/","title":"Concordante en discordante transcriptomische kenmerken van tweelingplacenta's bij pre-eclampsie","title_en":"Concordant and Discordant Transcriptomic Signatures of Twin Placentas in the Setting of Preeclampsia","published":"2026-02-05"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(25)02276-7/fulltext":[{"url":"https://hartvaat.nl/2026/02/05/efimosfermine-alfa-bij-mash-met-f2-f3-fibrose-fase-2-resultaten/","title":"Efimosfermine alfa bij MASH met F2/F3-fibrose: fase 2-resultaten","title_en":"Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial","published":"2026-02-05"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(25)02431-6/fulltext":[{"url":"https://hartvaat.nl/2026/02/05/eenmaal-per-maand-efimosfermine-bij-niet-cirrotische-mash/","title":"Eenmaal per maand efimosfermine bij niet-cirrotische MASH","title_en":"Once-monthly efimosfermin for non-cirrhotic MASH","published":"2026-02-05"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25795":[{"url":"https://hartvaat.nl/2026/02/05/geslachtsspecifieke-bloeddruk-en-hersenvasculaire-kenmerken-bij-laag-renine-hype/","title":"Geslachtsspecifieke bloeddruk en hersenvasculaire kenmerken bij laag-renine hypertensie","title_en":"Sex-Specific Blood Pressure and Brain Microvascular Traits in a Model of Low-Renin Hypertension","published":"2026-02-05"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25460":[{"url":"https://hartvaat.nl/2026/02/05/circmfn2-reguleert-igf2bp3-pdk4-bij-pulmonale-hypertensie/","title":"circMFN2 reguleert IGF2BP3-PDK4 bij pulmonale hypertensie","title_en":"circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension","published":"2026-02-05"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(26)00139-x/fulltext":[{"url":"https://hartvaat.nl/2026/02/05/tenecteplase-bij-basilarisocclusie-tot-24-uur-veelbelovende-lancet-data/","title":"Tenecteplase bij basilarisocclusie tot 24 uur: veelbelovende Lancet-data","title_en":"Intravenous tenecteplase for acute ischaemic stroke within 24 h due to basilar artery occlusion","published":"2026-02-05"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(25)02633-9/fulltext":[{"url":"https://hartvaat.nl/2026/02/05/tenecteplase-versus-standaardbehandeling-bij-basilaris-occlusie-in-the-lancet/","title":"Tenecteplase versus standaardbehandeling bij basilaris-occlusie in The Lancet","title_en":"Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial","published":"2026-02-05"}],"10.1093/europace/euag022":[{"url":"https://hartvaat.nl/2026/02/05/driejaarsuitkomsten-van-linker-hartoorsluiting-met-of-zonder-ablatie-record-stud/","title":"Driejaarsuitkomsten van linker hartoorsluiting met of zonder ablatie: RECORD-studie","title_en":"Three-year clinical outcomes of left atrial appendage occlusion with or without ablation: insight from the RECORD study.","published":"2026-02-05"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003875?rss=1":[{"url":"https://hartvaat.nl/2026/02/04/200-joule-als-startenergie-voor-elektrische-cardioversie-bij-atriumfibrilleren-w/","title":"200 joule als startenergie voor elektrische cardioversie bij atriumfibrilleren werkt goed en veilig","title_en":"200 J-first, fixed-escalation biphasic electrical cardioversion for atrial fibrillation >48 hours in the emergency department: a single-centre retrospective observational study","published":"2026-02-04"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003798?rss=1":[{"url":"https://hartvaat.nl/2026/02/04/pulsed-field-ablatie-bereikt-vaker-complete-achterwandisolatie-dan-radiofrequent/","title":"Pulsed-field-ablatie bereikt vaker complete achterwandisolatie dan radiofrequente ablatie bij persisterend atriumfibrilleren","title_en":"Clinical outcomes of pulsed field versus radiofrequency ablation, incorporating posterior wall isolation, in persistent atrial fibrillation","published":"2026-02-04"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25962":[{"url":"https://hartvaat.nl/2026/02/04/bacteriele-extracellulaire-vesikels-reguleren-bloeddruk-via-microbiota-gastheer-/","title":"Bacteriële extracellulaire vesikels reguleren bloeddruk via microbiota-gastheer-communicatie","title_en":"Bacterial Extracellular Vesicles Mediate Microbiota-Host Communication to Regulate Blood Pressure in Male Rats","published":"2026-02-04"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25938":[{"url":"https://hartvaat.nl/2026/02/04/c-type-natriuretisch-peptide-beschermt-vasculaire-en-cardiale-functie-bij-sepsis/","title":"C-type natriuretisch peptide beschermt vasculaire en cardiale functie bij sepsis","title_en":"C-Type Natriuretic Peptide Preserves Vascular and Cardiac Function in Sepsis","published":"2026-02-04"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26236":[{"url":"https://hartvaat.nl/2026/02/04/determinanten-van-placentaire-versus-maternale-pre-eclampsie/","title":"Determinanten van placentaire versus maternale pre-eclampsie","title_en":"Determinants of Placental Versus Maternal Preeclampsia","published":"2026-02-04"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25889":[{"url":"https://hartvaat.nl/2026/02/04/endotheliaal-lrrc8c-reguleert-vasculaire-reactiviteit-en-bloeddruk/","title":"Endotheliaal LRRC8C reguleert vasculaire reactiviteit en bloeddruk","title_en":"Endothelial LRRC8C Associates With LRRC8A and LRRC8B to Regulate Vascular Reactivity and Blood Pressure","published":"2026-02-04"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25881":[{"url":"https://hartvaat.nl/2026/02/04/verlies-van-ror2-tyrosinekinase-veroorzaakt-endotheeldisfunctie-bij-pah/","title":"Verlies van ROR2-tyrosinekinase veroorzaakt endotheeldisfunctie bij PAH","title_en":"Loss of ROR2 Tyrosine Kinase Receptor Is Associated With Endothelial Dysfunction in PAH via Inappropriate Integrin β1 Activation","published":"2026-02-04"}],"10.1093/eschf/xvaf042":[{"url":"https://hartvaat.nl/2026/02/03/neuromusculaire-elektrostimulatie-bij-ernstig-hartfalen-functionele-verbetering/","title":"Neuromusculaire elektrostimulatie bij ernstig hartfalen: functionele verbetering","title_en":"Improved performance after neuromuscular electrical stimulation in hospitalized patients with severe heart failure.","published":"2026-02-03"}],"10.1093/eschf/xvaf020":[{"url":"https://hartvaat.nl/2026/02/03/adaptieve-bloeddrukgemoduleerde-atriale-pacing-bij-hypertensief-hfpef-eerste-rct/","title":"Adaptieve bloeddrukgemoduleerde atriale pacing bij hypertensief HFpEF: eerste RCT","title_en":"Adaptive blood pressure-modulated atrial pacing in hypertensive HFpEF patients: a randomized, first-in-human study.","published":"2026-02-03"}],"10.1093/eschf/xvag026":[{"url":"https://hartvaat.nl/2026/02/03/mortaliteit-en-hospitalisaties-bij-hfpef-versus-hfref-vergelijkende-analyse/","title":"Mortaliteit en hospitalisaties bij HFpEF versus HFrEF: vergelijkende analyse","title_en":"Mortality and heart failure hospitalizations in heart failure with preserved ejection fraction compared to heart failure with reduced ejection fraction: a systematic review and meta-analysis.","published":"2026-02-03"}],"10.1093/eschf/xvaf004":[{"url":"https://hartvaat.nl/2026/02/03/vochtbeperking-versus-liberale-inname-bij-hartfalen-meta-analyse-van-rct-s/","title":"Vochtbeperking versus liberale inname bij hartfalen: meta-analyse van RCT's","title_en":"Fluid restriction vs liberal intake in patients with heart failure: a meta-analysis of randomized trials.","published":"2026-02-03"}],"10.1093/eschf/xvag021":[{"url":"https://hartvaat.nl/2026/02/03/levosimendan-infusies-en-klinisch-beloop-bij-hartfalen-levo-d-resultaten/","title":"Levosimendan-infusies en klinisch beloop bij hartfalen: LEVO-D resultaten","title_en":"The possible impact of levosimendan infusions on clinical course of heart failure: the results of the LEIA-HF study.","published":"2026-02-03"}],"10.1093/europace/euag002":[{"url":"https://hartvaat.nl/2026/02/03/ice-bij-af-ablatie-veiligheid-en-effectiviteit-meta-analyse/","title":"ICE bij AF-ablatie: veiligheid en effectiviteit — meta-analyse","title_en":"Safety and efficacy of intracardiac echocardiography in atrial fibrillation ablation: a meta-analysis.","published":"2026-02-03"}],"10.1161/circulationaha.125.077447":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","title":"DARE-AF: dapagliflozine vermindert vroeg AF-recidief na ablatie","title_en":"Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.","published":"2026-02-03"}],"10.1093/eschf/xvaf040":[{"url":"https://hartvaat.nl/2026/02/03/cumulatieve-blootstelling-aan-cardiometabole-index-en-risico-op-hartfalen/","title":"Cumulatieve blootstelling aan cardiometabole index en risico op hartfalen","title_en":"Association between cumulative exposure to cardiometabolic index and risk of heart failure: a prospective cohort study.","published":"2026-02-03"}],"10.1093/eschf/xvag012":[{"url":"https://hartvaat.nl/2026/02/03/kenmerken-van-asymptomatische-patienten-met-hartfalen-en-verminderde-ejectiefrac/","title":"Kenmerken van asymptomatische patiënten met hartfalen en verminderde ejectiefractie","title_en":"Baseline characteristics in the TransitionCHF study: asymptomatic patients with heart failure and reduced ejection fraction.","published":"2026-02-03"}],"10.1093/europace/euaf313":[{"url":"https://hartvaat.nl/2026/02/03/plotse-hartstilstand-tijdens-duursporten-tien-jaar-parijse-registerdata/","title":"Plotse hartstilstand tijdens duursporten: tien jaar Parijse registerdata","title_en":"Characteristics of sudden cardiac arrest during endurance racing: a decade of the Paris registry.","published":"2026-02-03"}],"10.1093/europace/euag020":[{"url":"https://hartvaat.nl/2026/02/03/coronaire-vaatspasmen-bij-overlevenden-van-hartstilstand/","title":"Coronaire vaatspasmen bij overlevenden van hartstilstand","title_en":"Coronary artery spasm in cardiac arrest survivors.","published":"2026-02-03"}],"10.1093/europace/euag010":[{"url":"https://hartvaat.nl/2026/02/03/intracardiale-elektrogrammen-bij-perforatie-tijdens-linkerbundeltakpacing/","title":"Intracardiale elektrogrammen bij perforatie tijdens linkerbundeltakpacing","title_en":"Distinct intracardiac electrogram waveforms with perforation during left bundle branch area pacing implantation.","published":"2026-02-03"}],"10.1093/europace/euag017":[{"url":"https://hartvaat.nl/2026/02/03/gecombineerde-pulsed-field-ablatie-en-linker-atriumoorsluiting-haalbaarheid-en-u/","title":"Gecombineerde pulsed field-ablatie en linker-atriumoorsluiting: haalbaarheid en uitkomsten","title_en":"Feasibility, procedural efficiency, and early imaging outcomes of concomitant pulsed field ablation and left atrial appendage closure: a prospective single-centre study.","published":"2026-02-03"}],"10.1093/eschf/xvag013":[{"url":"https://hartvaat.nl/2026/02/03/langetermijnwaarde-van-inspanningstesten-bij-hypertrofische-cardiomyopathie/","title":"Langetermijnwaarde van inspanningstesten bij hypertrofische cardiomyopathie","title_en":"Long-term prognostic value of cardiopulmonary exercise testing in patients with hypertrophic cardiomyopathy.","published":"2026-02-03"}],"10.1093/eschf/xvag001":[{"url":"https://hartvaat.nl/2026/02/03/metformine-remt-proliferatie-van-fibro-adipogene-stamcellen-uit-falende-harten/","title":"Metformine remt proliferatie van fibro-adipogene stamcellen uit falende harten","title_en":"Metformin inhibits proliferation of residing fibroadipogenic progenitor cells from failing human hearts.","published":"2026-02-03"}],"10.1093/europace/euaf323":[{"url":"https://hartvaat.nl/2026/02/03/aanbesteding-van-cardiale-implanteerbare-devices-in-europa-waarde-of-kosten/","title":"Aanbesteding van cardiale implanteerbare devices in Europa: waarde of kosten?","title_en":"Public procurement of cardiac implantable electronic devices across Europe: are we purchasing value or cost-effectiveness?","published":"2026-02-03"}],"10.1093/eschf/xvaf012":[{"url":"https://hartvaat.nl/2026/02/03/rechterhart-hemodynamiek-voor-risicostratificatie-bij-pulmonale-arteriele-hypert/","title":"Rechterhart-hemodynamiek voor risicostratificatie bij pulmonale arteriële hypertensie","title_en":"Value of right heart haemodynamics for risk stratification of patients with pulmonary arterial hypertension at follow-up.","published":"2026-02-03"}],"10.1093/eschf/xvag003":[{"url":"https://hartvaat.nl/2026/02/03/effect-van-mavacamten-op-risicoscores-voor-plotse-hartdood-bij-hypertrofische-ca/","title":"Effect van mavacamten op risicoscores voor plotse hartdood bij hypertrofische cardiomyopathie","title_en":"Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy.","published":"2026-02-03"}],"10.1093/europace/euag023":[{"url":"https://hartvaat.nl/2026/02/03/upgrade-van-draadloze-pacemaker-van-enkelvoudig-naar-tweekamersysteem/","title":"Upgrade van draadloze pacemaker: van enkelvoudig naar tweekamersysteem","title_en":"Upgrading expandable leadless pacemakers from single- to dual-chamber.","published":"2026-02-03"}],"10.1093/europace/euag033":[{"url":"https://hartvaat.nl/2026/02/03/kortste-af-cycluslengte-in-de-longvenen-identificeert-pvi-responders/","title":"Kortste AF-cycluslengte in de longvenen identificeert PVI-responders","title_en":"Shortest pulmonary vein atrial fibrillation cycle length identifies pulmonary vein isolation responders beyond clinical atrial fibrillation pattern: the FARS-AF II study.","published":"2026-02-03"}],"10.1093/europace/euag018":[{"url":"https://hartvaat.nl/2026/02/03/semaglutide-als-aanvulling-op-katheterablatie-bij-obesitas-gerelateerd-atriumfib/","title":"Semaglutide als aanvulling op katheterablatie bij obesitas-gerelateerd atriumfibrilleren","title_en":"Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.","published":"2026-02-03"}],"10.1093/europace/euaf325":[{"url":"https://hartvaat.nl/2026/02/03/atriumfibrilleren-bij-kankerpatienten-de-esc-richtlijn-2025-in-de-praktijk/","title":"Atriumfibrilleren bij kankerpatiënten: de ESC-richtlijn 2025 in de praktijk","title_en":"Contemporary management of atrial fibrillation in patients with cancer-the 2025 European Heart Rhythm Association survey.","published":"2026-02-03"}],"10.1093/eschf/xvag018":[{"url":"https://hartvaat.nl/2026/02/03/vroeg-starten-met-mra-na-acuut-hartfalen-of-myocardinfarct-meta-analyse/","title":"Vroeg starten met MRA na acuut hartfalen of myocardinfarct: meta-analyse","title_en":"Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: a meta-analysis of randomized clinical trials.","published":"2026-02-03"}],"10.1093/eschf/xvaf018":[{"url":"https://hartvaat.nl/2026/02/03/intraveneus-ijzer-bij-hartfalen-met-ijzertekort-meta-analyse-met-trial-sequentie/","title":"Intraveneus ijzer bij hartfalen met ijzertekort: meta-analyse met trial-sequentiële analyse","title_en":"Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.","published":"2026-02-03"}],"10.1093/eschf/xvag002":[{"url":"https://hartvaat.nl/2026/02/03/bio-impedantie-voor-vochtstatusbepaling-en-prognose-bij-chronisch-hartfalen/","title":"Bio-impedantie voor vochtstatusbepaling en prognose bij chronisch hartfalen","title_en":"Bioimpedance-derived compartmental fluid status and prognosis in chronic heart failure.","published":"2026-02-03"}],"10.1093/eschf/xvag004":[{"url":"https://hartvaat.nl/2026/02/03/geslachtsverschillen-bij-patienten-met-gevorderd-hartfalen/","title":"Geslachtsverschillen bij patiënten met gevorderd hartfalen","title_en":"Sex differences in patients with advanced heart failure: an analysis of the HELP-HF registry.","published":"2026-02-03"}],"10.1093/eschf/xvag042":[{"url":"https://hartvaat.nl/2026/02/03/semaglutide-versus-tirzepatide-bij-patienten-met-obesitas-en-hfpef/","title":"Semaglutide versus tirzepatide bij patiënten met obesitas en HFpEF","title_en":"Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.","published":"2026-02-03"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00025-0/fulltext":[{"url":"https://hartvaat.nl/2026/02/03/statine-intolerantie-bij-kinderen-met-familiaire-hypercholesterolemie-15-jaar-kl/","title":"Statine-intolerantie bij kinderen met familiaire hypercholesterolemie: 15 jaar klinische ervaring","title_en":"Statin-associated symptoms and Statin Intolerance in Children with Familial Hypercholesterolemia: Insights from 15 Years of Clinical Practice","published":"2026-02-03"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003790?rss=1":[{"url":"https://hartvaat.nl/2026/02/02/machine-learning-nomogram-voorspelt-vroeg-transplantaatfalen-na-harttransplantat/","title":"Machine-learning-nomogram voorspelt vroeg transplantaatfalen na harttransplantatie (UNOS + Chinese validatie)","title_en":"Bridging machine learning and clinical practice: a multicentre nomogram for 90-day graft failure risk stratification in heart transplantation","published":"2026-02-02"}],"10.1016/j.jacc.2025.12.004":[{"url":"https://hartvaat.nl/2026/02/02/jamac-studie-slechte-5-jaarsprognose-bij-mitralisstenose-door-mitralisringverkal/","title":"JAMAC-studie: slechte 5-jaarsprognose bij mitralisstenose door mitralisringverkalking","title_en":"Mitral Annular Calcification-Related Mitral Stenosis: 5-Year Outcomes and Prognostic Determinants in the JAMAC Study","published":"2026-02-02"}],"10.1001/jamanetworkopen.2025.59227":[{"url":"https://hartvaat.nl/2026/02/02/medische-kosten-en-productiviteitsverlies-door-atriumfibrilleren-in-de-vs/","title":"Medische kosten en productiviteitsverlies door atriumfibrilleren in de VS","title_en":"Medical Costs and Productivity Losses of Atrial Fibrillation Among US Privately Insured Employees.","published":"2026-02-02"}],"10.1001/jamanetworkopen.2025.60429":[{"url":"https://hartvaat.nl/2026/02/02/sglt2-remmers-en-cardiorenale-uitkomsten-bij-diabetes-type-2-met-levercirrose/","title":"SGLT2-remmers en cardiorenale uitkomsten bij diabetes type 2 met levercirrose","title_en":"SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis.","published":"2026-02-02"}],"10.1001/jamanetworkopen.2025.56937":[{"url":"https://hartvaat.nl/2026/02/02/gezamenlijke-besluitvorming-bij-percutane-linker-atriumoorsluiting/","title":"Gezamenlijke besluitvorming bij percutane linker-atriumoorsluiting","title_en":"Shared Decision-Making and Patient Decision Aids for Percutaneous Left Atrial Appendage Occlusion.","published":"2026-02-02"}],"10.3390/medicina62020297":[{"url":"https://hartvaat.nl/2026/02/02/apob-apoa-i-ratio-voor-diagnostiek-en-ernst-van-coronairlijden-bij-statinegebrui/","title":"ApoB/ApoA-I-ratio voor diagnostiek en ernst van coronairlijden bij statinegebruikers","title_en":"Diagnostic and Severity Assessment of Coronary Artery Disease Using ApoB/ApoA-I Ratio: Insights from a Statin-Treated Eastern European Cohort.","published":"2026-02-02"}],"10.1001/jamacardio.2025.4723":[{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neoatherosclerose-na-stemi-secundaire-analyse/","title":"LDL-cholesterol en neoatherosclerose na STEMI: secundaire analyse","title_en":"Low-Density Lipoprotein Cholesterol Levels and Neoatherosclerosis After STEMI: A Secondary Analysis of the CONNECT Randomized Clinical Trial.","published":"2026-02-01"}],"10.1161/hypertensionaha.124.25516":[{"url":"https://hartvaat.nl/2026/02/01/cox-2-remming-en-bloeddrukrespons-graad-van-remming-is-bepalend/","title":"COX-2-remming en bloeddrukrespons: graad van remming is bepalend","title_en":"Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response.","published":"2026-02-01"}],"10.1161/hypertensionaha.125.25563":[{"url":"https://hartvaat.nl/2026/02/01/aprocitentan-bij-ckd-en-resistente-hypertensie/","title":"Aprocitentan bij CKD en resistente hypertensie","title_en":"Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.","published":"2026-02-01"}],"10.1161/hypertensionaha.125.25575":[{"url":"https://hartvaat.nl/2026/02/01/antihypertensieve-behandeling-na-acuut-ischemisch-cva-continueren-of-niet/","title":"Antihypertensieve behandeling na acuut ischemisch CVA: continueren of niet?","title_en":"Antihypertensive Treatments After Acute Ischemic Stroke: to Continue or Not?","published":"2026-02-01"}],"10.1161/hypertensionaha.125.25955":[{"url":"https://hartvaat.nl/2026/02/01/dapagliflozine-bij-cv-risico-met-zonder-diabetes-cardiorenale-effecten/","title":"Dapagliflozine bij CV-risico met/zonder diabetes: cardiorenale effecten","title_en":"Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.","published":"2026-02-01"}],"10.1161/hypertensionaha.125.26055":[{"url":"https://hartvaat.nl/2026/02/01/cagrisema-verlaagt-bloeddruk-bij-overgewicht-obesitas-redefine-1/","title":"CagriSema verlaagt bloeddruk bij overgewicht/obesitas: REDEFINE 1","title_en":"CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.","published":"2026-02-01"}],"10.1161/hypertensionaha.124.24263":[{"url":"https://hartvaat.nl/2026/02/01/postpartum-diureticabehandeling-bij-hypertensieve-zwangerschapsstoornissen/","title":"Postpartum diureticabehandeling bij hypertensieve zwangerschapsstoornissen","title_en":"Effects of Immediate Postpartum Diuretic Treatment on Postpartum Blood Pressure Among Individuals With Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis.","published":"2026-02-01"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01527-8/fulltext":[{"url":"https://hartvaat.nl/2026/02/01/kanttekeningen-bij-statistische-analyse-van-nhanes-data-en-orale-microbioomstudi/","title":"Kanttekeningen bij statistische analyse van NHANES-data en orale microbioomstudie","title_en":"Considerations on statistical analysis of NHANES data in oral microbiome diversity and mortality study","published":"2026-02-01"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01524-2/fulltext":[{"url":"https://hartvaat.nl/2026/02/01/is-er-een-nieuwe-keerzijde-van-persisterende-chylomicronemie/","title":"Is er een nieuwe keerzijde van persisterende chylomicronemie?","title_en":"Is there a new dark side of persistent chylomicronemia?","published":"2026-02-01"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01528-x/fulltext":[{"url":"https://hartvaat.nl/2026/02/01/reactie-op-kanttekeningen-bij-statistiek-van-orale-microbioomdiversiteit-en-mort/","title":"Reactie op kanttekeningen bij statistiek van orale microbioomdiversiteit en mortaliteit","title_en":"Reply to: “Considerations on statistical analysis of NHANES data in oral microbiome diversity and mortality study”","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2841165":[{"url":"https://hartvaat.nl/2026/02/01/klonale-hematopoese-en-incident-hartfalen/","title":"Klonale hematopoëse en incident hartfalen","title_en":"Clonal Hematopoiesis and Incident Heart Failure","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2841166":[{"url":"https://hartvaat.nl/2026/02/01/klonale-hematopoese-kans-om-de-hartfalenepidemie-aan-te-pakken/","title":"Klonale hematopoëse: kans om de hartfalenepidemie aan te pakken","title_en":"Clonal Hematopoiesis—An Opportunity to Confront the Heart Failure Epidemic","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843428":[{"url":"https://hartvaat.nl/2026/02/01/coronaire-reperfusie-bij-stemi-patienten-die-overplaatsing-vereisen/","title":"Coronaire reperfusie bij STEMI-patiënten die overplaatsing vereisen","title_en":"Coronary Reperfusion in Patients With ST-Elevation MI Requiring Transfer","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2841169":[{"url":"https://hartvaat.nl/2026/02/01/detectie-van-transthyretine-cardiale-amyloidose-met-kunstmatige-intelligentie/","title":"Detectie van transthyretine cardiale amyloïdose met kunstmatige intelligentie","title_en":"Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2842752":[{"url":"https://hartvaat.nl/2026/02/01/correctie-naam-van-niet-auteur-in-surtavi-trial/","title":"Correctie: naam van niet-auteur in SURTAVI-trial","title_en":"Error in Nonauthor Collaborator’s Name","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843432":[{"url":"https://hartvaat.nl/2026/02/01/inspanningssyncope-bij-een-tienermeisje/","title":"Inspanningssyncope bij een tienermeisje","title_en":"Exertional Syncope in a Female Teenage Student","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843039":[{"url":"https://hartvaat.nl/2026/02/01/richtlijnnaleving-bij-myocardinfarctbehandeling-ingezonden-brief/","title":"Richtlijnnaleving bij myocardinfarctbehandeling — ingezonden brief","title_en":"Guideline Adherence in Myocardial Infarction Treatment","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843038":[{"url":"https://hartvaat.nl/2026/02/01/richtlijnnaleving-bij-myocardinfarctbehandeling-reactie/","title":"Richtlijnnaleving bij myocardinfarctbehandeling — reactie","title_en":"Guideline Adherence in Myocardial Infarction Treatment—Reply","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2841170":[{"url":"https://hartvaat.nl/2026/02/01/implementatie-intelligentie-met-ai-prospectieve-evaluaties-nodig/","title":"Implementatie-intelligentie met AI: prospectieve evaluaties nodig","title_en":"Implementation Intelligence With AI—Prospective Evaluations Needed","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843037":[{"url":"https://hartvaat.nl/2026/02/01/ldl-cholesterol-en-neo-atherosclerose-na-stemi/","title":"LDL-cholesterol en neo-atherosclerose na STEMI","title_en":"Low-Density Lipoprotein Cholesterol Levels and Neoatherosclerosis After STEMI","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843036":[{"url":"https://hartvaat.nl/2026/02/01/myocarddisfunctie-bij-primaire-mitralisinsufficientie/","title":"Myocarddisfunctie bij primaire mitralisinsufficiëntie","title_en":"Myocardial Dysfunction in Primary Mitral Regurgitation","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843040":[{"url":"https://hartvaat.nl/2026/02/01/uitkomsten-na-wisseling-van-cardiale-troponine-assays-bij-acs/","title":"Uitkomsten na wisseling van cardiale troponine-assays bij ACS","title_en":"Outcomes After Switching Cardiac Troponin Assays in ACS","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843433":[{"url":"https://hartvaat.nl/2026/02/01/shr-1918-bij-homozygote-familiaire-hypercholesterolemie/","title":"SHR-1918 bij homozygote familiaire hypercholesterolemie","title_en":"SHR-1918 for Homozygous Familial Hypercholesterolemia","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843245":[{"url":"https://hartvaat.nl/2026/02/01/semaglutide-en-ziekenhuisopnames-bij-obesitas-met-hart-en-vaatziekten/","title":"Semaglutide en ziekenhuisopnames bij obesitas met hart- en vaatziekten","title_en":"Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843430":[{"url":"https://hartvaat.nl/2026/02/01/sociale-determinanten-van-gezondheid-en-uitkomsten-bij-hypertrofische-cardiomyop/","title":"Sociale determinanten van gezondheid en uitkomsten bij hypertrofische cardiomyopathie","title_en":"Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843429":[{"url":"https://hartvaat.nl/2026/02/01/dertigjaars-cardiovasculair-risico-bij-vrouwen-naar-lipoproteine-a-drempelwaarde/","title":"Dertigjaars cardiovasculair risico bij vrouwen naar lipoproteïne(a)-drempelwaarden","title_en":"Thirty-Year Risk of Cardiovascular Disease Among Women According to Thresholds of Lipoprotein(a)","published":"2026-02-01"}],"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843431":[{"url":"https://hartvaat.nl/2026/02/01/betablokkers-na-myocardinfarct-bij-behouden-ejectiefractie-meta-analyse/","title":"Bètablokkers na myocardinfarct bij behouden ejectiefractie: meta-analyse","title_en":"β-Blockers After Myocardial Infarction in Patients With Preserved Ejection Fraction","published":"2026-02-01"}],"https://pubmed.ncbi.nlm.nih.gov/41736604/":[{"url":"https://hartvaat.nl/2026/02/01/renale-denervatie-bij-resistente-hypertensie-het-tel-aviv-register/","title":"Renale denervatie bij resistente hypertensie: het Tel Aviv-register","title_en":"Clinical Outcomes of Renal Denervation for Resistant Hypertension: The Tel Aviv Renal Denervation Prospective Registry.","published":"2026-02-01"}],"10.1002/clc.70263":[{"url":"https://hartvaat.nl/2026/02/01/factor-xi-xia-remmers-bij-atriumfibrilleren-dosisrespons-werkzaamheid-en-veiligh/","title":"Factor XI/XIa-remmers bij atriumfibrilleren: dosisrespons, werkzaamheid en veiligheid","title_en":"Dose-Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta-Analysis With Subgroup Exploration and Trial Sequential Validation.","published":"2026-02-01"}],"10.1111/echo.70413":[{"url":"https://hartvaat.nl/2026/02/01/sacubitril-valsartan-bij-secundaire-mitralisinsufficientie-en-reverse-remodeling/","title":"Sacubitril-valsartan bij secundaire mitralisinsufficiëntie en reverse remodeling","title_en":"Effect of Sacubitril-Valsartan on Secondary Mitral Regurgitation and Left Ventricular Reverse Remodeling in Patients With Heart Failure With Reduced Ejection Fraction: A 2D and 3D Echocardiographic Study.","published":"2026-02-01"}],"10.1016/j.eclinm.2026.103798":[{"url":"https://hartvaat.nl/2026/02/01/nierbeschermende-effecten-van-statines-bij-ckd-patienten-in-hong-kong/","title":"Nierbeschermende effecten van statines bij CKD-patiënten in Hong Kong","title_en":"Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation.","published":"2026-02-01"}],"10.1093/ckj/sfag011":[{"url":"https://hartvaat.nl/2026/02/01/innovatieve-wereldwijde-modellen-voor-ckd-zorg-casestudies-en-strategieen/","title":"Innovatieve wereldwijde modellen voor CKD-zorg: casestudies en strategieën","title_en":"Transformative global models for CKD care: case studies and strategies.","published":"2026-02-01"}],"https://pubmed.ncbi.nlm.nih.gov/41732931/":[{"url":"https://hartvaat.nl/2026/02/01/therapeutische-innovaties-in-de-secundaire-preventie-van-cardiovasculair-risico/","title":"Therapeutische innovaties in de secundaire preventie van cardiovasculair risico","title_en":"[Therapeutic innovations in secondary prevention of cardiovascular risk].","published":"2026-02-01"}],"10.1002/clc.70257":[{"url":"https://hartvaat.nl/2026/02/01/preventie-van-atherosclerotische-hart-en-vaatziekten-bij-jonge-mannelijke-anabol/","title":"Preventie van atherosclerotische hart- en vaatziekten bij jonge mannelijke anabolengebruikers","title_en":"Preventing Atherosclerotic Cardiovascular Disease in Young Male Androgen Abusers.","published":"2026-02-01"}],"10.1038/s44161-025-00775-2":[{"url":"https://hartvaat.nl/2026/02/01/gedeeld-gennetwerk-verklaart-de-wisselwerking-tussen-atriumfibrilleren-en-hartfa/","title":"Gedeeld gennetwerk verklaart de wisselwerking tussen atriumfibrilleren en hartfalen","title_en":"A reduced TBX5-dependent gene regulatory network links atrial fibrillation and heart failure.","published":"2026-02-01"}],"10.1111/eci.70173":[{"url":"https://hartvaat.nl/2026/02/01/praktische-overwegingen-bij-vericiguat-voor-oudere-patienten-met-hartfalen/","title":"Praktische overwegingen bij vericiguat voor oudere patiënten met hartfalen","title_en":"Practical considerations for the use of vericiguat in older patients with heart failure and reduced ejection fraction.","published":"2026-02-01"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01519-9/fulltext":[{"url":"https://hartvaat.nl/2026/02/01/de-verborgen-nierschade-bij-chylomicronemiesyndromen/","title":"De verborgen nierschade bij chylomicronemiesyndromen","title_en":"The hidden burden of kidney damage in chylomicronemia syndromes","published":"2026-02-01"}],"10.1093/ndt/gfag018":[{"url":"https://hartvaat.nl/2026/01/31/wereldwijde-ziektelast-van-chronische-nierziekte-bij-kinderen-en-adolescenten/","title":"Wereldwijde ziektelast van chronische nierziekte bij kinderen en adolescenten","title_en":"Global, Regional, and National Burden of CKD in Children and Adolescents.","published":"2026-01-31"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003865?rss=1":[{"url":"https://hartvaat.nl/2026/01/30/lager-opleidingsniveau-hangt-samen-met-meer-halsslagaderplaques-los-van-risicofa/","title":"Lager opleidingsniveau hangt samen met meer halsslagaderplaques, los van risicofactoren (ACE 1950)","title_en":"Association between socioeconomic variables and carotid plaque in middle-aged adults: data from the Akershus Cardiac Examination (ACE) 1950 Study","published":"2026-01-30"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003770?rss=1":[{"url":"https://hartvaat.nl/2026/01/30/kosteneffectiviteit-van-een-dual-energy-lattice-tip-katheter-sphere-9-versus-rad/","title":"Kosteneffectiviteit van een dual-energy lattice-tip-katheter (Sphere-9) versus radiofrequente ablatie bij persisterend AF","title_en":"Economic evaluation of a novel dual-energy, large focal lattice-tip catheter versus conventional contact-force sensing radiofrequency catheter for persistent atrial fibrillation ablation, from the English NHS perspective","published":"2026-01-30"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003839?rss=1":[{"url":"https://hartvaat.nl/2026/01/30/off-label-lage-dosis-bloedplaatjesremmers-bij-coronairlijden-minder-infarcten-en/","title":"Off-label lage dosis bloedplaatjesremmers bij coronairlijden: minder infarcten en bloedingen (vooral Aziatische data)","title_en":"Efficacy and safety of off-label low-dose compared with standard-dose antiplatelet agents in patients with coronary heart disease: a meta-analysis","published":"2026-01-30"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.075951":[{"url":"https://hartvaat.nl/2026/01/30/dapk2-reguleert-pkm2-fosforylering-bij-verstoorde-stroming-geinduceerde-atherosc/","title":"DAPK2 reguleert PKM2-fosforylering bij verstoorde-stroming-geïnduceerde atherosclerose","title_en":"DAPK2 Regulates PKM2 Phosphorylation at Threonine 45 to Facilitate Disturbed Flow-Induced Atherosclerosis","published":"2026-01-30"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26006":[{"url":"https://hartvaat.nl/2026/01/30/galectine-1-is-een-marker-maar-geen-mediator-van-hfpef/","title":"Galectine-1 is een marker maar geen mediator van HFpEF","title_en":"Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction","published":"2026-01-30"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001420":[{"url":"https://hartvaat.nl/2026/01/30/retractie-proteasoom-afhankelijke-degradatie-van-gtp-cyclohydrolase-i-bij-diabet/","title":"Retractie: proteasoom-afhankelijke degradatie van GTP-cyclohydrolase I bij diabetes","title_en":"Retraction of: Proteasome-Dependent Degradation of Guanosine 5’-Triphosphate Cyclohydrolase I Causes Tetrahydrobiopterin Deficiency in Diabetes Mellitus","published":"2026-01-30"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.075275":[{"url":"https://hartvaat.nl/2026/01/30/systemische-embolische-events-bij-boezemfibrilleren-een-meta-analyse-op-patientn/","title":"Systemische embolische events bij boezemfibrilleren: een meta-analyse op patiëntniveau","title_en":"Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin","published":"2026-01-30"}],"10.1016/j.jacl.2026.01.020":[{"url":"https://hartvaat.nl/2026/01/30/familiaire-hypercholesterolemie-gemaskeerd-door-een-pcsk9-verlies-van-functievar/","title":"Familiaire hypercholesterolemie gemaskeerd door een PCSK9-verlies-van-functievariant","title_en":"Familial hypercholesterolemia concealed by a protein-truncating variant of PCSK9.","published":"2026-01-30"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003851?rss=1":[{"url":"https://hartvaat.nl/2026/01/29/obesitasparadox-bij-het-takotsubosyndroom-ondergewicht-geeft-de-hoogste-sterfte-/","title":"Obesitasparadox bij het takotsubosyndroom: ondergewicht geeft de hoogste sterfte (InterTAK)","title_en":"Body weight and mortality in Takotsubo syndrome: insights from the International Takotsubo (InterTAK) Registry","published":"2026-01-29"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003816?rss=1":[{"url":"https://hartvaat.nl/2026/01/29/lineaire-ablatie-van-de-voorwand-van-het-linkeratrium-vermindert-af-recidieven-b/","title":"Lineaire ablatie van de voorwand van het linkeratrium vermindert AF-recidieven bij aorta-inkapseling","title_en":"Left atrial anterior wall ablation reduces the recurrence of atrial fibrillation in patients with aortic encroachment","published":"2026-01-29"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003872?rss=1":[{"url":"https://hartvaat.nl/2026/01/29/tavi-versus-afwachtend-beleid-bij-ernstige-aortastenose-groot-en-blijvend-overle/","title":"TAVI versus afwachtend beleid bij ernstige aortastenose: groot en blijvend overlevingsvoordeel","title_en":"Multidisciplinary team-guided management of severe aortic stenosis: 5-year outcomes following TAVI versus conservative treatment","published":"2026-01-29"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003506?rss=1":[{"url":"https://hartvaat.nl/2026/01/29/verminderde-pompfunctie-na-een-hartinfarct-hoge-symptoomlast-en-slechtere-secund/","title":"Verminderde pompfunctie na een hartinfarct: hoge symptoomlast en slechtere secundaire preventie (SWEDEHEART)","title_en":"Symptom burden and secondary prevention in patients with left ventricular systolic dysfunction after acute myocardial infarction: a nationwide register-based study in Sweden","published":"2026-01-29"}],"10.1056/nejmoa2512761":[{"url":"https://hartvaat.nl/2026/01/29/olezarsen-bij-ernstige-hypertriglyceridemie-en-pancreatitisrisico/","title":"Olezarsen bij ernstige hypertriglyceridemie en pancreatitisrisico","title_en":"Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.","published":"2026-01-29"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25680":[{"url":"https://hartvaat.nl/2026/01/29/abnormale-pro-inflammatoire-immuuncelresponsen-voorafgaand-aan-hypertensieve-zwa/","title":"Abnormale pro-inflammatoire immuuncelresponsen voorafgaand aan hypertensieve zwangerschapsaandoeningen","title_en":"Abnormal Proinflammatory Immune Cell Responses Precede Clinical Onset of Hypertensive Disorders of Pregnancy","published":"2026-01-29"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26344":[{"url":"https://hartvaat.nl/2026/01/29/ijzeroverbelasting-geinduceerde-ferroptose-veroorzaakt-placentadisfunctie-bij-pr/","title":"IJzeroverbelasting-geïnduceerde ferroptose veroorzaakt placentadisfunctie bij pre-eclampsie","title_en":"Iron Overload-Induced Ferroptosis Drives Placental Dysfunction in Preeclampsia","published":"2026-01-29"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077117":[{"url":"https://hartvaat.nl/2026/01/29/trainingsbelasting-gemeten-met-wearables-en-coronaire-atherosclerose-bij-middelb/","title":"Trainingsbelasting gemeten met wearables en coronaire atherosclerose bij middelbare leeftijd","title_en":"Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study","published":"2026-01-29"}],"10.1016/j.jacl.2026.01.011":[{"url":"https://hartvaat.nl/2026/01/29/nla-consensusupdate-familiaire-hypercholesterolemie-screening-diagnostiek-en-beh/","title":"NLA-consensusupdate familiaire hypercholesterolemie: screening, diagnostiek en behandeling","title_en":"Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association.","published":"2026-01-29"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003812?rss=1":[{"url":"https://hartvaat.nl/2026/01/28/risicocommunicatie-instrument-in-de-huisartsenpraktijk-verlaagt-bloeddruk-en-cho/","title":"Risicocommunicatie-instrument in de huisartsenpraktijk verlaagt bloeddruk en cholesterol (Deense RCT)","title_en":"Danish evaluation of Your Heart Forecast: a cluster randomised controlled trial aimed at improving modifiable risk factors of CVD","published":"2026-01-28"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.24344":[{"url":"https://hartvaat.nl/2026/01/28/hypertensie-bij-dialysepatienten-de-kloof-tussen-bewijs-en-praktijk/","title":"Hypertensie bij dialysepatiënten: de kloof tussen bewijs en praktijk","title_en":"Hypertension in Patients With End-Stage Kidney Disease Requiring Dialysis: Bridging the Divide Between Evidence and Practice","published":"2026-01-28"}],"10.1093/ndt/gfag014":[{"url":"https://hartvaat.nl/2026/01/28/kdigo-2026-richtlijn-anemie-bij-chronische-nierziekte-europees-commentaar/","title":"KDIGO 2026-richtlijn anemie bij chronische nierziekte: Europees commentaar","title_en":"KDIGO 2026 clinical practice guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP).","published":"2026-01-28"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003612?rss=1":[{"url":"https://hartvaat.nl/2026/01/27/minimaal-invasieve-mitralisklepchirurgie-sneller-herstel-even-veilig-als-de-conv/","title":"Minimaal-invasieve mitralisklepchirurgie: sneller herstel, even veilig als de conventionele operatie","title_en":"Minimally invasive versus conventional mitral valve surgery: a systematic review and meta-analysis of randomised clinical trials","published":"2026-01-27"}],"10.1016/j.jacc.2025.10.086":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","title":"ORBITA-2: leeftijd en PCI-effectiviteit bij stabiel coronairlijden","title_en":"Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.","published":"2026-01-27"}],"10.1161/circulationaha.125.077174":[{"url":"https://hartvaat.nl/2026/01/27/prognostische-implicaties-van-universele-definities-van-periprocedureel-mi/","title":"Prognostische implicaties van universele definities van periprocedureel MI","title_en":"Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.","published":"2026-01-27"}],"10.1016/j.jacc.2025.10.058":[{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","title":"NEO-MINOR: potente P2Y12-monotherapie versus DAPT na PCI bij STEMI","title_en":"Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.","published":"2026-01-27"}],"10.1016/j.jacc.2025.09.1598":[{"url":"https://hartvaat.nl/2026/01/27/vroege-versus-late-gestageerde-pci-na-subintimale-re-entry-bij-cto/","title":"Vroege versus late gestageerde PCI na subintimale re-entry bij CTO","title_en":"Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions: A Randomized Trial.","published":"2026-01-27"}],"10.1001/jama.2025.21056":[{"url":"https://hartvaat.nl/2026/01/27/decaf-cafeinehoudende-koffie-en-af-gerandomiseerde-trial/","title":"DECAF: cafeïnehoudende koffie en AF — gerandomiseerde trial","title_en":"Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.","published":"2026-01-27"}],"10.1016/j.jacc.2025.10.008":[{"url":"https://hartvaat.nl/2026/01/27/intracoronair-lage-dosis-rtpa-bij-primaire-pci-voor-stemi-rct/","title":"Intracoronair lage-dosis rtPA bij primaire PCI voor STEMI: RCT","title_en":"Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial.","published":"2026-01-27"}],"10.1016/j.jacc.2025.10.027":[{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","title":"REC-CAGEFREE: DCB versus stenting bij de novo CAD — driejaarsdata","title_en":"Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial.","published":"2026-01-27"}],"10.1016/j.jacc.2025.09.1577":[{"url":"https://hartvaat.nl/2026/01/27/pci-van-natief-coronairvat-versus-veneuze-graft-na-eerdere-cabg-rct/","title":"PCI van natief coronairvat versus veneuze graft na eerdere CABG: RCT","title_en":"PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery: A Multicenter, Randomized Trial.","published":"2026-01-27"}],"10.1136/heartjnl-2025-325826":[{"url":"https://hartvaat.nl/2026/01/27/colchicine-bij-acs-meta-analyse-van-alle-rct-s/","title":"Colchicine bij ACS: meta-analyse van alle RCT's","title_en":"Colchicine in acute coronary syndromes: a systematic review and meta-analysis of randomised controlled trials.","published":"2026-01-27"}],"10.1093/ndt/gfag013":[{"url":"https://hartvaat.nl/2026/01/27/aldosteronsynthase-remmers-bij-ongecontroleerde-en-resistente-hypertensie-bij-ck/","title":"Aldosteronsynthase-remmers bij ongecontroleerde en resistente hypertensie bij CKD","title_en":"Aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD: an assessment from bench to bedside.","published":"2026-01-27"}],"10.3390/diseases14020041":[{"url":"https://hartvaat.nl/2026/01/27/lp-a-verstoort-de-ldl-cholesterolberekening-welke-formule-is-het-meest-betrouwba/","title":"Lp(a) verstoort de LDL-cholesterolberekening: welke formule is het meest betrouwbaar?","title_en":"Lipoprotein(a) Concentration and Achieving Target Values of Low-Density Lipoprotein Cholesterol Calculated by Different Equations.","published":"2026-01-27"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25159":[{"url":"https://hartvaat.nl/2026/01/26/impact-van-britse-zoutreductiedoelen-2024-op-cardiovasculaire-uitkomsten-modelle/","title":"Impact van Britse zoutreductiedoelen 2024 op cardiovasculaire uitkomsten: modelleerstudie","title_en":"Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study","published":"2026-01-26"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25977":[{"url":"https://hartvaat.nl/2026/01/26/zoutreductie-in-het-franse-stokbrood-heeft-duizenden-levens-gered/","title":"Zoutreductie in het Franse stokbrood heeft duizenden levens gered","title_en":"From French Gastronomy to Cardiovascular Health: Cutting Salt in the Baguette Has Saved Thousands of Lives in France","published":"2026-01-26"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00014-6/fulltext":[{"url":"https://hartvaat.nl/2026/01/26/isolinderalacton-remt-nlrp3-inflammasoomactivatie-bij-atherosclerose/","title":"Isolinderalacton remt NLRP3-inflammasoomactivatie bij atherosclerose","title_en":"Isolinderalactone alleviates atherosclerosis by inhibiting NLRP3 inflammasome activation and inflammatory response in macrophages","published":"2026-01-26"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26008":[{"url":"https://hartvaat.nl/2026/01/26/zittende-zoutbelastingstest-voor-lateralisatie-van-primair-aldosteronisme/","title":"Zittende zoutbelastingstest voor lateralisatie van primair aldosteronisme","title_en":"Seated Saline Suppression Test for Lateralizing Primary Aldosteronism","published":"2026-01-26"}],"10.1093/ndt/gfag007":[{"url":"https://hartvaat.nl/2026/01/24/oproep-tot-actie-europese-trials-nodig-tegen-tsunami-van-nierfalen/","title":"Oproep tot actie: Europese trials nodig tegen tsunami van nierfalen","title_en":"Randomised controlled trials in Europe: a call to action to protect national health care systems from the upcoming tsunami of kidney failure.","published":"2026-01-24"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003794?rss=1":[{"url":"https://hartvaat.nl/2026/01/23/multidisciplinair-cardiogene-shockteam-verbetert-de-1-jaarsoverleving-bij-infarc/","title":"Multidisciplinair cardiogene-shockteam verbetert de 1-jaarsoverleving bij infarct-gerelateerde shock","title_en":"Advanced Cardiogenic-shock Team versus standard care in cardiogenic shock: a single centre service evaluation project","published":"2026-01-23"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003808?rss=1":[{"url":"https://hartvaat.nl/2026/01/23/etnische-verschillen-in-aortadiameters-indiase-versus-nederlandse-patienten-amst/","title":"Etnische verschillen in aortadiameters: Indiase versus Nederlandse patiënten (Amsterdam UMC)","title_en":"Ethnic variation in thoracic aortic dimensions in the general population: a comparison between Indian and Dutch populations","published":"2026-01-23"}],"https://www.kidney-international.org/article/s0085-2538(26)00054-2/fulltext":[{"url":"https://hartvaat.nl/2026/01/23/cellulaire-senescentie-als-therapeutisch-doelwit-bij-diabetische-nierziekte/","title":"Cellulaire senescentie als therapeutisch doelwit bij diabetische nierziekte","title_en":"Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches","published":"2026-01-23"}],"10.1056/nejmoa2509688":[{"url":"https://hartvaat.nl/2026/01/22/antitrombotische-therapie-na-succesvolle-af-ablatie-gerandomiseerde-trial/","title":"Antitrombotische therapie na succesvolle AF-ablatie: gerandomiseerde trial","title_en":"Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.","published":"2026-01-22"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25783":[{"url":"https://hartvaat.nl/2026/01/22/verschil-tussen-klinische-en-ambulante-bloeddruk-en-valrisico-bij-ouderen/","title":"Verschil tussen klinische en ambulante bloeddruk en valrisico bij ouderen","title_en":"Association of Clinic Blood Pressure and Out-of-Clinic Blood Pressure Difference With Falls Among Older Adults With Hypertension","published":"2026-01-22"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25589":[{"url":"https://hartvaat.nl/2026/01/22/nieuw-ratmodel-voor-chronisch-trombo-embolische-pulmonale-hypertensie/","title":"Nieuw ratmodel voor chronisch trombo-embolische pulmonale hypertensie","title_en":"Development and Characterization of a Novel Chronic Thromboembolic Pulmonary Hypertension Rat Model: Identifying Sell-Podxl as Potential Regulators","published":"2026-01-22"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26048":[{"url":"https://hartvaat.nl/2026/01/22/werkzaamheid-en-veiligheid-van-finerenon-bij-primair-aldosteronisme/","title":"Werkzaamheid en veiligheid van finerenon bij primair aldosteronisme","title_en":"Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study","published":"2026-01-22"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25739":[{"url":"https://hartvaat.nl/2026/01/22/finerenon-verbetert-albuminurie-via-mr-trpc-signalering-bij-diabetische-nierziek/","title":"Finerenon verbetert albuminurie via MR-TRPC-signalering bij diabetische nierziekte","title_en":"Finerenone Improves Albuminuria via MR-TRPC Signaling in Diabetic Kidney Disease","published":"2026-01-22"}],"https://www.kidney-international.org/article/s0085-2538(26)00013-x/fulltext":[{"url":"https://hartvaat.nl/2026/01/22/heat-shock-eiwitten-70-als-modificatoren-van-endotheelfunctie-bij-de-ziekte-van-/","title":"Heat shock-eiwitten 70 als modificatoren van endotheelfunctie bij de ziekte van Fabry","title_en":"Heat shock protein 70s are modifiers of endothelial function in Fabry disease","published":"2026-01-22"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25364":[{"url":"https://hartvaat.nl/2026/01/22/microbiele-metaboliet-4eps-remt-at1r-en-verlaagt-bloeddruk-en-aorta-aneurysmavor/","title":"Microbiële metaboliet 4EPS remt AT1R en verlaagt bloeddruk en aorta-aneurysmavorming","title_en":"Microbial Metabolite 4EPS Inhibits AT1R to Reduce Blood Pressure and Aortic Aneurysm Outcome","published":"2026-01-22"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25199":[{"url":"https://hartvaat.nl/2026/01/22/nachtelijke-hypertensie-en-prognose-bij-zeer-oude-patienten/","title":"Nachtelijke hypertensie en prognose bij zeer oude patiënten","title_en":"Nocturnal Hypertension and Prognosis in Patients of Very Advanced Age","published":"2026-01-22"}],"https://www.kidney-international.org/article/s0085-2538(26)00053-0/fulltext":[{"url":"https://hartvaat.nl/2026/01/22/primaire-hyperoxalurie-van-trials-naar-real-world-data-en-pijplijntherapieen/","title":"Primaire hyperoxalurie: van trials naar real-world data en pijplijntherapieën","title_en":"Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies","published":"2026-01-22"}],"10.1093/ndt/gfag008":[{"url":"https://hartvaat.nl/2026/01/22/medicatiebeheer-van-ras-remmers-en-sglt2-remmers-bij-chronische-nierziekte/","title":"Medicatiebeheer van RAS-remmers en SGLT2-remmers bij chronische nierziekte","title_en":"Drug stewardship for RAS-inhibitors and SGLT2-inhibitors in chronic kidney disease: stay on, restart.","published":"2026-01-22"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003838?rss=1":[{"url":"https://hartvaat.nl/2026/01/21/genetische-test-bij-cardiomyopathie-huidige-britse-criteria-missen-een-op-de-zev/","title":"Genetische test bij cardiomyopathie: huidige Britse criteria missen één op de zeven dragers","title_en":"Genetic testing in cardiomyopathies: do we need to redefine the UK national testing criteria?","published":"2026-01-21"}],"https://www.kidney-international.org/article/s0085-2538(25)00677-5/fulltext":[{"url":"https://hartvaat.nl/2026/01/21/patientgerapporteerde-uitkomsten-verbeteren-voorspelling-van-mortaliteit-bij-dia/","title":"Patiëntgerapporteerde uitkomsten verbeteren voorspelling van mortaliteit bij dialysepatiënten","title_en":"A predictor finding study found patient-reported outcomes improve the prediction of mortality of incident dialysis patients","published":"2026-01-21"}],"https://www.kidney-international.org/article/s0085-2538(26)00052-9/fulltext":[{"url":"https://hartvaat.nl/2026/01/21/niertransplantatie-bij-ouderen-indicaties-timing-en-orgaankwaliteit/","title":"Niertransplantatie bij ouderen: indicaties, timing en orgaankwaliteit","title_en":"Eligibility, timing, and organ quality: indications and outcomes of kidney transplantation in older patients","published":"2026-01-21"}],"10.1093/ndt/gfag006":[{"url":"https://hartvaat.nl/2026/01/21/body-roundness-index-en-mortaliteit-bij-hemodialysepatienten/","title":"Body Roundness Index en mortaliteit bij hemodialysepatiënten","title_en":"Association between body roundness index and all-cause and cardiovascular disease mortality in maintenance hemodialysis patients: evidence from a prospective cohort study in Southern China.","published":"2026-01-21"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001412":[{"url":"https://hartvaat.nl/2026/01/21/hart-en-vaatziektestatistieken-2026-wereldwijde-cijfers-van-de-aha/","title":"Hart- en vaatziektestatistieken 2026: wereldwijde cijfers van de AHA","title_en":"2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association","published":"2026-01-21"}],"10.1001/jama.2025.20834":[{"url":"https://hartvaat.nl/2026/01/20/sglt2-remmers-en-nieruitkomsten-naar-gfr-en-albuminurie-mega-meta-analyse/","title":"SGLT2-remmers en nieruitkomsten naar GFR en albuminurie: mega-meta-analyse","title_en":"SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.","published":"2026-01-20"}],"10.1161/circulationaha.125.075388":[{"url":"https://hartvaat.nl/2026/01/20/es-bempedacs-triple-versus-duale-lipidenbehandeling-na-acs/","title":"ES-BempedACS: triple versus duale lipidenbehandeling na ACS","title_en":"Triple Versus Dual Lipid-Lowering Therapy in Acute Coronary Syndrome: The ES-BempedACS Randomized Clinical Trial.","published":"2026-01-20"}],"10.1016/j.jacc.2025.09.024":[{"url":"https://hartvaat.nl/2026/01/20/af-screening-naar-genetisch-risico-loop-subanalyse/","title":"AF-screening naar genetisch risico: LOOP subanalyse","title_en":"Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study.","published":"2026-01-20"}],"https://www.kidney-international.org/article/s0085-2538(26)00005-0/fulltext":[{"url":"https://hartvaat.nl/2026/01/20/voorspelling-van-individuele-corticosteroidrespons-bij-iga-nefropathie-testing-t/","title":"Voorspelling van individuele corticosteroïdrespons bij IgA-nefropathie (TESTING-trial)","title_en":"A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy","published":"2026-01-20"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.079034":[{"url":"https://hartvaat.nl/2026/01/20/milieustressoren-en-cardiovasculaire-gezondheid-gezamenlijk-statement-esc-acc-ah/","title":"Milieustressoren en cardiovasculaire gezondheid: gezamenlijk statement ESC, ACC, AHA en WHF","title_en":"Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A Statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation","published":"2026-01-20"}],"https://www.kidney-international.org/article/s0085-2538(26)00010-4/fulltext":[{"url":"https://hartvaat.nl/2026/01/20/multi-omics-onthult-pathogene-rol-van-iga-7-cellen-bij-iga-nefropathie/","title":"Multi-omics onthult pathogene rol van IgA+β7+ cellen bij IgA-nefropathie","title_en":"Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+β7+ cells in IgA nephropathy","published":"2026-01-20"}],"https://www.kidney-international.org/article/s0085-2538(26)00011-6/fulltext":[{"url":"https://hartvaat.nl/2026/01/20/het-onbekende-uit-ckdu-halen-optimale-benaderingen-voor-epidemische-nierziekte/","title":"Het 'onbekende' uit CKDu halen: optimale benaderingen voor epidemische nierziekte","title_en":"Taking the “unknown” out of CKDu—optimizing approaches to uncover the cause(s) of epidemic-level kidney disease in low- and middle-income settings: a report from the ISN’s International Consortium of CKDu Collaborators (ISN i3C)","published":"2026-01-20"}],"https://www.kidney-international.org/article/s0085-2538(26)00006-2/fulltext":[{"url":"https://hartvaat.nl/2026/01/20/uremie-en-bijschildklierhormoon-hebben-verschillende-effecten-op-boteiwit-en-gen/","title":"Uremie en bijschildklierhormoon hebben verschillende effecten op boteiwit en genexpressie","title_en":"Uremia and parathyroid hormone have distinct effects on bone protein and gene expression","published":"2026-01-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26125":[{"url":"https://hartvaat.nl/2026/01/19/bloeddrukdoelen-en-niergezondheid-risico-op-nierziekte-door-ras-remmers/","title":"Bloeddrukdoelen en niergezondheid: risico op nierziekte door RAS-remmers","title_en":"Balancing Blood Pressure Targets and Kidney Health: The Potential Risk of Kidney Disease Due to Concentric Arterial and Arteriolar Hypertrophy From Renin-Angiotensin-Aldosterone Inhibitors","published":"2026-01-19"}],"https://www.kidney-international.org/article/s0085-2538(26)00007-4/fulltext":[{"url":"https://hartvaat.nl/2026/01/19/genotype-fenotypekenmerken-bij-fan1-gerelateerde-karyomegale-tubulointerstitiele/","title":"Genotype-fenotypekenmerken bij FAN1-gerelateerde karyomegale tubulointerstitiële nefropathie","title_en":"Genotype-phenotype characteristics and disease progression of FAN1-related karyomegalic tubulointerstitial nephropathy","published":"2026-01-19"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26077":[{"url":"https://hartvaat.nl/2026/01/19/neurale-upregulatie-van-sglt2-map17-pdzk1-complex-in-nieren-bij-hartfalen/","title":"Neurale upregulatie van SGLT2-MAP17-PDZK1-complex in nieren bij hartfalen","title_en":"Neural Upregulation of SGLT2-MAP17-PDZK1 Complex in Kidneys of Rats With Heart Failure","published":"2026-01-19"}],"https://www.kidney-international.org/article/s0085-2538(26)00008-6/fulltext":[{"url":"https://hartvaat.nl/2026/01/19/parasympathische-zenuwen-in-het-nierbekken-reguleren-de-bloeddruk/","title":"Parasympathische zenuwen in het nierbekken reguleren de bloeddruk","title_en":"Parasympathetic nerves in the kidney pelvis contribute to blood pressure regulation","published":"2026-01-19"}],"https://www.kidney-international.org/article/s0085-2538(26)00009-8/fulltext":[{"url":"https://hartvaat.nl/2026/01/19/sglt2-remming-behoudt-antibacteriele-respons-van-de-nier-door-complement-c1q-ver/","title":"SGLT2-remming behoudt antibacteriële respons van de nier door complement C1q-verlaging","title_en":"Sodium glucose transporter 2 inhibition maintains kidney antibacterial response by decreasing complement C1q","published":"2026-01-19"}],"10.1016/s0140-6736(25)02157-9":[{"url":"https://hartvaat.nl/2026/01/17/abluminus-des-versus-ees-bij-diabetes-en-coronairlijden/","title":"Abluminus DES+ versus EES bij diabetes en coronairlijden","title_en":"Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.","published":"2026-01-17"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003859?rss=1":[{"url":"https://hartvaat.nl/2026/01/16/aortaklepsclerose-ongeveer-een-op-de-zeven-gaat-binnen-vier-jaar-over-in-aortast/","title":"Aortaklepsclerose: ongeveer één op de zeven gaat binnen vier jaar over in aortastenose","title_en":"Prognostic implications of aortic valve sclerosis in the development of aortic stenosis: a systematic review and meta-analysis","published":"2026-01-16"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003845?rss=1":[{"url":"https://hartvaat.nl/2026/01/16/nt-probnp-voorspelt-sterfte-na-een-stemi-onafhankelijk-van-de-ejectiefractie/","title":"NT-proBNP voorspelt sterfte na een STEMI, onafhankelijk van de ejectiefractie","title_en":"Prognostic value of N-terminal pro-B-type natriuretic peptide and C reactive protein testing in patients with acute ST-segment elevation myocardial infarction","published":"2026-01-16"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003563?rss=1":[{"url":"https://hartvaat.nl/2026/01/16/seismocardiografie-spoort-ernstige-aortastenose-op-met-een-eenvoudige-sensor/","title":"Seismocardiografie spoort ernstige aortastenose op met een eenvoudige sensor","title_en":"Severe aortic stenosis detection using seismocardiography","published":"2026-01-16"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003642?rss=1":[{"url":"https://hartvaat.nl/2026/01/16/sekseverschillen-na-tavi-vrouwen-lagere-sterfte-bij-intermediair-risico-maar-mee/","title":"Sekseverschillen na TAVI: vrouwen lagere sterfte bij intermediair risico, maar meer bloedingen","title_en":"Sex-based differences in outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis of randomised trials","published":"2026-01-16"}],"10.1093/eurheartj/ehaf592":[{"url":"https://hartvaat.nl/2026/01/16/statinegebruik-in-de-zwangerschap-en-congenitale-afwijkingen-noors-cohort/","title":"Statinegebruik in de zwangerschap en congenitale afwijkingen: Noors cohort","title_en":"Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study.","published":"2026-01-16"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00010-9/fulltext":[{"url":"https://hartvaat.nl/2026/01/16/non-hdl-c-doelen-halen-in-de-eerste-en-tweede-lijn-een-da-vinci-deelanalyse/","title":"Non-HDL-C doelen halen in de eerste en tweede lijn: een DA VINCI-deelanalyse","title_en":"Attainment of Non-High-Density Lipoprotein Cholesterol Targets in Secondary and Primary Care: A secondary-analysis of the DA VINCI study","published":"2026-01-16"}],"https://www.kidney-international.org/article/s0085-2538(25)00989-5/fulltext":[{"url":"https://hartvaat.nl/2026/01/15/populatiegebaseerde-egfr-verdelingen-voor-vroege-identificatie-van-chronische-ni/","title":"Populatiegebaseerde eGFR-verdelingen voor vroege identificatie van chronische nierziekte","title_en":"Population-based estimated Glomerular Filtration Rate distributions and associated health outcomes provide opportunities for early identification of and primary prevention of chronic kidney disease","published":"2026-01-15"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001395":[{"url":"https://hartvaat.nl/2026/01/15/sociaaleconomische-barrieres-bij-het-aanpakken-van-obesitas-aha-statement/","title":"Sociaaleconomische barrières bij het aanpakken van obesitas: AHA-statement","title_en":"Socioeconomic and Structural Barriers to Addressing Obesity in Communities: A Scientific Statement From the American Heart Association","published":"2026-01-15"}],"https://www.thelancet.com/journals/lancet/article/piis0140-6736(25)02105-1/fulltext":[{"url":"https://hartvaat.nl/2026/01/14/glp-1-receptoragonisten-en-de-volgende-generatie-incretinegebaseerde-middelen/","title":"GLP-1-receptoragonisten en de volgende generatie incretinegebaseerde middelen","title_en":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","published":"2026-01-14"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26399":[{"url":"https://hartvaat.nl/2026/01/14/polygene-risicoscore-voorspelt-langetermijn-bloeddrukcontrole-en-therapieresiste/","title":"Polygene risicoscore voorspelt langetermijn bloeddrukcontrole en therapieresistente hypertensie","title_en":"Blood Pressure Polygenic Score Predicts Long-Term Blood Pressure Control and Treatment-Resistant Hypertension","published":"2026-01-14"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25490":[{"url":"https://hartvaat.nl/2026/01/14/geslachtsspecifieke-bloeddrukdrempels-bij-volwassenen-van-middelbare-leeftijd/","title":"Geslachtsspecifieke bloeddrukdrempels bij volwassenen van middelbare leeftijd","title_en":"Sex-Specific Blood Pressure Thresholds in Middle-Aged Adults","published":"2026-01-14"}],"10.1001/jama.2025.20620":[{"url":"https://hartvaat.nl/2026/01/13/enlicitide-orale-pcsk9-remmer-bij-heterozygote-fh-fase-3/","title":"Enlicitide: orale PCSK9-remmer bij heterozygote FH — fase 3","title_en":"Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.","published":"2026-01-13"}],"10.1161/circulationaha.125.077549":[{"url":"https://hartvaat.nl/2026/01/13/effectiviteit-en-veiligheid-van-zeer-laag-bereikt-ldl-na-ischemisch-cva/","title":"Effectiviteit en veiligheid van zeer laag bereikt LDL na ischemisch CVA","title_en":"Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke.","published":"2026-01-13"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01413-3/fulltext":[{"url":"https://hartvaat.nl/2026/01/13/risicofactoren-en-plaquevolume-op-coronaire-ct-angiografie-lessen-uit-het-advanc/","title":"Risicofactoren en plaquevolume op coronaire CT-angiografie: lessen uit het ADVANCE-register","title_en":"The association of risk factors on coronary computed tomography angiography derived atherosclerotic plaque volume - Lessons from the ADVANCE registry","published":"2026-01-13"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.24881":[{"url":"https://hartvaat.nl/2026/01/12/werkzaamheid-en-veiligheid-van-lage-doses-spironolacton-bij-primair-aldosteronis/","title":"Werkzaamheid en veiligheid van lage doses spironolacton bij primair aldosteronisme","title_en":"Efficacy and Safety of Treatment With Low Doses of Spironolactone in Patients With Primary Aldosteronism: A Retrospective Observational Study in a Tertiary Center","published":"2026-01-12"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26346":[{"url":"https://hartvaat.nl/2026/01/12/late-menopauze-vermindert-aortastijfheid-in-de-postmenopauzale-periode/","title":"Late menopauze vermindert aortastijfheid in de postmenopauzale periode","title_en":"Late-Onset Menopause Attenuates Aortic Stiffness in the Postmenopausal Period","published":"2026-01-12"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01398-x/fulltext":[{"url":"https://hartvaat.nl/2026/01/12/lipide-inhoud-in-verkalkte-plaques-kenmerken-en-respons-op-lage-ldl-c/","title":"Lipide-inhoud in verkalkte plaques: kenmerken en respons op lage LDL-C","title_en":"Lipidic contents within calcified plaques: Characteristics and response to LDL-C<55 mg/dL on multi-modality imaging","published":"2026-01-12"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00002-x/fulltext":[{"url":"https://hartvaat.nl/2026/01/11/zeventien-jaar-voor-verandering-doorbreken-de-2025-esc-eas-dyslipidemierichtlijn/","title":"Zeventien jaar voor verandering: doorbreken de 2025 ESC/EAS-dyslipidemierichtlijnen de cyclus?","title_en":"Seventeen years to change practice: will the 2025 ESC/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?","published":"2026-01-11"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003785?rss=1":[{"url":"https://hartvaat.nl/2026/01/09/hartfalendiagnostiek-na-corona-bijna-niemand-kreeg-de-echo-binnen-de-aanbevolen-/","title":"Hartfalendiagnostiek na corona: bijna niemand kreeg de echo binnen de aanbevolen termijn","title_en":"Post-COVID-19 era heart failure diagnosis and outcomes: adherence to NICE Guidelines","published":"2026-01-09"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003764?rss=1":[{"url":"https://hartvaat.nl/2026/01/09/endocarditis-van-de-natieve-klep-verschuift-naar-ouderen-chirurgie-blijft-levens/","title":"Endocarditis van de natieve klep verschuift naar ouderen — chirurgie blijft levens redden (Korea, 18 jaar)","title_en":"Changing epidemiology and outcomes of native valve infective endocarditis: a nationwide study, 2006-2023","published":"2026-01-09"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003799?rss=1":[{"url":"https://hartvaat.nl/2026/01/09/littekenweefsel-voorspelt-plotse-hartdood-na-een-infarct-grotendeels-buiten-de-e/","title":"Littekenweefsel voorspelt plotse hartdood na een infarct grotendeels buiten de ejectiefractie om","title_en":"Replacement fibrosis, left ventricular ejection fraction and sudden cardiac death in patients after myocardial infarction: a mediation analysis","published":"2026-01-09"}],"10.1056/nejmoa2514428":[{"url":"https://hartvaat.nl/2026/01/08/evolocumab-bij-patienten-zonder-eerder-mi-of-cva-fourier-subanalyse/","title":"Evolocumab bij patiënten zonder eerder MI of CVA: FOURIER subanalyse","title_en":"Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.","published":"2026-01-08"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25985":[{"url":"https://hartvaat.nl/2026/01/08/atriale-strain-overtreft-ventriculaire-strain-bij-detectie-van-hypertensieve-hfp/","title":"Atriale strain overtreft ventriculaire strain bij detectie van hypertensieve HFpEF","title_en":"Atrial Strain Outperforms Ventricular Strain for Detecting Hypertensive HFpEF Using CMR Feature Tracking","published":"2026-01-08"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25442":[{"url":"https://hartvaat.nl/2026/01/08/eindpuntgebaseerde-drempel-voor-de-ambulante-arteriele-stijfheidsindex/","title":"Eindpuntgebaseerde drempel voor de ambulante arteriële stijfheidsindex","title_en":"End Point–Based Threshold for the Ambulatory Arterial Stiffness Index","published":"2026-01-08"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25050":[{"url":"https://hartvaat.nl/2026/01/08/urokinase-bevordert-intratubulair-c3a-maar-niet-enac-gedreven-hypertensie-bij-do/","title":"Urokinase bevordert intratubulair C3a maar niet ENaC-gedreven hypertensie bij DOCA/zout-nierletsel","title_en":"Urokinase Promotes Redundantly Intratubular C3a-Formation But Not ENaC-Driven Hypertension in DOCA/Salt Kidney Injury","published":"2026-01-08"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003565?rss=1":[{"url":"https://hartvaat.nl/2026/01/07/machine-learningmodel-schat-het-cardiovasculaire-risico-van-niet-cardiale-chirur/","title":"Machine-learningmodel schat het cardiovasculaire risico van niet-cardiale chirurgie nauwkeurig in","title_en":"Machine learning-based cardiovascular risk calculator for non-cardiac surgery","published":"2026-01-07"}],"10.1093/eurheartj/ehaf563":[{"url":"https://hartvaat.nl/2026/01/07/hartfalentherapie-staken-na-ef-herstel-door-af-ritmecontrole/","title":"Hartfalentherapie staken na EF-herstel door AF-ritmecontrole","title_en":"Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.","published":"2026-01-07"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25247":[{"url":"https://hartvaat.nl/2026/01/07/afferente-niersenuwen-veroorzaken-sympathische-overactivatie-en-hypertensief-har/","title":"Afferente niersenuwen veroorzaken sympathische overactivatie en hypertensief hartfalen","title_en":"Afferent Renal Nerves Drive Sympathoexcitation and Hypertensive Heart Failure","published":"2026-01-07"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076976":[{"url":"https://hartvaat.nl/2026/01/07/cxcr6-t-cellen-veroorzaken-immuuncheckpointremmer-myocarditis/","title":"CXCR6+ T-cellen veroorzaken immuuncheckpointremmer-myocarditis","title_en":"CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis","published":"2026-01-07"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26379":[{"url":"https://hartvaat.nl/2026/01/07/circulerend-malat1-bij-pre-eclampsie-en-cardiometabool-risico/","title":"Circulerend MALAT1 bij pre-eclampsie en cardiometabool risico","title_en":"Circulating MALAT1 in Preeclampsia and Association With Cardiometabolic Risk","published":"2026-01-07"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00003-1/fulltext":[{"url":"https://hartvaat.nl/2026/01/07/klinische-proteomics-in-de-cardiovasculaire-geneeskunde-huidige-stand-en-toekoms/","title":"Klinische proteomics in de cardiovasculaire geneeskunde: huidige stand en toekomst","title_en":"Clinical proteomics in cardiovascular medicine: Current capabilities, limitations, and future directions","published":"2026-01-07"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25832":[{"url":"https://hartvaat.nl/2026/01/07/serpinb1-beschermt-tegen-hypoxie-geinduceerde-pulmonale-hypertensie-via-macrofaa/","title":"SerpinB1 beschermt tegen hypoxie-geïnduceerde pulmonale hypertensie via macrofaag-PASMC-crosstalk","title_en":"Targeting Macrophage Crosstalk to PASMC by Blunting Inflammatory Phenotype Via SerpinB1 Protects Against Hypoxia-Induced Pulmonary Hypertension","published":"2026-01-07"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25444":[{"url":"https://hartvaat.nl/2026/01/07/weekendstrijder-bewegingspatroon-en-mortaliteit-bij-hypertensie-uk-biobank/","title":"Weekendstrijder-bewegingspatroon en mortaliteit bij hypertensie (UK Biobank)","title_en":"Weekend Warrior Physical Activity Pattern and Mortality in Patients With Hypertension: A Prospective Cohort Study From UK Biobank","published":"2026-01-07"}],"10.1093/tbm/ibaf094":[{"url":"https://hartvaat.nl/2026/01/07/gedragsveranderingstheorie-bij-implementatie-van-thuisbloeddrukmeting/","title":"Gedragsveranderingstheorie bij implementatie van thuisbloeddrukmeting","title_en":"Applying behavior change theory to intervention design: promoting clinic-level implementation of self-measured blood pressure monitoring in safety net primary care settings.","published":"2026-01-07"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003767?rss=1":[{"url":"https://hartvaat.nl/2026/01/06/machine-learning-algoritme-mi3-helpt-een-infarct-uitsluiten-bij-een-onduidelijke/","title":"Machine-learning-algoritme MI3 helpt een infarct uitsluiten bij een onduidelijke troponinewaarde","title_en":"Diagnostic performance of the Myocardial-Ischaemic-Injury index machine-learning algorithm in patients with an initial indeterminate troponin","published":"2026-01-06"}],"http://openheart.bmj.com/cgi/content/short/13/1/e003867?rss=1":[{"url":"https://hartvaat.nl/2026/01/06/biomarkers-onderscheiden-type-2-hartinfarct-nog-onvoldoende-van-type-1/","title":"Biomarkers onderscheiden type 2-hartinfarct nog onvoldoende van type 1","title_en":"Utility of biomarkers in patients with a type 2 myocardial infarction: a systematic review","published":"2026-01-06"}],"10.1001/jama.2025.19808":[{"url":"https://hartvaat.nl/2026/01/06/sacubitril-valsartan-versus-enalapril-bij-chagas-hartfalen/","title":"Sacubitril/valsartan versus enalapril bij Chagas-hartfalen","title_en":"Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial.","published":"2026-01-06"}],"10.1001/jama.2025.19843":[{"url":"https://hartvaat.nl/2026/01/06/levoecmo-levosimendan-bij-ecmo-weaning-bij-cardiogene-shock/","title":"LEVOECMO: levosimendan bij ECMO-weaning bij cardiogene shock","title_en":"Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.","published":"2026-01-06"}],"10.1161/circulationaha.125.077603":[{"url":"https://hartvaat.nl/2026/01/06/caviar-alirocumab-bij-cardiale-allograft-vasculopathie-na-harttransplantatie/","title":"CAVIAR: alirocumab bij cardiale allograft vasculopathie na harttransplantatie","title_en":"Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.","published":"2026-01-06"}],"10.1001/jama.2025.21112":[{"url":"https://hartvaat.nl/2026/01/06/gofresh-dash-boodschappen-en-bloeddrukeffect-rct/","title":"GoFresh: DASH-boodschappen en bloeddrukeffect — RCT","title_en":"DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial.","published":"2026-01-06"}],"10.1016/j.jacc.2025.08.092":[{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","title":"ESPRIT: intensieve bloeddrukcontrole bij fragiele patiënten — post-hoc analyse","title_en":"Effects of Intensive Blood Pressure Control in Patients With Frailty: A Post Hoc Analysis From ESPRIT.","published":"2026-01-06"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077780":[{"url":"https://hartvaat.nl/2026/01/06/remming-van-annexine-a2-bevordert-mitofagie-en-vermindert-hartschade-na-infarct/","title":"Remming van annexine A2 bevordert mitofagie en vermindert hartschade na infarct","title_en":"Inhibition of Annexin A2 Facilitates PHB2-Mediated Mitophagy in Cardiomyocytes to Alleviate Cardiac Injury and Remodeling After Infarction","published":"2026-01-06"}],"10.1093/eurheartj/ehaf706":[{"url":"https://hartvaat.nl/2026/01/05/magnesium-en-uitkomsten-bij-hfref-galactic-hf-subanalyse/","title":"Magnesium en uitkomsten bij HFrEF: GALACTIC-HF subanalyse","title_en":"Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.","published":"2026-01-05"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.075943":[{"url":"https://hartvaat.nl/2026/01/05/klinisch-spectrum-van-parvovirus-b19-geassocieerde-acute-myocarditis-bij-kindere/","title":"Klinisch spectrum van parvovirus B19-geassocieerde acute myocarditis bij kinderen","title_en":"Clinical Spectrum of Children With Parvovirus B19–Associated Acute Myocarditis","published":"2026-01-05"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(26)00001-8/fulltext":[{"url":"https://hartvaat.nl/2026/01/05/samenstelling-en-classificatie-van-coronaire-atherosclerotische-plaques-bij-hype/","title":"Samenstelling en classificatie van coronaire atherosclerotische plaques bij hypercholesterolemische varkens","title_en":"Coronary atherosclerotic plaque composition and classification in hypercholesterolemic pigs","published":"2026-01-05"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.074700":[{"url":"https://hartvaat.nl/2026/01/05/grsf1-beschermt-tegen-hartfalen-door-bcaa-homeostase-te-handhaven/","title":"GRSF1 beschermt tegen hartfalen door BCAA-homeostase te handhaven","title_en":"GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis","published":"2026-01-05"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.075789":[{"url":"https://hartvaat.nl/2026/01/05/myocardherstel-bij-mechanische-ondersteuning-hangt-samen-met-alternatieve-splici/","title":"Myocardherstel bij mechanische ondersteuning hangt samen met alternatieve splicing van CAMK2D","title_en":"Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D","published":"2026-01-05"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01531-x/fulltext":[{"url":"https://hartvaat.nl/2026/01/02/albuminurie-en-cardiovasculair-risico-gemiste-kans-in-de-2025-esc-eas-dyslipidem/","title":"Albuminurie en cardiovasculair risico: gemiste kans in de 2025 ESC/EAS-dyslipidemierichtlijnen","title_en":"Albuminuria and cardiovascular risk: A missed opportunity in the 2025 focused update of the ESC/EAS dyslipidaemia guidelines","published":"2026-01-02"}],"10.1161/hypertensionaha.125.24666":[{"url":"https://hartvaat.nl/2026/01/01/insulineresistentie-en-bloeddrukcontrole-op-cognitieve-uitkomsten/","title":"Insulineresistentie en bloeddrukcontrole op cognitieve uitkomsten","title_en":"Insulin Resistance and Blood Pressure Control on Cognitive Outcomes.","published":"2026-01-01"}],"10.1161/hypertensionaha.125.24723":[{"url":"https://hartvaat.nl/2026/01/01/consistentie-van-bloeddrukrespons-op-kaliumverrijkt-zout-ssass-subanalyse/","title":"Consistentie van bloeddrukrespons op kaliumverrijkt zout: SSaSS subanalyse","title_en":"Consistency of Blood Pressure Response to Potassium-Enriched Salt in the China Salt Substitute Study.","published":"2026-01-01"}],"10.1161/hypertensionaha.125.25021":[{"url":"https://hartvaat.nl/2026/01/01/haptoglobinefenotype-en-cv-risico-accord-bloeddruk-rct/","title":"Haptoglobinefenotype en CV-risico: ACCORD bloeddruk-RCT","title_en":"Haptoglobin Phenotype and Cardiovascular Risk: The ACCORD Blood Pressure RCT.","published":"2026-01-01"}],"10.1161/hypertensionaha.125.25069":[{"url":"https://hartvaat.nl/2026/01/01/renale-histologie-bij-maligne-hypertensie-systematische-review/","title":"Renale histologie bij maligne hypertensie: systematische review","title_en":"Renal Histology Findings in Malignant Hypertension, a Systematic Review.","published":"2026-01-01"}],"10.3389/fendo.2026.1753126":[{"url":"https://hartvaat.nl/2026/01/01/effect-van-finerenon-op-de-nierfunctie-bij-diabetische-nefropathie-type-2/","title":"Effect van finerenon op de nierfunctie bij diabetische nefropathie type 2","title_en":"Effect of finerenone on renal function in patients with type 2 diabetic nephropathy: a retrospective cohort study.","published":"2026-01-01"}],"10.3389/fimmu.2026.1750021":[{"url":"https://hartvaat.nl/2026/01/01/3-hydroxystearinezuur-bevordert-cholesterolefflux-en-vermindert-atherosclerose-v/","title":"3-Hydroxystearinezuur bevordert cholesterolefflux en vermindert atherosclerose via ALKBH5/PAX-8/ABCA1","title_en":"3-Hydroxystearic acid promotes cholesterol efflux and attenuates atherosclerosis via the ALKBH5/PAX-8/ABCA1 pathway.","published":"2026-01-01"}],"10.31744/einstein_journal/2026ao1470":[{"url":"https://hartvaat.nl/2026/01/01/matig-gewichtsverlies-verbetert-hartslagvariabiliteit-bij-obese-patienten-met-ho/","title":"Matig gewichtsverlies verbetert hartslagvariabiliteit bij obese patiënten met hoog cardiovasculair risico","title_en":"A tertiary care study on the effectiveness of moderate weight loss on heart rate variability frequency-domain components in obese patients at high cardiovascular risk.","published":"2026-01-01"}],"10.3389/fmed.2026.1744404":[{"url":"https://hartvaat.nl/2026/01/01/west-nijlvirus-meningo-encefalitis-bij-een-patient-op-ixekizumab-en-prednison/","title":"West-Nijlvirus-meningo-encefalitis bij een patiënt op ixekizumab en prednison","title_en":"Case Report: First case of West Nile virus meningoencephalitis in Southwest Michigan in a patient on ixekizumab and prednisone.","published":"2026-01-01"}],"10.1155/cdr/5113761":[{"url":"https://hartvaat.nl/2026/01/01/effect-van-sglt2-remmers-op-atriumfibrilleren-bij-diabetes-met-gedilateerde-card/","title":"Effect van SGLT2-remmers op atriumfibrilleren bij diabetes met gedilateerde cardiomyopathie","title_en":"Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study.","published":"2026-01-01"}],"10.1177/15579883261424111":[{"url":"https://hartvaat.nl/2026/01/01/werving-van-zwarte-mannen-met-beroerte-voor-een-gerandomiseerde-klinische-trial/","title":"Werving van zwarte mannen met beroerte voor een gerandomiseerde klinische trial","title_en":"Engaging and Recruiting Black Men With Stroke or TIA in a Randomized Clinical Trial Conducted: Addressing Research Barriers and Developing Solutions for Successful Engagement.","published":"2026-01-01"}],"10.3389/fnut.2026.1714573":[{"url":"https://hartvaat.nl/2026/01/01/factoren-geassocieerd-met-anemie-bij-chronische-nierziekte-in-brazilie/","title":"Factoren geassocieerd met anemie bij chronische nierziekte in Brazilië","title_en":"Factors associated with anemia in chronic kidney disease in the Brazilian population: national health survey.","published":"2026-01-01"}],"10.1371/journal.pone.0341633":[{"url":"https://hartvaat.nl/2026/01/01/rivaroxaban-discontinueringspercentages-bij-niet-valvulair-af-in-de-italiaanse-p/","title":"Rivaroxaban-discontinueringspercentages bij niet-valvulair AF in de Italiaanse praktijk","title_en":"Rivaroxaban treatment discontinuation rates in patients with nonvalvular atrial fibrillation in Italian clinical practice: RITMUS-AF.","published":"2026-01-01"}],"10.1371/journal.pone.0339967":[{"url":"https://hartvaat.nl/2026/01/01/rosuvastatine-beschermt-tegen-oxldl-geinduceerde-endotheelstress-en-atherosclero/","title":"Rosuvastatine beschermt tegen oxLDL-geïnduceerde endotheelstress en atherosclerose via NF-κB","title_en":"Rosuvastatin protects against oxLDL-induced endothelial cell oxidative stress and attenuates atherosclerotic plaque formation in ApoE-/- mice through the NF-κB pathway.","published":"2026-01-01"}],"10.1155/mi/5524066":[{"url":"https://hartvaat.nl/2026/01/01/sophocarpine-beschermt-tegen-pulmonale-hypertensie-in-preklinische-modellen/","title":"Sophocarpine beschermt tegen pulmonale hypertensie in preklinische modellen","title_en":"Targeting Pulmonary Hypertension: Elucidating Sophocarpine's Protective Role via Preclinical Models.","published":"2026-01-01"}],"10.3389/fendo.2026.1764481":[{"url":"https://hartvaat.nl/2026/01/01/metabole-score-voor-visceraal-vet-en-risico-op-perifeer-arterieel-vaatlijden-bij/","title":"Metabole score voor visceraal vet en risico op perifeer arterieel vaatlijden bij hypertensie","title_en":"The metabolic score for visceral fat and risk of peripheral arterial disease in hypertension patients: a prospective cohort study.","published":"2026-01-01"}],"10.1371/journal.pone.0328947":[{"url":"https://hartvaat.nl/2026/01/01/transcriptomische-onderdrukking-van-immuun-en-ecm-stabiliteit-in-skeletspier-bij/","title":"Transcriptomische onderdrukking van immuun- en ECM-stabiliteit in skeletspier bij CKD","title_en":"Transcriptomic suppression of immune and ECM stability in skeletal muscle of patients with chronic kidney disease.","published":"2026-01-01"}],"10.17116/hirurgia2026021100":[{"url":"https://hartvaat.nl/2026/01/01/iatrogene-letsels-en-trombotische-complicaties-bij-spoed-endovasculaire-interven/","title":"Iatrogene letsels en trombotische complicaties bij spoed-endovasculaire interventies","title_en":"[Iatrogenic injuries and thrombotic complications following emergency endovascular interventions].","published":"2026-01-01"}],"10.21470/1678-9741-2025-0277":[{"url":"https://hartvaat.nl/2026/01/01/jackson-pratt-drains-verminderen-pericardeffusie-en-atriumfibrilleren-na-cabg/","title":"Jackson-Pratt-drains verminderen pericardeffusie en atriumfibrilleren na CABG","title_en":"Efficacy of Jackson-Pratt Mediastinal Drains in Reducing Pericardial Effusion and Atrial Fibrillation After Coronary Artery Bypass Grafting: A Retrospective Cohort Study.","published":"2026-01-01"}],"10.23785/praxis.2026.01.002":[{"url":"https://hartvaat.nl/2026/01/01/matig-alcoholgebruik-gezond-of-riskant-een-kritisch-perspectief/","title":"Matig alcoholgebruik: gezond of riskant? Een kritisch perspectief","title_en":"[Moderate alcohol consumption - healthy or risky? A critical perspective on existing research and WHO guidelines].","published":"2026-01-01"}],"10.2147/vhrm.s576743":[{"url":"https://hartvaat.nl/2026/01/01/diabetes-obesitas-en-de-metabole-drijfveren-van-perifeer-arterieel-vaatlijden/","title":"Diabetes, obesitas en de metabole drijfveren van perifeer arterieel vaatlijden","title_en":"Diabetes, Obesity, and the Metabolic Drivers of Peripheral Artery Disease: Lessons from Recent Forecasts.","published":"2026-01-01"}],"10.70401/alr.2026.0005":[{"url":"https://hartvaat.nl/2026/01/01/lp-a-geoxideerde-fosfolipiden-en-apob100-bij-acuut-ischemisch-herseninfarct/","title":"Lp(a), geoxideerde fosfolipiden en apoB100 bij acuut ischemisch herseninfarct","title_en":"Association of lipoprotein(a), oxidized phospholipids and apolipoprotein B100 in acute ischemic stroke cohort.","published":"2026-01-01"}],"10.1177/11795514261422310":[{"url":"https://hartvaat.nl/2026/01/01/dyslipidemie-bij-diabetes-een-complex-landschap-voor-betere-cardiovasculaire-uit/","title":"Dyslipidemie bij diabetes: een complex landschap voor betere cardiovasculaire uitkomsten","title_en":"Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes.","published":"2026-01-01"}],"10.3389/fendo.2026.1652682":[{"url":"https://hartvaat.nl/2026/01/01/overgewicht-en-de-tyg-index-als-voorspellers-van-sterfte-bij-diabetes-type-2/","title":"Overgewicht en de TyG-index als voorspellers van sterfte bij diabetes type 2","title_en":"Individual and joint effects of overweight/obesity and the triglyceride-glucose index on mortality risk in type 2 diabetic patients: a retrospective cohort study in China.","published":"2026-01-01"}],"10.1371/journal.pone.0342704":[{"url":"https://hartvaat.nl/2026/01/01/lipoproteine-a-gecombineerd-met-catlet-score-voorspelt-events-na-spoed-pci/","title":"Lipoproteïne(a) gecombineerd met CatLet-score voorspelt events na spoed-PCI","title_en":"Clinical value of Lipoprotein(a) combined with CatLet coronary score in predicting adverse events after emergency PCI for AMI patients.","published":"2026-01-01"}],"10.3389/fendo.2026.1765770":[{"url":"https://hartvaat.nl/2026/01/01/apolipoproteine-e-genpolymorfismen-en-het-risico-op-coronairlijden/","title":"Apolipoproteïne E-genpolymorfismen en het risico op coronairlijden","title_en":"Association of apolipoprotein E gene polymorphisms with risk of coronary artery disease in a Han Chinese population at middle and high altitude in China.","published":"2026-01-01"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26400":[{"url":"https://hartvaat.nl/2025/12/30/ire1-bemiddelt-hypertensie-en-vasculaire-remodeling/","title":"IRE1α bemiddelt hypertensie en vasculaire remodeling","title_en":"Inositol Requiring Enzyme 1α Mediates Hypertension and Vascular Remodeling","published":"2025-12-30"}],"https://www.kidney-international.org/article/s0085-2538(25)01028-2/fulltext":[{"url":"https://hartvaat.nl/2025/12/30/overgang-van-aki-naar-ckd-rol-van-niermacrofagen-en-neutrofielen/","title":"Overgang van AKI naar CKD: rol van niermacrofagen en neutrofielen","title_en":"Key drivers and potential therapeutic targets in the AKI-to-CKD transition: roles of kidney-resident macrophages and neutrophils","published":"2025-12-30"}],"https://www.kidney-international.org/article/s0085-2538(25)01008-7/fulltext":[{"url":"https://hartvaat.nl/2025/12/30/transcriptanalyse-van-langdurige-varken-naar-primaat-nierxenograften/","title":"Transcriptanalyse van langdurige varken-naar-primaat nierxenograften","title_en":"Mechanistic insights from transcript analysis of long-term pig to non-human primate kidney xenografts","published":"2025-12-30"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01532-1/fulltext":[{"url":"https://hartvaat.nl/2025/12/29/effect-van-cilostazol-op-de-prognose-van-perifeer-arterieel-vaatlijden-bij-diabe/","title":"Effect van cilostazol op de prognose van perifeer arterieel vaatlijden bij diabetes in Korea","title_en":"Effects of cilostazol on the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus in Korea: A nationwide population-based study","published":"2025-12-29"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076321":[{"url":"https://hartvaat.nl/2025/12/29/gemodificeerde-regulatoire-t-lymfocyten-bevorderen-herstel-van-het-geinfarceerde/","title":"Gemodificeerde regulatoire T-lymfocyten bevorderen herstel van het geïnfarceerde hart","title_en":"Engineered Regulatory T Lymphocytes Promote Infarcted Heart Repair","published":"2025-12-29"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01530-8/fulltext":[{"url":"https://hartvaat.nl/2025/12/29/functionele-en-morfologische-karakterisering-van-coronaire-atherosclerose/","title":"Functionele en morfologische karakterisering van coronaire atherosclerose","title_en":"Functional and morphological characterization of coronary atherosclerosis","published":"2025-12-29"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01529-1/fulltext":[{"url":"https://hartvaat.nl/2025/12/29/monocyt-hdl-ratio-en-risico-op-beroerte-myocardinfarct-en-mortaliteit/","title":"Monocyt-HDL-ratio en risico op beroerte, myocardinfarct en mortaliteit","title_en":"Monocyte to high-density lipoprotein ratio and risk of incident stroke, myocardial infarction, and mortality: A large prospective cohort study","published":"2025-12-29"}],"https://www.kidney-international.org/article/s0085-2538(25)01010-5/fulltext":[{"url":"https://hartvaat.nl/2025/12/26/pth-suppressieprofielen-na-orale-calciumbelasting-bij-niertransplantatiepatiente/","title":"PTH-suppressieprofielen na orale calciumbelasting bij niertransplantatiepatiënten","title_en":"Parathyroid hormone suppression profiles following oral calcium challenge in kidney transplant recipients","published":"2025-12-26"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01523-0/fulltext":[{"url":"https://hartvaat.nl/2025/12/26/systematische-identificatie-van-familiaire-hypercholesterolemie-geactualiseerde-/","title":"Systematische identificatie van familiaire hypercholesterolemie: geactualiseerde review","title_en":"Systematic identification of familial hypercholesterolaemia: An updated systematic review and meta-analysis","published":"2025-12-26"}],"https://www.kidney-international.org/article/s0085-2538(25)01024-5/fulltext":[{"url":"https://hartvaat.nl/2025/12/24/infectiepreventie-bij-nieuwe-complementremmers-ingekapselde-micro-organismen/","title":"Infectiepreventie bij nieuwe complementremmers: ingekapselde micro-organismen","title_en":"Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors","published":"2025-12-24"}],"https://www.kidney-international.org/article/s0085-2538(25)01023-3/fulltext":[{"url":"https://hartvaat.nl/2025/12/24/genomische-ontdekking-bij-nefrotisch-syndroom-mefv-varianten-als-risicofactor-vo/","title":"Genomische ontdekking bij nefrotisch syndroom: MEFV-varianten als risicofactor voor FSGS","title_en":"Nephrotic syndrome genomic discovery in the Mass General Brigham Biobank identifies monoallelic MEFV variants as a risk factor for focal segmental glomerulosclerosis","published":"2025-12-24"}],"https://www.kidney-international.org/article/s0085-2538(25)01015-4/fulltext":[{"url":"https://hartvaat.nl/2025/12/24/risicovoorspellingsmodellen-voor-ouderen-met-chronische-nierziekte/","title":"Risicovoorspellingsmodellen voor ouderen met chronische nierziekte","title_en":"Utilizing risk prediction models for older patients with chronic kidney disease","published":"2025-12-24"}],"10.1001/jama.2025.20841":[{"url":"https://hartvaat.nl/2025/12/23/top-liberaal-versus-restrictief-transfusiebeleid-bij-hoogrisico-hartchirurgie/","title":"TOP: liberaal versus restrictief transfusiebeleid bij hoogrisico hartchirurgie","title_en":"Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial.","published":"2025-12-23"}],"10.1161/circulationaha.125.077469":[{"url":"https://hartvaat.nl/2025/12/23/korte-anticoagulatie-versus-dapt-na-laa-occlusie-devicetrombosepreventie/","title":"Korte anticoagulatie versus DAPT na LAA-occlusie: devicetrombosepreventie","title_en":"Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial.","published":"2025-12-23"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01521-7/fulltext":[{"url":"https://hartvaat.nl/2025/12/23/kwetsbaarheid-genetische-gevoeligheid-en-risico-op-abdominaal-aorta-aneurysma/","title":"Kwetsbaarheid, genetische gevoeligheid en risico op abdominaal aorta-aneurysma","title_en":"Frailty, genetic susceptibility, and the risk of abdominal aortic aneurysm: Evidence from the UK Biobank cohort study","published":"2025-12-23"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01522-9/fulltext":[{"url":"https://hartvaat.nl/2025/12/23/plasma-proteomische-biomarkers-voor-risico-en-therapeutische-doelen-bij-abdomina/","title":"Plasma-proteomische biomarkers voor risico en therapeutische doelen bij abdominaal aorta-aneurysma","title_en":"Identifying plasma proteomic biomarkers for risk prediction and therapeutic targets of abdominal aortic aneurysm: Prospective cohort and Mendelian randomization analyses","published":"2025-12-23"}],"https://www.kidney-international.org/article/s0085-2538(25)01019-1/fulltext":[{"url":"https://hartvaat.nl/2025/12/23/meta-organismaal-tryptofaanmetabolisme-als-therapeutisch-doelwit-bij-ckd-mbd/","title":"Meta-organismaal tryptofaanmetabolisme als therapeutisch doelwit bij CKD-MBD","title_en":"Meta-organismal tryptophan metabolism: an appealing therapeutic target in CKD-MBD","published":"2025-12-23"}],"https://www.kidney-international.org/article/s0085-2538(25)01020-8/fulltext":[{"url":"https://hartvaat.nl/2025/12/23/sglt2-remming-verbetert-leeftijdsafhankelijke-microvasculaire-rarefactie-van-de-/","title":"SGLT2-remming verbetert leeftijdsafhankelijke microvasculaire rarefactie van de nier","title_en":"Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction","published":"2025-12-23"}],"https://www.kidney-international.org/article/s0085-2538(25)01007-5/fulltext":[{"url":"https://hartvaat.nl/2025/12/22/sefaxersen-bij-iga-nefropathie-fase-2-trial-van-complementfactor-b-remming/","title":"Sefaxersen bij IgA-nefropathie: fase 2-trial van complementfactor B-remming","title_en":"A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy","published":"2025-12-22"}],"https://www.kidney-international.org/article/s0085-2538(25)01012-9/fulltext":[{"url":"https://hartvaat.nl/2025/12/22/complementactivatie-drijft-compartiment-specifieke-immuunrespons-bij-c3-glomerul/","title":"Complementactivatie drijft compartiment-specifieke immuunrespons bij C3-glomerulopathie","title_en":"Complement activation drives a compartmentalized innate immune response in C3 glomerulopathy contributing to the disease phenotype","published":"2025-12-22"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01525-4/fulltext":[{"url":"https://hartvaat.nl/2025/12/22/evinacumab-bij-kinderen-van-5-17-jaar-met-homozygote-familiaire-hypercholesterol/","title":"Evinacumab bij kinderen van 5-17 jaar met homozygote familiaire hypercholesterolemie","title_en":"Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia","published":"2025-12-22"}],"https://www.kidney-international.org/article/s0085-2538(25)01022-1/fulltext":[{"url":"https://hartvaat.nl/2025/12/22/therapeutische-herprogrammering-van-myeloide-cellen-via-sirp-vesikels-bij-acuut-/","title":"Therapeutische herprogrammering van myeloïde cellen via SIRPα-vesikels bij acuut nierletsel","title_en":"Therapeutic reprogramming of circulating myeloid cells via signal regulatory protein α extracellular vesicles in acute kidney injury","published":"2025-12-22"}],"10.1016/s0140-6736(24)02100-7":[{"url":"https://hartvaat.nl/2025/12/21/tavi-plus-ffr-geleide-pci-gecombineerde-benadering-onderzocht/","title":"TAVI plus FFR-geleide PCI: gecombineerde benadering onderzocht","title_en":"TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial.","published":"2025-12-21"}],"10.1016/s0140-6736(25)02165-8":[{"url":"https://hartvaat.nl/2025/12/20/orforglipron-bij-obesitas-nejm-definitieve-fase-3-resultaten/","title":"Orforglipron bij obesitas: NEJM definitieve fase 3 resultaten","title_en":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.","published":"2025-12-20"}],"10.1056/nejmoa2505928":[{"url":"https://hartvaat.nl/2025/12/18/tirzepatide-versus-dulaglutide-en-cv-uitkomsten-bij-type-2-diabetes/","title":"Tirzepatide versus dulaglutide en CV-uitkomsten bij type 2 diabetes","title_en":"Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.","published":"2025-12-18"}],"https://www.ahajournals.org/doi/abs/10.1161/cir.0000000000001402":[{"url":"https://hartvaat.nl/2025/12/18/2025-acc-aha-richtlijn-voor-behandeling-van-volwassenen-met-aangeboren-hartafwij/","title":"2025 ACC/AHA-richtlijn voor behandeling van volwassenen met aangeboren hartafwijkingen","title_en":"2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines","published":"2025-12-18"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.124.071774":[{"url":"https://hartvaat.nl/2025/12/18/endotheliale-transcriptiefactor-eb-beschermt-tegen-doxorubicine-cardiotoxiciteit/","title":"Endotheliale transcriptiefactor EB beschermt tegen doxorubicine-cardiotoxiciteit","title_en":"Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction","published":"2025-12-18"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.074041":[{"url":"https://hartvaat.nl/2025/12/18/improve-dice-veiligheid-en-werkzaamheid-van-ninerafaxstat-bij-cardiometabole-syn/","title":"IMPROVE-DiCE: veiligheid en werkzaamheid van ninerafaxstat bij cardiometabole syndromen","title_en":"IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes","published":"2025-12-18"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.26149":[{"url":"https://hartvaat.nl/2025/12/18/gedeeltelijk-succesvolle-bijniervenesampling-bij-subtypering-van-primair-aldoste/","title":"Gedeeltelijk succesvolle bijniervenesampling bij subtypering van primair aldosteronisme","title_en":"Partially Successful Adrenal Vein Sampling With and Without Cross-Sectional Imaging in Primary Aldosteronism Subtyping","published":"2025-12-18"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076170":[{"url":"https://hartvaat.nl/2025/12/18/bradycardie-bij-topsporters-prevalentie-mechanismen-en-risico-s/","title":"Bradycardie bij topsporters: prevalentie, mechanismen en risico's","title_en":"Bradycardia in Athletes: Prevalence, Mechanisms, and Risks","published":"2025-12-18"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.076514":[{"url":"https://hartvaat.nl/2025/12/18/trim31-in-macrofagen-remt-atherosclerotische-plaquevorming-via-lox-1-afbraak/","title":"TRIM31 in macrofagen remt atherosclerotische plaquevorming via LOX-1-afbraak","title_en":"Macrophage-Specific E3 Ubiquitin Ligase TRIM31 Reduces Atherosclerotic Plaque Formation by Targeting LOX-1","published":"2025-12-18"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01520-5/fulltext":[{"url":"https://hartvaat.nl/2025/12/17/geintegreerde-mirnomics-en-lipidomics-bij-muizen-met-veranderd-lipoproteinemetab/","title":"Geïntegreerde miRNomics en lipidomics bij muizen met veranderd lipoproteïnemetabolisme","title_en":"Integrated high-throughput miRNomics and lipidomics in mice with altered lipoprotein metabolism","published":"2025-12-17"}],"10.1161/circulationaha.125.073855":[{"url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","title":"Geoxideerde fosfolipiden, Lp(a) en CV-uitkomsten na ACS","title_en":"Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.","published":"2025-12-16"}],"10.1016/j.jacc.2025.08.089":[{"url":"https://hartvaat.nl/2025/12/16/danish-langetermijn-icd-bij-niet-ischemische-hfref-uitgebreide-follow-up/","title":"DANISH langetermijn: ICD bij niet-ischemische HFrEF — uitgebreide follow-up","title_en":"Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISH.","published":"2025-12-16"}],"10.1016/j.jacc.2025.08.051":[{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","title":"VICTOR: vericiguat en totale hartfalengebeurtenissen bij stabiel HFrEF","title_en":"Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.","published":"2025-12-16"}],"10.1016/j.jacc.2025.08.054":[{"url":"https://hartvaat.nl/2025/12/16/farmacologische-behandeling-van-hfref-geactualiseerde-systematische-review/","title":"Farmacologische behandeling van HFrEF: geactualiseerde systematische review","title_en":"Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.","published":"2025-12-16"}],"10.1093/eurheartj/ehaf623":[{"url":"https://hartvaat.nl/2025/12/15/hypokaliemie-en-af-gedetecteerd-door-implanteerbare-loop-recorders/","title":"Hypokaliëmie en AF gedetecteerd door implanteerbare loop recorders","title_en":"Hypokalaemia and atrial fibrillation detected by implanted loop recorders.","published":"2025-12-15"}],"10.1093/eurheartj/ehaf386":[{"url":"https://hartvaat.nl/2025/12/15/circadiaanse-patronen-van-af-en-ziekteprogressie-via-implanted-loop-recorders/","title":"Circadiaanse patronen van AF en ziekteprogressie via implanted loop recorders","title_en":"Circadian patterns of atrial fibrillation and disease progression assessed by implanted loop recorders.","published":"2025-12-15"}],"https://www.kidney-international.org/article/s0085-2538(25)00988-3/fulltext":[{"url":"https://hartvaat.nl/2025/12/15/aldh1a1-reguleert-pd-l1-transcriptie-combinatietherapie-bij-adpkd/","title":"ALDH1A1 reguleert PD-L1-transcriptie: combinatietherapie bij ADPKD","title_en":"Aldehyde dehydrogenase 1 A1 regulates the transcription of PD-L1 and its targeting with disulfiram together with PD-L1 immunotherapy synergistically delays cyst growth in ADPKD","published":"2025-12-15"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25949":[{"url":"https://hartvaat.nl/2025/12/15/geslachtsspecifieke-exosoom-inhoud-onthult-nieuwe-mechanismen-van-zoutgevoelige-/","title":"Geslachtsspecifieke exosoom-inhoud onthult nieuwe mechanismen van zoutgevoelige hypertensie","title_en":"Sex-Specific Exosome Cargo Reveals Potential New Mechanisms of Salt-Sensitive Hypertension","published":"2025-12-15"}],"https://www.ahajournals.org/doi/abs/10.1161/hyp.0000000000000258":[{"url":"https://hartvaat.nl/2025/12/15/enkelvoudige-pil-combinatietherapie-bij-hypertensie-aha-wetenschappelijk-stateme/","title":"Enkelvoudige-pil combinatietherapie bij hypertensie: AHA-wetenschappelijk statement","title_en":"Single-Pill Combination Therapy for the Management of Hypertension: A Scientific Statement From the American Heart Association","published":"2025-12-15"}],"https://www.kidney-international.org/article/s0085-2538(25)00990-1/fulltext":[{"url":"https://hartvaat.nl/2025/12/15/m7g-methyltransferase-mettl1-bevordert-acuut-nierletsel-via-mitochondriale-disfu/","title":"m7G-methyltransferase METTL1 bevordert acuut nierletsel via mitochondriale disfunctie","title_en":"The m7G methyltransferase METTL1 promotes acute kidney inflammation by disrupting mitochondrial function","published":"2025-12-15"}],"10.1016/s0140-6736(25)02170-1":[{"url":"https://hartvaat.nl/2025/12/13/complete-revascularisation-evaluation-meta-analyse-van-individuele-patientdata/","title":"Complete Revascularisation Evaluation: meta-analyse van individuele patiëntdata","title_en":"Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials.","published":"2025-12-13"}],"10.1056/nejmoa2508026":[{"url":"https://hartvaat.nl/2025/12/11/ticagrelor-plus-aspirine-versus-aspirine-na-cabg-voor-acs-gerandomiseerde-trial/","title":"Ticagrelor plus aspirine versus aspirine na CABG voor ACS: gerandomiseerde trial","title_en":"Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.","published":"2025-12-11"}],"10.1136/heartjnl-2024-325605":[{"url":"https://hartvaat.nl/2025/12/11/pulmonale-hemodynamiek-op-hoogte-bij-hfpef/","title":"Pulmonale hemodynamiek op hoogte bij HFpEF","title_en":"Pulmonary haemodynamics and right heart function during exercise at high versus low altitude in patients with pulmonary vascular disease: a randomised crossover trial.","published":"2025-12-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25187":[{"url":"https://hartvaat.nl/2025/12/11/klinische-fenotypen-bij-hypertensie-datagestuurde-risicostratificatie/","title":"Klinische fenotypen bij hypertensie: datagestuurde risicostratificatie","title_en":"Clinical Phenotypes in Hypertension: A Data-Driven Approach to Risk Stratification","published":"2025-12-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hyp.0000000000000254":[{"url":"https://hartvaat.nl/2025/12/11/manchetloze-bloeddrukmeting-aha-wetenschappelijk-statement/","title":"Manchetloze bloeddrukmeting: AHA-wetenschappelijk statement","title_en":"Cuffless Devices for the Measurement of Blood Pressure: A Scientific Statement From the American Heart Association","published":"2025-12-11"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25855":[{"url":"https://hartvaat.nl/2025/12/10/invloed-van-leeftijd-geslacht-en-ras-op-testinterpretatie-bij-primair-aldosteron/","title":"Invloed van leeftijd, geslacht en ras op testinterpretatie bij primair aldosteronisme","title_en":"Impact of Age, Sex, and Race on Primary Aldosteronism Test Interpretations","published":"2025-12-10"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25718":[{"url":"https://hartvaat.nl/2025/12/10/nox4-en-metabole-stress-in-nieren-bij-zoutgevoelige-hypertensie/","title":"NOX4 en metabole stress in nieren bij zoutgevoelige hypertensie","title_en":"NADPH Oxidase 4 and Metabolic Stress in Dahl Salt-Sensitive Rat Kidneys","published":"2025-12-10"}],"10.1016/j.jacc.2025.09.1593":[{"url":"https://hartvaat.nl/2025/12/09/nieuw-bifasisch-pfa-systeem-versus-thermale-ablatie-bij-paroxysmaal-af/","title":"Nieuw bifasisch PFA-systeem versus thermale ablatie bij paroxysmaal AF","title_en":"Pulsed Field Ablation Using a Novel Biphasic Catheter vs Thermal Ablation for Paroxysmal Atrial Fibrillation: InsightPFA Trial.","published":"2025-12-09"}],"10.1161/circulationaha.125.076263":[{"url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","title":"ASPREE: cardiale stress en bloeddrukmanagement bij ouderen","title_en":"Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial.","published":"2025-12-09"}],"10.1016/j.jacc.2025.08.040":[{"url":"https://hartvaat.nl/2025/12/09/gepersonaliseerde-versus-standaard-dapt-duur-na-pci-gerandomiseerde-trial/","title":"Gepersonaliseerde versus standaard DAPT-duur na PCI: gerandomiseerde trial","title_en":"Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The PARTHENOPE Randomized Trial.","published":"2025-12-09"}],"10.1016/j.jacc.2025.08.041":[{"url":"https://hartvaat.nl/2025/12/09/tweemaal-daags-clopidogrel-versus-ticagrelor-voor-korttermijn-mace-na-pci/","title":"Tweemaal daags clopidogrel versus ticagrelor voor korttermijn MACE na PCI","title_en":"Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial.","published":"2025-12-09"}],"https://www.kidney-international.org/article/s0085-2538(25)00943-3/fulltext":[{"url":"https://hartvaat.nl/2025/12/08/bijdrage-van-genetische-varianten-aan-nefrolithiase/","title":"Bijdrage van genetische varianten aan nefrolithiase","title_en":"Contribution of genetic variants to nephrolithiasis","published":"2025-12-08"}],"https://www.kidney-international.org/article/s0085-2538(25)00942-1/fulltext":[{"url":"https://hartvaat.nl/2025/12/05/hypoxie-responsieve-trna-fragmenten-als-regulatoren-van-rna-autofagie-en-nierbes/","title":"Hypoxie-responsieve tRNA-fragmenten als regulatoren van RNA-autofagie en nierbescherming","title_en":"Small but mighty: hypoxia-responsive tRNA-derived small RNA as a novel regulator of RNA autophagy and kidney protection","published":"2025-12-05"}],"https://www.kidney-international.org/article/s0085-2538(25)00934-2/fulltext":[{"url":"https://hartvaat.nl/2025/12/05/hyperactivatie-van-yap-in-podocyten-verstoort-de-rust-van-glomerulaire-cellen/","title":"Hyperactivatie van YAP in podocyten verstoort de rust van glomerulaire cellen","title_en":"When YAP is hyperactivated in podocytes, it persistently “yaps,” disrupting the quiescence of neighboring glomerular cells","published":"2025-12-05"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01506-0/fulltext":[{"url":"https://hartvaat.nl/2025/12/03/galectine-1-herprogrammeert-macrofagen-en-moduleert-t-celimmuniteit-bij-atherosc/","title":"Galectine-1 herprogrammeert macrofagen en moduleert T-celimmuniteit bij atherosclerose","title_en":"Galectin-1 induces macrophage immunometabolic reprogramming, modulates T cell immunity and attenuates atherosclerotic plaque formation","published":"2025-12-03"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01505-9/fulltext":[{"url":"https://hartvaat.nl/2025/12/03/risicoverfijning-in-het-tijdperk-van-een-cac-score-van-nul-de-meerwaarde-van-fit/","title":"Risicoverfijning in het tijdperk van een CAC-score van nul: de meerwaarde van fitheid","title_en":"Refining risk in the power of zero era: The added value of cardiorespiratory fitness","published":"2025-12-03"}],"10.1001/jama.2025.17578":[{"url":"https://hartvaat.nl/2025/12/02/discordantie-creatinine-versus-cystatine-c-egfr-en-klinische-uitkomsten-meta-ana/","title":"Discordantie creatinine- versus cystatine C-eGFR en klinische uitkomsten: meta-analyse","title_en":"Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis.","published":"2025-12-02"}],"10.1001/jama.2025.17235":[{"url":"https://hartvaat.nl/2025/12/02/geindividualiseerd-perioperatief-bloeddrukmanagement-bij-grote-buikchirurgie/","title":"Geïndividualiseerd perioperatief bloeddrukmanagement bij grote buikchirurgie","title_en":"Individualized Perioperative Blood Pressure Management in Patients Undergoing Major Abdominal Surgery: The IMPROVE-multi Randomized Clinical Trial.","published":"2025-12-02"}],"10.1001/jamacardio.2025.4151":[{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","title":"ARTESIA: majeure bloedingen met apixaban versus aspirine — subanalyse","title_en":"Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.","published":"2025-12-01"}],"10.1093/europace/euaf292":[{"url":"https://hartvaat.nl/2025/12/01/comorbiditeitsbelasting-en-uitkomsten-van-ablatie-versus-medicatie-bij-af/","title":"Comorbiditeitsbelasting en uitkomsten van ablatie versus medicatie bij AF","title_en":"Association between comorbidity burden and outcomes of catheter ablation vs. medical therapy for atrial fibrillation: insights from the CABANA trial.","published":"2025-12-01"}],"10.1001/jamacardio.2025.4007":[{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","title":"ARREST-AF: agressieve risicofactorreductie en ablatie-uitkomsten","title_en":"Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial.","published":"2025-12-01"}],"10.1001/jamacardio.2025.3687":[{"url":"https://hartvaat.nl/2025/12/01/ice-versus-tee-bij-af-ablatie-gerandomiseerde-trial/","title":"ICE versus TEE bij AF-ablatie: gerandomiseerde trial","title_en":"Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial.","published":"2025-12-01"}],"10.1093/europace/euaf163":[{"url":"https://hartvaat.nl/2025/12/01/lawt-geleide-pvi-bij-persisterend-af-gepersonaliseerde-benadering/","title":"LAWT-geleide PVI bij persisterend AF: gepersonaliseerde benadering","title_en":"Personalized pulmonary vein isolation guided by left atrial wall thickness for persistent atrial fibrillation ablation: the PeAF-by-LAWT randomized trial.","published":"2025-12-01"}],"10.1002/ehf2.70017":[{"url":"https://hartvaat.nl/2025/12/01/economische-ziektelast-van-hartfalen-in-europa-systematische-review/","title":"Economische ziektelast van hartfalen in Europa: systematische review","title_en":"Economic burden of heart failure in Europe: A systematic review of costs and cost-effectiveness.","published":"2025-12-01"}],"10.1161/hypertensionaha.125.25202":[{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukcontrole-en-cerebrale-small-vessel-disease-markers/","title":"Intensieve bloeddrukcontrole en cerebrale small vessel disease markers","title_en":"Effect of Intensive Systolic Blood Pressure Control on Markers of Cerebral Small Vessel Disease by Age.","published":"2025-12-01"}],"10.1161/hypertensionaha.125.25730":[{"url":"https://hartvaat.nl/2025/12/01/hoog-versus-laag-natrium-oxybaat-en-bloeddruk-bij-narcolepsie/","title":"Hoog versus laag natrium-oxybaat en bloeddruk bij narcolepsie","title_en":"Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy.","published":"2025-12-01"}],"10.1002/ehf2.15448":[{"url":"https://hartvaat.nl/2025/12/01/istaroxime-bij-hf-gerelateerde-cardiogene-shock-hemodynamische-effecten/","title":"Istaroxime bij HF-gerelateerde cardiogene shock: hemodynamische effecten","title_en":"Haemodynamic effects of istaroxime in SCAI stage B HF-related cardiogenic shock: Insights from the SEISMiC trial.","published":"2025-12-01"}],"10.1002/ehf2.15446":[{"url":"https://hartvaat.nl/2025/12/01/scai-shockklassen-en-prognose-bij-ami-cardiogene-shock-danger-substudie/","title":"SCAI-shockklassen en prognose bij AMI-cardiogene shock: DanGer substudie","title_en":"Prognostic impact of SCAI shock severity classes in AMI-related cardiogenic shock: A sub-study of the ECLS-SHOCK Trial.","published":"2025-12-01"}],"10.1161/hypertensionaha.125.25511":[{"url":"https://hartvaat.nl/2025/12/01/tijd-in-streefwaarde-van-bloeddruk-en-acute-nierschade-bij-hypertensie/","title":"Tijd-in-streefwaarde van bloeddruk en acute nierschade bij hypertensie","title_en":"Systolic Blood Pressure Time in Target Range and Acute Kidney Injury in Patients With Hypertension.","published":"2025-12-01"}],"10.1002/ehf2.15435":[{"url":"https://hartvaat.nl/2025/12/01/intensieve-bloeddrukverlaging-bij-ongediagnosticeerde-hfpef-met-hoog-risico/","title":"Intensieve bloeddrukverlaging bij ongediagnosticeerde HFpEF met hoog risico","title_en":"Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients.","published":"2025-12-01"}],"10.1002/ehf2.15432":[{"url":"https://hartvaat.nl/2025/12/01/gelijktijdige-griep-en-rsv-vaccinatie-bij-hoogrisico-hartfalenpatienten/","title":"Gelijktijdige griep- en RSV-vaccinatie bij hoogrisico hartfalenpatiënten","title_en":"Simultaneous vaccination against influenza and respiratory syncytial virus in high-risk heart failure patients.","published":"2025-12-01"}],"10.1002/ehf2.15416":[{"url":"https://hartvaat.nl/2025/12/01/geografische-variatie-in-hfref-patientkenmerken-en-behandeling/","title":"Geografische variatie in HFrEF: patiëntkenmerken en behandeling","title_en":"Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.","published":"2025-12-01"}],"10.1002/ehf2.15423":[{"url":"https://hartvaat.nl/2025/12/01/supar-en-uitkomsten-bij-hfpef-topcat-subanalyse/","title":"suPAR en uitkomsten bij HFpEF: TOPCAT subanalyse","title_en":"Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.","published":"2025-12-01"}],"10.1002/ehf2.15420":[{"url":"https://hartvaat.nl/2025/12/01/dapagliflozine-na-mi-naar-ef-cardiometabole-uitkomsten/","title":"Dapagliflozine na MI naar EF: cardiometabole uitkomsten","title_en":"Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.","published":"2025-12-01"}],"10.1002/ehf2.15393":[{"url":"https://hartvaat.nl/2025/12/01/empagliflozine-na-mi-met-en-zonder-diabetes-en-ckd-empact-mi-subanalyse/","title":"Empagliflozine na MI met en zonder diabetes en CKD: EMPACT-MI subanalyse","title_en":"Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.","published":"2025-12-01"}],"10.1002/ehf2.15412":[{"url":"https://hartvaat.nl/2025/12/01/re-perfuse-relaxinereceptoragonist-en-renale-perfusie-bij-hfref-fase-1b/","title":"Re-PERFUSE: relaxinereceptoragonist en renale perfusie bij HFrEF — fase 1b","title_en":"Re-PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients.","published":"2025-12-01"}],"10.1002/ehf2.15404":[{"url":"https://hartvaat.nl/2025/12/01/hartrevalidatie-en-kwaliteit-van-leven-bij-hfpef-meta-analyse/","title":"Hartrevalidatie en kwaliteit van leven bij HFpEF: meta-analyse","title_en":"Cardiac rehabilitation and health-related quality of life in preserved ejection fraction heart failure: A meta-analysis.","published":"2025-12-01"}],"10.1002/ehf2.15401":[{"url":"https://hartvaat.nl/2025/12/01/hfpef-fenotypen-in-device-en-chirurgische-trials-karakterisatie/","title":"HFpEF-fenotypen in device- en chirurgische trials: karakterisatie","title_en":"Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials.","published":"2025-12-01"}],"10.5830/cvja-2025-083":[{"url":"https://hartvaat.nl/2025/11/28/sekseverschillen-in-mortaliteit-en-hospitalisatie-bij-hartfalenpatienten/","title":"Sekseverschillen in mortaliteit en hospitalisatie bij hartfalenpatiënten","title_en":"Sex differences in mortality and hospitalisation in heart failure patients: sex differences in heart failure.","published":"2025-11-28"}],"10.1056/nejmoa2508808":[{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-laagrisico-acuut-mi/","title":"Vroege aspirinestop na PCI bij laagrisico acuut MI","title_en":"Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.","published":"2025-11-27"}],"10.1056/nejmoa2507980":[{"url":"https://hartvaat.nl/2025/11/27/vroege-aspirinestop-na-pci-bij-acs-gerandomiseerde-trial/","title":"Vroege aspirinestop na PCI bij ACS: gerandomiseerde trial","title_en":"Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.","published":"2025-11-27"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01485-6/fulltext":[{"url":"https://hartvaat.nl/2025/11/26/lipideveranderingen-bij-vrouwen-met-fh-tijdens-de-menopauzale-transitie/","title":"Lipideveranderingen bij vrouwen met FH tijdens de menopauzale transitie","title_en":"Lipid changes in females with familial hypercholesterolemia during the menopausal transition period","published":"2025-11-26"}],"10.1136/heartjnl-2025-326174":[{"url":"https://hartvaat.nl/2025/11/25/frequente-pvc-s-en-risico-op-af-hf-cva-en-sterfte/","title":"Frequente PVC's en risico op AF, HF, CVA en sterfte","title_en":"Frequent premature ventricular complexes and risk of atrial fibrillation, heart failure, stroke and mortality: a meta-analysis.","published":"2025-11-25"}],"10.1161/circulationaha.125.076725":[{"url":"https://hartvaat.nl/2025/11/25/abc-af-risicoscores-voor-gepersonaliseerde-af-behandeling/","title":"ABC-AF risicoscores voor gepersonaliseerde AF-behandeling","title_en":"Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study.","published":"2025-11-25"}],"10.1136/heartjnl-2025-325773":[{"url":"https://hartvaat.nl/2025/11/25/amphilimus-versus-zotarolimus-eluting-stent-bij-diabetes-en-coronairlijden/","title":"Amphilimus versus zotarolimus-eluting stent bij diabetes en coronairlijden","title_en":"Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial.","published":"2025-11-25"}],"10.1056/nejmoa2509542":[{"url":"https://hartvaat.nl/2025/11/20/kaliumverhoging-bij-hoogrisicopatienten-voor-ventriculaire-aritmieen-rct/","title":"Kaliumverhoging bij hoogrisicopatiënten voor ventriculaire aritmieën: RCT","title_en":"Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.","published":"2025-11-20"}],"10.1056/nejmoa2508157":[{"url":"https://hartvaat.nl/2025/11/20/afbouw-van-antihypertensieve-behandeling-bij-verpleeghuisbewoners-rct/","title":"Afbouw van antihypertensieve behandeling bij verpleeghuisbewoners: RCT","title_en":"Reduction of Antihypertensive Treatment in Nursing Home Residents.","published":"2025-11-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.25360":[{"url":"https://hartvaat.nl/2025/11/20/primair-aldosteronisme-kleine-molecuulantagonisten-van-gemuteerde-kcnj5-kaliumka/","title":"Primair aldosteronisme: kleine molecuulantagonisten van gemuteerde KCNJ5-kaliumkanalen","title_en":"Primary Aldosteronism: Small Molecule Antagonists of Mutant KCNJ5 Potassium Channels","published":"2025-11-20"}],"10.1016/j.jacc.2025.08.046":[{"url":"https://hartvaat.nl/2025/11/18/sekseverschillen-in-semaglutide-effect-bij-pad-stride-subanalyse/","title":"Sekseverschillen in semaglutide-effect bij PAD: STRIDE-subanalyse","title_en":"Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.","published":"2025-11-18"}],"10.1016/j.jacc.2025.08.027":[{"url":"https://hartvaat.nl/2025/11/18/cv-effecten-en-verdraagbaarheid-van-glp-1-agonisten-meta-analyse/","title":"CV-effecten en verdraagbaarheid van GLP-1-agonisten: meta-analyse","title_en":"Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.","published":"2025-11-18"}],"10.1161/circulationaha.125.076575":[{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","title":"DAPA ACT HF-TIMI 68: dapagliflozine bij gehospitaliseerd hartfalen — NEJM","title_en":"Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.","published":"2025-11-18"}],"10.1016/j.jacc.2025.08.012":[{"url":"https://hartvaat.nl/2025/11/18/adipositas-gerelateerde-antropometrie-en-uitkomsten-bij-hfmref-hfpef/","title":"Adipositas-gerelateerde antropometrie en uitkomsten bij HFmrEF/HFpEF","title_en":"Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.","published":"2025-11-18"}],"10.1016/j.jacc.2025.05.008":[{"url":"https://hartvaat.nl/2025/11/18/2025-acc-scientific-statement-obesitasmanagement-bij-hartfalen/","title":"2025 ACC Scientific Statement: obesitasmanagement bij hartfalen","title_en":"2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology.","published":"2025-11-18"}],"https://www.kidney-international.org/article/s0085-2538(25)00877-4/fulltext":[{"url":"https://hartvaat.nl/2025/11/18/monocyten-hun-verdiende-erkenning-geven-cd47-sirp-herkadert-allograaftstoting/","title":"Monocyten hun verdiende erkenning geven: CD47-SIRPα herkadert allograaftstoting","title_en":"Giving monocytes their due: how CD47–SIRP-α reframes allograft rejection","published":"2025-11-18"}],"10.1093/eurheartj/ehaf457":[{"url":"https://hartvaat.nl/2025/11/14/nierfunctietrajecten-voor-en-na-hospitalisatie-voor-hfref/","title":"Nierfunctietrajecten vóór en na hospitalisatie voor HFrEF","title_en":"Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.","published":"2025-11-14"}],"10.1056/nejmoa2505985":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-bij-patienten-zonder-hartfalen-definitieve-trial/","title":"Bètablokkers na MI bij patiënten zonder hartfalen: definitieve trial","title_en":"Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.","published":"2025-11-13"}],"10.1056/nejmoa2504735":[{"url":"https://hartvaat.nl/2025/11/13/betablokkers-na-mi-zonder-gereduceerde-ef-definitieve-meta-analyse/","title":"Bètablokkers na MI zonder gereduceerde EF: definitieve meta-analyse","title_en":"Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.","published":"2025-11-13"}],"10.1016/j.jacc.2025.08.059":[{"url":"https://hartvaat.nl/2025/11/11/risicostratificatie-met-hoog-sensitief-troponine-op-de-seh-veiligheidsanalyse/","title":"Risicostratificatie met hoog-sensitief troponine op de SEH: veiligheidsanalyse","title_en":"Safety of Using Risk Stratification Along With High-Sensitivity Cardiac Troponin in the Emergency Department: A Secondary Analysis.","published":"2025-11-11"}],"10.1001/jama.2025.16189":[{"url":"https://hartvaat.nl/2025/11/11/ffr-geleide-complete-versus-culprit-only-revascularisatie-bij-nstemi/","title":"FFR-geleide complete versus culprit-only revascularisatie bij NSTEMI","title_en":"Fractional Flow Reserve-Guided Complete vs Culprit-Only Revascularization in Non-ST-Elevation Myocardial Infarction and Multivessel Disease: The SLIM Randomized Clinical Trial.","published":"2025-11-11"}],"10.1016/j.jacc.2025.07.060":[{"url":"https://hartvaat.nl/2025/11/11/ct-angiografie-of-standaardzorg-na-pci-van-de-linker-hoofdstam/","title":"CT-angiografie of standaardzorg na PCI van de linker hoofdstam","title_en":"Computed Tomography Angiography or Standard Care After Left Main PCI?","published":"2025-11-11"}],"https://www.ahajournals.org/doi/abs/10.1161/circulationaha.125.077801":[{"url":"https://hartvaat.nl/2025/11/10/hoog-gedoseerd-griepvaccin-vermindert-cardiovasculaire-events-bij-ouderen/","title":"Hoog gedoseerd griepvaccin vermindert cardiovasculaire events bij ouderen","title_en":"High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis","published":"2025-11-10"}],"10.1016/s0140-6736(25)01571-5":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","title":"HOST-REDUCE: DAPT na PCI naar bloedingsrisico","title_en":"Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.","published":"2025-11-08"}],"10.1093/eurheartj/ehaf451":[{"url":"https://hartvaat.nl/2025/11/07/crrf-peaf-cryoballon-versus-rf-ablatie-bij-persisterend-af/","title":"CRRF-PeAF: cryoballon versus RF-ablatie bij persisterend AF","title_en":"Cryoballoon vs radiofrequency ablation in persistent atrial fibrillation: the CRRF-PeAF trial.","published":"2025-11-07"}],"10.1056/nejmoa2511774":[{"url":"https://hartvaat.nl/2025/11/06/orforglipron-voor-obesitasbehandeling-nejm-fase-3/","title":"Orforglipron voor obesitasbehandeling: NEJM fase 3","title_en":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.","published":"2025-11-06"}],"10.1016/j.jacc.2025.08.001":[{"url":"https://hartvaat.nl/2025/11/04/risicobeoordeling-voor-bloeddrukmanagement-begeleidend-document/","title":"Risicobeoordeling voor bloeddrukmanagement: begeleidend document","title_en":"Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.","published":"2025-11-04"}],"10.1016/j.jacc.2025.07.010":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-op-een-blik/","title":"2025 AHA/ACC hypertensierichtlijn op een blik","title_en":"2025 High Blood Pressure Guideline-at-a-Glance.","published":"2025-11-04"}],"10.1016/j.jacc.2025.05.007":[{"url":"https://hartvaat.nl/2025/11/04/2025-aha-acc-hypertensierichtlijn-circulation-editie/","title":"2025 AHA/ACC hypertensierichtlijn: Circulation-editie","title_en":"2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2025-11-04"}],"10.1001/jamacardio.2025.3043":[{"url":"https://hartvaat.nl/2025/11/01/pneumokokkenvaccinatie-en-cv-eventpreventie-ipd-meta-analyse/","title":"Pneumokokkenvaccinatie en CV-eventpreventie: IPD meta-analyse","title_en":"Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial.","published":"2025-11-01"}],"10.1001/jamacardio.2025.3393":[{"url":"https://hartvaat.nl/2025/11/01/abelacimab-bij-af-naar-nierfunctie-veiligheidssubanalyse/","title":"Abelacimab bij AF naar nierfunctie: veiligheidssubanalyse","title_en":"Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.","published":"2025-11-01"}],"10.1001/jamacardio.2025.3337":[{"url":"https://hartvaat.nl/2025/11/01/sbp-en-impella-geassocieerde-overleving-bij-cardiogene-shock/","title":"SBP en Impella-geassocieerde overleving bij cardiogene shock","title_en":"Systolic Blood Pressure and Microaxial Flow Pump-Associated Survival in Infarct-Related Cardiogenic Shock: A Post Hoc Analysis of the DanGer Shock Randomized Clinical Trial.","published":"2025-11-01"}],"10.1001/jamacardio.2025.3099":[{"url":"https://hartvaat.nl/2025/11/01/fysiologisch-geleide-complete-revascularisatie-bij-ouderen-met-mi-driejaarsdata/","title":"Fysiologisch geleide complete revascularisatie bij ouderen met MI: driejaarsdata","title_en":"Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction: Three-Year Outcomes of a Randomized Clinical Trial.","published":"2025-11-01"}],"10.1161/hypertensionaha.125.25129":[{"url":"https://hartvaat.nl/2025/11/01/magnesiumsuppletie-en-bloeddruk-meta-analyse-van-rct-s/","title":"Magnesiumsuppletie en bloeddruk: meta-analyse van RCT's","title_en":"Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","published":"2025-11-01"}],"10.1161/hypertensionaha.125.24854":[{"url":"https://hartvaat.nl/2025/11/01/bloeddrukzelfmanagement-en-vasculaire-remodelling-na-hypertensieve-zwangerschap/","title":"Bloeddrukzelfmanagement en vasculaire remodelling na hypertensieve zwangerschap","title_en":"Impact of Blood Pressure Self-Management on Vascular Remodeling After Hypertensive Pregnancy.","published":"2025-11-01"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01468-6/fulltext":[{"url":"https://hartvaat.nl/2025/11/01/causaal-verband-tussen-mitochondriale-genen-en-carotisplaques-multi-omics-mr-stu/","title":"Causaal verband tussen mitochondriale genen en carotisplaques: multi-omics MR-studie","title_en":"Exploring the causal biological association between mitochondrial genes and carotid plaques: A multiomics Mendelian randomization study","published":"2025-11-01"}],"10.1093/europace/euaf281":[{"url":"https://hartvaat.nl/2025/10/31/vrouwen-met-persisterend-af-pvi-alleen-is-onvoldoende/","title":"Vrouwen met persisterend AF: PVI alleen is onvoldoende","title_en":"Women with persistent atrial fibrillation need more than pulmonary vein isolation: personalised extra-pulmonary vein ablation strategy vs. pulmonary vein isolation alone in the TAILORED-AF trial.","published":"2025-10-31"}],"10.1093/europace/euaf242":[{"url":"https://hartvaat.nl/2025/10/31/pfa-versus-thermale-ablatie-periprocedurale-en-middellangetermijneffecten/","title":"PFA versus thermale ablatie: periprocedurale en middellangetermijneffecten","title_en":"Peri-procedure and Mid-Long Term Effects of Pulsed Field Ablation vs. Thermal Ablation (Cryo- or Radiofrequency) on Autonomic Nervous System Function in Atrial Fibrillation: A Systematic and Quantitative Pooled-Analysis with Potential Implications for Patient Selection (The PULSE-COLD-HEAT-ANS Collaboration).","published":"2025-10-31"}],"10.1093/europace/euaf232":[{"url":"https://hartvaat.nl/2025/10/31/herhaalde-in-situ-ablatie-versus-uitgebreide-ablatie-bij-recidief-persisterend-a/","title":"Herhaalde in-situ ablatie versus uitgebreide ablatie bij recidief persisterend AF","title_en":"Repeat in situ ablation vs. extensive ablation for recurrent persistent atrial fibrillation.","published":"2025-10-31"}],"10.1136/heartjnl-2024-325429":[{"url":"https://hartvaat.nl/2025/10/29/cannabis-en-cardiovasculair-risico-systematische-review-en-meta-analyse/","title":"Cannabis en cardiovasculair risico: systematische review en meta-analyse","title_en":"Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis.","published":"2025-10-29"}],"10.1016/j.jacc.2025.07.037":[{"url":"https://hartvaat.nl/2025/10/28/prevent-vergelijkingen-voor-intensieve-versus-standaard-bloeddrukcontrole/","title":"PREVENT-vergelijkingen voor intensieve versus standaard bloeddrukcontrole","title_en":"Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT.","published":"2025-10-28"}],"10.1016/j.jacc.2025.06.045":[{"url":"https://hartvaat.nl/2025/10/28/step-6-jaarsresultaten-intensieve-bloeddrukcontrole-bij-ouderen-langetermijn/","title":"STEP 6-jaarsresultaten: intensieve bloeddrukcontrole bij ouderen — langetermijn","title_en":"Intensive Blood Pressure Control in Older Patients With Hypertension: 6-Year Results of the STEP Trial.","published":"2025-10-28"}],"10.1016/j.jacc.2025.06.010":[{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","title":"ESPRIT: bescheiden effecten van intensieve bloeddrukverlaging op kwaliteit van leven","title_en":"Modest Effects of Intensive Blood Pressure-Lowering on Quality of Life in Patients at High Cardiovascular Risk: The ESPRIT Trial.","published":"2025-10-28"}],"10.1016/j.jacc.2025.05.020":[{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","title":"ESPRIT: intensieve bloeddrukverlaging en retinale microvasculatuur","title_en":"Effect of Intensive Blood Pressure Lowering Treatment on Retinal Microvasculature: Secondary Analysis From ESPRIT.","published":"2025-10-28"}],"10.1001/jama.2025.15405":[{"url":"https://hartvaat.nl/2025/10/28/rsv-vaccin-vermindert-cv-hospitalisaties-bij-ouderen/","title":"RSV-vaccin vermindert CV-hospitalisaties bij ouderen","title_en":"Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial.","published":"2025-10-28"}],"10.1016/j.jacc.2025.07.055":[{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukcontrole-en-cva-preventie/","title":"ESPRIT: intensieve bloeddrukcontrole en CVA-preventie","title_en":"Effect of Intensive Blood Pressure Control on Stroke: A Prespecified Secondary Analysis of the ESPRIT Trial.","published":"2025-10-28"}],"10.1161/circulationaha.125.075254":[{"url":"https://hartvaat.nl/2025/10/28/prince-remote-ischemische-preconditionering-en-myocardletsel-bij-niet-cardiale-c/","title":"PRINCE: remote ischemische preconditionering en myocardletsel bij niet-cardiale chirurgie","title_en":"Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial.","published":"2025-10-28"}],"https://www.nejm.org/doi/full/10.1056/nejmoa2512918&rss=currentissue":[{"url":"https://hartvaat.nl/2025/10/28/directe-of-uitgestelde-pci-van-niet-culprit-laesie-bij-myocardinfarct/","title":"Directe of uitgestelde PCI van niet-culprit laesie bij myocardinfarct","title_en":"Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction","published":"2025-10-28"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.125.24825":[{"url":"https://hartvaat.nl/2025/10/27/rol-van-stressresponsief-nr4a2-bij-aldosteron-producerende-celclustervorming/","title":"Rol van stressresponsief NR4A2 bij aldosteron-producerende celclustervorming","title_en":"Role of Stress-Responsive NR4A2 in Aldosterone-Producing Cell Cluster Formation","published":"2025-10-27"}],"https://www.nejm.org/doi/full/10.1056/nejmoa2509766&rss=currentissue":[{"url":"https://hartvaat.nl/2025/10/27/transkatheter-versus-chirurgische-aortaklepvervanging-bij-laagrisicopatienten-na/","title":"Transkatheter versus chirurgische aortaklepvervanging bij laagrisicopatiënten na 7 jaar","title_en":"Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years","published":"2025-10-27"}],"10.1056/nejmoa2508170":[{"url":"https://hartvaat.nl/2025/10/23/sotatercept-bij-pah-binnen-het-eerste-jaar-na-diagnose-stellar-subanalyse/","title":"Sotatercept bij PAH binnen het eerste jaar na diagnose: STELLAR subanalyse","title_en":"Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.","published":"2025-10-23"}],"10.1056/nejmoa2507532":[{"url":"https://hartvaat.nl/2025/10/23/aspirine-bij-chronisch-coronairsyndroom-plus-oac-wel-of-niet/","title":"Aspirine bij chronisch coronairsyndroom plus OAC: wel of niet?","title_en":"Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.","published":"2025-10-23"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01448-0/fulltext":[{"url":"https://hartvaat.nl/2025/10/22/lagere-cardiorespiratoire-fitheid-en-atherosclerose-ondanks-cac-score-nul-scapis/","title":"Lagere cardiorespiratoire fitheid en atherosclerose ondanks CAC-score nul (SCAPIS)","title_en":"Lower cardiorespiratory fitness is associated with coronary artery atherosclerosis in individuals with a zero CAC score – cross-sectional results from SCAPIS","published":"2025-10-22"}],"10.1001/jama.2025.15440":[{"url":"https://hartvaat.nl/2025/10/21/amalfi-remote-screening-voor-asymptomatisch-af-gerandomiseerde-trial/","title":"AMALFI: remote screening voor asymptomatisch AF — gerandomiseerde trial","title_en":"Remote Screening for Asymptomatic Atrial Fibrillation: The AMALFI Randomized Clinical Trial.","published":"2025-10-21"}],"https://www.kidney-international.org/article/s0085-2538(25)00826-9/fulltext":[{"url":"https://hartvaat.nl/2025/10/20/dynamische-controle-van-na-cl-cotransporter-door-wnk1-kinase-bifasische-respons-/","title":"Dynamische controle van Na-Cl-cotransporter door WNK1-kinase: bifasische respons op kalium","title_en":"Dynamic control of Na-Cl cotransporter by kidney-specific with-no-lysine 1 kinase: a biphasic response to K+ via condensate signaling","published":"2025-10-20"}],"https://www.kidney-international.org/article/s0085-2538(25)00785-9/fulltext":[{"url":"https://hartvaat.nl/2025/10/20/gwas-verplaatst-endotheline-naar-vasculaire-gladde-spiercellen-en-bloeddrukregul/","title":"GWAS verplaatst endotheline naar vasculaire gladde spiercellen en bloeddrukregulatie","title_en":"GWAS moves endothelin directly to vascular smooth muscle and blood pressure regulation","published":"2025-10-20"}],"https://www.ahajournals.org/doi/abs/10.1161/hypertensionaha.124.24395":[{"url":"https://hartvaat.nl/2025/10/17/peptidedeformylase-reguleert-aldosteronproductie-via-calbindine-1/","title":"Peptidedeformylase reguleert aldosteronproductie via calbindine 1","title_en":"Peptide Deformylase Regulates Aldosterone Production Through Calbindin 1","published":"2025-10-17"}],"10.1001/jama.2025.14679":[{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","title":"ALONE-AF: langetermijn anticoagulatieonthouding na AF-ablatie — RCT","title_en":"Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial.","published":"2025-10-14"}],"10.1093/eurheartj/ehaf504":[{"url":"https://hartvaat.nl/2025/10/14/ffr-versus-angiografie-voor-pci-begeleiding-ipd-meta-analyse/","title":"FFR versus angiografie voor PCI-begeleiding: IPD meta-analyse","title_en":"Fractional flow reserve vs angiography to guide percutaneous coronary intervention: an individual patient data meta-analysis.","published":"2025-10-14"}],"10.1093/eurheartj/ehaf481":[{"url":"https://hartvaat.nl/2025/10/14/heparine-bij-eerste-medisch-contact-versus-voor-primaire-pci-bij-stemi/","title":"Heparine bij eerste medisch contact versus vóór primaire PCI bij STEMI","title_en":"Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.","published":"2025-10-14"}],"10.1056/nejmoa2507109":[{"url":"https://hartvaat.nl/2025/10/09/baxdrostat-bij-ongecontroleerde-en-resistente-hypertensie-effectiviteit-en-veili/","title":"Baxdrostat bij ongecontroleerde en resistente hypertensie: effectiviteit en veiligheid","title_en":"Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.","published":"2025-10-09"}],"10.1093/europace/euaf236":[{"url":"https://hartvaat.nl/2025/10/07/vroege-substraatablatie-versus-antiaritmica-bij-vt-gerandomiseerde-trial/","title":"Vroege substraatablatie versus antiaritmica bij VT: gerandomiseerde trial","title_en":"Early substrate-based catheter ablation vs. antiarrhythmic drug therapy for ventricular tachyarrhythmias among patients with prior myocardial infarction: the MANTRA-VT randomized trial.","published":"2025-10-07"}],"10.1093/europace/euaf256":[{"url":"https://hartvaat.nl/2025/10/07/atriale-cardiomyopathie-bij-recent-gediagnosticeerd-af-prevalentie-en-ernst/","title":"Atriale cardiomyopathie bij recent gediagnosticeerd AF: prevalentie en ernst","title_en":"Prevalence and severity of atrial cardiomyopathy in patients with recently diagnosed atrial fibrillation and stroke risk factors and its association with early rhythm control: a secondary analysis of EAST-AFNET 4.","published":"2025-10-07"}],"10.1093/europace/euaf234":[{"url":"https://hartvaat.nl/2025/10/07/cti-blok-na-pfa-versus-rf-cryo-ablatie-gerandomiseerde-vergelijking/","title":"CTI-blok na PFA versus RF/cryo-ablatie: gerandomiseerde vergelijking","title_en":"Acute durability of cavotricuspid isthmus block after pulsed electric field ablation: randomized comparison of two pentaspline catheter configurations (SECTION trial).","published":"2025-10-07"}],"10.1161/circulationaha.124.073585":[{"url":"https://hartvaat.nl/2025/10/07/nieuwe-inspanningsherstelpatronen-als-maat-voor-cardiale-prestatie/","title":"Nieuwe inspanningsherstelpatronen als maat voor cardiale prestatie","title_en":"Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.","published":"2025-10-07"}],"10.1016/j.jacc.2025.07.056":[{"url":"https://hartvaat.nl/2025/10/07/obicetrapib-en-mace-bij-hoogrisicopatienten-gepoolde-analyse/","title":"Obicetrapib en MACE bij hoogrisicopatiënten: gepoolde analyse","title_en":"Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.","published":"2025-10-07"}],"10.1001/jama.2025.15047":[{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","title":"HELP-MI: Helicobacter pylori-screening na acuut MI — cluster-RCT","title_en":"Helicobacter pylori Screening After Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI SWEDEHEART Trial.","published":"2025-10-07"}],"10.1093/europace/euaf198":[{"url":"https://hartvaat.nl/2025/10/07/laa-occlusie-bij-terminale-nierziekte-ipd-meta-analyse/","title":"LAA-occlusie bij terminale nierziekte: IPD meta-analyse","title_en":"Left atrial appendage occlusion in patients with end-stage renal disease: an individual patient-level meta-analysis.","published":"2025-10-07"}],"https://www.kidney-international.org/article/s0085-2538(25)00774-4/fulltext":[{"url":"https://hartvaat.nl/2025/10/07/relatie-tussen-obesitas-en-ckd-conclusies-van-een-kdigo-conferentie/","title":"Relatie tussen obesitas en CKD: conclusies van een KDIGO-conferentie","title_en":"The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","published":"2025-10-07"}],"10.1056/nejmoa2509958":[{"url":"https://hartvaat.nl/2025/10/02/thuisgebaseerde-hypertensiezorg-in-ruraal-zuid-afrika-gerandomiseerde-trial/","title":"Thuisgebaseerde hypertensiezorg in ruraal Zuid-Afrika: gerandomiseerde trial","title_en":"Home-Based Care for Hypertension in Rural South Africa.","published":"2025-10-02"}],"10.1056/nejmoa2507227":[{"url":"https://hartvaat.nl/2025/10/02/olezarsen-bij-matige-hypertriglyceridemie-cv-uitkomstpotentieel/","title":"Olezarsen bij matige hypertriglyceridemie: CV-uitkomstpotentieel","title_en":"Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.","published":"2025-10-02"}],"10.1001/jamacardio.2025.2827":[{"url":"https://hartvaat.nl/2025/10/01/gepersonaliseerde-versnelde-pacing-bij-hfpef-klinische-uitkomsten/","title":"Gepersonaliseerde versnelde pacing bij HFpEF: klinische uitkomsten","title_en":"Clinical Outcomes With Personalized Accelerated Physiologic Pacing in Heart Failure With Preserved Ejection Fraction: Follow-up of the myPACE Trial.","published":"2025-10-01"}],"10.1161/hypertensionaha.125.25209":[{"url":"https://hartvaat.nl/2025/10/01/langetermijneffect-van-cacao-extract-op-incident-hypertensie/","title":"Langetermijneffect van cacao-extract op incident hypertensie","title_en":"Long-Term Effect of Cocoa Extract Supplementation on Incident Hypertension.","published":"2025-10-01"}],"10.1161/hyp.0000000000000249":[{"url":"https://hartvaat.nl/2025/10/01/2025-aha-acc-hypertensierichtlijn-jacc-editie/","title":"2025 AHA/ACC hypertensierichtlijn: JACC-editie","title_en":"2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2025-10-01"}],"10.1002/ehf2.15391":[{"url":"https://hartvaat.nl/2025/10/01/piek-vo2-en-prognose-bij-hartfalen-meta-analyse/","title":"Piek-VO2 en prognose bij hartfalen: meta-analyse","title_en":"Prognostic impact of peak oxygen consumption in heart failure: A systematic review and meta-analysis.","published":"2025-10-01"}],"10.1002/ehf2.15380":[{"url":"https://hartvaat.nl/2025/10/01/intra-abdominale-druk-en-pocus-voor-decongestiebegeleiding-bij-hf/","title":"Intra-abdominale druk en POCUS voor decongestiebegeleiding bij HF","title_en":"The role of intra-abdominal pressure and point of care ultrasound to guide decongestive therapies in acute heart failure.","published":"2025-10-01"}],"10.1002/ehf2.15358":[{"url":"https://hartvaat.nl/2025/10/01/ambulante-iv-diurese-bij-chronisch-hf-decongest-inzichten/","title":"Ambulante IV-diurese bij chronisch HF: DECONGEST-inzichten","title_en":"Efficacy of ambulatory intravenous diuresis for chronic heart failure patients: Insights from the DEA-HF trial.","published":"2025-10-01"}],"10.1002/ehf2.15356":[{"url":"https://hartvaat.nl/2025/10/01/dapagliflozine-als-toevoeging-aan-iv-lisdiureticum-bij-acuut-hf-congestieverlich/","title":"Dapagliflozine als toevoeging aan IV-lisdiureticum bij acuut HF: congestieverlichting","title_en":"Pulmonary congestion relief by adding dapagliflozin to intravenous loop diuretic in acute heart failure patients.","published":"2025-10-01"}],"10.1002/ehf2.15341":[{"url":"https://hartvaat.nl/2025/10/01/heart-camp-connect-beweegadherentie-bij-hfpef-patienten/","title":"HEART Camp Connect: beweegadherentie bij HFpEF-patiënten","title_en":"HEART Camp Connect-Promoting adherence to exercise in adults with heart failure with preserved ejection fraction.","published":"2025-10-01"}],"https://www.kidney-international.org/article/s0085-2538(25)00752-5/fulltext":[{"url":"https://hartvaat.nl/2025/09/30/granzyme-k-zet-het-complementsysteem-in-beweging/","title":"Granzyme K zet het complementsysteem in beweging","title_en":"Granzyme K sets complement in motion","published":"2025-09-30"}],"10.1016/s0140-6736(25)01665-4":[{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","title":"VICTOR: vericiguat bij chronisch HFrEF — dubbelblinde fase 3b trial","title_en":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.","published":"2025-09-27"}],"10.1016/s0140-6736(25)01682-4":[{"url":"https://hartvaat.nl/2025/09/27/vericiguat-over-het-risicospectrum-bij-hfref/","title":"Vericiguat over het risicospectrum bij HFrEF","title_en":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.","published":"2025-09-27"}],"10.1056/nejmoa2415471":[{"url":"https://hartvaat.nl/2025/09/25/digitoxine-bij-hfref-gerandomiseerde-trial-nejm/","title":"Digitoxine bij HFrEF: gerandomiseerde trial — NEJM","title_en":"Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.","published":"2025-09-25"}],"10.1136/heartjnl-2024-325431":[{"url":"https://hartvaat.nl/2025/09/25/cardiale-cachexie-en-uitkomsten-bij-hartfalen-meta-analyse/","title":"Cardiale cachexie en uitkomsten bij hartfalen: meta-analyse","title_en":"Association between cardiac cachexia and adverse outcomes in patients with heart failure: a meta-analysis of cohort studies.","published":"2025-09-25"}],"10.1016/j.jacc.2025.07.027":[{"url":"https://hartvaat.nl/2025/09/23/intensief-versus-conventioneel-intraoperatief-bloeddrukmanagement-en-cv-events-n/","title":"Intensief versus conventioneel intraoperatief bloeddrukmanagement en CV-events na chirurgie","title_en":"Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial.","published":"2025-09-23"}],"10.1161/circulationaha.125.073591":[{"url":"https://hartvaat.nl/2025/09/23/pci-versus-cabg-en-gezondheidsstatus-bij-stabiel-coronairlijden/","title":"PCI versus CABG en gezondheidsstatus bij stabiel coronairlijden","title_en":"Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.","published":"2025-09-23"}],"10.1016/s0140-6736(25)01633-2":[{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","title":"NEWTON-CABG: evolocumab en veneuze graftpatency na CABG","title_en":"Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.","published":"2025-09-20"}],"10.1056/nejmoa2505669":[{"url":"https://hartvaat.nl/2025/09/18/orforglipron-bij-vroeg-type-2-diabetes-nejm-fase-3/","title":"Orforglipron bij vroeg type 2 diabetes: NEJM fase 3","title_en":"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.","published":"2025-09-18"}],"10.1016/j.jacc.2025.06.044":[{"url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","title":"ISCHEMIA: anginatrajecten na invasieve versus conservatieve strategie","title_en":"Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.","published":"2025-09-16"}],"10.1161/cir.0000000000001355":[{"url":"https://hartvaat.nl/2025/09/16/risicobeoordeling-voor-bloeddrukmanagement-bij-primaire-preventie/","title":"Risicobeoordeling voor bloeddrukmanagement bij primaire preventie","title_en":"Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.","published":"2025-09-16"}],"10.1161/cir.0000000000001356":[{"url":"https://hartvaat.nl/2025/09/16/2025-aha-acc-hypertensierichtlijn-preventie-detectie-en-management/","title":"2025 AHA/ACC hypertensierichtlijn: preventie, detectie en management","title_en":"2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2025-09-16"}],"https://www.kidney-international.org/article/s0085-2538(25)00692-1/fulltext":[{"url":"https://hartvaat.nl/2025/09/16/causale-inferentie-via-regressiediscontinuiteit-lessen-uit-de-gordelroosvaccinat/","title":"Causale inferentie via regressiediscontinuïteit: lessen uit de gordelroosvaccinatie","title_en":"Causal inference using regression discontinuity analysis: what can the nephrologist learn from herpes zoster vaccination?","published":"2025-09-16"}],"10.1016/s0140-6736(25)01592-2":[{"url":"https://hartvaat.nl/2025/09/13/betablokkers-na-mi-met-milde-ef-verlaging-ipd-meta-analyse/","title":"Bètablokkers na MI met milde EF-verlaging: IPD meta-analyse","title_en":"β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.","published":"2025-09-13"}],"10.1056/nejmoa2502799":[{"url":"https://hartvaat.nl/2025/09/11/multidomein-revalidatie-bij-ouderen-na-mi-gerandomiseerde-trial-nejm/","title":"Multidomein revalidatie bij ouderen na MI: gerandomiseerde trial — NEJM","title_en":"Multidomain Rehabilitation for Older Patients with Myocardial Infarction.","published":"2025-09-11"}],"10.1136/heartjnl-2024-325107":[{"url":"https://hartvaat.nl/2025/09/11/ivus-geleide-pci-versus-cabg-langetermijnuitkomsten/","title":"IVUS-geleide PCI versus CABG: langetermijnuitkomsten","title_en":"Long-term outcomes of intravascular ultrasound-guided percutaneous coronary intervention versus coronary artery bypass grafting for multivessel coronary artery disease.","published":"2025-09-11"}],"10.1016/j.jacc.2025.06.052":[{"url":"https://hartvaat.nl/2025/09/09/pathogene-cardiomyopathie-genvarianten-en-prognose-bij-af/","title":"Pathogene cardiomyopathie-genvarianten en prognose bij AF","title_en":"Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.","published":"2025-09-09"}],"10.1016/j.jacc.2025.06.058":[{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","title":"SUMMIT: tirzepatide-effect bij HFpEF met en zonder diabetes","title_en":"Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.","published":"2025-09-09"}],"10.1016/s0140-6736(25)01391-1":[{"url":"https://hartvaat.nl/2025/09/06/voordeel-nadeel-afwegingen-van-intensieve-bloeddrukcontrole/","title":"Voordeel-nadeel afwegingen van intensieve bloeddrukcontrole","title_en":"Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.","published":"2025-09-06"}],"10.1016/s0140-6736(25)01529-6":[{"url":"https://hartvaat.nl/2025/09/06/directe-versus-gestageerde-complete-revascularisatie-tijdens-index-opname-bij-st/","title":"Directe versus gestageerde complete revascularisatie tijdens index-opname bij STEMI","title_en":"Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.","published":"2025-09-06"}],"10.1016/s0140-6736(25)01485-0":[{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","title":"PANDA II: griepvaccinatie bij acuut hartfalen — multicenter RCT","title_en":"Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.","published":"2025-09-06"}],"10.1093/eurheartj/ehaf356":[{"url":"https://hartvaat.nl/2025/09/02/coronaire-flow-capaciteits-geleide-revascularisatie-versus-standaardzorg-rct/","title":"Coronaire flow-capaciteits-geleide revascularisatie versus standaardzorg: RCT","title_en":"Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial.","published":"2025-09-02"}],"10.1093/europace/euaf200":[{"url":"https://hartvaat.nl/2025/09/01/af-en-icd-bij-niet-ischemische-hfref-impliciaties-voor-devicetherapie/","title":"AF en ICD bij niet-ischemische HFrEF: impliciaties voor devicetherapie","title_en":"Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial.","published":"2025-09-01"}],"10.1093/europace/euaf156":[{"url":"https://hartvaat.nl/2025/09/01/sedatie-versus-narcose-bij-af-catheterablatie-meta-analyse/","title":"Sedatie versus narcose bij AF-catheterablatie: meta-analyse","title_en":"Sedation vs. general anaesthesia in patients with atrial fibrillation undergoing catheter ablation: a systematic review and meta-analysis.","published":"2025-09-01"}],"10.1093/europace/euaf205":[{"url":"https://hartvaat.nl/2025/09/01/nierfunctie-en-effectiviteit-van-lva-ablatie-na-pvi-bij-af/","title":"Nierfunctie en effectiviteit van LVA-ablatie na PVI bij AF","title_en":"Impact of renal function on the efficacy of low-voltage area ablation after pulmonary vein isolation: a sub-analysis of the SUPPRESS-AF trial.","published":"2025-09-01"}],"10.1093/europace/euaf206":[{"url":"https://hartvaat.nl/2025/09/01/la-low-voltage-prevalentie-en-voorspellers-bij-paroxysmaal-versus-niet-paroxysma/","title":"LA low-voltage prevalentie en voorspellers bij paroxysmaal versus niet-paroxysmaal AF","title_en":"Prevalence and multiple predictors of left atrial low voltage in paroxysmal and non-paroxysmal atrial fibrillation patients undergoing ablation: a systematic review and meta-analysis.","published":"2025-09-01"}],"10.1093/europace/euaf195":[{"url":"https://hartvaat.nl/2025/09/01/kosteneffectiviteit-van-apixaban-versus-aspirine-bij-hoogrisico-subclinisch-af/","title":"Kosteneffectiviteit van apixaban versus aspirine bij hoogrisico subclinisch AF","title_en":"Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.","published":"2025-09-01"}],"10.1093/europace/euaf192":[{"url":"https://hartvaat.nl/2025/09/01/csp-sync-geleidingssysteempacing-versus-biventriculaire-pacing-voor-crt-rct/","title":"CSP-SYNC: geleidingssysteempacing versus biventriculaire pacing voor CRT — RCT","title_en":"Conduction system pacing vs. biventricular pacing for cardiac resynchronization: the CSP-SYNC randomized single centre study.","published":"2025-09-01"}],"10.1093/europace/euaf190":[{"url":"https://hartvaat.nl/2025/09/01/systematische-af-screening-met-gedetailleerde-fenotypering-en-risicopredictie/","title":"Systematische AF-screening met gedetailleerde fenotypering en risicopredictie","title_en":"Systematic, randomized atrial fibrillation screening using detailed phenotyping with a risk prediction model combined with patch electrocardiogram in a Swedish population aged 65 years or older: the CONSIDERING-AF trial.","published":"2025-09-01"}],"10.1093/europace/euaf175":[{"url":"https://hartvaat.nl/2025/09/01/pvi-met-of-zonder-empirische-svc-isolatie-bij-af-ablatie/","title":"PVI met of zonder empirische SVC-isolatie bij AF-ablatie","title_en":"Pulmonary vein isolation with or without empiric superior vena cava isolation in patients undergoing ablation for paroxysmal atrial fibrillation: the randomized ESVCI-AF trial.","published":"2025-09-01"}],"10.1001/jamacardio.2025.2374":[{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","title":"EAST-AFNET 4: diabetes, obesitas en vroege ritmecontrole bij AF","title_en":"Diabetes and Obesity and Treatment Effect of Early Rhythm Control vs Usual Care in Patients With Atrial Fibrillation: A Secondary Analysis of the EAST-AFNET 4 Randomized Clinical Trial.","published":"2025-09-01"}],"10.1001/jamacardio.2025.2155":[{"url":"https://hartvaat.nl/2025/09/01/medicatietrouw-bij-hypertensie-cluster-gerandomiseerde-trial/","title":"Medicatietrouw bij hypertensie: cluster-gerandomiseerde trial","title_en":"Medication Adherence in Hypertension: A Cluster Randomized Clinical Trial.","published":"2025-09-01"}],"10.1001/jamacardio.2025.1920":[{"url":"https://hartvaat.nl/2025/09/01/preoperatief-cv-risico-en-raas-remmergebruik-postoperatieve-uitkomsten/","title":"Preoperatief CV-risico en RAAS-remmergebruik: postoperatieve uitkomsten","title_en":"Preoperative Cardiovascular Risk and Postoperative Outcomes by Renin-Angiotensin System Inhibitor Use: A Secondary Analysis of a Randomized Clinical Trial.","published":"2025-09-01"}],"10.1161/hypertensionaha.125.25089":[{"url":"https://hartvaat.nl/2025/09/01/veranderde-bloeddrukrefexen-bij-vrouwen-met-endometriose/","title":"Veranderde bloeddrukrefexen bij vrouwen met endometriose","title_en":"Altered Blood Pressure Reflexes in Women With Endometriosis.","published":"2025-09-01"}],"10.1161/hypertensionaha.124.24483":[{"url":"https://hartvaat.nl/2025/09/01/systolische-bloeddrukamplificatie-ipd-meta-analyse/","title":"Systolische bloeddrukamplificatie: IPD meta-analyse","title_en":"Systolic BP Amplification: Systematic Review and Individual Participant Meta-Analysis.","published":"2025-09-01"}],"10.1016/s0140-6736(25)00991-2":[{"url":"https://hartvaat.nl/2025/08/30/bloeddrukverlagende-effectiviteit-van-antihypertensiva-en-combinaties-uitgebreid/","title":"Bloeddrukverlagende effectiviteit van antihypertensiva en combinaties: uitgebreide meta-analyse","title_en":"Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials.","published":"2025-08-30"}],"10.1016/j.jacc.2025.06.042":[{"url":"https://hartvaat.nl/2025/08/26/flavour-langetermijn-ffr-versus-ivus-voor-pci-begeleiding/","title":"FLAVOUR langetermijn: FFR versus IVUS voor PCI-begeleiding","title_en":"Long-Term Outcomes After Fractional Flow Reserve vs Intravascular Ultrasound to Guide PCI: The FLAVOUR Trial Extended Follow-Up.","published":"2025-08-26"}],"10.1016/j.jacc.2025.06.037":[{"url":"https://hartvaat.nl/2025/08/26/hepa-luchtzuivering-en-bloeddruk-pragmatische-cross-over-trial/","title":"HEPA-luchtzuivering en bloeddruk: pragmatische cross-over trial","title_en":"Effect of HEPA Filtration Air Purifiers on Blood Pressure: A Pragmatic Randomized Crossover Trial.","published":"2025-08-26"}],"10.1161/circulationaha.124.073385":[{"url":"https://hartvaat.nl/2025/08/26/minder-zitten-of-meer-staan-effect-op-bloeddruk-en-glucose/","title":"Minder zitten of meer staan: effect op bloeddruk en glucose","title_en":"Impacts of Reducing Sitting Time or Increasing Sit-to-Stand Transitions on Blood Pressure and Glucose Regulation in Postmenopausal Women: Three-Arm Randomized Controlled Trial.","published":"2025-08-26"}],"10.1093/eurheartj/ehaf331":[{"url":"https://hartvaat.nl/2025/08/21/oct-versus-angiografie-bij-pci-van-verkalkte-laesies-driejaarsdata/","title":"OCT versus angiografie bij PCI van verkalkte laesies: driejaarsdata","title_en":"Optical coherence tomography- vs angiography-guided coronary stent implantation in calcified lesions: the ILUMIEN IV trial.","published":"2025-08-21"}],"10.1093/eurheartj/ehaf273":[{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","title":"PREVENT: langetermijn follow-up van preventieve PCI bij kwetsbare plaques","title_en":"Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial.","published":"2025-08-21"}],"10.1016/j.jacc.2025.05.062":[{"url":"https://hartvaat.nl/2025/08/19/paclitaxel-gecoate-ballon-bij-multilayer-in-stent-restenose-agent-ide-subgroep/","title":"Paclitaxel-gecoate ballon bij multilayer in-stent restenose: AGENT IDE subgroep","title_en":"Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis: AGENT IDE Subgroup Analysis.","published":"2025-08-19"}],"10.1016/j.jacc.2025.05.010":[{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","title":"MASTER DAPT: recurrente events analyse van verkorte versus standaard DAPT","title_en":"Recurrent Events Analysis of MASTER DAPT: Total Ischemic and Bleeding Events After Abbreviated vs Prolonged DAPT in HBR Patients.","published":"2025-08-19"}],"10.1016/s0140-6736(25)01198-5":[{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","title":"ACHIEVE: spironolacton bij dialysepatiënten — internationale RCT","title_en":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.","published":"2025-08-16"}],"10.1056/nejmoa2502081":[{"url":"https://hartvaat.nl/2025/08/14/cagrisema-gecombineerd-cagrilintide-en-semaglutide-bij-overgewicht-nejm/","title":"CagriSema: gecombineerd cagrilintide en semaglutide bij overgewicht — NEJM","title_en":"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.","published":"2025-08-14"}],"10.1093/eurheartj/ehaf323":[{"url":"https://hartvaat.nl/2025/08/14/hartfalen-mondiale-economische-ziektelast/","title":"Hartfalen: mondiale economische ziektelast","title_en":"Heart failure: assessment of the global economic burden.","published":"2025-08-14"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01379-6/fulltext":[{"url":"https://hartvaat.nl/2025/08/14/plaque-remodeling-als-surrogaat-voor-ernstige-cardiale-events/","title":"Plaque-remodeling als surrogaat voor ernstige cardiale events","title_en":"Plaque remodelling as a surrogate for major adverse cardiac events","published":"2025-08-14"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01380-2/fulltext":[{"url":"https://hartvaat.nl/2025/08/14/kanttekening-bij-coronaire-plaquefenotypeveranderingen-onder-lipidenverlagende-t/","title":"Kanttekening bij coronaire plaquefenotypeveranderingen onder lipidenverlagende therapie","title_en":"Regarding “Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events”: a compelling hypothesis warranting cautious interpretation","published":"2025-08-14"}],"10.1016/j.jacc.2025.05.060":[{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","title":"COMBINE AF: overstap naar nieuwer anticoagulans versus warfarine bij ouderen","title_en":"Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy.","published":"2025-08-12"}],"10.1136/heartjnl-2024-324668":[{"url":"https://hartvaat.nl/2025/08/12/catheterablatie-versus-rate-control-bij-persisterend-af-en-ouder-hartfalen/","title":"Catheterablatie versus rate control bij persisterend AF en ouder hartfalen","title_en":"Catheter ablation versus medical rate control for persistent atrial fibrillation in older heart failure patients with reduced ejection fraction.","published":"2025-08-12"}],"10.1093/eurheartj/ehaf220":[{"url":"https://hartvaat.nl/2025/08/08/abpm-esc-streefwaarden-en-cv-uitkomsten-ipd-meta-analyse/","title":"ABPM, ESC-streefwaarden en CV-uitkomsten: IPD meta-analyse","title_en":"Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis.","published":"2025-08-08"}],"10.1016/j.jacc.2025.05.033":[{"url":"https://hartvaat.nl/2025/08/05/sglt2-remmer-met-en-zonder-mra-bij-hartfalen-gecombineerde-analyse/","title":"SGLT2-remmer met en zonder MRA bij hartfalen: gecombineerde analyse","title_en":"Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial.","published":"2025-08-05"}],"10.1001/jama.2025.9413":[{"url":"https://hartvaat.nl/2025/08/05/lorundrostat-bij-ongecontroleerde-en-therapieresistente-hypertensie-fase-3-resul/","title":"Lorundrostat bij ongecontroleerde en therapieresistente hypertensie: fase 3 resultaten","title_en":"Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.","published":"2025-08-05"}],"10.1161/circulationaha.125.074037":[{"url":"https://hartvaat.nl/2025/08/05/abelacimab-versus-rivaroxaban-bij-af-op-antiplaatjestherapie-subanalyse/","title":"Abelacimab versus rivaroxaban bij AF op antiplaatjestherapie: subanalyse","title_en":"Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.","published":"2025-08-05"}],"10.1093/europace/euaf181":[{"url":"https://hartvaat.nl/2025/08/04/lbbap-versus-rv-pacing-tweejaarsresultaten-bij-pacemakergeindiceerde-patienten/","title":"LBBAP versus RV-pacing: tweejaarsresultaten bij pacemakergeïndiceerde patiënten","title_en":"Two-year outcomes of left bundle branch area pacing versus traditional right ventricular pacing in middle-aged adults: a registry-based trial.","published":"2025-08-04"}],"10.1093/europace/euaf176":[{"url":"https://hartvaat.nl/2025/08/04/pvi-met-versus-zonder-lineaire-ablatie-bij-persisterend-af-gerandomiseerde-trial/","title":"PVI met versus zonder lineaire ablatie bij persisterend AF: gerandomiseerde trial","title_en":"Circumferential pulmonary vein isolation with adjunctive linear ablation vs. circumferential pulmonary vein isolation alone for long-standing persistent atrial fibrillation: a randomized pilot study.","published":"2025-08-04"}],"10.1093/europace/euaf105":[{"url":"https://hartvaat.nl/2025/08/04/zeer-hoog-vermogen-70w-rf-ablatie-met-flexibele-tip-voor-pvi-bij-af/","title":"Zeer hoog vermogen (70W) RF-ablatie met flexibele tip voor PVI bij AF","title_en":"Very high-power short-duration using 70W and a flexible tip ablation catheter for pulmonary vein isolation: the POWER PULSE randomized controlled trial.","published":"2025-08-04"}],"10.1001/jamacardio.2025.1775":[{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","title":"FINEARTS-HF: finerenon naar frailteit bij hartfalen","title_en":"Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.","published":"2025-08-01"}],"10.1001/jamacardio.2025.1592":[{"url":"https://hartvaat.nl/2025/08/01/cellulaire-adhesiemoleculen-en-uitkomsten-bij-chronisch-hf-dapa-hf-analyse/","title":"Cellulaire adhesiemoleculen en uitkomsten bij chronisch HF: DAPA-HF analyse","title_en":"Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical Trial.","published":"2025-08-01"}],"10.1093/eurheartj/ehaf170":[{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","title":"REDUCE-AMI: bètablokker-interruptie en bloeddruk/hartfrequentie-effecten na MI","title_en":"Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial.","published":"2025-08-01"}],"10.1093/eurheartj/ehae589":[{"url":"https://hartvaat.nl/2025/08/01/biodegradeerbare-versus-duurzame-polymeer-ees-langetermijn-neoatherosclerose/","title":"Biodegradeerbare versus duurzame polymeer EES: langetermijn neoatherosclerose","title_en":"Long-term effect of biodegradable vs. durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial.","published":"2025-08-01"}],"10.1161/hypertensionaha.125.25162":[{"url":"https://hartvaat.nl/2025/08/01/voordeel-en-risico-van-intensieve-bloeddrukcontrole-naar-cv-risico/","title":"Voordeel en risico van intensieve bloeddrukcontrole naar CV-risico","title_en":"Benefit and Harm of Intensive Blood Pressure Control by Cardiovascular Risk.","published":"2025-08-01"}],"10.1161/hypertensionaha.124.24523":[{"url":"https://hartvaat.nl/2025/08/01/ctrh-als-biomarker-voor-medicijneffectiviteit-real-world-bewijs/","title":"CTRH als biomarker voor medicijneffectiviteit: real-world bewijs","title_en":"CTRH as Biomarker of Drug Efficacy: In-Depth Assessment of Real-World Evidence.","published":"2025-08-01"}],"10.1161/hypertensionaha.125.24749":[{"url":"https://hartvaat.nl/2025/08/01/sympathische-overactiviteit-bij-resistente-hypertensie-meta-analyse/","title":"Sympathische overactiviteit bij resistente hypertensie: meta-analyse","title_en":"Sympathetic Overactivation in the Resistant Hypertensive Phenotype: A Meta-Analysis of Published Studies.","published":"2025-08-01"}],"10.1002/ehf2.15315":[{"url":"https://hartvaat.nl/2025/08/01/lipideparameters-en-prognose-bij-hartfalen-meta-analyse/","title":"Lipideparameters en prognose bij hartfalen: meta-analyse","title_en":"Prognostic value of lipid parameters among patients with heart failure: A systematic review and meta-analysis.","published":"2025-08-01"}],"10.1002/ehf2.15326":[{"url":"https://hartvaat.nl/2025/08/01/nt-probnp-veranderingen-en-klinische-uitkomsten-bij-pediatrisch-hartfalen/","title":"NT-proBNP-veranderingen en klinische uitkomsten bij pediatrisch hartfalen","title_en":"Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF.","published":"2025-08-01"}],"10.1002/ehf2.15302":[{"url":"https://hartvaat.nl/2025/08/01/linkeratriale-strain-en-prognose-bij-acuut-en-chronisch-hartfalen-meta-analyse/","title":"Linkeratriale strain en prognose bij acuut en chronisch hartfalen: meta-analyse","title_en":"Prognostic value of left atrial strain in acute and chronic heart failure: A meta-analysis.","published":"2025-08-01"}],"10.1002/ehf2.15303":[{"url":"https://hartvaat.nl/2025/08/01/tricuspidalisinsufficientie-en-hartfalenuitkomsten-meta-analyse/","title":"Tricuspidalisinsufficiëntie en hartfalenuitkomsten: meta-analyse","title_en":"Association between tricuspid regurgitation and heart failure outcomes: A meta-analysis.","published":"2025-08-01"}],"10.1002/ehf2.15300":[{"url":"https://hartvaat.nl/2025/08/01/opnameduur-en-eerdere-hf-opnames-bij-frailteit-en-hartfalen-systematische-review/","title":"Opnameduur en eerdere HF-opnames bij frailteit en hartfalen: systematische review","title_en":"Length of stay and prior heart failure admission in frailty and heart failure: A systematic review and meta-analysis.","published":"2025-08-01"}],"10.1002/ehf2.15275":[{"url":"https://hartvaat.nl/2025/08/01/vroege-diuretische-respons-en-uitkomstvoorspelling-bij-ambulant-verslechterend-h/","title":"Vroege diuretische respons en uitkomstvoorspelling bij ambulant verslechterend HF","title_en":"Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis.","published":"2025-08-01"}],"10.1002/ehf2.15256":[{"url":"https://hartvaat.nl/2025/08/01/inspanningsmodaliteiten-en-fysieke-functie-bij-hfpef-meta-analyse/","title":"Inspanningsmodaliteiten en fysieke functie bij HFpEF: meta-analyse","title_en":"Effects of exercise modalities on physical function and quality of life in patients with heart failure: A systematic review and network meta-analysis.","published":"2025-08-01"}],"10.1016/j.jacc.2025.04.059":[{"url":"https://hartvaat.nl/2025/07/29/summit-bmi-centrale-adipositas-en-gewichtsverlies-beinvloeden-tirzepatide-effect/","title":"SUMMIT: BMI, centrale adipositas en gewichtsverlies beïnvloeden tirzepatide-effect bij HFpEF","title_en":"Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.","published":"2025-07-29"}],"10.1136/heartjnl-2024-325104":[{"url":"https://hartvaat.nl/2025/07/28/ascot-legacy-atorvastatine-verlaagt-cv-events-over-20-jaar/","title":"ASCOT-Legacy: atorvastatine verlaagt CV-events over 20 jaar","title_en":"Long-term benefits of atorvastatin on the incidence of cardiovascular events: the ASCOT-Legacy 20-year follow-up.","published":"2025-07-28"}],"10.1136/heartjnl-2024-325254":[{"url":"https://hartvaat.nl/2025/07/28/routine-invasieve-strategie-en-herinfarctrisico-bij-fragiele-ouderen-met-nste-ac/","title":"Routine invasieve strategie en herinfarctrisico bij fragiele ouderen met NSTE-ACS","title_en":"Effects of routine invasive management on reinfarction risk in older adults with frailty and non-ST-segment elevation myocardial infarction: a subanalysis of a randomised clinical trial.","published":"2025-07-28"}],"10.1016/j.jacc.2025.04.049":[{"url":"https://hartvaat.nl/2025/07/22/victorion-initiate-inclisiran-monotherapie-bij-patienten-zonder-ascvd/","title":"VICTORION-INITIATE: inclisiran monotherapie bij patiënten zonder ASCVD","title_en":"Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial.","published":"2025-07-22"}],"10.1161/circulationaha.125.074427":[{"url":"https://hartvaat.nl/2025/07/22/cooperative-pfa-driearmige-gerandomiseerde-trial-van-pfa-versus-rf-versus-cryo/","title":"COOPERATIVE-PFA: driearmige gerandomiseerde trial van PFA versus RF versus cryo","title_en":"COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial.","published":"2025-07-22"}],"10.1093/eurheartj/ehaf352":[{"url":"https://hartvaat.nl/2025/07/21/antitrombotische-middelen-bij-acs-bij-vrouwen-seksegecorrigeerde-behandeling/","title":"Antitrombotische middelen bij ACS bij vrouwen: seksegecorrigeerde behandeling","title_en":"Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.","published":"2025-07-21"}],"10.1016/j.jacc.2025.05.019":[{"url":"https://hartvaat.nl/2025/07/15/oct-gebaseerde-post-pci-fysiologiebeoordeling-voorspelt-klinische-uitkomsten/","title":"OCT-gebaseerde post-PCI fysiologiebeoordeling voorspelt klinische uitkomsten","title_en":"Impact of Optical Coherence Tomography-Based Post-PCI Physiology Assessment to Predict Clinical Outcomes: An ILUMIEN-IV Substudy.","published":"2025-07-15"}],"10.1016/j.jacc.2025.05.012":[{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","title":"SORT OUT XI: biomatrix versus duale-therapie sirolimus-eluting stent bij PCI","title_en":"Biolimus-Eluting Biomatrix Stent vs a Dual-Therapy Sirolimus-Eluting Stent in PCI: The SORT OUT XI Randomized Trial.","published":"2025-07-15"}],"10.1016/j.jacc.2025.05.013":[{"url":"https://hartvaat.nl/2025/07/15/complete-versus-culprit-only-revascularisatie-bij-stemi-tienjaarsresultaten/","title":"Complete versus culprit-only revascularisatie bij STEMI: tienjaarsresultaten","title_en":"10-Year Outcome of Complete or Infarct Artery-Only Revascularization in STEMI With Multivessel Disease: The DANAMI-3-PRIMULTI Study.","published":"2025-07-15"}],"10.1093/eurheartj/ehaf291":[{"url":"https://hartvaat.nl/2025/07/14/hartfrequentieverlagende-middelen-en-uitkomsten-bij-hypertensie-cvd-meta-analyse/","title":"Hartfrequentieverlagende middelen en uitkomsten bij hypertensie/CVD: meta-analyse","title_en":"Heart rate-lowering drugs and outcomes in hypertension and/or cardiovascular disease: a meta-analysis.","published":"2025-07-14"}],"10.1136/heartjnl-2024-324505":[{"url":"https://hartvaat.nl/2025/07/14/depressietrajecten-bij-hfpef-impact-op-uitkomsten/","title":"Depressietrajecten bij HFpEF: impact op uitkomsten","title_en":"Influence of depression trajectories in heart failure patients with preserved ejection fractions: a secondary analysis of adverse outcomes in the TOPCAT trial.","published":"2025-07-14"}],"10.1016/s0140-6736(25)01185-7":[{"url":"https://hartvaat.nl/2025/07/12/amycretine-fase-2-subcutaan-toegediend-bij-obesitas/","title":"Amycretine fase 2: subcutaan toegediend bij obesitas","title_en":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.","published":"2025-07-12"}],"10.1016/s0140-6736(25)01176-6":[{"url":"https://hartvaat.nl/2025/07/12/amycretine-eerste-glp-1-amyline-agonist-fase-1-veiligheid-en-farmacologie/","title":"Amycretine: eerste GLP-1/amyline-agonist — fase 1 veiligheid en farmacologie","title_en":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.","published":"2025-07-12"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01331-0/fulltext":[{"url":"https://hartvaat.nl/2025/07/09/coronaire-plaquefenotypeveranderingen-bij-lipidenverlagende-therapie-en-cardiova/","title":"Coronaire plaquefenotypeveranderingen bij lipidenverlagende therapie en cardiovasculaire events","title_en":"Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events: a systematic review and meta-regression analysis","published":"2025-07-09"}],"10.1016/j.jacc.2025.03.535":[{"url":"https://hartvaat.nl/2025/07/08/amulet-versus-watchman-flx-driejaarsresultaten-laa-sluiting/","title":"Amulet versus Watchman FLX: driejaarsresultaten LAA-sluiting","title_en":"3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial.","published":"2025-07-08"}],"10.1016/j.jacc.2025.04.042":[{"url":"https://hartvaat.nl/2025/07/08/catheterablatie-versus-leefstijlmodificatie-plus-antiaritmica-bij-af-gerandomise/","title":"Catheterablatie versus leefstijlmodificatie plus antiaritmica bij AF: gerandomiseerde trial","title_en":"Catheter Ablation vs Lifestyle Modification With Antiarrhythmic Drugs to Treat Atrial Fibrillation: PRAGUE-25 Trial.","published":"2025-07-08"}],"10.1093/eurheartj/ehaf210":[{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-cv-preventie-meta-analyse-van-alle-trials/","title":"Colchicine voor secundaire CV-preventie: meta-analyse van alle trials","title_en":"Colchicine for secondary prevention of vascular events: a meta-analysis of trials.","published":"2025-07-07"}],"10.1093/eurheartj/ehaf174":[{"url":"https://hartvaat.nl/2025/07/07/colchicine-voor-secundaire-vasculaire-preventie-meta-analyse-van-lange-trials/","title":"Colchicine voor secundaire vasculaire preventie: meta-analyse van lange trials","title_en":"Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis.","published":"2025-07-07"}],"10.1016/s0140-6736(25)00439-8":[{"url":"https://hartvaat.nl/2025/07/05/optimale-timing-van-anticoagulatie-na-ischemisch-cva-en-af-collaboratief-project/","title":"Optimale timing van anticoagulatie na ischemisch CVA en AF: collaboratief project","title_en":"Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST).","published":"2025-07-05"}],"10.1056/nejmoa2415820":[{"url":"https://hartvaat.nl/2025/07/03/obicetrapib-bij-hoog-cv-risico-veiligheid-en-effectiviteit-fase-3/","title":"Obicetrapib bij hoog CV-risico: veiligheid en effectiviteit — fase 3","title_en":"Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.","published":"2025-07-03"}],"10.1093/europace/euaf106":[{"url":"https://hartvaat.nl/2025/07/01/geleidingssysteempacing-versus-biventriculaire-pacing-bij-av-blok-vergelijkende-/","title":"Geleidingssysteempacing versus biventriculaire pacing bij AV-blok: vergelijkende analyse","title_en":"A comparative analysis of conduction system pacing and biventricular pacing in patients undergoing atrioventricular node ablation: a systematic review and meta-analysis.","published":"2025-07-01"}],"10.1016/j.jacc.2025.04.062":[{"url":"https://hartvaat.nl/2025/07/01/danger-shock-hemodynamische-effecten-van-impella-bij-stemi-en-cardiogene-shock/","title":"DanGer Shock: hemodynamische effecten van Impella bij STEMI en cardiogene shock","title_en":"Effect of Microaxial Flow Pump on Hemodynamics in STEMI-Related Cardiogenic Shock.","published":"2025-07-01"}],"10.1093/europace/euaf129":[{"url":"https://hartvaat.nl/2025/07/01/ventriculaire-aritmieen-na-lvad-implantatie-meta-analyse/","title":"Ventriculaire aritmieën na LVAD-implantatie: meta-analyse","title_en":"Ventricular arrhythmias following left ventricular assist device implantation: a systematic review and meta-analysis of incidence and clinical impact.","published":"2025-07-01"}],"10.1001/jama.2025.6681":[{"url":"https://hartvaat.nl/2025/07/01/kardia-2-zilebesiran-als-toevoeging-bij-ongecontroleerde-hypertensie-rct/","title":"KARDIA-2: zilebesiran als toevoeging bij ongecontroleerde hypertensie — RCT","title_en":"Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.","published":"2025-07-01"}],"10.1001/jamacardio.2025.1101":[{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","title":"FINEARTS-HF: finerenon bij hartfalen met verbeterde ejectiefractie","title_en":"Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.","published":"2025-07-01"}],"10.1001/jamacardio.2025.0741":[{"url":"https://hartvaat.nl/2025/07/01/calcified-oct-versus-angiografie-bij-pci-van-verkalkte-laesies/","title":"CALCIFIED: OCT versus angiografie bij PCI van verkalkte laesies","title_en":"OCT vs Angiography for Guidance of Percutaneous Coronary Intervention of Calcified Lesions: The CALIPSO Randomized Clinical Trial.","published":"2025-07-01"}],"10.1001/jamacardio.2025.0675":[{"url":"https://hartvaat.nl/2025/07/01/touch-seh-educatie-en-mhealth-voor-hypertensie-gerandomiseerde-trial/","title":"TOUCH: SEH-educatie en mHealth voor hypertensie — gerandomiseerde trial","title_en":"Emergency Department-Based Education and mHealth Empowerment Intervention for Hypertension: The TOUCHED Randomized Clinical Trial.","published":"2025-07-01"}],"10.1001/jamacardio.2025.0871":[{"url":"https://hartvaat.nl/2025/07/01/bestaande-cv-data-benutten-voor-hypertensiedetectie-en-behandeling-vital-trial/","title":"Bestaande CV-data benutten voor hypertensiedetectie en -behandeling: VITAL-trial","title_en":"Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial.","published":"2025-07-01"}],"10.1001/jamacardio.2025.0860":[{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","title":"FINEARTS-HF: modus van overlijden bij HFmrEF/HFpEF","title_en":"Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.","published":"2025-07-01"}],"10.1001/jamacardio.2025.0848":[{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","title":"FINEARTS-HF: finerenon en atriumfibrilleren bij hartfalen","title_en":"Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.","published":"2025-07-01"}],"10.1093/eurheartj/ehaf057":[{"url":"https://hartvaat.nl/2025/07/01/centrale-adipositas-bijna-universeel-bij-hfpef-fenotypering/","title":"Centrale adipositas bijna universeel bij HFpEF: fenotypering","title_en":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.","published":"2025-07-01"}],"10.1161/hypertensionaha.124.24472":[{"url":"https://hartvaat.nl/2025/07/01/cardiale-structuur-en-functie-bij-hypertensieve-zwangerschapsstoornissen-systema/","title":"Cardiale structuur en functie bij hypertensieve zwangerschapsstoornissen: systematische review","title_en":"Cardiac Structure, Function and Mechanics in Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis.","published":"2025-07-01"}],"10.1161/circulationaha.124.073233":[{"url":"https://hartvaat.nl/2025/06/24/inclisiran-bij-adolescenten-met-homozygote-fh-effectiviteit-en-veiligheid/","title":"Inclisiran bij adolescenten met homozygote FH: effectiviteit en veiligheid","title_en":"Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.","published":"2025-06-24"}],"10.1016/j.jacc.2025.04.018":[{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","title":"AZALEA-TIMI 71: langwerkende factor XI-remmer en periprocedurale bloedingen","title_en":"Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71.","published":"2025-06-17"}],"10.1001/jama.2025.5129":[{"url":"https://hartvaat.nl/2025/06/17/spironolacton-versus-amiloride-bij-resistente-hypertensie-gerandomiseerde-trial/","title":"Spironolacton versus amiloride bij resistente hypertensie: gerandomiseerde trial","title_en":"Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.","published":"2025-06-17"}],"10.1001/jama.2025.4390":[{"url":"https://hartvaat.nl/2025/06/17/bedmed-timing-van-antihypertensieve-medicatie-en-cv-events-jama-definitieve-tria/","title":"BedMed: timing van antihypertensieve medicatie en CV-events — JAMA definitieve trial","title_en":"Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial.","published":"2025-06-17"}],"10.1136/heartjnl-2024-324908":[{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","title":"IRONMAN: leeftijdgestratificeerde effecten van IV-ijzer bij HF","title_en":"Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial.","published":"2025-06-13"}],"10.1136/heartjnl-2024-324360":[{"url":"https://hartvaat.nl/2025/06/13/frailteit-en-intensieve-bloeddrukcontrole-bij-diabetes/","title":"Frailteit en intensieve bloeddrukcontrole bij diabetes","title_en":"The Impact of frailty on the effectiveness of intensive blood pressure control for patients with type 2 diabetes: a secondary analysis of a randomised controlled trial.","published":"2025-06-13"}],"https://www.atherosclerosis-journal.com/article/s0021-9150(25)01303-6/fulltext":[{"url":"https://hartvaat.nl/2025/06/13/griepvaccinatie-en-cardiovasculaire-bescherming-inflammatie-heroverwogen-bij-isc/","title":"Griepvaccinatie en cardiovasculaire bescherming: inflammatie heroverwogen bij ischemische hartziekte","title_en":"The flu shot and cardiovascular Protection: Rethinking inflammation in ischemic heart disease","published":"2025-06-13"}],"10.1001/jama.2025.3833":[{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","title":"FAIR-HF2: IV ferricarboxymaltose bij hartfalen met ijzerdeficiëntie — definitieve RCT","title_en":"Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial.","published":"2025-06-10"}],"10.1161/circulationaha.125.074536":[{"url":"https://hartvaat.nl/2025/06/10/triluminate-tweejaarsresultaten-transcatheter-tr-repair-duurzaam-effectief/","title":"TRILUMINATE tweejaarsresultaten: transcatheter TR-repair duurzaam effectief","title_en":"Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial.","published":"2025-06-10"}],"10.1161/circulationaha.125.074545":[{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","title":"SOUL: oraal semaglutide CV-voordeel naar SGLT2i-gebruik","title_en":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.","published":"2025-06-10"}],"10.1016/j.jacc.2024.11.009":[{"url":"https://hartvaat.nl/2025/06/10/2025-acc-aha-acs-richtlijn-jacc-editie/","title":"2025 ACC/AHA ACS-richtlijn: JACC-editie","title_en":"2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2025-06-10"}],"10.1093/eurheartj/ehaf135":[{"url":"https://hartvaat.nl/2025/06/09/remote-ischemische-preconditionering-en-nierschade-na-coronairangiografie/","title":"Remote ischemische preconditionering en nierschade na coronairangiografie","title_en":"Remote ischaemic pre-conditioning, kidney injury, and outcomes after coronary angiography and intervention: a randomized trial.","published":"2025-06-09"}],"10.1093/eurheartj/ehaf098":[{"url":"https://hartvaat.nl/2025/06/09/tino-stents-versus-des-bij-acs-ipd-meta-analyse/","title":"TiNO-stents versus DES bij ACS: IPD meta-analyse","title_en":"Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis.","published":"2025-06-09"}],"10.1093/europace/euaf110":[{"url":"https://hartvaat.nl/2025/06/03/af-ablatie-timing-naar-af-duur-impact-op-aritmierecidief/","title":"AF-ablatie timing naar AF-duur: impact op aritmierecidief","title_en":"Impact of catheter ablation timing according to duration of atrial fibrillation history on arrhythmia recurrences and clinical outcomes: a meta-analysis.","published":"2025-06-03"}],"10.1016/j.jacc.2025.03.499":[{"url":"https://hartvaat.nl/2025/06/03/pursuit-orale-pcsk9-remmer-voor-hypercholesterolemie-gerandomiseerde-trial/","title":"PURSUIT: orale PCSK9-remmer voor hypercholesterolemie — gerandomiseerde trial","title_en":"An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial.","published":"2025-06-03"}],"10.1093/europace/euaf070":[{"url":"https://hartvaat.nl/2025/06/03/multipoint-pacing-vermindert-hf-hospitalisaties-en-sterfte-bij-crt-non-responder/","title":"Multipoint pacing vermindert HF-hospitalisaties en sterfte bij CRT-non-responders","title_en":"Multipoint pacing is associated with reduction of heart failure hospitalizations or death in patients who do not respond to cardiac resynchronization therapy: results of the MORE-CRT MPP randomized trial.","published":"2025-06-03"}],"10.1001/jamacardio.2025.0277":[{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","title":"OCEANIC-AF: asundexian naar eerder OAC-gebruik","title_en":"Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.","published":"2025-06-01"}],"10.1001/jamacardio.2025.0103":[{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","title":"HuMAIN-HFpEF: nieuwe metabole accelerator bij obesitas-HFpEF — RCT","title_en":"Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial.","published":"2025-06-01"}],"10.1001/jamacardio.2025.0095":[{"url":"https://hartvaat.nl/2025/06/01/ffr-geleide-pci-versus-cabg-bij-diffuus-coronairlijden/","title":"FFR-geleide PCI versus CABG bij diffuus coronairlijden","title_en":"FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes.","published":"2025-06-01"}],"10.1001/jamacardio.2025.0025":[{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","title":"FINEARTS-HF: finerenon en PREDICT-HFpEF risicoscore","title_en":"Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF.","published":"2025-06-01"}],"10.1161/hypertensionaha.124.24816":[{"url":"https://hartvaat.nl/2025/06/01/bloeddrukcontrole-en-arteriele-stijfheidsmechanismen-in-sprint/","title":"Bloeddrukcontrole en arteriële stijfheidsmechanismen in SPRINT","title_en":"Effects of Blood Pressure Control on Arterial Stiffness Mechanisms in SPRINT: A Randomized Controlled Trial.","published":"2025-06-01"}],"10.1002/ehf2.15228":[{"url":"https://hartvaat.nl/2025/06/01/seksegerelateerde-pathofysiologie-voor-hfpef-symptomen/","title":"Seksegerelateerde pathofysiologie vóór HFpEF-symptomen","title_en":"Sex-related pathophysiological mechanisms may be present before symptoms of HFpEF develop.","published":"2025-06-01"}],"10.1002/ehf2.15156":[{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","title":"STRONG-HF: socio-economische status beïnvloedt GDMT-effect niet","title_en":"Socio-economic status and the effect of guideline-directed medical therapy in the STRONG-HF study.","published":"2025-06-01"}],"10.1002/ehf2.15225":[{"url":"https://hartvaat.nl/2025/06/01/trainingseffect-op-diastolische-functie-bij-hfpef/","title":"Trainingseffect op diastolische functie bij HFpEF","title_en":"Training-induced change of diastolic function in heart failure with preserved ejection fraction.","published":"2025-06-01"}],"10.1002/ehf2.15235":[{"url":"https://hartvaat.nl/2025/06/01/steroidstoot-bij-acuut-hartfalen-kwaliteit-van-leven-cortahf-inzichten/","title":"Steroïdstoot bij acuut hartfalen: kwaliteit van leven — CORTAHF inzichten","title_en":"Burst steroid therapy and quality of life in patients with acute heart failure: Insights from the CORTAHF trial.","published":"2025-06-01"}],"10.1002/ehf2.15236":[{"url":"https://hartvaat.nl/2025/06/01/rv-disfunctie-voorspelt-langetermijnherstel-bij-de-novo-hfref-prolong-ii/","title":"RV-disfunctie voorspelt langetermijnherstel bij de novo HFrEF: PROLONG-II","title_en":"Right ventricular dysfunction for prediction of long-term recovery in de novo HFrEF : a PROLONG-II substudy.","published":"2025-06-01"}],"10.1002/ehf2.15212":[{"url":"https://hartvaat.nl/2025/06/01/dapagliflozine-bij-acuut-gedecompenseerd-hartfalen-en-nierfunctie-rct/","title":"Dapagliflozine bij acuut gedecompenseerd hartfalen en nierfunctie: RCT","title_en":"Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure.","published":"2025-06-01"}],"10.1002/ehf2.15232":[{"url":"https://hartvaat.nl/2025/06/01/egfr-en-incident-hartfalen-bij-intensieve-bloeddrukbehandeling/","title":"eGFR en incident hartfalen bij intensieve bloeddrukbehandeling","title_en":"Association of baseline eGFR and incident heart failure on patients receiving intensive blood pressure treatment.","published":"2025-06-01"}],"10.1002/ehf2.15222":[{"url":"https://hartvaat.nl/2025/06/01/cardiale-myosinebindend-eiwit-c-en-troponine-i-tijdens-inspanningstraining-bij-h/","title":"Cardiale myosinebindend eiwit C en troponine I tijdens inspanningstraining bij HF","title_en":"Cardiac myosin binding protein C correlate with cardiac troponin I during an exercise training program in patients with HFrEF.","published":"2025-06-01"}],"10.1002/ehf2.15184":[{"url":"https://hartvaat.nl/2025/06/01/nierfunctie-en-dapagliflozine-effect-op-gezondheidsstatus-define-hf/","title":"Nierfunctie en dapagliflozine-effect op gezondheidsstatus: DEFINE-HF","title_en":"Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF.","published":"2025-06-01"}],"10.1056/nejmoa2501006":[{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","title":"SOUL: oraal semaglutide en CV-uitkomsten bij hoogrisico type 2 diabetes — NEJM","title_en":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.","published":"2025-05-29"}],"10.1016/j.jacc.2025.03.477":[{"url":"https://hartvaat.nl/2025/05/27/vutrisiran-bij-attr-cm-impact-van-hartfalenernst-op-effectiviteit/","title":"Vutrisiran bij ATTR-CM: impact van hartfalenernst op effectiviteit","title_en":"Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy.","published":"2025-05-27"}],"10.1161/circulationaha.124.072756":[{"url":"https://hartvaat.nl/2025/05/20/intensieve-ldl-verlaging-met-evolocumab-bij-auto-immuunziekten-rct/","title":"Intensieve LDL-verlaging met evolocumab bij auto-immuunziekten: RCT","title_en":"Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.","published":"2025-05-20"}],"10.1016/j.jacc.2025.03.008":[{"url":"https://hartvaat.nl/2025/05/20/angptl3-antilichaam-bij-suboptimaal-gecontroleerde-hyperlipidemie-fase-2/","title":"ANGPTL3-antilichaam bij suboptimaal gecontroleerde hyperlipidemie: fase 2","title_en":"Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.","published":"2025-05-20"}],"10.1016/j.jacc.2025.03.005":[{"url":"https://hartvaat.nl/2025/05/20/solbinsiran-angptl3-remming-van-preklinisch-tot-eerste-humane-studies/","title":"Solbinsiran: ANGPTL3-remming van preklinisch tot eerste humane studies","title_en":"Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies.","published":"2025-05-20"}],"10.1016/j.jacc.2025.03.496":[{"url":"https://hartvaat.nl/2025/05/20/plozasiran-en-lipoproteine-deeltjesgrootte-bij-hypertriglyceridemie/","title":"Plozasiran en lipoproteïne-deeltjesgrootte bij hypertriglyceridemie","title_en":"Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia.","published":"2025-05-20"}],"10.1016/s0140-6736(25)00721-4":[{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","title":"TANDEM: obicetrapib plus ezetimibe voor LDL-verlaging — Lancet fase 3","title_en":"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.","published":"2025-05-17"}],"10.1016/j.jacc.2025.03.503":[{"url":"https://hartvaat.nl/2025/05/13/empagliflozine-erytropoese-en-ijzermobilisatie-bij-hartfalen/","title":"Empagliflozine, erytropoëse en ijzermobilisatie bij hartfalen","title_en":"Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR Program.","published":"2025-05-13"}],"10.1016/j.jacc.2025.02.034":[{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","title":"ORBITA-2: dobutamine-stress-echo voorspelt PCI-effectiviteit","title_en":"Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results From the ORBITA-2 Trial.","published":"2025-05-13"}],"10.1016/j.jacc.2025.03.009":[{"url":"https://hartvaat.nl/2025/05/13/summit-tirzepatide-en-ckd-interactie-bij-hfpef-met-obesitas/","title":"SUMMIT: tirzepatide en CKD-interactie bij HFpEF met obesitas","title_en":"Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.","published":"2025-05-13"}],"10.1056/nejmoa2501440":[{"url":"https://hartvaat.nl/2025/05/08/lorundrostat-bij-ongecontroleerde-hypertensie-fase-3-nejm/","title":"Lorundrostat bij ongecontroleerde hypertensie: fase 3 — NEJM","title_en":"Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension.","published":"2025-05-08"}],"10.1093/europace/euaf095":[{"url":"https://hartvaat.nl/2025/05/07/aanvullende-substraatmodificatie-bij-persisterend-af-met-low-voltage-gebieden/","title":"Aanvullende substraatmodificatie bij persisterend AF met low-voltage gebieden","title_en":"Persistent atrial fibrillation with left atrial low-voltage area: who benefit from additional modification?","published":"2025-05-07"}],"10.1093/europace/euaf066":[{"url":"https://hartvaat.nl/2025/05/07/hoog-vermogen-korte-duur-rf-ablatie-versus-cryoballon-bij-paroxysmaal-af-rct/","title":"Hoog-vermogen korte duur RF-ablatie versus cryoballon bij paroxysmaal AF: RCT","title_en":"HIgh Power short duration radiofrequency ablation or cryoballoon ablation for paroxysmal Atrial Fibrillation (HIPAF trial).","published":"2025-05-07"}],"10.1016/s0140-6736(25)00507-0":[{"url":"https://hartvaat.nl/2025/05/03/solbinsiran-langwerkend-sirna-tegen-angptl3-duurzaamheid-en-effectiviteit/","title":"Solbinsiran: langwerkend siRNA tegen ANGPTL3 — duurzaamheid en effectiviteit","title_en":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial.","published":"2025-05-03"}],"10.1016/s0140-6736(25)00509-4":[{"url":"https://hartvaat.nl/2025/05/03/semaglutide-en-loopafstand-bij-perifeer-vaatlijden-en-diabetes/","title":"Semaglutide en loopafstand bij perifeer vaatlijden en diabetes","title_en":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.","published":"2025-05-03"}],"10.1093/eurheartj/ehaf002":[{"url":"https://hartvaat.nl/2025/05/02/paclitaxel-gecoate-ballonnen-versus-des-bij-kleine-vaten-ipd-meta-analyse/","title":"Paclitaxel-gecoate ballonnen versus DES bij kleine vaten: IPD meta-analyse","title_en":"Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study.","published":"2025-05-02"}],"10.1136/heartjnl-2024-325144":[{"url":"https://hartvaat.nl/2025/05/02/determinanten-van-medicatietrouw-na-acs-secundaire-analyse/","title":"Determinanten van medicatietrouw na ACS: secundaire analyse","title_en":"Determinants of medication adherence in patients with acute coronary syndrome: a secondary analysis of a randomised clinical trial.","published":"2025-05-02"}],"10.1001/jamacardio.2025.0244":[{"url":"https://hartvaat.nl/2025/05/01/apothekerverwijzingen-voor-statine-start-twee-cluster-rct-s/","title":"Apothekerverwijzingen voor statine-start: twee cluster-RCT's","title_en":"Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation: Two Cluster Randomized Clinical Trials.","published":"2025-05-01"}],"10.1001/jamacardio.2024.4030":[{"url":"https://hartvaat.nl/2025/05/01/aspirine-versus-clopidogrel-na-coronaire-stenting-naar-bloedingsrisico-en-comple/","title":"Aspirine versus clopidogrel na coronaire stenting naar bloedingsrisico en complexiteit","title_en":"Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity.","published":"2025-05-01"}],"10.1016/j.jacc.2025.03.003":[{"url":"https://hartvaat.nl/2025/04/29/vroege-iabp-bij-hartfalen-gerelateerde-cardiogene-shock-gerandomiseerde-trial/","title":"Vroege IABP bij hartfalen-gerelateerde cardiogene shock: gerandomiseerde trial","title_en":"Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial.","published":"2025-04-29"}],"10.1016/s0140-6736(25)00505-7":[{"url":"https://hartvaat.nl/2025/04/26/ffr-geleide-pci-versus-cabg-langetermijn-uitkomsten-vergelijking/","title":"FFR-geleide PCI versus CABG: langetermijn uitkomsten vergelijking","title_en":"Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.","published":"2025-04-26"}],"10.1016/s0140-6736(25)00504-5":[{"url":"https://hartvaat.nl/2025/04/26/angiografie-afgeleide-ffr-versus-ivus-bij-pci-gerandomiseerde-trial/","title":"Angiografie-afgeleide FFR versus IVUS bij PCI: gerandomiseerde trial","title_en":"Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.","published":"2025-04-26"}],"10.1161/circulationaha.124.073521":[{"url":"https://hartvaat.nl/2025/04/22/thoracentese-bij-acuut-hartfalen-gerandomiseerde-trial/","title":"Thoracentese bij acuut hartfalen: gerandomiseerde trial","title_en":"A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.","published":"2025-04-22"}],"10.1093/eurheartj/ehae917":[{"url":"https://hartvaat.nl/2025/04/22/anemie-beinvloedt-ijzerhomeostase-en-empagliflozine-respons-bij-hf/","title":"Anemie beïnvloedt ijzerhomeostase en empagliflozine-respons bij HF","title_en":"Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.","published":"2025-04-22"}],"10.1056/nejmoa2502280":[{"url":"https://hartvaat.nl/2025/04/17/pfa-versus-cryoballon-bij-paroxysmaal-af-gerandomiseerde-trial/","title":"PFA versus cryoballon bij paroxysmaal AF: gerandomiseerde trial","title_en":"Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.","published":"2025-04-17"}],"10.1016/s0140-6736(25)00449-0":[{"url":"https://hartvaat.nl/2025/04/12/clopidogrel-versus-aspirine-monotherapie-bij-hoog-risico-op-recidief-cva/","title":"Clopidogrel versus aspirine monotherapie bij hoog risico op recidief-CVA","title_en":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.","published":"2025-04-12"}],"10.1016/s0140-6736(25)00450-7":[{"url":"https://hartvaat.nl/2025/04/12/orbitale-atherectomie-versus-ballonangioplastie-voor-des-bij-ernstig-verkalkte-l/","title":"Orbitale atherectomie versus ballonangioplastie vóór DES bij ernstig verkalkte laesies","title_en":"Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.","published":"2025-04-12"}],"10.1056/nejmoa2500366":[{"url":"https://hartvaat.nl/2025/04/10/dapagliflozine-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","title":"Dapagliflozine bij patiënten die TAVI ondergaan: gerandomiseerde trial — NEJM","title_en":"Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.","published":"2025-04-10"}],"10.1093/eurheartj/ehae938":[{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","title":"EMPERIAL: empagliflozine bij resistente hypertensie en HFpEF","title_en":"Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.","published":"2025-04-07"}],"10.1093/eurheartj/ehae780":[{"url":"https://hartvaat.nl/2025/04/07/sglt2-remmers-voorkomen-nieuw-ontstane-diabetes-bij-cv-en-nierziekte/","title":"SGLT2-remmers voorkomen nieuw-ontstane diabetes bij CV- en nierziekte","title_en":"Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.","published":"2025-04-07"}],"10.1056/nejmoa2408308":[{"url":"https://hartvaat.nl/2025/04/03/laa-sluiting-na-af-ablatie-gerandomiseerde-trial-nejm/","title":"LAA-sluiting na AF-ablatie: gerandomiseerde trial — NEJM","title_en":"Left Atrial Appendage Closure after Ablation for Atrial Fibrillation.","published":"2025-04-03"}],"10.1016/j.jacc.2025.01.029":[{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","title":"ISCHEMIA: invasief versus conservatief bij chronische totale occlusie","title_en":"Invasive vs Conservative Management of Patients With Chronic Total Occlusion: Results From the ISCHEMIA Trial.","published":"2025-04-01"}],"10.1016/j.jacc.2025.01.028":[{"url":"https://hartvaat.nl/2025/04/01/gdmt-en-uitkomsten-in-ischemia-trial/","title":"GDMT en uitkomsten in ISCHEMIA-trial","title_en":"Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial.","published":"2025-04-01"}],"10.1001/jamacardio.2024.5124":[{"url":"https://hartvaat.nl/2025/04/01/behandelstrategieen-voor-bloeddrukcontrole-in-tanzania-en-lesotho-rct/","title":"Behandelstrategieën voor bloeddrukcontrole in Tanzania en Lesotho: RCT","title_en":"Treatment Strategies to Control Blood Pressure in People With Hypertension in Tanzania and Lesotho: A Randomized Clinical Trial.","published":"2025-04-01"}],"10.1093/eurheartj/ehae694":[{"url":"https://hartvaat.nl/2025/04/01/symptomatisch-versus-asymptomatisch-af-en-klinische-uitkomsten-meta-analyse/","title":"Symptomatisch versus asymptomatisch AF en klinische uitkomsten: meta-analyse","title_en":"Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis.","published":"2025-04-01"}],"10.1161/cir.0000000000001309":[{"url":"https://hartvaat.nl/2025/04/01/2025-acc-aha-acs-richtlijn-management-van-acuut-coronair-syndroom/","title":"2025 ACC/AHA ACS-richtlijn: management van acuut coronair syndroom","title_en":"2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2025-04-01"}],"10.1161/hypertensionaha.124.23962":[{"url":"https://hartvaat.nl/2025/04/01/aldosteronsynthaseremmers-bij-hypertensie-meta-analyse-van-rct-s/","title":"Aldosteronsynthaseremmers bij hypertensie: meta-analyse van RCT's","title_en":"Efficacy and Safety of Aldosterone Synthase Inhibitors for Hypertension: A Meta-Analysis of Randomized Controlled Trials and Systematic Review.","published":"2025-04-01"}],"10.1161/hypertensionaha.124.24222":[{"url":"https://hartvaat.nl/2025/04/01/hypotensieve-episodes-op-24-uurs-abpm-en-cognitieve-functie-sprint-inzichten/","title":"Hypotensieve episodes op 24-uurs ABPM en cognitieve functie: SPRINT inzichten","title_en":"Hypotensive Episodes on 24-Hour Ambulatory Blood Pressure and Cognitive Function: Insights From the SPRINT Study.","published":"2025-04-01"}],"10.1161/hypertensionaha.124.24142":[{"url":"https://hartvaat.nl/2025/04/01/aprocitentan-bij-zwarte-patienten-met-hypertensie/","title":"Aprocitentan bij zwarte patiënten met hypertensie","title_en":"Aprocitentan for Blood Pressure Reduction in Black Patients.","published":"2025-04-01"}],"10.1002/ehf2.15125":[{"url":"https://hartvaat.nl/2025/04/01/ultrafiltratie-bij-cardiorenaal-syndroom-systematische-review/","title":"Ultrafiltratie bij cardiorenaal syndroom: systematische review","title_en":"Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review.","published":"2025-04-01"}],"10.1002/ehf2.15162":[{"url":"https://hartvaat.nl/2025/04/01/clip-hfpef-cilostazol-bij-hfpef-gerandomiseerde-trial/","title":"CLIP-HFpEF: cilostazol bij HFpEF — gerandomiseerde trial","title_en":"Cilostazol in patients with heart failure and preserved ejection fraction-The CLIP-HFpEF trial.","published":"2025-04-01"}],"10.1002/ehf2.15082":[{"url":"https://hartvaat.nl/2025/04/01/sacubitril-valsartan-na-acuut-mi-meta-analyse-van-in-hospital-initiatie/","title":"Sacubitril/valsartan na acuut MI: meta-analyse van in-hospital initiatie","title_en":"The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis.","published":"2025-04-01"}],"10.1002/ehf2.15134":[{"url":"https://hartvaat.nl/2025/04/01/vericiguat-voordeel-geprojecteerd-op-paradigm-hf-en-dapa-hf-populaties/","title":"Vericiguat-voordeel geprojecteerd op PARADIGM-HF en DAPA-HF populaties","title_en":"Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.","published":"2025-04-01"}],"10.1002/ehf2.14986":[{"url":"https://hartvaat.nl/2025/04/01/socio-economische-ongelijkheid-en-hartfalenuitkomsten-systematische-review/","title":"Socio-economische ongelijkheid en hartfalenuitkomsten: systematische review","title_en":"Socio-economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis.","published":"2025-04-01"}],"10.1002/ehf2.15075":[{"url":"https://hartvaat.nl/2025/04/01/cardiale-akoestische-biomarkers-bij-hartfalenmonitoring-systematische-review/","title":"Cardiale akoestische biomarkers bij hartfalenmonitoring: systematische review","title_en":"The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review.","published":"2025-04-01"}],"10.1002/ehf2.15036":[{"url":"https://hartvaat.nl/2025/04/01/sotagliflozine-duale-sglt1-sglt2-remmer-bij-hartfalen-meta-analyse/","title":"Sotagliflozine (duale SGLT1/SGLT2-remmer) bij hartfalen: meta-analyse","title_en":"Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes.","published":"2025-04-01"}],"10.1002/ehf2.14841":[{"url":"https://hartvaat.nl/2025/04/01/ambulante-behandeling-van-gedecompenseerd-hartfalen-meta-analyse/","title":"Ambulante behandeling van gedecompenseerd hartfalen: meta-analyse","title_en":"Outpatient treatment of decompensated heart failure: A systematic review and study level meta-analysis.","published":"2025-04-01"}],"10.1002/ehf2.14958":[{"url":"https://hartvaat.nl/2025/04/01/copd-en-slechtere-uitkomsten-bij-hfpef-meta-analyse/","title":"COPD en slechtere uitkomsten bij HFpEF: meta-analyse","title_en":"Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction.","published":"2025-04-01"}],"10.1002/ehf2.14831":[{"url":"https://hartvaat.nl/2025/04/01/icd-deactivatie-aan-het-levenseinde-de-moeilijke-discussie/","title":"ICD-deactivatie aan het levenseinde: de moeilijke discussie","title_en":"The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review.","published":"2025-04-01"}],"10.1093/europace/euaf080":[{"url":"https://hartvaat.nl/2025/03/28/athena-post-hoc-dronedaron-als-effectieve-vroege-ritmecontrole/","title":"ATHENA post-hoc: dronedaron als effectieve vroege ritmecontrole","title_en":"Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria.","published":"2025-03-28"}],"10.1093/europace/euaf064":[{"url":"https://hartvaat.nl/2025/03/28/geinhaleerde-flecainide-voor-cardioversie-van-recent-onset-af-lancet/","title":"Geïnhaleerde flecaïnide voor cardioversie van recent-onset AF: Lancet","title_en":"Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial.","published":"2025-03-28"}],"10.1056/nejmoa2412006":[{"url":"https://hartvaat.nl/2025/03/27/intensieve-bloeddrukcontrole-bij-type-2-diabetes-nejm/","title":"Intensieve bloeddrukcontrole bij type 2 diabetes — NEJM","title_en":"Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.","published":"2025-03-27"}],"10.1136/heartjnl-2024-324761":[{"url":"https://hartvaat.nl/2025/03/26/rate-af-kosteneffectiviteit-van-digoxine-versus-betablokkers-bij-permanent-af/","title":"RATE-AF: kosteneffectiviteit van digoxine versus bètablokkers bij permanent AF","title_en":"Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) randomised trial.","published":"2025-03-26"}],"10.1016/j.jacc.2024.10.125":[{"url":"https://hartvaat.nl/2025/03/25/antitrombotische-therapie-bij-af-na-acs-pci-augustus-gecombineerde-inzichten/","title":"Antitrombotische therapie bij AF na ACS/PCI: AUGUSTUS gecombineerde inzichten","title_en":"Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS.","published":"2025-03-25"}],"10.1016/j.jacc.2024.12.030":[{"url":"https://hartvaat.nl/2025/03/25/anticoagulatie-en-antiplaatjestherapie-bij-af-en-stabiel-coronairlijden-meta-ana/","title":"Anticoagulatie en antiplaatjestherapie bij AF en stabiel coronairlijden: meta-analyse","title_en":"Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.","published":"2025-03-25"}],"10.1001/jama.2024.27402":[{"url":"https://hartvaat.nl/2025/03/25/leeftijds-en-sekseverschillen-in-effectiviteit-van-diabetesbehandeling-netwerk-m/","title":"Leeftijds- en sekseverschillen in effectiviteit van diabetesbehandeling: netwerk-meta-analyse","title_en":"Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.","published":"2025-03-25"}],"10.1016/j.jacc.2024.10.101":[{"url":"https://hartvaat.nl/2025/03/25/amulet-ide-vijfjaarsresultaten-laa-occlusie-met-amulet/","title":"AMULET IDE vijfjaarsresultaten: LAA-occlusie met Amulet","title_en":"5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial.","published":"2025-03-25"}],"10.1093/eurheartj/ehae613":[{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","title":"FLOW: semaglutide CV-voordelen naar CKD-ernst bij diabetes","title_en":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.","published":"2025-03-24"}],"10.1016/j.jacc.2024.11.014":[{"url":"https://hartvaat.nl/2025/03/18/natriumzirconiumcyclosilicaat-voor-spironolacton-optitratie-na-hf-gerandomiseerd/","title":"Natriumzirconiumcyclosilicaat voor spironolacton-optitratie na HF: gerandomiseerde trial","title_en":"Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.","published":"2025-03-18"}],"10.1016/s0140-6736(25)00333-2":[{"url":"https://hartvaat.nl/2025/03/15/doac-s-versus-geen-anticoagulatie-na-intracraniele-bloeding-bij-af-meta-analyse/","title":"DOAC's versus geen anticoagulatie na intracraniële bloeding bij AF: meta-analyse","title_en":"Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.","published":"2025-03-15"}],"10.1136/heartjnl-2024-324565":[{"url":"https://hartvaat.nl/2025/03/13/minoca-pathologische-bevindingen-bij-invasieve-beoordeling-meta-analyse/","title":"MINOCA: pathologische bevindingen bij invasieve beoordeling — meta-analyse","title_en":"Pathological findings at invasive assessment in MINOCA: a systematic review and meta-analysis.","published":"2025-03-13"}],"10.1161/circulationaha.124.072679":[{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","title":"SUMMIT: tirzepatide en klinisch traject bij HFpEF met obesitas — langetermijn","title_en":"Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.","published":"2025-03-11"}],"10.1016/j.jacc.2024.10.070":[{"url":"https://hartvaat.nl/2025/03/11/tavr-bij-systolisch-hartfalen-en-matige-aortastenose-nejm/","title":"TAVR bij systolisch hartfalen en matige aortastenose — NEJM","title_en":"Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD.","published":"2025-03-11"}],"10.1093/europace/euaf029":[{"url":"https://hartvaat.nl/2025/03/05/biventriculair-versus-rv-pacing-bij-patienten-met-verwachte-frequente-pacing/","title":"Biventriculair versus RV-pacing bij patiënten met verwachte frequente pacing","title_en":"Biventricular vs. right ventricular pacing devices in patients anticipated to require frequent ventricular pacing (BioPace).","published":"2025-03-05"}],"10.1093/europace/euaf019":[{"url":"https://hartvaat.nl/2025/03/05/af-last-in-klinische-praktijk-onderzoek-en-technologie-consensus-document/","title":"AF-last in klinische praktijk, onderzoek en technologie: consensus document","title_en":"Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association.","published":"2025-03-05"}],"10.1161/circulationaha.124.071153":[{"url":"https://hartvaat.nl/2025/03/04/stapsgewijze-provisionale-versus-systematische-dualstent-bij-ware-linker-hoofdst/","title":"Stapsgewijze provisionale versus systematische dualstent bij ware linker hoofdstam bifurcatie","title_en":"Stepwise Provisional Versus Systematic Dual-Stent Strategies for Treatment of True Left Main Coronary Bifurcation Lesions.","published":"2025-03-04"}],"10.1001/jamacardio.2024.4849":[{"url":"https://hartvaat.nl/2025/03/01/aspirine-en-hemocompatibiliteit-na-lvad-bij-atherosclerotisch-vaatlijden/","title":"Aspirine en hemocompatibiliteit na LVAD bij atherosclerotisch vaatlijden","title_en":"Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial.","published":"2025-03-01"}],"10.1001/jamacardio.2024.4417":[{"url":"https://hartvaat.nl/2025/03/01/kaliumnitraat-bij-hfpef-gerandomiseerde-trial/","title":"Kaliumnitraat bij HFpEF: gerandomiseerde trial","title_en":"Potassium Nitrate in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.","published":"2025-03-01"}],"10.1161/hypertensionaha.124.24214":[{"url":"https://hartvaat.nl/2025/03/01/frailteit-en-antihypertensieve-behandeling-bij-ouderen-meta-analyse/","title":"Frailteit en antihypertensieve behandeling bij ouderen: meta-analyse","title_en":"Impact of Frailty on Antihypertensive Treatment in Older Adults.","published":"2025-03-01"}],"10.1161/hypertensionaha.124.24013":[{"url":"https://hartvaat.nl/2025/03/01/tijd-in-streefwaarde-voor-bloeddruk-en-gezondheidsuitkomsten-systematische-revie/","title":"Tijd-in-streefwaarde voor bloeddruk en gezondheidsuitkomsten: systematische review","title_en":"Time in Target Range for Blood Pressure and Adverse Health Outcomes: A Systematic Review.","published":"2025-03-01"}],"10.1016/j.jacc.2024.10.097":[{"url":"https://hartvaat.nl/2025/02/25/ambulante-hf-verslechtering-bij-attr-cm-attr-act-subanalyse/","title":"Ambulante HF-verslechtering bij ATTR-CM: ATTR-ACT subanalyse","title_en":"Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial.","published":"2025-02-25"}],"10.1016/j.jacc.2024.11.007":[{"url":"https://hartvaat.nl/2025/02/25/systolische-bloeddruk-en-polsdruk-bij-hartfalen-gepoolde-ipd-analyse/","title":"Systolische bloeddruk en polsdruk bij hartfalen: gepoolde IPD analyse","title_en":"Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials.","published":"2025-02-25"}],"10.1016/j.jacc.2024.11.015":[{"url":"https://hartvaat.nl/2025/02/25/ambulante-hartfalenverslechtering-bij-attr-cardiomyopathie-attr-act-analyse/","title":"Ambulante hartfalenverslechtering bij ATTR-cardiomyopathie: ATTR-ACT analyse","title_en":"Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial.","published":"2025-02-25"}],"10.1016/j.jacc.2024.11.001":[{"url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","title":"SUMMIT: tirzepatide vermindert LV-massa en paracardiaal vetweefsel bij HFpEF","title_en":"Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.","published":"2025-02-25"}],"10.1056/nejmoa2409501":[{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","title":"VANISH2: catheterablatie versus antiaritmica bij ventriculaire tachycardie — NEJM","title_en":"Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.","published":"2025-02-20"}],"10.1016/j.jacc.2024.11.003":[{"url":"https://hartvaat.nl/2025/02/18/impella-bij-ouderen-met-cardiogene-shock-is-het-veilig/","title":"Impella bij ouderen met cardiogene shock: is het veilig?","title_en":"Treating Older Patients in Cardiogenic Shock With a Microaxial Flow Pump: Is it DANGERous?","published":"2025-02-18"}],"10.1016/j.jacc.2024.10.074":[{"url":"https://hartvaat.nl/2025/02/18/lage-dosis-sirolimus-bdp-stent-versus-tweede-generatie-des-non-inferioriteit/","title":"Lage-dosis sirolimus BDP-stent versus tweede-generatie DES: non-inferioriteit","title_en":"Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial.","published":"2025-02-18"}],"10.1056/nejmoa2405922":[{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","title":"CLEAR SYNERGY: colchicine bij acuut MI — NEJM","title_en":"Colchicine in Acute Myocardial Infarction.","published":"2025-02-13"}],"10.1056/nejmoa2405923":[{"url":"https://hartvaat.nl/2025/02/13/routine-spironolacton-na-acuut-mi-gerandomiseerde-trial-nejm/","title":"Routine spironolacton na acuut MI: gerandomiseerde trial — NEJM","title_en":"Routine Spironolactone in Acute Myocardial Infarction.","published":"2025-02-13"}],"10.1056/nejmoa2403991":[{"url":"https://hartvaat.nl/2025/02/13/cabozantinib-bij-gevorderde-neuro-endocriene-tumoren-fase-3/","title":"Cabozantinib bij gevorderde neuro-endocriene tumoren: fase 3","title_en":"Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.","published":"2025-02-13"}],"10.1016/j.jacc.2024.11.019":[{"url":"https://hartvaat.nl/2025/02/11/langetermijn-evolocumab-bij-ouderen-effectiviteit-en-veiligheid/","title":"Langetermijn evolocumab bij ouderen: effectiviteit en veiligheid","title_en":"Long-Term Lipid Lowering With Evolocumab in Older Individuals.","published":"2025-02-11"}],"10.1016/j.jacc.2024.11.004":[{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","title":"Look AHEAD: intensieve leefstijlinterventie, cardiale biomarkers en CV-uitkomsten bij diabetes","title_en":"Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study.","published":"2025-02-11"}],"10.1093/europace/euaf015":[{"url":"https://hartvaat.nl/2025/02/05/smartphone-ppg-voor-af-detectie-en-management-verbeterde-screening/","title":"Smartphone-PPG voor AF-detectie en -management: verbeterde screening","title_en":"Improving atrial fibrillation or flutter detection and management by smartphone-based photoplethysmography rhythm monitoring following cardiac surgery: a pragmatic randomized trial.","published":"2025-02-05"}],"10.1001/jama.2024.24438":[{"url":"https://hartvaat.nl/2025/02/04/pvi-met-geoptimaliseerde-lineaire-ablatie-versus-pvi-alleen-bij-persisterend-af/","title":"PVI met geoptimaliseerde lineaire ablatie versus PVI alleen bij persisterend AF","title_en":"Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial.","published":"2025-02-04"}],"10.1093/eurheartj/ehae742":[{"url":"https://hartvaat.nl/2025/02/03/klinische-risicopredictie-ct-coronairangiografie-en-cv-events-bij-nieuwe-angina/","title":"Klinische risicopredictie, CT-coronairangiografie en CV-events bij nieuwe angina","title_en":"Clinical risk prediction, coronary computed tomography angiography, and cardiovascular events in new-onset chest pain: the PROMISE and SCOT-HEART trials.","published":"2025-02-03"}],"10.1001/jamacardio.2024.3911":[{"url":"https://hartvaat.nl/2025/02/01/alternatieve-ldl-verlagingsstrategie-versus-hoge-dosis-statine-bij-ascvd-meta-an/","title":"Alternatieve LDL-verlagingsstrategie versus hoge-dosis statine bij ASCVD: meta-analyse","title_en":"Alternative LDL Cholesterol-Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease: A Systematic Review and Individual Patient Data Meta-Analysis.","published":"2025-02-01"}],"10.1001/jamacardio.2024.3782":[{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","title":"FINEARTS-HF: geschatte langetermijnvoordelen van finerenon bij hartfalen","title_en":"Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.","published":"2025-02-01"}],"10.1161/hypertensionaha.124.23887":[{"url":"https://hartvaat.nl/2025/02/01/digitale-interventie-voor-dash-dieet-en-bloeddrukverlaging-bij-vs-volwassenen/","title":"Digitale interventie voor DASH-dieet en bloeddrukverlaging bij VS-volwassenen","title_en":"Effects of a Digital Intervention to Improve DASH and Blood Pressure Among US Adults.","published":"2025-02-01"}],"10.1002/ehf2.15074":[{"url":"https://hartvaat.nl/2025/02/01/transveneuze-frenische-zenuwstimulatie-bij-centraal-slaapapneu-en-hartfalen/","title":"Transveneuze frenische zenuwstimulatie bij centraal slaapapneu en hartfalen","title_en":"Win ratio analysis of transvenous phrenic nerve stimulation to treat central sleep apnoea in heart failure.","published":"2025-02-01"}],"10.1002/ehf2.15069":[{"url":"https://hartvaat.nl/2025/02/01/diureticaresistentie-bij-acuut-hartfalen-prevalentie-en-kenmerken/","title":"Diureticaresistentie bij acuut hartfalen: prevalentie en kenmerken","title_en":"Prevalence and characteristics of upfront diuretic resistance in acute heart failure: The P-Value-AHF study.","published":"2025-02-01"}],"10.1002/ehf2.14962":[{"url":"https://hartvaat.nl/2025/02/01/finerenon-en-lvh-bij-ckd-en-diabetes/","title":"Finerenon en LVH bij CKD en diabetes","title_en":"Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes.","published":"2025-02-01"}],"10.1002/ehf2.14905":[{"url":"https://hartvaat.nl/2025/02/01/iv-ijzer-bij-hartfalen-en-ijzerdeficientie-geactualiseerde-meta-analyse-van-rct-/","title":"IV-ijzer bij hartfalen en ijzerdeficiëntie: geactualiseerde meta-analyse van RCT's","title_en":"Intravenous iron therapy for heart failure and iron deficiency: An updated meta-analysis of randomized clinical trials.","published":"2025-02-01"}],"10.1056/nejmoa2410027":[{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","title":"SUMMIT: tirzepatide bij HFpEF met obesitas — NEJM","title_en":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.","published":"2025-01-30"}],"10.1056/nejmoa2407794":[{"url":"https://hartvaat.nl/2025/01/30/oac-continueren-versus-onderbreken-tijdens-tavi-gerandomiseerde-trial-nejm/","title":"OAC continueren versus onderbreken tijdens TAVI: gerandomiseerde trial — NEJM","title_en":"Continuation versus Interruption of Oral Anticoagulation during TAVI.","published":"2025-01-30"}],"10.1161/circulationaha.124.069556":[{"url":"https://hartvaat.nl/2025/01/28/lp-a-en-ldl-cholesterol-onafhankelijke-cv-risicopaden/","title":"Lp(a) en LDL-cholesterol: onafhankelijke CV-risicopaden","title_en":"Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.","published":"2025-01-28"}],"10.1016/s0140-6736(24)02679-5":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","title":"SCOT-HEART: CT-coronairangiografie bij stabiele thoracale pijn — tienjaarsresultaten","title_en":"Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.","published":"2025-01-25"}],"10.1056/nejmoa2406674":[{"url":"https://hartvaat.nl/2025/01/23/abelacimab-versus-rivaroxaban-bij-af-nejm/","title":"Abelacimab versus rivaroxaban bij AF — NEJM","title_en":"Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.","published":"2025-01-23"}],"10.1016/j.jacc.2024.11.020":[{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","title":"FINEARTS-HF: initiële eGFR-dip met finerenon bij HFpEF is veilig","title_en":"Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.","published":"2025-01-21"}],"10.1016/j.jacc.2024.10.111":[{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","title":"FINEARTS-HF: finerenon en obesitas bij HFmrEF/HFpEF","title_en":"Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.","published":"2025-01-21"}],"10.1001/jama.2024.24017":[{"url":"https://hartvaat.nl/2025/01/21/muvalaplin-orale-lp-a-verlaging-nejm-gerandomiseerde-trial/","title":"Muvalaplin: orale Lp(a)-verlaging — NEJM gerandomiseerde trial","title_en":"Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.","published":"2025-01-21"}],"10.1016/j.jacc.2024.09.023":[{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","title":"FINEARTS-HF: finerenon en KCCQ bij HFmrEF/HFpEF","title_en":"Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.","published":"2025-01-21"}],"10.1016/j.jacc.2024.10.091":[{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","title":"FINEARTS-HF: finerenon en nieruitkomsten bij HFpEF","title_en":"Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial.","published":"2025-01-21"}],"10.1001/jama.2024.22730":[{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","title":"EVOLVED: vroege interventie bij asymptomatische ernstige aortastenose met myocardfibrose","title_en":"Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.","published":"2025-01-21"}],"10.1161/circulationaha.124.072281":[{"url":"https://hartvaat.nl/2025/01/21/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerd-pci-effect/","title":"FFR en iFR als voorspellers van placebo-gecontroleerd PCI-effect","title_en":"Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease.","published":"2025-01-21"}],"10.1016/j.jacc.2024.09.004":[{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","title":"FINEARTS-HF: finerenon bij recent verslechterend hartfalen","title_en":"Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial.","published":"2025-01-21"}],"10.1001/jama.2024.21189":[{"url":"https://hartvaat.nl/2025/01/14/tri-fr-transcatheter-edge-to-edge-repair-bij-geisoleerde-ernstige-tr-rct/","title":"Tri.Fr: transcatheter edge-to-edge repair bij geïsoleerde ernstige TR — RCT","title_en":"Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid Regurgitation: The Tri.Fr Randomized Clinical Trial.","published":"2025-01-14"}],"10.1161/circulationaha.124.072055":[{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","title":"FINEARTS-HF: finerenon met en zonder SGLT2-remmer bij HFpEF","title_en":"Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.","published":"2025-01-14"}],"10.1136/heartjnl-2024-324685":[{"url":"https://hartvaat.nl/2025/01/13/nt-probnp-en-af-risico-systematische-review-en-meta-analyse/","title":"NT-proBNP en AF-risico: systematische review en meta-analyse","title_en":"Association between NT-proBNP levels and risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies.","published":"2025-01-13"}],"10.1056/nejmoa2401918":[{"url":"https://hartvaat.nl/2025/01/09/transcatheter-klepvervanging-bij-ernstige-tricuspidalisinsufficientie-nejm/","title":"Transcatheter klepvervanging bij ernstige tricuspidalisinsufficiëntie — NEJM","title_en":"Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","published":"2025-01-09"}],"10.1056/nejmoa2409368":[{"url":"https://hartvaat.nl/2025/01/09/plozasiran-bij-persisterende-chylomicronemie-en-pancreatitisrisico-nejm/","title":"Plozasiran bij persisterende chylomicronemie en pancreatitisrisico — NEJM","title_en":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.","published":"2025-01-09"}],"10.1016/j.jacc.2024.09.1231":[{"url":"https://hartvaat.nl/2025/01/07/optimale-strategie-voor-complete-revascularisatie-bij-stemi-met-meervatslijden-m/","title":"Optimale strategie voor complete revascularisatie bij STEMI met meervatslijden: meta-analyse","title_en":"Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis.","published":"2025-01-07"}],"10.1093/eurheartj/ehae804":[{"url":"https://hartvaat.nl/2025/01/07/urinair-wijnzuur-als-biomarker-voor-wijnconsumptie-en-cv-risico-predimed/","title":"Urinair wijnzuur als biomarker voor wijnconsumptie en CV-risico: PREDIMED","title_en":"Urinary tartaric acid as a biomarker of wine consumption and cardiovascular risk: the PREDIMED trial.","published":"2025-01-07"}],"10.1093/eurheartj/ehae724":[{"url":"https://hartvaat.nl/2025/01/07/euroheart-definities-van-klinische-studie-eindpunten-voor-cvd/","title":"EuroHeart: definities van klinische studie-eindpunten voor CVD","title_en":"Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).","published":"2025-01-07"}],"10.1016/j.jacc.2024.08.067":[{"url":"https://hartvaat.nl/2025/01/07/dcb-voor-zijtak-bij-provisionale-stenting-gerandomiseerde-trial/","title":"DCB voor zijtak bij provisionale stenting: gerandomiseerde trial","title_en":"Drug-Coated Balloon Angioplasty of the Side Branch During Provisional Stenting: The Multicenter Randomized DCB-BIF Trial.","published":"2025-01-07"}],"10.1161/circulationaha.124.072011":[{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","title":"FINEARTS-HF: finerenon effectief over het hele EF-spectrum bij HFmrEF/HFpEF","title_en":"Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.","published":"2025-01-07"}],"10.1093/eurheartj/ehae580":[{"url":"https://hartvaat.nl/2025/01/07/pvi-met-versus-zonder-posteriore-wand-isolatie-bij-persisterend-af-rct/","title":"PVI met versus zonder posteriore wand-isolatie bij persisterend AF: RCT","title_en":"Radiofrequency catheter ablation of persistent atrial fibrillation by pulmonary vein isolation with or without left atrial posterior wall isolation: long-term outcomes of the CAPLA trial.","published":"2025-01-07"}],"10.1056/nejmoa2407105":[{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","title":"OCEANIC-AF: asundexian versus apixaban bij AF — NEJM","title_en":"Asundexian versus Apixaban in Patients with Atrial Fibrillation.","published":"2025-01-02"}],"10.1001/jamacardio.2024.4613":[{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","title":"FINEARTS-HF: finerenon gelijk effectief bij vrouwen en mannen met HFpEF","title_en":"Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.","published":"2025-01-01"}],"10.1001/jamacardio.2024.4639":[{"url":"https://hartvaat.nl/2025/01/01/gedeeltelijke-cardiale-denervatie-voorkomt-af-na-cabg-rct/","title":"Gedeeltelijke cardiale denervatie voorkomt AF na CABG: RCT","title_en":"Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: The pCAD-POAF Randomized Clinical Trial.","published":"2025-01-01"}],"10.1001/jamacardio.2024.4648":[{"url":"https://hartvaat.nl/2025/01/01/nudge-flu-subanalyse-griepvaccinatie-nudges-bij-mi-langetermijn/","title":"NUDGE-FLU subanalyse: griepvaccinatie-nudges bij MI — langetermijn","title_en":"Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical Trials.","published":"2025-01-01"}],"10.1001/jamacardio.2024.4539":[{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","title":"FINEARTS-HF: finerenon, kalium en klinische uitkomsten bij HFpEF","title_en":"Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.","published":"2025-01-01"}],"10.1001/jamacardio.2024.4470":[{"url":"https://hartvaat.nl/2025/01/01/kccq-interpretatie-bij-hartfalen-patient-ankering/","title":"KCCQ-interpretatie bij hartfalen: patiënt-ankering","title_en":"Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire: A Patient-Level Meta-Analysis.","published":"2025-01-01"}],"10.1001/jamacardio.2024.4197":[{"url":"https://hartvaat.nl/2025/01/01/danger-shock-hemodynamische-en-metabole-effecten-van-impella-bij-cardiogene-shoc/","title":"DanGer Shock: hemodynamische en metabole effecten van Impella bij cardiogene shock","title_en":"Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial.","published":"2025-01-01"}],"10.1001/jamacardio.2024.3314":[{"url":"https://hartvaat.nl/2025/01/01/ffr-versus-ifr-bij-coronaire-revascularisatie-vijfjaars-follow-up/","title":"FFR versus iFR bij coronaire revascularisatie: vijfjaars follow-up","title_en":"Coronary Revascularization Guided With Fractional Flow Reserve or Instantaneous Wave-Free Ratio: A 5-Year Follow-Up of the DEFINE FLAIR Randomized Clinical Trial.","published":"2025-01-01"}],"10.1161/hypertensionaha.124.23549":[{"url":"https://hartvaat.nl/2025/01/01/reproduceerbaarheid-en-behandeleffect-op-kantoor-versus-ambulante-bloeddrukrelat/","title":"Reproduceerbaarheid en behandeleffect op kantoor- versus ambulante bloeddrukrelatie","title_en":"Reproducibility and Treatment Effect on Office and Ambulatory Pressure Relation.","published":"2025-01-01"}],"10.1016/j.kint.2024.10.007":[{"url":"https://hartvaat.nl/2025/01/01/poise-3-substudie-perioperatieve-hypotensievermijding-en-orgaanschade/","title":"POISE-3 substudie: perioperatieve hypotensievermijding en orgaanschade","title_en":"A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury.","published":"2025-01-01"}],"10.1016/j.kint.2024.10.010":[{"url":"https://hartvaat.nl/2025/01/01/dialysaat-kalium-3-0-mmol-l-met-natriumzirconiumcyclosilicaat-bij-dialyse/","title":"Dialysaat-kalium 3.0 mmol/L met natriumzirconiumcyclosilicaat bij dialyse","title_en":"Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.","published":"2025-01-01"}],"10.3389/fendo.2025.1706353":[{"url":"https://hartvaat.nl/2025/01/01/nieuwe-therapeutische-mogelijkheden-voor-cholesterolverlaging-een-expertreview/","title":"Nieuwe therapeutische mogelijkheden voor cholesterolverlaging: een expertreview","title_en":"An expert narrative review on the mechanisms and therapeutic potential of gut microbiota-derived metabolites in multi-organ crosstalk.","published":"2025-01-01"}],"10.1093/europace/euae211":[{"url":"https://hartvaat.nl/2024/12/26/gerichte-patienteneducatie-vermindert-ongeplande-cv-events-bij-af/","title":"Gerichte patiënteneducatie vermindert ongeplande CV-events bij AF","title_en":"Effect of targeted education of patients with atrial fibrillation on unplanned cardiovascular outcomes: results of the multicentre randomized AF-EduCare trial.","published":"2024-12-26"}],"10.1161/circulationaha.124.072370":[{"url":"https://hartvaat.nl/2024/12/17/danger-shock-impella-en-nieruitkomsten-bij-cardiogene-shock/","title":"DanGer Shock: Impella en nieruitkomsten bij cardiogene shock","title_en":"Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.","published":"2024-12-17"}],"10.1161/circulationaha.124.069993":[{"url":"https://hartvaat.nl/2024/12/17/ablatiestrategie-bij-af-recidief-na-duurzame-pvi/","title":"Ablatiestrategie bij AF-recidief na duurzame PVI","title_en":"Ablation Strategies for Repeat Procedures in Atrial Fibrillation Recurrences Despite Durable Pulmonary Vein Isolation: The Prospective Randomized ASTRO AF Multicenter Trial.","published":"2024-12-17"}],"10.1093/eurheartj/ehae614":[{"url":"https://hartvaat.nl/2024/12/16/apoa-i-infusie-na-mi-naar-lp-a-niveau-aegis-ii-subanalyse/","title":"ApoA-I infusie na MI naar Lp(a)-niveau: AEGIS-II subanalyse","title_en":"Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial.","published":"2024-12-16"}],"10.1093/eurheartj/ehae587":[{"url":"https://hartvaat.nl/2024/12/16/gp-iib-iiia-remmers-bij-acuut-mi-en-microvasculaire-obstructie-meta-analyse/","title":"GP IIb/IIIa-remmers bij acuut MI en microvasculaire obstructie: meta-analyse","title_en":"Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial.","published":"2024-12-16"}],"10.1093/eurheartj/ehae573":[{"url":"https://hartvaat.nl/2024/12/16/scoff-nuchter-versus-niet-nuchter-voor-hartkatheterisatie-rct/","title":"SCOFF: nuchter versus niet-nuchter vóór hartkatheterisatie — RCT","title_en":"Fasting vs. no fasting prior to catheterization laboratory procedures: the SCOFF trial.","published":"2024-12-16"}],"10.1093/eurheartj/ehae611":[{"url":"https://hartvaat.nl/2024/12/16/biomarkervoorspelling-van-sinusritme-bij-af-east-afnet-4-biomoleculaire-analyse/","title":"Biomarkervoorspelling van sinusritme bij AF: EAST-AFNET 4 biomoleculaire analyse","title_en":"Biomarker-based prediction of sinus rhythm in atrial fibrillation patients: the EAST-AFNET 4 biomolecule study.","published":"2024-12-16"}],"10.1093/eurheartj/ehae617":[{"url":"https://hartvaat.nl/2024/12/16/aspirine-versus-clopidogrel-na-pci-eenjaars-follow-up-van-rct/","title":"Aspirine versus clopidogrel na PCI: eenjaars follow-up van RCT","title_en":"Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial.","published":"2024-12-16"}],"10.1056/nejmoa2401513":[{"url":"https://hartvaat.nl/2024/12/12/pci-bij-patienten-die-tavi-ondergaan-gerandomiseerde-trial-nejm/","title":"PCI bij patiënten die TAVI ondergaan: gerandomiseerde trial — NEJM","title_en":"PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.","published":"2024-12-12"}],"10.1016/j.jacc.2024.07.065":[{"url":"https://hartvaat.nl/2024/12/10/ernstige-bloeding-en-mortaliteit-na-revascularisatie-van-linker-hoofdstam/","title":"Ernstige bloeding en mortaliteit na revascularisatie van linker hoofdstam","title_en":"Major Bleeding and Mortality After Revascularization of Left Main Disease.","published":"2024-12-10"}],"10.1161/circulationaha.124.070553":[{"url":"https://hartvaat.nl/2024/12/10/cognitieve-disfunctie-bij-hfpef-klinische-correlaten-en-prognostische-impact/","title":"Cognitieve disfunctie bij HFpEF: klinische correlaten en prognostische impact","title_en":"Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.","published":"2024-12-10"}],"10.1161/circulationaha.124.070870":[{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","title":"RELIEVE-HF: interatriale shunt bij hartfalen — negatieve gerandomiseerde trial","title_en":"Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.","published":"2024-12-10"}],"10.1016/j.jacc.2024.08.027":[{"url":"https://hartvaat.nl/2024/12/10/hospitalisatie-bij-symptomatische-hf-met-matige-tot-ernstige-functionele-mr/","title":"Hospitalisatie bij symptomatische HF met matige tot ernstige functionele MR","title_en":"Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2.","published":"2024-12-10"}],"10.1016/j.jacc.2024.08.025":[{"url":"https://hartvaat.nl/2024/12/10/lage-dosis-triple-combinatiepil-versus-placebo-bij-initiele-hypertensiebehandeli/","title":"Lage-dosis triple combinatiepil versus placebo bij initiële hypertensiebehandeling","title_en":"Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension.","published":"2024-12-10"}],"10.1093/eurheartj/ehae596":[{"url":"https://hartvaat.nl/2024/12/07/anticoagulatie-bij-device-gedetecteerd-af-met-zonder-vaatlijden-noah-artesia-gec/","title":"Anticoagulatie bij device-gedetecteerd AF met/zonder vaatlijden: NOAH+ARTESIA gecombineerd","title_en":"Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.","published":"2024-12-07"}],"10.1056/nejmoa2407362":[{"url":"https://hartvaat.nl/2024/12/05/edoxaban-bij-af-en-stabiel-coronairlijden-antitrombotische-monotherapie/","title":"Edoxaban bij AF en stabiel coronairlijden: antitrombotische monotherapie","title_en":"Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.","published":"2024-12-05"}],"10.1056/nejmoa2405182":[{"url":"https://hartvaat.nl/2024/12/05/inflammatie-cholesterol-lp-a-en-30-jaars-cv-uitkomsten-bij-vrouwen/","title":"Inflammatie, cholesterol, Lp(a) en 30-jaars CV-uitkomsten bij vrouwen","title_en":"Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.","published":"2024-12-05"}],"10.1093/europace/euae292":[{"url":"https://hartvaat.nl/2024/12/03/ct-gestuurde-atriale-wanddiktemapping-bij-cryoballon-pvi/","title":"CT-gestuurde atriale wanddiktemapping bij cryoballon PVI","title_en":"Using computed tomography atrial myocardial thickness maps in cryoballoon pulmonary vein isolation: the UTMOST AF II randomized clinical trial.","published":"2024-12-03"}],"10.1093/europace/euae293":[{"url":"https://hartvaat.nl/2024/12/03/pfa-versus-cryoballon-voor-af-ablatie-multielectrode-vergelijking/","title":"PFA versus cryoballon voor AF-ablatie: multielectrode vergelijking","title_en":"Multielectrode catheter-based pulsed electric field vs. cryoballoon for atrial fibrillation ablation: a systematic review and meta-analysis.","published":"2024-12-03"}],"10.1161/circulationaha.124.071176":[{"url":"https://hartvaat.nl/2024/12/03/nt-probnp-en-ecg-screening-bij-75-jarigen-voor-af-detectie-rct/","title":"NT-proBNP en ECG screening bij 75-jarigen voor AF-detectie: RCT","title_en":"Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year-Olds to Detect Atrial Fibrillation: STROKESTOP II.","published":"2024-12-03"}],"10.1161/circulationaha.124.071208":[{"url":"https://hartvaat.nl/2024/12/03/restrictief-versus-liberaal-transfusiebeleid-bij-type-1-versus-type-2-mi-reality/","title":"Restrictief versus liberaal transfusiebeleid bij type 1 versus type 2 MI: REALITY subanalyse","title_en":"Restrictive Versus Liberal Transfusion in Patients With Type 1 or Type 2 Myocardial Infarction: A Prespecified Analysis of the MINT Trial.","published":"2024-12-03"}],"10.1001/jamacardio.2024.3649":[{"url":"https://hartvaat.nl/2024/12/01/polygene-risicoscore-en-chloortalidone-respons/","title":"Polygene risicoscore en chloortalidone-respons","title_en":"Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response.","published":"2024-12-01"}],"10.1001/jamacardio.2024.3216":[{"url":"https://hartvaat.nl/2024/12/01/korte-dapt-na-des-bij-acs-ipd-meta-analyse-bevestigt-veiligheid/","title":"Korte DAPT na DES bij ACS: IPD meta-analyse bevestigt veiligheid","title_en":"Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.","published":"2024-12-01"}],"10.1001/jamacardio.2024.2612":[{"url":"https://hartvaat.nl/2024/12/01/splanchnische-zenuwablatie-bij-hfpef-endovasculaire-benadering/","title":"Splanchnische zenuwablatie bij HFpEF: endovasculaire benadering","title_en":"Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Randomized Clinical Trial.","published":"2024-12-01"}],"10.1001/jamacardio.2024.3200":[{"url":"https://hartvaat.nl/2024/12/01/ldl-verlaging-en-lesie-niveau-effecten-na-acuut-mi/","title":"LDL-verlaging en lesie-niveau effecten na acuut MI","title_en":"Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial.","published":"2024-12-01"}],"10.1093/eurheartj/ehae538":[{"url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","title":"COLICA: colchicine bij acuut gedecompenseerd hartfalen","title_en":"Colchicine in acutely decompensated heart failure: the COLICA trial.","published":"2024-12-01"}],"10.1002/ehf2.14951":[{"url":"https://hartvaat.nl/2024/12/01/nt-probnp-voorspelt-nieuw-ontstaan-af-bij-hfpef/","title":"NT-proBNP voorspelt nieuw-ontstaan AF bij HFpEF","title_en":"Predictive value of NT pro BNP for new-onset atrial fibrillation in heart failure and preserved ejection fraction.","published":"2024-12-01"}],"10.1002/ehf2.15000":[{"url":"https://hartvaat.nl/2024/12/01/hartfrequentiereactiviteit-en-inspanningstolerantie-bij-hartfalen/","title":"Hartfrequentiereactiviteit en inspanningstolerantie bij hartfalen","title_en":"Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure.","published":"2024-12-01"}],"10.1002/ehf2.15008":[{"url":"https://hartvaat.nl/2024/12/01/mortaliteitsvoorspelling-bij-hfpef-systematische-review-en-meta-analyse/","title":"Mortaliteitsvoorspelling bij HFpEF: systematische review en meta-analyse","title_en":"Systematic review and meta-analysis to predict mortality in heart failure with preserved ejection fraction: Development and validation of the HF-DANAS score.","published":"2024-12-01"}],"10.1002/ehf2.14957":[{"url":"https://hartvaat.nl/2024/12/01/dynamische-optimalisatie-bij-crt-systematische-review-en-netwerk-meta-analyse/","title":"Dynamische optimalisatie bij CRT: systematische review en netwerk-meta-analyse","title_en":"Emergent role of dynamic optimization in cardiac resynchronization therapy: Systematic review and network meta-analysis.","published":"2024-12-01"}],"10.1002/ehf2.14993":[{"url":"https://hartvaat.nl/2024/12/01/sglt2-remming-en-cardiale-reverse-remodelling-bij-hartfalen-systematische-review/","title":"SGLT2-remming en cardiale reverse remodelling bij hartfalen: systematische review","title_en":"Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis.","published":"2024-12-01"}],"10.1002/ehf2.14979":[{"url":"https://hartvaat.nl/2024/12/01/sekseverschillen-in-effect-van-sglt2-remmers-en-glp-1-agonisten-meta-analyse/","title":"Sekseverschillen in effect van SGLT2-remmers en GLP-1-agonisten: meta-analyse","title_en":"Effect of sex on sodium-glucose co-transporter-2 antagonists and glucagon-like peptide-1 agonists in heart failure.","published":"2024-12-01"}],"10.1002/ehf2.14925":[{"url":"https://hartvaat.nl/2024/12/01/science-ii-mesenchymale-stamcellen-bij-niet-ischemisch-hartfalen-negatieve-trial/","title":"SCIENCE II: mesenchymale stamcellen bij niet-ischemisch hartfalen — negatieve trial","title_en":"Mesenchymal stromal cells to treat patients with non-ischaemic heart failure: Results from SCIENCE II pilot study.","published":"2024-12-01"}],"10.1161/circulationaha.123.066605":[{"url":"https://hartvaat.nl/2024/11/26/panorama-hf-sacubitril-valsartan-bij-pediatrisch-hartfalen-nejm/","title":"PANORAMA-HF: sacubitril/valsartan bij pediatrisch hartfalen — NEJM","title_en":"Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.","published":"2024-11-26"}],"10.1016/j.jacc.2024.08.001":[{"url":"https://hartvaat.nl/2024/11/26/aegis-ii-subanalyse-apoa-i-infusie-en-ischemische-eventlast-na-mi/","title":"AEGIS-II subanalyse: apoA-I infusie en ischemische eventlast na MI","title_en":"ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial.","published":"2024-11-26"}],"10.1161/circulationaha.124.069903":[{"url":"https://hartvaat.nl/2024/11/26/artesia-subanalyse-cva-risico-naar-frequentie-en-duur-van-subclinisch-af/","title":"ARTESIA subanalyse: CVA-risico naar frequentie en duur van subclinisch AF","title_en":"Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.","published":"2024-11-26"}],"10.1161/circulationaha.124.071689":[{"url":"https://hartvaat.nl/2024/11/26/glp-1-agonisten-alleen-en-met-sglt2-remmers-cv-renale-en-veiligheidsuitkomsten/","title":"GLP-1-agonisten alleen en met SGLT2-remmers: CV, renale en veiligheidsuitkomsten","title_en":"Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","published":"2024-11-26"}],"10.1016/j.jacc.2024.08.019":[{"url":"https://hartvaat.nl/2024/11/19/screening-op-niet-gediagnosticeerd-af-voor-cva-preventie-gerandomiseerde-trial/","title":"Screening op niet-gediagnosticeerd AF voor CVA-preventie: gerandomiseerde trial","title_en":"Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention.","published":"2024-11-19"}],"10.1161/circulationaha.124.071186":[{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","title":"AFLOAT: flecaïnide voorkomt AF na PFO-sluiting — RCT","title_en":"Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial.","published":"2024-11-19"}],"10.1093/eurheartj/ehae326":[{"url":"https://hartvaat.nl/2024/11/14/plotse-hartdood-na-mi-ipd-analyse-van-gepoolde-cohorten/","title":"Plotse hartdood na MI: IPD analyse van gepoolde cohorten","title_en":"Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts.","published":"2024-11-14"}],"10.1056/nejmoa2408739":[{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","title":"MATTERHORN: transcatheter repair versus chirurgie bij secundaire MR — NEJM","title_en":"Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation.","published":"2024-11-14"}],"10.1056/nejmoa2314328":[{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","title":"RESHAPE-HF2: transcatheter kleprepair bij HF met matige tot ernstige MR — NEJM","title_en":"Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.","published":"2024-11-14"}],"10.1093/eurheartj/ehae521":[{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","title":"ILUMIEN IV: OCT-predictoren van klinische uitkomsten na stentimplantatie","title_en":"Optical coherence tomography predictors of clinical outcomes after stent implantation: the ILUMIEN IV trial.","published":"2024-11-14"}],"10.1016/j.jacc.2024.09.012":[{"url":"https://hartvaat.nl/2024/11/12/recaticimab-als-toevoeging-aan-statines-fase-3-remain-2/","title":"Recaticimab als toevoeging aan statines: fase 3 REMAIN-2","title_en":"Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial.","published":"2024-11-12"}],"10.1016/j.jacc.2024.07.035":[{"url":"https://hartvaat.nl/2024/11/12/recaticimab-monotherapie-bij-niet-familiaire-hypercholesterolemie-fase-3-remain-/","title":"Recaticimab monotherapie bij niet-familiaire hypercholesterolemie: fase 3 REMAIN-1","title_en":"Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial.","published":"2024-11-12"}],"10.1161/circulationaha.124.069709":[{"url":"https://hartvaat.nl/2024/11/12/renale-denervatie-bij-hypertensie-uitgebreide-meta-analyse-van-alle-trials/","title":"Renale denervatie bij hypertensie: uitgebreide meta-analyse van alle trials","title_en":"Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.","published":"2024-11-12"}],"10.1161/circulationaha.124.069215":[{"url":"https://hartvaat.nl/2024/11/12/rf-renale-denervatie-bij-ongecontroleerde-hypertensie-in-china-gerandomiseerde-t/","title":"RF-renale denervatie bij ongecontroleerde hypertensie in China: gerandomiseerde trial","title_en":"Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial.","published":"2024-11-12"}],"10.1016/j.jacc.2024.07.028":[{"url":"https://hartvaat.nl/2024/11/12/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-met-zonder-card/","title":"Complete versus culprit-only revascularisatie bij ouderen met MI met/zonder cardiogene shock","title_en":"Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction With or Without ST-Segment Elevation.","published":"2024-11-12"}],"10.1016/j.jacc.2024.07.013":[{"url":"https://hartvaat.nl/2024/11/12/sglt2-remming-en-proteomische-handtekeningen-bij-hartfalen-bevestiging/","title":"SGLT2-remming en proteomische handtekeningen bij hartfalen: bevestiging","title_en":"Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.","published":"2024-11-12"}],"10.1161/circulationaha.124.069732":[{"url":"https://hartvaat.nl/2024/11/12/ketonester-bij-type-2-diabetes-en-hartfalen-cross-over-trial/","title":"Ketonester bij type 2 diabetes en hartfalen: cross-over trial","title_en":"Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.","published":"2024-11-12"}],"10.1016/s0140-6736(24)02175-5":[{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","title":"FAVOR IV-QVAS: QFR versus FFR bij coronaire revascularisatiedecisies — Lancet","title_en":"Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.","published":"2024-11-09"}],"10.1093/eurheartj/ehae561":[{"url":"https://hartvaat.nl/2024/11/08/premier-in-hospital-start-van-sacubitril-valsartan-bij-acuut-hartfalen/","title":"PREMIER: in-hospital start van sacubitril/valsartan bij acuut hartfalen","title_en":"In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.","published":"2024-11-08"}],"10.1056/nejmoa2407791":[{"url":"https://hartvaat.nl/2024/11/07/invasieve-strategie-bij-ouderen-met-mi-gerandomiseerde-trial-nejm/","title":"Invasieve strategie bij ouderen met MI: gerandomiseerde trial — NEJM","title_en":"Invasive Treatment Strategy for Older Patients with Myocardial Infarction.","published":"2024-11-07"}],"10.1161/circulationaha.124.071493":[{"url":"https://hartvaat.nl/2024/11/05/complete-versus-culprit-only-bij-ouderen-met-stemi-gerandomiseerde-trial/","title":"Complete versus culprit-only bij ouderen met STEMI: gerandomiseerde trial","title_en":"Complete Versus Culprit-Only Revascularization in Older Patients With ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis.","published":"2024-11-05"}],"10.1016/s0140-6736(24)02227-x":[{"url":"https://hartvaat.nl/2024/11/02/bioadaptor-implantaat-versus-drug-eluting-stent-bij-stabiel-coronairlijden/","title":"Bioadaptor implantaat versus drug-eluting stent bij stabiel coronairlijden","title_en":"Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.","published":"2024-11-02"}],"10.1093/europace/euae259":[{"url":"https://hartvaat.nl/2024/11/01/multipoint-pacing-verbetert-crt-prognose-en-respons/","title":"Multipoint pacing verbetert CRT-prognose en respons","title_en":"Multipoint pacing is associated with improved prognosis and cardiac resynchronization therapy response: MORE-CRT MPP randomized study secondary analyses.","published":"2024-11-01"}],"10.1001/jamacardio.2024.2526":[{"url":"https://hartvaat.nl/2024/11/01/cultureel-aangepaste-leefstijlinterventie-voor-zuid-aziatische-volwassenen-met-c/","title":"Cultureel aangepaste leefstijlinterventie voor Zuid-Aziatische volwassenen met CV-risico","title_en":"Culturally Adapted Lifestyle Intervention for South Asian Adults With Cardiovascular Risk Factors: The SAHELI Randomized Clinical Trial.","published":"2024-11-01"}],"10.1001/jamacardio.2024.2566":[{"url":"https://hartvaat.nl/2024/11/01/sacubitril-valsartan-vermindert-alle-hospitalisaties-bij-hartfalen-post-hoc-anal/","title":"Sacubitril/valsartan vermindert alle hospitalisaties bij hartfalen: post-hoc analyse","title_en":"Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials.","published":"2024-11-01"}],"10.1161/hypertensionaha.124.23597":[{"url":"https://hartvaat.nl/2024/11/01/optimale-antihypertensieve-systolische-bloeddruk-meta-analyse/","title":"Optimale antihypertensieve systolische bloeddruk: meta-analyse","title_en":"Optimal Antihypertensive Systolic Blood Pressure: A Systematic Review and Meta-Analysis.","published":"2024-11-01"}],"10.1161/hypertensionaha.124.23382":[{"url":"https://hartvaat.nl/2024/11/01/bloeddrukverlagende-medicatie-en-natriumbeperking-gecombineerd-effect/","title":"Bloeddrukverlagende medicatie en natriumbeperking: gecombineerd effect","title_en":"Blood Pressure-Lowering Medications, Sodium Reduction, and Blood Pressure.","published":"2024-11-01"}],"10.1016/j.jacc.2024.08.052":[{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","title":"IRONMAN: adjudicatie van hospitalisaties en sterfgevallen — heranalyse","title_en":"Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure.","published":"2024-10-29"}],"10.1016/j.jacc.2024.08.012":[{"url":"https://hartvaat.nl/2024/10/29/asymptomatische-versus-symptomatische-hypotensie-bij-sacubitril-valsartan-en-hfr/","title":"Asymptomatische versus symptomatische hypotensie bij sacubitril/valsartan en HFrEF","title_en":"Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HF.","published":"2024-10-29"}],"10.1161/circulationaha.123.068564":[{"url":"https://hartvaat.nl/2024/10/29/reset-bp-minder-sedentair-gedrag-verlaagt-bloeddruk-bij-kantoorwerkers/","title":"RESET-BP: minder sedentair gedrag verlaagt bloeddruk bij kantoorwerkers","title_en":"Effects of Sedentary Behavior Reduction on Blood Pressure in Desk Workers: Results From the RESET-BP Randomized Clinical Trial.","published":"2024-10-29"}],"10.1136/heartjnl-2024-323926":[{"url":"https://hartvaat.nl/2024/10/28/g-csf-voor-stamcelmobilisatie-na-acuut-mi-meta-analyse/","title":"G-CSF voor stamcelmobilisatie na acuut MI: meta-analyse","title_en":"Granulocyte colony-stimulating factor for stem cell mobilisation in acute myocardial infarction: a randomised controlled trial.","published":"2024-10-28"}],"10.1056/nejmoa2407107":[{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","title":"FINEARTS-HF: finerenon bij HFmrEF/HFpEF — NEJM","title_en":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.","published":"2024-10-24"}],"10.1016/j.jacc.2024.08.021":[{"url":"https://hartvaat.nl/2024/10/22/semaglutide-en-cardiale-structuur-functie-bij-hfpef-step-hfpef-echoanalyse/","title":"Semaglutide en cardiale structuur/functie bij HFpEF: STEP-HFpEF echoanalyse","title_en":"Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.","published":"2024-10-22"}],"10.1016/j.jacc.2024.08.023":[{"url":"https://hartvaat.nl/2024/10/22/af-en-semaglutide-bij-hfpef-met-obesitas-step-hfpef-analyse/","title":"AF en semaglutide bij HFpEF met obesitas: STEP-HFpEF analyse","title_en":"Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.","published":"2024-10-22"}],"10.1016/j.jacc.2024.08.028":[{"url":"https://hartvaat.nl/2024/10/22/inflammatie-bij-obesitas-gerelateerd-hfpef-step-hfpef-mechanistisch-inzicht/","title":"Inflammatie bij obesitas-gerelateerd HFpEF: STEP-HFpEF mechanistisch inzicht","title_en":"Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.","published":"2024-10-22"}],"10.1016/j.jacc.2024.08.004":[{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","title":"FLOW: semaglutide vermindert hartfalen bij diabetes en CKD","title_en":"Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.","published":"2024-10-22"}],"10.1093/eurheartj/ehae551":[{"url":"https://hartvaat.nl/2024/10/21/dieet-en-af-risico-systematische-review/","title":"Dieet en AF-risico: systematische review","title_en":"Diet and risk of atrial fibrillation: a systematic review.","published":"2024-10-21"}],"10.1093/eurheartj/ehae532":[{"url":"https://hartvaat.nl/2024/10/21/shensong-yangxin-voorkomt-af-recidief-na-ablatie-bij-persisterend-af/","title":"Shensong Yangxin voorkomt AF-recidief na ablatie bij persisterend AF","title_en":"Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial.","published":"2024-10-21"}],"10.1016/s0140-6736(24)01744-6":[{"url":"https://hartvaat.nl/2024/10/19/lage-dosis-triple-combinatiepil-bij-milde-hypertensie-gerandomiseerde-trial/","title":"Lage-dosis triple combinatiepil bij milde hypertensie: gerandomiseerde trial","title_en":"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.","published":"2024-10-19"}],"10.1016/j.jacc.2024.07.045":[{"url":"https://hartvaat.nl/2024/10/15/bright-4-bevestiging-bivalirudine-superieur-aan-heparine-bij-stemi/","title":"BRIGHT-4 bevestiging: bivalirudine superieur aan heparine bij STEMI","title_en":"Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results.","published":"2024-10-15"}],"10.1161/cir.0000000000001273":[{"url":"https://hartvaat.nl/2024/10/15/aha-scientific-statement-nierdisfunctie-bij-gevorderd-hartfalen/","title":"AHA Scientific Statement: nierdisfunctie bij gevorderd hartfalen","title_en":"Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association.","published":"2024-10-15"}],"10.1093/eurheartj/ehae610":[{"url":"https://hartvaat.nl/2024/10/14/ecls-shock-eenjaarsresultaten-ecmo-bij-cardiogene-shock-blijft-negatief/","title":"ECLS-SHOCK eenjaarsresultaten: ECMO bij cardiogene shock blijft negatief","title_en":"Routine extracorporeal life support in infarct-related cardiogenic shock: 1-year results of the ECLS-SHOCK trial.","published":"2024-10-14"}],"10.1056/nejmoa2404204":[{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","title":"REDUCE-AMI: bètablokkers na MI met behouden EF niet nodig — bevestiging","title_en":"Beta-Blocker Interruption or Continuation after Myocardial Infarction.","published":"2024-10-10"}],"10.1093/eurheartj/ehae564":[{"url":"https://hartvaat.nl/2024/10/07/semaglutide-en-bloeddruk-ipd-meta-analyse/","title":"Semaglutide en bloeddruk: IPD meta-analyse","title_en":"Semaglutide and blood pressure: an individual patient data meta-analysis.","published":"2024-10-07"}],"10.1093/eurheartj/ehae178":[{"url":"https://hartvaat.nl/2024/10/07/2024-esc-richtlijn-voor-management-van-hypertensie/","title":"2024 ESC-richtlijn voor management van hypertensie","title_en":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension.","published":"2024-10-07"}],"10.1093/eurheartj/ehae479":[{"url":"https://hartvaat.nl/2024/10/05/iv-ferricarboxymaltose-en-inspanningscapaciteit-bij-hfpef-met-ijzerdeficientie/","title":"IV ferricarboxymaltose en inspanningscapaciteit bij HFpEF met ijzerdeficiëntie","title_en":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.","published":"2024-10-05"}],"10.1093/europace/euae233":[{"url":"https://hartvaat.nl/2024/10/03/uitgebreide-versus-standaard-remote-monitoring-bij-crt-en-hartfalen/","title":"Uitgebreide versus standaard remote monitoring bij CRT en hartfalen","title_en":"Comprehensive vs. standard remote monitoring of cardiac resynchronization devices in heart failure patients: results of the ECOST-CRT study.","published":"2024-10-03"}],"10.1093/europace/euae232":[{"url":"https://hartvaat.nl/2024/10/03/geisoleerde-versus-hybride-thoracoscopische-ablatie-bij-af-korte-en-langetermijn/","title":"Geïsoleerde versus hybride thoracoscopische ablatie bij AF: korte en langetermijn","title_en":"Short- and long-term outcomes in isolated vs. hybrid thoracoscopic ablation in patients with atrial fibrillation: a systematic review and reconstructed individual patient data meta-analysis.","published":"2024-10-03"}],"10.1016/j.jacc.2024.05.079":[{"url":"https://hartvaat.nl/2024/10/01/patiromer-faciliteert-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie/","title":"Patiromer faciliteert RAAS-remmer-optitratie bij HFrEF met hyperkaliëmie","title_en":"Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia.","published":"2024-10-01"}],"10.1001/jama.2024.18080":[{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-drievoudige-pil-versus-standaardzorg-bij-hypertensie-in-nigeria/","title":"Lage-dosis drievoudige pil versus standaardzorg bij hypertensie in Nigeria","title_en":"Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial.","published":"2024-10-01"}],"10.1001/jamacardio.2024.2298":[{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","title":"PULSE-MI: prehospitale puls-dosis glucocorticoïd bij STEMI","title_en":"Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial.","published":"2024-10-01"}],"10.1001/jamacardio.2024.2435":[{"url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","title":"AMETHYST: verinurad plus allopurinol bij HFpEF — negatieve trial","title_en":"Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial.","published":"2024-10-01"}],"10.1001/jamacardio.2024.2356":[{"url":"https://hartvaat.nl/2024/10/01/plotse-dood-na-mi-inzichten-uit-valiant-en-paradise-mi/","title":"Plotse dood na MI: inzichten uit VALIANT en PARADISE-MI","title_en":"Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials.","published":"2024-10-01"}],"10.1001/jamacardio.2024.2335":[{"url":"https://hartvaat.nl/2024/10/01/lage-dosis-doac-versus-dapt-na-laa-occlusie-gerandomiseerde-trial/","title":"Lage-dosis DOAC versus DAPT na LAA-occlusie: gerandomiseerde trial","title_en":"Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial.","published":"2024-10-01"}],"10.1001/jamacardio.2024.2050":[{"url":"https://hartvaat.nl/2024/10/01/draadloos-ultrasound-gebaseerd-crt-systeem-bij-hartfalen/","title":"Draadloos ultrasound-gebaseerd CRT-systeem bij hartfalen","title_en":"Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure.","published":"2024-10-01"}],"10.1161/hypertensionaha.124.23416":[{"url":"https://hartvaat.nl/2024/10/01/binge-alcoholconsumptie-verhoogt-sympathische-bloeddrukrespons-rct/","title":"Binge-alcoholconsumptie verhoogt sympathische bloeddrukrespons: RCT","title_en":"Binge Alcohol Consumption Elevates Sympathetic Transduction to Blood Pressure: A Randomized Controlled Trial.","published":"2024-10-01"}],"10.1161/circulationaha.124.069440":[{"url":"https://hartvaat.nl/2024/10/01/neurofilament-light-chain-en-cva-risico-bij-af/","title":"Neurofilament light chain en CVA-risico bij AF","title_en":"Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation.","published":"2024-10-01"}],"10.1161/hypertensionaha.123.22437":[{"url":"https://hartvaat.nl/2024/10/01/oraal-butyraat-verlaagt-bloeddruk-bij-hypertensie-rct/","title":"Oraal butyraat verlaagt bloeddruk bij hypertensie: RCT","title_en":"Effects of Oral Butyrate on Blood Pressure in Patients With Hypertension: A Randomized, Placebo-Controlled Trial.","published":"2024-10-01"}],"10.1002/ehf2.14919":[{"url":"https://hartvaat.nl/2024/10/01/af-ablatie-verbetert-uitkomsten-bij-hartfalen-geactualiseerde-meta-analyse/","title":"AF-ablatie verbetert uitkomsten bij hartfalen: geactualiseerde meta-analyse","title_en":"Catheter ablation of atrial fibrillation improves outcomes in heart failure: An updated meta-analysis.","published":"2024-10-01"}],"10.1002/ehf2.14916":[{"url":"https://hartvaat.nl/2024/10/01/bdnf-en-hartfalen-systematische-review-en-meta-analyse/","title":"BDNF en hartfalen: systematische review en meta-analyse","title_en":"Circulating brain-derived neurotrophic factor levels and heart failure: A systematic review and meta-analysis.","published":"2024-10-01"}],"10.1002/ehf2.14851":[{"url":"https://hartvaat.nl/2024/10/01/natriuretische-peptiden-en-crp-bij-hartfalen-en-ondervoeding-systematische-revie/","title":"Natriuretische peptiden en CRP bij hartfalen en ondervoeding: systematische review","title_en":"Natriuretic peptides and C-reactive protein in in heart failure and malnutrition: a systematic review and meta-analysis.","published":"2024-10-01"}],"10.1002/ehf2.14835":[{"url":"https://hartvaat.nl/2024/10/01/crt-bij-inotroop-afhankelijk-hartfalen-meta-analyse/","title":"CRT bij inotroop-afhankelijk hartfalen: meta-analyse","title_en":"Cardiac resynchronization therapy in inotrope-dependent heart failure: a meta-analysis.","published":"2024-10-01"}],"10.1002/ehf2.14813":[{"url":"https://hartvaat.nl/2024/10/01/galectine-3-en-langetermijnuitkomsten-bij-hartfalen-meta-analyse/","title":"Galectine-3 en langetermijnuitkomsten bij hartfalen: meta-analyse","title_en":"Galectin-3 levels and long-term all-cause mortality and hospitalization in heart failure patients: a meta-analysis.","published":"2024-10-01"}],"10.1002/ehf2.14837":[{"url":"https://hartvaat.nl/2024/10/01/zink-en-koperbiomarkers-en-hartfalen-meta-analyse/","title":"Zink- en koperbiomarkers en hartfalen: meta-analyse","title_en":"Association between biomarkers of zinc and copper status and heart failure: a meta-analysis.","published":"2024-10-01"}],"10.1002/ehf2.14814":[{"url":"https://hartvaat.nl/2024/10/01/catheterablatie-voor-af-bij-hartfalen-meta-analyse-van-rct-s-geactualiseerd/","title":"Catheterablatie voor AF bij hartfalen: meta-analyse van RCT's — geactualiseerd","title_en":"Efficacy of catheter ablation for atrial fibrillation in heart failure: a meta-analysis of randomized controlled trials.","published":"2024-10-01"}],"10.1093/eurheartj/ehae176":[{"url":"https://hartvaat.nl/2024/09/29/2024-esc-richtlijn-voor-management-van-atriumfibrilleren/","title":"2024 ESC-richtlijn voor management van atriumfibrilleren","title_en":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).","published":"2024-09-29"}],"10.1093/eurheartj/ehae471":[{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","title":"ISCHEMIA: atherosclerosekwantificering en CV-risico","title_en":"Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.","published":"2024-09-29"}],"10.1136/heartjnl-2024-324038":[{"url":"https://hartvaat.nl/2024/09/25/obesitasmaten-en-hypertensieve-zwangerschapsstoornissen-meta-analyse-en-mr/","title":"Obesitasmaten en hypertensieve zwangerschapsstoornissen: meta-analyse en MR","title_en":"Impact of multiple obesity metrics on hypertensive disorders of pregnancy: a meta-analysis and Mendelian randomisation study.","published":"2024-09-25"}],"10.1161/circulationaha.124.069917":[{"url":"https://hartvaat.nl/2024/09/24/reality-subanalyse-restrictief-transfusiebeleid-bij-mi-en-anemie-langere-follow-/","title":"REALITY subanalyse: restrictief transfusiebeleid bij MI en anemie — langere follow-up","title_en":"Restrictive or Liberal Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: 6-Month Mortality in the MINT Trial.","published":"2024-09-24"}],"10.1001/jama.2024.17888":[{"url":"https://hartvaat.nl/2024/09/24/tight-k-kaliumsuppletie-voorkomt-af-na-hartchirurgie-rct/","title":"TIGHT K: kaliumsuppletie voorkomt AF na hartchirurgie — RCT","title_en":"Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery: The TIGHT K Randomized Clinical Trial.","published":"2024-09-24"}],"10.1161/circulationaha.124.069808":[{"url":"https://hartvaat.nl/2024/09/24/colchicine-en-coronaire-plaquestabiliteit-na-acs-oct-studie/","title":"Colchicine en coronaire plaquestabiliteit na ACS: OCT-studie","title_en":"Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial.","published":"2024-09-24"}],"10.1016/j.jacc.2024.06.002":[{"url":"https://hartvaat.nl/2024/09/24/2024-acc-beslispad-klinische-beoordeling-en-trajectmanagement-bij-hfpef/","title":"2024 ACC beslispad: klinische beoordeling en trajectmanagement bij HFpEF","title_en":"2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2024-09-24"}],"10.1161/circulationaha.124.068788":[{"url":"https://hartvaat.nl/2024/09/24/dapagliflozine-verbetert-arteriele-en-veneuze-compliantie-bij-hfpef/","title":"Dapagliflozine verbetert arteriële en veneuze compliantie bij HFpEF","title_en":"Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial.","published":"2024-09-24"}],"10.1016/s0140-6736(24)01733-1":[{"url":"https://hartvaat.nl/2024/09/21/mra-bij-hartfalen-ipd-meta-analyse-bevestigt-overlevingsvoordeel/","title":"MRA bij hartfalen: IPD meta-analyse bevestigt overlevingsvoordeel","title_en":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.","published":"2024-09-21"}],"10.1016/j.jacc.2024.06.036":[{"url":"https://hartvaat.nl/2024/09/17/sotagliflozine-en-gezondheidsstatus-bij-verslechterend-hartfalen-soloist-whf/","title":"Sotagliflozine en gezondheidsstatus bij verslechterend hartfalen: SOLOIST-WHF","title_en":"Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.","published":"2024-09-17"}],"10.1016/j.jacc.2024.05.014":[{"url":"https://hartvaat.nl/2024/09/17/2024-acc-aha-kwaliteitsmaatstaven-voor-hartfalen-geactualiseerd/","title":"2024 ACC/AHA kwaliteitsmaatstaven voor hartfalen geactualiseerd","title_en":"2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures.","published":"2024-09-17"}],"10.1136/heartjnl-2024-324301":[{"url":"https://hartvaat.nl/2024/09/16/langetermijn-hartfalenrisico-bij-volwassen-kankeroverlevenden-meta-analyse/","title":"Langetermijn hartfalenrisico bij volwassen kankeroverlevenden: meta-analyse","title_en":"Long-term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis.","published":"2024-09-16"}],"10.1136/heartjnl-2024-324170":[{"url":"https://hartvaat.nl/2024/09/16/tirzepatide-en-bloeddrukverlaging-surmount-1-gestratificeerde-analyse/","title":"Tirzepatide en bloeddrukverlaging: SURMOUNT-1 gestratificeerde analyse","title_en":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.","published":"2024-09-16"}],"10.1136/heartjnl-2023-323796":[{"url":"https://hartvaat.nl/2024/09/16/spironolacton-en-urinaire-proteomics-evidence-uit-homage/","title":"Spironolacton en urinaire proteomics: evidence uit HOMAGE","title_en":"Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial.","published":"2024-09-16"}],"10.1016/s0140-6736(24)01454-5":[{"url":"https://hartvaat.nl/2024/09/14/oct-geleide-versus-angiografie-geleide-pci-bij-acs-gerandomiseerde-trial/","title":"OCT-geleide versus angiografie-geleide PCI bij ACS: gerandomiseerde trial","title_en":"Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.","published":"2024-09-14"}],"10.1016/s0140-6736(24)01594-0":[{"url":"https://hartvaat.nl/2024/09/14/drug-coated-balloon-versus-intended-stenting-bij-de-novo-coronairlaesies/","title":"Drug-coated balloon versus intended stenting bij de novo coronairlaesies","title_en":"Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.","published":"2024-09-14"}],"10.1016/s0140-6736(24)01448-x":[{"url":"https://hartvaat.nl/2024/09/14/temporaire-mechanische-circulatie-bij-cardiogene-shock-ipd-meta-analyse/","title":"Temporaire mechanische circulatie bij cardiogene shock: IPD meta-analyse","title_en":"Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.","published":"2024-09-14"}],"10.1093/eurheartj/ehae417":[{"url":"https://hartvaat.nl/2024/09/14/sekseverschillen-in-fh-behandeling-meta-analyse/","title":"Sekseverschillen in FH-behandeling: meta-analyse","title_en":"Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis.","published":"2024-09-14"}],"10.1093/eurheartj/ehae322":[{"url":"https://hartvaat.nl/2024/09/14/semaglutide-en-diureticagebruik-bij-hfpef-met-obesitas-step-hfpef-analyse/","title":"Semaglutide en diureticagebruik bij HFpEF met obesitas: STEP-HFpEF analyse","title_en":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.","published":"2024-09-14"}],"10.1056/nejmoa2404147":[{"url":"https://hartvaat.nl/2024/09/12/zodasiran-sirna-tegen-angptl3-bij-gemengde-hyperlipidemie-nejm/","title":"Zodasiran: siRNA tegen ANGPTL3 bij gemengde hyperlipidemie — NEJM","title_en":"Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.","published":"2024-09-12"}],"10.1056/nejmoa2404143":[{"url":"https://hartvaat.nl/2024/09/12/plozasiran-sirna-tegen-apoc3-bij-gemengde-hyperlipidemie-nejm/","title":"Plozasiran: siRNA tegen APOC3 bij gemengde hyperlipidemie — NEJM","title_en":"Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.","published":"2024-09-12"}],"10.1016/j.jacc.2024.06.035":[{"url":"https://hartvaat.nl/2024/09/10/triglyceriden-alirocumab-en-cv-uitkomsten-na-acs/","title":"Triglyceriden, alirocumab en CV-uitkomsten na ACS","title_en":"Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.","published":"2024-09-10"}],"10.1001/jama.2024.11463":[{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","title":"TACT-2: chelatietherapie na MI bij diabetes — negatieve trial","title_en":"Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial.","published":"2024-09-10"}],"10.1016/s0140-6736(24)01616-7":[{"url":"https://hartvaat.nl/2024/09/07/de-escalatie-naar-ticagrelor-monotherapie-bij-diabetespatienten-na-acs/","title":"De-escalatie naar ticagrelor monotherapie bij diabetespatiënten na ACS","title_en":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.","published":"2024-09-07"}],"10.1016/s0140-6736(24)01643-x":[{"url":"https://hartvaat.nl/2024/09/07/semaglutide-bij-hfmref-hfpef-gerandomiseerde-trial/","title":"Semaglutide bij HFmrEF/HFpEF: gerandomiseerde trial","title_en":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.","published":"2024-09-07"}],"10.1016/j.jacc.2024.06.022":[{"url":"https://hartvaat.nl/2024/09/03/augustus-4-weg-vergelijking-antitrombotische-strategieen-bij-af-na-acs-pci/","title":"AUGUSTUS 4-weg vergelijking: antitrombotische strategieën bij AF na ACS/PCI","title_en":"Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS.","published":"2024-09-03"}],"10.1001/jamacardio.2024.1914":[{"url":"https://hartvaat.nl/2024/09/01/dapagliflozine-en-rv-pulmonale-interactie-bij-hfpef/","title":"Dapagliflozine en RV-pulmonale interactie bij HFpEF","title_en":"Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial.","published":"2024-09-01"}],"10.1001/jamacardio.2024.2019":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","title":"ADAPTABLE: bijdrage van klinische trial-data naar databron","title_en":"Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial.","published":"2024-09-01"}],"10.1093/eurheartj/ehae423":[{"url":"https://hartvaat.nl/2024/09/01/strip-20-jaarsresultaten-van-dieetinterventie-vanaf-de-zuigelingenleeftijd/","title":"STRIP: 20-jaarsresultaten van dieetinterventie vanaf de zuigelingenleeftijd","title_en":"Randomized 20-year infancy-onset dietary intervention, life-long cardiovascular risk factors and retinal microvasculature.","published":"2024-09-01"}],"10.1001/jamacardio.2024.1712":[{"url":"https://hartvaat.nl/2024/09/01/aspirinedosering-voor-secundaire-preventie-bij-mannen-versus-vrouwen/","title":"Aspirinedosering voor secundaire preventie bij mannen versus vrouwen","title_en":"Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.","published":"2024-09-01"}],"10.1001/jamacardio.2024.1793":[{"url":"https://hartvaat.nl/2024/09/01/eldercare-af-subanalyse-dosisreductie-edoxaban-bij-80-jarigen-met-af/","title":"ELDERCARE-AF subanalyse: dosisreductie edoxaban bij ≥80-jarigen met AF","title_en":"Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.","published":"2024-09-01"}],"10.1001/jamacardio.2024.1659":[{"url":"https://hartvaat.nl/2024/09/01/lerodalcibep-bij-ascvd-of-hoog-risico-fase-3-resultaten/","title":"Lerodalcibep bij ASCVD of hoog risico: fase 3 resultaten","title_en":"Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.","published":"2024-09-01"}],"10.1001/jamacardio.2024.1556":[{"url":"https://hartvaat.nl/2024/09/01/post-pci-subanalyse-routine-stresstesten-niet-zinvol-bij-acs-noch-stabiel/","title":"POST-PCI subanalyse: routine stresstesten niet zinvol bij ACS noch stabiel","title_en":"Routine Stress Testing After PCI in Patients With and Without Acute Coronary Syndrome: A Secondary Analysis of the POST-PCI Randomized Clinical Trial.","published":"2024-09-01"}],"10.1001/jamacardio.2024.1449":[{"url":"https://hartvaat.nl/2024/09/01/multifactorieel-intensief-bloeddrukmodel-bij-ouderen-en-jongeren/","title":"Multifactorieel intensief bloeddrukmodel bij ouderen en jongeren","title_en":"Multifaceted Intensive Blood Pressure Control Model in Older and Younger Individuals With Hypertension: A Randomized Clinical Trial.","published":"2024-09-01"}],"10.1093/eurheartj/ehae249":[{"url":"https://hartvaat.nl/2024/09/01/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vier-trials/","title":"Ticagrelor monotherapie na ACS: IPD meta-analyse van vier trials","title_en":"Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials.","published":"2024-09-01"}],"10.1093/eurheartj/ehae266":[{"url":"https://hartvaat.nl/2024/09/01/periprocedureel-mi-na-pci-en-langetermijnmortaliteit-meta-analyse/","title":"Periprocedureel MI na PCI en langetermijnmortaliteit: meta-analyse","title_en":"Periprocedural myocardial infarction after percutaneous coronary intervention and long-term mortality: a meta-analysis.","published":"2024-09-01"}],"10.1161/hypertensionaha.124.23439":[{"url":"https://hartvaat.nl/2024/09/01/hypertensieduur-en-effect-van-intensieve-bloeddrukbehandeling/","title":"Hypertensieduur en effect van intensieve bloeddrukbehandeling","title_en":"Impact of Hypertension Duration on the Cardiovascular Benefit of Intensive Blood Pressure Control.","published":"2024-09-01"}],"10.1161/hypertensionaha.124.22999":[{"url":"https://hartvaat.nl/2024/09/01/nieuwe-metabolieten-geassocieerd-met-bloeddrukrespons-op-dieetinterventies/","title":"Nieuwe metabolieten geassocieerd met bloeddrukrespons op dieetinterventies","title_en":"Novel Metabolites Associated With Blood Pressure After Dietary Interventions.","published":"2024-09-01"}],"10.1161/hypertensionaha.124.22876":[{"url":"https://hartvaat.nl/2024/09/01/troponine-nt-probnp-en-cognitieve-uitkomsten-in-sprint/","title":"Troponine, NT-proBNP en cognitieve uitkomsten in SPRINT","title_en":"High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT.","published":"2024-09-01"}],"10.1093/europace/euae226":[{"url":"https://hartvaat.nl/2024/08/30/simultane-hybride-ablatie-versus-thoracoscopische-chirurgische-ablatie-bij-persi/","title":"Simultane hybride ablatie versus thoracoscopische chirurgische ablatie bij persisterend AF","title_en":"Comparing simultaneous hybrid ablation with stand-alone thoracoscopic surgical ablation for the treatment of non-paroxysmal atrial fibrillation: a prospective randomized controlled trial.","published":"2024-08-30"}],"10.1016/j.jacc.2024.05.065":[{"url":"https://hartvaat.nl/2024/08/27/stop-semaglutide-vermindert-epicardiaal-vetweefsel-bij-type-2-diabetes/","title":"STOP: semaglutide vermindert epicardiaal vetweefsel bij type 2 diabetes","title_en":"Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.","published":"2024-08-27"}],"10.1016/j.jacc.2024.06.001":[{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","title":"STEP-HFpEF: semaglutide even effectief bij mannen en vrouwen","title_en":"Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.","published":"2024-08-27"}],"10.1016/s0140-6736(24)01498-3":[{"url":"https://hartvaat.nl/2024/08/24/select-subanalyse-semaglutide-verbetert-cv-uitkomsten-bij-obesitas-met-hartfalen/","title":"SELECT subanalyse: semaglutide verbetert CV-uitkomsten bij obesitas met hartfalen","title_en":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.","published":"2024-08-24"}],"10.1093/eurheartj/ehae323":[{"url":"https://hartvaat.nl/2024/08/21/pa-drukmonitoring-bij-chronisch-hartfalen-effecten-over-klinische-subgroepen/","title":"PA-drukmonitoring bij chronisch hartfalen: effecten over klinische subgroepen","title_en":"Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.","published":"2024-08-21"}],"10.1161/circulationaha.124.069340":[{"url":"https://hartvaat.nl/2024/08/20/tadalafil-bij-gecombineerde-post-en-precapillaire-ph-en-hfpef/","title":"Tadalafil bij gecombineerde post- en precapillaire PH en HFpEF","title_en":"Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.","published":"2024-08-20"}],"10.1093/eurheartj/ehae306":[{"url":"https://hartvaat.nl/2024/08/16/impella-cp-bij-door-mi-gecompliceerde-cardiogene-shock-journal-scan/","title":"Impella CP bij door MI gecompliceerde cardiogene shock: journal scan","title_en":"Weekly Journal Scan: Impella CP in myocardial infarction complicated by cardiogenic shock.","published":"2024-08-16"}],"10.1161/circulationaha.124.069396":[{"url":"https://hartvaat.nl/2024/08/13/anti-il-6-therapie-bij-acuut-mi-fase-iia-trial/","title":"Anti-IL-6 therapie bij acuut MI: fase IIa trial","title_en":"Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI).","published":"2024-08-13"}],"10.1001/jama.2024.5880":[{"url":"https://hartvaat.nl/2024/08/06/perioperatief-management-van-antitrombotische-therapie-actueel-overzicht/","title":"Perioperatief management van antitrombotische therapie: actueel overzicht","title_en":"Perioperative Management of Antithrombotic Therapy.","published":"2024-08-06"}],"10.1161/circulationaha.123.065520":[{"url":"https://hartvaat.nl/2024/08/06/racing-subanalyse-matige-statine-plus-ezetimibe-voor-secundaire-preventie/","title":"RACING subanalyse: matige statine plus ezetimibe voor secundaire preventie","title_en":"Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).","published":"2024-08-06"}],"10.1161/circulationaha.124.069726":[{"url":"https://hartvaat.nl/2024/08/06/doac-bij-heartmate-3-lvad-eerste-gerandomiseerde-trial/","title":"DOAC bij HeartMate 3 LVAD: eerste gerandomiseerde trial","title_en":"A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study.","published":"2024-08-06"}],"10.1093/europace/euae212":[{"url":"https://hartvaat.nl/2024/08/03/device-algoritmen-voor-rv-pacingminimalisatie-meta-analyse-van-uitkomsten/","title":"Device-algoritmen voor RV-pacingminimalisatie: meta-analyse van uitkomsten","title_en":"Systematic review and meta-analysis on the impact on outcomes of device algorithms for minimizing right ventricular pacing.","published":"2024-08-03"}],"10.1093/europace/euae200":[{"url":"https://hartvaat.nl/2024/08/03/dagontslag-versus-overnachting-na-af-ablatie-uitgebreide-meta-analyse/","title":"Dagontslag versus overnachting na AF-ablatie: uitgebreide meta-analyse","title_en":"Same-day discharge vs. overnight stay following catheter ablation for atrial fibrillation: a comprehensive review and meta-analysis by the European Heart Rhythm Association Health Economics Committee.","published":"2024-08-03"}],"10.1093/eurheartj/ehae341":[{"url":"https://hartvaat.nl/2024/08/03/cardiale-shockwave-therapie-bij-cabg-verbetert-myocardfunctie/","title":"Cardiale shockwave-therapie bij CABG verbetert myocardfunctie","title_en":"Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial.","published":"2024-08-03"}],"10.1093/eurheartj/ehae267":[{"url":"https://hartvaat.nl/2024/08/03/anticoagulatie-bij-postoperatief-af-na-geisoleerde-cabg-meta-analyse/","title":"Anticoagulatie bij postoperatief AF na geïsoleerde CABG: meta-analyse","title_en":"Anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting: a meta-analysis.","published":"2024-08-03"}],"10.1093/eurheartj/ehae291":[{"url":"https://hartvaat.nl/2024/08/03/catheterablatie-bij-persisterend-af-recidiefpatronen-en-kwaliteit-van-leven/","title":"Catheterablatie bij persisterend AF: recidiefpatronen en kwaliteit van leven","title_en":"Catheter ablation for persistent atrial fibrillation: patterns of recurrence and impact on quality of life and health care utilization.","published":"2024-08-03"}],"10.1161/hypertensionaha.124.23088":[{"url":"https://hartvaat.nl/2024/08/01/baroreflexactivatietherapie-bij-resistente-hypertensie-sham-gecontroleerde-pilot/","title":"Baroreflexactivatietherapie bij resistente hypertensie: sham-gecontroleerde pilotstudie","title_en":"Sham-Controlled Randomized Pilot Trial on Baroreflex Activation Therapy in Resistant Hypertension.","published":"2024-08-01"}],"10.1161/hypertensionaha.123.22571":[{"url":"https://hartvaat.nl/2024/08/01/sociale-determinanten-en-hypertensie-uitkomsten-systematische-review/","title":"Sociale determinanten en hypertensie-uitkomsten: systematische review","title_en":"Impact of Social Determinants of Health on Hypertension Outcomes: A Systematic Review.","published":"2024-08-01"}],"10.1161/hypertensionaha.124.23011":[{"url":"https://hartvaat.nl/2024/08/01/sarcopenie-en-intensieve-bloeddrukbehandeling-sprint-subanalyse/","title":"Sarcopenie en intensieve bloeddrukbehandeling: SPRINT subanalyse","title_en":"Relationship Between Sarcopenia and Intensive Blood Pressure Control Efficacy and Safety: A Secondary Analysis of SPRINT.","published":"2024-08-01"}],"10.1161/hypertensionaha.124.22703":[{"url":"https://hartvaat.nl/2024/08/01/alcohol-en-hypertensierisico-dosis-respons-meta-analyse-van-niet-experimentele-s/","title":"Alcohol en hypertensierisico: dosis-respons meta-analyse van niet-experimentele studies","title_en":"Alcohol Intake and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Nonexperimental Cohort Studies.","published":"2024-08-01"}],"10.1002/ehf2.14854":[{"url":"https://hartvaat.nl/2024/08/01/adaptieve-atriale-pacing-gereguleerd-door-bloeddruk-pilotstudie/","title":"Adaptieve atriale pacing gereguleerd door bloeddruk: pilotstudie","title_en":"Safety and efficacy of adaptive atrial pacing regulated by blood pressure during low-level exercise: a proof-of-concept study.","published":"2024-08-01"}],"10.1002/ehf2.14715":[{"url":"https://hartvaat.nl/2024/08/01/candesartan-dosering-bij-mannen-versus-vrouwen-met-chronisch-hartfalen/","title":"Candesartan dosering bij mannen versus vrouwen met chronisch hartfalen","title_en":"Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM.","published":"2024-08-01"}],"10.1002/ehf2.14626":[{"url":"https://hartvaat.nl/2024/08/01/coronaire-microvasculaire-disfunctie-bij-hfpef-meta-analyse/","title":"Coronaire microvasculaire disfunctie bij HFpEF: meta-analyse","title_en":"Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis.","published":"2024-08-01"}],"10.1002/ehf2.14759":[{"url":"https://hartvaat.nl/2024/08/01/echocardiografische-monitoring-bij-heartmate-3-systematische-review/","title":"Echocardiografische monitoring bij HeartMate 3: systematische review","title_en":"Echocardiographic haemodynamic monitoring in the context of HeartMate 3™ therapy: a systematic review.","published":"2024-08-01"}],"10.1016/j.jacc.2024.05.002":[{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","title":"ARTESIA: apixaban versus aspirine naar CHA₂DS₂-VASc bij subclinisch AF","title_en":"Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA.","published":"2024-07-23"}],"10.1016/j.jacc.2024.04.055":[{"url":"https://hartvaat.nl/2024/07/23/snelle-optitratie-van-neurohormonale-blokkade-en-duurzame-decongestie-bij-hf/","title":"Snelle optitratie van neurohormonale blokkade en duurzame decongestie bij HF","title_en":"Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF.","published":"2024-07-23"}],"10.1161/circulationaha.124.068774":[{"url":"https://hartvaat.nl/2024/07/23/sacubitril-valsartan-en-cognitieve-functie-bij-hfpef/","title":"Sacubitril/valsartan en cognitieve functie bij HFpEF","title_en":"Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.","published":"2024-07-23"}],"10.1016/j.jacc.2024.04.037":[{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","title":"ILUMIEN IV: OCT-geleide PCI bij complexe laesies — subanalyse","title_en":"OCT-Guided vs Angiography-Guided Coronary Stent Implantation in Complex Lesions: An ILUMIEN IV Substudy.","published":"2024-07-23"}],"10.1016/j.jacc.2024.04.043":[{"url":"https://hartvaat.nl/2024/07/23/anatomische-versus-viabiliteitsgerichte-completeness-van-revascularisatie/","title":"Anatomische versus viabiliteitsgerichte completeness van revascularisatie","title_en":"Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy.","published":"2024-07-23"}],"10.1016/s0140-6736(24)01028-6":[{"url":"https://hartvaat.nl/2024/07/20/sbp-120-versus-140-mmhg-bij-hoog-cv-risico-meta-analyse-van-intensieve-behandeli/","title":"SBP <120 versus <140 mmHg bij hoog CV-risico: meta-analyse van intensieve behandeling","title_en":"Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.","published":"2024-07-20"}],"10.1161/circulationaha.124.069622":[{"url":"https://hartvaat.nl/2024/07/16/rich-life-gelijkwaardige-hypertensiezorg-voor-achtergestelde-populaties/","title":"RICH LIFE: gelijkwaardige hypertensiezorg voor achtergestelde populaties","title_en":"Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial.","published":"2024-07-16"}],"10.1016/j.jacc.2024.04.051":[{"url":"https://hartvaat.nl/2024/07/16/revascularisatiestrategieen-na-mi-systematische-review-en-meta-analyse/","title":"Revascularisatiestrategieën na MI: systematische review en meta-analyse","title_en":"Percutaneous Coronary Revascularization Strategies After Myocardial Infarction: A Systematic Review and Network Meta-Analysis.","published":"2024-07-16"}],"10.1161/circulationaha.124.068962":[{"url":"https://hartvaat.nl/2024/07/16/interventie-voor-evidence-based-zorg-bij-diabetes-en-cv-risico/","title":"Interventie voor evidence-based zorg bij diabetes en CV-risico","title_en":"Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.","published":"2024-07-16"}],"10.1016/j.jacc.2024.04.038":[{"url":"https://hartvaat.nl/2024/07/16/semaglutide-en-nyha-klasse-bij-hfpef-met-obesitas-step-hfpef-analyse/","title":"Semaglutide en NYHA-klasse bij HFpEF met obesitas: STEP-HFpEF analyse","title_en":"Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.","published":"2024-07-16"}],"10.1016/s0140-6736(24)00968-1":[{"url":"https://hartvaat.nl/2024/07/13/convince-langetermijn-colchicine-voor-preventie-van-recidief-niet-cardioembolisc/","title":"CONVINCE: langetermijn colchicine voor preventie van recidief niet-cardioembolisch CVA — Lancet","title_en":"Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.","published":"2024-07-13"}],"10.1093/eurheartj/ehae325":[{"url":"https://hartvaat.nl/2024/07/12/evinacumab-bij-homozygote-fh-langetermijn-veiligheid-en-effectiviteit/","title":"Evinacumab bij homozygote FH: langetermijn veiligheid en effectiviteit","title_en":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.","published":"2024-07-12"}],"10.1093/eurheartj/ehae233":[{"url":"https://hartvaat.nl/2024/07/12/aerobe-kracht-of-gecombineerde-training-en-cv-risicoprofiel-bij-obesitas/","title":"Aerobe, kracht- of gecombineerde training en CV-risicoprofiel bij obesitas","title_en":"Aerobic, resistance, or combined exercise training and its outcomes on cardiovascular risk profile in overweight or obese adults via a CardioRACE trial: a gap.","published":"2024-07-12"}],"10.1093/eurheartj/ehae245":[{"url":"https://hartvaat.nl/2024/07/12/nste-acs-na-cabg-meta-analyse-van-behandelstrategieen/","title":"NSTE-ACS na CABG: meta-analyse van behandelstrategieën","title_en":"Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: a meta-analysis of invasive vs. conservative management.","published":"2024-07-12"}],"10.1056/nejmoa2403347":[{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","title":"FLOW: semaglutide beschermt nieren bij type 2 diabetes en CKD — NEJM-gerelateerd","title_en":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.","published":"2024-07-11"}],"10.1136/heartjnl-2024-324078":[{"url":"https://hartvaat.nl/2024/07/10/intracoronaire-trombolyse-bij-stemi-meta-analyse/","title":"Intracoronaire trombolyse bij STEMI: meta-analyse","title_en":"Intracoronary thrombolysis in ST-elevation myocardial infarction: a systematic review and meta-analysis.","published":"2024-07-10"}],"10.1016/j.jacc.2024.04.048":[{"url":"https://hartvaat.nl/2024/07/09/bempedoinezuur-versus-statines-vergelijking-van-cv-voordelen/","title":"Bempedoïnezuur versus statines: vergelijking van CV-voordelen","title_en":"Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs.","published":"2024-07-09"}],"10.1161/circulationaha.124.068938":[{"url":"https://hartvaat.nl/2024/07/09/cangrelor-en-infarctgrootte-bij-stemi-gerandomiseerde-trial/","title":"Cangrelor en infarctgrootte bij STEMI: gerandomiseerde trial","title_en":"Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial).","published":"2024-07-09"}],"10.1016/j.jacc.2024.03.380":[{"url":"https://hartvaat.nl/2024/07/09/selectieve-aldosereductaseremmer-bij-diabetische-cardiomyopathie-rct/","title":"Selectieve aldosereductaseremmer bij diabetische cardiomyopathie: RCT","title_en":"Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.","published":"2024-07-09"}],"10.1093/europace/euae179":[{"url":"https://hartvaat.nl/2024/07/02/upgrade-rv-naar-crt-pacing-bij-hartfalen-met-af-voordelen-bevestigd/","title":"Upgrade RV-naar CRT-pacing bij hartfalen met AF: voordelen bevestigd","title_en":"Benefits of upgrading right ventricular to biventricular pacing in heart failure patients with atrial fibrillation.","published":"2024-07-02"}],"10.1093/europace/euae175":[{"url":"https://hartvaat.nl/2024/07/02/closed-loop-stimulatie-vermindert-ahre-s-versus-conventionele-rate-adaptieve-pac/","title":"Closed-loop stimulatie vermindert AHRE's versus conventionele rate-adaptieve pacing","title_en":"Closed loop stimulation reduces the incidence of atrial high-rate episodes compared with conventional rate-adaptive pacing in patients with sinus node dysfunctions.","published":"2024-07-02"}],"10.1016/j.jacc.2024.05.001":[{"url":"https://hartvaat.nl/2024/07/02/pfa-versus-thermale-ablatie-bij-paroxysmaal-af-aritmielastanalyse/","title":"PFA versus thermale ablatie bij paroxysmaal AF: aritmielastanalyse","title_en":"Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden.","published":"2024-07-02"}],"10.1001/jama.2024.6609":[{"url":"https://hartvaat.nl/2024/07/02/thuisbloeddruktelemonitoring-en-nurse-case-management-na-cva-jama-rct/","title":"Thuisbloeddruktelemonitoring en nurse case management na CVA: JAMA RCT","title_en":"Home Blood Pressure Telemonitoring and Nurse Case Management in Black and Hispanic Patients With Stroke: A Randomized Clinical Trial.","published":"2024-07-02"}],"10.1016/j.jacc.2024.04.022":[{"url":"https://hartvaat.nl/2024/07/02/semaglutide-en-nt-probnp-bij-hfpef-met-obesitas-step-hfpef-programma/","title":"Semaglutide en NT-proBNP bij HFpEF met obesitas: STEP-HFpEF programma","title_en":"Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.","published":"2024-07-02"}],"10.1016/j.jacc.2024.04.016":[{"url":"https://hartvaat.nl/2024/07/02/orbita-2-subanalyse-symptomen-voorspellen-pci-effect-bij-stabiel-coronairlijden/","title":"ORBITA-2 subanalyse: symptomen voorspellen PCI-effect bij stabiel coronairlijden","title_en":"Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease.","published":"2024-07-02"}],"10.1161/circulationaha.124.069324":[{"url":"https://hartvaat.nl/2024/07/02/vroege-versus-late-doac-na-cva-met-hemorrhagische-transformatie-bij-af/","title":"Vroege versus late DOAC na CVA met hemorrhagische transformatie bij AF","title_en":"Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial.","published":"2024-07-02"}],"10.1016/j.jacc.2024.04.001":[{"url":"https://hartvaat.nl/2024/07/02/n-of-1-trial-voor-anginaverificatie-voor-pci/","title":"N-of-1 trial voor anginaverificatie vóór PCI","title_en":"N-of-1 Trial of Angina Verification Before Percutaneous Coronary Intervention.","published":"2024-07-02"}],"10.1001/jamacardio.2024.1091":[{"url":"https://hartvaat.nl/2024/07/01/dubbele-versus-enkele-cardioversie-bij-af-en-obesitas-jama-cardiology-rct/","title":"Dubbele versus enkele cardioversie bij AF en obesitas: JAMA Cardiology RCT","title_en":"Dual vs Single Cardioversion of Atrial Fibrillation in Patients With Obesity: A Randomized Clinical Trial.","published":"2024-07-01"}],"10.1001/jamacardio.2024.0959":[{"url":"https://hartvaat.nl/2024/07/01/plozasiran-sirna-tegen-apoc3-bij-ernstige-hypertriglyceridemie-shasta-2/","title":"Plozasiran: siRNA tegen APOC3 bij ernstige hypertriglyceridemie — SHASTA-2","title_en":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.","published":"2024-07-01"}],"10.1161/hypertensionaha.123.22436":[{"url":"https://hartvaat.nl/2024/07/01/bloeddrukverlaging-en-polsgolfsnelheid-meta-analyse/","title":"Bloeddrukverlaging en polsgolfsnelheid: meta-analyse","title_en":"Influence of Blood Pressure Reduction on Pulse Wave Velocity in Primary Hypertension: A Meta-Analysis and Comparison With an Acute Modulation of Transmural Pressure.","published":"2024-07-01"}],"10.1161/hypertensionaha.124.22832":[{"url":"https://hartvaat.nl/2024/07/01/value-trial-cv-uitkomsten-bij-hypertensie-met-perifeer-vaatlijden/","title":"VALUE-trial: CV-uitkomsten bij hypertensie met perifeer vaatlijden","title_en":"Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial.","published":"2024-07-01"}],"10.1161/hypertensionaha.123.22563":[{"url":"https://hartvaat.nl/2024/07/01/af-screening-tijdens-bloeddrukmeting-diagnostische-nauwkeurigheid/","title":"AF-screening tijdens bloeddrukmeting: diagnostische nauwkeurigheid","title_en":"Atrial Fibrillation Screening During Routine Automated Office, Home, and Ambulatory Blood Pressure Measurement: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis.","published":"2024-07-01"}],"10.1016/j.jacc.2024.04.034":[{"url":"https://hartvaat.nl/2024/06/25/vasculair-zorgteam-versus-educatie-bij-perifeer-arterieel-vaatlijden/","title":"Vasculair zorgteam versus educatie bij perifeer arterieel vaatlijden","title_en":"Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease.","published":"2024-06-25"}],"10.1001/jama.2024.6774":[{"url":"https://hartvaat.nl/2024/06/25/raas-blokkade-bij-hartfalen-voordeel-onafhankelijk-van-etniciteit-jama-meta-anal/","title":"RAAS-blokkade bij hartfalen: voordeel onafhankelijk van etniciteit — JAMA meta-analyse","title_en":"Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.","published":"2024-06-25"}],"10.1161/circulationaha.123.068107":[{"url":"https://hartvaat.nl/2024/06/18/sildenafil-dosisvergelijking-bij-pulmonale-arteriele-hypertensie/","title":"Sildenafil dosisvergelijking bij pulmonale arteriële hypertensie","title_en":"Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.","published":"2024-06-18"}],"10.1016/j.jacc.2024.03.426":[{"url":"https://hartvaat.nl/2024/06/18/mra-bij-hartfalen-met-nierfunctiestoornissen-veiligheid-en-effectiviteit/","title":"MRA bij hartfalen met nierfunctiestoornissen: veiligheid en effectiviteit","title_en":"Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function.","published":"2024-06-18"}],"10.1093/eurheartj/ehae151":[{"url":"https://hartvaat.nl/2024/06/14/invasief-versus-conservatief-bij-ouderen-met-nste-acs-ipd-meta-analyse/","title":"Invasief versus conservatief bij ouderen met NSTE-ACS: IPD meta-analyse","title_en":"Invasive vs. conservative management of older patients with non-ST-elevation acute coronary syndrome: individual patient data meta-analysis.","published":"2024-06-14"}],"10.1161/circulationaha.124.069144":[{"url":"https://hartvaat.nl/2024/06/11/effort-ertugliflozine-bij-functionele-mitralisinsufficientie-en-hartfalen/","title":"EFFORT: ertugliflozine bij functionele mitralisinsufficiëntie en hartfalen","title_en":"Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial.","published":"2024-06-11"}],"10.1016/j.jacc.2024.03.405":[{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","title":"EMPACT-MI: LV-functie, congestie en empagliflozine-effect na MI","title_en":"Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.","published":"2024-06-11"}],"10.1016/j.jacc.2024.03.398":[{"url":"https://hartvaat.nl/2024/06/11/remote-beoordeling-na-acs-gerandomiseerde-trial/","title":"Remote beoordeling na ACS: gerandomiseerde trial","title_en":"Randomized Trial of Remote Assessment of Patients After an Acute Coronary Syndrome.","published":"2024-06-11"}],"10.1161/circulationaha.124.069291":[{"url":"https://hartvaat.nl/2024/06/11/target-bp-i-alcohol-gemedieerde-renale-denervatie-bij-hypertensie/","title":"TARGET BP I: alcohol-gemedieerde renale denervatie bij hypertensie","title_en":"Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial.","published":"2024-06-11"}],"10.1056/nejmoa2312573":[{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","title":"SMART: zelf-expanderend versus ballonexpandeerbaar TAVR bij kleine annulus — NEJM","title_en":"Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus.","published":"2024-06-06"}],"10.1016/j.jacc.2024.03.396":[{"url":"https://hartvaat.nl/2024/06/04/apoa-i-infusie-na-mi-geen-effect-op-recidief-ischemische-events/","title":"ApoA-I infusie na MI: geen effect op recidief ischemische events","title_en":"Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.","published":"2024-06-04"}],"10.1016/j.jacc.2024.03.392":[{"url":"https://hartvaat.nl/2024/06/04/sacubitril-valsartan-bij-hartfalen-over-het-nierfunctiespectrum/","title":"Sacubitril/valsartan bij hartfalen over het nierfunctiespectrum","title_en":"Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.","published":"2024-06-04"}],"10.1161/circulationaha.124.069494":[{"url":"https://hartvaat.nl/2024/06/04/drive-remote-management-verbetert-richtlijnmedicatie-bij-hartfalen/","title":"DRIVE: remote management verbetert richtlijnmedicatie bij hartfalen","title_en":"Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.","published":"2024-06-04"}],"10.1161/circulationaha.124.069568":[{"url":"https://hartvaat.nl/2024/06/04/sglt2-remmers-en-mace-smart-c-collaboratieve-mega-meta-analyse/","title":"SGLT2-remmers en MACE: SMART-C collaboratieve mega-meta-analyse","title_en":"Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.","published":"2024-06-04"}],"10.1093/europace/euae121":[{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","title":"EAST-AFNET 4: natriumkanaalblokkers veilig en effectief voor langetermijn ritmecontrole","title_en":"Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial.","published":"2024-06-03"}],"10.1001/jamacardio.2024.0804":[{"url":"https://hartvaat.nl/2024/06/01/complete-versus-culprit-only-revascularisatie-bij-ouderen-met-mi-en-hoog-bloedin/","title":"Complete versus culprit-only revascularisatie bij ouderen met MI en hoog bloedingsrisico","title_en":"Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk: A Randomized Clinical Trial.","published":"2024-06-01"}],"10.1001/jamacardio.2024.0675":[{"url":"https://hartvaat.nl/2024/06/01/af-ablatie-bij-hfref-versus-hfpef-meta-analyse/","title":"AF-ablatie bij HFrEF versus HFpEF: meta-analyse","title_en":"Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","published":"2024-06-01"}],"10.1001/jamacardio.2024.0520":[{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","title":"REDUCE LAP-HF II: atriaal shuntdevice bij HFpEF — cardiale effecten","title_en":"Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial.","published":"2024-06-01"}],"10.1001/jamacardio.2024.0534":[{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","title":"OPT-BIRISK: clopidogrel monotherapie bij ACS met hoog ischemisch én bloedingsrisico","title_en":"Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.","published":"2024-06-01"}],"10.1001/jamacardio.2024.0468":[{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","title":"INVESTED: griepvaccin immuunrespons bij hoog-risico CV-patiënten","title_en":"Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial.","published":"2024-06-01"}],"10.1093/eurheartj/ehae049":[{"url":"https://hartvaat.nl/2024/06/01/pah-behandeling-ipd-netwerk-meta-analyse-van-alle-therapieen/","title":"PAH-behandeling: IPD netwerk-meta-analyse van alle therapieën","title_en":"Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.","published":"2024-06-01"}],"10.1161/hypertensionaha.123.21653":[{"url":"https://hartvaat.nl/2024/06/01/bloeddrukverlaging-bij-centrale-hypertensie-gerandomiseerde-trial/","title":"Bloeddrukverlaging bij centrale hypertensie: gerandomiseerde trial","title_en":"Blood Pressure Lowering in Patients With Central Hypertension: A Randomized Clinical Trial.","published":"2024-06-01"}],"10.1161/hypertensionaha.123.22314":[{"url":"https://hartvaat.nl/2024/06/01/renale-denervatie-langetermijn-bloeddrukeffect-bevestigd-meta-analyse/","title":"Renale denervatie: langetermijn bloeddrukeffect bevestigd — meta-analyse","title_en":"Long-Term Blood Pressure Reductions Following Catheter-Based Renal Denervation: A Systematic Review and Meta-Analysis.","published":"2024-06-01"}],"10.1161/hypertensionaha.123.22418":[{"url":"https://hartvaat.nl/2024/06/01/zwangerschapsdiabetes-en-hypertensierisico-meta-analyse-met-dosis-respons/","title":"Zwangerschapsdiabetes en hypertensierisico: meta-analyse met dosis-respons","title_en":"Association Between Gestational Diabetes Mellitus and Hypertension: A Systematic Review and Meta-Analysis of Cohort Studies With a Quantitative Bias Analysis of Uncontrolled Confounding.","published":"2024-06-01"}],"10.1002/ehf2.14726":[{"url":"https://hartvaat.nl/2024/06/01/nieuwe-antihyperglycemische-middelen-en-cv-uitkomsten-bij-diabetes-meta-analyse/","title":"Nieuwe antihyperglycemische middelen en CV-uitkomsten bij diabetes: meta-analyse","title_en":"Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.","published":"2024-06-01"}],"10.1002/ehf2.14689":[{"url":"https://hartvaat.nl/2024/06/01/s2i2n0-3-score-voorspelt-mortaliteit-bij-hfref-guide-it-subanalyse/","title":"S2I2N0-3 score voorspelt mortaliteit bij HFrEF: GUIDE-IT subanalyse","title_en":"S2I2N0-3 score predicts short- and long-term mortality and morbidity in HFrEF: a post-hoc analysis of the GUIDE-IT trial.","published":"2024-06-01"}],"10.1002/ehf2.14696":[{"url":"https://hartvaat.nl/2024/06/01/prognostische-modellen-voor-hfpef-systematische-review/","title":"Prognostische modellen voor HFpEF: systematische review","title_en":"Prognostic models for patients suffering a heart failure with a preserved ejection fraction: a systematic review.","published":"2024-06-01"}],"10.1002/ehf2.14679":[{"url":"https://hartvaat.nl/2024/06/01/triglyceride-glucose-index-en-cv-uitkomsten-na-pci-chinese-meta-analyse/","title":"Triglyceride-glucose-index en CV-uitkomsten na PCI: Chinese meta-analyse","title_en":"Triglyceride-glucose index's link to cardiovascular outcomes post-percutaneous coronary intervention in China: a meta-analysis.","published":"2024-06-01"}],"10.1002/ehf2.14627":[{"url":"https://hartvaat.nl/2024/06/01/glycemische-variabiliteit-en-mortaliteit-bij-hartfalen-meta-analyse/","title":"Glycemische variabiliteit en mortaliteit bij hartfalen: meta-analyse","title_en":"A meta-analysis of the relationship between glycaemic variability and the mortality of patients with heart failure.","published":"2024-06-01"}],"10.1056/nejmoa2314741":[{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","title":"RIGHT-2: ambulancebloeddrukverlaging bij hyperacuut CVA — NEJM vervolgresultaten","title_en":"Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke.","published":"2024-05-30"}],"10.1161/circulationaha.124.069624":[{"url":"https://hartvaat.nl/2024/05/28/pro-hf-routine-prom-meting-in-hartfalenpolikliniek-verbetert-uitkomsten/","title":"PRO-HF: routine PROM-meting in hartfalenpolikliniek verbetert uitkomsten","title_en":"Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial.","published":"2024-05-28"}],"10.1093/eurheartj/ehae235":[{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","title":"NUDGE-FLU: elektronische nudges verhogen griepvaccinatie na MI","title_en":"Electronic nudges increase influenza vaccination utilization after myocardial infarction: the nationwide NUDGE-FLU implementation trial.","published":"2024-05-27"}],"10.1161/circulationaha.124.069217":[{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","title":"EMPACT-MI: empagliflozine en hartfalenuitkomsten na MI","title_en":"Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.","published":"2024-05-21"}],"10.1016/j.jacc.2024.03.385":[{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","title":"DAPA-HF: dapagliflozine en dagen in volledige gezondheid","title_en":"Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.","published":"2024-05-21"}],"10.1056/nejmoa2313040":[{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","title":"ANNEXA-I: andexanet alfa bij factor Xa-remmer-geassocieerde intracerebrale bloeding — NEJM","title_en":"Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.","published":"2024-05-16"}],"10.1056/nejmoa2402309":[{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-hypertriglyceridemie-en-hoog-cv-risico-nejm/","title":"Olezarsen bij hypertriglyceridemie en hoog CV-risico: NEJM","title_en":"Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.","published":"2024-05-16"}],"10.1056/nejmoa2400201":[{"url":"https://hartvaat.nl/2024/05/16/olezarsen-bij-familiaire-chylomicronemie-nejm-fase-3/","title":"Olezarsen bij familiaire chylomicronemie: NEJM fase 3","title_en":"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.","published":"2024-05-16"}],"10.1093/eurheartj/ehae100":[{"url":"https://hartvaat.nl/2024/05/13/nitrate-cin-nitraat-beschermt-tegen-contrastnefropathie-na-acs/","title":"NITRATE-CIN: nitraat beschermt tegen contrastnefropathie na ACS","title_en":"Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial.","published":"2024-05-13"}],"10.1016/s0140-6736(24)00282-4":[{"url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","title":"IVUS-ACS: IVUS-geleide PCI bij ACS superieur — Lancet","title_en":"Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.","published":"2024-05-11"}],"10.1016/s0140-6736(24)00473-2":[{"url":"https://hartvaat.nl/2024/05/11/ticagrelor-monotherapie-versus-dapt-na-1-maand-bij-acs-lancet-rct/","title":"Ticagrelor monotherapie versus DAPT na 1 maand bij ACS: Lancet RCT","title_en":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.","published":"2024-05-11"}],"10.1016/j.jacc.2024.03.359":[{"url":"https://hartvaat.nl/2024/05/07/mandibulaire-advancementsplint-versus-cpap-voor-bloeddrukverlaging-bij-osa/","title":"Mandibulaire advancementsplint versus CPAP voor bloeddrukverlaging bij OSA","title_en":"Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients With Obstructive Sleep Apnea.","published":"2024-05-07"}],"10.1016/j.jacc.2024.02.035":[{"url":"https://hartvaat.nl/2024/05/07/sacubitril-valsartan-en-hypotensie-bij-hfpef-hfmref/","title":"Sacubitril/valsartan en hypotensie bij HFpEF/HFmrEF","title_en":"Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.","published":"2024-05-07"}],"10.1161/circulationaha.123.067971":[{"url":"https://hartvaat.nl/2024/05/07/orale-ketonester-bij-hfref-gerandomiseerde-trial/","title":"Orale ketonester bij HFrEF: gerandomiseerde trial","title_en":"Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.","published":"2024-05-07"}],"10.1016/s0140-6736(24)00413-6":[{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","title":"PREVENT: preventieve PCI versus medicatie bij kwetsbare coronaire plaques — Lancet","title_en":"Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.","published":"2024-05-04"}],"10.1093/europace/euae109":[{"url":"https://hartvaat.nl/2024/05/02/preventieve-substraatablatie-vermindert-icd-interventies-bij-ischemische-cmp/","title":"Preventieve substraatablatie vermindert ICD-interventies bij ischemische CMP","title_en":"Impact of preventive substrate catheter ablation on implantable cardioverter-defibrillator interventions in patients with ischaemic cardiomyopathy and infarct-related coronary chronic total occlusion.","published":"2024-05-02"}],"10.1093/europace/euae105":[{"url":"https://hartvaat.nl/2024/05/02/style-af-veneuze-closure-device-versus-figuur-van-acht-hechting-na-af-ablatie/","title":"STYLE-AF: veneuze closure device versus figuur-van-acht hechting na AF-ablatie","title_en":"Venous vascular closure system vs. figure-of-eight suture following atrial fibrillation ablation: the STYLE-AF Study.","published":"2024-05-02"}],"10.1093/europace/euae104":[{"url":"https://hartvaat.nl/2024/05/02/decaaf-ii-af-last-en-symptoomreductie-na-ablatie/","title":"DECAAF II: AF-last en symptoomreductie na ablatie","title_en":"Comprehensive atrial fibrillation burden and symptom reduction post-ablation: insights from DECAAF II.","published":"2024-05-02"}],"10.1056/nejmoa2400969":[{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","title":"AEGIS-II: apoA1-infusie na acuut MI verbetert uitkomsten niet — NEJM","title_en":"Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.","published":"2024-05-02"}],"10.1001/jamacardio.2024.0291":[{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","title":"RENOVATE-COMPLEX-PCI: beeldvorming-geleide PCI bij vrouwen versus mannen","title_en":"Intravascular Imaging-Guided Optimization of Complex Percutaneous Coronary Intervention by Sex: A Subgroup Analysis of the RENOVATE-COMPLEX-PCI Trial.","published":"2024-05-01"}],"10.1001/jamacardio.2024.0133":[{"url":"https://hartvaat.nl/2024/05/01/p2y12-monotherapie-versus-dapt-na-pci-ipd-meta-analyse/","title":"P2Y12-monotherapie versus DAPT na PCI: IPD meta-analyse","title_en":"Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.","published":"2024-05-01"}],"10.1001/jamacardio.2024.0059":[{"url":"https://hartvaat.nl/2024/05/01/angiografie-versus-ivus-voor-des-implantatie-gerandomiseerde-trial/","title":"Angiografie versus IVUS voor DES-implantatie: gerandomiseerde trial","title_en":"Quantitative Coronary Angiography vs Intravascular Ultrasonography to Guide Drug-Eluting Stent Implantation: A Randomized Clinical Trial.","published":"2024-05-01"}],"10.1161/hypertensionaha.123.22284":[{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","title":"QUARTET: therapeutische inertie bij lage-dosis viervoudige combinatietherapie","title_en":"Therapeutic Inertia With Initial Low-Dose Quadruple Combination Therapy for Hypertension: Results From the QUARTET Trial.","published":"2024-05-01"}],"10.1161/hypertensionaha.123.22410":[{"url":"https://hartvaat.nl/2024/05/01/ssass-secundaire-analyse-kaliumverrijkt-zout-en-cardiale-uitkomsten/","title":"SSaSS secundaire analyse: kaliumverrijkt zout en cardiale uitkomsten","title_en":"Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes.","published":"2024-05-01"}],"10.1161/hypertensionaha.123.22610":[{"url":"https://hartvaat.nl/2024/05/01/bloeddrukstreefwaarden-en-residueel-risico-systematische-review-en-meta-regressi/","title":"Bloeddrukstreefwaarden en residueel risico: systematische review en meta-regressie","title_en":"Revisiting Cardiovascular Benefits of Blood Pressure Reduction in Primary and Secondary Prevention: Focus on Targets and Residual Risk-A Systematic Review and Meta-Analysis.","published":"2024-05-01"}],"10.1161/hypertensionaha.123.22251":[{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","title":"SPYRAL HTN-ON MED: renale denervatie en medicatiewijzigingen","title_en":"Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED.","published":"2024-05-01"}],"10.1016/j.jacc.2024.03.377":[{"url":"https://hartvaat.nl/2024/04/30/ticagrelor-plus-aspirine-en-ledematenuitkomsten-bij-diabetes-met-atherosclerose/","title":"Ticagrelor plus aspirine en ledematenuitkomsten bij diabetes met atherosclerose","title_en":"Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.","published":"2024-04-30"}],"10.1016/s0140-6736(24)00469-0":[{"url":"https://hartvaat.nl/2024/04/27/semaglutide-bij-hfpef-met-obesitas-lancet-gepoolde-analyse-van-twee-nejm-trials/","title":"Semaglutide bij HFpEF met obesitas: Lancet gepoolde analyse van twee NEJM-trials","title_en":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.","published":"2024-04-27"}],"10.1056/nejmoa2314149":[{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","title":"FRAME-AMI: FFR-geleide versus complete PCI bij MI — NEJM","title_en":"FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.","published":"2024-04-25"}],"10.1056/nejmoa2314051":[{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","title":"DAPA-MI: empagliflozine na acuut MI zonder HF of diabetes — NEJM","title_en":"Empagliflozin after Acute Myocardial Infarction.","published":"2024-04-25"}],"10.1016/j.jacc.2024.02.016":[{"url":"https://hartvaat.nl/2024/04/23/lp-a-en-cv-risicoreductie-met-icosapent-ethyl-reduce-it-analyse/","title":"Lp(a) en CV-risicoreductie met icosapent ethyl: REDUCE-IT analyse","title_en":"Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.","published":"2024-04-23"}],"10.1161/circulationaha.123.065571":[{"url":"https://hartvaat.nl/2024/04/23/pci-versus-cabg-bij-linker-hoofdstam-met-en-zonder-diabetes-precombat-follow-up/","title":"PCI versus CABG bij linker hoofdstam met en zonder diabetes: PRECOMBAT follow-up","title_en":"Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With and Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials.","published":"2024-04-23"}],"10.1093/eurheartj/ehae086":[{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","title":"IRONMAN: ijzerdeficiëntiedefinities en klinische respons op IV-ijzer bij HF","title_en":"Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.","published":"2024-04-21"}],"10.1016/s0140-6736(24)00256-3":[{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","title":"ORBITA-COSMIC: coronaire sinusreducer bij refractaire angina — sham-gecontroleerd","title_en":"Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.","published":"2024-04-20"}],"10.1056/nejmoa2401479":[{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","title":"ABYSS: bètablokkers na MI met behouden EF niet nodig — NEJM","title_en":"Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.","published":"2024-04-18"}],"10.1056/nejmoa2312572":[{"url":"https://hartvaat.nl/2024/04/18/danger-shock-impella-versus-standaardzorg-bij-cardiogene-shock-nejm/","title":"DanGer Shock: Impella versus standaardzorg bij cardiogene shock — NEJM","title_en":"Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.","published":"2024-04-18"}],"10.1056/nejmoa2313917":[{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","title":"STEP-HFpEF-DM: semaglutide bij HFpEF met obesitas en type 2 diabetes — NEJM","title_en":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.","published":"2024-04-18"}],"10.1016/j.jacc.2024.02.020":[{"url":"https://hartvaat.nl/2024/04/16/sglt2-remming-waterconservatie-domineert-over-osmotische-diurese-bij-hf/","title":"SGLT2-remming: waterconservatie domineert over osmotische diurese bij HF","title_en":"Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.","published":"2024-04-16"}],"10.1016/j.jacc.2023.12.024":[{"url":"https://hartvaat.nl/2024/04/16/2024-acc-expert-consensus-behandeling-van-hfref-beslispad-geactualiseerd/","title":"2024 ACC Expert Consensus: behandeling van HFrEF — beslispad geactualiseerd","title_en":"2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2024-04-16"}],"10.1161/circulationaha.123.067079":[{"url":"https://hartvaat.nl/2024/04/16/postprocedurale-anticoagulatie-na-primaire-pci-voor-stemi-multicenter-studie/","title":"Postprocedurale anticoagulatie na primaire PCI voor STEMI: multicenter studie","title_en":"Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial.","published":"2024-04-16"}],"10.1016/j.jacc.2024.02.009":[{"url":"https://hartvaat.nl/2024/04/09/dapagliflozine-bij-acuut-hartfalen-effectiviteit-en-veiligheid/","title":"Dapagliflozine bij acuut hartfalen: effectiviteit en veiligheid","title_en":"Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure.","published":"2024-04-09"}],"10.1056/nejmoa2311708":[{"url":"https://hartvaat.nl/2024/04/04/pragmatische-trial-van-hospitalisatieratio-bij-ckd-nejm/","title":"Pragmatische trial van hospitalisatieratio bij CKD — NEJM","title_en":"Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease.","published":"2024-04-04"}],"10.1001/jama.2024.3026":[{"url":"https://hartvaat.nl/2024/04/02/amaze-pvi-met-of-zonder-laa-ligatie-bij-af-jama-rct/","title":"aMAZE: PVI met of zonder LAA-ligatie bij AF — JAMA RCT","title_en":"Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation: The aMAZE Randomized Clinical Trial.","published":"2024-04-02"}],"10.1161/circulationaha.123.067583":[{"url":"https://hartvaat.nl/2024/04/02/ivus-versus-oct-versus-angiografie-voor-pci-begeleiding-meta-analyse/","title":"IVUS versus OCT versus angiografie voor PCI-begeleiding: meta-analyse","title_en":"Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.","published":"2024-04-02"}],"10.1001/jamacardio.2024.0011":[{"url":"https://hartvaat.nl/2024/04/01/polygene-risicoscore-voor-aortastenose-naast-klinische-risicofactoren/","title":"Polygene risicoscore voor aortastenose naast klinische risicofactoren","title_en":"Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis.","published":"2024-04-01"}],"10.1001/jamacardio.2023.5627":[{"url":"https://hartvaat.nl/2024/04/01/interventies-voor-optimalisatie-van-richtlijnmedicatie-bij-hartfalen-systematisc/","title":"Interventies voor optimalisatie van richtlijnmedicatie bij hartfalen: systematische review","title_en":"Interventions for Optimization of Guideline-Directed Medical Therapy: A Systematic Review.","published":"2024-04-01"}],"10.1001/jamacardio.2023.5605":[{"url":"https://hartvaat.nl/2024/04/01/lp-a-en-hscrp-als-cv-risicofactoren-primaire-en-secundaire-preventie/","title":"Lp(a) en hsCRP als CV-risicofactoren: primaire en secundaire preventie","title_en":"Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.","published":"2024-04-01"}],"10.1001/jamacardio.2023.5500":[{"url":"https://hartvaat.nl/2024/04/01/betablokkerstaken-verbetert-inspanningscapaciteit-bij-hfpef/","title":"Bètablokkerstaken verbetert inspanningscapaciteit bij HFpEF","title_en":"β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction.","published":"2024-04-01"}],"10.1093/eurheartj/ehae043":[{"url":"https://hartvaat.nl/2024/04/01/notion-10-jaar-tavr-versus-chirurgie-bij-laagrisico-aortastenose/","title":"NOTION 10 jaar: TAVR versus chirurgie bij laagrisico aortastenose","title_en":"Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial.","published":"2024-04-01"}],"10.1093/eurheartj/ehad889":[{"url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","title":"Icosapent ethyl na ACS: REDUCE-IT subanalyse","title_en":"Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.","published":"2024-04-01"}],"10.1093/eurheartj/ehad827":[{"url":"https://hartvaat.nl/2024/04/01/cardiorace-aeroob-krachttraining-of-gecombineerd-en-cardiovasculair-risicoprofie/","title":"CardioRACE: aeroob, krachttraining of gecombineerd en cardiovasculair risicoprofiel","title_en":"Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial.","published":"2024-04-01"}],"10.1093/eurheartj/ehad716":[{"url":"https://hartvaat.nl/2024/04/01/space-raas-remmers-stoppen-versus-continueren-voor-niet-cardiale-chirurgie/","title":"SPACE: RAAS-remmers stoppen versus continueren voor niet-cardiale chirurgie","title_en":"Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial.","published":"2024-04-01"}],"10.1002/ehf2.14674":[{"url":"https://hartvaat.nl/2024/04/01/inspanningstraining-en-hoog-sensitief-troponine-i-bij-hfref/","title":"Inspanningstraining en hoog-sensitief troponine I bij HFrEF","title_en":"Exercise training and high-sensitivity cardiac troponin-I in patients with heart failure with reduced ejection fraction.","published":"2024-04-01"}],"10.1002/ehf2.14662":[{"url":"https://hartvaat.nl/2024/04/01/halp-score-hemoglobine-albumine-lymfocyten-trombocyten-en-mortaliteit-bij-hartfa/","title":"HALP-score (hemoglobine, albumine, lymfocyten, trombocyten) en mortaliteit bij hartfalen","title_en":"Association between haemoglobin, albumin, lymphocytes, and platelets and mortality in patients with heart failure.","published":"2024-04-01"}],"10.1002/ehf2.14633":[{"url":"https://hartvaat.nl/2024/04/01/veiligheid-van-sglt2-remmers-bij-hartfalen-meta-analyse/","title":"Veiligheid van SGLT2-remmers bij hartfalen: meta-analyse","title_en":"Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis.","published":"2024-04-01"}],"10.1002/ehf2.14630":[{"url":"https://hartvaat.nl/2024/04/01/iv-ferricarboxymaltose-verbetert-linkeratriale-strain-bij-hartfalen-myocardial-i/","title":"IV ferricarboxymaltose verbetert linkeratriale strain bij hartfalen: Myocardial-IRON","title_en":"Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial.","published":"2024-04-01"}],"10.1093/europace/euae087":[{"url":"https://hartvaat.nl/2024/03/30/qdot-by-lawt-gepersonaliseerde-pvi-gestuurd-door-linkeratriale-wanddikte/","title":"QDOT-by-LAWT: gepersonaliseerde PVI gestuurd door linkeratriale wanddikte","title_en":"Personalized pulmonary vein isolation with very high-power short-duration lesions guided by left atrial wall thickness: the QDOT-by-LAWT randomized trial.","published":"2024-03-30"}],"10.1016/j.jacc.2024.01.027":[{"url":"https://hartvaat.nl/2024/03/26/sacubitril-valsartan-bij-gedecompenseerd-hartfalen-tijdens-opname/","title":"Sacubitril/valsartan bij gedecompenseerd hartfalen tijdens opname","title_en":"Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.","published":"2024-03-26"}],"10.1161/circulationaha.123.066604":[{"url":"https://hartvaat.nl/2024/03/26/grade-cv-uitkomsten-van-glucoseverlagende-middelen-bij-type-2-diabetes/","title":"GRADE: CV-uitkomsten van glucoseverlagende middelen bij type 2 diabetes","title_en":"Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).","published":"2024-03-26"}],"10.1161/circulationaha.123.067512":[{"url":"https://hartvaat.nl/2024/03/26/doac-s-bij-device-gedetecteerd-af-meta-analyse-noah-afnet-6-en-artesia/","title":"DOAC's bij device-gedetecteerd AF: meta-analyse NOAH-AFNET 6 en ARTESIA","title_en":"Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.","published":"2024-03-26"}],"10.1016/s0140-6736(23)02577-1":[{"url":"https://hartvaat.nl/2024/03/23/photon-aflibercept-8-mg-bij-diabetisch-macula-oedeem-verlengd-doseerinterval/","title":"PHOTON: aflibercept 8 mg bij diabetisch macula-oedeem — verlengd doseerinterval","title_en":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.","published":"2024-03-23"}],"10.1016/j.jacc.2024.01.012":[{"url":"https://hartvaat.nl/2024/03/19/heropname-na-revascularisatie-voor-hoofdstamziekte-incidentie-en-impact/","title":"Heropname na revascularisatie voor hoofdstamziekte: incidentie en impact","title_en":"Incidence, Predictors, and Impact of Hospital Readmission After Revascularization for Left Main Coronary Disease.","published":"2024-03-19"}],"10.1016/j.jacc.2024.01.016":[{"url":"https://hartvaat.nl/2024/03/19/nierschade-na-minimale-contrasttoediening-bij-acs/","title":"Nierschade na minimale contrasttoediening bij ACS","title_en":"Kidney Injury After Minimal Radiographic Contrast Administration in Patients With Acute Coronary Syndromes.","published":"2024-03-19"}],"10.1161/circulationaha.123.066279":[{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","title":"COMBINE AF: NOAC's versus warfarine over BMI-spectrum bij AF","title_en":"Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.","published":"2024-03-19"}],"10.1016/s0140-6736(23)02554-0":[{"url":"https://hartvaat.nl/2024/03/16/firstmappp-sunitinib-bij-metastatische-feochromocytomen-en-paragangliomen/","title":"FIRSTMAPPP: sunitinib bij metastatische feochromocytomen en paragangliomen","title_en":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.","published":"2024-03-16"}],"10.1136/heartjnl-2023-323513":[{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","title":"RAPID NSTEMI: zeer vroege invasieve strategie bij hoger risico NSTEMI","title_en":"Very early invasive strategy in higher risk non-ST-elevation acute coronary syndrome: the RAPID NSTEMI trial.","published":"2024-03-12"}],"10.1093/eurheartj/ehad811":[{"url":"https://hartvaat.nl/2024/03/07/mra-s-verminderen-af-risico-meta-analyse-van-klinische-trials/","title":"MRA's verminderen AF-risico: meta-analyse van klinische trials","title_en":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.","published":"2024-03-07"}],"10.1016/j.jacc.2024.01.002":[{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","title":"PARADISE-MI: sacubitril/valsartan bij STEMI versus NSTEMI","title_en":"Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.","published":"2024-03-05"}],"10.1161/circulationaha.123.066941":[{"url":"https://hartvaat.nl/2024/03/05/radiance-gepoolde-analyse-ultrageluid-renale-denervatie-na-medicatie-optitratie/","title":"RADIANCE gepoolde analyse: ultrageluid renale denervatie na medicatie-optitratie","title_en":"Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.","published":"2024-03-05"}],"10.1161/circulationaha.123.067312":[{"url":"https://hartvaat.nl/2024/03/05/gelijktijdige-laa-occlusie-en-tavr-bij-af-haalbaarheid/","title":"Gelijktijdige LAA-occlusie en TAVR bij AF: haalbaarheid","title_en":"Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients With Atrial Fibrillation.","published":"2024-03-05"}],"10.1016/s0140-6736(23)02454-6":[{"url":"https://hartvaat.nl/2024/03/02/intravasculaire-beeldvorming-bij-des-implantatie-lancet-netwerk-meta-analyse/","title":"Intravasculaire beeldvorming bij DES-implantatie: Lancet netwerk-meta-analyse","title_en":"Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.","published":"2024-03-02"}],"10.1093/europace/euae039":[{"url":"https://hartvaat.nl/2024/03/01/svc-isolatie-bij-paroxysmaal-af-zonder-geinduceerde-svc-aritmieen/","title":"SVC-isolatie bij paroxysmaal AF zonder geïnduceerde SVC-aritmieën","title_en":"Role of electroanatomical mapping-guided superior vena cava isolation in paroxysmal atrial fibrillation patients without provoked superior vena cava triggers: a randomized controlled study.","published":"2024-03-01"}],"10.1001/jamacardio.2023.5318":[{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","title":"DELIVER: dapagliflozine vermindert plotse hartdood bij verbeterde EF","title_en":"Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial.","published":"2024-03-01"}],"10.1001/jamacardio.2023.5155":[{"url":"https://hartvaat.nl/2024/03/01/clear-outcomes-bempedoinezuur-vermindert-totale-cv-events-bij-statine-intolerant/","title":"CLEAR Outcomes: bempedoïnezuur vermindert totale CV-events bij statine-intolerantie","title_en":"Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.","published":"2024-03-01"}],"10.1093/eurheartj/ehad722":[{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","title":"POST-PCI: routine stresstesten bij diabetespatiënten na PCI niet zinvol","title_en":"Routine stress testing in diabetic patients after percutaneous coronary intervention: the POST-PCI trial.","published":"2024-03-01"}],"10.1161/hypertensionaha.123.22109":[{"url":"https://hartvaat.nl/2024/03/01/thuisbloeddruk-geleide-farmacotherapie-via-telezorg-meta-analyse-van-vs-trials/","title":"Thuisbloeddruk-geleide farmacotherapie via telezorg: meta-analyse van VS-trials","title_en":"Self-Measured Blood Pressure-Guided Pharmacotherapy: A Systematic Review and Meta-Analysis of United States-Based Telemedicine Trials.","published":"2024-03-01"}],"10.1136/heartjnl-2023-323067":[{"url":"https://hartvaat.nl/2024/02/23/ar-brillen-voor-ef-schatting-bij-hartfalen-haalbaarheidstudie/","title":"AR-brillen voor EF-schatting bij hartfalen: haalbaarheidstudie","title_en":"Accuracy of visual estimation of ejection fraction in patients with heart failure using augmented reality glasses.","published":"2024-02-23"}],"10.1016/j.jacc.2023.12.013":[{"url":"https://hartvaat.nl/2024/02/20/zoutvervanger-voorkomt-hypertensie-bij-normotensieve-volwassenen/","title":"Zoutvervanger voorkomt hypertensie bij normotensieve volwassenen","title_en":"Effect of a Salt Substitute on Incidence of Hypertension and Hypotension Among Normotensive Adults.","published":"2024-02-20"}],"10.1161/circulationaha.123.066720":[{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","title":"STOPDAPT-3: aspirinevrij versus standaard DAPT na coronaire stenting","title_en":"An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.","published":"2024-02-20"}],"10.1161/circulationaha.123.066943":[{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","title":"T-PASS: ticagrelor monotherapie binnen 1 maand na stenting bij ACS","title_en":"Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.","published":"2024-02-20"}],"10.1161/circulationaha.123.067283":[{"url":"https://hartvaat.nl/2024/02/20/ticagrelor-monotherapie-na-acs-ipd-meta-analyse-van-vroege-aspirinestop/","title":"Ticagrelor monotherapie na ACS: IPD meta-analyse van vroege aspirinestop","title_en":"Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.","published":"2024-02-20"}],"10.1093/eurheartj/ehad572":[{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","title":"CIRCA-DOSE: AF-progressie na cryoablatie versus RF-ablatie","title_en":"Atrial fibrillation progression after cryoablation vs. radiofrequency ablation: the CIRCA-DOSE trial.","published":"2024-02-16"}],"10.1016/j.jacc.2023.11.030":[{"url":"https://hartvaat.nl/2024/02/13/implanteerbare-hemodynamische-monitoren-verbeteren-overleving-bij-hfref/","title":"Implanteerbare hemodynamische monitoren verbeteren overleving bij HFrEF","title_en":"Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction.","published":"2024-02-13"}],"10.1016/j.jacc.2023.11.032":[{"url":"https://hartvaat.nl/2024/02/13/bariatrische-chirurgie-en-bloeddruk-na-5-jaar-gerandomiseerde-trial/","title":"Bariatrische chirurgie en bloeddruk na 5 jaar: gerandomiseerde trial","title_en":"Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years.","published":"2024-02-13"}],"10.1161/circulationaha.123.067597":[{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","title":"POP-HT: bloeddrukzelfmanagement verbetert cardiale remodelling na hypertensieve zwangerschap","title_en":"Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Substudy.","published":"2024-02-13"}],"10.1161/circulationaha.123.067599":[{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","title":"SWISS-APERO: Amulet versus Watchman na 1 jaar voor LAA-sluiting","title_en":"One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS-APERO Randomized Clinical Trial.","published":"2024-02-06"}],"10.1093/europace/euae040":[{"url":"https://hartvaat.nl/2024/02/01/sequentiele-hybride-ablatie-versus-chirurgische-cryomaze-bij-af-met-structurele-/","title":"Sequentiële hybride ablatie versus chirurgische CryoMaze bij AF met structurele hartziekte","title_en":"Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial.","published":"2024-02-01"}],"10.1093/europace/euae038":[{"url":"https://hartvaat.nl/2024/02/01/pulmonaalvenenstenose-na-pfa-versus-thermale-ablatie-vergelijking/","title":"Pulmonaalvenenstenose na PFA versus thermale ablatie: vergelijking","title_en":"Pulmonary vein narrowing after pulsed field versus thermal ablation.","published":"2024-02-01"}],"10.1001/jamacardio.2023.4587":[{"url":"https://hartvaat.nl/2024/02/01/talos-ami-dapt-de-escalatie-veilig-bij-mi-met-hoog-ischemisch-risico/","title":"TALOS-AMI: DAPT de-escalatie veilig bij MI met hoog ischemisch risico","title_en":"Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial.","published":"2024-02-01"}],"10.1001/jamacardio.2023.4501":[{"url":"https://hartvaat.nl/2024/02/01/message-hf-geautomatiseerde-sms-na-hartfalenopname-verbetert-uitkomsten-niet/","title":"MESSAGE-HF: geautomatiseerde sms na hartfalenopname verbetert uitkomsten niet","title_en":"Multifaceted Strategy Based on Automated Text Messaging After a Recent Heart Failure Admission: The MESSAGE-HF Randomized Clinical Trial.","published":"2024-02-01"}],"10.1001/jamacardio.2023.4776":[{"url":"https://hartvaat.nl/2024/02/01/transform-hf-torsemide-versus-furosemide-bij-nieuw-vs-chronisch-hartfalen/","title":"TRANSFORM-HF: torsemide versus furosemide bij nieuw vs chronisch hartfalen","title_en":"Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial.","published":"2024-02-01"}],"10.1001/jamacardio.2023.4664":[{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","title":"DELIVER: eGFR-dip na dapagliflozine bij HFpEF is veilig","title_en":"Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.","published":"2024-02-01"}],"10.1002/ehf2.14580":[{"url":"https://hartvaat.nl/2024/02/01/acyl-ghreline-verbetert-cardiac-output-met-behoud-van-rv-pa-koppeling-bij-hf/","title":"Acyl-ghreline verbetert cardiac output met behoud van RV-PA koppeling bij HF","title_en":"Acyl ghrelin increases cardiac output while preserving right ventricular-pulmonary arterial coupling in heart failure.","published":"2024-02-01"}],"10.1002/ehf2.14586":[{"url":"https://hartvaat.nl/2024/02/01/maggic-score-voor-mortaliteitsvoorspelling-bij-klepziekte/","title":"MAGGIC-score voor mortaliteitsvoorspelling bij klepziekte","title_en":"Meta-Analysis Global Group in Chronic Heart Failure score for the prediction of mortality in valvular heart disease.","published":"2024-02-01"}],"10.1002/ehf2.14588":[{"url":"https://hartvaat.nl/2024/02/01/nieuwe-kaliumbinders-verbeteren-raas-remmer-gebruik-bij-hartfalen-meta-analyse/","title":"Nieuwe kaliumbinders verbeteren RAAS-remmer-gebruik bij hartfalen: meta-analyse","title_en":"The efficacy and safety of new potassium binders on renin-angiotensin-aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis.","published":"2024-02-01"}],"10.1002/ehf2.14577":[{"url":"https://hartvaat.nl/2024/02/01/ivabradine-vermindert-mr-getriggerde-atriale-fibrose-niet-versus-carvedilol/","title":"Ivabradine vermindert MR-getriggerde atriale fibrose niet versus carvedilol","title_en":"Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol.","published":"2024-02-01"}],"10.1002/ehf2.14564":[{"url":"https://hartvaat.nl/2024/02/01/hydralazine-bij-ernstige-systolische-disfunctie-en-mitralisinsufficientie/","title":"Hydralazine bij ernstige systolische disfunctie en mitralisinsufficiëntie","title_en":"Hydralazine combined with conventional therapy improved outcomes in severe systolic dysfunction and mitral regurgitation.","published":"2024-02-01"}],"10.1002/ehf2.14535":[{"url":"https://hartvaat.nl/2024/02/01/urinezuur-als-biomarker-maar-niet-therapeutisch-doel-bij-hartfalen-meta-analyse/","title":"Urinezuur als biomarker maar niet therapeutisch doel bij hartfalen: meta-analyse","title_en":"Uric acid is a biomarker for heart failure, but not therapeutic target: result from a comprehensive meta-analysis.","published":"2024-02-01"}],"10.1161/circulationaha.123.067528":[{"url":"https://hartvaat.nl/2024/01/30/edoxaban-versus-warfarine-bij-chronische-trombo-embolische-pulmonale-hypertensie/","title":"Edoxaban versus warfarine bij chronische trombo-embolische pulmonale hypertensie","title_en":"A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.","published":"2024-01-30"}],"10.1161/circulationaha.122.063460":[{"url":"https://hartvaat.nl/2024/01/30/orion-5-inclisiran-bij-homozygote-fh/","title":"ORION-5: inclisiran bij homozygote FH","title_en":"Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.","published":"2024-01-30"}],"10.1161/circulationaha.123.066485":[{"url":"https://hartvaat.nl/2024/01/23/switchen-van-vka-naar-noac-bij-fragiele-ouderen-met-af-veilig/","title":"Switchen van VKA naar NOAC bij fragiele ouderen met AF: veilig","title_en":"Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.","published":"2024-01-23"}],"10.1056/nejmoa2304542":[{"url":"https://hartvaat.nl/2024/01/18/raft-langetermijn-crt-d-bij-hartfalen-nejm-14-jaarsresultaten/","title":"RAFT langetermijn: CRT-D bij hartfalen — NEJM 14-jaarsresultaten","title_en":"Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure.","published":"2024-01-18"}],"10.1001/jama.2023.24035":[{"url":"https://hartvaat.nl/2024/01/16/connect-palliatieve-telezorg-verbetert-kwaliteit-van-leven-bij-hartfalen-jama/","title":"CONNECT: palliatieve telezorg verbetert kwaliteit van leven bij hartfalen — JAMA","title_en":"Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical Trial.","published":"2024-01-16"}],"10.1161/circulationaha.123.067395":[{"url":"https://hartvaat.nl/2024/01/16/watchful-leefstijl-wandelinterventie-bij-hfref/","title":"WATCHFUL: leefstijl-wandelinterventie bij HFrEF","title_en":"Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.","published":"2024-01-16"}],"10.1093/eurheartj/ehad828":[{"url":"https://hartvaat.nl/2024/01/14/residuele-lekkage-na-laa-occlusie-en-uitkomsten-meta-analyse/","title":"Residuele lekkage na LAA-occlusie en uitkomsten: meta-analyse","title_en":"Residual leaks following percutaneous left atrial appendage occlusion and outcomes: a meta-analysis.","published":"2024-01-14"}],"10.1056/nejmoa2310234":[{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","title":"ARTESIA: apixaban bij subclinisch AF — NEJM","title_en":"Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.","published":"2024-01-11"}],"10.1016/j.jacc.2023.10.021":[{"url":"https://hartvaat.nl/2024/01/02/2023-af-richtlijn-op-een-blik-samenvatting/","title":"2023 AF-richtlijn op een blik: samenvatting","title_en":"2023 Atrial Fibrillation Guideline-at-a-Glance.","published":"2024-01-02"}],"10.1016/j.jacc.2023.08.017":[{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-af-richtlijn-jacc-editie/","title":"2023 ACC/AHA AF-richtlijn: JACC-editie","title_en":"2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2024-01-02"}],"10.1161/cir.0000000000001193":[{"url":"https://hartvaat.nl/2024/01/02/2023-acc-aha-accp-hrs-af-richtlijn-nieuwe-classificatie-en-behandelaanpak/","title":"2023 ACC/AHA/ACCP/HRS AF-richtlijn: nieuwe classificatie en behandelaanpak","title_en":"2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2024-01-02"}],"10.1016/j.jacc.2023.10.013":[{"url":"https://hartvaat.nl/2024/01/02/clopidogrel-versus-aspirine-als-langetermijnmonotherapie-na-pci-bevestiging/","title":"Clopidogrel versus aspirine als langetermijnmonotherapie na PCI: bevestiging","title_en":"Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.","published":"2024-01-02"}],"10.1001/jamacardio.2023.4316":[{"url":"https://hartvaat.nl/2024/01/01/verkorte-dapt-bij-hoog-bloedingsrisico-geen-sekseverschillen/","title":"Verkorte DAPT bij hoog bloedingsrisico: geen sekseverschillen","title_en":"Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial.","published":"2024-01-01"}],"10.1001/jamacardio.2023.4147":[{"url":"https://hartvaat.nl/2024/01/01/tafamidis-en-cardiale-functie-bij-attr-cm-post-hoc-attr-act-analyse/","title":"Tafamidis en cardiale functie bij ATTR-CM: post-hoc ATTR-ACT analyse","title_en":"Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.","published":"2024-01-01"}],"10.1056/nejmoa2307983":[{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","title":"REALITY: restrictief versus liberaal transfusiebeleid bij MI en anemie — NEJM","title_en":"Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia.","published":"2023-12-28"}],"10.1056/nejmoa2310610":[{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","title":"ORBITA-2: PCI versus placebo bij stabiele angina pectoris — NEJM","title_en":"A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.","published":"2023-12-21"}],"10.1093/eurheartj/ehad586":[{"url":"https://hartvaat.nl/2023/12/21/iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-ipd-meta-analyse/","title":"IV ferricarboxymaltose bij hartfalen met ijzerdeficiëntie: IPD meta-analyse","title_en":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.","published":"2023-12-21"}],"10.1136/heartjnl-2022-321868":[{"url":"https://hartvaat.nl/2023/12/20/ticagrelor-versus-prasugrel-en-coronaire-microcirculatie-bij-pci/","title":"Ticagrelor versus prasugrel en coronaire microcirculatie bij PCI","title_en":"Effects of ticagrelor and prasugrel on coronary microcirculation in elective percutaneous coronary intervention.","published":"2023-12-20"}],"10.1001/jama.2023.22295":[{"url":"https://hartvaat.nl/2023/12/19/ai-diagnostiek-bij-gehospitaliseerde-patienten-jama-vignettenstudie/","title":"AI-diagnostiek bij gehospitaliseerde patiënten: JAMA vignettenstudie","title_en":"Measuring the Impact of AI in the Diagnosis of Hospitalized Patients: A Randomized Clinical Vignette Survey Study.","published":"2023-12-19"}],"10.1161/circulationaha.123.066170":[{"url":"https://hartvaat.nl/2023/12/19/synchronisatie-van-voetstap-en-hartfase-bij-crt-patienten/","title":"Synchronisatie van voetstap en hartfase bij CRT-patiënten","title_en":"Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.","published":"2023-12-19"}],"10.1056/nejmoa2307563":[{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","title":"SELECT: semaglutide vermindert CV-events bij obesitas zonder diabetes — NEJM","title_en":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.","published":"2023-12-14"}],"10.1161/circulationaha.122.063806":[{"url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","title":"VOYAGER PAD: rivaroxaban plus aspirine na endovasculaire revascularisatie voor PAD","title_en":"Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.","published":"2023-12-12"}],"10.1093/europace/euad349":[{"url":"https://hartvaat.nl/2023/12/06/gemodificeerde-transseptale-punctie-bij-laa-occlusie-rct/","title":"Gemodificeerde transseptale punctie bij LAA-occlusie: RCT","title_en":"Angioplasty Guidewire-Assisted vs. Conventional Transseptal Puncture for Left Atrial Appendage Occlusion: a multicentre randomized controlled trial.","published":"2023-12-06"}],"10.1016/j.jacc.2023.09.823":[{"url":"https://hartvaat.nl/2023/12/05/intravasculaire-beeldvorming-versus-functionele-versus-angiografische-pci-begele/","title":"Intravasculaire beeldvorming versus functionele versus angiografische PCI-begeleiding vergeleken","title_en":"Comparison of Intravascular Imaging, Functional, or Angiographically Guided Coronary Intervention.","published":"2023-12-05"}],"10.1161/circulationaha.123.066012":[{"url":"https://hartvaat.nl/2023/12/05/bloeddruk-en-zuurstofstreefwaarden-en-nierschade-na-hartstilstand/","title":"Bloeddruk- en zuurstofstreefwaarden en nierschade na hartstilstand","title_en":"Blood Pressure and Oxygen Targets on Kidney Injury After Cardiac Arrest.","published":"2023-12-05"}],"10.1161/hypertensionaha.123.21932":[{"url":"https://hartvaat.nl/2023/12/01/kaliummagnesiumcitraat-versus-kaliumchloride-bij-thiazide-bijwerkingen/","title":"Kaliummagnesiumcitraat versus kaliumchloride bij thiazide-bijwerkingen","title_en":"Potassium Magnesium Citrate Is Superior to Potassium Chloride in Reversing Metabolic Side Effects of Chlorthalidone.","published":"2023-12-01"}],"10.1161/hypertensionaha.123.21892":[{"url":"https://hartvaat.nl/2023/12/01/step-trial-diastolische-bloeddruk-beinvloedt-effect-van-intensieve-behandeling/","title":"STEP-trial: diastolische bloeddruk beïnvloedt effect van intensieve behandeling","title_en":"Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering: Results From the STEP Randomized Trial.","published":"2023-12-01"}],"10.1002/ehf2.14556":[{"url":"https://hartvaat.nl/2023/12/01/adaptieve-servoventilatie-en-hypoxemische-belasting-bij-hartfalen/","title":"Adaptieve servoventilatie en hypoxemische belasting bij hartfalen","title_en":"Hypoxaemic burden in heart failure patients receiving adaptive servo-ventilation.","published":"2023-12-01"}],"10.1002/ehf2.14520":[{"url":"https://hartvaat.nl/2023/12/01/acute-nierschade-bij-hartfalen-incidentie-mortaliteit-en-voorspellers-meta-analy/","title":"Acute nierschade bij hartfalen: incidentie, mortaliteit en voorspellers — meta-analyse","title_en":"Incidence, mortality, and predictors of acute kidney injury in patients with heart failure: a systematic review.","published":"2023-12-01"}],"10.1016/j.kint.2023.08.005":[{"url":"https://hartvaat.nl/2023/12/01/nierziekteverloop-na-acute-nierschade-prospectieve-cohortstudie/","title":"Nierziekteverloop na acute nierschade: prospectieve cohortstudie","title_en":"A comprehensive description of kidney disease progression after acute kidney injury from a prospective, parallel-group cohort study.","published":"2023-12-01"}],"10.1001/jama.2023.21523":[{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","title":"POP-HT: zelfmanagement van bloeddruk na hypertensieve zwangerschap — JAMA RCT","title_en":"Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management: The POP-HT Randomized Clinical Trial.","published":"2023-11-28"}],"10.1136/heartjnl-2019-316375":[{"url":"https://hartvaat.nl/2023/11/27/slaapgerelateerde-ademhalingsstoornissen-en-cv-ziekte-wie-testen-en-hoe-behandel/","title":"Slaapgerelateerde ademhalingsstoornissen en CV-ziekte: wie testen en hoe behandelen","title_en":"Sleep-disordered breathing and cardiovascular disease: who and why to test and how to intervene?","published":"2023-11-27"}],"10.1016/s0140-6736(23)02230-4":[{"url":"https://hartvaat.nl/2023/11/25/zenith-ckd-zibotentan-plus-dapagliflozine-bij-ckd-lancet/","title":"ZENITH-CKD: zibotentan plus dapagliflozine bij CKD — Lancet","title_en":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.","published":"2023-11-25"}],"10.1016/s0140-6736(23)02197-9":[{"url":"https://hartvaat.nl/2023/11/25/biodegradeerbare-versus-duurzame-polymeer-des-bij-stemi-langetermijndata/","title":"Biodegradeerbare versus duurzame polymeer DES bij STEMI: langetermijndata","title_en":"Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.","published":"2023-11-25"}],"10.1056/nejmoa2307447":[{"url":"https://hartvaat.nl/2023/11/23/partner-3-vijfjaarsresultaten-tavr-vergelijkbaar-met-chirurgie-bij-laagrisico-ne/","title":"PARTNER 3 vijfjaarsresultaten: TAVR vergelijkbaar met chirurgie bij laagrisico — NEJM","title_en":"Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.","published":"2023-11-23"}],"10.1161/circulationaha.123.066179":[{"url":"https://hartvaat.nl/2023/11/14/early-unload-vroege-lv-ontlading-bij-va-ecmo-gerandomiseerde-trial/","title":"EARLY-UNLOAD: vroege LV-ontlading bij VA-ECMO — gerandomiseerde trial","title_en":"Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial.","published":"2023-11-14"}],"10.1136/heartjnl-2023-322635":[{"url":"https://hartvaat.nl/2023/11/10/rate-control-bij-af-calciumantagonisten-versus-betablokkers/","title":"Rate control bij AF: calciumantagonisten versus bètablokkers","title_en":"Rate control in atrial fibrillation, calcium channel blockers versus beta-blockers.","published":"2023-11-10"}],"10.1136/heartjnl-2023-322529":[{"url":"https://hartvaat.nl/2023/11/10/transcatheter-asd-sluiting-bij-ouderen-systematische-review-en-meta-analyse/","title":"Transcatheter ASD-sluiting bij ouderen: systematische review en meta-analyse","title_en":"Transcatheter closure of atrial septal defect in the elderly: a systematic review and meta-analysis.","published":"2023-11-10"}],"10.1016/j.jacc.2023.08.045":[{"url":"https://hartvaat.nl/2023/11/07/renale-denervatie-veilig-en-effectief-bij-patienten-op-antihypertensiva/","title":"Renale denervatie veilig en effectief bij patiënten op antihypertensiva","title_en":"Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.","published":"2023-11-07"}],"10.1016/s0140-6736(23)01689-6":[{"url":"https://hartvaat.nl/2023/11/04/colchicine-vermindert-perioperatief-af-na-thoraxchirurgie-lancet-rct/","title":"Colchicine vermindert perioperatief AF na thoraxchirurgie: Lancet RCT","title_en":"Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial.","published":"2023-11-04"}],"10.1093/europace/euad335":[{"url":"https://hartvaat.nl/2023/11/02/duurzaamheid-van-pvi-bij-af-meta-analyse/","title":"Duurzaamheid van PVI bij AF: meta-analyse","title_en":"Durability of pulmonary vein isolation for atrial fibrillation: a meta-analysis and systematic review.","published":"2023-11-02"}],"10.1056/nejmoa2307291":[{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","title":"ADVENT: pulsed field ablatie non-inferieur aan thermale ablatie bij AF — NEJM","title_en":"Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation.","published":"2023-11-02"}],"10.1001/jamacardio.2023.3364":[{"url":"https://hartvaat.nl/2023/11/01/enterisch-gecoat-versus-ongecoat-aspirine-geen-verschil-in-gi-bloedingen-adaptab/","title":"Enterisch-gecoat versus ongecoat aspirine: geen verschil in GI-bloedingen — ADAPTABLE","title_en":"Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.","published":"2023-11-01"}],"10.1001/jamacardio.2023.3208":[{"url":"https://hartvaat.nl/2023/11/01/posterior-wand-isolatie-bij-af-ablatie-en-systolisch-hartfalen-castle-af-subanal/","title":"Posterior wand-isolatie bij AF-ablatie en systolisch hartfalen: CASTLE-AF subanalyse","title_en":"The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial.","published":"2023-11-01"}],"10.1001/jamacardio.2023.3003":[{"url":"https://hartvaat.nl/2023/11/01/beta3-lvh-mirabegron-bij-linkerventrikel-hypertrofie-fase-2b-rct/","title":"Beta3-LVH: mirabegron bij linkerventrikel hypertrofie — fase 2b RCT","title_en":"Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial.","published":"2023-11-01"}],"10.1001/jamacardio.2023.2921":[{"url":"https://hartvaat.nl/2023/11/01/evinacumab-bij-refractaire-hypercholesterolemie-langetermijn-effectiviteit-en-ve/","title":"Evinacumab bij refractaire hypercholesterolemie: langetermijn effectiviteit en veiligheid","title_en":"Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.","published":"2023-11-01"}],"10.1093/eurheartj/ehad582":[{"url":"https://hartvaat.nl/2023/11/01/ifr-versus-ffr-en-vijfjaarsmortaliteit-swedeheart-en-define-flair/","title":"iFR versus FFR en vijfjaarsmortaliteit: SWEDEHEART en DEFINE FLAIR","title_en":"Instantaneous wave free ratio vs. fractional flow reserve and 5-year mortality: iFR SWEDEHEART and DEFINE FLAIR.","published":"2023-11-01"}],"10.1016/s0140-6736(23)02117-7":[{"url":"https://hartvaat.nl/2023/11/01/covid-19-en-vertraagde-cardiovasculaire-zorg-in-europa-lancet-systematische-revi/","title":"COVID-19 en vertraagde cardiovasculaire zorg in Europa: Lancet systematische review","title_en":"Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.","published":"2023-11-01"}],"10.1161/hypertensionaha.123.20967":[{"url":"https://hartvaat.nl/2023/11/01/gemaskeerde-hypertensie-bij-kinderen-prevalentie-en-cv-risico-meta-analyse/","title":"Gemaskeerde hypertensie bij kinderen: prevalentie en CV-risico — meta-analyse","title_en":"Prevalence of Pediatric Masked Hypertension and Risk of Subclinical Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.","published":"2023-11-01"}],"10.1161/hypertensionaha.123.21651":[{"url":"https://hartvaat.nl/2023/11/01/tijd-in-streefwaarde-van-bloeddruk-en-af-sprint-inzichten/","title":"Tijd-in-streefwaarde van bloeddruk en AF: SPRINT-inzichten","title_en":"Systolic Blood Pressure Time in Target Range and Incident Atrial Fibrillation in Patients With Hypertension: Insights From the SPRINT Trial.","published":"2023-11-01"}],"10.1161/hypertensionaha.123.21496":[{"url":"https://hartvaat.nl/2023/11/01/sekseverschillen-in-effect-van-bloeddrukverlaging-ipd-meta-analyse/","title":"Sekseverschillen in effect van bloeddrukverlaging: IPD meta-analyse","title_en":"Sex-Specific Effects of Blood Pressure Lowering Pharmacotherapy for the Prevention of Cardiovascular Disease: An Individual Participant-Level Data Meta-Analysis.","published":"2023-11-01"}],"10.1016/j.jacc.2023.08.010":[{"url":"https://hartvaat.nl/2023/10/31/antitrombotische-therapie-na-laa-occlusie-netwerk-meta-analyse/","title":"Antitrombotische therapie na LAA-occlusie: netwerk-meta-analyse","title_en":"Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion.","published":"2023-10-31"}],"10.1001/jama.2023.19524":[{"url":"https://hartvaat.nl/2023/10/24/cts-ami-tongxinluo-bij-acuut-mi-jama-mega-trial/","title":"CTS-AMI: Tongxinluo bij acuut MI — JAMA mega-trial","title_en":"Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction: The CTS-AMI Randomized Clinical Trial.","published":"2023-10-24"}],"10.1161/circulationaha.122.060315":[{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","title":"LAAOS III: LAA-occlusie en anticoagulatiegebruik","title_en":"Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III.","published":"2023-10-24"}],"10.1161/circulationaha.123.064090":[{"url":"https://hartvaat.nl/2023/10/24/graftfalen-na-cabg-individuele-patientdata-meta-analyse/","title":"Graftfalen na CABG: individuele-patiëntdata meta-analyse","title_en":"Graft Failure After Coronary Artery Bypass Grafting and Its Association With Patient Characteristics and Clinical Events: A Pooled Individual Patient Data Analysis of Clinical Trials With Imaging Follow-Up.","published":"2023-10-24"}],"10.1161/circulationaha.122.062464":[{"url":"https://hartvaat.nl/2023/10/24/inhalatief-epoprostenol-versus-no-bij-rechterventrikel-falen-na-hartchirurgie/","title":"Inhalatief epoprostenol versus NO bij rechterventrikel falen na hartchirurgie","title_en":"Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.","published":"2023-10-24"}],"10.1093/eurheartj/ehad512":[{"url":"https://hartvaat.nl/2023/10/21/prompt-ahf-epd-alerts-verbeteren-hartfalenmedicatie-bij-ontslag/","title":"PROMPT-AHF: EPD-alerts verbeteren hartfalenmedicatie bij ontslag","title_en":"Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial.","published":"2023-10-21"}],"10.1093/eurheartj/ehad596":[{"url":"https://hartvaat.nl/2023/10/21/lerodalcibep-bij-familiaire-hypercholesterolemie-liberate-hefh-langetermijndata/","title":"Lerodalcibep bij familiaire hypercholesterolemie: LIBerate-HeFH langetermijndata","title_en":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial.","published":"2023-10-21"}],"10.1093/eurheartj/ehad564":[{"url":"https://hartvaat.nl/2023/10/21/minimalisatie-van-atriale-pacing-bij-sinusknoopziekte-vermindert-af/","title":"Minimalisatie van atriale pacing bij sinusknoopziekte vermindert AF","title_en":"Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial.","published":"2023-10-21"}],"10.1093/eurheartj/ehad591":[{"url":"https://hartvaat.nl/2023/10/21/upgrade-van-rv-pacing-naar-crt-bij-hartfalen-gerandomiseerde-trial/","title":"Upgrade van RV-pacing naar CRT bij hartfalen: gerandomiseerde trial","title_en":"Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial.","published":"2023-10-21"}],"10.1056/nejmoa2305861":[{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","title":"ILUMIEN IV: OCT-geleide versus angiografie-geleide PCI — NEJM","title_en":"Optical Coherence Tomography-Guided versus Angiography-Guided PCI.","published":"2023-10-19"}],"10.1056/nejmoa2307770":[{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","title":"OCTOBER: OCT-geleide PCI bij complexe bifurcatielaesies — NEJM","title_en":"OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions.","published":"2023-10-19"}],"10.1001/jama.2023.18497":[{"url":"https://hartvaat.nl/2023/10/17/orthostatische-hypotensie-en-intensieve-bloeddrukbehandeling-ipd-meta-analyse-in/","title":"Orthostatische hypotensie en intensieve bloeddrukbehandeling: IPD meta-analyse in JAMA","title_en":"Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.","published":"2023-10-17"}],"10.1001/jama.2023.19597":[{"url":"https://hartvaat.nl/2023/10/17/million-hearts-betaald-cv-risicomanagement-vermindert-mi-en-cva-jama-rct/","title":"Million Hearts: betaald CV-risicomanagement vermindert MI en CVA — JAMA RCT","title_en":"Effects of the Million Hearts Model on Myocardial Infarctions, Strokes, and Medicare Spending: A Randomized Clinical Trial.","published":"2023-10-17"}],"10.1016/j.jacc.2023.07.031":[{"url":"https://hartvaat.nl/2023/10/17/antiplaatjesmonotherapie-na-pci-clopidogrel-versus-aspirine-naar-risicoprofiel/","title":"Antiplaatjesmonotherapie na PCI: clopidogrel versus aspirine naar risicoprofiel","title_en":"Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.","published":"2023-10-17"}],"10.1161/circulationaha.123.063946":[{"url":"https://hartvaat.nl/2023/10/17/bivalirudine-versus-heparine-bij-nstemi-ipd-meta-analyse/","title":"Bivalirudine versus heparine bij NSTEMI: IPD meta-analyse","title_en":"Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.","published":"2023-10-17"}],"10.1161/circulationaha.123.066429":[{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","title":"OCTIVUS: OCT-geleide versus IVUS-geleide PCI — non-inferioriteit bevestigd","title_en":"Optical Coherence Tomography-Guided or Intravascular Ultrasound-Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial.","published":"2023-10-17"}],"10.1016/s0140-6736(23)01607-0":[{"url":"https://hartvaat.nl/2023/10/14/va-ecmo-bij-cardiogene-shock-ipd-meta-analyse-lancet/","title":"VA-ECMO bij cardiogene shock: IPD meta-analyse — Lancet","title_en":"Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials.","published":"2023-10-14"}],"10.1056/nejmoa2307823":[{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","title":"MULTISTARS AMI: timing van complete revascularisatie bij STEMI — NEJM","title_en":"Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.","published":"2023-10-12"}],"10.1056/nejmoa2306037":[{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","title":"CASTLE-HTx: AF-ablatie bij eindstadium hartfalen — NEJM","title_en":"Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.","published":"2023-10-12"}],"10.1093/eurheartj/ehad447":[{"url":"https://hartvaat.nl/2023/10/12/aromi-prehospitale-copeptine-versnelt-mi-uitsluiting/","title":"AROMI: prehospitale copeptine versnelt MI-uitsluiting","title_en":"Accelerated -Rule-Out of acute Myocardial Infarction using prehospital copeptin and in-hospital troponin: The AROMI study.","published":"2023-10-12"}],"10.1136/heartjnl-2023-322492":[{"url":"https://hartvaat.nl/2023/10/12/anticoagulatie-bij-af-na-eerdere-intracraniele-bloeding-meta-analyse/","title":"Anticoagulatie bij AF na eerdere intracraniële bloeding: meta-analyse","title_en":"Anticoagulant in atrial fibrillation patients with prior intracranial haemorrhage: a meta-analysis.","published":"2023-10-12"}],"10.1016/s0140-6736(23)01573-8":[{"url":"https://hartvaat.nl/2023/10/07/inte-africa-geintegreerd-management-van-hiv-diabetes-en-hypertensie-lancet/","title":"INTE-AFRICA: geïntegreerd management van HIV, diabetes en hypertensie — Lancet","title_en":"Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.","published":"2023-10-07"}],"10.1093/europace/euad294":[{"url":"https://hartvaat.nl/2023/10/05/more-crt-mpp-multipoint-pacing-bij-crt-non-responders/","title":"MORE-CRT MPP: multipoint pacing bij CRT non-responders","title_en":"Cardiac resynchronization therapy non-responder to responder conversion rate in the MORE-CRT MPP trial.","published":"2023-10-05"}],"10.1093/europace/euad288":[{"url":"https://hartvaat.nl/2023/10/05/rivaroxaban-dosering-bij-af-on-label-versus-off-label-in-azie-en-niet-azie/","title":"Rivaroxaban dosering bij AF: on-label versus off-label in Azië en niet-Azië","title_en":"Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.","published":"2023-10-05"}],"10.1056/nejmoa2307227":[{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","title":"ECLS-SHOCK: ECMO bij infarctgerelateerde cardiogene shock — NEJM","title_en":"Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.","published":"2023-10-05"}],"10.1056/nejmoa2206916":[{"url":"https://hartvaat.nl/2023/10/05/vijf-modificeerbare-risicofactoren-en-mondiale-cv-sterfte-nejm-pure-analyse/","title":"Vijf modificeerbare risicofactoren en mondiale CV-sterfte: NEJM PURE-analyse","title_en":"Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.","published":"2023-10-05"}],"10.1001/jama.2023.17002":[{"url":"https://hartvaat.nl/2023/10/03/egfr-en-albuminurie-voorspellen-cv-events-ipd-mega-meta-analyse/","title":"eGFR en albuminurie voorspellen CV-events: IPD mega-meta-analyse","title_en":"Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.","published":"2023-10-03"}],"10.1001/jama.2023.17465":[{"url":"https://hartvaat.nl/2023/10/03/cpap-therapietrouw-en-recidief-cv-events-meta-analyse/","title":"CPAP-therapietrouw en recidief CV-events: meta-analyse","title_en":"Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis.","published":"2023-10-03"}],"10.1161/circulationaha.122.063602":[{"url":"https://hartvaat.nl/2023/10/03/vericiguat-bij-hfref-is-kosteneffectief-victoria-analyse/","title":"Vericiguat bij HFrEF is kosteneffectief: VICTORIA analyse","title_en":"Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.","published":"2023-10-03"}],"10.1093/eurheartj/ehad557":[{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","title":"ADVOR: nierfunctie en decongestie met acetazolamide","title_en":"Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial.","published":"2023-10-01"}],"10.1001/jamacardio.2023.2614":[{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","title":"PRECISE: uitgesteld testen bij stabiel coronairlijden is veilig","title_en":"Deferred Testing in Stable Outpatients With Suspected Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized Clinical Trial.","published":"2023-10-01"}],"10.1093/eurheartj/ehad522":[{"url":"https://hartvaat.nl/2023/10/01/mra-plus-sglt2-remmer-bij-hartfalen-meta-analyse-toont-synergistisch-voordeel/","title":"MRA plus SGLT2-remmer bij hartfalen: meta-analyse toont synergistisch voordeel","title_en":"Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.","published":"2023-10-01"}],"10.1093/eurheartj/ehad346":[{"url":"https://hartvaat.nl/2023/10/01/pa-drukmonitoring-bij-chronisch-hartfalen-meta-analyse-van-drie-rct-s/","title":"PA-drukmonitoring bij chronisch hartfalen: meta-analyse van drie RCT's","title_en":"Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials.","published":"2023-10-01"}],"10.1002/ehf2.14418":[{"url":"https://hartvaat.nl/2023/10/01/trimetazidine-bij-hfpef-gerandomiseerde-cross-over-trial/","title":"Trimetazidine bij HFpEF: gerandomiseerde cross-over trial","title_en":"Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.","published":"2023-10-01"}],"10.1002/ehf2.14473":[{"url":"https://hartvaat.nl/2023/10/01/baroreflexactivatietherapie-bij-hfref-systematische-review/","title":"Baroreflexactivatietherapie bij HFrEF: systematische review","title_en":"Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review.","published":"2023-10-01"}],"10.1161/hypertensionaha.123.21224":[{"url":"https://hartvaat.nl/2023/10/01/alcoholconsumptie-en-bloeddruk-dosis-respons-meta-analyse/","title":"Alcoholconsumptie en bloeddruk: dosis-respons meta-analyse","title_en":"Alcohol Intake and Blood Pressure Levels: A Dose-Response Meta-Analysis of Nonexperimental Cohort Studies.","published":"2023-10-01"}],"10.1002/ehf2.14455":[{"url":"https://hartvaat.nl/2023/10/01/ivabradine-bij-hoogrisico-hartfalenpatienten-shift-analyse/","title":"Ivabradine bij hoogrisico hartfalenpatiënten: SHIFT-analyse","title_en":"Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial).","published":"2023-10-01"}],"10.1016/s0140-6736(23)00912-1":[{"url":"https://hartvaat.nl/2023/09/30/adaptresponse-adaptieve-versus-conventionele-crt-bij-hartfalen-lancet/","title":"AdaptResponse: adaptieve versus conventionele CRT bij hartfalen — Lancet","title_en":"Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.","published":"2023-09-30"}],"10.1056/nejmoa2303062":[{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","title":"NOAH-AFNET 6: edoxaban bij atriaal high-rate episodes — NEJM","title_en":"Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.","published":"2023-09-28"}],"10.1136/heartjnl-2022-322289":[{"url":"https://hartvaat.nl/2023/09/28/pijn-op-de-borst-bij-mi-met-en-zonder-diabetes-meta-analyse/","title":"Pijn op de borst bij MI met en zonder diabetes: meta-analyse","title_en":"Chest pain symptoms during myocardial infarction in patients with and without diabetes: a systematic review and meta-analysis.","published":"2023-09-28"}],"10.1161/circulationaha.123.065448":[{"url":"https://hartvaat.nl/2023/09/26/biodegradeerbare-versus-duurzame-polymeer-stents-bij-hoog-bloedingsrisico/","title":"Biodegradeerbare versus duurzame polymeer-stents bij hoog bloedingsrisico","title_en":"Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.","published":"2023-09-26"}],"10.1161/circulationaha.123.065748":[{"url":"https://hartvaat.nl/2023/09/26/geblindeerde-stopstudie-voordelen-empagliflozine-verdwijnen-na-staken-bij-hf/","title":"Geblindeerde stopstudie: voordelen empagliflozine verdwijnen na staken bij HF","title_en":"Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.","published":"2023-09-26"}],"10.1056/nejmoa2306963":[{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","title":"STEP-HFpEF: semaglutide bij HFpEF en obesitas — NEJM","title_en":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.","published":"2023-09-21"}],"10.1001/jama.2023.4934":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-evidence-review-screening-op-hypertensieve-zwangerschapsstoornissen/","title":"USPSTF evidence review: screening op hypertensieve zwangerschapsstoornissen","title_en":"Screening for Hypertensive Disorders of Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2023-09-19"}],"10.1001/jama.2023.16991":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","title":"USPSTF: screening op hypertensieve zwangerschapsstoornissen aanbevolen","title_en":"Screening for Hypertensive Disorders of Pregnancy: US Preventive Services Task Force Final Recommendation Statement.","published":"2023-09-19"}],"10.1161/circulationaha.123.065770":[{"url":"https://hartvaat.nl/2023/09/19/fame-3-driejaarsresultaten-ffr-geleide-pci-versus-cabg-bij-drievatslijden/","title":"FAME 3 driejaarsresultaten: FFR-geleide PCI versus CABG bij drievatslijden","title_en":"Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial.","published":"2023-09-19"}],"10.1016/j.jacc.2023.06.015":[{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","title":"ISCHEMIA: impact van complete revascularisatie op uitkomsten","title_en":"Impact of Complete Revascularization in the ISCHEMIA Trial.","published":"2023-09-19"}],"10.1056/nejmoa2304968":[{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","title":"HEART-FID: IV ferricarboxymaltose bij hartfalen met ijzerdeficiëntie — NEJM","title_en":"Ferric Carboxymaltose in Heart Failure with Iron Deficiency.","published":"2023-09-14"}],"10.1136/heartjnl-2022-322044":[{"url":"https://hartvaat.nl/2023/09/13/prognostische-modellen-voor-hartfalen-bij-type-2-diabetes-systematische-review/","title":"Prognostische modellen voor hartfalen bij type 2 diabetes: systematische review","title_en":"Prognostic models for heart failure in patients with type 2 diabetes: a systematic review and meta-analysis.","published":"2023-09-13"}],"10.1001/jama.2023.14685":[{"url":"https://hartvaat.nl/2023/09/12/af-ablatie-vermindert-psychologische-distress-jama-rct/","title":"AF-ablatie vermindert psychologische distress: JAMA RCT","title_en":"Atrial Fibrillation Catheter Ablation vs Medical Therapy and Psychological Distress: A Randomized Clinical Trial.","published":"2023-09-12"}],"10.1056/nejmoa2300468":[{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","title":"FIRE: complete revascularisatie bij ouderen ≥75 jaar met MI — NEJM","title_en":"Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.","published":"2023-09-07"}],"10.1056/nejmoa2302392":[{"url":"https://hartvaat.nl/2023/09/07/orforglipron-dagelijkse-orale-glp-1-agonist-bij-obesitas-nejm/","title":"Orforglipron: dagelijkse orale GLP-1-agonist bij obesitas — NEJM","title_en":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.","published":"2023-09-07"}],"10.1001/jama.2023.14330":[{"url":"https://hartvaat.nl/2023/09/05/best-ii-bloeddrukmanagement-na-trombectomie-bij-cva-jama/","title":"BEST-II: bloeddrukmanagement na trombectomie bij CVA — JAMA","title_en":"Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial.","published":"2023-09-05"}],"10.1001/jama.2023.14590":[{"url":"https://hartvaat.nl/2023/09/05/optimal-bp-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-jama/","title":"OPTIMAL-BP: intensieve bloeddrukverlaging na trombectomie bij CVA — JAMA","title_en":"Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial.","published":"2023-09-05"}],"10.1161/circulationaha.123.065134":[{"url":"https://hartvaat.nl/2023/09/05/cameo-dapa-cardiale-en-metabole-effecten-van-dapagliflozine-bij-hfpef/","title":"CAMEO-DAPA: cardiale en metabole effecten van dapagliflozine bij HFpEF","title_en":"Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.","published":"2023-09-05"}],"10.1001/jamacardio.2023.2222":[{"url":"https://hartvaat.nl/2023/09/01/matige-statine-plus-ezetimibe-bij-zeer-hoog-ascvd-risico-non-inferioriteitstudie/","title":"Matige statine plus ezetimibe bij zeer hoog ASCVD-risico: non-inferioriteitstudie","title_en":"Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.","published":"2023-09-01"}],"10.1161/hypertensionaha.123.21318":[{"url":"https://hartvaat.nl/2023/09/01/drempelwaarde-voor-aortale-polsgolfsnelheid-en-cv-events-ipd-meta-analyse/","title":"Drempelwaarde voor aortale polsgolfsnelheid en CV-events: IPD meta-analyse","title_en":"Derivation of an Outcome-Driven Threshold for Aortic Pulse Wave Velocity: An Individual-Participant Meta-Analysis.","published":"2023-09-01"}],"10.1161/hypertensionaha.122.20732":[{"url":"https://hartvaat.nl/2023/09/01/step-substudie-intensieve-bloeddrukverlaging-verbetert-lvh-bij-ouderen/","title":"STEP-substudie: intensieve bloeddrukverlaging verbetert LVH bij ouderen","title_en":"Intensive Blood Pressure Lowering Improves Left Ventricular Hypertrophy in Older Patients with Hypertension: The STEP Trial.","published":"2023-09-01"}],"10.1161/circulationaha.123.064521":[{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","title":"STREAM-2: halve-dosis tenecteplase bij ouderen met STEMI","title_en":"STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.","published":"2023-08-29"}],"10.1056/nejmoa2304146":[{"url":"https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/","title":"REPRIEVE: pitavastatine vermindert CV-events bij HIV — NEJM","title_en":"Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.","published":"2023-08-24"}],"10.1136/heartjnl-2022-322278":[{"url":"https://hartvaat.nl/2023/08/24/vaste-dosiscombinatietherapie-voor-primaire-cv-preventie-ipd-meta-analyse/","title":"Vaste-dosiscombinatietherapie voor primaire CV-preventie: IPD meta-analyse","title_en":"Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.","published":"2023-08-24"}],"10.1136/heartjnl-2022-321943":[{"url":"https://hartvaat.nl/2023/08/24/fysieke-activiteitsniveaus-bij-hartfalen-meta-analyse/","title":"Fysieke activiteitsniveaus bij hartfalen: meta-analyse","title_en":"Habitual physical activity levels of adults with heart failure: systematic review and meta-analysis.","published":"2023-08-24"}],"10.1093/eurheartj/ehad338":[{"url":"https://hartvaat.nl/2023/08/14/cva-bij-hartfalen-met-gereduceerde-versus-behouden-ejectiefractie/","title":"CVA bij hartfalen met gereduceerde versus behouden ejectiefractie","title_en":"Stroke in patients with heart failure and reduced or preserved ejection fraction.","published":"2023-08-14"}],"10.1093/eurheartj/ehad335":[{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","title":"STRONG-HF: NT-proBNP-geleide intensieve optitratie na acuut HF","title_en":"NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial.","published":"2023-08-14"}],"10.1093/eurheartj/ehad280":[{"url":"https://hartvaat.nl/2023/08/14/telemonitoring-bij-hartfalen-meta-analyse-van-alle-strategieen/","title":"Telemonitoring bij hartfalen: meta-analyse van alle strategieën","title_en":"Telemonitoring for heart failure: a meta-analysis.","published":"2023-08-14"}],"10.1093/eurheartj/ehad344":[{"url":"https://hartvaat.nl/2023/08/14/sacubitril-valsartan-bij-hfmref-hfpef-gepoolde-analyse-van-drie-trials/","title":"Sacubitril/valsartan bij HFmrEF/HFpEF: gepoolde analyse van drie trials","title_en":"Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.","published":"2023-08-14"}],"10.1093/eurheartj/ehad341":[{"url":"https://hartvaat.nl/2023/08/14/dapagliflozine-versus-metolazone-bij-diureticaresistent-hartfalen/","title":"Dapagliflozine versus metolazone bij diureticaresistent hartfalen","title_en":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.","published":"2023-08-14"}],"10.1016/s0140-6736(23)01053-x":[{"url":"https://hartvaat.nl/2023/08/12/retatrutide-triple-gip-glp-1-glucagonagonist-bij-type-2-diabetes-lancet-fase-2/","title":"Retatrutide: triple GIP/GLP-1/glucagonagonist bij type 2 diabetes — Lancet fase 2","title_en":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.","published":"2023-08-12"}],"10.1001/jama.2023.11887":[{"url":"https://hartvaat.nl/2023/08/08/stop-ca-atorvastatine-beschermt-tegen-antracycline-cardiotoxiciteit/","title":"STOP-CA: atorvastatine beschermt tegen antracycline-cardiotoxiciteit","title_en":"Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.","published":"2023-08-08"}],"10.1016/j.jacc.2023.05.048":[{"url":"https://hartvaat.nl/2023/08/08/glp-1-agonisten-met-en-zonder-sglt2-remmers-bij-type-2-diabetes-jacc-analyse/","title":"GLP-1-agonisten met en zonder SGLT2-remmers bij type 2 diabetes: JACC analyse","title_en":"GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.","published":"2023-08-08"}],"10.1093/europace/euad267":[{"url":"https://hartvaat.nl/2023/08/02/gerichte-lv-leadplaatsing-bij-crt-meta-analyse-van-beeldvorming-en-elektrisch-ge/","title":"Gerichte LV-leadplaatsing bij CRT: meta-analyse van beeldvorming- en elektrisch geleide benaderingen","title_en":"Targeted left ventricular lead positioning to the site of latest activation in cardiac resynchronization therapy: a systematic review and meta-analysis.","published":"2023-08-02"}],"10.1093/europace/euad256":[{"url":"https://hartvaat.nl/2023/08/02/af-ablatie-bij-hypertrofische-cardiomyopathie-meta-analyse/","title":"AF-ablatie bij hypertrofische cardiomyopathie: meta-analyse","title_en":"Catheter ablation of atrial fibrillation in patients with and without hypertrophic cardiomyopathy: systematic review and meta-analysis.","published":"2023-08-02"}],"10.1093/europace/euad237":[{"url":"https://hartvaat.nl/2023/08/02/peri-device-lekkage-bij-laa-occluders-mechanismen-en-voorspellers/","title":"Peri-device lekkage bij LAA-occluders: mechanismen en voorspellers","title_en":"Mechanisms, predictors, and evolution of severe peri-device leaks with two different left atrial appendage occluders.","published":"2023-08-02"}],"10.1093/europace/euad199":[{"url":"https://hartvaat.nl/2023/08/02/decaaf-ii-fibroselocatie-beinvloedt-af-recidief-na-ablatie/","title":"DECAAF II: fibroselocatie beïnvloedt AF-recidief na ablatie","title_en":"Effect of fibrosis regionality on atrial fibrillation recurrence: insights from DECAAF II.","published":"2023-08-02"}],"10.1016/j.jacc.2023.05.040":[{"url":"https://hartvaat.nl/2023/08/01/mondiale-vergelijking-van-heropnamepercentages-bij-hartfalen/","title":"Mondiale vergelijking van heropnamepercentages bij hartfalen","title_en":"Global Comparison of Readmission Rates for Patients With Heart Failure.","published":"2023-08-01"}],"10.1002/ehf2.14384":[{"url":"https://hartvaat.nl/2023/08/01/atrial-flow-regulator-en-overleving-bij-hartfalen-voorspelde-impact/","title":"Atrial flow regulator en overleving bij hartfalen: voorspelde impact","title_en":"Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction.","published":"2023-08-01"}],"10.1002/ehf2.14421":[{"url":"https://hartvaat.nl/2023/08/01/hfa-peff-score-voor-hfpef-diagnose-validatie-meta-analyse/","title":"HFA-PEFF score voor HFpEF-diagnose: validatie meta-analyse","title_en":"Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta-analysis.","published":"2023-08-01"}],"10.1161/hypertensionaha.123.21132":[{"url":"https://hartvaat.nl/2023/08/01/combinatietabletten-voor-intensieve-bloeddrukbehandeling-sprint-analyse/","title":"Combinatietabletten voor intensieve bloeddrukbehandeling: SPRINT analyse","title_en":"Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial.","published":"2023-08-01"}],"10.1161/hypertensionaha.123.20954":[{"url":"https://hartvaat.nl/2023/08/01/bloeddrukstreefwaarden-bij-type-2-diabetes-netwerk-meta-analyse/","title":"Bloeddrukstreefwaarden bij type 2 diabetes: netwerk-meta-analyse","title_en":"Systolic Blood Pressure Control Targets to Prevent Major Cardiovascular Events and Death in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","published":"2023-08-01"}],"10.1002/ehf2.14398":[{"url":"https://hartvaat.nl/2023/08/01/bio-impedantieanalyse-bij-overgewicht-en-acuut-hartfalen-pilotstudie/","title":"Bio-impedantieanalyse bij overgewicht en acuut hartfalen: pilotstudie","title_en":"The role of bioimpedance analysis in overweight and obese patients with acute heart failure: a pilot study.","published":"2023-08-01"}],"10.1002/ehf2.14405":[{"url":"https://hartvaat.nl/2023/08/01/telerevalidatie-haalbaar-voor-hartfalenpatienten-zonder-toegang-tot-poliklinisch/","title":"Telerevalidatie haalbaar voor hartfalenpatiënten zonder toegang tot poliklinische revalidatie","title_en":"Feasibility of telerehabilitation for heart failure patients inaccessible for outpatient rehabilitation.","published":"2023-08-01"}],"10.1016/s0140-6736(23)00688-8":[{"url":"https://hartvaat.nl/2023/07/29/cradle-4-geplande-bevalling-versus-afwachten-bij-laat-preterm-pre-eclampsie-in-l/","title":"CRADLE-4: geplande bevalling versus afwachten bij laat-preterm pre-eclampsie in LMIC's","title_en":"Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.","published":"2023-07-29"}],"10.1016/s0140-6736(23)00874-7":[{"url":"https://hartvaat.nl/2023/07/29/luspatercept-versus-epoetine-alfa-bij-mds-gerelateerde-anemie-lancet-trial/","title":"Luspatercept versus epoëtine alfa bij MDS-gerelateerde anemie: Lancet-trial","title_en":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.","published":"2023-07-29"}],"10.1016/j.jacc.2023.05.024":[{"url":"https://hartvaat.nl/2023/07/25/omega-3-biomarkers-en-incident-af-ipd-analyse/","title":"Omega-3 biomarkers en incident AF: IPD analyse","title_en":"Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation.","published":"2023-07-25"}],"10.1093/eurheartj/ehad336":[{"url":"https://hartvaat.nl/2023/07/21/rood-vlees-cardiovasculaire-ziekte-en-diabetes-systematische-review/","title":"Rood vlees, cardiovasculaire ziekte en diabetes: systematische review","title_en":"Red meat consumption, cardiovascular diseases, and diabetes: a systematic review and meta-analysis.","published":"2023-07-21"}],"10.1093/eurheartj/ehad211":[{"url":"https://hartvaat.nl/2023/07/21/vegetarisch-of-veganistisch-dieet-en-bloedlipiden-meta-analyse-van-rct-s/","title":"Vegetarisch of veganistisch dieet en bloedlipiden: meta-analyse van RCT's","title_en":"Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials.","published":"2023-07-21"}],"10.1056/nejmoa2208391":[{"url":"https://hartvaat.nl/2023/07/20/zilebesiran-rna-interferentietherapie-voor-hypertensie-nejm/","title":"Zilebesiran: RNA-interferentietherapie voor hypertensie — NEJM","title_en":"Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.","published":"2023-07-20"}],"10.1056/nejmoa2303765":[{"url":"https://hartvaat.nl/2023/07/20/ni006-antilichaam-voor-afbraak-van-cardiale-transthyretine-amyloid-nejm-fase-1/","title":"NI006: antilichaam voor afbraak van cardiale transthyretine-amyloid — NEJM fase 1","title_en":"Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.","published":"2023-07-20"}],"10.1001/jama.2023.8867":[{"url":"https://hartvaat.nl/2023/07/18/uspstf-evidence-review-lipidescreening-bij-kinderen-geactualiseerd/","title":"USPSTF evidence review: lipidescreening bij kinderen geactualiseerd","title_en":"Screening for Lipid Disorders in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2023-07-18"}],"10.1001/jama.2023.11330":[{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","title":"USPSTF: screening op lipidestoornissen bij kinderen en adolescenten","title_en":"Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.","published":"2023-07-18"}],"10.1016/j.jacc.2023.05.003":[{"url":"https://hartvaat.nl/2023/07/18/bioresorbeerbare-coronaire-scaffolds-vijfjaarsuitkomsten-met-verbeterde-techniek/","title":"Bioresorbeerbare coronaire scaffolds: vijfjaarsuitkomsten met verbeterde techniek","title_en":"5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique.","published":"2023-07-18"}],"10.1161/circulationaha.122.063263":[{"url":"https://hartvaat.nl/2023/07/18/sglt2-remmers-verbeteren-kwaliteit-van-leven-gelijk-bij-zwarte-en-witte-hartfale/","title":"SGLT2-remmers verbeteren kwaliteit van leven gelijk bij zwarte en witte hartfalenpatiënten","title_en":"Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.","published":"2023-07-18"}],"10.1093/eurheartj/ehad247":[{"url":"https://hartvaat.nl/2023/07/14/vroege-versus-late-af-ablatie-impact-op-aritmierecidief/","title":"Vroege versus late AF-ablatie: impact op aritmierecidief","title_en":"Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences.","published":"2023-07-14"}],"10.1056/nejmoa2215025":[{"url":"https://hartvaat.nl/2023/07/13/traverse-testosteronsubstitutie-cardiovasculair-veilig-bij-hypogonadisme/","title":"TRAVERSE: testosteronsubstitutie cardiovasculair veilig bij hypogonadisme","title_en":"Cardiovascular Safety of Testosterone-Replacement Therapy.","published":"2023-07-13"}],"10.1016/j.jacc.2023.04.051":[{"url":"https://hartvaat.nl/2023/07/11/p2y12-monotherapie-versus-aspirine-voor-langetermijnsecundaire-preventie-meta-an/","title":"P2Y12-monotherapie versus aspirine voor langetermijnsecundaire preventie: meta-analyse","title_en":"P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.","published":"2023-07-11"}],"10.1016/j.jacc.2023.04.047":[{"url":"https://hartvaat.nl/2023/07/11/ondervoeding-verslechtert-prognose-bij-hartfalen-en-mr-coapt-analyse/","title":"Ondervoeding verslechtert prognose bij hartfalen en MR: COAPT-analyse","title_en":"Impact of Malnutrition in Patients With Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial.","published":"2023-07-11"}],"10.1161/circulationaha.123.064842":[{"url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","title":"TRANSFORM-HF: torsemide versus furosemide — geen verschil in symptomen","title_en":"Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.","published":"2023-07-11"}],"10.1016/j.jacc.2023.04.044":[{"url":"https://hartvaat.nl/2023/07/04/cognitieve-gedragstherapie-verbetert-kwaliteit-van-leven-bij-symptomatisch-af/","title":"Cognitieve gedragstherapie verbetert kwaliteit van leven bij symptomatisch AF","title_en":"Cognitive Behavioral Therapy Improves Quality of Life in Patients With Symptomatic Paroxysmal Atrial Fibrillation.","published":"2023-07-04"}],"10.1093/europace/euad169":[{"url":"https://hartvaat.nl/2023/07/04/colchicine-voorkomt-postoperatief-af-na-hartchirurgie-meta-analyse/","title":"Colchicine voorkomt postoperatief AF na hartchirurgie: meta-analyse","title_en":"Safety and efficacy of colchicine for the prevention of post-operative atrial fibrillation in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.","published":"2023-07-04"}],"10.1016/j.jacc.2023.04.019":[{"url":"https://hartvaat.nl/2023/07/04/sacubitril-valsartan-bij-hfmref-hfpef-met-verslechterend-hartfalen/","title":"Sacubitril/valsartan bij HFmrEF/HFpEF met verslechterend hartfalen","title_en":"Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.","published":"2023-07-04"}],"10.1016/s0140-6736(23)00806-1":[{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","title":"INTERACT3: bundeled care bij acute intracerebrale bloeding — Lancet","title_en":"The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.","published":"2023-07-01"}],"10.1001/jamacardio.2023.1342":[{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","title":"DELIVER: dapagliflozine verbetert individuele KCCQ-componenten bij HFpEF","title_en":"Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.","published":"2023-07-01"}],"10.1001/jamacardio.2023.1373":[{"url":"https://hartvaat.nl/2023/07/01/tino-gecoate-versus-everolimus-eluting-stents-bij-acs-tides-acs-vijfjaarsdata/","title":"TiNO-gecoate versus everolimus-eluting stents bij ACS: TIDES-ACS vijfjaarsdata","title_en":"Titanium-Nitride-Oxide-Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome: 5-Year Clinical Outcomes of the TIDES-ACS Randomized Clinical Trial.","published":"2023-07-01"}],"10.1093/eurheartj/ehad238":[{"url":"https://hartvaat.nl/2023/07/01/statinoplaaddosis-voor-cabg-gerandomiseerde-trial/","title":"Statinoplaaddosis voor CABG: gerandomiseerde trial","title_en":"Statin loading before coronary artery bypass grafting: a randomized trial.","published":"2023-07-01"}],"10.1161/hypertensionaha.122.20862":[{"url":"https://hartvaat.nl/2023/07/01/timing-van-antihypertensiva-meta-analyse-van-rct-s-bevestigt-flexibiliteit/","title":"Timing van antihypertensiva: meta-analyse van RCT's bevestigt flexibiliteit","title_en":"Timing of Antihypertensive Drug Therapy: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","published":"2023-07-01"}],"10.1161/hypertensionaha.123.21054":[{"url":"https://hartvaat.nl/2023/07/01/familiair-hyperaldosteronisme-type-1-therapeutische-opties-en-langetermijnuitkom/","title":"Familiair hyperaldosteronisme type 1: therapeutische opties en langetermijnuitkomsten","title_en":"Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.","published":"2023-07-01"}],"10.1161/hypertensionaha.123.21323":[{"url":"https://hartvaat.nl/2023/07/01/leeftijdsbias-draagt-bij-aan-therapeutische-inertie-bij-bloeddrukmanagement/","title":"Leeftijdsbias draagt bij aan therapeutische inertie bij bloeddrukmanagement","title_en":"Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT.","published":"2023-07-01"}],"10.1161/hypertensionaha.123.20901":[{"url":"https://hartvaat.nl/2023/07/01/metabolomics-en-bloeddrukrespons-op-dash-dieet/","title":"Metabolomics en bloeddrukrespons op DASH-dieet","title_en":"Metabolomic Profiles Associated With Blood Pressure Reduction in Response to the DASH and DASH-Sodium Dietary Interventions.","published":"2023-07-01"}],"10.1056/nejmoa2303048":[{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","title":"ELAN: vroege versus late anticoagulatie na CVA bij AF — NEJM","title_en":"Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.","published":"2023-06-29"}],"10.1016/j.jacc.2023.04.034":[{"url":"https://hartvaat.nl/2023/06/27/sglt2-remmers-en-cv-uitkomsten-over-patientpopulaties-jacc-overzicht/","title":"SGLT2-remmers en CV-uitkomsten over patiëntpopulaties: JACC overzicht","title_en":"Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.","published":"2023-06-27"}],"10.1136/heartjnl-2022-322074":[{"url":"https://hartvaat.nl/2023/06/26/opioiden-bij-dyspneu-en-hartfalen-meta-analyse-toont-geen-voordeel/","title":"Opioïden bij dyspneu en hartfalen: meta-analyse toont geen voordeel","title_en":"Effect of opioids for breathlessness in heart failure: a systematic review and meta-analysis.","published":"2023-06-26"}],"10.1093/eurheartj/ehad276":[{"url":"https://hartvaat.nl/2023/06/25/dapagliflozine-en-perifeer-arterieel-vaatlijden-bij-hartfalen-dapa-hf-deliver-me/","title":"Dapagliflozine en perifeer arterieel vaatlijden bij hartfalen: DAPA-HF/DELIVER meta-analyse","title_en":"Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.","published":"2023-06-25"}],"10.1093/eurheartj/ehad210":[{"url":"https://hartvaat.nl/2023/06/25/cystatine-c-voor-gfr-schatting-bij-hartfalen-paradigm-hf-analyse/","title":"Cystatine C voor GFR-schatting bij hartfalen: PARADIGM-HF analyse","title_en":"Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial.","published":"2023-06-25"}],"10.1016/s0140-6736(23)00923-6":[{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","title":"MONITOR-HF: PA-drukmonitoring bij hartfalen effectief in Europa — Lancet RCT","title_en":"Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial.","published":"2023-06-24"}],"10.1161/circulationaha.123.064361":[{"url":"https://hartvaat.nl/2023/06/13/loop-substudie-nt-probnp-verbetert-af-screeningsopbrengst/","title":"LOOP-substudie: NT-proBNP verbetert AF-screeningsopbrengst","title_en":"Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.","published":"2023-06-13"}],"10.1093/eurheartj/ehad236":[{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","title":"ADVOR: bicarbonaatwaarden en decongestie-effect van acetazolamide","title_en":"Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial.","published":"2023-06-09"}],"10.1093/eurheartj/ehad100":[{"url":"https://hartvaat.nl/2023/06/09/acyl-ghreline-verbetert-hartfunctie-bij-hartfalen/","title":"Acyl-ghreline verbetert hartfunctie bij hartfalen","title_en":"Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization.","published":"2023-06-09"}],"10.1056/nejmoa2214956":[{"url":"https://hartvaat.nl/2023/06/08/behandeling-van-vroeg-gediagnosticeerde-zwangerschapsdiabetes-nejm-trial/","title":"Behandeling van vroeg gediagnosticeerde zwangerschapsdiabetes: NEJM trial","title_en":"Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy.","published":"2023-06-08"}],"10.1016/j.jacc.2023.03.426":[{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","title":"STRONG-HF: optitratie effectief over het hele EF-spectrum na HF-opname","title_en":"Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction.","published":"2023-06-06"}],"10.1161/circulationaha.122.062752":[{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","title":"COMBINE AF: DOAC's versus warfarine over het nierfunctiespectrum — IPD meta-analyse","title_en":"Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.","published":"2023-06-06"}],"10.1001/jamacardio.2023.0845":[{"url":"https://hartvaat.nl/2023/06/01/intensieve-bloeddrukcontrole-en-geleidingsziekten-sprint-post-hoc-analyse/","title":"Intensieve bloeddrukcontrole en geleidingsziekten: SPRINT post-hoc analyse","title_en":"Association Between Intensive vs Standard Blood Pressure Control and Incident Left Ventricular Conduction Disease: A Post Hoc Analysis of the SPRINT Randomized Clinical Trial.","published":"2023-06-01"}],"10.1001/jamacardio.2023.0720":[{"url":"https://hartvaat.nl/2023/06/01/lage-dosis-drievoudige-viervoudige-combinatiepil-versus-monotherapie-bij-hyperte/","title":"Lage-dosis drievoudige/viervoudige combinatiepil versus monotherapie bij hypertensie: meta-analyse","title_en":"Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis.","published":"2023-06-01"}],"10.1093/eurheartj/ehad142":[{"url":"https://hartvaat.nl/2023/06/01/genetische-bijdrage-aan-aortastenose-dyslipidemie-inflammatie-en-verkalking/","title":"Genetische bijdrage aan aortastenose: dyslipidemie, inflammatie en verkalking","title_en":"Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study.","published":"2023-06-01"}],"10.1056/nejmoa2300213":[{"url":"https://hartvaat.nl/2023/06/01/coapt-vijfjaarsresultaten-mitraclip-duurzaam-effectief-bij-secundaire-mr/","title":"COAPT vijfjaarsresultaten: MitraClip duurzaam effectief bij secundaire MR","title_en":"Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation.","published":"2023-06-01"}],"10.1002/ehf2.14335":[{"url":"https://hartvaat.nl/2023/06/01/igfbp7-en-lv-massaregressie-met-empagliflozine-empa-heart-subanalyse/","title":"IGFBP7 en LV-massaregressie met empagliflozine: EMPA-HEART subanalyse","title_en":"IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial.","published":"2023-06-01"}],"10.1002/ehf2.14351":[{"url":"https://hartvaat.nl/2023/06/01/nlr-en-cardiale-remodelling-met-empagliflozine-empa-heart-subanalyse/","title":"NLR en cardiale remodelling met empagliflozine: EMPA-HEART subanalyse","title_en":"Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling.","published":"2023-06-01"}],"10.1002/ehf2.14357":[{"url":"https://hartvaat.nl/2023/06/01/diabetesduur-beinvloedt-lv-massaregressie-met-empagliflozine/","title":"Diabetesduur beïnvloedt LV-massaregressie met empagliflozine","title_en":"Impact of diabetes duration on left ventricular mass regression with empagliflozin.","published":"2023-06-01"}],"10.1161/hypertensionaha.122.20934":[{"url":"https://hartvaat.nl/2023/06/01/remote-ischemische-conditionering-bij-milde-hypertensie-zonder-medicatie-rct/","title":"Remote ischemische conditionering bij milde hypertensie zonder medicatie: RCT","title_en":"Chronic Remote Ischemic Conditioning on Mild Hypertension in the Absence of Antihypertensive Medication: A Multicenter, Randomized, Double-Blind, Proof-of-Concept Clinical Trial.","published":"2023-06-01"}],"10.1002/ehf2.14353":[{"url":"https://hartvaat.nl/2023/06/01/betablokkers-bij-systolisch-hartfalen-en-pacemakerritme-mortaliteitseffect/","title":"Bètablokkers bij systolisch hartfalen en pacemakerritme: mortaliteitseffect","title_en":"Beta-blocker use and mortality among patients with systolic heart failure and pacemaker rhythm.","published":"2023-06-01"}],"10.1002/ehf2.14355":[{"url":"https://hartvaat.nl/2023/06/01/sglt2-remmers-bij-hartfalen-systematisch-overzicht-van-mechanismen-en-kliniek/","title":"SGLT2-remmers bij hartfalen: systematisch overzicht van mechanismen en kliniek","title_en":"Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.","published":"2023-06-01"}],"10.1002/ehf2.14284":[{"url":"https://hartvaat.nl/2023/06/01/hartfalentherapie-bij-hfmref-netwerk-meta-analyse/","title":"Hartfalentherapie bij HFmrEF: netwerk-meta-analyse","title_en":"The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis.","published":"2023-06-01"}],"10.1161/hypertensionaha.122.20292":[{"url":"https://hartvaat.nl/2023/06/01/team-based-care-bij-hypertensie-meta-analyse-bevestigt-effectiviteit-en-kostenef/","title":"Team-based care bij hypertensie: meta-analyse bevestigt effectiviteit en kosteneffectiviteit","title_en":"Effectiveness and Cost-Effectiveness of Team-Based Care for Hypertension: A Meta-Analysis and Simulation Study.","published":"2023-06-01"}],"10.1161/hypertensionaha.122.20190":[{"url":"https://hartvaat.nl/2023/06/01/eindorgaanschade-bij-kinderen-met-primaire-hypertensie-meta-analyse/","title":"Eindorgaanschade bij kinderen met primaire hypertensie: meta-analyse","title_en":"Risk of Target Organ Damage in Children With Primary Ambulatory Hypertension: A Systematic Review and Meta-Analysis.","published":"2023-06-01"}],"10.1002/ehf2.14314":[{"url":"https://hartvaat.nl/2023/06/01/natriuretisch-peptide-screening-voor-lv-disfunctie-diagnostische-nauwkeurigheid/","title":"Natriuretisch peptide screening voor LV-disfunctie: diagnostische nauwkeurigheid","title_en":"Diagnostic accuracy of natriuretic peptide screening for left ventricular systolic dysfunction in the community: systematic review and meta-analysis.","published":"2023-06-01"}],"10.1002/ehf2.14313":[{"url":"https://hartvaat.nl/2023/06/01/angiotensinepathways-onder-empagliflozine-bij-chronisch-hartfalen/","title":"Angiotensinepathways onder empagliflozine bij chronisch hartfalen","title_en":"Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure.","published":"2023-06-01"}],"10.1016/j.jacc.2023.03.418":[{"url":"https://hartvaat.nl/2023/05/30/complicaties-van-af-ablatie-actueel-overzicht/","title":"Complicaties van AF-ablatie: actueel overzicht","title_en":"Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation.","published":"2023-05-30"}],"10.1161/circulationaha.122.062021":[{"url":"https://hartvaat.nl/2023/05/30/empagliflozine-en-cardiale-energiestofwisseling-bij-hartfalen-empa-vision/","title":"Empagliflozine en cardiale energiestofwisseling bij hartfalen: EMPA-VISION","title_en":"Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.","published":"2023-05-30"}],"10.1161/circulationaha.122.060757":[{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","title":"AFFIRM-AHF: hemoglobine beïnvloedt IV-ijzereffect bij acuut hartfalen","title_en":"Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.","published":"2023-05-30"}],"10.1016/s0140-6736(23)00462-2":[{"url":"https://hartvaat.nl/2023/05/27/best-cli-veneuze-bypass-versus-endovasculair-bij-chronische-kritieke-ischemie/","title":"BEST-CLI: veneuze bypass versus endovasculair bij chronische kritieke ischemie","title_en":"A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.","published":"2023-05-27"}],"10.1093/eurheartj/ehad200":[{"url":"https://hartvaat.nl/2023/05/21/prognose-van-ischemisch-cva-onder-orale-anticoagulatie-bij-af/","title":"Prognose van ischemisch CVA onder orale anticoagulatie bij AF","title_en":"Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation.","published":"2023-05-21"}],"10.1093/europace/euad090":[{"url":"https://hartvaat.nl/2023/05/19/drie-substraatstrategieen-voor-persisterend-af-vergeleken-multicenter-rct/","title":"Drie substraatstrategieën voor persisterend AF vergeleken: multicenter RCT","title_en":"Multi-centre, prospective randomized comparison of three different substrate ablation strategies for persistent atrial fibrillation.","published":"2023-05-19"}],"10.1093/europace/euad080":[{"url":"https://hartvaat.nl/2023/05/19/slokdarmkoeling-voorkomt-oesofagale-schade-bij-af-ablatie-meta-analyse/","title":"Slokdarmkoeling voorkomt oesofagale schade bij AF-ablatie: meta-analyse","title_en":"Role of oesophageal cooling in the prevention of oesophageal injury in atrial fibrillation catheter ablation: a systematic review and meta-analysis of randomized controlled trials.","published":"2023-05-19"}],"10.1093/europace/euad086":[{"url":"https://hartvaat.nl/2023/05/19/fluoroscopievrije-cryoballonablatie-met-ice-begeleiding-bij-af/","title":"Fluoroscopievrije cryoballonablatie met ICE-begeleiding bij AF","title_en":"Safety and efficacy of intracardiac echocardiography-guided zero-fluoroscopic cryoballoon ablation for atrial fibrillation: a prospective randomized controlled trial.","published":"2023-05-19"}],"10.1093/europace/euad051":[{"url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","title":"EAST-AFNET 4: vroege ritmecontrole bij AF is kosteneffectief","title_en":"Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial.","published":"2023-05-19"}],"10.1093/europace/euad019":[{"url":"https://hartvaat.nl/2023/05/19/geleidingssysteempacing-in-europa-inzichten-uit-klinische-praktijk/","title":"Geleidingssysteempacing in Europa: inzichten uit klinische praktijk","title_en":"Conduction system pacing, a European survey: insights from clinical practice.","published":"2023-05-19"}],"10.1056/nejmoa2300525":[{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","title":"TRILUMINATE: transcatheter tricuspidaliskleprepair bij ernstige TR — NEJM","title_en":"Transcatheter Repair for Patients with Tricuspid Regurgitation.","published":"2023-05-18"}],"10.1161/circulationaha.123.064188":[{"url":"https://hartvaat.nl/2023/05/16/afschaffen-eigen-bijdrage-medicatie-vermindert-cardiovasculair-risico-bij-oudere/","title":"Afschaffen eigen bijdrage medicatie vermindert cardiovasculair risico bij ouderen","title_en":"Eliminating Medication Copayments for Low-Income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial.","published":"2023-05-16"}],"10.1161/circulationaha.123.064189":[{"url":"https://hartvaat.nl/2023/05/16/zelfmanagement-via-reclameprincipes-bij-ouderen-met-hoog-cv-risico/","title":"Zelfmanagement via reclameprincipes bij ouderen met hoog CV-risico","title_en":"Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial.","published":"2023-05-16"}],"10.1136/heartjnl-2022-321885":[{"url":"https://hartvaat.nl/2023/05/15/implanteerbare-hemodynamische-monitoring-bij-hartfalen-meta-analyse-over-ef-spec/","title":"Implanteerbare hemodynamische monitoring bij hartfalen: meta-analyse over EF-spectrum","title_en":"Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis.","published":"2023-05-15"}],"10.1093/eurheartj/ehad056":[{"url":"https://hartvaat.nl/2023/05/14/prehospitale-troponine-voor-uitsluiting-nste-acs-gerandomiseerde-trial/","title":"Prehospitale troponine voor uitsluiting NSTE-ACS: gerandomiseerde trial","title_en":"Rule-out of non-ST-segment elevation acute coronary syndrome by a single, pre-hospital troponin measurement: a randomized trial.","published":"2023-05-14"}],"10.1016/j.jacc.2023.03.393":[{"url":"https://hartvaat.nl/2023/05/09/2023-acc-expert-consensus-management-van-hfpef/","title":"2023 ACC Expert Consensus: management van HFpEF","title_en":"2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2023-05-09"}],"10.1056/nejmoa2216607":[{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","title":"RENOVATE-COMPLEX-PCI: intravasculaire beeldvorming versus angiografie bij complexe PCI","title_en":"Intravascular Imaging-Guided or Angiography-Guided Complex PCI.","published":"2023-05-04"}],"10.1161/circulationaha.123.064264":[{"url":"https://hartvaat.nl/2023/05/02/korte-versus-standaard-dapt-na-pci-met-moderne-des-meta-analyse/","title":"Korte versus standaard DAPT na PCI met moderne DES: meta-analyse","title_en":"Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.","published":"2023-05-02"}],"10.1161/circulationaha.123.064226":[{"url":"https://hartvaat.nl/2023/05/02/gepersonaliseerde-beslisondersteuning-verhoogt-statinegebruik-bij-ascvd/","title":"Gepersonaliseerde beslisondersteuning verhoogt statinegebruik bij ASCVD","title_en":"Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease.","published":"2023-05-02"}],"10.1001/jamacardio.2023.0212":[{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","title":"AWARE: uitgebreide ablatie vermindert AF-recidief niet boven standaard PVI","title_en":"Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence: The AWARE Randomized Clinical Trial.","published":"2023-05-01"}],"10.1001/jamacardio.2023.0019":[{"url":"https://hartvaat.nl/2023/05/01/cardiale-biomarkers-en-cv-events-bij-diabetes-declare-timi-58-subanalyse/","title":"Cardiale biomarkers en CV-events bij diabetes: DECLARE-TIMI 58 subanalyse","title_en":"Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.","published":"2023-05-01"}],"10.1161/hypertensionaha.122.20426":[{"url":"https://hartvaat.nl/2023/05/01/dyslipidemie-en-pre-eclampsierisico-mendeliaanse-randomisatie/","title":"Dyslipidemie en pre-eclampsierisico: Mendeliaanse randomisatie","title_en":"Dyslipidemia and Risk of Preeclampsia: A Multiancestry Mendelian Randomization Study.","published":"2023-05-01"}],"10.1016/j.jacc.2023.02.018":[{"url":"https://hartvaat.nl/2023/04/25/mk-0616-eerste-orale-pcsk9-remmer-in-fase-2b/","title":"MK-0616: eerste orale PCSK9-remmer in fase 2b","title_en":"Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.","published":"2023-04-25"}],"10.1093/eurheartj/ehac726":[{"url":"https://hartvaat.nl/2023/04/21/cardiometabole-gezondheid-bij-kinderen-geboren-na-ivf/","title":"Cardiometabole gezondheid bij kinderen geboren na IVF","title_en":"Long-term cardiometabolic health in people born after assisted reproductive technology: a multi-cohort analysis.","published":"2023-04-21"}],"10.1056/nejmoa2213558":[{"url":"https://hartvaat.nl/2023/04/20/stellar-sotatercept-bij-pulmonale-arteriele-hypertensie-nejm-fase-3/","title":"STELLAR: sotatercept bij pulmonale arteriële hypertensie — NEJM fase 3","title_en":"Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.","published":"2023-04-20"}],"10.1016/j.jacc.2023.02.012":[{"url":"https://hartvaat.nl/2023/04/18/aha-scientific-statement-gestructureerde-inspanningstraining-bij-hfpef/","title":"AHA Scientific Statement: gestructureerde inspanningstraining bij HFpEF","title_en":"Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.","published":"2023-04-18"}],"10.1001/jama.2023.2854":[{"url":"https://hartvaat.nl/2023/04/18/gecoordineerde-zorg-optimaliseert-cv-preventie-bij-type-2-diabetes-jama-rct/","title":"Gecoördineerde zorg optimaliseert CV-preventie bij type 2 diabetes: JAMA RCT","title_en":"Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.","published":"2023-04-18"}],"10.1161/circulationaha.122.063399":[{"url":"https://hartvaat.nl/2023/04/18/optimaal-bereikt-ldl-cholesterol-en-langetermijn-cv-uitkomsten-fourier-analyse/","title":"Optimaal bereikt LDL-cholesterol en langetermijn CV-uitkomsten: FOURIER analyse","title_en":"Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.","published":"2023-04-18"}],"10.1093/eurheartj/ehac829":[{"url":"https://hartvaat.nl/2023/04/17/dapt-de-escalatie-na-acs-ipd-meta-analyse/","title":"DAPT de-escalatie na ACS: IPD meta-analyse","title_en":"Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.","published":"2023-04-17"}],"10.1093/eurheartj/ehad026":[{"url":"https://hartvaat.nl/2023/04/17/in-stent-restenose-tienjaarsuitkomsten-plain-balloon-vs-dcb-vs-des-isar-desire-3/","title":"In-stent restenose: tienjaarsuitkomsten plain balloon vs DCB vs DES — ISAR-DESIRE 3","title_en":"Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial.","published":"2023-04-17"}],"10.1016/s0140-6736(23)00215-5":[{"url":"https://hartvaat.nl/2023/04/15/inflammatie-en-cholesterol-als-cv-voorspellers-onder-statinetherapie-lancet-anal/","title":"Inflammatie en cholesterol als CV-voorspellers onder statinetherapie: Lancet analyse","title_en":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.","published":"2023-04-15"}],"10.1056/nejmoa2215024":[{"url":"https://hartvaat.nl/2023/04/13/clear-outcomes-bempedoinezuur-vermindert-cv-events-bij-statine-intolerantie/","title":"CLEAR Outcomes: bempedoïnezuur vermindert CV-events bij statine-intolerantie","title_en":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.","published":"2023-04-13"}],"10.1001/jama.2023.3322":[{"url":"https://hartvaat.nl/2023/04/11/heterogeniteit-in-bloeddrukrespons-op-antihypertensiva-jama-cross-over-rct/","title":"Heterogeniteit in bloeddrukrespons op antihypertensiva: JAMA cross-over RCT","title_en":"Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.","published":"2023-04-11"}],"10.1016/j.jacc.2023.02.007":[{"url":"https://hartvaat.nl/2023/04/11/matige-statine-plus-ezetimibe-bij-ouderen-met-atherosclerose-jacc-studie/","title":"Matige statine plus ezetimibe bij ouderen met atherosclerose: JACC-studie","title_en":"Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis.","published":"2023-04-11"}],"10.1016/j.jacc.2023.02.005":[{"url":"https://hartvaat.nl/2023/04/11/ambulante-beslisondersteuning-verbetert-mra-voorschrijving-bij-hfref/","title":"Ambulante beslisondersteuning verbetert MRA-voorschrijving bij HFrEF","title_en":"Cluster-Randomized Trial Comparing Ambulatory Decision Support Tools to Improve Heart Failure Care.","published":"2023-04-11"}],"10.1016/s0140-6736(23)00351-3":[{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","title":"BIOVASC: directe versus gestageerde complete revascularisatie bij ACS met meervatslijden","title_en":"Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.","published":"2023-04-08"}],"10.1001/jama.2023.2487":[{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","title":"LODESTAR: treat-to-target versus hoge-dosis statine bij coronairlijden","title_en":"Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.","published":"2023-04-04"}],"10.1161/circulationaha.122.062349":[{"url":"https://hartvaat.nl/2023/04/04/genetisch-risico-op-primair-aldosteronisme-en-bijdrage-aan-hypertensie-gwas-meta/","title":"Genetisch risico op primair aldosteronisme en bijdrage aan hypertensie: GWAS meta-analyse","title_en":"Genetic Risk of Primary Aldosteronism and Its Contribution to Hypertension: A Cross-Ancestry Meta-Analysis of Genome-Wide Association Studies.","published":"2023-04-04"}],"10.1001/jamacardio.2023.0065":[{"url":"https://hartvaat.nl/2023/04/01/parable-sacubitril-valsartan-vermindert-linkeratriumvolume-bij-pre-hfpef/","title":"PARABLE: sacubitril/valsartan vermindert linkeratriumvolume bij pre-HFpEF","title_en":"Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.","published":"2023-04-01"}],"10.1001/jamacardio.2022.5608":[{"url":"https://hartvaat.nl/2023/04/01/dapagliflozine-verlaagt-urinezuur-en-vermindert-jichtaanvallen-bij-hartfalen/","title":"Dapagliflozine verlaagt urinezuur en vermindert jichtaanvallen bij hartfalen","title_en":"Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.","published":"2023-04-01"}],"10.1161/hypertensionaha.122.20602":[{"url":"https://hartvaat.nl/2023/04/01/lichaamshouding-en-orthostatische-hypotensie-bij-hypertensie-syst-eur-analyse/","title":"Lichaamshouding en orthostatische hypotensie bij hypertensie: Syst-Eur analyse","title_en":"Body Position and Orthostatic Hypotension in Hypertensive Adults: Results from the Syst-Eur Trial.","published":"2023-04-01"}],"10.1002/ehf2.14310":[{"url":"https://hartvaat.nl/2023/04/01/intraveneus-ijzer-bij-hartfalen-meta-analyse-op-studieniveau/","title":"Intraveneus ijzer bij hartfalen: meta-analyse op studieniveau","title_en":"Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis.","published":"2023-04-01"}],"10.1002/ehf2.14298":[{"url":"https://hartvaat.nl/2023/04/01/sglt2-remmers-raas-remmers-en-arni-vergeleken-bij-hartfalen-meta-analyse/","title":"SGLT2-remmers, RAAS-remmers en ARNI vergeleken bij hartfalen: meta-analyse","title_en":"The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.","published":"2023-04-01"}],"10.1002/ehf2.14297":[{"url":"https://hartvaat.nl/2023/04/01/indirecte-vergelijking-van-sglt2-remmers-bij-hartfalen-bayesiaanse-analyse/","title":"Indirecte vergelijking van SGLT2-remmers bij hartfalen: Bayesiaanse analyse","title_en":"Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.","published":"2023-04-01"}],"10.1002/ehf2.14281":[{"url":"https://hartvaat.nl/2023/04/01/mesenchymale-stamcellen-bij-ischemisch-hartfalen-deense-fase-ii-trial/","title":"Mesenchymale stamcellen bij ischemisch hartfalen: Deense fase II trial","title_en":"Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.","published":"2023-04-01"}],"10.1002/ehf2.14269":[{"url":"https://hartvaat.nl/2023/04/01/aspirine-in-primaire-preventie-en-hartfalenrisico-meta-analyse/","title":"Aspirine in primaire preventie en hartfalenrisico: meta-analyse","title_en":"Aspirin in primary prevention and the risk of heart failure: a systematic review and meta-analysis of controlled trials.","published":"2023-04-01"}],"10.1002/ehf2.14268":[{"url":"https://hartvaat.nl/2023/04/01/natriumzirconiumcyclosilicaat-bij-hyperkaliemie-en-hartfalen/","title":"Natriumzirconiumcyclosilicaat bij hyperkaliëmie en hartfalen","title_en":"Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.","published":"2023-04-01"}],"10.1002/ehf2.14207":[{"url":"https://hartvaat.nl/2023/04/01/multicomponent-geintegreerde-zorg-bij-chronisch-hartfalen-meta-analyse/","title":"Multicomponent geïntegreerde zorg bij chronisch hartfalen: meta-analyse","title_en":"Multicomponent integrated care for patients with chronic heart failure: systematic review and meta-analysis.","published":"2023-04-01"}],"10.1093/europace/euac253":[{"url":"https://hartvaat.nl/2023/03/30/ablatie-versus-antiaritmica-voor-vermindering-van-ziekenhuisbezoeken-bij-af/","title":"Ablatie versus antiaritmica voor vermindering van ziekenhuisbezoeken bij AF","title_en":"Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation: a prospective, randomized, multi-centre, open label trial.","published":"2023-03-30"}],"10.1093/europace/euac231":[{"url":"https://hartvaat.nl/2023/03/30/biatriale-tachycardieen-ablatiestrategie-en-linkeratriale-epicardiale-geleiding/","title":"Biatriale tachycardieën: ablatiestrategie en linkeratriale epicardiale geleiding","title_en":"Revisiting the characteristics and ablation strategy of biatrial tachycardias: a case series and systematic review.","published":"2023-03-30"}],"10.1093/europace/euac188":[{"url":"https://hartvaat.nl/2023/03/30/upgrade-van-rv-pacemaker-naar-crt-of-geleidingssysteempacing-meta-analyse/","title":"Upgrade van RV-pacemaker naar CRT of geleidingssysteempacing: meta-analyse","title_en":"Upgrading right ventricular pacemakers to biventricular pacing or conduction system pacing: a systematic review and meta-analysis.","published":"2023-03-30"}],"10.1001/jama.2023.3184":[{"url":"https://hartvaat.nl/2023/03/28/secundaire-hypertensie-bij-kinderen-jama-klinische-diagnostiek/","title":"Secundaire hypertensie bij kinderen: JAMA klinische diagnostiek","title_en":"Does This Child With High Blood Pressure Have Secondary Hypertension?: The Rational Clinical Examination Systematic Review.","published":"2023-03-28"}],"10.1016/j.jacc.2023.01.029":[{"url":"https://hartvaat.nl/2023/03/28/culprit-interventie-bij-cardiogene-shock-met-hartstilstand/","title":"Culprit-interventie bij cardiogene shock met hartstilstand","title_en":"Influence of Culprit Lesion Intervention on Outcomes in Infarct-Related Cardiogenic Shock With Cardiac Arrest.","published":"2023-03-28"}],"10.1161/circulationaha.122.063716":[{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","title":"AMPLITUDE-O: dosisrespons van efpeglenatide op CV-uitkomsten bij diabetes","title_en":"Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.","published":"2023-03-28"}],"10.1093/eurheartj/ehad016":[{"url":"https://hartvaat.nl/2023/03/21/genetische-varianten-geassocieerd-met-syncope-neurale-en-autonome-processen/","title":"Genetische varianten geassocieerd met syncope: neurale en autonome processen","title_en":"Genetic variants associated with syncope implicate neural and autonomic processes.","published":"2023-03-21"}],"10.1093/eurheartj/ehac611":[{"url":"https://hartvaat.nl/2023/03/21/coronairangiografie-na-hartstilstand-zonder-stemi-netwerk-meta-analyse/","title":"Coronairangiografie na hartstilstand zonder STEMI: netwerk-meta-analyse","title_en":"Coronary angiography after cardiac arrest without ST-elevation myocardial infarction: a network meta-analysis.","published":"2023-03-21"}],"10.1016/s0140-6736(22)02603-4":[{"url":"https://hartvaat.nl/2023/03/18/intensieve-bloeddrukinterventie-door-niet-artsen-in-lage-inkomenslanden-lancet-r/","title":"Intensieve bloeddrukinterventie door niet-artsen in lage-inkomenslanden: Lancet RCT","title_en":"Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.","published":"2023-03-18"}],"10.1016/j.jacc.2022.12.024":[{"url":"https://hartvaat.nl/2023/03/14/real-time-remote-monitoring-voorspelt-maligne-ventriculaire-aritmieen/","title":"Real-time remote monitoring voorspelt maligne ventriculaire aritmieën","title_en":"Predicting Malignant Ventricular Arrhythmias Using Real-Time Remote Monitoring.","published":"2023-03-14"}],"10.1093/eurheartj/ehac709":[{"url":"https://hartvaat.nl/2023/03/14/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-diabetes-en-ascvd/","title":"Matige statine plus ezetimibe versus hoge-dosis statine bij diabetes en ASCVD","title_en":"Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.","published":"2023-03-14"}],"10.1093/eurheartj/ehac706":[{"url":"https://hartvaat.nl/2023/03/14/dapt-duur-na-pci-bij-hoog-bloedingsrisico-meta-analyse-van-rct-s/","title":"DAPT-duur na PCI bij hoog bloedingsrisico: meta-analyse van RCT's","title_en":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.","published":"2023-03-14"}],"10.1136/heartjnl-2022-321702":[{"url":"https://hartvaat.nl/2023/03/10/mondiale-prevalentie-uitkomsten-en-kosten-van-hartfalen-careme-studie/","title":"Mondiale prevalentie, uitkomsten en kosten van hartfalen: CaReMe-studie","title_en":"Prevalence, outcomes and costs of a contemporary, multinational population with heart failure.","published":"2023-03-10"}],"10.1016/j.jacc.2022.11.061":[{"url":"https://hartvaat.nl/2023/03/07/mesenchymale-precursorcellen-bij-hfref-gerandomiseerde-trial/","title":"Mesenchymale precursorcellen bij HFrEF: gerandomiseerde trial","title_en":"Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure.","published":"2023-03-07"}],"10.1001/jamacardio.2022.5320":[{"url":"https://hartvaat.nl/2023/03/01/gepersonaliseerde-versnelde-pacing-bij-hfpef-met-pacemaker/","title":"Gepersonaliseerde versnelde pacing bij HFpEF met pacemaker","title_en":"Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial.","published":"2023-03-01"}],"10.1161/hypertensionaha.122.20112":[{"url":"https://hartvaat.nl/2023/03/01/diastolische-bloeddruk-en-cognitie-bij-intensieve-behandeling-sprint-mind/","title":"Diastolische bloeddruk en cognitie bij intensieve behandeling: SPRINT MIND","title_en":"Diastolic Blood Pressure and Intensive Blood Pressure Control on Cognitive Outcomes: Insights From the SPRINT MIND Trial.","published":"2023-03-01"}],"10.1161/hypertensionaha.122.20503":[{"url":"https://hartvaat.nl/2023/03/01/renale-denervatie-en-sympathische-activiteit-systematische-review/","title":"Renale denervatie en sympathische activiteit: systematische review","title_en":"Effects of Renal Denervation on Sympathetic Nerve Traffic and Correlates in Drug-Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-Analysis.","published":"2023-03-01"}],"10.1161/hypertensionaha.122.20373":[{"url":"https://hartvaat.nl/2023/03/01/antihypertensieve-regimes-in-sprint-gedetailleerd-beschreven/","title":"Antihypertensieve regimes in SPRINT gedetailleerd beschreven","title_en":"Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial.","published":"2023-03-01"}],"10.1161/hypertensionaha.122.20458":[{"url":"https://hartvaat.nl/2023/03/01/korttermijn-bloeddrukmetingen-voorspellen-langetermijneffect-van-behandeling/","title":"Korttermijn bloeddrukmetingen voorspellen langetermijneffect van behandeling","title_en":"Clinical Utility of Short-Term Blood Pressure Measures to Inform Long-Term Blood Pressure Management.","published":"2023-03-01"}],"10.1001/jama.2023.0713":[{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","title":"RADIANCE II: ultrageluid renale denervatie bij milde tot matige hypertensie","title_en":"Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.","published":"2023-02-28"}],"10.1161/circulationaha.122.062746":[{"url":"https://hartvaat.nl/2023/02/28/incidenteel-coronair-calcium-op-ct-thorax-ai-gestuurde-screening-verbetert-stati/","title":"Incidenteel coronair calcium op CT-thorax: AI-gestuurde screening verbetert statinegebruik","title_en":"Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project).","published":"2023-02-28"}],"10.1136/heartjnl-2022-321640":[{"url":"https://hartvaat.nl/2023/02/23/ct-coronairangiografie-bij-75-jarigen-met-nste-acs/","title":"CT-coronairangiografie bij ≥75-jarigen met NSTE-ACS","title_en":"Coronary CT and timing of invasive coronary angiography in patients ≥75 years old with non-ST segment elevation acute coronary syndromes.","published":"2023-02-23"}],"10.1093/europace/euac199":[{"url":"https://hartvaat.nl/2023/02/16/technieken-om-cardioversiesucces-bij-af-te-verbeteren-meta-analyse/","title":"Technieken om cardioversiesucces bij AF te verbeteren: meta-analyse","title_en":"Techniques improving electrical cardioversion success for patients with atrial fibrillation: a systematic review and meta-analysis.","published":"2023-02-16"}],"10.1093/europace/euac210":[{"url":"https://hartvaat.nl/2023/02/16/p-golfduur-voorspelt-af-recidief-na-catheterablatie-meta-analyse/","title":"P-golfduur voorspelt AF-recidief na catheterablatie: meta-analyse","title_en":"P-wave duration and atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.","published":"2023-02-16"}],"10.1093/europace/euac190":[{"url":"https://hartvaat.nl/2023/02/16/hoog-vermogen-korte-duur-versus-laag-vermogen-langere-duur-posteriore-ablatie-bi/","title":"Hoog vermogen korte duur versus laag vermogen langere duur posteriore ablatie bij AF","title_en":"Higher power short duration vs. lower power longer duration posterior wall ablation for atrial fibrillation and oesophageal injury outcomes: a prospective multi-centre randomized controlled study (Hi-Lo HEAT trial).","published":"2023-02-16"}],"10.1093/europace/euac173":[{"url":"https://hartvaat.nl/2023/02/16/catheterablatie-verbetert-cv-uitkomsten-bij-af-en-hartfalen-meta-analyse-van-rct/","title":"Catheterablatie verbetert CV-uitkomsten bij AF en hartfalen: meta-analyse van RCT's","title_en":"Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials.","published":"2023-02-16"}],"10.1161/circulationaha.122.062049":[{"url":"https://hartvaat.nl/2023/02/14/sekseverschillen-in-tienjaarsuitkomsten-na-pci-decade-samenwerking/","title":"Sekseverschillen in tienjaarsuitkomsten na PCI: DECADE-samenwerking","title_en":"Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation.","published":"2023-02-14"}],"10.1016/j.jacc.2022.11.041":[{"url":"https://hartvaat.nl/2023/02/14/p2y12-monotherapie-versus-dapt-na-complexe-pci/","title":"P2Y12-monotherapie versus DAPT na complexe PCI","title_en":"P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.","published":"2023-02-14"}],"10.1136/heartjnl-2022-321729":[{"url":"https://hartvaat.nl/2023/02/14/cryoballon-pvi-als-eerstelijnsbehandeling-voor-typisch-atriumflutter/","title":"Cryoballon PVI als eerstelijnsbehandeling voor typisch atriumflutter","title_en":"Cryoballoon Pulmonary Vein Isolation as First-Line Treatment for Typical Atrial Flutter.","published":"2023-02-14"}],"10.1093/europace/euac122":[{"url":"https://hartvaat.nl/2023/02/08/redo-firm-firm-geleide-ablatie-verbetert-uitkomst-niet-bij-recidief-af/","title":"REDO-FIRM: FIRM-geleide ablatie verbetert uitkomst niet bij recidief-AF","title_en":"Randomized evaluation of redo ablation procedures of atrial fibrillation with focal impulse and rotor modulation-guided procedures: the REDO-FIRM study.","published":"2023-02-08"}],"10.1093/europace/euac143":[{"url":"https://hartvaat.nl/2023/02/08/voorspellers-van-af-recidief-na-ablatie-en-cardioversie-umbrella-review/","title":"Voorspellers van AF-recidief na ablatie en cardioversie: umbrella review","title_en":"Predictors of recurrence after catheter ablation and electrical cardioversion of atrial fibrillation: an umbrella review of meta-analyses.","published":"2023-02-08"}],"10.1093/europace/euac130":[{"url":"https://hartvaat.nl/2023/02/08/stolling-en-atriumfibrilleren-systematische-review-en-meta-analyse/","title":"Stolling en atriumfibrilleren: systematische review en meta-analyse","title_en":"The association of coagulation and atrial fibrillation: a systematic review and meta-analysis.","published":"2023-02-08"}],"10.1093/eurheartj/ehac747":[{"url":"https://hartvaat.nl/2023/02/07/inspanningsgerichte-hartrevalidatie-bij-coronairlijden-geactualiseerde-meta-anal/","title":"Inspanningsgerichte hartrevalidatie bij coronairlijden: geactualiseerde meta-analyse","title_en":"Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis.","published":"2023-02-07"}],"10.1093/eurheartj/ehac763":[{"url":"https://hartvaat.nl/2023/02/07/ffr-geleide-versus-angiografie-geleide-pci-bij-acuut-mi-met-meervatslijden/","title":"FFR-geleide versus angiografie-geleide PCI bij acuut MI met meervatslijden","title_en":"Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial.","published":"2023-02-07"}],"10.1161/circulationaha.122.062949":[{"url":"https://hartvaat.nl/2023/02/07/ecmo-cs-ecmo-bij-cardiogene-shock-verbetert-overleving-niet/","title":"ECMO-CS: ECMO bij cardiogene shock verbetert overleving niet","title_en":"Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial.","published":"2023-02-07"}],"10.1056/nejmoa2213169":[{"url":"https://hartvaat.nl/2023/02/02/baxdrostat-aldosteronsynthaseremmer-bij-resistente-hypertensie-nejm-fase-2/","title":"Baxdrostat: aldosteronsynthaseremmer bij resistente hypertensie — NEJM fase 2","title_en":"Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.","published":"2023-02-02"}],"10.1001/jamacardio.2022.4903":[{"url":"https://hartvaat.nl/2023/02/01/fysieke-revalidatie-bij-fragiele-ouderen-met-acuut-hartfalen/","title":"Fysieke revalidatie bij fragiele ouderen met acuut hartfalen","title_en":"Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure: A Secondary Analysis of a Randomized Clinical Trial.","published":"2023-02-01"}],"10.1001/jamacardio.2022.4873":[{"url":"https://hartvaat.nl/2023/02/01/cv-risicomodellen-bij-hiv-patienten-systematische-review/","title":"CV-risicomodellen bij HIV-patiënten: systematische review","title_en":"Performance of Cardiovascular Risk Prediction Models Among People Living With HIV: A Systematic Review and Meta-analysis.","published":"2023-02-01"}],"10.1001/jamacardio.2022.4427":[{"url":"https://hartvaat.nl/2023/02/01/nyha-klasse-versus-objectieve-metingen-bij-mild-hartfalen-paradigm-hf-analyse/","title":"NYHA-klasse versus objectieve metingen bij mild hartfalen: PARADIGM-HF analyse","title_en":"Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.","published":"2023-02-01"}],"10.1093/eurheartj/ehac689":[{"url":"https://hartvaat.nl/2023/02/01/clorotic-thiazide-toevoegen-aan-lisdiureticum-bij-acuut-hartfalen/","title":"CLOROTIC: thiazide toevoegen aan lisdiureticum bij acuut hartfalen","title_en":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.","published":"2023-02-01"}],"10.1161/hypertensionaha.122.19399":[{"url":"https://hartvaat.nl/2023/02/01/hypertensieve-zwangerschapscomplicaties-en-dementierisico-meta-analyse/","title":"Hypertensieve zwangerschapscomplicaties en dementierisico: meta-analyse","title_en":"Association Between Hypertensive Disorders of Pregnancy and Dementia: a Systematic Review and Meta-Analysis.","published":"2023-02-01"}],"10.1016/j.kint.2022.09.023":[{"url":"https://hartvaat.nl/2023/02/01/aspirine-en-cardiovasculaire-uitkomsten-bij-chronische-nierziekte/","title":"Aspirine en cardiovasculaire uitkomsten bij chronische nierziekte","title_en":"Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease.","published":"2023-02-01"}],"10.1002/ehf2.14213":[{"url":"https://hartvaat.nl/2023/02/01/nnt-van-nieuwe-antidiabetica-voor-cv-uitkomsten-meta-analyse/","title":"NNT van nieuwe antidiabetica voor CV-uitkomsten: meta-analyse","title_en":"Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.","published":"2023-02-01"}],"10.1002/ehf2.14208":[{"url":"https://hartvaat.nl/2023/02/01/hartfalenrisicoscores-vergelijking-voor-mortaliteit-en-heropname/","title":"Hartfalenrisicoscores: vergelijking voor mortaliteit en heropname","title_en":"Performance of the heart failure risk scores in predicting 1 year mortality and short-term readmission of patients.","published":"2023-02-01"}],"10.1161/hypertensionaha.122.19751":[{"url":"https://hartvaat.nl/2023/02/01/nifedipine-retard-intrapartum-bij-ernstige-pre-eclampsie-preventietrial/","title":"Nifedipine retard intrapartum bij ernstige pre-eclampsie: preventietrial","title_en":"Trial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features.","published":"2023-02-01"}],"10.1002/ehf2.14170":[{"url":"https://hartvaat.nl/2023/02/01/multifactoriele-optimalisatie-van-chronisch-hartfalen-gerandomiseerde-studie/","title":"Multifactoriële optimalisatie van chronisch hartfalen: gerandomiseerde studie","title_en":"Effects of multifaceted optimization management for chronic heart failure: a multicentre, randomized controlled study.","published":"2023-02-01"}],"10.1002/ehf2.14166":[{"url":"https://hartvaat.nl/2023/02/01/diabetes-en-sacubitril-valsartan-titratie-bij-hartfalen-na-opname/","title":"Diabetes en sacubitril/valsartan-titratie bij hartfalen na opname","title_en":"Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.","published":"2023-02-01"}],"10.1016/j.jacc.2022.10.037":[{"url":"https://hartvaat.nl/2023/01/31/tromboseprofylaxe-bij-fontan-circulatie-aspirine-warfarine-of-noac/","title":"Tromboseprofylaxe bij Fontan-circulatie: aspirine, warfarine of NOAC","title_en":"Thromboprophylaxis in Patients With Fontan Circulation.","published":"2023-01-31"}],"10.1161/circulationaha.122.061828":[{"url":"https://hartvaat.nl/2023/01/31/hfpef-inspanningsbeperking-niet-alleen-door-hemodynamiek/","title":"HFpEF: inspanningsbeperking niet alleen door hemodynamiek","title_en":"Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?","published":"2023-01-31"}],"10.1016/j.jacc.2022.10.030":[{"url":"https://hartvaat.nl/2023/01/24/pcsk9-remming-bij-covid-19-anti-inflammatoir-potentieel-onderzocht/","title":"PCSK9-remming bij COVID-19: anti-inflammatoir potentieel onderzocht","title_en":"PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.","published":"2023-01-24"}],"10.1161/circulationaha.122.062779":[{"url":"https://hartvaat.nl/2023/01/24/axadia-afnet-8-apixaban-versus-vka-bij-af-op-hemodialyse/","title":"AXADIA-AFNET 8: apixaban versus VKA bij AF op hemodialyse","title_en":"A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.","published":"2023-01-24"}],"10.1161/circulationaha.122.062769":[{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","title":"EMPA-HEART 2: empagliflozine vermindert LV-massa niet bij patiënten zonder diabetes of HF","title_en":"Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.","published":"2023-01-24"}],"10.1093/eurheartj/ehac577":[{"url":"https://hartvaat.nl/2023/01/21/gdf-15-en-cardiovasculair-risico-ipd-meta-analyse/","title":"GDF-15 en cardiovasculair risico: IPD meta-analyse","title_en":"Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.","published":"2023-01-21"}],"10.1001/jama.2022.23924":[{"url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","title":"TRANSFORM-HF: torsemide biedt geen overlevingsvoordeel boven furosemide","title_en":"Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.","published":"2023-01-17"}],"10.1161/circulationaha.122.062762":[{"url":"https://hartvaat.nl/2023/01/17/option-indobufen-als-aspirine-alternatief-in-dapt-na-pci/","title":"OPTION: indobufen als aspirine-alternatief in DAPT na PCI","title_en":"Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.","published":"2023-01-17"}],"10.1161/circulationaha.122.062486":[{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","title":"ADVOR: acetazolamide effectief over het hele EF-spectrum bij acuut hartfalen","title_en":"Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.","published":"2023-01-17"}],"10.1093/eurheartj/ehac547":[{"url":"https://hartvaat.nl/2023/01/14/strokestop-af-screening-is-kosteneffectief-bij-75-76-jarigen/","title":"STROKESTOP: AF-screening is kosteneffectief bij 75-76-jarigen","title_en":"Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study.","published":"2023-01-14"}],"10.1056/nejmoa2212540":[{"url":"https://hartvaat.nl/2023/01/12/early-af-2-jaar-cryoablatie-vertraagt-af-progressie-beter-dan-antiaritmica/","title":"EARLY-AF 2 jaar: cryoablatie vertraagt AF-progressie beter dan antiaritmica","title_en":"Progression of Atrial Fibrillation after Cryoablation or Drug Therapy.","published":"2023-01-12"}],"10.1056/nejmoa2204233":[{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","title":"EMPA-KIDNEY: empagliflozine beschermt nieren bij brede CKD-populatie","title_en":"Empagliflozin in Patients with Chronic Kidney Disease.","published":"2023-01-12"}],"10.1136/heartjnl-2022-321610":[{"url":"https://hartvaat.nl/2023/01/11/metamfetamine-geassocieerd-hartfalen-systematische-review/","title":"Metamfetamine-geassocieerd hartfalen: systematische review","title_en":"Methamphetamine-associated heart failure: a systematic review of observational studies.","published":"2023-01-11"}],"10.1136/heartjnl-2022-321114":[{"url":"https://hartvaat.nl/2023/01/11/inadequate-noac-dosering-bij-af-uitkomsten-en-oorzaken-meta-analyse/","title":"Inadequate NOAC-dosering bij AF: uitkomsten en oorzaken — meta-analyse","title_en":"Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis.","published":"2023-01-11"}],"10.1001/jama.2022.23722":[{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","title":"CAPLA: posterior wand-isolatie verbetert uitkomst niet bij persisterend AF","title_en":"Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial.","published":"2023-01-10"}],"10.1161/circulationaha.122.061288":[{"url":"https://hartvaat.nl/2023/01/10/dagelijkse-stappen-en-cardiovasculaire-ziekte-geharmoniseerde-meta-analyse/","title":"Dagelijkse stappen en cardiovasculaire ziekte: geharmoniseerde meta-analyse","title_en":"Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis.","published":"2023-01-10"}],"10.1161/circulationaha.122.062770":[{"url":"https://hartvaat.nl/2023/01/10/host-exam-extended-clopidogrel-superieur-aan-aspirine-als-monotherapie-na-pci/","title":"HOST-EXAM Extended: clopidogrel superieur aan aspirine als monotherapie na PCI","title_en":"Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.","published":"2023-01-10"}],"10.1056/nejmoa2211680":[{"url":"https://hartvaat.nl/2023/01/05/nejm-interventie-voor-snelle-ambulante-follow-up-na-acuut-hartfalen/","title":"NEJM: interventie voor snelle ambulante follow-up na acuut hartfalen","title_en":"Trial of an Intervention to Improve Acute Heart Failure Outcomes.","published":"2023-01-05"}],"10.1016/j.jacc.2022.10.020":[{"url":"https://hartvaat.nl/2023/01/03/aficamten-bij-obstructieve-hypertrofische-cardiomyopathie-fase-2-resultaten/","title":"Aficamten bij obstructieve hypertrofische cardiomyopathie: fase 2 resultaten","title_en":"Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.","published":"2023-01-03"}],"10.1016/j.jacc.2022.10.013":[{"url":"https://hartvaat.nl/2023/01/03/rosuvastatine-versus-voedingssupplementen-voor-lipidenmanagement/","title":"Rosuvastatine versus voedingssupplementen voor lipidenmanagement","title_en":"Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.","published":"2023-01-03"}],"10.1161/circulationaha.122.062714":[{"url":"https://hartvaat.nl/2023/01/03/ischemia-langetermijn-geen-overlevingsverschil-invasief-versus-conservatief-bij-/","title":"ISCHEMIA langetermijn: geen overlevingsverschil invasief versus conservatief bij stabiel coronairlijden","title_en":"Survival After Invasive or Conservative Management of Stable Coronary Disease.","published":"2023-01-03"}],"10.1001/jamacardio.2022.4373":[{"url":"https://hartvaat.nl/2023/01/01/nudging-verhoogt-statinevoorschrijving-bij-zowel-arts-als-patient/","title":"Nudging verhoogt statinevoorschrijving bij zowel arts als patiënt","title_en":"Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing: A Cluster Randomized Clinical Trial.","published":"2023-01-01"}],"10.1001/jamacardio.2022.4250":[{"url":"https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/","title":"Vitamine D voorkomt statine-gerelateerde spierklachten niet","title_en":"Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo.","published":"2023-01-01"}],"10.1001/jamacardio.2022.4210":[{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","title":"DELIVER: dapagliflozine beschermt ook de nieren bij HFpEF","title_en":"Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.","published":"2023-01-01"}],"10.1093/eurheartj/ehac530":[{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","title":"EMPULSE: empagliflozine verbetert decongestie bij acuut hartfalen","title_en":"Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.","published":"2023-01-01"}],"10.1161/hypertensionaha.122.20286":[{"url":"https://hartvaat.nl/2023/01/01/opleiding-intelligentie-en-cognitie-onafhankelijke-verbanden-met-hypertensie/","title":"Opleiding, intelligentie en cognitie: onafhankelijke verbanden met hypertensie","title_en":"Independent Associations of Education, Intelligence, and Cognition With Hypertension and the Mediating Effects of Cardiometabolic Risk Factors: A Mendelian Randomization Study.","published":"2023-01-01"}],"10.1056/nejmoa2212270":[{"url":"https://hartvaat.nl/2022/12/29/chloortalidon-versus-hydrochloorthiazide-geen-verschil-in-cv-events/","title":"Chloortalidon versus hydrochloorthiazide: geen verschil in CV-events","title_en":"Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.","published":"2022-12-29"}],"10.1136/heartjnl-2022-321276":[{"url":"https://hartvaat.nl/2022/12/22/orthostatische-bloeddruk-en-intensieve-behandeling-sprint-inzichten/","title":"Orthostatische bloeddruk en intensieve behandeling: SPRINT-inzichten","title_en":"Relationship between orthostatic blood pressure changes and intensive blood pressure management in patients with hypertension.","published":"2022-12-22"}],"10.1093/eurheartj/ehac615":[{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","title":"ORION-11: inclisiran verlaagt LDL effectief bij primaire preventie","title_en":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.","published":"2022-12-21"}],"10.1093/eurheartj/ehac584":[{"url":"https://hartvaat.nl/2022/12/21/bloeddrukverlaging-en-dementiepreventie-ipd-meta-analyse/","title":"Bloeddrukverlaging en dementiepreventie: IPD meta-analyse","title_en":"Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis.","published":"2022-12-21"}],"10.1093/eurheartj/ehac495":[{"url":"https://hartvaat.nl/2022/12/21/empagliflozine-en-het-circulerend-proteoom-bij-hartfalen-emperor-mechanismen/","title":"Empagliflozine en het circulerend proteoom bij hartfalen: EMPEROR-mechanismen","title_en":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.","published":"2022-12-21"}],"10.1016/s0140-6736(22)02083-9":[{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","title":"IRONMAN: intraveneus ijzer bij hartfalen met ijzerdeficiëntie — Lancet RCT","title_en":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.","published":"2022-12-17"}],"10.1016/j.jacc.2022.09.048":[{"url":"https://hartvaat.nl/2022/12/13/micronutrientensuppletie-en-cardiovasculair-risico-jacc-systematische-review/","title":"Micronutriëntensuppletie en cardiovasculair risico: JACC systematische review","title_en":"Micronutrient Supplementation to Reduce Cardiovascular Risk.","published":"2022-12-13"}],"10.1016/s0140-6736(22)00625-0":[{"url":"https://hartvaat.nl/2022/12/10/urbanisatie-en-cardiometabool-risico-bij-inheemse-braziliaanse-volkeren/","title":"Urbanisatie en cardiometabool risico bij inheemse Braziliaanse volkeren","title_en":"The impact of urbanisation on the cardiometabolic health of Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the Brazilian Health registry.","published":"2022-12-10"}],"10.1093/europace/euac098":[{"url":"https://hartvaat.nl/2022/12/09/ideale-blankingperiode-na-af-ablatie-bewijs-voor-herziening/","title":"Ideale blankingperiode na AF-ablatie: bewijs voor herziening","title_en":"Evidence-based insights on ideal blanking period duration following atrial fibrillation catheter ablation.","published":"2022-12-09"}],"10.1161/circulationaha.121.054990":[{"url":"https://hartvaat.nl/2022/12/06/apixaban-bij-af-op-hemodialyse-eerste-gerandomiseerde-trial/","title":"Apixaban bij AF op hemodialyse: eerste gerandomiseerde trial","title_en":"Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.","published":"2022-12-06"}],"10.1161/circulationaha.122.060841":[{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","title":"PARADISE-MI: sacubitril/valsartan vermindert coronaire events niet na MI","title_en":"The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.","published":"2022-12-06"}],"10.1016/s0140-6736(22)02034-7":[{"url":"https://hartvaat.nl/2022/12/03/precision-aprocitentan-bij-resistente-hypertensie-eerste-endothelineantagonist/","title":"PRECISION: aprocitentan bij resistente hypertensie — eerste endothelineantagonist","title_en":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.","published":"2022-12-03"}],"10.1016/s0140-6736(22)02076-1":[{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","title":"STRONG-HF: snelle optitratie van hartfalenmedicatie na ziekenhuis is veilig en effectief","title_en":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.","published":"2022-12-03"}],"10.1001/jamacardio.2022.3904":[{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","title":"RADIANCE-HTN TRIO: renale denervatie effectief na medicatie-optitratie","title_en":"Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial.","published":"2022-12-01"}],"10.1001/jamacardio.2022.3627":[{"url":"https://hartvaat.nl/2022/12/01/serieel-hoog-sensitief-troponine-t-voorspelt-cv-events-na-acs-odyssey-analyse/","title":"Serieel hoog-sensitief troponine T voorspelt CV-events na ACS: ODYSSEY analyse","title_en":"Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.","published":"2022-12-01"}],"10.1001/jamacardio.2022.3750":[{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","title":"DELIVER: snel voordeel van dapagliflozine bij HFpEF — binnen weken merkbaar","title_en":"Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.","published":"2022-12-01"}],"10.1161/hypertensionaha.122.19816":[{"url":"https://hartvaat.nl/2022/12/01/apotheker-geleide-telezorg-versus-poliklinische-zorg-bij-ongecontroleerde-hypert/","title":"Apotheker-geleide telezorg versus poliklinische zorg bij ongecontroleerde hypertensie","title_en":"Comparing Pharmacist-Led Telehealth Care and Clinic-Based Care for Uncontrolled High Blood Pressure: The Hyperlink 3 Pragmatic Cluster-Randomized Trial.","published":"2022-12-01"}],"10.1161/hypertensionaha.122.18878":[{"url":"https://hartvaat.nl/2022/12/01/klebsiella-pneumoniae-als-mogelijke-oorzaak-van-hypertensie/","title":"Klebsiella pneumoniae als mogelijke oorzaak van hypertensie","title_en":"Causality of Opportunistic Pathogen Klebsiella pneumoniae to Hypertension Development.","published":"2022-12-01"}],"10.1161/hypertensionaha.122.19744":[{"url":"https://hartvaat.nl/2022/12/01/finerenon-bloeddrukeffecten-en-cardiorenale-uitkomsten-bij-ckd-en-diabetes/","title":"Finerenon: bloeddrukeffecten en cardiorenale uitkomsten bij CKD en diabetes","title_en":"Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.","published":"2022-12-01"}],"10.1002/ehf2.14118":[{"url":"https://hartvaat.nl/2022/12/01/hartfalen-tijdens-de-covid-19-pandemie-klinische-en-organisatorische-dilemma-s/","title":"Hartfalen tijdens de COVID-19-pandemie: klinische en organisatorische dilemma's","title_en":"Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas.","published":"2022-12-01"}],"10.1002/ehf2.14140":[{"url":"https://hartvaat.nl/2022/12/01/immuuncelsubsets-voorspellen-incident-hartfalen-in-populatiestudies/","title":"Immuuncelsubsets voorspellen incident hartfalen in populatiestudies","title_en":"Association of immune cell subsets with incident heart failure in two population-based cohorts.","published":"2022-12-01"}],"10.1002/ehf2.14145":[{"url":"https://hartvaat.nl/2022/12/01/digitale-hartrevalidatie-bij-hartfalen-systematische-review/","title":"Digitale hartrevalidatie bij hartfalen: systematische review","title_en":"Efficacy and safety of digital therapeutics-based cardiac rehabilitation in heart failure patients: a systematic review.","published":"2022-12-01"}],"10.1002/ehf2.14125":[{"url":"https://hartvaat.nl/2022/12/01/langetermijnmortaliteit-bij-hfmref-systematische-review-en-meta-analyse/","title":"Langetermijnmortaliteit bij HFmrEF: systematische review en meta-analyse","title_en":"Long-term mortality in heart failure with mid-range ejection fraction: systematic review and meta-analysis.","published":"2022-12-01"}],"10.1002/ehf2.14109":[{"url":"https://hartvaat.nl/2022/12/01/daprodustat-bij-anemie-en-hartfalen-met-ckd-gerandomiseerde-studie/","title":"Daprodustat bij anemie en hartfalen met CKD: gerandomiseerde studie","title_en":"Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study.","published":"2022-12-01"}],"10.1002/ehf2.14050":[{"url":"https://hartvaat.nl/2022/12/01/vericiguat-en-nt-probnp-bij-hfref-victoria-subanalyse/","title":"Vericiguat en NT-proBNP bij HFrEF: VICTORIA subanalyse","title_en":"Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial.","published":"2022-12-01"}],"10.1016/j.jacc.2022.09.007":[{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","title":"FAVOR III: QFR-geleide PCI verbetert tweejaarsuitkomsten","title_en":"2-Year Outcomes of Angiographic Quantitative Flow Ratio-Guided Coronary Interventions.","published":"2022-11-29"}],"10.1016/s0140-6736(22)02033-5":[{"url":"https://hartvaat.nl/2022/11/26/triple-gip-glp-1-glucagonreceptoragonist-bij-type-2-diabetes-fase-1b/","title":"Triple GIP/GLP-1/glucagonreceptoragonist bij type 2 diabetes: fase 1b","title_en":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.","published":"2022-11-26"}],"10.1016/s0140-6736(22)01999-7":[{"url":"https://hartvaat.nl/2022/11/26/bivalirudine-versus-heparine-bij-primaire-pci-voor-stemi-lancet-trial/","title":"Bivalirudine versus heparine bij primaire PCI voor STEMI: Lancet-trial","title_en":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.","published":"2022-11-26"}],"10.1056/nejmoa2210645":[{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","title":"PROMINENT: pemafibrate verlaagt triglyceriden maar vermindert CV-events niet","title_en":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.","published":"2022-11-24"}],"10.1136/heartjnl-2022-320990":[{"url":"https://hartvaat.nl/2022/11/24/protecct-ct-bij-verdenking-acs-met-intermediaire-troponinewaarden/","title":"PROTECCT: CT bij verdenking ACS met intermediaire troponinewaarden","title_en":"Prospective RandOmised Trial of Emergency Cardiac Computerised Tomography (PROTECCT).","published":"2022-11-24"}],"10.1161/circulationaha.122.062188":[{"url":"https://hartvaat.nl/2022/11/22/ees-versus-cabg-bij-meervatslijden-langetermijn-follow-up-van-rct-s/","title":"EES versus CABG bij meervatslijden: langetermijn follow-up van RCT's","title_en":"Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Outcomes of Multicenter Randomized Controlled BEST Trial.","published":"2022-11-22"}],"10.1093/europace/euac096":[{"url":"https://hartvaat.nl/2022/11/22/cva-risicoscores-bij-af-vergeleken-cha2ds2-vasc-blijft-de-beste/","title":"CVA-risicoscores bij AF vergeleken: CHA₂DS₂-VASc blijft de beste","title_en":"Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation.","published":"2022-11-22"}],"10.1093/europace/euab208":[{"url":"https://hartvaat.nl/2022/11/22/athena-subanalyse-dronedaron-effectief-ongeacht-leeftijd-en-geslacht-bij-af/","title":"ATHENA-subanalyse: dronedaron effectief ongeacht leeftijd en geslacht bij AF","title_en":"Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter.","published":"2022-11-22"}],"10.1016/s0140-6736(22)02074-8":[{"url":"https://hartvaat.nl/2022/11/19/sglt2-remmers-en-nieruitkomsten-diabetes-maakt-niet-uit-lancet-meta-analyse/","title":"SGLT2-remmers en nieruitkomsten: diabetes maakt niet uit — Lancet meta-analyse","title_en":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","published":"2022-11-19"}],"10.1056/nejmoa2211023":[{"url":"https://hartvaat.nl/2022/11/17/olpasiran-sirna-verlaagt-lipoproteine-a-spectaculair-in-fase-2-trial/","title":"Olpasiran: siRNA verlaagt lipoproteïne(a) spectaculair in fase 2 trial","title_en":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.","published":"2022-11-17"}],"10.1016/j.jacc.2022.08.803":[{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","title":"COAPT: MitraClip vermindert hospitalisaties bij secundaire MR en hartfalen","title_en":"Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial.","published":"2022-11-15"}],"10.1161/circulationaha.122.059631":[{"url":"https://hartvaat.nl/2022/11/15/fgf21-sirtuin-3-hoe-inspanning-beschermt-tegen-diabetische-cardiomyopathie/","title":"FGF21-Sirtuin 3: hoe inspanning beschermt tegen diabetische cardiomyopathie","title_en":"FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity.","published":"2022-11-15"}],"10.1016/j.jacc.2022.08.747":[{"url":"https://hartvaat.nl/2022/11/08/mtor-remming-bij-stemi-sirolimus-vermindert-infarctgrootte-niet/","title":"mTOR-remming bij STEMI: sirolimus vermindert infarctgrootte niet","title_en":"Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction.","published":"2022-11-08"}],"10.1016/s0140-6736(22)01882-7":[{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","title":"ENCHANTED2/MT: intensieve bloeddrukverlaging na trombectomie bij CVA is schadelijk","title_en":"Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.","published":"2022-11-05"}],"10.1001/jamacardio.2022.3032":[{"url":"https://hartvaat.nl/2022/11/01/complete-revascularisatie-bij-stemi-verbetert-angina-gerelateerde-kwaliteit-van-/","title":"Complete revascularisatie bij STEMI verbetert angina-gerelateerde kwaliteit van leven","title_en":"Complete Revascularization vs Culprit Lesion-Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial.","published":"2022-11-01"}],"10.1001/jamacardio.2022.2924":[{"url":"https://hartvaat.nl/2022/11/01/empagliflozine-vermindert-albuminurie-bij-hartfalen-emperor-pooled-analyse/","title":"Empagliflozine vermindert albuminurie bij hartfalen: EMPEROR-Pooled analyse","title_en":"Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.","published":"2022-11-01"}],"10.1016/j.jacc.2022.08.718":[{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","title":"DELIVER: dapagliflozine effectief bij HFpEF ongeacht atriumfibrilleren","title_en":"Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.","published":"2022-11-01"}],"10.1093/eurheartj/ehac494":[{"url":"https://hartvaat.nl/2022/11/01/emmy-empagliflozine-na-acuut-myocardinfarct-verbetert-nt-probnp-en-remodelling/","title":"EMMY: empagliflozine na acuut myocardinfarct verbetert NT-proBNP en remodelling","title_en":"Empagliflozin in acute myocardial infarction: the EMMY trial.","published":"2022-11-01"}],"10.1093/eurheartj/ehac472":[{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","title":"VIP-ACS: dubbele-dosis griepvaccinatie na ACS verbetert uitkomsten niet","title_en":"Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial.","published":"2022-11-01"}],"10.1093/eurheartj/ehac401":[{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","title":"DIAMOND: patiromer maakt RAAS-remmer-optitratie bij HFrEF met hyperkaliëmie mogelijk","title_en":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.","published":"2022-11-01"}],"10.1161/hypertensionaha.122.19865":[{"url":"https://hartvaat.nl/2022/11/01/checkpoint-remmers-verhogen-korttermijnrisico-op-hypertensie-niet-meta-analyse/","title":"Checkpoint-remmers verhogen korttermijnrisico op hypertensie niet: meta-analyse","title_en":"Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis.","published":"2022-11-01"}],"10.1161/hypertensionaha.121.18333":[{"url":"https://hartvaat.nl/2022/11/01/antihypertensieve-combinaties-bij-afrikaanse-patienten-creole-secundaire-analyse/","title":"Antihypertensieve combinaties bij Afrikaanse patiënten: CREOLE secundaire analyse","title_en":"Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on Blood Pressure Variability in Black African Patients: Secondary Analyses of the CREOLE Trial.","published":"2022-11-01"}],"10.1161/circulationaha.122.061527":[{"url":"https://hartvaat.nl/2022/11/01/radiale-versus-femorale-toegang-bij-coronairangiografie-meta-analyse-toont-morta/","title":"Radiale versus femorale toegang bij coronairangiografie: meta-analyse toont mortaliteitsvoordeel","title_en":"Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials.","published":"2022-11-01"}],"10.1016/j.kint.2022.07.026":[{"url":"https://hartvaat.nl/2022/11/01/arteriele-stijfheid-en-endotheeldysfunctie-bij-anca-geassocieerde-vasculitis/","title":"Arteriële stijfheid en endotheeldysfunctie bij ANCA-geassocieerde vasculitis","title_en":"Arterial stiffness, endothelial dysfunction and impaired fibrinolysis are pathogenic mechanisms contributing to cardiovascular risk in ANCA-associated vasculitis.","published":"2022-11-01"}],"10.1136/heartjnl-2022-320934":[{"url":"https://hartvaat.nl/2022/10/28/pci-versus-cabg-bij-drievatslijden-met-proximale-lad-betrokkenheid/","title":"PCI versus CABG bij drievatslijden met proximale LAD-betrokkenheid","title_en":"Mortality after multivessel revascularisation involving the proximal left anterior descending artery.","published":"2022-10-28"}],"10.1016/j.jacc.2022.05.012":[{"url":"https://hartvaat.nl/2022/10/25/2022-acc-aha-datadefinities-voor-pijn-op-de-borst-en-acuut-myocardinfarct/","title":"2022 ACC/AHA datadefinities voor pijn op de borst en acuut myocardinfarct","title_en":"2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Data Standards.","published":"2022-10-25"}],"10.1016/s0140-6736(22)01786-x":[{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","title":"TIME: avonddosering antihypertensiva biedt geen voordeel boven ochtenddosering","title_en":"Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.","published":"2022-10-22"}],"10.1016/s0140-6736(22)01787-1":[{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","title":"SYMPLICITY HTN-3: langetermijn follow-up renale denervatie bij resistente hypertensie","title_en":"Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.","published":"2022-10-22"}],"10.1056/nejmoa2208687":[{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","title":"BOX: bloeddrukdoelen bij comateuze overlevenden van hartstilstand","title_en":"Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest.","published":"2022-10-20"}],"10.1016/j.jacc.2022.08.737":[{"url":"https://hartvaat.nl/2022/10/18/dosisrespons-van-sacubitril-valsartan-bij-hfref/","title":"Dosisrespons van sacubitril/valsartan bij HFrEF","title_en":"Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.","published":"2022-10-18"}],"10.1016/j.jacc.2022.08.735":[{"url":"https://hartvaat.nl/2022/10/18/intensieve-bloeddrukverlaging-bij-maligne-linkerventrikel-hypertrofie/","title":"Intensieve bloeddrukverlaging bij maligne linkerventrikel hypertrofie","title_en":"Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy.","published":"2022-10-18"}],"10.1161/circulationaha.122.061612":[{"url":"https://hartvaat.nl/2022/10/18/asundexian-factor-xia-remmer-na-acs-fase-2-dosisfindingsstudie/","title":"Asundexian (factor XIa-remmer) na ACS: fase 2 dosisfindingsstudie","title_en":"A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.","published":"2022-10-18"}],"10.1161/circulationaha.122.061754":[{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","title":"DELIVER: dapagliflozine effectief ongeacht frailteit bij HFpEF","title_en":"Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.","published":"2022-10-18"}],"10.1093/eurheartj/ehac374":[{"url":"https://hartvaat.nl/2022/10/14/dal-gene-farmacogenetica-geleide-dalcetrapib-na-acs/","title":"dal-GenE: farmacogenetica-geleide dalcetrapib na ACS","title_en":"Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.","published":"2022-10-14"}],"10.1056/nejmoa2206606":[{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","title":"REVIVED-BCIS2: PCI verbetert overleving niet bij ischemische LV-disfunctie","title_en":"Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.","published":"2022-10-13"}],"10.1093/europace/euac089":[{"url":"https://hartvaat.nl/2022/10/13/low-voltage-substraatmodificatie-bij-af-ablatie-meta-analyse/","title":"Low-voltage substraatmodificatie bij AF-ablatie: meta-analyse","title_en":"Low-voltage area substrate modification for atrial fibrillation ablation: a systematic review and meta-analysis of clinical trials.","published":"2022-10-13"}],"10.1093/europace/euac063":[{"url":"https://hartvaat.nl/2022/10/13/voorbehandeling-met-antiaritmica-voor-cardioversie-bij-af-netwerk-meta-analyse/","title":"Voorbehandeling met antiaritmica voor cardioversie bij AF: netwerk-meta-analyse","title_en":"Pre-treatment with antiarrhythmic drugs for elective electrical cardioversion of atrial fibrillation: a systematic review and network meta-analysis.","published":"2022-10-13"}],"10.1093/europace/euac058":[{"url":"https://hartvaat.nl/2022/10/13/gecombineerde-epicardiale-en-endocardiale-redo-ablatie-bij-persisterend-af/","title":"Gecombineerde epicardiale en endocardiale redo-ablatie bij persisterend AF","title_en":"Combined epicardial and endocardial approach for redo radiofrequency catheter ablation in patients with persistent atrial fibrillation: a randomized clinical trial.","published":"2022-10-13"}],"10.1093/europace/euac059":[{"url":"https://hartvaat.nl/2022/10/13/intensieve-bloeddrukcontrole-bij-af-inzichten-uit-sprint/","title":"Intensieve bloeddrukcontrole bij AF: inzichten uit SPRINT","title_en":"Effects of intensive blood pressure control on cardiovascular and cognitive outcomes in patients with atrial fibrillation: insights from the SPRINT trial.","published":"2022-10-13"}],"10.1093/europace/euac068":[{"url":"https://hartvaat.nl/2022/10/13/dagopname-na-af-ablatie-even-veilig-als-overnachting-meta-analyse/","title":"Dagopname na AF-ablatie even veilig als overnachting: meta-analyse","title_en":"Efficacy and safety of same-day discharge after atrial fibrillation ablation compared with post-procedural overnight stay: a systematic review and meta-analysis.","published":"2022-10-13"}],"10.1136/heartjnl-2021-320768":[{"url":"https://hartvaat.nl/2022/10/13/ffr-geleide-versus-angiografie-geleide-revascularisatie-meta-analyse-van-rct-s/","title":"FFR-geleide versus angiografie-geleide revascularisatie: meta-analyse van RCT's","title_en":"Fractional flow reserve versus angiography alone in guiding myocardial revascularisation: a systematic review and meta-analysis of randomised trials.","published":"2022-10-13"}],"10.1093/europace/euac028":[{"url":"https://hartvaat.nl/2022/10/13/cerebrale-microbloedingen-en-risico-bij-af-systematische-review/","title":"Cerebrale microbloedingen en risico bij AF: systematische review","title_en":"Epidemiology of cerebral microbleeds and risk of adverse outcomes in atrial fibrillation: a systematic review and meta-analysis.","published":"2022-10-13"}],"10.1161/circulationaha.122.061620":[{"url":"https://hartvaat.nl/2022/10/11/langetermijn-evolocumab-bij-atherosclerotisch-vaatlijden-open-label-extensie-fou/","title":"Langetermijn evolocumab bij atherosclerotisch vaatlijden: open-label extensie FOURIER","title_en":"Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.","published":"2022-10-11"}],"10.1016/s0140-6736(22)01657-9":[{"url":"https://hartvaat.nl/2022/10/08/all-heart-allopurinol-verbetert-cv-uitkomsten-niet-bij-ischemische-hartziekte/","title":"ALL-HEART: allopurinol verbetert CV-uitkomsten niet bij ischemische hartziekte","title_en":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.","published":"2022-10-08"}],"10.1161/circulationaha.122.059755":[{"url":"https://hartvaat.nl/2022/10/04/empagliflozine-bij-hfpef-gelijk-effect-bij-vrouwen-en-mannen/","title":"Empagliflozine bij HFpEF: gelijk effect bij vrouwen en mannen","title_en":"Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.","published":"2022-10-04"}],"10.1161/circulationaha.122.059210":[{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","title":"PARADISE-MI: sacubitril/valsartan versus ramipril na acuut MI — echocardiografie","title_en":"Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.","published":"2022-10-04"}],"10.1161/circulationaha.122.060666":[{"url":"https://hartvaat.nl/2022/10/04/timing-vroege-versus-late-noac-start-na-ischemisch-cva-bij-af/","title":"TIMING: vroege versus late NOAC-start na ischemisch CVA bij AF","title_en":"Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study.","published":"2022-10-04"}],"10.1016/j.jacc.2022.07.021":[{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","title":"DELIVER: dapagliflozine effectief bij recent gehospitaliseerde HFpEF-patiënten","title_en":"Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.","published":"2022-10-04"}],"10.1016/j.jacc.2022.07.006":[{"url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","title":"2022 ACC Expert Consensus: niet-statine therapieën voor LDL-verlaging bij ASCVD","title_en":"2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2022-10-04"}],"10.1001/jamacardio.2022.2825":[{"url":"https://hartvaat.nl/2022/10/01/sekseverschillen-in-af-risico-vital-rhythm-studie/","title":"Sekseverschillen in AF-risico: VITAL Rhythm studie","title_en":"Sex Differences in Atrial Fibrillation Risk: The VITAL Rhythm Study.","published":"2022-10-01"}],"10.1161/hypertensionaha.122.19685":[{"url":"https://hartvaat.nl/2022/10/01/smartphone-app-thuisbloeddrukmeting-versus-kantoor-en-ambulante-meting/","title":"Smartphone-app thuisbloeddrukmeting versus kantoor- en ambulante meting","title_en":"Smartphone Application-Assisted Home Blood Pressure Monitoring Compared With Office and Ambulatory Blood Pressure Monitoring in Patients With Hypertension: the AMUSE-BP Study.","published":"2022-10-01"}],"10.1161/hypertensionaha.121.18921":[{"url":"https://hartvaat.nl/2022/10/01/bloeddruk-in-hogere-versus-lagere-arm-en-cv-uitkomsten-interpress-ipd-meta-analy/","title":"Bloeddruk in hogere versus lagere arm en CV-uitkomsten: INTERPRESS-IPD meta-analyse","title_en":"Higher Arm Versus Lower Arm Systolic Blood Pressure and Cardiovascular Outcomes: a Meta-Analysis of Individual Participant Data From the INTERPRESS-IPD Collaboration.","published":"2022-10-01"}],"10.1002/ehf2.14012":[{"url":"https://hartvaat.nl/2022/10/01/alfa-antagonisten-en-cardiovasculaire-uitkomsten-meta-analyse-nuanceert-risico/","title":"Alfa-antagonisten en cardiovasculaire uitkomsten: meta-analyse nuanceert risico","title_en":"Do adrenergic alpha-antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta-analysis.","published":"2022-10-01"}],"10.1161/hypertensionaha.122.19568":[{"url":"https://hartvaat.nl/2022/10/01/financiele-prikkels-verbeteren-hypertensiecontrole-chinese-rct/","title":"Financiële prikkels verbeteren hypertensiecontrole: Chinese RCT","title_en":"Effect of Financial Incentives on Hypertension Control: A Multicenter Randomized Controlled Trial in China.","published":"2022-10-01"}],"10.1002/ehf2.14073":[{"url":"https://hartvaat.nl/2022/10/01/bloedbiomerkers-voor-prognose-bij-hypertrofische-cardiomyopathie-meta-analyse/","title":"Bloedbiomerkers voor prognose bij hypertrofische cardiomyopathie: meta-analyse","title_en":"Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis.","published":"2022-10-01"}],"10.1002/ehf2.14021":[{"url":"https://hartvaat.nl/2022/10/01/intraveneus-tolvaptan-versus-orale-formulering-bij-congestief-hartfalen/","title":"Intraveneus tolvaptan versus orale formulering bij congestief hartfalen","title_en":"Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.","published":"2022-10-01"}],"10.1002/ehf2.13772":[{"url":"https://hartvaat.nl/2022/10/01/mitraclip-bij-secundaire-mitralisklepinsufficientie-meta-analyse-ischemisch-vs-n/","title":"MitraClip bij secundaire mitralisklepinsufficiëntie: meta-analyse ischemisch vs niet-ischemisch","title_en":"Edge-to-edge percutaneous mitral repair for functional ischaemic and non-ischaemic mitral regurgitation: a systematic review and meta-analysis.","published":"2022-10-01"}],"10.1002/ehf2.14019":[{"url":"https://hartvaat.nl/2022/10/01/bnp-nt-probnp-stratificeert-prognose-gelijk-met-en-zonder-hartfalen-meta-analyse/","title":"BNP/NT-proBNP stratificeert prognose gelijk met en zonder hartfalen: meta-analyse","title_en":"Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis.","published":"2022-10-01"}],"10.1002/ehf2.14020":[{"url":"https://hartvaat.nl/2022/10/01/orale-ijzersuppletie-bij-hartfalen-systematische-review-en-meta-analyse/","title":"Orale ijzersuppletie bij hartfalen: systematische review en meta-analyse","title_en":"Oral iron supplementation in patients with heart failure: a systematic review and meta-analysis.","published":"2022-10-01"}],"10.1002/ehf2.13979":[{"url":"https://hartvaat.nl/2022/10/01/inspanningshemodynamiek-bij-hfpef-systematische-review-en-meta-analyse/","title":"Inspanningshemodynamiek bij HFpEF: systematische review en meta-analyse","title_en":"Exercise haemodynamics in heart failure with preserved ejection fraction: a systematic review and meta-analysis.","published":"2022-10-01"}],"10.1002/ehf2.14032":[{"url":"https://hartvaat.nl/2022/10/01/verschillende-trainingsvormen-en-hdl-functie-bij-hfpef-optimex-substudie/","title":"Verschillende trainingsvormen en HDL-functie bij HFpEF: OptimEx substudie","title_en":"Impact of different training modalities on high-density lipoprotein function in HFpEF patients: a substudy of the OptimEx trial.","published":"2022-10-01"}],"10.1056/nejmoa2203094":[{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","title":"ADVOR: acetazolamide bij acuut gedecompenseerd hartfalen met volumeoverbelasting","title_en":"Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.","published":"2022-09-29"}],"10.1016/j.jacc.2022.07.016":[{"url":"https://hartvaat.nl/2022/09/27/verkorte-antiplaatjestherapie-na-stenting-bij-hoog-bloedingsrisico-en-acs/","title":"Verkorte antiplaatjestherapie na stenting bij hoog bloedingsrisico en ACS","title_en":"Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk.","published":"2022-09-27"}],"10.1016/j.jacc.2022.07.019":[{"url":"https://hartvaat.nl/2022/09/27/linkerbundeltakpacing-versus-biventriculaire-pacing-voor-crt-gerandomiseerde-tri/","title":"Linkerbundeltakpacing versus biventriculaire pacing voor CRT: gerandomiseerde trial","title_en":"Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy.","published":"2022-09-27"}],"10.1001/jama.2022.16197":[{"url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","title":"MOMENTUM 3: vijfjaarsresultaten HeartMate 3 versus axiale LVAD","title_en":"Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial.","published":"2022-09-27"}],"10.1161/circulationaha.122.060511":[{"url":"https://hartvaat.nl/2022/09/27/ijzerdeficientie-bij-hartfalen-en-het-effect-van-dapagliflozine-dapa-hf/","title":"IJzerdeficiëntie bij hartfalen en het effect van dapagliflozine: DAPA-HF","title_en":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.","published":"2022-09-27"}],"10.1136/heartjnl-2022-321332":[{"url":"https://hartvaat.nl/2022/09/26/zoutvervangers-verminderen-cardiovasculaire-events-systematische-review/","title":"Zoutvervangers verminderen cardiovasculaire events: systematische review","title_en":"Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis.","published":"2022-09-26"}],"10.1136/heartjnl-2021-320417":[{"url":"https://hartvaat.nl/2022/09/26/smartphone-detectie-van-af-via-fotoplethysmografie-meta-analyse/","title":"Smartphone-detectie van AF via fotoplethysmografie: meta-analyse","title_en":"Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis.","published":"2022-09-26"}],"10.1056/nejmoa2200436":[{"url":"https://hartvaat.nl/2022/09/22/grade-vergelijking-glucoseverlagende-middelen-op-microvasculaire-en-cv-uitkomste/","title":"GRADE: vergelijking glucoseverlagende middelen op microvasculaire en CV-uitkomsten","title_en":"Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.","published":"2022-09-22"}],"10.1056/nejmoa2206286":[{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","title":"DELIVER: dapagliflozine effectief bij HFmrEF en HFpEF","title_en":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.","published":"2022-09-22"}],"10.1093/eurheartj/ehac389":[{"url":"https://hartvaat.nl/2022/09/21/riociguat-bij-pulmonale-hypertensie-en-hfpef-haemodynamic-trial/","title":"Riociguat bij pulmonale hypertensie en HFpEF: haemoDYNAMIC-trial","title_en":"Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.","published":"2022-09-21"}],"10.1016/j.jacc.2022.06.037":[{"url":"https://hartvaat.nl/2022/09/20/sacubitril-valsartan-en-frailteit-bij-hfpef-paragon-hf-analyse/","title":"Sacubitril/valsartan en frailteit bij HFpEF: PARAGON-HF analyse","title_en":"Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.","published":"2022-09-20"}],"10.1161/circulationaha.122.059325":[{"url":"https://hartvaat.nl/2022/09/20/recombinant-lcat-bij-acuut-stemi-fase-2b-trial/","title":"Recombinant LCAT bij acuut STEMI: fase 2b trial","title_en":"Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B.","published":"2022-09-20"}],"10.1016/j.jacc.2022.07.005":[{"url":"https://hartvaat.nl/2022/09/20/harmonisatie-van-acc-aha-en-esc-esh-bloeddrukrichtlijnen/","title":"Harmonisatie van ACC/AHA en ESC/ESH bloeddrukrichtlijnen","title_en":"Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations.","published":"2022-09-20"}],"10.1056/nejmoa2209051":[{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","title":"INVICTUS: rivaroxaban versus warfarine bij reumatische hartziekte en AF","title_en":"Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.","published":"2022-09-15"}],"10.1056/nejmoa2208275":[{"url":"https://hartvaat.nl/2022/09/15/polypill-voor-secundaire-cardiovasculaire-preventie-secure-trial-in-nejm/","title":"Polypill voor secundaire cardiovasculaire preventie: SECURE-trial in NEJM","title_en":"Polypill Strategy in Secondary Cardiovascular Prevention.","published":"2022-09-15"}],"10.1161/circulationaha.122.060274":[{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","title":"EAST-AFNET4: vroege ritmecontrole effectief ook bij hoge comorbiditeit","title_en":"Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden.","published":"2022-09-13"}],"10.1016/s0140-6736(22)01545-8":[{"url":"https://hartvaat.nl/2022/09/10/statines-en-spiersymptomen-lancet-ipd-meta-analyse-ontkracht-breed-probleem/","title":"Statines en spiersymptomen: Lancet IPD meta-analyse ontkracht breed probleem","title_en":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.","published":"2022-09-10"}],"10.1056/nejmoa2208335":[{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","title":"POST-PCI: routine functionele testen versus standaardzorg na PCI bij hoog risico","title_en":"Routine Functional Testing or Standard Care in High-Risk Patients after PCI.","published":"2022-09-08"}],"10.1093/eurheartj/ehac339":[{"url":"https://hartvaat.nl/2022/09/07/aortastenose-bij-homozygote-familiaire-hypercholesterolemie-paradigmaverschuivin/","title":"Aortastenose bij homozygote familiaire hypercholesterolemie: paradigmaverschuiving","title_en":"Aortic stenosis in homozygous familial hypercholesterolaemia: a paradigm shift over a century.","published":"2022-09-07"}],"10.1093/eurheartj/ehac015":[{"url":"https://hartvaat.nl/2022/09/07/prevalentie-van-statine-intolerantie-meta-analyse-nuanceert-het-probleem/","title":"Prevalentie van statine-intolerantie: meta-analyse nuanceert het probleem","title_en":"Prevalence of statin intolerance: a meta-analysis.","published":"2022-09-07"}],"10.1001/jama.2022.13382":[{"url":"https://hartvaat.nl/2022/09/06/klinisch-beslisondersteuning-vermindert-acute-nierschade-bij-coronairangiografie/","title":"Klinisch beslisondersteuning vermindert acute nierschade bij coronairangiografie","title_en":"Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial.","published":"2022-09-06"}],"10.1016/s0140-6736(22)01429-5":[{"url":"https://hartvaat.nl/2022/09/03/sglt2-remmers-bij-hartfalen-mega-meta-analyse-van-vijf-grote-trials/","title":"SGLT2-remmers bij hartfalen: mega-meta-analyse van vijf grote trials","title_en":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.","published":"2022-09-03"}],"10.1056/nejmoa2201546":[{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","title":"FLAVOUR: FFR versus IVUS voor PCI-beslissingen bij coronairlijden","title_en":"Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI.","published":"2022-09-01"}],"10.1093/eurheartj/ehac227":[{"url":"https://hartvaat.nl/2022/09/01/collaterale-schade-van-covid-19-aan-cardiovasculaire-zorg-meta-analyse/","title":"Collaterale schade van COVID-19 aan cardiovasculaire zorg: meta-analyse","title_en":"The collateral damage of COVID-19 to cardiovascular services: a meta-analysis.","published":"2022-09-01"}],"10.1001/jamacardio.2022.2006":[{"url":"https://hartvaat.nl/2022/09/01/dapagliflozine-effectief-ongeacht-cv-achtergrondmedicatie-declare-subanalyse/","title":"Dapagliflozine effectief ongeacht CV-achtergrondmedicatie: DECLARE subanalyse","title_en":"Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.","published":"2022-09-01"}],"10.1093/eurheartj/ehac260":[{"url":"https://hartvaat.nl/2022/09/01/orbita-substudie-inspanningstesten-en-pci-effectiviteit/","title":"ORBITA-substudie: inspanningstesten en PCI-effectiviteit","title_en":"Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial.","published":"2022-09-01"}],"10.1093/eurheartj/ehac213":[{"url":"https://hartvaat.nl/2022/09/01/timing-van-invasieve-strategie-bij-nste-acs-meta-analyse-van-rct-s/","title":"Timing van invasieve strategie bij NSTE-ACS: meta-analyse van RCT's","title_en":"Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials.","published":"2022-09-01"}],"10.1093/europace/euac003":[{"url":"https://hartvaat.nl/2022/09/01/af-voorspelt-cognitieve-achteruitgang-meta-analyse-van-2-8-miljoen-personen/","title":"AF voorspelt cognitieve achteruitgang: meta-analyse van 2,8 miljoen personen","title_en":"Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals.","published":"2022-09-01"}],"10.1161/hypertensionaha.122.19333":[{"url":"https://hartvaat.nl/2022/09/01/bloeddruk-beinvloedt-opbrengst-van-af-screening-loop-substudie/","title":"Bloeddruk beïnvloedt opbrengst van AF-screening: LOOP-substudie","title_en":"Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy).","published":"2022-09-01"}],"10.1161/hypertensionaha.122.19288":[{"url":"https://hartvaat.nl/2022/09/01/obstructief-slaapapneu-sympathische-activiteit-en-bloeddruk-meta-analyse/","title":"Obstructief slaapapneu, sympathische activiteit en bloeddruk: meta-analyse","title_en":"Influence of Obstructive Sleep Apnea Severity on Muscle Sympathetic Nerve Activity and Blood Pressure: a Systematic Review and Meta-Analysis.","published":"2022-09-01"}],"10.1161/hypertensionaha.121.17233":[{"url":"https://hartvaat.nl/2022/09/01/bloeddrukinterventie-en-controle-in-sprint-nader-geanalyseerd/","title":"Bloeddrukinterventie en -controle in SPRINT nader geanalyseerd","title_en":"Blood Pressure Intervention and Control in SPRINT.","published":"2022-09-01"}],"10.1161/hypertensionaha.121.18858":[{"url":"https://hartvaat.nl/2022/09/01/primair-aldosteronisme-in-de-zwangerschap-systematische-review/","title":"Primair aldosteronisme in de zwangerschap: systematische review","title_en":"Management and Outcomes of Primary Aldosteronism in Pregnancy: A Systematic Review.","published":"2022-09-01"}],"10.1016/j.jacc.2022.05.051":[{"url":"https://hartvaat.nl/2022/08/30/biomarkers-voorspellen-complexe-coronaire-revascularisatie-in-fourier/","title":"Biomarkers voorspellen complexe coronaire revascularisatie in FOURIER","title_en":"Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial.","published":"2022-08-30"}],"10.1161/circulationaha.121.057793":[{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","title":"RIPCORD 2: routinematige FFR-meting versus conventionele angiografie","title_en":"Routine Pressure Wire Assessment Versus Conventional Angiography in the Management of Patients With Coronary Artery Disease: The RIPCORD 2 Trial.","published":"2022-08-30"}],"10.1161/circulationaha.121.057807":[{"url":"https://hartvaat.nl/2022/08/30/apob-en-residueel-cv-risico-na-acs-effect-van-alirocumab/","title":"ApoB en residueel CV-risico na ACS: effect van alirocumab","title_en":"Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.","published":"2022-08-30"}],"10.1161/circulationaha.122.059785":[{"url":"https://hartvaat.nl/2022/08/30/empagliflozine-bij-hfpef-consistent-effect-met-en-zonder-diabetes/","title":"Empagliflozine bij HFpEF: consistent effect met en zonder diabetes","title_en":"Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.","published":"2022-08-30"}],"10.1056/nejmoa2204225":[{"url":"https://hartvaat.nl/2022/08/25/aflibercept-versus-bevacizumab-eerst-bij-diabetisch-macula-oedeem/","title":"Aflibercept versus bevacizumab-eerst bij diabetisch macula-oedeem","title_en":"Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.","published":"2022-08-25"}],"10.1001/jama.2022.12138":[{"url":"https://hartvaat.nl/2022/08/23/uspstf-evidence-review-statines-voor-primaire-cv-preventie-geactualiseerd/","title":"USPSTF evidence review: statines voor primaire CV-preventie geactualiseerd","title_en":"Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2022-08-23"}],"10.1001/jama.2022.13044":[{"url":"https://hartvaat.nl/2022/08/23/uspstf-aanbeveling-statinegebruik-voor-primaire-cardiovasculaire-preventie/","title":"USPSTF-aanbeveling: statinegebruik voor primaire cardiovasculaire preventie","title_en":"Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.","published":"2022-08-23"}],"10.1016/j.jacc.2022.04.065":[{"url":"https://hartvaat.nl/2022/08/23/impact-van-therapieontrouw-op-duale-antiplaatjestherapie-in-klinische-trial/","title":"Impact van therapieontrouw op duale antiplaatjestherapie in klinische trial","title_en":"Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy.","published":"2022-08-23"}],"10.1161/circulationaha.121.058635":[{"url":"https://hartvaat.nl/2022/08/23/klinische-verslechtering-als-surrogaat-voor-mortaliteit-bij-pulmonale-arteriele-/","title":"Klinische verslechtering als surrogaat voor mortaliteit bij pulmonale arteriële hypertensie","title_en":"Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","published":"2022-08-23"}],"10.1161/circulationaha.122.058575":[{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","title":"CABANA: catheterablatie bij AF is kosteneffectief vergeleken met antiaritmica","title_en":"Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial.","published":"2022-08-16"}],"10.1093/eurheartj/ehab530":[{"url":"https://hartvaat.nl/2022/08/14/obesitas-en-dapagliflozine-bij-type-2-diabetes-declare-timi-58-subanalyse/","title":"Obesitas en dapagliflozine bij type 2 diabetes: DECLARE-TIMI 58 subanalyse","title_en":"Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.","published":"2022-08-14"}],"10.1136/heartjnl-2021-320131":[{"url":"https://hartvaat.nl/2022/08/11/prevalentie-incidentie-en-overleving-bij-hartfalen-wereldwijde-systematische-rev/","title":"Prevalentie, incidentie en overleving bij hartfalen: wereldwijde systematische review","title_en":"Prevalence, incidence and survival of heart failure: a systematic review.","published":"2022-08-11"}],"10.1001/jama.2022.11966":[{"url":"https://hartvaat.nl/2022/08/09/ticagrelor-dapt-en-veneuze-graftfalen-na-cabg-systematische-review/","title":"Ticagrelor DAPT en veneuze graftfalen na CABG: systematische review","title_en":"Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis.","published":"2022-08-09"}],"10.1016/j.jacc.2022.05.027":[{"url":"https://hartvaat.nl/2022/08/09/vertraagde-afgifteformulering-van-ivabradine-bij-systolisch-hartfalen/","title":"Vertraagde-afgifteformulering van ivabradine bij systolisch hartfalen","title_en":"Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.","published":"2022-08-09"}],"10.1161/circulationaha.122.059150":[{"url":"https://hartvaat.nl/2022/08/09/renale-en-vasculaire-effecten-van-gecombineerde-sglt2-en-ace-remming/","title":"Renale en vasculaire effecten van gecombineerde SGLT2- en ACE-remming","title_en":"Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition.","published":"2022-08-09"}],"10.1161/circulationaha.121.058910":[{"url":"https://hartvaat.nl/2022/08/09/initiele-egfr-dip-na-start-dapagliflozine-bij-hfref-dapa-hf-analyse/","title":"Initiële eGFR-dip na start dapagliflozine bij HFrEF: DAPA-HF analyse","title_en":"Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.","published":"2022-08-09"}],"10.1161/circulationaha.122.059410":[{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","title":"REDUCE-IT: icosapent ethyl vermindert inflammatiemarkers","title_en":"Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy.","published":"2022-08-02"}],"10.1001/jamacardio.2022.1561":[{"url":"https://hartvaat.nl/2022/08/01/rivaroxaban-monotherapie-versus-combinatie-met-plaatjesremmers-bij-af-en-coronai/","title":"Rivaroxaban monotherapie versus combinatie met plaatjesremmers bij AF en coronairlijden","title_en":"Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.","published":"2022-08-01"}],"10.1161/hypertensionaha.122.19362":[{"url":"https://hartvaat.nl/2022/08/01/schone-kookbrandstof-en-bloeddruk-tijdens-zwangerschap-hapin-trial/","title":"Schone kookbrandstof en bloeddruk tijdens zwangerschap: HAPIN-trial","title_en":"Effects of a Liquefied Petroleum Gas Stove Intervention on Gestational Blood Pressure: Intention-to-Treat and Exposure-Response Findings From the HAPIN Trial.","published":"2022-08-01"}],"10.1161/hypertensionaha.122.19312":[{"url":"https://hartvaat.nl/2022/08/01/ramipril-bij-hypertensieve-kinderen-op-hemodialyse-search-trial/","title":"Ramipril bij hypertensieve kinderen op hemodialyse: SEARCH-trial","title_en":"Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.","published":"2022-08-01"}],"10.1161/hypertensionaha.122.19324":[{"url":"https://hartvaat.nl/2022/08/01/hele-genoomsequencing-onthult-nieuwe-bloeddruk-loci/","title":"Hele-genoomsequencing onthult nieuwe bloeddruk-loci","title_en":"Insights From a Large-Scale Whole-Genome Sequencing Study of Systolic Blood Pressure, Diastolic Blood Pressure, and Hypertension.","published":"2022-08-01"}],"10.1002/ehf2.13985":[{"url":"https://hartvaat.nl/2022/08/01/cardiorenaal-syndroom-en-fitheid-bij-hartfalen-telerevalidatie-trial/","title":"Cardiorenaal syndroom en fitheid bij hartfalen: telerevalidatie-trial","title_en":"Cardiorenal syndrome and the association with fitness: Data from a telerehabilitation randomized clinical trial.","published":"2022-08-01"}],"10.1002/ehf2.13955":[{"url":"https://hartvaat.nl/2022/08/01/empagliflozine-vermindert-nierletselmarkers-bij-acuut-hartfalen/","title":"Empagliflozine vermindert nierletselmarkers bij acuut hartfalen","title_en":"Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.","published":"2022-08-01"}],"10.1002/ehf2.13974":[{"url":"https://hartvaat.nl/2022/08/01/sekseverschillen-in-effectiviteit-van-hartfalenmedicatie-meta-analyse/","title":"Sekseverschillen in effectiviteit van hartfalenmedicatie: meta-analyse","title_en":"Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.","published":"2022-08-01"}],"10.1002/ehf2.13988":[{"url":"https://hartvaat.nl/2022/08/01/b-lijnen-geleide-hartfalenbehandeling-verbetert-uitkomsten-na-ontslag/","title":"B-lijnen-geleide hartfalenbehandeling verbetert uitkomsten na ontslag","title_en":"Impact of B-lines-guided intensive heart failure management on outcome of discharged heart failure patients with residual B-lines.","published":"2022-08-01"}],"10.1002/ehf2.13934":[{"url":"https://hartvaat.nl/2022/08/01/thuisrevalidatie-met-ict-voor-fragiele-hartfalenpatienten/","title":"Thuisrevalidatie met ICT voor fragiele hartfalenpatiënten","title_en":"Home-based cardiac rehabilitation using information and communication technology for heart failure patients with frailty.","published":"2022-08-01"}],"10.1016/s0140-6736(22)00916-3":[{"url":"https://hartvaat.nl/2022/07/30/matige-statine-plus-ezetimibe-versus-hoge-dosis-statine-bij-coronairlijden-lance/","title":"Matige statine plus ezetimibe versus hoge-dosis statine bij coronairlijden: Lancet-studie","title_en":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.","published":"2022-07-30"}],"10.1136/heartjnl-2021-320556":[{"url":"https://hartvaat.nl/2022/07/27/veiligheid-van-pcsk9-remmers-systematische-review-en-meta-analyse/","title":"Veiligheid van PCSK9-remmers: systematische review en meta-analyse","title_en":"Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.","published":"2022-07-27"}],"10.1136/heartjnl-2021-320171":[{"url":"https://hartvaat.nl/2022/07/27/langetermijneffect-van-antihypertensiva-op-bloeddruk-meta-analyse-op-individueel/","title":"Langetermijneffect van antihypertensiva op bloeddruk: meta-analyse op individueel niveau","title_en":"Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials.","published":"2022-07-27"}],"10.1001/jama.2022.10951":[{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","title":"USPSTF: gedragsinterventies voor gezonde leefstijl bij cardiovasculaire preventie","title_en":"Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recommendation Statement.","published":"2022-07-26"}],"10.1161/circulationaha.122.059045":[{"url":"https://hartvaat.nl/2022/07/26/chinees-hartgezond-dieet-verlaagt-bloeddruk-effectief-gerandomiseerde-trial/","title":"Chinees hartgezond dieet verlaagt bloeddruk effectief: gerandomiseerde trial","title_en":"Effects of Cuisine-Based Chinese Heart-Healthy Diet in Lowering Blood Pressure Among Adults in China: Multicenter, Single-Blind, Randomized, Parallel Controlled Feeding Trial.","published":"2022-07-26"}],"10.1161/circulationaha.122.059038":[{"url":"https://hartvaat.nl/2022/07/26/empag-hf-vroege-empagliflozine-bij-acuut-hartfalen-verbetert-diurese/","title":"EMPAG-HF: vroege empagliflozine bij acuut hartfalen verbetert diurese","title_en":"Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).","published":"2022-07-26"}],"10.1161/circulationaha.122.059725":[{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","title":"EMPULSE: empagliflozine verbetert symptomen en kwaliteit van leven bij acuut hartfalen","title_en":"Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.","published":"2022-07-26"}],"10.1093/europace/euac005":[{"url":"https://hartvaat.nl/2022/07/21/posterior-wand-isolatie-met-cryoballon-bij-persisterend-af-meerwaarde-onderzocht/","title":"Posterior wand-isolatie met cryoballon bij persisterend AF: meerwaarde onderzocht","title_en":"Does isolation of the left atrial posterior wall using cryoballoon ablation improve clinical outcomes in patients with persistent atrial fibrillation? A prospective randomized controlled trial.","published":"2022-07-21"}],"10.1093/europace/euac008":[{"url":"https://hartvaat.nl/2022/07/21/permanente-pacemaker-na-tavi-langetermijneffect-op-klinische-uitkomsten/","title":"Permanente pacemaker na TAVI: langetermijneffect op klinische uitkomsten","title_en":"Long-term clinical impact of permanent pacemaker implantation in patients undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis.","published":"2022-07-21"}],"10.1001/jama.2022.11016":[{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","title":"METEORIC-HF: omecamtiv mecarbil verbetert inspanningscapaciteit niet bij HFrEF","title_en":"Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.","published":"2022-07-19"}],"10.1093/europace/euab298":[{"url":"https://hartvaat.nl/2022/07/15/vt-ablatie-versus-antiaritmica-bij-myocardinfarct-locatie-maakt-uit/","title":"VT-ablatie versus antiaritmica bij myocardinfarct: locatie maakt uit","title_en":"Comparative effectiveness of ventricular tachycardia ablation vs. escalated antiarrhythmic drug therapy by location of myocardial infarction: a sub-study of the VANISH trial.","published":"2022-07-15"}],"10.1093/europace/euab303":[{"url":"https://hartvaat.nl/2022/07/15/wereldwijde-trends-in-orale-antistollingsgebruik-bij-af-2010-2018/","title":"Wereldwijde trends in orale antistollingsgebruik bij AF (2010-2018)","title_en":"Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis.","published":"2022-07-15"}],"10.1093/europace/euab305":[{"url":"https://hartvaat.nl/2022/07/15/geindividualiseerde-versus-standaard-cryoballonablatie-bij-paroxysmaal-af/","title":"Geïndividualiseerde versus standaard cryoballonablatie bij paroxysmaal AF","title_en":"Individualized or fixed approach to pulmonary vein isolation utilizing the fourth-generation cryoballoon in patients with paroxysmal atrial fibrillation: the randomized INDI-FREEZE trial.","published":"2022-07-15"}],"10.1093/europace/euab270":[{"url":"https://hartvaat.nl/2022/07/15/race-3-langetermijnresultaten-gerichte-behandeling-bij-vroeg-persisterend-af-en-/","title":"RACE 3 langetermijnresultaten: gerichte behandeling bij vroeg persisterend AF en hartfalen","title_en":"Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial.","published":"2022-07-15"}],"10.1093/eurheartj/ehac114":[{"url":"https://hartvaat.nl/2022/07/14/guide-hf-en-de-impact-van-covid-19-op-hartfalenuitkomsten/","title":"GUIDE-HF en de impact van COVID-19 op hartfalenuitkomsten","title_en":"The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.","published":"2022-07-14"}],"10.1136/heartjnl-2021-319794":[{"url":"https://hartvaat.nl/2022/07/13/atriumfibrilleren-na-transcatheter-asd-sluiting-systematische-review/","title":"Atriumfibrilleren na transcatheter ASD-sluiting: systematische review","title_en":"Atrial fibrillation following transcatheter atrial septal defect closure: a systematic review and meta-analysis.","published":"2022-07-13"}],"10.1161/circulationaha.122.059983":[{"url":"https://hartvaat.nl/2022/07/12/frailteit-beinvloedt-effect-van-inspanningstraining-bij-hartfalen-hf-action-anal/","title":"Frailteit beïnvloedt effect van inspanningstraining bij hartfalen: HF-ACTION analyse","title_en":"Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial.","published":"2022-07-12"}],"10.1161/circulationaha.121.056805":[{"url":"https://hartvaat.nl/2022/07/05/deep-lipidomics-cardiometabool-risico-en-effect-van-voedingsvet/","title":"Deep lipidomics: cardiometabool risico en effect van voedingsvet","title_en":"Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation.","published":"2022-07-05"}],"10.1001/jamacardio.2022.1166":[{"url":"https://hartvaat.nl/2022/07/01/augustus-analyse-apixaban-versus-warfarine-bij-af-na-acs-of-pci/","title":"AUGUSTUS-analyse: apixaban versus warfarine bij AF na ACS of PCI","title_en":"Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.","published":"2022-07-01"}],"10.1001/jamacardio.2022.1188":[{"url":"https://hartvaat.nl/2022/07/01/behandeling-van-acuut-coronair-syndroom-in-ruraal-australie-moracs-trial/","title":"Behandeling van acuut coronair syndroom in ruraal Australië: MORACS-trial","title_en":"Management of Acute Coronary Syndromes in Patients in Rural Australia: The MORACS Randomized Clinical Trial.","published":"2022-07-01"}],"10.1161/hypertensionaha.121.18641":[{"url":"https://hartvaat.nl/2022/07/01/pulsatiele-hemodynamiek-voorspelt-bloeddrukrespons-op-renale-denervatie/","title":"Pulsatiele hemodynamiek voorspelt bloeddrukrespons op renale denervatie","title_en":"Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial.","published":"2022-07-01"}],"10.1016/j.kint.2022.02.019":[{"url":"https://hartvaat.nl/2022/07/01/hoog-sensitief-troponine-en-myocardinfarct-bij-nierfunctiestoornissen/","title":"Hoog-sensitief troponine en myocardinfarct bij nierfunctiestoornissen","title_en":"High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairment.","published":"2022-07-01"}],"10.1001/jama.2022.8831":[{"url":"https://hartvaat.nl/2022/06/21/mri-geleide-fibroseablatie-versus-conventionele-ablatie-bij-persisterend-af/","title":"MRI-geleide fibroseablatie versus conventionele ablatie bij persisterend AF","title_en":"Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial.","published":"2022-06-21"}],"10.1161/circulationaha.122.059598":[{"url":"https://hartvaat.nl/2022/06/21/timing-van-vt-ablatie-bij-icd-patienten-partita-trial/","title":"Timing van VT-ablatie bij ICD-patiënten: PARTITA-trial","title_en":"Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial.","published":"2022-06-21"}],"10.1093/eurheartj/ehac151":[{"url":"https://hartvaat.nl/2022/06/14/euroheart-datastandaarden-voor-hartfalenregistraties/","title":"EuroHeart datastandaarden voor hartfalenregistraties","title_en":"Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).","published":"2022-06-14"}],"10.1093/eurheartj/ehac144":[{"url":"https://hartvaat.nl/2022/06/14/omecamtiv-mecarbil-bij-hartfalen-met-en-zonder-atriumfibrilleren-galactic-hf/","title":"Omecamtiv mecarbil bij hartfalen met en zonder atriumfibrilleren: GALACTIC-HF","title_en":"Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.","published":"2022-06-14"}],"10.1136/heartjnl-2021-320495":[{"url":"https://hartvaat.nl/2022/06/10/echogeleide-lvad-snelheidsoptimalisatie-voor-betere-inspanningstolerantie/","title":"Echogeleide LVAD-snelheidsoptimalisatie voor betere inspanningstolerantie","title_en":"Echo-guided left ventricular assist device speed optimisation for exercise maximisation.","published":"2022-06-10"}],"10.1136/heartjnl-2021-320036":[{"url":"https://hartvaat.nl/2022/06/10/voorspelling-van-atriumfibrilleren-in-elektronische-gezondheidsdossiers-systemat/","title":"Voorspelling van atriumfibrilleren in elektronische gezondheidsdossiers: systematische review","title_en":"Prediction of incident atrial fibrillation in community-based electronic health records: a systematic review with meta-analysis.","published":"2022-06-10"}],"10.1016/j.jacc.2022.03.338":[{"url":"https://hartvaat.nl/2022/06/07/elektronische-alerts-verbeteren-hartfalenbehandeling-in-de-polikliniek/","title":"Elektronische alerts verbeteren hartfalenbehandeling in de polikliniek","title_en":"Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.","published":"2022-06-07"}],"10.1161/circulationaha.121.057095":[{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","title":"RAFT-AF: ablatie versus rate control bij hartfalen en atriumfibrilleren","title_en":"Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.","published":"2022-06-07"}],"10.1001/jamacardio.2022.0553":[{"url":"https://hartvaat.nl/2022/06/01/digitale-gamificatie-interventie-verhoogt-lichaamsbeweging-na-hypertensieve-zwan/","title":"Digitale gamificatie-interventie verhoogt lichaamsbeweging na hypertensieve zwangerschap","title_en":"Effectiveness of a Text-Based Gamification Intervention to Improve Physical Activity Among Postpartum Individuals With Hypertensive Disorders of Pregnancy: A Randomized Clinical Trial.","published":"2022-06-01"}],"10.1001/jamacardio.2022.0480":[{"url":"https://hartvaat.nl/2022/06/01/edoxaban-15-mg-bij-zeer-oude-patienten-met-atriumfibrilleren-eldercare-subanalys/","title":"Edoxaban 15 mg bij zeer oude patiënten met atriumfibrilleren: ELDERCARE subanalyse","title_en":"Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.","published":"2022-06-01"}],"10.1001/jamacardio.2022.0471":[{"url":"https://hartvaat.nl/2022/06/01/lage-dosis-drievoudige-combinatietherapie-bij-hypertensie-triumph-secundaire-ana/","title":"Lage-dosis drievoudige combinatietherapie bij hypertensie: TRIUMPH secundaire analyse","title_en":"Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical Trial.","published":"2022-06-01"}],"10.1093/eurheartj/ehab922":[{"url":"https://hartvaat.nl/2022/06/01/finger-trial-multidomein-leefstijlinterventie-verlaagt-cardiovasculair-risico-bi/","title":"FINGER-trial: multidomein-leefstijlinterventie verlaagt cardiovasculair risico bij ouderen","title_en":"Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: the FINGER trial.","published":"2022-06-01"}],"10.1093/eurheartj/ehab721":[{"url":"https://hartvaat.nl/2022/06/01/vijf-jaar-inspanningstraining-verbetert-cardiovasculair-risicoprofiel-bij-oudere/","title":"Vijf jaar inspanningstraining verbetert cardiovasculair risicoprofiel bij ouderen","title_en":"Effect of 5 years of exercise training on the cardiovascular risk profile of older adults: the Generation 100 randomized trial.","published":"2022-06-01"}],"10.1002/ehf2.13812":[{"url":"https://hartvaat.nl/2022/06/01/milrinone-versus-dobutamine-bij-hartfalen-meta-analyse/","title":"Milrinone versus dobutamine bij hartfalen: meta-analyse","title_en":"Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis.","published":"2022-06-01"}],"10.1002/ehf2.13905":[{"url":"https://hartvaat.nl/2022/06/01/sglt2-remmers-bij-hartfalen-geupdatete-meta-analyse-bevestigt-breed-voordeel/","title":"SGLT2-remmers bij hartfalen: geüpdatete meta-analyse bevestigt breed voordeel","title_en":"Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.","published":"2022-06-01"}],"10.1002/ehf2.13911":[{"url":"https://hartvaat.nl/2022/06/01/interatriale-shuntdevices-bij-hartfalen-systematische-review-en-meta-analyse/","title":"Interatriale shuntdevices bij hartfalen: systematische review en meta-analyse","title_en":"Haemodynamic changes of interatrial shunting devices for heart failure: a systematic review and meta-analysis.","published":"2022-06-01"}],"10.1161/circulationaha.121.056756":[{"url":"https://hartvaat.nl/2022/05/31/langetermijneffect-van-metformine-en-leefstijlinterventie-op-cardiovasculaire-ev/","title":"Langetermijneffect van metformine en leefstijlinterventie op cardiovasculaire events","title_en":"Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.","published":"2022-05-31"}],"10.1161/circulationaha.122.060049":[{"url":"https://hartvaat.nl/2022/05/31/kwaliteit-van-leven-na-ffr-geleide-pci-versus-coronaire-bypasschirurgie/","title":"Kwaliteit van leven na FFR-geleide PCI versus coronaire bypasschirurgie","title_en":"Quality of Life After Fractional Flow Reserve-Guided PCI Compared With Coronary Bypass Surgery.","published":"2022-05-31"}],"10.1136/heartjnl-2021-320588":[{"url":"https://hartvaat.nl/2022/05/25/jbs-richtlijn-management-van-hartstilstand-in-het-cathlab/","title":"JBS-richtlijn: management van hartstilstand in het cathlab","title_en":"Joint British Societies' guideline on management of cardiac arrest in the cardiac catheter laboratory.","published":"2022-05-25"}],"10.1136/heartjnl-2021-319716":[{"url":"https://hartvaat.nl/2022/05/25/hydratie-ter-preventie-van-nierschade-na-primaire-pci-gerandomiseerde-trial/","title":"Hydratie ter preventie van nierschade na primaire PCI: gerandomiseerde trial","title_en":"Hydration for prevention of kidney injury after primary coronary intervention for acute myocardial infarction: a randomised clinical trial.","published":"2022-05-25"}],"10.1161/circulationaha.121.058103":[{"url":"https://hartvaat.nl/2022/05/24/dapagliflozine-naar-baseline-bloeddruk-bij-diabetes-type-2-declare-timi-58/","title":"Dapagliflozine naar baseline bloeddruk bij diabetes type 2: DECLARE-TIMI 58","title_en":"Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.","published":"2022-05-24"}],"10.1161/circulationaha.122.059486":[{"url":"https://hartvaat.nl/2022/05/24/latent-pulmonaal-vaatlijden-en-respons-op-atriale-shunt-bij-hf/","title":"Latent pulmonaal vaatlijden en respons op atriale shunt bij HF","title_en":"Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.","published":"2022-05-24"}],"10.1016/s0140-6736(22)00325-7":[{"url":"https://hartvaat.nl/2022/05/21/dorpsarts-geleide-multifacet-interventie-voor-bloeddrukcontrole-in-ruraal-china-/","title":"Dorpsarts-geleide multifacet-interventie voor bloeddrukcontrole in ruraal China: Lancet","title_en":"A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial.","published":"2022-05-21"}],"10.1093/eurheartj/ehac071":[{"url":"https://hartvaat.nl/2022/05/21/bariatrische-chirurgie-en-cardiovasculaire-ziekte-meta-analyse/","title":"Bariatrische chirurgie en cardiovasculaire ziekte: meta-analyse","title_en":"Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.","published":"2022-05-21"}],"10.1161/circulationaha.121.057642":[{"url":"https://hartvaat.nl/2022/05/17/voedingscholesterol-serumcholesterol-en-eiconsumptie-en-mortaliteit-meta-analyse/","title":"Voedingscholesterol, serumcholesterol en eiconsumptie en mortaliteit: meta-analyse","title_en":"Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality: Systematic Review and Updated Meta-Analysis.","published":"2022-05-17"}],"10.1161/circulationaha.122.059573":[{"url":"https://hartvaat.nl/2022/05/17/kosteneffectiviteit-van-zoutsubstitutie-ssass-analyse/","title":"Kosteneffectiviteit van zoutsubstitutie: SSaSS analyse","title_en":"Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study.","published":"2022-05-17"}],"10.1056/nejmoa2201295":[{"url":"https://hartvaat.nl/2022/05/12/behandeling-van-milde-chronische-hypertensie-in-de-zwangerschap-nejm-chap/","title":"Behandeling van milde chronische hypertensie in de zwangerschap: NEJM CHAP","title_en":"Treatment for Mild Chronic Hypertension during Pregnancy.","published":"2022-05-12"}],"10.1161/circulationaha.121.056161":[{"url":"https://hartvaat.nl/2022/05/10/sms-voor-medicatietrouw-en-secundaire-preventie-na-acs-textmeds/","title":"SMS voor medicatietrouw en secundaire preventie na ACS: TEXTMEDS","title_en":"Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial.","published":"2022-05-10"}],"10.1001/jama.2022.5218":[{"url":"https://hartvaat.nl/2022/05/10/alirocumab-plus-statine-op-coronaire-atherosclerose-na-mi-jama-pacman-ami/","title":"Alirocumab plus statine op coronaire atherosclerose na MI: JAMA PACMAN-AMI","title_en":"Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.","published":"2022-05-10"}],"10.1001/jama.2022.4712":[{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-hypertensie-diagnose-bij-risicozwangerschap-jama-bump-1/","title":"Zelfmeting bloeddruk en hypertensie-diagnose bij risicozwangerschap: JAMA BUMP 1","title_en":"Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial.","published":"2022-05-03"}],"10.1001/jama.2022.4726":[{"url":"https://hartvaat.nl/2022/05/03/zelfmeting-bloeddruk-en-bloeddrukcontrole-bij-risicozwangerschap-jama-bump-2/","title":"Zelfmeting bloeddruk en bloeddrukcontrole bij risicozwangerschap: JAMA BUMP 2","title_en":"Effect of Self-monitoring of Blood Pressure on Blood Pressure Control in Pregnant Individuals With Chronic or Gestational Hypertension: The BUMP 2 Randomized Clinical Trial.","published":"2022-05-03"}],"10.1016/j.jacc.2022.02.035":[{"url":"https://hartvaat.nl/2022/05/03/icosapent-ethyl-en-cv-preventie-bij-eerder-mi-reduce-it/","title":"Icosapent-ethyl en CV-preventie bij eerder MI: REDUCE-IT","title_en":"Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.","published":"2022-05-03"}],"10.1016/j.jacc.2021.12.011":[{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-executive-summary/","title":"2022 AHA/ACC/HFSA hartfalenrichtlijn: executive summary","title_en":"2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2022-05-03"}],"10.1016/j.jacc.2021.12.012":[{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-jacc-editie/","title":"2022 AHA/ACC/HFSA hartfalenrichtlijn: JACC-editie","title_en":"2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2022-05-03"}],"10.1161/circulationaha.122.059266":[{"url":"https://hartvaat.nl/2022/05/03/vupanorsen-en-non-hdl-cholesterol-bij-statinebehandelde-patienten-translate-timi/","title":"Vupanorsen en non-HDL-cholesterol bij statinebehandelde patiënten: TRANSLATE-TIMI 70","title_en":"Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.","published":"2022-05-03"}],"10.1001/jama.2022.5050":[{"url":"https://hartvaat.nl/2022/05/03/korte-interfererende-rna-tegen-lp-a-jama-fase-1-dosisstudie/","title":"Korte interfererende RNA tegen Lp(a): JAMA fase-1 dosisstudie","title_en":"Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.","published":"2022-05-03"}],"10.1161/cir.0000000000001063":[{"url":"https://hartvaat.nl/2022/05/03/2022-aha-acc-hfsa-hartfalenrichtlijn-circulation-editie/","title":"2022 AHA/ACC/HFSA hartfalenrichtlijn: Circulation-editie","title_en":"2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2022-05-03"}],"10.1093/europace/euab267":[{"url":"https://hartvaat.nl/2022/05/03/triventriculaire-pacing-bij-hf-strive-hf-gerandomiseerde-trial/","title":"Triventriculaire pacing bij HF: STRIVE HF gerandomiseerde trial","title_en":"Standard care vs. TRIVEntricular pacing in Heart Failure (STRIVE HF): a prospective multicentre randomized controlled trial of triventricular pacing vs. conventional biventricular pacing in patients with heart failure and intermediate QRS left bundle branch block.","published":"2022-05-03"}],"10.1093/europace/euab314":[{"url":"https://hartvaat.nl/2022/05/03/multimodaliteitsbeeldvorming-geleide-lv-leadplaatsing-bij-crt-langetermijn/","title":"Multimodaliteitsbeeldvorming-geleide LV-leadplaatsing bij CRT: langetermijn","title_en":"Long-term outcomes in a randomized controlled trial of multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy.","published":"2022-05-03"}],"10.1093/europace/euab266":[{"url":"https://hartvaat.nl/2022/05/03/af-risico-bij-laag-matig-alcoholgebruik-naar-geslacht-en-regio-meta-analyse/","title":"AF-risico bij laag-matig alcoholgebruik naar geslacht en regio: meta-analyse","title_en":"Risk of incident atrial fibrillation with low-to-moderate alcohol consumption is associated with gender, region, alcohol category: a systematic review and meta-analysis.","published":"2022-05-03"}],"10.1093/europace/euab253":[{"url":"https://hartvaat.nl/2022/05/03/radiale-strain-geleide-leadplaatsing-voor-crt-bij-ischemisch-hf/","title":"Radiale strain geleide leadplaatsing voor CRT bij ischemisch HF","title_en":"Radial strain imaging-guided lead placement for improving response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy: the Raise CRT trial.","published":"2022-05-03"}],"10.1093/eurheartj/ehac026":[{"url":"https://hartvaat.nl/2022/05/01/nierdisfunctie-en-uitkomsten-bij-hf-met-mr-coapt/","title":"Nierdisfunctie en uitkomsten bij HF met MR: COAPT","title_en":"Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.","published":"2022-05-01"}],"10.1161/hypertensionaha.121.18369":[{"url":"https://hartvaat.nl/2022/05/01/antihypertensivaklasse-en-uitkomsten-in-sprint/","title":"Antihypertensivaklasse en uitkomsten in SPRINT","title_en":"Impact of Antihypertensive Drug Class on Outcomes in SPRINT.","published":"2022-05-01"}],"10.1161/hypertensionaha.121.18773":[{"url":"https://hartvaat.nl/2022/05/01/risicostratificatie-door-kruisclassificatie-van-centrale-en-brachiale-systolisch/","title":"Risicostratificatie door kruisclassificatie van centrale en brachiale systolische bloeddruk","title_en":"Risk Stratification by Cross-Classification of Central and Brachial Systolic Blood Pressure.","published":"2022-05-01"}],"10.1161/hypertensionaha.121.18255":[{"url":"https://hartvaat.nl/2022/05/01/antihypertensieve-behandeling-en-cerebrale-bloedflow-meta-analyse/","title":"Antihypertensieve behandeling en cerebrale bloedflow: meta-analyse","title_en":"Effect of Antihypertensive Treatment on Cerebral Blood Flow in Older Adults: a Systematic Review and Meta-Analysis.","published":"2022-05-01"}],"10.1136/heartjnl-2021-319455":[{"url":"https://hartvaat.nl/2022/05/01/remote-ischemische-conditionering-bij-stemi-registergebaseerde-gerandomiseerde-t/","title":"Remote ischemische conditionering bij STEMI: registergebaseerde gerandomiseerde trial","title_en":"Remote ischaemic conditioning in ST elevation myocardial infarction: a registry-based randomised trial.","published":"2022-05-01"}],"10.1016/s0140-6736(22)00367-1":[{"url":"https://hartvaat.nl/2022/04/30/abiraterone-bij-gemetastaseerd-castratiegevoelig-prostaatkanker-peace-1/","title":"Abiraterone bij gemetastaseerd castratiegevoelig prostaatkanker: PEACE-1","title_en":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.","published":"2022-04-30"}],"10.1001/jama.2022.4983":[{"url":"https://hartvaat.nl/2022/04/26/aspirine-voor-cv-preventie-uspstf-aanbeveling-2022/","title":"Aspirine voor CV-preventie: USPSTF aanbeveling 2022","title_en":"Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.","published":"2022-04-26"}],"10.1016/j.jacc.2022.01.049":[{"url":"https://hartvaat.nl/2022/04/19/externe-validatie-van-de-freedom-score-voor-pci-versus-cabg/","title":"Externe validatie van de FREEDOM-score voor PCI versus CABG","title_en":"External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI.","published":"2022-04-19"}],"10.1016/j.jacc.2022.01.050":[{"url":"https://hartvaat.nl/2022/04/19/substraatablatie-versus-antiaritmica-bij-symptomatische-vt/","title":"Substraatablatie versus antiaritmica bij symptomatische VT","title_en":"Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.","published":"2022-04-19"}],"10.1161/circulationaha.121.056663":[{"url":"https://hartvaat.nl/2022/04/19/therapeutische-doelen-voor-hf-via-proteomics-en-mendeliaanse-randomisatie/","title":"Therapeutische doelen voor HF via proteomics en Mendeliaanse randomisatie","title_en":"Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.","published":"2022-04-19"}],"10.1093/eurheartj/ehab804":[{"url":"https://hartvaat.nl/2022/04/19/alirocumab-na-acs-bij-patienten-met-hf-voorgeschiedenis-odyssey-outcomes/","title":"Alirocumab na ACS bij patiënten met HF-voorgeschiedenis: ODYSSEY OUTCOMES","title_en":"Alirocumab after acute coronary syndrome in patients with a history of heart failure.","published":"2022-04-19"}],"10.1093/eurheartj/ehab775":[{"url":"https://hartvaat.nl/2022/04/19/coronaire-flowreserve-en-cardiovasculaire-uitkomsten-meta-analyse/","title":"Coronaire flowreserve en cardiovasculaire uitkomsten: meta-analyse","title_en":"Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis.","published":"2022-04-19"}],"10.1016/s0140-6736(22)00455-x":[{"url":"https://hartvaat.nl/2022/04/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-langetermijn/","title":"Renale denervatie met antihypertensiva: Lancet SPYRAL HTN-ON MED langetermijn","title_en":"Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.","published":"2022-04-09"}],"10.1016/s0140-6736(22)00456-1":[{"url":"https://hartvaat.nl/2022/04/09/asundexian-factor-xia-remmer-versus-apixaban-bij-af-lancet-pacific-af/","title":"Asundexian (factor XIa-remmer) versus apixaban bij AF: Lancet PACIFIC-AF","title_en":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.","published":"2022-04-09"}],"10.1016/s0140-6736(22)00369-5":[{"url":"https://hartvaat.nl/2022/04/09/natriumreductie-100-mmol-bij-hartfalen-lancet-sodium-hf/","title":"Natriumreductie <100 mmol bij hartfalen: Lancet SODIUM-HF","title_en":"Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial.","published":"2022-04-09"}],"10.1093/eurheartj/ehab820":[{"url":"https://hartvaat.nl/2022/04/06/apoc-iii-reductie-bij-matige-hypertriglyceridemie-met-hoog-cv-risico/","title":"ApoC-III-reductie bij matige hypertriglyceridemie met hoog CV-risico","title_en":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.","published":"2022-04-06"}],"10.1093/eurheartj/ehab832":[{"url":"https://hartvaat.nl/2022/04/06/nierfunctiebeoordeling-en-eindpuntbepaling-in-klinische-trials-ehj/","title":"Nierfunctiebeoordeling en eindpuntbepaling in klinische trials: EHJ","title_en":"Kidney function assessment and endpoint ascertainment in clinical trials.","published":"2022-04-06"}],"10.1093/eurheartj/ehab863":[{"url":"https://hartvaat.nl/2022/04/06/langetermijn-veiligheid-en-werkzaamheid-van-anacetrapib-ehj/","title":"Langetermijn veiligheid en werkzaamheid van anacetrapib: EHJ","title_en":"Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.","published":"2022-04-06"}],"10.1093/europace/euab200":[{"url":"https://hartvaat.nl/2022/04/05/antistolling-comorbiditeitsbehandeling-en-vroege-ritmecontrole-east-afnet-4-patr/","title":"Antistolling, comorbiditeitsbehandeling en vroege ritmecontrole: EAST-AFNET 4 patronen","title_en":"Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial.","published":"2022-04-05"}],"10.1001/jamacardio.2022.0052":[{"url":"https://hartvaat.nl/2022/04/01/prasugrel-dosis-de-escalatie-na-complexe-pci-bij-acs-jama-cardiology/","title":"Prasugrel dosis-de-escalatie na complexe PCI bij ACS: JAMA Cardiology","title_en":"Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial.","published":"2022-04-01"}],"10.1001/jamacardio.2021.5244":[{"url":"https://hartvaat.nl/2022/04/01/clopidogrel-monotherapie-na-1-2-maanden-dapt-versus-12-maanden-dapt-jama-cardiol/","title":"Clopidogrel monotherapie na 1-2 maanden DAPT versus 12 maanden DAPT: JAMA Cardiology","title_en":"Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.","published":"2022-04-01"}],"10.1002/ehf2.13805":[{"url":"https://hartvaat.nl/2022/04/01/sglt2-remmers-bij-hfref-of-hfpef-meta-analyse/","title":"SGLT2-remmers bij HFrEF of HFpEF: meta-analyse","title_en":"Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.","published":"2022-04-01"}],"10.1002/ehf2.13810":[{"url":"https://hartvaat.nl/2022/04/01/icd-bij-niet-ischemisch-systolisch-hf-met-coronaire-atherosclerose-danish/","title":"ICD bij niet-ischemisch systolisch HF met coronaire atherosclerose: DANISH","title_en":"Effect of implantable cardioverter-defibrillators in patients with non-ischaemic systolic heart failure and concurrent coronary atherosclerosis.","published":"2022-04-01"}],"10.1002/ehf2.13822":[{"url":"https://hartvaat.nl/2022/04/01/glucoseverlagende-middelen-bij-niet-diabetisch-hf-bayesiaanse-netwerkmeta-analys/","title":"Glucoseverlagende middelen bij niet-diabetisch HF: Bayesiaanse netwerkmeta-analyse","title_en":"Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis.","published":"2022-04-01"}],"10.1161/hypertensionaha.121.18348":[{"url":"https://hartvaat.nl/2022/04/01/dpp-4-remming-en-catecholamines-tijdens-ace-remming/","title":"DPP-4-remming en catecholamines tijdens ACE-remming","title_en":"DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.","published":"2022-04-01"}],"10.1002/ehf2.13786":[{"url":"https://hartvaat.nl/2022/04/01/5-jaarsfollow-up-van-intracoronaire-celtherapie-na-mi-regenerate-ami/","title":"5-jaarsfollow-up van intracoronaire celtherapie na MI: REGENERATE-AMI","title_en":"Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trial.","published":"2022-04-01"}],"10.1002/ehf2.13785":[{"url":"https://hartvaat.nl/2022/04/01/robuustheid-van-sglt2-remmer-hf-trials-evaluatie/","title":"Robuustheid van SGLT2-remmer HF-trials: evaluatie","title_en":"Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.","published":"2022-04-01"}],"10.1093/eurheartj/ehab790":[{"url":"https://hartvaat.nl/2022/03/31/amphilimus-versus-zotarolimus-stents-bij-diabetes-sugar-gerandomiseerde-trial/","title":"Amphilimus versus zotarolimus stents bij diabetes: SUGAR gerandomiseerde trial","title_en":"Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.","published":"2022-03-31"}],"10.1093/eurheartj/ehab537":[{"url":"https://hartvaat.nl/2022/03/31/enkele-of-meervoudige-arteriele-cabg-versus-pci-bij-drievaten-hoofdstam-meta-ana/","title":"Enkele of meervoudige arteriële CABG versus PCI bij drievaten/hoofdstam: meta-analyse","title_en":"Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease.","published":"2022-03-31"}],"10.1161/circulationaha.121.057014":[{"url":"https://hartvaat.nl/2022/03/29/af-screening-bij-ouderen-in-de-huisartsenpraktijk-vital-af-gerandomiseerde-trial/","title":"AF-screening bij ouderen in de huisartsenpraktijk: VITAL-AF gerandomiseerde trial","title_en":"Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial.","published":"2022-03-29"}],"10.1161/circulationaha.120.045373":[{"url":"https://hartvaat.nl/2022/03/29/insuline-voorkomt-hypercholesterolemie-via-12-gehydroxyleerde-galzuren/","title":"Insuline voorkomt hypercholesterolemie via 12α-gehydroxyleerde galzuren","title_en":"Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.","published":"2022-03-29"}],"10.1016/j.jacc.2021.12.032":[{"url":"https://hartvaat.nl/2022/03/22/pelacarsen-op-lp-a-cholesterol-en-gecorrigeerd-ldl-cholesterol/","title":"Pelacarsen op Lp(a)-cholesterol en gecorrigeerd LDL-cholesterol","title_en":"Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol.","published":"2022-03-22"}],"10.1161/circulationaha.121.056320":[{"url":"https://hartvaat.nl/2022/03/22/mri-hersenlaesies-en-cognitie-bij-af-na-laa-ablatie/","title":"MRI-hersenlaesies en cognitie bij AF na LAA-ablatie","title_en":"MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial.","published":"2022-03-22"}],"10.1093/eurheartj/ehab593":[{"url":"https://hartvaat.nl/2022/03/21/vroege-ritmecontrole-bij-af-met-of-zonder-symptomen-east-afnet-4/","title":"Vroege ritmecontrole bij AF met of zonder symptomen: EAST-AFNET 4","title_en":"Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial.","published":"2022-03-21"}],"10.1016/j.jacc.2021.12.030":[{"url":"https://hartvaat.nl/2022/03/15/5-jaars-ifr-versus-ffr-geleide-pci-define-flair-ifr-swedeheart/","title":"5-jaars iFR versus FFR-geleide PCI: DEFINE-FLAIR/iFR-SWEDEHEART","title_en":"5-Year Outcomes of PCI Guided by Measurement of Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve.","published":"2022-03-15"}],"10.1161/circulationaha.121.055297":[{"url":"https://hartvaat.nl/2022/03/15/leeftijd-en-uitkomsten-van-katheterablatie-versus-medicatie-bij-af-cabana/","title":"Leeftijd en uitkomsten van katheterablatie versus medicatie bij AF: CABANA","title_en":"Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial.","published":"2022-03-15"}],"10.1161/circulationaha.121.056464":[{"url":"https://hartvaat.nl/2022/03/08/periodieke-repolarisatiedynamiek-identificeert-icd-responders-bij-nicm-danish/","title":"Periodieke repolarisatiedynamiek identificeert ICD-responders bij NICM: DANISH","title_en":"Periodic Repolarization Dynamics Identifies ICD Responders in Nonischemic Cardiomyopathy: A DANISH Substudy.","published":"2022-03-08"}],"10.1161/circulationaha.121.057859":[{"url":"https://hartvaat.nl/2022/03/08/amulet-versus-watchman-voor-laa-sluiting-swiss-apero-gerandomiseerde-trial/","title":"Amulet versus Watchman voor LAA-sluiting: SWISS-APERO gerandomiseerde trial","title_en":"Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial.","published":"2022-03-08"}],"10.1093/eurheartj/ehab836":[{"url":"https://hartvaat.nl/2022/03/07/geleide-versus-potente-p2y12-therapie-bij-acs-netwerkmeta-analyse-van-61-898-pat/","title":"Geleide versus potente P2Y12-therapie bij ACS: netwerkmeta-analyse van 61.898 patiënten","title_en":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.","published":"2022-03-07"}],"10.1093/europace/euab186":[{"url":"https://hartvaat.nl/2022/03/02/kenmerken-van-patienten-met-atriale-high-rate-episodes-bij-icd-crt/","title":"Kenmerken van patiënten met atriale high-rate episodes bij ICD/CRT","title_en":"Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices.","published":"2022-03-02"}],"10.1093/europace/euab191":[{"url":"https://hartvaat.nl/2022/03/02/frequentiecontrolemiddelen-verschillen-in-preventie-van-af-progressie/","title":"Frequentiecontrolemiddelen verschillen in preventie van AF-progressie","title_en":"Rate control drugs differ in the prevention of progression of atrial fibrillation.","published":"2022-03-02"}],"10.1161/circulationaha.121.057190":[{"url":"https://hartvaat.nl/2022/03/01/edoxaban-15-mg-naar-nierfunctie-bij-zeer-oude-af-eldercare-subanalyse/","title":"Edoxaban 15 mg naar nierfunctie bij zeer oude AF: ELDERCARE subanalyse","title_en":"Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial.","published":"2022-03-01"}],"10.1161/hypertensionaha.121.18415":[{"url":"https://hartvaat.nl/2022/03/01/orale-antihypertensiva-bij-niet-ernstige-zwangerschapshypertensie-netwerkmeta-an/","title":"Orale antihypertensiva bij niet-ernstige zwangerschapshypertensie: netwerkmeta-analyse","title_en":"Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses.","published":"2022-03-01"}],"10.1161/circulationaha.121.056546":[{"url":"https://hartvaat.nl/2022/03/01/bloeddruk-hypertensie-en-risico-op-aortadissectie-j-sch-en-uk-biobank/","title":"Bloeddruk, hypertensie en risico op aortadissectie: J-SCH en UK Biobank","title_en":"Blood Pressure, Hypertension, and the Risk of Aortic Dissection Incidence and Mortality: Results From the J-SCH Study, the UK Biobank Study, and a Meta-Analysis of Cohort Studies.","published":"2022-03-01"}],"10.1016/j.jacc.2021.08.078":[{"url":"https://hartvaat.nl/2022/02/22/temporaire-ruggenmergstimulatie-ter-preventie-van-postoperatief-af/","title":"Temporaire ruggenmergstimulatie ter preventie van postoperatief AF","title_en":"Temporary Spinal Cord Stimulation to Prevent Postcardiac Surgery Atrial Fibrillation: 30-Day Safety and Efficacy Outcomes.","published":"2022-02-22"}],"10.1016/s0140-6736(22)00018-6":[{"url":"https://hartvaat.nl/2022/02/19/faricimab-bij-diabetisch-maculaoedeem-met-verlengde-dosering-lancet/","title":"Faricimab bij diabetisch maculaoedeem met verlengde dosering: Lancet","title_en":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.","published":"2022-02-19"}],"10.1093/eurheartj/ehab777":[{"url":"https://hartvaat.nl/2022/02/10/finerenon-cv-en-renale-uitkomsten-bij-diabetes-met-ckd-fidelity-gepoolde-analyse/","title":"Finerenon CV en renale uitkomsten bij diabetes met CKD: FIDELITY gepoolde analyse","title_en":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.","published":"2022-02-10"}],"10.1093/eurheartj/ehab644":[{"url":"https://hartvaat.nl/2022/02/10/propionaat-vermindert-atherosclerose-via-immuunregulatie-van-intestinaal-cholest/","title":"Propionaat vermindert atherosclerose via immuunregulatie van intestinaal cholesterolmetabolisme","title_en":"Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism.","published":"2022-02-10"}],"10.1161/circulationaha.121.057909":[{"url":"https://hartvaat.nl/2022/02/08/1-jaars-cv-events-bij-restrictieve-versus-liberale-transfusie-na-acuut-mi-realit/","title":"1-jaars CV-events bij restrictieve versus liberale transfusie na acuut MI: REALITY","title_en":"One-Year Major Cardiovascular Events After Restrictive Versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Trial.","published":"2022-02-08"}],"10.1016/j.jacc.2021.11.027":[{"url":"https://hartvaat.nl/2022/02/08/stress-cardiale-biomarkers-en-cv-renale-uitkomsten-bij-canagliflozine/","title":"Stress cardiale biomarkers en CV/renale uitkomsten bij canagliflozine","title_en":"Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.","published":"2022-02-08"}],"10.1016/j.jacc.2021.11.035":[{"url":"https://hartvaat.nl/2022/02/08/antitrombotische-therapie-bij-af-na-acs-of-pci-jacc-overzicht/","title":"Antitrombotische therapie bij AF na ACS of PCI: JACC overzicht","title_en":"Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.","published":"2022-02-08"}],"10.1161/circulationaha.121.057983":[{"url":"https://hartvaat.nl/2022/02/08/finerenon-vermindert-incident-hf-bij-ckd-met-diabetes-fidelity/","title":"Finerenon vermindert incident HF bij CKD met diabetes: FIDELITY","title_en":"Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.","published":"2022-02-08"}],"10.1093/europace/euab281":[{"url":"https://hartvaat.nl/2022/02/02/cryoballon-versus-rf-bij-persisterend-af-noorse-no-pers-af-gerandomiseerde-trial/","title":"Cryoballon versus RF bij persisterend AF: Noorse NO-PERS AF gerandomiseerde trial","title_en":"Cryoballoon vs. radiofrequency catheter ablation: insights from NOrwegian randomized study of PERSistent Atrial Fibrillation (NO-PERSAF study).","published":"2022-02-02"}],"10.1093/europace/euab221":[{"url":"https://hartvaat.nl/2022/02/02/remote-monitoring-en-klinische-uitkomsten-bij-europese-hf-met-icd-langetermijn/","title":"Remote monitoring en klinische uitkomsten bij Europese HF met ICD: langetermijn","title_en":"Effect of remote monitoring on clinical outcomes in European heart failure patients with an implantable cardioverter-defibrillator: secondary results of the REMOTE-CIED randomized trial.","published":"2022-02-02"}],"10.1093/europace/euab170":[{"url":"https://hartvaat.nl/2022/02/02/thuismonitoring-temporele-trends-en-baseline-risico-voor-hf-voorspelling-bij-icd/","title":"Thuismonitoring temporele trends en baseline risico voor HF-voorspelling bij ICD","title_en":"Combining home monitoring temporal trends from implanted defibrillators and baseline patient risk profile to predict heart failure hospitalizations: results from the SELENE HF study.","published":"2022-02-02"}],"10.1001/jama.2021.24776":[{"url":"https://hartvaat.nl/2022/02/01/matige-hypothermie-versus-normothermie-bij-cardiogene-shock-met-va-ecmo-jama-hyp/","title":"Matige hypothermie versus normothermie bij cardiogene shock met VA-ECMO: JAMA HYPERION2","title_en":"Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical Trial.","published":"2022-02-01"}],"10.1001/jamacardio.2021.4836":[{"url":"https://hartvaat.nl/2022/02/01/economische-uitkomsten-van-revalidatie-bij-ouderen-met-acuut-hf-rehab-hf/","title":"Economische uitkomsten van revalidatie bij ouderen met acuut HF: REHAB-HF","title_en":"Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial: A Secondary Analysis of a Randomized Clinical Trial.","published":"2022-02-01"}],"10.1001/jamacardio.2021.4822":[{"url":"https://hartvaat.nl/2022/02/01/optimalisatie-van-trainingsrespons-voor-vrouwen-in-hartrevalidatie-jama-cardiolo/","title":"Optimalisatie van trainingsrespons voor vrouwen in hartrevalidatie: JAMA Cardiology","title_en":"Optimizing Training Response for Women in Cardiac Rehabilitation: A Randomized Clinical Trial.","published":"2022-02-01"}],"10.1001/jamacardio.2021.5010":[{"url":"https://hartvaat.nl/2022/02/01/geindividualiseerde-triggerstudies-bij-paroxysmaal-af-jama-i-stop-afib/","title":"Geïndividualiseerde triggerstudies bij paroxysmaal AF: JAMA I-STOP-AFib","title_en":"Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation: The I-STOP-AFib Randomized Clinical Trial.","published":"2022-02-01"}],"10.1002/ehf2.13683":[{"url":"https://hartvaat.nl/2022/02/01/luseogliflozine-en-geschat-plasmavolume-bij-hfpef/","title":"Luseogliflozine en geschat plasmavolume bij HFpEF","title_en":"Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction.","published":"2022-02-01"}],"10.1161/hypertensionaha.121.18123":[{"url":"https://hartvaat.nl/2022/02/01/myocardiale-mechanica-bij-hypertensieve-zwangerschapsaandoeningen-meta-analyse/","title":"Myocardiale mechanica bij hypertensieve zwangerschapsaandoeningen: meta-analyse","title_en":"Myocardial Mechanics in Hypertensive Disorders of Pregnancy: a Systematic Review and Meta-Analysis.","published":"2022-02-01"}],"10.1002/ehf2.13733":[{"url":"https://hartvaat.nl/2022/02/01/sekse-en-gender-in-crt-studies-systematische-review/","title":"Sekse en gender in CRT-studies: systematische review","title_en":"Integrating sex and gender in studies of cardiac resynchronization therapy: a systematic review.","published":"2022-02-01"}],"10.1136/heartjnl-2021-319773":[{"url":"https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/","title":"CCTA-afgeleide FFR: prognostische waarde — meta-analyse","title_en":"Prognostic value of coronary computed tomography angiographic derived fractional flow reserve: a systematic review and meta-analysis.","published":"2022-02-01"}],"10.1001/jama.2021.21811":[{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-geactualiseerde-evidence-report-2022/","title":"Screening op AF: USPSTF geactualiseerde evidence report 2022","title_en":"Screening for Atrial Fibrillation: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2022-01-25"}],"10.1001/jama.2021.23732":[{"url":"https://hartvaat.nl/2022/01/25/screening-op-af-uspstf-aanbeveling-2022/","title":"Screening op AF: USPSTF aanbeveling 2022","title_en":"Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement.","published":"2022-01-25"}],"10.1161/circulationaha.121.056355":[{"url":"https://hartvaat.nl/2022/01/25/doac-s-versus-warfarine-bij-af-patient-niveau-netwerkmeta-analyse-van-gerandomis/","title":"DOAC's versus warfarine bij AF: patiënt-niveau netwerkmeta-analyse van gerandomiseerde trials","title_en":"Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.","published":"2022-01-25"}],"10.1016/j.jacc.2021.09.005":[{"url":"https://hartvaat.nl/2022/01/18/2021-acc-aha-scai-richtlijn-voor-coronaire-revascularisatie-executive-summary/","title":"2021 ACC/AHA/SCAI richtlijn voor coronaire revascularisatie: executive summary","title_en":"2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","published":"2022-01-18"}],"10.1016/j.jacc.2021.10.028":[{"url":"https://hartvaat.nl/2022/01/18/magnetisch-gecontroleerde-capsule-endoscopie-voor-antiplaatjestherapie-gi-schade/","title":"Magnetisch gecontroleerde capsule-endoscopie voor antiplaatjestherapie GI-schade","title_en":"Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy-Induced Gastrointestinal Injury.","published":"2022-01-18"}],"10.1056/nejmoa2112299":[{"url":"https://hartvaat.nl/2022/01/13/ffr-geleide-pci-versus-cabg-nejm-fame-3/","title":"FFR-geleide PCI versus CABG: NEJM FAME 3","title_en":"Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery.","published":"2022-01-13"}],"10.1093/eurheartj/ehab581":[{"url":"https://hartvaat.nl/2022/01/13/risicofactoren-voor-type-1-en-type-2-mi/","title":"Risicofactoren voor type 1 en type 2 MI","title_en":"Risk factors for type 1 and type 2 myocardial infarction.","published":"2022-01-13"}],"10.1016/j.jacc.2021.10.023":[{"url":"https://hartvaat.nl/2022/01/04/4-jaars-laa-sluiting-versus-niet-warfarine-oac-bij-af/","title":"4-jaars LAA-sluiting versus niet-warfarine OAC bij AF","title_en":"4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation.","published":"2022-01-04"}],"10.1093/europace/euab177":[{"url":"https://hartvaat.nl/2022/01/04/sglt2-remmers-en-plotse-hartdood-ventriculaire-aritmie-meta-analyse/","title":"SGLT2-remmers en plotse hartdood/ventriculaire aritmie: meta-analyse","title_en":"Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.","published":"2022-01-04"}],"10.1093/europace/euab133":[{"url":"https://hartvaat.nl/2022/01/04/enkele-freeze-cryoballonablatie-bij-af-ehra-systematische-review/","title":"Enkele freeze cryoballonablatie bij AF: EHRA systematische review","title_en":"Effectiveness and safety of a single freeze strategy of cryoballoon ablation of atrial fibrillation: an EHRA systematic review and meta-analysis.","published":"2022-01-04"}],"10.1001/jamacardio.2021.4567":[{"url":"https://hartvaat.nl/2022/01/01/sacubitril-valsartan-bij-gevorderd-hfref-jama-cardiology-life-gerandomiseerde-tr/","title":"Sacubitril/valsartan bij gevorderd HFrEF: JAMA Cardiology LIFE gerandomiseerde trial","title_en":"Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.","published":"2022-01-01"}],"10.1001/jamacardio.2021.4027":[{"url":"https://hartvaat.nl/2022/01/01/omecamtiv-mecarbil-bij-ernstig-hf-galactic-hf-post-hoc-analyse/","title":"Omecamtiv mecarbil bij ernstig HF: GALACTIC-HF post-hoc analyse","title_en":"Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.","published":"2022-01-01"}],"10.1161/hypertensionaha.121.18192":[{"url":"https://hartvaat.nl/2022/01/01/farmacologische-hypertensiebehandeling-bij-volwassenen-who-richtlijn-samenvattin/","title":"Farmacologische hypertensiebehandeling bij volwassenen: WHO-richtlijn samenvatting","title_en":"Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary.","published":"2022-01-01"}],"10.1136/heartjnl-2021-319185":[{"url":"https://hartvaat.nl/2022/01/01/sglt2-remmers-over-het-cv-ziektespectrum-overzicht/","title":"SGLT2-remmers over het CV-ziektespectrum: overzicht","title_en":"Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases.","published":"2022-01-01"}],"10.1136/heartjnl-2020-318654":[{"url":"https://hartvaat.nl/2022/01/01/telomeerlengte-en-mortaliteit-bij-chronisch-hartfalen/","title":"Telomeerlengte en mortaliteit bij chronisch hartfalen","title_en":"Telomere length is independently associated with all-cause mortality in chronic heart failure.","published":"2022-01-01"}],"10.1056/nejmoa2108793":[{"url":"https://hartvaat.nl/2021/12/30/dolutegravir-als-eerste-of-tweedelijnbehandeling-voor-hiv-1-bij-kinderen-nejm/","title":"Dolutegravir als eerste- of tweedelijnbehandeling voor HIV-1 bij kinderen: NEJM","title_en":"Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.","published":"2021-12-30"}],"10.1056/nejmoa2110730":[{"url":"https://hartvaat.nl/2021/12/30/chlorthalidon-bij-hypertensie-met-gevorderde-ckd-nejm-click/","title":"Chlorthalidon bij hypertensie met gevorderde CKD: NEJM CLICK","title_en":"Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.","published":"2021-12-30"}],"10.1056/nejmoa2101909":[{"url":"https://hartvaat.nl/2021/12/30/angiografie-na-buitenziekenhuis-hartstilstand-zonder-st-elevatie-nejm-tomahawk/","title":"Angiografie na buitenziekenhuis-hartstilstand zonder ST-elevatie: NEJM TOMAHAWK","title_en":"Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation.","published":"2021-12-30"}],"10.1093/eurheartj/ehab441":[{"url":"https://hartvaat.nl/2021/12/28/10-jaars-mortaliteit-na-pci-of-cabg-bij-diabetes-met-complex-coronairlijden/","title":"10-jaars mortaliteit na PCI of CABG bij diabetes met complex coronairlijden","title_en":"Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease.","published":"2021-12-28"}],"10.1093/eurheartj/ehab504":[{"url":"https://hartvaat.nl/2021/12/28/sekseverschillen-na-cabg-gepoolde-ipd-analyse/","title":"Sekseverschillen na CABG: gepoolde IPD analyse","title_en":"Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data.","published":"2021-12-28"}],"10.1161/circulationaha.121.055654":[{"url":"https://hartvaat.nl/2021/12/21/langdurige-omega-3-suppletie-en-af-risico-meta-analyse-van-cv-trials/","title":"Langdurige omega-3 suppletie en AF-risico: meta-analyse van CV-trials","title_en":"Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.","published":"2021-12-21"}],"10.1093/eurheartj/ehab411":[{"url":"https://hartvaat.nl/2021/12/21/iv-ijzercarboxymaltose-en-cardiale-reverse-remodellering-na-crt-iron-crt/","title":"IV ijzercarboxymaltose en cardiale reverse remodellering na CRT: IRON-CRT","title_en":"The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.","published":"2021-12-21"}],"10.1016/s0140-6736(21)02334-5":[{"url":"https://hartvaat.nl/2021/12/18/pci-met-des-versus-cabg-bij-hoofdstamlijden-lancet-precombat-10-jaars/","title":"PCI met DES versus CABG bij hoofdstamlijden: Lancet PRECOMBAT 10-jaars","title_en":"Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.","published":"2021-12-18"}],"10.1056/nejmoa2113380":[{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-niet-dialysepatienten-nejm/","title":"Daprodustat bij anemie bij niet-dialysepatiënten: NEJM","title_en":"Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.","published":"2021-12-16"}],"10.1056/nejmoa2113379":[{"url":"https://hartvaat.nl/2021/12/16/daprodustat-bij-anemie-bij-dialysepatienten-nejm/","title":"Daprodustat bij anemie bij dialysepatiënten: NEJM","title_en":"Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.","published":"2021-12-16"}],"10.1016/s0140-6736(21)02248-0":[{"url":"https://hartvaat.nl/2021/12/11/qfr-geleide-coronaire-interventie-lancet-favor-iii-china-sham-gecontroleerd/","title":"QFR-geleide coronaire interventie: Lancet FAVOR III China sham-gecontroleerd","title_en":"Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.","published":"2021-12-11"}],"10.1056/nejmoa2110956":[{"url":"https://hartvaat.nl/2021/12/09/finerenon-bij-nierziekte-met-diabetes-type-2-nejm-figaro-dkd/","title":"Finerenon bij nierziekte met diabetes type 2: NEJM FIGARO-DKD","title_en":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.","published":"2021-12-09"}],"10.1093/eurheartj/ehab569":[{"url":"https://hartvaat.nl/2021/12/07/av-junctieablatie-plus-crt-bij-permanent-af-met-smal-qrs-apaf-crt-mortaliteitsan/","title":"AV-junctieablatie plus CRT bij permanent AF met smal QRS: APAF-CRT mortaliteitsanalyse","title_en":"AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial.","published":"2021-12-07"}],"10.1093/europace/euab175":[{"url":"https://hartvaat.nl/2021/12/07/minimaal-onderbroken-versus-continue-doac-bij-af-ablatie-meta-analyse/","title":"Minimaal onderbroken versus continue DOAC bij AF-ablatie: meta-analyse","title_en":"Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation.","published":"2021-12-07"}],"10.1093/europace/euab168":[{"url":"https://hartvaat.nl/2021/12/07/gold-force-multi-elektrode-rf-versus-irrigated-rf-bij-af-gerandomiseerde-trial/","title":"GOLD FORCE multi-elektrode RF versus irrigated RF bij AF: gerandomiseerde trial","title_en":"Efficacy and safety of the GOLD FORCE multicentre randomized clinical trial: multielectrode phased radiofrequency vs. irrigated radiofrequency single-tip catheter with contact force ablation for treatment of symptomatic paroxysmal atrial fibrillation.","published":"2021-12-07"}],"10.1016/s0140-6736(21)02490-9":[{"url":"https://hartvaat.nl/2021/12/04/posterieure-pericardiotomie-ter-preventie-van-af-na-hartchirurgie-lancet-palacs/","title":"Posterieure pericardiotomie ter preventie van AF na hartchirurgie: Lancet PALACS","title_en":"Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial.","published":"2021-12-04"}],"10.1056/nejmoa2111016":[{"url":"https://hartvaat.nl/2021/12/02/edoxaban-versus-vka-bij-af-na-tavr-nejm-envisage-tavi-af/","title":"Edoxaban versus VKA bij AF na TAVR: NEJM ENVISAGE-TAVI AF","title_en":"Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.","published":"2021-12-02"}],"10.1093/eurheartj/ehab702":[{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-hoog-bloedingsrisico-na-pci-twilight-hbr/","title":"Ticagrelor monotherapie bij hoog bloedingsrisico na PCI: TWILIGHT-HBR","title_en":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.","published":"2021-12-01"}],"10.1001/jamacardio.2021.3651":[{"url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-uitgebreide-fda-labeling-jama-cardiology-implicaties/","title":"Sacubitril/valsartan uitgebreide FDA-labeling: JAMA Cardiology implicaties","title_en":"Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.","published":"2021-12-01"}],"10.1001/jamacardio.2021.3187":[{"url":"https://hartvaat.nl/2021/12/01/hs-troponine-en-natriuretische-peptiden-na-intensieve-bp-verlaging-sprint-biomar/","title":"hs-troponine en natriuretische peptiden na intensieve BP-verlaging: SPRINT-biomarkers","title_en":"Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial.","published":"2021-12-01"}],"10.1093/eurheartj/ehab533":[{"url":"https://hartvaat.nl/2021/12/01/ticagrelor-monotherapie-bij-ckd-na-pci-twilight-ckd/","title":"Ticagrelor monotherapie bij CKD na PCI: TWILIGHT-CKD","title_en":"Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD.","published":"2021-12-01"}],"10.1093/eurheartj/ehab433":[{"url":"https://hartvaat.nl/2021/12/01/thin-cap-fibroatheroom-voorspelt-events-bij-diabetes-met-normale-ffr-combine-oct/","title":"Thin-cap fibroatheroom voorspelt events bij diabetes met normale FFR: COMBINE OCT-FFR","title_en":"Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial.","published":"2021-12-01"}],"10.1093/eurheartj/ehab449":[{"url":"https://hartvaat.nl/2021/12/01/post-stenting-ffr-versus-angiografie-voor-pci-optimalisatie-target-ffr/","title":"Post-stenting FFR versus angiografie voor PCI-optimalisatie: TARGET-FFR","title_en":"Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR).","published":"2021-12-01"}],"10.1093/eurheartj/ehab246":[{"url":"https://hartvaat.nl/2021/12/01/cardiale-mortaliteit-bij-electieve-revascularisatie-plus-medicamenteus-versus-me/","title":"Cardiale mortaliteit bij electieve revascularisatie plus medicamenteus versus medicamenteus alleen: meta-analyse","title_en":"Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis.","published":"2021-12-01"}],"10.1161/hypertensionaha.121.18099":[{"url":"https://hartvaat.nl/2021/12/01/acute-aerobe-training-en-kortdurende-ambulante-bloeddrukreductie-bij-hypertensie/","title":"Acute aerobe training en kortdurende ambulante bloeddrukreductie bij hypertensie: meta-analyse","title_en":"Acute Aerobic Exercise Induces Short-Term Reductions in Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis.","published":"2021-12-01"}],"10.1002/ehf2.13670":[{"url":"https://hartvaat.nl/2021/12/01/intermitterend-levosimendan-bij-gevorderd-hf-laica-studie/","title":"Intermitterend levosimendan bij gevorderd HF: LAICA-studie","title_en":"Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study.","published":"2021-12-01"}],"10.1002/ehf2.13677":[{"url":"https://hartvaat.nl/2021/12/01/sacubitril-valsartan-na-acuut-mi-meta-analyse/","title":"Sacubitril/valsartan na acuut MI: meta-analyse","title_en":"The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.","published":"2021-12-01"}],"10.1002/ehf2.13645":[{"url":"https://hartvaat.nl/2021/12/01/sglt2-remmers-en-cardiale-remodellering-meta-analyse-van-mri-trials/","title":"SGLT2-remmers en cardiale remodellering: meta-analyse van MRI-trials","title_en":"SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials.","published":"2021-12-01"}],"10.1002/ehf2.13557":[{"url":"https://hartvaat.nl/2021/12/01/egfr-variabiliteit-en-uitkomsten-bij-real-world-hf/","title":"eGFR-variabiliteit en uitkomsten bij real-world HF","title_en":"Variability in estimated glomerular filtration rate and patients' outcomes in a real-world heart failure population.","published":"2021-12-01"}],"10.1002/ehf2.13560":[{"url":"https://hartvaat.nl/2021/12/01/lv-dimensies-en-cv-uitkomsten-bij-systolisch-hf-warcef/","title":"LV-dimensies en CV-uitkomsten bij systolisch HF: WARCEF","title_en":"Left ventricular dimensions and cardiovascular outcomes in systolic heart failure: the WARCEF trial.","published":"2021-12-01"}],"10.1002/ehf2.13622":[{"url":"https://hartvaat.nl/2021/12/01/empagliflozine-en-vaatfunctie-bij-chronisch-hf/","title":"Empagliflozine en vaatfunctie bij chronisch HF","title_en":"Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.","published":"2021-12-01"}],"10.1002/ehf2.13516":[{"url":"https://hartvaat.nl/2021/12/01/sms-strategie-bij-patienten-na-recente-hf-opname-studieontwerp/","title":"SMS-strategie bij patiënten na recente HF-opname: studieontwerp","title_en":"Design of a multifaceted strategy based on automated text messaging in patients with recent heart failure admission.","published":"2021-12-01"}],"10.1002/ehf2.13526":[{"url":"https://hartvaat.nl/2021/12/01/hartfalen-en-atriumflutter-systematische-review/","title":"Hartfalen en atriumflutter: systematische review","title_en":"Heart failure and atrial flutter: a systematic review of current knowledge and practices.","published":"2021-12-01"}],"10.1002/ehf2.13593":[{"url":"https://hartvaat.nl/2021/12/01/baseline-parameters-en-1-jaars-qol-bij-hf-na-crt-d-esc-hf/","title":"Baseline parameters en 1-jaars QoL bij HF na CRT-D: ESC HF","title_en":"Influence of baseline parameters on one-year physical, mental, and health-related quality of life in patients with heart failure and preserved ejection fraction.","published":"2021-12-01"}],"10.1016/j.kint.2021.07.024":[{"url":"https://hartvaat.nl/2021/12/01/longechogeleide-behandeling-bij-hemodialysepatienten-met-hoog-cv-risico-gerandom/","title":"Longechogeleide behandeling bij hemodialysepatiënten met hoog CV-risico: gerandomiseerde trial","title_en":"A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk.","published":"2021-12-01"}],"10.1136/heartjnl-2021-319243":[{"url":"https://hartvaat.nl/2021/12/01/predictieve-modellen-voor-cv-en-renale-uitkomsten-bij-diabetes-type-2-meta-analy/","title":"Predictieve modellen voor CV en renale uitkomsten bij diabetes type 2: meta-analyse","title_en":"Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses.","published":"2021-12-01"}],"10.1161/circulationaha.121.055176":[{"url":"https://hartvaat.nl/2021/11/30/voorspellers-van-af-ontwikkeling-bij-embolic-stroke-of-undetermined-source-re-sp/","title":"Voorspellers van AF-ontwikkeling bij embolic stroke of undetermined source: RE-SPECT ESUS","title_en":"Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.","published":"2021-11-30"}],"10.1016/j.jacc.2021.08.073":[{"url":"https://hartvaat.nl/2021/11/23/betablokkerstaken-en-functionele-capaciteit-bij-hfpef/","title":"Bètablokkerstaken en functionele capaciteit bij HFpEF","title_en":"Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction.","published":"2021-11-23"}],"10.1001/jama.2021.18463":[{"url":"https://hartvaat.nl/2021/11/16/sacubitril-valsartan-versus-standaardtherapie-op-nt-probnp-en-inspanningscapacit/","title":"Sacubitril/valsartan versus standaardtherapie op NT-proBNP en inspanningscapaciteit: JAMA PARALLAX","title_en":"Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.","published":"2021-11-16"}],"10.1093/eurheartj/ehab360":[{"url":"https://hartvaat.nl/2021/11/14/regionale-en-etnische-invloeden-op-empagliflozine-bij-hfref-emperor-reduced/","title":"Regionale en etnische invloeden op empagliflozine bij HFrEF: EMPEROR-Reduced","title_en":"Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.","published":"2021-11-14"}],"10.1016/s0140-6736(21)01920-6":[{"url":"https://hartvaat.nl/2021/11/13/bloeddrukverlaging-en-risico-op-diabetes-type-2-lancet-bplttc-ipd-meta-analyse/","title":"Bloeddrukverlaging en risico op diabetes type 2: Lancet BPLTTC IPD meta-analyse","title_en":"Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.","published":"2021-11-13"}],"10.1016/s0140-6736(21)02188-7":[{"url":"https://hartvaat.nl/2021/11/13/tirzepatide-versus-insuline-glargine-bij-diabetes-type-2-met-hoog-cv-risico-lanc/","title":"Tirzepatide versus insuline glargine bij diabetes type 2 met hoog CV-risico: Lancet SURPASS-4","title_en":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.","published":"2021-11-13"}],"10.1056/nejmoa2104508":[{"url":"https://hartvaat.nl/2021/11/11/sacubitril-valsartan-bij-acuut-mi-nejm-paradise-mi/","title":"Sacubitril/valsartan bij acuut MI: NEJM PARADISE-MI","title_en":"Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.","published":"2021-11-11"}],"10.1161/circulationaha.121.054610":[{"url":"https://hartvaat.nl/2021/11/09/colchicine-na-acs-2-jaars-cops-follow-up/","title":"Colchicine na ACS: 2-jaars COPS follow-up","title_en":"Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial.","published":"2021-11-09"}],"10.1016/j.jacc.2021.08.061":[{"url":"https://hartvaat.nl/2021/11/09/ffr-voor-behandeling-van-multivatencoronairlijden-jacc/","title":"FFR voor behandeling van multivatencoronairlijden: JACC","title_en":"Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease.","published":"2021-11-09"}],"10.1093/europace/euab095":[{"url":"https://hartvaat.nl/2021/11/08/preoperatieve-tte-voor-voorspelling-van-postoperatief-af-meta-analyse/","title":"Preoperatieve TTE voor voorspelling van postoperatief AF: meta-analyse","title_en":"Role of pre-operative transthoracic echocardiography in predicting post-operative atrial fibrillation after cardiac surgery: a systematic review of the literature and meta-analysis.","published":"2021-11-08"}],"10.1093/europace/euab110":[{"url":"https://hartvaat.nl/2021/11/08/closed-loop-stimulatie-en-cardiopulmonale-variabelen-bij-chronisch-hf-met-chrono/","title":"Closed loop stimulatie en cardiopulmonale variabelen bij chronisch HF met chronotrope incompetentie","title_en":"Impact of closed loop stimulation on prognostic cardiopulmonary variables in patients with chronic heart failure and severe chronotropic incompetence: a pilot, randomized, crossover study.","published":"2021-11-08"}],"10.1016/j.jacc.2021.08.048":[{"url":"https://hartvaat.nl/2021/11/02/hogere-intraoperatieve-bloeddrukstreefwaarden-en-cv-events-bij-niet-cardiale-chi/","title":"Hogere intraoperatieve bloeddrukstreefwaarden en CV-events bij niet-cardiale chirurgie","title_en":"Targeting Higher Intraoperative Blood Pressures Does Not Reduce Adverse Cardiovascular Events Following Noncardiac Surgery.","published":"2021-11-02"}],"10.1161/circulationaha.121.057042":[{"url":"https://hartvaat.nl/2021/11/02/griepvaccinatie-na-mi-iami-dubbelblinde-gerandomiseerde-multicenter-trial/","title":"Griepvaccinatie na MI: IAMI dubbelblinde gerandomiseerde multicenter trial","title_en":"Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.","published":"2021-11-02"}],"10.1001/jamacardio.2021.3063":[{"url":"https://hartvaat.nl/2021/11/01/af-last-en-qol-na-af-ablatie-cabana-substudie/","title":"AF-last en QoL na AF-ablatie: CABANA-substudie","title_en":"Association of Atrial Fibrillation Burden With Health-Related Quality of Life After Atrial Fibrillation Ablation: Substudy of the Cryoballoon vs Contact-Force Atrial Fibrillation Ablation (CIRCA-DOSE) Randomized Clinical Trial.","published":"2021-11-01"}],"10.1001/jamacardio.2021.2735":[{"url":"https://hartvaat.nl/2021/11/01/inspanningstraining-en-ambulante-bloeddruk-bij-resistente-hypertensie-jama-cardi/","title":"Inspanningstraining en ambulante bloeddruk bij resistente hypertensie: JAMA Cardiology","title_en":"Effect of Exercise Training on Ambulatory Blood Pressure Among Patients With Resistant Hypertension: A Randomized Clinical Trial.","published":"2021-11-01"}],"10.1001/jamacardio.2021.2632":[{"url":"https://hartvaat.nl/2021/11/01/langetermijn-event-vrije-en-totale-overleving-met-dapagliflozine-bij-hfref-jama-/","title":"Langetermijn event-vrije en totale overleving met dapagliflozine bij HFrEF: JAMA Cardiology","title_en":"Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.","published":"2021-11-01"}],"10.1161/hypertensionaha.121.17496":[{"url":"https://hartvaat.nl/2021/11/01/rustduur-voor-bloeddrukmeting-best-rest-trial/","title":"Rustduur vóór bloeddrukmeting: Best Rest Trial","title_en":"Effects of Different Rest Period Durations Prior to Blood Pressure Measurement: The Best Rest Trial.","published":"2021-11-01"}],"10.1161/hypertensionaha.121.17797":[{"url":"https://hartvaat.nl/2021/11/01/bloeddrukvariabiliteit-en-dementie-cognitieve-stoornis-meta-analyse/","title":"Bloeddrukvariabiliteit en dementie/cognitieve stoornis: meta-analyse","title_en":"Association Between Blood Pressure Variability With Dementia and Cognitive Impairment: A Systematic Review and Meta-Analysis.","published":"2021-11-01"}],"10.1136/heartjnl-2021-319321":[{"url":"https://hartvaat.nl/2021/11/01/aspirine-versus-p2y12-remmer-met-antistolling-bij-af/","title":"Aspirine versus P2Y12-remmer met antistolling bij AF","title_en":"Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation.","published":"2021-11-01"}],"10.1136/heartjnl-2020-318045":[{"url":"https://hartvaat.nl/2021/11/01/antiplaatjestherapie-bij-mi-zonder-obstructief-coronairlijden-minoca/","title":"Antiplaatjestherapie bij MI zonder obstructief coronairlijden (MINOCA)","title_en":"Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease.","published":"2021-11-01"}],"10.1056/nejmoa2108749":[{"url":"https://hartvaat.nl/2021/10/28/dapt-na-pci-bij-hoog-bloedingsrisico-nejm-master-dapt/","title":"DAPT na PCI bij hoog bloedingsrisico: NEJM MASTER DAPT","title_en":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.","published":"2021-10-28"}],"10.1016/j.jacc.2021.08.036":[{"url":"https://hartvaat.nl/2021/10/26/vroege-impedantie-geleide-interventie-verbetert-langetermijn-hf-uitkomsten/","title":"Vroege impedantie-geleide interventie verbetert langetermijn HF-uitkomsten","title_en":"Early Impedance-Guided Intervention Improves Long-Term Outcome in Patients With Heart Failure.","published":"2021-10-26"}],"10.1016/s0140-6736(21)01637-8":[{"url":"https://hartvaat.nl/2021/10/23/systematische-af-screening-en-klinische-uitkomsten-lancet-strokestop/","title":"Systematische AF-screening en klinische uitkomsten: Lancet STROKESTOP","title_en":"Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial.","published":"2021-10-23"}],"10.1093/eurheartj/ehab559":[{"url":"https://hartvaat.nl/2021/10/21/digitale-therapeutica-bij-essentiele-hypertensie-herb-dh1-pivottrial/","title":"Digitale therapeutica bij essentiële hypertensie: HERB-DH1 pivottrial","title_en":"Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial.","published":"2021-10-21"}],"10.1016/j.jacc.2021.08.020":[{"url":"https://hartvaat.nl/2021/10/19/diabetes-met-cardiomyopathie-in-de-community-prevalentie-en-prognose/","title":"Diabetes met cardiomyopathie in de community: prevalentie en prognose","title_en":"Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults.","published":"2021-10-19"}],"10.1161/circulationaha.121.056824":[{"url":"https://hartvaat.nl/2021/10/19/empagliflozine-en-verslechterende-hf-events-bij-hfpef-emperor-preserved-analyse/","title":"Empagliflozine en verslechterende HF-events bij HFpEF: EMPEROR-Preserved analyse","title_en":"Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.","published":"2021-10-19"}],"10.1016/s0140-6736(21)01638-x":[{"url":"https://hartvaat.nl/2021/10/16/betablokker-respons-bij-hf-met-sinusritme-en-af-machine-learning-clusteranalyse/","title":"Bètablokker-respons bij HF met sinusritme en AF: machine learning clusteranalyse","title_en":"Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.","published":"2021-10-16"}],"10.1056/nejmoa2107038":[{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-bij-hfpef-nejm-emperor-preserved/","title":"Empagliflozine bij HFpEF: NEJM EMPEROR-Preserved","title_en":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction.","published":"2021-10-14"}],"10.1056/nejmc2112411":[{"url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","title":"Empagliflozine en renale uitkomsten bij hartfalen: NEJM EMPEROR-Reduced renal","title_en":"Empagliflozin and Major Renal Outcomes in Heart Failure.","published":"2021-10-14"}],"10.1093/eurheartj/ehab557":[{"url":"https://hartvaat.nl/2021/10/14/lignocaine-versus-opioiden-op-antiplaatjeseffect-van-ticagrelor-local-trial/","title":"Lignocaïne versus opioïden op antiplaatjeseffect van ticagrelor: LOCAL trial","title_en":"Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial.","published":"2021-10-14"}],"10.1016/j.jacc.2021.08.013":[{"url":"https://hartvaat.nl/2021/10/12/overbrugging-van-antiplaatjestherapie-na-pci-jacc-review/","title":"Overbrugging van antiplaatjestherapie na PCI: JACC review","title_en":"Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.","published":"2021-10-12"}],"10.1016/j.jacc.2021.08.009":[{"url":"https://hartvaat.nl/2021/10/12/reductie-in-ischemische-events-door-onderzoekers-en-adjudicatiecommissie-reduce-/","title":"Reductie in ischemische events door onderzoekers en adjudicatiecommissie: REDUCE-IT","title_en":"Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.","published":"2021-10-12"}],"10.1016/j.jacc.2021.08.011":[{"url":"https://hartvaat.nl/2021/10/12/baseline-ldl-en-klinische-uitkomsten-van-ezetimibe-plus-statine-improve-it/","title":"Baseline LDL en klinische uitkomsten van ezetimibe plus statine: IMPROVE-IT","title_en":"Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.","published":"2021-10-12"}],"10.1161/circulationaha.121.055329":[{"url":"https://hartvaat.nl/2021/10/12/leefstijlmodificatie-bij-resistente-hypertensie-triumph-gerandomiseerde-trial/","title":"Leefstijlmodificatie bij resistente hypertensie: TRIUMPH gerandomiseerde trial","title_en":"Effects of Lifestyle Modification on Patients With Resistant Hypertension: Results of the TRIUMPH Randomized Clinical Trial.","published":"2021-10-12"}],"10.1016/s0140-6736(21)01445-8":[{"url":"https://hartvaat.nl/2021/10/09/ongeleide-de-escalatie-van-ticagrelor-naar-clopidogrel-na-mi-met-pci-lancet-talo/","title":"Ongeleide de-escalatie van ticagrelor naar clopidogrel na MI met PCI: Lancet TALOS-AMI","title_en":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.","published":"2021-10-09"}],"10.1093/europace/euab087":[{"url":"https://hartvaat.nl/2021/10/09/klinische-risicofactoren-voor-cva-bij-anticoagulantie-naieve-af-meta-analyse/","title":"Klinische risicofactoren voor CVA bij anticoagulantie-naïeve AF: meta-analyse","title_en":"A meta-analysis of clinical risk factors for stroke in anticoagulant-naïve patients with atrial fibrillation.","published":"2021-10-09"}],"10.1093/europace/euab084":[{"url":"https://hartvaat.nl/2021/10/09/voorspellers-van-sinusritme-6-weken-na-af-cardioversie-x-vert/","title":"Voorspellers van sinusritme 6 weken na AF-cardioversie: X-VeRT","title_en":"Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial.","published":"2021-10-09"}],"10.1093/europace/euab122":[{"url":"https://hartvaat.nl/2021/10/09/gewichtsverlies-voor-af-ablatie-sort-af-gerandomiseerde-trial/","title":"Gewichtsverlies voor AF-ablatie: SORT-AF gerandomiseerde trial","title_en":"Supervised Obesity Reduction Trial for AF ablation patients: results from the SORT-AF trial.","published":"2021-10-09"}],"10.1016/j.jacc.2021.07.054":[{"url":"https://hartvaat.nl/2021/10/05/ketonlichamen-en-functionele-uitkomsten-na-stemi/","title":"Ketonlichamen en functionele uitkomsten na STEMI","title_en":"Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction.","published":"2021-10-05"}],"10.1001/jamacardio.2021.2247":[{"url":"https://hartvaat.nl/2021/10/01/paroxetine-grk2-remming-versus-placebo-bij-anterieur-mi-jama-cardiology/","title":"Paroxetine GRK2-remming versus placebo bij anterieur MI: JAMA Cardiology","title_en":"Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial Infarction: A Randomized Clinical Trial.","published":"2021-10-01"}],"10.1001/jamacardio.2021.2228":[{"url":"https://hartvaat.nl/2021/10/01/ticagrelor-of-prasugrel-na-pci-voor-acs-isar-react-5-pre-gespecificeerde-analyse/","title":"Ticagrelor of prasugrel na PCI voor ACS: ISAR-REACT 5 pre-gespecificeerde analyse","title_en":"Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.","published":"2021-10-01"}],"10.1093/eurheartj/ehab283":[{"url":"https://hartvaat.nl/2021/10/01/ebc-hoofdstam-stentstudie-provisional-versus-systematisch-dubbel-stenten/","title":"EBC hoofdstam-stentstudie: provisional versus systematisch dubbel stenten","title_en":"The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN).","published":"2021-10-01"}],"10.1002/ehf2.13553":[{"url":"https://hartvaat.nl/2021/10/01/acute-pleiotrope-effecten-van-dapagliflozine-bij-diabetes-type-2-met-hfref-cross/","title":"Acute pleiotrope effecten van dapagliflozine bij diabetes type 2 met HFrEF: crossover","title_en":"Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial.","published":"2021-10-01"}],"10.1136/heartjnl-2021-319023":[{"url":"https://hartvaat.nl/2021/10/01/aortaklepcalcificatie-en-cv-risicofactoren-bij-oudere-deense-mannen/","title":"Aortaklepcalcificatie en CV-risicofactoren bij oudere Deense mannen","title_en":"Cross-sectional study of aortic valve calcification and cardiovascular risk factors in older Danish men.","published":"2021-10-01"}],"10.1002/ehf2.13543":[{"url":"https://hartvaat.nl/2021/10/01/uitgebreide-vasodilatatie-en-qol-bij-acuut-hf-substudie/","title":"Uitgebreide vasodilatatie en QoL bij acuut HF: substudie","title_en":"Effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life among patients with acute heart failure.","published":"2021-10-01"}],"10.1002/ehf2.13547":[{"url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-in-real-life-europese-hfref-meta-analyse/","title":"Sacubitril/valsartan in real-life Europese HFrEF: meta-analyse","title_en":"Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis.","published":"2021-10-01"}],"10.1002/ehf2.13510":[{"url":"https://hartvaat.nl/2021/10/01/niet-invasieve-technieken-en-biomarkers-voor-poliklinisch-vochtmanagement-bij-hf/","title":"Niet-invasieve technieken en biomarkers voor poliklinisch vochtmanagement bij HF","title_en":"Use of novel non-invasive techniques and biomarkers to guide outpatient management of fluid overload and reduce hospital readmission: systematic review and meta-analysis.","published":"2021-10-01"}],"10.1002/ehf2.13511":[{"url":"https://hartvaat.nl/2021/10/01/iv-furosemide-plus-hypertone-zoutoplossing-en-hf-markers/","title":"IV furosemide plus hypertone zoutoplossing en HF-markers","title_en":"Effects of intravenous furosemide plus small-volume hypertonic saline solutions on markers of heart failure.","published":"2021-10-01"}],"10.1136/heartjnl-2021-319496":[{"url":"https://hartvaat.nl/2021/10/01/katheterablatie-als-eerstelijns-paf-therapie-meta-analyse/","title":"Katheterablatie als eerstelijns PAF-therapie: meta-analyse","title_en":"Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis.","published":"2021-10-01"}],"10.1002/ehf2.13508":[{"url":"https://hartvaat.nl/2021/10/01/apothekerzorg-bij-poliklinisch-hf-meta-analyse/","title":"Apothekerzorg bij poliklinisch HF: meta-analyse","title_en":"The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis.","published":"2021-10-01"}],"10.1002/ehf2.13498":[{"url":"https://hartvaat.nl/2021/10/01/revalidatie-bij-chronisch-hf-systematische-review-van-inspanningsinterventies/","title":"Revalidatie bij chronisch HF: systematische review van inspanningsinterventies","title_en":"A systematic review of rehabilitation in chronic heart failure: evaluating the reporting of exercise interventions.","published":"2021-10-01"}],"10.1002/ehf2.13509":[{"url":"https://hartvaat.nl/2021/10/01/empagliflozine-en-nierprotectie-bij-acuut-mi-met-diabetes-pilot/","title":"Empagliflozine en nierprotectie bij acuut MI met diabetes: pilot","title_en":"Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.","published":"2021-10-01"}],"10.1002/ehf2.13483":[{"url":"https://hartvaat.nl/2021/10/01/sglt2-remmers-en-hf-hospitalisatie-en-hartfunctie-systematische-review/","title":"SGLT2-remmers en HF-hospitalisatie en hartfunctie: systematische review","title_en":"Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review.","published":"2021-10-01"}],"10.1002/ehf2.13478":[{"url":"https://hartvaat.nl/2021/10/01/inspiratoire-spiertraining-plus-aerobe-training-en-neurovasculaire-controle-bij-/","title":"Inspiratoire spiertraining plus aerobe training en neurovasculaire controle bij chronisch HF","title_en":"Effects of inspiratory muscle training combined with aerobic exercise training on neurovascular control in chronic heart failure patients.","published":"2021-10-01"}],"10.1002/ehf2.13475":[{"url":"https://hartvaat.nl/2021/10/01/niet-invasieve-thuistelemonitoring-bij-gedecompenseerd-hf-meta-analyse/","title":"Niet-invasieve thuistelemonitoring bij gedecompenseerd HF: meta-analyse","title_en":"Non-invasive home telemonitoring in patients with decompensated heart failure: a systematic review and meta-analysis.","published":"2021-10-01"}],"10.1002/ehf2.13491":[{"url":"https://hartvaat.nl/2021/10/01/sacubitril-valsartan-verbetert-hartfunctie-bij-chinese-hf-patienten-real-world/","title":"Sacubitril/valsartan verbetert hartfunctie bij Chinese HF-patiënten: real-world","title_en":"Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.","published":"2021-10-01"}],"10.1056/nejmoa2033617":[{"url":"https://hartvaat.nl/2021/09/30/ozanimod-bij-colitis-ulcerosa-nejm/","title":"Ozanimod bij colitis ulcerosa: NEJM","title_en":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.","published":"2021-09-30"}],"10.1056/nejmoa2111437":[{"url":"https://hartvaat.nl/2021/09/30/intensieve-bloeddrukcontrole-bij-oudere-patienten-met-hypertensie-nejm-step/","title":"Intensieve bloeddrukcontrole bij oudere patiënten met hypertensie: NEJM STEP","title_en":"Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.","published":"2021-09-30"}],"10.1016/j.jacc.2021.07.049":[{"url":"https://hartvaat.nl/2021/09/28/empagliflozine-verbetert-cv-en-renale-uitkomsten-ongeacht-systolische-bloeddruk-/","title":"Empagliflozine verbetert CV en renale uitkomsten ongeacht systolische bloeddruk bij HF","title_en":"Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.","published":"2021-09-28"}],"10.1016/j.jacc.2021.07.046":[{"url":"https://hartvaat.nl/2021/09/28/nt-probnp-prognose-en-empagliflozine-effect-bij-emperor-reduced/","title":"NT-proBNP prognose en empagliflozine-effect bij EMPEROR-Reduced","title_en":"Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.","published":"2021-09-28"}],"10.1161/circulationaha.121.054117":[{"url":"https://hartvaat.nl/2021/09/21/1-jaar-inspanningstraining-keert-lv-stijfheid-om-bij-stadium-b-hf/","title":"1 jaar inspanningstraining keert LV-stijfheid om bij stadium B HF","title_en":"One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction.","published":"2021-09-21"}],"10.1016/j.jacc.2021.07.031":[{"url":"https://hartvaat.nl/2021/09/21/pcsk9-remming-en-geoxideerde-fosfolipiden/","title":"PCSK9-remming en geoxideerde fosfolipiden","title_en":"PCSK9 Inhibition and Oxidized Phospholipids.","published":"2021-09-21"}],"10.1016/j.jacc.2021.07.022":[{"url":"https://hartvaat.nl/2021/09/21/bijwerkingspatronen-in-crossover-trial-statine-placebo-geen-behandeling-statinwi/","title":"Bijwerkingspatronen in crossover trial statine/placebo/geen behandeling: StatinWISE","title_en":"Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.","published":"2021-09-21"}],"10.1093/eurheartj/ehab560":[{"url":"https://hartvaat.nl/2021/09/21/dapagliflozine-en-ventriculaire-aritmieen-en-plotse-dood-bij-hf-dapa-hf/","title":"Dapagliflozine en ventriculaire aritmieën en plotse dood bij HF: DAPA-HF","title_en":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.","published":"2021-09-21"}],"10.1093/eurheartj/ehab499":[{"url":"https://hartvaat.nl/2021/09/21/sacubitril-valsartan-bij-schijnbaar-resistente-hypertensie-met-hfpef/","title":"Sacubitril/valsartan bij schijnbaar resistente hypertensie met HFpEF","title_en":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.","published":"2021-09-21"}],"10.1016/s0140-6736(21)01922-x":[{"url":"https://hartvaat.nl/2021/09/18/kwartdosis-viervoudige-combinatiepil-versus-standaardzorg-bij-hypertensie-lancet/","title":"Kwartdosis viervoudige combinatiepil versus standaardzorg bij hypertensie: Lancet QUARTET","title_en":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.","published":"2021-09-18"}],"10.1056/nejmoa2105675":[{"url":"https://hartvaat.nl/2021/09/16/zoutsubstitutie-en-cv-events-en-sterfte-nejm-ssass/","title":"Zoutsubstitutie en CV-events en sterfte: NEJM SSaSS","title_en":"Effect of Salt Substitution on Cardiovascular Events and Death.","published":"2021-09-16"}],"10.1093/eurheartj/ehab453":[{"url":"https://hartvaat.nl/2021/09/14/copd-bij-af-prevalentie-management-en-impact-meta-analyse/","title":"COPD bij AF: prevalentie, management en impact — meta-analyse","title_en":"Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients.","published":"2021-09-14"}],"10.1016/s0140-6736(21)01754-2":[{"url":"https://hartvaat.nl/2021/09/11/hemodynamisch-geleid-hf-management-lancet-guide-hf/","title":"Hemodynamisch geleid HF-management: Lancet GUIDE-HF","title_en":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.","published":"2021-09-11"}],"10.1093/europace/euab062":[{"url":"https://hartvaat.nl/2021/09/08/antiaritmica-bij-vroeg-persisterend-af-met-hf-race-3/","title":"Antiaritmica bij vroeg persisterend AF met HF: RACE 3","title_en":"Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study.","published":"2021-09-08"}],"10.1016/j.jacc.2021.06.044":[{"url":"https://hartvaat.nl/2021/09/07/hartfrequentie-en-uitkomsten-van-renale-denervatie-bij-ongecontroleerde-hyperten/","title":"Hartfrequentie en uitkomsten van renale denervatie bij ongecontroleerde hypertensie","title_en":"Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension.","published":"2021-09-07"}],"10.1056/nejmoa2108269":[{"url":"https://hartvaat.nl/2021/09/02/efpeglenatide-en-cv-en-renale-uitkomsten-bij-diabetes-type-2-nejm-amplitude-o/","title":"Efpeglenatide en CV en renale uitkomsten bij diabetes type 2: NEJM AMPLITUDE-O","title_en":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.","published":"2021-09-02"}],"10.1001/jamacardio.2021.1565":[{"url":"https://hartvaat.nl/2021/09/01/million-hearts-cv-risicoreductiemodel-en-medicatie-initiatie-jama-cardiology/","title":"Million Hearts CV-risicoreductiemodel en medicatie-initiatie: JAMA Cardiology","title_en":"Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial.","published":"2021-09-01"}],"10.1001/jamacardio.2021.1720":[{"url":"https://hartvaat.nl/2021/09/01/sekseverschillen-bij-ticagrelor-aspirine-na-pci-bij-hoog-risico-twilight/","title":"Sekseverschillen bij ticagrelor ± aspirine na PCI bij hoog risico: TWILIGHT","title_en":"Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.","published":"2021-09-01"}],"10.1161/hypertensionaha.121.17579":[{"url":"https://hartvaat.nl/2021/09/01/normalisatie-van-arteriele-stijfheid-en-cv-events-sparte-studie/","title":"Normalisatie van arteriële stijfheid en CV-events: SPARTE-studie","title_en":"SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk.","published":"2021-09-01"}],"10.1161/hypertensionaha.121.17990":[{"url":"https://hartvaat.nl/2021/09/01/ace-remmer-plus-calciumantagonist-bij-zwarte-hypertensieve-patienten/","title":"ACE-remmer plus calciumantagonist bij zwarte hypertensieve patiënten","title_en":"Cardiovascular Benefits of Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Black Hypertensive Patients.","published":"2021-09-01"}],"10.1161/hypertensionaha.121.17873":[{"url":"https://hartvaat.nl/2021/09/01/arts-apotheker-samenwerkingsmodel-en-time-in-target-bloeddruk-post-hoc-analyse/","title":"Arts-apotheker samenwerkingsmodel en time-in-target bloeddruk: post-hoc analyse","title_en":"Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial.","published":"2021-09-01"}],"10.1161/hypertensionaha.120.15946":[{"url":"https://hartvaat.nl/2021/09/01/zorginterventies-voor-hypertensie-bij-achtergestelde-populaties-in-de-vs-meta-an/","title":"Zorginterventies voor hypertensie bij achtergestelde populaties in de VS: meta-analyse","title_en":"Health Care Delivery Interventions for Hypertension Management in Underserved Populations in the United States: A Systematic Review.","published":"2021-09-01"}],"10.1161/hypertensionaha.121.17788":[{"url":"https://hartvaat.nl/2021/09/01/langetermijn-bloeddrukvariabiliteit-en-dementierisico-meta-analyse/","title":"Langetermijn bloeddrukvariabiliteit en dementierisico: meta-analyse","title_en":"Long-Term Blood Pressure Variability Increases Risks of Dementia and Cognitive Decline: A Meta-Analysis of Longitudinal Studies.","published":"2021-09-01"}],"10.1161/hypertensionaha.121.17323":[{"url":"https://hartvaat.nl/2021/09/01/albuminurietesting-bij-hypertensie-en-diabetes-ipd-meta-analyse/","title":"Albuminurietesting bij hypertensie en diabetes: IPD meta-analyse","title_en":"Albuminuria Testing in Hypertension and Diabetes: An Individual-Participant Data Meta-Analysis in a Global Consortium.","published":"2021-09-01"}],"10.1161/hypertensionaha.121.17622":[{"url":"https://hartvaat.nl/2021/09/01/slaaprestrictie-en-ambulante-en-slaap-bloeddruk-gerandomiseerde-crossover/","title":"Slaaprestrictie en ambulante en slaap-bloeddruk: gerandomiseerde crossover","title_en":"Effects of Experimental Sleep Restriction on Ambulatory and Sleep Blood Pressure in Healthy Young Adults: A Randomized Crossover Study.","published":"2021-09-01"}],"10.1161/hypertensionaha.121.17049":[{"url":"https://hartvaat.nl/2021/09/01/bloed-hersenbarriere-kruisende-raas-middelen-en-cognitie-bij-ouderen-meta-analys/","title":"Bloed-hersenbarrière kruisende RAAS-middelen en cognitie bij ouderen: meta-analyse","title_en":"Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis.","published":"2021-09-01"}],"10.1136/heartjnl-2020-318192":[{"url":"https://hartvaat.nl/2021/09/01/bloeddrukverlagende-middelen-en-antibiotica-en-aaa-groei-meta-analyse/","title":"Bloeddrukverlagende middelen en antibiotica en AAA-groei: meta-analyse","title_en":"Effect of blood pressure lowering drugs and antibiotics on abdominal aortic aneurysm growth: a systematic review and meta-analysis.","published":"2021-09-01"}],"10.1016/j.jacc.2021.06.037":[{"url":"https://hartvaat.nl/2021/08/31/colchicine-bij-chronisch-coronairlijden-met-versus-zonder-eerder-acs/","title":"Colchicine bij chronisch coronairlijden met versus zonder eerder ACS","title_en":"Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome.","published":"2021-08-31"}],"10.1016/j.jacc.2021.06.011":[{"url":"https://hartvaat.nl/2021/08/31/2021-acc-consensus-ascvd-risicoreductie-bij-persistente-hypertriglyceridemie/","title":"2021 ACC consensus: ASCVD-risicoreductie bij persistente hypertriglyceridemie","title_en":"2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2021-08-31"}],"10.1016/j.jacc.2021.06.012":[{"url":"https://hartvaat.nl/2021/08/24/de-escalatie-van-dapt-bij-acs-jacc-review/","title":"De-escalatie van DAPT bij ACS: JACC review","title_en":"De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes.","published":"2021-08-24"}],"10.1093/eurheartj/ehab234":[{"url":"https://hartvaat.nl/2021/08/17/iv-ijzercarboxymaltose-en-qol-bij-ijzerdeficient-acuut-hf-affirm-ahf/","title":"IV ijzercarboxymaltose en QoL bij ijzerdeficiënt acuut HF: AFFIRM-AHF","title_en":"The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.","published":"2021-08-17"}],"10.1093/eurheartj/ehab225":[{"url":"https://hartvaat.nl/2021/08/17/cholesterol-en-bloeddrukverlaging-na-hope-3-8-7-jaars-follow-up/","title":"Cholesterol- en bloeddrukverlaging na HOPE-3: 8,7-jaars follow-up","title_en":"Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.","published":"2021-08-17"}],"10.1016/s0140-6736(21)01443-4":[{"url":"https://hartvaat.nl/2021/08/14/tirzepatide-versus-insuline-degludec-bij-diabetes-type-2-lancet-surpass-3/","title":"Tirzepatide versus insuline degludec bij diabetes type 2: Lancet SURPASS-3","title_en":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.","published":"2021-08-14"}],"10.1093/europace/euab014":[{"url":"https://hartvaat.nl/2021/08/06/orale-antiaritmica-voor-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","title":"Orale antiaritmica voor cardioversie van recent-onset AF: netwerkmeta-analyse","title_en":"Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials.","published":"2021-08-06"}],"10.1093/europace/euaa414":[{"url":"https://hartvaat.nl/2021/08/06/ventriculaire-aritmie-bij-crt-responders-en-super-responders-meta-analyse/","title":"Ventriculaire aritmie bij CRT-responders en super-responders: meta-analyse","title_en":"Risk of ventricular arrhythmia in cardiac resynchronization therapy responders and super-responders: a systematic review and meta-analysis.","published":"2021-08-06"}],"10.1056/nejmoa2026845":[{"url":"https://hartvaat.nl/2021/08/05/milrinone-versus-dobutamine-bij-cardiogene-shock-nejm-doremi/","title":"Milrinone versus dobutamine bij cardiogene shock: NEJM DOREMI","title_en":"Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.","published":"2021-08-05"}],"10.1016/j.jacc.2021.04.102":[{"url":"https://hartvaat.nl/2021/08/03/lp-a-en-pcsk9-remmingsvoordeel-bij-nominaal-gecontroleerd-ldl/","title":"Lp(a) en PCSK9-remmingsvoordeel bij nominaal gecontroleerd LDL","title_en":"Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.","published":"2021-08-03"}],"10.1161/hypertensionaha.121.17319":[{"url":"https://hartvaat.nl/2021/08/01/aobp-na-nul-versus-vijf-minuten-rust-gerandomiseerde-trial/","title":"AOBP na nul versus vijf minuten rust: gerandomiseerde trial","title_en":"Randomized Controlled Trial Comparing Automated Office Blood Pressure Readings After Zero or Five Minutes of Rest.","published":"2021-08-01"}],"10.1161/hypertensionaha.121.17364":[{"url":"https://hartvaat.nl/2021/08/01/fenotype-van-cpap-responders-bij-resistente-hypertensie-hiparco/","title":"Fenotype van CPAP-responders bij resistente hypertensie: HIPARCO","title_en":"Clinical Phenotype of Resistant Hypertension Responders to Continuous Positive Airway Pressure Treatment: Results From the HIPARCO Randomized Clinical Trial.","published":"2021-08-01"}],"10.1002/ehf2.13373":[{"url":"https://hartvaat.nl/2021/08/01/motivational-interviewing-en-zorggebruik-en-mortaliteit-bij-hf-motivate-hf/","title":"Motivational interviewing en zorggebruik en mortaliteit bij HF: MOTIVATE-HF","title_en":"Effectiveness of motivational interviewing on health-service use and mortality: a secondary outcome analysis of the MOTIVATE-HF trial.","published":"2021-08-01"}],"10.1002/ehf2.13348":[{"url":"https://hartvaat.nl/2021/08/01/gdf-15-en-liraglutide-behandeling-bij-hf-patienten/","title":"GDF-15 en liraglutide-behandeling bij HF-patiënten","title_en":"Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.","published":"2021-08-01"}],"10.1002/ehf2.13380":[{"url":"https://hartvaat.nl/2021/08/01/geschiktheid-van-poliklinische-chronische-hf-patienten-voor-sglt2-remmers/","title":"Geschiktheid van poliklinische chronische HF-patiënten voor SGLT2-remmers","title_en":"Eligibility of outpatients with chronic heart failure for sodium-glucose co-transporter-2 inhibitors.","published":"2021-08-01"}],"10.1161/hypertensionaha.120.16817":[{"url":"https://hartvaat.nl/2021/08/01/polsgolfcalibratie-en-implicaties-voor-bloeddrukmeting-meta-analyse/","title":"Polsgolfcalibratie en implicaties voor bloeddrukmeting: meta-analyse","title_en":"Pulse Wave Calibration and Implications for Blood Pressure Measurement: Systematic Review and Meta-Analysis.","published":"2021-08-01"}],"10.1002/ehf2.13359":[{"url":"https://hartvaat.nl/2021/08/01/echo-optimalisatie-van-lvad-en-functionele-capaciteit-gerandomiseerde-trial/","title":"Echo-optimalisatie van LVAD en functionele capaciteit: gerandomiseerde trial","title_en":"Effects of echo-optimization of left ventricular assist devices on functional capacity, a randomized controlled trial.","published":"2021-08-01"}],"10.1002/ehf2.13344":[{"url":"https://hartvaat.nl/2021/08/01/klinische-fenotypen-zijn-effectiever-dan-ef-categorieen-voor-hf-uitkomsten/","title":"Klinische fenotypen zijn effectiever dan EF-categorieën voor HF-uitkomsten","title_en":"Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes.","published":"2021-08-01"}],"10.1001/jama.2021.8844":[{"url":"https://hartvaat.nl/2021/07/27/ziekenhuis-en-post-ontslagkwaliteitsinterventie-bij-hf-jama-connect-hf/","title":"Ziekenhuis- en post-ontslagkwaliteitsinterventie bij HF: JAMA CONNECT-HF","title_en":"Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial.","published":"2021-07-27"}],"10.1001/jama.2021.4533":[{"url":"https://hartvaat.nl/2021/07/27/heeft-deze-volwassene-hypertensie-jama-rational-clinical-examination/","title":"Heeft deze volwassene hypertensie? JAMA Rational Clinical Examination","title_en":"Does This Adult Patient Have Hypertension?: The Rational Clinical Examination Systematic Review.","published":"2021-07-27"}],"10.1056/nejmoa2104650":[{"url":"https://hartvaat.nl/2021/07/22/multivaten-pci-geleid-door-ffr-of-angiografie-bij-mi-nejm-flower-mi/","title":"Multivaten-PCI geleid door FFR of angiografie bij MI: NEJM FLOWER-MI","title_en":"Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction.","published":"2021-07-22"}],"10.1093/eurheartj/ehab115":[{"url":"https://hartvaat.nl/2021/07/21/laaggedoseerd-colchicine-bij-coronairlijden-meta-analyse-van-gerandomiseerde-tri/","title":"Laaggedoseerd colchicine bij coronairlijden: meta-analyse van gerandomiseerde trials","title_en":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.","published":"2021-07-21"}],"10.1093/europace/euab036":[{"url":"https://hartvaat.nl/2021/07/18/smartphone-ecg-voor-af-detectie-na-cerebrovasculair-event-multicenter-rct/","title":"Smartphone-ECG voor AF-detectie na cerebrovasculair event: multicenter RCT","title_en":"Smartphone electrocardiogram for detecting atrial fibrillation after a cerebral ischaemic event: a multicentre randomized controlled trial.","published":"2021-07-18"}],"10.1093/europace/euab029":[{"url":"https://hartvaat.nl/2021/07/18/cryoballonablatie-versus-antiaritmica-als-eerstelijns-paf-therapie/","title":"Cryoballonablatie versus antiaritmica als eerstelijns PAF-therapie","title_en":"Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation.","published":"2021-07-18"}],"10.1093/europace/euab041":[{"url":"https://hartvaat.nl/2021/07/18/letselrisico-bij-vasovagale-syncope-systematische-review-en-meta-analyse/","title":"Letselrisico bij vasovagale syncope: systematische review en meta-analyse","title_en":"Likelihood of injury due to vasovagal syncope: a systematic review and meta-analysis.","published":"2021-07-18"}],"10.1093/europace/euaa415":[{"url":"https://hartvaat.nl/2021/07/18/procedurevolume-en-complicaties-bij-af-ablatie-meta-analyse/","title":"Procedurevolume en complicaties bij AF-ablatie: meta-analyse","title_en":"Relationship between procedural volume and complication rates for catheter ablation of atrial fibrillation: a systematic review and meta-analysis.","published":"2021-07-18"}],"10.1093/eurheartj/ehab280":[{"url":"https://hartvaat.nl/2021/07/15/ultradunne-versus-conventionele-2e-generatie-des-langetermijn-meta-analyse/","title":"Ultradunne versus conventionele 2e-generatie DES: langetermijn meta-analyse","title_en":"Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.","published":"2021-07-15"}],"10.1056/nejmoa2026141":[{"url":"https://hartvaat.nl/2021/07/15/fysieke-revalidatie-bij-oudere-gehospitaliseerde-hf-patienten-nejm-rehab-hf/","title":"Fysieke revalidatie bij oudere gehospitaliseerde HF-patiënten: NEJM REHAB-HF","title_en":"Physical Rehabilitation for Older Patients Hospitalized for Heart Failure.","published":"2021-07-15"}],"10.1016/j.jacc.2021.04.092":[{"url":"https://hartvaat.nl/2021/07/13/ablatie-versus-medicatie-bij-af-naar-ras-en-etniciteit/","title":"Ablatie versus medicatie bij AF naar ras en etniciteit","title_en":"Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities.","published":"2021-07-13"}],"10.1016/j.jacc.2021.04.079":[{"url":"https://hartvaat.nl/2021/07/13/finerenon-vermindert-nieuw-onset-af-bij-ckd-met-diabetes-fidelio-dkd/","title":"Finerenon vermindert nieuw-onset AF bij CKD met diabetes: FIDELIO-DKD","title_en":"Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.","published":"2021-07-13"}],"10.1016/j.jacc.2021.04.065":[{"url":"https://hartvaat.nl/2021/07/13/ef-en-uitkomsten-bij-omecamtiv-mecarbil-galactic-hf/","title":"EF en uitkomsten bij omecamtiv mecarbil: GALACTIC-HF","title_en":"Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.","published":"2021-07-13"}],"10.1161/circulationaha.120.046289":[{"url":"https://hartvaat.nl/2021/07/13/10-jaars-mortaliteit-naar-compleetheid-van-revascularisatie-bij-drievaten-hoofds/","title":"10-jaars mortaliteit naar compleetheid van revascularisatie bij drievaten/hoofdstamlijden","title_en":"Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study.","published":"2021-07-13"}],"10.1161/circulationaha.121.055009":[{"url":"https://hartvaat.nl/2021/07/13/late-rapid-tnt-uitkomsten-0-1-uur-hs-troponine-t-bij-verdenking-acs/","title":"Late RAPID-TnT uitkomsten: 0/1-uur hs-troponine T bij verdenking ACS","title_en":"Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS.","published":"2021-07-13"}],"10.1016/s0140-6736(21)01324-6":[{"url":"https://hartvaat.nl/2021/07/10/tirzepatide-bij-diabetes-type-2-lancet-surpass-1-fase-3/","title":"Tirzepatide bij diabetes type 2: Lancet SURPASS-1 fase-3","title_en":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.","published":"2021-07-10"}],"10.1093/eurheartj/ehaa777":[{"url":"https://hartvaat.nl/2021/07/08/cv-uitkomsten-bij-diabetes-met-vastgesteld-of-hoog-risico-coronairlijden-dulaglu/","title":"CV-uitkomsten bij diabetes met vastgesteld of hoog-risico coronairlijden: dulaglutide","title_en":"Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.","published":"2021-07-08"}],"10.1093/eurheartj/ehaa375":[{"url":"https://hartvaat.nl/2021/07/08/grace-2-0-score-bij-type-1-en-type-2-mi/","title":"GRACE 2.0-score bij type 1 en type 2 MI","title_en":"Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction.","published":"2021-07-08"}],"10.1016/j.jacc.2021.04.087":[{"url":"https://hartvaat.nl/2021/07/06/optimale-medicamenteuze-therapie-en-10-jaarsmortaliteit-na-revascularisatie/","title":"Optimale medicamenteuze therapie en 10-jaarsmortaliteit na revascularisatie","title_en":"Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization.","published":"2021-07-06"}],"10.1016/j.jacc.2021.04.083":[{"url":"https://hartvaat.nl/2021/07/06/mortaliteitsvoordeel-van-rivaroxaban-plus-aspirine-bij-chronisch-vaatlijden-comp/","title":"Mortaliteitsvoordeel van rivaroxaban plus aspirine bij chronisch vaatlijden: COMPASS","title_en":"Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.","published":"2021-07-06"}],"10.1001/jamacardio.2021.0676":[{"url":"https://hartvaat.nl/2021/07/01/camkii-delta-remming-en-ventriculaire-remodellering-na-mi-jama-cardiology/","title":"CaMKII delta-remming en ventriculaire remodellering na MI: JAMA Cardiology","title_en":"Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial.","published":"2021-07-01"}],"10.1001/jamacardio.2021.0660":[{"url":"https://hartvaat.nl/2021/07/01/dapagliflozine-naar-nierfunctie-en-albuminurie-bij-diabetes-declare/","title":"Dapagliflozine naar nierfunctie en albuminurie bij diabetes: DECLARE","title_en":"Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.","published":"2021-07-01"}],"10.1001/jamacardio.2021.0475":[{"url":"https://hartvaat.nl/2021/07/01/revacept-gpvi-antagonist-bij-pci-jama-cardiology/","title":"Revacept GPVI-antagonist bij PCI: JAMA Cardiology","title_en":"Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial.","published":"2021-07-01"}],"10.1093/eurheartj/ehab098":[{"url":"https://hartvaat.nl/2021/07/01/transformatie-van-klinisch-onderzoek-door-patientbetrokkenheid-rate-af/","title":"Transformatie van klinisch onderzoek door patiëntbetrokkenheid: RATE-AF","title_en":"Transforming clinical research by involving and empowering patients- the RATE-AF randomized trial.","published":"2021-07-01"}],"10.1001/jamacardio.2020.6827":[{"url":"https://hartvaat.nl/2021/07/01/empagliflozine-en-lv-volumes-en-functie-bij-hfref-jama-cardiology/","title":"Empagliflozine en LV-volumes en functie bij HFrEF: JAMA Cardiology","title_en":"Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.","published":"2021-07-01"}],"10.1001/jamacardio.2020.6721":[{"url":"https://hartvaat.nl/2021/07/01/remote-post-ontslag-behandeling-na-mi-door-paramedici-versus-standaardzorg-jama-/","title":"Remote post-ontslag behandeling na MI door paramedici versus standaardzorg: JAMA Cardiology","title_en":"Remote Postdischarge Treatment of Patients With Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care: The IMMACULATE Randomized Clinical Trial.","published":"2021-07-01"}],"10.1136/heartjnl-2020-318758":[{"url":"https://hartvaat.nl/2021/07/01/cv-gevolgen-van-stoppen-met-laaggedoseerd-rivaroxaban-bij-chronisch-vaatlijden/","title":"CV-gevolgen van stoppen met laaggedoseerd rivaroxaban bij chronisch vaatlijden","title_en":"Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.","published":"2021-07-01"}],"10.1161/hypertensionaha.121.17073":[{"url":"https://hartvaat.nl/2021/07/01/kbp-5074-en-bloeddruk-bij-gevorderde-ckd-block-ckd/","title":"KBP-5074 en bloeddruk bij gevorderde CKD: BLOCK-CKD","title_en":"Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study.","published":"2021-07-01"}],"10.1016/s0140-6736(21)01063-1":[{"url":"https://hartvaat.nl/2021/06/26/aspirine-versus-clopidogrel-voor-chronische-monotherapie-na-pci-lancet-host-exam/","title":"Aspirine versus clopidogrel voor chronische monotherapie na PCI: Lancet HOST-EXAM","title_en":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.","published":"2021-06-26"}],"10.1016/s0140-6736(21)00788-1":[{"url":"https://hartvaat.nl/2021/06/26/echografie-renale-denervatie-bij-triple-pilresistente-hypertensie-lancet-radianc/","title":"Echografie renale denervatie bij triple-pilresistente hypertensie: Lancet RADIANCE-HTN TRIO","title_en":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.","published":"2021-06-26"}],"10.1016/j.jacc.2021.04.036":[{"url":"https://hartvaat.nl/2021/06/15/prevalentie-van-linkeratriumtrombus-bij-geanticoaguleerde-af-patienten/","title":"Prevalentie van linkeratriumtrombus bij geanticoaguleerde AF-patiënten","title_en":"Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation.","published":"2021-06-15"}],"10.1016/j.jacc.2021.04.044":[{"url":"https://hartvaat.nl/2021/06/15/plasma-renine-activiteit-na-renale-sympathische-denervatie/","title":"Plasma-renine-activiteit na renale sympathische denervatie","title_en":"Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation.","published":"2021-06-15"}],"10.1093/eurheartj/ehaa696":[{"url":"https://hartvaat.nl/2021/06/14/gestandaardiseerde-inspanningstraining-bij-pah-en-cteph-haalbaarheid-en-veilighe/","title":"Gestandaardiseerde inspanningstraining bij PAH en CTEPH: haalbaarheid en veiligheid","title_en":"Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial.","published":"2021-06-14"}],"10.1001/jama.2021.2741":[{"url":"https://hartvaat.nl/2021/06/08/interventies-bij-secundaire-mitralisklepinsufficientie-jama-klinisch-overzicht/","title":"Interventies bij secundaire mitralisklepinsufficiëntie: JAMA klinisch overzicht","title_en":"Interventions for Patients With Secondary Mitral Regurgitation.","published":"2021-06-08"}],"10.1016/j.jacc.2021.04.016":[{"url":"https://hartvaat.nl/2021/06/08/10-jaarsfollow-up-na-revascularisatie-bij-oudere-patienten-met-complex-coronairl/","title":"10-jaarsfollow-up na revascularisatie bij oudere patiënten met complex coronairlijden","title_en":"10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease.","published":"2021-06-08"}],"10.1056/nejmoa2101897":[{"url":"https://hartvaat.nl/2021/06/03/linker-hartoorsluiting-tijdens-hartchirurgie-ter-preventie-van-cva-nejm-laaos-ii/","title":"Linker-hartoorsluiting tijdens hartchirurgie ter preventie van CVA: NEJM LAAOS III","title_en":"Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke.","published":"2021-06-03"}],"10.1001/jama.2021.6128":[{"url":"https://hartvaat.nl/2021/06/01/implanteerbare-versus-verlengde-externe-ecg-monitoring-voor-af-na-ischemisch-cva/","title":"Implanteerbare versus verlengde externe ECG-monitoring voor AF na ischemisch CVA: JAMA","title_en":"Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial.","published":"2021-06-01"}],"10.1001/jama.2021.6470":[{"url":"https://hartvaat.nl/2021/06/01/continue-cardiale-monitoring-versus-standaardzorg-bij-cryptogeen-cva-jama/","title":"Continue cardiale monitoring versus standaardzorg bij cryptogeen CVA: JAMA","title_en":"Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial.","published":"2021-06-01"}],"10.1016/j.jacc.2021.03.320":[{"url":"https://hartvaat.nl/2021/06/01/dieet-en-natriumreductie-op-cardiale-schade-en-inflammatie-dash-sodium/","title":"Dieet en natriumreductie op cardiale schade en inflammatie: DASH-Sodium","title_en":"Effects of Diet and Sodium Reduction on Cardiac Injury, Strain, and Inflammation: The DASH-Sodium Trial.","published":"2021-06-01"}],"10.1001/jamacardio.2021.0852":[{"url":"https://hartvaat.nl/2021/06/01/katheterablatie-of-antiaritmica-als-eerstelijnstherapie-bij-af-jama-cardiology-m/","title":"Katheterablatie of antiaritmica als eerstelijnstherapie bij AF: JAMA Cardiology meta-analyse","title_en":"Assessment of Catheter Ablation or Antiarrhythmic Drugs for First-line Therapy of Atrial Fibrillation: A Meta-analysis of Randomized Clinical Trials.","published":"2021-06-01"}],"10.1001/jamacardio.2021.0379":[{"url":"https://hartvaat.nl/2021/06/01/dapagliflozine-bij-hfref-naar-geslacht-dapa-hf-pre-gespecificeerde-analyse/","title":"Dapagliflozine bij HFrEF naar geslacht: DAPA-HF pre-gespecificeerde analyse","title_en":"Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.","published":"2021-06-01"}],"10.1093/eurheartj/ehab111":[{"url":"https://hartvaat.nl/2021/06/01/geisoleerde-diastolische-hypertensie-cohort-en-meta-analyse-voor-behandeldrempel/","title":"Geïsoleerde diastolische hypertensie: cohort en meta-analyse voor behandeldrempel","title_en":"A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment.","published":"2021-06-01"}],"10.1001/jamacardio.2020.6455":[{"url":"https://hartvaat.nl/2021/06/01/klinische-uitkomsten-en-respons-op-vericiguat-naar-index-hf-event-victoria/","title":"Klinische uitkomsten en respons op vericiguat naar index HF-event: VICTORIA","title_en":"Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.","published":"2021-06-01"}],"10.1161/circulationaha.120.053463":[{"url":"https://hartvaat.nl/2021/06/01/metabole-effecten-van-empagliflozine-bij-hf-empire-hf-metabolic-gerandomiseerde-/","title":"Metabole effecten van empagliflozine bij HF: Empire HF Metabolic gerandomiseerde trial","title_en":"Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).","published":"2021-06-01"}],"10.1161/hypertensionaha.120.15192":[{"url":"https://hartvaat.nl/2021/06/01/aanhoudend-voordeel-van-gedragsinterventies-voor-hypertensie-gerandomiseerde-tri/","title":"Aanhoudend voordeel van gedragsinterventies voor hypertensie: gerandomiseerde trial","title_en":"Sustained Benefit of Alternate Behavioral Interventions to Improve Hypertension Control: A Randomized Clinical Trial.","published":"2021-06-01"}],"10.1161/circulationaha.120.052766":[{"url":"https://hartvaat.nl/2021/06/01/cd34-antilichaam-sirolimus-eluting-combo-stent-versus-orsiro-gerandomiseerde-tri/","title":"CD34-antilichaam sirolimus-eluting Combo stent versus Orsiro: gerandomiseerde trial","title_en":"Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial.","published":"2021-06-01"}],"10.1002/ehf2.13311":[{"url":"https://hartvaat.nl/2021/06/01/diagnostiek-van-hartfalen-in-de-huisartsenpraktijk-ipd-meta-analyse/","title":"Diagnostiek van hartfalen in de huisartsenpraktijk: IPD meta-analyse","title_en":"Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies.","published":"2021-06-01"}],"10.1002/ehf2.13310":[{"url":"https://hartvaat.nl/2021/06/01/inspanningstraining-en-hs-troponine-t-bij-hfref/","title":"Inspanningstraining en hs-troponine T bij HFrEF","title_en":"Exercise training and high-sensitivity cardiac troponin T in patients with heart failure with reduced ejection fraction.","published":"2021-06-01"}],"10.1002/ehf2.13313":[{"url":"https://hartvaat.nl/2021/06/01/sglt2-remmers-versus-arni-bij-hfref-meta-analyse/","title":"SGLT2-remmers versus ARNI bij HFrEF: meta-analyse","title_en":"SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.","published":"2021-06-01"}],"10.1002/ehf2.13295":[{"url":"https://hartvaat.nl/2021/06/01/serumkalium-en-prognose-bij-symptomatisch-hf/","title":"Serumkalium en prognose bij symptomatisch HF","title_en":"Serum potassium levels provide prognostic information in symptomatic heart failure beyond traditional clinical variables.","published":"2021-06-01"}],"10.1002/ehf2.13263":[{"url":"https://hartvaat.nl/2021/06/01/palliatieve-zorg-bij-ph-met-congenitaal-hartlijden-expertopinie/","title":"Palliatieve zorg bij PH met congenitaal hartlijden: expertopinie","title_en":"Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion.","published":"2021-06-01"}],"10.1002/ehf2.13248":[{"url":"https://hartvaat.nl/2021/06/01/roken-en-hartfalen-mendeliaanse-randomisatie-en-mediatie-analyse/","title":"Roken en hartfalen: Mendeliaanse randomisatie en mediatie-analyse","title_en":"Smoking and heart failure: a Mendelian randomization and mediation analysis.","published":"2021-06-01"}],"10.1056/nejmoa2102137":[{"url":"https://hartvaat.nl/2021/05/27/vergelijkende-effectiviteit-van-aspirinedoseringen-bij-cvd-nejm-adaptable/","title":"Vergelijkende effectiviteit van aspirinedoseringen bij CVD: NEJM ADAPTABLE","title_en":"Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.","published":"2021-05-27"}],"10.1001/jama.2021.4230":[{"url":"https://hartvaat.nl/2021/05/25/gedragsinterventies-voor-gezond-gewicht-in-de-zwangerschap-jama-uspstf-evidence-/","title":"Gedragsinterventies voor gezond gewicht in de zwangerschap: JAMA USPSTF evidence report","title_en":"Counseling and Behavioral Interventions for Healthy Weight and Weight Gain in Pregnancy: Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2021-05-25"}],"10.1093/europace/euaa314":[{"url":"https://hartvaat.nl/2021/05/21/extrapulmonale-vein-driver-mapping-bij-persisterend-af-bij-obese-patienten/","title":"Extrapulmonale vein driver mapping bij persisterend AF bij obese patiënten","title_en":"Extra-pulmonary vein driver mapping and ablation for persistent atrial fibrillation in obese patients.","published":"2021-05-21"}],"10.1093/europace/euaa327":[{"url":"https://hartvaat.nl/2021/05/21/high-power-short-duration-versus-conventionele-rf-ablatie-bij-af-meta-analyse/","title":"High-power short-duration versus conventionele RF-ablatie bij AF: meta-analyse","title_en":"High-power short duration vs. conventional radiofrequency ablation of atrial fibrillation: a systematic review and meta-analysis.","published":"2021-05-21"}],"10.1093/europace/euaa356":[{"url":"https://hartvaat.nl/2021/05/21/katheterablatie-versus-medicatie-bij-persisterend-en-langdurig-persisterend-af-l/","title":"Katheterablatie versus medicatie bij persisterend en langdurig persisterend AF: langetermijn","title_en":"Long-term observation of catheter ablation vs. pharmacotherapy in the management of persistent and long-standing persistent atrial fibrillation (CAPA study).","published":"2021-05-21"}],"10.1093/europace/euaa378":[{"url":"https://hartvaat.nl/2021/05/21/firm-ablatie-versus-pvi-bij-paroxysmaal-af-gerandomiseerde-resultaten/","title":"FIRM-ablatie versus PVI bij paroxysmaal AF: gerandomiseerde resultaten","title_en":"Focal Impulse and Rotor Modulation Ablation vs. Pulmonary Vein isolation for the treatment of paroxysmal Atrial Fibrillation: results from the FIRMAP AF study.","published":"2021-05-21"}],"10.1056/nejmoa1901281":[{"url":"https://hartvaat.nl/2021/05/20/intensieve-versus-standaard-bloeddrukcontrole-nejm-sprint-definitief-rapport/","title":"Intensieve versus standaard bloeddrukcontrole: NEJM SPRINT definitief rapport","title_en":"Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.","published":"2021-05-20"}],"10.1016/j.jacc.2021.03.298":[{"url":"https://hartvaat.nl/2021/05/18/diabetes-factoren-en-ticagrelor-plus-aspirine-themis-en-themis-pci/","title":"Diabetes-factoren en ticagrelor plus aspirine: THEMIS en THEMIS-PCI","title_en":"Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials.","published":"2021-05-18"}],"10.1001/jama.2021.4348":[{"url":"https://hartvaat.nl/2021/05/11/digitale-interventie-voor-depressie-bij-hypertensie-diabetes-in-brazilie-en-peru/","title":"Digitale interventie voor depressie bij hypertensie/diabetes in Brazilië en Peru: JAMA","title_en":"Effect of a Digital Intervention on Depressive Symptoms in Patients With Comorbid Hypertension or Diabetes in Brazil and Peru: Two Randomized Clinical Trials.","published":"2021-05-11"}],"10.1016/j.jacc.2021.03.232":[{"url":"https://hartvaat.nl/2021/05/11/geindividualiseerde-voedingsondersteuning-bij-gehospitaliseerd-chronisch-hf/","title":"Geïndividualiseerde voedingsondersteuning bij gehospitaliseerd chronisch HF","title_en":"Individualized Nutritional Support for Hospitalized Patients With Chronic Heart Failure.","published":"2021-05-11"}],"10.1161/hypertensionaha.120.16676":[{"url":"https://hartvaat.nl/2021/05/05/intensieve-bloeddruk-en-aortastijfheid-sprint-heart/","title":"Intensieve bloeddruk en aortastijfheid: SPRINT-HEART","title_en":"Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART.","published":"2021-05-05"}],"10.1161/hypertensionaha.120.16757":[{"url":"https://hartvaat.nl/2021/05/05/bloeddrukvariabiliteit-en-uitkomsten-bij-hfpef/","title":"Bloeddrukvariabiliteit en uitkomsten bij HFpEF","title_en":"Visit-to-Visit Blood Pressure Variability and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.","published":"2021-05-05"}],"10.1161/hypertensionaha.120.16370":[{"url":"https://hartvaat.nl/2021/05/05/chronische-milde-slaaprestrictie-verhoogt-bloeddruk-bij-vrouwen-aha-go-red/","title":"Chronische milde slaaprestrictie verhoogt bloeddruk bij vrouwen: AHA Go Red","title_en":"Sustained Mild Sleep Restriction Increases Blood Pressure in Women: An Update From the American Heart Association Go Red for Women Strategically Focused Research Network.","published":"2021-05-05"}],"10.1161/hypertensionaha.120.16590":[{"url":"https://hartvaat.nl/2021/05/05/veroorzaken-betablokkers-depressie-systematische-review-en-meta-analyse/","title":"Veroorzaken bètablokkers depressie? Systematische review en meta-analyse","title_en":"Do β-Blockers Cause Depression?: Systematic Review and Meta-Analysis of Psychiatric Adverse Events During β-Blocker Therapy.","published":"2021-05-05"}],"10.1161/hypertensionaha.120.16133":[{"url":"https://hartvaat.nl/2021/05/05/furosemide-voor-versneld-bloeddrukherstel-postpartum-bij-hypertensieve-zwangersc/","title":"Furosemide voor versneld bloeddrukherstel postpartum bij hypertensieve zwangerschap: RCT","title_en":"Furosemide for Accelerated Recovery of Blood Pressure Postpartum in women with a hypertensive disorder of pregnancy: A Randomized Controlled Trial.","published":"2021-05-05"}],"10.1016/s0140-6736(21)00590-0":[{"url":"https://hartvaat.nl/2021/05/01/bloeddrukverlaging-voor-primaire-en-secundaire-preventie-over-alle-niveaus-lance/","title":"Bloeddrukverlaging voor primaire en secundaire preventie over alle niveaus: Lancet BPLTTC meta-analyse","title_en":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.","published":"2021-05-01"}],"10.1001/jamacardio.2021.0038":[{"url":"https://hartvaat.nl/2021/05/01/screening-op-af-bij-ouderen-jama-cardiology-gerandomiseerde-trial/","title":"Screening op AF bij ouderen: JAMA Cardiology gerandomiseerde trial","title_en":"Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial.","published":"2021-05-01"}],"10.1001/jamacardio.2020.7585":[{"url":"https://hartvaat.nl/2021/05/01/time-to-clinical-benefit-van-dapagliflozine-bij-hfref-dapa-hf/","title":"Time to clinical benefit van dapagliflozine bij HFrEF: DAPA-HF","title_en":"Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.","published":"2021-05-01"}],"10.1001/jamacardio.2020.5392":[{"url":"https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/","title":"MCP-1 en cardiovasculaire mortaliteit: populatie-gebaseerde meta-analyse","title_en":"Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies.","published":"2021-05-01"}],"10.1136/heartjnl-2020-317229":[{"url":"https://hartvaat.nl/2021/05/01/vroegtijdig-permanent-staken-van-apixaban-of-warfarine-bij-af/","title":"Vroegtijdig permanent staken van apixaban of warfarine bij AF","title_en":"Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.","published":"2021-05-01"}],"10.1001/jama.2020.21669":[{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-evidence-update-2021/","title":"Screening op hypertensie bij volwassenen: USPSTF evidence update 2021","title_en":"Screening for Hypertension in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2021-04-27"}],"10.1001/jama.2021.4987":[{"url":"https://hartvaat.nl/2021/04/27/screening-op-hypertensie-bij-volwassenen-uspstf-herbevestiging-2021/","title":"Screening op hypertensie bij volwassenen: USPSTF herbevestiging 2021","title_en":"Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement.","published":"2021-04-27"}],"10.1016/j.jacc.2021.03.002":[{"url":"https://hartvaat.nl/2021/04/27/groepsmedisch-consult-en-microfinanciering-bij-diabetes-hypertensie-in-kenia/","title":"Groepsmedisch consult en microfinanciering bij diabetes/hypertensie in Kenia","title_en":"Group Medical Visit and Microfinance Intervention for Patients With Diabetes or Hypertension in Kenya.","published":"2021-04-27"}],"10.1016/j.jacc.2021.02.058":[{"url":"https://hartvaat.nl/2021/04/27/patientselectie-voor-intensieve-bloeddrukbehandeling-naar-voordeel-en-bijwerking/","title":"Patiëntselectie voor intensieve bloeddrukbehandeling naar voordeel en bijwerkingen","title_en":"Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.","published":"2021-04-27"}],"10.1016/j.jacc.2021.03.001":[{"url":"https://hartvaat.nl/2021/04/27/pneumonie-incidentie-en-uitkomsten-bij-hartfalen/","title":"Pneumonie-incidentie en uitkomsten bij hartfalen","title_en":"Incidence and Outcomes of Pneumonia in Patients With Heart Failure.","published":"2021-04-27"}],"10.1161/circulationaha.120.052503":[{"url":"https://hartvaat.nl/2021/04/27/empagliflozine-en-pulmonalisdruk-bij-hf-embrace-hf/","title":"Empagliflozine en pulmonalisdruk bij HF: EMBRACE-HF","title_en":"Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.","published":"2021-04-27"}],"10.1016/j.jacc.2020.11.012":[{"url":"https://hartvaat.nl/2021/04/27/2021-acc-aha-kerngegevenselementen-voor-hartfalen/","title":"2021 ACC/AHA kerngegevenselementen voor hartfalen","title_en":"2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure).","published":"2021-04-27"}],"10.1016/j.jacc.2021.02.049":[{"url":"https://hartvaat.nl/2021/04/20/il-6-receptorremming-bij-acuut-stemi-gerandomiseerde-trial/","title":"IL-6-receptorremming bij acuut STEMI: gerandomiseerde trial","title_en":"Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction.","published":"2021-04-20"}],"10.1161/circulationaha.120.050371":[{"url":"https://hartvaat.nl/2021/04/20/natriumreductie-en-bloeddruk-dosis-respons-meta-analyse-van-experimentele-studie/","title":"Natriumreductie en bloeddruk: dosis-respons meta-analyse van experimentele studies","title_en":"Blood Pressure Effects of Sodium Reduction: Dose-Response Meta-Analysis of Experimental Studies.","published":"2021-04-20"}],"10.1016/s0140-6736(21)00533-x":[{"url":"https://hartvaat.nl/2021/04/17/geleide-versus-standaard-antiplaatjestherapie-na-pci-lancet-meta-analyse/","title":"Geleide versus standaard antiplaatjestherapie na PCI: Lancet meta-analyse","title_en":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.","published":"2021-04-17"}],"10.1093/eurheartj/ehaa575":[{"url":"https://hartvaat.nl/2021/04/07/2020-esc-richtlijn-voor-nste-acs-management/","title":"2020 ESC-richtlijn voor NSTE-ACS management","title_en":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","published":"2021-04-07"}],"10.1093/europace/euaa341":[{"url":"https://hartvaat.nl/2021/04/06/ventriculaire-aritmie-bij-niet-ischemisch-hf-prevalentie-en-prognose-danish/","title":"Ventriculaire aritmie bij niet-ischemisch HF: prevalentie en prognose — DANISH","title_en":"Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trial.","published":"2021-04-06"}],"10.1093/europace/euaa293":[{"url":"https://hartvaat.nl/2021/04/06/pvi-alleen-versus-uitgebreide-ablatie-bij-persisterend-af-meta-analyse/","title":"PVI alleen versus uitgebreide ablatie bij persisterend AF: meta-analyse","title_en":"Pulmonary vein isolation alone vs. more extensive ablation with defragmentation and linear ablation of persistent atrial fibrillation: the EARNEST-PVI trial.","published":"2021-04-06"}],"10.1001/jamacardio.2020.7200":[{"url":"https://hartvaat.nl/2021/04/01/ero-lvedv-ratio-en-respons-op-mitraclip-jama-cardiology/","title":"ERO/LVEDV-ratio en respons op MitraClip: JAMA Cardiology","title_en":"Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial.","published":"2021-04-01"}],"10.1161/hypertensionaha.120.16107":[{"url":"https://hartvaat.nl/2021/04/01/aerobe-training-bevordert-angiogenese-en-verlaagt-bloeddruk-bij-hypertensie-exca/","title":"Aerobe training bevordert angiogenese en verlaagt bloeddruk bij hypertensie: EXCAVATION-CHN","title_en":"Promotion of Aerobic Exercise Induced Angiogenesis Is Associated With Decline in Blood Pressure in Hypertension: Result of EXCAVATION-CHN1.","published":"2021-04-01"}],"10.1002/ehf2.13236":[{"url":"https://hartvaat.nl/2021/04/01/canagliflozine-naar-diureticagebruik-canvas-post-hoc-analyse/","title":"Canagliflozine naar diureticagebruik: CANVAS post-hoc analyse","title_en":"Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.","published":"2021-04-01"}],"10.1161/hypertensionaha.120.16027":[{"url":"https://hartvaat.nl/2021/04/01/intensieve-versus-standaard-bloeddruk-op-cva-subtypes-sprint/","title":"Intensieve versus standaard bloeddruk op CVA-subtypes: SPRINT","title_en":"Effect of Intensive Versus Standard Blood Pressure Control on Stroke Subtypes.","published":"2021-04-01"}],"10.1002/ehf2.13255":[{"url":"https://hartvaat.nl/2021/04/01/sarcopenie-bij-hartfalen-systematische-review-en-meta-analyse/","title":"Sarcopenie bij hartfalen: systematische review en meta-analyse","title_en":"Sarcopenia in heart failure: a systematic review and meta-analysis.","published":"2021-04-01"}],"10.1002/ehf2.13247":[{"url":"https://hartvaat.nl/2021/04/01/lv-longitudinale-systolische-functieparameters-als-voorspellers-bij-hfpef/","title":"LV longitudinale systolische functieparameters als voorspellers bij HFpEF","title_en":"Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction.","published":"2021-04-01"}],"10.1002/ehf2.13242":[{"url":"https://hartvaat.nl/2021/04/01/cardio-microstroomdevice-bij-chronisch-hf-eerste-klinische-studie/","title":"Cardio-microstroomdevice bij chronisch HF: eerste klinische studie","title_en":"Cardio-microcurrent device for chronic heart failure: first-in-human clinical study.","published":"2021-04-01"}],"10.1002/ehf2.13241":[{"url":"https://hartvaat.nl/2021/04/01/sglt2-remmers-bij-hfref-meta-analyse-van-vier-effectmodificatoren/","title":"SGLT2-remmers bij HFrEF: meta-analyse van vier effectmodificatoren","title_en":"Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF.","published":"2021-04-01"}],"10.1002/ehf2.13189":[{"url":"https://hartvaat.nl/2021/04/01/telereh-hf-etiologie-subanalyse-van-telerevalidatie-bij-hartfalen/","title":"TELEREH-HF: etiologie-subanalyse van telerevalidatie bij hartfalen","title_en":"An aetiology-based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) trial.","published":"2021-04-01"}],"10.1002/ehf2.13208":[{"url":"https://hartvaat.nl/2021/04/01/ventriculaire-aritmie-of-overlijden-na-stemi-versus-takotsubo/","title":"Ventriculaire aritmie of overlijden na STEMI versus takotsubo","title_en":"Risk of in-hospital life-threatening ventricular arrhythmia or death after ST-elevation myocardial infarction vs. the Takotsubo syndrome.","published":"2021-04-01"}],"10.1002/ehf2.13213":[{"url":"https://hartvaat.nl/2021/04/01/eiwitrijk-versus-standaard-dieet-bij-obees-hf-met-diabetes/","title":"Eiwitrijk versus standaard dieet bij obees HF met diabetes","title_en":"High-protein vs. standard-protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro-HEART trial.","published":"2021-04-01"}],"10.1002/ehf2.13152":[{"url":"https://hartvaat.nl/2021/04/01/betrokkenheid-van-huisartsenzorg-bij-multidisciplinair-hf-management-meta-analys/","title":"Betrokkenheid van huisartsenzorg bij multidisciplinair HF-management: meta-analyse","title_en":"Impact of primary care involvement and setting on multidisciplinary heart failure management: a systematic review and meta-analysis.","published":"2021-04-01"}],"10.1002/ehf2.13080":[{"url":"https://hartvaat.nl/2021/04/01/va-ecls-bij-harttransplantatie-en-vad-centra-meta-analyse/","title":"VA-ECLS bij harttransplantatie en VAD-centra: meta-analyse","title_en":"Veno-Arterial Extracorporeal Life Support in Heart Transplant and Ventricle Assist Device Centres. Meta-analysis.","published":"2021-04-01"}],"10.1093/eurheartj/ehab094":[{"url":"https://hartvaat.nl/2021/03/31/dapagliflozine-en-mortaliteit-bij-ckd-dapa-ckd-pre-gespecificeerde-analyse/","title":"Dapagliflozine en mortaliteit bij CKD: DAPA-CKD pre-gespecificeerde analyse","title_en":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.","published":"2021-03-31"}],"10.1016/j.jacc.2021.01.044":[{"url":"https://hartvaat.nl/2021/03/23/mra-en-empagliflozine-interactie-bij-hf-emperor-reduced/","title":"MRA en empagliflozine interactie bij HF: EMPEROR-Reduced","title_en":"Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.","published":"2021-03-23"}],"10.1016/j.jacc.2021.01.033":[{"url":"https://hartvaat.nl/2021/03/23/empagliflozine-bij-hfref-met-volume-overbelasting-emperor-reduced/","title":"Empagliflozine bij HFrEF met volume-overbelasting: EMPEROR-Reduced","title_en":"Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.","published":"2021-03-23"}],"10.1001/jama.2021.1489":[{"url":"https://hartvaat.nl/2021/03/16/omega-3-en-vitamine-d-en-incident-af-jama-vital-af/","title":"Omega-3 en vitamine D en incident AF: JAMA VITAL-AF","title_en":"Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial.","published":"2021-03-16"}],"10.1016/j.jacc.2021.01.014":[{"url":"https://hartvaat.nl/2021/03/16/systolische-bloeddruk-time-in-target-en-cv-uitkomsten-bij-hypertensie/","title":"Systolische bloeddruk time-in-target en CV-uitkomsten bij hypertensie","title_en":"Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension.","published":"2021-03-16"}],"10.1016/j.jacc.2021.01.015":[{"url":"https://hartvaat.nl/2021/03/16/plaatjesreactiviteit-bij-acs-in-afwachting-van-chirurgische-revascularisatie/","title":"Plaatjesreactiviteit bij ACS in afwachting van chirurgische revascularisatie","title_en":"Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization.","published":"2021-03-16"}],"10.1161/circulationaha.120.049447":[{"url":"https://hartvaat.nl/2021/03/16/alirocumab-naar-bereikte-ldl-na-acs-odyssey-outcomes/","title":"Alirocumab naar bereikte LDL na ACS: ODYSSEY OUTCOMES","title_en":"Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.","published":"2021-03-16"}],"10.1161/circulationaha.120.051700":[{"url":"https://hartvaat.nl/2021/03/16/duurzame-versus-biodegradeerbare-polymer-des-bij-acs-meta-analyse/","title":"Duurzame versus biodegradeerbare polymer DES bij ACS: meta-analyse","title_en":"Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS Trial.","published":"2021-03-16"}],"10.1016/j.jacc.2020.12.057":[{"url":"https://hartvaat.nl/2021/03/09/spironolacton-bij-hfpef-met-verslechterende-nierfunctie-topcat/","title":"Spironolacton bij HFpEF met verslechterende nierfunctie: TOPCAT","title_en":"Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.","published":"2021-03-09"}],"10.1016/j.jacc.2020.12.053":[{"url":"https://hartvaat.nl/2021/03/09/halve-versus-volle-dosis-edoxaban-bij-af-gerandomiseerde-vergelijking/","title":"Halve versus volle dosis edoxaban bij AF: gerandomiseerde vergelijking","title_en":"Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.","published":"2021-03-09"}],"10.1016/j.jacc.2020.12.059":[{"url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","title":"10-jaarsfollow-up EES versus BMS bij STEMI: EXAMINATION","title_en":"10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction.","published":"2021-03-09"}],"10.1161/circulationaha.120.051620":[{"url":"https://hartvaat.nl/2021/03/09/bloeddrukverlagende-medicatie-naar-hypertensierichtlijn-in-lage-middeninkomensla/","title":"Bloeddrukverlagende medicatie naar hypertensierichtlijn in lage/middeninkomenslanden","title_en":"Variation in the Proportion of Adults in Need of Blood Pressure-Lowering Medications by Hypertension Care Guideline in Low- and Middle-Income Countries: A Cross-Sectional Study of 1 037 215 Individuals From 50 Nationally Representative Surveys.","published":"2021-03-09"}],"10.1093/europace/euaa298":[{"url":"https://hartvaat.nl/2021/03/08/katheterablatie-om-af-progressie-te-vertragen-attest-gerandomiseerde-trial/","title":"Katheterablatie om AF-progressie te vertragen: ATTEST gerandomiseerde trial","title_en":"Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST).","published":"2021-03-08"}],"10.1093/europace/euaa289":[{"url":"https://hartvaat.nl/2021/03/08/multi-katheter-cryotherapie-versus-rf-ablatie-bij-langdurig-persisterend-af-gera/","title":"Multi-katheter cryotherapie versus RF-ablatie bij langdurig persisterend AF: gerandomiseerde trial","title_en":"Multi-catheter cryotherapy compared with radiofrequency ablation in long-standing persistent atrial fibrillation: a randomized clinical trial.","published":"2021-03-08"}],"10.1161/hypertensionaha.120.15580":[{"url":"https://hartvaat.nl/2021/03/03/verminderde-verkeersgerelateerde-luchtvervuiling-en-bloeddruk-gerandomiseerde-cr/","title":"Verminderde verkeersgerelateerde luchtvervuiling en bloeddruk: gerandomiseerde crossover trial","title_en":"Effect of Reducing Ambient Traffic-Related Air Pollution on Blood Pressure: A Randomized Crossover Trial.","published":"2021-03-03"}],"10.1016/j.jacc.2020.12.047":[{"url":"https://hartvaat.nl/2021/03/02/3-jaarsuitkomsten-van-transcatheter-mitraalklepherstel-bij-hf-coapt/","title":"3-jaarsuitkomsten van transcatheter mitraalklepherstel bij HF: COAPT","title_en":"3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure.","published":"2021-03-02"}],"10.1093/eurheartj/ehaa1040":[{"url":"https://hartvaat.nl/2021/03/01/genoomwijde-analyse-identificeert-nieuwe-mi-gevoeligheidsloci/","title":"Genoomwijde analyse identificeert nieuwe MI-gevoeligheidsloci","title_en":"Genome-wide analysis identifies novel susceptibility loci for myocardial infarction.","published":"2021-03-01"}],"10.1001/jamacardio.2020.6314":[{"url":"https://hartvaat.nl/2021/03/01/objectieve-risicobeoordeling-versus-standaardzorg-bij-acs-jama-cardiology/","title":"Objectieve risicobeoordeling versus standaardzorg bij ACS: JAMA Cardiology","title_en":"Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical Trial.","published":"2021-03-01"}],"10.1016/j.kint.2020.10.026":[{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-bloeddruk-bij-ckd-executive-summary/","title":"KDIGO 2021 bloeddruk bij CKD: executive summary","title_en":"Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.","published":"2021-03-01"}],"10.1016/j.kint.2020.11.003":[{"url":"https://hartvaat.nl/2021/03/01/kdigo-2021-richtlijn-voor-bloeddrukmanagement-bij-ckd/","title":"KDIGO 2021 richtlijn voor bloeddrukmanagement bij CKD","title_en":"KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.","published":"2021-03-01"}],"10.1136/heartjnl-2020-316823":[{"url":"https://hartvaat.nl/2021/03/01/langetermijn-overlevingsvoordeel-van-ramipril-bij-mi-met-hf/","title":"Langetermijn overlevingsvoordeel van ramipril bij MI met HF","title_en":"Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure.","published":"2021-03-01"}],"10.1136/heartjnl-2020-317182":[{"url":"https://hartvaat.nl/2021/03/01/bnp-en-cardiale-remodellering-na-mi-gerandomiseerde-trial/","title":"BNP en cardiale remodellering na MI: gerandomiseerde trial","title_en":"B-type natriuretic peptide and cardiac remodelling after myocardial infarction: a randomised trial.","published":"2021-03-01"}],"10.1161/circulationaha.120.047987":[{"url":"https://hartvaat.nl/2021/02/23/myocardinfarct-in-de-ischemia-trial-impact-van-verschillende-mi-definities/","title":"Myocardinfarct in de ISCHEMIA-trial: impact van verschillende MI-definities","title_en":"Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons.","published":"2021-02-23"}],"10.1016/j.jacc.2020.11.066":[{"url":"https://hartvaat.nl/2021/02/16/progressie-van-tricuspidalisinsufficientie-na-chirurgie-voor-ischemische-mr/","title":"Progressie van tricuspidalisinsufficiëntie na chirurgie voor ischemische MR","title_en":"Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation.","published":"2021-02-16"}],"10.1016/j.jacc.2020.11.022":[{"url":"https://hartvaat.nl/2021/02/16/2021-acc-hf-behandeloptimalisatie-update-antwoorden-op-10-cruciale-vragen/","title":"2021 ACC HF-behandeloptimalisatie update: antwoorden op 10 cruciale vragen","title_en":"2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2021-02-16"}],"10.1016/j.jacc.2020.11.013":[{"url":"https://hartvaat.nl/2021/02/16/2021-acc-consensus-same-day-ontslag-na-pci/","title":"2021 ACC consensus: same-day ontslag na PCI","title_en":"2021 ACC Expert Consensus Decision Pathway on Same-Day Discharge After Percutaneous Coronary Intervention: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2021-02-16"}],"10.1016/s0140-6736(21)00100-8":[{"url":"https://hartvaat.nl/2021/02/13/transdermaal-oestradiol-bij-prostaatkanker-langetermijn-cv-uitkomsten-lancet/","title":"Transdermaal oestradiol bij prostaatkanker: langetermijn CV-uitkomsten — Lancet","title_en":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.","published":"2021-02-13"}],"10.1093/eurheartj/ehaa968":[{"url":"https://hartvaat.nl/2021/02/11/neprilysineremming-en-empagliflozine-bij-chronisch-hfref-emperor-reduced-interac/","title":"Neprilysineremming en empagliflozine bij chronisch HFrEF: EMPEROR-Reduced interactie","title_en":"Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.","published":"2021-02-11"}],"10.1093/eurheartj/ehaa943":[{"url":"https://hartvaat.nl/2021/02/11/empagliflozine-en-inspanningsvermogen-bij-hfref-en-hfpef-emperial/","title":"Empagliflozine en inspanningsvermogen bij HFrEF en HFpEF: EMPERIAL","title_en":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.","published":"2021-02-11"}],"10.1093/eurheartj/ehaa758":[{"url":"https://hartvaat.nl/2021/02/11/spironolacton-en-cardiovasculaire-functie-bij-risico-op-hf-ehj/","title":"Spironolacton en cardiovasculaire functie bij risico op HF: EHJ","title_en":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.","published":"2021-02-11"}],"10.1001/jama.2021.0135":[{"url":"https://hartvaat.nl/2021/02/09/restrictieve-versus-liberale-transfusie-bij-acuut-mi-jama-reality/","title":"Restrictieve versus liberale transfusie bij acuut MI: JAMA REALITY","title_en":"Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.","published":"2021-02-09"}],"10.1001/jama.2020.26812":[{"url":"https://hartvaat.nl/2021/02/09/hiit-matig-continu-of-richtlijnadvies-en-piek-vo2-bij-hfref-jama-smartex-hf/","title":"HIIT, matig continu of richtlijnadvies en piek-VO2 bij HFrEF: JAMA SMARTEX-HF","title_en":"Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.","published":"2021-02-09"}],"10.1016/j.jacc.2020.11.055":[{"url":"https://hartvaat.nl/2021/02/09/10-jaarsmortaliteit-na-pci-of-cabg-bij-totale-coronairocclusie/","title":"10-jaarsmortaliteit na PCI of CABG bij totale coronairocclusie","title_en":"Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions.","published":"2021-02-09"}],"10.1016/j.jacc.2020.09.011":[{"url":"https://hartvaat.nl/2021/02/09/2020-acc-consensus-anticoagulatie-en-antiplaatjestherapie-bij-af-of-vte/","title":"2020 ACC consensus: anticoagulatie en antiplaatjestherapie bij AF of VTE","title_en":"2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2021-02-09"}],"10.1161/circulationaha.120.051898":[{"url":"https://hartvaat.nl/2021/02/09/finerenon-en-cardiovasculaire-uitkomsten-bij-ckd-met-diabetes-type-2-fidelio-dkd/","title":"Finerenon en cardiovasculaire uitkomsten bij CKD met diabetes type 2: FIDELIO-DKD","title_en":"Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.","published":"2021-02-09"}],"10.1161/circulationaha.120.052209":[{"url":"https://hartvaat.nl/2021/02/09/omega-3-vetzuren-bij-oudere-mi-patienten-omemi-gerandomiseerde-trial/","title":"Omega-3 vetzuren bij oudere MI-patiënten: OMEMI gerandomiseerde trial","title_en":"Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial.","published":"2021-02-09"}],"10.1161/circulationaha.120.052186":[{"url":"https://hartvaat.nl/2021/02/09/empagliflozine-en-lv-volumes-bij-diabetes-prediabetes-met-hfref-sugar-dm-hf/","title":"Empagliflozine en LV-volumes bij diabetes/prediabetes met HFrEF: SUGAR-DM-HF","title_en":"Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).","published":"2021-02-09"}],"10.1093/europace/euaa266":[{"url":"https://hartvaat.nl/2021/02/05/laa-isolatie-tijdens-af-ablatie-geactualiseerde-meta-analyse/","title":"LAA-isolatie tijdens AF-ablatie: geactualiseerde meta-analyse","title_en":"Efficacy and safety of left atrial appendage electrical isolation during catheter ablation of atrial fibrillation: an updated meta-analysis.","published":"2021-02-05"}],"10.1093/europace/euaa276":[{"url":"https://hartvaat.nl/2021/02/05/slokdarmbescherming-met-temperatuurcontroleren-bij-af-ablatie-impact/","title":"Slokdarmbescherming met temperatuurcontroleren bij AF-ablatie: IMPACT","title_en":"Randomized comparison of oesophageal protection with a temperature control device: results of the IMPACT study.","published":"2021-02-05"}],"10.1016/j.jacc.2020.11.046":[{"url":"https://hartvaat.nl/2021/02/02/dalend-hemoglobine-en-prognose-bij-acs-hospitalisatie/","title":"Dalend hemoglobine en prognose bij ACS-hospitalisatie","title_en":"Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes.","published":"2021-02-02"}],"10.1001/jamacardio.2020.5763":[{"url":"https://hartvaat.nl/2021/02/01/zelfzorginterventie-en-90-daags-uitkomsten-bij-acuut-hf-na-seh-ontslag-jama-card/","title":"Zelfzorginterventie en 90-daags uitkomsten bij acuut HF na SEH-ontslag: JAMA Cardiology","title_en":"Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department: A Randomized Clinical Trial.","published":"2021-02-01"}],"10.1001/jamacardio.2020.4511":[{"url":"https://hartvaat.nl/2021/02/01/sglt2-remmers-en-cv-renale-uitkomsten-bij-diabetes-type-2-jama-cardiology-meta-a/","title":"SGLT2-remmers en CV/renale uitkomsten bij diabetes type 2: JAMA Cardiology meta-analyse","title_en":"Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.","published":"2021-02-01"}],"10.1001/jamacardio.2020.3151":[{"url":"https://hartvaat.nl/2021/02/01/evolocumab-bij-metabool-syndroom-na-acs-fourier/","title":"Evolocumab bij metabool syndroom na ACS: FOURIER","title_en":"Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.","published":"2021-02-01"}],"10.1161/hypertensionaha.120.15781":[{"url":"https://hartvaat.nl/2021/02/01/therapietrouw-aan-single-pill-versus-vrije-combinatietherapie-bij-hypertensie-me/","title":"Therapietrouw aan single-pill versus vrije combinatietherapie bij hypertensie: meta-analyse","title_en":"Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis.","published":"2021-02-01"}],"10.1161/hypertensionaha.120.16277":[{"url":"https://hartvaat.nl/2021/02/01/polsdruk-prognose-en-sacubitril-valsartan-bij-hfpef-paragon-hf/","title":"Polsdruk, prognose en sacubitril/valsartan bij HFpEF: PARAGON-HF","title_en":"Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.","published":"2021-02-01"}],"10.1161/hypertensionaha.120.16547":[{"url":"https://hartvaat.nl/2021/02/01/urinezuur-bloeddruk-en-cv-ziekte-mendeliaanse-randomisatie-en-meta-analyse/","title":"Urinezuur, bloeddruk en CV-ziekte: Mendeliaanse randomisatie en meta-analyse","title_en":"Urate, Blood Pressure, and Cardiovascular Disease: Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials.","published":"2021-02-01"}],"10.1002/ehf2.13141":[{"url":"https://hartvaat.nl/2021/02/01/revascularisatie-bij-ernstig-verminderde-lvef-korte-en-langetermijnuitkomsten/","title":"Revascularisatie bij ernstig verminderde LVEF: korte- en langetermijnuitkomsten","title_en":"Short-term and long-term outcomes of revascularization interventions for patients with severely reduced left ventricular ejection fraction: a meta-analysis.","published":"2021-02-01"}],"10.1056/nejmoa2008470":[{"url":"https://hartvaat.nl/2021/01/28/inhalatietreprostinil-bij-pulmonale-hypertensie-door-interstitiele-longziekte-ne/","title":"Inhalatietreprostinil bij pulmonale hypertensie door interstitiële longziekte: NEJM INCREASE","title_en":"Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.","published":"2021-01-28"}],"10.1056/nejmoa2029980":[{"url":"https://hartvaat.nl/2021/01/28/cryoablatie-of-medicatie-als-initiele-af-behandeling-nejm-stop-af-first/","title":"Cryoablatie of medicatie als initiële AF-behandeling: NEJM STOP AF First","title_en":"Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation.","published":"2021-01-28"}],"10.1056/nejmoa2029554":[{"url":"https://hartvaat.nl/2021/01/28/cryoballonablatie-als-initiele-therapie-voor-af-nejm-early-af/","title":"Cryoballonablatie als initiële therapie voor AF: NEJM EARLY-AF","title_en":"Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation.","published":"2021-01-28"}],"10.1093/europace/euaa199":[{"url":"https://hartvaat.nl/2021/01/27/periprocedurele-antistolling-bij-eliminate-af-ononderbroken-edoxaban-versus-vka/","title":"Periprocedurele antistolling bij ELIMINATE-AF: ononderbroken edoxaban versus VKA","title_en":"Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.","published":"2021-01-27"}],"10.1093/europace/euaa242":[{"url":"https://hartvaat.nl/2021/01/27/doac-s-en-fractuurrisico-systematische-review-en-meta-analyse/","title":"DOAC's en fractuurrisico: systematische review en meta-analyse","title_en":"Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis.","published":"2021-01-27"}],"10.1093/europace/euaa139":[{"url":"https://hartvaat.nl/2021/01/27/mobiele-gezondheidstoepassingen-voor-af-detectie-systematische-review/","title":"Mobiele gezondheidstoepassingen voor AF-detectie: systematische review","title_en":"Mobile health applications for the detection of atrial fibrillation: a systematic review.","published":"2021-01-27"}],"10.1016/j.jacc.2020.08.037":[{"url":"https://hartvaat.nl/2021/01/26/2020-acc-aha-kwaliteitsmaten-voor-af-geactualiseerd/","title":"2020 ACC/AHA kwaliteitsmaten voor AF: geactualiseerd","title_en":"2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.","published":"2021-01-26"}],"10.1016/j.jacc.2020.11.008":[{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-bij-niet-diabetische-hfref-emperor-reduced-subanalyse/","title":"Empagliflozine bij niet-diabetische HFrEF: EMPEROR-Reduced subanalyse","title_en":"Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.","published":"2021-01-26"}],"10.1161/circulationaha.120.051783":[{"url":"https://hartvaat.nl/2021/01/26/empagliflozine-en-klinische-stabiliteit-bij-hfref-emperor-reduced/","title":"Empagliflozine en klinische stabiliteit bij HFrEF: EMPEROR-Reduced","title_en":"Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.","published":"2021-01-26"}],"10.1093/eurheartj/ehaa739":[{"url":"https://hartvaat.nl/2021/01/21/korte-dapt-gevolgd-door-p2y12-mono-versus-verlengde-dapt-meta-analyse/","title":"Korte DAPT gevolgd door P2Y12 mono versus verlengde DAPT: meta-analyse","title_en":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.","published":"2021-01-21"}],"10.1056/nejmoa2028220":[{"url":"https://hartvaat.nl/2021/01/21/polypil-met-of-zonder-aspirine-bij-personen-zonder-cvd-nejm-polypill-tips-3/","title":"Polypil met of zonder aspirine bij personen zonder CVD: NEJM PolyPill-TIPS-3","title_en":"Polypill with or without Aspirin in Persons without Cardiovascular Disease.","published":"2021-01-21"}],"10.1001/jama.2020.25864":[{"url":"https://hartvaat.nl/2021/01/19/stoppen-versus-doorgaan-met-ace-remmers-arb-s-bij-gehospitaliseerde-patienten-ja/","title":"Stoppen versus doorgaan met ACE-remmers/ARB's bij gehospitaliseerde patiënten: JAMA REPLACE-COVID","title_en":"Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.","published":"2021-01-19"}],"10.1016/j.jacc.2020.11.025":[{"url":"https://hartvaat.nl/2021/01/19/residuele-syntax-score-bij-cardiogene-shock/","title":"Residuele SYNTAX-score bij cardiogene shock","title_en":"Predictive Value of the Residual SYNTAX Score in Patients With Cardiogenic Shock.","published":"2021-01-19"}],"10.1056/nejmoa2030183":[{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-recent-verslechterend-hf-nejm-soloist-whf/","title":"Sotagliflozine bij diabetes met recent verslechterend HF: NEJM SOLOIST-WHF","title_en":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.","published":"2021-01-14"}],"10.1056/nejmoa2030186":[{"url":"https://hartvaat.nl/2021/01/14/sotagliflozine-bij-diabetes-met-ckd-nejm-scored/","title":"Sotagliflozine bij diabetes met CKD: NEJM SCORED","title_en":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.","published":"2021-01-14"}],"10.1056/nejmoa2025797":[{"url":"https://hartvaat.nl/2021/01/14/omecamtiv-mecarbil-bij-systolisch-hartfalen-nejm-galactic-hf/","title":"Omecamtiv mecarbil bij systolisch hartfalen: NEJM GALACTIC-HF","title_en":"Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.","published":"2021-01-14"}],"10.1093/eurheartj/ehaa898":[{"url":"https://hartvaat.nl/2021/01/07/antisense-tegen-microrna-132-bij-hartfalen-fase-1b-resultaten/","title":"Antisense tegen microRNA-132 bij hartfalen: fase 1b resultaten","title_en":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.","published":"2021-01-07"}],"10.1016/j.jacc.2020.10.049":[{"url":"https://hartvaat.nl/2021/01/05/calcium-geinduceerde-autonome-denervatie-bij-postoperatief-af/","title":"Calcium-geïnduceerde autonome denervatie bij postoperatief AF","title_en":"Calcium-Induced Autonomic Denervation in Patients With Post-Operative Atrial Fibrillation.","published":"2021-01-05"}],"10.1016/j.jacc.2020.10.047":[{"url":"https://hartvaat.nl/2021/01/05/leeftijd-en-10-jaarsuitkomsten-na-cabg-art-trial/","title":"Leeftijd en 10-jaarsuitkomsten na CABG: ART-trial","title_en":"Association of Age With 10-Year Outcomes After Coronary Surgery in the Arterial Revascularization Trial.","published":"2021-01-05"}],"10.1001/jama.2020.22176":[{"url":"https://hartvaat.nl/2021/01/05/management-van-pfo-patienten-met-cva-of-tia-jama-klinisch-overzicht/","title":"Management van PFO-patiënten met CVA of TIA: JAMA klinisch overzicht","title_en":"Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA.","published":"2021-01-05"}],"10.1001/jama.2020.23649":[{"url":"https://hartvaat.nl/2021/01/05/hoog-dosis-versus-standaarddosis-griepvaccin-en-mortaliteit-bij-ouderen-jama/","title":"Hoog-dosis versus standaarddosis griepvaccin en mortaliteit bij ouderen: JAMA","title_en":"Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.","published":"2021-01-05"}],"10.1161/circulationaha.120.050276":[{"url":"https://hartvaat.nl/2021/01/05/revascularisatiereductie-met-icosapent-ethyl-reduce-it-analyse/","title":"Revascularisatiereductie met icosapent-ethyl: REDUCE-IT analyse","title_en":"Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.","published":"2021-01-05"}],"10.1001/jamacardio.2020.4730":[{"url":"https://hartvaat.nl/2021/01/01/passive-choice-en-active-choice-interventies-voor-statinevoorschrijving-jama-car/","title":"Passive choice en active choice interventies voor statinevoorschrijving: JAMA Cardiology","title_en":"Effect of Passive Choice and Active Choice Interventions in the Electronic Health Record to Cardiologists on Statin Prescribing: A Cluster Randomized Clinical Trial.","published":"2021-01-01"}],"10.1001/jamacardio.2020.4390":[{"url":"https://hartvaat.nl/2021/01/01/rivaroxaban-plus-aspirine-bij-symptomatisch-pav-compass-subanalyse/","title":"Rivaroxaban plus aspirine bij symptomatisch PAV: COMPASS subanalyse","title_en":"Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.","published":"2021-01-01"}],"10.1161/hypertensionaha.120.16061":[{"url":"https://hartvaat.nl/2021/01/01/plasmatrogconcentraties-van-antihypertensiva-voor-therapietrouwbeoordeling-meta-/","title":"Plasmatrogconcentraties van antihypertensiva voor therapietrouwbeoordeling: meta-analyse","title_en":"Plasma Trough Concentrations of Antihypertensive Drugs for the Assessment of Treatment Adherence: A Meta-Analysis.","published":"2021-01-01"}],"10.1161/hypertensionaha.120.16156":[{"url":"https://hartvaat.nl/2021/01/01/dash-dieet-verbetert-bloeddruk-en-vaatgezondheid-bij-jongeren-met-verhoogde-bloe/","title":"DASH-dieet verbetert bloeddruk en vaatgezondheid bij jongeren met verhoogde bloeddruk","title_en":"Dietary Approaches to Stop Hypertension Dietary Intervention Improves Blood Pressure and Vascular Health in Youth With Elevated Blood Pressure.","published":"2021-01-01"}],"10.1001/jama.2020.23138":[{"url":"https://hartvaat.nl/2020/12/22/digoxine-versus-bisoprolol-voor-frequentiecontrole-bij-af-en-qol-jama-rate-af/","title":"Digoxine versus bisoprolol voor frequentiecontrole bij AF en QoL: JAMA RATE-AF","title_en":"Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.","published":"2020-12-22"}],"10.1161/circulationaha.120.049287":[{"url":"https://hartvaat.nl/2020/12/22/fentanyl-versus-morfine-op-ticagrelor-plaatjesremming-bij-stemi/","title":"Fentanyl versus morfine op ticagrelor-plaatjesremming bij STEMI","title_en":"Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: The PERSEUS Randomized Trial.","published":"2020-12-22"}],"10.1161/circulationaha.120.050941":[{"url":"https://hartvaat.nl/2020/12/22/lichaamssamenstelling-en-risico-op-hartfalen-en-mi-prospectieve-analyse/","title":"Lichaamssamenstelling en risico op hartfalen en MI: prospectieve analyse","title_en":"Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial.","published":"2020-12-22"}],"10.1001/jama.2020.23027":[{"url":"https://hartvaat.nl/2020/12/15/aflibercept-versus-vitrectomie-bij-diabetische-glasvochtbloeding-jama-drcr-net-p/","title":"Aflibercept versus vitrectomie bij diabetische glasvochtbloeding: JAMA DRCR.net Protocol AB","title_en":"Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.","published":"2020-12-15"}],"10.1161/circulationaha.120.051532":[{"url":"https://hartvaat.nl/2020/12/15/prehospitaal-gemalen-prasugrel-bij-stemi-gerandomiseerde-trial/","title":"Prehospitaal gemalen prasugrel bij STEMI: gerandomiseerde trial","title_en":"Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.","published":"2020-12-15"}],"10.1161/circulationaha.120.050244":[{"url":"https://hartvaat.nl/2020/12/15/ticagrelor-of-prasugrel-bij-stemi-met-primaire-pci-isar-react-5-stemi/","title":"Ticagrelor of prasugrel bij STEMI met primaire PCI: ISAR-REACT 5 STEMI","title_en":"Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.","published":"2020-12-15"}],"10.1093/eurheartj/ehaa658":[{"url":"https://hartvaat.nl/2020/12/14/katheterablatie-versus-thoracoscopische-ablatie-bij-langdurig-persisterend-af-ca/","title":"Katheterablatie versus thoracoscopische ablatie bij langdurig persisterend AF: CASA-AF","title_en":"Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial.","published":"2020-12-14"}],"10.1093/eurheartj/ehaa617":[{"url":"https://hartvaat.nl/2020/12/14/edoxaban-bij-af-met-pci-naar-acute-versus-chronische-coronaire-presentatie-entru/","title":"Edoxaban bij AF met PCI naar acute versus chronische coronaire presentatie: ENTRUST","title_en":"Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.","published":"2020-12-14"}],"10.1016/s0140-6736(20)32339-4":[{"url":"https://hartvaat.nl/2020/12/12/ijzercarboxymaltose-bij-ijzerdeficientie-na-ontslag-voor-acuut-hf-lancet-affirm-/","title":"IJzercarboxymaltose bij ijzerdeficiëntie na ontslag voor acuut HF: Lancet AFFIRM-AHF","title_en":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.","published":"2020-12-12"}],"10.1056/nejmoa2031049":[{"url":"https://hartvaat.nl/2020/12/10/evinacumab-bij-refractaire-hypercholesterolemie-nejm/","title":"Evinacumab bij refractaire hypercholesterolemie: NEJM","title_en":"Evinacumab in Patients with Refractory Hypercholesterolemia.","published":"2020-12-10"}],"10.1016/j.jacc.2020.08.089":[{"url":"https://hartvaat.nl/2020/12/08/laa-sluiting-versus-oac-bij-af-meta-analyse-van-gerandomiseerde-trials/","title":"LAA-sluiting versus OAC bij AF: meta-analyse van gerandomiseerde trials","title_en":"Left Atrial Appendage Closure Versus Oral Anticoagulants in Atrial Fibrillation: A Meta-Analysis of Randomized Trials.","published":"2020-12-08"}],"10.1016/j.jacc.2020.10.005":[{"url":"https://hartvaat.nl/2020/12/08/empagliflozine-en-hemodynamiek-bij-hfref/","title":"Empagliflozine en hemodynamiek bij HFrEF","title_en":"Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction.","published":"2020-12-08"}],"10.1016/j.jacc.2020.10.008":[{"url":"https://hartvaat.nl/2020/12/08/remnant-cholesterol-versus-ldl-en-incident-cv-ziekte/","title":"Remnant cholesterol versus LDL en incident CV-ziekte","title_en":"Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease.","published":"2020-12-08"}],"10.1001/jama.2020.22258":[{"url":"https://hartvaat.nl/2020/12/08/hoog-dosis-omega-3-versus-maisolie-bij-hoog-cv-risico-jama-strength/","title":"Hoog-dosis omega-3 versus maisolie bij hoog CV-risico: JAMA STRENGTH","title_en":"Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.","published":"2020-12-08"}],"10.1161/circulationaha.120.050255":[{"url":"https://hartvaat.nl/2020/12/08/ertugliflozine-en-hf-events-bij-diabetes-met-atherosclerotische-cvd-vertis-cv/","title":"Ertugliflozine en HF-events bij diabetes met atherosclerotische CVD: VERTIS CV","title_en":"Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.","published":"2020-12-08"}],"10.1016/j.jacc.2020.09.609":[{"url":"https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/","title":"Pulmonale hypertensie bij MitraClip: COAPT-analyse","title_en":"Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation: The COAPT Trial.","published":"2020-12-01"}],"10.1001/jamacardio.2020.3670":[{"url":"https://hartvaat.nl/2020/12/01/coronairangiografie-na-hartstilstand-zonder-st-elevatie-coact-1-jaarsuitkomsten/","title":"Coronairangiografie na hartstilstand zonder ST-elevatie: COACT 1-jaarsuitkomsten","title_en":"Coronary Angiography After Cardiac Arrest Without ST Segment Elevation: One-Year Outcomes of the COACT Randomized Clinical Trial.","published":"2020-12-01"}],"10.1001/jamacardio.2020.3377":[{"url":"https://hartvaat.nl/2020/12/01/culprit-laesielocatie-en-uitkomsten-van-culprit-only-vs-multivaten-pci-culprit-s/","title":"Culprit-laesielocatie en uitkomsten van culprit-only vs multivaten-PCI: CULPRIT-SHOCK","title_en":"Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial.","published":"2020-12-01"}],"10.1002/ehf2.13169":[{"url":"https://hartvaat.nl/2020/12/01/sglt2-remmers-bij-hartfalen-systematische-review-en-meta-analyse/","title":"SGLT2-remmers bij hartfalen: systematische review en meta-analyse","title_en":"Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.","published":"2020-12-01"}],"10.1002/ehf2.13146":[{"url":"https://hartvaat.nl/2020/12/01/ijzercarboxymaltose-bij-ijzerdeficient-hartfalen-meta-analyse/","title":"IJzercarboxymaltose bij ijzerdeficiënt hartfalen: meta-analyse","title_en":"Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis.","published":"2020-12-01"}],"10.1161/hypertensionaha.120.16160":[{"url":"https://hartvaat.nl/2020/12/01/mindfulness-gebaseerde-stressreductie-bij-verhoogde-bloeddruk-meta-analyse/","title":"Mindfulness-gebaseerde stressreductie bij verhoogde bloeddruk: meta-analyse","title_en":"Effect and Acceptability of Mindfulness-Based Stress Reduction Program on Patients With Elevated Blood Pressure or Hypertension: A Meta-Analysis of Randomized Controlled Trials.","published":"2020-12-01"}],"10.1161/hypertensionaha.120.16209":[{"url":"https://hartvaat.nl/2020/12/01/langetermijn-bloeddrukvariabiliteit-en-cv-risico-bij-ouderen-in-de-community/","title":"Langetermijn bloeddrukvariabiliteit en CV-risico bij ouderen in de community","title_en":"Long-Term Blood Pressure Variability and Risk of Cardiovascular Disease Events Among Community-Dwelling Elderly.","published":"2020-12-01"}],"10.1161/hypertensionaha.120.15868":[{"url":"https://hartvaat.nl/2020/12/01/intensieve-bloeddrukcontrole-en-alle-hospitalisaties-sprint/","title":"Intensieve bloeddrukcontrole en alle hospitalisaties: SPRINT","title_en":"Effects of Intensive Systolic Blood Pressure Control on All-Cause Hospitalizations.","published":"2020-12-01"}],"10.1161/hypertensionaha.120.15870":[{"url":"https://hartvaat.nl/2020/12/01/verlaagd-il-10-bij-pre-eclampsie-systematische-review-en-meta-analyse/","title":"Verlaagd IL-10 bij pre-eclampsie: systematische review en meta-analyse","title_en":"Preeclamptic Women Have Decreased Circulating IL-10 (Interleukin-10) Values at the Time of Preeclampsia Diagnosis: Systematic Review and Meta-Analysis.","published":"2020-12-01"}],"10.1136/heartjnl-2020-316612":[{"url":"https://hartvaat.nl/2020/12/01/qol-cognitie-en-functionele-status-na-af-ablatie/","title":"QoL, cognitie en functionele status na AF-ablatie","title_en":"Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation.","published":"2020-12-01"}],"10.1136/heartjnl-2019-316429":[{"url":"https://hartvaat.nl/2020/12/01/longechogeleide-therapie-vermindert-acute-decompensatie-bij-chronisch-hf/","title":"Longechogeleide therapie vermindert acute decompensatie bij chronisch HF","title_en":"Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure.","published":"2020-12-01"}],"10.1016/s0140-6736(20)32236-4":[{"url":"https://hartvaat.nl/2020/11/28/ticagrelor-versus-clopidogrel-bij-electieve-pci-lancet-alpheus/","title":"Ticagrelor versus clopidogrel bij electieve PCI: Lancet ALPHEUS","title_en":"Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.","published":"2020-11-28"}],"10.1056/nejmoa2029603":[{"url":"https://hartvaat.nl/2020/11/26/rivaroxaban-bij-af-met-bioprothese-mitralisklep-nejm-river/","title":"Rivaroxaban bij AF met bioprothese-mitralisklep: NEJM RIVER","title_en":"Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.","published":"2020-11-26"}],"10.1056/nejmc2031173":[{"url":"https://hartvaat.nl/2020/11/26/n-of-1-trial-van-statine-placebo-of-geen-behandeling-voor-bijwerkingen-nejm-stat/","title":"N-of-1 trial van statine, placebo of geen behandeling voor bijwerkingen: NEJM StatinWISE","title_en":"N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects.","published":"2020-11-26"}],"10.1001/jama.2020.21749":[{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-cv-preventie-bij-risicoadulten-jama-uspstf-evidence-revie/","title":"Gedragscounseling voor CV-preventie bij risicoadulten: JAMA USPSTF evidence review","title_en":"Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.","published":"2020-11-24"}],"10.1001/jama.2020.17108":[{"url":"https://hartvaat.nl/2020/11/24/gedragscounseling-voor-gezond-dieet-en-beweging-bij-cv-risico-jama-uspstf/","title":"Gedragscounseling voor gezond dieet en beweging bij CV-risico: JAMA USPSTF","title_en":"Behavioral Counseling to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2020-11-24"}],"10.1016/j.jacc.2020.09.584":[{"url":"https://hartvaat.nl/2020/11/24/ticagrelor-of-prasugrel-bij-nste-acs-isar-react-5-subanalyse/","title":"Ticagrelor of prasugrel bij NSTE-ACS: ISAR-REACT 5 subanalyse","title_en":"Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.","published":"2020-11-24"}],"10.1016/j.jacc.2020.07.023":[{"url":"https://hartvaat.nl/2020/11/24/2020-acc-aha-prestatie-en-kwaliteitsmaten-voor-hartfalen/","title":"2020 ACC/AHA prestatie- en kwaliteitsmaten voor hartfalen","title_en":"2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.","published":"2020-11-24"}],"10.1161/circulationaha.120.049569":[{"url":"https://hartvaat.nl/2020/11/24/vroege-coronairangiografie-versus-uitstel-na-hartstilstand-zonder-st-elevatie-pi/","title":"Vroege coronairangiografie versus uitstel na hartstilstand zonder ST-elevatie: pilot RCT","title_en":"Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation: The PEARL Study.","published":"2020-11-24"}],"10.1016/j.jacc.2020.08.053":[{"url":"https://hartvaat.nl/2020/11/24/timing-van-orale-p2y12-remmer-bij-nste-acs/","title":"Timing van orale P2Y12-remmer bij NSTE-ACS","title_en":"Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.","published":"2020-11-24"}],"10.1016/s0140-6736(20)32332-1":[{"url":"https://hartvaat.nl/2020/11/21/ldl-verlaging-bij-ouderen-lancet-meta-analyse-werkzaamheid-en-veiligheid/","title":"LDL-verlaging bij ouderen: Lancet meta-analyse werkzaamheid en veiligheid","title_en":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.","published":"2020-11-21"}],"10.1093/eurheartj/ehaa649":[{"url":"https://hartvaat.nl/2020/11/21/alirocumab-lp-a-verlaging-en-totale-cv-eventlast-onafhankelijk-van-ldl-odyssey-o/","title":"Alirocumab Lp(a)-verlaging en totale CV-eventlast onafhankelijk van LDL: ODYSSEY OUTCOMES","title_en":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.","published":"2020-11-21"}],"10.1056/nejmoa2027187":[{"url":"https://hartvaat.nl/2020/11/19/lorlatinib-versus-crizotinib-bij-alk-positief-longkanker-nejm/","title":"Lorlatinib versus crizotinib bij ALK-positief longkanker: NEJM","title_en":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.","published":"2020-11-19"}],"10.1001/jama.2020.19378":[{"url":"https://hartvaat.nl/2020/11/17/seh-zorgbundel-en-30-daags-ontslag-en-overleving-bij-oudere-hf-patienten-jama/","title":"SEH-zorgbundel en 30-daags ontslag en overleving bij oudere HF-patiënten: JAMA","title_en":"Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial.","published":"2020-11-17"}],"10.1016/j.jacc.2020.09.550":[{"url":"https://hartvaat.nl/2020/11/17/transcatheter-bariatrische-embolotherapie-voor-gewichtsreductie-bij-obesitas/","title":"Transcatheter bariatrische embolotherapie voor gewichtsreductie bij obesitas","title_en":"Transcatheter Bariatric Embolotherapy for Weight Reduction in Obesity.","published":"2020-11-17"}],"10.1016/j.jacc.2020.09.547":[{"url":"https://hartvaat.nl/2020/11/17/pci-voor-kwetsbare-coronaire-plaque/","title":"PCI voor kwetsbare coronaire plaque","title_en":"Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque.","published":"2020-11-17"}],"10.1161/circulationaha.120.050771":[{"url":"https://hartvaat.nl/2020/11/17/colchicine-bij-acs-australische-cops-gerandomiseerde-trial/","title":"Colchicine bij ACS: Australische COPS gerandomiseerde trial","title_en":"Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial.","published":"2020-11-17"}],"10.1001/jama.2020.20122":[{"url":"https://hartvaat.nl/2020/11/10/screening-op-hoge-bloeddruk-bij-kinderen-uspstf-aanbeveling-2020/","title":"Screening op hoge bloeddruk bij kinderen: USPSTF aanbeveling 2020","title_en":"Screening for High Blood Pressure in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.","published":"2020-11-10"}],"10.1001/jama.2020.11119":[{"url":"https://hartvaat.nl/2020/11/10/screening-op-hypertensie-bij-kinderen-uspstf-evidence-report-2020/","title":"Screening op hypertensie bij kinderen: USPSTF evidence report 2020","title_en":"Screening for Hypertension in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2020-11-10"}],"10.1001/jama.2020.16909":[{"url":"https://hartvaat.nl/2020/11/10/vitamine-d-omega-3-of-krachttraining-en-klinische-uitkomsten-bij-ouderen-jama-do/","title":"Vitamine D, omega-3 of krachttraining en klinische uitkomsten bij ouderen: JAMA DO-HEALTH","title_en":"Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial.","published":"2020-11-10"}],"10.1161/circulationaha.120.046685":[{"url":"https://hartvaat.nl/2020/11/10/chinese-kruidenformule-voor-gemaskeerde-hypertensie-gerandomiseerde-placebogecon/","title":"Chinese kruidenformule voor gemaskeerde hypertensie: gerandomiseerde placebogecontroleerde trial","title_en":"Treatment of Masked Hypertension with a Chinese Herbal Formula: A Randomized, Placebo-Controlled Trial.","published":"2020-11-10"}],"10.1161/circulationaha.120.050749":[{"url":"https://hartvaat.nl/2020/11/10/ticagrelor-plus-aspirine-en-safeneuze-graft-patency-na-cabg/","title":"Ticagrelor plus aspirine en safeneuze graft-patency na CABG","title_en":"Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial.","published":"2020-11-10"}],"10.1016/s0140-6736(20)32173-5":[{"url":"https://hartvaat.nl/2020/11/07/drug-coated-balloons-versus-des-bij-kleine-coronairarterien-lancet-basket-small-/","title":"Drug-coated balloons versus DES bij kleine coronairarteriën: Lancet BASKET-SMALL 2 langetermijn","title_en":"Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.","published":"2020-11-07"}],"10.1093/eurheartj/ehaa659":[{"url":"https://hartvaat.nl/2020/11/07/colchicine-timing-en-cv-uitkomsten-na-mi-colcot-analyse/","title":"Colchicine timing en CV-uitkomsten na MI: COLCOT analyse","title_en":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).","published":"2020-11-07"}],"10.1093/eurheartj/ehaa498":[{"url":"https://hartvaat.nl/2020/11/07/alirocumab-en-mace-naar-nierfunctie-na-acs-odyssey-outcomes/","title":"Alirocumab en MACE naar nierfunctie na ACS: ODYSSEY OUTCOMES","title_en":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.","published":"2020-11-07"}],"10.1093/eurheartj/ehz896":[{"url":"https://hartvaat.nl/2020/11/07/complete-revascularisatie-vermindert-cv-dood-bij-stemi-met-multivatenlijden-meta/","title":"Complete revascularisatie vermindert CV-dood bij STEMI met multivatenlijden: meta-analyse","title_en":"Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials.","published":"2020-11-07"}],"10.1001/jama.2020.18977":[{"url":"https://hartvaat.nl/2020/11/03/online-gewichtsmanagementprogramma-geintegreerd-met-populatiegezondheidsbeheer-j/","title":"Online gewichtsmanagementprogramma geïntegreerd met populatiegezondheidsbeheer: JAMA","title_en":"Effect of an Online Weight Management Program Integrated With Population Health Management on Weight Change: A Randomized Clinical Trial.","published":"2020-11-03"}],"10.1016/j.jacc.2020.09.004":[{"url":"https://hartvaat.nl/2020/11/03/canagliflozine-en-nt-probnp-implicaties-voor-cv-risicoreductie/","title":"Canagliflozine en NT-proBNP: implicaties voor CV-risicoreductie","title_en":"Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.","published":"2020-11-03"}],"10.1161/circulationaha.120.048739":[{"url":"https://hartvaat.nl/2020/11/03/sglt2-remming-plus-lisdiuretica-bij-diabetes-type-2-met-ckd-renale-en-cv-effecte/","title":"SGLT2-remming plus lisdiuretica bij diabetes type 2 met CKD: renale en CV-effecten","title_en":"Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.","published":"2020-11-03"}],"10.1161/circulationaha.120.050304":[{"url":"https://hartvaat.nl/2020/11/03/invasief-versus-conservatief-bij-stabiel-coronairlijden-met-hf-of-lage-ef-ischem/","title":"Invasief versus conservatief bij stabiel coronairlijden met HF of lage EF: ISCHEMIA substudie","title_en":"Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial.","published":"2020-11-03"}],"10.1093/eurheartj/ehaa697":[{"url":"https://hartvaat.nl/2020/11/01/ace2-niveaus-en-covid-19-risicofactoren-bij-af-patienten/","title":"ACE2-niveaus en COVID-19 risicofactoren bij AF-patiënten","title_en":"Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.","published":"2020-11-01"}],"10.1093/europace/euaa224":[{"url":"https://hartvaat.nl/2020/11/01/ablatie-index-geleide-af-ablatie-geactualiseerde-meta-analyse/","title":"Ablatie-index-geleide AF-ablatie: geactualiseerde meta-analyse","title_en":"Efficacy and safety of ablation index-guided catheter ablation for atrial fibrillation: an updated meta-analysis.","published":"2020-11-01"}],"10.1001/jamacardio.2020.2981":[{"url":"https://hartvaat.nl/2020/11/01/klinische-toepassing-van-hs-troponine-in-het-ascvd-raamwerk-jama-cardiology/","title":"Klinische toepassing van hs-troponine in het ASCVD-raamwerk: JAMA Cardiology","title_en":"Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines.","published":"2020-11-01"}],"10.1001/jamacardio.2020.2855":[{"url":"https://hartvaat.nl/2020/11/01/invloed-van-acs-trials-buiten-de-primaire-hypothese-systematische-review/","title":"Invloed van ACS-trials buiten de primaire hypothese: systematische review","title_en":"Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis: A Systematic Review.","published":"2020-11-01"}],"10.1001/jamacardio.2020.2739":[{"url":"https://hartvaat.nl/2020/11/01/lage-dosis-triple-combinatie-en-therapeutische-inertie-bij-hypertensie-jama-card/","title":"Lage-dosis triple combinatie en therapeutische inertie bij hypertensie: JAMA Cardiology","title_en":"Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial.","published":"2020-11-01"}],"10.1161/hypertensionaha.120.15075":[{"url":"https://hartvaat.nl/2020/11/01/20-jaars-dieetinterventie-vanaf-zuigelingenleeftijd-en-bloeddruk-strip-studie/","title":"20-jaars dieetinterventie vanaf zuigelingenleeftijd en bloeddruk: STRIP-studie","title_en":"Attainment of Targets of the 20-Year Infancy-Onset Dietary Intervention and Blood Pressure Across Childhood and Young Adulthood: The Special Turku Coronary Risk Factor Intervention Project (STRIP).","published":"2020-11-01"}],"10.1161/hypertensionaha.120.15989":[{"url":"https://hartvaat.nl/2020/11/01/raas-remmers-en-covid-19-risico-systematische-review-en-meta-analyse/","title":"RAAS-remmers en COVID-19 risico: systematische review en meta-analyse","title_en":"Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis.","published":"2020-11-01"}],"10.1136/heartjnl-2019-316432":[{"url":"https://hartvaat.nl/2020/11/01/random-uitstel-van-pci-bij-diabetes-met-stabiel-coronairlijden/","title":"Random uitstel van PCI bij diabetes met stabiel coronairlijden","title_en":"Effect of random deferral of percutaneous coronary intervention in patients with diabetes and stable ischaemic heart disease.","published":"2020-11-01"}],"10.1136/heartjnl-2019-316349":[{"url":"https://hartvaat.nl/2020/11/01/inspanningsinterventie-verbetert-qol-na-mi-bij-ouderen-gerandomiseerde-trial/","title":"Inspanningsinterventie verbetert QoL na MI bij ouderen: gerandomiseerde trial","title_en":"Exercise intervention improves quality of life in older adults after myocardial infarction: randomised clinical trial.","published":"2020-11-01"}],"10.1016/s0140-6736(20)32114-0":[{"url":"https://hartvaat.nl/2020/10/31/syntax-score-ii-herontwikkeling-voor-gepersonaliseerde-revascularisatiebeslissin/","title":"SYNTAX Score II herontwikkeling voor gepersonaliseerde revascularisatiebeslissing: Lancet","title_en":"Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation.","published":"2020-10-31"}],"10.1056/nejmoa2012883":[{"url":"https://hartvaat.nl/2020/10/29/laaggedoseerd-edoxaban-bij-zeer-oude-af-patienten-nejm-eldercare-af/","title":"Laaggedoseerd edoxaban bij zeer oude AF-patiënten: NEJM ELDERCARE-AF","title_en":"Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.","published":"2020-10-29"}],"10.1001/jama.2020.16195":[{"url":"https://hartvaat.nl/2020/10/27/af-ablatie-met-vena-van-marshall-ethanol-versus-ablatie-alleen-jama-venus/","title":"AF-ablatie met vena van Marshall ethanol versus ablatie alleen: JAMA VENUS","title_en":"Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial.","published":"2020-10-27"}],"10.1161/circulationaha.120.047480":[{"url":"https://hartvaat.nl/2020/10/27/dapagliflozine-en-poliklinische-verslechtering-bij-hfref-dapa-hf/","title":"Dapagliflozine en poliklinische verslechtering bij HFrEF: DAPA-HF","title_en":"Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.","published":"2020-10-27"}],"10.1093/eurheartj/ehaa652":[{"url":"https://hartvaat.nl/2020/10/21/icosapent-ethyl-en-coronaire-atheroscleroseprogressie-bij-verhoogde-triglyceride/","title":"Icosapent-ethyl en coronaire atheroscleroseprogressie bij verhoogde triglyceriden: EVAPORATE","title_en":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.","published":"2020-10-21"}],"10.1093/eurheartj/ehaa689":[{"url":"https://hartvaat.nl/2020/10/21/vupanorsen-angptl3-antisense-en-triglyceriden-ehj/","title":"Vupanorsen ANGPTL3-antisense en triglyceriden: EHJ","title_en":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.","published":"2020-10-21"}],"10.1001/jama.2020.17024":[{"url":"https://hartvaat.nl/2020/10/20/medische-zorg-voor-volwassenen-met-syndroom-van-down-jama-klinische-richtlijn/","title":"Medische zorg voor volwassenen met syndroom van Down: JAMA klinische richtlijn","title_en":"Medical Care of Adults With Down Syndrome: A Clinical Guideline.","published":"2020-10-20"}],"10.1001/jama.2020.16641":[{"url":"https://hartvaat.nl/2020/10/20/praliciguat-en-piek-vo2-bij-hfpef-jama-capacity-hfpef/","title":"Praliciguat en piek-VO2 bij HFpEF: JAMA CAPACITY-HFpEF","title_en":"Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.","published":"2020-10-20"}],"10.1001/jama.2020.15922":[{"url":"https://hartvaat.nl/2020/10/20/vericiguat-en-kwaliteit-van-leven-bij-hfpef-jama-vitality-hfpef/","title":"Vericiguat en kwaliteit van leven bij HFpEF: JAMA VITALITY-HFpEF","title_en":"Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.","published":"2020-10-20"}],"10.1001/jama.2020.14205":[{"url":"https://hartvaat.nl/2020/10/13/palliatieve-zorginterventies-bij-hartfalen-jama-associatie-met-qol-en-symptoomla/","title":"Palliatieve zorginterventies bij hartfalen: JAMA associatie met QoL en symptoomlast","title_en":"Association of Receipt of Palliative Care Interventions With Health Care Use, Quality of Life, and Symptom Burden Among Adults With Chronic Noncancer Illness: A Systematic Review and Meta-analysis.","published":"2020-10-13"}],"10.1161/circulationaha.120.048770":[{"url":"https://hartvaat.nl/2020/10/13/laaggedoseerd-ticagrelor-versus-standaard-clopidogrel-bij-diabetes-farmacodynami/","title":"Laaggedoseerd ticagrelor versus standaard clopidogrel bij diabetes: farmacodynamiek","title_en":"Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.","published":"2020-10-13"}],"10.1161/circulationaha.120.046308":[{"url":"https://hartvaat.nl/2020/10/13/dapt-na-pci-met-des-netwerkmeta-analyse-van-duur-en-intensiteit/","title":"DAPT na PCI met DES: netwerkmeta-analyse van duur en intensiteit","title_en":"Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.","published":"2020-10-13"}],"10.1016/s0140-6736(20)31791-8":[{"url":"https://hartvaat.nl/2020/10/10/prasugrel-gebaseerde-dapt-de-escalatie-na-pci-bij-acs-lancet-host-reduce-polytec/","title":"Prasugrel-gebaseerde DAPT de-escalatie na PCI bij ACS: Lancet HOST-REDUCE-POLYTECH-ACS","title_en":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.","published":"2020-10-10"}],"10.1056/nejmoa2024816":[{"url":"https://hartvaat.nl/2020/10/08/dapagliflozine-bij-chronische-nierziekte-nejm-dapa-ckd/","title":"Dapagliflozine bij chronische nierziekte: NEJM DAPA-CKD","title_en":"Dapagliflozin in Patients with Chronic Kidney Disease.","published":"2020-10-08"}],"10.1056/nejmoa2004967":[{"url":"https://hartvaat.nl/2020/10/08/ertugliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-vertis-cv/","title":"Ertugliflozine en cardiovasculaire uitkomsten bij diabetes type 2: NEJM VERTIS CV","title_en":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.","published":"2020-10-08"}],"10.1056/nejmoa2022190":[{"url":"https://hartvaat.nl/2020/10/08/empagliflozine-bij-hartfalen-cardiovasculaire-en-renale-uitkomsten-nejm-emperor-/","title":"Empagliflozine bij hartfalen: cardiovasculaire en renale uitkomsten — NEJM EMPEROR-Reduced","title_en":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.","published":"2020-10-08"}],"10.1161/circulationaha.120.046940":[{"url":"https://hartvaat.nl/2020/10/06/postoperatief-af-en-langetermijn-cva-risico-na-geisoleerde-cabg/","title":"Postoperatief AF en langetermijn CVA-risico na geïsoleerde CABG","title_en":"Postoperative Atrial Fibrillation and Long-Term Risk of Stroke After Isolated Coronary Artery Bypass Graft Surgery.","published":"2020-10-06"}],"10.1016/j.jacc.2020.08.009":[{"url":"https://hartvaat.nl/2020/10/06/periprocedureel-mi-en-uitkomsten-na-revascularisatie/","title":"Periprocedureel MI en uitkomsten na revascularisatie","title_en":"Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization.","published":"2020-10-06"}],"10.1016/j.jacc.2020.08.016":[{"url":"https://hartvaat.nl/2020/10/06/implicaties-van-alternatieve-mi-definities-na-coronaire-revascularisatie/","title":"Implicaties van alternatieve MI-definities na coronaire revascularisatie","title_en":"Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization.","published":"2020-10-06"}],"10.1093/eurheartj/ehaa670":[{"url":"https://hartvaat.nl/2020/10/01/ticagrelor-monotherapie-versus-dapt-na-pci-bij-nstemi-subanalyse/","title":"Ticagrelor monotherapie versus DAPT na PCI bij NSTEMI: subanalyse","title_en":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.","published":"2020-10-01"}],"10.1056/nejmoa2019422":[{"url":"https://hartvaat.nl/2020/10/01/vroege-ritmecontrole-bij-af-nejm-east-afnet-4/","title":"Vroege ritmecontrole bij AF: NEJM EAST-AFNET 4","title_en":"Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.","published":"2020-10-01"}],"10.1056/nejmoa2019910":[{"url":"https://hartvaat.nl/2020/10/01/evolocumab-bij-pediatrische-heterozygoot-fh-nejm-hauser-rct/","title":"Evolocumab bij pediatrische heterozygoot FH: NEJM HAUSER-RCT","title_en":"Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.","published":"2020-10-01"}],"10.1093/europace/euaa209":[{"url":"https://hartvaat.nl/2020/10/01/slokdarmsonde-bij-rf-ablatie-voor-af-opera-prospectieve-gerandomiseerde-trial/","title":"Slokdarmsonde bij RF-ablatie voor AF: OPERA prospectieve gerandomiseerde trial","title_en":"Oesophageal Probe Evaluation in Radiofrequency Ablation of Atrial Fibrillation (OPERA): results from a prospective randomized trial.","published":"2020-10-01"}],"10.1093/europace/euaa144":[{"url":"https://hartvaat.nl/2020/10/01/high-power-short-duration-ablatie-bij-af-prospectieve-gerandomiseerde-trial/","title":"High-power short-duration ablatie bij AF: prospectieve gerandomiseerde trial","title_en":"Efficacy of high-power and short-duration ablation in patients with atrial fibrillation: a prospective randomized controlled trial.","published":"2020-10-01"}],"10.1093/europace/euaa147":[{"url":"https://hartvaat.nl/2020/10/01/optimale-interlaesieafstand-bij-ablatie-index-geleide-af-ablatie-gerandomiseerde/","title":"Optimale interlaesieafstand bij ablatie-index-geleide AF-ablatie: gerandomiseerde studie","title_en":"Randomized study defining the optimum target interlesion distance in ablation index-guided atrial fibrillation ablation.","published":"2020-10-01"}],"10.1001/jamacardio.2020.2497":[{"url":"https://hartvaat.nl/2020/10/01/natuurlijk-beloop-van-asymptomatische-ernstige-aortastenose-jama-cardiology-meta/","title":"Natuurlijk beloop van asymptomatische ernstige aortastenose: JAMA Cardiology meta-analyse","title_en":"Natural History of Asymptomatic Severe Aortic Stenosis and the Association of Early Intervention With Outcomes: A Systematic Review and Meta-analysis.","published":"2020-10-01"}],"10.1001/jamacardio.2020.2413":[{"url":"https://hartvaat.nl/2020/10/01/crp-op-lp-a-geassocieerd-cv-risico-bij-optimaal-behandelde-hoogrisicopatienten/","title":"CRP op Lp(a)-geassocieerd CV-risico bij optimaal behandelde hoogrisicopatiënten","title_en":"Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.","published":"2020-10-01"}],"10.1002/ehf2.12809":[{"url":"https://hartvaat.nl/2020/10/01/mortaliteitsrisico-bij-dilaterende-cardiomyopathie-vergelijking-van-prognostisch/","title":"Mortaliteitsrisico bij dilaterende cardiomyopathie: vergelijking van prognostische modellen","title_en":"Mortality risk in dilated cardiomyopathy: the accuracy of heart failure prognostic models and dilated cardiomyopathy-tailored prognostic model.","published":"2020-10-01"}],"10.1161/hypertensionaha.120.15300":[{"url":"https://hartvaat.nl/2020/10/01/intensieve-versus-standaard-bloeddrukbehandeling-op-white-coat-effect-en-gemaske/","title":"Intensieve versus standaard bloeddrukbehandeling op white-coat effect en gemaskeerde hypertensie: SPRINT","title_en":"Effects of Intensive Versus Standard Office-Based Hypertension Treatment Strategy on White-Coat Effect and Masked Uncontrolled Hypertension: From the SPRINT ABPM Ancillary Study.","published":"2020-10-01"}],"10.1002/ehf2.12914":[{"url":"https://hartvaat.nl/2020/10/01/sekseverschillen-in-kenmerken-en-qol-bij-crt-patienten/","title":"Sekseverschillen in kenmerken en QoL bij CRT-patiënten","title_en":"Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy.","published":"2020-10-01"}],"10.1002/ehf2.12782":[{"url":"https://hartvaat.nl/2020/10/01/diabetes-en-risico-op-nieuw-en-recidiverend-hartfalen-meta-analyse/","title":"Diabetes en risico op nieuw en recidiverend hartfalen: meta-analyse","title_en":"Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis.","published":"2020-10-01"}],"10.1002/ehf2.12902":[{"url":"https://hartvaat.nl/2020/10/01/cardiale-contractiliteitsmodulatie-bij-hf-uitgebreide-ipd-meta-analyse/","title":"Cardiale contractiliteitsmodulatie bij HF: uitgebreide IPD meta-analyse","title_en":"A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failure-related quality of life.","published":"2020-10-01"}],"10.1002/ehf2.12680":[{"url":"https://hartvaat.nl/2020/10/01/crp-sst2-en-gdf-15-multimarker-voor-prognostische-stratificatie-bij-stabiel-hf/","title":"CRP, sST2 en GDF-15 multimarker voor prognostische stratificatie bij stabiel HF","title_en":"Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure.","published":"2020-10-01"}],"10.1002/ehf2.12781":[{"url":"https://hartvaat.nl/2020/10/01/accelerometrie-bij-cv-patienten-systematische-review-met-praktische-aanbevelinge/","title":"Accelerometrie bij CV-patiënten: systematische review met praktische aanbevelingen","title_en":"Advances in accelerometry for cardiovascular patients: a systematic review with practical recommendations.","published":"2020-10-01"}],"10.1002/ehf2.12832":[{"url":"https://hartvaat.nl/2020/10/01/sequentiele-nefronblokkade-met-gecombineerde-diuretica-bij-resistente-hypertensi/","title":"Sequentiële nefronblokkade met gecombineerde diuretica bij resistente hypertensie","title_en":"Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension.","published":"2020-10-01"}],"10.1136/heartjnl-2020-316773":[{"url":"https://hartvaat.nl/2020/10/01/thuismonitoring-met-technologie-ondersteund-management-bij-chronisch-hf-gerandom/","title":"Thuismonitoring met technologie-ondersteund management bij chronisch HF: gerandomiseerde trial","title_en":"Home monitoring with technology-supported management in chronic heart failure: a randomised trial.","published":"2020-10-01"}],"10.1136/heartjnl-2020-316692":[{"url":"https://hartvaat.nl/2020/10/01/troponine-grenswaarde-ontslagstrategie-versus-standaardzorg-gerandomiseerde-tria/","title":"Troponine-grenswaarde ontslagstrategie versus standaardzorg: gerandomiseerde trial","title_en":"Limit of detection of troponin discharge strategy versus usual care: randomised controlled trial.","published":"2020-10-01"}],"10.1161/circulationaha.120.047643":[{"url":"https://hartvaat.nl/2020/09/29/arni-en-renale-uitkomsten-bij-hfpef-paragon-hf/","title":"ARNI en renale uitkomsten bij HFpEF: PARAGON-HF","title_en":"Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.","published":"2020-09-29"}],"10.1016/j.jacc.2020.07.044":[{"url":"https://hartvaat.nl/2020/09/22/sekse-specifieke-cv-risicofactoren-en-biomarkers-bij-incident-hartfalen/","title":"Sekse-specifieke CV-risicofactoren en biomarkers bij incident hartfalen","title_en":"Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure.","published":"2020-09-22"}],"10.1093/eurheartj/ehaa419":[{"url":"https://hartvaat.nl/2020/09/21/dapagliflozine-op-lv-hypertrofie-bij-diabetes-type-2-dapa-lvh-gerandomiseerde-tr/","title":"Dapagliflozine op LV-hypertrofie bij diabetes type 2: DAPA-LVH gerandomiseerde trial","title_en":"A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.","published":"2020-09-21"}],"10.1016/s0140-6736(20)31824-9":[{"url":"https://hartvaat.nl/2020/09/19/sglt2-remmers-bij-hfref-meta-analyse-van-emperor-reduced-en-dapa-hf/","title":"SGLT2-remmers bij HFrEF: meta-analyse van EMPEROR-Reduced en DAPA-HF","title_en":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.","published":"2020-09-19"}],"10.1016/s0140-6736(20)31790-6":[{"url":"https://hartvaat.nl/2020/09/19/trimetazidine-na-pci-lancet-atpci-gerandomiseerde-trial/","title":"Trimetazidine na PCI: Lancet ATPCI gerandomiseerde trial","title_en":"Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.","published":"2020-09-19"}],"10.1016/j.jacc.2020.07.035":[{"url":"https://hartvaat.nl/2020/09/15/tricuspidalisinsufficientie-en-uitkomsten-na-mitraclip-coapt/","title":"Tricuspidalisinsufficiëntie en uitkomsten na MitraClip: COAPT","title_en":"Impact of Tricuspid Regurgitation on Clinical Outcomes: The COAPT Trial.","published":"2020-09-15"}],"10.1016/j.jacc.2020.07.034":[{"url":"https://hartvaat.nl/2020/09/15/non-culprit-laesie-ernst-en-uitkomsten-bij-stemi-met-multivatenlijden/","title":"Non-culprit laesie-ernst en uitkomsten bij STEMI met multivatenlijden","title_en":"Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease.","published":"2020-09-15"}],"10.1161/circulationaha.120.047077":[{"url":"https://hartvaat.nl/2020/09/15/dapagliflozine-en-diureticagebruik-bij-hfref-dapa-hf/","title":"Dapagliflozine en diureticagebruik bij HFrEF: DAPA-HF","title_en":"Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.","published":"2020-09-15"}],"10.1161/circulationaha.120.045691":[{"url":"https://hartvaat.nl/2020/09/15/empagliflozine-bij-hartfalen-diuretische-en-cardiorenale-effecten/","title":"Empagliflozine bij hartfalen: diuretische en cardiorenale effecten","title_en":"Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.","published":"2020-09-15"}],"10.1016/j.jacc.2020.04.039":[{"url":"https://hartvaat.nl/2020/09/15/ami-management-tijdens-covid-19-scai-positiedocument/","title":"AMI-management tijdens COVID-19: SCAI positiedocument","title_en":"Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP).","published":"2020-09-15"}],"10.1093/eurheartj/ehaa082":[{"url":"https://hartvaat.nl/2020/09/14/glp-1-agonisten-bij-diabetes-type-2-met-en-zonder-cvd-meta-analyse/","title":"GLP-1-agonisten bij diabetes type 2 met en zonder CVD: meta-analyse","title_en":"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.","published":"2020-09-14"}],"10.1093/eurheartj/ehaa135":[{"url":"https://hartvaat.nl/2020/09/07/des-versus-cabg-bij-hoofdstamlijden-mortaliteits-meta-analyse/","title":"DES versus CABG bij hoofdstamlijden: mortaliteits meta-analyse","title_en":"Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials.","published":"2020-09-07"}],"10.1016/j.jacc.2020.06.073":[{"url":"https://hartvaat.nl/2020/09/01/arni-naar-hf-voorgeschiedenis-en-raas-antagonistgebruik/","title":"ARNI naar HF-voorgeschiedenis en RAAS-antagonistgebruik","title_en":"Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.","published":"2020-09-01"}],"10.1016/j.jacc.2020.07.010":[{"url":"https://hartvaat.nl/2020/09/01/voorspellers-van-klinische-respons-op-transcatheter-mr-reductie-coapt/","title":"Voorspellers van klinische respons op transcatheter MR-reductie: COAPT","title_en":"Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation: The COAPT Trial.","published":"2020-09-01"}],"10.1016/j.jacc.2020.05.037":[{"url":"https://hartvaat.nl/2020/09/01/2020-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","title":"2020 ACC Expert Consensus: nieuwe therapieën voor CV-risicoreductie bij diabetes type 2","title_en":"2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2020-09-01"}],"10.1093/eurheartj/ehz917":[{"url":"https://hartvaat.nl/2020/09/01/clopidogrel-versus-prasugrel-versus-ticagrelor-op-endotheelfunctie-en-inflammati/","title":"Clopidogrel versus prasugrel versus ticagrelor op endotheelfunctie en inflammatie bij ACS","title_en":"Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study.","published":"2020-09-01"}],"10.1161/circulationaha.120.048194":[{"url":"https://hartvaat.nl/2020/09/01/routine-revascularisatie-versus-medicamenteus-bij-stabiel-coronairlijden-meta-an/","title":"Routine revascularisatie versus medicamenteus bij stabiel coronairlijden: meta-analyse","title_en":"Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials.","published":"2020-09-01"}],"10.1161/hypertensionaha.120.14875":[{"url":"https://hartvaat.nl/2020/09/01/preconceptiebloeddruk-en-verandering-naar-vroege-zwangerschap-risicofactor-voor-/","title":"Preconceptiebloeddruk en verandering naar vroege zwangerschap: risicofactor voor pre-eclampsie","title_en":"Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension.","published":"2020-09-01"}],"10.1161/hypertensionaha.120.15267":[{"url":"https://hartvaat.nl/2020/09/01/carbidopa-bij-afferente-baroreflexfalen-bij-familiaire-dysautonomie-gerandomisee/","title":"Carbidopa bij afferente baroreflexfalen bij familiaire dysautonomie: gerandomiseerde trial","title_en":"Carbidopa for Afferent Baroreflex Failure in Familial Dysautonomia: A Double-Blind Randomized Crossover Clinical Trial.","published":"2020-09-01"}],"10.1001/jama.2020.12443":[{"url":"https://hartvaat.nl/2020/08/25/genotype-geleide-p2y12-selectie-versus-clopidogrel-na-pci-jama-tailor-pci/","title":"Genotype-geleide P2Y12-selectie versus clopidogrel na PCI: JAMA TAILOR-PCI","title_en":"Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.","published":"2020-08-25"}],"10.1016/j.jacc.2020.06.061":[{"url":"https://hartvaat.nl/2020/08/25/machine-learning-voor-lv-diastolische-functie-op-ecg/","title":"Machine learning voor LV diastolische functie op ECG","title_en":"Machine Learning Assessment of Left Ventricular Diastolic Function Based on Electrocardiographic Features.","published":"2020-08-25"}],"10.1016/j.jacc.2020.06.064":[{"url":"https://hartvaat.nl/2020/08/25/pulmonale-arterie-denervatie-bij-residuele-ph-na-endarterectomie/","title":"Pulmonale arterie denervatie bij residuele PH na endarterectomie","title_en":"Pulmonary Artery Denervation for Patients With Residual Pulmonary Hypertension After Pulmonary Endarterectomy.","published":"2020-08-25"}],"10.1016/j.jacc.2020.06.066":[{"url":"https://hartvaat.nl/2020/08/25/sekseverschillen-in-mortaliteit-na-complexe-coronaire-revascularisatie-10-jaar/","title":"Sekseverschillen in mortaliteit na complexe coronaire revascularisatie: 10 jaar","title_en":"Sex Differences in All-Cause Mortality in the Decade Following Complex Coronary Revascularization.","published":"2020-08-25"}],"10.1161/circulationaha.119.044775":[{"url":"https://hartvaat.nl/2020/08/25/dapagliflozine-en-cardiale-renale-en-ledemaat-uitkomsten-bij-pav-declare-timi-58/","title":"Dapagliflozine en cardiale, renale en ledemaat-uitkomsten bij PAV: DECLARE-TIMI 58","title_en":"Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.","published":"2020-08-25"}],"10.1161/circulationaha.120.046774":[{"url":"https://hartvaat.nl/2020/08/25/carotisatherosclerose-evolutie-bij-ldl-streefwaarde-70-na-ischemisch-cva-tst-sub/","title":"Carotisatherosclerose-evolutie bij LDL-streefwaarde <70 na ischemisch CVA: TST substudie","title_en":"Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <70 mg/dL After an Ischemic Stroke of Atherosclerotic Origin.","published":"2020-08-25"}],"10.1056/nejmoa2004215":[{"url":"https://hartvaat.nl/2020/08/20/evinacumab-bij-homozygoot-familiaire-hypercholesterolemie-nejm/","title":"Evinacumab bij homozygoot familiaire hypercholesterolemie: NEJM","title_en":"Evinacumab for Homozygous Familial Hypercholesterolemia.","published":"2020-08-20"}],"10.1001/jama.2020.11747":[{"url":"https://hartvaat.nl/2020/08/18/collaboratieve-zorg-voor-depressie-hba1c-bloeddruk-en-cholesterol-bij-diabetes-j/","title":"Collaboratieve zorg voor depressie, HbA1c, bloeddruk en cholesterol bij diabetes: JAMA","title_en":"Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial.","published":"2020-08-18"}],"10.1016/j.jacc.2020.06.043":[{"url":"https://hartvaat.nl/2020/08/18/optimale-bloeddruk-bij-shock-na-mi-en-hartstilstand/","title":"Optimale bloeddruk bij shock na MI en hartstilstand","title_en":"Optimum Blood Pressure in Patients With Shock After Acute Myocardial Infarction and Cardiac Arrest.","published":"2020-08-18"}],"10.1161/circulationaha.120.046361":[{"url":"https://hartvaat.nl/2020/08/18/carotis-intima-media-dikte-als-surrogaatmarker-meta-analyse-van-119-trials/","title":"Carotis intima-media dikte als surrogaatmarker: meta-analyse van 119 trials","title_en":"Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.","published":"2020-08-18"}],"10.1093/eurheartj/ehaa160":[{"url":"https://hartvaat.nl/2020/08/14/il-6-crp-en-ldl-als-biomarkers-van-residueel-risico-vergelijking/","title":"IL-6, CRP en LDL als biomarkers van residueel risico: vergelijking","title_en":"Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.","published":"2020-08-14"}],"10.1161/circulationaha.120.046251":[{"url":"https://hartvaat.nl/2020/08/11/veiligheid-van-aspirinestaken-met-p2y12-achtergrond-na-pci-meta-analyse/","title":"Veiligheid van aspirinestaken met P2Y12-achtergrond na PCI: meta-analyse","title_en":"The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.","published":"2020-08-11"}],"10.1093/eurheartj/ehaa055":[{"url":"https://hartvaat.nl/2020/08/07/geintegreerd-af-management-in-de-huisartsenpraktijk-all-in-clustergerandomiseerd/","title":"Geïntegreerd AF-management in de huisartsenpraktijk: ALL-IN clustergerandomiseerde trial","title_en":"Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial.","published":"2020-08-07"}],"10.1161/circulationaha.120.046928":[{"url":"https://hartvaat.nl/2020/08/04/cangrelor-tirofiban-en-prasugrel-bij-stemi-primaire-resultaten/","title":"Cangrelor, tirofiban en prasugrel bij STEMI: primaire resultaten","title_en":"Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial.","published":"2020-08-04"}],"10.1016/j.jacc.2020.05.072":[{"url":"https://hartvaat.nl/2020/08/04/sacubitril-valsartan-en-ecm-biomarkers-bij-hfpef-paragon-hf/","title":"Sacubitril/valsartan en ECM-biomarkers bij HFpEF: PARAGON-HF","title_en":"Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.","published":"2020-08-04"}],"10.1016/j.jacc.2020.04.053":[{"url":"https://hartvaat.nl/2020/08/04/2020-acc-bloedingsmanagement-bij-oac-expert-consensus-decision-pathway/","title":"2020 ACC bloedingsmanagement bij OAC: expert consensus decision pathway","title_en":"2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee.","published":"2020-08-04"}],"10.1001/jamacardio.2020.1567":[{"url":"https://hartvaat.nl/2020/08/01/inspannings-ecg-versus-ccta-bij-stabiele-angina-post-hoc-vergelijking/","title":"Inspannings-ECG versus CCTA bij stabiele angina: post-hoc vergelijking","title_en":"Exercise Electrocardiography and Computed Tomography Coronary Angiography for Patients With Suspected Stable Angina Pectoris: A Post Hoc Analysis of the Randomized SCOT-HEART Trial.","published":"2020-08-01"}],"10.1001/jamacardio.2020.0285":[{"url":"https://hartvaat.nl/2020/08/01/seksegerelateerde-uitkomsten-bij-hoog-bloedingsrisico-na-pci-leaders-free/","title":"Seksegerelateerde uitkomsten bij hoog bloedingsrisico na PCI: LEADERS FREE","title_en":"Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial.","published":"2020-08-01"}],"10.1001/jamacardio.2020.1251":[{"url":"https://hartvaat.nl/2020/08/01/complete-versus-culprit-only-revascularisatie-bij-stemi-jama-cardiology-meta-ana/","title":"Complete versus culprit-only revascularisatie bij STEMI: JAMA Cardiology meta-analyse","title_en":"Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis.","published":"2020-08-01"}],"10.1161/hypertensionaha.120.14791":[{"url":"https://hartvaat.nl/2020/08/01/antidiabetica-en-cardiovasculaire-geneeskunde-meta-analyse-en-perspectief/","title":"Antidiabetica en cardiovasculaire geneeskunde: meta-analyse en perspectief","title_en":"Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design.","published":"2020-08-01"}],"10.1002/ehf2.12783":[{"url":"https://hartvaat.nl/2020/08/01/tolvaptan-versus-furosemide-bij-hf-hospitalisatie-met-hyponatriemie-aqua-ahf/","title":"Tolvaptan versus furosemide bij HF-hospitalisatie met hyponatriëmie: AQUA-AHF","title_en":"Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).","published":"2020-08-01"}],"10.1161/hypertensionaha.120.15572":[{"url":"https://hartvaat.nl/2020/08/01/raas-remmers-en-covid-19-mortaliteit-bij-hypertensie-meta-analyse/","title":"RAAS-remmers en COVID-19 mortaliteit bij hypertensie: meta-analyse","title_en":"Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.","published":"2020-08-01"}],"10.1136/heartjnl-2020-316611":[{"url":"https://hartvaat.nl/2020/08/01/diagnostische-nauwkeurigheid-van-handheld-ecg-devices-voor-af-community-versus-z/","title":"Diagnostische nauwkeurigheid van handheld ECG-devices voor AF: community versus ziekenhuis","title_en":"Diagnostic accuracy of handheld electrocardiogram devices in detecting atrial fibrillation in adults in community versus hospital settings: a systematic review and meta-analysis.","published":"2020-08-01"}],"10.1002/ehf2.12707":[{"url":"https://hartvaat.nl/2020/08/01/canagliflozine-bij-diabetes-type-2-met-chronisch-hf-candle-gerandomiseerde-trial/","title":"Canagliflozine bij diabetes type 2 met chronisch HF: CANDLE gerandomiseerde trial","title_en":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).","published":"2020-08-01"}],"10.1136/heartjnl-2019-315889":[{"url":"https://hartvaat.nl/2020/08/01/cardiovasculaire-risicovoorspelling-bij-inheemse-australiers/","title":"Cardiovasculaire risicovoorspelling bij Inheemse Australiërs","title_en":"Performance of cardiovascular risk prediction equations in Indigenous Australians.","published":"2020-08-01"}],"10.1161/circulationaha.120.046320":[{"url":"https://hartvaat.nl/2020/07/28/evolocumab-op-atherogene-lipoproteinen-in-de-peri-infarctperiode-gerandomiseerde/","title":"Evolocumab op atherogene lipoproteïnen in de peri-infarctperiode: gerandomiseerde trial","title_en":"Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial.","published":"2020-07-28"}],"10.1016/j.jacc.2020.05.061":[{"url":"https://hartvaat.nl/2020/07/28/langetermijn-icd-uitkomsten-scd-heft/","title":"Langetermijn ICD-uitkomsten: SCD-HeFT","title_en":"Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.","published":"2020-07-28"}],"10.1001/jama.2020.9389":[{"url":"https://hartvaat.nl/2020/07/21/levothyroxine-bij-subklinische-hypothyreoidie-na-acuut-mi-jama/","title":"Levothyroxine bij subklinische hypothyreoïdie na acuut MI: JAMA","title_en":"Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction: A Randomized Clinical Trial.","published":"2020-07-21"}],"10.1161/circulationaha.120.048180":[{"url":"https://hartvaat.nl/2020/07/21/stemi-zorgsystemen-tijdens-covid-19-aha-mission-lifeline-noodrichtlijn/","title":"STEMI-zorgsystemen tijdens COVID-19: AHA Mission Lifeline noodrichtlijn","title_en":"Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic: AHA's Mission: Lifeline.","published":"2020-07-21"}],"10.1016/s0140-6736(20)30631-0":[{"url":"https://hartvaat.nl/2020/07/18/dexmedetomidine-voor-af-en-delier-na-hartchirurgie-lancet-decade/","title":"Dexmedetomidine voor AF en delier na hartchirurgie: Lancet DECADE","title_en":"Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial.","published":"2020-07-18"}],"10.1001/jama.2020.8228":[{"url":"https://hartvaat.nl/2020/07/14/radiale-arterie-versus-vena-saphena-graft-bij-cabg-jama-langetermijn-meta-analys/","title":"Radiale arterie versus vena saphena graft bij CABG: JAMA langetermijn meta-analyse","title_en":"Association of Radial Artery Graft vs Saphenous Vein Graft With Long-term Cardiovascular Outcomes Among Patients Undergoing Coronary Artery Bypass Grafting: A Systematic Review and Meta-analysis.","published":"2020-07-14"}],"10.1016/j.jacc.2020.05.027":[{"url":"https://hartvaat.nl/2020/07/14/alirocumab-bij-homozygoot-fh-odyssey-hofh/","title":"Alirocumab bij homozygoot FH: ODYSSEY HoFH","title_en":"Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.","published":"2020-07-14"}],"10.1093/eurheartj/ehaa543":[{"url":"https://hartvaat.nl/2020/07/14/twee-stent-versus-provisional-stenting-bij-complexe-bifurcatielaesies-multicente/","title":"Twee-stent versus provisional stenting bij complexe bifurcatielaesies: multicenter RCT","title_en":"Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial.","published":"2020-07-14"}],"10.1161/circulationaha.120.046786":[{"url":"https://hartvaat.nl/2020/07/14/vergelijking-van-orale-p2y12-remmers-bij-acs-netwerkmeta-analyse-van-52-816-pati/","title":"Vergelijking van orale P2Y12-remmers bij ACS: netwerkmeta-analyse van 52.816 patiënten","title_en":"Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials.","published":"2020-07-14"}],"10.1016/s0140-6736(20)30748-0":[{"url":"https://hartvaat.nl/2020/07/11/levenslang-voordeel-van-uitgebreide-hfref-farmacotherapie-lancet-schatting/","title":"Levenslang voordeel van uitgebreide HFrEF-farmacotherapie: Lancet schatting","title_en":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.","published":"2020-07-11"}],"10.1001/jama.2020.5493":[{"url":"https://hartvaat.nl/2020/07/07/systemische-amyloidose-herkenning-prognose-en-therapie-jama-systematische-review/","title":"Systemische amyloïdose: herkenning, prognose en therapie — JAMA systematische review","title_en":"Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.","published":"2020-07-07"}],"10.1016/j.jacc.2020.05.016":[{"url":"https://hartvaat.nl/2020/07/07/statinegebruik-en-invaliditeitsvrije-overleving-bij-gezonde-ouderen/","title":"Statinegebruik en invaliditeitsvrije overleving bij gezonde ouderen","title_en":"Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults.","published":"2020-07-07"}],"10.1016/j.jacc.2020.05.015":[{"url":"https://hartvaat.nl/2020/07/07/baroreflexactivatietherapie-bij-hfref-beat-hf/","title":"Baroreflexactivatietherapie bij HFrEF: BeAT-HF","title_en":"Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.","published":"2020-07-07"}],"10.1001/jamacardio.2020.0640":[{"url":"https://hartvaat.nl/2020/07/01/barrieres-voor-optimale-hf-medicatie-guide-it-analyse/","title":"Barrières voor optimale HF-medicatie: GUIDE-IT analyse","title_en":"Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.","published":"2020-07-01"}],"10.1093/europace/euaa030":[{"url":"https://hartvaat.nl/2020/07/01/subklinische-atherosclerose-en-incident-af-meta-analyse/","title":"Subklinische atherosclerose en incident AF: meta-analyse","title_en":"Subclinical atherosclerosis is associated with incident atrial fibrillation: a systematic review and meta-analysis.","published":"2020-07-01"}],"10.1161/hypertensionaha.120.15199":[{"url":"https://hartvaat.nl/2020/07/01/mra-bij-hypertensie-met-gevorderde-ckd-block-ckd-trial/","title":"MRA bij hypertensie met gevorderde CKD: BLOCK-CKD trial","title_en":"Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.","published":"2020-07-01"}],"10.1161/hypertensionaha.120.14973":[{"url":"https://hartvaat.nl/2020/07/01/nieuwe-dna-methyleringsloci-voor-bloeddruk-erfelijkheid-en-genexpressie/","title":"Nieuwe DNA-methyleringsloci voor bloeddruk: erfelijkheid en genexpressie","title_en":"Identification, Heritability, and Relation With Gene Expression of Novel DNA Methylation Loci for Blood Pressure.","published":"2020-07-01"}],"10.1161/hypertensionaha.119.14456":[{"url":"https://hartvaat.nl/2020/07/01/thuisluchtzuivering-en-bloeddruk-systematische-review/","title":"Thuisluchtzuivering en bloeddruk: systematische review","title_en":"Effects of Home Particulate Air Filtration on Blood Pressure: A Systematic Review.","published":"2020-07-01"}],"10.1161/hypertensionaha.120.14793":[{"url":"https://hartvaat.nl/2020/07/01/phactr1-en-fibromusculaire-dysplasie-arcadia-pol-meta-analyse/","title":"PHACTR1 en fibromusculaire dysplasie: ARCADIA-POL meta-analyse","title_en":"Genetic Study of PHACTR1 and Fibromuscular Dysplasia, Meta-Analysis and Effects on Clinical Features of Patients: The ARCADIA-POL Study.","published":"2020-07-01"}],"10.1161/hypertensionaha.120.14800":[{"url":"https://hartvaat.nl/2020/07/01/natriumreductie-verhoogt-korte-keten-vetzuren-bij-onbehandelde-hypertensie/","title":"Natriumreductie verhoogt korte-keten vetzuren bij onbehandelde hypertensie","title_en":"Modest Sodium Reduction Increases Circulating Short-Chain Fatty Acids in Untreated Hypertensives: A Randomized, Double-Blind, Placebo-Controlled Trial.","published":"2020-07-01"}],"10.1161/hypertensionaha.119.14627":[{"url":"https://hartvaat.nl/2020/07/01/white-coat-hypertensie-in-de-zwangerschap-maternale-en-perinatale-uitkomsten/","title":"White-coat hypertensie in de zwangerschap: maternale en perinatale uitkomsten","title_en":"Maternal and Perinatal Outcomes of White Coat Hypertension During Pregnancy: A Systematic Review and Meta-Analysis.","published":"2020-07-01"}],"10.1161/hypertensionaha.120.14993":[{"url":"https://hartvaat.nl/2020/07/01/bloeddruk-en-cognitieve-stoornis-en-dementie-meta-analyse-van-209-studies/","title":"Bloeddruk en cognitieve stoornis en dementie: meta-analyse van 209 studies","title_en":"Blood Pressure and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 209 Prospective Studies.","published":"2020-07-01"}],"10.1136/heartjnl-2019-316343":[{"url":"https://hartvaat.nl/2020/07/01/esc-0-1-uur-troponine-algoritme-voor-mi-veiligheid-en-werkzaamheid-meta-analyse/","title":"ESC 0/1-uur troponine-algoritme voor MI: veiligheid en werkzaamheid — meta-analyse","title_en":"Safety and efficacy of the European Society of Cardiology 0/1-hour algorithm for diagnosis of myocardial infarction: systematic review and meta-analysis.","published":"2020-07-01"}],"10.1016/j.jacc.2020.04.067":[{"url":"https://hartvaat.nl/2020/06/30/laa-sluiting-versus-doac-bij-hoogrisico-af-vergelijkende-analyse/","title":"LAA-sluiting versus DOAC bij hoogrisico AF: vergelijkende analyse","title_en":"Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.","published":"2020-06-30"}],"10.1016/j.jacc.2020.04.065":[{"url":"https://hartvaat.nl/2020/06/30/af-recidief-na-ablatie-versus-antiaritmica-in-cabana/","title":"AF-recidief na ablatie versus antiaritmica in CABANA","title_en":"Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial.","published":"2020-06-30"}],"10.1161/circulationaha.119.040241":[{"url":"https://hartvaat.nl/2020/06/23/polymeervrije-biolimus-stent-versus-ultradunne-biodegradeerbare-sirolimus-stent/","title":"Polymeervrije biolimus-stent versus ultradunne biodegradeerbare sirolimus-stent","title_en":"Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial.","published":"2020-06-23"}],"10.1093/eurheartj/ehz310":[{"url":"https://hartvaat.nl/2020/06/21/statinetherapie-verhoogt-lipoproteine-a-spiegels/","title":"Statinetherapie verhoogt lipoproteïne(a)-spiegels","title_en":"Statin therapy increases lipoprotein(a) levels.","published":"2020-06-21"}],"10.1016/s0140-6736(20)30848-5":[{"url":"https://hartvaat.nl/2020/06/20/hoog-dosis-tranexaminezuur-bij-acute-gastro-intestinale-bloeding-lancet-halt-it/","title":"Hoog-dosis tranexaminezuur bij acute gastro-intestinale bloeding: Lancet HALT-IT","title_en":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.","published":"2020-06-20"}],"10.1001/jama.2020.7580":[{"url":"https://hartvaat.nl/2020/06/16/ticagrelor-monotherapie-versus-dapt-op-bloedingen-en-cv-events-bij-acs-jama-tico/","title":"Ticagrelor monotherapie versus DAPT op bloedingen en CV-events bij ACS: JAMA TICO","title_en":"Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.","published":"2020-06-16"}],"10.1161/circulationaha.120.046448":[{"url":"https://hartvaat.nl/2020/06/09/combinatie-antiplaatjes-antistolling-bij-diabetes-met-cv-ziekte-compass-inzichte/","title":"Combinatie antiplaatjes + antistolling bij diabetes met CV-ziekte: COMPASS-inzichten","title_en":"Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.","published":"2020-06-09"}],"10.1093/eurheartj/ehaa461":[{"url":"https://hartvaat.nl/2020/06/07/hartfalentrials-tijdens-en-na-covid-19-expert-consensus/","title":"Hartfalentrials tijdens en na COVID-19: expert consensus","title_en":"Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).","published":"2020-06-07"}],"10.1161/circulationaha.119.044795":[{"url":"https://hartvaat.nl/2020/06/02/prevalentie-van-fh-bij-atherosclerotische-cv-ziekte-meta-analyse/","title":"Prevalentie van FH bij atherosclerotische CV-ziekte: meta-analyse","title_en":"Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.","published":"2020-06-02"}],"10.1001/jamacardio.2020.0728":[{"url":"https://hartvaat.nl/2020/06/01/pcsk9-remming-en-aortastenose-fourier-exploratieve-analyse/","title":"PCSK9-remming en aortastenose: FOURIER exploratieve analyse","title_en":"An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.","published":"2020-06-01"}],"10.1001/jamacardio.2020.0359":[{"url":"https://hartvaat.nl/2020/06/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-acs-trials-jama-cardiology/","title":"Inclusie van ouderen, vrouwen en minderheden in ACS-trials: JAMA Cardiology","title_en":"Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review.","published":"2020-06-01"}],"10.1093/europace/euaa024":[{"url":"https://hartvaat.nl/2020/06/01/farmacologische-cardioversie-van-recent-onset-af-netwerkmeta-analyse/","title":"Farmacologische cardioversie van recent-onset AF: netwerkmeta-analyse","title_en":"Pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis.","published":"2020-06-01"}],"10.1093/eurheartj/ehz773":[{"url":"https://hartvaat.nl/2020/06/01/trends-in-plotse-hartdood-bij-hf-met-crt-systematische-review/","title":"Trends in plotse hartdood bij HF met CRT: systematische review","title_en":"Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review.","published":"2020-06-01"}],"10.1161/hypertensionaha.120.15026":[{"url":"https://hartvaat.nl/2020/06/01/2020-ish-mondiale-hypertensie-praktijkrichtlijnen/","title":"2020 ISH mondiale hypertensie-praktijkrichtlijnen","title_en":"2020 International Society of Hypertension Global Hypertension Practice Guidelines.","published":"2020-06-01"}],"10.1161/hypertensionaha.120.14690":[{"url":"https://hartvaat.nl/2020/06/01/incidentie-en-implicaties-van-af-bij-hypertensie-sprint-inzichten/","title":"Incidentie en implicaties van AF bij hypertensie: SPRINT-inzichten","title_en":"Incidence and Implications of Atrial Fibrillation/Flutter in Hypertension: Insights From the SPRINT Trial.","published":"2020-06-01"}],"10.1161/hypertensionaha.120.14766":[{"url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","title":"Intensieve bloeddrukverlaging en risico op AF: SPRINT-analyse","title_en":"Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation.","published":"2020-06-01"}],"10.1002/ehf2.12733":[{"url":"https://hartvaat.nl/2020/06/01/motivational-interviewing-bij-hartfalen-voor-zelfzorg-motivate-hf-gerandomiseerd/","title":"Motivational interviewing bij hartfalen voor zelfzorg: MOTIVATE-HF gerandomiseerde trial","title_en":"Motivational interviewing to improve self-care in heart failure patients (MOTIVATE-HF): a randomized controlled trial.","published":"2020-06-01"}],"10.1161/hypertensionaha.119.14443":[{"url":"https://hartvaat.nl/2020/06/01/arb-versus-calciumantagonist-bloeddrukprofiel-en-klinische-effecten-vergelijking/","title":"ARB versus calciumantagonist: bloeddrukprofiel en klinische effecten vergelijking","title_en":"Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.","published":"2020-06-01"}],"10.1161/hypertensionaha.119.13982":[{"url":"https://hartvaat.nl/2020/06/01/il-1-receptorantagonist-verhoogt-ang-1-7-en-verlaagt-bloeddruk-bij-obesitas/","title":"IL-1-receptorantagonist verhoogt Ang-(1-7) en verlaagt bloeddruk bij obesitas","title_en":"IL (Interleukin)-1 Receptor Antagonist Increases Ang (Angiotensin [1-7]) and Decreases Blood Pressure in Obese Individuals.","published":"2020-06-01"}],"10.1002/ehf2.12690":[{"url":"https://hartvaat.nl/2020/06/01/tolvaptan-en-sympathische-activiteit-bij-acuut-hfpef/","title":"Tolvaptan en sympathische activiteit bij acuut HFpEF","title_en":"Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction.","published":"2020-06-01"}],"10.1002/ehf2.12660":[{"url":"https://hartvaat.nl/2020/06/01/variatie-in-uitkomsten-tussen-complexe-hfpef-fenotypen/","title":"Variatie in uitkomsten tussen complexe HFpEF-fenotypen","title_en":"Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes.","published":"2020-06-01"}],"10.1002/ehf2.12677":[{"url":"https://hartvaat.nl/2020/06/01/poliklinische-iv-en-sc-diureticabehandeling-bij-verslechterend-hf-systematische-/","title":"Poliklinische IV en SC diureticabehandeling bij verslechterend HF: systematische review","title_en":"Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature.","published":"2020-06-01"}],"10.1002/ehf2.12606":[{"url":"https://hartvaat.nl/2020/06/01/economische-impact-van-hfpef-aldo-dhf-inzichten/","title":"Economische impact van HFpEF: ALDO-DHF-inzichten","title_en":"Economic impact of heart failure with preserved ejection fraction: insights from the ALDO-DHF trial.","published":"2020-06-01"}],"10.1001/jama.2020.4871":[{"url":"https://hartvaat.nl/2020/05/26/antihypertensieve-medicatiereductie-versus-standaardzorg-bij-ouderen-jama-optimi/","title":"Antihypertensieve medicatiereductie versus standaardzorg bij ouderen: JAMA OPTIMISE","title_en":"Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial.","published":"2020-05-26"}],"10.1016/j.jacc.2020.03.059":[{"url":"https://hartvaat.nl/2020/05/26/subcutaan-selatogrel-remt-plaatjesaggregatie-bij-acuut-mi/","title":"Subcutaan selatogrel remt plaatjesaggregatie bij acuut MI","title_en":"Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.","published":"2020-05-26"}],"10.1016/j.jacc.2020.03.057":[{"url":"https://hartvaat.nl/2020/05/26/wereldwijde-prevalentie-van-familiaire-hypercholesterolemie-meta-analyse-van-11-/","title":"Wereldwijde prevalentie van familiaire hypercholesterolemie: meta-analyse van 11 miljoen deelnemers","title_en":"Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.","published":"2020-05-26"}],"10.1161/circulationaha.119.045066":[{"url":"https://hartvaat.nl/2020/05/26/gepersonaliseerde-rate-response-programmering-verbetert-inspanningstolerantie-bi/","title":"Gepersonaliseerde rate-response programmering verbetert inspanningstolerantie bij CIED","title_en":"Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study.","published":"2020-05-26"}],"10.1016/j.jacc.2020.03.025":[{"url":"https://hartvaat.nl/2020/05/26/evolocumab-bij-hiv-met-dyslipidemie-beijerinck-gerandomiseerde-studie/","title":"Evolocumab bij HIV met dyslipidemie: BEIJERINCK gerandomiseerde studie","title_en":"Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.","published":"2020-05-26"}],"10.1001/jama.2020.4249":[{"url":"https://hartvaat.nl/2020/05/19/bloeddrukverlaging-en-dementie-of-cognitieve-stoornis-jama-meta-analyse/","title":"Bloeddrukverlaging en dementie of cognitieve stoornis: JAMA meta-analyse","title_en":"Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis.","published":"2020-05-19"}],"10.1016/j.jacc.2020.03.011":[{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-na-complexe-pci-twilight-complex-pci/","title":"Ticagrelor met of zonder aspirine na complexe PCI: TWILIGHT-complex PCI","title_en":"Ticagrelor With or Without Aspirin After Complex PCI.","published":"2020-05-19"}],"10.1016/j.jacc.2020.03.008":[{"url":"https://hartvaat.nl/2020/05/19/ticagrelor-met-of-zonder-aspirine-bij-diabetes-na-pci-twilight-diabetes/","title":"Ticagrelor met of zonder aspirine bij diabetes na PCI: TWILIGHT-diabetes","title_en":"Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.","published":"2020-05-19"}],"10.1161/circulationaha.120.046524":[{"url":"https://hartvaat.nl/2020/05/19/pav-en-vte-na-acs-rol-van-lp-a-en-modificatie-door-alirocumab/","title":"PAV en VTE na ACS: rol van Lp(a) en modificatie door alirocumab","title_en":"Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.","published":"2020-05-19"}],"10.1161/circulationaha.120.046397":[{"url":"https://hartvaat.nl/2020/05/19/pcsk9-remming-en-risico-op-veneuze-trombo-embolie/","title":"PCSK9-remming en risico op veneuze trombo-embolie","title_en":"The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.","published":"2020-05-19"}],"10.1093/eurheartj/ehaa381":[{"url":"https://hartvaat.nl/2020/05/14/eapci-positiedocument-invasief-acs-management-tijdens-covid-19/","title":"EAPCI positiedocument: invasief ACS-management tijdens COVID-19","title_en":"EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic.","published":"2020-05-14"}],"10.1056/nejmoa1915928":[{"url":"https://hartvaat.nl/2020/05/14/vericiguat-bij-hfref-nejm-victoria/","title":"Vericiguat bij HFrEF: NEJM VICTORIA","title_en":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.","published":"2020-05-14"}],"10.1016/j.jacc.2020.03.029":[{"url":"https://hartvaat.nl/2020/05/12/kosteneffectiviteit-van-alirocumab-na-acs-odyssey-outcomes/","title":"Kosteneffectiviteit van alirocumab na ACS: ODYSSEY OUTCOMES","title_en":"Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.","published":"2020-05-12"}],"10.1016/j.jacc.2020.03.039":[{"url":"https://hartvaat.nl/2020/05/12/cognitie-na-ldl-verlaging-met-evolocumab-fourier-follow-up/","title":"Cognitie na LDL-verlaging met evolocumab: FOURIER follow-up","title_en":"Cognition After Lowering LDL-Cholesterol With Evolocumab.","published":"2020-05-12"}],"10.1161/cir.0000000000000766":[{"url":"https://hartvaat.nl/2020/05/12/management-van-stabiel-coronairlijden-bij-diabetes-type-2-aha-scientific-stateme/","title":"Management van stabiel coronairlijden bij diabetes type 2: AHA scientific statement","title_en":"Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association.","published":"2020-05-12"}],"10.1161/circulationaha.119.044407":[{"url":"https://hartvaat.nl/2020/05/12/ritme-monitoringstrategieen-voor-af-screening-uitgebreide-evaluatie/","title":"Ritme-monitoringstrategieën voor AF-screening: uitgebreide evaluatie","title_en":"Comprehensive Evaluation of Rhythm Monitoring Strategies in Screening for Atrial Fibrillation: Insights From Patients at Risk Monitored Long Term With an Implantable Loop Recorder.","published":"2020-05-12"}],"10.1016/s0140-6736(20)30315-9":[{"url":"https://hartvaat.nl/2020/05/09/p2y12-monotherapie-of-aspirine-voor-secundaire-preventie-lancet-meta-analyse/","title":"P2Y12-monotherapie of aspirine voor secundaire preventie: Lancet meta-analyse","title_en":"Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.","published":"2020-05-09"}],"10.1016/j.jacc.2020.02.059":[{"url":"https://hartvaat.nl/2020/05/05/triglyceriderijk-lipoproteinecholesterol-small-dense-ldl-en-cv-events/","title":"Triglyceriderijk lipoproteïnecholesterol, small dense LDL en CV-events","title_en":"Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease.","published":"2020-05-05"}],"10.1161/circulationaha.120.046039":[{"url":"https://hartvaat.nl/2020/05/05/des-versus-cabg-bij-linker-hoofdstam-10-jaarsresultaten-excel-extended/","title":"DES versus CABG bij linker-hoofdstam: 10-jaarsresultaten EXCEL extended","title_en":"Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow-Up of the PRECOMBAT Trial.","published":"2020-05-05"}],"10.1016/j.jacc.2020.03.015":[{"url":"https://hartvaat.nl/2020/05/05/atorvastatine-vermindert-eerste-en-volgende-vasculaire-events-sparcl/","title":"Atorvastatine vermindert eerste en volgende vasculaire events: SPARCL","title_en":"Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.","published":"2020-05-05"}],"10.1016/j.jacc.2020.03.002":[{"url":"https://hartvaat.nl/2020/05/05/gezondheidsstatus-en-uitkomsten-bij-hf-met-mr-coapt/","title":"Gezondheidsstatus en uitkomsten bij HF met MR: COAPT","title_en":"Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation: COAPT Trial.","published":"2020-05-05"}],"10.1161/circulationaha.119.044720":[{"url":"https://hartvaat.nl/2020/05/05/laag-attenuatie-plaque-op-ccta-voorspelt-mi-scot-heart-resultaten/","title":"Laag-attenuatie plaque op CCTA voorspelt MI: SCOT-HEART resultaten","title_en":"Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the HEART).","published":"2020-05-05"}],"10.1016/s0140-6736(20)30554-7":[{"url":"https://hartvaat.nl/2020/05/02/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med-pivotal/","title":"Renale denervatie zonder antihypertensiva: Lancet SPYRAL HTN-OFF MED Pivotal","title_en":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.","published":"2020-05-02"}],"10.1093/europace/euaa072":[{"url":"https://hartvaat.nl/2020/05/01/remote-monitoring-vermindert-hospitalisaties-bij-icd-patienten-result-studie/","title":"Remote monitoring vermindert hospitalisaties bij ICD-patiënten: RESULT-studie","title_en":"Remote Supervision to Decrease Hospitalization Rate (RESULT) study in patients with implanted cardioverter-defibrillator.","published":"2020-05-01"}],"10.1093/europace/euaa041":[{"url":"https://hartvaat.nl/2020/05/01/predictie-van-af-recidief-na-ablatie-systematische-review-van-prognostische-mode/","title":"Predictie van AF-recidief na ablatie: systematische review van prognostische modellen","title_en":"Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models.","published":"2020-05-01"}],"10.1001/jamacardio.2020.0125":[{"url":"https://hartvaat.nl/2020/05/01/zelfgerapporteerde-versus-apotheekgeregistreerde-medicatietrouw-compass-analyse/","title":"Zelfgerapporteerde versus apotheekgeregistreerde medicatietrouw: COMPASS-analyse","title_en":"Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial.","published":"2020-05-01"}],"10.1001/jamacardio.2019.6161":[{"url":"https://hartvaat.nl/2020/05/01/werkplek-multicomponentinterventie-voor-hypertensie-jama-cardiology/","title":"Werkplek-multicomponentinterventie voor hypertensie: JAMA Cardiology","title_en":"Effect of a Workplace-Based Multicomponent Intervention on Hypertension Control: A Randomized Clinical Trial.","published":"2020-05-01"}],"10.1001/jamacardio.2019.6192":[{"url":"https://hartvaat.nl/2020/05/01/langetermijnvoordeel-van-intensieve-bloeddrukcontrole-op-resterende-levensduur-s/","title":"Langetermijnvoordeel van intensieve bloeddrukcontrole op resterende levensduur: SPRINT","title_en":"Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).","published":"2020-05-01"}],"10.1001/jamacardio.2019.6175":[{"url":"https://hartvaat.nl/2020/05/01/optimaal-antitrombotisch-regime-bij-af-na-pci-jama-cardiology-netwerkmeta-analys/","title":"Optimaal antitrombotisch regime bij AF na PCI: JAMA Cardiology netwerkmeta-analyse update","title_en":"Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.","published":"2020-05-01"}],"10.1093/europace/euaa005":[{"url":"https://hartvaat.nl/2020/05/01/predictiemodellen-voor-af-in-de-community-meta-analyse/","title":"Predictiemodellen voor AF in de community: meta-analyse","title_en":"Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis.","published":"2020-05-01"}],"10.1093/eurheartj/ehz821":[{"url":"https://hartvaat.nl/2020/05/01/langdurig-ticagrelor-na-mi-zonder-stent-voorgeschiedenis-pegasus-timi-54-inzicht/","title":"Langdurig ticagrelor na MI zonder stent-voorgeschiedenis: PEGASUS-TIMI 54 inzichten","title_en":"Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.","published":"2020-05-01"}],"10.1016/j.kint.2020.01.046":[{"url":"https://hartvaat.nl/2020/05/01/bloeddruk-en-volumemanagement-bij-dialyse-kdigo-controverseconferentie/","title":"Bloeddruk- en volumemanagement bij dialyse: KDIGO controverseconferentie","title_en":"Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","published":"2020-05-01"}],"10.1136/heartjnl-2019-316075":[{"url":"https://hartvaat.nl/2020/05/01/pci-versus-medicamenteus-bij-angina-met-ffr-in-de-grijze-zone/","title":"PCI versus medicamenteus bij angina met FFR in de grijze zone","title_en":"Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial.","published":"2020-05-01"}],"10.1001/jama.2020.3308":[{"url":"https://hartvaat.nl/2020/04/28/apabetalone-en-cv-events-bij-acs-met-diabetes-type-2-jama-betonmace/","title":"Apabetalone en CV-events bij ACS met diabetes type 2: JAMA BETonMACE","title_en":"Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.","published":"2020-04-28"}],"10.1161/circulationaha.119.044059":[{"url":"https://hartvaat.nl/2020/04/28/apixaban-versus-warfarine-bij-af-met-gevorderde-ckd/","title":"Apixaban versus warfarine bij AF met gevorderde CKD","title_en":"Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.","published":"2020-04-28"}],"10.1161/circulationaha.119.043353":[{"url":"https://hartvaat.nl/2020/04/28/open-label-drop-in-van-glucoseverlagende-medicatie-en-exscel-uitkomsten/","title":"Open-label drop-in van glucoseverlagende medicatie en EXSCEL-uitkomsten","title_en":"Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.","published":"2020-04-28"}],"10.1016/s0140-6736(20)30325-1":[{"url":"https://hartvaat.nl/2020/04/25/clopidogrel-versus-ticagrelor-of-prasugrel-bij-70-plussers-met-nste-acs-lancet-p/","title":"Clopidogrel versus ticagrelor of prasugrel bij 70-plussers met NSTE-ACS: Lancet POPular AGE","title_en":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.","published":"2020-04-25"}],"10.1056/nejmoa1915925":[{"url":"https://hartvaat.nl/2020/04/23/management-van-coronairlijden-bij-gevorderde-nierziekte-nejm-ischemia-ckd/","title":"Management van coronairlijden bij gevorderde nierziekte: NEJM ISCHEMIA-CKD","title_en":"Management of Coronary Disease in Patients with Advanced Kidney Disease.","published":"2020-04-23"}],"10.1056/nejmoa1916374":[{"url":"https://hartvaat.nl/2020/04/23/gezondheidsstatus-na-invasieve-of-conservatieve-zorg-bij-coronairlijden-met-gevo/","title":"Gezondheidsstatus na invasieve of conservatieve zorg bij coronairlijden met gevorderde CKD: NEJM ISCHEMIA-CKD QoL","title_en":"Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease.","published":"2020-04-23"}],"10.1161/circulationaha.119.042816":[{"url":"https://hartvaat.nl/2020/04/21/morfine-met-metoclopramide-en-ticagrelor-plaatjesremming-bij-acuut-mi/","title":"Morfine met metoclopramide en ticagrelor-plaatjesremming bij acuut MI","title_en":"Impact of Morphine Treatment With and Without Metoclopramide Coadministration on Ticagrelor-Induced Platelet Inhibition in Acute Myocardial Infarction: The Randomized MonAMI Trial.","published":"2020-04-21"}],"10.1056/nejmoa1913805":[{"url":"https://hartvaat.nl/2020/04/16/inclisiran-bij-heterozygote-familiaire-hypercholesterolemie-nejm-orion-9/","title":"Inclisiran bij heterozygote familiaire hypercholesterolemie: NEJM ORION-9","title_en":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.","published":"2020-04-16"}],"10.1056/nejmoa1912387":[{"url":"https://hartvaat.nl/2020/04/16/inclisiran-fase-3-bij-verhoogd-ldl-nejm-orion-10-en-orion-11/","title":"Inclisiran fase 3 bij verhoogd LDL: NEJM ORION-10 en ORION-11","title_en":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.","published":"2020-04-16"}],"10.1016/j.jacc.2020.01.056":[{"url":"https://hartvaat.nl/2020/04/14/langetermijnuitkomsten-bij-vrouwen-en-mannen-na-pci/","title":"Langetermijnuitkomsten bij vrouwen en mannen na PCI","title_en":"Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention.","published":"2020-04-14"}],"10.1001/jama.2020.1906":[{"url":"https://hartvaat.nl/2020/04/14/dapagliflozine-bij-hf-met-en-zonder-diabetes-jama-dapa-hf-uitkomsten/","title":"Dapagliflozine bij HF met en zonder diabetes: JAMA DAPA-HF uitkomsten","title_en":"Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.","published":"2020-04-14"}],"10.1016/j.jacc.2020.02.009":[{"url":"https://hartvaat.nl/2020/04/14/systolische-bloeddruk-bij-hfpef-behandeld-met-sacubitril-valsartan-paragon-hf/","title":"Systolische bloeddruk bij HFpEF behandeld met sacubitril/valsartan: PARAGON-HF","title_en":"Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.","published":"2020-04-14"}],"10.1056/nejmoa1915922":[{"url":"https://hartvaat.nl/2020/04/09/initieel-invasief-of-conservatief-bij-stabiel-coronairlijden-nejm-ischemia/","title":"Initieel invasief of conservatief bij stabiel coronairlijden: NEJM ISCHEMIA","title_en":"Initial Invasive or Conservative Strategy for Stable Coronary Disease.","published":"2020-04-09"}],"10.1016/j.jacc.2020.01.050":[{"url":"https://hartvaat.nl/2020/04/07/yoga-gebaseerde-hartrevalidatie-na-acuut-mi-gerandomiseerde-trial/","title":"Yoga-gebaseerde hartrevalidatie na acuut MI: gerandomiseerde trial","title_en":"Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction: A Randomized Trial.","published":"2020-04-07"}],"10.1016/j.jacc.2020.01.052":[{"url":"https://hartvaat.nl/2020/04/07/mobiele-gezondheidstechnologie-voor-af-zorg/","title":"Mobiele gezondheidstechnologie voor AF-zorg","title_en":"Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation.","published":"2020-04-07"}],"10.1093/europace/euz301":[{"url":"https://hartvaat.nl/2020/04/01/intraprocedurele-eindpunten-voor-duurzame-pvi-gerandomiseerde-trial-van-vier-tec/","title":"Intraprocedurele eindpunten voor duurzame PVI: gerandomiseerde trial van vier technieken","title_en":"Intraprocedural endpoints to predict durable pulmonary vein isolation: a randomized trial of four post-ablation techniques.","published":"2020-04-01"}],"10.1093/europace/euz345":[{"url":"https://hartvaat.nl/2020/04/01/intracraniele-bloedingen-versus-stenttrombose-met-doac-antiplaatjes-versus-tripl/","title":"Intracraniële bloedingen versus stenttrombose met DOAC + antiplaatjes versus triple: meta-analyse","title_en":"Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.","published":"2020-04-01"}],"10.1001/jamacardio.2019.5323":[{"url":"https://hartvaat.nl/2020/04/01/lvad-gebruik-als-bridge-to-transplant-versus-destination-therapy-momentum-3/","title":"LVAD-gebruik als bridge-to-transplant versus destination therapy: MOMENTUM 3","title_en":"Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial.","published":"2020-04-01"}],"10.1002/ehf2.12663":[{"url":"https://hartvaat.nl/2020/04/01/sst2-voor-hartfalenmanagement-stade-hf-pilotstudie/","title":"sST2 voor hartfalenmanagement: STADE-HF pilotstudie","title_en":"STADE-HF (sST2 As a help for management of HF): a pilot study.","published":"2020-04-01"}],"10.1161/hypertensionaha.119.14168":[{"url":"https://hartvaat.nl/2020/04/01/verhoogde-bloeddruk-op-kinder-adolescentenleeftijd-en-cv-uitkomsten-bij-volwasse/","title":"Verhoogde bloeddruk op kinder-/adolescentenleeftijd en CV-uitkomsten bij volwassenen","title_en":"Elevated Blood Pressure in Childhood or Adolescence and Cardiovascular Outcomes in Adulthood: A Systematic Review.","published":"2020-04-01"}],"10.1161/hypertensionaha.119.14504":[{"url":"https://hartvaat.nl/2020/04/01/aprocitentan-bij-hypertensie-gerandomiseerde-dosis-responsstudie/","title":"Aprocitentan bij hypertensie: gerandomiseerde dosis-responsstudie","title_en":"Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.","published":"2020-04-01"}],"10.1136/heartjnl-2019-315963":[{"url":"https://hartvaat.nl/2020/04/01/p2y12-remmers-met-oac-bij-af-na-pci-meta-analyse/","title":"P2Y12-remmers met OAC bij AF na PCI: meta-analyse","title_en":"P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis.","published":"2020-04-01"}],"10.1002/ehf2.12521":[{"url":"https://hartvaat.nl/2020/04/01/biomarkers-bij-hf-met-centrale-slaapapneu-serve-hf/","title":"Biomarkers bij HF met centrale slaapapneu: SERVE-HF","title_en":"Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE-HF trial.","published":"2020-04-01"}],"10.1016/j.jacc.2020.01.040":[{"url":"https://hartvaat.nl/2020/03/31/staken-van-neurohumorale-blokkade-na-crt/","title":"Staken van neurohumorale blokkade na CRT","title_en":"Withdrawal of Neurohumoral Blockade After Cardiac Resynchronization Therapy.","published":"2020-03-31"}],"10.1016/j.jacc.2020.01.041":[{"url":"https://hartvaat.nl/2020/03/31/laaggedoseerde-alteplase-bij-primaire-pci-naar-ischemietijd/","title":"Laaggedoseerde alteplase bij primaire PCI naar ischemietijd","title_en":"Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time.","published":"2020-03-31"}],"10.1056/nejmoa1910021":[{"url":"https://hartvaat.nl/2020/03/26/polymer-versus-polymeervrije-stents-bij-hoog-bloedingsrisico-nejm-leaders-free-2/","title":"Polymer- versus polymeervrije stents bij hoog bloedingsrisico: NEJM LEADERS FREE 2","title_en":"Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk.","published":"2020-03-26"}],"10.1016/j.jacc.2020.01.016":[{"url":"https://hartvaat.nl/2020/03/24/screening-en-profylactisch-amiodaron-vermindert-postoperatief-af/","title":"Screening en profylactisch amiodaron vermindert postoperatief AF","title_en":"Screening and Prophylactic Amiodarone Reduces Post-Operative Atrial Fibrillation in At-Risk Patients.","published":"2020-03-24"}],"10.1016/j.jacc.2019.12.060":[{"url":"https://hartvaat.nl/2020/03/17/klinische-en-farmacologische-effecten-van-apixaban-dosisaanpassing-aristotle/","title":"Klinische en farmacologische effecten van apixaban-dosisaanpassing: ARISTOTLE","title_en":"Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.","published":"2020-03-17"}],"10.1016/j.jacc.2019.12.063":[{"url":"https://hartvaat.nl/2020/03/17/liraglutide-cv-uitkomsten-bij-diabetes-met-of-zonder-hartfalen-leader/","title":"Liraglutide CV-uitkomsten bij diabetes met of zonder hartfalen: LEADER","title_en":"Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.","published":"2020-03-17"}],"10.1016/j.jacc.2019.12.067":[{"url":"https://hartvaat.nl/2020/03/17/non-culprit-mi-na-pci-bij-acs/","title":"Non-culprit MI na PCI bij ACS","title_en":"Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.","published":"2020-03-17"}],"10.1016/j.jacc.2019.09.030":[{"url":"https://hartvaat.nl/2020/03/17/2020-acc-hfsa-ishlt-verklaring-voor-gevorderd-hf-en-transplantatiespecialisten/","title":"2020 ACC/HFSA/ISHLT verklaring voor gevorderd HF en transplantatiespecialisten","title_en":"2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists: A Report of the ACC Competency Management Committee.","published":"2020-03-17"}],"10.1016/j.jacc.2019.11.065":[{"url":"https://hartvaat.nl/2020/03/10/overleving-na-revascularisatie-met-paclitaxel-gecoate-ballonnen/","title":"Overleving na revascularisatie met paclitaxel-gecoate ballonnen","title_en":"Survival After Coronary Revascularization With Paclitaxel-Coated Balloons.","published":"2020-03-10"}],"10.1161/circulationaha.119.043052":[{"url":"https://hartvaat.nl/2020/03/10/kokosolie-en-cardiovasculaire-risicofactoren-meta-analyse-van-klinische-trials/","title":"Kokosolie en cardiovasculaire risicofactoren: meta-analyse van klinische trials","title_en":"The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials.","published":"2020-03-10"}],"10.1161/circulationaha.119.043964":[{"url":"https://hartvaat.nl/2020/03/10/routine-versus-selectieve-cardiale-mri-bij-niet-ischemisch-hf-outsmart-hf/","title":"Routine versus selectieve cardiale MRI bij niet-ischemisch HF: OUTSMART HF","title_en":"OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B).","published":"2020-03-10"}],"10.1093/eurheartj/ehz385":[{"url":"https://hartvaat.nl/2020/03/07/alert-gebaseerde-beslissingsondersteuning-voor-anticoagulatie-bij-af-in-het-ziek/","title":"Alert-gebaseerde beslissingsondersteuning voor anticoagulatie bij AF in het ziekenhuis","title_en":"Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT).","published":"2020-03-07"}],"10.1161/circulationaha.119.044645":[{"url":"https://hartvaat.nl/2020/03/03/vitamine-d-en-omega-3-en-hartfalen-hospitalisatie-vital-heart-failure/","title":"Vitamine D en omega-3 en hartfalen-hospitalisatie: VITAL-Heart Failure","title_en":"Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization: VITAL-Heart Failure.","published":"2020-03-03"}],"10.1161/circulationaha.119.044584":[{"url":"https://hartvaat.nl/2020/03/03/stenttrombose-bij-af-na-coronaire-stenting-augustus-trial/","title":"Stenttrombose bij AF na coronaire stenting: AUGUSTUS-trial","title_en":"Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.","published":"2020-03-03"}],"10.1093/europace/euz361":[{"url":"https://hartvaat.nl/2020/03/01/gewicht-en-werkzaamheid-veiligheid-van-doac-s-bij-niet-valvulair-af-meta-analyse/","title":"Gewicht en werkzaamheid/veiligheid van DOAC's bij niet-valvulair AF: meta-analyse","title_en":"Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis.","published":"2020-03-01"}],"10.1001/jamacardio.2019.5006":[{"url":"https://hartvaat.nl/2020/03/01/hybride-telerevalidatie-bij-hartfalen-jama-cardiology-tele-hf-trial/","title":"Hybride telerevalidatie bij hartfalen: JAMA Cardiology Tele-HF-trial","title_en":"Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure: The Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial.","published":"2020-03-01"}],"10.1161/hypertensionaha.119.14310":[{"url":"https://hartvaat.nl/2020/03/01/slagvolumeveranderingen-na-renale-denervatie-cardiale-mri-inzichten/","title":"Slagvolumeveranderingen na renale denervatie: cardiale MRI-inzichten","title_en":"Changes in Stroke Volume After Renal Denervation: Insight From Cardiac Magnetic Resonance Imaging.","published":"2020-03-01"}],"10.1161/hypertensionaha.119.14309":[{"url":"https://hartvaat.nl/2020/03/01/orthostatische-hypotensie-cv-uitkomsten-en-adverse-events-sprint-resultaten/","title":"Orthostatische hypotensie, CV-uitkomsten en adverse events: SPRINT-resultaten","title_en":"Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results From SPRINT.","published":"2020-03-01"}],"10.1161/hypertensionaha.119.14111":[{"url":"https://hartvaat.nl/2020/03/01/foetale-groeirestrictie-en-bloeddruk-tegenstrijdige-effecten-bij-mens-en-rat-met/","title":"Foetale groeirestrictie en bloeddruk: tegenstrijdige effecten bij mens en rat — meta-analyse","title_en":"Conflicting Effects of Fetal Growth Restriction on Blood Pressure Between Human and Rat Offspring: A Meta-Analysis.","published":"2020-03-01"}],"10.1161/hypertensionaha.119.13932":[{"url":"https://hartvaat.nl/2020/03/01/natriumreductie-en-energie-metabolisme-gewicht-en-dorst-dash-resultaten/","title":"Natriumreductie en energie, metabolisme, gewicht en dorst: DASH-resultaten","title_en":"Effects of Sodium Reduction on Energy, Metabolism, Weight, Thirst, and Urine Volume: Results From the DASH (Dietary Approaches to Stop Hypertension)-Sodium Trial.","published":"2020-03-01"}],"10.1161/hypertensionaha.119.14230":[{"url":"https://hartvaat.nl/2020/03/01/bloeddruk-en-uitkomsten-bij-acute-beroerte-trombectomie/","title":"Bloeddruk en uitkomsten bij acute beroerte-trombectomie","title_en":"Association of Blood Pressure With Outcomes in Acute Stroke Thrombectomy.","published":"2020-03-01"}],"10.1136/heartjnl-2019-315193":[{"url":"https://hartvaat.nl/2020/03/01/griepvaccinatie-bij-hartfalen-meta-analyse-van-observationele-studies/","title":"Griepvaccinatie bij hartfalen: meta-analyse van observationele studies","title_en":"Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies.","published":"2020-03-01"}],"10.1136/heartjnl-2019-315034":[{"url":"https://hartvaat.nl/2020/03/01/ambulancedienst-vertragingen-bij-stemi-meta-analyse/","title":"Ambulancedienst-vertragingen bij STEMI: meta-analyse","title_en":"Emergency medical service delays in ST-elevation myocardial infarction: a meta-analysis.","published":"2020-03-01"}],"10.1016/s0140-6736(20)30058-1":[{"url":"https://hartvaat.nl/2020/02/29/versnelde-versus-standaard-chirurgie-bij-heupfractuur-lancet-hip-attack/","title":"Versnelde versus standaard chirurgie bij heupfractuur: Lancet HIP ATTACK","title_en":"Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.","published":"2020-02-29"}],"10.1161/circulationaha.119.043805":[{"url":"https://hartvaat.nl/2020/02/25/genetische-risicoscore-voorspelt-voordeel-van-evolocumab-fourier/","title":"Genetische risicoscore voorspelt voordeel van evolocumab: FOURIER","title_en":"Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.","published":"2020-02-25"}],"10.1161/circulationaha.119.044434":[{"url":"https://hartvaat.nl/2020/02/25/polygene-risicoscore-en-voordeel-van-alirocumab-bij-coronairlijden-odyssey-outco/","title":"Polygene risicoscore en voordeel van alirocumab bij coronairlijden: ODYSSEY OUTCOMES","title_en":"Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.","published":"2020-02-25"}],"10.1056/nejmoa1911965":[{"url":"https://hartvaat.nl/2020/02/20/community-interventie-voor-hypertensie-in-ruraal-zuid-azie-nejm/","title":"Community-interventie voor hypertensie in ruraal Zuid-Azië: NEJM","title_en":"A Community-Based Intervention for Managing Hypertension in Rural South Asia.","published":"2020-02-20"}],"10.1016/j.jacc.2019.11.058":[{"url":"https://hartvaat.nl/2020/02/18/stent-gerelateerde-events-1-jaar-na-pci/","title":"Stent-gerelateerde events >1 jaar na PCI","title_en":"Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention.","published":"2020-02-18"}],"10.1016/j.jacc.2019.11.056":[{"url":"https://hartvaat.nl/2020/02/18/ticagrelor-met-of-zonder-aspirine-na-pci-twilight-plaatjessubstudie/","title":"Ticagrelor met of zonder aspirine na PCI: TWILIGHT plaatjessubstudie","title_en":"Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.","published":"2020-02-18"}],"10.1093/eurheartj/ehz595":[{"url":"https://hartvaat.nl/2020/02/14/danami-2-16-jaarsfollow-up-primaire-pci-versus-fibrinolyse/","title":"DANAMI-2 16-jaarsfollow-up: primaire PCI versus fibrinolyse","title_en":"16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction.","published":"2020-02-14"}],"10.1016/j.jacc.2019.11.051":[{"url":"https://hartvaat.nl/2020/02/11/haptoglobinefenotype-wijzigt-het-effect-van-intensieve-glycemische-controle-op-c/","title":"Haptoglobinefenotype wijzigt het effect van intensieve glycemische controle op CV-uitkomsten","title_en":"Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular Outcomes.","published":"2020-02-11"}],"10.1016/j.jacc.2019.12.012":[{"url":"https://hartvaat.nl/2020/02/11/ct-coronairangiografie-bij-nste-acs-verdict-cta-substudie/","title":"CT-coronairangiografie bij NSTE-ACS: VERDICT-CTA substudie","title_en":"Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.","published":"2020-02-11"}],"10.1161/circulationaha.119.041658":[{"url":"https://hartvaat.nl/2020/02/11/disfunctioneel-hdl-en-incidentie-van-acs-bij-hoog-cardiovasculair-risico/","title":"Disfunctioneel HDL en incidentie van ACS bij hoog cardiovasculair risico","title_en":"Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk: A Nested Case-Control Study.","published":"2020-02-11"}],"10.1016/j.jacc.2019.11.030":[{"url":"https://hartvaat.nl/2020/02/04/aanhoudende-ldl-verlaging-met-alirocumab-in-odyssey-outcomes/","title":"Aanhoudende LDL-verlaging met alirocumab in ODYSSEY OUTCOMES","title_en":"Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES.","published":"2020-02-04"}],"10.1161/circulationaha.119.044440":[{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","title":"REDUCE-IT USA: resultaten bij 3.146 Amerikaanse deelnemers","title_en":"REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.","published":"2020-02-04"}],"10.1161/circulationaha.119.044359":[{"url":"https://hartvaat.nl/2020/02/04/canagliflozine-bij-diabetes-type-2-met-ckd-evaluatie-van-cv-en-renale-events/","title":"Canagliflozine bij diabetes type 2 met CKD: evaluatie van CV- en renale events","title_en":"Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.","published":"2020-02-04"}],"10.1016/s0140-6736(19)32994-0":[{"url":"https://hartvaat.nl/2020/02/01/elektrische-versus-farmacologische-cardioversie-bij-acuut-af-op-de-seh-lancet-ra/","title":"Elektrische versus farmacologische cardioversie bij acuut AF op de SEH: Lancet RAFF2","title_en":"Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial.","published":"2020-02-01"}],"10.1001/jamacardio.2019.4852":[{"url":"https://hartvaat.nl/2020/02/01/femorale-versus-radiale-toegang-bij-stemi-jama-cardiology-safari-stemi/","title":"Femorale versus radiale toegang bij STEMI: JAMA Cardiology SAFARI-STEMI","title_en":"Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction: The SAFARI-STEMI Randomized Clinical Trial.","published":"2020-02-01"}],"10.1001/jamacardio.2019.4665":[{"url":"https://hartvaat.nl/2020/02/01/arni-initiatie-na-acuut-gedecompenseerd-hf-pioneer-hf-open-label-extensie/","title":"ARNI-initiatie na acuut gedecompenseerd HF: PIONEER-HF open-label extensie","title_en":"Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.","published":"2020-02-01"}],"10.1093/europace/euz321":[{"url":"https://hartvaat.nl/2020/02/01/crt-bij-verlengd-av-interval-real-crt-gerandomiseerde-trial/","title":"CRT bij verlengd AV-interval: REAL-CRT gerandomiseerde trial","title_en":"A randomized controlled trial of cardiac resynchronization therapy in patients with prolonged atrioventricular interval: the REAL-CRT pilot study.","published":"2020-02-01"}],"10.1093/eurheartj/ehz666":[{"url":"https://hartvaat.nl/2020/02/01/verpleegkundig-geleide-versus-standaard-af-zorg/","title":"Verpleegkundig geleide versus standaard AF-zorg","title_en":"Nurse-led vs. usual-care for atrial fibrillation.","published":"2020-02-01"}],"10.1093/eurheartj/ehz585":[{"url":"https://hartvaat.nl/2020/02/01/maximum-vaste-energie-schokken-voor-af-cardioversie/","title":"Maximum-vaste-energie schokken voor AF-cardioversie","title_en":"Maximum-fixed energy shocks for cardioverting atrial fibrillation.","published":"2020-02-01"}],"10.1002/ehf2.12559":[{"url":"https://hartvaat.nl/2020/02/01/disease-management-bij-hfpef-systematische-review/","title":"Disease management bij HFpEF: systematische review","title_en":"Heart failure disease management: a systematic review of effectiveness in heart failure with preserved ejection fraction.","published":"2020-02-01"}],"10.1002/ehf2.12543":[{"url":"https://hartvaat.nl/2020/02/01/baroreflexactivatietherapie-bij-hfref-snelle-systematische-review/","title":"Baroreflexactivatietherapie bij HFrEF: snelle systematische review","title_en":"Safety and efficacy of baroreflex activation therapy for heart failure with reduced ejection fraction: a rapid systematic review.","published":"2020-02-01"}],"10.1161/hypertensionaha.119.13642":[{"url":"https://hartvaat.nl/2020/02/01/il-1-remming-en-bloeddruk-hypertensie-en-residueel-inflammatoir-risico-cantos/","title":"IL-1β-remming en bloeddruk, hypertensie en residueel inflammatoir risico: CANTOS","title_en":"Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS.","published":"2020-02-01"}],"10.1161/hypertensionaha.118.12572":[{"url":"https://hartvaat.nl/2020/02/01/bloeddrukcontrole-en-diabetes-incidentie-sprint-resultaten/","title":"Bloeddrukcontrole en diabetes-incidentie: SPRINT-resultaten","title_en":"Blood Pressure Control and the Association With Diabetes Mellitus Incidence: Results From SPRINT Randomized Trial.","published":"2020-02-01"}],"10.1161/hypertensionaha.119.14102":[{"url":"https://hartvaat.nl/2020/02/01/geschatte-cva-vrije-overleving-van-foliumzuurtherapie-bij-hypertensie-csppt/","title":"Geschatte CVA-vrije overleving van foliumzuurtherapie bij hypertensie: CSPPT","title_en":"Estimated Stroke-Free Survival of Folic Acid Therapy for Hypertensive Adults: Projection Based on the CSPPT.","published":"2020-02-01"}],"10.1002/ehf2.12528":[{"url":"https://hartvaat.nl/2020/02/01/geschiktheid-voor-sglt2-remmers-bij-diabetespatienten-opgenomen-met-hartfalen/","title":"Geschiktheid voor SGLT2-remmers bij diabetespatiënten opgenomen met hartfalen","title_en":"Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.","published":"2020-02-01"}],"10.1016/j.jacc.2019.11.035":[{"url":"https://hartvaat.nl/2020/01/28/morfine-en-cv-uitkomsten-bij-nste-acs-jacc-analyse/","title":"Morfine en CV-uitkomsten bij NSTE-ACS: JACC analyse","title_en":"Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography.","published":"2020-01-28"}],"10.1016/j.jacc.2019.10.059":[{"url":"https://hartvaat.nl/2020/01/28/orale-antistolling-bij-af-op-langdurige-hemodialyse/","title":"Orale antistolling bij AF op langdurige hemodialyse","title_en":"Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis.","published":"2020-01-28"}],"10.1016/j.jacc.2019.11.003":[{"url":"https://hartvaat.nl/2020/01/28/eerdere-hf-hospitalisatie-en-sacubitril-valsartan-versus-valsartan-bij-hfpef-par/","title":"Eerdere HF-hospitalisatie en sacubitril/valsartan versus valsartan bij HFpEF: PARAGON-HF","title_en":"Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.","published":"2020-01-28"}],"10.1001/jama.2019.21187":[{"url":"https://hartvaat.nl/2020/01/21/renale-denervatie-plus-katheterablatie-versus-ablatie-alleen-bij-af-met-hyperten/","title":"Renale denervatie plus katheterablatie versus ablatie alleen bij AF met hypertensie: JAMA ERADICATE-AF","title_en":"Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.","published":"2020-01-21"}],"10.1016/j.jacc.2019.10.057":[{"url":"https://hartvaat.nl/2020/01/21/alirocumab-en-lp-a-en-cv-risico-na-acs-odyssey-outcomes/","title":"Alirocumab en Lp(a) en CV-risico na ACS: ODYSSEY OUTCOMES","title_en":"Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.","published":"2020-01-21"}],"10.1161/cir.0000000000000743":[{"url":"https://hartvaat.nl/2020/01/21/voedingscholesterol-en-cv-risico-aha-science-advisory/","title":"Voedingscholesterol en CV-risico: AHA science advisory","title_en":"Dietary Cholesterol and Cardiovascular Risk: A Science Advisory From the American Heart Association.","published":"2020-01-21"}],"10.1161/circulationaha.119.042960":[{"url":"https://hartvaat.nl/2020/01/21/hoog-sensitief-troponine-en-de-universele-mi-definitie/","title":"Hoog-sensitief troponine en de universele MI-definitie","title_en":"High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction.","published":"2020-01-21"}],"10.1016/s0140-6736(19)32972-1":[{"url":"https://hartvaat.nl/2020/01/18/pci-versus-cabg-bij-onbeschermde-hoofdstam-lancet-noble-5-jaars-update/","title":"PCI versus CABG bij onbeschermde hoofdstam: Lancet NOBLE 5-jaars update","title_en":"Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.","published":"2020-01-18"}],"10.1056/nejmoa1905239":[{"url":"https://hartvaat.nl/2020/01/16/lp-a-verlaging-bij-cardiovasculaire-ziekte-nejm/","title":"Lp(a)-verlaging bij cardiovasculaire ziekte: NEJM","title_en":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.","published":"2020-01-16"}],"10.1161/circulationaha.119.044138":[{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-en-symptomen-functie-en-qol-bij-hfref-dapa-hf/","title":"Dapagliflozine en symptomen, functie en QoL bij HFrEF: DAPA-HF","title_en":"Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.","published":"2020-01-14"}],"10.1161/circulationaha.119.044133":[{"url":"https://hartvaat.nl/2020/01/14/dapagliflozine-bij-hfref-naar-leeftijd-dapa-hf-inzichten/","title":"Dapagliflozine bij HFrEF naar leeftijd: DAPA-HF-inzichten","title_en":"Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.","published":"2020-01-14"}],"10.1056/nejmoa1911426":[{"url":"https://hartvaat.nl/2020/01/09/verminderde-klepbeweging-na-tavr-nejm/","title":"Verminderde klepbeweging na TAVR: NEJM","title_en":"Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.","published":"2020-01-09"}],"10.1056/nejmoa1911425":[{"url":"https://hartvaat.nl/2020/01/09/rivaroxaban-na-tavr-nejm-galileo/","title":"Rivaroxaban na TAVR: NEJM GALILEO","title_en":"A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.","published":"2020-01-09"}],"10.1161/circulationaha.119.041296":[{"url":"https://hartvaat.nl/2020/01/07/nsaid-s-en-oac-bij-af-aristotle-analyse/","title":"NSAID's en OAC bij AF: ARISTOTLE-analyse","title_en":"Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial.","published":"2020-01-07"}],"10.1093/eurheartj/ehz621":[{"url":"https://hartvaat.nl/2020/01/07/hypoglykemie-cv-uitkomsten-en-empagliflozine-empa-reg-outcome/","title":"Hypoglykemie, CV-uitkomsten en empagliflozine: EMPA-REG OUTCOME","title_en":"Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.","published":"2020-01-07"}],"10.1056/nejmoa1817591":[{"url":"https://hartvaat.nl/2020/01/02/alcoholonthouding-bij-drinkers-met-af-nejm-gerandomiseerde-trial/","title":"Alcoholonthouding bij drinkers met AF: NEJM gerandomiseerde trial","title_en":"Alcohol Abstinence in Drinkers with Atrial Fibrillation.","published":"2020-01-02"}],"10.1056/nejmoa1910355":[{"url":"https://hartvaat.nl/2020/01/02/vergelijking-van-twee-ldl-streefwaarden-na-ischemisch-cva-nejm-tst/","title":"Vergelijking van twee LDL-streefwaarden na ischemisch CVA: NEJM TST","title_en":"A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.","published":"2020-01-02"}],"10.1093/europace/euz255":[{"url":"https://hartvaat.nl/2020/01/01/stapsgewijze-af-screening-met-nt-probnp-strokestop-ii-resultaten/","title":"Stapsgewijze AF-screening met NT-proBNP: STROKESTOP II resultaten","title_en":"Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study.","published":"2020-01-01"}],"10.1001/jamacardio.2019.4408":[{"url":"https://hartvaat.nl/2020/01/01/p2y12-copay-reductie-en-therapietrouw-aan-andere-secundaire-preventiemiddelen/","title":"P2Y12-copay reductie en therapietrouw aan andere secundaire preventiemiddelen","title_en":"Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.","published":"2020-01-01"}],"10.1001/jamacardio.2019.4296":[{"url":"https://hartvaat.nl/2020/01/01/sekseverschillen-bij-pci-global-leaders-subanalyse/","title":"Sekseverschillen bij PCI: GLOBAL LEADERS subanalyse","title_en":"Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.","published":"2020-01-01"}],"10.1093/europace/euz259":[{"url":"https://hartvaat.nl/2020/01/01/weglaten-van-aspirine-bij-gecombineerde-antitrombotische-therapie-voor-af-acs-he/","title":"Weglaten van aspirine bij gecombineerde antitrombotische therapie voor AF+ACS: heranalyse","title_en":"Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.","published":"2020-01-01"}],"10.1016/j.kint.2019.09.013":[{"url":"https://hartvaat.nl/2020/01/01/renale-hemodynamische-effecten-van-dapagliflozine-postglomerulaire-vasodilatatie/","title":"Renale hemodynamische effecten van dapagliflozine: postglomerulaire vasodilatatie","title_en":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.","published":"2020-01-01"}],"10.1161/hypertensionaha.119.13569":[{"url":"https://hartvaat.nl/2020/01/01/esaxerenon-versus-eplerenon-bij-essentiele-hypertensie-esax-htn-fase-3/","title":"Esaxerenon versus eplerenon bij essentiële hypertensie: ESAX-HTN fase-3","title_en":"Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).","published":"2020-01-01"}],"10.1136/heartjnl-2019-314770":[{"url":"https://hartvaat.nl/2020/01/01/obesitas-opzettelijk-gewichtsverlies-en-hartfalen-meta-analyse/","title":"Obesitas, opzettelijk gewichtsverlies en hartfalen: meta-analyse","title_en":"Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis.","published":"2020-01-01"}],"10.1136/heartjnl-2019-315130":[{"url":"https://hartvaat.nl/2020/01/01/hiit-en-plaatjesfunctie-bij-hartrevalidatie-gerandomiseerde-trial/","title":"HIIT en plaatjesfunctie bij hartrevalidatie: gerandomiseerde trial","title_en":"Effects of high-intensity interval training on platelet function in cardiac rehabilitation: a randomised controlled trial.","published":"2020-01-01"}],"10.1136/heartjnl-2019-314952":[{"url":"https://hartvaat.nl/2020/01/01/ischemische-postconditionering-en-trombectomie-bij-stemi-interactie-analyse/","title":"Ischemische postconditionering en trombectomie bij STEMI: interactie-analyse","title_en":"Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction.","published":"2020-01-01"}],"10.1056/nejmoa1912388":[{"url":"https://hartvaat.nl/2019/12/26/laaggedoseerd-colchicine-na-myocardinfarct-nejm-colcot/","title":"Laaggedoseerd colchicine na myocardinfarct: NEJM COLCOT","title_en":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.","published":"2019-12-26"}],"10.1016/j.jacc.2019.10.033":[{"url":"https://hartvaat.nl/2019/12/24/langetermijnfollow-up-van-complete-versus-laesie-only-revascularisatie-bij-stemi/","title":"Langetermijnfollow-up van complete versus laesie-only revascularisatie bij STEMI: CvLPRIT","title_en":"Long-Term Follow-Up of Complete Versus Lesion-Only Revascularization in STEMI and Multivessel Disease: The CvLPRIT Trial.","published":"2019-12-24"}],"10.1016/j.jacc.2019.09.065":[{"url":"https://hartvaat.nl/2019/12/17/uitkomsten-van-vrouwen-versus-mannen-na-nste-acs/","title":"Uitkomsten van vrouwen versus mannen na NSTE-ACS","title_en":"Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes.","published":"2019-12-17"}],"10.1001/jama.2019.18598":[{"url":"https://hartvaat.nl/2019/12/17/uitgebreide-vasodilatatie-versus-standaardzorg-bij-acuut-hf-jama-galactic-hf-pil/","title":"Uitgebreide vasodilatatie versus standaardzorg bij acuut HF: JAMA GALACTIC-HF pilot","title_en":"Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial.","published":"2019-12-17"}],"10.1161/circulationaha.119.043337":[{"url":"https://hartvaat.nl/2019/12/17/biomarkers-in-risicobeoordeling-voor-antihypertensieve-therapie-acc-aha-2017/","title":"Biomarkers in risicobeoordeling voor antihypertensieve therapie: ACC/AHA 2017","title_en":"Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis.","published":"2019-12-17"}],"10.1161/circulationaha.119.043826":[{"url":"https://hartvaat.nl/2019/12/17/alirocumab-en-cva-reductie-odyssey-outcomes/","title":"Alirocumab en CVA-reductie: ODYSSEY OUTCOMES","title_en":"Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.","published":"2019-12-17"}],"10.1016/j.jacc.2019.09.017":[{"url":"https://hartvaat.nl/2019/12/17/echo-uitkomsten-na-mitraclip-bij-secundaire-mr-coapt-echocardiografisch/","title":"Echo-uitkomsten na MitraClip bij secundaire MR: COAPT echocardiografisch","title_en":"Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation: The COAPT Trial.","published":"2019-12-17"}],"10.1016/j.jacc.2019.09.059":[{"url":"https://hartvaat.nl/2019/12/10/nierfunctiestoornis-en-betablokkereffectiviteit-bij-hartfalen/","title":"Nierfunctiestoornis en bètablokkereffectiviteit bij hartfalen","title_en":"Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.","published":"2019-12-10"}],"10.1016/j.jacc.2019.09.063":[{"url":"https://hartvaat.nl/2019/12/10/echocardiografische-kenmerken-bij-hfpef/","title":"Echocardiografische kenmerken bij HFpEF","title_en":"Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.","published":"2019-12-10"}],"10.1093/eurheartj/ehz732":[{"url":"https://hartvaat.nl/2019/12/07/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-veiligheid-en-werk/","title":"Dubbele versus triple antitrombotische therapie bij AF na PCI: veiligheid en werkzaamheid","title_en":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.","published":"2019-12-07"}],"10.1093/eurheartj/ehz404":[{"url":"https://hartvaat.nl/2019/12/07/individueel-levenslang-voordeel-en-bloedingsrisico-van-rivaroxaban-plus-aspirine/","title":"Individueel levenslang voordeel en bloedingsrisico van rivaroxaban plus aspirine: COMPASS","title_en":"Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.","published":"2019-12-07"}],"10.1016/j.jacc.2019.09.050":[{"url":"https://hartvaat.nl/2019/12/03/natuurlijk-beloop-van-subklinisch-af-gedetecteerd-door-implanteerbare-looprecord/","title":"Natuurlijk beloop van subklinisch AF gedetecteerd door implanteerbare looprecorders","title_en":"Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders.","published":"2019-12-03"}],"10.1016/j.jacc.2019.09.051":[{"url":"https://hartvaat.nl/2019/12/03/timing-van-non-culprit-revascularisatie-bij-stemi-complete-trial/","title":"Timing van non-culprit revascularisatie bij STEMI: COMPLETE-trial","title_en":"Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial.","published":"2019-12-03"}],"10.1161/circulationaha.119.043308":[{"url":"https://hartvaat.nl/2019/12/03/antitrombotische-therapie-bij-af-met-acs-medicamenteus-of-met-pci/","title":"Antitrombotische therapie bij AF met ACS: medicamenteus of met PCI","title_en":"Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.","published":"2019-12-03"}],"10.1161/circulationaha.119.043467":[{"url":"https://hartvaat.nl/2019/12/03/magnesium-resorbeerbare-scaffold-versus-metallic-stent-bij-stemi-biosolve-iii/","title":"Magnesium-resorbeerbare scaffold versus metallic stent bij STEMI: BIOSOLVE-III","title_en":"Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial.","published":"2019-12-03"}],"10.1161/circulationaha.119.041766":[{"url":"https://hartvaat.nl/2019/12/03/klinisch-significante-bloedingen-met-ticagrelor-versus-clopidogrel-bij-koreaanse/","title":"Klinisch significante bloedingen met ticagrelor versus clopidogrel bij Koreaanse ACS-patiënten","title_en":"Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial.","published":"2019-12-03"}],"10.1001/jamacardio.2019.3080":[{"url":"https://hartvaat.nl/2019/12/01/eerste-en-recidiverende-cv-events-met-liraglutide-bij-diabetes-type-2-leader/","title":"Eerste en recidiverende CV-events met liraglutide bij diabetes type 2: LEADER","title_en":"Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.","published":"2019-12-01"}],"10.1001/jamacardio.2019.4101":[{"url":"https://hartvaat.nl/2019/12/01/absorb-scaffold-5-jaarsresultaten-systematische-meta-analyse/","title":"Absorb scaffold 5-jaarsresultaten: systematische meta-analyse","title_en":"Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study.","published":"2019-12-01"}],"10.1093/europace/euz209":[{"url":"https://hartvaat.nl/2019/12/01/geintegreerde-gespecialiseerde-af-poliklinieken-verlagen-totale-mortaliteit-post/","title":"Geïntegreerde gespecialiseerde AF-poliklinieken verlagen totale mortaliteit: post-hoc analyse","title_en":"Integrated specialized atrial fibrillation clinics reduce all-cause mortality: post hoc analysis of a randomized clinical trial.","published":"2019-12-01"}],"10.1002/ehf2.12555":[{"url":"https://hartvaat.nl/2019/12/01/hoogtepunten-in-hartfalen-2019/","title":"Hoogtepunten in hartfalen 2019","title_en":"Highlights in heart failure.","published":"2019-12-01"}],"10.1161/hypertensionaha.119.13510":[{"url":"https://hartvaat.nl/2019/12/01/genetische-gevoeligheid-eiwitinname-en-bloeddrukverandering-pounds-lost/","title":"Genetische gevoeligheid, eiwitinname en bloeddrukverandering: POUNDS Lost","title_en":"Genetic Susceptibility, Dietary Protein Intake, and Changes of Blood Pressure: The POUNDS Lost Trial.","published":"2019-12-01"}],"10.1002/ehf2.12516":[{"url":"https://hartvaat.nl/2019/12/01/gestoorde-glucosetolerantie-en-albuminurie-bij-chronisch-hf-support-trial/","title":"Gestoorde glucosetolerantie en albuminurie bij chronisch HF: SUPPORT-trial","title_en":"Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial.","published":"2019-12-01"}],"10.1002/ehf2.12513":[{"url":"https://hartvaat.nl/2019/12/01/gunstige-effecten-van-ivabradine-bij-hf-met-lage-ef-en-hartfrequentie-77-bpm/","title":"Gunstige effecten van ivabradine bij HF met lage EF en hartfrequentie >77 bpm","title_en":"Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.","published":"2019-12-01"}],"10.1002/ehf2.12477":[{"url":"https://hartvaat.nl/2019/12/01/hepatorenale-disfunctie-identificeert-hoogrisico-acuut-hf-relax-ahf/","title":"Hepatorenale disfunctie identificeert hoogrisico acuut HF: RELAX-AHF","title_en":"Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial.","published":"2019-12-01"}],"10.1136/heartjnl-2019-315174":[{"url":"https://hartvaat.nl/2019/12/01/linkeratriumdimensie-en-cv-uitkomsten-bij-patienten-met-en-zonder-af-meta-analys/","title":"Linkeratriumdimensie en CV-uitkomsten bij patiënten met en zonder AF: meta-analyse","title_en":"Left atrial dimension and cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis.","published":"2019-12-01"}],"10.1002/ehf2.12498":[{"url":"https://hartvaat.nl/2019/12/01/orale-morfine-bij-dyspneu-bij-chronisch-hartfalen-gerandomiseerde-placebogecontr/","title":"Orale morfine bij dyspneu bij chronisch hartfalen: gerandomiseerde placebogecontroleerde trial","title_en":"Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo-controlled trial.","published":"2019-12-01"}],"10.1136/heartjnl-2019-314931":[{"url":"https://hartvaat.nl/2019/12/01/gewichtsverandering-en-risico-op-af-systematische-review-en-meta-analyse/","title":"Gewichtsverandering en risico op AF: systematische review en meta-analyse","title_en":"Weight change and the risk of incident atrial fibrillation: a systematic review and meta-analysis.","published":"2019-12-01"}],"10.1016/j.jacc.2019.09.038":[{"url":"https://hartvaat.nl/2019/11/26/werkzaamheid-en-veiligheid-van-stents-bij-stemi-jacc-analyse/","title":"Werkzaamheid en veiligheid van stents bij STEMI: JACC analyse","title_en":"Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction.","published":"2019-11-26"}],"10.1016/j.jacc.2019.08.1062":[{"url":"https://hartvaat.nl/2019/11/26/interatriale-shunt-en-pulmonale-vaatfunctie-bij-hfpef/","title":"Interatriale shunt en pulmonale vaatfunctie bij HFpEF","title_en":"Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction.","published":"2019-11-26"}],"10.1016/j.jacc.2019.10.001":[{"url":"https://hartvaat.nl/2019/11/26/2019-aha-acc-prestatie-en-kwaliteitsmaten-voor-hoge-bloeddruk/","title":"2019 AHA/ACC prestatie- en kwaliteitsmaten voor hoge bloeddruk","title_en":"2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.","published":"2019-11-26"}],"10.1161/circulationaha.119.042622":[{"url":"https://hartvaat.nl/2019/11/26/cryoballon-versus-rf-ablatie-bij-af-beoordeeld-met-continue-monitoring-cryo-firs/","title":"Cryoballon versus RF-ablatie bij AF beoordeeld met continue monitoring: CRYO-FIRST","title_en":"Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial.","published":"2019-11-26"}],"10.1056/nejmoa1908419":[{"url":"https://hartvaat.nl/2019/11/21/ticagrelor-met-of-zonder-aspirine-na-pci-bij-hoog-risico-nejm-twilight/","title":"Ticagrelor met of zonder aspirine na PCI bij hoog risico: NEJM TWILIGHT","title_en":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI.","published":"2019-11-21"}],"10.1056/nejmoa1911303":[{"url":"https://hartvaat.nl/2019/11/21/dapagliflozine-bij-hartfalen-met-verminderde-ejectiefractie-nejm-dapa-hf/","title":"Dapagliflozine bij hartfalen met verminderde ejectiefractie: NEJM DAPA-HF","title_en":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.","published":"2019-11-21"}],"10.1093/eurheartj/ehz427":[{"url":"https://hartvaat.nl/2019/11/21/rivaroxaban-en-cva-tia-bij-hf-met-coronairlijden-en-sinusritme-commander-hf/","title":"Rivaroxaban en CVA/TIA bij HF met coronairlijden en sinusritme: COMMANDER HF","title_en":"A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.","published":"2019-11-21"}],"10.1093/eurheartj/ehz554":[{"url":"https://hartvaat.nl/2019/11/21/diureticastaken-bij-stabiel-mild-hf-zonder-vochtretentie/","title":"Diureticastaken bij stabiel mild HF zonder vochtretentie","title_en":"Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.","published":"2019-11-21"}],"10.1016/j.jacc.2019.09.027":[{"url":"https://hartvaat.nl/2019/11/19/beeldvorming-geleide-versus-routinezorg-bij-nstemi-jacc/","title":"Beeldvorming-geleide versus routinezorg bij NSTEMI: JACC","title_en":"Initial Imaging-Guided Strategy Versus Routine Care in Patients With Non-ST-Segment Elevation Myocardial Infarction.","published":"2019-11-19"}],"10.1016/j.jacc.2019.08.010":[{"url":"https://hartvaat.nl/2019/11/19/evolocumab-voor-vroege-ldl-verlaging-bij-acs-evopacs/","title":"Evolocumab voor vroege LDL-verlaging bij ACS: EVOPACS","title_en":"Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).","published":"2019-11-19"}],"10.1161/circulationaha.119.042375":[{"url":"https://hartvaat.nl/2019/11/19/empagliflozine-en-lv-massa-bij-diabetes-type-2-met-coronairlijden-empa-heart/","title":"Empagliflozine en LV-massa bij diabetes type 2 met coronairlijden: EMPA-HEART","title_en":"Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.","published":"2019-11-19"}],"10.1016/s0140-6736(19)32317-7":[{"url":"https://hartvaat.nl/2019/11/16/vergelijking-van-eerstelijns-antihypertensiva-lancet-systematische-multinational/","title":"Vergelijking van eerstelijns antihypertensiva: Lancet systematische multinationale analyse","title_en":"Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.","published":"2019-11-16"}],"10.1001/jama.2019.16585":[{"url":"https://hartvaat.nl/2019/11/12/bempedoinezuur-toegevoegd-aan-statines-bij-hoog-cv-risico-jama-clear-harmony/","title":"Bempedoïnezuur toegevoegd aan statines bij hoog CV-risico: JAMA CLEAR Harmony","title_en":"Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.","published":"2019-11-12"}],"10.1161/circulationaha.119.041603":[{"url":"https://hartvaat.nl/2019/11/12/intensieve-versus-standaard-ambulante-bloeddrukcontrole-en-cerebrovasculaire-uit/","title":"Intensieve versus standaard ambulante bloeddrukcontrole en cerebrovasculaire uitkomsten bij ouderen: INFINITY","title_en":"Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY).","published":"2019-11-12"}],"10.1056/nejmoa1909406":[{"url":"https://hartvaat.nl/2019/11/07/5-jaarsuitkomsten-na-pci-of-cabg-bij-hoofdstamlijden-nejm-excel/","title":"5-jaarsuitkomsten na PCI of CABG bij hoofdstamlijden: NEJM EXCEL","title_en":"Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.","published":"2019-11-07"}],"10.1016/j.jacc.2019.08.1038":[{"url":"https://hartvaat.nl/2019/11/05/ticagrelor-monotherapie-versus-dapt-vanaf-1-maand-na-des-tico-trial/","title":"Ticagrelor monotherapie versus DAPT vanaf 1 maand na DES: TICO-trial","title_en":"Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.","published":"2019-11-05"}],"10.1161/circulationaha.119.042891":[{"url":"https://hartvaat.nl/2019/11/05/1-uur-troponine-t-protocol-bij-verdenking-acs-gerandomiseerde-rapid-tnt-trial/","title":"1-uur troponine T-protocol bij verdenking ACS: gerandomiseerde RAPID-TnT-trial","title_en":"A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes: The Rapid Assessment of Possible Acute Coronary Syndrome in the Emergency Department With High-Sensitivity Troponin T Study (RAPID-TnT).","published":"2019-11-05"}],"10.1161/circulationaha.119.042551":[{"url":"https://hartvaat.nl/2019/11/05/risicoclassificatie-volgens-de-nieuwe-acc-aha-cholesterolrichtlijn-en-stenting-u/","title":"Risicoclassificatie volgens de nieuwe ACC/AHA cholesterolrichtlijn en stenting-uitkomsten","title_en":"Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.","published":"2019-11-05"}],"10.1001/jamacardio.2019.3355":[{"url":"https://hartvaat.nl/2019/11/01/aspirine-plus-ticagrelor-bij-acs-voordeel-risicoanalyse-van-global-leaders/","title":"Aspirine plus ticagrelor bij ACS: voordeel-risicoanalyse van GLOBAL LEADERS","title_en":"Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.","published":"2019-11-01"}],"10.1001/jamacardio.2019.3502":[{"url":"https://hartvaat.nl/2019/11/01/inclisiran-1-of-2-dosis-en-ldl-cholesterol-orion-1-1-jaarsfollow-up/","title":"Inclisiran 1- of 2-dosis en LDL-cholesterol: ORION-1 1-jaarsfollow-up","title_en":"Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.","published":"2019-11-01"}],"10.1093/eurheartj/ehz707":[{"url":"https://hartvaat.nl/2019/11/01/themis-en-themis-pci-editorial-perspectief/","title":"THEMIS en THEMIS-PCI: editorial perspectief","title_en":"THEMIS and THEMIS-PCI.","published":"2019-11-01"}],"10.1093/eurheartj/ehz646":[{"url":"https://hartvaat.nl/2019/11/01/causaal-verband-periodontitis-en-hypertensie-mendeliaanse-randomisatie-en-rct/","title":"Causaal verband periodontitis en hypertensie: Mendeliaanse randomisatie en RCT","title_en":"Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy.","published":"2019-11-01"}],"10.1001/jamacardio.2019.3066":[{"url":"https://hartvaat.nl/2019/11/01/interventies-voor-statinevoorschrijving-bij-primaire-cv-preventie-meta-analyse/","title":"Interventies voor statinevoorschrijving bij primaire CV-preventie: meta-analyse","title_en":"Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention: A Systematic Review of Randomized Clinical Trials.","published":"2019-11-01"}],"10.1093/europace/euz213":[{"url":"https://hartvaat.nl/2019/11/01/determinanten-van-linkeratriumtrombi-bij-geplande-cardioversie-ensure-af/","title":"Determinanten van linkeratriumtrombi bij geplande cardioversie: ENSURE-AF","title_en":"Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.","published":"2019-11-01"}],"10.1093/eurheartj/ehz203":[{"url":"https://hartvaat.nl/2019/11/01/metformine-en-linkerventrikelhypertrofie-bij-coronairlijden-zonder-diabetes-gera/","title":"Metformine en linkerventrikelhypertrofie bij coronairlijden zonder diabetes: gerandomiseerde trial","title_en":"A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial.","published":"2019-11-01"}],"10.1161/hypertensionaha.119.13664":[{"url":"https://hartvaat.nl/2019/11/01/bloeddrukvariabiliteit-en-progressie-van-klinische-alzheimer/","title":"Bloeddrukvariabiliteit en progressie van klinische Alzheimer","title_en":"Blood Pressure Variability and Progression of Clinical Alzheimer Disease.","published":"2019-11-01"}],"10.1016/j.kint.2019.05.019":[{"url":"https://hartvaat.nl/2019/11/01/acute-egfr-daling-door-enalapril-en-mortaliteit-bij-hf-met-ckd/","title":"Acute eGFR-daling door enalapril en mortaliteit bij HF met CKD","title_en":"Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.","published":"2019-11-01"}],"10.1136/heartjnl-2019-314977":[{"url":"https://hartvaat.nl/2019/11/01/hartfalenrisicovoorspelling-bij-congenitale-hartafwijkingen-systematische-review/","title":"Hartfalenrisicovoorspelling bij congenitale hartafwijkingen: systematische review","title_en":"Heart failure risk predictions in adult patients with congenital heart disease: a systematic review.","published":"2019-11-01"}],"10.1016/j.jacc.2019.08.1024":[{"url":"https://hartvaat.nl/2019/10/29/langetermijn-werkzaamheid-en-veiligheid-van-evolocumab-bij-hypercholesterolemie/","title":"Langetermijn werkzaamheid en veiligheid van evolocumab bij hypercholesterolemie","title_en":"Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.","published":"2019-10-29"}],"10.1016/s0140-6736(19)32135-x":[{"url":"https://hartvaat.nl/2019/10/26/patiromer-voor-spironolactongebruik-bij-resistente-hypertensie-met-ckd-lancet-am/","title":"Patiromer voor spironolactongebruik bij resistente hypertensie met CKD: Lancet AMBER","title_en":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.","published":"2019-10-26"}],"10.1056/nejmoa1907096":[{"url":"https://hartvaat.nl/2019/10/24/genotype-geleide-p2y12-remmerkeuze-bij-primaire-pci-nejm-popular-genetics/","title":"Genotype-geleide P2Y12-remmerkeuze bij primaire PCI: NEJM POPular Genetics","title_en":"A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.","published":"2019-10-24"}],"10.1056/nejmoa1908655":[{"url":"https://hartvaat.nl/2019/10/24/sacubitril-valsartan-bij-hfpef-nejm-paragon-hf/","title":"Sacubitril/valsartan bij HFpEF: NEJM PARAGON-HF","title_en":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.","published":"2019-10-24"}],"10.1016/j.jacc.2019.07.083":[{"url":"https://hartvaat.nl/2019/10/22/individualisering-van-revascularisatiestrategie-bij-diabetes-met-multivatenlijde/","title":"Individualisering van revascularisatiestrategie bij diabetes met multivatenlijden","title_en":"Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease.","published":"2019-10-22"}],"10.1016/j.jacc.2019.07.085":[{"url":"https://hartvaat.nl/2019/10/22/ccta-geleide-therapie-verbetert-uitkomsten-bij-stabiele-pijn-op-de-borst/","title":"CCTA-geleide therapie verbetert uitkomsten bij stabiele pijn op de borst","title_en":"Guiding Therapy by Coronary CT Angiography Improves Outcomes in Patients With Stable Chest Pain.","published":"2019-10-22"}],"10.1016/j.jacc.2019.07.084":[{"url":"https://hartvaat.nl/2019/10/22/implanteerbare-monitor-voor-snellere-behandeling-bij-acs/","title":"Implanteerbare monitor voor snellere behandeling bij ACS","title_en":"Implanted Monitor Alerting to Reduce Treatment Delay in Patients With Acute Coronary Syndrome Events.","published":"2019-10-22"}],"10.1016/j.jacc.2019.07.082":[{"url":"https://hartvaat.nl/2019/10/22/sekse-specifieke-troponinedrempels-bij-verdenking-acs/","title":"Sekse-specifieke troponinedrempels bij verdenking ACS","title_en":"Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome.","published":"2019-10-22"}],"10.1016/j.jacc.2019.08.997":[{"url":"https://hartvaat.nl/2019/10/22/ticagrelor-monotherapie-bij-multivaten-pci-werkzaamheid-en-veiligheid/","title":"Ticagrelor monotherapie bij multivaten-PCI: werkzaamheid en veiligheid","title_en":"Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.","published":"2019-10-22"}],"10.1093/eurheartj/ehz395":[{"url":"https://hartvaat.nl/2019/10/21/digoxine-en-mortaliteit-gerandomiseerd-versus-observationeel-in-de-dig-trial/","title":"Digoxine en mortaliteit: gerandomiseerd versus observationeel in de DIG-trial","title_en":"Digoxin-mortality: randomized vs. observational comparison in the DIG trial.","published":"2019-10-21"}],"10.1093/eurheartj/ehz240":[{"url":"https://hartvaat.nl/2019/10/21/cv-biomarkers-bij-acuut-gedecompenseerd-hf-met-sacubitril-valsartan-pioneer-hf/","title":"CV-biomarkers bij acuut gedecompenseerd HF met sacubitril/valsartan: PIONEER-HF","title_en":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.","published":"2019-10-21"}],"10.1016/s0140-6736(19)32039-2":[{"url":"https://hartvaat.nl/2019/10/19/remote-ischemische-conditionering-en-mi-uitkomsten-lancet-condi-2-eric-ppci/","title":"Remote ischemische conditionering en MI-uitkomsten: Lancet CONDI-2/ERIC-PPCI","title_en":"Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.","published":"2019-10-19"}],"10.1056/nejmoa1908973":[{"url":"https://hartvaat.nl/2019/10/17/ticagrelor-of-prasugrel-bij-acuut-coronair-syndroom-nejm-isar-react-5/","title":"Ticagrelor of prasugrel bij acuut coronair syndroom: NEJM ISAR-REACT 5","title_en":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.","published":"2019-10-17"}],"10.1161/circulationaha.119.041998":[{"url":"https://hartvaat.nl/2019/10/15/triglyceridenverlaging-en-cv-risicoreductie-over-therapeutische-klassen-meta-ana/","title":"Triglyceridenverlaging en CV-risicoreductie over therapeutische klassen: meta-analyse","title_en":"Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.","published":"2019-10-15"}],"10.1016/j.jacc.2019.08.003":[{"url":"https://hartvaat.nl/2019/10/15/community-health-workers-verbeteren-koppeling-met-hypertensiezorg-in-kenia/","title":"Community health workers verbeteren koppeling met hypertensiezorg in Kenia","title_en":"Community Health Workers Improve Linkage to Hypertension Care in Western Kenya.","published":"2019-10-15"}],"10.1016/s0140-6736(19)31872-0":[{"url":"https://hartvaat.nl/2019/10/12/edoxaban-versus-vka-gebaseerd-antitrombotisch-regime-na-stenting-bij-af-lancet-e/","title":"Edoxaban- versus VKA-gebaseerd antitrombotisch regime na stenting bij AF: Lancet ENTRUST-AF PCI","title_en":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.","published":"2019-10-12"}],"10.1016/s0140-6736(19)31997-x":[{"url":"https://hartvaat.nl/2019/10/12/pci-versus-cabg-bij-drievaten-of-hoofdstamlijden-lancet-syntax-extended-10-jaars/","title":"PCI versus CABG bij drievaten- of hoofdstamlijden: Lancet SYNTAX extended 10-jaars","title_en":"Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.","published":"2019-10-12"}],"10.1056/nejmoa1907775":[{"url":"https://hartvaat.nl/2019/10/10/complete-revascularisatie-met-multivaten-pci-bij-mi-nejm-complete/","title":"Complete revascularisatie met multivaten-PCI bij MI: NEJM COMPLETE","title_en":"Complete Revascularization with Multivessel PCI for Myocardial Infarction.","published":"2019-10-10"}],"10.1016/s0140-6736(19)31877-x":[{"url":"https://hartvaat.nl/2019/10/05/biodegradeerbare-versus-duurzame-polymer-des-bij-stemi-gerandomiseerde-trial/","title":"Biodegradeerbare versus duurzame polymer DES bij STEMI: gerandomiseerde trial","title_en":"Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.","published":"2019-10-05"}],"10.1016/s0140-6736(19)31949-x":[{"url":"https://hartvaat.nl/2019/10/05/uitgebreide-community-interventie-bij-hypertensie-lancet-hope-4/","title":"Uitgebreide community-interventie bij hypertensie: Lancet HOPE 4","title_en":"A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.","published":"2019-10-05"}],"10.1056/nejmoa1908077":[{"url":"https://hartvaat.nl/2019/10/03/ticagrelor-bij-stabiel-coronairlijden-met-diabetes-nejm-themis/","title":"Ticagrelor bij stabiel coronairlijden met diabetes: NEJM THEMIS","title_en":"Ticagrelor in Patients with Stable Coronary Disease and Diabetes.","published":"2019-10-03"}],"10.1016/j.jacc.2019.07.058":[{"url":"https://hartvaat.nl/2019/10/01/verbetering-van-communicatie-bij-hartfalenpatientenzorg/","title":"Verbetering van communicatie bij hartfalenpatiëntenzorg","title_en":"Improving Communication in Heart Failure Patient Care.","published":"2019-10-01"}],"10.1093/europace/euz196":[{"url":"https://hartvaat.nl/2019/10/01/quadripolaire-versus-bipolaire-lv-leads-bij-crt-klinische-uitkomsten/","title":"Quadripolaire versus bipolaire LV-leads bij CRT: klinische uitkomsten","title_en":"Clinical outcomes after implantation of quadripolar compared to bipolar left ventricular leads in patients undergoing cardiac resynchronization therapy: a systematic review and meta-analysis.","published":"2019-10-01"}],"10.1093/europace/euz179":[{"url":"https://hartvaat.nl/2019/10/01/sekseverschillen-bij-katheterablatie-van-af-meta-analyse/","title":"Sekseverschillen bij katheterablatie van AF: meta-analyse","title_en":"Sex-related differences in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.","published":"2019-10-01"}],"10.1002/ehf2.12511":[{"url":"https://hartvaat.nl/2019/10/01/beeldvorming-bij-cardiale-amyloidose-diagnostische-prestatie-meta-analyse/","title":"Beeldvorming bij cardiale amyloïdose: diagnostische prestatie — meta-analyse","title_en":"Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis.","published":"2019-10-01"}],"10.1161/hypertensionaha.119.13445":[{"url":"https://hartvaat.nl/2019/10/01/antihypertensivaklasse-en-vallen-syncope-en-orthostatische-hypotensie-bij-oudere/","title":"Antihypertensivaklasse en vallen, syncope en orthostatische hypotensie bij ouderen: ALLHAT","title_en":"Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.","published":"2019-10-01"}],"10.1002/ehf2.12504":[{"url":"https://hartvaat.nl/2019/10/01/neuromusculaire-elektrische-stimulatie-bij-acuut-hartfalen-haalbaarheid/","title":"Neuromusculaire elektrische stimulatie bij acuut hartfalen: haalbaarheid","title_en":"Neuromuscular electrical stimulation is feasible in patients with acute heart failure.","published":"2019-10-01"}],"10.1161/hypertensionaha.119.12625":[{"url":"https://hartvaat.nl/2019/10/01/arteriele-golfvormclusters-en-langetermijn-klinisch-nut/","title":"Arteriële golfvormclusters en langetermijn klinisch nut","title_en":"Identification of Distinct Arterial Waveform Clusters and a Longitudinal Evaluation of Their Clinical Usefulness.","published":"2019-10-01"}],"10.1016/j.kint.2019.04.027":[{"url":"https://hartvaat.nl/2019/10/01/bardoxolone-en-urine-albumine-creatinine-ratio-bij-diabetes-met-ckd-stadium-4/","title":"Bardoxolone en urine albumine-creatinine ratio bij diabetes met CKD stadium 4","title_en":"Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.","published":"2019-10-01"}],"10.1136/heartjnl-2019-314965":[{"url":"https://hartvaat.nl/2019/10/01/bloeddruk-na-stenting-bij-aortacoarctatie-systematische-review-en-meta-analyse/","title":"Bloeddruk na stenting bij aortacoarctatie: systematische review en meta-analyse","title_en":"Medium-term systemic blood pressure after stenting of aortic coarctation: a systematic review and meta-analysis.","published":"2019-10-01"}],"10.1136/heartjnl-2018-314539":[{"url":"https://hartvaat.nl/2019/10/01/telemedicine-en-mortaliteit-bij-acuut-mi-systematische-review-en-meta-analyse/","title":"Telemedicine en mortaliteit bij acuut MI: systematische review en meta-analyse","title_en":"Impact of telemedicine interventions on mortality in patients with acute myocardial infarction: a systematic review and meta-analysis.","published":"2019-10-01"}],"10.1136/heartjnl-2018-314386":[{"url":"https://hartvaat.nl/2019/10/01/lage-arteriele-compliance-en-cv-morbiditeit-bij-aortaklepstenose/","title":"Lage arteriële compliance en CV-morbiditeit bij aortaklepstenose","title_en":"Low systemic arterial compliance is associated with increased cardiovascular morbidity and mortality in aortic valve stenosis.","published":"2019-10-01"}],"10.1016/s0140-6736(19)31887-2":[{"url":"https://hartvaat.nl/2019/09/28/ticagrelor-bij-diabetes-met-stabiel-coronairlijden-en-eerder-pci-lancet-themis-p/","title":"Ticagrelor bij diabetes met stabiel coronairlijden en eerder PCI: Lancet THEMIS-PCI","title_en":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.","published":"2019-09-28"}],"10.1016/j.jacc.2019.07.068":[{"url":"https://hartvaat.nl/2019/09/24/asymptomatische-patienten-met-abnormale-ffr-medicamenteus-versus-pci/","title":"Asymptomatische patiënten met abnormale FFR: medicamenteus versus PCI","title_en":"Asymptomatic Patients With Abnormal Fractional Flow Reserve Treated With Medication Alone or With PCI.","published":"2019-09-24"}],"10.1161/circulationaha.119.041320":[{"url":"https://hartvaat.nl/2019/09/24/interne-versus-externe-cardioversie-bij-atriale-aritmieen-met-icd/","title":"Interne versus externe cardioversie bij atriale aritmieën met ICD","title_en":"Internal Versus External Electrical Cardioversion of Atrial Arrhythmia in Patients With Implantable Cardioverter-Defibrillator: A Randomized Clinical Trial.","published":"2019-09-24"}],"10.1016/s0140-6736(19)31282-6":[{"url":"https://hartvaat.nl/2019/09/21/orale-antihypertensiva-bij-ernstige-hypertensie-in-de-zwangerschap-lancet-vergel/","title":"Orale antihypertensiva bij ernstige hypertensie in de zwangerschap: Lancet vergelijking","title_en":"Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.","published":"2019-09-21"}],"10.1093/eurheartj/ehz190":[{"url":"https://hartvaat.nl/2019/09/21/ononderbroken-edoxaban-versus-vka-bij-af-ablatie-eliminate-af/","title":"Ononderbroken edoxaban versus VKA bij AF-ablatie: ELIMINATE-AF","title_en":"Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.","published":"2019-09-21"}],"10.1056/nejmoa1815359":[{"url":"https://hartvaat.nl/2019/09/19/polypil-voor-cv-preventie-bij-onderbehandelde-populatie-nejm/","title":"Polypil voor CV-preventie bij onderbehandelde populatie: NEJM","title_en":"Polypill for Cardiovascular Disease Prevention in an Underserved Population.","published":"2019-09-19"}],"10.1056/nejmoa1904143":[{"url":"https://hartvaat.nl/2019/09/19/antitrombotische-therapie-bij-af-met-stabiel-coronairlijden-nejm-afire/","title":"Antitrombotische therapie bij AF met stabiel coronairlijden: NEJM AFIRE","title_en":"Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.","published":"2019-09-19"}],"10.1016/j.jacc.2019.07.037":[{"url":"https://hartvaat.nl/2019/09/17/ldl-cholesterol-en-micro-versus-macrovasculaire-ziekte-mendeliaanse-randomisatie/","title":"LDL-cholesterol en micro- versus macrovasculaire ziekte: Mendeliaanse randomisatie","title_en":"Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study.","published":"2019-09-17"}],"10.1093/eurheartj/ehz109":[{"url":"https://hartvaat.nl/2019/09/14/crt-non-responder-naar-responder-conversie-more-crt-mpp/","title":"CRT non-responder naar responder conversie: MORE-CRT MPP","title_en":"Cardiac resynchronization therapy non-responder to responder conversion rate in the more response to cardiac resynchronization therapy with MultiPoint Pacing (MORE-CRT MPP) study: results from Phase I.","published":"2019-09-14"}],"10.1056/nejmoa1901713":[{"url":"https://hartvaat.nl/2019/09/12/roxadustat-bij-anemie-bij-langdurige-dialysepatienten-nejm/","title":"Roxadustat bij anemie bij langdurige dialysepatiënten: NEJM","title_en":"Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.","published":"2019-09-12"}],"10.1056/nejmoa1813599":[{"url":"https://hartvaat.nl/2019/09/12/roxadustat-bij-anemie-bij-nierziekte-zonder-dialyse-nejm/","title":"Roxadustat bij anemie bij nierziekte zonder dialyse: NEJM","title_en":"Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.","published":"2019-09-12"}],"10.1016/j.jacc.2019.06.055":[{"url":"https://hartvaat.nl/2019/09/03/natriuretisch-peptiderespons-en-uitkomsten-bij-chronisch-hfref/","title":"Natriuretisch peptiderespons en uitkomsten bij chronisch HFrEF","title_en":"Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.","published":"2019-09-03"}],"10.1016/j.jacc.2019.07.015":[{"url":"https://hartvaat.nl/2019/09/03/alirocumab-na-cabg-effecten-op-cv-events-odyssey-outcomes/","title":"Alirocumab na CABG: effecten op CV-events — ODYSSEY OUTCOMES","title_en":"Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.","published":"2019-09-03"}],"10.1016/j.jacc.2019.03.013":[{"url":"https://hartvaat.nl/2019/09/03/alirocumab-bij-polyvasculaire-ziekte-na-acs-odyssey-outcomes/","title":"Alirocumab bij polyvasculaire ziekte na ACS: ODYSSEY OUTCOMES","title_en":"Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.","published":"2019-09-03"}],"10.1093/eurheartj/ehz209":[{"url":"https://hartvaat.nl/2019/09/01/galnac-geconjugeerd-antisense-tegen-apoc3-triglyceriden-en-atherogene-lipoprotei/","title":"GalNAc-geconjugeerd antisense tegen APOC3: triglyceriden en atherogene lipoproteïnen","title_en":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.","published":"2019-09-01"}],"10.1001/jamacardio.2019.2306":[{"url":"https://hartvaat.nl/2019/09/01/simvastatine-ezetimibe-versus-simvastatine-na-acs-bij-75-plussers-jama-cardiolog/","title":"Simvastatine-ezetimibe versus simvastatine na ACS bij 75-plussers: JAMA Cardiology","title_en":"Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.","published":"2019-09-01"}],"10.1001/jamacardio.2019.2298":[{"url":"https://hartvaat.nl/2019/09/01/ifr-versus-ffr-bij-diabetespatienten-jama-cardiology/","title":"iFR versus FFR bij diabetespatiënten: JAMA Cardiology","title_en":"Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial.","published":"2019-09-01"}],"10.1093/europace/euz184":[{"url":"https://hartvaat.nl/2019/09/01/elektrisch-versus-beeldvorming-geleide-lv-leadplaatsing-bij-crt-gerandomiseerde-/","title":"Elektrisch versus beeldvorming-geleide LV-leadplaatsing bij CRT: gerandomiseerde trial","title_en":"Electrically vs. imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial.","published":"2019-09-01"}],"10.1093/europace/euz140":[{"url":"https://hartvaat.nl/2019/09/01/remote-monitoring-en-patientgerapporteerde-uitkomsten-bij-europese-hf-patienten-/","title":"Remote monitoring en patiëntgerapporteerde uitkomsten bij Europese HF-patiënten met ICD","title_en":"Effect of remote monitoring on patient-reported outcomes in European heart failure patients with an implantable cardioverter-defibrillator: primary results of the REMOTE-CIED randomized trial.","published":"2019-09-01"}],"10.1093/eurheartj/ehz299":[{"url":"https://hartvaat.nl/2019/09/01/alirocumab-en-mi-types-odyssey-outcomes-inzichten/","title":"Alirocumab en MI-types: ODYSSEY OUTCOMES-inzichten","title_en":"Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.","published":"2019-09-01"}],"10.1093/europace/euz125":[{"url":"https://hartvaat.nl/2019/09/01/icd-en-overleving-bij-gevorderd-hf-met-continue-flow-lvad/","title":"ICD en overleving bij gevorderd HF met continue-flow LVAD","title_en":"Implantable cardioverter-defibrillators and survival in advanced heart failure patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis.","published":"2019-09-01"}],"10.1093/eurheartj/ehy862":[{"url":"https://hartvaat.nl/2019/09/01/persisterende-arteriele-wandinflammatie-bij-verhoogd-lp-a-ondanks-lage-ldl/","title":"Persisterende arteriële wandinflammatie bij verhoogd Lp(a) ondanks lage LDL","title_en":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.","published":"2019-09-01"}],"10.1161/hypertensionaha.119.13138":[{"url":"https://hartvaat.nl/2019/09/01/edoxaban-versus-warfarine-naar-gemiddelde-bloeddruk-bij-af-met-hypertensie/","title":"Edoxaban versus warfarine naar gemiddelde bloeddruk bij AF met hypertensie","title_en":"Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.","published":"2019-09-01"}],"10.1161/hypertensionaha.119.13273":[{"url":"https://hartvaat.nl/2019/09/01/interactieve-mobiele-gezondheidsinterventie-en-bloeddrukmanagement/","title":"Interactieve mobiele gezondheidsinterventie en bloeddrukmanagement","title_en":"Interactive Mobile Health Intervention and Blood Pressure Management in Adults.","published":"2019-09-01"}],"10.1136/heartjnl-2019-314767":[{"url":"https://hartvaat.nl/2019/09/01/oac-bij-af-met-kleplijden-en-bioprothese-overzicht/","title":"OAC bij AF met kleplijden en bioprothese: overzicht","title_en":"Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves.","published":"2019-09-01"}],"10.1136/heartjnl-2019-314758":[{"url":"https://hartvaat.nl/2019/09/01/advance-care-planning-bij-hartfalen-systematische-review/","title":"Advance care planning bij hartfalen: systematische review","title_en":"Clinician-targeted interventions to improve advance care planning in heart failure: a systematic review and meta-analysis.","published":"2019-09-01"}],"10.1136/heartjnl-2018-314381":[{"url":"https://hartvaat.nl/2019/09/01/antistolling-bij-hf-met-sinusritme-systematische-review-en-meta-analyse/","title":"Antistolling bij HF met sinusritme: systematische review en meta-analyse","title_en":"Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis.","published":"2019-09-01"}],"10.1136/heartjnl-2018-314639":[{"url":"https://hartvaat.nl/2019/09/01/metformine-en-aorta-aneurysma-systematische-review-en-meta-analyse/","title":"Metformine en aorta-aneurysma: systematische review en meta-analyse","title_en":"Metformin prescription and aortic aneurysm: systematic review and meta-analysis.","published":"2019-09-01"}],"10.1056/nejmoa1901118":[{"url":"https://hartvaat.nl/2019/08/29/orale-semaglutide-en-cv-uitkomsten-bij-diabetes-type-2-nejm-pioneer-6/","title":"Orale semaglutide en CV-uitkomsten bij diabetes type 2: NEJM PIONEER 6","title_en":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.","published":"2019-08-29"}],"10.1161/circulationaha.119.042007":[{"url":"https://hartvaat.nl/2019/08/27/canagliflozine-bij-diabetes-type-2-met-ckd-primaire-en-secundaire-preventie/","title":"Canagliflozine bij diabetes type 2 met CKD: primaire en secundaire preventie","title_en":"Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.","published":"2019-08-27"}],"10.1016/s0140-6736(19)31791-x":[{"url":"https://hartvaat.nl/2019/08/24/polypil-voor-primaire-en-secundaire-cv-preventie-lancet-polyiran/","title":"Polypil voor primaire en secundaire CV-preventie: Lancet PolyIran","title_en":"Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.","published":"2019-08-24"}],"10.1016/s0140-6736(19)30955-9":[{"url":"https://hartvaat.nl/2019/08/24/hypertensiezorg-in-44-lage-en-middeninkomenslanden-lancet/","title":"Hypertensiezorg in 44 lage- en middeninkomenslanden: Lancet","title_en":"The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults.","published":"2019-08-24"}],"10.1016/s0140-6736(19)31145-6":[{"url":"https://hartvaat.nl/2019/08/24/trends-in-hypertensiedetectie-behandeling-en-controle-in-12-hoge-inkomenslanden-/","title":"Trends in hypertensiedetectie, behandeling en controle in 12 hoge-inkomenslanden: Lancet","title_en":"Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys.","published":"2019-08-24"}],"10.1056/nejmoa1801291":[{"url":"https://hartvaat.nl/2019/08/22/serelaxine-bij-acuut-hartfalen-nejm-relax-ahf-2/","title":"Serelaxine bij acuut hartfalen: NEJM RELAX-AHF-2","title_en":"Effects of Serelaxin in Patients with Acute Heart Failure.","published":"2019-08-22"}],"10.1161/circulationaha.118.039357":[{"url":"https://hartvaat.nl/2019/08/20/dna-methylering-in-leukocyten-voorspelt-mi-en-coronairlijden/","title":"DNA-methylering in leukocyten voorspelt MI en coronairlijden","title_en":"Blood Leukocyte DNA Methylation Predicts Risk of Future Myocardial Infarction and Coronary Heart Disease.","published":"2019-08-20"}],"10.1161/cir.0000000000000629":[{"url":"https://hartvaat.nl/2019/08/20/fysiologische-versus-rechterkamerpacing-bij-lvef-35/","title":"Fysiologische versus rechterkamerpacing bij LVEF >35%","title_en":"Impact of Physiologic Pacing Versus Right Ventricular Pacing Among Patients With Left Ventricular Ejection Fraction Greater Than 35%: A Systematic Review for the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.","published":"2019-08-20"}],"10.1161/cir.0000000000000628":[{"url":"https://hartvaat.nl/2019/08/20/2018-acc-aha-hrs-richtlijn-voor-bradycardie-en-geleidingsstoornissen/","title":"2018 ACC/AHA/HRS richtlijn voor bradycardie en geleidingsstoornissen","title_en":"2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.","published":"2019-08-20"}],"10.1093/eurheartj/ehz453":[{"url":"https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/","title":"Langetermijn ticagrelor monotherapie na 1 maand DAPT bij complexe PCI: GLOBAL LEADERS","title_en":"Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.","published":"2019-08-14"}],"10.1001/jama.2019.10551":[{"url":"https://hartvaat.nl/2019/08/13/intensieve-versus-standaard-bloeddruk-en-cerebrale-wittestoflaesies-jama-sprint-/","title":"Intensieve versus standaard bloeddruk en cerebrale wittestoflaesies: JAMA SPRINT MIND MRI","title_en":"Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions.","published":"2019-08-13"}],"10.1016/j.jacc.2019.05.063":[{"url":"https://hartvaat.nl/2019/08/13/off-pump-versus-on-pump-cabg-bij-hoofdstamcoronairlijden/","title":"Off-pump versus on-pump CABG bij hoofdstamcoronairlijden","title_en":"Off-Pump Versus On-Pump Bypass Surgery for Left Main Coronary Artery Disease.","published":"2019-08-13"}],"10.1161/circulationaha.119.039609":[{"url":"https://hartvaat.nl/2019/08/13/rivaroxaban-met-of-zonder-aspirine-bij-hf-met-coronair-of-perifeer-vaatlijden/","title":"Rivaroxaban met of zonder aspirine bij HF met coronair of perifeer vaatlijden","title_en":"Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.","published":"2019-08-13"}],"10.1056/nejmoa1715944":[{"url":"https://hartvaat.nl/2019/08/08/volanesorsen-en-triglyceriden-bij-familiair-chylomicronemiesyndroom-nejm/","title":"Volanesorsen en triglyceriden bij familiair chylomicronemiesyndroom: NEJM","title_en":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.","published":"2019-08-08"}],"10.1016/j.jacc.2019.05.052":[{"url":"https://hartvaat.nl/2019/08/06/leeftijdsafhankelijke-kenmerken-en-uitkomsten-bij-hfpef/","title":"Leeftijdsafhankelijke kenmerken en uitkomsten bij HFpEF","title_en":"Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.","published":"2019-08-06"}],"10.1161/circulationaha.118.039107":[{"url":"https://hartvaat.nl/2019/08/06/angptl3-remming-met-monoklonaal-antilichaam-verlaagt-triglyceriden/","title":"ANGPTL3-remming met monoklonaal antilichaam verlaagt triglyceriden","title_en":"Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.","published":"2019-08-06"}],"10.1093/europace/euz114":[{"url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","title":"ICD bij diabetes met niet-ischemisch systolisch HF: DANISH-analyse","title_en":"The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.","published":"2019-08-01"}],"10.1093/europace/euz175":[{"url":"https://hartvaat.nl/2019/08/01/vernakalant-voor-cardioversie-van-recent-onset-af-meta-analyse/","title":"Vernakalant voor cardioversie van recent-onset AF: meta-analyse","title_en":"Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis.","published":"2019-08-01"}],"10.1001/jamacardio.2019.2138":[{"url":"https://hartvaat.nl/2019/08/01/temporele-veranderingen-in-coronaire-hemodynamiek-bij-niet-culprit-vaten-na-stem/","title":"Temporele veranderingen in coronaire hemodynamiek bij niet-culprit vaten na STEMI","title_en":"Temporal Changes in Coronary Hyperemic and Resting Hemodynamic Indices in Nonculprit Vessels of Patients With ST-Segment Elevation Myocardial Infarction.","published":"2019-08-01"}],"10.1001/jamacardio.2019.1880":[{"url":"https://hartvaat.nl/2019/08/01/antitrombotische-strategieen-bij-af-na-pci-jama-cardiology-veiligheids-en-werkza/","title":"Antitrombotische strategieën bij AF na PCI: JAMA Cardiology veiligheids- en werkzaamheidsanalyse","title_en":"Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.","published":"2019-08-01"}],"10.1093/europace/euz108":[{"url":"https://hartvaat.nl/2019/08/01/optimale-laesieset-bij-persisterend-af-ablatie-meta-regressie/","title":"Optimale laesieset bij persisterend AF-ablatie: meta-regressie","title_en":"Optimum lesion set and predictors of outcome in persistent atrial fibrillation ablation: a meta-regression analysis.","published":"2019-08-01"}],"10.1093/europace/euz115":[{"url":"https://hartvaat.nl/2019/08/01/eenvoudige-techniek-voor-pvi-van-linker-longvenen-gerandomiseerde-studie/","title":"Eenvoudige techniek voor PVI van linker longvenen: gerandomiseerde studie","title_en":"Evaluation of a simple technique aiming at optimizing point-by-point isolation of the left pulmonary veins: a randomized study.","published":"2019-08-01"}],"10.1002/ehf2.12493":[{"url":"https://hartvaat.nl/2019/08/01/hartfalen-door-kankerbehandeling-kunnen-we-het-voorkomen/","title":"Hartfalen door kankerbehandeling: kunnen we het voorkomen?","title_en":"Heart failure from cancer therapy: can we prevent it?","published":"2019-08-01"}],"10.1161/hypertensionaha.119.12634":[{"url":"https://hartvaat.nl/2019/08/01/hypertensieve-zwangerschapsaandoeningen-en-dna-methylering-bij-pasgeborenen/","title":"Hypertensieve zwangerschapsaandoeningen en DNA-methylering bij pasgeborenen","title_en":"Hypertensive Disorders of Pregnancy and DNA Methylation in Newborns.","published":"2019-08-01"}],"10.1161/hypertensionaha.119.13019":[{"url":"https://hartvaat.nl/2019/08/01/renale-denervatie-bij-geisoleerde-systolische-hypertensie-vergelijking-van-kathe/","title":"Renale denervatie bij geïsoleerde systolische hypertensie: vergelijking van katheterstechnieken","title_en":"Renal Denervation in Isolated Systolic Hypertension Using Different Catheter Techniques and Technologies.","published":"2019-08-01"}],"10.1161/hypertensionaha.119.12892":[{"url":"https://hartvaat.nl/2019/08/01/nilvadipine-en-cerebrale-bloedflow-bij-alzheimer-gerandomiseerde-trial/","title":"Nilvadipine en cerebrale bloedflow bij Alzheimer: gerandomiseerde trial","title_en":"Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease.","published":"2019-08-01"}],"10.1161/hypertensionaha.119.12919":[{"url":"https://hartvaat.nl/2019/08/01/endothelinereceptorantagonisme-verbetert-lipidenprofielen-en-verlaagt-pcsk9-bij-/","title":"Endothelinereceptorantagonisme verbetert lipidenprofielen en verlaagt PCSK9 bij pulmonale hypertensie","title_en":"Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease.","published":"2019-08-01"}],"10.1002/ehf2.12462":[{"url":"https://hartvaat.nl/2019/08/01/ijzercarboxymaltose-en-plasmavolumestatus-bij-hf-fair-hf-substudie/","title":"IJzercarboxymaltose en plasmavolumestatus bij HF: FAIR-HF substudie","title_en":"Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.","published":"2019-08-01"}],"10.1016/j.kint.2019.02.033":[{"url":"https://hartvaat.nl/2019/08/01/empagliflozine-voorkomt-progressie-van-ckd-empa-reg-outcome-renale-analyse/","title":"Empagliflozine voorkomt progressie van CKD: EMPA-REG OUTCOME renale analyse","title_en":"Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.","published":"2019-08-01"}],"10.1002/ehf2.12448":[{"url":"https://hartvaat.nl/2019/08/01/hoog-versus-laag-zuurstof-bij-acuut-hartfalen-hilo-hf-pilot/","title":"Hoog versus laag zuurstof bij acuut hartfalen: HiLo-HF pilot","title_en":"High vs. low oxygen therapy in patients with acute heart failure: HiLo-HF pilot trial.","published":"2019-08-01"}],"10.1002/ehf2.12442":[{"url":"https://hartvaat.nl/2019/08/01/strain-encoded-mri-voor-beoordeling-van-myocardiale-deformatie/","title":"Strain-encoded MRI voor beoordeling van myocardiale deformatie","title_en":"Strain-encoded magnetic resonance: a method for the assessment of myocardial deformation.","published":"2019-08-01"}],"10.1016/j.jacc.2019.03.012":[{"url":"https://hartvaat.nl/2019/07/23/ag10-transthyretinestabilisator-bij-symptomatische-attr-cardiomyopathie/","title":"AG10 transthyretinestabilisator bij symptomatische ATTR-cardiomyopathie","title_en":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.","published":"2019-07-23"}],"10.1016/s0140-6736(19)31126-2":[{"url":"https://hartvaat.nl/2019/07/20/drug-coated-balloon-bij-de-novo-coronairlaesies-met-hoog-bloedingsrisico-lancet-/","title":"Drug-coated balloon bij de-novo coronairlaesies met hoog bloedingsrisico: Lancet DEBUT","title_en":"Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial.","published":"2019-07-20"}],"10.1016/j.jacc.2019.04.061":[{"url":"https://hartvaat.nl/2019/07/16/edoxaban-versus-warfarine-bij-af-met-leverziekte-engage-af-timi-48/","title":"Edoxaban versus warfarine bij AF met leverziekte: ENGAGE AF-TIMI 48","title_en":"Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.","published":"2019-07-16"}],"10.1016/s0140-6736(19)31149-3":[{"url":"https://hartvaat.nl/2019/07/13/dulaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-rewind/","title":"Dulaglutide en cardiovasculaire uitkomsten bij diabetes type 2: Lancet REWIND","title_en":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","published":"2019-07-13"}],"10.1161/circulationaha.118.038840":[{"url":"https://hartvaat.nl/2019/07/09/alirocumab-en-mortaliteit-na-acs-odyssey-outcomes-analyse/","title":"Alirocumab en mortaliteit na ACS: ODYSSEY OUTCOMES-analyse","title_en":"Effect of Alirocumab on Mortality After Acute Coronary Syndromes.","published":"2019-07-09"}],"10.1016/j.jacc.2019.04.026":[{"url":"https://hartvaat.nl/2019/07/09/his-correctieve-pacing-versus-biventriculaire-pacing-voor-crt-bij-hartfalen/","title":"His-correctieve pacing versus biventriculaire pacing voor CRT bij hartfalen","title_en":"His Corrective Pacing or Biventricular Pacing for Cardiac Resynchronization in Heart Failure.","published":"2019-07-09"}],"10.1016/j.jacc.2019.01.011":[{"url":"https://hartvaat.nl/2019/07/09/2019-aha-acc-hrs-gerichte-update-van-de-af-richtlijn/","title":"2019 AHA/ACC/HRS gerichte update van de AF-richtlijn","title_en":"2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.","published":"2019-07-09"}],"10.1001/jamacardio.2019.1510":[{"url":"https://hartvaat.nl/2019/07/01/p2y12-remmerwisseling-op-basis-van-cyp2c19-status-na-acs-jama-cardiology/","title":"P2Y12-remmerwisseling op basis van CYP2C19-status na ACS: JAMA Cardiology","title_en":"P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.","published":"2019-07-01"}],"10.1001/jamacardio.2019.0886":[{"url":"https://hartvaat.nl/2019/07/01/evolocumab-en-totale-cv-events-bij-cardiovasculaire-ziekte-fourier-analyse/","title":"Evolocumab en totale CV-events bij cardiovasculaire ziekte: FOURIER-analyse","title_en":"Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.","published":"2019-07-01"}],"10.1001/jamacardio.2019.1776":[{"url":"https://hartvaat.nl/2019/07/01/uitkomsten-van-des-in-kleine-coronairen-naar-strutdikte-jama-cardiology-meta-ana/","title":"Uitkomsten van DES in kleine coronairen naar strutdikte: JAMA Cardiology meta-analyse","title_en":"Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.","published":"2019-07-01"}],"10.1093/eurheartj/ehz149":[{"url":"https://hartvaat.nl/2019/07/01/cv-uitkomsten-en-bereikte-bloeddruk-bij-hoog-cv-risico-met-en-zonder-diabetes/","title":"CV-uitkomsten en bereikte bloeddruk bij hoog CV-risico met en zonder diabetes","title_en":"Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.","published":"2019-07-01"}],"10.1093/europace/euz021":[{"url":"https://hartvaat.nl/2019/07/01/hospitalisatieredenen-en-mortaliteitsrisico-bij-af-met-dabigatran-versus-warfari/","title":"Hospitalisatieredenen en mortaliteitsrisico bij AF met dabigatran versus warfarine: RE-LY","title_en":"Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial.","published":"2019-07-01"}],"10.1093/europace/euz028":[{"url":"https://hartvaat.nl/2019/07/01/qt-als-voorspeller-van-af-recidief-na-ablatie-en-amiodaronimpact-amio-cat/","title":"QT als voorspeller van AF-recidief na ablatie en amiodaronimpact: AMIO-CAT","title_en":"QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial.","published":"2019-07-01"}],"10.1161/hypertensionaha.119.12880":[{"url":"https://hartvaat.nl/2019/07/01/natriumreductie-metaboloom-en-cv-risico-bij-onbehandelde-zwarte-hypertensie/","title":"Natriumreductie, metaboloom en CV-risico bij onbehandelde zwarte hypertensie","title_en":"Sodium Reduction, Metabolomic Profiling, and Cardiovascular Disease Risk in Untreated Black Hypertensives.","published":"2019-07-01"}],"10.1016/j.kint.2019.01.028":[{"url":"https://hartvaat.nl/2019/07/01/kosteneffectiviteit-van-statines-en-ezetimibe-bij-chronische-nierziekte/","title":"Kosteneffectiviteit van statines en ezetimibe bij chronische nierziekte","title_en":"Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.","published":"2019-07-01"}],"10.1136/heartjnl-2018-314086":[{"url":"https://hartvaat.nl/2019/07/01/lokale-hemodynamische-krachten-en-fenotype-van-coronaire-plaques/","title":"Lokale hemodynamische krachten en fenotype van coronaire plaques","title_en":"Implications of the local haemodynamic forces on the phenotype of coronary plaques.","published":"2019-07-01"}],"10.1001/jama.2019.8146":[{"url":"https://hartvaat.nl/2019/06/25/p2y12-remmer-monotherapie-versus-dapt-na-pci-jama-smart-choice/","title":"P2Y12-remmer monotherapie versus DAPT na PCI: JAMA SMART-CHOICE","title_en":"Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.","published":"2019-06-25"}],"10.1001/jama.2019.8145":[{"url":"https://hartvaat.nl/2019/06/25/1-maand-dapt-gevolgd-door-clopidogrel-versus-12-maanden-dapt-jama-stopdapt-2/","title":"1 maand DAPT gevolgd door clopidogrel versus 12 maanden DAPT: JAMA STOPDAPT-2","title_en":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.","published":"2019-06-25"}],"10.1016/j.jacc.2018.11.004":[{"url":"https://hartvaat.nl/2019/06/25/systematische-review-voor-de-2018-aha-acc-cholesterolrichtlijn-jacc/","title":"Systematische review voor de 2018 AHA/ACC cholesterolrichtlijn: JACC","title_en":"Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2019-06-25"}],"10.1016/j.jacc.2018.11.003":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-volledig-rapport/","title":"2018 AHA/ACC cholesterolrichtlijn: JACC volledig rapport","title_en":"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2019-06-25"}],"10.1016/j.jacc.2018.11.002":[{"url":"https://hartvaat.nl/2019/06/25/2018-aha-acc-cholesterolrichtlijn-jacc-executive-summary/","title":"2018 AHA/ACC cholesterolrichtlijn: JACC executive summary","title_en":"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2019-06-25"}],"10.1016/s0140-6736(19)30474-x":[{"url":"https://hartvaat.nl/2019/06/22/des-versus-bms-lancet-ipd-systematische-review-en-meta-analyse/","title":"DES versus BMS: Lancet IPD systematische review en meta-analyse","title_en":"Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.","published":"2019-06-22"}],"10.1093/eurheartj/ehz202":[{"url":"https://hartvaat.nl/2019/06/21/plaatjesreactiviteit-en-uitkomsten-bij-acs-met-prasugrel-versus-clopidogrel/","title":"Plaatjesreactiviteit en uitkomsten bij ACS met prasugrel versus clopidogrel","title_en":"Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.","published":"2019-06-21"}],"10.1093/eurheartj/ehz113":[{"url":"https://hartvaat.nl/2019/06/21/impact-van-groot-periprocedureel-mi-op-mortaliteit-na-pci-en-cabg/","title":"Impact van groot periprocedureel MI op mortaliteit na PCI en CABG","title_en":"Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial.","published":"2019-06-21"}],"10.1093/eurheartj/ehz074":[{"url":"https://hartvaat.nl/2019/06/21/comfortable-ami-5-jaarsuitkomsten-biolimus-versus-bare-metal-stent/","title":"COMFORTABLE AMI 5-jaarsuitkomsten: biolimus versus bare-metal stent","title_en":"Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction.","published":"2019-06-21"}],"10.1056/nejmoa1901113":[{"url":"https://hartvaat.nl/2019/06/20/vergelijking-van-duale-therapieen-voor-bloeddrukverlaging-bij-afrikaanse-afrikan/","title":"Vergelijking van duale therapieën voor bloeddrukverlaging bij Afrikaanse Afrikanen: NEJM","title_en":"Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans.","published":"2019-06-20"}],"10.1016/j.jacc.2019.03.513":[{"url":"https://hartvaat.nl/2019/06/18/evolocumab-bij-ckd-werkzaamheid-en-veiligheid-in-de-fourier-trial/","title":"Evolocumab bij CKD: werkzaamheid en veiligheid in de FOURIER-trial","title_en":"Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.","published":"2019-06-18"}],"10.1161/cir.0000000000000626":[{"url":"https://hartvaat.nl/2019/06/18/systematische-review-voor-de-2018-aha-acc-cholesterolrichtlijn/","title":"Systematische review voor de 2018 AHA/ACC cholesterolrichtlijn","title_en":"Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2019-06-18"}],"10.1161/cir.0000000000000625":[{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-volledig-rapport/","title":"2018 AHA/ACC cholesterolrichtlijn: volledig rapport","title_en":"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2019-06-18"}],"10.1161/cir.0000000000000624":[{"url":"https://hartvaat.nl/2019/06/18/2018-aha-acc-cholesterolrichtlijn-executive-summary/","title":"2018 AHA/ACC cholesterolrichtlijn: executive summary","title_en":"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2019-06-18"}],"10.1056/nejmoa1811744":[{"url":"https://hartvaat.nl/2019/06/13/canagliflozine-en-renale-uitkomsten-bij-diabetes-type-2-met-nefropathie-nejm-cre/","title":"Canagliflozine en renale uitkomsten bij diabetes type 2 met nefropathie: NEJM CREDENCE","title_en":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.","published":"2019-06-13"}],"10.1016/j.jacc.2019.03.489":[{"url":"https://hartvaat.nl/2019/06/11/inspanningsvoordelen-bij-pulmonale-hypertensie-jacc-review/","title":"Inspanningsvoordelen bij pulmonale hypertensie: JACC review","title_en":"Exercise Benefits in Pulmonary Hypertension.","published":"2019-06-11"}],"10.1016/j.jacc.2019.03.011":[{"url":"https://hartvaat.nl/2019/06/11/ticagrelor-versus-clopidogrel-bij-stemi-na-fibrinolyse-treat-trial/","title":"Ticagrelor versus clopidogrel bij STEMI na fibrinolyse: TREAT-trial","title_en":"Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial.","published":"2019-06-11"}],"10.1016/j.jacc.2019.02.032":[{"url":"https://hartvaat.nl/2019/06/11/icosapent-ethyl-en-totale-ischemische-events-reduce-it-analyse/","title":"Icosapent-ethyl en totale ischemische events: REDUCE-IT analyse","title_en":"Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.","published":"2019-06-11"}],"10.1016/j.jacc.2019.03.006":[{"url":"https://hartvaat.nl/2019/06/11/sonotrombolyse-bij-stemi-behandeld-met-primaire-pci/","title":"Sonotrombolyse bij STEMI behandeld met primaire PCI","title_en":"Sonothrombolysis in ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.","published":"2019-06-11"}],"10.1093/eurheartj/ehz119":[{"url":"https://hartvaat.nl/2019/06/07/febuxostat-voor-cerebraal-en-cardiorenovasculaire-eventpreventie-freed/","title":"Febuxostat voor cerebraal en cardiorenovasculaire eventpreventie: FREED","title_en":"Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.","published":"2019-06-07"}],"10.1001/jama.2019.6717":[{"url":"https://hartvaat.nl/2019/06/04/neladenoson-bialanaat-en-inspanningscapaciteit-bij-hfpef-jama-panache/","title":"Neladenoson bialanaat en inspanningscapaciteit bij HFpEF: JAMA PANACHE","title_en":"Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.","published":"2019-06-04"}],"10.1016/j.jacc.2019.03.002":[{"url":"https://hartvaat.nl/2019/06/04/microvasculaire-ziekte-en-cv-events-bij-diabetes-type-2/","title":"Microvasculaire ziekte en CV-events bij diabetes type 2","title_en":"Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes.","published":"2019-06-04"}],"10.1161/circulationaha.119.039818":[{"url":"https://hartvaat.nl/2019/06/04/profylactische-icd-bij-dialysepatienten-ter-preventie-van-plotse-hartdood/","title":"Profylactische ICD bij dialysepatiënten ter preventie van plotse hartdood","title_en":"Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.","published":"2019-06-04"}],"10.1001/jamacardio.2019.1049":[{"url":"https://hartvaat.nl/2019/06/01/rivaroxaban-en-trombo-embolische-events-bij-hf-met-coronairlijden-en-sinusritme-/","title":"Rivaroxaban en trombo-embolische events bij HF met coronairlijden en sinusritme: COMMANDER HF post-hoc","title_en":"Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.","published":"2019-06-01"}],"10.1093/europace/euz057":[{"url":"https://hartvaat.nl/2019/06/01/heparinedosering-bij-ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-re/","title":"Heparinedosering bij ononderbroken dabigatran versus warfarine bij AF-ablatie: RE-CIRCUIT","title_en":"Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study.","published":"2019-06-01"}],"10.1093/europace/euy310":[{"url":"https://hartvaat.nl/2019/06/01/amiodaron-voor-en-na-electrische-cardioversie-van-af-meta-analyse/","title":"Amiodaron vóór en na electrische cardioversie van AF: meta-analyse","title_en":"Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis.","published":"2019-06-01"}],"10.1093/europace/euz018":[{"url":"https://hartvaat.nl/2019/06/01/icd-implantatie-en-gezondheidsgerelateerde-kwaliteit-van-leven-danish/","title":"ICD-implantatie en gezondheidsgerelateerde kwaliteit van leven: DANISH","title_en":"The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial.","published":"2019-06-01"}],"10.1161/hypertensionaha.118.12415":[{"url":"https://hartvaat.nl/2019/06/01/kosteneffectiviteit-van-telemonitoring-en-zelfmeting-van-bloeddruk-tasminh4/","title":"Kosteneffectiviteit van telemonitoring en zelfmeting van bloeddruk: TASMINH4","title_en":"Cost-Effectiveness of Telemonitoring and Self-Monitoring of Blood Pressure for Antihypertensive Titration in Primary Care (TASMINH4).","published":"2019-06-01"}],"10.1161/hypertensionaha.119.12697":[{"url":"https://hartvaat.nl/2019/06/01/mortaliteitsuitkomsten-bij-intensieve-bloeddrukstreefwaarden-bij-ckd/","title":"Mortaliteitsuitkomsten bij intensieve bloeddrukstreefwaarden bij CKD","title_en":"Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients.","published":"2019-06-01"}],"10.1161/hypertensionaha.118.12414":[{"url":"https://hartvaat.nl/2019/06/01/bloeddrukverlaging-naar-uitgangsdruk-en-cv-risico-bij-diabetes-type-2/","title":"Bloeddrukverlaging naar uitgangsdruk en CV-risico bij diabetes type 2","title_en":"Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.","published":"2019-06-01"}],"10.1016/j.kint.2019.02.018":[{"url":"https://hartvaat.nl/2019/06/01/longechogeleide-drooggewichtreductie-en-ambulante-bloeddruk-bij-hemodialyse/","title":"Longechogeleide drooggewichtreductie en ambulante bloeddruk bij hemodialyse","title_en":"The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial.","published":"2019-06-01"}],"10.1002/ehf2.12426":[{"url":"https://hartvaat.nl/2019/06/01/klinische-predictieregels-voor-diagnostiek-van-chronisch-hartfalen-systematische/","title":"Klinische predictieregels voor diagnostiek van chronisch hartfalen: systematische review","title_en":"A systematic review of clinical prediction rules for the diagnosis of chronic heart failure.","published":"2019-06-01"}],"10.1136/heartjnl-2018-314036":[{"url":"https://hartvaat.nl/2019/06/01/zoutsubstituten-met-laag-natrium-en-bloeddruk-cva-en-mortaliteit-meta-analyse/","title":"Zoutsubstituten met laag natrium en bloeddruk, CVA en mortaliteit: meta-analyse","title_en":"Effect of low-sodium salt substitutes on blood pressure, detected hypertension, stroke and mortality.","published":"2019-06-01"}],"10.1161/circulationaha.119.040057":[{"url":"https://hartvaat.nl/2019/05/28/canagliflozine-en-hf-uitkomsten-bij-behouden-versus-verminderde-ef-canvas/","title":"Canagliflozine en HF-uitkomsten bij behouden versus verminderde EF: CANVAS","title_en":"Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.","published":"2019-05-28"}],"10.1161/circulationaha.119.039996":[{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-cv-uitkomsten-bij-diabetes-type-2-met-eerder-mi/","title":"Dapagliflozine en CV-uitkomsten bij diabetes type 2 met eerder MI","title_en":"Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.","published":"2019-05-28"}],"10.1161/circulationaha.119.040130":[{"url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","title":"Dapagliflozine en hartfalen en mortaliteit bij diabetes type 2: DECLARE-TIMI 58 HF-analyse","title_en":"Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.","published":"2019-05-28"}],"10.1016/j.jacc.2019.03.470":[{"url":"https://hartvaat.nl/2019/05/21/vroegtijdig-staken-van-ticagrelor-bij-secundaire-cv-preventie-jacc-review/","title":"Vroegtijdig staken van ticagrelor bij secundaire CV-preventie: JACC review","title_en":"Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week.","published":"2019-05-21"}],"10.1016/j.jacc.2019.02.062":[{"url":"https://hartvaat.nl/2019/05/21/pacemakerimplantatie-na-mitralisklepchirurgie-met-af-ablatie/","title":"Pacemakerimplantatie na mitralisklepchirurgie met AF-ablatie","title_en":"Pacemaker Implantation After Mitral Valve Surgery With Atrial Fibrillation Ablation.","published":"2019-05-21"}],"10.1001/jama.2019.5790":[{"url":"https://hartvaat.nl/2019/05/21/aflibercept-versus-fotocoagulatie-versus-observatie-bij-diabetisch-maculaoedeem-/","title":"Aflibercept versus fotocoagulatie versus observatie bij diabetisch maculaoedeem: JAMA DRCR.net","title_en":"Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.","published":"2019-05-21"}],"10.1161/circulationaha.118.038516":[{"url":"https://hartvaat.nl/2019/05/21/ijzerisomaltosides-en-skeletspierdenergie-bij-chronisch-hf-met-ijzerdeficientie/","title":"IJzerisomaltosides en skeletspierdenergie bij chronisch HF met ijzerdeficiëntie","title_en":"Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.","published":"2019-05-21"}],"10.1016/j.jacc.2019.02.044":[{"url":"https://hartvaat.nl/2019/05/14/ecls-bij-cardiogene-shock-na-acuut-mi/","title":"ECLS bij cardiogene shock na acuut MI","title_en":"Extracorporeal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction.","published":"2019-05-14"}],"10.1016/j.jacc.2019.02.048":[{"url":"https://hartvaat.nl/2019/05/14/rivaroxaban-plus-aspirine-bij-vaatlijden-met-nierdisfunctie-compass/","title":"Rivaroxaban plus aspirine bij vaatlijden met nierdisfunctie: COMPASS","title_en":"Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.","published":"2019-05-14"}],"10.1093/eurheartj/ehz059":[{"url":"https://hartvaat.nl/2019/05/14/dabigatran-duale-therapie-met-ticagrelor-of-clopidogrel-na-pci-bij-af-re-dual-pc/","title":"Dabigatran duale therapie met ticagrelor of clopidogrel na PCI bij AF: RE-DUAL PCI","title_en":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.","published":"2019-05-14"}],"10.1093/eurheartj/ehy861":[{"url":"https://hartvaat.nl/2019/05/14/bmi-en-uitkomsten-bij-af-behandeld-met-edoxaban-of-warfarine-engage-af-timi-48/","title":"BMI en uitkomsten bij AF behandeld met edoxaban of warfarine: ENGAGE AF-TIMI 48","title_en":"Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.","published":"2019-05-14"}],"10.1093/eurheartj/ehy870":[{"url":"https://hartvaat.nl/2019/05/14/wanneer-doac-stoppen-voor-af-ablatie-multicenter-analyse/","title":"Wanneer DOAC stoppen vóór AF-ablatie? Multicenter analyse","title_en":"When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.","published":"2019-05-14"}],"10.1093/eurheartj/ehy802":[{"url":"https://hartvaat.nl/2019/05/14/verlaagde-dosis-doac-bij-af-werkzaamheid-en-veiligheid-meta-analyse/","title":"Verlaagde dosis DOAC bij AF: werkzaamheid en veiligheid — meta-analyse","title_en":"Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.","published":"2019-05-14"}],"10.1093/eurheartj/ehy807":[{"url":"https://hartvaat.nl/2019/05/14/edoxaban-bij-aziatische-af-patienten-concentraties-en-anti-xa-activiteit/","title":"Edoxaban bij Aziatische AF-patiënten: concentraties en anti-Xa activiteit","title_en":"Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.","published":"2019-05-14"}],"10.1001/jama.2019.3820":[{"url":"https://hartvaat.nl/2019/05/07/zwangerschapsgewichtstoename-en-maternale-en-neonatale-uitkomsten-jama-meta-anal/","title":"Zwangerschapsgewichtstoename en maternale en neonatale uitkomsten: JAMA meta-analyse","title_en":"Association of Gestational Weight Gain With Adverse Maternal and Infant Outcomes.","published":"2019-05-07"}],"10.1161/circulationaha.118.039331":[{"url":"https://hartvaat.nl/2019/05/07/sacubitril-valsartan-of-enalapril-bij-acuut-gedecompenseerd-hf-pioneer-hf-klinis/","title":"Sacubitril/valsartan of enalapril bij acuut gedecompenseerd HF: PIONEER-HF klinische uitkomsten","title_en":"Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.","published":"2019-05-07"}],"10.1016/j.jacc.2019.02.010":[{"url":"https://hartvaat.nl/2019/05/07/gezondheidsstatus-na-mitraclip-bij-hf-met-secundaire-mr-coapt/","title":"Gezondheidsstatus na MitraClip bij HF met secundaire MR: COAPT","title_en":"Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial.","published":"2019-05-07"}],"10.1016/s0140-6736(18)33212-4":[{"url":"https://hartvaat.nl/2019/05/04/plgf-voor-beoordeling-van-pre-eclampsie-lancet-parrot-stepped-wedge-trial/","title":"PlGF voor beoordeling van pre-eclampsie: Lancet PARROT stepped-wedge trial","title_en":"Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.","published":"2019-05-04"}],"10.1056/nejmoa1814052":[{"url":"https://hartvaat.nl/2019/05/02/tavr-met-ballonexpandeerbare-klep-bij-laagrisicopatienten-nejm-partner-3/","title":"TAVR met ballonexpandeerbare klep bij laagrisicopatiënten: NEJM PARTNER 3","title_en":"Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients.","published":"2019-05-02"}],"10.1056/nejmoa1816885":[{"url":"https://hartvaat.nl/2019/05/02/tavr-met-zelfexpanderende-klep-bij-laagrisicopatienten-nejm-evolut-low-risk/","title":"TAVR met zelfexpanderende klep bij laagrisicopatiënten: NEJM Evolut Low Risk","title_en":"Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients.","published":"2019-05-02"}],"10.1001/jamacardio.2019.0897":[{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-bij-acs-in-resource-beperkte-ziekenhuizen-jama-cardiology-/","title":"Kwaliteitsverbetering bij ACS in resource-beperkte ziekenhuizen: JAMA Cardiology China","title_en":"Effect of a Quality of Care Improvement Initiative in Patients With Acute Coronary Syndrome in Resource-Constrained Hospitals in China: A Randomized Clinical Trial.","published":"2019-05-01"}],"10.1001/jamacardio.2019.0649":[{"url":"https://hartvaat.nl/2019/05/01/kwaliteitsverbetering-en-evidence-based-prescriptie-bij-hoog-cv-risico-jama-card/","title":"Kwaliteitsverbetering en evidence-based prescriptie bij hoog CV-risico: JAMA Cardiology","title_en":"Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial.","published":"2019-05-01"}],"10.1093/europace/euy325":[{"url":"https://hartvaat.nl/2019/05/01/thoracoscopische-versus-katheterablatie-bij-af-langetermijn-fast-trial/","title":"Thoracoscopische versus katheterablatie bij AF: langetermijn FAST-trial","title_en":"Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial.","published":"2019-05-01"}],"10.1093/europace/euy276":[{"url":"https://hartvaat.nl/2019/05/01/frequente-premature-atriale-contracties-en-af-hersenischemie-en-mortaliteit-meta/","title":"Frequente premature atriale contracties en AF, hersenischemie en mortaliteit: meta-analyse","title_en":"Frequent premature atrial contractions are associated with atrial fibrillation, brain ischaemia, and mortality: a systematic review and meta-analysis.","published":"2019-05-01"}],"10.1161/hypertensionaha.118.12766":[{"url":"https://hartvaat.nl/2019/05/01/walnotendieet-en-24-uurs-ambulante-bloeddruk-bij-ouderen/","title":"Walnotendieet en 24-uurs ambulante bloeddruk bij ouderen","title_en":"Effect of a Walnut Diet on Office and 24-Hour Ambulatory Blood Pressure in Elderly Individuals.","published":"2019-05-01"}],"10.1136/heartjnl-2018-314216":[{"url":"https://hartvaat.nl/2019/05/01/inflammatiemarkers-en-risico-op-hypertensie-meta-analyse-van-cohortstudies/","title":"Inflammatiemarkers en risico op hypertensie: meta-analyse van cohortstudies","title_en":"Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies.","published":"2019-05-01"}],"10.1016/j.jacc.2018.11.067":[{"url":"https://hartvaat.nl/2019/04/30/leefstijl-hba1c-en-overleving-bij-stabiel-coronairlijden-met-diabetes/","title":"Leefstijl, HbA1c en overleving bij stabiel coronairlijden met diabetes","title_en":"Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes.","published":"2019-04-30"}],"10.1161/circulationaha.118.036459":[{"url":"https://hartvaat.nl/2019/04/30/ketonlichaam-3-hydroxybutyraat-bij-chronisch-hartfalen-cardiovasculaire-effecten/","title":"Ketonlichaam 3-hydroxybutyraat bij chronisch hartfalen: cardiovasculaire effecten","title_en":"Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.","published":"2019-04-30"}],"10.1161/circulationaha.118.036568":[{"url":"https://hartvaat.nl/2019/04/30/empagliflozine-antihyperglycemische-en-bloeddrukeffecten-bij-zwarte-diabetespati/","title":"Empagliflozine: antihyperglycemische en bloeddrukeffecten bij zwarte diabetespatiënten","title_en":"Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.","published":"2019-04-30"}],"10.1056/nejmoa1900486":[{"url":"https://hartvaat.nl/2019/04/25/heartmate-3-lvad-definitief-rapport-nejm-momentum-3-final/","title":"HeartMate 3 LVAD — definitief rapport: NEJM MOMENTUM 3 final","title_en":"A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report.","published":"2019-04-25"}],"10.1016/j.jacc.2018.12.090":[{"url":"https://hartvaat.nl/2019/04/23/hedendaagse-uitkomsten-na-cabg-voor-hoofdstamlijden/","title":"Hedendaagse uitkomsten na CABG voor hoofdstamlijden","title_en":"Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease.","published":"2019-04-23"}],"10.1016/j.jacc.2019.01.014":[{"url":"https://hartvaat.nl/2019/04/23/implanteerbaar-cardiaal-alertsysteem-voor-vroege-herkenning-van-stemi/","title":"Implanteerbaar cardiaal alertsysteem voor vroege herkenning van STEMI","title_en":"Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction.","published":"2019-04-23"}],"10.1161/circulationaha.118.038868":[{"url":"https://hartvaat.nl/2019/04/23/glp-1-agonisten-versus-sglt2-remmers-voor-cv-en-renale-preventie-vergelijkende-m/","title":"GLP-1-agonisten versus SGLT2-remmers voor CV- en renale preventie: vergelijkende meta-analyse","title_en":"Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.","published":"2019-04-23"}],"10.1056/nejmoa1817083":[{"url":"https://hartvaat.nl/2019/04/18/antitrombotische-therapie-na-acs-of-pci-bij-af-nejm-augustus/","title":"Antitrombotische therapie na ACS of PCI bij AF: NEJM AUGUSTUS","title_en":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.","published":"2019-04-18"}],"10.1056/nejmoa1900353":[{"url":"https://hartvaat.nl/2019/04/18/vroege-of-uitgestelde-cardioversie-bij-recent-onset-af-nejm-race-7-acwas/","title":"Vroege of uitgestelde cardioversie bij recent-onset AF: NEJM RACE 7 ACWAS","title_en":"Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation.","published":"2019-04-18"}],"10.1093/eurheartj/ehy860":[{"url":"https://hartvaat.nl/2019/04/14/aki-en-bloedingen-en-mortaliteit-na-radiale-versus-femorale-toegang-bij-acs/","title":"AKI en bloedingen en mortaliteit na radiale versus femorale toegang bij ACS","title_en":"Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial.","published":"2019-04-14"}],"10.1056/nejmoa1816897":[{"url":"https://hartvaat.nl/2019/04/11/coronairangiografie-na-hartstilstand-zonder-st-elevatie-nejm-coact/","title":"Coronairangiografie na hartstilstand zonder ST-elevatie: NEJM COACT","title_en":"Coronary Angiography after Cardiac Arrest without ST-Segment Elevation.","published":"2019-04-11"}],"10.1161/circulationaha.118.035225":[{"url":"https://hartvaat.nl/2019/04/09/rood-vlees-en-cardiovasculaire-risicofactoren-meta-analyse-van-gerandomiseerde-t/","title":"Rood vlees en cardiovasculaire risicofactoren: meta-analyse van gerandomiseerde trials","title_en":"Meta-Analysis of Randomized Controlled Trials of Red Meat Consumption in Comparison With Various Comparison Diets on Cardiovascular Risk Factors.","published":"2019-04-09"}],"10.1016/j.jacc.2018.12.082":[{"url":"https://hartvaat.nl/2019/04/09/sham-gecontroleerde-rct-s-van-renale-denervatie-meta-analyse/","title":"Sham-gecontroleerde RCT's van renale denervatie: meta-analyse","title_en":"Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension.","published":"2019-04-09"}],"10.1016/j.jacc.2019.01.037":[{"url":"https://hartvaat.nl/2019/04/09/cabg-of-stenting-bij-hoofdstamlijden-bij-diabetes/","title":"CABG of stenting bij hoofdstamlijden bij diabetes","title_en":"Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes.","published":"2019-04-09"}],"10.1016/j.jacc.2018.12.072":[{"url":"https://hartvaat.nl/2019/04/02/inspanningsrevalidatie-bij-hf-ipd-meta-analyse-van-inspanningscapaciteit-en-qol/","title":"Inspanningsrevalidatie bij HF: IPD meta-analyse van inspanningscapaciteit en QoL","title_en":"Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure: Individual Participant Meta-Analysis.","published":"2019-04-02"}],"10.1001/jama.2019.0693":[{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-antiaritmica-bij-af-mortaliteit-en-cva-jama-cabana/","title":"Katheterablatie versus antiaritmica bij AF: mortaliteit en CVA: JAMA CABANA","title_en":"Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.","published":"2019-04-02"}],"10.1001/jama.2019.0692":[{"url":"https://hartvaat.nl/2019/04/02/katheterablatie-versus-medicamenteus-bij-af-en-kwaliteit-van-leven-jama-cabana-q/","title":"Katheterablatie versus medicamenteus bij AF en kwaliteit van leven: JAMA CABANA QoL","title_en":"Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.","published":"2019-04-02"}],"10.1161/circulationaha.118.031313":[{"url":"https://hartvaat.nl/2019/04/02/pci-bij-chronische-totale-occlusie-gerandomiseerde-decision-cto-trial/","title":"PCI bij chronische totale occlusie: gerandomiseerde DECISION-CTO trial","title_en":"Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion.","published":"2019-04-02"}],"10.1161/circulationaha.118.038317":[{"url":"https://hartvaat.nl/2019/04/02/cangrelor-en-gemalen-ticagrelor-bij-stemi-met-primaire-pci/","title":"Cangrelor en gemalen ticagrelor bij STEMI met primaire PCI","title_en":"Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.","published":"2019-04-02"}],"10.1001/jamacardio.2019.0175":[{"url":"https://hartvaat.nl/2019/04/01/ffr-verbetering-na-pci-en-uitkomsten-inclusief-symptoomverlichting/","title":"FFR-verbetering na PCI en uitkomsten inclusief symptoomverlichting","title_en":"Association of Improvement in Fractional Flow Reserve With Outcomes, Including Symptomatic Relief, After Percutaneous Coronary Intervention.","published":"2019-04-01"}],"10.1001/jamacardio.2019.0179":[{"url":"https://hartvaat.nl/2019/04/01/initieel-en-serieel-crp-en-cv-events-en-dood-na-acs-jama-cardiology/","title":"Initieel en serieel CRP en CV-events en dood na ACS: JAMA Cardiology","title_en":"Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.","published":"2019-04-01"}],"10.1093/europace/euy313":[{"url":"https://hartvaat.nl/2019/04/01/lineaire-versus-focale-cfae-ablatie-bij-niet-paroxysmaal-af/","title":"Lineaire versus focale CFAE-ablatie bij niet-paroxysmaal AF","title_en":"Comparison between linear and focal ablation of complex fractionated atrial electrograms in patients with non-paroxysmal atrial fibrillation: a prospective randomized trial.","published":"2019-04-01"}],"10.1093/europace/euy286":[{"url":"https://hartvaat.nl/2019/04/01/pr-interval-en-pacingmodus-en-af-incidentie-bij-tweekamer-pacemaker/","title":"PR-interval en pacingmodus en AF-incidentie bij tweekamer pacemaker","title_en":"Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial.","published":"2019-04-01"}],"10.1093/europace/euy311":[{"url":"https://hartvaat.nl/2019/04/01/upstream-therapie-verbetert-qol-bij-persisterend-af-arrest-af/","title":"Upstream therapie verbetert QoL bij persisterend AF: ARREST-AF","title_en":"Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study.","published":"2019-04-01"}],"10.1093/europace/euy224":[{"url":"https://hartvaat.nl/2019/04/01/periprocedurele-antistolling-en-silent-stroke-na-af-ablatie/","title":"Periprocedurele antistolling en silent stroke na AF-ablatie","title_en":"Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy.","published":"2019-04-01"}],"10.1093/eurheartj/ehy435":[{"url":"https://hartvaat.nl/2019/04/01/restrictieve-versus-liberale-transfusie-bij-hartchirurgie-meta-analyse/","title":"Restrictieve versus liberale transfusie bij hartchirurgie: meta-analyse","title_en":"Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis.","published":"2019-04-01"}],"10.1002/ehf2.12407":[{"url":"https://hartvaat.nl/2019/04/01/icd-mortaliteit-naar-hartfalenetiologie-propensity-matched-analyse/","title":"ICD-mortaliteit naar hartfalenetiologie: propensity-matched analyse","title_en":"Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.","published":"2019-04-01"}],"10.1161/hypertensionaha.118.12373":[{"url":"https://hartvaat.nl/2019/04/01/ochtendbeweging-met-of-zonder-zitonderbrekingen-en-bloeddruk-bij-ouderen/","title":"Ochtendbeweging met of zonder zitonderbrekingen en bloeddruk bij ouderen","title_en":"Effect of Morning Exercise With or Without Breaks in Prolonged Sitting on Blood Pressure in Older Overweight/Obese Adults.","published":"2019-04-01"}],"10.1016/j.kint.2018.11.025":[{"url":"https://hartvaat.nl/2019/04/01/spironolacton-en-lv-massa-bij-hemodialysepatienten-gerandomiseerde-trial/","title":"Spironolacton en LV-massa bij hemodialysepatiënten: gerandomiseerde trial","title_en":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.","published":"2019-04-01"}],"10.1136/heartjnl-2018-313705":[{"url":"https://hartvaat.nl/2019/04/01/prehospitale-hypothermie-bij-stemi-gerandomiseerde-trial/","title":"Prehospitale hypothermie bij STEMI: gerandomiseerde trial","title_en":"Out-of-hospital initiation of hypothermia in ST-segment elevation myocardial infarction: a randomised trial.","published":"2019-04-01"}],"10.1001/jama.2019.2341":[{"url":"https://hartvaat.nl/2019/03/26/intramyocardiale-mesenchymale-precursorcellen-en-lvad-weaning-jama/","title":"Intramyocardiale mesenchymale precursorcellen en LVAD-weaning: JAMA","title_en":"Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial.","published":"2019-03-26"}],"10.1016/j.jacc.2019.01.018":[{"url":"https://hartvaat.nl/2019/03/26/bnp-tijdens-sacubitril-valsartan-paradigm-hf/","title":"BNP tijdens sacubitril/valsartan: PARADIGM-HF","title_en":"B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.","published":"2019-03-26"}],"10.1161/circulationaha.118.037585":[{"url":"https://hartvaat.nl/2019/03/19/aanbevolen-hf-medicatie-en-bijwerkingen-bij-vrouwen/","title":"Aanbevolen HF-medicatie en bijwerkingen bij vrouwen","title_en":"Recommended Heart Failure Medications and Adverse Drug Reactions in Women.","published":"2019-03-19"}],"10.1001/jama.2019.0335":[{"url":"https://hartvaat.nl/2019/03/19/katheterablatie-versus-antiaritmica-en-kwaliteit-van-leven-bij-af-jama-captaf/","title":"Katheterablatie versus antiaritmica en kwaliteit van leven bij AF: JAMA CAPTAF","title_en":"Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial.","published":"2019-03-19"}],"10.1001/jama.2019.1264":[{"url":"https://hartvaat.nl/2019/03/19/management-van-af-jama-klinisch-overzicht/","title":"Management van AF: JAMA klinisch overzicht","title_en":"Management of Patients With Atrial Fibrillation.","published":"2019-03-19"}],"10.1161/circulationaha.118.037184":[{"url":"https://hartvaat.nl/2019/03/19/lp-a-pcsk9-remming-en-cardiovasculair-risico/","title":"Lp(a), PCSK9-remming en cardiovasculair risico","title_en":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.","published":"2019-03-19"}],"10.1056/nejmoa1803917":[{"url":"https://hartvaat.nl/2019/03/14/bempedoinezuur-voor-ldl-verlaging-nejm-veiligheid-en-werkzaamheid/","title":"Bempedoïnezuur voor LDL-verlaging: NEJM veiligheid en werkzaamheid","title_en":"Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.","published":"2019-03-14"}],"10.1161/circulationaha.118.037778":[{"url":"https://hartvaat.nl/2019/03/12/empagliflozine-vermindert-mortaliteit-en-hf-hospitalisatie-over-het-cv-risicospe/","title":"Empagliflozine vermindert mortaliteit en HF-hospitalisatie over het CV-risicospecttum: EMPA-REG","title_en":"Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.","published":"2019-03-12"}],"10.1161/circulationaha.118.037077":[{"url":"https://hartvaat.nl/2019/03/12/arni-bij-functionele-mitralisklepinsufficientie/","title":"ARNI bij functionele mitralisklepinsufficiëntie","title_en":"Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.","published":"2019-03-12"}],"10.1016/s0140-6736(18)32467-x":[{"url":"https://hartvaat.nl/2019/03/09/ultradunne-sirolimus-eluting-stent-lancet-talent-trial/","title":"Ultradunne sirolimus-eluting stent: Lancet TALENT-trial","title_en":"Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.","published":"2019-03-09"}],"10.1016/s0140-6736(19)30194-1":[{"url":"https://hartvaat.nl/2019/03/09/prehospitaal-nitroglycerine-bij-vermoedelijk-ultra-acuut-cva-lancet-right-2/","title":"Prehospitaal nitroglycerine bij vermoedelijk ultra-acuut CVA: Lancet RIGHT-2","title_en":"Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial.","published":"2019-03-09"}],"10.1016/j.jacc.2018.11.055":[{"url":"https://hartvaat.nl/2019/03/05/timing-van-prasugrel-start-en-coronairangiografie-bij-nstemi/","title":"Timing van prasugrel-start en coronairangiografie bij NSTEMI","title_en":"Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction.","published":"2019-03-05"}],"10.1016/j.jacc.2018.11.056":[{"url":"https://hartvaat.nl/2019/03/05/inspanningstest-versus-ccta-bij-diabetes-met-verdenking-coronairlijden/","title":"Inspanningstest versus CCTA bij diabetes met verdenking coronairlijden","title_en":"Stress Testing Versus CT Angiography in Patients With Diabetes and Suspected Coronary Artery Disease.","published":"2019-03-05"}],"10.1161/circulationaha.118.038010":[{"url":"https://hartvaat.nl/2019/03/05/canakinumab-ter-preventie-van-hartfalen-hospitalisatie-cantos-analyse/","title":"Canakinumab ter preventie van hartfalen-hospitalisatie: CANTOS-analyse","title_en":"Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.","published":"2019-03-05"}],"10.1016/s0140-6736(19)30038-8":[{"url":"https://hartvaat.nl/2019/03/02/intensieve-bloeddrukverlaging-bij-iv-trombolyse-voor-acuut-cva-lancet-enchanted/","title":"Intensieve bloeddrukverlaging bij IV trombolyse voor acuut CVA: Lancet ENCHANTED","title_en":"Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.","published":"2019-03-02"}],"10.1001/jamacardio.2018.4847":[{"url":"https://hartvaat.nl/2019/03/01/trimetazidine-bij-niet-obstructieve-hcm-jama-cardiology-gerandomiseerde-trial/","title":"Trimetazidine bij niet-obstructieve HCM: JAMA Cardiology gerandomiseerde trial","title_en":"Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.","published":"2019-03-01"}],"10.1093/eurheartj/ehy871":[{"url":"https://hartvaat.nl/2019/03/01/ambulante-hartfrequentiereductie-na-renale-denervatie-bij-hypertensie-zonder-med/","title":"Ambulante hartfrequentiereductie na renale denervatie bij hypertensie zonder medicatie","title_en":"Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial.","published":"2019-03-01"}],"10.1136/heartjnl-2018-314129":[{"url":"https://hartvaat.nl/2019/03/01/ziekenhuisgebaseerde-kwaliteitsinterventies-bij-hartfalen-systematische-review/","title":"Ziekenhuisgebaseerde kwaliteitsinterventies bij hartfalen: systematische review","title_en":"Hospital-based quality improvement interventions for patients with heart failure: a systematic review.","published":"2019-03-01"}],"10.1161/hypertensionaha.118.12290":[{"url":"https://hartvaat.nl/2019/03/01/bariatrische-chirurgie-versus-medicamenteus-beleid-op-24-uurs-ambulante-bloeddru/","title":"Bariatrische chirurgie versus medicamenteus beleid op 24-uurs ambulante bloeddruk en resistente HTN","title_en":"Effects of Bariatric Surgery Versus Medical Therapy on the 24-Hour Ambulatory Blood Pressure and the Prevalence of Resistant Hypertension.","published":"2019-03-01"}],"10.1161/hypertensionaha.118.12074":[{"url":"https://hartvaat.nl/2019/03/01/natriumreductie-tot-1000-mg-dag-vermindert-neurovasculaire-transductie-zonder-sy/","title":"Natriumreductie tot 1000 mg/dag vermindert neurovasculaire transductie zonder sympathische activatie","title_en":"Reducing Dietary Sodium to 1000 mg per Day Reduces Neurovascular Transduction Without Stimulating Sympathetic Outflow.","published":"2019-03-01"}],"10.1161/hypertensionaha.118.12259":[{"url":"https://hartvaat.nl/2019/03/01/mediterraan-dieet-verbetert-systolische-bloeddruk-en-arteriele-stijfheid-bij-oud/","title":"Mediterraan dieet verbetert systolische bloeddruk en arteriële stijfheid bij ouderen","title_en":"Mediterranean-Style Diet Improves Systolic Blood Pressure and Arterial Stiffness in Older Adults.","published":"2019-03-01"}],"10.1001/jama.2019.0710":[{"url":"https://hartvaat.nl/2019/02/26/patientgerichte-transitional-care-bij-hf-hospitalisatie-jama-pact-hf/","title":"Patiëntgerichte transitional care bij HF-hospitalisatie: JAMA PACT-HF","title_en":"Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial.","published":"2019-02-26"}],"10.1016/j.jacc.2018.11.042":[{"url":"https://hartvaat.nl/2019/02/26/sacubitril-valsartan-en-biomarkers-van-extracellulaire-matrixregulatie-bij-hfref/","title":"Sacubitril/valsartan en biomarkers van extracellulaire matrixregulatie bij HFrEF","title_en":"Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.","published":"2019-02-26"}],"10.1016/j.jacc.2018.12.023":[{"url":"https://hartvaat.nl/2019/02/26/postprocedurele-bivalirudine-infusie-bij-acs-vol-versus-laag-regime/","title":"Postprocedurele bivalirudine-infusie bij ACS: vol versus laag regime","title_en":"Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome.","published":"2019-02-26"}],"10.1056/nejmoa1809798":[{"url":"https://hartvaat.nl/2019/02/21/laaggedoseerd-methotrexaat-voor-preventie-van-atherosclerotische-events-nejm-cir/","title":"Laaggedoseerd methotrexaat voor preventie van atherosclerotische events: NEJM CIRT","title_en":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.","published":"2019-02-21"}],"10.1016/j.jacc.2018.10.085":[{"url":"https://hartvaat.nl/2019/02/19/lv-unloading-tijdens-ecmo-bij-cardiogene-shock/","title":"LV-unloading tijdens ECMO bij cardiogene shock","title_en":"Left Ventricular Unloading During Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock.","published":"2019-02-19"}],"10.1016/j.jacc.2018.11.001":[{"url":"https://hartvaat.nl/2019/02/19/langetermijnoverleving-na-multivatenrevascularisatie-bij-diabetes-freedom-follow/","title":"Langetermijnoverleving na multivatenrevascularisatie bij diabetes: FREEDOM follow-on","title_en":"Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study.","published":"2019-02-19"}],"10.1093/eurheartj/ehy653":[{"url":"https://hartvaat.nl/2019/02/14/gelijkstelling-van-vier-cv-risicoalgoritmen-na-hercalibratie-ipd-meta-analyse/","title":"Gelijkstelling van vier CV-risicoalgoritmen na hercalibratie: IPD meta-analyse","title_en":"Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies.","published":"2019-02-14"}],"10.1161/circulationaha.118.038602":[{"url":"https://hartvaat.nl/2019/02/12/genetisch-risico-op-coronairlijden-en-ontwikkeling-van-hfref-versus-hfpef/","title":"Genetisch risico op coronairlijden en ontwikkeling van HFrEF versus HFpEF","title_en":"Differential Association of Genetic Risk of Coronary Artery Disease With Development of Heart Failure With Reduced Versus Preserved Ejection Fraction.","published":"2019-02-12"}],"10.1001/jama.2018.21442":[{"url":"https://hartvaat.nl/2019/02/12/intensieve-versus-standaard-bloeddrukcontrole-en-waarschijnlijke-dementie-jama-s/","title":"Intensieve versus standaard bloeddrukcontrole en waarschijnlijke dementie: JAMA SPRINT MIND","title_en":"Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial.","published":"2019-02-12"}],"10.1056/nejmoa1812851":[{"url":"https://hartvaat.nl/2019/02/07/angiotensine-neprilysineremming-bij-acuut-gedecompenseerd-hf-nejm-pioneer-hf/","title":"Angiotensine-neprilysineremming bij acuut gedecompenseerd HF: NEJM PIONEER-HF","title_en":"Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.","published":"2019-02-07"}],"10.1161/circulationaha.118.036068":[{"url":"https://hartvaat.nl/2019/02/05/glycemische-controle-en-cardiale-auto-immuniteit-bij-diabetes-type-1-en-langeter/","title":"Glycemische controle en cardiale auto-immuniteit bij diabetes type 1 en langetermijn CV-risico","title_en":"Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus.","published":"2019-02-05"}],"10.1161/circulationaha.118.038312":[{"url":"https://hartvaat.nl/2019/02/05/abc-scores-voor-cva-en-bloedingsrisico-bij-af-prestatieverbetering/","title":"ABC-scores voor CVA- en bloedingsrisico bij AF: prestatieverbetering","title_en":"Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.","published":"2019-02-05"}],"10.1016/j.jacc.2018.10.039":[{"url":"https://hartvaat.nl/2019/02/05/alirocumab-vermindert-totale-niet-fatale-cv-en-fatale-events-odyssey-outcomes/","title":"Alirocumab vermindert totale niet-fatale CV en fatale events: ODYSSEY OUTCOMES","title_en":"Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.","published":"2019-02-05"}],"10.1016/s0140-6736(18)31942-1":[{"url":"https://hartvaat.nl/2019/02/02/statines-bij-ouderen-lancet-ipd-meta-analyse-van-28-gerandomiseerde-trials/","title":"Statines bij ouderen: Lancet IPD meta-analyse van 28 gerandomiseerde trials","title_en":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.","published":"2019-02-02"}],"10.1001/jamacardio.2018.4615":[{"url":"https://hartvaat.nl/2019/02/01/genetische-schildklierfunctievoorspellers-en-af-jama-cardiology-mendeliaanse-ran/","title":"Genetische schildklierfunctievoorspellers en AF: JAMA Cardiology Mendeliaanse randomisatie","title_en":"Association of Thyroid Function Genetic Predictors With Atrial Fibrillation: A Phenome-Wide Association Study and Inverse-Variance Weighted Average Meta-analysis.","published":"2019-02-01"}],"10.1093/europace/euy266":[{"url":"https://hartvaat.nl/2019/02/01/contact-force-sensing-en-veiligheid-werkzaamheid-van-af-ablatie-geactualiseerde-/","title":"Contact force sensing en veiligheid/werkzaamheid van AF-ablatie: geactualiseerde meta-analyse","title_en":"Updated systematic review and meta-analysis of the impact of contact force sensing on the safety and efficacy of atrial fibrillation ablation: discrepancy between observational studies and randomized control trial data.","published":"2019-02-01"}],"10.1093/europace/euy253":[{"url":"https://hartvaat.nl/2019/02/01/edoxaban-en-implanteerbare-cardiale-devices-engage-af-timi-48/","title":"Edoxaban en implanteerbare cardiale devices: ENGAGE AF-TIMI 48","title_en":"Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.","published":"2019-02-01"}],"10.1093/eurheartj/ehy641":[{"url":"https://hartvaat.nl/2019/02/01/tricuspidalisinsufficientie-en-mortaliteit-onafhankelijk-van-ph-en-rechterventri/","title":"Tricuspidalisinsufficiëntie en mortaliteit onafhankelijk van PH en rechterventrikelfalen: meta-analyse","title_en":"Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis.","published":"2019-02-01"}],"10.1093/europace/euy148":[{"url":"https://hartvaat.nl/2019/02/01/ononderbroken-versus-onderbroken-doac-bij-af-ablatie-prospectieve-trial/","title":"Ononderbroken versus onderbroken DOAC bij AF-ablatie: prospectieve trial","title_en":"Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events.","published":"2019-02-01"}],"10.1161/hypertensionaha.118.12079":[{"url":"https://hartvaat.nl/2019/02/01/geautomatiseerde-praktijkmeting-versus-andere-bloeddrukmeetmethoden/","title":"Geautomatiseerde praktijkmeting versus andere bloeddrukmeetmethoden","title_en":"Comparison of Automated Office Blood Pressure With Office and Out-Off-Office Measurement Techniques.","published":"2019-02-01"}],"10.1002/ehf2.12380":[{"url":"https://hartvaat.nl/2019/02/01/sms-na-ontslag-verbetert-kortetermijnuitkomsten-en-zelfzorg-bij-chronisch-hf/","title":"SMS na ontslag verbetert kortetermijnuitkomsten en zelfzorg bij chronisch HF","title_en":"Post-discharge short message service improves short-term clinical outcome and self-care behaviour in chronic heart failure.","published":"2019-02-01"}],"10.1002/ehf2.12366":[{"url":"https://hartvaat.nl/2019/02/01/herhaalde-levosimendan-infusies-bij-gevorderd-chronisch-hf-in-de-kwetsbare-postd/","title":"Herhaalde levosimendan-infusies bij gevorderd chronisch HF in de kwetsbare postdischargeperiode","title_en":"Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.","published":"2019-02-01"}],"10.1002/ehf2.12370":[{"url":"https://hartvaat.nl/2019/02/01/snelle-gewichtstoename-van-2-3-kg-is-niet-geassocieerd-met-heropname-bij-hf/","title":"Snelle gewichtstoename van 2,3 kg is niet geassocieerd met heropname bij HF","title_en":"Rapid 5 lb weight gain is not associated with readmission in patients with heart failure.","published":"2019-02-01"}],"10.1136/heartjnl-2018-313351":[{"url":"https://hartvaat.nl/2019/02/01/apixaban-versus-warfarine-en-coagulatiemerkers-bij-af/","title":"Apixaban versus warfarine en coagulatiemerkers bij AF","title_en":"Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.","published":"2019-02-01"}],"10.1136/heartjnl-2018-313182":[{"url":"https://hartvaat.nl/2019/02/01/spironolacton-en-collageenmetabolisme-biomarkers-bij-ongecontroleerde-hypertensi/","title":"Spironolacton en collageenmetabolisme-biomarkers bij ongecontroleerde hypertensie","title_en":"Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure.","published":"2019-02-01"}],"10.1056/nejmoa1808783":[{"url":"https://hartvaat.nl/2019/01/31/bilaterale-versus-enkele-mammaria-interna-grafts-na-10-jaar-nejm-art/","title":"Bilaterale versus enkele mammaria interna-grafts na 10 jaar: NEJM ART","title_en":"Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years.","published":"2019-01-31"}],"10.1016/j.jacc.2018.10.066":[{"url":"https://hartvaat.nl/2019/01/29/coronaire-plaquekenmerken-en-adverse-uitkomsten-scot-heart/","title":"Coronaire plaquekenmerken en adverse uitkomsten: SCOT-HEART","title_en":"Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study.","published":"2019-01-29"}],"10.1161/circulationaha.118.035931":[{"url":"https://hartvaat.nl/2019/01/29/microvasculaire-schade-bij-gerevasculariseerde-stemi-met-ticagrelor-versus-prasu/","title":"Microvasculaire schade bij gerevasculariseerde STEMI met ticagrelor versus prasugrel","title_en":"Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.","published":"2019-01-29"}],"10.1161/circulationaha.118.036768":[{"url":"https://hartvaat.nl/2019/01/29/oac-met-of-zonder-antiplaatjes-bij-af-na-pci-1-jaar-gerandomiseerde-trial/","title":"OAC met of zonder antiplaatjes bij AF na PCI >1 jaar: gerandomiseerde trial","title_en":"Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation.","published":"2019-01-29"}],"10.1161/circulationaha.118.037654":[{"url":"https://hartvaat.nl/2019/01/29/drie-armen-vergelijkende-renale-denervatie-radiosound-htn/","title":"Drie armen vergelijkende renale denervatie: RADIOSOUND-HTN","title_en":"A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN).","published":"2019-01-29"}],"10.1056/nejmoa1812389":[{"url":"https://hartvaat.nl/2019/01/24/dapagliflozine-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-declare-t/","title":"Dapagliflozine en cardiovasculaire uitkomsten bij diabetes type 2: NEJM DECLARE-TIMI 58","title_en":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.","published":"2019-01-24"}],"10.1001/jama.2018.20578":[{"url":"https://hartvaat.nl/2019/01/22/aspirine-voor-primaire-preventie-jama-meta-analyse-van-cv-events-en-bloedingen/","title":"Aspirine voor primaire preventie: JAMA meta-analyse van CV-events en bloedingen","title_en":"Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.","published":"2019-01-22"}],"10.1161/circulationaha.117.032722":[{"url":"https://hartvaat.nl/2019/01/22/milde-hypothermie-bij-cardiogene-shock-complicerend-mi/","title":"Milde hypothermie bij cardiogene shock complicerend MI","title_en":"Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction.","published":"2019-01-22"}],"10.1161/circulationaha.118.038269":[{"url":"https://hartvaat.nl/2019/01/15/lv-unloading-voor-reperfusie-bij-anterieure-stemi-dtu-stemi-pilot/","title":"LV-unloading vóór reperfusie bij anterieure STEMI: DTU-STEMI pilot","title_en":"Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment-Elevation Myocardial Infarction.","published":"2019-01-15"}],"10.1161/circulationaha.118.038065":[{"url":"https://hartvaat.nl/2019/01/15/10-jaarsuitkomsten-van-drie-limus-eluting-stents-coating-vergelijking/","title":"10-jaarsuitkomsten van drie limus-eluting stents: coating vergelijking","title_en":"Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.","published":"2019-01-15"}],"10.1161/circulationaha.118.038352":[{"url":"https://hartvaat.nl/2019/01/15/linagliptine-en-hartfalenuitkomsten-bij-diabetes-type-2-carmelina/","title":"Linagliptine en hartfalenuitkomsten bij diabetes type 2: CARMELINA","title_en":"Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.","published":"2019-01-15"}],"10.1016/s0140-6736(18)32818-6":[{"url":"https://hartvaat.nl/2019/01/12/visualisatie-van-asymptomatische-atherosclerose-voor-cv-preventie-lancet-vipviza/","title":"Visualisatie van asymptomatische atherosclerose voor CV-preventie: Lancet VIPVIZA","title_en":"Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.","published":"2019-01-12"}],"10.1056/nejmoa1812390":[{"url":"https://hartvaat.nl/2019/01/10/endoscopische-versus-open-veneoogst-bij-cabg-nejm-regroup/","title":"Endoscopische versus open veneoogst bij CABG: NEJM REGROUP","title_en":"Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass.","published":"2019-01-10"}],"10.1016/j.jacc.2018.09.081":[{"url":"https://hartvaat.nl/2019/01/08/hfref-differentiele-impact-op-mannen-en-vrouwen/","title":"HFrEF: differentiële impact op mannen en vrouwen","title_en":"Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women.","published":"2019-01-08"}],"10.1161/circulationaha.118.037231":[{"url":"https://hartvaat.nl/2019/01/08/cva-analyse-in-momentum-3-langetermijncohort/","title":"CVA-analyse in MOMENTUM 3 langetermijncohort","title_en":"Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study.","published":"2019-01-08"}],"10.1093/eurheartj/ehy812":[{"url":"https://hartvaat.nl/2019/01/07/ffr-geleide-pci-versus-medicamenteuze-therapie-bij-stabiele-coronairlaesies-meta/","title":"FFR-geleide PCI versus medicamenteuze therapie bij stabiele coronairlaesies: meta-analyse","title_en":"Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.","published":"2019-01-07"}],"10.1093/eurheartj/ehy710":[{"url":"https://hartvaat.nl/2019/01/07/bioresorbeerbare-scaffold-versus-ees-bij-stabiel-coronairlijden-prospectieve-tri/","title":"Bioresorbeerbare scaffold versus EES bij stabiel coronairlijden: prospectieve trial","title_en":"Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.","published":"2019-01-07"}],"10.1016/s0140-6736(18)32484-x":[{"url":"https://hartvaat.nl/2019/01/05/staken-van-hf-medicatie-bij-herstelde-dilaterende-cardiomyopathie-lancet-tred-hf/","title":"Staken van HF-medicatie bij herstelde dilaterende cardiomyopathie: Lancet TRED-HF","title_en":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.","published":"2019-01-05"}],"10.1016/s0140-6736(18)32590-x":[{"url":"https://hartvaat.nl/2019/01/05/sglt2-remmers-voor-primaire-en-secundaire-cv-en-renale-preventie-bij-diabetes-la/","title":"SGLT2-remmers voor primaire en secundaire CV- en renale preventie bij diabetes: Lancet meta-analyse","title_en":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","published":"2019-01-05"}],"10.1056/nejmoa1812792":[{"url":"https://hartvaat.nl/2019/01/03/icosapent-ethyl-en-cardiovasculaire-uitkomsten-bij-hypertriglyceridemie-nejm-red/","title":"Icosapent-ethyl en cardiovasculaire uitkomsten bij hypertriglyceridemie: NEJM REDUCE-IT","title_en":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.","published":"2019-01-03"}],"10.1161/circulationaha.118.038165":[{"url":"https://hartvaat.nl/2019/01/02/duurzaamheid-van-bloeddrukeffect-van-kapper-interventie/","title":"Duurzaamheid van bloeddrukeffect van kapper-interventie","title_en":"Sustainability of Blood Pressure Reduction in Black Barbershops.","published":"2019-01-02"}],"10.1161/circulationaha.118.037707":[{"url":"https://hartvaat.nl/2019/01/02/permanente-versus-polymeervrije-des-all-comers-gerandomiseerde-trial/","title":"Permanente versus polymeervrije DES: all-comers gerandomiseerde trial","title_en":"Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.","published":"2019-01-02"}],"10.1161/circulationaha.118.033575":[{"url":"https://hartvaat.nl/2019/01/02/macitentan-bij-eisenmenger-syndroom/","title":"Macitentan bij Eisenmenger-syndroom","title_en":"Evaluation of Macitentan in Patients With Eisenmenger Syndrome.","published":"2019-01-02"}],"10.1161/circulationaha.118.036536":[{"url":"https://hartvaat.nl/2019/01/02/preventie-van-cardiogene-shock-na-acuut-mi/","title":"Preventie van cardiogene shock na acuut MI","title_en":"Prevention of Cardiogenic Shock After Acute Myocardial Infarction.","published":"2019-01-02"}],"10.1001/jama.2018.19802":[{"url":"https://hartvaat.nl/2019/01/01/laaggedoseerd-intracoronair-alteplase-bij-primaire-pci-jama-t-time/","title":"Laaggedoseerd intracoronair alteplase bij primaire PCI: JAMA T-TIME","title_en":"Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial.","published":"2019-01-01"}],"10.1001/jama.2018.19791":[{"url":"https://hartvaat.nl/2019/01/01/medicatie-copay-vouchers-en-p2y12-gebruik-en-cv-events-na-mi-jama/","title":"Medicatie-copay vouchers en P2Y12-gebruik en CV-events na MI: JAMA","title_en":"Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.","published":"2019-01-01"}],"10.1001/jamacardio.2018.4171":[{"url":"https://hartvaat.nl/2019/01/01/mi-bij-pav-patienten-incidentie-en-uitkomsten-euclid/","title":"MI bij PAV-patiënten: incidentie en uitkomsten — EUCLID","title_en":"Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.","published":"2019-01-01"}],"10.1001/jamacardio.2018.4178":[{"url":"https://hartvaat.nl/2019/01/01/interindividuele-variatie-in-ldl-verlaging-met-evolocumab-fourier-analyse/","title":"Interindividuele variatie in LDL-verlaging met evolocumab: FOURIER-analyse","title_en":"Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.","published":"2019-01-01"}],"10.1001/jama.2018.18269":[{"url":"https://hartvaat.nl/2019/01/01/linagliptine-versus-placebo-bij-diabetes-type-2-met-hoog-cv-en-renaal-risico-jam/","title":"Linagliptine versus placebo bij diabetes type 2 met hoog CV- en renaal risico: JAMA CARMELINA","title_en":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.","published":"2019-01-01"}],"10.1093/europace/euy121":[{"url":"https://hartvaat.nl/2019/01/01/slokdarmletsel-bij-af-ablatie-prevalentie-en-preventie-meta-analyse/","title":"Slokdarmletsel bij AF-ablatie: prevalentie en preventie — meta-analyse","title_en":"Prevalence and prevention of oesophageal injury during atrial fibrillation ablation: a systematic review and meta-analysis.","published":"2019-01-01"}],"10.1093/europace/euy059":[{"url":"https://hartvaat.nl/2019/01/01/hotspots-van-gefractioneerde-elektrogrammen-in-linker-en-rechter-atrium-bij-af/","title":"Hotspots van gefractioneerde elektrogrammen in linker en rechter atrium bij AF","title_en":"Anatomical hotspots of fractionated electrograms in the left and right atrium: do they exist?","published":"2019-01-01"}],"10.1161/hypertensionaha.118.11635":[{"url":"https://hartvaat.nl/2019/01/01/levenslangrisico-op-cva-en-coronairlijden-naar-bloeddrukniveau-epoch-japan/","title":"Levenslangrisico op CVA en coronairlijden naar bloeddrukniveau: EPOCH-JAPAN","title_en":"Lifetime Risk of Stroke and Coronary Heart Disease Deaths According to Blood Pressure Level: EPOCH-JAPAN (Evidence for Cardiovascular Prevention From Observational Cohorts in Japan).","published":"2019-01-01"}],"10.1161/hypertensionaha.118.12060":[{"url":"https://hartvaat.nl/2019/01/01/acute-creatininestijging-bij-start-ace-remmer-en-effecten-van-voortzetting-analy/","title":"Acute creatininestijging bij start ACE-remmer en effecten van voortzetting: analyse","title_en":"Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.","published":"2019-01-01"}],"10.1161/hypertensionaha.118.11742":[{"url":"https://hartvaat.nl/2019/01/01/bloeddrukstijging-bij-jonge-vrouwen-met-turner-syndroom-ongeacht-oestradiol-dosi/","title":"Bloeddrukstijging bij jonge vrouwen met Turner syndroom ongeacht oestradiol dosis: 5-jaars RCT","title_en":"Five-Year Randomized Study Demonstrates Blood Pressure Increases in Young Women With Turner Syndrome Regardless of Estradiol Dose.","published":"2019-01-01"}],"10.1136/heartjnl-2018-313398":[{"url":"https://hartvaat.nl/2019/01/01/implementatie-van-mi-zorgsystemen-in-lage-en-middeninkomenslanden/","title":"Implementatie van MI-zorgsystemen in lage- en middeninkomenslanden","title_en":"Implementing myocardial infarction systems of care in low/middle-income countries.","published":"2019-01-01"}],"10.1136/heartjnl-2018-313599":[{"url":"https://hartvaat.nl/2019/01/01/globale-prevalentie-van-therapieresistente-hypertensie-meta-analyse-van-3-2-milj/","title":"Globale prevalentie van therapieresistente hypertensie: meta-analyse van 3,2 miljoen patiënten","title_en":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients.","published":"2019-01-01"}],"10.1136/heartjnl-2018-313108":[{"url":"https://hartvaat.nl/2019/01/01/polypil-en-cardiovasculaire-preventie-meta-analyse-van-gerandomiseerde-trials/","title":"Polypil en cardiovasculaire preventie: meta-analyse van gerandomiseerde trials","title_en":"Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.","published":"2019-01-01"}],"10.1016/j.jacc.2018.09.078":[{"url":"https://hartvaat.nl/2018/12/25/cv-en-ledemaat-uitkomsten-bij-diabetes-met-pav-euclid/","title":"CV- en ledemaat-uitkomsten bij diabetes met PAV: EUCLID","title_en":"Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.","published":"2018-12-25"}],"10.1093/eurheartj/ehy294":[{"url":"https://hartvaat.nl/2018/12/21/culprit-shock-integratie-in-2017-esc-stemi-richtlijn-richtlijncommissie-standpun/","title":"CULPRIT-SHOCK integratie in 2017 ESC STEMI-richtlijn: richtlijncommissie standpunt","title_en":"Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force.","published":"2018-12-21"}],"10.1161/circulationaha.118.036418":[{"url":"https://hartvaat.nl/2018/12/18/liraglutide-bij-diabetes-type-2-met-ckd-leader-renale-analyse/","title":"Liraglutide bij diabetes type 2 met CKD: LEADER renale analyse","title_en":"Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.","published":"2018-12-18"}],"10.1161/circulationaha.118.034516":[{"url":"https://hartvaat.nl/2018/12/18/liraglutide-cv-uitkomsten-met-of-zonder-eerder-mi-leader/","title":"Liraglutide CV-uitkomsten met of zonder eerder MI: LEADER","title_en":"Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.","published":"2018-12-18"}],"10.1016/j.jacc.2018.09.020":[{"url":"https://hartvaat.nl/2018/12/18/2018-acc-expert-consensus-nieuwe-therapieen-voor-cv-risicoreductie-bij-diabetes-/","title":"2018 ACC Expert Consensus: nieuwe therapieën voor CV-risicoreductie bij diabetes type 2","title_en":"2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","published":"2018-12-18"}],"10.1016/j.jacc.2018.09.013":[{"url":"https://hartvaat.nl/2018/12/18/ivus-versus-angiografie-geleide-des-implantatie-de-ultimate-trial/","title":"IVUS versus angiografie-geleide DES-implantatie: de ULTIMATE-trial","title_en":"Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial.","published":"2018-12-18"}],"10.1056/nejmoa1806640":[{"url":"https://hartvaat.nl/2018/12/13/transcatheter-mitraalklepherstel-bij-hartfalen-nejm-coapt/","title":"Transcatheter mitraalklepherstel bij hartfalen: NEJM COAPT","title_en":"Transcatheter Mitral-Valve Repair in Patients with Heart Failure.","published":"2018-12-13"}],"10.1056/nejmoa1805374":[{"url":"https://hartvaat.nl/2018/12/13/percutaan-herstel-of-medicamenteuze-therapie-bij-secundaire-mr-nejm-mitra-fr/","title":"Percutaan herstel of medicamenteuze therapie bij secundaire MR: NEJM MITRA-FR","title_en":"Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.","published":"2018-12-13"}],"10.1161/circulationaha.118.036220":[{"url":"https://hartvaat.nl/2018/12/11/langetermijneffecten-van-zuurstof-op-sterfte-of-hf-hospitalisatie-na-verdenking-/","title":"Langetermijneffecten van zuurstof op sterfte of HF-hospitalisatie na verdenking MI","title_en":"Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction.","published":"2018-12-11"}],"10.1161/circulationaha.118.037152":[{"url":"https://hartvaat.nl/2018/12/11/vroeg-versus-standaard-invasief-onderzoek-bij-nste-acs-verdict-gerandomiseerde-t/","title":"Vroeg versus standaard invasief onderzoek bij NSTE-ACS: VERDICT gerandomiseerde trial","title_en":"Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.","published":"2018-12-11"}],"10.1016/j.jacc.2018.09.046":[{"url":"https://hartvaat.nl/2018/12/11/syntax-score-bij-diabetes-met-coronaire-revascularisatie-freedom/","title":"SYNTAX-score bij diabetes met coronaire revascularisatie: FREEDOM","title_en":"SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization in the FREEDOM Trial.","published":"2018-12-11"}],"10.1093/eurheartj/ehy562":[{"url":"https://hartvaat.nl/2018/12/07/laesiecomplexiteit-en-periprocedurele-events-bij-potente-iv-antiplaatjestherapie/","title":"Laesiecomplexiteit en periprocedurele events bij potente IV antiplaatjestherapie","title_en":"Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.","published":"2018-12-07"}],"10.1016/j.jacc.2018.08.2201":[{"url":"https://hartvaat.nl/2018/12/04/echocardiografische-screening-op-ph-bij-aangeboren-hartafwijkingen-jacc-review/","title":"Echocardiografische screening op PH bij aangeboren hartafwijkingen: JACC review","title_en":"Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week.","published":"2018-12-04"}],"10.1016/j.jacc.2018.09.043":[{"url":"https://hartvaat.nl/2018/12/04/ffr-versus-angiografie-geleide-cabg/","title":"FFR versus angiografie-geleide CABG","title_en":"Fractional Flow Reserve Versus Angiographically-Guided Coronary Artery Bypass Grafting.","published":"2018-12-04"}],"10.1001/jamacardio.2018.3957":[{"url":"https://hartvaat.nl/2018/12/01/number-needed-to-treat-met-arni-voor-preventie-van-cv-dood-of-hf-hospitalisatie/","title":"Number needed to treat met ARNI voor preventie van CV-dood of HF-hospitalisatie","title_en":"Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.","published":"2018-12-01"}],"10.1001/jamacardio.2018.3945":[{"url":"https://hartvaat.nl/2018/12/01/ras-etniciteit-en-oac-gebruik-bij-af-orbit-af/","title":"Ras/etniciteit en OAC-gebruik bij AF: ORBIT-AF","title_en":"Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.","published":"2018-12-01"}],"10.1001/jamacardio.2018.3811":[{"url":"https://hartvaat.nl/2018/12/01/multipele-biomarkers-en-mortaliteitsrisico-na-acs-jama-cardiology/","title":"Multipele biomarkers en mortaliteitsrisico na ACS: JAMA Cardiology","title_en":"Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.","published":"2018-12-01"}],"10.1001/jamacardio.2018.3680":[{"url":"https://hartvaat.nl/2018/12/01/cardiovasculaire-risicocommunicatie-en-patientperceptie-jama-cardiology/","title":"Cardiovasculaire risicocommunicatie en patiëntperceptie: JAMA Cardiology","title_en":"Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences.","published":"2018-12-01"}],"10.1093/eurheartj/ehy555":[{"url":"https://hartvaat.nl/2018/12/01/av-junctieablatie-plus-crt-bij-permanent-af-gerandomiseerde-trial/","title":"AV-junctieablatie plus CRT bij permanent AF: gerandomiseerde trial","title_en":"A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS.","published":"2018-12-01"}],"10.1093/europace/euy141":[{"url":"https://hartvaat.nl/2018/12/01/edoxaban-verhoogt-behandeltevredenheid-en-vermindert-zorggebruik-engage-af-timi-/","title":"Edoxaban verhoogt behandeltevredenheid en vermindert zorggebruik: ENGAGE AF-TIMI 48","title_en":"Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study.","published":"2018-12-01"}],"10.1161/hypertensionaha.118.11944":[{"url":"https://hartvaat.nl/2018/12/01/creatininestijging-tijdens-bloeddrukbehandeling-en-uitkomsten-bij-diabetes-type-/","title":"Creatininestijging tijdens bloeddrukbehandeling en uitkomsten bij diabetes type 2","title_en":"Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus.","published":"2018-12-01"}],"10.1002/ehf2.12349":[{"url":"https://hartvaat.nl/2018/12/01/ularitide-en-andere-vasoactieve-stoffen-bij-acuut-hf-systematische-review/","title":"Ularitide en andere vasoactieve stoffen bij acuut HF: systematische review","title_en":"Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis.","published":"2018-12-01"}],"10.1002/ehf2.12353":[{"url":"https://hartvaat.nl/2018/12/01/prognose-van-hfmref-systematische-review-en-meta-analyse/","title":"Prognose van HFmrEF: systematische review en meta-analyse","title_en":"The prognosis of mid-range ejection fraction heart failure: a systematic review and meta-analysis.","published":"2018-12-01"}],"10.1002/ehf2.12339":[{"url":"https://hartvaat.nl/2018/12/01/mitraclip-plus-medicamenteus-versus-medicamenteus-alleen-bij-hf-met-mr-meta-anal/","title":"MitraClip plus medicamenteus versus medicamenteus alleen bij HF met MR: meta-analyse","title_en":"A meta-analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients.","published":"2018-12-01"}],"10.1002/ehf2.12312":[{"url":"https://hartvaat.nl/2018/12/01/pro-gastrin-releasing-peptide-en-uitkomsten-bij-hf-met-anemie-red-hf/","title":"Pro-gastrin-releasing peptide en uitkomsten bij HF met anemie: RED-HF","title_en":"Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.","published":"2018-12-01"}],"10.1002/ehf2.12334":[{"url":"https://hartvaat.nl/2018/12/01/liraglutide-en-gewicht-bij-gevorderd-hfref-fight-trial-inzichten/","title":"Liraglutide en gewicht bij gevorderd HFrEF: FIGHT-trial inzichten","title_en":"Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.","published":"2018-12-01"}],"10.1002/ehf2.12337":[{"url":"https://hartvaat.nl/2018/12/01/lvad-implantatie-verbetert-glycemische-controle-meta-analyse/","title":"LVAD-implantatie verbetert glycemische controle: meta-analyse","title_en":"Left ventricular assist device implantation improves glycaemic control: a systematic review and meta-analysis.","published":"2018-12-01"}],"10.1136/heartjnl-2018-313091":[{"url":"https://hartvaat.nl/2018/12/01/dagelijkse-remote-ischemische-conditionering-na-acuut-mi-gerandomiseerde-trial/","title":"Dagelijkse remote ischemische conditionering na acuut MI: gerandomiseerde trial","title_en":"Daily remote ischaemic conditioning following acute myocardial infarction: a randomised controlled trial.","published":"2018-12-01"}],"10.1056/nejmoa1801174":[{"url":"https://hartvaat.nl/2018/11/29/alirocumab-en-cardiovasculaire-uitkomsten-na-acs-nejm-odyssey-outcomes/","title":"Alirocumab en cardiovasculaire uitkomsten na ACS: NEJM ODYSSEY OUTCOMES","title_en":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.","published":"2018-11-29"}],"10.1161/circulationaha.118.034942":[{"url":"https://hartvaat.nl/2018/11/27/metabolome-consequenties-van-pcsk9-remming-versus-statinetherapie/","title":"Metabolome consequenties van PCSK9-remming versus statinetherapie","title_en":"Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.","published":"2018-11-27"}],"10.1016/j.jacc.2018.08.2184":[{"url":"https://hartvaat.nl/2018/11/27/economische-en-qol-uitkomsten-van-nt-probnp-geleide-hf-therapie/","title":"Economische en QoL-uitkomsten van NT-proBNP-geleide HF-therapie","title_en":"Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure.","published":"2018-11-27"}],"10.1016/s0140-6736(18)32328-6":[{"url":"https://hartvaat.nl/2018/11/24/lorcaserine-en-preventie-remissie-van-diabetes-type-2-bij-obesitas-camellia-timi/","title":"Lorcaserine en preventie/remissie van diabetes type 2 bij obesitas: CAMELLIA-TIMI 61","title_en":"Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.","published":"2018-11-24"}],"10.1093/eurheartj/ehy413":[{"url":"https://hartvaat.nl/2018/11/21/voortzetten-versus-onderbreken-doac-bij-device-chirurgie-bruise-control-2/","title":"Voortzetten versus onderbreken DOAC bij device-chirurgie: BRUISE CONTROL-2","title_en":"Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).","published":"2018-11-21"}],"10.1016/s0140-6736(18)32260-8":[{"url":"https://hartvaat.nl/2018/11/17/ly3298176-duale-gip-glp-1-agonist-bij-diabetes-type-2-lancet-tirzepatide-fase-2/","title":"LY3298176 duale GIP/GLP-1-agonist bij diabetes type 2: Lancet tirzepatide fase-2","title_en":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.","published":"2018-11-17"}],"10.1161/circulationaha.118.034456":[{"url":"https://hartvaat.nl/2018/11/13/ultradunne-versus-dikkere-drug-eluting-stents-systematische-review/","title":"Ultradunne versus dikkere drug-eluting stents: systematische review","title_en":"Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease.","published":"2018-11-13"}],"10.1001/jama.2018.14852":[{"url":"https://hartvaat.nl/2018/11/06/anorganisch-nitriet-versus-placebo-bij-inspanningscapaciteit-bij-hfpef-jama-indi/","title":"Anorganisch nitriet versus placebo bij inspanningscapaciteit bij HFpEF: JAMA INDIE-HFpEF","title_en":"Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.","published":"2018-11-06"}],"10.1093/eurheartj/ehy581":[{"url":"https://hartvaat.nl/2018/11/01/ct-coronairangiografie-voor-heart-team-besluitvorming-bij-multivatenlijden/","title":"CT-coronairangiografie voor Heart Team-besluitvorming bij multivatenlijden","title_en":"Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease.","published":"2018-11-01"}],"10.1001/jamacardio.2018.3408":[{"url":"https://hartvaat.nl/2018/11/01/timing-van-atorvastatine-oplaaddosis-voor-pci-bij-acs-jama-cardiology/","title":"Timing van atorvastatine-oplaaddosis vóór PCI bij ACS: JAMA Cardiology","title_en":"Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial.","published":"2018-11-01"}],"10.1056/nejmoa1808788":[{"url":"https://hartvaat.nl/2018/11/01/1-jaarsuitkomsten-na-pci-strategieen-bij-cardiogene-shock-nejm-culprit-shock/","title":"1-jaarsuitkomsten na PCI-strategieën bij cardiogene shock: NEJM CULPRIT-SHOCK","title_en":"One-Year Outcomes after PCI Strategies in Cardiogenic Shock.","published":"2018-11-01"}],"10.1093/europace/eux297":[{"url":"https://hartvaat.nl/2018/11/01/uitkomsten-van-ablatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","title":"Uitkomsten van ablatie bij persisterend en langdurig persisterend AF: meta-analyse","title_en":"Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis.","published":"2018-11-01"}],"10.1093/europace/eux310":[{"url":"https://hartvaat.nl/2018/11/01/individueel-aangepaste-versus-gestandaardiseerde-substraatmodificatie-bij-rf-abl/","title":"Individueel aangepaste versus gestandaardiseerde substraatmodificatie bij RF-ablatie voor AF","title_en":"Individually tailored vs. standardized substrate modification during radiofrequency catheter ablation for atrial fibrillation: a randomized study.","published":"2018-11-01"}],"10.1093/europace/eux267":[{"url":"https://hartvaat.nl/2018/11/01/nmarq-pvac-en-thoracoscopische-ablatie-bij-paroxysmaal-af-gerandomiseerde-trial/","title":"nMARQ, PVAC en thoracoscopische ablatie bij paroxysmaal AF: gerandomiseerde trial","title_en":"Results of the first investigator-initiated randomized clinical trial of nMARQTM, PVACTM, and thoracoscopic ablation for paroxysmal atrial fibrillation.","published":"2018-11-01"}],"10.1093/europace/eux253":[{"url":"https://hartvaat.nl/2018/11/01/kwaliteit-van-leven-na-mitralisklepchirurgie-met-en-zonder-epicardiale-cryoablat/","title":"Kwaliteit van leven na mitralisklepchirurgie met en zonder epicardiale cryoablatie voor AF","title_en":"Quality of life is not improved after mitral valve surgery combined with epicardial left atrial cryoablation as compared with mitral valve surgery alone: a substudy of the double blind randomized SWEDish Multicentre Atrial Fibrillation study (SWEDMAF).","published":"2018-11-01"}],"10.1161/hyp.0000000000000084":[{"url":"https://hartvaat.nl/2018/11/01/therapieresistente-hypertensie-aha-scientific-statement-over-detectie-evaluatie-/","title":"Therapieresistente hypertensie: AHA scientific statement over detectie, evaluatie en management","title_en":"Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.","published":"2018-11-01"}],"10.1136/heartjnl-2018-312950":[{"url":"https://hartvaat.nl/2018/11/01/aldosteronblokkade-bij-myocardinfarct-ipd-analyse-van-twee-trials/","title":"Aldosteronblokkade bij myocardinfarct: IPD analyse van twee trials","title_en":"Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction.","published":"2018-11-01"}],"10.1136/heartjnl-2017-312850":[{"url":"https://hartvaat.nl/2018/11/01/longitudinale-bloeddrukverandering-en-cv-mortaliteit-in-een-chinees-cohort/","title":"Longitudinale bloeddrukverandering en CV-mortaliteit in een Chinees cohort","title_en":"Longitudinal change in blood pressure is associated with cardiovascular disease mortality in a Chinese cohort.","published":"2018-11-01"}],"10.1161/circulationaha.118.033933":[{"url":"https://hartvaat.nl/2018/10/30/endogene-factor-xa-activiteit-en-edoxaban-farmacodynamische-marker-en-klinische-/","title":"Endogene factor Xa-activiteit en edoxaban: farmacodynamische marker en klinische uitkomsten","title_en":"Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.","published":"2018-10-30"}],"10.1161/circulationaha.118.035722":[{"url":"https://hartvaat.nl/2018/10/30/zorggebruik-en-kosten-in-momentum-3-langetermijnstudie/","title":"Zorggebruik en kosten in MOMENTUM 3: langetermijnstudie","title_en":"Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study.","published":"2018-10-30"}],"10.1016/s0140-6736(18)32261-x":[{"url":"https://hartvaat.nl/2018/10/27/albiglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-lancet-harmony-ou/","title":"Albiglutide en cardiovasculaire uitkomsten bij diabetes type 2: Lancet Harmony Outcomes","title_en":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","published":"2018-10-27"}],"10.1016/s0140-6736(18)32283-9":[{"url":"https://hartvaat.nl/2018/10/27/absorb-iv-bioresorbeerbare-scaffold-30-daags-en-1-jaarsresultaten/","title":"ABSORB IV bioresorbeerbare scaffold: 30-daags en 1-jaarsresultaten","title_en":"Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.","published":"2018-10-27"}],"10.1161/cir.0000000000000601":[{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-systematische-review-circulation/","title":"2017 ACC/AHA hypertensierichtlijn: systematische review (Circulation)","title_en":"Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2018-10-23"}],"10.1161/cir.0000000000000597":[{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-executive-summary/","title":"2017 ACC/AHA hypertensierichtlijn: executive summary","title_en":"2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2018-10-23"}],"10.1161/cir.0000000000000596":[{"url":"https://hartvaat.nl/2018/10/23/2017-acc-aha-hypertensierichtlijn-circulation-editie/","title":"2017 ACC/AHA hypertensierichtlijn: Circulation-editie","title_en":"2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2018-10-23"}],"10.1016/j.jacc.2018.06.078":[{"url":"https://hartvaat.nl/2018/10/23/evolocumab-en-coronaire-plaquesamenstelling-glagov-beeldvorming/","title":"Evolocumab en coronaire plaquesamenstelling: GLAGOV beeldvorming","title_en":"Effect of Evolocumab on Coronary Plaque Composition.","published":"2018-10-23"}],"10.1161/circulationaha.118.033801":[{"url":"https://hartvaat.nl/2018/10/23/ffr-en-ifr-als-voorspellers-van-placebo-gecontroleerde-pci-respons-orbita/","title":"FFR en iFR als voorspellers van placebo-gecontroleerde PCI-respons: ORBITA","title_en":"Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.","published":"2018-10-23"}],"10.1161/circulationaha.117.031356":[{"url":"https://hartvaat.nl/2018/10/23/lpa-varianten-en-residueel-cv-risico-bij-statinebehandelde-patienten/","title":"LPA-varianten en residueel CV-risico bij statinebehandelde patiënten","title_en":"LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.","published":"2018-10-23"}],"10.1056/nejmoa1804989":[{"url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","title":"Omega-3 vetzuursupplementen bij diabetes: NEJM ASCEND omega-3","title_en":"Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.","published":"2018-10-18"}],"10.1056/nejmoa1804988":[{"url":"https://hartvaat.nl/2018/10/18/aspirine-voor-primaire-preventie-bij-diabetes-nejm-ascend/","title":"Aspirine voor primaire preventie bij diabetes: NEJM ASCEND","title_en":"Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.","published":"2018-10-18"}],"10.1016/j.jacc.2018.07.083":[{"url":"https://hartvaat.nl/2018/10/16/doac-s-halveren-trombo-embolische-events-na-af-cardioversie-versus-warfarine/","title":"DOAC's halveren trombo-embolische events na AF-cardioversie versus warfarine","title_en":"Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin.","published":"2018-10-16"}],"10.1016/j.jacc.2018.07.075":[{"url":"https://hartvaat.nl/2018/10/16/hoge-coronaire-shear-stress-voorspelt-myocardinfarct/","title":"Hoge coronaire shear stress voorspelt myocardinfarct","title_en":"High Coronary Shear Stress in Patients With Coronary Artery Disease Predicts Myocardial Infarction.","published":"2018-10-16"}],"10.1161/circulationaha.118.034125":[{"url":"https://hartvaat.nl/2018/10/16/biomarkers-voor-specifieke-doodsoorzaken-bij-af/","title":"Biomarkers voor specifieke doodsoorzaken bij AF","title_en":"Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation.","published":"2018-10-16"}],"10.1016/s0140-6736(18)31652-0":[{"url":"https://hartvaat.nl/2018/10/13/lp-a-baseline-en-on-statin-voor-cv-eventvoorspelling-lancet-ipd-meta-analyse/","title":"Lp(a) baseline en on-statin voor CV-eventvoorspelling: Lancet IPD meta-analyse","title_en":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.","published":"2018-10-13"}],"10.1161/circulationaha.118.035588":[{"url":"https://hartvaat.nl/2018/10/09/24-uurs-ambulante-bloeddrukreductie-na-renale-denervatie-spyral-htn-off-med/","title":"24-uurs ambulante bloeddrukreductie na renale denervatie: SPYRAL HTN-OFF MED","title_en":"Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial.","published":"2018-10-09"}],"10.1016/j.jacc.2018.07.067":[{"url":"https://hartvaat.nl/2018/10/09/hypoglykemie-en-troponine-elevatie-bij-diabetes-met-coronairlijden/","title":"Hypoglykemie en troponine-elevatie bij diabetes met coronairlijden","title_en":"Hypoglycemia and Elevated Troponin in Patients With Diabetes and Coronary Artery Disease.","published":"2018-10-09"}],"10.1161/circulationaha.118.034818":[{"url":"https://hartvaat.nl/2018/10/09/sacubitril-valsartan-versus-irbesartan-bij-chronische-nierziekte/","title":"Sacubitril/valsartan versus irbesartan bij chronische nierziekte","title_en":"Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.","published":"2018-10-09"}],"10.1016/s0140-6736(18)32001-4":[{"url":"https://hartvaat.nl/2018/10/06/resolute-onyx-versus-orsiro-stent-lancet-gerandomiseerde-non-inferioriteitstrial/","title":"Resolute Onyx versus Orsiro stent: Lancet gerandomiseerde non-inferioriteitstrial","title_en":"Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.","published":"2018-10-06"}],"10.1056/nejmoa1808848":[{"url":"https://hartvaat.nl/2018/10/04/rivaroxaban-bij-hartfalen-met-sinusritme-en-coronairlijden-nejm-commander-hf/","title":"Rivaroxaban bij hartfalen met sinusritme en coronairlijden: NEJM COMMANDER HF","title_en":"Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.","published":"2018-10-04"}],"10.1016/j.jacc.2018.07.041":[{"url":"https://hartvaat.nl/2018/10/02/cangrelor-bij-ticagrelor-geladen-stemi-patienten-tijdens-primaire-pci/","title":"Cangrelor bij ticagrelor-geladen STEMI-patiënten tijdens primaire PCI","title_en":"Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.","published":"2018-10-02"}],"10.1016/j.jacc.2018.07.047":[{"url":"https://hartvaat.nl/2018/10/02/trombusaspiratie-bij-hoge-trombuslast-total-trial/","title":"Trombusaspiratie bij hoge trombuslast: TOTAL-trial","title_en":"Thrombus Aspiration in Patients With High Thrombus Burden in the TOTAL Trial.","published":"2018-10-02"}],"10.1016/j.jacc.2018.07.046":[{"url":"https://hartvaat.nl/2018/10/02/cv-uitkomsten-na-endovasculaire-versus-chirurgische-revascularisatie-onderste-le/","title":"CV-uitkomsten na endovasculaire versus chirurgische revascularisatie onderste ledematen: EUCLID","title_en":"Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial.","published":"2018-10-02"}],"10.1161/circulationaha.117.031457":[{"url":"https://hartvaat.nl/2018/10/02/periprocedurele-uitkomsten-van-doac-versus-warfarine-bij-niet-valvulair-af/","title":"Periprocedurele uitkomsten van DOAC versus warfarine bij niet-valvulair AF","title_en":"Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.","published":"2018-10-02"}],"10.1001/jamacardio.2018.2936":[{"url":"https://hartvaat.nl/2018/10/01/transcatheter-interatriale-shunt-bij-hfpef-1-jaarsresultaten/","title":"Transcatheter interatriale shunt bij HFpEF: 1-jaarsresultaten","title_en":"One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial.","published":"2018-10-01"}],"10.1001/jamacardio.2018.2559":[{"url":"https://hartvaat.nl/2018/10/01/inclusie-van-ouderen-vrouwen-en-minderheden-in-hf-trials-jama-cardiology-review/","title":"Inclusie van ouderen, vrouwen en minderheden in HF-trials: JAMA Cardiology review","title_en":"Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review.","published":"2018-10-01"}],"10.1001/jamacardio.2018.2568":[{"url":"https://hartvaat.nl/2018/10/01/natriuretische-peptiden-en-cardiovasculaire-prognose-bij-hfpef-topcat/","title":"Natriuretische peptiden en cardiovasculaire prognose bij HFpEF: TOPCAT","title_en":"Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.","published":"2018-10-01"}],"10.1093/eurheartj/ehy407":[{"url":"https://hartvaat.nl/2018/10/01/associatie-is-geen-causaliteit-behandeleffecten-bij-hartfalen-en-observationele-/","title":"Associatie is geen causaliteit: behandeleffecten bij hartfalen en observationele data","title_en":"Association is not causation: treatment effects cannot be estimated from observational data in heart failure.","published":"2018-10-01"}],"10.1093/europace/euy133":[{"url":"https://hartvaat.nl/2018/10/01/ononderbroken-doac-versus-vka-bij-af-ablatie-meta-analyse/","title":"Ononderbroken DOAC versus VKA bij AF-ablatie: meta-analyse","title_en":"Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.","published":"2018-10-01"}],"10.1093/europace/euy014":[{"url":"https://hartvaat.nl/2018/10/01/enkele-versus-dubbele-cryoballon-applicatie-bij-af-effectiviteit-en-veiligheid/","title":"Enkele versus dubbele cryoballon-applicatie bij AF: effectiviteit en veiligheid","title_en":"Acute and long-term efficacy and safety with a single cryoballoon application as compared with the standard dual application strategy: a prospective randomized study using the second-generation cryoballoon for pulmonary vein isolation in patients with symptomatic atrial fibrillation.","published":"2018-10-01"}],"10.1161/hypertensionaha.118.11499":[{"url":"https://hartvaat.nl/2018/10/01/prognostische-waarde-van-gemaskeerd-ongecontroleerde-hypertensie/","title":"Prognostische waarde van gemaskeerd ongecontroleerde hypertensie","title_en":"Prognostic Value of Masked Uncontrolled Hypertension.","published":"2018-10-01"}],"10.1161/hypertensionaha.118.11337":[{"url":"https://hartvaat.nl/2018/10/01/hypertensiebehandeling-en-orthostatische-hypotensie-relatie-met-cv-ziekte/","title":"Hypertensiebehandeling en orthostatische hypotensie: relatie met CV-ziekte","title_en":"Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease.","published":"2018-10-01"}],"10.1161/hypertensionaha.118.11101":[{"url":"https://hartvaat.nl/2018/10/01/ochtend-versus-avonddosering-van-antihypertensiva-gerandomiseerde-crossover-tria/","title":"Ochtend- versus avonddosering van antihypertensiva: gerandomiseerde crossover-trial","title_en":"Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure.","published":"2018-10-01"}],"10.1002/ehf2.12331":[{"url":"https://hartvaat.nl/2018/10/01/linkeratriumvolume-en-cv-uitkomsten-bij-systolisch-hf-antitromboticaeffect/","title":"Linkeratriumvolume en CV-uitkomsten bij systolisch HF: antitromboticaeffect","title_en":"Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment.","published":"2018-10-01"}],"10.1002/ehf2.12308":[{"url":"https://hartvaat.nl/2018/10/01/atriumfibrilleren-bij-wild-type-transthyretine-cardiale-amyloidose-review/","title":"Atriumfibrilleren bij wild-type transthyretine cardiale amyloïdose: review","title_en":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.","published":"2018-10-01"}],"10.1136/heartjnl-2017-312510":[{"url":"https://hartvaat.nl/2018/10/01/geschat-individueel-levensvoordeel-van-pcsk9-remming-bij-statinebehandelde-cad-p/","title":"Geschat individueel levensvoordeel van PCSK9-remming bij statinebehandelde CAD-patiënten","title_en":"Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.","published":"2018-10-01"}],"10.1136/heartjnl-2017-312774":[{"url":"https://hartvaat.nl/2018/10/01/danegaptide-bij-primaire-pci-voor-acuut-mi-fase-2-gerandomiseerde-trial/","title":"Danegaptide bij primaire PCI voor acuut MI: fase-2 gerandomiseerde trial","title_en":"Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial.","published":"2018-10-01"}],"10.1136/heartjnl-2018-313089":[{"url":"https://hartvaat.nl/2018/10/01/zuurstof-bij-verdenking-acuut-mi-meta-analyse-van-gerandomiseerde-trials/","title":"Zuurstof bij verdenking acuut MI: meta-analyse van gerandomiseerde trials","title_en":"Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials.","published":"2018-10-01"}],"10.1016/s0140-6736(18)31776-8":[{"url":"https://hartvaat.nl/2018/09/29/langetermijnmortaliteit-na-bloeddruk-en-lipidenverlaging-bij-hypertensie-ascot-l/","title":"Langetermijnmortaliteit na bloeddruk- en lipidenverlaging bij hypertensie: ASCOT legacy","title_en":"Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.","published":"2018-09-29"}],"10.1056/nejmoa1800781":[{"url":"https://hartvaat.nl/2018/09/27/draagbare-cardioverter-defibrillator-na-myocardinfarct-nejm-vest/","title":"Draagbare cardioverter-defibrillator na myocardinfarct: NEJM VEST","title_en":"Wearable Cardioverter-Defibrillator after Myocardial Infarction.","published":"2018-09-27"}],"10.1056/nejmoa1808561":[{"url":"https://hartvaat.nl/2018/09/27/6-maandsuitkomsten-van-restrictieve-versus-liberale-transfusie-bij-hartchirurgie/","title":"6-maandsuitkomsten van restrictieve versus liberale transfusie bij hartchirurgie: NEJM TRICS III","title_en":"Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery.","published":"2018-09-27"}],"10.1016/j.jacc.2018.07.037":[{"url":"https://hartvaat.nl/2018/09/25/edoxaban-versus-warfarine-bij-latijns-amerikaanse-af-patienten-engage-af-timi-48/","title":"Edoxaban versus warfarine bij Latijns-Amerikaanse AF-patiënten: ENGAGE AF-TIMI 48","title_en":"Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.","published":"2018-09-25"}],"10.1161/circulationaha.118.034710":[{"url":"https://hartvaat.nl/2018/09/25/sirna-tegen-pcsk9-en-atherogene-lipoproteinen-orion-1-secundaire-eindpunten/","title":"siRNA tegen PCSK9 en atherogene lipoproteïnen: ORION 1 secundaire eindpunten","title_en":"Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.","published":"2018-09-25"}],"10.1016/s0140-6736(18)31924-x":[{"url":"https://hartvaat.nl/2018/09/22/aspirine-voor-primaire-preventie-bij-matig-cv-risico-lancet-arrive/","title":"Aspirine voor primaire preventie bij matig CV-risico: Lancet ARRIVE","title_en":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.","published":"2018-09-22"}],"10.1016/s0140-6736(18)31880-4":[{"url":"https://hartvaat.nl/2018/09/22/telemedische-interventie-bij-hartfalen-lancet-tim-hf2/","title":"Telemedische interventie bij hartfalen: Lancet TIM-HF2","title_en":"Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial.","published":"2018-09-22"}],"10.1056/nejmoa1808721":[{"url":"https://hartvaat.nl/2018/09/20/cardiovasculaire-veiligheid-van-lorcaserine-bij-obesitas-nejm-camellia/","title":"Cardiovasculaire veiligheid van lorcaserine bij obesitas: NEJM CAMELLIA","title_en":"Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.","published":"2018-09-20"}],"10.1161/circulationaha.118.034763":[{"url":"https://hartvaat.nl/2018/09/18/hartfalen-na-cva-tia-bij-insulineresistente-patienten-behandeld-met-pioglitazon/","title":"Hartfalen na CVA/TIA bij insulineresistente patiënten behandeld met pioglitazon","title_en":"Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.","published":"2018-09-18"}],"10.1016/s0140-6736(18)31923-8":[{"url":"https://hartvaat.nl/2018/09/15/hoog-sensitief-troponine-bij-verdenking-acs-lancet-stepped-wedge-clustergerandom/","title":"Hoog-sensitief troponine bij verdenking ACS: Lancet stepped-wedge clustergerandomiseerde trial","title_en":"High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial.","published":"2018-09-15"}],"10.1016/s0140-6736(18)31858-0":[{"url":"https://hartvaat.nl/2018/09/15/ticagrelor-monotherapie-na-1-maand-dapt-lancet-global-leaders/","title":"Ticagrelor monotherapie na 1 maand DAPT: Lancet GLOBAL LEADERS","title_en":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.","published":"2018-09-15"}],"10.1056/nejmoa1805689":[{"url":"https://hartvaat.nl/2018/09/13/tafamidis-bij-transthyretine-amyloid-cardiomyopathie-nejm-attr-act/","title":"Tafamidis bij transthyretine amyloïd cardiomyopathie: NEJM ATTR-ACT","title_en":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.","published":"2018-09-13"}],"10.1016/s0140-6736(18)31719-7":[{"url":"https://hartvaat.nl/2018/09/08/drug-coated-balloons-bij-kleine-coronairarterien-lancet-basket-small-2/","title":"Drug-coated balloons bij kleine coronairarteriën: Lancet BASKET-SMALL 2","title_en":"Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.","published":"2018-09-08"}],"10.1016/s0140-6736(18)31714-8":[{"url":"https://hartvaat.nl/2018/09/08/radiale-versus-femorale-toegang-en-bivalirudine-versus-ufh-bij-acs-lancet-matrix/","title":"Radiale versus femorale toegang en bivalirudine versus UFH bij ACS: Lancet MATRIX","title_en":"Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.","published":"2018-09-08"}],"10.1056/nejmoa1805971":[{"url":"https://hartvaat.nl/2018/09/06/ct-coronairangiografie-en-5-jaars-mi-risico-nejm-scot-heart/","title":"CT-coronairangiografie en 5-jaars MI-risico: NEJM SCOT-HEART","title_en":"Coronary CT Angiography and 5-Year Risk of Myocardial Infarction.","published":"2018-09-06"}],"10.1016/j.jacc.2018.06.051":[{"url":"https://hartvaat.nl/2018/09/04/troponine-i-en-cardiovasculair-risico-bij-copd/","title":"Troponine I en cardiovasculair risico bij COPD","title_en":"Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.","published":"2018-09-04"}],"10.1016/s0140-6736(18)31715-x":[{"url":"https://hartvaat.nl/2018/09/01/ultradunne-biodegradeerbare-versus-dunne-duurzame-stents-lancet-gerandomiseerde-/","title":"Ultradunne biodegradeerbare versus dunne duurzame stents: Lancet gerandomiseerde non-inferioriteit","title_en":"Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.","published":"2018-09-01"}],"10.1093/eurheartj/ehy451":[{"url":"https://hartvaat.nl/2018/09/01/bloeddruk-hartfrequentie-en-mortaliteit-bij-copd-summit-trial/","title":"Bloeddruk, hartfrequentie en mortaliteit bij COPD: SUMMIT-trial","title_en":"Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial.","published":"2018-09-01"}],"10.1001/jamacardio.2018.2258":[{"url":"https://hartvaat.nl/2018/09/01/verdere-ldl-verlaging-bij-reeds-zeer-lage-niveaus-jama-cardiology-meta-analyse/","title":"Verdere LDL-verlaging bij reeds zeer lage niveaus: JAMA Cardiology meta-analyse","title_en":"Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.","published":"2018-09-01"}],"10.1093/eurheartj/ehy418":[{"url":"https://hartvaat.nl/2018/09/01/orthostatische-hypotensie-verhoogt-risico-op-cognitieve-stoornissen/","title":"Orthostatische hypotensie verhoogt risico op cognitieve stoornissen","title_en":"Orthostatic hypotension and symptomatic subclinical orthostatic hypotension increase risk of cognitive impairment: an integrated evidence review and analysis of a large older adult hypertensive cohort.","published":"2018-09-01"}],"10.1001/jamacardio.2018.2112":[{"url":"https://hartvaat.nl/2018/09/01/hdl-mimeticum-met-recombinant-apoa-i-milano-en-coronairlijden-jama-cardiology/","title":"HDL-mimeticum met recombinant apoA-I Milano en coronairlijden: JAMA Cardiology","title_en":"Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial.","published":"2018-09-01"}],"10.1001/jamacardio.2018.2121":[{"url":"https://hartvaat.nl/2018/09/01/cer-001-hdl-mimeticum-en-coronaire-atherosclerose-na-acs-jama-cardiology/","title":"CER-001 HDL-mimeticum en coronaire atherosclerose na ACS: JAMA Cardiology","title_en":"Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.","published":"2018-09-01"}],"10.1093/eurheartj/ehy287":[{"url":"https://hartvaat.nl/2018/09/01/bereikte-diastolische-bloeddruk-en-polsdruk-bij-streef-sbp-en-cv-uitkomsten-bij-/","title":"Bereikte diastolische bloeddruk en polsdruk bij streef-SBP en CV-uitkomsten bij HF","title_en":"Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.","published":"2018-09-01"}],"10.1093/europace/eux356":[{"url":"https://hartvaat.nl/2018/09/01/last-van-atriale-high-rate-episodes-en-cva-risico-systematische-review/","title":"Last van atriale high-rate episodes en CVA-risico: systematische review","title_en":"Burden of atrial high-rate episodes and risk of stroke: a systematic review.","published":"2018-09-01"}],"10.1093/europace/eux336":[{"url":"https://hartvaat.nl/2018/09/01/chirurgische-af-ablatie-systematische-review-en-meta-analyse-van-rct-s/","title":"Chirurgische AF-ablatie: systematische review en meta-analyse van RCT's","title_en":"Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.","published":"2018-09-01"}],"10.1093/europace/eux319":[{"url":"https://hartvaat.nl/2018/09/01/pace-capture-geleide-ablatie-na-contact-force-pvi-dragon-gerandomiseerde-trial/","title":"Pace-capture-geleide ablatie na contact-force PVI: DRAGON gerandomiseerde trial","title_en":"Pace-capture-guided ablation after contact-force-guided pulmonary vein isolation: results of the randomized controlled DRAGON trial.","published":"2018-09-01"}],"10.1161/hypertensionaha.118.10917":[{"url":"https://hartvaat.nl/2018/09/01/thuis-versus-praktijkbloeddrukmeting-in-de-zwangerschap/","title":"Thuis- versus praktijkbloeddrukmeting in de zwangerschap","title_en":"How Do Home and Clinic Blood Pressure Readings Compare in Pregnancy?","published":"2018-09-01"}],"10.1136/heartjnl-2017-312832":[{"url":"https://hartvaat.nl/2018/09/01/hartrevalidatie-en-lichamelijke-activiteit-systematische-review-en-meta-analyse/","title":"Hartrevalidatie en lichamelijke activiteit: systematische review en meta-analyse","title_en":"Cardiac rehabilitation and physical activity: systematic review and meta-analysis.","published":"2018-09-01"}],"10.1136/heartjnl-2017-312698":[{"url":"https://hartvaat.nl/2018/09/01/langetermijnimpact-van-cto-rekanalisatie-bij-stemi-patienten/","title":"Langetermijnimpact van CTO-rekanalisatie bij STEMI-patiënten","title_en":"Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction.","published":"2018-09-01"}],"10.1093/eurheartj/ehy148":[{"url":"https://hartvaat.nl/2018/08/21/apixaban-versus-heparine-vka-bij-cardioversie-voor-af-emanate-trial/","title":"Apixaban versus heparine/VKA bij cardioversie voor AF: EMANATE-trial","title_en":"Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.","published":"2018-08-21"}],"10.1161/circulationaha.118.034309":[{"url":"https://hartvaat.nl/2018/08/21/klinisch-voordeel-van-evolocumab-naar-ernst-van-coronairlijden-fourier/","title":"Klinisch voordeel van evolocumab naar ernst van coronairlijden: FOURIER","title_en":"Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.","published":"2018-08-21"}],"10.1093/eurheartj/ehy176":[{"url":"https://hartvaat.nl/2018/08/21/apixaban-bij-af-ablatie-veiligheid-bij-patienten-met-cva-risico/","title":"Apixaban bij AF-ablatie: veiligheid bij patiënten met CVA-risico","title_en":"Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.","published":"2018-08-21"}],"10.1093/eurheartj/ehx739":[{"url":"https://hartvaat.nl/2018/08/21/behandeling-van-onderliggende-aandoeningen-verbetert-sinusritme-na-af-arrest-af/","title":"Behandeling van onderliggende aandoeningen verbetert sinusritme na AF: ARREST-AF","title_en":"Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.","published":"2018-08-21"}],"10.1001/jama.2018.10359":[{"url":"https://hartvaat.nl/2018/08/14/drievoudige-lage-dosis-antihypertensivacombinatie-versus-standaardzorg-jama-gera/","title":"Drievoudige lage-dosis antihypertensivacombinatie versus standaardzorg: JAMA gerandomiseerde trial","title_en":"Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.","published":"2018-08-14"}],"10.1016/j.jacc.2018.05.057":[{"url":"https://hartvaat.nl/2018/08/14/hoofdstamrevascularisatie-bij-ckd-pci-versus-cabg-in-de-excel-trial/","title":"Hoofdstamrevascularisatie bij CKD: PCI versus CABG in de EXCEL-trial","title_en":"Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial.","published":"2018-08-14"}],"10.1016/j.jacc.2018.05.058":[{"url":"https://hartvaat.nl/2018/08/14/adma-en-sdma-voorspellen-uitkomsten-bij-af-aristotle-substudie/","title":"ADMA en SDMA voorspellen uitkomsten bij AF: ARISTOTLE-substudie","title_en":"Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy.","published":"2018-08-14"}],"10.1001/jama.2018.10321":[{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-aanbeveling-2018/","title":"ECG-screening op AF: USPSTF-aanbeveling 2018","title_en":"Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement.","published":"2018-08-07"}],"10.1001/jama.2018.4190":[{"url":"https://hartvaat.nl/2018/08/07/ecg-screening-op-af-uspstf-evidence-report-en-systematische-review/","title":"ECG-screening op AF: USPSTF evidence report en systematische review","title_en":"Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2018-08-07"}],"10.1161/circulationaha.118.034489":[{"url":"https://hartvaat.nl/2018/08/07/adenosine-en-ticagrelorspiegels-bij-patienten-met-en-zonder-ticagrelor-dyspneu/","title":"Adenosine en ticagrelorspiegels bij patiënten met en zonder ticagrelor-dyspneu","title_en":"Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea.","published":"2018-08-07"}],"10.1093/eurheartj/ehy326":[{"url":"https://hartvaat.nl/2018/08/01/zuurstoftherapie-bij-stemi-overzichtsartikel/","title":"Zuurstoftherapie bij STEMI: overzichtsartikel","title_en":"Oxygen therapy in ST-elevation myocardial infarction.","published":"2018-08-01"}],"10.1093/eurheartj/ehy332":[{"url":"https://hartvaat.nl/2018/08/01/leeftijd-en-geleide-de-escalatie-van-antiplaatjestherapie-na-acs-tropical-acs/","title":"Leeftijd en geleide de-escalatie van antiplaatjestherapie na ACS: TROPICAL-ACS","title_en":"Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.","published":"2018-08-01"}],"10.1093/eurheartj/ehy232":[{"url":"https://hartvaat.nl/2018/08/01/inhalatie-stikstofoxide-bij-stemi-nomi-gerandomiseerde-trial/","title":"Inhalatie-stikstofoxide bij STEMI: NOMI gerandomiseerde trial","title_en":"Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial.","published":"2018-08-01"}],"10.1093/europace/euy054":[{"url":"https://hartvaat.nl/2018/08/01/2018-ehra-praktische-gids-doac-s-bij-af-europace-editie/","title":"2018 EHRA praktische gids DOAC's bij AF (Europace-editie)","title_en":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.","published":"2018-08-01"}],"10.1093/europace/eux372":[{"url":"https://hartvaat.nl/2018/08/01/linker-hartoorisolatie-bij-persisterend-en-langdurig-persisterend-af-meta-analys/","title":"Linker-hartoorisolatie bij persisterend en langdurig persisterend AF: meta-analyse","title_en":"Benefit of left atrial appendage electrical isolation for persistent and long-standing persistent atrial fibrillation: a systematic review and meta-analysis.","published":"2018-08-01"}],"10.1002/ehf2.12293":[{"url":"https://hartvaat.nl/2018/08/01/laagfrequente-elektrische-spierstimulatie-en-endotheelfunctie-bij-gevorderd-hart/","title":"Laagfrequente elektrische spierstimulatie en endotheelfunctie bij gevorderd hartfalen","title_en":"Low frequency electrical muscle stimulation and endothelial function in advanced heart failure patients.","published":"2018-08-01"}],"10.1161/hypertensionaha.118.11408":[{"url":"https://hartvaat.nl/2018/08/01/intensieve-bloeddrukbehandeling-bij-diabetes-type-2-zonder-intensieve-glycemisch/","title":"Intensieve bloeddrukbehandeling bij diabetes type 2 zonder intensieve glycemische controle","title_en":"Benefits of Intensive Blood Pressure Treatment in Patients With Type 2 Diabetes Mellitus Receiving Standard but Not Intensive Glycemic Control.","published":"2018-08-01"}],"10.1161/hypertensionaha.118.10911":[{"url":"https://hartvaat.nl/2018/08/01/zelfmanagement-van-postnatale-hypertensie-de-snap-ht-trial/","title":"Zelfmanagement van postnatale hypertensie: de SNAP-HT-trial","title_en":"Self-Management of Postnatal Hypertension: The SNAP-HT Trial.","published":"2018-08-01"}],"10.1161/hypertensionaha.118.10862":[{"url":"https://hartvaat.nl/2018/08/01/farmacologische-behandeling-van-hypertensie-bij-kinderen-netwerkmeta-analyse/","title":"Farmacologische behandeling van hypertensie bij kinderen: netwerkmeta-analyse","title_en":"Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis.","published":"2018-08-01"}],"10.1161/hypertensionaha.118.10854":[{"url":"https://hartvaat.nl/2018/08/01/raas-profielen-bij-zwangeren-met-chronische-hypertensie/","title":"RAAS-profielen bij zwangeren met chronische hypertensie","title_en":"Renin-Angiotensin-Aldosterone Profiles in Pregnant Women With Chronic Hypertension.","published":"2018-08-01"}],"10.1161/hypertensionaha.118.11180":[{"url":"https://hartvaat.nl/2018/08/01/renale-denervatie-bij-resistente-hypertensie-met-obstructieve-slaapapneu-proof-o/","title":"Renale denervatie bij resistente hypertensie met obstructieve slaapapneu: proof-of-concept trial","title_en":"Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial.","published":"2018-08-01"}],"10.1161/hypertensionaha.118.11038":[{"url":"https://hartvaat.nl/2018/08/01/sympathische-zenuwactivatie-bij-essentiele-hypertensie-meta-analyse/","title":"Sympathische zenuwactivatie bij essentiële hypertensie: meta-analyse","title_en":"Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates: Systematic Reviews and Meta-Analyses.","published":"2018-08-01"}],"10.1002/ehf2.12292":[{"url":"https://hartvaat.nl/2018/08/01/langetermijn-patiromer-bij-hyperkaliemie-met-mild-hf-en-diabetische-nefropathie/","title":"Langetermijn patiromer bij hyperkaliëmie met mild HF en diabetische nefropathie","title_en":"Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.","published":"2018-08-01"}],"10.1002/ehf2.12283":[{"url":"https://hartvaat.nl/2018/08/01/kenmerken-en-prognose-van-hfmref-versus-hfref-en-hfpef-langetermijn/","title":"Kenmerken en prognose van HFmrEF versus HFrEF en HFpEF: langetermijn","title_en":"Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis.","published":"2018-08-01"}],"10.1002/ehf2.12285":[{"url":"https://hartvaat.nl/2018/08/01/inspanningstraining-met-vasculaire-occlusie-bij-chronisch-hartfalen/","title":"Inspanningstraining met vasculaire occlusie bij chronisch hartfalen","title_en":"The impact of aerobic exercise training with vascular occlusion in patients with chronic heart failure.","published":"2018-08-01"}],"10.1136/heartjnl-2017-312781":[{"url":"https://hartvaat.nl/2018/08/01/opportunistische-hf-screening-met-natriuretische-peptiden-bij-af-ipd-meta-analys/","title":"Opportunistische HF-screening met natriuretische peptiden bij AF: IPD meta-analyse","title_en":"Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies.","published":"2018-08-01"}],"10.1136/heartjnl-2017-312517":[{"url":"https://hartvaat.nl/2018/08/01/door-to-balloon-tijd-en-uitkomsten-bij-stemi-meta-analyse/","title":"Door-to-balloon tijd en uitkomsten bij STEMI: meta-analyse","title_en":"Coronary intervention door-to-balloon time and outcomes in ST-elevation myocardial infarction: a meta-analysis.","published":"2018-08-01"}],"10.1136/heartjnl-2017-312272":[{"url":"https://hartvaat.nl/2018/08/01/uitkomsten-bij-af-met-oac-bij-mitralis-of-aortakleplijden/","title":"Uitkomsten bij AF met OAC bij mitralis- of aortakleplijden","title_en":"Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease.","published":"2018-08-01"}],"10.1161/circulationaha.118.034722":[{"url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","title":"Antitrombotische therapie bij AF met OAC na PCI: AHA scientific statement","title_en":"Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.","published":"2018-07-31"}],"10.1161/circulationaha.118.033631":[{"url":"https://hartvaat.nl/2018/07/31/bnp-bij-linker-hoofdstamrevascularisatie-excel-analyse/","title":"BNP bij linker-hoofdstamrevascularisatie: EXCEL-analyse","title_en":"B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial.","published":"2018-07-31"}],"10.1161/circulationaha.118.034222":[{"url":"https://hartvaat.nl/2018/07/31/canagliflozine-en-hartfalen-bij-diabetes-type-2-canvas-programma/","title":"Canagliflozine en hartfalen bij diabetes type 2: CANVAS programma","title_en":"Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.","published":"2018-07-31"}],"10.1001/jama.2018.9422":[{"url":"https://hartvaat.nl/2018/07/24/escitalopram-versus-placebo-bij-depressie-na-acs-en-langetermijn-cardiale-uitkom/","title":"Escitalopram versus placebo bij depressie na ACS en langetermijn cardiale uitkomsten: JAMA","title_en":"Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.","published":"2018-07-24"}],"10.1016/j.jacc.2018.04.071":[{"url":"https://hartvaat.nl/2018/07/24/cva-incidentie-na-cabg-versus-pci/","title":"CVA-incidentie na CABG versus PCI","title_en":"Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.","published":"2018-07-24"}],"10.1016/s0140-6736(18)31363-1":[{"url":"https://hartvaat.nl/2018/07/21/baricitinib-bij-sle-lancet-fase-2-dubbelblinde-trial/","title":"Baricitinib bij SLE: Lancet fase-2 dubbelblinde trial","title_en":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.","published":"2018-07-21"}],"10.1056/nejmoa1803538":[{"url":"https://hartvaat.nl/2018/07/19/5-jaarsuitkomsten-van-ffr-geleide-pci-nejm-fame-2/","title":"5-jaarsuitkomsten van FFR-geleide PCI: NEJM FAME 2","title_en":"Five-Year Outcomes with PCI Guided by Fractional Flow Reserve.","published":"2018-07-19"}],"10.1056/nejmoa1800410":[{"url":"https://hartvaat.nl/2018/07/19/clopidogrel-plus-aspirine-bij-acuut-ischemisch-cva-en-hoogrisico-tia-nejm-point/","title":"Clopidogrel plus aspirine bij acuut ischemisch CVA en hoogrisico-TIA: NEJM POINT","title_en":"Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.","published":"2018-07-19"}],"10.1016/j.jacc.2018.04.063":[{"url":"https://hartvaat.nl/2018/07/17/oac-plus-nsaid-bij-af-risico-op-ernstige-bloedingen/","title":"OAC plus NSAID bij AF: risico op ernstige bloedingen","title_en":"Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.","published":"2018-07-17"}],"10.1093/eurheartj/ehx450":[{"url":"https://hartvaat.nl/2018/07/14/ldl-verlaging-en-cv-events-met-pcsk9-remmers-meta-analyse-van-gerandomiseerde-tr/","title":"LDL-verlaging en CV-events met PCSK9-remmers: meta-analyse van gerandomiseerde trials","title_en":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.","published":"2018-07-14"}],"10.1001/jama.2018.8102":[{"url":"https://hartvaat.nl/2018/07/10/draagbare-ecg-plakker-voor-af-detectie-thuis-jama-mstops-gerandomiseerde-trial/","title":"Draagbare ECG-plakker voor AF-detectie thuis: JAMA mSToPS gerandomiseerde trial","title_en":"Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial.","published":"2018-07-10"}],"10.1016/j.jacc.2018.04.053":[{"url":"https://hartvaat.nl/2018/07/10/il-8-en-infarctgrootte-en-klinische-uitkomsten-bij-stemi/","title":"IL-8 en infarctgrootte en klinische uitkomsten bij STEMI","title_en":"Association of IL-8 With Infarct Size and Clinical Outcomes in Patients With STEMI.","published":"2018-07-10"}],"10.1016/j.jacc.2018.04.051":[{"url":"https://hartvaat.nl/2018/07/10/epinefrine-versus-norepinefrine-bij-cardiogene-shock-na-acuut-mi/","title":"Epinefrine versus norepinefrine bij cardiogene shock na acuut MI","title_en":"Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.","published":"2018-07-10"}],"10.1016/j.jacc.2018.04.055":[{"url":"https://hartvaat.nl/2018/07/10/fatale-of-irreversibele-bloedingen-en-ischemische-events-met-rivaroxaban-bij-acs/","title":"Fatale of irreversibele bloedingen en ischemische events met rivaroxaban bij ACS","title_en":"Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.","published":"2018-07-10"}],"10.1161/circulationaha.118.034645":[{"url":"https://hartvaat.nl/2018/07/10/residueel-inflammatoir-risico-bij-pcsk9-remming-plus-statine/","title":"Residueel inflammatoir risico bij PCSK9-remming plus statine","title_en":"Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.","published":"2018-07-10"}],"10.1161/circulationaha.118.034032":[{"url":"https://hartvaat.nl/2018/07/10/inflammatie-en-cholesterol-in-de-fourier-trial/","title":"Inflammatie en cholesterol in de FOURIER-trial","title_en":"Inflammatory and Cholesterol Risk in the FOURIER Trial.","published":"2018-07-10"}],"10.1093/eurheartj/ehy275":[{"url":"https://hartvaat.nl/2018/07/07/orbusneich-combo-stent-japan-usa-harmonee-gerandomiseerde-multicenter-trial/","title":"OrbusNeich Combo stent: Japan-USA HARMONEE gerandomiseerde multicenter trial","title_en":"Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome.","published":"2018-07-07"}],"10.1093/eurheartj/ehy220":[{"url":"https://hartvaat.nl/2018/07/07/revascularisatie-versus-optimale-medicamenteuze-therapie-bij-cto-gerandomiseerde/","title":"Revascularisatie versus optimale medicamenteuze therapie bij CTO: gerandomiseerde trial","title_en":"A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions.","published":"2018-07-07"}],"10.1093/europace/eux370":[{"url":"https://hartvaat.nl/2018/07/01/rotorablatie-bij-atriumfibrilleren-systematische-review/","title":"Rotorablatie bij atriumfibrilleren: systematische review","title_en":"Clinical impact of rotor ablation in atrial fibrillation: a systematic review.","published":"2018-07-01"}],"10.1093/europace/eux175":[{"url":"https://hartvaat.nl/2018/07/01/echogeleide-versus-conventionele-femorale-venepunctie-bij-af-ablatie-gerandomise/","title":"Echogeleide versus conventionele femorale venepunctie bij AF-ablatie: gerandomiseerde trial","title_en":"Ultrasound-guided versus conventional femoral venipuncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ULTRA-FAST trial).","published":"2018-07-01"}],"10.1161/hypertensionaha.118.10893":[{"url":"https://hartvaat.nl/2018/07/01/hypertensie-bij-hiv-nieuwe-pathofysiologische-mechanismen/","title":"Hypertensie bij HIV: nieuwe pathofysiologische mechanismen","title_en":"Hypertension in HIV-Infected Adults: Novel Pathophysiologic Mechanisms.","published":"2018-07-01"}],"10.1136/heartjnl-2017-312594":[{"url":"https://hartvaat.nl/2018/07/01/sport-versus-beroepsmatige-lichamelijke-activiteit-en-cardiovasculair-risico/","title":"Sport versus beroepsmatige lichamelijke activiteit en cardiovasculair risico","title_en":"Differing associations for sport versus occupational physical activity and cardiovascular risk.","published":"2018-07-01"}],"10.1016/s0140-6736(18)30726-8":[{"url":"https://hartvaat.nl/2018/06/30/glp-1-glucagon-duale-agonist-bij-obesitas-met-diabetes-type-2-lancet-fase-2/","title":"GLP-1/glucagon duale agonist bij obesitas met diabetes type 2: Lancet fase-2","title_en":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.","published":"2018-06-30"}],"10.1056/nejmoa1802917":[{"url":"https://hartvaat.nl/2018/06/21/ibrutinib-plus-rituximab-bij-waldenstrom-nejm-fase-3-trial/","title":"Ibrutinib plus rituximab bij Waldenström: NEJM fase-3-trial","title_en":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.","published":"2018-06-21"}],"10.1093/eurheartj/ehx597":[{"url":"https://hartvaat.nl/2018/06/21/cpap-en-cardiovasculaire-events-bij-obstructieve-slaapapneu-meta-analyse/","title":"CPAP en cardiovasculaire events bij obstructieve slaapapneu: meta-analyse","title_en":"A meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea.","published":"2018-06-21"}],"10.1016/j.jacc.2018.04.016":[{"url":"https://hartvaat.nl/2018/06/19/cardioprotectieve-therapieen-en-area-at-risk-bij-gereperfuseerd-stemi-cmr-analys/","title":"Cardioprotectieve therapieën en area at risk bij gereperfuseerd STEMI: CMR-analyse","title_en":"Impact of Cardioprotective Therapies on the Edema-Based Area at Risk by CMR in Reperfused STEMI.","published":"2018-06-19"}],"10.1093/eurheartj/ehy185":[{"url":"https://hartvaat.nl/2018/06/14/langetermijnuitkomsten-bij-angina-zonder-obstructief-coronairlijden-systematisch/","title":"Langetermijnuitkomsten bij angina zonder obstructief coronairlijden: systematische review","title_en":"Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis.","published":"2018-06-14"}],"10.1016/j.jacc.2018.03.009":[{"url":"https://hartvaat.nl/2018/06/12/sglt2-remmers-en-cardiovasculaire-events-de-cvd-real-2-real-world-studie/","title":"SGLT2-remmers en cardiovasculaire events: de CVD-REAL 2 real-world studie","title_en":"Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.","published":"2018-06-12"}],"10.1016/s0140-6736(18)30832-8":[{"url":"https://hartvaat.nl/2018/06/09/dabigatran-bij-myocardschade-na-niet-cardiale-chirurgie-lancet-manage-trial/","title":"Dabigatran bij myocardschade na niet-cardiale chirurgie: Lancet MANAGE-trial","title_en":"Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.","published":"2018-06-09"}],"10.1016/s0140-6736(18)31082-1":[{"url":"https://hartvaat.nl/2018/06/09/endovasculaire-echografie-renale-denervatie-lancet-radiance-htn-solo/","title":"Endovasculaire echografie renale denervatie: Lancet RADIANCE-HTN SOLO","title_en":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.","published":"2018-06-09"}],"10.1016/s0140-6736(18)30951-6":[{"url":"https://hartvaat.nl/2018/06/09/renale-denervatie-met-antihypertensiva-lancet-spyral-htn-on-med-6-maandsresultat/","title":"Renale denervatie met antihypertensiva: Lancet SPYRAL HTN-ON MED 6-maandsresultaten","title_en":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.","published":"2018-06-09"}],"10.1161/circulationaha.117.032180":[{"url":"https://hartvaat.nl/2018/06/05/verlaagde-dosis-prasugrel-versus-standaard-clopidogrel-bij-oudere-acs-patienten/","title":"Verlaagde dosis prasugrel versus standaard clopidogrel bij oudere ACS-patiënten","title_en":"Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization.","published":"2018-06-05"}],"10.1001/jamacardio.2018.0653":[{"url":"https://hartvaat.nl/2018/06/01/fgf-23-en-recidiverende-cv-events-na-acs/","title":"FGF-23 en recidiverende CV-events na ACS","title_en":"Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.","published":"2018-06-01"}],"10.1001/jamacardio.2018.0589":[{"url":"https://hartvaat.nl/2018/06/01/maatschappelijk-werker-palliatieve-zorg-bij-hoogrisico-hf-swap-hf-pilot/","title":"Maatschappelijk werker-palliatieve zorg bij hoogrisico-HF: SWAP-HF pilot","title_en":"Social Worker-Aided Palliative Care Intervention in High-risk Patients With Heart Failure (SWAP-HF): A Pilot Randomized Clinical Trial.","published":"2018-06-01"}],"10.1001/jamacardio.2018.0398":[{"url":"https://hartvaat.nl/2018/06/01/sacubitril-valsartan-en-fysieke-en-sociale-activiteitsbeperkingen-bij-hf-paradig/","title":"Sacubitril/valsartan en fysieke en sociale activiteitsbeperkingen bij HF: PARADIGM-HF","title_en":"Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.","published":"2018-06-01"}],"10.1161/hypertensionaha.117.10646":[{"url":"https://hartvaat.nl/2018/06/01/intensieve-versus-standaard-bloeddruk-naar-tertielen-in-sprint/","title":"Intensieve versus standaard bloeddruk naar tertielen in SPRINT","title_en":"Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial).","published":"2018-06-01"}],"10.1161/hypertensionaha.117.10689":[{"url":"https://hartvaat.nl/2018/06/01/amenorroe-duur-bij-start-antihypertensiva-in-de-zwangerschap-chips-secundaire-an/","title":"Amenorroe-duur bij start antihypertensiva in de zwangerschap: CHIPS secundaire analyse","title_en":"Influence of Gestational Age at Initiation of Antihypertensive Therapy: Secondary Analysis of CHIPS Trial Data (Control of Hypertension in Pregnancy Study).","published":"2018-06-01"}],"10.1161/hypertensionaha.118.10923":[{"url":"https://hartvaat.nl/2018/06/01/interarmbloeddrukverschil-en-beroerte-ipd-meta-analyse/","title":"Interarmbloeddrukverschil en beroerte: IPD meta-analyse","title_en":"Simultaneously Measured Interarm Blood Pressure Difference and Stroke: An Individual Participants Data Meta-Analysis.","published":"2018-06-01"}],"10.1002/ehf2.12272":[{"url":"https://hartvaat.nl/2018/06/01/hemodynamische-effecten-van-levosimendan-bij-gevorderd-stabiel-chronisch-hartfal/","title":"Hemodynamische effecten van levosimendan bij gevorderd stabiel chronisch hartfalen","title_en":"Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.","published":"2018-06-01"}],"10.1002/ehf2.12258":[{"url":"https://hartvaat.nl/2018/06/01/implementatie-van-sacubitril-valsartan-in-de-klinische-praktijk-inzichten/","title":"Implementatie van sacubitril/valsartan in de klinische praktijk: inzichten","title_en":"Insights into implementation of sacubitril/valsartan into clinical practice.","published":"2018-06-01"}],"10.1002/ehf2.12266":[{"url":"https://hartvaat.nl/2018/06/01/complementactivatie-bij-acuut-hartfalen-na-mi-correlatie-met-ernst/","title":"Complementactivatie bij acuut hartfalen na MI: correlatie met ernst","title_en":"Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock.","published":"2018-06-01"}],"10.1002/ehf2.12265":[{"url":"https://hartvaat.nl/2018/06/01/geindividualiseerd-patiromer-doseringsregime-bij-hf-met-ckd-en-hyperkaliemie/","title":"Geïndividualiseerd patiromer-doseringsregime bij HF met CKD en hyperkaliëmie","title_en":"Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.","published":"2018-06-01"}],"10.1002/ehf2.12240":[{"url":"https://hartvaat.nl/2018/06/01/ivabradine-bij-hartfalen-door-chagas-ziekte-shift-post-hoc-analyse/","title":"Ivabradine bij hartfalen door Chagas-ziekte: SHIFT post-hoc analyse","title_en":"Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial.","published":"2018-06-01"}],"10.1136/heartjnl-2017-311546":[{"url":"https://hartvaat.nl/2018/06/01/preventie-van-atriumfibrilleren-beoordeling-van-huidig-bewijs/","title":"Preventie van atriumfibrilleren: beoordeling van huidig bewijs","title_en":"Atrial fibrillation prevention: an appraisal of current evidence.","published":"2018-06-01"}],"10.1161/hyp.0000000000000067":[{"url":"https://hartvaat.nl/2018/06/01/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn-hypertension-edit/","title":"Systematische review voor de 2017 ACC/AHA hypertensierichtlijn (Hypertension-editie)","title_en":"Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2018-06-01"}],"10.1136/heartjnl-2017-312045":[{"url":"https://hartvaat.nl/2018/06/01/gwas-van-pr-interval-bij-hispanic-latino-s-nieuw-locus-bij-id2/","title":"GWAS van PR-interval bij Hispanic/Latino's: nieuw locus bij ID2","title_en":"Genome-wide association study of PR interval in Hispanics/Latinos identifies novel locus at ID2.","published":"2018-06-01"}],"10.1016/s0140-6736(18)30801-8":[{"url":"https://hartvaat.nl/2018/05/19/des-versus-bms-in-veneuze-bypass-grafts-lancet-dubbelblinde-trial/","title":"DES versus BMS in veneuze bypass grafts: Lancet dubbelblinde trial","title_en":"Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.","published":"2018-05-19"}],"10.1161/circulationaha.118.033898":[{"url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","title":"Liraglutide bij diabetes type 2 met polyvasculaire ziekte: LEADER-analyse","title_en":"Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.","published":"2018-05-15"}],"10.1016/j.jacc.2018.02.072":[{"url":"https://hartvaat.nl/2018/05/15/trombocytenaantal-beinvloedt-werkzaamheid-van-foliumzuur-bij-cva-preventie/","title":"Trombocytenaantal beïnvloedt werkzaamheid van foliumzuur bij CVA-preventie","title_en":"Platelet Count Affects Efficacy of Folic Acid in Preventing First Stroke.","published":"2018-05-15"}],"10.1016/j.jacc.2017.11.004":[{"url":"https://hartvaat.nl/2018/05/15/systematische-review-voor-de-2017-acc-aha-hypertensierichtlijn/","title":"Systematische review voor de 2017 ACC/AHA hypertensierichtlijn","title_en":"Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2018-05-15"}],"10.1093/eurheartj/ehy162":[{"url":"https://hartvaat.nl/2018/05/14/dubbele-versus-triple-antitrombotische-therapie-bij-af-na-pci-meta-analyse/","title":"Dubbele versus triple antitrombotische therapie bij AF na PCI: meta-analyse","title_en":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.","published":"2018-05-14"}],"10.1001/jama.2018.4528":[{"url":"https://hartvaat.nl/2018/05/08/vasopressine-plus-catecholamines-en-af-bij-distributieve-shock-jama-meta-analyse/","title":"Vasopressine plus catecholamines en AF bij distributieve shock: JAMA meta-analyse","title_en":"Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.","published":"2018-05-08"}],"10.1161/circulationaha.117.032615":[{"url":"https://hartvaat.nl/2018/05/08/hoog-versus-laaggedoseerd-pitavastatine-bij-stabiel-coronairlijden-real-cad/","title":"Hoog- versus laaggedoseerd pitavastatine bij stabiel coronairlijden: REAL-CAD","title_en":"High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.","published":"2018-05-08"}],"10.1161/cir.0000000000000564":[{"url":"https://hartvaat.nl/2018/05/08/spontane-coronaire-arterie-dissectie-aha-scientific-statement/","title":"Spontane coronaire arterie dissectie: AHA scientific statement","title_en":"Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association.","published":"2018-05-08"}],"10.1161/circulationaha.117.030112":[{"url":"https://hartvaat.nl/2018/05/08/nierfunctieverslechtering-bij-acuut-hartfalen-met-agressieve-diurese-geen-tubula/","title":"Nierfunctieverslechtering bij acuut hartfalen met agressieve diurese: geen tubulaire schade","title_en":"Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury.","published":"2018-05-08"}],"10.1093/eurheartj/ehx488":[{"url":"https://hartvaat.nl/2018/05/07/esc-eapci-taskforce-rapport-over-bioresorbeerbare-scaffolds-executive-summary/","title":"ESC-EAPCI taskforce-rapport over bioresorbeerbare scaffolds: executive summary","title_en":"Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary.","published":"2018-05-07"}],"10.1016/j.jacc.2018.02.029":[{"url":"https://hartvaat.nl/2018/05/01/farmacogenomisch-gestuurd-antiplaatjestherapie-bij-acs-pharmclo-trial/","title":"Farmacogenomisch gestuurd antiplaatjestherapie bij ACS: PHARMCLO-trial","title_en":"Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial.","published":"2018-05-01"}],"10.1001/jamacardio.2018.0612":[{"url":"https://hartvaat.nl/2018/05/01/ticagrelor-versus-clopidogrel-na-fibrinolyse-bij-stemi-jama-cardiology-gerandomi/","title":"Ticagrelor versus clopidogrel na fibrinolyse bij STEMI: JAMA Cardiology gerandomiseerde trial","title_en":"Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial.","published":"2018-05-01"}],"10.1093/europace/eux206":[{"url":"https://hartvaat.nl/2018/05/01/risicostratificatie-met-geintegreerde-devicediagnostiek-bij-hartfalen/","title":"Risicostratificatie met geïntegreerde devicediagnostiek bij hartfalen","title_en":"Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator.","published":"2018-05-01"}],"10.1093/europace/euw446":[{"url":"https://hartvaat.nl/2018/05/01/crt-voordeel-bij-concordant-versus-discordant-linksbundeltakblok-esc-hf-pilot/","title":"CRT-voordeel bij concordant versus discordant linksbundeltakblok: ESC-HF pilot","title_en":"The prognostic benefit of cardiac resynchronization therapy is greater in concordant vs. discordant left bundle branch block in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).","published":"2018-05-01"}],"10.1161/hypertensionaha.117.10705":[{"url":"https://hartvaat.nl/2018/05/01/bloeddruk-voor-conceptie-en-reproductieve-uitkomsten/","title":"Bloeddruk vóór conceptie en reproductieve uitkomsten","title_en":"Preconception Blood Pressure Levels and Reproductive Outcomes in a Prospective Cohort of Women Attempting Pregnancy.","published":"2018-05-01"}],"10.1161/hypertensionaha.117.10177":[{"url":"https://hartvaat.nl/2018/05/01/verlaging-van-diastolische-druk-bij-patienten-met-en-zonder-cardiovasculaire-zie/","title":"Verlaging van diastolische druk bij patiënten met en zonder cardiovasculaire ziekte: SPRINT","title_en":"Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).","published":"2018-05-01"}],"10.1161/hypertensionaha.117.10602":[{"url":"https://hartvaat.nl/2018/05/01/natriuminname-en-bloeddruk-varieren-met-energie-inname-dash-secundaire-analyse/","title":"Natriuminname en bloeddruk variëren met energie-inname: DASH secundaire analyse","title_en":"Relationship of Sodium Intake and Blood Pressure Varies With Energy Intake: Secondary Analysis of the DASH (Dietary Approaches to Stop Hypertension)-Sodium Trial.","published":"2018-05-01"}],"10.1161/hypertensionaha.117.10479":[{"url":"https://hartvaat.nl/2018/05/01/bloeddrukmeting-in-sprint-methodologische-overwegingen/","title":"Bloeddrukmeting in SPRINT: methodologische overwegingen","title_en":"Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial).","published":"2018-05-01"}],"10.1136/heartjnl-2017-312122":[{"url":"https://hartvaat.nl/2018/05/01/klinische-score-verbetert-risicostratificatie-bij-stressechocardiografie/","title":"Klinische score verbetert risicostratificatie bij stressechocardiografie","title_en":"Simple six-item clinical score improves risk prediction capability of stress echocardiography.","published":"2018-05-01"}],"10.1016/s0140-6736(18)30479-3":[{"url":"https://hartvaat.nl/2018/04/28/liberale-versus-conservatieve-zuurstoftherapie-bij-acuut-zieke-volwassenen-lance/","title":"Liberale versus conservatieve zuurstoftherapie bij acuut zieke volwassenen: Lancet IOTA meta-analyse","title_en":"Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.","published":"2018-04-28"}],"10.1161/circulationaha.117.030308":[{"url":"https://hartvaat.nl/2018/04/24/hoge-versus-lage-bloeddrukstreefwaarden-tijdens-cardiopulmonale-bypass-en-cerebr/","title":"Hoge versus lage bloeddrukstreefwaarden tijdens cardiopulmonale bypass en cerebraal letsel","title_en":"High-Target Versus Low-Target Blood Pressure Management During Cardiopulmonary Bypass to Prevent Cerebral Injury in Cardiac Surgery Patients: A Randomized Controlled Trial.","published":"2018-04-24"}],"10.1093/eurheartj/ehy136":[{"url":"https://hartvaat.nl/2018/04/21/2018-ehra-praktische-gids-voor-doac-gebruik-bij-af/","title":"2018 EHRA praktische gids voor DOAC-gebruik bij AF","title_en":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.","published":"2018-04-21"}],"10.1093/eurheartj/ehx731":[{"url":"https://hartvaat.nl/2018/04/21/subklinisch-device-gedetecteerd-af-en-cva-risico-meta-analyse/","title":"Subklinisch device-gedetecteerd AF en CVA-risico: meta-analyse","title_en":"Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis.","published":"2018-04-21"}],"10.1093/eurheartj/ehx762":[{"url":"https://hartvaat.nl/2018/04/21/telemonitoring-verbetert-doac-therapietrouw-bij-af/","title":"Telemonitoring verbetert DOAC-therapietrouw bij AF","title_en":"Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.","published":"2018-04-21"}],"10.1093/eurheartj/ehx666":[{"url":"https://hartvaat.nl/2018/04/21/pvi-met-versus-zonder-antiaritmica-bij-recidiverend-af-powder-af/","title":"PVI met versus zonder antiaritmica bij recidiverend AF: POWDER-AF","title_en":"PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial.","published":"2018-04-21"}],"10.1001/jama.2018.3024":[{"url":"https://hartvaat.nl/2018/04/17/sglt2-remmers-glp-1-agonisten-en-dpp-4-remmers-vergelijkende-cardiovasculaire-me/","title":"SGLT2-remmers, GLP-1-agonisten en DPP-4-remmers: vergelijkende cardiovasculaire meta-analyse","title_en":"Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.","published":"2018-04-17"}],"10.1001/jama.2018.2525":[{"url":"https://hartvaat.nl/2018/04/17/uitgangs-ldl-en-mortaliteitsreductie-na-ldl-verlaging-jama-meta-analyse/","title":"Uitgangs-LDL en mortaliteitsreductie na LDL-verlaging: JAMA meta-analyse","title_en":"Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.","published":"2018-04-17"}],"10.1016/j.jacc.2018.01.074":[{"url":"https://hartvaat.nl/2018/04/17/cardiovasculair-risico-en-relatief-voordeel-van-intensieve-hypertensiebehandelin/","title":"Cardiovasculair risico en relatief voordeel van intensieve hypertensiebehandeling","title_en":"Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension.","published":"2018-04-17"}],"10.1161/circulationaha.117.029882":[{"url":"https://hartvaat.nl/2018/04/17/nt-probnp-geleide-therapie-bij-acuut-gedecompenseerd-hartfalen-prima-ii/","title":"NT-proBNP-geleide therapie bij acuut gedecompenseerd hartfalen: PRIMA II","title_en":"NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).","published":"2018-04-17"}],"10.1093/eurheartj/ehx700":[{"url":"https://hartvaat.nl/2018/04/14/sildenafil-bij-persisterende-pulmonale-hypertensie-na-klepchirurgie/","title":"Sildenafil bij persisterende pulmonale hypertensie na klepchirurgie","title_en":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.","published":"2018-04-14"}],"10.1056/nejmoa1800866":[{"url":"https://hartvaat.nl/2018/04/12/heartmate-3-2-jaarsresultaten-bij-gevorderd-hartfalen-nejm-momentum-3/","title":"HeartMate 3 2-jaarsresultaten bij gevorderd hartfalen: NEJM MOMENTUM 3","title_en":"Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure.","published":"2018-04-12"}],"10.1016/j.jacc.2018.01.069":[{"url":"https://hartvaat.nl/2018/04/10/geen-verband-tussen-hartfalen-en-kankerincidentie/","title":"Geen verband tussen hartfalen en kankerincidentie","title_en":"Lack of Association Between Heart Failure and Incident Cancer.","published":"2018-04-10"}],"10.1161/circulationaha.117.030617":[{"url":"https://hartvaat.nl/2018/04/10/sedentaire-veroudering-omkeren-op-middelbare-leeftijd-gerandomiseerde-trial-voor/","title":"Sedentaire veroudering omkeren op middelbare leeftijd: gerandomiseerde trial voor HF-preventie","title_en":"Reversing the Cardiac Effects of Sedentary Aging in Middle Age-A Randomized Controlled Trial: Implications For Heart Failure Prevention.","published":"2018-04-10"}],"10.1161/circulationaha.117.030950":[{"url":"https://hartvaat.nl/2018/04/10/ezetimibe-bij-diabetes-versus-zonder-diabetes-improve-it-subanalyse/","title":"Ezetimibe bij diabetes versus zonder diabetes: IMPROVE-IT-subanalyse","title_en":"Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).","published":"2018-04-10"}],"10.1093/eurheartj/ehx566":[{"url":"https://hartvaat.nl/2018/04/07/statines-en-niet-statine-ldl-verlagers-en-cardiovasculaire-uitkomsten-meta-analy/","title":"Statines en niet-statine LDL-verlagers en cardiovasculaire uitkomsten: meta-analyse","title_en":"Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.","published":"2018-04-07"}],"10.1093/eurheartj/ehx549":[{"url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","title":"2017 ESC/EAS praktische gids voor PCSK9-remming","title_en":"2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.","published":"2018-04-07"}],"10.1056/nejmoa1717250":[{"url":"https://hartvaat.nl/2018/04/05/bloeddrukverlaging-bij-kappersbezoek-nejm-clustergerandomiseerde-trial/","title":"Bloeddrukverlaging bij kappersbezoek: NEJM clustergerandomiseerde trial","title_en":"A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops.","published":"2018-04-05"}],"10.1001/jama.2018.2444":[{"url":"https://hartvaat.nl/2018/04/03/oplaaddosis-atorvastatine-voor-pci-jama-gerandomiseerde-trial/","title":"Oplaaddosis atorvastatine vóór PCI: JAMA gerandomiseerde trial","title_en":"Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.","published":"2018-04-03"}],"10.1001/jamacardio.2018.0005":[{"url":"https://hartvaat.nl/2018/04/01/2017-acc-aha-richtlijn-voor-hoge-bloeddruk-bij-volwassenen-jama-cardiology-overz/","title":"2017 ACC/AHA-richtlijn voor hoge bloeddruk bij volwassenen: JAMA Cardiology overzicht","title_en":"The 2017 American College of Cardiology/American Heart Association Clinical Practice Guideline for High Blood Pressure in Adults.","published":"2018-04-01"}],"10.1093/eurheartj/ehy013":[{"url":"https://hartvaat.nl/2018/04/01/fibrinestoleigenschappen-en-klinische-uitkomsten-na-acs-plato-substudie/","title":"Fibrinestoleigenschappen en klinische uitkomsten na ACS: PLATO-substudie","title_en":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.","published":"2018-04-01"}],"10.1161/hypertensionaha.117.10662":[{"url":"https://hartvaat.nl/2018/04/01/spironolacton-versus-clonidine-als-vierde-middel-bij-resistente-hypertensie-reho/","title":"Spironolacton versus clonidine als vierde middel bij resistente hypertensie: ReHOT","title_en":"Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).","published":"2018-04-01"}],"10.1002/ehf2.12250":[{"url":"https://hartvaat.nl/2018/04/01/eenmalig-intraveneus-ijzer-bij-hartfalen-in-zuidoost-azie-practice-asia-hf-pilot/","title":"Eenmalig intraveneus ijzer bij hartfalen in Zuidoost-Azië: PRACTICE-ASIA-HF pilot","title_en":"Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).","published":"2018-04-01"}],"10.1002/ehf2.12249":[{"url":"https://hartvaat.nl/2018/04/01/valsartan-en-linkerkamerremodellering-na-mi/","title":"Valsartan en linkerkamerremodellering na MI","title_en":"The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling.","published":"2018-04-01"}],"10.1136/heartjnl-2017-312003":[{"url":"https://hartvaat.nl/2018/04/01/sekseverschillen-in-effectiviteit-van-orale-p2y12-remmers-meta-analyse/","title":"Sekseverschillen in effectiviteit van orale P2Y12-remmers: meta-analyse","title_en":"Differences in relative and absolute effectiveness of oral P2Y 12 inhibition in men and women: a meta-analysis and modelling study.","published":"2018-04-01"}],"10.1016/s0140-6736(18)30493-8":[{"url":"https://hartvaat.nl/2018/03/31/6-versus-12-maanden-dapt-na-pci-bij-acs-lancet-netwerkmeta-analyse/","title":"6 versus 12+ maanden DAPT na PCI bij ACS: Lancet netwerkmeta-analyse","title_en":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.","published":"2018-03-31"}],"10.1016/j.jacc.2018.01.042":[{"url":"https://hartvaat.nl/2018/03/27/crt-bij-hartfalen-met-smal-qrs-complex/","title":"CRT bij hartfalen met smal QRS-complex","title_en":"Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes.","published":"2018-03-27"}],"10.1161/circulationaha.117.031276":[{"url":"https://hartvaat.nl/2018/03/27/hdl-subspecies-met-apoliproteine-c-iii-en-coronairlijden-vier-cohorten/","title":"HDL-subspecies met apoliproteïne C-III en coronairlijden: vier cohorten","title_en":"High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts.","published":"2018-03-27"}],"10.1016/j.jacc.2018.01.027":[{"url":"https://hartvaat.nl/2018/03/20/effecten-van-ticagrelor-prasugrel-of-clopidogrel-op-endotheelfunctie/","title":"Effecten van ticagrelor, prasugrel of clopidogrel op endotheelfunctie","title_en":"Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function.","published":"2018-03-20"}],"10.1016/j.jacc.2018.01.033":[{"url":"https://hartvaat.nl/2018/03/20/bivalirudine-of-heparine-bij-invasief-acs-management/","title":"Bivalirudine of heparine bij invasief ACS-management","title_en":"Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes.","published":"2018-03-20"}],"10.1016/j.jacc.2017.12.060":[{"url":"https://hartvaat.nl/2018/03/13/digoxine-en-mortaliteit-bij-patienten-met-atriumfibrilleren/","title":"Digoxine en mortaliteit bij patiënten met atriumfibrilleren","title_en":"Digoxin and Mortality in Patients With Atrial Fibrillation.","published":"2018-03-13"}],"10.1161/circulationaha.117.030088":[{"url":"https://hartvaat.nl/2018/03/13/caloriearm-vegetarisch-versus-mediterraan-dieet-voor-gewicht-en-cv-profiel-cardi/","title":"Caloriearm vegetarisch versus mediterraan dieet voor gewicht en CV-profiel: CARDIVEG","title_en":"Low-Calorie Vegetarian Versus Mediterranean Diets for Reducing Body Weight and Improving Cardiovascular Risk Profile: CARDIVEG Study (Cardiovascular Prevention With Vegetarian Diet).","published":"2018-03-13"}],"10.1161/circulationaha.117.030501":[{"url":"https://hartvaat.nl/2018/03/13/leefstijlinterventies-en-mobilisatie-van-vetstapeling-central-mri-gerandomiseerd/","title":"Leefstijlinterventies en mobilisatie van vetstapeling: CENTRAL MRI gerandomiseerde trial","title_en":"Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial.","published":"2018-03-13"}],"10.1161/circulationaha.117.032130":[{"url":"https://hartvaat.nl/2018/03/13/bariatrische-chirurgie-bij-obese-patienten-met-hypertensie-gateway-gerandomiseer/","title":"Bariatrische chirurgie bij obese patiënten met hypertensie: GATEWAY gerandomiseerde trial","title_en":"Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension).","published":"2018-03-13"}],"10.1161/circulationaha.117.028513":[{"url":"https://hartvaat.nl/2018/03/13/doac-s-bij-af-met-ckd-systematische-review-werkzaamheid-en-veiligheid/","title":"DOAC's bij AF met CKD: systematische review werkzaamheid en veiligheid","title_en":"Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.","published":"2018-03-13"}],"10.1016/s0140-6736(18)30309-x":[{"url":"https://hartvaat.nl/2018/03/10/zelfgemeten-bloeddruk-met-of-zonder-telemonitoring-voor-medicatietitratie-lancet/","title":"Zelfgemeten bloeddruk met of zonder telemonitoring voor medicatietitratie: Lancet TASMINH4","title_en":"Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial.","published":"2018-03-10"}],"10.1016/s0140-6736(18)30423-9":[{"url":"https://hartvaat.nl/2018/03/10/cabg-versus-pci-met-stenting-bij-coronairlijden-lancet-10-jaarsfollow-up-systema/","title":"CABG versus PCI met stenting bij coronairlijden: Lancet 10-jaarsfollow-up systematische review","title_en":"Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.","published":"2018-03-10"}],"10.1161/circulationaha.117.028213":[{"url":"https://hartvaat.nl/2018/03/06/proteomics-voor-vroege-detectie-van-geneesmiddelveiligheid-lessen-van-hf-trials/","title":"Proteomics voor vroege detectie van geneesmiddelveiligheid: lessen van HF-trials","title_en":"Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.","published":"2018-03-06"}],"10.1001/jamacardio.2017.5306":[{"url":"https://hartvaat.nl/2018/03/01/doac-plus-antiplaatjestherapie-voor-secundaire-preventie-na-acs-meta-analyse/","title":"DOAC plus antiplaatjestherapie voor secundaire preventie na ACS: meta-analyse","title_en":"Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis.","published":"2018-03-01"}],"10.1001/jamacardio.2017.5205":[{"url":"https://hartvaat.nl/2018/03/01/omega-3-vetzuursupplementen-en-cv-risico-jama-cardiology-meta-analyse-van-10-tri/","title":"Omega-3 vetzuursupplementen en CV-risico: JAMA Cardiology meta-analyse van 10 trials","title_en":"Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.","published":"2018-03-01"}],"10.1001/jamacardio.2017.5250":[{"url":"https://hartvaat.nl/2018/03/01/poliklinische-verslechtering-van-hartfalen-als-therapiedoel-jama-cardiology-revi/","title":"Poliklinische verslechtering van hartfalen als therapiedoel: JAMA Cardiology review","title_en":"Outpatient Worsening Heart Failure as a Target for Therapy: A Review.","published":"2018-03-01"}],"10.1093/europace/eux094":[{"url":"https://hartvaat.nl/2018/03/01/doodsoorzaken-bij-crt-met-en-zonder-defibrillator-meta-analyse/","title":"Doodsoorzaken bij CRT met en zonder defibrillator: meta-analyse","title_en":"Cause-of-death analysis in patients with cardiac resynchronization therapy with or without a defibrillator: a systematic review and proportional meta-analysis.","published":"2018-03-01"}],"10.1136/heartjnl-2017-311986":[{"url":"https://hartvaat.nl/2018/03/01/voorspellers-van-succesvolle-cto-pci-systematische-review-en-meta-analyse/","title":"Voorspellers van succesvolle CTO-PCI: systematische review en meta-analyse","title_en":"Predictors of successful chronic total occlusion percutaneous coronary interventions: a systematic review and meta-analysis.","published":"2018-03-01"}],"10.1136/heartjnl-2017-311681":[{"url":"https://hartvaat.nl/2018/03/01/twee-geavanceerde-en-verlengde-hartrevalidatieprogramma-s-gerandomiseerde-trial/","title":"Twee geavanceerde en verlengde hartrevalidatieprogramma's: gerandomiseerde trial","title_en":"Randomised controlled trial of two advanced and extended cardiac rehabilitation programmes.","published":"2018-03-01"}],"10.1136/heartjnl-2017-311652":[{"url":"https://hartvaat.nl/2018/03/01/medicamenteuze-behandeling-en-uitkomsten-bij-hfpef-systematische-review-en-meta-/","title":"Medicamenteuze behandeling en uitkomsten bij HFpEF: systematische review en meta-analyse","title_en":"Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.","published":"2018-03-01"}],"10.1161/circulationaha.117.032479":[{"url":"https://hartvaat.nl/2018/02/20/genetica-leefstijl-en-ldl-cholesterol-bij-jonge-gezonde-vrouwen/","title":"Genetica, leefstijl en LDL-cholesterol bij jonge gezonde vrouwen","title_en":"Genetics, Lifestyle, and Low-Density Lipoprotein Cholesterol in Young and Apparently Healthy Women.","published":"2018-02-20"}],"10.1161/circulationaha.117.030526":[{"url":"https://hartvaat.nl/2018/02/20/sekseverschillen-bij-ischemisch-hartfalen-na-cabg-stich-trial/","title":"Sekseverschillen bij ischemisch hartfalen na CABG: STICH-trial","title_en":"Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure).","published":"2018-02-20"}],"10.1016/j.jacc.2017.12.010":[{"url":"https://hartvaat.nl/2018/02/20/morbiditeit-bij-pulmonaal-arteriele-hypertensie-als-prognostische-marker-voor-mo/","title":"Morbiditeit bij pulmonaal arteriële hypertensie als prognostische marker voor mortaliteit","title_en":"Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.","published":"2018-02-20"}],"10.1016/j.jacc.2017.12.012":[{"url":"https://hartvaat.nl/2018/02/20/nieuw-onset-af-na-pci-of-cabg-bij-hoofdstamziekte-excel-trial/","title":"Nieuw-onset AF na PCI of CABG bij hoofdstamziekte: EXCEL-trial","title_en":"New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial.","published":"2018-02-20"}],"10.1016/j.jacc.2017.12.011":[{"url":"https://hartvaat.nl/2018/02/20/cva-risico-bij-verminderde-ef-na-mi-zonder-af/","title":"CVA-risico bij verminderde EF na MI zonder AF","title_en":"Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation.","published":"2018-02-20"}],"10.1001/jama.2017.21906":[{"url":"https://hartvaat.nl/2018/02/13/kwaliteitsverbeteringsinterventie-bij-acuut-mi-in-india-jama-acs-quik/","title":"Kwaliteitsverbeteringsinterventie bij acuut MI in India: JAMA ACS QUIK","title_en":"Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial.","published":"2018-02-13"}],"10.1016/j.jacc.2017.11.068":[{"url":"https://hartvaat.nl/2018/02/13/richtlijngetrouwe-medicamenteuze-therapie-in-contemporaine-revascularisatietrial/","title":"Richtlijngetrouwe medicamenteuze therapie in contemporaine revascularisatietrials","title_en":"Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials.","published":"2018-02-13"}],"10.1093/eurheartj/ehx584":[{"url":"https://hartvaat.nl/2018/02/07/abc-doodsscore-bij-af-biomarkergebaseerde-risicoscore-voor-mortaliteit/","title":"ABC-doodsscore bij AF: biomarkergebaseerde risicoscore voor mortaliteit","title_en":"A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.","published":"2018-02-07"}],"10.1016/j.jacc.2017.11.050":[{"url":"https://hartvaat.nl/2018/02/06/ticagrelor-voor-secundaire-preventie-bij-multivaten-coronairlijden/","title":"Ticagrelor voor secundaire preventie bij multivaten coronairlijden","title_en":"Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.","published":"2018-02-06"}],"10.1016/s0140-6736(17)33103-3":[{"url":"https://hartvaat.nl/2018/02/03/sirolimus-eluting-bioabsorbeerbare-stent-versus-everolimus-eluting-stent-na-mi-l/","title":"Sirolimus-eluting bioabsorbeerbare stent versus everolimus-eluting stent na MI: Lancet","title_en":"A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.","published":"2018-02-03"}],"10.1056/nejmoa1707855":[{"url":"https://hartvaat.nl/2018/02/01/katheterablatie-bij-af-met-hartfalen-nejm-castle-af/","title":"Katheterablatie bij AF met hartfalen: NEJM CASTLE-AF","title_en":"Catheter Ablation for Atrial Fibrillation with Heart Failure.","published":"2018-02-01"}],"10.1001/jamacardio.2017.4228":[{"url":"https://hartvaat.nl/2018/02/01/cv-uitkomsten-naar-albumin-en-nierziekte-bij-diabetes-type-2-met-hoog-cv-risico/","title":"CV-uitkomsten naar albumin en nierziekte bij diabetes type 2 met hoog CV-risico","title_en":"Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.","published":"2018-02-01"}],"10.1001/jamacardio.2017.3833":[{"url":"https://hartvaat.nl/2018/02/01/lipoproteine-a-en-recidiverende-ischemische-events-na-acs-dal-outcomes-analyse/","title":"Lipoproteïne(a) en recidiverende ischemische events na ACS: dal-Outcomes-analyse","title_en":"Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.","published":"2018-02-01"}],"10.1093/eurheartj/ehx511":[{"url":"https://hartvaat.nl/2018/02/01/empagliflozine-en-cv-dood-en-hf-hospitalisatie-over-het-hf-spectrum-empa-reg-out/","title":"Empagliflozine en CV-dood en HF-hospitalisatie over het HF-spectrum: EMPA-REG OUTCOME","title_en":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.","published":"2018-02-01"}],"10.1093/eurheartj/ehx373":[{"url":"https://hartvaat.nl/2018/02/01/differentiele-effecten-van-pcsk9-varianten-op-coronairlijden-versus-ischemisch-c/","title":"Differentiële effecten van PCSK9-varianten op coronairlijden versus ischemisch CVA","title_en":"Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.","published":"2018-02-01"}],"10.1093/europace/eux022":[{"url":"https://hartvaat.nl/2018/02/01/dabigatran-versus-warfarine-bij-af-met-linkerventrikelhypertrofie-re-ly/","title":"Dabigatran versus warfarine bij AF met linkerventrikelhypertrofie: RE-LY","title_en":"Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.","published":"2018-02-01"}],"10.1002/ehf2.12241":[{"url":"https://hartvaat.nl/2018/02/01/autonome-regulatietherapie-bij-hfpef-anthem-hfpef/","title":"Autonome regulatietherapie bij HFpEF: ANTHEM-HFpEF","title_en":"Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study.","published":"2018-02-01"}],"10.1161/hypertensionaha.117.10295":[{"url":"https://hartvaat.nl/2018/02/01/nauwkeurigheid-van-bloeddrukmeters-in-de-zwangerschap-systematische-review/","title":"Nauwkeurigheid van bloeddrukmeters in de zwangerschap: systematische review","title_en":"Accuracy of Blood Pressure Measurement Devices in Pregnancy: A Systematic Review of Validation Studies.","published":"2018-02-01"}],"10.1002/ehf2.12227":[{"url":"https://hartvaat.nl/2018/02/01/hoeveelheid-of-intensiteit-van-inspanning-bij-hfpef/","title":"Hoeveelheid of intensiteit van inspanning bij HFpEF","title_en":"Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction.","published":"2018-02-01"}],"10.1002/ehf2.12206":[{"url":"https://hartvaat.nl/2018/02/01/bnp-prognostische-waarde-bij-hartfalen-met-lvef-35/","title":"BNP-prognostische waarde bij hartfalen met LVEF >35%","title_en":"The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub-analysis of the J-MELODIC study.","published":"2018-02-01"}],"10.1136/heartjnl-2017-311508":[{"url":"https://hartvaat.nl/2018/02/01/ct-coronairangiografie-volgens-2016-nice-richtlijn-diagnostisch-en-prognostisch-/","title":"CT-coronairangiografie volgens 2016 NICE-richtlijn: diagnostisch en prognostisch voordeel","title_en":"Diagnostic and prognostic benefits of computed tomography coronary angiography using the 2016 National Institute for Health and Care Excellence guidance within a randomised trial.","published":"2018-02-01"}],"10.1002/ehf2.12197":[{"url":"https://hartvaat.nl/2018/02/01/herstel-zonder-hartfalen-na-acs-en-revascularisatie/","title":"Herstel zonder hartfalen na ACS en revascularisatie","title_en":"Recovery free of heart failure after acute coronary syndrome and coronary revascularization.","published":"2018-02-01"}],"10.1016/j.jacc.2017.11.008":[{"url":"https://hartvaat.nl/2018/01/30/prasugrel-versus-ticagrelor-bij-primaire-pci-voor-mi-1-jaarsuitkomsten/","title":"Prasugrel versus ticagrelor bij primaire PCI voor MI: 1-jaarsuitkomsten","title_en":"1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.","published":"2018-01-30"}],"10.1161/circulationaha.117.031907":[{"url":"https://hartvaat.nl/2018/01/30/kosteneffectiviteit-van-ffr-geleide-pci-bij-stabiele-coronairlijden/","title":"Kosteneffectiviteit van FFR-geleide PCI bij stabiele coronairlijden","title_en":"Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation).","published":"2018-01-30"}],"10.1161/circulationaha.117.031843":[{"url":"https://hartvaat.nl/2018/01/30/absorb-bioresorbeerbare-scaffold-3-jaarsresultaten-ipd-meta-analyse/","title":"Absorb bioresorbeerbare scaffold 3-jaarsresultaten: IPD meta-analyse","title_en":"Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.","published":"2018-01-30"}],"10.1161/circulationaha.117.032094":[{"url":"https://hartvaat.nl/2018/01/23/transcatheter-interatriale-shunt-bij-hfpef-reduce-lap-hf-i/","title":"Transcatheter interatriale shunt bij HFpEF: REDUCE LAP-HF I","title_en":"Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial.","published":"2018-01-23"}],"10.1161/circulationaha.117.032235":[{"url":"https://hartvaat.nl/2018/01/23/ldl-verlaging-met-evolocumab-en-uitkomsten-bij-pav-fourier-inzichten/","title":"LDL-verlaging met evolocumab en uitkomsten bij PAV: FOURIER-inzichten","title_en":"Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).","published":"2018-01-23"}],"10.1161/circulationaha.117.032038":[{"url":"https://hartvaat.nl/2018/01/23/canagliflozine-voor-primaire-en-secundaire-cardiovasculaire-preventie-canvas/","title":"Canagliflozine voor primaire en secundaire cardiovasculaire preventie: CANVAS","title_en":"Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).","published":"2018-01-23"}],"10.1161/circulationaha.117.032031":[{"url":"https://hartvaat.nl/2018/01/23/empagliflozine-bij-diabetes-type-2-met-perifeer-vaatlijden-empa-reg-outcome/","title":"Empagliflozine bij diabetes type 2 met perifeer vaatlijden: EMPA-REG OUTCOME","title_en":"Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.","published":"2018-01-23"}],"10.1016/s0140-6736(17)32409-1":[{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-perifeer-vaatlijden-lancet-compas/","title":"Rivaroxaban met of zonder aspirine bij stabiel perifeer vaatlijden: Lancet COMPASS PAD","title_en":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.","published":"2018-01-20"}],"10.1016/s0140-6736(17)32458-3":[{"url":"https://hartvaat.nl/2018/01/20/rivaroxaban-met-of-zonder-aspirine-bij-stabiel-coronairlijden-lancet-compass/","title":"Rivaroxaban met of zonder aspirine bij stabiel coronairlijden: Lancet COMPASS","title_en":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.","published":"2018-01-20"}],"10.1001/jama.2017.20313":[{"url":"https://hartvaat.nl/2018/01/16/laparoscopische-sleeve-gastrectomie-versus-gastric-bypass-bij-obesitas-jama-5-ja/","title":"Laparoscopische sleeve gastrectomie versus gastric bypass bij obesitas: JAMA 5-jaarsresultaten","title_en":"Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial.","published":"2018-01-16"}],"10.1161/circulationaha.117.031560":[{"url":"https://hartvaat.nl/2018/01/16/hoog-sensitief-troponine-t-bij-chronisch-hartfalen-individuele-patientdata-meta-/","title":"Hoog-sensitief troponine T bij chronisch hartfalen: individuele patiëntdata meta-analyse","title_en":"Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis.","published":"2018-01-16"}],"10.1161/circulationaha.117.031678":[{"url":"https://hartvaat.nl/2018/01/16/intraveneus-fentanyl-en-ticagrelorabsorptie-bij-pci/","title":"Intraveneus fentanyl en ticagrelorabsorptie bij PCI","title_en":"Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl).","published":"2018-01-16"}],"10.1161/circulationaha.117.030656":[{"url":"https://hartvaat.nl/2018/01/09/risico-s-van-overinterpretatie-van-interimdata-lessen-uit-de-total-trial/","title":"Risico's van overinterpretatie van interimdata: lessen uit de TOTAL-trial","title_en":"Risks of Overinterpreting Interim Data: Lessons From the TOTAL Trial (Thrombectomy With PCI Versus PCI Alone in Patients With STEMI).","published":"2018-01-09"}],"10.1161/circulationaha.117.030848":[{"url":"https://hartvaat.nl/2018/01/09/diastolische-bloeddruk-en-intensieve-bloeddrukcontrole-sprint-analyse/","title":"Diastolische bloeddruk en intensieve bloeddrukcontrole: SPRINT-analyse","title_en":"Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control.","published":"2018-01-09"}],"10.1161/circulationaha.117.028268":[{"url":"https://hartvaat.nl/2018/01/09/empagliflozine-bij-diabetes-type-2-met-cardiovasculaire-ziekte-en-ckd-empa-reg-o/","title":"Empagliflozine bij diabetes type 2 met cardiovasculaire ziekte en CKD: EMPA-REG OUTCOME","title_en":"Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.","published":"2018-01-09"}],"10.1093/eurheartj/ehx393":[{"url":"https://hartvaat.nl/2018/01/07/2017-esc-richtlijn-voor-stemi-management/","title":"2017 ESC-richtlijn voor STEMI-management","title_en":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).","published":"2018-01-07"}],"10.1016/s0140-6736(17)32714-9":[{"url":"https://hartvaat.nl/2018/01/06/pci-bij-stabiele-angina-lancet-orbita-dubbelblinde-gerandomiseerde-trial/","title":"PCI bij stabiele angina: Lancet ORBITA dubbelblinde gerandomiseerde trial","title_en":"Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.","published":"2018-01-06"}],"10.1016/s0140-6736(17)32713-7":[{"url":"https://hartvaat.nl/2018/01/06/drug-eluting-stents-bij-oudere-patienten-met-coronairlijden-lancet-senior-trial/","title":"Drug-eluting stents bij oudere patiënten met coronairlijden: Lancet SENIOR-trial","title_en":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.","published":"2018-01-06"}],"10.1001/jamacardio.2017.4293":[{"url":"https://hartvaat.nl/2018/01/01/genetische-associatie-van-lipiden-en-lipide-doelwitten-met-abdominaal-aorta-aneu/","title":"Genetische associatie van lipiden en lipide-doelwitten met abdominaal aorta-aneurysma","title_en":"Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.","published":"2018-01-01"}],"10.1093/eurheartj/ehx564":[{"url":"https://hartvaat.nl/2018/01/01/betablokkers-bij-hfref-hfmref-en-hfpef-individuele-patientanalyse/","title":"Bètablokkers bij HFrEF, HFmrEF en HFpEF: individuele patiëntanalyse","title_en":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.","published":"2018-01-01"}],"10.1093/europace/eux275":[{"url":"https://hartvaat.nl/2018/01/01/2017-af-ablatieconsensus-samenvatting/","title":"2017 AF-ablatieconsensus: samenvatting","title_en":"2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary.","published":"2018-01-01"}],"10.1093/europace/eux274":[{"url":"https://hartvaat.nl/2018/01/01/2017-hrs-ehra-ecas-aphrs-solaece-expertconsensus-katheter-en-chirurgische-af-abl/","title":"2017 HRS/EHRA/ECAS/APHRS/SOLAECE expertconsensus: katheter- en chirurgische AF-ablatie","title_en":"2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.","published":"2018-01-01"}],"10.1093/europace/eux013":[{"url":"https://hartvaat.nl/2018/01/01/linkeratriumvolume-voorspelt-af-recidief-na-radiofrequentieablatie-meta-analyse/","title":"Linkeratriumvolume voorspelt AF-recidief na radiofrequentieablatie: meta-analyse","title_en":"Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a meta-analysis.","published":"2018-01-01"}],"10.1093/europace/euw381":[{"url":"https://hartvaat.nl/2018/01/01/endocardiale-linkerkamer-pacing-voor-crt-systematische-review-en-meta-analyse/","title":"Endocardiale linkerkamer pacing voor CRT: systematische review en meta-analyse","title_en":"Endocardial left ventricular pacing for cardiac resynchronization: systematic review and meta-analysis.","published":"2018-01-01"}],"10.1093/europace/euw329":[{"url":"https://hartvaat.nl/2018/01/01/supraventriculaire-ectopie-na-af-ablatie-voorspelt-recidief/","title":"Supraventriculaire ectopie na AF-ablatie voorspelt recidief","title_en":"Higher burden of supraventricular ectopic complexes early after catheter ablation for atrial fibrillation is associated with increased risk of recurrent atrial fibrillation.","published":"2018-01-01"}],"10.1093/europace/euw307":[{"url":"https://hartvaat.nl/2018/01/01/energiebron-en-vroeg-af-recidief-cryoballon-versus-radiofrequentie/","title":"Energiebron en vroeg AF-recidief: cryoballon versus radiofrequentie","title_en":"Influence of energy source on early atrial fibrillation recurrences: a comparison of cryoballoon vs. radiofrequency current energy ablation with the endpoint of unexcitability in pulmonary vein isolation.","published":"2018-01-01"}],"10.1161/hypertensionaha.117.09294":[{"url":"https://hartvaat.nl/2018/01/01/bijniervenesampling-als-voorkeursmethode-bij-primair-hyperaldosteronisme/","title":"Bijniervenesampling als voorkeursmethode bij primair hyperaldosteronisme","title_en":"Adrenal Vein Sampling Is the Preferred Method to Select Patients With Primary Aldosteronism for Adrenalectomy: Con Side of the Argument.","published":"2018-01-01"}],"10.1161/hypertensionaha.117.10224":[{"url":"https://hartvaat.nl/2018/01/01/sacubitril-valsartan-en-inspanningsgemedieerd-lipidenmetabolisme-bij-obesitas-me/","title":"Sacubitril/valsartan en inspanningsgemedieerd lipidenmetabolisme bij obesitas met hypertensie","title_en":"Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.","published":"2018-01-01"}],"10.1016/j.jacc.2017.10.036":[{"url":"https://hartvaat.nl/2017/12/26/kwaliteit-van-leven-na-ees-of-cabg-bij-hoofdstamlijden-excel-qol/","title":"Kwaliteit van leven na EES of CABG bij hoofdstamlijden: EXCEL QoL","title_en":"Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease: Results From the EXCEL Trial.","published":"2017-12-26"}],"10.1056/nejmoa1710261":[{"url":"https://hartvaat.nl/2017/12/21/pci-strategieen-bij-acuut-mi-met-cardiogene-shock-nejm-culprit-shock/","title":"PCI-strategieën bij acuut MI met cardiogene shock: NEJM CULPRIT-SHOCK","title_en":"PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock.","published":"2017-12-21"}],"10.1093/eurheartj/ehx467":[{"url":"https://hartvaat.nl/2017/12/21/lilrb5-variant-geassocieerd-met-statine-intolerantie-en-myalgie/","title":"LILRB5-variant geassocieerd met statine-intolerantie en myalgie","title_en":"A common missense variant of LILRB5 is associated with statin intolerance and myalgia.","published":"2017-12-21"}],"10.1016/j.jacc.2017.10.029":[{"url":"https://hartvaat.nl/2017/12/19/chirurgische-versus-percutane-revascularisatie-bij-diabetes-met-acs/","title":"Chirurgische versus percutane revascularisatie bij diabetes met ACS","title_en":"Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes.","published":"2017-12-19"}],"10.1016/j.jacc.2017.10.021":[{"url":"https://hartvaat.nl/2017/12/19/5-jaarsuitkomsten-na-linker-hartoorsluiting-prevail-en-protect-af/","title":"5-jaarsuitkomsten na linker-hartoorsluiting: PREVAIL en PROTECT AF","title_en":"5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.","published":"2017-12-19"}],"10.1161/circulationaha.117.029095":[{"url":"https://hartvaat.nl/2017/12/19/cva-preventie-met-ezetimibe-bij-acs-improve-it-analyse/","title":"CVA-preventie met ezetimibe bij ACS: IMPROVE-IT-analyse","title_en":"Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).","published":"2017-12-19"}],"10.1093/eurheartj/ehx363":[{"url":"https://hartvaat.nl/2017/12/14/mechanische-ondersteuning-bij-cardiogene-shock-systematische-review-en-meta-anal/","title":"Mechanische ondersteuning bij cardiogene shock: systematische review en meta-analyse","title_en":"Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials.","published":"2017-12-14"}],"10.1016/j.jacc.2017.10.011":[{"url":"https://hartvaat.nl/2017/12/12/natriumreductie-en-dash-dieet-naar-uitgangs-bloeddruk/","title":"Natriumreductie en DASH-dieet naar uitgangs bloeddruk","title_en":"Effects of Sodium Reduction and the DASH Diet in Relation to Baseline Blood Pressure.","published":"2017-12-12"}],"10.1016/j.jacc.2017.09.1106":[{"url":"https://hartvaat.nl/2017/12/12/implantatiechniek-en-uitkomsten-van-bioresorbeerbare-scaffolds-absorb-analyses/","title":"Implantatiechniek en uitkomsten van bioresorbeerbare scaffolds: ABSORB-analyses","title_en":"Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials.","published":"2017-12-12"}],"10.1016/j.jacc.2017.10.010":[{"url":"https://hartvaat.nl/2017/12/12/3-jaarsresultaten-van-bioresorbeerbare-scaffolds-absorb-iii-trial/","title":"3-jaarsresultaten van bioresorbeerbare scaffolds: ABSORB III-trial","title_en":"3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.","published":"2017-12-12"}],"10.1016/j.jacc.2017.09.1111":[{"url":"https://hartvaat.nl/2017/12/05/abdominale-obesitas-en-totale-mortaliteit-bij-hfpef/","title":"Abdominale obesitas en totale mortaliteit bij HFpEF","title_en":"Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF.","published":"2017-12-05"}],"10.1161/circulationaha.117.030342":[{"url":"https://hartvaat.nl/2017/12/05/j-curve-bij-gerandomiseerde-bloeddrukstreefwaarden-sprint-experimentele-analyse/","title":"J-curve bij gerandomiseerde bloeddrukstreefwaarden: SPRINT experimentele analyse","title_en":"J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets: An Experimental Approach to an Observational Paradigm.","published":"2017-12-05"}],"10.1001/jamacardio.2017.3944":[{"url":"https://hartvaat.nl/2017/12/01/evolocumab-bij-hoogrisicopatienten-met-laag-ldl-op-statine-fourier-subanalyse/","title":"Evolocumab bij hoogrisicopatiënten met laag LDL op statine: FOURIER-subanalyse","title_en":"Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.","published":"2017-12-01"}],"10.1001/jamacardio.2017.3868":[{"url":"https://hartvaat.nl/2017/12/01/kauwen-versus-slikken-van-ticagrelor-en-plaatjesremming-bij-stemi/","title":"Kauwen versus slikken van ticagrelor en plaatjesremming bij STEMI","title_en":"Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial.","published":"2017-12-01"}],"10.1093/europace/euw364":[{"url":"https://hartvaat.nl/2017/12/01/enkelvoudige-versus-tweekamer-pacing-bij-sick-sinus-syndroom-danpace-langetermij/","title":"Enkelvoudige versus tweekamer pacing bij sick sinus syndroom: DANPACE langetermijnfollow-up","title_en":"Single lead atrial vs. dual chamber pacing in sick sinus syndrome: extended register-based follow-up in the DANPACE trial.","published":"2017-12-01"}],"10.1161/hypertensionaha.117.09950":[{"url":"https://hartvaat.nl/2017/12/01/voorkeur-voor-pikant-eten-versterkt-zoutwaarneming-en-vermindert-zoutinname-en-b/","title":"Voorkeur voor pikant eten versterkt zoutwaarneming en vermindert zoutinname en bloeddruk","title_en":"Enjoyment of Spicy Flavor Enhances Central Salty-Taste Perception and Reduces Salt Intake and Blood Pressure.","published":"2017-12-01"}],"10.1161/hypertensionaha.117.10150":[{"url":"https://hartvaat.nl/2017/12/01/placental-growth-factor-als-prognostisch-instrument-bij-hypertensieve-zwangersch/","title":"Placental growth factor als prognostisch instrument bij hypertensieve zwangerschapscomplicaties","title_en":"Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review.","published":"2017-12-01"}],"10.1161/hypertensionaha.117.10142":[{"url":"https://hartvaat.nl/2017/12/01/centrale-iliacale-av-anastomose-bij-ongecontroleerde-hypertensie-rox-control-htn/","title":"Centrale iliacale AV-anastomose bij ongecontroleerde hypertensie: ROX CONTROL HTN 1-jaarsresultaten","title_en":"Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial.","published":"2017-12-01"}],"10.1136/heartjnl-2017-311233":[{"url":"https://hartvaat.nl/2017/12/01/revascularisatie-versus-medicamenteus-beleid-bij-nste-acs-bij-ouderen-meta-analy/","title":"Revascularisatie versus medicamenteus beleid bij NSTE-ACS bij ouderen: meta-analyse","title_en":"Revascularisation compared with initial medical therapy for non-ST-elevation acute coronary syndromes in the elderly: a meta-analysis.","published":"2017-12-01"}],"10.1136/heartjnl-2016-310952":[{"url":"https://hartvaat.nl/2017/12/01/geintegreerde-zorg-bij-atriumfibrilleren-systematische-review-en-meta-analyse/","title":"Geïntegreerde zorg bij atriumfibrilleren: systematische review en meta-analyse","title_en":"Integrated care in atrial fibrillation: a systematic review and meta-analysis.","published":"2017-12-01"}],"10.1056/nejmoa1711818":[{"url":"https://hartvaat.nl/2017/11/30/restrictieve-versus-liberale-bloedtransfusie-bij-hartchirurgie-nejm-trics-iii/","title":"Restrictieve versus liberale bloedtransfusie bij hartchirurgie: NEJM TRICS III","title_en":"Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery.","published":"2017-11-30"}],"10.1161/circulationaha.117.029994":[{"url":"https://hartvaat.nl/2017/11/28/ct-coronairangiografie-en-initiatie-van-cardioprotectieve-medicatie/","title":"CT-coronairangiografie en initiatie van cardioprotectieve medicatie","title_en":"Impact of Coronary Computed Tomography Angiography Findings on Initiation of Cardioprotective Medications.","published":"2017-11-28"}],"10.1016/j.jacc.2017.09.1088":[{"url":"https://hartvaat.nl/2017/11/28/xenon-inhalatie-vermindert-myocardschade-bij-overlevenden-van-hartstilstand-xe-h/","title":"Xenon-inhalatie vermindert myocardschade bij overlevenden van hartstilstand: Xe-Hypotheca","title_en":"Inhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The Xe-Hypotheca Trial.","published":"2017-11-28"}],"10.1016/j.jacc.2017.09.1066":[{"url":"https://hartvaat.nl/2017/11/28/double-kissing-crush-versus-provisional-stenting-bij-hoofdstambifurcatie-dkcrush/","title":"Double kissing crush versus provisional stenting bij hoofdstambifurcatie: DKCRUSH-V","title_en":"Double Kissing Crush Versus Provisional Stenting for Left Main Distal Bifurcation Lesions: DKCRUSH-V Randomized Trial.","published":"2017-11-28"}],"10.1161/circulationaha.117.028753":[{"url":"https://hartvaat.nl/2017/11/28/schildklierfunctie-en-risico-op-af-subclinische-hypothyreoidie/","title":"Schildklierfunctie en risico op AF: subclinische hypothyreoïdie","title_en":"Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation.","published":"2017-11-28"}],"10.1001/jama.2017.17488":[{"url":"https://hartvaat.nl/2017/11/21/hoog-sensitief-troponine-i-en-uitkomsten-bij-verdenking-acs-jama-studie/","title":"Hoog-sensitief troponine I en uitkomsten bij verdenking ACS: JAMA-studie","title_en":"Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome.","published":"2017-11-21"}],"10.1093/eurheartj/ehx525":[{"url":"https://hartvaat.nl/2017/11/21/sacubitril-valsartan-versus-olmesartan-en-cardiovasculaire-remodellering-bij-hyp/","title":"Sacubitril/valsartan versus olmesartan en cardiovasculaire remodellering bij hypertensie: PARAMETER-2","title_en":"The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.","published":"2017-11-21"}],"10.1093/eurheartj/ehx508":[{"url":"https://hartvaat.nl/2017/11/21/bloeddrukeffecten-van-ibuprofen-naproxen-en-celecoxib-bij-artritis-precision-abp/","title":"Bloeddrukeffecten van ibuprofen, naproxen en celecoxib bij artritis: PRECISION-ABPM","title_en":"Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.","published":"2017-11-21"}],"10.1161/circulationaha.117.030578":[{"url":"https://hartvaat.nl/2017/11/21/coronair-calcium-en-prognostische-waarde-bij-pijn-op-de-borst-promise-studie/","title":"Coronair calcium en prognostische waarde bij pijn op de borst: PROMISE-studie","title_en":"Prognostic Value of Coronary Artery Calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain).","published":"2017-11-21"}],"10.1016/j.jacc.2017.09.027":[{"url":"https://hartvaat.nl/2017/11/14/af-type-en-uitkomsten-bij-hfref/","title":"AF-type en uitkomsten bij HFrEF","title_en":"Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.","published":"2017-11-14"}],"10.1161/circulationaha.117.029779":[{"url":"https://hartvaat.nl/2017/11/14/timing-van-angiografie-bij-hoogrisico-nstemi-acuity-analyse/","title":"Timing van angiografie bij hoogrisico-NSTEMI: ACUITY-analyse","title_en":"Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban).","published":"2017-11-14"}],"10.1161/circulationaha.117.027966":[{"url":"https://hartvaat.nl/2017/11/14/ldl-verlaging-voor-primaire-preventie-bij-mannen-met-primaire-ldl-verhoging/","title":"LDL-verlaging voor primaire preventie bij mannen met primaire LDL-verhoging","title_en":"Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.","published":"2017-11-14"}],"10.1016/s0140-6736(17)32281-x":[{"url":"https://hartvaat.nl/2017/11/11/renale-denervatie-zonder-antihypertensiva-lancet-spyral-htn-off-med/","title":"Renale denervatie zonder antihypertensiva: Lancet SPYRAL HTN-OFF MED","title_en":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.","published":"2017-11-11"}],"10.1093/eurheartj/ehx351":[{"url":"https://hartvaat.nl/2017/11/07/optische-frequentiedomeinbeeldvorming-versus-ivus-bij-pci-opinion-trial/","title":"Optische frequentiedomeinbeeldvorming versus IVUS bij PCI: OPINION-trial","title_en":"Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results.","published":"2017-11-07"}],"10.1093/eurheartj/ehx437":[{"url":"https://hartvaat.nl/2017/11/07/stentontwerp-en-dapt-duur-effect-op-ischemie-en-bloedingen-netwerkmeta-analyse/","title":"Stentontwerp en DAPT-duur: effect op ischemie en bloedingen — netwerkmeta-analyse","title_en":"Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients.","published":"2017-11-07"}],"10.1161/circulationaha.117.028829":[{"url":"https://hartvaat.nl/2017/11/07/leeftijd-en-uitkomsten-van-primaire-preventie-icd-bij-niet-ischemisch-hartfalen-/","title":"Leeftijd en uitkomsten van primaire preventie-ICD bij niet-ischemisch hartfalen: DANISH","title_en":"Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.","published":"2017-11-07"}],"10.1161/circulationaha.117.030583":[{"url":"https://hartvaat.nl/2017/11/07/alivecor-kardia-voor-af-screening-de-rehearse-af-studie/","title":"AliveCor Kardia voor AF-screening: de REHEARSE-AF-studie","title_en":"Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study.","published":"2017-11-07"}],"10.1093/eurheartj/ehx418":[{"url":"https://hartvaat.nl/2017/11/01/totale-occlusie-van-de-culprit-arterie-bij-nstemi-meta-analyse/","title":"Totale occlusie van de culprit arterie bij NSTEMI: meta-analyse","title_en":"Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis.","published":"2017-11-01"}],"10.1093/eurheartj/ehx175":[{"url":"https://hartvaat.nl/2017/11/01/switchen-van-dapt-na-acs-de-topic-trial/","title":"Switchen van DAPT na ACS: de TOPIC-trial","title_en":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.","published":"2017-11-01"}],"10.1093/europace/euw306":[{"url":"https://hartvaat.nl/2017/11/01/defibrillatie-drempelwaarden-bij-rechtspectorale-icd-en-golfvorm-tuning/","title":"Defibrillatie-drempelwaarden bij rechtspectorale ICD en golfvorm-tuning","title_en":"Defibrillation thresholds with right pectoral implantable cardioverter defibrillators and impact of waveform tuning (the Tilt and Tune trial).","published":"2017-11-01"}],"10.1161/hypertensionaha.117.10017":[{"url":"https://hartvaat.nl/2017/11/01/tijdsverloop-van-bloeddrukverandering-door-zoutreductie-en-dash-dieet/","title":"Tijdsverloop van bloeddrukverandering door zoutreductie en DASH-dieet","title_en":"Time Course of Change in Blood Pressure From Sodium Reduction and the DASH Diet.","published":"2017-11-01"}],"10.1002/ehf2.12226":[{"url":"https://hartvaat.nl/2017/11/01/iv-lisdiuretica-bij-acuut-hartfalen-diur-ahf-studieontwerp/","title":"IV lisdiuretica bij acuut hartfalen: DIUR-AHF studieontwerp","title_en":"Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR-AHF.","published":"2017-11-01"}],"10.1161/hypertensionaha.117.10003":[{"url":"https://hartvaat.nl/2017/11/01/zoutbuffering-in-de-huid-bij-mensen-een-nieuw-mechanisme/","title":"Zoutbuffering in de huid bij mensen: een nieuw mechanisme","title_en":"Novel Mechanism for Buffering Dietary Salt in Humans: Effects of Salt Loading on Skin Sodium, Vascular Endothelial Growth Factor C, and Blood Pressure.","published":"2017-11-01"}],"10.1161/hypertensionaha.117.10106":[{"url":"https://hartvaat.nl/2017/11/01/bloeddrukvariabiliteit-en-uitkomsten-bij-af-affirm-studie/","title":"Bloeddrukvariabiliteit en uitkomsten bij AF: AFFIRM-studie","title_en":"Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation: The AFFIRM Study (Atrial Fibrillation Follow-Up Investigation of Rhythm Management).","published":"2017-11-01"}],"10.1161/hypertensionaha.117.09714":[{"url":"https://hartvaat.nl/2017/11/01/gemiddelde-bloeddruk-en-visit-to-visit-variabiliteit-als-gecombineerde-voorspell/","title":"Gemiddelde bloeddruk en visit-to-visit variabiliteit als gecombineerde voorspellers: ONTARGET/TRANSCEND","title_en":"Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.","published":"2017-11-01"}],"10.1002/ehf2.12157":[{"url":"https://hartvaat.nl/2017/11/01/klinische-presentatie-bij-eerste-hartfalenhospitalisatie-voorspelt-geen-heropnam/","title":"Klinische presentatie bij eerste hartfalenhospitalisatie voorspelt geen heropname","title_en":"Clinical presentation at first heart failure hospitalization does not predict recurrent heart failure admission.","published":"2017-11-01"}],"10.1161/hypertensionaha.117.09972":[{"url":"https://hartvaat.nl/2017/11/01/labetalol-versus-nifedipine-bij-chronische-hypertensie-in-de-zwangerschap-gerand/","title":"Labetalol versus nifedipine bij chronische hypertensie in de zwangerschap: gerandomiseerde trial","title_en":"Labetalol Versus Nifedipine as Antihypertensive Treatment for Chronic Hypertension in Pregnancy: A Randomized Controlled Trial.","published":"2017-11-01"}],"10.1161/hypertensionaha.117.09690":[{"url":"https://hartvaat.nl/2017/11/01/sildenafil-tijdens-de-zwangerschap-preklinische-meta-analyse-over-foetale-groei-/","title":"Sildenafil tijdens de zwangerschap: preklinische meta-analyse over foetale groei en bloeddruk","title_en":"Sildenafil During Pregnancy: A Preclinical Meta-Analysis on Fetal Growth and Maternal Blood Pressure.","published":"2017-11-01"}],"10.1002/ehf2.12204":[{"url":"https://hartvaat.nl/2017/11/01/raas-blokkade-bij-hfpef-systematische-review-en-meta-analyse/","title":"RAAS-blokkade bij HFpEF: systematische review en meta-analyse","title_en":"Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.","published":"2017-11-01"}],"10.1161/hypertensionaha.117.09482":[{"url":"https://hartvaat.nl/2017/11/01/hypertensiecontrole-bij-diabetes-met-recidiverende-cv-events-tecos-globale-resul/","title":"Hypertensiecontrole bij diabetes met recidiverende CV-events: TECOS globale resultaten","title_en":"Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin.","published":"2017-11-01"}],"10.1002/ehf2.12177":[{"url":"https://hartvaat.nl/2017/11/01/rehospitalisatie-na-intermitterend-levosimendan-bij-gevorderd-hartfalen-meta-ana/","title":"Rehospitalisatie na intermitterend levosimendan bij gevorderd hartfalen: meta-analyse","title_en":"Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials.","published":"2017-11-01"}],"10.1016/j.jacc.2017.09.011":[{"url":"https://hartvaat.nl/2017/10/31/laesiecomplexiteit-en-uitkomsten-van-verlengde-dapt-na-pci/","title":"Laesiecomplexiteit en uitkomsten van verlengde DAPT na PCI","title_en":"Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.","published":"2017-10-31"}],"10.1016/s0140-6736(17)32290-0":[{"url":"https://hartvaat.nl/2017/10/28/zeer-lage-ldl-concentraties-met-evolocumab-lancet-fourier-subanalyse/","title":"Zeer lage LDL-concentraties met evolocumab: Lancet FOURIER-subanalyse","title_en":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.","published":"2017-10-28"}],"10.1016/s0140-6736(17)32247-x":[{"url":"https://hartvaat.nl/2017/10/21/canakinumab-en-longkankerincidentie-bij-atherosclerose-lancet-cantos-exploratief/","title":"Canakinumab en longkankerincidentie bij atherosclerose: Lancet CANTOS exploratief","title_en":"Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.","published":"2017-10-21"}],"10.1016/s0140-6736(17)32249-3":[{"url":"https://hartvaat.nl/2017/10/21/ultradunne-bioresorbeerbare-versus-dunne-duurzame-polymer-stents-lancet-bioscien/","title":"Ultradunne bioresorbeerbare versus dunne duurzame polymer stents: Lancet BIOSCIENCE","title_en":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.","published":"2017-10-21"}],"10.1056/nejmoa1708454":[{"url":"https://hartvaat.nl/2017/10/19/dubbele-antitrombotische-therapie-met-dabigatran-na-pci-bij-af-nejm-re-dual-pci/","title":"Dubbele antitrombotische therapie met dabigatran na PCI bij AF: NEJM RE-DUAL PCI","title_en":"Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.","published":"2017-10-19"}],"10.1016/j.jacc.2017.08.031":[{"url":"https://hartvaat.nl/2017/10/17/laaggedoseerd-ticagrelor-versus-clopidogrel-na-eerder-mi/","title":"Laaggedoseerd ticagrelor versus clopidogrel na eerder MI","title_en":"Low-Dose Ticagrelor Versus Clopidogrel in Patients With Prior Myocardial Infarction.","published":"2017-10-17"}],"10.1016/j.jacc.2017.08.041":[{"url":"https://hartvaat.nl/2017/10/17/katheterablatie-versus-frequentiecontrole-bij-af-met-systolische-disfunctie-came/","title":"Katheterablatie versus frequentiecontrole bij AF met systolische disfunctie: CAMERA-MRI","title_en":"Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study.","published":"2017-10-17"}],"10.1161/circulationaha.117.030582":[{"url":"https://hartvaat.nl/2017/10/17/farmaco-invasieve-strategie-met-halve-dosis-alteplase-versus-primaire-pci-bij-st/","title":"Farmaco-invasieve strategie met halve dosis alteplase versus primaire PCI bij STEMI","title_en":"Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).","published":"2017-10-17"}],"10.1093/eurheartj/ehx342":[{"url":"https://hartvaat.nl/2017/10/14/tmao-als-cardiovasculaire-risicobiomarker-systematische-review-en-meta-analyse/","title":"TMAO als cardiovasculaire risicobiomarker: systematische review en meta-analyse","title_en":"Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis.","published":"2017-10-14"}],"10.1016/s0140-6736(17)32165-7":[{"url":"https://hartvaat.nl/2017/10/14/multifacet-interventie-voor-oac-gebruik-bij-af-lancet-impact-af/","title":"Multifacet-interventie voor OAC-gebruik bij AF: Lancet IMPACT-AF","title_en":"A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial.","published":"2017-10-14"}],"10.1016/s0140-6736(17)32155-4":[{"url":"https://hartvaat.nl/2017/10/14/geleide-de-escalatie-van-antiplaatjestherapie-na-acs-met-pci-lancet-tropical-acs/","title":"Geleide de-escalatie van antiplaatjestherapie na ACS met PCI: Lancet TROPICAL-ACS","title_en":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.","published":"2017-10-14"}],"10.1093/eurheartj/ehx188":[{"url":"https://hartvaat.nl/2017/10/14/intracoronaire-beenmergceltransfer-na-mi-de-boost-2-gerandomiseerde-trial/","title":"Intracoronaire beenmergceltransfer na MI: de BOOST-2 gerandomiseerde trial","title_en":"Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial.","published":"2017-10-14"}],"10.1016/j.jacc.2017.08.010":[{"url":"https://hartvaat.nl/2017/10/10/pulmonalisdrukgeleide-therapie-bij-hfref/","title":"Pulmonalisdrukgeleide therapie bij HFrEF","title_en":"Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction.","published":"2017-10-10"}],"10.1016/j.jacc.2017.08.018":[{"url":"https://hartvaat.nl/2017/10/10/dagelijks-ischemie-en-bloedingsrisico-na-primaire-pci-voor-stemi/","title":"Dagelijks ischemie- en bloedingsrisico na primaire PCI voor STEMI","title_en":"Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI.","published":"2017-10-10"}],"10.1001/jama.2017.14172":[{"url":"https://hartvaat.nl/2017/10/10/geindividualiseerd-versus-standaard-bloeddrukbeleid-bij-hoog-risico-chirurgiepat/","title":"Geïndividualiseerd versus standaard bloeddrukbeleid bij hoog-risico chirurgiepatiënten: JAMA-trial","title_en":"Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery: A Randomized Clinical Trial.","published":"2017-10-10"}],"10.1016/j.jacc.2017.07.745":[{"url":"https://hartvaat.nl/2017/10/03/2017-acc-gerichte-update-niet-statinetherapie-voor-ldl-verlaging/","title":"2017 ACC gerichte update: niet-statinetherapie voor LDL-verlaging","title_en":"2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","published":"2017-10-03"}],"10.1161/circulationaha.117.028885":[{"url":"https://hartvaat.nl/2017/10/03/ridaforolimus-versus-zotarolimus-eluting-stents-gerandomiseerde-primaire-resulta/","title":"Ridaforolimus- versus zotarolimus-eluting stents: gerandomiseerde primaire resultaten","title_en":"Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis).","published":"2017-10-03"}],"10.1001/jamacardio.2017.2895":[{"url":"https://hartvaat.nl/2017/10/01/pci-versus-cabg-bij-linker-hoofdstamstenose-jama-cardiology-systematische-review/","title":"PCI versus CABG bij linker-hoofdstamstenose: JAMA Cardiology systematische review en meta-analyse","title_en":"Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis.","published":"2017-10-01"}],"10.1093/eurheartj/ehx250":[{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-bij-stabiel-coronairlijden-stability-inzic/","title":"Visit-to-visit bloeddrukvariabiliteit bij stabiel coronairlijden: STABILITY-inzichten","title_en":"Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial.","published":"2017-10-01"}],"10.1093/europace/euw409":[{"url":"https://hartvaat.nl/2017/10/01/korte-dabigatran-onderbreking-voor-device-implantatie-re-ly-multicenterervaring/","title":"Korte dabigatran-onderbreking vóór device-implantatie: RE-LY multicenterervaring","title_en":"Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial.","published":"2017-10-01"}],"10.1093/europace/euw384":[{"url":"https://hartvaat.nl/2017/10/01/antazoline-voor-snelle-cardioversie-van-paroxysmaal-af-de-anpaf-studie/","title":"Antazoline voor snelle cardioversie van paroxysmaal AF: de AnPAF-studie","title_en":"Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).","published":"2017-10-01"}],"10.1093/europace/euw266":[{"url":"https://hartvaat.nl/2017/10/01/terminatie-van-persisterend-af-tijdens-pvi-inzichten-uit-magic-af/","title":"Terminatie van persisterend AF tijdens PVI: inzichten uit MAGIC-AF","title_en":"Termination of persistent atrial fibrillation during pulmonary vein isolation: insight from the MAGIC-AF trial.","published":"2017-10-01"}],"10.1161/hypertensionaha.117.09788":[{"url":"https://hartvaat.nl/2017/10/01/visit-to-visit-bloeddrukvariabiliteit-en-cv-uitkomsten-in-sprint/","title":"Visit-to-visit bloeddrukvariabiliteit en CV-uitkomsten in SPRINT","title_en":"Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial).","published":"2017-10-01"}],"10.1136/heartjnl-2017-311181":[{"url":"https://hartvaat.nl/2017/10/01/langetermijnmortaliteit-en-prehospitale-tirofibanbehandeling-bij-stemi/","title":"Langetermijnmortaliteit en prehospitale tirofibanbehandeling bij STEMI","title_en":"Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction.","published":"2017-10-01"}],"10.1136/heartjnl-2016-310875":[{"url":"https://hartvaat.nl/2017/10/01/il-6-remming-en-coronaire-microvasculaire-en-endotheelfunctie-bij-myocardinfarct/","title":"IL-6-remming en coronaire microvasculaire en endotheelfunctie bij myocardinfarct","title_en":"Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction.","published":"2017-10-01"}],"10.1136/heartjnl-2016-310897":[{"url":"https://hartvaat.nl/2017/10/01/inhalatiecorticosteroid-beta-2-agonist-en-cardiovasculaire-uitkomsten-bij-copd/","title":"Inhalatiecorticosteroïd/bèta-2-agonist en cardiovasculaire uitkomsten bij COPD","title_en":"Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.","published":"2017-10-01"}],"10.1056/nejmoa1612917":[{"url":"https://hartvaat.nl/2017/09/28/exenatide-eenmaal-per-week-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-ne/","title":"Exenatide eenmaal per week en cardiovasculaire uitkomsten bij diabetes type 2: NEJM EXSCEL","title_en":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.","published":"2017-09-28"}],"10.1056/nejmoa1706444":[{"url":"https://hartvaat.nl/2017/09/28/anacetrapib-bij-atherosclerotisch-vaatlijden-nejm-hps3-timi55-reveal/","title":"Anacetrapib bij atherosclerotisch vaatlijden: NEJM HPS3/TIMI55-REVEAL","title_en":"Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.","published":"2017-09-28"}],"10.1056/nejmoa1706222":[{"url":"https://hartvaat.nl/2017/09/28/zuurstoftherapie-bij-vermoedelijk-acuut-myocardinfarct-nejm-deto2x-ami/","title":"Zuurstoftherapie bij vermoedelijk acuut myocardinfarct: NEJM DETO2X-AMI","title_en":"Oxygen Therapy in Suspected Acute Myocardial Infarction.","published":"2017-09-28"}],"10.1016/j.jacc.2017.07.765":[{"url":"https://hartvaat.nl/2017/09/26/verlaging-van-arteriele-stijfheid-onafhankelijk-van-bloeddruk-de-vasera-trial/","title":"Verlaging van arteriële stijfheid onafhankelijk van bloeddruk: de VaSera-trial","title_en":"Reducing Arterial Stiffness Independently of Blood Pressure: The VaSera Trial.","published":"2017-09-26"}],"10.1016/j.jacc.2017.07.767":[{"url":"https://hartvaat.nl/2017/09/26/sams-ci-score-toegepast-op-gerandomiseerde-trial-over-statine-myopathie/","title":"SAMS-CI score toegepast op gerandomiseerde trial over statine-myopathie","title_en":"Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy.","published":"2017-09-26"}],"10.1161/circulationaha.117.027252":[{"url":"https://hartvaat.nl/2017/09/26/secundaire-cardiovasculaire-preventie-bij-diabetes-type-2-tecos-internationale-i/","title":"Secundaire cardiovasculaire preventie bij diabetes type 2: TECOS internationale inzichten","title_en":"Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).","published":"2017-09-26"}],"10.1056/nejmoa1707914":[{"url":"https://hartvaat.nl/2017/09/21/anti-inflammatoire-therapie-met-canakinumab-bij-atherosclerose-nejm-cantos/","title":"Anti-inflammatoire therapie met canakinumab bij atherosclerose: NEJM CANTOS","title_en":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.","published":"2017-09-21"}],"10.1056/nejmoa1706443":[{"url":"https://hartvaat.nl/2017/09/21/bivalirudine-versus-heparine-monotherapie-bij-myocardinfarct-nejm-validate-swede/","title":"Bivalirudine versus heparine monotherapie bij myocardinfarct: NEJM VALIDATE-SWEDEHEART","title_en":"Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.","published":"2017-09-21"}],"10.1001/jama.2017.11358":[{"url":"https://hartvaat.nl/2017/09/19/community-health-worker-interventie-voor-bloeddrukcontrole-in-argentina-jama-tri/","title":"Community health worker-interventie voor bloeddrukcontrole in Argentina: JAMA-trial","title_en":"Effect of a Community Health Worker-Led Multicomponent Intervention on Blood Pressure Control in Low-Income Patients in Argentina: A Randomized Clinical Trial.","published":"2017-09-19"}],"10.1161/circulationaha.117.029529":[{"url":"https://hartvaat.nl/2017/09/19/empagliflozine-en-vasculaire-functie-en-centrale-hemodynamiek-bij-diabetes-type-/","title":"Empagliflozine en vasculaire functie en centrale hemodynamiek bij diabetes type 2","title_en":"Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.","published":"2017-09-19"}],"10.1056/nejmoa1705915":[{"url":"https://hartvaat.nl/2017/09/14/pfo-sluiting-of-antistolling-versus-antiplaatjestherapie-na-cva-nejm-reduce/","title":"PFO-sluiting of antistolling versus antiplaatjestherapie na CVA: NEJM REDUCE","title_en":"Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.","published":"2017-09-14"}],"10.1056/nejmoa1707404":[{"url":"https://hartvaat.nl/2017/09/14/pfo-sluiting-of-antiplaatjestherapie-bij-cryptogeen-cva-nejm-close/","title":"PFO-sluiting of antiplaatjestherapie bij cryptogeen CVA: NEJM CLOSE","title_en":"Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.","published":"2017-09-14"}],"10.1016/j.jacc.2017.07.768":[{"url":"https://hartvaat.nl/2017/09/12/werkzaamheid-en-veiligheid-van-ticagrelor-over-tijd-na-mi-pegasus-timi-54/","title":"Werkzaamheid en veiligheid van ticagrelor over tijd na MI: PEGASUS-TIMI 54","title_en":"Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54.","published":"2017-09-12"}],"10.1016/j.jacc.2017.07.740":[{"url":"https://hartvaat.nl/2017/09/12/centrale-apneus-gedurende-24-uur-en-prognose-bij-hartfalen/","title":"Centrale apneus gedurende 24 uur en prognose bij hartfalen","title_en":"Prognostic Significance of Central Apneas Throughout a 24-Hour Period in Patients With Heart Failure.","published":"2017-09-12"}],"10.1161/circulationaha.117.028002":[{"url":"https://hartvaat.nl/2017/09/12/lichamelijke-activiteit-en-prognose-bij-hfpef-topcat-analyse/","title":"Lichamelijke activiteit en prognose bij HFpEF: TOPCAT-analyse","title_en":"Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).","published":"2017-09-12"}],"10.1016/j.jacc.2017.07.725":[{"url":"https://hartvaat.nl/2017/09/05/ivabradine-bij-kinderen-met-dilaterende-cardiomyopathie-en-symptomatisch-hartfal/","title":"Ivabradine bij kinderen met dilaterende cardiomyopathie en symptomatisch hartfalen","title_en":"Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure.","published":"2017-09-05"}],"10.1016/j.jacc.2017.07.753":[{"url":"https://hartvaat.nl/2017/09/05/cardiovasculair-risico-na-fertiliteitstherapie-systematische-review-en-meta-anal/","title":"Cardiovasculair risico na fertiliteitstherapie: systematische review en meta-analyse","title_en":"Cardiovascular Risk Following Fertility Therapy: Systematic Review and Meta-Analysis.","published":"2017-09-05"}],"10.1161/circulationaha.117.027575":[{"url":"https://hartvaat.nl/2017/09/05/n-acetylcysteine-met-nitraat-bij-primaire-pci-voor-stemi/","title":"N-acetylcysteïne met nitraat bij primaire PCI voor STEMI","title_en":"Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]).","published":"2017-09-05"}],"10.1001/jamacardio.2017.2198":[{"url":"https://hartvaat.nl/2017/09/01/spironolacton-bij-acuut-hartfalen-de-athena-hf-gerandomiseerde-trial/","title":"Spironolacton bij acuut hartfalen: de ATHENA-HF gerandomiseerde trial","title_en":"Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.","published":"2017-09-01"}],"10.1093/eurheartj/ehx155":[{"url":"https://hartvaat.nl/2017/09/01/late-trombotische-events-na-bioresorbeerbare-scaffold-meta-analyse-van-gerandomi/","title":"Late trombotische events na bioresorbeerbare scaffold: meta-analyse van gerandomiseerde trials","title_en":"Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials.","published":"2017-09-01"}],"10.1093/europace/eux027":[{"url":"https://hartvaat.nl/2017/09/01/validiteit-en-reproduceerbaarheid-van-echocardiografie-bij-af-systematische-revi/","title":"Validiteit en reproduceerbaarheid van echocardiografie bij AF: systematische review","title_en":"Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review.","published":"2017-09-01"}],"10.1093/europace/euw193":[{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","title":"BUDAPEST-CRT Upgrade Study: studieontwerp voor CRT-upgrade","title_en":"Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial.","published":"2017-09-01"}],"10.1136/heartjnl-2016-310917":[{"url":"https://hartvaat.nl/2017/09/01/slagvolume-en-cardiovasculair-risico-bij-progressie-van-aortaklepstenose/","title":"Slagvolume en cardiovasculair risico bij progressie van aortaklepstenose","title_en":"Impact of stroke volume on cardiovascular risk during progression of aortic valve stenosis.","published":"2017-09-01"}],"10.1136/heartjnl-2016-310929":[{"url":"https://hartvaat.nl/2017/09/01/provisional-versus-twee-stentstrategie-bij-bifurcatielaesies-meta-analyse/","title":"Provisional versus twee-stentstrategie bij bifurcatielaesies: meta-analyse","title_en":"Long-term outcomes of provisional stenting compared with a two-stent strategy for bifurcation lesions: a meta-analysis of randomised trials.","published":"2017-09-01"}],"10.1016/j.jacc.2017.06.058":[{"url":"https://hartvaat.nl/2017/08/29/rosuvastatine-bij-kinderen-met-homozygote-familiaire-hypercholesterolemie/","title":"Rosuvastatine bij kinderen met homozygote familiaire hypercholesterolemie","title_en":"Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations.","published":"2017-08-29"}],"10.1056/nejmoa1611179":[{"url":"https://hartvaat.nl/2017/08/24/intensieve-bloeddrukbehandeling-en-patientgerapporteerde-uitkomsten-nejm-sprint-/","title":"Intensieve bloeddrukbehandeling en patiëntgerapporteerde uitkomsten: NEJM SPRINT-QOL","title_en":"Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.","published":"2017-08-24"}],"10.1056/nejmoa1615692":[{"url":"https://hartvaat.nl/2017/08/24/degludec-versus-glargine-bij-diabetes-type-2-nejm-devote-werkzaamheid-en-veiligh/","title":"Degludec versus glargine bij diabetes type 2: NEJM DEVOTE werkzaamheid en veiligheid","title_en":"Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.","published":"2017-08-24"}],"10.1001/jama.2017.10565":[{"url":"https://hartvaat.nl/2017/08/22/natriuretisch-peptide-geleide-therapie-bij-hoogrisico-hartfalen-jama-guide-it/","title":"Natriuretisch peptide-geleide therapie bij hoogrisico hartfalen: JAMA GUIDE-IT","title_en":"Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.","published":"2017-08-22"}],"10.1016/s0140-6736(17)31441-1":[{"url":"https://hartvaat.nl/2017/08/19/vergelijking-van-fibrinolytica-bij-stemi-lancet-netwerkmeta-analyse/","title":"Vergelijking van fibrinolytica bij STEMI: Lancet netwerkmeta-analyse","title_en":"Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.","published":"2017-08-19"}],"10.1016/s0140-6736(17)31490-3":[{"url":"https://hartvaat.nl/2017/08/19/optimale-timing-van-invasieve-strategie-bij-nste-acs-lancet-meta-analyse/","title":"Optimale timing van invasieve strategie bij NSTE-ACS: Lancet meta-analyse","title_en":"Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials.","published":"2017-08-19"}],"10.1016/s0140-6736(17)31470-8":[{"url":"https://hartvaat.nl/2017/08/19/absorb-bioresorbeerbare-scaffold-lancet-2-jaars-systematische-review-en-meta-ana/","title":"Absorb bioresorbeerbare scaffold: Lancet 2-jaars systematische review en meta-analyse","title_en":"2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.","published":"2017-08-19"}],"10.1056/nejmoa1701131":[{"url":"https://hartvaat.nl/2017/08/17/cognitieve-functie-in-de-fourier-trial-met-evolocumab-nejm-ebbinghaus/","title":"Cognitieve functie in de FOURIER-trial met evolocumab: NEJM EBBINGHAUS","title_en":"Cognitive Function in a Randomized Trial of Evolocumab.","published":"2017-08-17"}],"10.1056/nejmoa1611925":[{"url":"https://hartvaat.nl/2017/08/17/canagliflozine-en-cardiovasculaire-en-renale-events-bij-diabetes-type-2-nejm-can/","title":"Canagliflozine en cardiovasculaire en renale events bij diabetes type 2: NEJM CANVAS","title_en":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.","published":"2017-08-17"}],"10.1161/circulationaha.116.026796":[{"url":"https://hartvaat.nl/2017/08/15/fijnstofblootstelling-en-stresshormoonspiegels-gerandomiseerde-luchtzuiveringstr/","title":"Fijnstofblootstelling en stresshormoonspiegels: gerandomiseerde luchtzuiveringstrial","title_en":"Particulate Matter Exposure and Stress Hormone Levels: A Randomized, Double-Blind, Crossover Trial of Air Purification.","published":"2017-08-15"}],"10.1016/j.jacc.2017.06.023":[{"url":"https://hartvaat.nl/2017/08/15/overleving-na-geisoleerde-postoperatieve-troponine-elevatie/","title":"Overleving na geïsoleerde postoperatieve troponine-elevatie","title_en":"Survival After Isolated Post-Operative Troponin Elevation.","published":"2017-08-15"}],"10.1016/s0140-6736(17)31367-3":[{"url":"https://hartvaat.nl/2017/08/12/foley-katheter-versus-misoprostol-voor-inleiden-bij-hypertensieve-zwangeren-in-i/","title":"Foley-katheter versus misoprostol voor inleiden bij hypertensieve zwangeren in India: INFORM","title_en":"Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India (INFORM): a multicentre, open-label, randomised controlled trial.","published":"2017-08-12"}],"10.1161/circulationaha.117.028745":[{"url":"https://hartvaat.nl/2017/08/08/prasugrel-of-ticagrelor-bij-stemi-met-diabetes/","title":"Prasugrel of ticagrelor bij STEMI met diabetes","title_en":"Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus.","published":"2017-08-08"}],"10.1016/j.jacc.2017.06.016":[{"url":"https://hartvaat.nl/2017/08/08/canagliflozine-en-cardiovasculaire-biomarkers-bij-oudere-diabetespatienten/","title":"Canagliflozine en cardiovasculaire biomarkers bij oudere diabetespatiënten","title_en":"Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.","published":"2017-08-08"}],"10.1016/j.jacc.2017.04.025":[{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-jacc-editie/","title":"2017 ACC/AHA/HFSA gerichte update hartfalenmanagement (JACC-editie)","title_en":"2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.","published":"2017-08-08"}],"10.1161/cir.0000000000000509":[{"url":"https://hartvaat.nl/2017/08/08/2017-acc-aha-hfsa-gerichte-update-hartfalenmanagement-circulation-editie/","title":"2017 ACC/AHA/HFSA gerichte update hartfalenmanagement (Circulation-editie)","title_en":"2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.","published":"2017-08-08"}],"10.1093/eurheartj/ehx227":[{"url":"https://hartvaat.nl/2017/08/07/remote-management-van-hartfalen-met-implanteerbare-devices-overzicht/","title":"Remote management van hartfalen met implanteerbare devices: overzicht","title_en":"Remote management of heart failure using implantable electronic devices.","published":"2017-08-07"}],"10.1093/eurheartj/ehx259":[{"url":"https://hartvaat.nl/2017/08/07/standaard-versus-geintensiveerd-hartfalenmanagement-en-zorgkosten-gerandomiseerd/","title":"Standaard versus geïntensiveerd hartfalenmanagement en zorgkosten: gerandomiseerde trial","title_en":"Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.","published":"2017-08-07"}],"10.1093/eurheartj/ehx196":[{"url":"https://hartvaat.nl/2017/08/07/trv027-biased-ligand-van-de-angiotensine-ii-receptor-bij-acuut-hartfalen-gerando/","title":"TRV027 biased ligand van de angiotensine-II-receptor bij acuut hartfalen: gerandomiseerde trial","title_en":"Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).","published":"2017-08-07"}],"10.1016/j.jacc.2017.05.064":[{"url":"https://hartvaat.nl/2017/08/01/nauwkeurigheid-van-manchetbloeddrukmeting-systematische-review-en-meta-analyse/","title":"Nauwkeurigheid van manchetbloeddrukmeting: systematische review en meta-analyse","title_en":"Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses.","published":"2017-08-01"}],"10.1016/j.jacc.2017.05.063":[{"url":"https://hartvaat.nl/2017/08/01/kosteneffectiviteit-van-langdurig-ticagrelor-na-mi-pegasus-timi-54/","title":"Kosteneffectiviteit van langdurig ticagrelor na MI: PEGASUS-TIMI 54","title_en":"Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.","published":"2017-08-01"}],"10.1161/circulationaha.117.027659":[{"url":"https://hartvaat.nl/2017/08/01/radiale-arterie-graft-als-aanvulling-op-mammaria-interna-grafts-bij-cabg/","title":"Radiale arterie-graft als aanvulling op mammaria interna-grafts bij CABG","title_en":"Associations Between Adding a Radial Artery Graft to Single and Bilateral Internal Thoracic Artery Grafts and Outcomes: Insights From the Arterial Revascularization Trial.","published":"2017-08-01"}],"10.1161/circulationaha.117.028441":[{"url":"https://hartvaat.nl/2017/08/01/intensieve-bloeddrukverlaging-en-linkerventrikelhypertrofie-sprint-echocardiogra/","title":"Intensieve bloeddrukverlaging en linkerventrikelhypertrofie: SPRINT echocardiografische substudie","title_en":"Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).","published":"2017-08-01"}],"10.1093/eurheartj/ehx235":[{"url":"https://hartvaat.nl/2017/08/01/vitamine-d-en-mortaliteit-bij-hartfalen-de-evita-3-jaars-gerandomiseerde-trial/","title":"Vitamine D en mortaliteit bij hartfalen: de EVITA 3-jaars gerandomiseerde trial","title_en":"Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.","published":"2017-08-01"}],"10.1093/eurheartj/ehx162":[{"url":"https://hartvaat.nl/2017/08/01/ldl-cholesterol-streefwaarden-met-pitavastatine-ezetimibe-bij-acs-met-dyslipidem/","title":"LDL-cholesterol streefwaarden met pitavastatine + ezetimibe bij ACS met dyslipidemie: HIJ-PROPER","title_en":"Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.","published":"2017-08-01"}],"10.1161/hypertensionaha.117.09027":[{"url":"https://hartvaat.nl/2017/08/01/cardiometabole-determinanten-van-carotis-en-aortadistensibiliteit-van-kindertijd/","title":"Cardiometabole determinanten van carotis- en aortadistensibiliteit van kindertijd tot jongvolwassenheid","title_en":"Cardiometabolic Determinants of Carotid and Aortic Distensibility From Childhood to Early Adulthood.","published":"2017-08-01"}],"10.1161/hypertensionaha.117.09404":[{"url":"https://hartvaat.nl/2017/08/01/foliumzuurtherapie-en-nieuwe-proteinurie-bij-chinese-hypertensieve-patienten-csp/","title":"Foliumzuurtherapie en nieuwe proteïnurie bij Chinese hypertensieve patiënten: CSPPT-subanalyse","title_en":"Effects of Folic Acid Therapy on the New-Onset Proteinuria in Chinese Hypertensive Patients: A Post Hoc Analysis of the Renal Substudy of CSPPT (China Stroke Primary Prevention Trial).","published":"2017-08-01"}],"10.1161/hypertensionaha.117.09359":[{"url":"https://hartvaat.nl/2017/08/01/bloeddrukvariabiliteit-en-vasculaire-events-bij-diabetes-type-2/","title":"Bloeddrukvariabiliteit en vasculaire events bij diabetes type 2","title_en":"Prognostic Value of Variability in Systolic Blood Pressure Related to Vascular Events and Premature Death in Type 2 Diabetes Mellitus: The ADVANCE-ON Study.","published":"2017-08-01"}],"10.1136/heartjnl-2016-310090":[{"url":"https://hartvaat.nl/2017/08/01/voorspelling-van-bloedingsrisico-tijdens-dapt-na-acs/","title":"Voorspelling van bloedingsrisico tijdens DAPT na ACS","title_en":"Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.","published":"2017-08-01"}],"10.1136/heartjnl-2016-310236":[{"url":"https://hartvaat.nl/2017/08/01/nt-probnp-bij-systematische-screening-op-atriumfibrilleren/","title":"NT-proBNP bij systematische screening op atriumfibrilleren","title_en":"N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation.","published":"2017-08-01"}],"10.1136/heartjnl-2016-310403":[{"url":"https://hartvaat.nl/2017/08/01/des-versus-bms-bij-acuut-mi-met-cardiogene-shock/","title":"DES versus BMS bij acuut MI met cardiogene shock","title_en":"Drug-eluting stents versus bare-metal stents in acute myocardial infarction with cardiogenic shock.","published":"2017-08-01"}],"10.1056/nejmoa1612790":[{"url":"https://hartvaat.nl/2017/07/20/genetische-en-farmacologische-inactivatie-van-angptl3-en-cardiovasculaire-ziekte/","title":"Genetische en farmacologische inactivatie van ANGPTL3 en cardiovasculaire ziekte — NEJM","title_en":"Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.","published":"2017-07-20"}],"10.1056/nejmoa1701329":[{"url":"https://hartvaat.nl/2017/07/20/angptl3-antisense-oligonucleotiden-cardiovasculaire-en-metabole-effecten-nejm/","title":"ANGPTL3 antisense-oligonucleotiden: cardiovasculaire en metabole effecten — NEJM","title_en":"Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.","published":"2017-07-20"}],"10.1016/j.jacc.2017.05.030":[{"url":"https://hartvaat.nl/2017/07/18/palliatieve-zorg-bij-hartfalen-de-pal-hf-gerandomiseerde-trial/","title":"Palliatieve zorg bij hartfalen: de PAL-HF gerandomiseerde trial","title_en":"Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial.","published":"2017-07-18"}],"10.1161/circulationaha.117.029190":[{"url":"https://hartvaat.nl/2017/07/18/sglt2-remmers-en-lager-risico-op-hartfalen-en-sterfte-versus-andere-glucoseverla/","title":"SGLT2-remmers en lager risico op hartfalen en sterfte versus andere glucoseverlagers: real-world","title_en":"Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).","published":"2017-07-18"}],"10.1093/eurheartj/ehx161":[{"url":"https://hartvaat.nl/2017/07/14/voorspelling-van-plotse-versus-niet-plotse-hartdood-na-mi-met-verminderde-lvef/","title":"Voorspelling van plotse versus niet-plotse hartdood na MI met verminderde LVEF","title_en":"Prediction of sudden and non-sudden cardiac death in post-infarction patients with reduced left ventricular ejection fraction by periodic repolarization dynamics: MADIT-II substudy.","published":"2017-07-14"}],"10.1056/nejmoa1703643":[{"url":"https://hartvaat.nl/2017/07/13/adjuvant-pertuzumab-en-trastuzumab-bij-vroege-her2-positieve-borstkanker-nejm-ap/","title":"Adjuvant pertuzumab en trastuzumab bij vroege HER2-positieve borstkanker: NEJM APHINITY","title_en":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.","published":"2017-07-13"}],"10.1001/jama.2017.7171":[{"url":"https://hartvaat.nl/2017/07/11/gedragscounseling-voor-gezonde-voeding-en-beweging-ter-cv-preventie-jama-uspstf-/","title":"Gedragscounseling voor gezonde voeding en beweging ter CV-preventie: JAMA USPSTF-review","title_en":"Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.","published":"2017-07-11"}],"10.1001/jama.2017.7967":[{"url":"https://hartvaat.nl/2017/07/11/positieve-luchtwegdruk-en-cv-events-bij-slaapapneu-jama-meta-analyse/","title":"Positieve luchtwegdruk en CV-events bij slaapapneu: JAMA meta-analyse","title_en":"Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis.","published":"2017-07-11"}],"10.1016/j.jacc.2017.05.029":[{"url":"https://hartvaat.nl/2017/07/11/arteriele-verstijving-bij-inspanning-bij-hfpef/","title":"Arteriële verstijving bij inspanning bij HFpEF","title_en":"Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction.","published":"2017-07-11"}],"10.1016/j.jacc.2017.05.028":[{"url":"https://hartvaat.nl/2017/07/04/arteriele-remodellering-na-bioresorbeerbare-scaffolds-versus-metallic-stents/","title":"Arteriële remodellering na bioresorbeerbare scaffolds versus metallic stents","title_en":"Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents.","published":"2017-07-04"}],"10.1161/circulationaha.116.025483":[{"url":"https://hartvaat.nl/2017/07/04/langetermijn-metformine-en-leefstijl-en-coronair-calcium-diabetes-prevention-pro/","title":"Langetermijn metformine en leefstijl en coronair calcium: Diabetes Prevention Program","title_en":"Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium.","published":"2017-07-04"}],"10.1001/jamacardio.2017.1421":[{"url":"https://hartvaat.nl/2017/07/01/systolische-bloeddrukreductie-en-cv-risico-netwerkmeta-analyse/","title":"Systolische bloeddrukreductie en CV-risico: netwerkmeta-analyse","title_en":"Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis.","published":"2017-07-01"}],"10.1093/eurheartj/ehx138":[{"url":"https://hartvaat.nl/2017/07/01/syntax-scores-en-uitkomsten-bij-diabetes-met-multivatenlijden-gepoolde-analyse/","title":"SYNTAX-scores en uitkomsten bij diabetes met multivatenlijden: gepoolde analyse","title_en":"Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials.","published":"2017-07-01"}],"10.1001/jamacardio.2017.0901":[{"url":"https://hartvaat.nl/2017/07/01/werkzaamheid-van-katheterablatie-bij-niet-paroxysmaal-atriumfibrilleren-jama-car/","title":"Werkzaamheid van katheterablatie bij niet-paroxysmaal atriumfibrilleren: JAMA Cardiology","title_en":"Efficacy of Catheter Ablation for Nonparoxysmal Atrial Fibrillation.","published":"2017-07-01"}],"10.1001/jamacardio.2016.5975":[{"url":"https://hartvaat.nl/2017/07/01/1-jaarsmortaliteit-bivalirudine-versus-heparine-in-de-ambulance-bij-stemi-matrix/","title":"1-jaarsmortaliteit bivalirudine versus heparine in de ambulance bij STEMI: MATRIX","title_en":"One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.","published":"2017-07-01"}],"10.1093/europace/euw136":[{"url":"https://hartvaat.nl/2017/07/01/crt-werkingsmechanismen-en-mogelijkheden-voor-verdere-verbetering/","title":"CRT: werkingsmechanismen en mogelijkheden voor verdere verbetering","title_en":"Cardiac resynchronization therapy: mechanisms of action and scope for further improvement in cardiac function.","published":"2017-07-01"}],"10.1161/hypertensionaha.117.09202":[{"url":"https://hartvaat.nl/2017/07/01/kwartdosis-antihypertensiva-systematische-review-en-meta-analyse/","title":"Kwartdosis antihypertensiva: systematische review en meta-analyse","title_en":"Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","published":"2017-07-01"}],"10.1161/hypertensionaha.117.09259":[{"url":"https://hartvaat.nl/2017/07/01/cardiovasculair-risico-bij-diabetes-op-betablokkers/","title":"Cardiovasculair risico bij diabetes op bètablokkers","title_en":"Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers.","published":"2017-07-01"}],"10.1161/hypertensionaha.117.09221":[{"url":"https://hartvaat.nl/2017/07/01/heterogeniteit-in-vroege-respons-op-antihypertensiva-allhat/","title":"Heterogeniteit in vroege respons op antihypertensiva: ALLHAT","title_en":"Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).","published":"2017-07-01"}],"10.1136/heartjnl-2016-310358":[{"url":"https://hartvaat.nl/2017/07/01/dabigatran-naar-leeftijd-bij-atriumfibrilleren-re-ly-analyse/","title":"Dabigatran naar leeftijd bij atriumfibrilleren: RE-LY-analyse","title_en":"Effects of dabigatran according to age in atrial fibrillation.","published":"2017-07-01"}],"10.1136/heartjnl-2016-310886":[{"url":"https://hartvaat.nl/2017/07/01/bioresorbeerbare-scaffold-versus-des-2-jaars-meta-analyse/","title":"Bioresorbeerbare scaffold versus DES: 2-jaars meta-analyse","title_en":"Two-year outcomes of bioresorbable vascular scaffold versus drug-eluting stents in coronary artery disease: a meta-analysis.","published":"2017-07-01"}],"10.1016/j.jacc.2017.04.043":[{"url":"https://hartvaat.nl/2017/06/27/hospitalisatie-voor-nieuw-gediagnosticeerd-versus-verslechterend-chronisch-hartf/","title":"Hospitalisatie voor nieuw gediagnosticeerd versus verslechterend chronisch hartfalen: ASCEND-HF","title_en":"Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.","published":"2017-06-27"}],"10.1016/s0140-6736(17)31075-9":[{"url":"https://hartvaat.nl/2017/06/24/bijwerkingen-bij-niet-geblindeerde-versus-geblindeerde-statinetherapie-lancet-as/","title":"Bijwerkingen bij niet-geblindeerde versus geblindeerde statinetherapie: Lancet ASCOT-LLA","title_en":"Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.","published":"2017-06-24"}],"10.1016/j.jacc.2017.04.001":[{"url":"https://hartvaat.nl/2017/06/20/hartfrequentie-en-ritme-en-het-voordeel-van-betablokkers-bij-hartfalen/","title":"Hartfrequentie en ritme en het voordeel van bètablokkers bij hartfalen","title_en":"Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.","published":"2017-06-20"}],"10.1161/circulationaha.116.025678":[{"url":"https://hartvaat.nl/2017/06/20/cholesteroleffluxcapaciteit-hdl-deeltjesaantal-en-cv-events-jupiter-analyse/","title":"Cholesteroleffluxcapaciteit, HDL-deeltjesaantal en CV-events: JUPITER-analyse","title_en":"Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).","published":"2017-06-20"}],"10.1056/nejmoa1614954":[{"url":"https://hartvaat.nl/2017/06/15/bioresorbeerbare-scaffolds-versus-metallic-stents-bij-routine-pci-nejm-aida/","title":"Bioresorbeerbare scaffolds versus metallic stents bij routine-PCI: NEJM AIDA","title_en":"Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.","published":"2017-06-15"}],"10.1093/eurheartj/ehw387":[{"url":"https://hartvaat.nl/2017/06/14/overschakelen-van-niet-selectieve-nsaid-s-naar-celecoxib-de-scot-trial/","title":"Overschakelen van niet-selectieve NSAID's naar celecoxib: de SCOT-trial","title_en":"Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).","published":"2017-06-14"}],"10.1016/j.jacc.2017.03.601":[{"url":"https://hartvaat.nl/2017/06/13/myocardschade-bij-uitgestelde-stenting-na-stemi-danami-3-defer-substudie/","title":"Myocardschade bij uitgestelde stenting na STEMI: DANAMI-3-DEFER substudie","title_en":"Myocardial Damage in Patients With Deferred Stenting After STEMI: A DANAMI-3-DEFER Substudy.","published":"2017-06-13"}],"10.1093/eurheartj/ehx015":[{"url":"https://hartvaat.nl/2017/06/07/dagelijkse-telemonitoring-van-icd-s-gepoolde-analyse-van-drie-gerandomiseerde-tr/","title":"Dagelijkse telemonitoring van ICD's: gepoolde analyse van drie gerandomiseerde trials","title_en":"Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST).","published":"2017-06-07"}],"10.1016/s0140-6736(17)31193-5":[{"url":"https://hartvaat.nl/2017/06/03/intravitreaal-aflibercept-versus-panretinale-fotocoagulatie-bij-proliferatieve-d/","title":"Intravitreaal aflibercept versus panretinale fotocoagulatie bij proliferatieve diabetische retinopathie","title_en":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.","published":"2017-06-03"}],"10.1016/s0140-6736(17)30754-7":[{"url":"https://hartvaat.nl/2017/06/03/bereikte-bloeddruk-en-cv-uitkomsten-bij-hoogrisicopatienten-ontarget-transcend/","title":"Bereikte bloeddruk en CV-uitkomsten bij hoogrisicopatiënten: ONTARGET/TRANSCEND","title_en":"Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.","published":"2017-06-03"}],"10.1001/jamacardio.2017.0175":[{"url":"https://hartvaat.nl/2017/06/01/maandelijks-hooggedoseerd-vitamine-d-en-cardiovasculaire-ziekte-gerandomiseerde-/","title":"Maandelijks hooggedoseerd vitamine D en cardiovasculaire ziekte: gerandomiseerde trial","title_en":"Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial.","published":"2017-06-01"}],"10.1001/jamacardio.2017.0176":[{"url":"https://hartvaat.nl/2017/06/01/voedingsstatus-en-langetermijn-multivitaminegebruik-en-cv-risico-phs-ii-analyse/","title":"Voedingsstatus en langetermijn multivitaminegebruik en CV-risico: PHS II analyse","title_en":"Effect of Baseline Nutritional Status on Long-term Multivitamin Use and Cardiovascular Disease Risk: A Secondary Analysis of the Physicians' Health Study II Randomized Clinical Trial.","published":"2017-06-01"}],"10.1001/jamacardio.2017.0630":[{"url":"https://hartvaat.nl/2017/06/01/primaire-preventie-icd-bij-niet-ischemische-cardiomyopathie-meta-analyse/","title":"Primaire preventie-ICD bij niet-ischemische cardiomyopathie: meta-analyse","title_en":"Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis.","published":"2017-06-01"}],"10.1001/jamacardio.2016.5669":[{"url":"https://hartvaat.nl/2017/06/01/korte-procedureduur-met-bivalirudine-en-risico-op-acute-stenttrombose-bij-stemi/","title":"Korte procedureduur met bivalirudine en risico op acute stenttrombose bij STEMI","title_en":"Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial.","published":"2017-06-01"}],"10.1093/europace/euw093":[{"url":"https://hartvaat.nl/2017/06/01/impact-van-ischemisch-cva-op-af-gerelateerde-zorgkosten-systematische-review/","title":"Impact van ischemisch CVA op AF-gerelateerde zorgkosten: systematische review","title_en":"The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review.","published":"2017-06-01"}],"10.1161/circulationaha.117.028479":[{"url":"https://hartvaat.nl/2017/05/30/tijdstrends-in-complicaties-van-bioresorbeerbare-versus-metallic-stents/","title":"Tijdstrends in complicaties van bioresorbeerbare versus metallic stents","title_en":"Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.","published":"2017-05-30"}],"10.1161/circulationaha.116.024436":[{"url":"https://hartvaat.nl/2017/05/30/polygene-risicoscore-en-relatief-voordeel-van-statinetherapie-primaire-preventie/","title":"Polygene risicoscore en relatief voordeel van statinetherapie: primaire preventie","title_en":"Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting.","published":"2017-05-30"}],"10.1056/nejmoa1616218":[{"url":"https://hartvaat.nl/2017/05/25/levosimendan-bij-lv-disfunctie-voor-hartchirurgie-nejm-levo-cts/","title":"Levosimendan bij LV-disfunctie voor hartchirurgie: NEJM LEVO-CTS","title_en":"Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.","published":"2017-05-25"}],"10.1161/circulationaha.117.028303":[{"url":"https://hartvaat.nl/2017/05/23/hemocompatibiliteitsuitkomsten-van-heartmate-3-na-6-maanden-momentum-3/","title":"Hemocompatibiliteitsuitkomsten van HeartMate 3 na 6 maanden: MOMENTUM 3","title_en":"Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.","published":"2017-05-23"}],"10.1016/j.jacc.2017.03.018":[{"url":"https://hartvaat.nl/2017/05/23/stralingsblootstelling-en-vasculaire-toegang-bij-acs-rad-matrix-trial/","title":"Stralingsblootstelling en vasculaire toegang bij ACS: RAD-Matrix-trial","title_en":"Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD-Matrix Trial.","published":"2017-05-23"}],"10.1056/nejmoa1609581":[{"url":"https://hartvaat.nl/2017/05/18/evacetrapib-en-cardiovasculaire-uitkomsten-bij-hoog-vasculair-risico-nejm-accele/","title":"Evacetrapib en cardiovasculaire uitkomsten bij hoog vasculair risico: NEJM ACCELERATE","title_en":"Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.","published":"2017-05-18"}],"10.1056/nejmoa1601895":[{"url":"https://hartvaat.nl/2017/05/18/ularitide-en-cardiovasculaire-mortaliteit-bij-acuut-hartfalen-nejm-true-ahf/","title":"Ularitide en cardiovasculaire mortaliteit bij acuut hartfalen: NEJM TRUE-AHF","title_en":"Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure.","published":"2017-05-18"}],"10.1001/jama.2017.5427":[{"url":"https://hartvaat.nl/2017/05/16/oraal-ijzer-bij-hfref-met-ijzerdeficientie-jama-ironout-hf/","title":"Oraal ijzer bij HFrEF met ijzerdeficiëntie: JAMA IRONOUT-HF","title_en":"Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.","published":"2017-05-16"}],"10.1016/j.jacc.2017.03.531":[{"url":"https://hartvaat.nl/2017/05/16/comorbiditeiten-en-crt-respons-madit-crt-langetermijnfollow-up/","title":"Comorbiditeiten en CRT-respons: MADIT-CRT langetermijnfollow-up","title_en":"Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up.","published":"2017-05-16"}],"10.1161/circulationaha.117.028271":[{"url":"https://hartvaat.nl/2017/05/16/statines-voor-primaire-preventie-bij-ouderen-meta-analyse-van-jupiter-en-hope-3/","title":"Statines voor primaire preventie bij ouderen: meta-analyse van JUPITER en HOPE-3","title_en":"Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials.","published":"2017-05-16"}],"10.1161/circulationaha.116.024632":[{"url":"https://hartvaat.nl/2017/05/16/serieel-hoog-sensitief-troponine-i-en-cv-uitkomsten-bij-diabetes-type-2-examine/","title":"Serieel hoog-sensitief troponine I en CV-uitkomsten bij diabetes type 2: EXAMINE","title_en":"Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).","published":"2017-05-16"}],"10.1056/nejmoa1700445":[{"url":"https://hartvaat.nl/2017/05/11/ifr-of-ffr-bij-pci-nejm-define-flair/","title":"iFR of FFR bij PCI: NEJM DEFINE-FLAIR","title_en":"Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI.","published":"2017-05-11"}],"10.1056/nejmoa1616540":[{"url":"https://hartvaat.nl/2017/05/11/instantaneous-wave-free-ratio-versus-ffr-voor-pci-indicatie-nejm-ifr-swedeheart/","title":"Instantaneous wave-free ratio versus FFR voor PCI-indicatie: NEJM iFR-SWEDEHEART","title_en":"Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI.","published":"2017-05-11"}],"10.1016/j.jacc.2017.02.056":[{"url":"https://hartvaat.nl/2017/05/09/ranolazine-na-incomplete-pci-bij-diabetes-versus-zonder-diabetes-river-pci/","title":"Ranolazine na incomplete PCI bij diabetes versus zonder diabetes: RIVER-PCI","title_en":"Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.","published":"2017-05-09"}],"10.1161/circulationaha.116.026230":[{"url":"https://hartvaat.nl/2017/05/09/agressieve-bloeddrukcontrole-en-recidief-van-af-na-ablatie-gerandomiseerde-trial/","title":"Agressieve bloeddrukcontrole en recidief van AF na ablatie: gerandomiseerde trial","title_en":"Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]).","published":"2017-05-09"}],"10.1016/s0140-6736(17)30751-1":[{"url":"https://hartvaat.nl/2017/05/06/bloedingen-met-laaggedoseerd-rivaroxaban-versus-aspirine-naast-p2y12-atlas-acs-2/","title":"Bloedingen met laaggedoseerd rivaroxaban versus aspirine naast P2Y12: ATLAS ACS 2-TIMI 51","title_en":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.","published":"2017-05-06"}],"10.1056/nejmoa1615664":[{"url":"https://hartvaat.nl/2017/05/04/evolocumab-en-klinische-uitkomsten-bij-cardiovasculaire-ziekte-nejm-fourier/","title":"Evolocumab en klinische uitkomsten bij cardiovasculaire ziekte: NEJM FOURIER","title_en":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.","published":"2017-05-04"}],"10.1161/circulationaha.116.024835":[{"url":"https://hartvaat.nl/2017/05/02/mi-risico-na-stoppen-van-thienopyridine-dapt-studie/","title":"MI-risico na stoppen van thienopyridine: DAPT-studie","title_en":"Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).","published":"2017-05-02"}],"10.1001/jamacardio.2017.0083":[{"url":"https://hartvaat.nl/2017/05/01/langetermijnveiligheid-van-zeer-lage-ldl-cholesterolniveaus-improve-it-analyse/","title":"Langetermijnveiligheid van zeer lage LDL-cholesterolniveaus: IMPROVE-IT-analyse","title_en":"Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.","published":"2017-05-01"}],"10.1001/jamacardio.2017.0022":[{"url":"https://hartvaat.nl/2017/05/01/ischemische-postconditionering-bij-primaire-pci-voor-stemi-jama-cardiology/","title":"Ischemische postconditionering bij primaire PCI voor STEMI: JAMA Cardiology","title_en":"Effect of Ischemic Postconditioning During Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial.","published":"2017-05-01"}],"10.1093/europace/euw398":[{"url":"https://hartvaat.nl/2017/05/01/epicardiaal-vet-en-atriumfibrilleren-systematische-review-en-meta-analyse/","title":"Epicardiaal vet en atriumfibrilleren: systematische review en meta-analyse","title_en":"Is epicardial fat depot associated with atrial fibrillation? A systematic review and meta-analysis.","published":"2017-05-01"}],"10.1093/europace/euw330":[{"url":"https://hartvaat.nl/2017/05/01/cryoablatie-versus-radiofrequentieablatie-bij-paroxysmaal-af-systematische-revie/","title":"Cryoablatie versus radiofrequentieablatie bij paroxysmaal AF: systematische review en meta-analyse","title_en":"Cryoablation vs. radiofrequency ablation for treatment of paroxysmal atrial fibrillation: a systematic review and meta-analysis.","published":"2017-05-01"}],"10.1093/europace/euw084":[{"url":"https://hartvaat.nl/2017/05/01/data-mining-van-de-antipaf-afnet-2-trial-angiotensine-ii-antagonisten-en-paroxys/","title":"Data-mining van de ANTIPAF-AFNET 2-trial: angiotensine-II-antagonisten en paroxysmaal AF","title_en":"Data mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: 'exposing the invisible'.","published":"2017-05-01"}],"10.1093/europace/euw105":[{"url":"https://hartvaat.nl/2017/05/01/ablatie-index-als-marker-voor-ablatielaesiekwaliteit-voorspelling-van-pv-reconne/","title":"Ablatie-index als marker voor ablatielaesiekwaliteit: voorspelling van PV-reconnectie","title_en":"Ablation index, a novel marker of ablation lesion quality: prediction of pulmonary vein reconnection at repeat electrophysiology study and regional differences in target values.","published":"2017-05-01"}],"10.1093/europace/euw108":[{"url":"https://hartvaat.nl/2017/05/01/automatische-pacing-timingaanpassingen-en-effectieve-lv-pacing-bij-crt/","title":"Automatische pacing-timingaanpassingen en effectieve LV-pacing bij CRT","title_en":"Influence of automatic frequent pace-timing adjustments on effective left ventricular pacing during cardiac resynchronization therapy.","published":"2017-05-01"}],"10.1161/hypertensionaha.116.08994":[{"url":"https://hartvaat.nl/2017/05/01/lichamelijke-activiteit-en-incidentie-van-hypertensie-dosis-responsemeta-analyse/","title":"Lichamelijke activiteit en incidentie van hypertensie: dosis-responsemeta-analyse","title_en":"Dose-Response Association Between Physical Activity and Incident Hypertension: A Systematic Review and Meta-Analysis of Cohort Studies.","published":"2017-05-01"}],"10.1161/hypertensionaha.117.09086":[{"url":"https://hartvaat.nl/2017/05/01/aanhoudende-bloeddrukreductie-met-baroreceptoractivatietherapie-6-jaarsfollow-up/","title":"Aanhoudende bloeddrukreductie met baroreceptoractivatietherapie: 6-jaarsfollow-up","title_en":"Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up.","published":"2017-05-01"}],"10.1161/hypertensionaha.116.07982":[{"url":"https://hartvaat.nl/2017/05/01/voortzetten-of-tijdelijk-stoppen-van-antihypertensiva-bij-acuut-cva-ipd-meta-ana/","title":"Voortzetten of tijdelijk stoppen van antihypertensiva bij acuut CVA: IPD meta-analyse","title_en":"Continuing or Temporarily Stopping Prestroke Antihypertensive Medication in Acute Stroke: An Individual Patient Data Meta-Analysis.","published":"2017-05-01"}],"10.1136/heartjnl-2016-310098":[{"url":"https://hartvaat.nl/2017/05/01/melatoninesecretie-en-myocardinfarctrisico-geneste-case-controlstudie/","title":"Melatoninesecretie en myocardinfarctrisico: geneste case-controlstudie","title_en":"A nested case-control study of the association between melatonin secretion and incident myocardial infarction.","published":"2017-05-01"}],"10.1056/nejmoa1701005":[{"url":"https://hartvaat.nl/2017/04/27/ononderbroken-dabigatran-versus-warfarine-bij-af-ablatie-nejm-re-circuit/","title":"Ononderbroken dabigatran versus warfarine bij AF-ablatie: NEJM RE-CIRCUIT","title_en":"Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.","published":"2017-04-27"}],"10.1016/j.jacc.2017.02.031":[{"url":"https://hartvaat.nl/2017/04/25/kwaliteit-van-leven-na-chirurgie-of-des-bij-drienvaten-of-hoofdstamlijden/","title":"Kwaliteit van leven na chirurgie of DES bij drienvaten- of hoofdstamlijden","title_en":"Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease.","published":"2017-04-25"}],"10.1016/j.jacc.2017.02.029":[{"url":"https://hartvaat.nl/2017/04/25/bloedingsgerelateerde-sterfte-naar-dapt-duur-na-coronaire-stenting/","title":"Bloedingsgerelateerde sterfte naar DAPT-duur na coronaire stenting","title_en":"Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting.","published":"2017-04-25"}],"10.1056/nejmoa1612836":[{"url":"https://hartvaat.nl/2017/04/20/frequentie-van-evidence-based-retinopathiescreening-bij-diabetes-type-1-nejm/","title":"Frequentie van evidence-based retinopathiescreening bij diabetes type 1: NEJM","title_en":"Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.","published":"2017-04-20"}],"10.1056/nejmoa1701488":[{"url":"https://hartvaat.nl/2017/04/20/cardiovasculaire-werkzaamheid-en-veiligheid-van-bococizumab-bij-hoogrisicopatien/","title":"Cardiovasculaire werkzaamheid en veiligheid van bococizumab bij hoogrisicopatiënten: NEJM","title_en":"Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.","published":"2017-04-20"}],"10.1056/nejmoa1614062":[{"url":"https://hartvaat.nl/2017/04/20/ldl-reductievariabiliteit-en-antilichaamvorming-bij-bococizumab-nejm/","title":"LDL-reductievariabiliteit en antilichaamvorming bij bococizumab: NEJM","title_en":"Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.","published":"2017-04-20"}],"10.1016/j.jacc.2017.02.027":[{"url":"https://hartvaat.nl/2017/04/18/risicostratificatie-bij-cardiogene-shock-na-acuut-myocardinfarct/","title":"Risicostratificatie bij cardiogene shock na acuut myocardinfarct","title_en":"Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction.","published":"2017-04-18"}],"10.1016/j.jacc.2017.02.023":[{"url":"https://hartvaat.nl/2017/04/18/vroeg-invasief-versus-selectieve-strategie-bij-nste-acs-ictus-trial-langetermijn/","title":"Vroeg invasief versus selectieve strategie bij NSTE-ACS: ICTUS-trial langetermijn","title_en":"Early Invasive Versus Selective Strategy for Non-ST-Segment Elevation Acute Coronary Syndrome: The ICTUS Trial.","published":"2017-04-18"}],"10.1093/eurheartj/ehw593":[{"url":"https://hartvaat.nl/2017/04/14/vericiguat-bij-verslechterend-chronisch-hfpef-socrates-preserved-resultaten/","title":"Vericiguat bij verslechterend chronisch HFpEF: SOCRATES-PRESERVED-resultaten","title_en":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.","published":"2017-04-14"}],"10.1093/eurheartj/ehx025":[{"url":"https://hartvaat.nl/2017/04/14/macitentan-en-hemodynamiek-bij-pah-seraphin-hemodynamische-substudie/","title":"Macitentan en hemodynamiek bij PAH: SERAPHIN hemodynamische substudie","title_en":"SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.","published":"2017-04-14"}],"10.1093/eurheartj/ehx099":[{"url":"https://hartvaat.nl/2017/04/14/zuurstofverrijkte-lucht-en-inspanningsprestatie-bij-precapillaire-pulmonale-hype/","title":"Zuurstofverrijkte lucht en inspanningsprestatie bij precapillaire pulmonale hypertensie","title_en":"Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial.","published":"2017-04-14"}],"10.1093/eurheartj/ehw570":[{"url":"https://hartvaat.nl/2017/04/14/systolische-bloeddruk-en-werkzaamheid-van-sacubitril-valsartan-bij-chronisch-hfr/","title":"Systolische bloeddruk en werkzaamheid van sacubitril/valsartan bij chronisch HFrEF","title_en":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.","published":"2017-04-14"}],"10.1056/nejmoa1615758":[{"url":"https://hartvaat.nl/2017/04/13/inclisiran-bij-patienten-met-hoog-cv-risico-en-verhoogd-ldl-nejm-orion-1/","title":"Inclisiran bij patiënten met hoog CV-risico en verhoogd LDL: NEJM ORION-1","title_en":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.","published":"2017-04-13"}],"10.1093/eurheartj/ehx048":[{"url":"https://hartvaat.nl/2017/04/07/radiale-versus-femorale-toegang-bij-acs-met-en-zonder-st-elevatie/","title":"Radiale versus femorale toegang bij ACS met en zonder ST-elevatie","title_en":"Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation.","published":"2017-04-07"}],"10.1093/eurheartj/ehw627":[{"url":"https://hartvaat.nl/2017/04/07/drie-zes-of-twaalf-maanden-dapt-na-des-met-of-zonder-acs-meta-analyse/","title":"Drie, zes of twaalf maanden DAPT na DES met of zonder ACS: meta-analyse","title_en":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.","published":"2017-04-07"}],"10.1056/nejmoa1606148":[{"url":"https://hartvaat.nl/2017/04/06/gewichtsfluctuaties-en-cardiovasculaire-uitkomsten-bij-coronairlijden-nejm/","title":"Gewichtsfluctuaties en cardiovasculaire uitkomsten bij coronairlijden: NEJM","title_en":"Body-Weight Fluctuations and Outcomes in Coronary Disease.","published":"2017-04-06"}],"10.1016/j.jacc.2017.01.032":[{"url":"https://hartvaat.nl/2017/04/04/inspanningstraining-bij-chronisch-hartfalen-met-atriumfibrilleren/","title":"Inspanningstraining bij chronisch hartfalen met atriumfibrilleren","title_en":"Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation.","published":"2017-04-04"}],"10.1093/europace/euw106":[{"url":"https://hartvaat.nl/2017/04/01/beperkte-chirurgische-linkeratriumablatie-bij-af-effectief-maar-vermindert-la-fu/","title":"Beperkte chirurgische linkeratriumablatie bij AF: effectief maar vermindert LA-functie","title_en":"Limited left atrial surgical ablation effectively treats atrial fibrillation but decreases left atrial function.","published":"2017-04-01"}],"10.1093/europace/euw039":[{"url":"https://hartvaat.nl/2017/04/01/aanvullende-elektroden-op-de-quartet-lv-lead-bieden-meer-crt-programmeringsmogel/","title":"Aanvullende elektroden op de Quartet LV-lead bieden meer CRT-programmeringsmogelijkheden","title_en":"Additional electrodes on the Quartet™ LV lead provide more programmable pacing options than bipolar and tripolar equivalents.","published":"2017-04-01"}],"10.1093/europace/euw201":[{"url":"https://hartvaat.nl/2017/04/01/rol-van-adenosine-geleide-pvi-bij-katheterablatie-voor-af-meta-analyse/","title":"Rol van adenosine-geleide PVI bij katheterablatie voor AF: meta-analyse","title_en":"Role of adenosine-guided pulmonary vein isolation in patients undergoing catheter ablation for atrial fibrillation: a meta-analysis.","published":"2017-04-01"}],"10.1001/jamacardio.2016.4828":[{"url":"https://hartvaat.nl/2017/04/01/fenofibraat-en-langetermijn-cardiovasculair-risico-bij-statinebehandelde-diabete/","title":"Fenofibraat en langetermijn cardiovasculair risico bij statinebehandelde diabetespatiënten","title_en":"Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.","published":"2017-04-01"}],"10.1093/eurheartj/ehw203":[{"url":"https://hartvaat.nl/2017/04/01/polymeervrije-biolimus-stent-bij-hoog-bloedingsrisico-met-acs-leaders-free-subst/","title":"Polymeervrije biolimus-stent bij hoog bloedingsrisico met ACS: Leaders Free substudie","title_en":"Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study.","published":"2017-04-01"}],"10.1161/hypertensionaha.116.08818":[{"url":"https://hartvaat.nl/2017/04/01/medicatietrouw-en-het-effect-van-renale-denervatie-de-sympathy-trial/","title":"Medicatietrouw en het effect van renale denervatie: de SYMPATHY-trial","title_en":"Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial.","published":"2017-04-01"}],"10.1161/hypertensionaha.116.08499":[{"url":"https://hartvaat.nl/2017/04/01/optimale-systolische-bloeddruk-voor-primaire-cva-preventie-bij-hypertensie-csppt/","title":"Optimale systolische bloeddruk voor primaire CVA-preventie bij hypertensie: CSPPT-bevindingen","title_en":"Optimal Systolic Blood Pressure Levels for Primary Prevention of Stroke in General Hypertensive Adults: Findings From the CSPPT (China Stroke Primary Prevention Trial).","published":"2017-04-01"}],"10.1136/heartjnl-2016-309852":[{"url":"https://hartvaat.nl/2017/04/01/oscillerende-whole-body-vibratie-verbetert-inspanningscapaciteit-bij-pah/","title":"Oscillerende whole-body vibratie verbetert inspanningscapaciteit bij PAH","title_en":"Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study.","published":"2017-04-01"}],"10.1136/heartjnl-2016-309621":[{"url":"https://hartvaat.nl/2017/04/01/hemodynamische-effecten-van-riociguat-bij-inoperabel-cteph/","title":"Hemodynamische effecten van riociguat bij inoperabel CTEPH","title_en":"Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.","published":"2017-04-01"}],"10.1136/heartjnl-2016-309901":[{"url":"https://hartvaat.nl/2017/04/01/niet-ernstige-bloedingen-met-apixaban-versus-warfarine-bij-af/","title":"Niet-ernstige bloedingen met apixaban versus warfarine bij AF","title_en":"Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.","published":"2017-04-01"}],"10.1136/heartjnl-2016-309748":[{"url":"https://hartvaat.nl/2017/04/01/intracoronair-nitriet-onderdrukt-de-inflammatoire-respons-na-primaire-pci/","title":"Intracoronair nitriet onderdrukt de inflammatoire respons na primaire PCI","title_en":"Intracoronary nitrite suppresses the inflammatory response following primary percutaneous coronary intervention.","published":"2017-04-01"}],"10.1056/nejmoa1701067":[{"url":"https://hartvaat.nl/2017/03/30/ffr-geleide-multivaten-pci-bij-myocardinfarct-nejm-compare-acute/","title":"FFR-geleide multivaten-PCI bij myocardinfarct: NEJM COMPARE-ACUTE","title_en":"Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction.","published":"2017-03-30"}],"10.1016/j.jacc.2017.01.041":[{"url":"https://hartvaat.nl/2017/03/28/adaptieve-servoventilatie-bij-hartfalen-de-cat-hf-trial/","title":"Adaptieve servoventilatie bij hartfalen: de CAT-HF-trial","title_en":"Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial.","published":"2017-03-28"}],"10.1161/circulationaha.116.026714":[{"url":"https://hartvaat.nl/2017/03/28/edoxaban-bij-af-met-bioprothese-hartkleppen-trombo-emboliepreventie/","title":"Edoxaban bij AF met bioprothese-hartkleppen: trombo-emboliepreventie","title_en":"Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.","published":"2017-03-28"}],"10.1016/j.jacc.2016.12.035":[{"url":"https://hartvaat.nl/2017/03/21/kortetermijneffecten-van-tolvaptan-bij-acuut-hartfalen-met-volume-overbelasting/","title":"Kortetermijneffecten van tolvaptan bij acuut hartfalen met volume-overbelasting","title_en":"Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.","published":"2017-03-21"}],"10.1016/j.jacc.2016.12.031":[{"url":"https://hartvaat.nl/2017/03/21/kleplijden-en-edoxaban-versus-warfarine-bij-af-engage-af-timi-48/","title":"Kleplijden en edoxaban versus warfarine bij AF: ENGAGE AF-TIMI 48","title_en":"Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.","published":"2017-03-21"}],"10.1016/j.jacc.2016.12.038":[{"url":"https://hartvaat.nl/2017/03/21/doac-s-bij-af-met-kleplijden-jacc-review/","title":"DOAC's bij AF met kleplijden: JACC-review","title_en":"Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.","published":"2017-03-21"}],"10.1161/circulationaha.116.026075":[{"url":"https://hartvaat.nl/2017/03/21/plotse-hartdood-bij-ischemisch-hartfalen-na-cabg-stich-resultaten/","title":"Plotse hartdood bij ischemisch hartfalen na CABG: STICH-resultaten","title_en":"Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure).","published":"2017-03-21"}],"10.1093/eurheartj/ehw565":[{"url":"https://hartvaat.nl/2017/03/21/nieuwe-risicovoorspellingsscore-bij-af-voor-netto-klinisch-resultaat-engage-af-t/","title":"Nieuwe risicovoorspellingsscore bij AF voor netto klinisch resultaat: ENGAGE AF-TIMI 48","title_en":"A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.","published":"2017-03-21"}],"10.1016/j.jacc.2016.09.004":[{"url":"https://hartvaat.nl/2017/03/21/werkzaamheid-en-veiligheid-van-tolvaptan-bij-gehospitaliseerd-acuut-hartfalen/","title":"Werkzaamheid en veiligheid van tolvaptan bij gehospitaliseerd acuut hartfalen","title_en":"Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.","published":"2017-03-21"}],"10.1093/eurheartj/ehw525":[{"url":"https://hartvaat.nl/2017/03/14/afweging-myocardinfarct-versus-bloedingstype-en-mortaliteit-na-acs-tra-2p-timi-5/","title":"Afweging myocardinfarct versus bloedingstype en mortaliteit na ACS: TRA 2°P-TIMI 50","title_en":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.","published":"2017-03-14"}],"10.1161/circulationaha.116.025453":[{"url":"https://hartvaat.nl/2017/03/14/drie-arteriele-grafts-verbeteren-langetermijnoverleving-meta-analyse-van-propens/","title":"Drie arteriële grafts verbeteren langetermijnoverleving: meta-analyse van propensity-matched studies","title_en":"Three Arterial Grafts Improve Late Survival: A Meta-Analysis of Propensity-Matched Studies.","published":"2017-03-14"}],"10.1016/s0140-6736(17)30260-x":[{"url":"https://hartvaat.nl/2017/03/11/kwartdosis-viervoudige-combinatietherapie-als-initiele-hypertensiebehandeling-la/","title":"Kwartdosis viervoudige combinatietherapie als initiële hypertensiebehandeling: Lancet gerandomiseerde trial","title_en":"Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.","published":"2017-03-11"}],"10.1093/eurheartj/ehw509":[{"url":"https://hartvaat.nl/2017/03/07/cva-risico-bij-chronisch-hartfalen-met-behouden-ef-zonder-af-charm-analyse/","title":"CVA-risico bij chronisch hartfalen met behouden EF zonder AF: CHARM-analyse","title_en":"Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.","published":"2017-03-07"}],"10.1093/eurheartj/ehw506":[{"url":"https://hartvaat.nl/2017/03/07/lv-global-longitudinal-strain-en-prognose-bij-hartfalen-met-smal-qrs-en-crt/","title":"LV global longitudinal strain en prognose bij hartfalen met smal QRS en CRT","title_en":"Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.","published":"2017-03-07"}],"10.1016/j.jacc.2016.10.089":[{"url":"https://hartvaat.nl/2017/03/07/dieetaanbevelingen-en-gewichtsverlies-en-cardiovasculaire-risicofactoren/","title":"Dieetaanbevelingen en gewichtsverlies en cardiovasculaire risicofactoren","title_en":"Effect of Current Dietary Recommendations on Weight Loss and Cardiovascular Risk Factors.","published":"2017-03-07"}],"10.1093/eurheartj/ehw526":[{"url":"https://hartvaat.nl/2017/03/07/contractiliteitssensor-geleide-crt-optimalisatie-respond-crt-trial/","title":"Contractiliteitssensor-geleide CRT-optimalisatie: RESPOND-CRT-trial","title_en":"Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial.","published":"2017-03-07"}],"10.1001/jamacardio.2016.5190":[{"url":"https://hartvaat.nl/2017/03/01/5-jaarsuitkomsten-van-zotarolimus-en-everolimus-eluting-stents-trial-en-real-wor/","title":"5-jaarsuitkomsten van zotarolimus- en everolimus-eluting stents: trial en real-world","title_en":"Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial.","published":"2017-03-01"}],"10.1093/eurheartj/ehw543":[{"url":"https://hartvaat.nl/2017/03/01/cardiopoietische-celtherapie-bij-gevorderd-ischemisch-hartfalen-c-cure-39-weeksr/","title":"Cardiopoietische celtherapie bij gevorderd ischemisch hartfalen: C-CURE 39-weeksresultaten","title_en":"Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.","published":"2017-03-01"}],"10.1093/europace/euw262":[{"url":"https://hartvaat.nl/2017/03/01/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-geactualiseerde-meta/","title":"Cryoballon versus radiofrequentieablatie bij paroxysmaal AF: geactualiseerde meta-analyse","title_en":"Cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: an updated meta-analysis of randomized and observational studies.","published":"2017-03-01"}],"10.1093/europace/euw088":[{"url":"https://hartvaat.nl/2017/03/01/bloedmarkers-voor-ablatie-en-af-recidief-meta-analyse/","title":"Bloedmarkers vóór ablatie en AF-recidief: meta-analyse","title_en":"Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis.","published":"2017-03-01"}],"10.1093/europace/euw035":[{"url":"https://hartvaat.nl/2017/03/01/vaste-versus-responsieve-pacingfrequentie-bij-permanent-af-met-pacemakerindicati/","title":"Vaste versus responsieve pacingfrequentie bij permanent AF met pacemakerindicatie","title_en":"Effect of fixed-rate vs. rate-RESPONSIve pacing on exercise capacity in patients with permanent, refractory atrial fibrillation and left ventricular dysfunction treated with atrioventricular junction aBLation and bivEntricular pacing (RESPONSIBLE): a prospective, multicentre, randomized, single-blind study.","published":"2017-03-01"}],"10.1161/hypertensionaha.116.08448":[{"url":"https://hartvaat.nl/2017/03/01/24-uurs-bloeddrukmonitoring-bij-renale-denervatie-denerhtn-studie/","title":"24-uurs bloeddrukmonitoring bij renale denervatie: DENERHTN-studie","title_en":"Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension).","published":"2017-03-01"}],"10.1161/hypertensionaha.116.08556":[{"url":"https://hartvaat.nl/2017/03/01/sacubitril-valsartan-versus-olmesartan-op-centrale-hemodynamiek-bij-ouderen-para/","title":"Sacubitril/valsartan versus olmesartan op centrale hemodynamiek bij ouderen: PARAMETER-studie","title_en":"Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.","published":"2017-03-01"}],"10.1136/heartjnl-2016-309781":[{"url":"https://hartvaat.nl/2017/03/01/katheterablatie-als-eerstelijnsbehandeling-bij-paroxysmaal-af-5-jaarsresultaten/","title":"Katheterablatie als eerstelijnsbehandeling bij paroxysmaal AF: 5-jaarsresultaten","title_en":"Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial.","published":"2017-03-01"}],"10.1016/j.jacc.2016.11.067":[{"url":"https://hartvaat.nl/2017/02/28/myocardiaal-herstel-bij-systolisch-hartfalen-met-auto-antilichamen-tegen-1-adren/","title":"Myocardiaal herstel bij systolisch hartfalen met auto-antilichamen tegen β1-adrenerge receptoren","title_en":"Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against β1-Adrenergic Receptors.","published":"2017-02-28"}],"10.1161/circulationaha.116.022924":[{"url":"https://hartvaat.nl/2017/02/28/hoog-intensieve-intervaltraining-bij-hartfalen-met-verminderde-ejectiefractie/","title":"Hoog-intensieve intervaltraining bij hartfalen met verminderde ejectiefractie","title_en":"High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction.","published":"2017-02-28"}],"10.1001/jama.2016.21037":[{"url":"https://hartvaat.nl/2017/02/21/fibrinogeenconcentraat-bij-intraoperatief-bloedverlies-tijdens-hoog-risico-hartc/","title":"Fibrinogeenconcentraat bij intraoperatief bloedverlies tijdens hoog-risico hartchirurgie: JAMA-trial","title_en":"Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial.","published":"2017-02-21"}],"10.1161/circulationaha.116.024593":[{"url":"https://hartvaat.nl/2017/02/21/diabetesstatus-en-cardiovasculaire-uitkomsten-bij-hfpef-klinische-en-echocardiog/","title":"Diabetesstatus en cardiovasculaire uitkomsten bij HFpEF: klinische en echocardiografische kenmerken","title_en":"Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).","published":"2017-02-21"}],"10.1161/circulationaha.116.024921":[{"url":"https://hartvaat.nl/2017/02/21/genetische-obesitas-en-risico-op-atriumfibrilleren-mendeliaanse-randomisatie/","title":"Genetische obesitas en risico op atriumfibrilleren: Mendeliaanse randomisatie","title_en":"Genetic Obesity and the Risk of Atrial Fibrillation: Causal Estimates from Mendelian Randomization.","published":"2017-02-21"}],"10.1056/nejmoa1600869":[{"url":"https://hartvaat.nl/2017/02/16/bariatrische-chirurgie-versus-intensieve-medicamenteuze-therapie-bij-diabetes-5-/","title":"Bariatrische chirurgie versus intensieve medicamenteuze therapie bij diabetes: 5-jaarsresultaten NEJM","title_en":"Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.","published":"2017-02-16"}],"10.1161/circulationaha.116.026793":[{"url":"https://hartvaat.nl/2017/02/14/doac-s-bij-af-met-kleplijden-excl-significante-mitralisstenose-meta-analyse/","title":"DOAC's bij AF met kleplijden (excl. significante mitralisstenose): meta-analyse","title_en":"Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves: A Meta-Analysis.","published":"2017-02-14"}],"10.1161/circulationaha.116.023712":[{"url":"https://hartvaat.nl/2017/02/14/mediterraan-dieet-verbetert-hdl-functie-bij-hoog-cardiovasculair-risico-gerandom/","title":"Mediterraan dieet verbetert HDL-functie bij hoog cardiovasculair risico: gerandomiseerde trial","title_en":"Mediterranean Diet Improves High-Density Lipoprotein Function in High-Cardiovascular-Risk Individuals: A Randomized Controlled Trial.","published":"2017-02-14"}],"10.1161/circulationaha.116.022146":[{"url":"https://hartvaat.nl/2017/02/14/cholesterolniveaus-en-de-rol-bij-het-identificeren-van-statinenontvangers/","title":"Cholesterolniveaus en de rol bij het identificeren van statinenontvangers","title_en":"Cholesterol Levels Should Play a More Important Role in Identifying Statin Recipients.","published":"2017-02-14"}],"10.1161/circulationaha.116.025760":[{"url":"https://hartvaat.nl/2017/02/14/laaggedoseerde-aspirine-voor-primaire-cardiovasculaire-preventie-bij-diabetes-ty/","title":"Laaggedoseerde aspirine voor primaire cardiovasculaire preventie bij diabetes type 2: 10-jaarsfollow-up","title_en":"Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.","published":"2017-02-14"}],"10.1016/j.jacc.2016.10.078":[{"url":"https://hartvaat.nl/2017/02/07/doodsoorzaken-bij-hartfalen-met-behouden-ejectiefractie/","title":"Doodsoorzaken bij hartfalen met behouden ejectiefractie","title_en":"Mode of Death in Heart Failure With Preserved Ejection Fraction.","published":"2017-02-07"}],"10.1016/j.jacc.2016.10.034":[{"url":"https://hartvaat.nl/2017/02/07/acc-aats-aha-2016-criteria-voor-gepaste-coronaire-revascularisatie-bij-acs-en-st/","title":"ACC/AATS/AHA 2016 criteria voor gepaste coronaire revascularisatie bij ACS en stabiel coronairlijden","title_en":"ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons.","published":"2017-02-07"}],"10.1056/nejmoa1602954":[{"url":"https://hartvaat.nl/2017/02/02/intrapericardiale-lvad-bij-gevorderd-hartfalen-nejm/","title":"Intrapericardiale LVAD bij gevorderd hartfalen: NEJM","title_en":"Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure.","published":"2017-02-02"}],"10.1056/nejmoa1610426":[{"url":"https://hartvaat.nl/2017/02/02/volledig-magnetisch-zwevende-circulatoire-pomp-bij-gevorderd-hartfalen-nejm-mome/","title":"Volledig magnetisch zwevende circulatoire pomp bij gevorderd hartfalen: NEJM MOMENTUM 3","title_en":"A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure.","published":"2017-02-02"}],"10.1093/europace/euw052":[{"url":"https://hartvaat.nl/2017/02/01/vernakalant-versus-ibutilide-voor-sinusritme-bij-recent-onset-af-gerandomiseerde/","title":"Vernakalant versus ibutilide voor sinusritme bij recent-onset AF: gerandomiseerde trial","title_en":"Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.","published":"2017-02-01"}],"10.1093/europace/euw242":[{"url":"https://hartvaat.nl/2017/02/01/ehra-eacpr-positiedocument-beheer-van-patienten-met-af-en-acute-coronaire-events/","title":"EHRA/EACPR positiedocument: beheer van patiënten met AF en acute coronaire events","title_en":"European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).","published":"2017-02-01"}],"10.1093/europace/euw221":[{"url":"https://hartvaat.nl/2017/02/01/reductie-van-onnodige-ventriculaire-pacing-en-klinische-uitkomsten-bij-behouden-/","title":"Reductie van onnodige ventriculaire pacing en klinische uitkomsten bij behouden LV-functie","title_en":"Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis.","published":"2017-02-01"}],"10.1093/europace/euw319":[{"url":"https://hartvaat.nl/2017/02/01/stapsgewijze-massascreening-op-af-met-nt-probnp-strokestop-ii-studieontwerp/","title":"Stapsgewijze massascreening op AF met NT-proBNP: STROKESTOP II studieontwerp","title_en":"Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design.","published":"2017-02-01"}],"10.1001/jamacardio.2016.4556":[{"url":"https://hartvaat.nl/2017/02/01/cangrelor-versus-gpiib-iiia-remmers-ischemie-en-bloedingsrisico-s-vergeleken/","title":"Cangrelor versus GPIIb/IIIa-remmers: ischemie- en bloedingsrisico's vergeleken","title_en":"Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.","published":"2017-02-01"}],"10.1161/hypertensionaha.116.08600":[{"url":"https://hartvaat.nl/2017/02/01/bereikte-bloeddruk-en-cardiovasculaire-uitkomsten-bij-oudere-patienten-met-geiso/","title":"Bereikte bloeddruk en cardiovasculaire uitkomsten bij oudere patiënten met geïsoleerde systolische hypertensie","title_en":"On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension.","published":"2017-02-01"}],"10.1161/hypertensionaha.116.08488":[{"url":"https://hartvaat.nl/2017/02/01/urinezuurverlagende-middelen-en-endotheelfunctie-gerandomiseerde-trial/","title":"Urinezuurverlagende middelen en endotheelfunctie: gerandomiseerde trial","title_en":"Effect of Uric Acid-Lowering Agents on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial.","published":"2017-02-01"}],"10.1161/hypertensionaha.116.08386":[{"url":"https://hartvaat.nl/2017/02/01/reverse-causality-in-de-associatie-bloeddruk-cardiovasculair-risico-bij-ckd/","title":"Reverse causality in de associatie bloeddruk-cardiovasculair risico bij CKD","title_en":"Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.","published":"2017-02-01"}],"10.1161/circulationaha.116.025783":[{"url":"https://hartvaat.nl/2017/01/24/heropnames-bij-af-patienten-na-stenting-twee-antitromboticastrategieen-vergeleke/","title":"Heropnames bij AF-patiënten na stenting: twee antitromboticastrategieën vergeleken","title_en":"Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.","published":"2017-01-24"}],"10.1016/j.jacc.2016.10.026":[{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-ondersteuning-versus-iabp-bij-cardiogene-shock-meta-analys/","title":"Percutane mechanische ondersteuning versus IABP bij cardiogene shock: meta-analyse","title_en":"Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump for Treating Cardiogenic Shock: Meta-Analysis.","published":"2017-01-24"}],"10.1016/j.jacc.2016.10.022":[{"url":"https://hartvaat.nl/2017/01/24/percutane-mechanische-circulatoire-ondersteuning-versus-iabp-bij-cardiogene-shoc/","title":"Percutane mechanische circulatoire ondersteuning versus IABP bij cardiogene shock na MI","title_en":"Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction.","published":"2017-01-24"}],"10.1016/j.jacc.2016.10.055":[{"url":"https://hartvaat.nl/2017/01/17/cangrelor-met-en-zonder-gpiib-iiia-remmers-bij-pci/","title":"Cangrelor met en zonder GPIIb/IIIa-remmers bij PCI","title_en":"Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.","published":"2017-01-17"}],"10.1016/j.jacc.2016.10.057":[{"url":"https://hartvaat.nl/2017/01/17/geoxideerde-fosfolipiden-op-apob-100-en-recidiverende-ischemische-events-na-cva/","title":"Geoxideerde fosfolipiden op apoB-100 en recidiverende ischemische events na CVA","title_en":"Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.","published":"2017-01-17"}],"10.1016/j.jacc.2016.10.043":[{"url":"https://hartvaat.nl/2017/01/17/dapt-versus-aspirine-monotherapie-bij-diabetes-met-multivatenlijden-na-cabg-free/","title":"DAPT versus aspirine monotherapie bij diabetes met multivatenlijden na CABG: FREEDOM","title_en":"Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.","published":"2017-01-17"}],"10.1016/j.jacc.2016.10.009":[{"url":"https://hartvaat.nl/2017/01/17/2-jaarsuitkomsten-van-drug-coated-stents-zonder-polymeer-bij-hoog-bloedingsrisic/","title":"2-jaarsuitkomsten van drug-coated stents zonder polymeer bij hoog bloedingsrisico","title_en":"2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.","published":"2017-01-17"}],"10.1136/heartjnl-2016-309782":[{"url":"https://hartvaat.nl/2017/01/15/linker-hartoorsluiting-versus-medicamenteuze-behandeling-bij-af-netwerkmeta-anal/","title":"Linker-hartoorsluiting versus medicamenteuze behandeling bij AF: netwerkmeta-analyse","title_en":"Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials.","published":"2017-01-15"}],"10.1161/circulationaha.116.025371":[{"url":"https://hartvaat.nl/2017/01/10/trombusaspiratie-bij-stemi-individuele-patientdata-meta-analyse/","title":"Trombusaspiratie bij STEMI: individuele patiëntdata meta-analyse","title_en":"Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration.","published":"2017-01-10"}],"10.1093/eurheartj/ehw325":[{"url":"https://hartvaat.nl/2017/01/07/verminderd-bloeddrukverlagend-effect-van-renale-denervatie-bij-geisoleerde-systo/","title":"Verminderd bloeddrukverlagend effect van renale denervatie bij geïsoleerde systolische hypertensie","title_en":"Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry.","published":"2017-01-07"}],"10.1056/nejmoa1609243":[{"url":"https://hartvaat.nl/2017/01/05/inclisiran-een-langwerkende-rna-interferentie-pcsk9-remmer-nejm/","title":"Inclisiran: een langwerkende RNA-interferentie PCSK9-remmer — NEJM","title_en":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.","published":"2017-01-05"}],"10.1161/circulationaha.116.024507":[{"url":"https://hartvaat.nl/2017/01/03/traditionele-cv-risicofactoren-en-veneuze-trombo-embolie-individuele-patientdata/","title":"Traditionele CV-risicofactoren en veneuze trombo-embolie: individuele patiëntdata meta-analyse","title_en":"Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Prospective Studies.","published":"2017-01-03"}],"10.1001/jamacardio.2016.4733":[{"url":"https://hartvaat.nl/2017/01/01/verminderd-hyperkaliemierisico-met-mra-door-sacubitril-valsartan-bij-hartfalen/","title":"Verminderd hyperkaliëmierisico met MRA door sacubitril/valsartan bij hartfalen","title_en":"Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.","published":"2017-01-01"}],"10.1001/jamacardio.2016.3756":[{"url":"https://hartvaat.nl/2017/01/01/richtlijnen-voor-listing-van-harttransplantatiekandidaten-10-jaarsupdate/","title":"Richtlijnen voor listing van harttransplantatiekandidaten: 10-jaarsupdate","title_en":"Guidelines for Listing Candidates for Heart Transplant: A 10-Year Update.","published":"2017-01-01"}],"10.1093/europace/euw368":[{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","title":"AXAFA-AFNET 5: apixaban versus VKA bij AF-ablatie — studieprotocol","title_en":"Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.","published":"2017-01-01"}],"10.1161/hypertensionaha.116.08158":[{"url":"https://hartvaat.nl/2017/01/01/ontwikkeling-van-linkerventrikelhypertrofie-bij-behandelde-hypertensie-campania-/","title":"Ontwikkeling van linkerventrikelhypertrofie bij behandelde hypertensie: Campania Salute Network","title_en":"Development of Left Ventricular Hypertrophy in Treated Hypertensive Outpatients: The Campania Salute Network.","published":"2017-01-01"}],"10.1161/hypertensionaha.116.08484":[{"url":"https://hartvaat.nl/2017/01/01/sacubitril-valsartan-en-natriurese-diurese-en-bloeddruk-bij-zoutgevoelige-hypert/","title":"Sacubitril/valsartan en natriurese, diurese en bloeddruk bij zoutgevoelige hypertensie","title_en":"Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.","published":"2017-01-01"}],"10.1161/hypertensionaha.116.08076":[{"url":"https://hartvaat.nl/2017/01/01/intensieve-versus-standaard-bloeddrukcontrole-op-ambulante-bloeddruk-sprint-resu/","title":"Intensieve versus standaard bloeddrukcontrole op ambulante bloeddruk: SPRINT-resultaten","title_en":"Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study.","published":"2017-01-01"}],"10.1161/hypertensionaha.116.08485":[{"url":"https://hartvaat.nl/2017/01/01/bloeddrukverlaging-en-secundaire-cva-preventie-meta-regressieanalyse/","title":"Bloeddrukverlaging en secundaire CVA-preventie: meta-regressieanalyse","title_en":"Blood Pressure Reduction and Secondary Stroke Prevention: A Systematic Review and Metaregression Analysis of Randomized Clinical Trials.","published":"2017-01-01"}],"10.1161/hypertensionaha.116.08267":[{"url":"https://hartvaat.nl/2017/01/01/genoomwijde-meta-analyse-van-bloeddrukrespons-op-hydrochloorthiazide/","title":"Genoomwijde meta-analyse van bloeddrukrespons op hydrochloorthiazide","title_en":"Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.","published":"2017-01-01"}],"10.1093/europace/euw141":[{"url":"https://hartvaat.nl/2017/01/01/percutane-linker-hartoorsluiting-munchen-consensusdocument-over-definities-en-ei/","title":"Percutane linker-hartoorsluiting: München-consensusdocument over definities en eindpunten","title_en":"Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies.","published":"2017-01-01"}],"10.1056/nejmoa1610021":[{"url":"https://hartvaat.nl/2016/12/29/bilaterale-versus-enkelvoudige-a-mammaria-interna-grafts-nejm-art-trial/","title":"Bilaterale versus enkelvoudige a. mammaria interna-grafts: NEJM ART-trial","title_en":"Randomized Trial of Bilateral versus Single Internal-Thoracic-Artery Grafts.","published":"2016-12-29"}],"10.1016/j.jacc.2016.10.037":[{"url":"https://hartvaat.nl/2016/12/27/hotballoon-pulmonaalvene-ablatie-bij-paroxysmaal-af-japanse-multicenter-trial/","title":"HotBalloon pulmonaalvene-ablatie bij paroxysmaal AF: Japanse multicenter trial","title_en":"HotBalloon Ablation of the Pulmonary Veins for Paroxysmal AF: A Multicenter Randomized Trial in Japan.","published":"2016-12-27"}],"10.1016/j.jacc.2016.10.020":[{"url":"https://hartvaat.nl/2016/12/27/hoog-sensitief-troponine-statinetherapie-en-risico-op-coronairlijden/","title":"Hoog-sensitief troponine, statinetherapie en risico op coronairlijden","title_en":"High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease.","published":"2016-12-27"}],"10.1056/nejmoa1611594":[{"url":"https://hartvaat.nl/2016/12/22/preventie-van-bloedingen-bij-af-patienten-die-pci-ondergaan-nejm-pioneer-af-pci/","title":"Preventie van bloedingen bij AF-patiënten die PCI ondergaan: NEJM PIONEER AF-PCI","title_en":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.","published":"2016-12-22"}],"10.1093/eurheartj/ehw388":[{"url":"https://hartvaat.nl/2016/12/21/alirocumab-bij-heterozygoot-fh-met-lipoproteine-aferese-odyssey-escape/","title":"Alirocumab bij heterozygoot FH met lipoproteïne-aferese: ODYSSEY ESCAPE","title_en":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.","published":"2016-12-21"}],"10.1093/eurheartj/ehw377":[{"url":"https://hartvaat.nl/2016/12/21/ezetimibe-bij-post-cabg-patienten-met-acs-improve-it-subanalyse/","title":"Ezetimibe bij post-CABG patiënten met ACS: IMPROVE-IT-subanalyse","title_en":"The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.","published":"2016-12-21"}],"10.1093/eurheartj/ehv734":[{"url":"https://hartvaat.nl/2016/12/21/statines-voor-primaire-preventie-bij-hiv-positieve-patienten-systematische-revie/","title":"Statines voor primaire preventie bij HIV-positieve patiënten: systematische review","title_en":"Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis.","published":"2016-12-21"}],"10.1161/circulationaha.116.024872":[{"url":"https://hartvaat.nl/2016/12/20/ticagrelor-versus-clopidogrel-bij-comateuze-overlevenden-van-reanimatie-met-pci/","title":"Ticagrelor versus clopidogrel bij comateuze overlevenden van reanimatie met PCI","title_en":"Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study.","published":"2016-12-20"}],"10.1016/j.jacc.2016.09.957":[{"url":"https://hartvaat.nl/2016/12/20/bloedingen-voor-coronairangiografie-bij-nste-acs/","title":"Bloedingen vóór coronairangiografie bij NSTE-ACS","title_en":"Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.","published":"2016-12-20"}],"10.1016/j.jacc.2016.09.966":[{"url":"https://hartvaat.nl/2016/12/20/off-label-doac-dosering-en-ongunstige-uitkomsten-orbit-af-ii-register/","title":"Off-label DOAC-dosering en ongunstige uitkomsten: ORBIT-AF II-register","title_en":"Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.","published":"2016-12-20"}],"10.1056/nejmoa1601564":[{"url":"https://hartvaat.nl/2016/12/15/off-pump-versus-on-pump-cabg-5-jaarsresultaten-nejm-coronary-trial/","title":"Off-pump versus on-pump CABG: 5-jaarsresultaten NEJM CORONARY-trial","title_en":"Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting.","published":"2016-12-15"}],"10.1136/heartjnl-2015-308660":[{"url":"https://hartvaat.nl/2016/12/15/infarctgrootte-en-linkerkamerremodellering-na-preventieve-pci/","title":"Infarctgrootte en linkerkamerremodellering na preventieve PCI","title_en":"Infarct size and left ventricular remodelling after preventive percutaneous coronary intervention.","published":"2016-12-15"}],"10.1161/circulationaha.116.025687":[{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","title":"CSL112: gereconstitueerd apoliproteïne A-I na acuut MI — veiligheid en verdraagbaarheid","title_en":"Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).","published":"2016-12-13"}],"10.1001/jama.2016.16951":[{"url":"https://hartvaat.nl/2016/12/13/evolocumab-en-progressie-van-coronairlijden-bij-statinebehandelde-patienten-jama/","title":"Evolocumab en progressie van coronairlijden bij statinebehandelde patiënten: JAMA GLAGOV-trial","title_en":"Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.","published":"2016-12-13"}],"10.1161/circulationaha.116.024604":[{"url":"https://hartvaat.nl/2016/12/13/alirocumab-en-reductie-in-atherogene-lipiden-en-cardiovasculaire-events-10-odyss/","title":"Alirocumab en reductie in atherogene lipiden en cardiovasculaire events: 10 ODYSSEY-trials","title_en":"Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.","published":"2016-12-13"}],"10.1016/s0140-6736(16)32049-9":[{"url":"https://hartvaat.nl/2016/12/10/omecamtiv-mecarbil-bij-chronisch-hartfalen-lancet-cosmic-hf-fase-2-trial/","title":"Omecamtiv mecarbil bij chronisch hartfalen: Lancet COSMIC-HF fase-2-trial","title_en":"Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.","published":"2016-12-10"}],"10.1056/nejmoa1610227":[{"url":"https://hartvaat.nl/2016/12/08/everolimus-eluting-stents-of-bypasschirurgie-bij-hoofdstamcoronairlijden-nejm-ex/","title":"Everolimus-eluting stents of bypasschirurgie bij hoofdstamcoronairlijden: NEJM EXCEL-trial","title_en":"Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.","published":"2016-12-08"}],"10.1093/eurheartj/ehw048":[{"url":"https://hartvaat.nl/2016/12/07/linker-hartoorsluiting-uitkomsten-en-kosten-van-trial-en-real-world-versus-orale/","title":"Linker-hartoorsluiting: uitkomsten en kosten van trial en real-world versus orale antistolling","title_en":"Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation.","published":"2016-12-07"}],"10.1016/j.jacc.2016.09.932":[{"url":"https://hartvaat.nl/2016/12/06/dalcetrapib-wijzigt-de-relatie-tussen-hdl-cholesterol-en-crp/","title":"Dalcetrapib wijzigt de relatie tussen HDL-cholesterol en CRP","title_en":"Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein.","published":"2016-12-06"}],"10.1016/j.jacc.2016.09.931":[{"url":"https://hartvaat.nl/2016/12/06/prognostische-implicaties-van-nt-probnp-veranderingen-bij-hartfalen/","title":"Prognostische implicaties van NT-proBNP-veranderingen bij hartfalen","title_en":"Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.","published":"2016-12-06"}],"10.1161/cir.0000000000000450":[{"url":"https://hartvaat.nl/2016/12/06/comorbiditeiten-bij-hartfalen-hypertensie-obesitas-diabetes-hyperlipidemie-en-me/","title":"Comorbiditeiten bij hartfalen: hypertensie, obesitas, diabetes, hyperlipidemie en metabool syndroom","title_en":"Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.","published":"2016-12-06"}],"10.1016/s0140-6736(16)32052-9":[{"url":"https://hartvaat.nl/2016/12/03/pci-versus-cabg-bij-onbeschermde-hoofdstamstenose-lancet-noble-trial/","title":"PCI versus CABG bij onbeschermde hoofdstamstenose: Lancet NOBLE-trial","title_en":"Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.","published":"2016-12-03"}],"10.1093/eurheartj/ehw343":[{"url":"https://hartvaat.nl/2016/12/01/tienjaarsuitkomsten-van-eerste-generatie-drug-eluting-stents-ses-versus-pes/","title":"Tienjaarsuitkomsten van eerste-generatie drug-eluting stents: SES versus PES","title_en":"Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial.","published":"2016-12-01"}],"10.1161/hypertensionaha.116.07703":[{"url":"https://hartvaat.nl/2016/12/01/empagliflozine-en-bloeddruk-bij-diabetes-type-2-met-hypertensie-naar-achtergrond/","title":"Empagliflozine en bloeddruk bij diabetes type 2 met hypertensie naar achtergrondtherapie","title_en":"Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.","published":"2016-12-01"}],"10.1161/hypertensionaha.116.08261":[{"url":"https://hartvaat.nl/2016/12/01/associaties-tussen-foetale-geimprinte-genen-en-maternale-bloeddruk-in-de-zwanger/","title":"Associaties tussen foetale geïmprinte genen en maternale bloeddruk in de zwangerschap","title_en":"Associations Between Fetal Imprinted Genes and Maternal Blood Pressure in Pregnancy.","published":"2016-12-01"}],"10.1161/hypertensionaha.116.07907":[{"url":"https://hartvaat.nl/2016/12/01/vasculaire-disfunctiemarkers-na-hypertensieve-zwangerschapsaandoeningen-meta-ana/","title":"Vasculaire disfunctiemarkers na hypertensieve zwangerschapsaandoeningen: meta-analyse","title_en":"Markers of Vascular Dysfunction After Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis.","published":"2016-12-01"}],"10.1161/hypertensionaha.116.08290":[{"url":"https://hartvaat.nl/2016/12/01/lacunes-in-hypertensierichtlijnen-in-lage-en-middeninkomenslanden-systematische-/","title":"Lacunes in hypertensierichtlijnen in lage- en middeninkomenslanden: systematische review","title_en":"Gaps in Hypertension Guidelines in Low- and Middle-Income Versus High-Income Countries: A Systematic Review.","published":"2016-12-01"}],"10.1093/europace/euv408":[{"url":"https://hartvaat.nl/2016/12/01/rivaroxaban-versus-vka-bij-periprocedurele-antistolling-rond-af-ablatie/","title":"Rivaroxaban versus VKA bij periprocedurele antistolling rond AF-ablatie","title_en":"Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.","published":"2016-12-01"}],"10.1161/circulationaha.116.024976":[{"url":"https://hartvaat.nl/2016/11/29/bmi-en-nauwkeurigheid-van-nt-probnp-en-bnp-voor-diagnose-van-acuut-hartfalen/","title":"BMI en nauwkeurigheid van NT-proBNP en BNP voor diagnose van acuut hartfalen","title_en":"Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).","published":"2016-11-29"}],"10.1016/j.jacc.2016.08.055":[{"url":"https://hartvaat.nl/2016/11/29/natuurlijk-beloop-van-coronaire-atherosclerose-met-ffr-prospectieve-studie/","title":"Natuurlijk beloop van coronaire atherosclerose met FFR: prospectieve studie","title_en":"A Prospective Natural History Study of Coronary Atherosclerosis Using Fractional Flow Reserve.","published":"2016-11-29"}],"10.1016/j.jacc.2016.08.023":[{"url":"https://hartvaat.nl/2016/11/29/presentatie-buiten-kantoortijden-versus-tijdens-kantoortijden-bij-stemi-champion/","title":"Presentatie buiten kantoortijden versus tijdens kantoortijden bij STEMI: CHAMPION PHOENIX","title_en":"\"Off-Hours\" Versus \"On-Hours\" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings.","published":"2016-11-29"}],"10.1161/circulationaha.116.022802":[{"url":"https://hartvaat.nl/2016/11/29/biomarkergebaseerde-cva-risicoscore-bij-atriumfibrilleren-validatie/","title":"Biomarkergebaseerde CVA-risicoscore bij atriumfibrilleren: validatie","title_en":"Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.","published":"2016-11-29"}],"10.1016/s0140-6736(16)31920-1":[{"url":"https://hartvaat.nl/2016/11/26/ultradunne-biodegradeerbare-versus-duurzame-polymer-des-lancet-gerandomiseerde-t/","title":"Ultradunne biodegradeerbare versus duurzame polymer DES: Lancet gerandomiseerde trial","title_en":"Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.","published":"2016-11-26"}],"10.1016/s0140-6736(16)31922-5":[{"url":"https://hartvaat.nl/2016/11/26/oct-versus-ivus-versus-angiografie-bij-coronaire-stentimplantatie-lancet-ilumien/","title":"OCT versus IVUS versus angiografie bij coronaire stentimplantatie: Lancet ILUMIEN III-trial","title_en":"Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.","published":"2016-11-26"}],"10.1161/circulationaha.116.023233":[{"url":"https://hartvaat.nl/2016/11/22/plasma-lipidomiek-verbetert-cardiovasculaire-risicovoorspelling-bij-diabetes-typ/","title":"Plasma-lipidomiek verbetert cardiovasculaire risicovoorspelling bij diabetes type 2","title_en":"Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus.","published":"2016-11-22"}],"10.1161/cir.0000000000000456":[{"url":"https://hartvaat.nl/2016/11/22/management-van-klinisch-significante-geneesmiddelinteracties-met-statines-aha-aa/","title":"Management van klinisch significante geneesmiddelinteracties met statines: AHA-aanbevelingen","title_en":"Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.","published":"2016-11-22"}],"10.1161/circulationaha.116.024823":[{"url":"https://hartvaat.nl/2016/11/22/prasugrel-versus-ticagrelor-bij-acuut-mi-met-primaire-pci-multicenter-trial/","title":"Prasugrel versus ticagrelor bij acuut MI met primaire PCI: multicenter trial","title_en":"Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.","published":"2016-11-22"}],"10.1001/jama.2016.15450":[{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","title":"Statines voor primaire cardiovasculaire preventie: USPSTF-aanbeveling","title_en":"Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.","published":"2016-11-15"}],"10.1001/jama.2015.15629":[{"url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-evidence-report/","title":"Statines voor primaire cardiovasculaire preventie: USPSTF evidence report","title_en":"Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2016-11-15"}],"10.1056/nejmoa1607141":[{"url":"https://hartvaat.nl/2016/11/10/semaglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-sustain-6/","title":"Semaglutide en cardiovasculaire uitkomsten bij diabetes type 2: NEJM SUSTAIN-6","title_en":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.","published":"2016-11-10"}],"10.1161/circulationaha.116.024073":[{"url":"https://hartvaat.nl/2016/11/08/onbehandelde-hypertensie-als-risicofactor-voor-lobaire-en-non-lobaire-hersenbloe/","title":"Onbehandelde hypertensie als risicofactor voor lobaire en non-lobaire hersenbloeding naar etniciteit","title_en":"Untreated Hypertension: A Powerful Risk Factor for Lobar and Nonlobar Intracerebral Hemorrhage in Whites, Blacks, and Hispanics.","published":"2016-11-08"}],"10.1161/circulationaha.116.021314":[{"url":"https://hartvaat.nl/2016/11/08/residueel-vasculair-risico-bij-secundaire-preventie-verdeling-van-10-jaarsrisico/","title":"Residueel vasculair risico bij secundaire preventie: verdeling van 10-jaarsrisico","title_en":"Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population.","published":"2016-11-08"}],"10.1093/eurheartj/ehw257":[{"url":"https://hartvaat.nl/2016/11/07/ace-remmer-en-groeisnelheid-van-kleine-abdominale-aorta-aneurysmata-gerandomisee/","title":"ACE-remmer en groeisnelheid van kleine abdominale aorta-aneurysmata: gerandomiseerde trial","title_en":"An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK).","published":"2016-11-07"}],"10.1016/j.jacc.2016.07.770":[{"url":"https://hartvaat.nl/2016/11/01/linker-hartoorisolatie-bij-langdurig-persisterend-af-de-belief-trial/","title":"Linker-hartoorisolatie bij langdurig persisterend AF: de BELIEF-trial","title_en":"Left Atrial Appendage Isolation in Patients With Longstanding Persistent AF Undergoing Catheter Ablation: BELIEF Trial.","published":"2016-11-01"}],"10.1161/circulationaha.116.023264":[{"url":"https://hartvaat.nl/2016/11/01/intensieve-bloeddrukbehandeling-120-80-mmhg-antagonist-standpunt/","title":"Intensieve bloeddrukbehandeling <120/80 mmHg: antagonist-standpunt","title_en":"Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? An Antagonist View From the HOPE-3 Trial (Heart Outcomes Evaluation-3).","published":"2016-11-01"}],"10.1161/circulationaha.116.023263":[{"url":"https://hartvaat.nl/2016/11/01/intensieve-bloeddrukbehandeling-120-80-mmhg-bij-cardiovasculair-risico-protagoni/","title":"Intensieve bloeddrukbehandeling <120/80 mmHg bij cardiovasculair risico: protagonist-standpunt","title_en":"Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? A Protagonist View From the SPRINT Trial (Systolic Blood Pressure Intervention Trial).","published":"2016-11-01"}],"10.1161/circulationaha.116.024800":[{"url":"https://hartvaat.nl/2016/11/01/tienjaarsuitkomsten-na-cabg-naar-leeftijd-bij-hartfalen-met-lv-systolische-disfu/","title":"Tienjaarsuitkomsten na CABG naar leeftijd bij hartfalen met LV-systolische disfunctie: STICH","title_en":"Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure).","published":"2016-11-01"}],"10.1093/eurheartj/ehw099":[{"url":"https://hartvaat.nl/2016/11/01/vochtstatustelemonitoring-bij-hartfalen-gerandomiseerde-trial/","title":"Vochtstatustelemonitoring bij hartfalen: gerandomiseerde trial","title_en":"Fluid status telemedicine alerts for heart failure: a randomized controlled trial.","published":"2016-11-01"}],"10.1161/hypertensionaha.116.08035":[{"url":"https://hartvaat.nl/2016/11/01/rol-van-het-autonome-zenuwstelsel-bij-regulatie-van-aortastijfheid/","title":"Rol van het autonome zenuwstelsel bij regulatie van aortastijfheid","title_en":"The Role of the Autonomic Nervous System in the Regulation of Aortic Stiffness.","published":"2016-11-01"}],"10.1161/hypertensionaha.116.07862":[{"url":"https://hartvaat.nl/2016/11/01/chips-trial-is-ernstige-hypertensie-in-de-zwangerschap-meer-dan-alleen-verhoogde/","title":"CHIPS-trial: is ernstige hypertensie in de zwangerschap meer dan alleen verhoogde bloeddruk?","title_en":"The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?","published":"2016-11-01"}],"10.1161/hypertensionaha.116.07854":[{"url":"https://hartvaat.nl/2016/11/01/langetermijnmortaliteit-bij-hypertensie-met-coronairlijden-invest-us-cohort/","title":"Langetermijnmortaliteit bij hypertensie met coronairlijden: INVEST US-cohort","title_en":"Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study.","published":"2016-11-01"}],"10.1161/hypertensionaha.116.08043":[{"url":"https://hartvaat.nl/2016/11/01/arts-apotheker-samenwerkingsmodel-verkleint-sociaaleconomische-bloeddrukverschil/","title":"Arts-apotheker samenwerkingsmodel verkleint sociaaleconomische bloeddrukverschillen","title_en":"Physician-Pharmacist Collaborative Management: Narrowing the Socioeconomic Blood Pressure Gap.","published":"2016-11-01"}],"10.1161/hypertensionaha.116.07316":[{"url":"https://hartvaat.nl/2016/11/01/therapieresistente-hypertensie-na-sprint-evaluatie-en-management/","title":"Therapieresistente hypertensie na SPRINT: evaluatie en management","title_en":"Resistant Hypertension: Insights on Evaluation and Management in the Post-SPRINT (Systolic Blood Pressure Intervention Trial) Era.","published":"2016-11-01"}],"10.1093/europace/euw295":[{"url":"https://hartvaat.nl/2016/11/01/2016-esc-af-richtlijn-europace-editie/","title":"2016 ESC AF-richtlijn: Europace-editie","title_en":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.","published":"2016-11-01"}],"10.1093/europace/euv462":[{"url":"https://hartvaat.nl/2016/11/01/flecainide-metoprolol-combinatie-vermindert-af-recidieven-1-jaarsresultaten/","title":"Flecaïnide-metoprolol combinatie vermindert AF-recidieven: 1-jaarsresultaten","title_en":"Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation.","published":"2016-11-01"}],"10.1016/j.jacc.2016.07.763":[{"url":"https://hartvaat.nl/2016/10/25/aldosteronantagonisme-en-inspanningstolerantie-bij-hfpef/","title":"Aldosteronantagonisme en inspanningstolerantie bij HFpEF","title_en":"Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.","published":"2016-10-25"}],"10.1016/s0140-6736(16)31474-x":[{"url":"https://hartvaat.nl/2016/10/22/edoxaban-versus-enoxaparine-warfarine-bij-cardioversie-van-af-ensure-af-trial/","title":"Edoxaban versus enoxaparine-warfarine bij cardioversie van AF: ENSURE-AF-trial","title_en":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.","published":"2016-10-22"}],"10.1016/s0140-6736(16)31323-x":[{"url":"https://hartvaat.nl/2016/10/22/plaatjesfunctiemonitoring-voor-antiplaatjesaanpassing-bij-oudere-acs-patienten-a/","title":"Plaatjesfunctiemonitoring voor antiplaatjesaanpassing bij oudere ACS-patiënten: ANTARCTIC-trial","title_en":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.","published":"2016-10-22"}],"10.1016/j.jacc.2016.07.768":[{"url":"https://hartvaat.nl/2016/10/18/canakinumab-en-arteriele-effecten-bij-atherosclerose-met-diabetes-of-glucosetole/","title":"Canakinumab en arteriële effecten bij atherosclerose met diabetes of glucosetolerantiestoornis","title_en":"Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance.","published":"2016-10-18"}],"10.1001/jama.2016.14194":[{"url":"https://hartvaat.nl/2016/10/18/high-flow-neuscanule-versus-non-invasieve-ventilatie-na-extubatie-jama-trial/","title":"High-flow neuscanule versus non-invasieve ventilatie na extubatie: JAMA-trial","title_en":"Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial.","published":"2016-10-18"}],"10.1016/s0140-6736(16)31276-4":[{"url":"https://hartvaat.nl/2016/10/15/vroeg-invasief-versus-conservatief-bij-nste-acs-15-jaarsfollow-up-frisc-ii/","title":"Vroeg invasief versus conservatief bij NSTE-ACS: 15-jaarsfollow-up FRISC-II","title_en":"Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.","published":"2016-10-15"}],"10.1093/eurheartj/ehw415":[{"url":"https://hartvaat.nl/2016/10/14/de-tien-geboden-van-de-2016-esc-eas-dyslipidemierichtlijn/","title":"De 'Tien Geboden' van de 2016 ESC/EAS dyslipidemierichtlijn","title_en":"'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias.","published":"2016-10-14"}],"10.1093/eurheartj/ehw272":[{"url":"https://hartvaat.nl/2016/10/14/2016-esc-eas-richtlijn-voor-het-management-van-dyslipidemieen/","title":"2016 ESC/EAS-richtlijn voor het management van dyslipidemieën","title_en":"2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.","published":"2016-10-14"}],"10.1093/eurheartj/ehw292":[{"url":"https://hartvaat.nl/2016/10/14/geen-effect-van-pcsk9-remmer-alirocumab-op-diabetes-incidentie-odyssey-analyse/","title":"Geen effect van PCSK9-remmer alirocumab op diabetes-incidentie: ODYSSEY-analyse","title_en":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.","published":"2016-10-14"}],"10.1016/j.jacc.2016.07.744":[{"url":"https://hartvaat.nl/2016/10/11/pci-van-chronische-totale-occlusie-bij-stemi-met-multivatenlijden-explore-trial/","title":"PCI van chronische totale occlusie bij STEMI met multivatenlijden: EXPLORE-trial","title_en":"Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial.","published":"2016-10-11"}],"10.1016/j.jacc.2016.07.745":[{"url":"https://hartvaat.nl/2016/10/11/natriuminname-en-totale-mortaliteit-over-20-jaar-trials-of-hypertension-preventi/","title":"Natriuminname en totale mortaliteit over 20 jaar: Trials of Hypertension Prevention","title_en":"Sodium Intake and All-Cause Mortality Over 20 Years in the Trials of Hypertension Prevention.","published":"2016-10-11"}],"10.1093/eurheartj/ehw370":[{"url":"https://hartvaat.nl/2016/10/07/de-tien-geboden-van-de-2016-esc-af-richtlijn/","title":"De 'Tien Geboden' van de 2016 ESC AF-richtlijn","title_en":"'Ten Commandments' of 2016 ESC Guidelines for the management of atrial fibrillation.","published":"2016-10-07"}],"10.1093/eurheartj/ehw210":[{"url":"https://hartvaat.nl/2016/10/07/2016-esc-richtlijn-voor-atriumfibrilleren-in-samenwerking-met-eacts/","title":"2016 ESC-richtlijn voor atriumfibrilleren (in samenwerking met EACTS)","title_en":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.","published":"2016-10-07"}],"10.1093/eurheartj/ehw285":[{"url":"https://hartvaat.nl/2016/10/07/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-af-herinterventierate-e/","title":"Cryoballon versus radiofrequentieablatie bij paroxysmaal AF: herinterventierate en kwaliteit van leven","title_en":"Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial.","published":"2016-10-07"}],"10.1001/jama.2016.14568":[{"url":"https://hartvaat.nl/2016/10/04/ldl-cholesterolverlagende-genetische-varianten-en-risico-op-diabetes-type-2-jama/","title":"LDL-cholesterolverlagende genetische varianten en risico op diabetes type 2: JAMA meta-analyse","title_en":"Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.","published":"2016-10-04"}],"10.1161/circulationaha.116.024531":[{"url":"https://hartvaat.nl/2016/10/04/impact-van-optimale-medicamenteuze-therapie-in-de-dapt-studie/","title":"Impact van optimale medicamenteuze therapie in de DAPT-studie","title_en":"Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.","published":"2016-10-04"}],"10.1001/jamacardio.2016.2811":[{"url":"https://hartvaat.nl/2016/10/01/langere-versus-korte-dapt-na-pci-met-en-zonder-periprocedureel-mi-jama-cardiolog/","title":"Langere versus korte DAPT na PCI met en zonder periprocedureel MI: JAMA Cardiology","title_en":"Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.","published":"2016-10-01"}],"10.1001/jamacardio.2016.2225":[{"url":"https://hartvaat.nl/2016/10/01/volwassen-stamceltherapie-bij-hartfalen-2000-2016-jama-cardiology-systematische-/","title":"Volwassen stamceltherapie bij hartfalen 2000-2016: JAMA Cardiology systematische review","title_en":"Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review.","published":"2016-10-01"}],"10.1136/heartjnl-2016-309406":[{"url":"https://hartvaat.nl/2016/10/01/katheterablatie-bij-af-met-hypertrofische-cardiomyopathie-systematische-review-e/","title":"Katheterablatie bij AF met hypertrofische cardiomyopathie: systematische review en meta-analyse","title_en":"Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis.","published":"2016-10-01"}],"10.1161/hypertensionaha.116.07466":[{"url":"https://hartvaat.nl/2016/10/01/kostenimplicaties-van-minder-strikte-versus-strikte-bloeddrukcontrole-bij-zwange/","title":"Kostenimplicaties van minder strikte versus strikte bloeddrukcontrole bij zwangerschap: CHIPS-trial","title_en":"The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial).","published":"2016-10-01"}],"10.1161/hypertensionaha.116.07681":[{"url":"https://hartvaat.nl/2016/10/01/autonome-blokkade-herstelt-endotheeldisfunctie-bij-obesitasgerelateerde-hyperten/","title":"Autonome blokkade herstelt endotheeldisfunctie bij obesitasgerelateerde hypertensie","title_en":"Autonomic Blockade Reverses Endothelial Dysfunction in Obesity-Associated Hypertension.","published":"2016-10-01"}],"10.1161/hypertensionaha.116.07910":[{"url":"https://hartvaat.nl/2016/10/01/bloeddruk-en-darmmicrobioom-veranderde-samenstelling-en-butyraat-bij-hypertensie/","title":"Bloeddruk en darmmicrobioom: veranderde samenstelling en butyraat bij hypertensie","title_en":"Increased Systolic and Diastolic Blood Pressure Is Associated With Altered Gut Microbiota Composition and Butyrate Production in Early Pregnancy.","published":"2016-10-01"}],"10.1161/hypertensionaha.116.07834":[{"url":"https://hartvaat.nl/2016/10/01/lijnzaad-verlaagt-centrale-aortabloeddruk-via-veranderingen-in-plasma-oxylipinen/","title":"Lijnzaad verlaagt centrale aortabloeddruk via veranderingen in plasma-oxylipinen","title_en":"Dietary Flaxseed Reduces Central Aortic Blood Pressure Without Cardiac Involvement but Through Changes in Plasma Oxylipins.","published":"2016-10-01"}],"10.1161/hypertensionaha.116.07721":[{"url":"https://hartvaat.nl/2016/10/01/cardiovasculair-risico-bij-hypertensie-in-relatie-tot-bereikte-bloeddruk-met-gea/","title":"Cardiovasculair risico bij hypertensie in relatie tot bereikte bloeddruk met geautomatiseerde praktijkmeting","title_en":"Cardiovascular Risk in Hypertension in Relation to Achieved Blood Pressure Using Automated Office Blood Pressure Measurement.","published":"2016-10-01"}],"10.1161/hypertensionaha.116.07474":[{"url":"https://hartvaat.nl/2016/10/01/orthostatische-hypotensie-in-de-accord-bloeddruk-trial-prevalentie-en-klinische-/","title":"Orthostatische hypotensie in de ACCORD bloeddruk-trial: prevalentie en klinische impact","title_en":"Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance.","published":"2016-10-01"}],"10.1093/europace/euv398":[{"url":"https://hartvaat.nl/2016/10/01/omega-3-vetzuren-en-p-golfparameters-of-atriale-connexinen-bij-hartchirurgie/","title":"Omega-3-vetzuren en P-golfparameters of atriale connexinen bij hartchirurgie","title_en":"Omega-3 fatty acids do not alter P-wave parameters in electrocardiogram or expression of atrial connexins in patients undergoing coronary artery bypass surgery.","published":"2016-10-01"}],"10.1056/nejmoa1607991":[{"url":"https://hartvaat.nl/2016/09/29/drug-eluting-of-bare-metal-stents-bij-coronairlijden-nejm-norstent-trial/","title":"Drug-eluting of bare-metal stents bij coronairlijden: NEJM NORSTENT-trial","title_en":"Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.","published":"2016-09-29"}],"10.1056/nejmoa1608029":[{"url":"https://hartvaat.nl/2016/09/29/icd-implantatie-bij-niet-ischemisch-systolisch-hartfalen-nejm-danish-trial/","title":"ICD-implantatie bij niet-ischemisch systolisch hartfalen: NEJM DANISH-trial","title_en":"Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.","published":"2016-09-29"}],"10.1001/jama.2016.13985":[{"url":"https://hartvaat.nl/2016/09/27/ldl-c-verlaging-en-cardiovasculaire-risicoreductie-jama-systematische-review-en-/","title":"LDL-C-verlaging en cardiovasculaire risicoreductie: JAMA systematische review en meta-analyse","title_en":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.","published":"2016-09-27"}],"10.1161/circulationaha.116.023480":[{"url":"https://hartvaat.nl/2016/09/27/intensieve-glucoseregulatie-bij-hyperglycemisch-acs-langetermijnfollow-up-biomar/","title":"Intensieve glucoseregulatie bij hyperglycemisch ACS: langetermijnfollow-up BIOMArCS-2","title_en":"Long-Term Follow-Up of the Randomized (BIOMArCS-2) Glucose Trial: Intensive Glucose Regulation in Hyperglycemic Acute Coronary Syndrome.","published":"2016-09-27"}],"10.1161/circulationaha.116.024393":[{"url":"https://hartvaat.nl/2016/09/27/oct-geleide-pci-optimalisatie-bij-nste-acs-gerandomiseerde-trial/","title":"OCT-geleide PCI-optimalisatie bij NSTE-ACS: gerandomiseerde trial","title_en":"Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting).","published":"2016-09-27"}],"10.1016/j.jacc.2016.05.011":[{"url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","title":"2016 ACC/AHA/HFSA gerichte update: nieuwe farmacologische hartfalentherapie","title_en":"2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.","published":"2016-09-27"}],"10.1016/j.jacc.2016.06.051":[{"url":"https://hartvaat.nl/2016/09/20/volledig-linkszijdig-reverse-remodelling-bij-crt-madit-crt-substudie/","title":"Volledig linkszijdig reverse remodelling bij CRT: MADIT-CRT-substudie","title_en":"Clinical Implications of Complete Left-Sided Reverse Remodeling With Cardiac Resynchronization Therapy: A MADIT-CRT Substudy.","published":"2016-09-20"}],"10.1161/circulationaha.116.022922":[{"url":"https://hartvaat.nl/2016/09/20/medicatietrouw-en-bloeddrukeffecten-van-renale-denervatie-rsd-pathway-2-analyse/","title":"Medicatietrouw en bloeddrukeffecten van renale denervatie: RSD PATHWAY-2-analyse","title_en":"Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial.","published":"2016-09-20"}],"10.1161/circulationaha.116.024637":[{"url":"https://hartvaat.nl/2016/09/20/cva-preventie-met-ticagrelor-na-myocardinfarct-pegasus-timi-54-inzichten/","title":"CVA-preventie met ticagrelor na myocardinfarct: PEGASUS-TIMI 54-inzichten","title_en":"Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).","published":"2016-09-20"}],"10.1056/nejmoa1603460":[{"url":"https://hartvaat.nl/2016/09/15/intensieve-bloeddrukverlaging-bij-acute-hersenbloeding-nejm-atach-2-trial/","title":"Intensieve bloeddrukverlaging bij acute hersenbloeding: NEJM ATACH-2-trial","title_en":"Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage.","published":"2016-09-15"}],"10.1161/circulationaha.116.023743":[{"url":"https://hartvaat.nl/2016/09/13/clopidogrel-versus-ticagrelor-bij-diabetes-na-pci-gerandomiseerde-trial/","title":"Clopidogrel versus ticagrelor bij diabetes na PCI: gerandomiseerde trial","title_en":"Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients).","published":"2016-09-13"}],"10.1016/j.jacc.2016.06.034":[{"url":"https://hartvaat.nl/2016/09/13/edoxaban-versus-warfarine-bij-af-patienten-met-valrisico-engage-af-timi-48-analy/","title":"Edoxaban versus warfarine bij AF-patiënten met valrisico: ENGAGE AF-TIMI 48-analyse","title_en":"Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.","published":"2016-09-13"}],"10.1016/j.jacc.2016.06.036":[{"url":"https://hartvaat.nl/2016/09/13/ganglionplexusablatie-bij-gevorderd-atriumfibrilleren-de-afact-studie/","title":"Ganglionplexusablatie bij gevorderd atriumfibrilleren: de AFACT-studie","title_en":"Ganglion Plexus Ablation in Advanced Atrial Fibrillation: The AFACT Study.","published":"2016-09-13"}],"10.1161/circulationaha.116.023402":[{"url":"https://hartvaat.nl/2016/09/13/prasugrel-versus-ticagrelor-bij-diabetes-type-2-met-coronairlijden-optimus-4-stu/","title":"Prasugrel versus ticagrelor bij diabetes type 2 met coronairlijden: OPTIMUS-4-studie","title_en":"Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.","published":"2016-09-13"}],"10.1016/j.jacc.2016.06.024":[{"url":"https://hartvaat.nl/2016/09/06/pci-versus-cabg-bij-onbeschermde-hoofdstamziekte-uitkomsten/","title":"PCI versus CABG bij onbeschermde hoofdstamziekte: uitkomsten","title_en":"Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease.","published":"2016-09-06"}],"10.1161/circulationaha.115.020829":[{"url":"https://hartvaat.nl/2016/09/06/consistente-reductie-in-periprocedureel-mi-met-cangrelor-champion-analyses/","title":"Consistente reductie in periprocedureel MI met cangrelor: CHAMPION-analyses","title_en":"Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).","published":"2016-09-06"}],"10.1016/j.jacc.2016.03.512":[{"url":"https://hartvaat.nl/2016/09/06/duur-van-dapt-systematische-review-voor-de-acc-aha-gerichte-update-2016/","title":"Duur van DAPT: systematische review voor de ACC/AHA gerichte update 2016","title_en":"Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","published":"2016-09-06"}],"10.1001/jamacardio.2016.1829":[{"url":"https://hartvaat.nl/2016/09/01/apixaban-5-mg-bij-af-met-hoge-leeftijd-laag-gewicht-of-hoog-creatinine-aristotle/","title":"Apixaban 5 mg bij AF met hoge leeftijd, laag gewicht of hoog creatinine: ARISTOTLE-analyse","title_en":"Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.","published":"2016-09-01"}],"10.1136/heartjnl-2015-309218":[{"url":"https://hartvaat.nl/2016/09/01/polyfenolrijk-dieet-en-cardiovasculair-risico-gerandomiseerde-trial/","title":"Polyfenolrijk dieet en cardiovasculair risico: gerandomiseerde trial","title_en":"Beneficial effect of a polyphenol-rich diet on cardiovascular risk: a randomised control trial.","published":"2016-09-01"}],"10.1161/hypertensionaha.116.07797":[{"url":"https://hartvaat.nl/2016/09/01/ace-remmers-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-met-dpp-4-remmers/","title":"ACE-remmers en cardiovasculaire uitkomsten bij diabetes type 2 met DPP-4-remmers","title_en":"Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.","published":"2016-09-01"}],"10.1161/hypertensionaha.116.07608":[{"url":"https://hartvaat.nl/2016/09/01/intensievere-versus-minder-intensieve-bloeddrukverlaging-cumulatief-bewijs-en-tr/","title":"Intensievere versus minder intensieve bloeddrukverlaging: cumulatief bewijs en trial sequential analysis","title_en":"More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis.","published":"2016-09-01"}],"10.1016/j.kint.2016.04.019":[{"url":"https://hartvaat.nl/2016/09/01/patiromer-verlaagt-aldosteron-bij-ckd-patienten-met-hyperkaliemie-op-raas-remmer/","title":"Patiromer verlaagt aldosteron bij CKD-patiënten met hyperkaliëmie op RAAS-remmers","title_en":"Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.","published":"2016-09-01"}],"10.1161/circulationaha.115.020950":[{"url":"https://hartvaat.nl/2016/08/23/dabigatran-versus-warfarine-bij-af-met-kleplijden-re-ly-analyse/","title":"Dabigatran versus warfarine bij AF met kleplijden: RE-LY-analyse","title_en":"Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).","published":"2016-08-23"}],"10.1001/jama.2016.10026":[{"url":"https://hartvaat.nl/2016/08/16/acute-aortadissectie-en-intramuraal-hematoom-jama-systematische-review/","title":"Acute aortadissectie en intramuraal hematoom: JAMA systematische review","title_en":"Acute Aortic Dissection and Intramural Hematoma: A Systematic Review.","published":"2016-08-16"}],"10.1016/j.jacc.2016.05.078":[{"url":"https://hartvaat.nl/2016/08/16/intracoronair-abciximab-bij-diabetespatienten-met-primaire-pci-1-jaarsresultaten/","title":"Intracoronair abciximab bij diabetespatiënten met primaire PCI: 1-jaarsresultaten","title_en":"1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention.","published":"2016-08-16"}],"10.1016/j.jacc.2016.05.053":[{"url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","title":"Bio-absorbeerbare intracoronaire matrix ter preventie van ventriculaire remodellering na MI","title_en":"Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction.","published":"2016-08-16"}],"10.1001/jama.2016.6176":[{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-voor-familiaire-hypercholesterolemie-uspstf-evidenc/","title":"Lipidescreening bij kinderen voor familiaire hypercholesterolemie: USPSTF evidence report","title_en":"Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2016-08-09"}],"10.1001/jama.2016.6423":[{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-voor-multifactoriele-dyslipidemie-uspstf-evidence-r/","title":"Lipidescreening bij kinderen voor multifactoriële dyslipidemie: USPSTF evidence report","title_en":"Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.","published":"2016-08-09"}],"10.1001/jama.2016.9852":[{"url":"https://hartvaat.nl/2016/08/09/lipidescreening-bij-kinderen-en-adolescenten-uspstf-aanbeveling/","title":"Lipidescreening bij kinderen en adolescenten: USPSTF-aanbeveling","title_en":"Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.","published":"2016-08-09"}],"10.1093/eurheartj/ehw171":[{"url":"https://hartvaat.nl/2016/08/07/il-6-receptorantagonist-tocilizumab-bij-nstemi-effect-op-inflammatie-en-troponin/","title":"IL-6-receptorantagonist tocilizumab bij NSTEMI: effect op inflammatie en troponine","title_en":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.","published":"2016-08-07"}],"10.1001/jama.2016.10260":[{"url":"https://hartvaat.nl/2016/08/02/liraglutide-en-klinische-stabiliteit-bij-gevorderd-hartfalen-met-verminderde-ef-/","title":"Liraglutide en klinische stabiliteit bij gevorderd hartfalen met verminderde EF: JAMA FIGHT-trial","title_en":"Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.","published":"2016-08-02"}],"10.1161/circulationaha.115.019949":[{"url":"https://hartvaat.nl/2016/08/02/omega-3-vetzuren-en-linkerkamerremodellering-na-acuut-mi-omega-remodel-trial/","title":"Omega-3-vetzuren en linkerkamerremodellering na acuut MI: OMEGA-REMODEL-trial","title_en":"Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial.","published":"2016-08-02"}],"10.1016/j.jacc.2016.05.042":[{"url":"https://hartvaat.nl/2016/08/02/impact-van-coronaire-laesielengte-op-uitkomsten-bij-ivus-geleide-pci/","title":"Impact van coronaire laesielengte op uitkomsten bij IVUS-geleide PCI","title_en":"Does the Baseline Coronary Lesion Length Impact Outcomes With IVUS-Guided Percutaneous Coronary Intervention?","published":"2016-08-02"}],"10.1001/jamacardio.2016.1035":[{"url":"https://hartvaat.nl/2016/08/01/digitale-gezondheidsinterventie-voor-cardiovasculaire-risicoverlaging-gerandomis/","title":"Digitale gezondheidsinterventie voor cardiovasculaire risicoverlaging: gerandomiseerde trial","title_en":"A Digital Health Intervention to Lower Cardiovascular Risk: A Randomized Clinical Trial.","published":"2016-08-01"}],"10.1001/jamacardio.2016.1567":[{"url":"https://hartvaat.nl/2016/08/01/sedentair-gedrag-en-cardiovasculair-risico-continue-dosis-responsrelatie-in-meta/","title":"Sedentair gedrag en cardiovasculair risico: continue dosis-responsrelatie in meta-analyse","title_en":"Continuous Dose-Response Association Between Sedentary Time and Risk for Cardiovascular Disease: A Meta-analysis.","published":"2016-08-01"}],"10.1093/eurheartj/ehw106":[{"url":"https://hartvaat.nl/2016/08/01/2016-europese-richtlijnen-voor-cardiovasculaire-preventie-in-de-klinische-prakti/","title":"2016 Europese richtlijnen voor cardiovasculaire preventie in de klinische praktijk","title_en":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).","published":"2016-08-01"}],"10.1136/heartjnl-2015-308840":[{"url":"https://hartvaat.nl/2016/08/01/eerder-clopidogrelgebruik-en-uitkomsten-bij-conservatief-behandeld-acs/","title":"Eerder clopidogrelgebruik en uitkomsten bij conservatief behandeld ACS","title_en":"Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.","published":"2016-08-01"}],"10.1161/hypertensionaha.116.07664":[{"url":"https://hartvaat.nl/2016/08/01/magnesiumsuppletie-en-bloeddruk-meta-analyse-van-dubbelblinde-placebogecontrolee/","title":"Magnesiumsuppletie en bloeddruk: meta-analyse van dubbelblinde placebogecontroleerde trials","title_en":"Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials.","published":"2016-08-01"}],"10.1016/j.kint.2016.04.027":[{"url":"https://hartvaat.nl/2016/08/01/apol1-nierrisicovarianten-en-cerebrale-wittestoflaesies/","title":"APOL1-nierrisicovarianten en cerebrale wittestoflaesies","title_en":"APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.","published":"2016-08-01"}],"10.1016/j.kint.2016.03.033":[{"url":"https://hartvaat.nl/2016/08/01/cabg-versus-pci-en-risico-op-myocardinfarct-en-revascularisatie-bij-ckd-patiente/","title":"CABG versus PCI en risico op myocardinfarct en revascularisatie bij CKD-patiënten","title_en":"Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease.","published":"2016-08-01"}],"10.1093/europace/euv404":[{"url":"https://hartvaat.nl/2016/08/01/hospitalisaties-bij-atriumfibrilleren-analyse-uit-rocket-af/","title":"Hospitalisaties bij atriumfibrilleren: analyse uit ROCKET AF","title_en":"Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF.","published":"2016-08-01"}],"10.1093/europace/euv395":[{"url":"https://hartvaat.nl/2016/08/01/vitamine-d-en-incidentie-van-atriumfibrilleren-de-aric-studie/","title":"Vitamine D en incidentie van atriumfibrilleren: de ARIC-studie","title_en":"Serum 25-hydroxyvitamin D and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.","published":"2016-08-01"}],"10.1056/nejmoa1515920":[{"url":"https://hartvaat.nl/2016/07/28/empagliflozine-en-progressie-van-nierziekte-bij-diabetes-type-2-nejm-empa-reg-re/","title":"Empagliflozine en progressie van nierziekte bij diabetes type 2: NEJM EMPA-REG RENAL","title_en":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.","published":"2016-07-28"}],"10.1056/nejmoa1603827":[{"url":"https://hartvaat.nl/2016/07/28/liraglutide-en-cardiovasculaire-uitkomsten-bij-diabetes-type-2-nejm-leader-trial/","title":"Liraglutide en cardiovasculaire uitkomsten bij diabetes type 2: NEJM LEADER-trial","title_en":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.","published":"2016-07-28"}],"10.1161/circulationaha.115.019861":[{"url":"https://hartvaat.nl/2016/07/26/atherotrombotische-risicostratificatie-en-vorapaxar-bij-stabiel-ischemisch-hartl/","title":"Atherotrombotische risicostratificatie en vorapaxar bij stabiel ischemisch hartlijden en PAV","title_en":"Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.","published":"2016-07-26"}],"10.1161/circulationaha.115.020627":[{"url":"https://hartvaat.nl/2016/07/19/visit-to-visit-ldl-cholesterolvariabiliteit-en-cognitieve-functie/","title":"Visit-to-visit LDL-cholesterolvariabiliteit en cognitieve functie","title_en":"Higher Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is Associated With Lower Cognitive Performance, Lower Cerebral Blood Flow, and Greater White Matter Hyperintensity Load in Older Subjects.","published":"2016-07-19"}],"10.1001/jama.2016.9400":[{"url":"https://hartvaat.nl/2016/07/19/glucoseverlagende-medicatie-en-cardiovasculaire-events-bij-diabetes-type-2-jama-/","title":"Glucoseverlagende medicatie en cardiovasculaire events bij diabetes type 2: JAMA meta-analyse","title_en":"Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.","published":"2016-07-19"}],"10.1016/j.jacc.2016.04.046":[{"url":"https://hartvaat.nl/2016/07/19/serieel-cardiaal-troponine-met-hoog-sensitieve-assay-bij-stabiel-ischemisch-hart/","title":"Serieel cardiaal troponine met hoog-sensitieve assay bij stabiel ischemisch hartlijden","title_en":"Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease.","published":"2016-07-19"}],"10.1016/j.jacc.2016.04.056":[{"url":"https://hartvaat.nl/2016/07/19/immatuur-plaatjesaantal-versus-gevestigde-voorspellers-van-plaatjesreactiviteit-/","title":"Immatuur plaatjesaantal versus gevestigde voorspellers van plaatjesreactiviteit bij thienopyridinetherapie","title_en":"Comparison of Immature Platelet Count to Established Predictors of Platelet Reactivity During Thienopyridine Therapy.","published":"2016-07-19"}],"10.1016/j.jacc.2016.04.047":[{"url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","title":"Sacubitril/valsartan en 30-daagse heropname na hartfalenhospitalisatie","title_en":"Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.","published":"2016-07-19"}],"10.1136/heartjnl-2015-308638":[{"url":"https://hartvaat.nl/2016/07/15/transitional-palliatieve-zorg-bij-eindstadium-hartfalen-gerandomiseerde-trial/","title":"Transitional palliatieve zorg bij eindstadium hartfalen: gerandomiseerde trial","title_en":"Effects of a transitional palliative care model on patients with end-stage heart failure: a randomised controlled trial.","published":"2016-07-15"}],"10.1093/eurheartj/ehw128":[{"url":"https://hartvaat.nl/2016/07/14/2016-esc-richtlijn-voor-diagnostiek-en-behandeling-van-acuut-en-chronisch-hartfa/","title":"2016 ESC-richtlijn voor diagnostiek en behandeling van acuut en chronisch hartfalen","title_en":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.","published":"2016-07-14"}],"10.1056/nejmoa1513614":[{"url":"https://hartvaat.nl/2016/07/14/ablatie-versus-escalatie-van-antiaritmica-bij-ventriculaire-tachycardie-nejm-van/","title":"Ablatie versus escalatie van antiaritmica bij ventriculaire tachycardie: NEJM VANISH-trial","title_en":"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.","published":"2016-07-14"}],"10.1093/eurheartj/ehw132":[{"url":"https://hartvaat.nl/2016/07/14/finerenon-versus-eplerenon-bij-hartfalen-met-diabetes-en-verslechterende-nierfun/","title":"Finerenon versus eplerenon bij hartfalen met diabetes en verslechterende nierfunctie: ARTS-HF","title_en":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.","published":"2016-07-14"}],"10.1016/j.jacc.2016.04.039":[{"url":"https://hartvaat.nl/2016/07/12/prasugrel-versus-clopidogrel-en-coronaire-microvasculaire-functie-bij-electieve-/","title":"Prasugrel versus clopidogrel en coronaire microvasculaire functie bij electieve PCI","title_en":"Effects of Prasugrel Versus Clopidogrel on Coronary Microvascular Function in Patients Undergoing Elective PCI.","published":"2016-07-12"}],"10.1016/j.jacc.2016.03.525":[{"url":"https://hartvaat.nl/2016/07/12/nervus-vagus-stimulatie-bij-hartfalen-de-inovate-hf-trial/","title":"Nervus vagus-stimulatie bij hartfalen: de INOVATE-HF-trial","title_en":"Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial.","published":"2016-07-12"}],"10.1161/circulationaha.116.021937":[{"url":"https://hartvaat.nl/2016/07/05/advance-care-planning-video-bij-gevorderd-hartfalen-gerandomiseerde-trial/","title":"Advance care planning video bij gevorderd hartfalen: gerandomiseerde trial","title_en":"Randomized, Controlled Trial of an Advance Care Planning Video Decision Support Tool for Patients With Advanced Heart Failure.","published":"2016-07-05"}],"10.1161/circulationaha.116.021890":[{"url":"https://hartvaat.nl/2016/07/05/verslechterende-nierfunctie-en-uitkomsten-met-rivaroxaban-versus-warfarine-rocke/","title":"Verslechterende nierfunctie en uitkomsten met rivaroxaban versus warfarine: ROCKET AF","title_en":"On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.","published":"2016-07-05"}],"10.1161/circulationaha.116.022361":[{"url":"https://hartvaat.nl/2016/07/05/nierfunctie-en-uitkomsten-met-edoxaban-in-de-engage-af-timi-48-trial/","title":"Nierfunctie en uitkomsten met edoxaban in de ENGAGE AF-TIMI 48-trial","title_en":"Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.","published":"2016-07-05"}],"10.1001/jamacardio.2016.1170":[{"url":"https://hartvaat.nl/2016/07/01/apixaban-versus-warfarine-bij-af-in-relatie-tot-nierfunctie-aristotle-analyse/","title":"Apixaban versus warfarine bij AF in relatie tot nierfunctie: ARISTOTLE-analyse","title_en":"Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.","published":"2016-07-01"}],"10.1001/jamacardio.2016.1017":[{"url":"https://hartvaat.nl/2016/07/01/langetermijnverdraagbaarheid-van-ticagrelor-voor-secundaire-cardiovasculaire-pre/","title":"Langetermijnverdraagbaarheid van ticagrelor voor secundaire cardiovasculaire preventie: PEGASUS-TIMI 54","title_en":"Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.","published":"2016-07-01"}],"10.1136/heartjnl-2015-309203":[{"url":"https://hartvaat.nl/2016/07/01/chocoladeconsumptie-en-risico-op-myocardinfarct-prospectieve-studie-en-meta-anal/","title":"Chocoladeconsumptie en risico op myocardinfarct: prospectieve studie en meta-analyse","title_en":"Chocolate consumption and risk of myocardial infarction: a prospective study and meta-analysis.","published":"2016-07-01"}],"10.1136/heartjnl-2015-308980":[{"url":"https://hartvaat.nl/2016/07/01/remote-ischemische-conditionering-en-vertraging-van-het-zorgsysteem-bij-stemi/","title":"Remote ischemische conditionering en vertraging van het zorgsysteem bij STEMI","title_en":"Remote ischaemic conditioning and healthcare system delay in patients with ST-segment elevation myocardial infarction.","published":"2016-07-01"}],"10.1136/heartjnl-2015-308120":[{"url":"https://hartvaat.nl/2016/07/01/natief-kleplijden-bij-af-patienten-op-warfarine-of-rivaroxaban/","title":"Natief kleplijden bij AF-patiënten op warfarine of rivaroxaban","title_en":"Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.","published":"2016-07-01"}],"10.1161/hypertensionaha.116.07218":[{"url":"https://hartvaat.nl/2016/07/01/luchtvervuiling-en-hypertensie-systematische-review-en-meta-analyse/","title":"Luchtvervuiling en hypertensie: systematische review en meta-analyse","title_en":"Associations of Short-Term and Long-Term Exposure to Ambient Air Pollutants With Hypertension: A Systematic Review and Meta-Analysis.","published":"2016-07-01"}],"10.1161/hypertensionaha.115.07023":[{"url":"https://hartvaat.nl/2016/07/01/polsgolfsnelheid-en-bloeddrukcontrole-als-onafhankelijke-voorspellers-van-cva-bi/","title":"Polsgolfsnelheid en bloeddrukcontrole als onafhankelijke voorspellers van CVA bij hypertensie","title_en":"Independent and Joint Effect of Brachial-Ankle Pulse Wave Velocity and Blood Pressure Control on Incident Stroke in Hypertensive Adults.","published":"2016-07-01"}],"10.1161/hypertensionaha.115.06960":[{"url":"https://hartvaat.nl/2016/07/01/medicatie-non-adherentie-en-visit-to-visit-bloeddrukvariabiliteit-target-bp-stud/","title":"Medicatie-non-adherentie en visit-to-visit bloeddrukvariabiliteit: TARGET BP-studie","title_en":"The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.","published":"2016-07-01"}],"10.1161/hypertensionaha.116.07431":[{"url":"https://hartvaat.nl/2016/07/01/bewegingsadvies-als-behandeling-van-prehypertensie-en-hypertensie-bij-jongvolwas/","title":"Bewegingsadvies als behandeling van prehypertensie en hypertensie bij jongvolwassenen: meta-analyse","title_en":"Will Exercise Advice Be Sufficient for Treatment of Young Adults With Prehypertension and Hypertension? A Systematic Review and Meta-Analysis.","published":"2016-07-01"}],"10.1093/europace/euv312":[{"url":"https://hartvaat.nl/2016/07/01/langetermijnevaluatie-van-dabigatran-150-versus-110-mg-bij-niet-valvulair-af/","title":"Langetermijnevaluatie van dabigatran 150 versus 110 mg bij niet-valvulair AF","title_en":"Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.","published":"2016-07-01"}],"10.1093/europace/euv367":[{"url":"https://hartvaat.nl/2016/07/01/implanteerbare-monitors-als-goudstandaard-voor-af-detectie-gerandomiseerde-verge/","title":"Implanteerbare monitors als goudstandaard voor AF-detectie: gerandomiseerde vergelijking","title_en":"Are implantable cardiac monitors the 'gold standard' for atrial fibrillation detection? A prospective randomized trial comparing atrial fibrillation monitoring using implantable cardiac monitors and DDDRP permanent pacemakers in post atrial fibrillation ablation patients.","published":"2016-07-01"}],"10.1001/jama.2016.7635":[{"url":"https://hartvaat.nl/2016/06/28/escitalopram-bij-hartfalen-en-depressie-de-mood-hf-trial/","title":"Escitalopram bij hartfalen en depressie: de MOOD-HF-trial","title_en":"Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.","published":"2016-06-28"}],"10.1001/jama.2016.7050":[{"url":"https://hartvaat.nl/2016/06/28/intensieve-versus-standaard-bloeddrukcontrole-bij-75-plussers-sprint-subanalyse/","title":"Intensieve versus standaard bloeddrukcontrole bij 75-plussers: SPRINT subanalyse","title_en":"Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.","published":"2016-06-28"}],"10.1093/eurheartj/ehw136":[{"url":"https://hartvaat.nl/2016/06/21/strategieen-om-microvasculaire-obstructie-te-verminderen-bij-primaire-pci-relief/","title":"Strategieën om microvasculaire obstructie te verminderen bij primaire PCI: RELIEF-MI-trial","title_en":"Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial.","published":"2016-06-21"}],"10.1093/eurheartj/ehw157":[{"url":"https://hartvaat.nl/2016/06/21/myocardiale-blush-en-microvasculaire-reperfusie-na-handmatige-trombectomie-bij-s/","title":"Myocardiale blush en microvasculaire reperfusie na handmatige trombectomie bij STEMI","title_en":"Myocardial blush and microvascular reperfusion following manual thrombectomy during percutaneous coronary intervention for ST elevation myocardial infarction: insights from the TOTAL trial.","published":"2016-06-21"}],"10.1016/j.jacc.2016.03.528":[{"url":"https://hartvaat.nl/2016/06/21/apothekerinterventies-en-cardiovasculair-risico-de-multicenter-rxeach-trial/","title":"Apothekerinterventies en cardiovasculair risico: de multicenter RxEACH-trial","title_en":"The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial.","published":"2016-06-21"}],"10.1056/nejmoa1515510":[{"url":"https://hartvaat.nl/2016/06/16/lage-versus-standaarddosis-alteplase-bij-acuut-ischemisch-cva-nejm-enchanted-tri/","title":"Lage versus standaarddosis alteplase bij acuut ischemisch CVA: NEJM ENCHANTED-trial","title_en":"Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.","published":"2016-06-16"}],"10.1016/j.jacc.2016.03.522":[{"url":"https://hartvaat.nl/2016/06/14/vroege-intraveneuze-betablokkade-voor-primaire-pci-bij-stemi/","title":"Vroege intraveneuze bètablokkade vóór primaire PCI bij STEMI","title_en":"Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention.","published":"2016-06-14"}],"10.1016/j.jacc.2016.03.524":[{"url":"https://hartvaat.nl/2016/06/14/ticagrelor-ter-preventie-van-ischemische-events-bij-mi-patienten-met-perifeer-va/","title":"Ticagrelor ter preventie van ischemische events bij MI-patiënten met perifeer vaatlijden","title_en":"Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.","published":"2016-06-14"}],"10.1016/j.jacc.2016.03.529":[{"url":"https://hartvaat.nl/2016/06/14/reductie-van-ischemische-events-met-ticagrelor-bij-diabetes-na-myocardinfarct-pe/","title":"Reductie van ischemische events met ticagrelor bij diabetes na myocardinfarct: PEGASUS-TIMI 54","title_en":"Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.","published":"2016-06-14"}],"10.1016/s0140-6736(16)30137-4":[{"url":"https://hartvaat.nl/2016/06/11/ixmyelocel-t-bij-ischemisch-hartfalen-lancet-dubbelblinde-gerandomiseerde-trial/","title":"Ixmyelocel-T bij ischemisch hartfalen: Lancet dubbelblinde gerandomiseerde trial","title_en":"Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.","published":"2016-06-11"}],"10.1056/nejmoa1602014":[{"url":"https://hartvaat.nl/2016/06/09/cryoballon-versus-radiofrequentieablatie-bij-paroxysmaal-atriumfibrilleren-nejm-/","title":"Cryoballon- versus radiofrequentieablatie bij paroxysmaal atriumfibrilleren: NEJM FIRE AND ICE-trial","title_en":"Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation.","published":"2016-06-09"}],"10.1016/j.jacc.2016.03.544":[{"url":"https://hartvaat.nl/2016/06/07/ischemie-en-infarct-bij-stemi-met-multivatenlijden-cvlprit-nucleaire-substudie/","title":"Ischemie en infarct bij STEMI met multivatenlijden: CvLPRIT nucleaire substudie","title_en":"Ischemia and Infarction in STEMI Patients With Multivessel Disease: Insights From the CvLPRIT Nuclear Substudy.","published":"2016-06-07"}],"10.1161/circulationaha.115.020729":[{"url":"https://hartvaat.nl/2016/06/07/klinische-verslechtering-van-poliklinisch-behandeld-hartfalen-paradigm-hf-analys/","title":"Klinische verslechtering van poliklinisch behandeld hartfalen: PARADIGM-HF-analyse","title_en":"Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).","published":"2016-06-07"}],"10.1016/j.jacc.2016.03.508":[{"url":"https://hartvaat.nl/2016/06/07/vitamine-d-bij-chronisch-hartfalen-de-vindicate-studie/","title":"Vitamine D bij chronisch hartfalen: de VINDICATE-studie","title_en":"Effects of Vitamin D on Cardiac Function in Patients With Chronic HF: The VINDICATE Study.","published":"2016-06-07"}],"10.1016/s0140-6736(16)00741-8":[{"url":"https://hartvaat.nl/2016/06/04/abc-bloedingsscore-bij-atriumfibrilleren-de-nieuwe-biomarkergebaseerde-risicosco/","title":"ABC-bloedingsscore bij atriumfibrilleren: de nieuwe biomarkergebaseerde risicoscore","title_en":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.","published":"2016-06-04"}],"10.1001/jamacardio.2016.0227":[{"url":"https://hartvaat.nl/2016/06/01/familiaire-belasting-en-statine-initiatie-bij-intermediair-cardiovasculair-risic/","title":"Familiaire belasting en statine-initiatie bij intermediair cardiovasculair risico: HOPE-3-analyse","title_en":"Association of a Family History of Coronary Heart Disease With Initiation of Statin Therapy in Individuals at Intermediate Risk: Post Hoc Analysis of a Randomized Clinical Trial.","published":"2016-06-01"}],"10.1001/jamacardio.2016.0305":[{"url":"https://hartvaat.nl/2016/06/01/pci-bij-insulinebehandelde-versus-niet-insulinebehandelde-diabetes-freedom-trial/","title":"PCI bij insulinebehandelde versus niet-insulinebehandelde diabetes: FREEDOM-trial","title_en":"Percutaneous Coronary Intervention in Patients With Insulin-Treated and Non-Insulin-Treated Diabetes Mellitus: Secondary Analysis of the TUXEDO Trial.","published":"2016-06-01"}],"10.1093/eurheartj/ehw022":[{"url":"https://hartvaat.nl/2016/06/01/preventie-van-cardiale-disfunctie-bij-borstkankerbehandeling-de-prada-trial/","title":"Preventie van cardiale disfunctie bij borstkankerbehandeling: de PRADA-trial","title_en":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.","published":"2016-06-01"}],"10.1093/eurheartj/ehv559":[{"url":"https://hartvaat.nl/2016/06/01/herhaalde-intracoronaire-beenmergcelinjectie-bij-hartfalen-resultaten-uit-een-re/","title":"Herhaalde intracoronaire beenmergcelinjectie bij hartfalen: resultaten uit een register","title_en":"Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT.","published":"2016-06-01"}],"10.1161/hypertensionaha.115.06637":[{"url":"https://hartvaat.nl/2016/06/01/matige-zoutreductie-verlaagt-bloeddruk-en-albuminurie-bij-gestoorde-glucosetoler/","title":"Matige zoutreductie verlaagt bloeddruk en albuminurie bij gestoorde glucosetolerantie en diabetes type 2","title_en":"Modest Salt Reduction Lowers Blood Pressure and Albumin Excretion in Impaired Glucose Tolerance and Type 2 Diabetes Mellitus: A Randomized Double-Blind Trial.","published":"2016-06-01"}],"10.1161/hypertensionaha.115.06979":[{"url":"https://hartvaat.nl/2016/06/01/chronische-nebivololbehandeling-onderdrukt-endotheline-1-gemedieerde-vasoconstri/","title":"Chronische nebivololbehandeling onderdrukt endotheline-1-gemedieerde vasoconstrictie bij verhoogde bloeddruk","title_en":"Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure.","published":"2016-06-01"}],"10.1161/hypertensionaha.116.07250":[{"url":"https://hartvaat.nl/2016/06/01/selectieve-hartfrequentieverlaging-met-ivabradine-verhoogt-centrale-bloeddruk-bi/","title":"Selectieve hartfrequentieverlaging met ivabradine verhoogt centrale bloeddruk bij stabiel coronairlijden","title_en":"Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease.","published":"2016-06-01"}],"10.1016/j.kint.2015.12.033":[{"url":"https://hartvaat.nl/2016/06/01/langetermijneffecten-van-atorvastatine-bij-diabetes-type-2-op-hemodialyse-4d-tri/","title":"Langetermijneffecten van atorvastatine bij diabetes type 2 op hemodialyse: 4D-trial follow-up","title_en":"Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis.","published":"2016-06-01"}],"10.1093/europace/euv129":[{"url":"https://hartvaat.nl/2016/06/01/crt-super-responders-met-en-zonder-pacing-middellangetermijnresultaten/","title":"CRT super-responders met en zonder pacing: middellangetermijnresultaten","title_en":"Mid-term clinical and echocardiographic evaluation of super responders with and without pacing: the preliminary results of a prospective, randomized, single-centre study.","published":"2016-06-01"}],"10.1016/j.jacc.2016.03.542":[{"url":"https://hartvaat.nl/2016/05/31/diagnostische-ultrageluidspulsen-verbeteren-microvasculaire-flow-bij-stemi-met-m/","title":"Diagnostische ultrageluidspulsen verbeteren microvasculaire flow bij STEMI met microbellen","title_en":"Diagnostic Ultrasound Impulses Improve Microvascular Flow in Patients With STEMI Receiving Intravenous Microbubbles.","published":"2016-05-31"}],"10.1016/j.jacc.2016.03.485":[{"url":"https://hartvaat.nl/2016/05/31/dapt-score-validatie-bij-patienten-met-en-zonder-eerder-myocardinfarct/","title":"DAPT Score: validatie bij patiënten met en zonder eerder myocardinfarct","title_en":"DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.","published":"2016-05-31"}],"10.1016/s0140-6736(16)30072-1":[{"url":"https://hartvaat.nl/2016/05/28/uitgestelde-versus-conventionele-stentimplantatie-bij-stemi-danami-3-defer-trial/","title":"Uitgestelde versus conventionele stentimplantatie bij STEMI: DANAMI 3-DEFER-trial","title_en":"Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial.","published":"2016-05-28"}],"10.1056/nejmoa1600175":[{"url":"https://hartvaat.nl/2016/05/26/bloeddrukverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculaire-/","title":"Bloeddrukverlaging bij personen met intermediair risico zonder cardiovasculaire ziekte: HOPE-3","title_en":"Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.","published":"2016-05-26"}],"10.1056/nejmoa1600176":[{"url":"https://hartvaat.nl/2016/05/26/cholesterolverlaging-bij-personen-met-intermediair-risico-zonder-cardiovasculair/","title":"Cholesterolverlaging bij personen met intermediair risico zonder cardiovasculaire ziekte: HOPE-3","title_en":"Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.","published":"2016-05-26"}],"10.1056/nejmoa1600177":[{"url":"https://hartvaat.nl/2016/05/26/bloeddruk-en-cholesterolverlaging-bij-personen-zonder-cardiovasculaire-ziekte-ho/","title":"Bloeddruk- en cholesterolverlaging bij personen zonder cardiovasculaire ziekte: HOPE-3","title_en":"Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.","published":"2016-05-26"}],"10.1016/j.jacc.2016.03.478":[{"url":"https://hartvaat.nl/2016/05/24/papillairspierbenadering-versus-restrictieve-annuloplastiek-bij-ernstige-ischemi/","title":"Papillairspierbenadering versus restrictieve annuloplastiek bij ernstige ischemische MR","title_en":"Papillary Muscle Approximation Versus Restrictive Annuloplasty Alone for Severe Ischemic Mitral Regurgitation.","published":"2016-05-24"}],"10.1093/eurheartj/ehw007":[{"url":"https://hartvaat.nl/2016/05/21/af-type-en-risico-op-trombo-embolie-mortaliteit-en-bloedingen-systematische-revi/","title":"AF-type en risico op trombo-embolie, mortaliteit en bloedingen: systematische review","title_en":"The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis.","published":"2016-05-21"}],"10.1093/eurheartj/ehw003":[{"url":"https://hartvaat.nl/2016/05/21/stapsgewijze-ablatie-gestuurd-door-laaggedoseerd-ibutilide-bij-chronisch-af-magi/","title":"Stapsgewijze ablatie gestuurd door laaggedoseerd ibutilide bij chronisch AF: MAGIC-AF-studie","title_en":"The modified stepwise ablation guided by low-dose ibutilide in chronic atrial fibrillation trial (The MAGIC-AF Study).","published":"2016-05-21"}],"10.1056/nejmoa1602002":[{"url":"https://hartvaat.nl/2016/05/19/frequentiecontrole-versus-ritmecontrole-bij-af-na-hartchirurgie-nejm-trial/","title":"Frequentiecontrole versus ritmecontrole bij AF na hartchirurgie: NEJM-trial","title_en":"Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.","published":"2016-05-19"}],"10.1056/nejmoa1602003":[{"url":"https://hartvaat.nl/2016/05/19/chirurgische-behandeling-van-matige-ischemische-mitralisklepinsufficientie-2-jaa/","title":"Chirurgische behandeling van matige ischemische mitralisklepinsufficiëntie: 2-jaarsresultaten","title_en":"Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation.","published":"2016-05-19"}],"10.1016/j.jacc.2016.03.475":[{"url":"https://hartvaat.nl/2016/05/17/biodegradeerbare-sirolimus-eluting-stents-de-panda-iii-trial/","title":"Biodegradeerbare sirolimus-eluting stents: de PANDA III-trial","title_en":"Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics: The PANDA III Trial.","published":"2016-05-17"}],"10.1016/j.jacc.2016.02.058":[{"url":"https://hartvaat.nl/2016/05/17/verminderde-cardiac-index-is-niet-de-primaire-oorzaak-van-nierdisfunctie-bij-har/","title":"Verminderde cardiac index is niet de primaire oorzaak van nierdisfunctie bij hartfalen","title_en":"Reduced Cardiac Index Is Not the Dominant Driver of Renal Dysfunction in Heart Failure.","published":"2016-05-17"}],"10.1016/j.jacc.2015.12.001":[{"url":"https://hartvaat.nl/2016/05/17/institutionele-en-operateurvereisten-voor-linker-hartoorocclusie-scai-acc-hrs-st/","title":"Institutionele en operateurvereisten voor linker-hartoorocclusie: SCAI/ACC/HRS-statement","title_en":"SCAI/ACC/HRS Institutional and Operator Requirements for Left Atrial Appendage Occlusion.","published":"2016-05-17"}],"10.1016/j.jacc.2016.02.051":[{"url":"https://hartvaat.nl/2016/05/10/biventriculaire-versus-rechterkamerpacing-klinische-verbetering-in-de-block-hf-s/","title":"Biventriculaire versus rechterkamerpacing: klinische verbetering in de BLOCK HF-studie","title_en":"Improvement in Clinical Outcomes With Biventricular Versus Right Ventricular Pacing: The BLOCK HF Study.","published":"2016-05-10"}],"10.1016/j.jacc.2016.02.056":[{"url":"https://hartvaat.nl/2016/05/10/validatie-van-barc-bloedingscriteria-bij-acuut-coronair-syndroom-tracer-trial/","title":"Validatie van BARC-bloedingscriteria bij acuut coronair syndroom: TRACER-trial","title_en":"Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.","published":"2016-05-10"}],"10.1016/j.jacc.2016.02.050":[{"url":"https://hartvaat.nl/2016/05/10/timing-van-metoprolol-bij-stemi-effect-op-infarctgrootte-en-ventrikelfunctie/","title":"Timing van metoprolol bij STEMI: effect op infarctgrootte en ventrikelfunctie","title_en":"Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function.","published":"2016-05-10"}],"10.1056/nejmoa1507750":[{"url":"https://hartvaat.nl/2016/05/05/perioperatief-rosuvastatine-bij-hartchirurgie-nejm-trial/","title":"Perioperatief rosuvastatine bij hartchirurgie: NEJM-trial","title_en":"Perioperative Rosuvastatin in Cardiac Surgery.","published":"2016-05-05"}],"10.1016/j.jacc.2016.02.045":[{"url":"https://hartvaat.nl/2016/05/03/gemalen-prasugrel-bij-stemi-met-primaire-pci-de-crush-studie/","title":"Gemalen prasugrel bij STEMI met primaire PCI: de CRUSH-studie","title_en":"Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.","published":"2016-05-03"}],"10.1161/circulationaha.115.016783":[{"url":"https://hartvaat.nl/2016/05/03/diabetes-en-preventie-van-laat-myocardinfarct-na-stenting-dapt-studie/","title":"Diabetes en preventie van laat myocardinfarct na stenting: DAPT-studie","title_en":"Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.","published":"2016-05-03"}],"10.1001/jamacardio.2016.0008":[{"url":"https://hartvaat.nl/2016/05/01/intracoronaire-adenylylcyclase-6-gentherapie-bij-hartfalen-gerandomiseerde-trial/","title":"Intracoronaire adenylylcyclase 6-gentherapie bij hartfalen: gerandomiseerde trial","title_en":"Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial.","published":"2016-05-01"}],"10.1001/jamacardio.2016.0103":[{"url":"https://hartvaat.nl/2016/05/01/sitagliptine-en-hartfalenrisico-bij-diabetes-type-2-secundaire-analyse-tecos-tri/","title":"Sitagliptine en hartfalenrisico bij diabetes type 2: secundaire analyse TECOS-trial","title_en":"Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.","published":"2016-05-01"}],"10.1001/jamacardio.2016.0096":[{"url":"https://hartvaat.nl/2016/05/01/lipoproteinen-insulineresistentie-en-rosuvastatine-bij-incident-type-2-diabetes/","title":"Lipoproteïnen, insulineresistentie en rosuvastatine bij incident type 2 diabetes","title_en":"Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.","published":"2016-05-01"}],"10.1093/eurheartj/ehw046":[{"url":"https://hartvaat.nl/2016/05/01/procentuele-ldl-verlaging-bij-hoogintensieve-statinetherapie-implicaties-voor-ri/","title":"Procentuele LDL-verlaging bij hoogintensieve statinetherapie: implicaties voor richtlijnen en PCSK9-remmers","title_en":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.","published":"2016-05-01"}],"10.1093/eurheartj/ehv707":[{"url":"https://hartvaat.nl/2016/05/01/ly3015014-een-nieuw-monoklonaal-pcsk9-antilichaam-gerandomiseerde-fase-2-trial/","title":"LY3015014, een nieuw monoklonaal PCSK9-antilichaam: gerandomiseerde fase-2-trial","title_en":"Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study.","published":"2016-05-01"}],"10.1136/heartjnl-2014-307238":[{"url":"https://hartvaat.nl/2016/05/01/genetische-diagnostiek-en-biomarkers-bij-pediatrische-pulmonale-hypertensie-expe/","title":"Genetische diagnostiek en biomarkers bij pediatrische pulmonale hypertensie: expertconsensus","title_en":"Genetic testing and blood biomarkers in paediatric pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.","published":"2016-05-01"}],"10.1136/heartjnl-2015-308246":[{"url":"https://hartvaat.nl/2016/05/01/cardiale-mri-en-ct-bij-kinderen-met-pulmonale-hypertensie-expertconsensus/","title":"Cardiale MRI en CT bij kinderen met pulmonale hypertensie: expertconsensus","title_en":"Cardiac MR and CT imaging in children with suspected or confirmed pulmonary hypertension/pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.","published":"2016-05-01"}],"10.1136/heartjnl-2015-308551":[{"url":"https://hartvaat.nl/2016/05/01/werkzame-mechanismen-van-disease-management-bij-hartfalen-systematische-review/","title":"Werkzame mechanismen van disease management bij hartfalen: systematische review","title_en":"A systematic review of the main mechanisms of heart failure disease management interventions.","published":"2016-05-01"}],"10.1136/heartjnl-2015-308559":[{"url":"https://hartvaat.nl/2016/05/01/therapeutische-hypothermie-bij-stemi-systematische-review-en-meta-analyse/","title":"Therapeutische hypothermie bij STEMI: systematische review en meta-analyse","title_en":"Therapeutic hypothermia in ST elevation myocardial infarction: a systematic review and meta-analysis of randomised control trials.","published":"2016-05-01"}],"10.1093/europace/euv368":[{"url":"https://hartvaat.nl/2016/05/01/katheterablatie-van-af-bij-chronisch-hartfalen-state-of-the-art-en-toekomstpersp/","title":"Katheterablatie van AF bij chronisch hartfalen: state-of-the-art en toekomstperspectieven","title_en":"Catheter ablation of atrial fibrillation in chronic heart failure: state-of-the-art and future perspectives.","published":"2016-05-01"}],"10.1093/europace/euv366":[{"url":"https://hartvaat.nl/2016/05/01/mineralocorticoidreceptorantagonisten-en-atriumfibrilleren-meta-analyse/","title":"Mineralocorticoïdreceptorantagonisten en atriumfibrilleren: meta-analyse","title_en":"Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.","published":"2016-05-01"}],"10.1016/s0140-6736(16)30069-1":[{"url":"https://hartvaat.nl/2016/04/30/fluticason-vilanterol-en-overleving-bij-copd-met-verhoogd-cardiovasculair-risico/","title":"Fluticason/vilanterol en overleving bij COPD met verhoogd cardiovasculair risico: SUMMIT-trial","title_en":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.","published":"2016-04-30"}],"10.1016/j.jacc.2016.02.023":[{"url":"https://hartvaat.nl/2016/04/26/ticagrelor-verbetert-perifere-arteriele-functie-bij-acs-relatie-met-adenosinespi/","title":"Ticagrelor verbetert perifere arteriële functie bij ACS: relatie met adenosinespiegels","title_en":"Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.","published":"2016-04-26"}],"10.1016/j.jacc.2016.02.033":[{"url":"https://hartvaat.nl/2016/04/26/vroege-aldosteronblokkade-bij-acuut-myocardinfarct-de-albatross-trial/","title":"Vroege aldosteronblokkade bij acuut myocardinfarct: de ALBATROSS-trial","title_en":"Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.","published":"2016-04-26"}],"10.1161/circulationaha.115.019406":[{"url":"https://hartvaat.nl/2016/04/26/ablatie-versus-amiodaron-bij-persisterend-af-met-hartfalen-en-icd-gerandomiseerd/","title":"Ablatie versus amiodaron bij persisterend AF met hartfalen en ICD: gerandomiseerde trial","title_en":"Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.","published":"2016-04-26"}],"10.1001/jama.2016.3775":[{"url":"https://hartvaat.nl/2016/04/26/predictieregel-voor-voordeel-en-schade-van-dapt-na-1-jaar-pci-jama-validatiestud/","title":"Predictieregel voor voordeel en schade van DAPT na 1 jaar PCI: JAMA-validatiestudie","title_en":"Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.","published":"2016-04-26"}],"10.1056/nejmoa1514859":[{"url":"https://hartvaat.nl/2016/04/21/aliskiren-enalapril-of-de-combinatie-bij-hartfalen-nejm-atmosphere-trial/","title":"Aliskiren, enalapril of de combinatie bij hartfalen: NEJM ATMOSPHERE-trial","title_en":"Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.","published":"2016-04-21"}],"10.1056/nejmoa1602001":[{"url":"https://hartvaat.nl/2016/04/21/coronaire-bypasschirurgie-bij-ischemische-cardiomyopathie-nejm-stich-trial/","title":"Coronaire bypasschirurgie bij ischemische cardiomyopathie: NEJM STICH-trial","title_en":"Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy.","published":"2016-04-21"}],"10.1093/eurheartj/ehv597":[{"url":"https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/","title":"MTP-131 bij reperfusieschade na STEMI: de EMBRACE STEMI fase-2a-trial","title_en":"EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.","published":"2016-04-21"}],"10.1093/eurheartj/ehv491":[{"url":"https://hartvaat.nl/2016/04/21/gdf-15-voorspelt-bloedingen-en-cardiovasculaire-events-bij-acuut-coronair-syndro/","title":"GDF-15 voorspelt bloedingen en cardiovasculaire events bij acuut coronair syndroom","title_en":"Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.","published":"2016-04-21"}],"10.1016/j.jacc.2016.02.014":[{"url":"https://hartvaat.nl/2016/04/19/statinebehandeling-en-plaquesamenstelling-dubbelblinde-gerandomiseerde-studie/","title":"Statinebehandeling en plaquesamenstelling: dubbelblinde gerandomiseerde studie","title_en":"Effect of Statin Treatment on Modifying Plaque Composition: A Double-Blind, Randomized Study.","published":"2016-04-19"}],"10.1016/j.jacc.2016.02.026":[{"url":"https://hartvaat.nl/2016/04/19/ct-coronairangiografie-voor-het-sturen-van-beleid-bij-coronairlijden/","title":"CT-coronairangiografie voor het sturen van beleid bij coronairlijden","title_en":"Use of Coronary Computed Tomographic Angiography to Guide Management of Patients With Coronary Disease.","published":"2016-04-19"}],"10.1001/jama.2016.3609":[{"url":"https://hartvaat.nl/2016/04/19/losmapimod-en-cardiovasculaire-uitkomsten-na-acuut-myocardinfarct-jama-trial/","title":"Losmapimod en cardiovasculaire uitkomsten na acuut myocardinfarct: JAMA-trial","title_en":"Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.","published":"2016-04-19"}],"10.1001/jama.2016.3608":[{"url":"https://hartvaat.nl/2016/04/19/evolocumab-versus-ezetimibe-bij-statine-intolerante-patienten-de-gauss-3-trial/","title":"Evolocumab versus ezetimibe bij statine-intolerante patiënten: de GAUSS-3-trial","title_en":"Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.","published":"2016-04-19"}],"10.1161/circulationaha.115.017299":[{"url":"https://hartvaat.nl/2016/04/19/trends-in-behandeling-en-uitkomsten-bij-nste-acs-naar-leeftijd/","title":"Trends in behandeling en uitkomsten bij NSTE-ACS naar leeftijd","title_en":"Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials.","published":"2016-04-19"}],"10.1016/j.jacc.2016.01.056":[{"url":"https://hartvaat.nl/2016/04/12/prognostische-waarde-van-residuele-coronairstenosen-na-functioneel-complete-reva/","title":"Prognostische waarde van residuele coronairstenosen na functioneel complete revascularisatie","title_en":"The Prognostic Value of Residual Coronary Stenoses After Functionally Complete Revascularization.","published":"2016-04-12"}],"10.1016/j.jacc.2016.01.069":[{"url":"https://hartvaat.nl/2016/04/12/infarctgrootte-en-uitkomsten-na-primaire-pci-patientanalyse-uit-10-trials/","title":"Infarctgrootte en uitkomsten na primaire PCI: patiëntanalyse uit 10 trials","title_en":"Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials.","published":"2016-04-12"}],"10.1016/j.jacc.2015.12.068":[{"url":"https://hartvaat.nl/2016/04/12/protonpompremmers-verminderen-gastro-intestinale-events-ongeacht-aspirinedosis-b/","title":"Protonpompremmers verminderen gastro-intestinale events ongeacht aspirinedosis bij DAPT","title_en":"Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.","published":"2016-04-12"}],"10.1056/nejmoa1506930":[{"url":"https://hartvaat.nl/2016/04/07/pioglitazon-na-ischemisch-cva-of-tia-gerandomiseerde-nejm-trial/","title":"Pioglitazon na ischemisch CVA of TIA: gerandomiseerde NEJM-trial","title_en":"Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.","published":"2016-04-07"}],"10.1093/eurheartj/ehv531":[{"url":"https://hartvaat.nl/2016/04/07/ischemisch-risico-en-werkzaamheid-van-ticagrelor-in-relatie-tot-stoptijd-p2y12-r/","title":"Ischemisch risico en werkzaamheid van ticagrelor in relatie tot stoptijd P2Y12-remmer na MI","title_en":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.","published":"2016-04-07"}],"10.1093/eurheartj/ehv498":[{"url":"https://hartvaat.nl/2016/04/07/cangrelor-en-toegangsplaats-effect-op-ischemische-en-bloedingsevents-champion-ph/","title":"Cangrelor en toegangsplaats: effect op ischemische en bloedingsevents (CHAMPION PHOENIX)","title_en":"The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.","published":"2016-04-07"}],"10.1161/circulationaha.115.018926":[{"url":"https://hartvaat.nl/2016/04/05/hartrevalidatie-versterkt-met-stressmanagementtraining-gerandomiseerde-trial/","title":"Hartrevalidatie versterkt met stressmanagementtraining: gerandomiseerde trial","title_en":"Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial.","published":"2016-04-05"}],"10.1016/s0140-6736(15)01238-6":[{"url":"https://hartvaat.nl/2016/04/02/bevacizumab-bij-pleuramesothelioom-de-maps-trial/","title":"Bevacizumab bij pleuramesothelioom: de MAPS-trial","title_en":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.","published":"2016-04-02"}],"10.1001/jamacardio.2015.0374":[{"url":"https://hartvaat.nl/2016/04/01/orale-antistolling-bij-atriumfibrilleren-over-het-spectrum-van-beroerterisico-ga/","title":"Orale antistolling bij atriumfibrilleren over het spectrum van beroerterisico: GARFIELD-AF","title_en":"Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry.","published":"2016-04-01"}],"10.1161/hypertensionaha.115.06981":[{"url":"https://hartvaat.nl/2016/04/01/prognostisch-effect-van-nachtelijke-bloeddrukdaling-bij-hypertensie-de-abc-h-stu/","title":"Prognostisch effect van nachtelijke bloeddrukdaling bij hypertensie: de ABC-H-studie","title_en":"Prognostic Effect of the Nocturnal Blood Pressure Fall in Hypertensive Patients: The Ambulatory Blood Pressure Collaboration in Patients With Hypertension (ABC-H) Meta-Analysis.","published":"2016-04-01"}],"10.1161/hypertensionaha.115.06853":[{"url":"https://hartvaat.nl/2016/04/01/effecten-van-dieetinterventies-op-bloeddruk-systematische-review-en-meta-analyse/","title":"Effecten van dieetinterventies op bloeddruk: systematische review en meta-analyse","title_en":"Effects of Different Dietary Interventions on Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials.","published":"2016-04-01"}],"10.1136/heartjnl-2015-308932":[{"url":"https://hartvaat.nl/2016/04/01/effect-van-extra-zuurstof-op-inspanningsprestatie-bij-chronisch-hartfalen/","title":"Effect van extra zuurstof op inspanningsprestatie bij chronisch hartfalen","title_en":"The effect of increasing inspired oxygen on exercise performance in patients with chronic heart failure.","published":"2016-04-01"}],"10.1136/heartjnl-2015-308963":[{"url":"https://hartvaat.nl/2016/04/01/veiligheid-en-werkzaamheid-van-ticagrelor-versus-clopidogrel-bij-primaire-pci-vo/","title":"Veiligheid en werkzaamheid van ticagrelor versus clopidogrel bij primaire PCI voor STEMI","title_en":"Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.","published":"2016-04-01"}],"10.1136/heartjnl-2015-308887":[{"url":"https://hartvaat.nl/2016/04/01/biomarkers-van-inflammatie-en-cardiovasculair-risico-bij-patienten-met-atriumfib/","title":"Biomarkers van inflammatie en cardiovasculair risico bij patiënten met atriumfibrilleren onder antistolling","title_en":"Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.","published":"2016-04-01"}],"10.1136/heartjnl-2015-308542":[{"url":"https://hartvaat.nl/2016/04/01/cardiovasculaire-effecten-en-veiligheid-van-langdurig-colchicinegebruik-cochrane/","title":"Cardiovasculaire effecten en veiligheid van langdurig colchicinegebruik: Cochrane review","title_en":"Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis.","published":"2016-04-01"}],"10.1136/heartjnl-2015-308075":[{"url":"https://hartvaat.nl/2016/04/01/ischemisch-risicogebied-en-reperfusiemethode-bij-stemi-klinische-implicaties/","title":"Ischemisch risicogebied en reperfusiemethode bij STEMI: klinische implicaties","title_en":"Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction.","published":"2016-04-01"}],"10.1093/europace/euv339":[{"url":"https://hartvaat.nl/2016/04/01/katheterablatie-bij-atriumfibrilleren-met-hypertrofische-cardiomyopathie-meta-an/","title":"Katheterablatie bij atriumfibrilleren met hypertrofische cardiomyopathie: meta-analyse","title_en":"Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis.","published":"2016-04-01"}],"10.1016/j.jacc.2015.10.104":[{"url":"https://hartvaat.nl/2016/03/29/drug-eluting-versus-bare-metal-stents-bij-pci-patienten-met-eindstadium-nierziek/","title":"Drug-eluting versus bare-metal stents bij PCI-patiënten met eindstadium nierziekte op dialyse","title_en":"Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis.","published":"2016-03-29"}],"10.1016/j.jacc.2016.01.031":[{"url":"https://hartvaat.nl/2016/03/29/omecamtiv-mecarbil-bij-acuut-hartfalen-de-atomic-ahf-studie/","title":"Omecamtiv mecarbil bij acuut hartfalen: de ATOMIC-AHF-studie","title_en":"Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.","published":"2016-03-29"}],"10.1016/j.jacc.2016.01.034":[{"url":"https://hartvaat.nl/2016/03/22/spontaan-myocardinfarct-na-nstemi-zonder-revascularisatie-trilogy-acs-trial/","title":"Spontaan myocardinfarct na NSTEMI zonder revascularisatie: TRILOGY ACS-trial","title_en":"Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.","published":"2016-03-22"}],"10.1161/circulationaha.115.020109":[{"url":"https://hartvaat.nl/2016/03/22/genetische-risicoscore-en-ldl-cholesterolbehandeling-bij-coronairlijden/","title":"Genetische risicoscore en LDL-cholesterolbehandeling bij coronairlijden","title_en":"Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial).","published":"2016-03-22"}],"10.1161/circulationaha.115.018006":[{"url":"https://hartvaat.nl/2016/03/22/zelfmanagementinterventies-bij-hartfalen-individuele-patientdata-meta-analyse/","title":"Zelfmanagementinterventies bij hartfalen: individuele patiëntdata meta-analyse","title_en":"Do Self-Management Interventions Work in Patients With Heart Failure? An Individual Patient Data Meta-Analysis.","published":"2016-03-22"}],"10.1093/eurheartj/ehv633":[{"url":"https://hartvaat.nl/2016/03/21/cardiovasculaire-uitkomsten-bij-verschillende-bereiktestreefdrukken-in-de-value-/","title":"Cardiovasculaire uitkomsten bij verschillende bereiktestreefdrukken in de VALUE-trial","title_en":"Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.","published":"2016-03-21"}],"10.1016/s0140-6736(16)00082-9":[{"url":"https://hartvaat.nl/2016/03/19/serca2a-gentherapie-bij-hartfalen-de-cupid-2-trial/","title":"SERCA2a-gentherapie bij hartfalen: de CUPID 2-trial","title_en":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.","published":"2016-03-19"}],"10.1056/nejmsa1508955":[{"url":"https://hartvaat.nl/2016/03/17/veiliger-voorschrijven-educatie-informatica-en-financiele-prikkels-in-de-eerstel/","title":"Veiliger voorschrijven: educatie, informatica en financiële prikkels in de eerstelijn","title_en":"Safer Prescribing--A Trial of Education, Informatics, and Financial Incentives.","published":"2016-03-17"}],"10.1056/nejmoa1505215":[{"url":"https://hartvaat.nl/2016/03/17/langetermijnresultaten-van-stenting-versus-endarteriectomie-bij-carotisstenose/","title":"Langetermijnresultaten van stenting versus endarteriëctomie bij carotisstenose","title_en":"Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis.","published":"2016-03-17"}],"10.1016/j.jacc.2015.12.042":[{"url":"https://hartvaat.nl/2016/03/15/voorspelling-van-persisterende-lv-disfunctie-na-myocardinfarct-de-predicts-studi/","title":"Voorspelling van persisterende LV-disfunctie na myocardinfarct: de PREDICTS-studie","title_en":"Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study.","published":"2016-03-15"}],"10.1016/j.jacc.2015.12.062":[{"url":"https://hartvaat.nl/2016/03/15/plaatjesremming-met-ticagrelor-60-mg-versus-90-mg-in-de-pegasus-timi-54-trial/","title":"Plaatjesremming met ticagrelor 60 mg versus 90 mg in de PEGASUS-TIMI 54-trial","title_en":"Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.","published":"2016-03-15"}],"10.1161/cir.0000000000000336":[{"url":"https://hartvaat.nl/2016/03/15/2015-acc-aha-scai-gerichte-update-primaire-pci-bij-stemi/","title":"2015 ACC/AHA/SCAI gerichte update: primaire PCI bij STEMI","title_en":"2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.","published":"2016-03-15"}],"10.1016/s0140-6736(15)01166-6":[{"url":"https://hartvaat.nl/2016/03/12/invasieve-versus-conservatieve-strategie-bij-80-plussers-met-nstemi-gerandomisee/","title":"Invasieve versus conservatieve strategie bij 80-plussers met NSTEMI: gerandomiseerde trial","title_en":"Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial.","published":"2016-03-12"}],"10.1001/jama.2016.1558":[{"url":"https://hartvaat.nl/2016/03/08/naltrexon-bupropion-en-cardiovasculaire-events-bij-obesitas-gerandomiseerde-tria/","title":"Naltrexon-bupropion en cardiovasculaire events bij obesitas: gerandomiseerde trial","title_en":"Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.","published":"2016-03-08"}],"10.1161/circulationaha.115.019355":[{"url":"https://hartvaat.nl/2016/03/08/acute-ledischemie-en-vorapaxar-bij-perifeer-arterieel-vaatlijden-tra-2p-timi-50-/","title":"Acute ledischemie en vorapaxar bij perifeer arterieel vaatlijden: TRA 2°P-TIMI 50-resultaten","title_en":"Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).","published":"2016-03-08"}],"10.1016/s0140-6736(15)01225-8":[{"url":"https://hartvaat.nl/2016/03/05/bloeddrukverlaging-ter-preventie-van-hart-en-vaatziekten-systematische-review-en/","title":"Bloeddrukverlaging ter preventie van hart- en vaatziekten: systematische review en meta-analyse","title_en":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.","published":"2016-03-05"}],"10.1016/j.jacc.2015.12.036":[{"url":"https://hartvaat.nl/2016/03/01/cyp2c19-metaboliseerdersstatus-en-uitkomsten-bij-acs-prasugrel-versus-clopidogre/","title":"CYP2C19-metaboliseerdersstatus en uitkomsten bij ACS: prasugrel versus clopidogrel","title_en":"Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.","published":"2016-03-01"}],"10.1016/j.jacc.2015.12.019":[{"url":"https://hartvaat.nl/2016/03/01/bioresorbeerbare-scaffold-trombose-multicenteranalyse-van-klinische-presentatie-/","title":"Bioresorbeerbare scaffold-trombose: multicenteranalyse van klinische presentatie en mechanismen","title_en":"Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors.","published":"2016-03-01"}],"10.1161/hypertensionaha.115.06851":[{"url":"https://hartvaat.nl/2016/03/01/voorschrijfpatronen-van-thiazidediuretica-in-de-sprint-trial/","title":"Voorschrijfpatronen van thiazidediuretica in de SPRINT-trial","title_en":"Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial.","published":"2016-03-01"}],"10.1161/hypertensionaha.115.06624":[{"url":"https://hartvaat.nl/2016/03/01/taurinesuppletie-verlaagt-bloeddruk-en-verbetert-vaatfunctie-bij-prehypertensie/","title":"Taurinesuppletie verlaagt bloeddruk en verbetert vaatfunctie bij prehypertensie","title_en":"Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension: Randomized, Double-Blind, Placebo-Controlled Study.","published":"2016-03-01"}],"10.1136/heartjnl-2015-308636":[{"url":"https://hartvaat.nl/2016/03/01/effect-van-aanvullende-zuurstoftoediening-op-myocardschade-bij-stemi/","title":"Effect van aanvullende zuurstoftoediening op myocardschade bij STEMI","title_en":"Effect of supplemental oxygen exposure on myocardial injury in ST-elevation myocardial infarction.","published":"2016-03-01"}],"10.1161/hypertensionaha.115.06345":[{"url":"https://hartvaat.nl/2016/03/01/farmacogenomische-meta-analyse-van-bloeddrukrespons-op-betablokkers-bij-afro-ame/","title":"Farmacogenomische meta-analyse van bloeddrukrespons op bètablokkers bij Afro-Amerikanen","title_en":"Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.","published":"2016-03-01"}],"10.1093/europace/euv293":[{"url":"https://hartvaat.nl/2016/03/01/intrathoracale-impedantiemonitoring-bij-chronisch-hartfalen-de-limit-chf-studie/","title":"Intrathoracale impedantiemonitoring bij chronisch hartfalen: de LIMIT-CHF-studie","title_en":"The lung impedance monitoring in treatment of chronic heart failure (the LIMIT-CHF study).","published":"2016-03-01"}],"10.1093/europace/euv351":[{"url":"https://hartvaat.nl/2016/03/01/aanvullende-cfae-ablatie-en-lineaire-laesies-bij-persistend-atriumfibrilleren-me/","title":"Aanvullende CFAE-ablatie en lineaire laesies bij persistend atriumfibrilleren: meta-analyse","title_en":"The impact of adjunctive complex fractionated atrial electrogram ablation and linear lesions on outcomes in persistent atrial fibrillation: a meta-analysis.","published":"2016-03-01"}],"10.1093/europace/euv263":[{"url":"https://hartvaat.nl/2016/03/01/eerste-trial-met-specifieke-ikach-blokker-toont-geen-reductie-in-af-last-bij-par/","title":"Eerste trial met specifieke IKACh-blokker toont geen reductie in AF-last bij paroxysmaal atriumfibrilleren","title_en":"First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation.","published":"2016-03-01"}],"10.1016/j.jacc.2015.11.050":[{"url":"https://hartvaat.nl/2016/02/23/inspanningstestvariabelen-als-mortaliteitsvoorspellers-bij-chronisch-systolisch-/","title":"Inspanningstestvariabelen als mortaliteitsvoorspellers bij chronisch systolisch hartfalen","title_en":"Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure.","published":"2016-02-23"}],"10.1016/j.jacc.2015.11.051":[{"url":"https://hartvaat.nl/2016/02/23/everolimus-versus-sirolimus-eluting-stents-5-jaarsresultaten-sort-out-iv/","title":"Everolimus- versus sirolimus-eluting stents: 5-jaarsresultaten SORT OUT IV","title_en":"Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.","published":"2016-02-23"}],"10.1016/j.jacc.2015.11.044":[{"url":"https://hartvaat.nl/2016/02/16/ticagrelor-versus-clopidogrel-bij-troponine-negatieve-laagrisico-acs-met-ad-hoc-/","title":"Ticagrelor versus clopidogrel bij troponine-negatieve laagrisico-ACS met ad-hoc PCI","title_en":"Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.","published":"2016-02-16"}],"10.1161/circulationaha.115.016801":[{"url":"https://hartvaat.nl/2016/02/16/bmi-abdominale-adipositas-en-hartfalen-systematische-review-en-dosis-responsmeta/","title":"BMI, abdominale adipositas en hartfalen: systematische review en dosis-responsmeta-analyse","title_en":"Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies.","published":"2016-02-16"}],"10.1093/eurheartj/ehv501":[{"url":"https://hartvaat.nl/2016/02/14/kortdurend-antiaritmica-na-katheterablatie-voor-atriumfibrilleren-east-af-trial/","title":"Kortdurend antiaritmica na katheterablatie voor atriumfibrilleren: EAST-AF-trial","title_en":"Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial.","published":"2016-02-14"}],"10.1161/circulationaha.115.017530":[{"url":"https://hartvaat.nl/2016/02/09/sms-berichten-ter-ondersteuning-van-therapietrouw-bij-hoge-bloeddruk-de-star-tri/","title":"SMS-berichten ter ondersteuning van therapietrouw bij hoge bloeddruk: de StAR-trial","title_en":"Mobile Phone Text Messages to Support Treatment Adherence in Adults With High Blood Pressure (SMS-Text Adherence Support [StAR]): A Single-Blind, Randomized Trial.","published":"2016-02-09"}],"10.1161/circulationaha.115.019657":[{"url":"https://hartvaat.nl/2016/02/09/intensieve-versus-standaard-bloeddrukcontrole-en-nierfunctie-na-lacunair-herseni/","title":"Intensieve versus standaard bloeddrukcontrole en nierfunctie na lacunair herseninfarct","title_en":"Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial.","published":"2016-02-09"}],"10.1016/j.jacc.2015.10.033":[{"url":"https://hartvaat.nl/2016/02/09/peergroepinterventie-voor-cardiovasculaire-risicofactoren-de-fifty-fifty-trial/","title":"Peergroepinterventie voor cardiovasculaire risicofactoren: de Fifty-Fifty-trial","title_en":"A Comprehensive Lifestyle Peer Group-Based Intervention on Cardiovascular Risk Factors: The Randomized Controlled Fifty-Fifty Program.","published":"2016-02-09"}],"10.1016/j.jacc.2015.10.037":[{"url":"https://hartvaat.nl/2016/02/09/generaliseerbaarheid-van-sprint-resultaten-naar-de-algemene-bevolking/","title":"Generaliseerbaarheid van SPRINT-resultaten naar de algemene bevolking","title_en":"Generalizability of SPRINT Results to the U.S. Adult Population.","published":"2016-02-09"}],"10.1093/eurheartj/ehv563":[{"url":"https://hartvaat.nl/2016/02/07/impact-van-pcsk9-remmers-op-lipidenniveaus-en-uitkomsten-netwerkmeta-analyse/","title":"Impact van PCSK9-remmers op lipidenniveaus en uitkomsten: netwerkmeta-analyse","title_en":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.","published":"2016-02-07"}],"10.1016/s0140-6736(15)00979-4":[{"url":"https://hartvaat.nl/2016/02/06/bioresorbeerbare-versus-metallic-stents-meta-analyse-van-gerandomiseerde-trials/","title":"Bioresorbeerbare versus metallic stents: meta-analyse van gerandomiseerde trials","title_en":"Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.","published":"2016-02-06"}],"10.1056/nejmoa1510491":[{"url":"https://hartvaat.nl/2016/02/04/risicoprojectie-voor-nierfalen-bij-levende-nierdonorkandidaten/","title":"Risicoprojectie voor nierfalen bij levende nierdonorkandidaten","title_en":"Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate.","published":"2016-02-04"}],"10.1016/j.jacc.2015.10.083":[{"url":"https://hartvaat.nl/2016/02/02/vergelijking-chlorthalidon-en-hydrochloorthiazide-op-24-uurs-ambulante-bloeddruk/","title":"Vergelijking chlorthalidon en hydrochloorthiazide op 24-uurs ambulante bloeddruk","title_en":"Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring.","published":"2016-02-02"}],"10.1016/j.jacc.2015.10.081":[{"url":"https://hartvaat.nl/2016/02/02/ciclosporine-a-bij-gereperfuseerd-myocardinfarct-de-multicenter-cycle-trial/","title":"Ciclosporine A bij gereperfuseerd myocardinfarct: de multicenter CYCLE-trial","title_en":"Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial.","published":"2016-02-02"}],"10.1016/j.jacc.2015.10.077":[{"url":"https://hartvaat.nl/2016/02/02/reductie-in-totale-cardiovasculaire-events-met-ezetimibe-simvastatine-na-acs-imp/","title":"Reductie in totale cardiovasculaire events met ezetimibe/simvastatine na ACS: IMPROVE-IT","title_en":"Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.","published":"2016-02-02"}],"10.1161/circulationaha.115.018220":[{"url":"https://hartvaat.nl/2016/02/02/aerobe-intervaltraining-vermindert-de-last-van-atriumfibrilleren-gerandomiseerde/","title":"Aerobe intervaltraining vermindert de last van atriumfibrilleren: gerandomiseerde trial","title_en":"Aerobic Interval Training Reduces the Burden of Atrial Fibrillation in the Short Term: A Randomized Trial.","published":"2016-02-02"}],"10.1093/eurheartj/ehv558":[{"url":"https://hartvaat.nl/2016/02/01/regionale-hartdisfunctie-en-prognose-na-myocardinfarct-met-lv-disfunctie-of-hart/","title":"Regionale hartdisfunctie en prognose na myocardinfarct met LV-disfunctie of hartfalen","title_en":"Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.","published":"2016-02-01"}],"10.1093/eurheartj/ehv422":[{"url":"https://hartvaat.nl/2016/02/01/rechterkamerseptumpacing-versus-apexpacing-bij-crt-defibrillator-gerandomiseerde/","title":"Rechterkamerseptumpacing versus apexpacing bij CRT-defibrillator: gerandomiseerde trial","title_en":"Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.","published":"2016-02-01"}],"10.1093/eurheartj/ehv464":[{"url":"https://hartvaat.nl/2016/02/01/invloed-van-ejectiefractie-op-uitkomsten-van-spironolacton-bij-hfpef/","title":"Invloed van ejectiefractie op uitkomsten van spironolacton bij HFpEF","title_en":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.","published":"2016-02-01"}],"10.1093/eurheartj/ehv436":[{"url":"https://hartvaat.nl/2016/02/01/peri-infarctpacing-ter-preventie-van-linkerkamerremodellering-na-groot-myocardin/","title":"Peri-infarctpacing ter preventie van linkerkamerremodellering na groot myocardinfarct","title_en":"Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.","published":"2016-02-01"}],"10.1016/j.kint.2015.12.024":[{"url":"https://hartvaat.nl/2016/02/01/sprint-resultaten-en-implicaties-voor-de-nefrologie/","title":"SPRINT-resultaten en implicaties voor de nefrologie","title_en":"A SPRINT to the finish, or just the beginning? Implications of the SPRINT results for nephrologists.","published":"2016-02-01"}],"10.1161/hypertensionaha.115.06526":[{"url":"https://hartvaat.nl/2016/02/01/spironolacton-versus-renale-denervatie-bij-therapieresistente-hypertensie-prague/","title":"Spironolacton versus renale denervatie bij therapieresistente hypertensie: PRAGUE-15 1-jaarsresultaten","title_en":"Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study.","published":"2016-02-01"}],"10.1161/hypertensionaha.115.06617":[{"url":"https://hartvaat.nl/2016/02/01/mineralocorticoidreceptoractivatie-draagt-bij-aan-supiene-hypertensie-bij-autono/","title":"Mineralocorticoïdreceptoractivatie draagt bij aan supiene hypertensie bij autonoom falen","title_en":"Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure.","published":"2016-02-01"}],"10.1161/hypertensionaha.115.06467":[{"url":"https://hartvaat.nl/2016/02/01/betablokkers-met-en-zonder-vasodilaterende-eigenschappen-en-centrale-bloeddruk-m/","title":"Bètablokkers met en zonder vasodilaterende eigenschappen en centrale bloeddruk: meta-analyse","title_en":"Effects of β-Blockers With and Without Vasodilating Properties on Central Blood Pressure: Systematic Review and Meta-Analysis of Randomized Trials in Hypertension.","published":"2016-02-01"}],"10.1136/heartjnl-2015-308055":[{"url":"https://hartvaat.nl/2016/02/01/nicotinezuurtherapie-en-het-risico-op-diabetes-meta-analyse-van-gerandomiseerde-/","title":"Nicotinezuurtherapie en het risico op diabetes: meta-analyse van gerandomiseerde trials","title_en":"Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials.","published":"2016-02-01"}],"10.1016/s0140-6736(15)00723-0":[{"url":"https://hartvaat.nl/2016/01/30/hemodynamische-telemonitoring-bij-chronisch-hartfalen-volledige-champion-resulta/","title":"Hemodynamische telemonitoring bij chronisch hartfalen: volledige CHAMPION-resultaten","title_en":"Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial.","published":"2016-01-30"}],"10.1016/s0140-6736(15)00805-3":[{"url":"https://hartvaat.nl/2016/01/30/intensieve-bloeddrukverlaging-en-cardiovasculaire-en-renale-uitkomsten-systemati/","title":"Intensieve bloeddrukverlaging en cardiovasculaire en renale uitkomsten: systematische review en meta-analyse","title_en":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.","published":"2016-01-30"}],"10.1056/nejmoa1512913":[{"url":"https://hartvaat.nl/2016/01/28/mitralisklepchirurgie-bij-ernstige-ischemische-mitralisklepinsufficientie-2-jaar/","title":"Mitralisklepchirurgie bij ernstige ischemische mitralisklepinsufficiëntie: 2-jaarsresultaten","title_en":"Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation.","published":"2016-01-28"}],"10.1016/j.jacc.2015.10.071":[{"url":"https://hartvaat.nl/2016/01/26/p-selectine-antagonist-inclacumab-bij-coronaire-bypasschirurgie-select-cabg-tria/","title":"P-selectine-antagonist inclacumab bij coronaire bypasschirurgie: SELECT-CABG-trial","title_en":"Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial.","published":"2016-01-26"}],"10.1016/j.jacc.2015.10.076":[{"url":"https://hartvaat.nl/2016/01/26/relatieve-wanddikte-en-risico-op-ventriculaire-tachyaritmieen-bij-linkerkamerdis/","title":"Relatieve wanddikte en risico op ventriculaire tachyaritmieën bij linkerkamerdisfunctie","title_en":"Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction.","published":"2016-01-26"}],"10.1016/j.jacc.2015.10.079":[{"url":"https://hartvaat.nl/2016/01/26/langketen-acylcarnitines-bij-hartfalen-prognostische-waarde-en-reversibiliteit-m/","title":"Langketen-acylcarnitines bij hartfalen: prognostische waarde en reversibiliteit met mechanische ondersteuning","title_en":"Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support.","published":"2016-01-26"}],"10.1161/circulationaha.115.018544":[{"url":"https://hartvaat.nl/2016/01/26/polyfarmacie-en-werkzaamheid-van-rivaroxaban-versus-warfarine-bij-atriumfibrille/","title":"Polyfarmacie en werkzaamheid van rivaroxaban versus warfarine bij atriumfibrilleren","title_en":"Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.","published":"2016-01-26"}],"10.1016/s0140-6736(15)00515-2":[{"url":"https://hartvaat.nl/2016/01/23/reg1-anticoagulatiesysteem-versus-bivalirudine-bij-pci-de-regulate-pci-trial/","title":"REG1-anticoagulatiesysteem versus bivalirudine bij PCI: de REGULATE-PCI-trial","title_en":"Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.","published":"2016-01-23"}],"10.1016/s0140-6736(15)00548-6":[{"url":"https://hartvaat.nl/2016/01/23/everolimus-eluting-stent-versus-bare-metal-stent-bij-stemi-5-jaarsresultaten-exa/","title":"Everolimus-eluting stent versus bare-metal stent bij STEMI: 5-jaarsresultaten EXAMINATION-trial","title_en":"Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial.","published":"2016-01-23"}],"10.1093/eurheartj/ehv611":[{"url":"https://hartvaat.nl/2016/01/21/neoplasiedetectie-bij-langdurige-dapt-met-prasugrel-versus-clopidogrel-triton-ti/","title":"Neoplasiedetectie bij langdurige DAPT met prasugrel versus clopidogrel: TRITON-TIMI 38-analyse","title_en":"Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.","published":"2016-01-21"}],"10.1093/eurheartj/ehv614":[{"url":"https://hartvaat.nl/2016/01/21/doodsoorzaken-bij-langdurige-dapt-na-coronaire-stents/","title":"Doodsoorzaken bij langdurige DAPT na coronaire stents","title_en":"Causes of late mortality with dual antiplatelet therapy after coronary stents.","published":"2016-01-21"}],"10.1093/eurheartj/ehv482":[{"url":"https://hartvaat.nl/2016/01/21/ticagrelor-bij-nierfunctiestoornissen-langetermijnpreventie-na-myocardinfarct-pe/","title":"Ticagrelor bij nierfunctiestoornissen: langetermijnpreventie na myocardinfarct (PEGASUS-TIMI 54)","title_en":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.","published":"2016-01-21"}],"10.1093/eurheartj/ehv481":[{"url":"https://hartvaat.nl/2016/01/21/stoppen-of-doorgaan-met-clopidogrel-12-maanden-na-drug-eluting-stent-optidual-tr/","title":"Stoppen of doorgaan met clopidogrel 12 maanden na drug-eluting stent: OPTIDUAL-trial","title_en":"Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.","published":"2016-01-21"}],"10.1093/eurheartj/ehv443":[{"url":"https://hartvaat.nl/2016/01/21/langdurige-duale-antiplaatjestherapie-bij-patienten-met-eerder-myocardinfarct-me/","title":"Langdurige duale antiplaatjestherapie bij patiënten met eerder myocardinfarct: meta-analyse","title_en":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.","published":"2016-01-21"}],"10.1161/circulationaha.115.017300":[{"url":"https://hartvaat.nl/2016/01/19/werkzaamheid-en-veiligheid-van-cangrelor-bij-vrouwen-versus-mannen-tijdens-pci-c/","title":"Werkzaamheid en veiligheid van cangrelor bij vrouwen versus mannen tijdens PCI: CHAMPION-analyse","title_en":"Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.","published":"2016-01-19"}],"10.1093/eurheartj/ehv547":[{"url":"https://hartvaat.nl/2016/01/14/morfine-vertraagt-en-vermindert-de-werking-van-ticagrelor-bij-myocardinfarct-de-/","title":"Morfine vertraagt en vermindert de werking van ticagrelor bij myocardinfarct: de IMPRESSION-trial","title_en":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.","published":"2016-01-14"}],"10.1093/eurheartj/ehv493":[{"url":"https://hartvaat.nl/2016/01/14/intracoronaire-beenmergcelinfusie-bij-acuut-myocardinfarct-de-regenerate-ami-tri/","title":"Intracoronaire beenmergcelinfusie bij acuut myocardinfarct: de REGENERATE-AMI-trial","title_en":"A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial†.","published":"2016-01-14"}],"10.1093/eurheartj/ehv500":[{"url":"https://hartvaat.nl/2016/01/14/bioresorbeerbare-versus-metallic-everolimus-eluting-stent-bij-stemi-gerandomisee/","title":"Bioresorbeerbare versus metallic everolimus-eluting stent bij STEMI: gerandomiseerde trial","title_en":"Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.","published":"2016-01-14"}],"10.1093/eurheartj/ehv320":[{"url":"https://hartvaat.nl/2016/01/14/2015-esc-richtlijn-voor-acute-coronaire-syndromen-zonder-persisterende-st-elevat/","title":"2015 ESC-richtlijn voor acute coronaire syndromen zonder persisterende ST-elevatie","title_en":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).","published":"2016-01-14"}],"10.1016/s0140-6736(15)00448-1":[{"url":"https://hartvaat.nl/2016/01/09/trombusaspiratie-bij-stemi-1-jaarsfollow-up-van-de-total-trial/","title":"Trombusaspiratie bij STEMI: 1-jaarsfollow-up van de TOTAL-trial","title_en":"Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial.","published":"2016-01-09"}],"10.1016/s0140-6736(15)00459-6":[{"url":"https://hartvaat.nl/2016/01/09/ranolazine-bij-incomplete-revascularisatie-na-pci-de-river-pci-trial/","title":"Ranolazine bij incomplete revascularisatie na PCI: de RIVER-PCI-trial","title_en":"Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.","published":"2016-01-09"}],"10.1093/eurheartj/ehv456":[{"url":"https://hartvaat.nl/2016/01/07/preoperatief-statinegebruik-en-cardiovasculaire-complicaties-bij-niet-cardiale-c/","title":"Preoperatief statinegebruik en cardiovasculaire complicaties bij niet-cardiale chirurgie: de VISION-studie","title_en":"Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study.","published":"2016-01-07"}],"10.1016/j.jacc.2015.10.043":[{"url":"https://hartvaat.nl/2016/01/05/doodsoorzaken-na-pci-versus-cabg-bij-complex-coronairlijden-5-jaarsfollow-up-van/","title":"Doodsoorzaken na PCI versus CABG bij complex coronairlijden: 5-jaarsfollow-up van SYNTAX","title_en":"Causes of Death Following PCI Versus CABG in Complex CAD: 5-Year Follow-Up of SYNTAX.","published":"2016-01-05"}],"10.1016/j.jacc.2015.10.045":[{"url":"https://hartvaat.nl/2016/01/05/ct-coronairangiografie-bij-verdenking-acs-in-het-tijdperk-van-hoog-sensitief-tro/","title":"CT-coronairangiografie bij verdenking ACS in het tijdperk van hoog-sensitief troponine","title_en":"Coronary CT Angiography for Suspected ACS in the Era of High-Sensitivity Troponins: Randomized Multicenter Study.","published":"2016-01-05"}],"10.1001/jama.2015.17346":[{"url":"https://hartvaat.nl/2016/01/05/calorierestrictie-of-aerobe-training-bij-obese-ouderen-met-hfpef-effect-op-vo2-p/","title":"Calorierestrictie of aerobe training bij obese ouderen met HFpEF: effect op VO2-piek en kwaliteit van leven","title_en":"Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.","published":"2016-01-05"}],"10.1161/circulationaha.115.019768":[{"url":"https://hartvaat.nl/2016/01/05/ranolazine-bij-angina-en-kwaliteit-van-leven-na-pci-met-incomplete-revascularisa/","title":"Ranolazine bij angina en kwaliteit van leven na PCI met incomplete revascularisatie","title_en":"Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.","published":"2016-01-05"}],"10.1161/circulationaha.115.019634":[{"url":"https://hartvaat.nl/2016/01/05/varenicline-voor-stoppen-met-roken-bij-patienten-opgenomen-met-acuut-coronair-sy/","title":"Varenicline voor stoppen met roken bij patiënten opgenomen met acuut coronair syndroom","title_en":"Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome.","published":"2016-01-05"}],"10.1093/eurheartj/ehv418":[{"url":"https://hartvaat.nl/2016/01/01/persisterende-echocardiografische-dyssynchronie-voorspelt-ongunstige-uitkomsten-/","title":"Persisterende echocardiografische dyssynchronie voorspelt ongunstige uitkomsten bij hartfalen met smal QRS","title_en":"Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial.","published":"2016-01-01"}],"10.1093/eurheartj/ehv317":[{"url":"https://hartvaat.nl/2016/01/01/2015-esc-ers-richtlijn-voor-diagnostiek-en-behandeling-van-pulmonale-hypertensie/","title":"2015 ESC/ERS-richtlijn voor diagnostiek en behandeling van pulmonale hypertensie","title_en":"2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).","published":"2016-01-01"}],"10.1093/eurheartj/ehv337":[{"url":"https://hartvaat.nl/2016/01/01/inspanningstraining-verbetert-zuurstofopname-en-hemodynamiek-bij-ernstige-pulmon/","title":"Inspanningstraining verbetert zuurstofopname en hemodynamiek bij ernstige pulmonale hypertensie","title_en":"Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial.","published":"2016-01-01"}],"10.1161/hypertensionaha.115.06066":[{"url":"https://hartvaat.nl/2016/01/01/centrale-versus-perifere-bloeddruk-en-doelorgaanschade-systematische-review-en-m/","title":"Centrale versus perifere bloeddruk en doelorgaanschade: systematische review en meta-analyse","title_en":"Association of Central Versus Brachial Blood Pressure With Target-Organ Damage: Systematic Review and Meta-Analysis.","published":"2016-01-01"}],"10.1161/hypertensionaha.115.06480":[{"url":"https://hartvaat.nl/2016/01/01/bereikte-bloeddruk-en-uitkomsten-in-de-sps3-trial-bij-lacunaire-herseninfarcten/","title":"Bereikte bloeddruk en uitkomsten in de SPS3-trial bij lacunaire herseninfarcten","title_en":"Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial.","published":"2016-01-01"}],"10.1136/heartjnl-2015-307798":[{"url":"https://hartvaat.nl/2016/01/01/point-of-care-echografie-voor-volumebeoordeling-bij-hartfalen-in-een-verpleegkun/","title":"Point-of-care echografie voor volumebeoordeling bij hartfalen in een verpleegkundig geleide polikliniek","title_en":"Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic. A randomised study.","published":"2016-01-01"}],"10.1093/europace/euv122":[{"url":"https://hartvaat.nl/2016/01/01/gesimuleerde-obstructieve-slaapapneu-bevordert-ritmestoornissen-bij-paroxysmaal-/","title":"Gesimuleerde obstructieve slaapapneu bevordert ritmestoornissen bij paroxysmaal atriumfibrilleren","title_en":"Intrathoracic pressure swings induced by simulated obstructive sleep apnoea promote arrhythmias in paroxysmal atrial fibrillation.","published":"2016-01-01"}],"10.1093/europace/euu366":[{"url":"https://hartvaat.nl/2016/01/01/katheterablatie-herstelt-verlaagde-plasma-mir-409-3p-en-mir-432-bij-atriumfibril/","title":"Katheterablatie herstelt verlaagde plasma miR-409-3p en miR-432 bij atriumfibrilleren","title_en":"Catheter ablation restores decreased plasma miR-409-3p and miR-432 in atrial fibrillation patients.","published":"2016-01-01"}]}}